PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Da Cruz, S; Xenarios, I; Langridge, J; Vilbois, F; Parone, PA; Martinou, JC				Da Cruz, S; Xenarios, I; Langridge, J; Vilbois, F; Parone, PA; Martinou, JC			Proteomic analysis of the mouse liver mitochondrial inner membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IDENTIFICATION; FUNCTIONAL-ANALYSIS; MASS-SPECTROMETRY; ATP; STOMATIN; CHANNELS; RECEPTOR; GENES; YME1	Mitochondria play a crucial role in cellular homeostasis, which justifies the increasing interest in mapping the different components of these organelles. Here we have focused our study on the identification of proteins of the mitochondrial inner membrane (MIM). This membrane is of particular interest because, besides the well known components of the respiratory chain complexes, it contains several ion channels and many carrier proteins that certainly play a key role in mitochondrial function and, therefore, deserve to be identified at the molecular level. To achieve this goal we have used a novel approach combining the use of highly purified mouse liver mitochondrial inner membranes, extraction of membrane proteins with organic acid, and two-dimensional liquid chromatography coupled to tandem mass spectrometry. This procedure allowed us to identify 182 proteins that are involved in several biochemical processes, such as the electron transport machinery, the protein import machinery, protein synthesis, lipid metabolism, and ion or substrate transport. The full range of isoelectric point (3.9-12.5), molecular mass ( 6 527 kDa), and hydrophobicity values ( up to 16 transmembrane predicted domains) were represented. In addition, of the 182 proteins found, 20 were unknown or had never previously been associated with the MIM. Overexpression of some of these proteins in mammalian cells confirmed their mitochondrial localization and resulted in severe remodeling of the mitochondrial network. This study provides the first proteome of the MIM and provides a basis for a more detailed study of the newly characterized proteins of this membrane.	Univ Geneva, Dept Cellular Biol, CH-1205 Geneva, Switzerland; Serono Int SA, Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Micromass UK Ltd, Manchester M23 9LZ, Lancs, England	University of Geneva; Merck & Company; Serono International S.A.	Martinou, JC (corresponding author), Univ Geneva, Dept Cellular Biol, 30 Quai E Ansermet, CH-1205 Geneva, Switzerland.	jean-claude.martinou@cellbio.unige.ch	Xenarios, Ioannis/ABD-5045-2021	Xenarios, Ioannis/0000-0002-3413-6841; martinou, Jean-claude/0000-0002-9847-2051				Anantharaman V, 2002, FEMS MICROBIOL LETT, V207, P55, DOI 10.1016/S0378-1097(01)00515-8; Barnes TM, 1996, J NEUROCHEM, V67, P46; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Fountoulakis M, 2002, ELECTROPHORESIS, V23, P311, DOI 10.1002/1522-2683(200202)23:2<311::AID-ELPS311>3.0.CO;2-0; Garlid KD, 1996, J BIOL CHEM, V271, P8796, DOI 10.1074/jbc.271.15.8796; Goodman MB, 2002, NATURE, V415, P1039, DOI 10.1038/4151039a; Hoppel C, 2001, ARCH BIOCHEM BIOPHYS, V392, P321, DOI 10.1006/abbi.2001.2463; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kremmidiotis G, 2001, GENOMICS, V76, P58, DOI 10.1006/geno.2001.6560; Lopez MF, 2000, ELECTROPHORESIS, V21, P3427, DOI 10.1002/1522-2683(20001001)21:16<3427::AID-ELPS3427>3.0.CO;2-L; Martinez LO, 2003, NATURE, V421, P75, DOI 10.1038/nature01250; Millar AH, 2001, PLANT PHYSIOL, V127, P1711, DOI 10.1104/pp.010387; Okamoto Y, 2002, J BIOL CHEM, V277, P46470, DOI 10.1074/jbc.M207779200; Parone PA, 2002, BIOCHIMIE, V84, P105, DOI 10.1016/S0300-9084(02)01380-9; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Rabilloud T, 1998, ELECTROPHORESIS, V19, P1006, DOI 10.1002/elps.1150190616; Stromhaug PE, 1998, BIOCHEM J, V335, P217, DOI 10.1042/bj3350217; Taylor SW, 2002, J PROTEOME RES, V1, P451, DOI 10.1021/pr025533g; TAYLOR SW, 2003, NAT BIOTECHNOL, V18, P18; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; Wang YJ, 2000, J BIOL CHEM, V275, P8062, DOI 10.1074/jbc.275.11.8062; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307; Xu WH, 2002, SCIENCE, V298, P1029, DOI 10.1126/science.1074360	25	200	213	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41566	41571		10.1074/jbc.M304940200	http://dx.doi.org/10.1074/jbc.M304940200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12865426	hybrid			2022-12-25	WOS:000185847200138
J	Demarchi, F; Bertoli, C; Sandy, P; Schneider, C				Demarchi, F; Bertoli, C; Sandy, P; Schneider, C			Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLYCOGEN-SYNTHASE KINASE-3; REQUIRES PHOSPHORYLATION; PRECURSOR P105; DEATH DOMAIN; MICE LACKING; ACTIVATION; PROTEIN; INHIBITION; UBIQUITINATION	A number of different kinases have been implicated in NF-kappaB regulation and survival function. Here we investigated the molecular cross-talk between glycogen synthase kinase-3beta (GSK-3beta) and the p105 precursor of the NF-kappaB p50 subunit. GSK-3beta forms an in vivo complex with and specifically phosphorylates NF-kappaB1/p105 at Ser-903 and Ser-907 in vitro. In addition, the p105 phosphorylation level is reduced in fibroblasts lacking GSK-3beta as compared with wild-type cells. GSK-3beta has a dual effect on p105: it stabilizes p105 under resting conditions and primes p105 for degradation upon tumor necrosis factor (TNF)-alpha treatment. Indeed, constitutive processing of p105 to p50 occurs at a higher rate in cells lacking GSK-3beta with respect to wild-type cells and can be reduced upon reintroduction of GSK-3beta by transfection. Moreover, p105 degradation in response to TNF-alpha is prevented in GSK-3 beta-/- fibroblasts and by a Ser to Ala point mutation on p105 at positions 903 or 907. Interestingly, the increased sensitiveness to TNF-alpha-induced death occurring in GSK-3 beta -/- fibroblasts, which is coupled to a perturbation of p50/105 ratio, can be reproduced by p105 silencing in wild-type fibroblasts.	Lab Nazl Consorzio Interuniv Biotecnol, I-34012 Trieste, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Schneider, C (corresponding author), Lab Nazl Consorzio Interuniv Biotecnol, Area Sci Pk,Padriciano 99, I-34012 Trieste, Italy.	schneide@lncib.it		Demarchi, Francesca/0000-0003-1565-3162				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beinke S, 2002, J BIOL CHEM, V277, P24162, DOI 10.1074/jbc.M201576200; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Boland MP, 1998, J BIOL CHEM, V273, P15494, DOI 10.1074/jbc.273.25.15494; Coux O, 1998, J BIOL CHEM, V273, P8820, DOI 10.1074/jbc.273.15.8820; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Harhaj EW, 1996, ONCOGENE, V12, P2385; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; Manoukian AS, 2002, ADV CANCER RES, V84, P203, DOI 10.1016/S0065-230X(02)84007-6; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; Nemeth ZH, 2002, J BIOL CHEM, V277, P7713, DOI 10.1074/jbc.M109711200; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; Ozes ON, 1999, NATURE, V401, P82; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Schotte P, 2001, J BIOL CHEM, V276, P25939, DOI 10.1074/jbc.M104014200; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sheridan CM, 2002, J BIOL CHEM, V277, P48664, DOI 10.1074/jbc.M207029200; Tolnay M, 2002, BIOCHEM J, V363, P127, DOI 10.1042/0264-6021:3630127; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	35	132	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39583	39590		10.1074/jbc.M305676200	http://dx.doi.org/10.1074/jbc.M305676200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12871932	hybrid			2022-12-25	WOS:000185713800041
J	Indiani, C; O'Donnell, M				Indiani, C; O'Donnell, M			Mechanism of the delta wrench in opening the beta sliding clamp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; ESCHERICHIA-COLI; ACCESSORY PROTEINS; GAMMA-COMPLEX; CRYSTAL-STRUCTURE; LOADER COMPLEX; SUBUNIT; REPLICATION; HOLOENZYME; PURIFICATION	The beta sliding clamp encircles DNA and tethers DNA polymerase III holoenzyme to the template for high processivity. The clamp loader, gamma complex (gamma(3)deltadelta'chipsi), assembles beta around DNA in an ATP-fueled reaction. The delta subunit of the clamp loader opens the beta ring and is referred to as the wrench; ATP modulates contact between beta and delta among other functions. Crystal structures of delta.beta and the gamma3deltadelta' minimal clamp loader make predictions of the clamp loader mechanism, which are tested in this report by mutagenesis. The delta wrench contacts beta at two sites. One site is at the beta dimer interface, where delta appears to distort the interface by via a steric clash between a helix on delta and a loop near the beta interface. The energy for this steric clash is thought to derive from the other site of interaction, in which delta binds to a hydrophobic pocket in beta. The current study demonstrates that rather than a simple steric clash with beta, delta specifically contacts beta at this site, but not through amino acid side chains, and thus is presumably mediated by peptide backbone atoms. The results also imply that the interaction of delta at the hydrophobic site on beta contributes to destabilization of the beta dimer interface rather than acting solely as a grip of delta on beta. Within the gamma complex, delta' is proposed to prevent delta from binding to beta in the absence of ATP. This report demonstrates that one or more gamma subunits also contribute to this role. The results also indicate that delta' acts as a backboard upon which the gamma subunits push to attain the ATP induced change needed for the delta wrench to bind and open the beta ring.	Rockefeller Univ, Howard Hughes Med Inst, Lab DNA Replicat, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	O'Donnell, M (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab DNA Replicat, 1230 York Ave, New York, NY 10021 USA.	odonnel@mail.rockefeller.edu		O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; Davey MJ, 2000, CURR OPIN CHEM BIOL, V4, P581, DOI 10.1016/S1367-5931(00)00134-4; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; Jeruzalmi D, 2002, CURR OPIN STRUC BIOL, V12, P217, DOI 10.1016/S0959-440X(02)00313-5; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; Johnson A, 2003, J BIOL CHEM, V278, P14406, DOI 10.1074/jbc.M212708200; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Leu FP, 2001, J BIOL CHEM, V276, P47185, DOI 10.1074/jbc.M106780200; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; Neuwald AF, 1999, GENOME RES, V9, P27; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; ONRUST R, 1993, J BIOL CHEM, V268, P11766; Shiomi Y, 2000, P NATL ACAD SCI USA, V97, P14127, DOI 10.1073/pnas.97.26.14127; Song MS, 2001, J BIOL CHEM, V276, P40668, DOI 10.1074/jbc.M106373200; Stewart J, 2001, J BIOL CHEM, V276, P19182, DOI 10.1074/jbc.M100592200; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; Turner J, 1995, METHOD ENZYMOL, V262, P442; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; XIAO H, 1993, J BIOL CHEM, V268, P11779; Yao N, 2000, J BIOL CHEM, V275, P11440, DOI 10.1074/jbc.275.15.11440; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	39	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40272	40281		10.1074/jbc.M305828200	http://dx.doi.org/10.1074/jbc.M305828200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12851392	hybrid			2022-12-25	WOS:000185713800120
J	Liu, H; Toman, RE; Goparaju, SK; Maceyka, M; Nava, VE; Sankala, H; Payne, SG; Bektas, M; Ishii, I; Chun, J; Milstien, S; Spiegel, S				Liu, H; Toman, RE; Goparaju, SK; Maceyka, M; Nava, VE; Sankala, H; Payne, SG; Bektas, M; Ishii, I; Chun, J; Milstien, S; Spiegel, S			Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-CHAIN BASES; BCL-X-L; CELL-MIGRATION; FUNCTIONAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; COUPLED RECEPTOR; CYTOCHROME-C; BH3 DOMAINS; 1-PHOSPHATE	There are two isoforms of sphingosine kinase (SphK) that catalyze the formation of sphingosine 1-phosphate, a potent sphingolipid mediator. Whereas SphK1 stimulates growth and survival, here we show that SphK2 enhanced apoptosis in diverse cell types and also suppressed cellular proliferation. Apoptosis was preceded by cytochrome c release and activation of caspase-3. SphK2-induced apoptosis was independent of activation of sphingosine 1-phosphate receptors. Sequence analysis revealed that SphK2 contains a 9-amino acid motif similar to that present in BH3-only proteins, a proapoptotic subgroup of the Bcl-2 family. As with other BH3-only proteins, co-immunoprecipitation demonstrated that SphK2 interacted with Bcl-x(L). Moreover, site-directed mutation of Leu-219, the conserved leucine residue present in all BH3 domains, markedly suppressed SphK2-induced apoptosis. Hence, the apoptotic effect of SphK2 might be because of its putative BH3 domain.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Georgetown Univ, Med Ctr, Interdisciplinary Program Neurosci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Biochem, Washington, DC 20007 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; Natl Inst Neurosci, Dept Mol Genet, Tokyo 1878502, Japan; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; NIMH, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	Virginia Commonwealth University; Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Center for Neurology & Psychiatry - Japan; Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.		Chun, Jerold/Y-4670-2019; Goparaju, Sravan/H-3422-2011; Maceyka, Michael/B-9277-2008	Ishii, Isao/0000-0002-5367-205X	NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH001039, ZIAMH001039, K02MH001723] Funding Source: NIH RePORTER; NCI NIH HHS [CA61774] Funding Source: Medline; NIMH NIH HHS [MH01723] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chittenden T, 2002, CANCER CELL, V2, P165, DOI 10.1016/S1535-6108(02)00128-9; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; Edsall LC, 1997, J NEUROSCI, V17, P6952; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; Ferguson-Yankey SR, 2002, YEAST, V19, P573, DOI 10.1002/yea.861; Funato K, 2003, J BIOL CHEM, V278, P7325, DOI 10.1074/jbc.M209925200; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Kim S, 2000, GENETICS, V156, P1519; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Nava VE, 2000, CANCER RES, V60, P4468; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	47	288	298	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40330	40336		10.1074/jbc.M304455200	http://dx.doi.org/10.1074/jbc.M304455200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12835323	hybrid			2022-12-25	WOS:000185713800126
J	Guerini, D; Pan, B; Carafoli, E				Guerini, D; Pan, B; Carafoli, E			Expression, purification, and characterization of isoform 1 of the plasma membrane Ca2+ pump - Focus on calpain sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; HUMAN-ERYTHROCYTE-MEMBRANE; HAND STRUCTURE-DOMAIN; CALCIUM-PUMP; MOLECULAR-CLONING; NEUTRAL PROTEASE; MESSENGER-RNAS; CA-2+-TRANSPORTING ATPASE; ENDOPLASMIC-RETICULUM; POLYACRYLAMIDE GELS	The plasma membrane Ca2+ ATPase isoform 1(PMCA1) is ubiquitously distributed in tissues and cells, but only scarce information is available on its properties. The isoform was overexpressed in Sf9 cells, purified on calmodulin columns, and characterized functionally. The level of expression was very low, but sufficient amounts of the protein could be isolated for biochemical characterization. The affinity of PMCA1 for calmodulin was similar to that of PMCA4, the other ubiquitous PMCA isoform. The affinity of PMCA1 for ATP, evaluated by the formation of the phosphorylated intermediate, was higher than that of the PMCA4 pump. The recombinant PMCA1 pump was a much better substrate for the cAMP-dependent protein kinase than the PMCA2 and PMCA4 isoforms. Pulse and chase experiments on Sf9 cells overexpressing the PMCA pumps showed that PMCA1 was much less stable than the PMCA4 and PMCA2 isoforms, i.e. PMCA1 had a much higher sensitivity to degradation by calpain. The effect of calpain was not the result of a general higher susceptibility of the PMCA1 to proteolytic degradation, because the pattern of degradation by trypsin was the same in the three isoforms.	Univ Padua, Dept Biochem, I-35121 Padua, Italy; ETH, Inst Biochem, CH-8092 Zurich, Switzerland; Venetian Inst Mol Med, I-35129 Padua, Italy	University of Padua; Swiss Federal Institutes of Technology Domain; ETH Zurich; Veneto Institute Molecular Medicine	Carafoli, E (corresponding author), Univ Padua, Dept Biochem, I-35121 Padua, Italy.		Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; ADAMO HP, 1992, J BIOL CHEM, V267, P14244; BENAIM G, 1984, J BIOL CHEM, V259, P8471; BERGER SL, 1979, BIOCHEMISTRY-US, V18, P5143, DOI 10.1021/bi00590a018; BRANDT P, 1992, J BIOL CHEM, V267, P4376; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARAFOLI E, 1993, TRENDS CARDIOVAS MED, V3, P177, DOI 10.1016/1050-1738(93)90003-O; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1994, J BIOL CHEM, V269, P41; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; FOLETTI D, 1995, FASEB J, V9, P670, DOI 10.1096/fasebj.9.8.7768360; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; GREEB J, 1989, J BIOL CHEM, V264, P18569; Guerini D, 1999, J BIOL CHEM, V274, P1667, DOI 10.1074/jbc.274.3.1667; GUERINI D, 1995, J BIOL CHEM, V270, P14643, DOI 10.1074/jbc.270.24.14643; HEIM R, 1992, J BIOL CHEM, V267, P24476; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; HOFMANN F, 1994, J BIOL CHEM, V269, P24298; JAMES P, 1989, J BIOL CHEM, V264, P8289; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KESSLER F, 1992, BIOCHEMISTRY-US, V31, P11785, DOI 10.1021/bi00162a016; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Liu BF, 1996, J BIOL CHEM, V271, P5536, DOI 10.1074/jbc.271.10.5536; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; MINAMI Y, 1987, J BIOCHEM-TOKYO, V101, P889, DOI 10.1093/oxfordjournals.jbchem.a121956; MINAMI Y, 1988, J BIOCHEM-TOKYO, V104, P927, DOI 10.1093/oxfordjournals.jbchem.a122585; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; NEYSES L, 1985, J BIOL CHEM, V260, P283; OLSON S, 1991, GENOMICS, V9, P629, DOI 10.1016/0888-7543(91)90356-J; Paszty K, 2002, J BIOL CHEM, V277, P6822, DOI 10.1074/jbc.M109548200; PHILIPSON K D, 1992, Current Opinion in Cell Biology, V4, P678, DOI 10.1016/0955-0674(92)90089-U; SALAMINO F, 1994, CELL CALCIUM, V15, P28, DOI 10.1016/0143-4160(94)90101-5; SAMBROOK J, 1989, MOLEC CLON LAB MAN, V1; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Seiz Preiano Brigitta, 1996, Biochemistry, V35, P7946, DOI 10.1021/bi9527404; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; SUMMERS MD, 1988, B TEXAS A M U, V1555; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMA AK, 1994, J BIOL CHEM, V269, P1687; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V260, P696, DOI 10.1016/0003-9861(88)90498-5; WANG MG, 1994, CYTOGENET CELL GENET, V67, P41, DOI 10.1159/000133794; ZURINI M, 1984, J BIOL CHEM, V259, P618; ZVARITCH E, 1995, J BIOL CHEM, V270, P2679, DOI 10.1074/jbc.270.6.2679	55	58	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38141	38148		10.1074/jbc.M302400200	http://dx.doi.org/10.1074/jbc.M302400200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12851406	hybrid			2022-12-25	WOS:000185575100008
J	Mousseau, DD; Chapelsky, S; De Crescenzo, G; Kirkitadze, MD; Magoon, J; Inoue, S; Teplow, DB; O'Connor-McCourt, MD				Mousseau, DD; Chapelsky, S; De Crescenzo, G; Kirkitadze, MD; Magoon, J; Inoue, S; Teplow, DB; O'Connor-McCourt, MD			A direct interaction between transforming growth Factor (TGF)-beta s and amyloid-beta protein affects fibrillogenesis in a TGF-beta receptor-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; TRANSGENIC MICE; FIBRIL FORMATION; PLAQUE-FORMATION; DEPOSITION; PEPTIDE; NEURONS; MODELS; GROWTH-FACTOR-BETA-1	Transforming growth factor-beta (TGF-beta) receptor-mediated signaling has been proposed to mediate both the beneficial and deleterious roles for this cytokine in amyloid-beta protein (Abeta) function. In order to assess receptor dependence of these events, we used PC12 cell cultures, which are devoid of TGF-beta receptors. Surprisingly, TGF-beta potentiated the neurotoxic effects of the 40-residue Abeta peptide, Abeta-(1 - 40), in this model suggesting that there may be a direct, receptor-independent interaction between TGF-beta and Abeta- (1 - 40). Surface plasmon resonance confirmed that TGF-beta binds with high affinity directly to Abeta- (1 - 40) and electron microscopy revealed that TGF-beta enhances Abeta- (1 - 40) oligomerization. Immunohistochemical examination of mouse brain revealed that hippocampal CA1 and dentate gyrus, two regions classically associated with Abeta- mediated pathology, lack TGF-beta Type I receptor immunoreactivity, thus indicating that TGF-beta receptor-mediated signaling would not be favored in these regions. Our observations not only provide for a unique, receptor-independent mechanism of action for TGF-beta, but also help to reconcile the literature interpreting the role of TGF-beta in Abeta function. These data support a critical etiological role for this mechanism in neuropathological amyloidoses.	Univ Saskatchewan, Dept Psychiat, Neuropsychiat Res Unit, Cell Signaling Grp, Saskatoon, SK S7N 5E4, Canada; Biotechnol Res Inst, Receptor Signaling & Proteom Grp, Hlth Sector, Montreal, PQ H4P 2R2, Canada; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	University of Saskatchewan; National Research Council Canada; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; McGill University	O'Connor-McCourt, MD (corresponding author), Univ Saskatchewan, Dept Psychiat, Neuropsychiat Res Unit, Cell Signaling Grp, Saskatoon, SK S7N 5E4, Canada.							Arnold SE, 1991, CEREB CORTEX, V1, P103, DOI 10.1093/cercor/1.1.103; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; BODMER S, 1990, BIOCHEM BIOPH RES CO, V171, P890, DOI 10.1016/0006-291X(90)91229-L; Calhoun ME, 1999, P NATL ACAD SCI USA, V96, P14088, DOI 10.1073/pnas.96.24.14088; Castillo GM, 1997, J NEUROCHEM, V69, P2452; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; De Crescenzo G, 2001, J BIOL CHEM, V276, P29632, DOI 10.1074/jbc.M009765200; De Crescenzo G, 2000, BIOCHEMISTRY-US, V39, P9466, DOI 10.1021/bi992987r; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Frautschy SA, 1996, NEUROBIOL AGING, V17, P311, DOI 10.1016/0197-4580(95)02073-X; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; Haass C, 2002, NAT MED, V8, P1195, DOI 10.1038/nm1102-1195; Harris-White ME, 1998, J NEUROSCI, V18, P10366; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8; Huang SS, 1998, J BIOL CHEM, V273, P27640, DOI 10.1074/jbc.273.42.27640; Inoue S, 2001, INT REV CYTOL, V210, P121; Irizarry MC, 2000, ACTA NEUROPATHOL, V100, P451, DOI 10.1007/s004010000263; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Lesne S, 2003, J BIOL CHEM, V278, P18408, DOI 10.1074/jbc.M300819200; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; McLaurin J, 2000, J STRUCT BIOL, V130, P259, DOI 10.1006/jsbi.2000.4289; Pfeifer M, 2002, SCIENCE, V298, P1379, DOI 10.1126/science.1078259; POULSEN KT, 1994, NEURON, V13, P1245, DOI 10.1016/0896-6273(94)90062-0; Prehn JHM, 1996, MOL PHARMACOL, V49, P319; Ramirez-Alvarado M, 2000, P NATL ACAD SCI USA, V97, P8979, DOI 10.1073/pnas.150091797; Ren RF, 1996, BRAIN RES, V732, P16, DOI 10.1016/0006-8993(96)00458-1; Ren RF, 1997, MOL BRAIN RES, V48, P315, DOI 10.1016/S0169-328X(97)00108-3; Schenk D, 2002, NAT REV NEUROSCI, V3, P824, DOI 10.1038/nrn938; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Wiesmann C, 2000, NAT STRUCT BIOL, V7, P440; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321	41	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38715	38722		10.1074/jbc.M304080200	http://dx.doi.org/10.1074/jbc.M304080200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12867422	hybrid			2022-12-25	WOS:000185575100077
J	Santiago, TC; Ben Mamoun, C				Santiago, TC; Ben Mamoun, C			Genome expression analysis in yeast reveals novel transcriptional regulation by inositol and choline and new regulatory functions for Opi1p, Ino2p, and Ino4p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHETIC-ENZYMES; SYNTHASE GENES FAS1; C-13 NMR ANALYSIS; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLSERINE SYNTHASE; INOSITOL-1-PHOSPHATE SYNTHASE; CDP-DIACYLGLYCEROL; TRANSPORTER GENES; AMINO-ACIDS; PROTEIN	In Saccharomyces cerevisiae, genes encoding phospholipid-synthesizing enzymes are regulated by inositol and choline (IC). The current model suggests that when these precursors become limiting, the transcriptional complex Ino2p-Ino4p activates the expression of these genes, whereas repression requires Opi1p and occurs when IC are available. In this study, microarray-based expression analysis was performed to assess the global transcriptional response to IC in a wild-type strain and in the opi1Delta, ino2Delta, and ino4Delta null mutant strains. Fifty genes were either activated or repressed by IC in the wild-type strain, including three already known IC-repressed genes. We demonstrated that the IC response was not limited to genes involved in membrane biogenesis, but encompassed various metabolic pathways such as biotin synthesis, one-carbon compound metabolism, nitrogen-containing compound transport and degradation, cell wall organization and biogenesis, and acetylCoA metabolism. The expression of a large number of IC-regulated genes did not change in the opi1Delta, ino2Delta, and ino4Delta strains, thus implicating new regulatory elements in the IC response. Our studies revealed that Opi1p, Ino2p, and Ino4p have dual regulatory activities, acting in both positive and negative transcriptional regulation of a large number of genes, most of which are not regulated by IC and only a subset of which is involved in membrane biogenesis. These data provide the first global response profile of yeast to IC and reveal novel regulatory mechanisms by these precursors.	Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of Connecticut; University of Connecticut	Ben Mamoun, C (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, E7041,263 Farmington Ave, Farmington, CT 06030 USA.							AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; ASHBURNER BP, 1995, MOL CELL BIOL, V15, P1709; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BARLOWE C K, 1988, Biofactors, V1, P171; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Didion T, 1998, MOL MICROBIOL, V27, P643, DOI 10.1046/j.1365-2958.1998.00714.x; Forsberg H, 2001, CURR GENET, V40, P91, DOI 10.1007/s002940100244; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; GREENBERG ML, 1982, MOL GEN GENET, V186, P157, DOI 10.1007/BF00331845; HASSLACHER M, 1993, J BIOL CHEM, V268, P10946; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOSAKA K, 1994, J BIOCHEM-TOKYO, V115, P131, DOI 10.1093/oxfordjournals.jbchem.a124287; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; Iraqui I, 1999, MOL CELL BIOL, V19, P989; Jiranek V, 1998, MICROBIOL-UK, V144, P2739, DOI 10.1099/00221287-144-10-2739; Klasson H, 1999, MOL CELL BIOL, V19, P5405; KO JS, 1994, J BACTERIOL, V176, P5181, DOI 10.1128/jb.176.16.5181-5183.1994; KODAKI T, 1991, J BACTERIOL, V173, P7992, DOI 10.1128/jb.173.24.7992-7995.1991; LAI K, 1994, J BIOL CHEM, V269, P2245; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P3987, DOI 10.1093/nar/19.14.3987; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; Murray M, 2000, MOL MICROBIOL, V36, P651, DOI 10.1046/j.1365-2958.2000.01886.x; NIKAWA J, 1991, J BIOL CHEM, V266, P11184; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; OGUR M, 1977, J BACTERIOL, V129, P926, DOI 10.1128/JB.129.2.926-933.1977; Oshiro J, 2000, J BIOL CHEM, V275, P40887, DOI 10.1074/jbc.M008144200; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P7166, DOI 10.1021/bi00189a020; Pasternack LB, 1996, ARCH BIOCHEM BIOPHYS, V326, P158, DOI 10.1006/abbi.1996.0060; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P74, DOI 10.1021/bi00167a010; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULLER HJ, 1992, NUCLEIC ACIDS RES, V20, P5955, DOI 10.1093/nar/20.22.5955; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; SCHULLER HJ, 1995, FEBS LETT, V370, P149, DOI 10.1016/0014-5793(95)00818-T; Schwank S, 1997, CURR GENET, V31, P462, DOI 10.1007/s002940050231; Shen HF, 1997, J BIOL CHEM, V272, P11215; Shen HF, 1998, J BIOL CHEM, V273, P11638, DOI 10.1074/jbc.273.19.11638; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; WHITE MJ, 1991, J BIOL CHEM, V266, P863; Wykoff DD, 2001, GENETICS, V159, P1491	47	69	71	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38723	38730		10.1074/jbc.M303008200	http://dx.doi.org/10.1074/jbc.M303008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871953	hybrid			2022-12-25	WOS:000185575100078
J	Haoudi, A; Daniels, RC; Wong, E; Kupfer, G; Semmes, OJ				Haoudi, A; Daniels, RC; Wong, E; Kupfer, G; Semmes, OJ			Human T-cell leukemia virus-I tax oncoprotein functionally targets a subnuclear complex involved in cellular DNA damage-response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATM-DEPENDENT PHOSPHORYLATION; DOUBLE-STRAND BREAKS; CHK2 PROTEIN-KINASE; TYPE-1 TAX; HTLV-I; HISTONE H2AX; GENOMIC INSTABILITY; IONIZING-RADIATION; HUMAN-LYMPHOCYTES; G2/M TRANSITION	The virally encoded oncoprotein Tax has been implicated in HTLV-1-mediated cellular transformation. The exact mechanism by which this protein contributes to the oncogenic process is not known. However, it has been hypothesized that Tax induces genomic instability via repression of cellular DNA repair. We examined the effect of de novo Tax expression upon the cell cycle, because appropriate activation of cell cycle checkpoints is essential to a robust damage-repair response. Upon induction of tax expression, Jurkat T-cells displayed a pronounced accumulation in G(2)/M that was reversible by caffeine. We examined the G(2)-specific checkpoint signaling response in these cells and found activation of the ATM/chk2-mediated pathway, whereas the ATR/chk1-mediated response was unaffected. Immunoprecipitation with anti-chk2 antibody results in co-precipitation of Tax demonstrating a direct interaction of Tax with a chk2-containing complex. We also show that Tax targets a discrete nuclear site and co-localizes with chk2 and not chk1. This nuclear site, previously identified as Tax Speckled Structures (TSS), also contains the early damage response factor 53BP1. The recruitment of 53BP1 to TSS is dependent upon ATM signaling and requires expression of Tax. Specifically, Tax expression induces redistribution of diffuse nuclear 53BP1 to the TSS foci. Taken together these data suggest that the TSS describe a unique nuclear site involved in DNA damage recognition, repair response, and cell cycle checkpoint activation. We suggest that association of Tax with this multifunctional subnuclear site results in disruption of a subset of the site-specific activities and contributes to cellular genomic instability.	Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA; Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA	Eastern Virginia Medical School; University of Virginia	Semmes, OJ (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA.		Semmes, Oliver/GQA-5179-2022					Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Chehab NH, 2000, GENE DEV, V14, P278; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elder RT, 2002, FRONT BIOSCI-LANDMRK, V7, pD349, DOI 10.2741/elder; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Fujimoto T, 1999, CANCER GENET CYTOGEN, V109, P1, DOI 10.1016/S0165-4608(98)00141-1; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Haoudi A, 2003, VIROLOGY, V305, P229, DOI 10.1006/viro.2002.1642; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KAMADA N, 1992, CANCER RES, V52, P1481; Kao SY, 2000, J BIOL CHEM, V275, P35926, DOI 10.1074/jbc.M004397200; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lemasson I, 2001, J BIOL CHEM, V276, P15720, DOI 10.1074/jbc.M100131200; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Liang MH, 2002, J VIROL, V76, P4022, DOI 10.1128/JVI.76.8.4022-4033.2002; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; MARUYAMA K, 1992, LEUKEMIA, V6, pS60; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mortreux F, 2001, J NATL CANCER I, V93, P367, DOI 10.1093/jnci/93.5.367; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Neuveut C, 2002, FRONT BIOSCI-LANDMRK, V7, pD157, DOI 10.2741/neuveut; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Ressler S, 1997, J VIROL, V71, P1181, DOI 10.1128/JVI.71.2.1181-1190.1997; Riou P, 2001, CELL GROWTH DIFFER, V12, P613; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Shieh SY, 2000, GENE DEV, V14, P289; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; Wang Y, 2000, GENE DEV, V14, P927; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	73	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37736	37744		10.1074/jbc.M301649200	http://dx.doi.org/10.1074/jbc.M301649200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12842897	hybrid			2022-12-25	WOS:000185437200091
J	Hubbard, PA; Liang, XQ; Schulz, H; Kim, JJP				Hubbard, PA; Liang, XQ; Schulz, H; Kim, JJP			The crystal structure and reaction mechanism of Escherichia coli 2,4-dienoyl-CoA reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; IRON-SULFUR FLAVOPROTEIN; OLD YELLOW ENZYME; BETA-OXIDATION; COENZYME-A; TRIMETHYLAMINE DEHYDROGENASE; GLUTATHIONE-REDUCTASE; DIFFRACTION DATA; RESOLUTION; PATHWAY	Escherichia coli 2,4-dienoyl-CoA reductase is an iron-sulfur flavoenzyme required for the metabolism of unsaturated fatty acids with double bonds at even carbon positions. The enzyme contains FMN, FAD, and a 4Fe-4S cluster and exhibits sequence homology to another iron-sulfur flavoprotein, trimethylamine dehydrogenase. It also requires NADPH as an electron source, resulting in reduction of the C4-C5 double bond of the acyl chain of the CoA thioester substrate. The structure presented here of a ternary complex of E. coli 2,4-dienoyl-CoA reductase with NADP(+) and a fatty acyl-CoA substrate reveals a possible mechanism for substrate reduction and provides details of a plausible electron transfer mechanism involving both flavins and the iron-sulfur cluster. The reaction is initiated by hydride transfer from NADPH to FAD, which in turn transfers electrons, one at a time, to FMN via the 4Fe-4S cluster. In the final stages of the reaction, the fully reduced FMN provides a hydride ion to the C5 atom of substrate, and Tyr-166 and His-252 are proposed to form a catalytic dyad that protonates the C4 atom of the substrate and complete the reaction. Inspection of the substrate binding pocket explains the relative promiscuity of the enzyme, catalyzing reduction of both 2-trans, 4-cis- and 2-trans, 4-trans- dienoyl-CoA thioesters.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; CUNY City Coll, Dept Chem, New York, NY 10031 USA; CUNY, Grad Sch, New York, NY 10031 USA	Medical College of Wisconsin; City University of New York (CUNY) System; City College of New York (CUNY); City University of New York (CUNY) System	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.				NCRR NIH HHS [RR 03060] Funding Source: Medline; NHLBI NIH HHS [HL 30847] Funding Source: Medline; NIGMS NIH HHS [GM 29076] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029076] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Brown BJ, 1998, J BIOL CHEM, V273, P32753, DOI 10.1074/jbc.273.49.32753; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P12067, DOI 10.1073/pnas.182431199; CUEBAS D, 1982, J BIOL CHEM, V257, P4140; CURRY WB, 1995, J BIOENERG BIOMEMBR, V27, P285, DOI 10.1007/BF02110098; Dobritzsch D, 2001, EMBO J, V20, P650, DOI 10.1093/emboj/20.4.650; DOMMES V, 1984, J BIOL CHEM, V259, P1781; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HE XY, 1995, BIOCHEM BIOPH RES CO, V215, P15, DOI 10.1006/bbrc.1995.2428; He XY, 1997, EUR J BIOCHEM, V248, P516, DOI 10.1111/j.1432-1033.1997.00516.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; Lancaster CRD, 2001, EUR J BIOCHEM, V268, P1820, DOI 10.1046/j.1432-1327.2001.02053.x; Levitt M, 1998, P NATL ACAD SCI USA, V95, P5913, DOI 10.1073/pnas.95.11.5913; Liang XQ, 2000, ARCH BIOCHEM BIOPHYS, V380, P373, DOI 10.1006/abbi.2000.1941; LIM LW, 1986, J BIOL CHEM, V261, P5140; MCPHERSON A, 1999, CRYSTALLIZATION BIOL, P176; Mcree D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; MIZUGAKI M, 1982, J BIOCHEM-TOKYO, V91, P1453, DOI 10.1093/oxfordjournals.jbchem.a133836; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROHLFS RJ, 1994, J BIOL CHEM, V269, P30869; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; STEINBACHER S, 2002, FLAVINS FLAVOPROTEIN, P941; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; van den Akker F, 1999, ACTA CRYSTALLOGR D, V55, P206, DOI 10.1107/S0907444998007161; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; YOU SY, 1989, J BIOL CHEM, V264, P16489	36	44	46	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37553	37560		10.1074/jbc.M304642200	http://dx.doi.org/10.1074/jbc.M304642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12840019	hybrid			2022-12-25	WOS:000185437200069
J	Kim, HS; Song, MC; Kwak, IH; Park, TJ; Lim, IK				Kim, HS; Song, MC; Kwak, IH; Park, TJ; Lim, IK			Constitutive induction of p-Erk1/2 accompanied by reduced activities of protein phosphatases 1 and 2A and MKP3 due to reactive oxygen species during cellular senescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DUAL-SPECIFICITY PHOSPHATASE; SIGNAL-REGULATED KINASE-2; RABBIT SKELETAL-MUSCLE; MAP KINASE; TYROSINE-PHOSPHATASE; HYDROGEN-PEROXIDE; REDOX REGULATION; PHOSPHORYLATION SITES; CATALYTIC SUBUNIT	The mechanism of senescence-associated cytoplasmic induction of p-Erk1/2 (SA-p-Erk1/2) proteins in human diploid fibroblasts was investigated. p-Erk1/2 proteins were efficiently dephosphorylated in vitro by protein phosphatases 1 and 2A (PP1/2A) and MAPK phosphatase 3 (MKP3). Specific activity of PP1/2A and MKP3 activity significantly decreased during cellular senescence, whereas their protein expression levels did not. To investigate possible mechanism of phosphatase inactivation, we measured reactive oxygen species (ROS) generation by fluorescence-activated cell sorting analysis and found it was much higher in mid-old cells than the young cells. Treating the young cells once with 1 mM H2O2 remarkably induced p-Erk1/2 expression; however, it was transient unless repeatedly treated until 72 h. Multiple treatment of the cells with 0.2 mM H2O2 significantly duplicated inactivation of PP1/2A; however, thiol-specific reagents could reverse the PP1/2A activities, suggesting the oxidation of cysteine molecule in PP1/2A by the increased ROS. When the cells were pretreated with 10 mM N-acetyl-L-cysteine for 1 h, Erk1/2 activation was completely blocked. To elucidate which cysteine residue and/or metal ion in PP1/2A was modified by H2O2, electrospray ionization-tandem mass spectrometry analyses were performed with purified PP1C-alpha and found Cys(62)-SO3H and Cys(105)-SO3H, implicating the tertiary structure perturbation. H2O2 inhibited purified PP1C-alpha activity by both oxidation of Cys residues and metal ion(s), evidenced by dithiothreitol and ascorbate-restoration assay. In summary, SA-p-Erk1/2 was most likely due to the oxidation of PP1/2A, which resulted from the continuous exposure of the cells to vast amounts of ROS generated during cellular senescence by oxidation of Cys(62) and Cys(105) in PP1C-alpha and metal ion(s).	Ajou Univ, Dept Biochem & Mol Biol, Sch Med, Suwon 442721, South Korea	Ajou University	Lim, IK (corresponding author), Ajou Univ, Dept Biochem & Mol Biol, Sch Med, Suwon 442721, South Korea.			Lim, In Kyoung/0000-0002-2399-607X				Abe MK, 1998, AM J RESP CELL MOL, V18, P562, DOI 10.1165/ajrcmb.18.4.2958; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Gallagher M, 1997, ANNU REV PSYCHOL, V48, P339, DOI 10.1146/annurev.psych.48.1.339; Genoux D, 2002, NATURE, V418, P970, DOI 10.1038/nature00928; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Gouveia AM, 2003, J BIOL CHEM, V278, P4389, DOI 10.1074/jbc.C200650200; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kanterewicz BI, 1998, J NEUROCHEM, V70, P1009; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Leclerc P, 1997, FREE RADICAL BIO MED, V22, P643, DOI 10.1016/S0891-5849(96)00379-6; Legakis JE, 2002, MOL BIOL CELL, V13, P4243, DOI 10.1091/mbc.E02-06-0322; Lim IK, 2000, MECH AGEING DEV, V119, P113, DOI 10.1016/S0047-6374(00)00167-6; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Macieira-Coelho A, 1975, Adv Exp Med Biol, V53, P51; Marais R, 1996, CANCER SURV, V27, P101; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; Morey M, 2001, DEV BIOL, V238, P145, DOI 10.1006/dbio.2001.0389; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muller JM, 1997, EUR J BIOCHEM, V244, P45, DOI 10.1111/j.1432-1033.1997.00045.x; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; Nishinaka T, 2001, FREE RADICAL BIO MED, V31, P205, DOI 10.1016/S0891-5849(01)00571-8; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POOLE LB, 1989, J BIOL CHEM, V264, P12330; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rao GN, 1996, ONCOGENE, V13, P713; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sommer D, 2002, ARCH BIOCHEM BIOPHYS, V404, P271, DOI 10.1016/S0003-9861(02)00242-4; START RD, 1991, INT J EXP PATHOL, V76, P647; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TAKAI A, 1995, BIOCHEM J, V306, P657, DOI 10.1042/bj3060657; TAKAI A, 1988, J MUSCLE RES CELL M, V9, P563, DOI 10.1007/BF01738761; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Trinkle-Mulcahy L, 1999, J CELL SCI, V112, P157; Vulsteke V, 1997, J BIOL CHEM, V272, P32972, DOI 10.1074/jbc.272.52.32972; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; WARA S, 1995, BIOCHEM J, V311, P17; Watson RWG, 1996, SURGERY, V120, P150; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526	69	104	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37497	37510		10.1074/jbc.M211739200	http://dx.doi.org/10.1074/jbc.M211739200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12840032	Green Published, hybrid			2022-12-25	WOS:000185437200063
J	Luo, SZ; Baumeister, P; Yang, SJ; Abcouwer, SF; Lee, AS				Luo, SZ; Baumeister, P; Yang, SJ; Abcouwer, SF; Lee, AS			Induction of Grp78/BiP by translational block - Activation of the Grp78 promoter by ATF4 through an upstream ATF/CRE site independent of the endoplasmic reticulum stress elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; GLUCOSE-REGULATED PROTEINS; NF-Y CBF; TRANSCRIPTION FACTOR; BINDING-PROTEIN; ER STRESS; CA2+ DEPLETION; CELL-SURVIVAL; MESSENGER-RNA; GENE	Mammalian cells respond to endoplasmic reticulum ( ER) stress by attenuation of protein translation mediated through the PERK-eIF2alpha pathway and transcriptional activation of genes such as Grp78/BiP encoding ER chaperone proteins. The disruption of PERK function or the blocking of eIF2alpha Ser(51) phosphorylation fails to attenuate translation after ER stress and also results in substantial impairment of Grp78/BiP induction by ER stress. While the activation of the Grp78 promoter by the ATF6 pathway through the endoplasmic reticulum stress elements (ERSEs) is well documented, the molecular mechanism linking PERK activation to Grp78 stress induction is unknown. We report here that ATF4, a transcription factor whose translation is up-regulated by the PERK-eIF2alpha pathway, can activate the Grp78 promoter independent of the ERSE. The ATF4-activating site is localized to an ATF/CRE sequence upstream of the ERSEs and is distinct from the C/EBP-ATF composite site previously identified as the ATF4 binding site in the ER stress-inducible chop promoter. In vitro translated ATF4 binding to the ATF/CRE site requires other nuclear co-factors from non-stressed cells, forming a complex that exhibits identical electrophoretic mobility as a thapsigargin-stress induced complex. Here we have identified the closely related ATF1 and CREB1 as nuclear co-factors that form in vivo complexes with endogenous ATF4. ER stress induces CREB1 phosphorylation and ATF1/CREB1 binding to the Grp78 promoter. Through the use of adenoviral vector expression systems, we provide evidence that when ATF4 function is suppressed and its binding partners are not able to compensate for its function, Grp78 induction by Tg and Tu is partially inhibited. Our studies resolve a mechanism responsible for inhibition of Grp78 mRNA induction by ER stress in cells that are functionally null for PERK or devoid of eIF2alpha phosphorylation.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90089 USA; Univ New Mexico, Sch Med, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA	University of Southern California; University of Southern California; University of New Mexico	Lee, AS (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, 1441 Eastlake Ave,Rm 5308, Los Angeles, CA 90089 USA.			Yang, Shujie/0000-0003-1753-3068; Abcouwer, Steven F/0000-0003-2580-1288; Lee, Amy/0000-0002-0378-5443	NATIONAL CANCER INSTITUTE [R37CA027607, R29CA072772, R01CA027607] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA72772, CA27607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDRE S, 1991, MOL ENDOCRINOL, V5, P1862, DOI 10.1210/mend-5-12-1862; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bleckmann SC, 2002, MOL CELL BIOL, V22, P1919, DOI 10.1128/MCB.22.6.1919-1925.2002; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Gupta P, 2002, J BIOL CHEM, V277, P50550, DOI 10.1074/jbc.M209799200; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hettmann T, 2000, DEV BIOL, V222, P110, DOI 10.1006/dbio.2000.9699; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LI WWF, 1993, J BIOL CHEM, V268, P12003; Luo S, 2002, BIOCHEM J, V366, P787, DOI 10.1042/BJ20011802; Ma YJ, 2003, J BIOL CHEM, V278, P34864, DOI 10.1074/jbc.M301107200; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Podust LM, 2001, J BIOL CHEM, V276, P505, DOI 10.1074/jbc.M005594200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Reddy RK, 2002, CANCER RES, V62, P7207; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Sambrook J., 2002, MOL CLONING LAB MANU; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	50	217	222	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37375	37385		10.1074/jbc.M303619200	http://dx.doi.org/10.1074/jbc.M303619200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871976	hybrid			2022-12-25	WOS:000185437200048
J	Martinez, LO; Agerholm-Larsen, B; Wang, N; Chen, WG; Tall, AR				Martinez, LO; Agerholm-Larsen, B; Wang, N; Chen, WG; Tall, AR			Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEIN; BINDING CASSETTE TRANSPORTER-1; CELLULAR CHOLESTEROL EFFLUX; CORONARY HEART-DISEASE; TANGIER-DISEASE; MEDIATED DEGRADATION; PLASMA-MEMBRANE; TRANSGENIC MICE; ATHEROSCLEROSIS	ATP-binding cassette transporter A1 (ABCA1), the defective molecule in Tangier disease, mediates the apoAI-dependent efflux of excess cholesterol from cells. We recently showed that ABCA1 proteolysis by calpain was dependent on a PEST sequence in the cytoplasmic region of ABCA1 and was reversed by apoA-I interaction with ABCA1. We show here that phosphorylation of ABCA1 in HEK293 cells was reduced by 63 +/- 2.4% after removal of the PEST sequence (ABCA1delPEST) or by incubation of cells with apoAI ( 58 +/- 3.3%). By contrast, ABCA1delPEST showed no further decrease of phosphorylation upon apoAI treatment. To assess the hypothesis that PEST sequence phosphorylation could regulate ABCA1 calpain proteolysis, we mutagenized S/T residues in the PEST sequence and identified Thr-1286 and Thr-1305 as constitutively phosphorylated residues. The ABCA1-T1286A/T1305A mutant was not degraded by calpain and was not further stabilized upon apoA-I treatment. The T1286A/T1305A mutant showed a 3.1-fold increase in cell surface expression and a 2.3-fold increase of apoAI-mediated cholesterol efflux compared with wild type ABCA1. In conclusion, we propose a mechanism of regulation of ABCA1 cell surface expression and function in which the interaction with apoA-I results in dephosphorylation of the ABCA1 PEST sequence and thereby inhibits calpain degradation leading to an increase of ABCA1 cell surface expression.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Martinez, LO (corresponding author), Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA.		Martinez, Laurent O./ABD-6880-2020; Martinez, Laurent O/B-8343-2015; Tall, Alan/AAT-8528-2021	Martinez, Laurent O./0000-0002-0985-3152; Martinez, Laurent O/0000-0002-0985-3152; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022682, R01HL022682] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22682] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P630, DOI 10.1161/01.ATV.0000014804.35824.DA; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Assmann G, 1999, CIRCULATION, V100, P1930, DOI 10.1161/01.CIR.100.18.1930; Beham-Schmid C, 2002, BLOOD, V99, P381, DOI 10.1182/blood.V99.1.381; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chiesa G, 1998, ARTERIOSCL THROM VAS, V18, P1417, DOI 10.1161/01.ATV.18.9.1417; DELAMATRE J, 1986, BIOCHIM BIOPHYS ACTA, V875, P419, DOI 10.1016/0005-2760(86)90061-5; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; HARA H, 1991, J BIOL CHEM, V266, P3080; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; MIYAZAKI A, 1995, ARTERIOSCL THROM VAS, V15, P1882, DOI 10.1161/01.ATV.15.11.1882; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; Singaraja RR, 2002, J CLIN INVEST, V110, P35, DOI 10.1172/JCI200215748; Sviridov D, 2002, ATHEROSCLEROSIS, V161, P245, DOI 10.1016/S0021-9150(01)00677-3; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Tall AR, 2002, J CLIN INVEST, V110, P899, DOI 10.1172/JCI200216391; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; Terasaka N, 2003, FEBS LETT, V536, P6, DOI 10.1016/S0014-5793(02)03578-0; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012; Young SG, 1999, NAT GENET, V22, P316, DOI 10.1038/11878; Zha XH, 2003, J BIOL CHEM, V278, P10002, DOI 10.1074/jbc.C300024200	37	160	164	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37368	37374		10.1074/jbc.M307161200	http://dx.doi.org/10.1074/jbc.M307161200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869555	hybrid			2022-12-25	WOS:000185437200047
J	Nanjundan, M; Sun, J; Zhao, J; Zhou, QS; Sims, PJ; Wiedmer, T				Nanjundan, M; Sun, J; Zhao, J; Zhou, QS; Sims, PJ; Wiedmer, T			Plasma membrane phospholipid scramblase 1 promotes EGF-dependent activation of c-src through the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN SHC; TRANSBILAYER MOVEMENT; PHOSPHOTYROSINE-BINDING; FAMILY; DOMAIN; CELLS; IMMORTALIZATION; PHOSPHORYLATION; PALMITOYLATION; GENE	Phospholipid scramblase (PLSCR1) is a multiply palmitoylated, calcium-binding endofacial membrane protein proposed to mediate transbilayer movement of plasma membrane phospholipids. PLSCR1 is a component of membrane lipid rafts and has been shown to both physically and functionally interact with activated epidermal growth factor (EGF) receptors and other raft-associated cell surface receptors. Cell stimulation by EGF results in Tyr phosphorylation of PLSCR1, its association with both Shc and EGF receptors, and rapid cycling of PLSCR1 between plasma membrane and endosomal compartments. We now report evidence that upon EGF stimulation, PLSCR1 is phosphorylated by c-Src, within the tandem repeat sequence (68)VYNQPVYNQP(77). The in vivo interaction between PLSCR1 and Shc requires the Src-mediated phosphorylation on tyrosines 69 and 74. In in vitro pull down studies, phosphorylated PLSCR1 was found to bind directly to Shc through the phosphotyrosine binding domain. Consistent with the potential role of PLSCR1 in growth factor signaling pathways, granulocyte precursors derived from mice deficient in PLSCR1 show impaired proliferation and maturation under cytokine stimulation. Using PLSCR1 -/- embryonic fibroblasts and kidney epithelial cells, we now demonstrate that deletion of PLSCR1 from the plasma membrane reduces the activation of c-Src by EGF, implying that PLSCR1 normally facilitates receptor-dependent activation of this kinase. We propose that PLSCR1, through its interaction with Shc, promotes Src kinase activation through the EGF receptor.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Wiedmer, T (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-275,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NHLBI NIH HHS [HL63819, HL61200, HL36946] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063819, R01HL061200, R01HL036946] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; Brabek J, 2002, BIOCHEM BIOPH RES CO, V296, P664, DOI 10.1016/S0006-291X(02)00884-7; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; Pellicena P, 2002, FRONT BIOSCI-LANDMRK, V7, pD256, DOI 10.2741/pellicen; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; ROMERO MF, 1992, KIDNEY INT, V42, P1130, DOI 10.1038/ki.1992.397; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; Sato K, 1997, FEBS LETT, V410, P136, DOI 10.1016/S0014-5793(97)00539-5; Sato K, 2000, GENES CELLS, V5, P749, DOI 10.1046/j.1365-2443.2000.00358.x; Sims PJ, 2001, THROMB HAEMOSTASIS, V86, P266; Sun J, 2002, BIOCHEMISTRY-US, V41, P6338, DOI 10.1021/bi025610l; Sun J, 2001, J BIOL CHEM, V276, P28984, DOI 10.1074/jbc.M102505200; TEVETHIA MJ, 1984, VIROLOGY, V137, P414, DOI 10.1016/0042-6822(84)90234-4; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Wiedmer T, 2000, BBA-BIOMEMBRANES, V1467, P244, DOI 10.1016/S0005-2736(00)00236-4; Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w; Woost PG, 1996, KIDNEY INT, V50, P125, DOI 10.1038/ki.1996.295; Yan KS, 2002, FEBS LETT, V513, P67, DOI 10.1016/S0014-5793(01)03305-1; Zhao J, 1998, BIOCHEMISTRY-US, V37, P6361, DOI 10.1021/bi980218m; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119; Zhou QS, 2000, BLOOD, V95, P2593, DOI 10.1182/blood.V95.8.2593.008k32_2593_2599; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	29	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37413	37418		10.1074/jbc.M306182200	http://dx.doi.org/10.1074/jbc.M306182200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871937	hybrid			2022-12-25	WOS:000185437200053
J	Valor, LM; Castillo, M; Ortiz, JA; Criado, M				Valor, LM; Castillo, M; Ortiz, JA; Criado, M			Transcriptional regulation by activation and repression elements located at the 5 '-noncoding region of the human alpha 9 nicotinic receptor subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COCHLEAR HAIR-CELLS; ACETYLCHOLINE-RECEPTOR; FUNCTIONAL-CHARACTERIZATION; 5'-UNTRANSLATED REGION; DNA-BINDING; EXPRESSION; PROMOTER; SOX10; PROTEINS; CLONING	The alpha9 subunit is a component of the neuronal nicotinic acetylcholine receptor gene superfamily that is expressed in very restricted locations. The promoter of the human gene has been analyzed in the human neuroblastoma SH-SY5Y, where alpha9 subunit expression was detected, and in C2C12 cells that do not express alpha9. A proximal promoter region ( from - 322 to + 113) showed maximal transcriptional activity in SH-SY5Y cells, whereas its activity in C1C12 cells was much lower. Two elements unusually located at the 5'-noncoding region exhibited opposite roles. A negative element located between + 15 and + 48 appears to be cell-specific because it was effective in C2C12 but not in SH-SY5Y cells, where it was counterbalanced by the presence of the promoter region 5' to the initiation site. An activating element located between + 66 and + 79 and formed by two adjacent Sox boxes increased the activity of the alpha9 promoter about 4-fold and was even able to activate other promoters. This element interacts with Sox proteins, probably through a cooperative mechanism in which the two Sox boxes are necessary. We propose that the Sox complex provides an initial scaffold that facilitates the recruiting of the transcriptional machinery responsible for alpha9 subunit expression.	Univ Miguel Hernandez, CSIC, Dept Biochem & Mol Biol, Alicante 03550, Spain; Univ Miguel Hernandez, CSIC, Inst Neurociencias, Alicante 03550, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Criado, M (corresponding author), Univ Miguel Hernandez, CSIC, Dept Biochem & Mol Biol, Alicante 03550, Spain.	Manuel.Criado@umh.es	Ortiz Salcedo, José Antonio/HHN-7691-2022; Valor, Luis/ABG-1754-2020; Criado, Manuel/K-5109-2014	Ortiz Salcedo, José Antonio/0000-0003-0505-3032; Criado, Manuel/0000-0002-3953-0346; Valor, Luis M./0000-0002-1229-0565				Andersen B, 2001, ENDOCR REV, V22, P2, DOI 10.1210/er.22.1.2; BESSIS A, 1995, NEUROSCIENCE, V69, P807, DOI 10.1016/0306-4522(95)00303-Z; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Campos-Caro A, 2001, DNA CELL BIOL, V20, P657, DOI 10.1089/104454901753340640; Carrasco-Serrano C, 1998, J BIOL CHEM, V273, P20021, DOI 10.1074/jbc.273.32.20021; Clarkson MJ, 2002, TRENDS ENDOCRIN MET, V13, P106, DOI 10.1016/S1043-2760(01)00541-0; Collignon J, 1996, DEVELOPMENT, V122, P509; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; Flora A, 2000, EUR J PHARMACOL, V393, P85, DOI 10.1016/S0014-2999(00)00040-6; Fornasari D, 1997, MOL PHARMACOL, V51, P250, DOI 10.1124/mol.51.2.250; FORNASARI KI, 1998, NEURONAL NICOTINIC R, P25; Fuchs P, 2002, AUDIOL NEURO-OTOL, V7, P40, DOI 10.1159/000046862; GARCIAGUZMAN M, 1995, EUR J NEUROSCI, V7, P647, DOI 10.1111/j.1460-9568.1995.tb00668.x; GARDNER PD, 1987, MOL BRAIN RES, V3, P69, DOI 10.1016/0169-328X(87)90046-5; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GrootKormelink PJ, 1997, FEBS LETT, V400, P309, DOI 10.1016/S0014-5793(96)01383-X; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Hernandez-Torres J, 2001, J BIOL CHEM, V276, P35405, DOI 10.1074/jbc.M104723200; Jagger DJ, 2000, J PHYSIOL-LONDON, V527, P49, DOI 10.1111/j.1469-7793.2000.t01-1-00049.x; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; Kamachi Y, 1999, MOL CELL BIOL, V19, P107; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P23033, DOI 10.1074/jbc.273.36.23033; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Liu Q, 1999, J NEUROSCI, V19, P9747; Maison SF, 2002, J NEUROSCI, V22, P10838; Nguyen VT, 2000, AM J PATHOL, V157, P1377, DOI 10.1016/S0002-9440(10)64651-2; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Peirano RI, 2000, MOL CELL BIOL, V20, P3198, DOI 10.1128/MCB.20.9.3198-3209.2000; Rivolta MN, 1998, P ROY SOC B-BIOL SCI, V265, P1595, DOI 10.1098/rspb.1998.0477; Rosenfeld MG, 2000, RECENT PROG HORM RES, V55, P1; Ryan AF, 2002, AUDIOL NEURO-OTOL, V7, P138, DOI 10.1159/000058298; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Simmons DD, 1998, MOL BRAIN RES, V56, P287, DOI 10.1016/S0169-328X(98)00056-4; Valor LM, 2002, J BIOL CHEM, V277, P8866, DOI 10.1074/jbc.M110454200; van der Stoep N, 2002, J IMMUNOL, V169, P5061, DOI 10.4049/jimmunol.169.9.5061; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Yamamoto K, 1999, J BIOL CHEM, V274, P4646, DOI 10.1074/jbc.274.8.4646	39	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37249	37255		10.1074/jbc.M307043200	http://dx.doi.org/10.1074/jbc.M307043200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12860975	hybrid			2022-12-25	WOS:000185437200033
J	Koutsoupakis, C; Soulimane, T; Varotsis, C				Koutsoupakis, C; Soulimane, T; Varotsis, C			Docking site dynamics of ba(3)-cytochrome c oxidase from Thermus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; HEME-COPPER OXIDASES; MOLECULAR-DYNAMICS; CARBON-MONOXIDE; MYOGLOBIN; COMPLEX; TEMPERATURE; POCKET; PHOTODISSOCIATION; HEMOGLOBIN	Ligand trajectories trapped within a docking site or within an internal cavity near the active site of proteins are important issues toward the elucidation of the mechanism of reaction of such complex systems, in which activity requires the shuttling of oriented ligands to and from their active site. The ligand motion within ba(3)-cytochrome c oxidase from Thermus thermophilus has been investigated by measuring time-resolved step-scan Fourier transform infrared difference spectra of photodissociated CO from heme a(3) at ambient temperature. Upon photodissociation, 15 - 20% of the CO is not covalently attached to Cu-B but is trapped within a docking site near the ring A of heme a(3) propionate. Two trajectories of CO that are distinguished spectroscopically and kinetically (nu(CO) = 2131 cm(-1), t(d) = 10 - 35 mus and nu(CO) = 2146 cm(-1), t(d) = 85 mus) are observed. At later times (t(d) = 110 mus) the docking site reorganizes about the CO and quickly establishes an energetic barrier that facilitates equilibration of the ligand with the protein solvent. The time-dependent shift of the CO trajectories we observe is attributed to a conformational motion of the docking site surrounding the ligand. The implications of these results with respect to the ability of the docking site to constrain ligand orientation and the reaction dynamics of the docking site are discussed herein.	Univ Crete, Dept Chem, Iraklion 71409, Greece; Paul Scherrer Inst, OSRA 008, CH-5232 Villigen, Switzerland	University of Crete; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Varotsis, C (corresponding author), Univ Crete, Dept Chem, Iraklion 71409, Greece.	varotsis@edu.uoc.gr		Varotsis, Constantinos/0000-0003-2771-8891				ALBEN JO, 1982, P NATL ACAD SCI-BIOL, V79, P3744, DOI 10.1073/pnas.79.12.3744; ALBEN JO, 1981, P NATL ACAD SCI-BIOL, V78, P234, DOI 10.1073/pnas.78.1.234; Anfinrud P, 1999, P NATL ACAD SCI USA, V96, P8328, DOI 10.1073/pnas.96.15.8328; ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; DYER RB, 1991, J AM CHEM SOC, V113, P6276, DOI 10.1021/ja00016a057; DYER RB, 1994, BIOCHEMISTRY-US, V33, P500, DOI 10.1021/bi00168a015; EINARSDOTTIR O, 1993, BIOCHEMISTRY-US, V32, P12013, DOI 10.1021/bi00096a011; ELBER R, 1987, SCIENCE, V235, P318, DOI 10.1126/science.3798113; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Frauenfelder H, 2001, P NATL ACAD SCI USA, V98, P2370, DOI 10.1073/pnas.041614298; Giuffre A, 1999, BIOCHEMISTRY-US, V38, P1057, DOI 10.1021/bi9815389; Giuffre A, 1999, P NATL ACAD SCI USA, V96, P14718, DOI 10.1073/pnas.96.26.14718; Koutsoupakis K, 2003, J BIOL CHEM, V278, P14893, DOI 10.1074/jbc.M210293200; Koutsoupakis K, 2002, J BIOL CHEM, V277, P32860, DOI 10.1074/jbc.M204943200; LIM M, 1995, SCIENCE, V269, P962, DOI 10.1126/science.7638619; LIM MH, 1995, J CHEM PHYS, V102, P4355, DOI 10.1063/1.469484; Lim MH, 1997, NAT STRUCT BIOL, V4, P209, DOI 10.1038/nsb0397-209; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; Pinakoulaki E, 2002, J BIOL CHEM, V277, P32867, DOI 10.1074/jbc.M205568200; Sagnella DE, 1999, P NATL ACAD SCI USA, V96, P14324, DOI 10.1073/pnas.96.25.14324; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; Stavrakis S, 2002, J AM CHEM SOC, V124, P3814, DOI 10.1021/ja0169825; WOODRUFF WH, 1993, J BIOENERG BIOMEMBR, V25, P177, DOI 10.1007/BF00762859	24	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36806	36809		10.1074/jbc.M307117200	http://dx.doi.org/10.1074/jbc.M307117200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851397	hybrid			2022-12-25	WOS:000185318300113
J	Wu, RF; Gu, Y; Xu, YC; Nwariaku, FE; Terada, LS				Wu, RF; Gu, Y; Xu, YC; Nwariaku, FE; Terada, LS			Vascular endothelial growth factor causes translocation of p47(phox) to membrane ruffles through WAVE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; SMOOTH-MUSCLE-CELLS; NADPH OXIDASE ACTIVITY; TYROSINE PHOSPHORYLATION; LIVING CELLS; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; TERMINAL KINASE; FACTOR RECEPTOR; ACTIVATION	Growth factors initiate cytoskeletal rearrangements tightly coordinated with nuclear signaling events. We hypothesized that the angiogenic growth factor, vascular endothelial growth factor ( VEGF), may utilize oxidants that are site-directed to a complex critical to both cytoskeletal and mitogenic signaling. We identified the WASP-family verprolin homologous protein-1 (WAVE1) as a binding partner for the NADPH oxidase adapter p47(phox) within membrane ruffles of VEGF-stimulated cells. Within 15 min of VEGF stimulation, p47(phox) coprecipitated with WAVE1, with the ruffle and oxidase agonist Rac1, and with the Rac1 effector PAK1. VEGF also increased p47(phox) phosphorylation, oxidant production, and ruffle formation, all of which were dependent upon PAK1 kinase activity. The antioxidant Mn(III) tetrakis( 4-benzoic acid) porphyrin and ectopic expression of either the p47-binding WAVE1 domain or the WAVE1-binding p47(phox) domain decreased VEGF-induced ruffling, whereas the active mutant p4-(S303D, S304D, S328D) stimulated oxidant production and formation of circular dorsal ruffles. Both kinase-dead PAK1-(K298A) and Mn ( III) tetrakis(4-benzoic acid) porphyrin decreased c-Jun N-terminal kinase (JNK) activation by VEGF, whereas dominant-negative JNK did not block ruffle formation, suggesting a bifurcation of mitogenic and cytoskeletal signaling events at or distal to the oxidase but proximal to JNK. Thus, WAVE1 may act as a scaffold to recruit the NADPH oxidase to a complex involved with both cytoskeletal regulation and downstream JNK activation.	Vet Adm Med Ctr, Dallas, TX 75216 USA; Univ Texas, SW Med Ctr, Dallas, TX 75216 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Terada, LS (corresponding author), Vet Adm Med Ctr, MC 151,4500 S Lancaster Rd, Dallas, TX 75216 USA.	Lance.Terada@med.va.gov		Terada, Lance/0000-0001-7441-9734	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067256, R01HL061897] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL67256, R01 HL061897, R01 HL067256, R01-HL61897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Ahern-Djamali SM, 1999, P NATL ACAD SCI USA, V96, P4977, DOI 10.1073/pnas.96.9.4977; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Bhunia AK, 2002, J BIOL CHEM, V277, P16396, DOI 10.1074/jbc.M200877200; Dahan I, 2002, J BIOL CHEM, V277, P8421, DOI 10.1074/jbc.M109778200; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; Dharmawardhane S, 2000, MOL BIOL CELL, V11, P3341, DOI 10.1091/mbc.11.10.3341; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Endo A, 2002, J BIOL CHEM, V277, P23747, DOI 10.1074/jbc.M111794200; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Gu Y, 2002, EXP CELL RES, V272, P62, DOI 10.1006/excr.2001.5404; Guinamard R, 1998, FEBS LETT, V434, P431, DOI 10.1016/S0014-5793(98)01016-3; Hahne P, 2001, FEBS LETT, V492, P215, DOI 10.1016/S0014-5793(01)02239-6; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; Heyworth PG, 1997, HISTOCHEM CELL BIOL, V108, P221, DOI 10.1007/s004180050162; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; Soderling SH, 2002, NAT CELL BIOL, V4, P970, DOI 10.1038/ncb886; Sun P, 2003, J BIOL CHEM, V278, P4063, DOI 10.1074/jbc.M208699200; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; Wu Y, 1998, J BIOL CHEM, V273, P5765, DOI 10.1074/jbc.273.10.5765; Xu YX, 2002, J BIOL CHEM, V277, P28051, DOI 10.1074/jbc.M202665200; Zhao Y, 1998, J CELL PHYSIOL, V174, P370, DOI 10.1002/(SICI)1097-4652(199803)174:3<370::AID-JCP11>3.0.CO;2-D	40	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36830	36840		10.1074/jbc.M302251200	http://dx.doi.org/10.1074/jbc.M302251200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855698	hybrid			2022-12-25	WOS:000185318300116
J	Zhang, M; Kalinec, GM; Urrutia, R; Billadeau, DD; Kalinec, F				Zhang, M; Kalinec, GM; Urrutia, R; Billadeau, DD; Kalinec, F			ROCK-dependent and ROCK-independent control of cochlear outer hair cell electromotility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG COCHLEA; MOTILITY-RELATED CHARGE; VOLTAGE-DEPENDENCE; BASILAR-MEMBRANE; MOTOR PROTEIN; GATING CHARGE; RHO; ADDUCIN; KINASE; RESPONSES	Outer hair cell electromotility is crucial for the proper function of the cochlear amplifier, the active process that enhances sensitivity and frequency discrimination of the mammalian ear. Previous work (Kalinec, F., Zhang, M., Urrutia, R., and Kalinec, G. ( 2000) J. Biol. Chem. 275, 28000 - 28005) has suggested a role for Rho GTPases in the regulation of outer hair cell electromotility, although the signaling pathways mediated by these enzymes remain to be established. Here we have investigated the cellular and molecular mechanisms underlying the homeostatic regulation of the electromotile response of guinea pig outer hair cells. Our findings defined a ROCK-mediated signaling cascade that continuously modulates outer hair cell electromotility by selectively targeting the cytoskeleton. A distinct ROCK-independent pathway functions as a fast resetting mechanism for this system. Neither pathway affects the function of prestin, the unique molecular motor of outer hair cells. These results extend our understanding of a basic mechanism of both normal human hearing and deafness, revealing the key role of the cytoskeleton in the regulation of outer hair cell electromotility and suggesting ROCK as a molecular target for modulating the function of the cochlear amplifier.	House Ear Res Inst, Gonda Dept Cell & Mol Biol, Los Angeles, CA 90057 USA; Univ So Calif, Dept Otolaryngol, Los Angeles, CA 90033 USA; Univ So Calif, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Speech Language & Hearing Sci, Lubbock, TX 79430 USA; Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Biol, Rochester, MN 55905 USA	House Research Institute; University of Southern California; University of Southern California; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Mayo Clinic; Mayo Clinic; Mayo Clinic	Kalinec, F (corresponding author), House Ear Res Inst, Gonda Dept Cell & Mol Biol, 2100 W 3rd St, Los Angeles, CA 90057 USA.				NIDCD NIH HHS [DC05220, DC05335] Funding Source: Medline; NIDDK NIH HHS [DK52913, DK56620] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056620, R56DK052913, R01DK052913] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R56DC005220, R01DC005220, R03DC005335] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Dallos P, 2002, NAT REV MOL CELL BIO, V3, P104, DOI 10.1038/nrm730; Dallos P, 1997, J NEUROSCI, V17, P2212; Frolenkov GI, 1997, BIOPHYS J, V73, P1665, DOI 10.1016/S0006-3495(97)78198-0; Frolenkov GI, 2000, J NEUROSCI, V20, P5940, DOI 10.1523/JNEUROSCI.20-16-05940.2000; Fukata Y, 1999, BIOPHYS CHEM, V82, P139, DOI 10.1016/S0301-4622(99)00113-1; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; HOLLEY MC, 1992, J CELL SCI, V102, P569; HOLLEY MC, 1996, SPR HDB AUD, V8, P386; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; KAKEHATA S, 1995, BIOPHYS J, V68, P2190, DOI 10.1016/S0006-3495(95)80401-7; KALINEC F, 1992, P NATL ACAD SCI USA, V89, P8671, DOI 10.1073/pnas.89.18.8671; Kalinec F, 2000, J BIOL CHEM, V275, P28000; Liberman MC, 2002, NATURE, V419, P300, DOI 10.1038/nature01059; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Matsuoka Y, 2000, CELL MOL LIFE SCI, V57, P884, DOI 10.1007/PL00000731; Murugasu E, 1996, J NEUROSCI, V16, P325; Murugasu E., 1995, AUDIT NEUROSCI, V1, P139; NEVES S, 2002, SCI STKE; Oliver D, 2001, SCIENCE, V292, P2340, DOI 10.1126/science.1060939; Patuzzi R., 1996, SPR HDB AUD, V8, P186; Ruggero M A, 1992, Curr Opin Neurobiol, V2, P449, DOI 10.1016/0959-4388(92)90179-O; RUSSELL IJ, 1986, HEARING RES, V22, P199, DOI 10.1016/0378-5955(86)90096-1; RUSSELL IJ, 1991, J PHYSIOL-LONDON, V435, P493, DOI 10.1113/jphysiol.1991.sp018521; RUSSELL IJ, 1992, PHILOS T ROY SOC B, V336, P317, DOI 10.1098/rstb.1992.0064; SANTOS-SACCHI J, 1991, J NEUROSCI, V11, P3096, DOI 10.1523/jneurosci.11-10-03096.1991; Santos-Sacchi J, 1998, J PHYSIOL-LONDON, V510, P225, DOI 10.1111/j.1469-7793.1998.225bz.x; Schneider ME, 2002, NATURE, V418, P837, DOI 10.1038/418837a; Takahashi S, 1999, J MEMBRANE BIOL, V169, P199, DOI 10.1007/s002329900531; Takahashi S, 2001, PFLUG ARCH EUR J PHY, V441, P506; Wu M, 1998, J MEMBRANE BIOL, V166, P111, DOI 10.1007/s002329900453; Zheng J, 2000, NATURE, V405, P149, DOI 10.1038/35012009	33	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35644	35650		10.1074/jbc.M301668200	http://dx.doi.org/10.1074/jbc.M301668200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12837763	hybrid			2022-12-25	WOS:000185164400109
J	Cheng, QC; Tikhomirov, O; Zhou, WL; Carpenter, G				Cheng, QC; Tikhomirov, O; Zhou, WL; Carpenter, G			Ectodomain cleavage of ErbB-4 - Characterization of the cleavage site and m80 fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR RECEPTOR; AMYLOID PRECURSOR PROTEIN; L-SELECTIN CD62L; INTRACELLULAR DOMAIN; TYROSINE KINASE; GAMMA-SECRETASE; STRUCTURAL REQUIREMENTS; CONVERTING-ENZYME; PROTEOLYSIS	Ectodomain cleavage of the ErbB-4 receptor tyrosine kinase generates a membrane-associated fragment of 80 kDa (m80) that has been subjected to N-terminal sequencing. The sequence obtained shows that the N terminus of this fragment begins with Ser-652 of ErbB-4. When a 12-residue peptide corresponding to ErbB-4 residues 646-657 was incubated with recombinant tumor necrosis factor-alpha-converting enzyme, fragments representing residues 646-651 and 652-657 were obtained. These data indicate that ectodomain cleavage of ErbB-4 occurs between His-651 and Ser-652, placing the cleavage site within the ectodomain stalk region approximately 8 residues prior to the transmembrane domain. Several experiments have characterized other aspects of the m80 ErbB-4 fragment. Inhibition of ErbB-4 tyrosine kinase activity with pan-ErbB tyrosine kinase inhibitors indicates that kinase activity is stringently required for heregulin-dependent, but not 12-O-tetradecanoylphorbol-13-acetate-induced, ErbB-4 ectodomain cleavage and formation of the m80 fragment. When the m80 ErbB-4 fragment is generated by cell treatment with heregulin or 12-O-tetradecanoylphorbol-13-acetate, the fragment associates with intact ErbB-2. However, this fragment does not associate with the intact ErbB-4 molecule.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.	Graham.Carpenter@mcmail.vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA097456, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [CA97456, CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; FONTINI MD, 2002, NAT REV MOL CELL BIO, V3, P673; Frears ER, 1999, NEUROREPORT, V10, P1699, DOI 10.1097/00001756-199906030-00014; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Mohan MJ, 2002, BIOCHEMISTRY-US, V41, P9462, DOI 10.1021/bi0260132; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Penuel E, 2002, J BIOL CHEM, V277, P28468, DOI 10.1074/jbc.M202510200; Penuel E, 2001, SEMIN ONCOL, V28, P36, DOI 10.1053/sonc.2001.29711; Phong MC, 2003, BIOCHEM BIOPH RES CO, V300, P563, DOI 10.1016/S0006-291X(02)02886-3; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Schlondorff J, 1999, J CELL SCI, V112, P3603; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Slichenmyer WJ, 2001, SEMIN ONCOL, V28, P80, DOI 10.1016/S0093-7754(01)90285-4; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; YI X, 2002, MOL BIOL CELL, V13, P2547; Zhao LC, 2001, J BIOL CHEM, V276, P30631, DOI 10.1074/jbc.M103748200; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200; Zhou WL, 2001, ONCOGENE, V20, P3918, DOI 10.1038/sj.onc.1204517; Zhu HJ, 2003, GROWTH FACTORS, V21, P15, DOI 10.1080/0897719031000096424	50	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38421	38427		10.1074/jbc.M302111200	http://dx.doi.org/10.1074/jbc.M302111200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12869563	hybrid			2022-12-25	WOS:000185575100042
J	Hwang, S; Tamilarasu, N; Kibler, K; Cao, H; Ali, A; Ping, YH; Jeang, KT; Rana, TM				Hwang, S; Tamilarasu, N; Kibler, K; Cao, H; Ali, A; Ping, YH; Jeang, KT; Rana, TM			Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; CELLULAR PROTEIN-KINASE; HIV-1 TAR; P-TEFB; TRANSCRIPTION-ELONGATION; IN-VITRO; GENE-EXPRESSION; TYPE-1 TAT; CYCLIN T1; RECOGNITION	Antiretroviral therapy to treat AIDS uses molecules that target the reverse transcriptase and protease enzymes of human immunodeficiency virus, type 1 (HIV-1). A major problem associated with these treatments, however, is the emergence of drug-resistant strains. Thus, there is a compelling need to find drugs against other viral targets. One such target is the interaction between Tat, an HIV-1 regulatory protein essential for viral replication, and trans-activation-responsive (TAR) RNA. Here we describe the design and synthesis of an encoded combinatorial library containing 39,304 unnatural small molecules. Using a rapid high through-put screening technology, we identified 59 compounds. Structure-activity relationship studies led to the synthesis of 19 compounds that bind TAR RNA with high affinities. In the presence of a representative Tat-TAR inhibitor (5 muM TR87), we observed potent and sustained suppression of HIV replication in cultured cells over 24 days. The same concentration of this inhibitor did not exhibit any toxicity in cell cultures or in mice. TR87 was also shown to specifically disrupt Tat-TAR binding in vitro and inhibit Tat-mediated transcriptional activation in vitro and in vivo, providing a strong correlation between its activities and inhibition of HIV-1 replication. These results provide a structural scaffold for further development of new drugs, alone or in combination with other drugs, for treatment of HIV-1-infected individuals. Our results also suggest a general strategy for discovering pharmacophores targeting RNA structures that are essential in progression of other infectious, inflammatory, and genetic diseases.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Chem Biol Program, Worcester, MA 01605 USA; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Rana, TM (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Chem Biol Program, 364 Plantat St, Worcester, MA 01605 USA.	tariq.rana@umassmed.edu	Jeang, Kuan-Teh/A-2424-2008	Ping, Yueh-Hsin/0000-0003-2604-9913	NIAID NIH HHS [AI41404, AI45466, R01 AI043198] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043198, Z01AI000547, R56AI041404, R21AI045466, R01AI045466, R01AI041404] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arzumanov A, 2001, BIOCHEMISTRY-US, V40, P14645, DOI 10.1021/bi011279e; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; CHASTAIN M, 1991, PROG NUCLEIC ACID RE, V41, P131; Chow CS, 1997, CHEM REV, V97, P1489, DOI 10.1021/cr960415w; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; Filikov AV, 2000, J COMPUT AID MOL DES, V14, P593, DOI 10.1023/A:1008121029716; Gallego J, 2001, ACCOUNTS CHEM RES, V34, P836, DOI 10.1021/ar000118k; Gelus N, 1999, BIOORGAN MED CHEM, V7, P1089, DOI 10.1016/S0968-0896(99)00041-3; Gelus N, 1999, BIOORGAN MED CHEM, V7, P1075, DOI 10.1016/S0968-0896(99)00030-9; Hamy F, 1998, BIOCHEMISTRY-US, V37, P5086, DOI 10.1021/bi972947s; Hamy F, 1997, P NATL ACAD SCI USA, V94, P3548, DOI 10.1073/pnas.94.8.3548; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Hermann T, 1998, CURR OPIN BIOTECH, V9, P66, DOI 10.1016/S0958-1669(98)80086-4; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; Huq I, 1999, BIOCHEMISTRY-US, V38, P5172, DOI 10.1021/bi982638h; Hwang S, 1999, P NATL ACAD SCI USA, V96, P12997, DOI 10.1073/pnas.96.23.12997; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Li K, 1997, BIOORGAN MED CHEM, V5, P1157; Lind KE, 2002, CHEM BIOL, V9, P185, DOI 10.1016/S1074-5521(02)00106-0; Litovchick A, 2001, BIOCHEMISTRY-US, V40, P15612, DOI 10.1021/bi0108655; MADORE SJ, 1993, J VIROL, V67, P3703, DOI 10.1128/JVI.67.7.3703-3711.1993; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Mei HY, 1997, BIOORGAN MED CHEM, V5, P1173, DOI 10.1016/S0968-0896(97)00064-3; Mei HY, 1998, BIOCHEMISTRY-US, V37, P14204, DOI 10.1021/bi981308u; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; Segal JA, 1999, BRAIN RES, V815, P270, DOI 10.1016/S0006-8993(98)01123-8; Sucheck SJ, 2000, CURR OPIN CHEM BIOL, V4, P678, DOI 10.1016/S1367-5931(00)00142-3; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Wang XL, 1997, J AM CHEM SOC, V119, P6444, DOI 10.1021/ja963895h; Yedavalli VSRK, 2003, J BIOL CHEM, V278, P6404, DOI 10.1074/jbc.M209162200; Zhang J, 2000, J BIOL CHEM, V275, P34314, DOI 10.1074/jbc.M006804200; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; ZUCKERMANN RN, 1992, J AM CHEM SOC, V114, P10646, DOI 10.1021/ja00052a076	49	69	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39092	39103		10.1074/jbc.M301749200	http://dx.doi.org/10.1074/jbc.M301749200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12857725	hybrid			2022-12-25	WOS:000185575100123
J	Burgueno, J; Blake, DJ; Benson, MA; Tinsley, CL; Esapa, CT; Canela, EI; Penela, P; Mallol, J; Mayro, F; Lluis, C; Franco, R; Ciruela, F				Burgueno, J; Blake, DJ; Benson, MA; Tinsley, CL; Esapa, CT; Canela, EI; Penela, P; Mallol, J; Mayro, F; Lluis, C; Franco, R; Ciruela, F			The adenosine A(2A) receptor interacts with the actin-binding protein alpha-actinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ACTIVATION; BETA-ARRESTINS; NMDA; CYTOSKELETON; INTERNALIZATION; CALMODULIN; LOCALIZATION; INACTIVATION; ENDOCYTOSIS; MODULATION	Recently, evidence has emerged that heptaspanning membrane or G protein-coupled receptors may be linked to intracellular proteins identified as regulators of receptor anchoring and signaling. Using a yeast two-hybrid screen, we identified alpha-actinin, a major F-actin-cross-linking protein, as a binding partner for the C-terminal domain of the adenosine A(2A) receptor (A(2A)R). Colocalization, co-immunoprecipitation, and pull-down experiments showed a close and specific interaction between A(2A)R and alpha-actinin in transfected HEK-293 cells and also in rat striatal tissue. A2AR activation by agonist induced the internalization of the receptor by a process that involved rapid beta-arrestin translocation from the cytoplasm to the cell surface. In the subsequent receptor traffic from the cell surface, the role of actin organization was shown to be crucial in transiently transfected HEK-293 cells, as actin depolymerization by cytochalasin D prevented its agonist-induced internalization. A(2A)DeltaCTR, a mutant version of A(2A)R that lacks the C-terminal domain and does not interact with alpha-actinin, was not able to internalize when activated by agonist. Interestingly, A(2A)DeltaCTR did not show aggregation or clustering after agonist stimulation, a process readily occurring with the wild-type receptor. These findings suggest an alpha-actinin-dependent association between the actin cytoskeleton and A(2A)R trafficking.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain	University of Barcelona; University of Oxford; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Ciruela, F (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, C-Marti & Franques 1, E-08028 Barcelona, Spain.	recep@bq.ub.es	Mallol, Josefa/I-4194-2015; Canela, Enric I./M-8726-2013; Franco, Rafael/C-3694-2015; Ciruela, F./A-5096-2013; Mayor, Federico/N-7644-2016; soler, martha maricel m gomez/L-6025-2014	Mallol, Josefa/0000-0002-2479-4162; Canela, Enric I./0000-0003-4992-7440; Franco, Rafael/0000-0003-2549-4919; Ciruela, F./0000-0003-0832-3739; soler, martha maricel m gomez/0000-0002-4412-8108; Benson, Matthew/0000-0003-4459-0439; Mayor Menendez, Federico/0000-0003-1434-8449				Benson MA, 2001, J BIOL CHEM, V276, P24232, DOI 10.1074/jbc.M010418200; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; Ciruela F, 1997, FEBS LETT, V418, P83, DOI 10.1016/S0014-5793(97)01353-7; Clark RAC, 1998, J NEUROCHEM, V70, P2594; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Dunah AW, 2000, MOL BRAIN RES, V79, P77, DOI 10.1016/S0169-328X(00)00102-9; Enz R, 2002, FEBS LETT, V514, P184, DOI 10.1016/S0014-5793(02)02361-X; Faulkner G, 2000, J BIOL CHEM, V275, P41234, DOI 10.1074/jbc.M007493200; Ferguson G, 2002, BIOCHEMISTRY-US, V41, P14748, DOI 10.1021/bi0262911; Ferre S, 1997, TRENDS NEUROSCI, V20, P482, DOI 10.1016/S0166-2236(97)01096-5; Ferre S, 2002, P NATL ACAD SCI USA, V99, P11940, DOI 10.1073/pnas.172393799; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; Hanley JG, 1999, NATURE, V397, P66, DOI 10.1038/16258; Hettinger BD, 2001, J COMP NEUROL, V431, P331, DOI 10.1002/1096-9861(20010312)431:3<331::AID-CNE1074>3.0.CO;2-W; Hillion J, 2002, J BIOL CHEM, V277, P18091, DOI 10.1074/jbc.M107731200; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Krupp JJ, 1999, J NEUROSCI, V19, P1165; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Lunn JA, 2000, AM J PHYSIOL-CELL PH, V279, pC2019, DOI 10.1152/ajpcell.2000.279.6.C2019; Luttrell LM, 2002, J CELL SCI, V115, P455; MARALA RB, 1993, J PHARMACOL EXP THER, V266, P294; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Mundell SJ, 2000, BIOCHEMISTRY-US, V39, P12828, DOI 10.1021/bi0010928; Munn AL, 2001, BBA-MOL BASIS DIS, V1535, P236, DOI 10.1016/S0925-4439(01)00028-X; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Penela P, 2000, EUR J BIOCHEM, V267, P4390, DOI 10.1046/j.1432-1327.2000.01484.x; Peyrollier K, 2000, BIOCHEM J, V352, P617, DOI 10.1042/0264-6021:3520617; Sebastiao AM, 1996, PROG NEUROBIOL, V48, P167, DOI 10.1016/0301-0082(95)00035-6; Sebastiao AM, 2000, TRENDS PHARMACOL SCI, V21, P341, DOI 10.1016/S0165-6147(00)01517-0; Wirkner K, 2000, BRIT J PHARMACOL, V130, P259, DOI 10.1038/sj.bjp.0703234; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	39	91	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37545	37552		10.1074/jbc.M302809200	http://dx.doi.org/10.1074/jbc.M302809200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12837758	Green Published, hybrid			2022-12-25	WOS:000185437200068
J	Ferrari, G; Rossi, R; Arosio, D; Vindigni, A; Biamonti, G; Montecucco, A				Ferrari, G; Rossi, R; Arosio, D; Vindigni, A; Biamonti, G; Montecucco, A			Cell cycle-dependent phosphorylation of human DNA ligase I at the cyclin-dependent kinase sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE ALPHA-PRIMASE; REPLICATION FACTORIES; NUCLEAR ANTIGEN; SEQUENCE; PCNA; PROTEINS; BINDING; CLONING; DIRECTS; DOMAIN	We have described previously that, during S-phase, human DNA ligase I is phosphorylated on Ser(66), a casein kinase II site. Here we investigate the phosphorylation status of DNA ligase I during the cell cycle by gel shift analysis and electrospray mass spectrometry. We show that three residues (Ser(51), Ser(76), and Ser(91)), which are part of cyclin-dependent kinase sites, are phosphorylated in a cell cycle-dependent manner. Phosphorylation of Ser(91) occurs at G(1)/S transition and depends on a cyclin binding site in the C-terminal part of the protein. This modification is required for the ensuing phosphorylation of Ser(76) detectable in G(2)/M extracts. The substitution of serines at positions 51, 66, 76, and 91 with aspartic acid to mimic the phosphorylated enzyme hampers the association of DNA ligase I with the replication foci. We suggest that the phosphorylation of DNA ligase I and possibly other replicative enzymes is part of the mechanism that directs the disassembly of the replication machinery at the completion of S-phase.	CNR, Ist Genet Mol, I-27100 Pavia, Italy; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); International Center for Genetic Engineering & Biotechnology (ICGEB)	Montecucco, A (corresponding author), CNR, Ist Genet Mol, Via Abbiategrasso 207, I-27100 Pavia, Italy.	montecucco@igm.cnr.it	arosio, daniele/B-3160-2012; Montecucco, Alessandra/B-8041-2015; Ferrari, Giovanni/F-7125-2010; Ferrari, Giovanni/A-3390-2009	Montecucco, Alessandra/0000-0002-9388-9149; BIAMONTI, GIUSEPPE/0000-0001-6804-4315; Ferrari, Giovanni/0000-0002-8863-2496				BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; Cardoso MC, 1997, J CELL BIOL, V139, P579, DOI 10.1083/jcb.139.3.579; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Dehde S, 2001, MOL CELL BIOL, V21, P2581, DOI 10.1128/MCB.21.7.2581-2593.2001; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Frouin I, 2003, EMBO REP, V4, P666, DOI 10.1038/sj.embor.embor886; Frouin I, 2002, EMBO J, V21, P2485, DOI 10.1093/emboj/21.10.2485; Henneke G, 2003, EMBO REP, V4, P252, DOI 10.1038/sj.embor.embor774; HOZAK P, 1994, J CELL SCI, V107, P2191; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Koundrioukoff S, 2000, J BIOL CHEM, V275, P22882, DOI 10.1074/jbc.M001850200; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Mackenney VJ, 1997, J BIOL CHEM, V272, P11550; Martin IV, 2002, GENOME BIOL, V3; Misteli T, 1999, CURR BIOL, V9, pR198, DOI 10.1016/S0960-9822(99)80128-6; MONTECUCCO A, 1995, EMBO J, V14, P5379, DOI 10.1002/j.1460-2075.1995.tb00222.x; Montecucco A, 2001, MOL BIOL CELL, V12, P2109, DOI 10.1091/mbc.12.7.2109; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Ott RD, 2002, MOL CELL BIOL, V22, P5669, DOI 10.1128/MCB.22.16.5669-5678.2002; PETRINI JHJ, 1995, MOL CELL BIOL, V15, P4303; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; SAVINI E, 1994, GENE, V144, P253, DOI 10.1016/0378-1119(94)90386-7; Schub O, 2001, J BIOL CHEM, V276, P38076; Stein Gary S., 1989, P133; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R	37	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37761	37767		10.1074/jbc.M304462200	http://dx.doi.org/10.1074/jbc.M304462200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12851383	hybrid			2022-12-25	WOS:000185437200094
J	He, M; Burghardt, TP; Vockley, J				He, M; Burghardt, TP; Vockley, J			A novel approach to the characterization of substrate specificity in short/branched chain Acyl-CoA dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DEHYDROGENASE; RAT-LIVER MITOCHONDRIA; CRYSTAL-STRUCTURES; MOLECULAR-CLONING; CATALYTIC RESIDUE; BETA-OXIDATION; WILD-TYPE; PURIFICATION; IDENTIFICATION; MECHANISM	Rat and human short/branched chain acyl-CoA dehydrogenases exhibit key differences in substrate specificity despite an overall amino acid identity of 85% between them. Rat short/branched chain acyl-CoA dehydrogenases ( SBCAD) are more active toward substrates with longer carbon side chains than human SBCAD, whereas the human enzyme utilizes substrates with longer primary carbon chains. The mechanism underlying this difference in substrate specificity was investigated with a novel surface plasmon resonance assay combined with absorbance and circular dichroism spectroscopy, and kinetics analysis of wild type SBCADs and mutants with altered amino acid residues in the substrate binding pocket. Results show that a relatively few amino acid residues are critical for determining the difference in substrate specificity seen between the human and rat enzymes and that alteration of these residues influences different portions of the enzyme mechanism. Molecular modeling of the SBCAD structure suggests that position 104 at the bottom of the substrate binding pocket is important in determining the length of the primary carbon chain that can be accommodated. Conformational changes caused by alteration of residues at positions 105 and 177 directly affect the rate of electron transfer in the dehydrogenation reactions, and are likely transmitted from the bottom of the substrate binding pocket to beta-sheet 3. Differences between the rat and human enzyme at positions 383, 222, and 220 alter substrate specificity without affecting substrate binding. Modeling predicts that these residues combine to determine the distance between the flavin ring of FAD and the catalytic base, without changing the opening of the substrate binding pocket.	Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Vockley, J (corresponding author), Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA.	vockley@mayo.edu	Vockley, Jerry/B-5210-2016; Vockley, Jerry/AAF-8523-2020	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054936] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR049277] Funding Source: Medline; NIDDK NIH HHS [R01 DK54936] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andresen BS, 2000, AM J HUM GENET, V67, P1095, DOI 10.1086/303105; AOYAMA T, 1995, J CLIN INVEST, V95, P2465, DOI 10.1172/JCI117947; AUER HE, 1980, J BIOL CHEM, V255, P8157; Battaile KP, 1996, BIOCHEMISTRY-US, V35, P15356, DOI 10.1021/bi961113r; BATTAILE KP, 1995, AM J HUM GENET, V57, P1001; BECKMANN JD, 1985, BIOCHEMISTRY-US, V24, P3922, DOI 10.1021/bi00336a017; BEINERT H, 1957, J BIOL CHEM, V225, P465; Bennett MJ, 2000, CRIT REV CL LAB SCI, V37, P1, DOI 10.1080/10408360091174169; Binzak B, 1998, BBA-PROTEIN STRUCT M, V1382, P137, DOI 10.1016/S0167-4838(97)00161-1; CUMMINGS JG, 1994, BIOCHEMISTRY-US, V33, P788, DOI 10.1021/bi00169a021; de Boer HA., 1986, MAXIMIZING GENE EXPR, P225; DJORDJEVIC S, 1995, BIOCHEMISTRY-US, V34, P2163, DOI 10.1021/bi00007a009; ENGEL PC, 1971, BIOCHEM J, V125, P879, DOI 10.1042/bj1250879; FINOCCHIARO G, 1988, J BIOL CHEM, V263, P15773; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; Gibson KM, 2000, PEDIATR RES, V47, P830, DOI 10.1203/00006450-200006000-00025; GOODMAN SI, 1995, HUM MOL GENET, V4, P1493; Gopalan KV, 2002, BIOCHEMISTRY-US, V41, P4638, DOI 10.1021/bi011676p; HALL CL, 1979, J BIOL CHEM, V254, P2023; IKEDA Y, 1985, BIOCHEMISTRY-US, V24, P7192, DOI 10.1021/bi00346a027; IKEDA Y, 1985, J BIOL CHEM, V260, P1326; IKEDA Y, 1983, J BIOL CHEM, V258, P1066; IKEDA Y, 1983, J BIOL CHEM, V258, P9477; IKEDA Y, 1983, J BIOL CHEM, V258, P1077; IZAI K, 1992, J BIOL CHEM, V267, P1027; JOHNSON JK, 1994, BIOCHEMISTRY-US, V33, P4738, DOI 10.1021/bi00181a033; JOHNSON JK, 1993, BIOCHEMISTRY-US, V32, P8004, DOI 10.1021/bi00082a023; Karlsson R, 2000, ANAL BIOCHEM, V278, P1, DOI 10.1006/abio.1999.4406; KARLSSON R, 1994, ANAL BIOCHEM, V221, P142, DOI 10.1006/abio.1994.1390; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HJ, 1996, BIOCHEMISTRY-US, V35, P12412, DOI 10.1021/bi9607867; MOHSEN AWA, 1995, BIOCHEMISTRY-US, V34, P10146, DOI 10.1021/bi00032a007; MOHSEN AWA, 1995, GENE, V160, P263, DOI 10.1016/0378-1119(95)00256-6; Mohsen AWA, 2001, MOL GENET METAB, V73, P126, DOI 10.1006/mgme.2001.3183; Nandy A, 1996, BIOCHEM SOC T, V24, P105, DOI 10.1042/bst0240105; Nguyen TV, 2002, BIOCHEMISTRY-US, V41, P11126, DOI 10.1021/bi026030r; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; Nishina Y, 1998, J BIOCHEM-TOKYO, V124, P200, DOI 10.1093/oxfordjournals.jbchem.a022081; Pellett JD, 2001, BIOCHEMISTRY-US, V40, P7720, DOI 10.1021/bi010206s; PETERSON KL, 1995, BIOCHEMISTRY-US, V34, P14942, DOI 10.1021/bi00045a039; Peterson KM, 2001, PROTEIN SCI, V10, P1822, DOI 10.1110/ps.51401; Peyser YM, 1997, BIOCHEMISTRY-US, V36, P5170, DOI 10.1021/bi970255y; Rodger A., 2000, SPECTROPHOTOMETRY SP, P99; ROE CR, 2001, METABOLIC MOL BASES, P2297; ROZEN R, 1994, GENOMICS, V24, P280, DOI 10.1006/geno.1994.1617; SCHOPFER LM, 1988, BIOCHEMISTRY-US, V27, P6599, DOI 10.1021/bi00417a059; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; Sweetman L., 2001, METABOLIC MOL BASES, P2125; Tamaoki H, 1999, J BIOCHEM, V125, P285, DOI 10.1093/oxfordjournals.jbchem.a022285; THORPE C, 1995, FASEB J, V9, P718, DOI 10.1096/fasebj.9.9.7601336; THORPE C, 1979, BIOCHEMISTRY-US, V18, P331, DOI 10.1021/bi00569a016; THORPE C, 1997, ACYL COA DEHYDROGENA, P597; Tiffany KA, 1997, BIOCHEMISTRY-US, V36, P8455, DOI 10.1021/bi970422u; van Aalten DMF, 2001, J MOL BIOL, V309, P181, DOI 10.1006/jmbi.2001.4749; Vockley J, 2000, METHOD ENZYMOL, V324, P241; Vockley J, 2002, CURR OPIN CLIN NUTR, V5, P601, DOI 10.1097/00075197-200211000-00002; Vockley J, 2002, NEUROMUSCULAR DISORD, V12, P235, DOI 10.1016/S0960-8966(01)00308-X; Willard J, 1996, ARCH BIOCHEM BIOPHYS, V331, P127, DOI 10.1006/abbi.1996.0290; YAO KW, 1993, ANAL BIOCHEM, V214, P528, DOI 10.1006/abio.1993.1534; Zhang J, 2002, BIOCHEM BIOPH RES CO, V297, P1033, DOI 10.1016/S0006-291X(02)02336-7	62	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37974	37986		10.1074/jbc.M306882200	http://dx.doi.org/10.1074/jbc.M306882200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855692	hybrid			2022-12-25	WOS:000185437200119
J	Paria, BC; Malik, AB; Kwiatek, AM; Rahman, A; May, MJ; Ghosh, S; Tiruppathi, C				Paria, BC; Malik, AB; Kwiatek, AM; Rahman, A; May, MJ; Ghosh, S; Tiruppathi, C			Tumor necrosis factor-alpha induces nuclear factor-kappa B-dependent TRPC1 expression in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-INDUCED INCREASE; OPERATED CATION CHANNELS; TIME-COURSE; CALCIUM; PERMEABILITY; ACTIVATION; RECEPTORS; ENTRY; GENE; HISTAMINE	We investigated the role of tumor necrosis factor-alpha (TNF-alpha) in activating the store-operated Ca2+ channels in endothelial cells via the expression of transient receptor potential channel (TRPC) isoforms. We observed that TNF-alpha exposure of human umbilical vein endothelial cells resulted in TRPC1 mRNA and protein expression, whereas it had no effect on TRPC3, TRPC4, or TRPC5 expression. The TRPC1 expression was associated with increased Ca2+ influx after intracellular Ca2+ store depletion with either thrombin or thapsigargin. We cloned the 5'-regulatory region of the human TRPC1 (hTRPC1) gene which contained a TATA box and CCAAT sequence close to the transcription initiation site. We also identified four nuclear factor-kappaB (NF-kappaB)-binding sites in the 5'-regulatory region. To address the contribution of NF-kappaB in the mechanism of TRPC1 expression, we determined the effects of TNF-alpha on expression of the reporter luciferase after transfection of hTRPC1 promoter-luciferase (hTRPC1-Pro-Luc) construct in the human dermal microvascular endothelial cell line. Reporter activity increased >4-fold at 4 h after TNF-alpha challenge. TNF-alpha-induced increase in reporter activity was markedly reduced by co-expression of either kinase-defective IKKbeta kinase mutant or non-phosphorylatable IkappaB mutant. Treatment with NEMO-binding domain peptide, which prevents NF-kappaB activation by selectively inhibiting IKKgamma interaction with IKK complex, also blocked the TNF-alpha-induced TRPC1 expression. Thus, TNF-alpha induces TRPC1 expression through an NF-kappaB-dependent pathway in endothelial cells, which can trigger augmented Ca2+ entry following Ca2+ store depletion. The augmented Ca2+ entry secondary to TRPC1 expression may be an important mechanism of endothelial injury induced by TNF-alpha.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Yale Univ, Sch Med, Immunol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Yale University; Howard Hughes Medical Institute; Yale University	Tiruppathi, C (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, M-C 868,835 S Wolcott Ave, Chicago, IL 60612 USA.	tiruc@uic.edu		May, Michael/0000-0002-2485-3716; Malik, Asrar/0000-0002-8205-7128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045638, T32HL007829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058531] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL-07829, HL45638] Funding Source: Medline; NIGMS NIH HHS [GM-58531] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerongen GPV, 1998, CIRC RES, V83, P1115, DOI 10.1161/01.RES.83.11.1115; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Ellis CA, 1999, AM J PHYSIOL-CELL PH, V276, pC38, DOI 10.1152/ajpcell.1999.276.1.C38; Fan J, 2001, AM J PHYSIOL-LUNG C, V281, pL1037, DOI 10.1152/ajplung.2001.281.5.L1037; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Freichel M, 1999, CELL PHYSIOL BIOCHEM, V9, P270, DOI 10.1159/000016321; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LIE X, 2000, J BIOL CHEM, V275, P3403; LUM H, 1992, AM J PHYSIOL, V263, pL219, DOI 10.1152/ajplung.1992.263.2.L219; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL574, DOI 10.1152/ajplung.1998.275.3.L574; Moy AB, 1996, J CLIN INVEST, V97, P1020, DOI 10.1172/JCI118493; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; PARIA BC, 2002, FASEB J, V16; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906; Sandoval R, 2001, AM J PHYSIOL-LUNG C, V280, pL239, DOI 10.1152/ajplung.2001.280.2.L239; Sandoval R, 2001, J PHYSIOL-LONDON, V533, P433, DOI 10.1111/j.1469-7793.2001.0433a.x; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; Tiruppathi C, 2001, AM J PHYSIOL-LUNG C, V281, pL958, DOI 10.1152/ajplung.2001.281.4.L958; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7; Vanhauwe JF, 2002, J BIOL CHEM, V277, P34143, DOI 10.1074/jbc.M204477200; Vogel SM, 2000, PHYSIOL GENOMICS, V4, P137, DOI 10.1152/physiolgenomics.2000.4.2.137; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	35	74	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37195	37203		10.1074/jbc.M304287200	http://dx.doi.org/10.1074/jbc.M304287200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855710	hybrid			2022-12-25	WOS:000185437200027
J	Yago, T; Leppanen, A; Carlyon, JA; Akkoyunlu, M; Karmakar, S; Fikrig, E; Cummings, RD; McEver, RP				Yago, T; Leppanen, A; Carlyon, JA; Akkoyunlu, M; Karmakar, S; Fikrig, E; Cummings, RD; McEver, RP			Structurally distinct requirements for binding of P-selectin glycoprotein ligand-1 and sialyl Lewis x to Anaplasma phagocytophilum and P-selectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GRANULOCYTIC EHRLICHIOSIS; TICK-BORNE INFECTIONS; N-TERMINAL RESIDUES; LINKED OLIGOSACCHARIDES; LEUKOCYTE RECRUITMENT; TYROSINE SULFATION; HUMAN NEUTROPHILS; AMINO-TERMINUS; UNITED-STATES; MYELOID CELLS	Colonization of neutrophils by the bacterium Anaplasma phagocytophilum causes the disease human granulocytic ehrlichiosis. The pathogen also infects mice, its natural host. Like binding of P-selectin, binding of A. phagocytophilum to human neutrophils requires expression of P-selectin glycoprotein ligand-1 (PSGL-1) and alpha1-3-fucosyltransferases that construct the glycan determinant sialyl Lewis x (sLe(x)). Binding of A. phagocytophilum to murine neutrophils, however, requires expression of alpha1-3-fucosyltransferases but not PSGL-1. To further characterize the molecular features that A. phagocytophilum recognizes, we measured bacterial binding to microspheres bearing specific glycoconjugates or to cells expressing human PSGL-1 and particular glycosyltransferases. Like P-selectin, A. phagocytophilum bound to purified human PSGL-1 and to glycopeptides modeled after the N terminus of human PSGL-1 that presented sLex on an O-glycan. Unlike P-selectin, A. phagocytophilum bound to glycopeptides that contained sLe(x) but lacked tyrosine sulfation or a specific core-2 orientation of sLe(x) on the O-glycan. A. phagocytophilum bound only to glycopeptides that contained a short amino acid sequence found in the N-terminal region of human but not murine PSGL-1. Unlike P-selectin, A. phagocytophilum bound to cells expressing PSGL-1 in cooperation with sLe(x) on both N- and O-glycans. Moreover, bacteria bound to microspheres coupled independently with glycopeptide lacking sLe(x) and with sLex lacking peptide. These results demonstrate that, unlike P-selectin, A. phagocytophilum binds cooperatively to a nonsulfated N- terminal peptide in human PSGL-1 and to sLe(x) expressed on PSGL-1 or other glycoproteins. Distinct bacterial adhesins may mediate these cooperative interactions.	Univ Oklahoma, Cardiovasc Biol Res Program, Hlth Sci Ctr, Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Yale Univ, Sch Med, Dept Internal Med, Rheumatol Sect, New Haven, CT 06520 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Yale University	McEver, RP (corresponding author), Univ Oklahoma, Cardiovasc Biol Res Program, Hlth Sci Ctr, Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA.		Akkoyunlu, Mustafa/I-5712-2012; Akkoyunlu, Mustafa/ABC-9013-2020	Akkoyunlu, Mustafa/0000-0001-9958-4031	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041440, R01AI048075, R21AI054630, R21AI041440, F32AI010554, R56AI041440] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 65631] Funding Source: Medline; NIAID NIH HHS [AI 041440, AI 054630, AI 48075, AI 10554] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AgueroRosenfeld ME, 1996, ANN INTERN MED, V125, P904, DOI 10.7326/0003-4819-125-11-199612010-00006; Akkoyunlu M, 2000, INFECT IMMUN, V68, P1827, DOI 10.1128/IAI.68.4.1827-1833.2000; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; Brunk DK, 1997, BIOPHYS J, V72, P2820, DOI 10.1016/S0006-3495(97)78924-0; CARLYON JA, 2003, IN PRESS BLOOD; CHEN SM, 1994, AM J TROP MED HYG, V50, P52, DOI 10.4269/ajtmh.1994.50.1.TM0500010052; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DUMLER JS, 1995, CLIN INFECT DIS, V20, P1102, DOI 10.1093/clinids/20.5.1102; Dumler JS, 2001, INT J SYST EVOL MICR, V51, P2145, DOI 10.1099/00207713-51-6-2145; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; Frenette PS, 2000, J EXP MED, V191, P1413, DOI 10.1084/jem.191.8.1413; Goodman JL, 1999, J CLIN INVEST, V103, P407, DOI 10.1172/JCI4230; HARDALO CJ, 1995, CLIN INFECT DIS, V21, P910, DOI 10.1093/clinids/21.4.910; Herron MJ, 2000, SCIENCE, V288, P1653, DOI 10.1126/science.288.5471.1653; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; HUANG J, 1992, ONCOL RES, V4, P507; Leppanen A, 2002, J BIOL CHEM, V277, P39749, DOI 10.1074/jbc.M206281200; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; Magnarelli LA, 1999, J WILDLIFE DIS, V35, P259, DOI 10.7589/0090-3558-35.2.259; Magnarelli LA, 1997, J WILDLIFE DIS, V33, P466, DOI 10.7589/0090-3558-33.3.466; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Ravyn MD, 2001, J CLIN MICROBIOL, V39, P335, DOI 10.1128/JCM.39.1.335-338.2001; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Walcheck B, 2002, BLOOD, V99, P4063, DOI 10.1182/blood-2001-12-0265; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Walker DH, 1997, ARCH PATHOL LAB MED, V121, P785; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Xia LJ, 2003, BLOOD, V101, P552, DOI 10.1182/blood-2001-11-0036; Yago T, 2002, J CELL BIOL, V158, P787, DOI 10.1083/jcb.200204041; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	51	41	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37987	37997		10.1074/jbc.M305778200	http://dx.doi.org/10.1074/jbc.M305778200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12847092	hybrid			2022-12-25	WOS:000185437200120
J	Avraham, HK; Lee, TH; Koh, YH; Kim, TA; Jiang, SX; Sussman, M; Samarel, AM; Avraham, S				Avraham, HK; Lee, TH; Koh, YH; Kim, TA; Jiang, SX; Sussman, M; Samarel, AM; Avraham, S			Vascular endothelial growth factor regulates focal adhesion assembly in human brain microvascular endothelial cells through activation of the focal adhesion kinase and related adhesion focal tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TRANSENDOTHELIAL MIGRATION; PROTEIN; PHOSPHORYLATION; EXPRESSION; INTEGRIN; ANGIOGENESIS; PERMEABILITY; RECEPTOR; FAK	Vascular endothelial growth factor ( VEGF) plays a significant role in blood-brain barrier breakdown and angiogenesis after brain injury. VEGF-induced endothelial cell migration is a key step in the angiogenic response and is mediated by an accelerated rate of focal adhesion complex assembly and disassembly. In this study, we identified the signaling mechanisms by which VEGF regulates human brain microvascular endothelial cell (HBMEC) integrity and assembly of focal adhesions, complexes comprised of scaffolding and signaling proteins organized by adhesion to the extracellular matrix. We found that VEGF treatment of HBMECs plated on laminin or fibronectin stimulated cytoskeletal organization and increased focal adhesion sites. Pretreating cells with VEGF antibodies or with the specific inhibitor SU-1498, which inhibits Flk-1/KDR receptor phosphorylation, blocked the ability of VEGF to stimulate focal adhesion assembly. VEGF induced the coupling of focal adhesion kinase (FAK) to integrin alpha(v)beta(5) and tyrosine phosphorylation of the cytoskeletal components paxillin and p130(cas). Additionally, FAK and related adhesion focal tyrosine kinase (RAFTK)/Pyk2 kinases were tyrosine-phosphorylated by VEGF and found to be important for focal adhesion sites. Overexpression of wild type RAFTK/Pyk2 increased cell spreading and the migration of HBMECs, whereas overexpression of catalytically inactive mutant RAFTK/Pyk2 markedly suppressed HBMEC spreading (similar to70%), adhesion (similar to82%), and migration (similar to65%). Furthermore, blocking of FAK by the dominant-interfering mutant FRNK (FAK-related non-kinase) significantly inhibited HBMEC spreading and migration and also disrupted focal adhesions. Thus, these studies define a mechanism for the regulatory role of VEGF in focal adhesion complex assembly in HBMECs via activation of FAK and RAFTK/Pyk2.	Beth Israel Deaconess Med Ctr, Dept Med, Div Expt Med & Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Hosp & Res Fdn, Div Mol Cardiovasc Biol, Cincinnati, OH 45249 USA; Loyola Univ, Stritch Sch Med, Cardiovasc Inst, Chicago, IL 60601 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Loyola University Chicago	Avraham, S (corresponding author), Beth Israel Deaconess Med Ctr, Harvard Inst Med, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	savraham@bidmc.harvard.edu	Samarel, Allen/Q-9810-2019; Sussman, Mark/H-2284-2014	Samarel, Allen/0000-0001-8765-9884; Avraham, Hava/0000-0002-7545-3640; Sussman, Mark/0000-0002-0104-4799	NCI NIH HHS [CA096805, CA76226] Funding Source: Medline; NHLBI NIH HHS [HL51456] Funding Source: Medline; NINDS NIH HHS [NS39558] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076226, R01CA096805] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039558] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Avraham H, 1999, METHODS, V17, P250, DOI 10.1006/meth.1998.0735; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Broday DM, 2000, B MATH BIOL, V62, P891, DOI 10.1006/bulm.2000.0183; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DeVries HE, 1997, PHARMACOL REV, V49, P143; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Esser S, 1998, J CELL SCI, V111, P1853; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GIRARD PR, 1995, J CELL PHYSIOL, V163, P179, DOI 10.1002/jcp.1041630121; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; Govindarajan G, 2000, CIRC RES, V87, P710, DOI 10.1161/01.RES.87.8.710; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Heidkamp MC, 2002, CIRC RES, V90, P1282, DOI 10.1161/01.RES.0000023201.41774.EA; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; ILLC D, 1995, NATURE, V377, P539; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Lee TH, 2003, J BIOL CHEM, V278, P5277, DOI 10.1074/jbc.M210063200; Lee TH, 2002, J BIOL CHEM, V277, P10445, DOI 10.1074/jbc.M107348200; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Melendez J, 2002, J BIOL CHEM, V277, P45203, DOI 10.1074/jbc.M204886200; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Park SY, 2000, J BIOL CHEM, V275, P19768, DOI 10.1074/jbc.M909932199; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PEER J, 1995, LAB INVEST, V72, P638; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Raja S, 1997, J BIOL CHEM, V272, P10941; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Shono T, 2001, EXP CELL RES, V264, P275, DOI 10.1006/excr.2001.5154; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Sorokin A, 2001, J BIOL CHEM, V276, P21521, DOI 10.1074/jbc.M008869200; Stoletov KV, 2001, J BIOL CHEM, V276, P22748, DOI 10.1074/jbc.M009720200; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Yang ZJ, 2002, J NEUROSCI RES, V70, P140, DOI 10.1002/jnr.10380; Yoshiji H, 1996, CANCER RES, V56, P2013	63	121	130	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36661	36668		10.1074/jbc.M301253200	http://dx.doi.org/10.1074/jbc.M301253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12844492	hybrid			2022-12-25	WOS:000185318300097
J	Jacobs, FMJ; van der Heide, LP; Wijchers, PJEC; Burbach, JPH; Hoekman, MFM; Smidt, MP				Jacobs, FMJ; van der Heide, LP; Wijchers, PJEC; Burbach, JPH; Hoekman, MFM; Smidt, MP			FoxO6, a novel member of the FoxO class of transcription factors with distinct shuttling dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION SITES; ENDOPIRIFORM NUCLEUS; FORKHEAD; FKHR; GENE; CONNECTIONS; INSULIN; PAX3	Forkhead transcription factors of the FoxO-group are associated with cellular processes like cell cycle progression and DNA-repair. FoxO function is regulated by protein kinase B (PKB) via the phosphatidylinositol 3-kinase/PKB survival pathway. Phosphorylation of serine and threonine residues in specific PKB phosphorylation motifs leads to exclusion of FoxO-proteins from the nucleus, which excludes them from exerting transactivating activity. Members of the FoxO-group have three highly conserved regions containing a PKB phosphorylation motif. This study describes the cloning and characterization of a novel forkhead domain gene from mouse that appeared to be highly related to the FoxO group of transcription factors and was therefore designated FoxO6. The FoxO6 gene was mapped in region D1 on mouse chromosome 4. In humans, FOXO6 is located on chromosomal region 1p34.1. Embryonic expression of FoxO6 is most apparent in the developing brain, and FoxO6 is expressed in a specific temporal and spatial pattern. Therefore it is probably involved in regulation of specific cellular differentiation. In the adult animal FoxO6 expression is maintained in areas of the nucleus accumbens, cingulate cortex, parts of the amygdala, and in the hippocampus. Structure function analysis of FoxO6 compared with its group members shows that the overall homology is high, but surprisingly a highly conserved region containing multiple phosphorylation sites is lacking. In transfection studies, FoxO6 coupled to GFP showed an unexpected high nuclear localization after stimulation with growth factors, in contrast to the predominant cytosolic localization of FoxO1 and FoxO3. We also show that nuclear export of FoxO6 is mediated through the phosphatidylinositol 3-kinase/PKB pathway. Furthermore, we show using a chimeric approach that we can fully restore the ability of FoxO6 to shuttle between nucleus and cytosol. In conclusion, the data presented here gives a new view on regulation of FoxO-function through multiple phosphorylation events and other mechanisms involved in the nuclear exclusion of FoxO-proteins.	Univ Med Ctr, Rudolf Magnus Inst Neurosci, Dept Pharmacol & Anat, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Smidt, MP (corresponding author), Univ Utrecht, Med Ctr, Rudolf Magnus Inst Neurosci, Dept Pharmacol & Anat, POB 85060, NL-3508 TA Utrecht, Netherlands.	m.p.smidt@med.uu.nl	Jacobs, Frank/GSD-3616-2022; Jacobs, Frank/O-1809-2014	Jacobs, Frank/0000-0003-4423-1479; Smidt, Marten/0000-0002-8815-747X; van der Heide, Lars P./0000-0003-1779-425X				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Behan M, 1999, J COMP NEUROL, V408, P532; Beneyto M, 2001, BRAIN RES BULL, V54, P485, DOI 10.1016/S0361-9230(00)00454-8; Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; DAVIS RJ, 1995, HUM MOL GENET, V4, P2355, DOI 10.1093/hmg/4.12.2355; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; So CW, 2003, BLOOD, V101, P633, DOI 10.1182/blood-2002-06-1785; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200	25	260	277	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35959	35967		10.1074/jbc.M302804200	http://dx.doi.org/10.1074/jbc.M302804200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857750	hybrid			2022-12-25	WOS:000185318300013
J	Kojima, H; Kanada, H; Shimizu, S; Kasama, E; Shibuya, K; Nakauchi, H; Nagasawa, T; Shibuya, A				Kojima, H; Kanada, H; Shimizu, S; Kasama, E; Shibuya, K; Nakauchi, H; Nagasawa, T; Shibuya, A			CD226 mediates platelet and megakaryocytic cell adhesion to vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL ASSOCIATION; PROPLATELET FORMATION; ACTIVATED PLATELETS; FORMATION INVITRO; IN-VIVO; INTEGRIN; ESTABLISHMENT; AGGREGATION; FIBRINOGEN; MECHANISM	Platelet adhesion to vascular endothelial cells is a pathophysiologically relevant cell-to-cell interaction. However, the mechanisms underlying this cellular interaction are incompletely understood. In search of the ligand for CD226 adhesion molecule expressed on platelets, we found that human umbilical vein endothelial cells (HUVEC) express significant amount of putative CD226 ligand. We demonstrated that thrombin-activated, but not resting, platelets bind to intact HUVEC. Anti-CD226 monoclonal antibody specifically inhibited the binding, indicating that CD226 mediates the intercellular binding between thrombin-activated platelets and HUVEC. We also demonstrated that platelet activation with thrombin induces tyrosine phosphorylation of CD226 as well as CD226-mediated platelet adhesion. Moreover, experiments using mutant transfectants suggested that the tyrosine at residue 322 of CD226 plays an important role for its adhesive function. CD226 was also expressed on primary megakaryocytes and megakaryocytic cell lines. Anti-CD226 monoclonal antibody inhibited binding of megakaryocytic cell lines to HUVEC. Taken together, these results reveal a novel mechanism for adhesion of platelets and megakaryocytic cells to vascular endothelial cells.	Univ Tsukuba, Inst Clin Med, Div Hematol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Basic Med Sci, Dept Immunol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Japan Sci & Technol Corp, CREST, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Japan Sci & Technol Corp, PRESTO, Tsukuba, Ibaraki 3058575, Japan; RIKEN, Res Ctr Allergy & Immunol, Lab Immune Receptor, Tsukuba, Ibaraki 3050074, Japan	University of Tsukuba; University of Tsukuba; Japan Science & Technology Agency (JST); University of Tsukuba; Japan Science & Technology Agency (JST); University of Tsukuba; RIKEN	Kojima, H (corresponding author), Univ Tsukuba, Inst Clin Med, Div Hematol, Tsukuba, Ibaraki 3058575, Japan.	hkojima@md.tsukuba.ac.jp						AVRAHAM H, 1993, J CLIN INVEST, V91, P2378, DOI 10.1172/JCI116470; Bombeli T, 1999, BLOOD, V93, P3831, DOI 10.1182/blood.V93.11.3831; Bombeli T, 1998, J EXP MED, V187, P329, DOI 10.1084/jem.187.3.329; ELDOR A, 1989, METHOD ENZYMOL, V169, P76; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Frenette PS, 1998, BLOOD, V91, P1318, DOI 10.1182/blood.V91.4.1318; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; Hamada T, 1998, J EXP MED, V188, P539, DOI 10.1084/jem.188.3.539; Hamazaki Y, 1998, ONCOGENE, V16, P2773, DOI 10.1038/sj.onc.1201799; HARKER LA, 1969, J CLIN INVEST, V48, P963, DOI 10.1172/JCI106077; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; KAUFMAN RM, 1965, BLOOD-J HEMATOL, V26, P720, DOI 10.1182/blood.V26.6.720.720; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kojima H, 1995, THROMB HAEMOSTASIS, V74, P1541; Komatsu N, 1996, BLOOD, V87, P4552, DOI 10.1182/blood.V87.11.4552.bloodjournal87114552; LANIER LL, 2000, PROTEIN REV WEB, V1, P68; LEVEN RM, 1995, J CELL PHYSIOL, V163, P597, DOI 10.1002/jcp.1041630321; LEVEN RM, 1992, EXP HEMATOL, V20, P1316; Li JM, 1996, J SURG RES, V61, P543, DOI 10.1006/jsre.1996.0161; Massberg S, 1999, BLOOD, V94, P3829, DOI 10.1182/blood.V94.11.3829.423k35_3829_3838; Massberg S, 1998, BLOOD, V92, P507, DOI 10.1182/blood.V92.2.507; Onishi M, 1996, EXP HEMATOL, V24, P324; Rosenblum WI, 1996, STROKE, V27, P709, DOI 10.1161/01.STR.27.4.709; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SCOTT JL, 1989, J BIOL CHEM, V264, P13475; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Shibuya A, 1998, J IMMUNOL, V161, P1671; Shibuya K, 1999, IMMUNITY, V11, P615, DOI 10.1016/S1074-7613(00)80136-3; TABLIN F, 1990, J CELL SCI, V97, P59; TROWBRIDGE EA, 1984, CLIN PHYS PHYSIOL M, V5, P145, DOI 10.1088/0143-0815/5/3/007	31	77	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36748	36753		10.1074/jbc.M300702200	http://dx.doi.org/10.1074/jbc.M300702200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847109	hybrid			2022-12-25	WOS:000185318300107
J	Zimmermann, J; Kuhne, R; Volkmer-Engert, R; Jarchau, T; Walter, U; Oschkinat, H; Ball, LJ				Zimmermann, J; Kuhne, R; Volkmer-Engert, R; Jarchau, T; Walter, U; Oschkinat, H; Ball, LJ			Design of N-substituted peptomer ligands for EVH1 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; ACTIN-BASED MOTILITY; PROLINE-RICH MOTIFS; LISTERIA-MONOCYTOGENES; SPOT-SYNTHESIS; CELLULOSE MEMBRANES; FOCAL-ADHESION; AXON GUIDANCE; PROTEINS; ENA/VASP	Ena/VASP proteins are implicated in cytoskeletal reorganization during actin-dependent motility processes. Recruitment to subcellular sites of actin polymerization is mediated by the highly conserved N-terminal EVH1 domain, which interacts with target proteins containing proline-rich motifs. The VASP EVH1 domain specifically binds peptides with the consensus motif FPPPP present in all its binding partners, including the Listerial ActA protein. Previous studies have shown that the Phe and first and final Pro residues are highly conserved and cannot be substituted with any other natural amino acid without significant loss of binding affinity. We have incorporated peptoid building blocks ( sarcosine derived, non-natural amino acids) into the peptide SFEFPPPPTEDEL from the Listerial ActA protein and were able to substitute the most highly conserved residues of this motif while maintaining binding to the VASP EVH1 domain with affinities in the range of 45-180 muM. We then used NMR chemical shift perturbations to locate specific domain residues involved in particular interactions. These studies may open up the way for designing selective modulators of VASP function for biological studies and for the development of novel therapeutics for diseases involving pathologically altered cell adhesion or cell motility.	Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany; Humboldt Univ, Univ Klinikum Charite, Inst Med Immunol, D-10098 Berlin, Germany; Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, D-97078 Wurzburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg	Ball, LJ (corresponding author), Forschungsinst Mol Pharmakol, Robert Rossle Str 10, D-13125 Berlin, Germany.	ball@fmp-berlin.de	Walter, ulrich/W-2478-2017; Ball, Linda J/E-8454-2011	Walter, ulrich/0000-0001-6784-2307; Ball, Linda J/0000-0002-0948-6954; Oschkinat, Hartmut/0000-0002-4384-9544; Volkmer, Rudolf/0000-0003-4710-1143				Ast T, 1999, TETRAHEDRON LETT, V40, P4317, DOI 10.1016/S0040-4039(99)00775-3; Ball LJ, 2000, EMBO J, V19, P4903, DOI 10.1093/emboj/19.18.4903; Ball LJ, 2002, FEBS LETT, V513, P45, DOI 10.1016/S0014-5793(01)03291-4; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; Cameron LA, 2000, NAT REV MOL CELL BIO, V1, P110, DOI 10.1038/35040061; CASE DA, 1997, AMBER 5; Cramer LP, 2002, CURR BIOL, V12, pR417, DOI 10.1016/S0960-9822(02)00912-0; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Hajduk PJ, 1997, J MED CHEM, V40, P3144, DOI 10.1021/jm9703404; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; Hoffman LM, 2003, MOL CELL BIOL, V23, P70, DOI 10.1128/MCB.23.1.70-79.2003; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Klostermann A, 2000, J BIOL CHEM, V275, P39647, DOI 10.1074/jbc.M006316200; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; Kramer A, 1998, METH MOL B, V87, P25; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; Krause M, 2002, J CELL SCI, V115, P4721, DOI 10.1242/jcs.00218; Kuruvilla FG, 2002, NATURE, V416, P653, DOI 10.1038/416653a; Machner MP, 2001, J BIOL CHEM, V276, P40096, DOI 10.1074/jbc.M104279200; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Nguyen JT, 2000, CHEM BIOL, V7, P463, DOI 10.1016/S1074-5521(00)00130-7; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Pornillos O, 2002, NAT STRUCT BIOL, V9, P812, DOI 10.1038/nsb856; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Reinhard M, 1996, FEBS LETT, V399, P103, DOI 10.1016/S0014-5793(96)01295-1; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Renfranz PJ, 2002, CURR OPIN CELL BIOL, V14, P88, DOI 10.1016/S0955-0674(01)00299-X; Shogren-Knaak MA, 2001, ANNU REV CELL DEV BI, V17, P405, DOI 10.1146/annurev.cellbio.17.1.405; VolkmerEngert R, 1997, TETRAHEDRON LETT, V38, P1029, DOI 10.1016/S0040-4039(96)02508-7; Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; Yu TW, 2002, NAT NEUROSCI, V5, P1147, DOI 10.1038/nn956	42	15	21	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36810	36818		10.1074/jbc.M305934200	http://dx.doi.org/10.1074/jbc.M305934200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857736	hybrid			2022-12-25	WOS:000185318300114
J	Chou, MM; Masuda-Robens, JM; Gupta, ML				Chou, MM; Masuda-Robens, JM; Gupta, ML			Cdc42 promotes G(1) progression through p70 S6 kinase-mediated induction of cyclin E expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RHO-FAMILY GTPASES; CELL-CYCLE; RETINOBLASTOMA PROTEIN; ACTIN POLYMERIZATION; DEPENDENT KINASES; PHASE-TRANSITION; MAMMALIAN-CELLS; GROWTH; PHOSPHORYLATION	The Rho family GTPase Cdc42 is recognized for its role in cellular proliferation and transformation. However, the mechanism by which it promotes cell cycle progression has remained undefined. Using an inducible expression system, we show that constitutively active Cdc42 (Cdc42V12) is sufficient by itself to induce anchorage-independent but not mitogen-independent growth in NIH3T3 cells. However, Cdc42V12 markedly accelerates activation of cyclin E-Cdk2 in response to mitogen. These effects were highly specific, as the kinetics of cyclin D-Cdk4 activation was unaltered. Cdc42V12 promotes Cdk2 activation by selectively inducing cyclin E expression without affecting other regulatory proteins such as the p27 Cdk inhibitor or Cdc25A. Furthermore, Cdc42V12 was able to activate a reporter gene driven by the cyclin E promoter in the absence of exogenous mitogen or adhesion. Cyclin E induction was sensitive to rapamycin but not inhibitors of mitogen-activated protein kinases, implicating p70 S6 kinase (p70S6k) as the relevant mediator. Consistent with this notion, wild type and constitutively active alleles of p70S6k were sufficient to activate the cyclin E promoter. In sum, these studies provide novel insights into the mechanism by which Cdc42 promotes G(1) progression.	Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Chou, MM (corresponding author), Univ Penn, Sch Med, Dept Cell & Dev Biol, 421 Curie Blvd,Bldg BRB2-3,Rm 1011, Philadelphia, PA 19104 USA.		Robens, Jeffrey/K-4621-2019	Robens, Jeffrey/0000-0003-2344-0036	NATIONAL CANCER INSTITUTE [R01CA081415] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA81415-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERS MW, 1993, J BIOL CHEM, V268, P22825; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Erickson JW, 2001, CURR OPIN CELL BIOL, V13, P153, DOI 10.1016/S0955-0674(00)00192-7; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Grewe M, 1999, CANCER RES, V59, P3581; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hirai A, 1997, J BIOL CHEM, V272, P13; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo Y, 1996, MOL CELL BIOL, V16, P6744; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MORICE WG, 1993, J BIOL CHEM, V268, P3734; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; PESTOV DG, 1994, P NATL ACAD SCI USA, V91, P12549, DOI 10.1073/pnas.91.26.12549; Philip A, 2000, J BIOL CHEM, V275, P5911, DOI 10.1074/jbc.275.8.5911; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Schwartz MA, 2001, J CELL SCI, V114, P2553; Seasholtz TM, 2001, CIRC RES, V89, P488, DOI 10.1161/hh1801.096337; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Takenawa T, 2001, J CELL SCI, V114, P1801; VAN AL, 1997, GENE DEV, V11, P2295; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WIMMEL A, 1994, ONCOGENE, V9, P995; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	65	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35241	35247		10.1074/jbc.M305246200	http://dx.doi.org/10.1074/jbc.M305246200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842876	hybrid			2022-12-25	WOS:000185164400061
J	Gallego, J; Greatorex, J; Zhang, H; Yang, B; Arunachalam, S; Fang, JH; Seamons, J; Lea, S; Pomerantz, RJ; Lever, AML				Gallego, J; Greatorex, J; Zhang, H; Yang, B; Arunachalam, S; Fang, JH; Seamons, J; Lea, S; Pomerantz, RJ; Lever, AML			Rev binds specifically to a purine loop in the SL1 region of the HIV-1 leader RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 PACKAGING SIGNAL; NUCLEOCAPSID PROTEIN; STEM-LOOP; SECONDARY STRUCTURE; GENOME RECOGNITION; RESPONSIVE ELEMENT; NMR STRUCTURE; ENCAPSIDATION; DIMERIZATION	The leader RNA sequence of human immunodeficiency virus type 1 (HIV-1) consists of a complex series of stem loop structures that are critical for viral replication. Three-dimensional structural analysis by NMR of one of these structures, the SL1 stem loop of the packaging signal region, revealed a highly conserved purine rich loop with a structure nearly identical to the Rev-binding loop of the Rev response element. Using band-shift assays, surface plasmon resonance, and further NMR analysis, we demonstrate that this loop binds Rev. HIV-1 appears to have a second Rev-binding site close to the major splice donor site that may have an additional role in the viral life cycle.	Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Thomas Jefferson Univ, Div Infect Dis, Ctr Human Virol, Philadelphia, PA 19107 USA; Univ Oxford, Mol Biophys Lab, Oxford OX1 3QU, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; MRC Laboratory Molecular Biology; Jefferson University; University of Oxford	Lever, AML (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England.		Lea, Susan M/B-7678-2009; Gallego, Jose/H-6360-2015	Lea, Susan M/0000-0001-9287-8053; Gallego, Jose/0000-0002-0627-6927	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043876] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43876] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbink TEM, 2003, J BIOL CHEM, V278, P11601, DOI 10.1074/jbc.M210291200; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; Amarasinghe GK, 2000, J MOL BIOL, V299, P145, DOI 10.1006/jmbi.2000.3710; Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979; Amarasinghe GK, 2001, J MOL BIOL, V314, P961, DOI 10.1006/jmbi.2000.5182; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; Berkhout B, 2002, J BIOL CHEM, V277, P19967, DOI 10.1074/jbc.M200950200; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; CLAVEL F, 1990, J VIROL, V64, P5230, DOI 10.1128/JVI.64.10.5230-5234.1990; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; Clever JL, 1999, J VIROL, V73, P101, DOI 10.1128/JVI.73.1.101-109.1999; Clever JL, 2002, J VIROL, V76, P12381, DOI 10.1128/JVI.76.23.12381-12387.2002; Clever JL, 1997, J VIROL, V71, P3407, DOI 10.1128/JVI.71.5.3407-3414.1997; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; Dale T, 2000, RNA, V6, P608, DOI 10.1017/S1355838200992495; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; Dirac AMG, 2002, NUCLEIC ACIDS RES, V30, P2647, DOI 10.1093/nar/gkf381; Gosser Y, 2001, NAT STRUCT BIOL, V8, P146, DOI 10.1038/84138; Greatorex J, 2002, J MOL BIOL, V322, P543, DOI 10.1016/S0022-2836(02)00776-3; HARRISON GP, 1992, J VIROL, V66, P4144, DOI 10.1128/JVI.66.7.4144-4153.1992; Harrison GP, 1998, J VIROL, V72, P5886, DOI 10.1128/JVI.72.7.5886-5896.1998; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Huthoff H, 2002, BIOCHEMISTRY-US, V41, P10439, DOI 10.1021/bi025993n; Kao C, 1999, RNA, V5, P1268, DOI 10.1017/S1355838299991033; KAYE JF, 1995, J VIROL, V69, P6588, DOI 10.1128/JVI.69.10.6588-6592.1995; KIM HJ, 1994, VIROLOGY, V198, P336, DOI 10.1006/viro.1994.1037; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; McBride MS, 1996, J VIROL, V70, P2963, DOI 10.1128/JVI.70.5.2963-2973.1996; McBride MS, 1997, J VIROL, V71, P4544, DOI 10.1128/JVI.71.6.4544-4554.1997; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Russell RS, 2003, J VIROL, V77, P84, DOI 10.1128/JVI.77.1.84-96.2003; Schambach A, 2000, MOL THER, V2, P435, DOI 10.1006/mthe.2000.0191; Yuan YQ, 2003, BIOCHEMISTRY-US, V42, P5259, DOI 10.1021/bi034084a; Zeffman A, 2000, J MOL BIOL, V297, P877, DOI 10.1006/jmbi.2000.3611	38	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40385	40391		10.1074/jbc.M301041200	http://dx.doi.org/10.1074/jbc.M301041200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12851400	hybrid			2022-12-25	WOS:000185713800132
J	Song, MS; Chen, WG; Zhang, M; Napoli, JL				Song, MS; Chen, WG; Zhang, M; Napoli, JL			Identification of a mouse short-chain dehydrogenase/reductase gene, retinol dehydrogenase-similar - Function of non-catalytic amino acid residues in enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGENIC 17-BETA-HYDROXYSTEROID DEHYDROGENASE; MOLECULAR CHARACTERIZATION; CDNA CLONING; INTACT-CELLS; SWISS-MODEL; BIOSYNTHESIS; METABOLISM; REDUCTASE; BINDING	We report a mouse short-chain dehydrogenase/reductase (SDR), retinol dehydrogenase-similar (RDH-S), with intense mRNA expression in liver and kidney. The RDH-S gene localizes to chromosome 10D3 with the SDR subfamily that catalyzes metabolism of retinoids and 3alpha-hydroxysteroids. RDH-S has no activity with prototypical retinoid/steroid substrates, despite 92% amino acid similarity to mouse RDH1. This afforded the opportunity to analyze for functions of non-catalytic SDR residues. We produced RDH-SDelta3 by mutating RDH-S to remove an "additional" Asn residue relative to RDH1 in its center, to convert three residues into RDH1 residues (L121P, S122N, and Q123E), and to substitute RDH1 sequence G(208)FKTCVTSSD for RDH-S sequence F(208)FLTGMASSA. RDH-SDelta3 catalyzed all-trans-retinol and 5alpha-androstane-3alpha,17alpha-diol (3alpha-adiol) metabolism 60-70% as efficiently (V-m/K-m) as RDH1. Conversely, substituting RDH-S sequence F(208)FLTGMASSA into RDH1 produced a chimera ( viz. C3) that was inactive with all-trans-retinol, but was 4-fold more efficient with 3alpha-adiol. A single RDH1 mutation in the C3 region (K210L) reduced efficiency for all-trans-retinol by > 1250-fold. In contrast, the C3 area mutation C212G enhanced efficiency with all-trans-retinol by similar to2.4-fold. This represents a > 6000-fold difference in catalytic efficiency for two enzymes that differ by a single non-catalytic amino acid residue. Another chimera (viz. C5) retained efficiency with all-trans-retinol, but was not saturated and was weakly active with 3alpha-adiol, stemming from three residue differences (K224Q, K229Q, and A230T). The residues studied contribute to the substrate-binding pocket: molecular modeling indicated that they would affect orientation of substrates with the catalytic residues. These data report a new member of the SDR gene family, provide insight into the function of non-catalytic SDR residues, and illustrate that limited changes in the multifunctional SDR yield major alterations in substrate specificity and/or catalytic efficiency.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Napoli, JL (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, 119 Morgan Hall,MC3104, Berkeley, CA 94720 USA.	jna@uclink4.berkeley.edu			NIDDK NIH HHS [DK36870] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036870] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azzi A, 1996, NAT STRUCT BIOL, V3, P665, DOI 10.1038/nsb0896-665; Bailey TL, 1997, J STEROID BIOCHEM, V62, P29, DOI 10.1016/S0960-0760(97)00013-7; Baker ME, 2001, MOL CELL ENDOCRINOL, V171, P211, DOI 10.1016/S0303-7207(00)00414-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; Chen WG, 2002, GENE, V294, P141, DOI 10.1016/S0378-1119(02)00757-6; Duax WL, 2000, VITAM HORM, V58, P121, DOI 10.1016/S0083-6729(00)58023-6; Fisher M, 2000, STRUCTURE, V8, P339, DOI 10.1016/S0969-2126(00)00115-5; Gamble MV, 1999, J LIPID RES, V40, P2279; Gamble MV, 2000, BBA-PROTEIN STRUCT M, V1476, P3, DOI 10.1016/S0167-4838(99)00232-0; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GHOSH D, 1995, STRUCTURE, V3, P503, DOI 10.1016/S0969-2126(01)00183-6; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Kedishvili NY, 2002, J BIOL CHEM, V277, P28909, DOI 10.1074/jbc.M202588200; Lei Z, 2003, BIOCHEMISTRY-US, V42, P4190, DOI 10.1021/bi026948i; MOORE S, 2002, GENE, V292, P149; Napoli JL, 2001, MOL CELL ENDOCRINOL, V171, P103, DOI 10.1016/S0303-7207(00)00392-0; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Su J, 1998, J BIOL CHEM, V273, P17910, DOI 10.1074/jbc.273.28.17910; Su J, 1999, ENDOCRINOLOGY, V140, P5275, DOI 10.1210/endo.140.11.7137; Wang J, 2001, BIOCHEMISTRY-US, V40, P12533, DOI 10.1021/bi011396+; Zhang M, 2001, J BIOL CHEM, V276, P44083, DOI 10.1074/jbc.M105748200; Zhuang R, 2002, BIOCHEMISTRY-US, V41, P3477, DOI 10.1021/bi0119316	28	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40079	40087		10.1074/jbc.M304910200	http://dx.doi.org/10.1074/jbc.M304910200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12855677	hybrid			2022-12-25	WOS:000185713800099
J	Stojanovic, A; Hwang, I; Khorana, HG; Hwa, J				Stojanovic, A; Hwang, I; Khorana, HG; Hwa, J			Retinitis pigmentosa rhodopsin mutations L125R and A164V perturb critical interhelical interactions - New insights through compensatory mutations and crystal structure analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A SUPPLEMENTATION; PROTEIN-COUPLED RECEPTOR; LIGHT-DEPENDENT CHANGES; SCHIFF-BASE COUNTERION; BOVINE RHODOPSIN; DISULFIDE BOND; CYSTEINE RESIDUE-110; TERTIARY STRUCTURE; CYTOPLASMIC END; MUTANTS	L125R, a severe retinitis pigmentosa rhodopsin missense mutation, results in rhodopsin protein misfolding, retinal degeneration, and ultimately blindness. The initiating structural events leading to this protein misfolding are unknown. Through the use of compensatory mutations, in conjunction with crystal structure-based molecular analysis, we established that the larger and positively charged Arg replacing Leu(125) sterically hinders both the adjacent Trp(126) and a critical interhelical interaction between transmembrane III (TM III) and transmembrane V (TM V; Glu(122) and His(211) salt bridge). Further, analysis of another retinitis pigmentosa mutation, A164V (TM IV), indicates that the larger Val interferes with residues Leu(119) and Ile(123) on TM III, leading to the disruption of the same critical Glu(122)- His(211) salt bridge (TM III-TM V interaction). Combined, these localized defects in interhelical interactions cause structural changes that interfere with the ability of opsin to bind 11-cis-retinal. These distortions ultimately lead to the formation of an abnormal disulfide bond, severe protein instability, aggregation, and endoplasmic reticulum retention. In the absence of a crystal or NMR structure of each retinitis pigmentosa mutation, compensatory mutagenesis and crystal structure-based analysis are powerful tools in determining the localized molecular disturbances. A detailed understanding of the initiating local perturbations created by missense mutations such as these, not only identifies critical factors required for correct folding and stability, but additionally opens avenues for rational drug design, mimicking the compensatory mutations and stabilizing the protein.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; MIT, Dept Biol & Chem, Cambridge, MA 02139 USA	Dartmouth College; Massachusetts Institute of Technology (MIT)	Hwa, J (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.							Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; Andres A, 2001, EUR J BIOCHEM, V268, P5696, DOI 10.1046/j.0014-2956.2001.02509.x; Beck M, 1998, BIOCHEMISTRY-US, V37, P7630, DOI 10.1021/bi9801560; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P1456, DOI 10.1001/archopht.1993.01090110014001; BOWNDS D, 1967, NATURE, V216, P1178, DOI 10.1038/2161178a0; Creemers AFL, 2002, P NATL ACAD SCI USA, V99, P9101, DOI 10.1073/pnas.112677599; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; Garriga P, 1996, P NATL ACAD SCI USA, V93, P4560, DOI 10.1073/pnas.93.10.4560; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; Hwa J, 1999, P NATL ACAD SCI USA, V96, P1932, DOI 10.1073/pnas.96.5.1932; Hwa J, 2001, P NATL ACAD SCI USA, V98, P4872, DOI 10.1073/pnas.061632798; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Klein-Seetharaman J, 2001, BIOCHEMISTRY-US, V40, P12472, DOI 10.1021/bi010746p; Li TS, 1998, P NATL ACAD SCI USA, V95, P11933, DOI 10.1073/pnas.95.20.11933; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Reeves PJ, 1999, P NATL ACAD SCI USA, V96, P1927, DOI 10.1073/pnas.96.5.1927; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; Saliba RS, 2002, J CELL SCI, V115, P2907; Shieh T, 1997, J MOL BIOL, V269, P373, DOI 10.1006/jmbi.1997.1035; Stojanovic A, 2002, RECEPTOR CHANNEL, V8, P33, DOI 10.1080/10606820212137; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; WANG JK, 1980, BIOCHEMISTRY-US, V19, P5111, DOI 10.1021/bi00563a027	33	23	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39020	39028		10.1074/jbc.M303625200	http://dx.doi.org/10.1074/jbc.M303625200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871954	hybrid			2022-12-25	WOS:000185575100114
J	Morse, D; Pischke, SE; Zhou, ZH; Davis, RJ; Flavell, RA; Loop, T; Otterbein, SL; Otterbein, LE; Choi, AMK				Morse, D; Pischke, SE; Zhou, ZH; Davis, RJ; Flavell, RA; Loop, T; Otterbein, SL; Otterbein, LE; Choi, AMK			Suppression of inflammatory cytokine production by carbon monoxide involves the JNK pathway and AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME OXYGENASE; KAPPA-B; INTERLEUKIN-6; SEPSIS; KINASE; LIPOPOLYSACCHARIDE; ACTIVATION; BILIRUBIN; ENDOTOXIN; DEFENSE	The stress-inducible protein heme oxygenase-1 provides protection against oxidative stress and modulates pro-inflammatory cytokines. As the sepsis syndrome results from the release of pro-inflammatory mediators, we postulated that heme oxygenase-1 and its enzymatic product CO would protect against lethality in a murine model of sepsis. Mice treated with a lethal dose of lipopolysaccharide (LPS) and subsequently exposed to inhaled CO had significantly better survival and lower serum interleukin (IL)-6 and IL-1beta levels than their untreated counterparts. In vitro, mouse macrophages exposed to LPS and CO had significantly attenuated IL-6 production; this effect was concentration-dependent and occurred at a transcriptional level. The same effect was seen with increased endogenous CO production through overexpression of heme oxygenase-1. Mutation within the AP-1-binding site in the IL-6 promoter diminished the effect of CO on promoter activity, and treatment of macrophages with CO decreased AP-1 binding in an electrophoretic mobility shift assay. Electrophoretic mobility supershift assay indicated that the JunB, JunD, and c-Fos components of AP-1 were particularly affected. Upstream of AP-1, CO decreased JNK phosphorylation in murine macrophages and lung endothelial cells. Mice deficient in the JNK pathway had decreased serum levels of IL-6 and IL-1beta in response to LPS compared with control mice, and no effect of CO on these cytokine levels was seen in Jnk1 or Jnk2 gene-deleted mice. In summary, these results suggest that CO provides protection in a murine model of sepsis through modulation of inflammatory cytokine production. For the first time, the effect of CO is shown to be mediated via the JNK signaling pathway and the transcription factor AP-1.	Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Univ Hosp, Dept Anesthesia, D-79098 Freiburg, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; Yale University; Yale University; University of Freiburg	Choi, AMK (corresponding author), Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, NW 628 UPMC Montefiore,3459 5th Ave, Pittsburgh, PA 15213 USA.	choiam@msx.upmc.edu	Pischke, Soeren Erik/AAX-9676-2021; Zhou, Z Hong/HDN-0747-2022	Pischke, Soeren Erik/0000-0003-2543-3251; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055330, R01HL060234, R29HL055330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60234, HL55330] Funding Source: Medline; NIAID NIH HHS [AI42365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ammit AJ, 2002, AM J RESP CELL MOL, V26, P465, DOI 10.1165/ajrcmb.26.4.4681; Arnalich F, 2000, INFECT IMMUN, V68, P1942, DOI 10.1128/IAI.68.4.1942-1945.2000; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Camhi SL, 1998, AM J RESP CELL MOL, V18, P226, DOI 10.1165/ajrcmb.18.2.2910; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dokter WHA, 1996, LEUKEMIA, V10, P1308; Downard PJ, 1997, J SURG RES, V71, P7, DOI 10.1006/jsre.1997.5135; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Friedman G, 1998, CRIT CARE MED, V26, P2078, DOI 10.1097/00003246-199812000-00045; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Gallagher J, 2001, INTENS CARE MED, V27, P1169, DOI 10.1007/s001340100973; Geppert A, 2002, CRIT CARE MED, V30, P1987, DOI 10.1097/00003246-200209000-00007; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Haustein KO, 2002, J INTERN MED, V252, P130, DOI 10.1046/j.1365-2796.2002.01014.x; Heesen M, 2002, EUR CYTOKINE NETW, V13, P72; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Moncure M, 1999, J TRAUMA, V46, P424, DOI 10.1097/00005373-199903000-00012; Oberle S, 1999, BIOCHEM BIOPH RES CO, V261, P28, DOI 10.1006/bbrc.1999.0941; Otani K, 2000, DIGEST DIS SCI, V45, P2313, DOI 10.1023/A:1005626622203; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Rodriguez-Gaspar M, 2001, CYTOKINE, V15, P232, DOI 10.1006/cyto.2001.0932; Santana C, 2001, ACTA PAEDIATR, V90, P1176, DOI 10.1080/080352501317061602; Sarady JK, 2002, AM J RESP CELL MOL, V27, P739, DOI 10.1165/rcmb.4816; Selberg O, 2000, CRIT CARE MED, V28, P2793, DOI 10.1097/00003246-200008000-00019; Spittler A, 2000, CLIN INFECT DIS, V31, P1338, DOI 10.1086/317499; Tamion F, 2001, AM J RESP CRIT CARE, V164, P1933, DOI 10.1164/ajrccm.164.10.2010074; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; van der Poll T, 1999, INFECT DIS CLIN N AM, V13, P413, DOI 10.1016/S0891-5520(05)70083-0; Ventura JJ, 2003, MOL CELL BIOL, V23, P2871, DOI 10.1128/MCB.23.8.2871-2882.2003; Wang Y, 2002, BIOCHEM BIOPH RES CO, V296, P742, DOI 10.1016/S0006-291X(02)00930-0; Wenzel RP, 1996, CLIN INFECT DIS, V22, P407, DOI 10.1093/clinids/22.3.407; Yesilkaya A, 2000, GEN PHARMACOL-VASC S, V35, P17, DOI 10.1016/S0306-3623(01)00084-2; Zegdi R, 2002, INTENS CARE MED, V28, P793, DOI 10.1007/s00134-002-1269-7	35	333	366	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					36993	36998		10.1074/jbc.M302942200	http://dx.doi.org/10.1074/jbc.M302942200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857751	hybrid			2022-12-25	WOS:000185437200004
J	Heller, U; Winklhofer, KF; Heske, J; Reintjes, A; Tatzelt, J				Heller, U; Winklhofer, KF; Heske, J; Reintjes, A; Tatzelt, J			Post-translational import of the prion protein into the endoplasmic reticulum interferes with cell viability - A critical role for the putative transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; PRECURSOR PROTEIN; FRAGMENT 106-126; SCRAPIE; NEUROTOXICITY; TRANSLOCATION; PRP; GLYCOSYLATION; CONTAINS	Aberrant folding of the mammalian prion protein (PrP) is linked to prion diseases in humans and animals. We show that during post-translational targeting of PrP to the endoplasmic reticulum (ER) the putative transmembrane domain induces misfolding of PrP in the cytosol and interferes with its import into the ER. Unglycosylated and misfolded PrP with an uncleaved N-terminal signal sequence associates with ER membranes, and, moreover, decreases cell viability. PrP expressed in the cytosol, lacking the N-terminal ER targeting sequence, also adopts a misfolded conformation; however, this has no adverse effect on cell growth. PrP processing, productive ER import, and cellular viability can be restored either by deleting the putative transmembrane domain or by using a N-terminal signal sequence specific for co-translational ER import. Our study reveals that the putative transmembrane domain features in the formation of misfolded PrP conformers and indicates that post-translational targeting of PrP to the ER can decrease cell viability.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany	Max Planck Society	Tatzelt, J (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	tatzelt@biochem.mpg.de		Winklhofer, Konstanze/0000-0002-7256-8231; Tatzelt, Jorg/0000-0001-5017-5528				Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Blochberger TC, 1997, PROTEIN ENG, V10, P1465, DOI 10.1093/protein/10.12.1465; BOLTON DC, 1985, J VIROL, V53, P596, DOI 10.1128/JVI.53.2.596-606.1985; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; Deli MA, 2000, NEUROREPORT, V11, P3931, DOI 10.1097/00001756-200011270-00064; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Galasinski W, 1996, Acta Pol Pharm, V53, P311; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; Haik S, 2000, NEUROBIOL DIS, V7, P644, DOI 10.1006/nbdi.2000.0316; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Holscher C, 2001, J BIOL CHEM, V276, P13388, DOI 10.1074/jbc.M007331200; KANE PM, 1992, J BIOL CHEM, V267, P447; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Kim SJ, 2002, MOL BIOL CELL, V13, P3775, DOI 10.1091/mbc.E02-05-0293; KLEBE RJ, 1969, J CELL BIOL, V43, pA69; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Kourie JI, 2001, J NEUROSCI RES, V66, P214, DOI 10.1002/jnr.1213; Lin MX, 1997, J BIOL CHEM, V272, P44; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Maiti NR, 2001, J BIOL CHEM, V276, P2427, DOI 10.1074/jbc.M007862200; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MEADEN P, 1990, MOL CELL BIOL, V10, P3013, DOI 10.1128/MCB.10.6.3013; MULLER G, 1987, EMBO J, V6, P2099, DOI 10.1002/j.1460-2075.1987.tb02476.x; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; Pilon M, 1999, CELL, V97, P679, DOI 10.1016/S0092-8674(00)80780-1; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHLENSTEDT G, 1987, EMBO J, V6, P699, DOI 10.1002/j.1460-2075.1987.tb04810.x; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; Walmsley AR, 2001, EMBO J, V20, P703, DOI 10.1093/emboj/20.4.703; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; Weissmann C, 1996, COLD SPRING HARB SYM, V61, P511; Winklhofer KF, 2003, TRAFFIC, V4, P313, DOI 10.1034/j.1600-0854.2003.00088.x; Winklhofer KF, 2003, J BIOL CHEM, V278, P14961, DOI 10.1074/jbc.M209942200; Winklhofer KF, 2001, J BIOL CHEM, V276, P45160, DOI 10.1074/jbc.M104873200; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; Zimmermann R, 1998, BIOL CHEM, V379, P275	59	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36139	36147		10.1074/jbc.M304002200	http://dx.doi.org/10.1074/jbc.M304002200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12853456	hybrid			2022-12-25	WOS:000185318300034
J	Kaneko, E; Matsuda, M; Yamada, Y; Tachibana, Y; Shimomura, I; Makishima, M				Kaneko, E; Matsuda, M; Yamada, Y; Tachibana, Y; Shimomura, I; Makishima, M			Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; CHOLESTEROL ABSORPTION; DIETARY-CHOLESTEROL; LXR; ACID; ABCG8; GENE; IDENTIFICATION; ACTIVATION; EXPRESSION	The nuclear receptors liver X receptor (LXR) alpha and LXRbeta serve as oxysterol receptors and regulate the expression of genes involved in lipid metabolism. LXR activation induces the expression of ATP-binding cassette (ABC) transporters, such as ABCG5 and ABCG8, which inhibit intestinal absorption of cholesterol and phytosterols. Although several synthetic LXR agonists have been generated, these compounds have limited clinical application, because they cause hypertriglycemia by inducing the expression of lipogenic genes in the liver. We synthesized derivatives of phytosterols and found some of them to act as LXR agonists. Among them, YT-32 [(22E)-ergost-22-ene-1alpha,3beta-diol], which is related to ergosterol and brassicasterol, is the most potent LXR agonist. YT-32 directly bound to LXRalpha and LXRbeta and induced the interaction of LXRalpha with cofactors, such as steroid receptor coactivator-1, as effectively as the natural ligands, 22(R)-hydroxycholesterol and 24(S),25-epoxycholesterol. Although the nonsteroidal synthetic LXR agonist T0901317 induced the expression of intestinal ABC transporters and liver lipogenic genes, oral administration of YT-32 selectively activated intestinal ABC transporters in mice. Unlike T0901317 treatment, YT-32 inhibited intestinal cholesterol absorption without increasing plasma triglyceride levels. The phytosterol-derived LXR agonist YT-32 might selectively modulate intestinal cholesterol metabolism.	Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan; Nisshin Flour Milling Co, Pharmaceut Res Ctr, Ooi, Saitama 3568511, Japan	Osaka University; Osaka University	Shimomura, I (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, 2-2 Yamadaoka,H2, Suita, Osaka 5650871, Japan.	ichi@fbs.osaka-u.ac.jp; maxima@fbs.osaka-u.ac.jp						Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Collins JL, 2002, J MED CHEM, V45, P1963, DOI 10.1021/jm0255116; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Glass CK, 2000, GENE DEV, V14, P121; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Inaba T, 2003, J BIOL CHEM, V278, P21344, DOI 10.1074/jbc.M213202200; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jones P J, 1999, Curr Atheroscler Rep, V1, P230, DOI 10.1007/s11883-999-0037-3; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Kaplan R, 2003, J LIPID RES, V44, P136, DOI 10.1194/jlr.M200367-JLR200; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lu KM, 2001, TRENDS ENDOCRIN MET, V12, P314, DOI 10.1016/S1043-2760(01)00433-7; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Moore LB, 2002, MOL ENDOCRINOL, V16, P977, DOI 10.1210/me.16.5.977; Nishizawa H, 2002, J BIOL CHEM, V277, P1586, DOI 10.1074/jbc.M104301200; Ohama T, 2002, BIOCHEM BIOPH RES CO, V296, P625, DOI 10.1016/S0006-291X(02)00853-7; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Plat J, 2002, FASEB J, V16, DOI 10.1096/fj.01-0718hyp; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Shimizugawa T, 2002, J BIOL CHEM, V277, P33742, DOI 10.1074/jbc.M203215200; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Song C, 2000, ENDOCRINOLOGY, V141, P4180, DOI 10.1210/en.141.11.4180; Sparrow CP, 2002, J BIOL CHEM, V277, P10021, DOI 10.1074/jbc.M108225200; Tabas I, 2002, J CLIN INVEST, V110, P583, DOI 10.1172/JCI200216381; TACHIBANA Y, 1993, STUDIES NATURAL PROD, V11, P379; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Wang DQH, 2003, J LIPID RES, V44, P1042, DOI 10.1194/jlr.D200041-JLR200; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2003, J BIOL CHEM, V278, P15565, DOI 10.1074/jbc.M301311200; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	42	154	166	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36091	36098		10.1074/jbc.M304153200	http://dx.doi.org/10.1074/jbc.M304153200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847102	hybrid			2022-12-25	WOS:000185318300029
J	Kordulakova, J; Gilleron, M; Puzo, G; Brennan, PJ; Gicquel, B; Mikusova, K; Jackson, M				Kordulakova, J; Gilleron, M; Puzo, G; Brennan, PJ; Gicquel, B; Mikusova, K; Jackson, M			Identification of the required acyltransferase step in the biosynthesis of the phosphatidylinositol mannosides of Mycobacterium species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; SURFACTANT PROTEIN-A; MYO-INOSITOL ANCHOR; MULTIACYLATED FORMS; DC-SIGN; TUBERCULOSIS; LIPOARABINOMANNANS; RECOGNITION; LIPOGLYCANS; RECEPTOR	Fatty acyl functions of the glycosylated phosphatidylinositol (GPI) anchors of the phosphatidylinositol mannosides (PIM), lipomannan (LM), and lipoarabinomannan (LAM) of mycobacteria play a critical role in both the physical properties and biological activities of these molecules. In a search for the acyltransferases that acylate the GPI anchors of PIM, LM, and LAM, we examined the function of the mycobacterial Rv2611c gene that encodes a putative acyltransferase involved in the early steps of phosphatidylinositol mannoside synthesis. A Rv2611c mutant of Mycobacterium smegmatis was constructed which exhibited severe growth defects and contained an increased amount of phosphatidylinositol mono- and di-mannosides and a decreased amount of acylated phosphatidylinositol di-mannosides compared with the wild-type parental strain. In cell-free assays, extracts from M. smegmatis overexpressing the M. tuberculosis Rv2611c gene incorporated [C-14]palmitate into acylated phosphatidylinositol mono- and di-mannosides, and transferred cold endogenous fatty acids onto C-14''-labeled phosphatidylinositol mono- and di-mannosides more efficiently than extracts from the wild-type strain. Cell-free extracts from the Rv2611c mutant of M. smegmatis were greatly impaired in these respects. This work provides evidence that Rv2611c is the acyltransferase that catalyzes the acylation of the 6-position of the mannose residue linked to position 2 of myo-inositol in phosphatidylinositol mono- and di-mannosides, with the mono- mannosylated lipid acceptor being the primary substrate of the enzyme. We also provide the first evidence that two distinct pathways lead to the formation of acylated PIM2 from PIM1 in mycobacteria.	Inst Pasteur, Unite Genet Mycobacterienne, F-75724 Paris 15, France; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Comenius Univ, Fac Nat Sci, Dept Biochem, Bratislava 84215, Slovakia; Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Comenius University Bratislava; Colorado State University	Jackson, M (corresponding author), Inst Pasteur, Unite Genet Mycobacterienne, 25 Rue Dr Roux, F-75724 Paris 15, France.	mjackson@pasteur.fr	Mikusova, Katarina/I-3622-2014; Kordulakova, Jana/I-3887-2014; Jackson, Mary/D-5345-2017	Kordulakova, Jana/0000-0003-2834-0165; Jackson, Mary/0000-0002-9212-0258; GILLERON, Martine/0000-0002-2581-3302; Mikusova, Katarina/0000-0002-0100-4877				BARNES PF, 1992, J IMMUNOL, V149, P541; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; BRENNAN P, 1968, J BIOL CHEM, V243, P2975; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P-298; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Gilleron M, 2000, J BIOL CHEM, V275, P677, DOI 10.1074/jbc.275.1.677; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; Gilleron M, 2001, J BIOL CHEM, V276, P34896, DOI 10.1074/jbc.M103908200; GILLERON M, 2001, GLYCANS CELL INTERAC, P113; GOREN MB, 1984, MYCOBACTERIA SOURCEB, V1, P379; HILL DL, 1966, J BIOL CHEM, V241, P895; Jackson M, 2000, J BIOL CHEM, V275, P30092, DOI 10.1074/jbc.M004658200; Kang BK, 1998, INFECT IMMUN, V66, P2769, DOI 10.1128/IAI.66.6.2769-2777.1998; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; LEOPOLD K, 1993, ANAL BIOCHEM, V208, P57, DOI 10.1006/abio.1993.1008; Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200; Matsumoto K, 1997, BBA-LIPID LIPID MET, V1348, P214, DOI 10.1016/S0005-2760(97)00110-0; Nigou J, 2002, MICROBES INFECT, V4, P945, DOI 10.1016/S1286-4579(02)01621-0; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nigou J, 1999, BIOCHEM J, V337, P453, DOI 10.1042/0264-6021:3370453; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; PANGBORN MC, 1966, J LIPID RES, V7, P627; Pelicic V, 1997, P NATL ACAD SCI USA, V94, P10955, DOI 10.1073/pnas.94.20.10955; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; Sidobre S, 2002, BIOCHEM J, V365, P89, DOI 10.1042/BJ20011659; Sidobre S, 2000, J BIOL CHEM, V275, P2415, DOI 10.1074/jbc.275.4.2415; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; TAKAYAMA K, 1969, BIOCHIM BIOPHYS ACTA, V176, P196, DOI 10.1016/0005-2760(69)90089-7; VENISSE A, 1995, EUR J BIOCHEM, V231, P440, DOI 10.1111/j.1432-1033.1995.tb20717.x; Vercellone A, 1998, FRONT BIOSCI-LANDMRK, V3, pE149	39	86	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36285	36295		10.1074/jbc.M303639200	http://dx.doi.org/10.1074/jbc.M303639200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851411	hybrid			2022-12-25	WOS:000185318300052
J	Sakurai, H; Suzuki, S; Kawasaki, N; Nakano, H; Okazaki, T; Chino, A; Doi, T; Saiki, I				Sakurai, H; Suzuki, S; Kawasaki, N; Nakano, H; Okazaki, T; Chino, A; Doi, T; Saiki, I			Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappa B p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; KINASE KINASE KINASE; IN-VIVO; TRANSCRIPTIONAL ACTIVITY; DEPENDENT TRANSCRIPTION; RELA/P65 SUBUNIT; ACTIVATION; PROTEIN; UBIQUITINATION; COMPLEX	The activation of NF-kappaB has been shown to be regulated by multiple phosphorylations of IkappaBs and the NF-kappaB p65 subunit. Here, we characterized the intracellular signaling pathway leading to phosphorylation of p65 on Ser-536 using a novel anti-phospho-p65 (Ser-536) antibody. The Ser-536 of endogenous p65 was rapidly phosphorylated in response to a wide variety of NF-kappaB stimulants including TNF-alpha in the cytoplasm and rapidly dephosphorylated in the nucleus. The TNF-alpha- but not IL-1beta-induced Ser-536 phosphorylation was severely impaired in murine embryonic fibroblasts derived from traf2(-/-) traf5(-/-) mice. Bay 11-7082, an inhibitor of IkappaB phosphorylation, inhibited the TNF-alpha-induced phosphorylation in vivo. In addition, overexpression of TGF-beta-activated kinase 1 (TAK1), IKKalpha and IKKbeta stimulated the phosphorylation, and their dominant negative mutants blocked the TNF-alpha- induced phosphorylation. Moreover, small interfering RNAs (siRNAs) against TAK1, IKKalpha and IKKbeta blocked the phosphorylation of endogenous p65. On the other hand, calyculin-A, a protein phosphatase inhibitor, blocked the dephosphorylation in the nucleus in vivo. These results indicate that similar signaling pathways were utilized for the phosphorylations of IkappaBalpha and p65, which further support the idea that both IkappaB and NF-kappaB are substrates for the IKK complex in the activation of NF-kappaB.	Toyama Med & Pharmaceut Univ, Inst Nat Med, Dept Pathogen Biochem, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Japanese Oriental Med, Toyama 9300194, Japan; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan; Japanese Sci Technol Corp, PRESTO, Tokyo 1510053, Japan; RIKEN, Subteam BioResponse Integrat, Ibaraki 3050074, Japan	University of Toyama; University of Toyama; Juntendo University; Japan Science & Technology Agency (JST); RIKEN	Sakurai, H (corresponding author), Toyama Med & Pharmaceut Univ, Inst Nat Med, Dept Pathogen Biochem, 2630 Sugitani, Toyama 9300194, Japan.	hsakurai@ms.toyama-mpu.ac.jp	Sakurai, Hiroaki/AAE-4294-2019	OKAZAKI, TATSUMA/0000-0002-7110-3168; Nakano, Hiroyasu/0000-0003-4843-1427; Sakurai, Hiroaki/0000-0003-0657-9570				Akiyama M, 2003, CANCER RES, V63, P18; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Doi TS, 1997, J EXP MED, V185, P953, DOI 10.1084/jem.185.5.953; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Liang SH, 1999, ONCOGENE, V18, P2163, DOI 10.1038/sj.onc.1202350; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SAKURAI H, 1992, J NEUROCHEM, V59, P2067; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Tanaka K, 2001, BIOCHIMIE, V83, P351, DOI 10.1016/S0300-9084(01)01237-8; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	63	294	306	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36916	36923		10.1074/jbc.M301598200	http://dx.doi.org/10.1074/jbc.M301598200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12842894	hybrid			2022-12-25	WOS:000185318300125
J	Thukkani, AK; Albert, CJ; Wildsmith, KR; Messner, MC; Martinson, BD; Hsu, FF; Ford, DA				Thukkani, AK; Albert, CJ; Wildsmith, KR; Messner, MC; Martinson, BD; Hsu, FF; Ford, DA			Myeloperoxidase-derived reactive chlorinating species from human monocytes target plasmalogens in low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-CHLORIDE SYSTEM; HYPOCHLOROUS ACID; PHOSPHOLIPASE A(2); ARACHIDONIC-ACID; PROTEIN-KINASE; NITRIC-OXIDE; ACTIVATION; ATHEROSCLEROSIS; IDENTIFICATION; EXPRESSION	A role for myeloperoxidase (MPO) in atherosclerosis has received considerable attention recently. To identify potential chlorinated lipid products in human low density lipoprotein (LDL), studies were designed to demonstrate that MPO-derived reactive chlorinating species (RCS) target the plasmalogen pool of LDL isolated from peripheral human blood in vitro. The vinyl ether bond of LDL plasmalogens was targeted by MPO-derived RCS, resulting in the release of the 16- and 18-carbon- containing alpha-chloro fatty aldehydes, 2-chloro-hexadecanal and 2-chlorooctadecanal, respectively, from the plasmalogen glycerol backbone. Targeting of the LDL plasmalogen vinyl ether bond was dependent on the presence of MPO-derived RCS. Electrospray ionization mass spectrometric analysis of MPO-treated LDL demonstrated that a novel population of unsaturated lysophosphatidylcholine molecular species was produced by a phospholipase A(2)-independent mechanism. Unsaturated lysophosphatidylcholine molecular species elicited cyclic AMP response element binding protein phosphorylation in RAW 264.7 cells. Additionally, MPO-mediated targeting of both monocyte and LDL plasmalogen pools was demonstrated in phorbol myristate acetate-stimulated human monocytes, resulting in the production of both 2-chlorohexadecanal and 2-chlorooctadecanal. In contrast, alpha-chloro fatty aldehydes were not produced in phorbol myristate acetate-stimulated mouse monocytes. Collectively, the present studies demonstrate a novel MPO-specific mechanism that mediates the production of a novel group of unsaturated lysophosphatidylcholine molecular species and chlorinated aldehydes from both LDL and monocyte plasmalogen pools that may have important effects during inflammatory reactions mediated by monocytes, most notably atherosclerosis.	St Louis Univ, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Washington Univ, Dept Med, St Louis, MO 63110 USA	Saint Louis University; Washington University (WUSTL)	Ford, DA (corresponding author), St Louis Univ, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	fordda@slu.edu	Ford, David/D-1819-2018	Ford, David/0000-0002-0029-1560; Hsu, Fong-Fu/0000-0001-5368-0183	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042665] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00954] Funding Source: Medline; NHLBI NIH HHS [R01 HL 42665] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert CJ, 2001, J BIOL CHEM, V276, P23733, DOI 10.1074/jbc.M101447200; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Caslake MJ, 2000, ATHEROSCLEROSIS, V150, P413, DOI 10.1016/S0021-9150(99)00406-2; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; ENGELMANN B, 1994, BIOCHEM BIOPH RES CO, V204, P1235, DOI 10.1006/bbrc.1994.2595; FORD DA, 1989, P NATL ACAD SCI USA, V86, P3479, DOI 10.1073/pnas.86.10.3479; Ford DA, 1996, FEBS LETT, V394, P99, DOI 10.1016/0014-5793(96)00930-1; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; GROSS RW, 1985, BIOCHEMISTRY-US, V24, P1662, DOI 10.1021/bi00328a014; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; HAN XL, 1994, P NATL ACAD SCI USA, V91, P10635, DOI 10.1073/pnas.91.22.10635; Hanasaki K, 2002, J BIOL CHEM, V277, P29116, DOI 10.1074/jbc.M202867200; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1996, J BIOL CHEM, V271, P23080, DOI 10.1074/jbc.271.38.23080; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HAZEN SL, 1993, J CLIN INVEST, V91, P2513, DOI 10.1172/JCI116487; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; Hsu FF, 1999, INT J MASS SPECTROM, V185, P795, DOI 10.1016/S1387-3806(98)14105-2; Hulthe J, 2001, ARTERIOSCL THROM VAS, V21, P269, DOI 10.1161/01.ATV.21.2.269; HUTERER SJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P204, DOI 10.1016/0005-2760(93)90163-4; JURGENS G, 1993, ARTERIOSCLER THROMB, V13, P1689, DOI 10.1161/01.ATV.13.11.1689; LAMPERT MB, 1983, BLOOD, V62, P645; Macphee Colin H., 2001, Current Opinion in Pharmacology, V1, P121, DOI 10.1016/S1471-4892(01)00024-8; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; Murohara T, 1996, CIRC RES, V78, P780, DOI 10.1161/01.RES.78.5.780; Nigam S, 2000, BBA-MOL CELL BIOL L, V1488, P167, DOI 10.1016/S1388-1981(00)00119-0; Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611; PAK JH, 1987, BIOCHEMISTRY-US, V26, P4824, DOI 10.1021/bi00389a033; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Rikitake Y, 2001, BIOCHEM BIOPH RES CO, V281, P1291, DOI 10.1006/bbrc.2001.4510; Sartipy P, 1999, TRENDS CARDIOVAS MED, V9, P232, DOI 10.1016/S1050-1738(00)00030-X; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; Thukkani AK, 2002, J BIOL CHEM, V277, P3842, DOI 10.1074/jbc.M109489200; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; Williams SD, 2001, AM J PHYSIOL-HEART C, V281, pH168, DOI 10.1152/ajpheart.2001.281.1.H168; Williams SD, 1997, FEBS LETT, V420, P33, DOI 10.1016/S0014-5793(97)01482-8; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; Zeng YC, 1998, BIOCHEMISTRY-US, V37, P2346, DOI 10.1021/bi9725172; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136	49	73	77	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36365	36372		10.1074/jbc.M305449200	http://dx.doi.org/10.1074/jbc.M305449200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12869568	hybrid			2022-12-25	WOS:000185318300063
J	Furman, MH; Loureiro, J; Ploegh, HL; Tortorella, D				Furman, MH; Loureiro, J; Ploegh, HL; Tortorella, D			Ubiquitinylation of the cytosolic domain of a type I membrane protein is not required to initiate its dislocation from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX CLASS-I; HUMAN CYTOMEGALOVIRUS US2; HEAVY-CHAINS; QUALITY-CONTROL; ER DEGRADATION; PATHWAY; POLYUBIQUITINATION; ASSOCIATION; EXPRESSION; PROTEASOME	Human cytomegalovirus US2 and US11 target newly synthesized class I major histocompatibility complex (MHC) heavy chains for rapid degradation by the proteasome through a process termed dislocation. The presence of US2 induces the formation of class I MHC heavy chain conjugates of increased molecular weight that are recognized by a conformation-specific monoclonal antibody, W6/32, suggesting that these class I MHC molecules retain their proper tertiary structure. These conjugates are properly folded glycosylated heavy chains modified by attachment of an estimated one, two, and three ubiquitin molecules. The folded ubiquitinated class I MHC heavy chains are not observed in control cells or in cells transfected with US11, suggesting that US2 targets class I MHC heavy chains for dislocation in a manner distinct from that used by US11. This is further supported by the fact that US2 and US11 show different requirements in terms of the conformation of the heavy chain molecule. Although ubiquitin conjugation may occur on the cytosolic tail of the class I MHC molecule, replacement of lysines in the cytosolic tail of heavy chains with arginine does not prevent their degradation by US2. In an in vitro system that recapitulates US2-mediated dislocation, heavy chains that lack these lysines still occur in an ubiquitin-modified form, but in the soluble ( cytoplasmic) fraction. Such ubiquitin conjugation can only occur on the class I MHC lumenal domain and is likely to take place once class I MHC heavy chains have been discharged from the endoplasmic reticulum. We conclude that ubiquitinylation of class I MHC heavy chain is not required during the initial step of the US2-mediated dislocation reaction.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ploegh, HL (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Tortorella, Domenico/0000-0003-0961-3535; Loureiro, Joana/0000-0003-2793-5810				Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Boname JM, 2001, IMMUNITY, V15, P627, DOI 10.1016/S1074-7613(01)00213-8; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fiebiger E, 2002, EMBO J, V21, P1041, DOI 10.1093/emboj/21.5.1041; Furman MH, 2002, J BIOL CHEM, V277, P3258, DOI 10.1074/jbc.M109765200; Gewurz BE, 2001, P NATL ACAD SCI USA, V98, P6794, DOI 10.1073/pnas.121172898; Gewurz BE, 2001, J VIROL, V75, P5197, DOI 10.1128/JVI.75.11.5197-5204.2001; HARLOW E, 1988, ANTIBODIES LABORATOR, P311; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; Huppa JB, 1997, J EXP MED, V186, P393, DOI 10.1084/jem.186.3.393; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; Kikkert M, 2001, BIOCHEM J, V358, P369, DOI 10.1042/0264-6021:3580369; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; PARHAM P, 1979, J IMMUNOL, V123, P342; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; PLOEGH HL, 1995, CURRENT PROTOCOLS PR; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; Story CM, 1999, P NATL ACAD SCI USA, V96, P8516, DOI 10.1073/pnas.96.15.8516; Tirosh B, 2003, J BIOL CHEM, V278, P6664, DOI 10.1074/jbc.M210158200; Tiwari S, 2001, J BIOL CHEM, V276, P16193, DOI 10.1074/jbc.M007640200; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Tortorella D, 1998, J CELL BIOL, V142, P365, DOI 10.1083/jcb.142.2.365; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wilhovsky S, 2000, MOL BIOL CELL, V11, P1697, DOI 10.1091/mbc.11.5.1697; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1	38	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34804	34811		10.1074/jbc.M300913200	http://dx.doi.org/10.1074/jbc.M300913200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832421	hybrid			2022-12-25	WOS:000185164400011
J	Hoy, M; Berggren, PO; Gromada, J				Hoy, M; Berggren, PO; Gromada, J			Involvement of protein kinase C-epsilon in inositol hexakisphosphate-induced exocytosis in mouse pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; CA2+; STIMULATION	Inositolhexakisphosphate (InsP(6)) plays a pivotal role in the pancreatic beta-cell stimulus-secretion coupling. We have used capacitance measurements to study the effects of InsP(6) on Ca2+-dependent exocytosis in single mouse pancreatic beta-cells. In the presence of inhibitors of the protein phosphatase calcineurin to block endocytosis, intracellular application of InsP(6) produced a dose-dependent stimulation of exocytosis, and half-maximal effect was observed at 22 muM. The stimulatory effect of InsP6 was dependent on protein kinase C (PKC) activity. Antisense oligonucleotides directed against specific PKC isoforms (alpha, betaII, delta, epsilon, xi) revealed the involvement of PKC-epsilon in InsP(6)-induced exocytosis. Furthermore, expression of dominant negative PKC-epsilon abolished InsP(6)-evoked exocytosis, whereas expression of wild-type PKC-epsilon led to a significant stimulation of InsP(6)-induced exocytosis. These data demonstrate that PKC-epsilon is involved in InsP(6)-induced exocytosis in pancreatic beta-cells.	Novo Nordisk AS, Lab Islet Cell Physiol, DK-2880 Bagsvaerd, Denmark; Karolinska Inst, Rolf Luft Ctr Diabet Res, Dept Mol Med, S-17176 Stockholm, Sweden	Novo Nordisk; Karolinska Institutet	Gromada, J (corresponding author), Lilly Res Labs, Essener Str 93, D-22419 Hamburg, Germany.			Berggren, Per-Olof/0000-0001-8991-413X	NIDDK NIH HHS [DK 58508] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058508] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Efanov AM, 1997, P NATL ACAD SCI USA, V94, P4435, DOI 10.1073/pnas.94.9.4435; Hilton JM, 2001, J BIOL CHEM, V276, P16341, DOI 10.1074/jbc.M011122200; Hoy M, 2002, P NATL ACAD SCI USA, V99, P6773, DOI 10.1073/pnas.102157499; Kaneto H, 2002, J BIOL CHEM, V277, P3680, DOI 10.1074/jbc.M109647200; Larsson O, 1997, SCIENCE, V278, P471, DOI 10.1126/science.278.5337.471; LI GD, 1992, J BIOL CHEM, V267, P4349; MARTELL AE, 1971, CRITICAL STABILITY C, V2; MARTELL AE, 1971, CRITICAL STABILITY C, V1; Olofsson CS, 2002, PFLUG ARCH EUR J PHY, V444, P43, DOI 10.1007/s00424-002-0781-5; Quignard JF, 2003, J PHYSIOL-LONDON, V549, P729, DOI 10.1113/jphysiol.2002.037473; Ranganathan G, 2002, J BIOL CHEM, V277, P38669, DOI 10.1074/jbc.M206917200; Rzymkiewicz DM, 1996, J BIOL CHEM, V271, P17241, DOI 10.1074/jbc.271.29.17241; Simpson RU, 1998, J BIOL CHEM, V273, P19587, DOI 10.1074/jbc.273.31.19587; Tian YM, 1996, MOL CELL ENDOCRINOL, V119, P185, DOI 10.1016/0303-7207(96)03811-7	14	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35168	35171		10.1074/jbc.M303927200	http://dx.doi.org/10.1074/jbc.M303927200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12837755	hybrid			2022-12-25	WOS:000185164400052
J	Mao, ZB; Shan, S; Zhu, YY; Yi, X; Zhang, H; Shang, YF; Tong, TJ				Mao, ZB; Shan, S; Zhu, YY; Yi, X; Zhang, H; Shang, YF; Tong, TJ			Transcriptional regulation of A33 antigen expression by gut-enriched Kruppel-like factor	ONCOGENE			English	Article						A33 antigen; GKLF; gene regulation	MONOCLONAL-ANTIBODY A33; ADVANCED COLON-CANCER; COXSACKIE B VIRUSES; GENE-EXPRESSION; INTESTINAL EPITHELIUM; ENDOTHELIAL-CELLS; PHASE I/II; PROMOTER; GROWTH; DIFFERENTIATION	A33 antigen is a membrane-bound protein that is expressed only in intestinal epithelium and in most human colon cancers. Thus, A33 antigen has been explored as a potential therapeutic target for the treatment of colon cancers. However, little is known about the mechanism responsible for the tissue-specific pattern of its expression. In this report, we demonstrate that gut-enriched Kruppel-like factor (GKLF) binds to the promoter region of A33 antigen gene in colonic carcinoma cells and that mutations in the GKLF binding sequence in this region lead to diminished expression of A33 antigen. In addition, the expression of GKLF is linked to the expression of A33 antigen and blocking the expression of GKLF leads to the abolishment of A33 antigen expression. These results suggest that GKLF is a critical regulator in inducing the expression of A33 antigen in intestinal epithelium. While it has been suggested that GKLF is a regulator in inducing cell growth arrest and differentiation of the intestine, our observation that A33 antigen gene is a downstream target for GKLF suggests a more complex and diverse role for GKLF in the gut.	Peking Univ, Ctr Hlth Sci, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China	Peking University	Shang, YF (corresponding author), Peking Univ, Ctr Hlth Sci, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China.							Abud HE, 2000, MECH DEVELOP, V98, P111, DOI 10.1016/S0925-4773(00)00438-X; Antoniw P, 1996, BRIT J CANCER, V74, P513, DOI 10.1038/bjc.1996.395; Barendswaard EC, 2001, J NUCL MED, V42, P1251; Behr R, 2002, MECH DEVELOP, V115, P167, DOI 10.1016/S0925-4773(02)00127-2; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Catimel B, 1996, J BIOL CHEM, V271, P25664, DOI 10.1074/jbc.271.41.25664; Chen ZY, 2002, J BIOL CHEM, V277, P46831, DOI 10.1074/jbc.M204816200; Chretien I, 1996, EUR J IMMUNOL, V26, P780, DOI 10.1002/eji.1830260409; Chretien I, 1998, EUR J IMMUNOL, V28, P4094; Foster KW, 2000, CANCER RES, V60, P6488; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Gray S, 2002, J BIOL CHEM, V277, P34322, DOI 10.1074/jbc.M201304200; Heath JK, 1997, P NATL ACAD SCI USA, V94, P469, DOI 10.1073/pnas.94.2.469; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Johnstone CN, 2002, J BIOL CHEM, V277, P34531, DOI 10.1074/jbc.M204865200; Katevuo K, 1999, J IMMUNOL, V162, P5685; Katz JP, 2002, DEVELOPMENT, V129, P2619; KING DJ, 1995, BRIT J CANCER, V72, P1364, DOI 10.1038/bjc.1995.516; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; Miller KA, 2001, J BIOL CHEM, V276, P42863, DOI 10.1074/jbc.M108130200; Nickenig G, 2002, FASEB J, V16, P1077, DOI 10.1096/fj.01-0570com; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Okano J, 2000, FEBS LETT, V473, P95, DOI 10.1016/S0014-5793(00)01468-X; Sakamoto J, 2000, CANCER CHEMOTH PHARM, V46, pS27, DOI 10.1007/PL00014045; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; WELT S, 1994, J CLIN ONCOL, V12, P1561, DOI 10.1200/JCO.1994.12.8.1561; Welt S, 1996, J CLIN ONCOL, V14, P1787, DOI 10.1200/JCO.1996.14.6.1787; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	38	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	2003	22	28					4434	4443		10.1038/sj.onc.1206508	http://dx.doi.org/10.1038/sj.onc.1206508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853980				2022-12-25	WOS:000183978900013
J	Haumaitre, C; Reber, M; Cereghini, S				Haumaitre, C; Reber, M; Cereghini, S			Functions of HNF1 family members in differentiation of the visceral endoderm cell lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE NUCLEAR FACTOR-1; TRANSCRIPTION FACTORS; MOUSE EMBRYO; HOMEOPROTEIN FAMILY; EPITHELIAL-CELLS; GENE-EXPRESSION; PROMOTER; VHNF1; HNF-1-ALPHA; MUTATIONS	The two members of the hepatocyte nuclear factor 1 (HNF1) transcription factor family, HNF1 and variant HNF1 (vHNF1), show a strong homology in their atypical POU-homeodomain and dimerization domain but differ in their transactivation domains. Moreover, two vHNF1 isoforms generated by alternative splicing are present in all tissues expressing this gene. vHnf1-deficient mouse embryos die soon after implantation due to defective visceral endoderm formation, an extraembryonic tissue essential for development and survival of the embryo proper. In contrast, invalidation of Hnf1, which is expressed at later developmental stages than vHnf1, does not lead to embryonic lethality or developmental defects. To examine the specific or potential equivalent functions of vHNF1 isoforms and HNF1 during the process of visceral endoderm differentiation, we stably reexpressed these factors in vHnf1-deficient embryonic stem cells. Analysis of these embryonic stem cells upon differentiation into embryoid bodies shows that vHNF1 isoforms exhibit specific behaviors depending on particular target genes and cooperate in the establishment of a functional visceral endoderm. Furthermore, forced expression of HNF1 in vHnf1-deficient embryonic stem cells fully restores the formation of a mature visceral endoderm with the correct expression profile of early and late markers of this lineage. Thus, in this context, HNF1 functionally replaces both vHNF1 isoforms, suggesting that the different developmental functions of these transcription factors are mainly due to the acquisition of novel expression patterns.	Hop Enfants Malad, INSERM, U423, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cereghini, S (corresponding author), Univ Paris 06, CNRS, UMR 7622, 9 Quai St Bernard,Batiment C Porte 718 Case 24, F-75252 Paris, France.	cereghini@necker.fr	Reber, Michael/D-6250-2012; Haumaitre, Cecile/E-5455-2017	Haumaitre, Cecile/0000-0003-3526-7832; Reber, Michael/0000-0001-8842-7276				Acampora D, 2000, INT J DEV BIOL, V44, P669; BACH I, 1991, NUCLEIC ACIDS RES, V19, P3553, DOI 10.1093/nar/19.13.3553; BACH I, 1993, EMBO J, V12, P4229, DOI 10.1002/j.1460-2075.1993.tb06107.x; Barbacci E, 1999, DEVELOPMENT, V126, P4795; Barbera JPM, 2000, DEVELOPMENT, V127, P2433; Beddington RSP, 1998, TRENDS GENET, V14, P277, DOI 10.1016/S0168-9525(98)01499-1; Belaoussoff M, 1998, DEVELOPMENT, V125, P5009; Boj SF, 2001, P NATL ACAD SCI USA, V98, P14481, DOI 10.1073/pnas.241349398; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; Bouchard M, 2000, DEVELOPMENT, V127, P3703; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Chi YI, 2002, MOL CELL, V10, P1129, DOI 10.1016/S1097-2765(02)00704-9; Clotman F, 2002, DEVELOPMENT, V129, P1819; Coffinier C, 1999, DEVELOPMENT, V126, P4785; Coffinier C, 1999, MECH DEVELOP, V89, P211, DOI 10.1016/S0925-4773(99)00221-X; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Coucouvanis E, 1999, DEVELOPMENT, V126, P535; DESIMONE V, 1989, NUCLEIC ACIDS RES, V17, P9407, DOI 10.1093/nar/17.22.9407; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; Duncan SA, 1997, DEVELOPMENT, V124, P279; Farrington SM, 1997, MECH DEVELOP, V62, P197, DOI 10.1016/S0925-4773(97)00664-3; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; Force A, 1999, GENETICS, V151, P1531; Fujikura J, 2002, GENE DEV, V16, P784, DOI 10.1101/gad.968802; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; Hatzis P, 2001, MOL CELL BIOL, V21, P7320, DOI 10.1128/MCB.21.21.7320-7330.2001; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; LAZZARO D, 1992, DEVELOPMENT, V114, P469; Le Hir H, 2003, TRENDS BIOCHEM SCI, V28, P215, DOI 10.1016/S0968-0004(03)00052-5; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; Maye P, 2000, MECH DEVELOP, V94, P117, DOI 10.1016/S0925-4773(00)00304-X; MOLNE M, 1989, NUCLEIC ACIDS RES, V17, P3447, DOI 10.1093/nar/17.9.3447; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Nammo T, 2002, DIABETOLOGIA, V45, P1142, DOI 10.1007/s00125-002-0892-8; OTT MO, 1991, MECH DEVELOP, V36, P47, DOI 10.1016/0925-4773(91)90071-D; OTT MO, 1984, EMBO J, V3, P2505, DOI 10.1002/j.1460-2075.1984.tb02164.x; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; Power SC, 1996, MOL CELL BIOL, V16, P778; Reber M, 2001, MECH DEVELOP, V100, P75, DOI 10.1016/S0925-4773(00)00493-7; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; RINGEISEN F, 1993, J BIOL CHEM, V268, P25706; Rodda SJ, 2002, INT J DEV BIOL, V46, P449; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shih DQ, 2001, DIABETES, V50, P2472, DOI 10.2337/diabetes.50.11.2472; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; Thomas H, 2001, HUM MOL GENET, V10, P2089, DOI 10.1093/hmg/10.19.2089; Thomas PQ, 1998, DEVELOPMENT, V125, P85; TOMEI L, 1992, EMBO J, V11, P4119, DOI 10.1002/j.1460-2075.1992.tb05505.x; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	58	25	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40933	40942		10.1074/jbc.M304372200	http://dx.doi.org/10.1074/jbc.M304372200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12860991	hybrid			2022-12-25	WOS:000185847200065
J	Rodionov, DA; Vitreschak, AG; Mironov, AA; Gelfand, MS				Rodionov, DA; Vitreschak, AG; Mironov, AA; Gelfand, MS			Comparative Genomics of the vitamin B-12 metabolism and regulation in prokaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBALAMIN VITAMIN-B-12; SALMONELLA-TYPHIMURIUM; HEMOGLOBIN RECEPTOR; ESCHERICHIA-COLI; ACID A,C-DIAMIDE; BIOSYNTHESIS; GENES; IDENTIFICATION; TRANSPORT; SEQUENCE	Using comparative analysis of genes, operons, and regulatory elements, we describe the cobalamin ( vitamin B-12) biosynthetic pathway in available prokaryotic genomes. Here we found a highly conserved RNA secondary structure, the regulatory B-12 element, which is widely distributed in the upstream regions of cobalamin biosynthetic/transport genes in eubacteria. In addition, the binding signal (CBL-box) for a hypothetical B-12 regulator was identified in some archaea. A search for B-12 elements and CBL-boxes and positional analysis identified a large number of new candidate B-12-regulated genes in various prokaryotes. Among newly assigned functions associated with the cobalamin biosynthesis, there are several new types of cobalt transporters, ChlI and ChlD subunits of the CobN-dependent cobaltochelatase complex, cobalt reductase BluB, adenosyltransferase PduO, several new proteins linked to the lower ligand assembly pathway, L-threonine kinase PduX, and a large number of other hypothetical proteins. Most missing genes detected within the cobalamin biosynthetic pathways of various bacteria were identified as nonorthologous substitutes. The variable parts of the cobalamin metabolism appear to be the cobalt transport and insertion, the CobG/CbiG- and CobF/CbiD-catalyzed reactions, and the lower ligand synthesis pathway. The most interesting result of analysis of B-12 elements is that B-12-independent isozymes of the methionine synthase and ribonucleotide reductase are regulated by B-12 elements in bacteria that have both B-12-dependent and B-12-independent isozymes. Moreover, B-12 regulons of various bacteria are thought to include enzymes from known B-12-dependent or alternative pathways.	State Sci Ctr GosNIIGenetika, Moscow 113545, Russia; Russian Acad Sci, Inst Problems Informat Transmiss, Moscow 101447, Russia; Integrated Genom Moscow, Moscow 117333, Russia	Russian Academy of Sciences	Rodionov, DA (corresponding author), State Sci Ctr GosNIIGenetika, Moscow 113545, Russia.	rodionov@genetika.ru	Mironov, Andrey/C-8024-2012; Gelfand, Mikhail S/F-3425-2012; Rodionov, Dmitry/V-2688-2018	Rodionov, Dmitry/0000-0002-0939-390X; Gelfand, Mikhail/0000-0003-4181-0846				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Banerjee R, 2001, BIOCHEMISTRY-US, V40, P6191, DOI 10.1021/bi0104423; Benning MM, 1998, J BIOL CHEM, V273, P33572, DOI 10.1074/jbc.273.50.33572; Benson DA, 2003, NUCLEIC ACIDS RES, V31, P23, DOI 10.1093/nar/gkg057; BLANCHE F, 1992, J BACTERIOL, V174, P7452, DOI 10.1128/jb.174.22.7452-7454.1992; Bobik TA, 1999, J BACTERIOL, V181, P5967, DOI 10.1128/JB.181.19.5967-5975.1999; Buckel W, 2001, APPL MICROBIOL BIOT, V57, P263, DOI 10.1007/s002530100773; Cadieux N, 2002, J BACTERIOL, V184, P706, DOI 10.1128/JB.184.3.706-717.2002; Cheong CG, 2001, J BIOL CHEM, V276, P37612, DOI 10.1074/jbc.M105390200; Daniel R, 1998, FEMS MICROBIOL REV, V22, P553, DOI 10.1111/j.1574-6976.1998.tb00387.x; DEBUSSCHE L, 1993, J BACTERIOL, V175, P7430, DOI 10.1128/JB.175.22.7430-7440.1993; DEBUSSCHE L, 1992, J BACTERIOL, V174, P7445, DOI 10.1128/jb.174.22.7445-7451.1992; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; Fonseca MV, 2001, J BIOL CHEM, V276, P32101, DOI 10.1074/jbc.M102510200; Gaudu P, 2000, J BACTERIOL, V182, P1788, DOI 10.1128/JB.182.7.1788-1793.2000; Gelfand M S, 2000, Brief Bioinform, V1, P357, DOI 10.1093/bib/1.4.357; Gelfand MS, 2000, NUCLEIC ACIDS RES, V28, P695, DOI 10.1093/nar/28.3.695; Johnson CLV, 2001, J BACTERIOL, V183, P1577, DOI 10.1128/JB.183.5.1577-1584.2001; Jordan A, 1997, P NATL ACAD SCI USA, V94, P13487, DOI 10.1073/pnas.94.25.13487; Kofoid E, 1999, J BACTERIOL, V181, P5317, DOI 10.1128/JB.181.17.5317-5329.1999; Komeda H, 1997, P NATL ACAD SCI USA, V94, P36, DOI 10.1073/pnas.94.1.36; Koster W, 2001, RES MICROBIOL, V152, P291, DOI 10.1016/S0923-2508(01)01200-1; Martens JH, 2002, APPL MICROBIOL BIOT, V58, P275, DOI 10.1007/s00253-001-0902-7; McGoldrick H, 2002, BIOCHEM SOC T, V30, P646, DOI 10.1042/bst0300646; McMillan DJ, 1998, GENE, V208, P243, DOI 10.1016/S0378-1119(97)00651-3; Mironov AA, 2000, MOL BIOL+, V34, P222, DOI 10.1007/BF02759643; Nahvi A, 2002, CHEM BIOL, V9, P1043, DOI 10.1016/S1074-5521(02)00224-7; Nou XW, 1998, J BACTERIOL, V180, P6719, DOI 10.1128/JB.180.24.6719-6728.1998; O'Toole G. A., 1994, ESCHERICHIA COLI SAL, P710; Olczak T, 2001, J BACTERIOL, V183, P5599, DOI 10.1128/JB.183.19.5599-5608.2001; Overbeek R, 2003, NUCLEIC ACIDS RES, V31, P164, DOI 10.1093/nar/gkg148; POLLICH M, 1995, J BACTERIOL, V177, P4481, DOI 10.1128/jb.177.15.4481-4487.1995; Raux E, 1997, J BACTERIOL, V179, P3202, DOI 10.1128/jb.179.10.3202-3212.1997; Raux E, 1998, BIOCHEM J, V335, P167, DOI 10.1042/bj3350167; Raux E, 2003, BIOCHEM J, V370, P505, DOI 10.1042/BJ20021443; Ravnum S, 2001, MOL MICROBIOL, V39, P1585, DOI 10.1046/j.1365-2958.2001.02346.x; Rodionov DA, 2002, J BIOL CHEM, V277, P48949, DOI 10.1074/jbc.M208965200; ROTH JR, 1993, J BACTERIOL, V175, P3303, DOI 10.1128/jb.175.11.3303-3316.1993; Sauer K, 1999, EUR J BIOCHEM, V261, P674, DOI 10.1046/j.1432-1327.1999.00355.x; Schubert HL, 1999, BIOCHEMISTRY-US, V38, P10660, DOI 10.1021/bi9906773; Scott AI, 2002, BIOCHEM SOC T, V30, P613, DOI 10.1042/bst0300613; Simpson W, 2000, J BACTERIOL, V182, P5737, DOI 10.1128/JB.182.20.5737-5748.2000; SMITH RL, 1993, J BIOL CHEM, V268, P14071; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Thomas MG, 2000, J BACTERIOL, V182, P4227, DOI 10.1128/JB.182.15.4227-4233.2000; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vitreschak AG, 2003, RNA, V9, P1084, DOI 10.1261/rna.5710303; Vitreschak AG, 2002, NUCLEIC ACIDS RES, V30, P3141, DOI 10.1093/nar/gkf433; VITRESCHAK AG, 2001, P 3 INT C COMPL SYST, P623	50	323	342	2	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41148	41159		10.1074/jbc.M305837200	http://dx.doi.org/10.1074/jbc.M305837200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12869542	hybrid			2022-12-25	WOS:000185847200091
J	Bentley, J; Itchayanan, D; Barnes, K; McIntosh, E; Tang, XW; Downes, CP; Holman, GD; Whetton, AD; Owen-Lynch, PJ; Baldwin, SA				Bentley, J; Itchayanan, D; Barnes, K; McIntosh, E; Tang, XW; Downes, CP; Holman, GD; Whetton, AD; Owen-Lynch, PJ; Baldwin, SA			Interleukin-3-mediated cell survival signals include phosphatidylinositol 3-kinase-dependent translocation of the glucose transporter GLUT1 to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; 3T3-L1 ADIPOCYTES; GROWTH-FACTOR; HEMATOPOIETIC-CELLS; PLASMA-MEMBRANE; IN-VITRO; ACTIVATION; APOPTOSIS; LINE; PROLIFERATION	Maintenance of glucose uptake is a key component in the response of hematopoietic cells to survival factors. To investigate the mechanism of this response we employed the interleukin-3 (IL-3)-dependent murine mast cell line IC2.9. In these cells, hexose uptake decreased markedly upon withdrawal of IL-3, whereas its readdition led to rapid (t(1/2) similar to 10 min) stimulation of transport, associated with an similar to4-fold increase in V-max but no change in Km. Immunocytochemistry and photoaffinity labeling revealed that IL-3 caused translocation of intracellular GLUT1 transporters to the cell surface, whereas a second transporter isoform, GLUT3, remained predominantly intracellular. The inhibitory effects of latrunculin B and jasplakinolide, and of nocodazole and colchicine, respectively, revealed a requirement for both the actin and microtubule cytoskeletons in GLUT1 translocation and transport stimulation. Both IL-3 stimulation of transport and GLUT1 translocation were also prevented by the phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002. The time courses for activation of phosphatidylinositol 3-kinase and its downstream target, protein kinase B, by IL-3 were consistent with a role in IL-3-induced transporter translocation and enhanced glucose uptake. We conclude that one component of the survival mechanisms elicited by IL-3 involves the subcellular redistribution of glucose transporters, thus ensuring the supply of a key metabolic substrate.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland; Univ Bath, Sch Biol & Biochem, Bath BA2 7AY, Avon, England; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Leukaemia Res Fund Unit, Manchester M60 1QD, Lancs, England	University of Leeds; University of Dundee; University of Bath; University of Manchester	Baldwin, SA (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Woodhouse Lane, Leeds LS2 9JT, W Yorkshire, England.	s.a.baldwin@leeds.ac.uk		Owen-Lynch, Penelope Jane/0000-0002-5928-2327; tang, xiuwen/0000-0002-6601-1234; Holman, Geoffrey/0000-0001-7045-1358; WHETTON, ANTHONY D/0000-0002-1098-3878				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arai A, 2002, ONCOGENE, V21, P2641, DOI 10.1038/sj.onc.1205346; Bentley J, 2001, BRIT J HAEMATOL, V112, P212, DOI 10.1046/j.1365-2141.2001.02428.x; Berridge MV, 1996, J IMMUNOL, V156, P4092; BERRIDGE MV, 1995, BIOCHEM J, V305, P843, DOI 10.1042/bj3050843; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; CHAPMAN RS, 1996, HEMATOPOIETIC CELL G, P151; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; Dijkers PF, 1999, ONCOGENE, V18, P3334, DOI 10.1038/sj.onc.1202678; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; EVANS CA, 1993, CANCER RES, V53, P1735; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; HENDERSON P J F, 1992, P277; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khan AH, 2002, DIABETOLOGIA, V45, P1475, DOI 10.1007/s00125-002-0974-7; Koumanov F, 1998, BIOCHEM J, V330, P1209, DOI 10.1042/bj3301209; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; McCoy KD, 1997, J BIOL CHEM, V272, P17276, DOI 10.1074/jbc.272.28.17276; Molero JC, 2001, J BIOL CHEM, V276, P43829, DOI 10.1074/jbc.M105452200; NAGAMATSU S, 1992, J BIOL CHEM, V267, P467; NEFESH I, 1991, INT IMMUNOL, V3, P827, DOI 10.1093/intimm/3.8.827; Nicholls SE, 1999, EXP HEMATOL, V27, P663, DOI 10.1016/S0301-472X(98)00072-1; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; OWEN PJ, 1993, J BIOL CHEM, V268, P15696; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; RAO P, 1994, CANCER RES, V54, P777; Shigematsu S, 2002, MOL ENDOCRINOL, V16, P1060, DOI 10.1210/me.16.5.1060; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; Thurmond DC, 2001, MOL MEMBR BIOL, V18, P237; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	43	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39337	39348		10.1074/jbc.M305689200	http://dx.doi.org/10.1074/jbc.M305689200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869574	hybrid			2022-12-25	WOS:000185713800011
J	Brotz-Oesterhelt, H; Knezevic, I; Bartel, S; Lampe, T; Warnecke-Eberz, U; Ziegelbauer, K; Habich, D; Labischinski, H				Brotz-Oesterhelt, H; Knezevic, I; Bartel, S; Lampe, T; Warnecke-Eberz, U; Ziegelbauer, K; Habich, D; Labischinski, H			Specific and potent inhibition of NAD(+)-dependent DNA ligase by pyridochromanones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID LIGASE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MECHANISM; DOMAIN; ADENYLATION; EXPRESSION; COMPLEX; GYRASE	Pyridochromanones were identified by high throughput screening as potent inhibitors of NAD(+)-dependent DNA ligase from Escherichia coli. Further characterization revealed that eubacterial DNA ligases from Gram-negative and Gram-positive sources were inhibited at nanomolar concentrations. In contrast, purified human DNA ligase I was not affected (IC50 > 75 muM), demonstrating remarkable specificity for the prokaryotic target. The binding mode is competitive with the eubacteria-specific cofactor NAD(+), and no intercalation into DNA was detected. Accordingly, the compounds were bactericidal for the prominent human pathogen Staphylococcus aureus in the low mug/ml range, whereas eukaryotic cells were not affected up to 60 mug/ml. The hypothesis that inhibition of DNA ligase is the antibacterial principle was proven in studies with a temperature-sensitive ligase-deficient E. coli strain. This mutant was highly susceptible for pyridochromanones at elevated temperatures but was rescued by heterologous expression of human DNA ligase I. A physiological consequence of ligase inhibition in bacteria was massive DNA degradation, as visualized by fluorescence microscopy of labeled DNA. In summary, the pyridochromanones demonstrate that diverse eubacterial DNA ligases can be addressed by a single inhibitor without affecting eukaryotic ligases or other DNA-binding enzymes, which proves the value of DNA ligase as a novel target in antibacterial therapy.	Bayer AG, Bayer Hlth Care, Pharma Res, Dept Antiinfect, D-42096 Wuppertal, Germany; Bayer AG, Bayer Hlth Care, Pharma Res, Dept Chem, D-42096 Wuppertal, Germany	Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals	Brotz-Oesterhelt, H (corresponding author), Bayer AG, Bayer Hlth Care, Pharma Res, Dept Antiinfect, Aprather Weg 18A, D-42096 Wuppertal, Germany.			Warnecke-Eberz, Ute/0000-0002-2833-5633				ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; Cheng CH, 1997, NUCLEIC ACIDS RES, V25, P1369, DOI 10.1093/nar/25.7.1369; CHEO DL, 1992, BIOCHIMIE, V74, P755, DOI 10.1016/0300-9084(92)90148-8; Ciarrocchi G, 1999, ANTIMICROB AGENTS CH, V43, P2766, DOI 10.1128/AAC.43.11.2766; DERMODY JJ, 1979, J BACTERIOL, V139, P701, DOI 10.1128/JB.139.2.701-704.1979; Drlica K, 1997, MICROBIOL MOL BIOL R, V61, P377, DOI 10.1128/.61.3.377-392.1997; Kaczmarek FS, 2001, J BACTERIOL, V183, P3016, DOI 10.1128/JB.183.10.3016-3024.2001; KAPUSCINSKI J, 1995, BIOTECH HISTOCHEM, V70, P220, DOI 10.3109/10520299509108199; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; LEHMAN IR, 1974, SCIENCE, V186, P790; LEPECQ JB, 1967, J MOL BIOL, V27, P87, DOI 10.1016/0022-2836(67)90353-1; Liu ZR, 1996, ANAL BIOCHEM, V236, P139, DOI 10.1006/abio.1996.0142; LOVE PE, 1984, J BACTERIOL, V160, P910, DOI 10.1128/JB.160.3.910-920.1984; MODRICH P, 1973, J BIOL CHEM, V248, P7502; MONTECUCCO A, 1991, NUCLEIC ACIDS RES, V19, P1067, DOI 10.1093/nar/19.5.1067; MONTECUCCO A, 1993, BIOCHEM PHARMACOL, V45, P1536, DOI 10.1016/0006-2952(93)90057-4; NOHARA A, 1992, Patent No. 2809720; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Olland AM, 2002, J BIOL CHEM, V277, P3698, DOI 10.1074/jbc.M109670200; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Petit MA, 2000, NUCLEIC ACIDS RES, V28, P4642, DOI 10.1093/nar/28.23.4642; Singleton MR, 1999, STRUCTURE, V7, P35, DOI 10.1016/S0969-2126(99)80007-0; SODERHALL S, 1973, J BIOL CHEM, V248, P672; Sriskanda V, 2002, J BIOL CHEM, V277, P9695, DOI 10.1074/jbc.M111164200; Sriskanda V, 2001, NUCLEIC ACIDS RES, V29, P4930, DOI 10.1093/nar/29.24.4930; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; Tan GT, 1996, BIOCHEM J, V314, P993, DOI 10.1042/bj3140993; Timson DJ, 2000, MUTAT RES-DNA REPAIR, V460, P301, DOI 10.1016/S0921-8777(00)00033-1; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; VAARA M, 1991, DRUG EXP CLIN RES, V17, P437; *WHO CDS CSR DRS, 2001, WHOCDSCSRDRS20012; Wilkinson A, 2001, MOL MICROBIOL, V40, P1241, DOI 10.1046/j.1365-2958.2001.02479.x	34	111	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39435	39442		10.1074/jbc.M306479200	http://dx.doi.org/10.1074/jbc.M306479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12867414	hybrid			2022-12-25	WOS:000185713800021
J	Harada, J; Kokura, K; Kanei-Ishii, C; Nomura, T; Khan, MM; Kim, Y; Ishii, S				Harada, J; Kokura, K; Kanei-Ishii, C; Nomura, T; Khan, MM; Kim, Y; Ishii, S			Requirement of the co-repressor homeodomain-interacting protein kinase 2 for Ski-mediated inhibition of bone morphogenetic protein-induced transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; HISTONE DEACETYLASE COMPLEX; TGF-BETA RECEPTOR; THYROID-HORMONE RECEPTOR; N-COR; COREPRESSOR COMPLEX; SIGNALING PATHWAYS; TUMOR-SUPPRESSOR; SMAD PROTEINS; MAD PROTEINS	Multiple co-repressors such as N-CoR/SMRT, mSin3, and the c-ski proto-oncogene product (c-Ski) mediate the transcriptional repression induced by Mad and the thyroid hormone receptor by recruiting the histone deacetylase complex. c-Ski also binds directly to Smad proteins, which are transcriptional activators in the transforming growth factor-beta (TGF-beta)/bone morphogenetic protein (BMP) signaling pathways, and inhibits TGF-beta/BMP-induced transcriptional activation. However, it remains unknown whether other co-repressor(s) are also involved with Ski in the negative regulation of the TGF-beta/BMP signaling pathways. Here, we report that the co-repressor homeodomain-interacting protein kinase 2 (HIPK2) directly binds to both c-Ski and Smad1. HIPK2 efficiently inhibited Smad1/4-induced transcription from the Smad site-containing promoter. A dominant negative form of HIPK2, in which the ATP binding motif in the kinase domain and the putative phosphorylation sites were mutated, enhanced Smad1/4-dependent transcription and the BMP-induced expression of alkaline phosphatase. Furthermore, the c-Ski-induced inhibition of the Smad1/4-dependent transcription was suppressed by a dominant negative form of HIPK2. The HIPK2 co-repressor activity may be regulated by an un-characterized HIPK2 kinase. These results indicate that HIPK2, together with c-Ski, plays an important role in the negative regulation of BMP-induced transcriptional activation.	RIKEN, Tsukuba Inst, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	RIKEN; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Ishii, S (corresponding author), RIKEN, Tsukuba Inst, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.		Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Engelhardt OG, 2003, EXP CELL RES, V283, P36, DOI 10.1016/S0014-4827(02)00025-3; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Guenther MG, 2000, GENE DEV, V14, P1048; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Huang EY, 2000, GENE DEV, V14, P45; Kao HY, 2000, GENE DEV, V14, P55; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	60	50	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38998	39005		10.1074/jbc.M307112200	http://dx.doi.org/10.1074/jbc.M307112200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874272	hybrid			2022-12-25	WOS:000185575100111
J	Hsieh, JC; Sisk, JM; Jurutka, PW; Haussler, CA; Slater, SA; Haussler, MR; Thompson, CC				Hsieh, JC; Sisk, JM; Jurutka, PW; Haussler, CA; Slater, SA; Haussler, MR; Thompson, CC			Physical and functional interaction between the vitamin D receptor and hairless corepressor, two proteins required for hair cycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY 1,25-DIHYDROXYVITAMIN-D-RESISTANT RICKETS; STEROID-HORMONE RECEPTOR; TRANSCRIPTION FACTOR IIB; D-RESPONSIVE ELEMENT; NUCLEAR RECEPTOR; COACTIVATOR INTERACTION; FOLLICLE MORPHOGENESIS; INTESTINAL RECEPTOR; BASAL TRANSCRIPTION; TARGETED ABLATION	Both the vitamin D receptor (VDR) and hairless (hr) genes play a role in the mammalian hair cycle, as inactivating mutations in either result in total alopecia. VDR is a nuclear receptor that functions as a ligand-activated transcription factor, whereas the hairless gene product ( Hr) acts as a corepressor of both the thyroid hormone receptor (TR) and the orphan nuclear receptor, RORalpha. In the present study, we show that VDR-mediated transactivation is strikingly inhibited by coexpression of rat Hr. The repressive effect of Hr is observed on both synthetic and naturally occurring VDR-responsive promoters and also when VDR-mediated transactivation is augmented by overexpression of its heterodimeric partner, retinoid X receptor. Utilizing in vitro pull down methods, we find that Hr binds directly to VDR but insignificantly to nuclear receptors that are not functionally repressed by Hr. Coimmunoprecipitation data demonstrate that Hr and VDR associate in a cellular milieu, suggesting in vivo interaction. The Hr contact site in human VDR is localized to the central portion of the ligand binding domain, a known corepressor docking region in other nuclear receptors separate from the activation function-2 domain. Coimmunoprecipitation and functional studies of Hr deletants reveal that VDR contacts a C-terminal region of Hr that includes motifs required for TR and RORalpha binding. Finally, in situ hybridization analysis of hr and VDR mRNAs in mouse skin demonstrates colocalization in cells of the hair follicle, consistent with a hypothesized intracellular interaction between these proteins to repress VDR target gene expression, in vivo.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Univ Arizona, Coll Med, Dept Biochem & Mol Biophys, Tucson, AZ 85724 USA	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; University of Arizona	Thompson, CC (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA.	thompsonc@kennedykrieger.org		Jurutka, Peter/0000-0002-4950-9161; Haussler, Mark/0000-0002-7097-1801; Haussler, Carol/0000-0001-8360-3066	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063930, R01DK033351, R37DK033351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041313] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK063930, DK33351] Funding Source: Medline; NINDS NIH HHS [NS41313] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmad W, 1998, SCIENCE, V279, P720, DOI 10.1126/science.279.5351.720; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; BERGER U, 1988, J CLIN ENDOCR METAB, V67, P607, DOI 10.1210/jcem-67-3-607; Botchkarev VA, 2001, FASEB J, V15, P2205, DOI 10.1096/fj.01-0207com; CACHONGONZALEZ MB, 1994, P NATL ACAD SCI USA, V91, P7717, DOI 10.1073/pnas.91.16.7717; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; Cichon S, 1998, HUM MOL GENET, V7, P1671, DOI 10.1093/hmg/7.11.1671; CLEMENS TL, 1988, ENDOCRINOLOGY, V122, P1224, DOI 10.1210/endo-122-4-1224; DANIELSEN M, 1989, CANCER RES, V49, pS2286; Dardenne O, 2001, ENDOCRINOLOGY, V142, P3135, DOI 10.1210/en.142.7.3135; DOMINGUEZ CE, 2002, INSIGHTS BIOCH LIFE, P175; Dussault I, 1998, MECH DEVELOP, V70, P147, DOI 10.1016/S0925-4773(97)00187-1; Falzon M, 1996, MOL ENDOCRINOL, V10, P672, DOI 10.1210/me.10.6.672; Foley J, 1998, J INVEST DERMATOL, V111, P1122, DOI 10.1046/j.1523-1747.1998.00428.x; Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961; Gill RK, 1998, MOL ENDOCRINOL, V12, P57, DOI 10.1210/mend.12.1.0048; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HIRST MA, 1985, J CLIN ENDOCR METAB, V60, P490, DOI 10.1210/jcem-60-3-490; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HSIEH JC, 1995, J STEROID BIOCHEM, V53, P583, DOI 10.1016/0960-0760(95)00112-D; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; Jabbour SA, 2003, AM J CLIN DERMATOL, V4, P315, DOI 10.2165/00128071-200304050-00003; Jin CH, 1996, MOL ENDOCRINOL, V10, P945, DOI 10.1210/me.10.8.945; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Jurutka P W, 2001, Rev Endocr Metab Disord, V2, P203, DOI 10.1023/A:1010062929140; Jurutka PW, 2000, MOL ENDOCRINOL, V14, P401, DOI 10.1210/me.14.3.401; Jurutka PW, 1997, J BIOL CHEM, V272, P14592, DOI 10.1074/jbc.272.23.14592; Jurutka PW, 2000, BIOCHEM BIOPH RES CO, V267, P813, DOI 10.1006/bbrc.1999.2044; Koibuchi N, 2000, TRENDS ENDOCRIN MET, V11, P123, DOI 10.1016/S1043-2760(00)00238-1; Kremer R, 1996, J BIOL CHEM, V271, P16310, DOI 10.1074/jbc.271.27.16310; KRISTJANSSON K, 1993, J CLIN INVEST, V92, P12, DOI 10.1172/JCI116539; Li M, 2000, NATURE, V407, P633, DOI 10.1038/35036595; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Malloy PJ, 2002, MOL ENDOCRINOL, V16, P2538, DOI 10.1210/me.2002-0152; Malloy PJ, 1999, ENDOCR REV, V20, P156, DOI 10.1210/er.20.2.156; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; Miller J, 2001, J INVEST DERMATOL, V117, P612, DOI 10.1046/j.0022-202x.2001.01438.x; Moraitis AN, 2002, MOL CELL BIOL, V22, P6831, DOI 10.1128/MCB.22.19.6831-6841.2002; NAKAJIMA S, 1994, MOL ENDOCRINOL, V8, P159, DOI 10.1210/me.8.2.159; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Panda DK, 2001, P NATL ACAD SCI USA, V98, P7498, DOI 10.1073/pnas.131029498; Panteleyev AA, 2000, AM J PATHOL, V157, P1071, DOI 10.1016/S0002-9440(10)64621-4; Panteleyev AA, 1998, EXP DERMATOL, V7, P249, DOI 10.1111/j.1600-0625.1998.tb00295.x-i1; Peters EMJ, 2001, J INVEST DERMATOL, V117, P173, DOI 10.1046/j.0022-202x.2001.01410.x; PIKE JW, 1983, J BIOL CHEM, V258, P1289; PIKE JW, 1987, J BIOL CHEM, V262, P1305; Potter GB, 2002, MOL ENDOCRINOL, V16, P2547, DOI 10.1210/me.2002-0115; Potter GB, 2001, GENE DEV, V15, P2687, DOI 10.1101/gad.916701; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; RIZKRABIN M, 1994, J CELL PHYSIOL, V159, P131, DOI 10.1002/jcp.1041590117; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; RUT AR, 1994, CLIN ENDOCRINOL, V41, P581, DOI 10.1111/j.1365-2265.1994.tb01822.x; Sakai Y, 2001, J CLIN INVEST, V107, P961, DOI 10.1172/JCI11676; Sato N, 1999, J CLIN INVEST, V104, P855, DOI 10.1172/JCI7691; STOYE JP, 1988, CELL, V54, P383, DOI 10.1016/0092-8674(88)90201-2; STUMPF WE, 1979, SCIENCE, V206, P1188, DOI 10.1126/science.505004; Tagami T, 1998, BIOCHEM BIOPH RES CO, V253, P358, DOI 10.1006/bbrc.1998.9799; TERPENING CM, 1991, MOL ENDOCRINOL, V5, P373, DOI 10.1210/mend-5-3-373; Thompson CC, 2000, CEREB CORTEX, V10, P939, DOI 10.1093/cercor/10.10.939; Thompson CC, 1996, J NEUROSCI, V16, P7832; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; Whitfield GK, 1996, MOL ENDOCRINOL, V10, P1617, DOI 10.1210/me.10.12.1617; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Xie ZJ, 2002, J BIOL CHEM, V277, P36987, DOI 10.1074/jbc.M201404200; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Yen PM, 1996, J BIOL CHEM, V271, P10910, DOI 10.1074/jbc.271.18.10910; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	78	159	164	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38665	38674		10.1074/jbc.M304886200	http://dx.doi.org/10.1074/jbc.M304886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12847098	hybrid			2022-12-25	WOS:000185575100071
J	Adinolfi, E; Kim, M; Young, MT; Di Virgilio, F; Surprenant, A				Adinolfi, E; Kim, M; Young, MT; Di Virgilio, F; Surprenant, A			Tyrosine phosphorylation of HSP90 within the P2X(7) receptor complex negatively regulates P2X(7) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; GLUCOCORTICOID-RECEPTOR; P2Z PURINORECEPTOR; P-2Z RECEPTOR; CELL-DEATH; KAPPA-B; KINASE; ACTIVATION; HETEROCOMPLEX; GELDANAMYCIN	The purinergic P2X(7) receptor not only gates the opening of a cationic channel, but also couples to several downstream signaling events such as rapid membrane blebbing, microvesicle shedding, and interleukin-1beta release. Protein-protein interactions are likely to be involved in most of these signaling cascades; and recently, a P2X(7) receptor-protein complex comprising at least 11 distinct proteins has been identified. We have studied one of these interacting proteins, HSP90, in human embryonic kidney cells expressing either human or rat P2X(7) receptors as well as in rat peritoneal macrophages using biochemical ( immunoprecipitation and Western blotting) and functional ( membrane blebbing and currents) assays. We found that HSP90 was tyrosine-phosphorylated in association with the P2X(7) receptor complex, but not in the cytosolic compartment. The HSP90 inhibitor geldanamycin decreased tyrosine phosphorylation of HSP90 and produced a 2-fold increase in the sensitivity of P2X(7) receptors to agonist. Protein expression and tyrosine phosphorylation of a mutant P2X(7) receptor in which a tyrosine in the C-terminal domain was substituted with phenylalanine (Y550F) were not changed, but tyrosine phosphorylation of HSP90 associated with this mutant P2X(7) receptor complex was significantly greater than that associated with the wild-type complex. P2X(7)-Y550F receptors showed a 15-fold lower sensitivity to agonist, which was reversed by geldanamycin. We conclude that selective tyrosine phosphorylation of P2X(7) receptor-associated HSP90 may act as a negative regulator of P2X(7) receptor complex formation and function.	Univ Sheffield, Dept Biomed Sci, Inst Mol Physiol, Sheffield S10 2TN, S Yorkshire, England; Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy	University of Sheffield; University of Ferrara	Surprenant, A (corresponding author), Univ Sheffield, Dept Biomed Sci, Inst Mol Physiol, Denny Bldg,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	a.surprenant@sheffield.ac.uk	Young, Mark T/E-8928-2010; Di Virgilio, Francesco/J-3754-2018; Adinolfi, Elena/F-9169-2010; DI VIRGILIO, Francesco/O-4634-2019	Young, Mark T/0000-0002-9615-9002; Di Virgilio, Francesco/0000-0003-3566-1362; Adinolfi, Elena/0000-0001-8129-9929; DI VIRGILIO, Francesco/0000-0003-3566-1362				AHAO C, 2002, EXP CELL RES, V275, P200; Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206; BEERE HM, 2001, SCI STKE; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Brouet A, 2001, CIRC RES, V89, P866, DOI 10.1161/hh2201.100319; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chessell IP, 1998, FEBS LETT, V439, P26, DOI 10.1016/S0014-5793(98)01332-5; Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Egerton M, 1996, BIOCHEM BIOPH RES CO, V224, P666, DOI 10.1006/bbrc.1996.1082; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; Falzoni S, 2000, MOL BIOL CELL, V11, P3169, DOI 10.1091/mbc.11.9.3169; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; Gudipaty L, 2001, AM J PHYSIOL-CELL PH, V280, pC943, DOI 10.1152/ajpcell.2001.280.4.C943; Guo YL, 2001, J BIOL CHEM, V276, P45791, DOI 10.1074/jbc.M105931200; Hayashi T, 1999, NATURE, V397, P72, DOI 10.1038/16269; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; Jiang LH, 2000, MOL PHARMACOL, V58, P82, DOI 10.1124/mol.58.1.82; Kanelakis KC, 2002, J BIOL CHEM, V277, P33698, DOI 10.1074/jbc.M204164200; KAPPERSTUCK M, 2001, J PHYSIOL-LONDON, V534, P25; Kim M, 2001, J BIOL CHEM, V276, P23262, DOI 10.1074/jbc.M102253200; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Kim SH, 1999, BIOCHEM BIOPH RES CO, V262, P516, DOI 10.1006/bbrc.1999.1229; Le Feuvre RA, 2002, J BIOL CHEM, V277, P3210, DOI 10.1074/jbc.M104388200; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Lopez-Maderuelo MD, 2001, FEBS LETT, V490, P23, DOI 10.1016/S0014-5793(01)02130-5; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Nollen EAA, 2002, J CELL SCI, V115, P2809; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Surprenant A, 2000, J AUTONOM NERV SYST, V81, P249, DOI 10.1016/S0165-1838(00)00123-5; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Virginio C, 1997, NEUROPHARMACOLOGY, V36, P1285, DOI 10.1016/S0028-3908(97)00141-X; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324	49	79	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37344	37351		10.1074/jbc.M301508200	http://dx.doi.org/10.1074/jbc.M301508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869560	hybrid			2022-12-25	WOS:000185437200044
J	Gao, JM; Choe, H; Bota, D; Wright, PL; Gerard, C; Gerard, NP				Gao, JM; Choe, H; Bota, D; Wright, PL; Gerard, C; Gerard, NP			Sulfation of tyrosine 174 in the human C3a receptor is essential for binding of C3a anaphylatoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR LOOP; C5A ANAPHYLATOXIN; HUMAN-COMPLEMENT; AMINO-TERMINUS; HIV-1 ENTRY; MAST-CELLS; CLONING; IDENTIFICATION; EXPRESSION; ACTIVATION	The complement anaphylatoxin C3a and its cellular seven-transmembrane segment receptor, C3aR, are implicated in a variety of pathological inflammatory processes. C3aR is a G-protein-coupled receptor with an exceptionally large second extracellular loop of 172 amino acids. Previously reported deletion studies have shown that at least part of this region plays a critical role in binding C3a. Our data now demonstrate that five tyrosines in the second extracellular loop of the C3aR are posttranslationally modified by the addition of sulfate. Blocking sulfation by mutation of tyrosine to phenylalanine at positions 184, 188, 317, and/or 318 does not affect ligand binding or signal transduction. However, when tyrosine 174 is mutated to phenylalanine, binding of native C3a is completely blocked. This variant efficiently mobilizes calcium in response to synthetic C3a agonist peptides, but not to native C3a. This finding is consistent with a two-site model of ligand association typical of many peptide ligand-receptor interactions and identifies sulfotyrosine 174 as the critical C3a docking site. Tyrosine sulfation in the amino-terminal extracellular domain has been shown to be important in several other seven-transmembrane segment receptors. Our data now demonstrate that tyrosine sulfate in other extracellular domains can function for ligand interactions as well.	Childrens Hosp, Ina Sue Perlmutter Lab, Boston, MA 02115 USA; Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div AIDS, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Gerard, NP (corresponding author), Childrens Hosp, Ina Sue Perlmutter Lab, 320 Longwood Ave, Boston, MA 02115 USA.	Norma.Gerard@TCH.harvard.edu			NHLBI NIH HHS [HL36162] Funding Source: Medline; NIAID NIH HHS [AI43891, AI41851] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036162, R37HL036162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043891, R01AI041851] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; Ames RS, 1996, J BIOL CHEM, V271, P20231, DOI 10.1074/jbc.271.34.20231; BAEUERLE PA, 1985, J BIOL CHEM, V260, P6434; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; Chao TH, 1999, J BIOL CHEM, V274, P9721, DOI 10.1074/jbc.274.14.9721; Choe H, 2003, CELL, V114, P161, DOI 10.1016/S0092-8674(03)00508-7; COCHRANE CG, 1968, J EXP MED, V127, P371, DOI 10.1084/jem.127.2.371; Crass T, 1999, J BIOL CHEM, V274, P8367, DOI 10.1074/jbc.274.13.8367; Crass T, 1996, EUR J IMMUNOL, V26, P1944, DOI 10.1002/eji.1830260840; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; EMBER JA, 1991, BIOCHEMISTRY-US, V30, P3603, DOI 10.1021/bi00229a003; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2002, J BIOL CHEM, V277, P29484, DOI 10.1074/jbc.M203361200; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; Fong AM, 2002, J BIOL CHEM, V277, P19418, DOI 10.1074/jbc.M201396200; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; HORTIN G, 1986, J BIOL CHEM, V261, P1786; HUANG SC, 1989, PEPTIDES, V10, P785, DOI 10.1016/0196-9781(89)90114-9; HUGLI TE, 1975, J BIOL CHEM, V250, P8293; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; KARP DR, 1983, J BIOL CHEM, V258, P2745; Kehoe JW, 2000, CHEM BIOL, V7, pR57, DOI 10.1016/S1074-5521(00)00093-4; KOLAKOWSKI LF, 1995, J BIOL CHEM, V270, P18077, DOI 10.1074/jbc.270.30.18077; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; NIEHRS C, 1990, J BIOL CHEM, V265, P9314; Nilsson G, 1996, J IMMUNOL, V157, P1693; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295; Roglic A, 1996, BBA-GENE STRUCT EXPR, V1305, P39, DOI 10.1016/0167-4781(95)00209-X; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; STIMLER NP, 1980, AM J PATHOL, V100, P327; STIMLERGERARD NP, 1987, J IMMUNOL, V138, P1908; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; VOGT W, 1986, Complement, V3, P177	36	37	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37902	37908		10.1074/jbc.M306061200	http://dx.doi.org/10.1074/jbc.M306061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871936	hybrid			2022-12-25	WOS:000185437200112
J	Park, CS; Schneider, IC; Haugh, JM				Park, CS; Schneider, IC; Haugh, JM			Kinetic analysis of platelet-derived growth factor receptor/phosphoinositide 3-kinase/Akt signaling in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PDGF BETA-RECEPTOR; 3-PHOSPHORYLATED INOSITOL LIPIDS; IMMUNOGLOBULIN-LIKE DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; ACTIVATED LIGAND; TYROSINE KINASES; ALPHA-RECEPTOR; EGF RECEPTORS	Isoforms of the serine-threonine kinase Akt coordinate multiple cell survival pathways in response to stimuli such as platelet-derived growth factor (PDGF). Activation of Akt is a multistep process, which relies on the production of 3'-phosphorylated phosphoinositide (PI) lipids by PI 3-kinases. To quantitatively assess the kinetics of PDGF receptor/PI 3-kinase/Akt signaling in fibroblasts, a systematic study of this pathway was performed, and a mechanistic mathematical model that describes its operation was formulated. We find that PDGF receptor phosphorylation exhibits positive cooperativity with respect to PDGF concentration, and its kinetics are quantitatively consistent with a mechanism in which receptor dimerization is initially mediated by the association of two 1:1 PDGF/PDGF receptor complexes. Receptor phosphorylation is transient at high concentrations of PDGF, consistent with the loss of activated receptors upon endocytosis. By comparison, Akt activation responds to lower PDGF concentrations and exhibits more sustained kinetics. Further analysis and modeling suggest that the pathway is saturated at the level of PI 3-kinase activation, and that the p110alpha catalytic subunit of PI 3-kinase contributes most to PDGF-stimulated 3'-PI production. Thus, at high concentrations of PDGF the kinetics of 3'-PI production are limited by the turnover rate of these lipids, while the Akt response is additionally influenced by the rate of Akt deactivation.	N Carolina State Univ, Dept Chem Engn, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Haugh, JM (corresponding author), N Carolina State Univ, Dept Chem Engn, Box 7905, Raleigh, NC 27695 USA.			Schneider, Ian/0000-0002-4414-3842; Haugh, Jason/0000-0002-2476-4027				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Chiarugi P, 2002, J BIOL CHEM, V277, P37331, DOI 10.1074/jbc.M205203200; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEUEL TF, 1991, ANNU REV MED, V42, P567, DOI 10.1146/annurev.me.42.020191.003031; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; DUAN DSR, 1991, J BIOL CHEM, V266, P413; Emaduddin M, 1999, BIOCHEM J, V341, P523, DOI 10.1042/0264-6021:3410523; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRETTO LJ, 1993, J BIOL CHEM, V268, P3625; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Haugh JM, 2002, J CELL SCI, V115, P303; Haugh JM, 1998, J THEOR BIOL, V195, P187, DOI 10.1006/jtbi.1998.0791; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HERREN B, 1993, J BIOL CHEM, V268, P15088; Hooshmand-Rad R, 2000, J CELL SCI, V113, P207; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; Jones SM, 1999, CURR BIOL, V9, P512, DOI 10.1016/S0960-9822(99)80235-8; KELLY JD, 1991, J BIOL CHEM, V266, P8987; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; LAUFFENBURGER DA, 1993, RECEPTORS MODELS BIN, P73; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lokker NA, 1997, J BIOL CHEM, V272, P33037, DOI 10.1074/jbc.272.52.33037; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; Miyazawa K, 1998, J BIOL CHEM, V273, P25495, DOI 10.1074/jbc.273.39.25495; Oatey PB, 1999, BIOCHEM J, V344, P511, DOI 10.1042/0264-6021:3440511; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Scheid MP, 2002, J BIOL CHEM, V277, P9027, DOI 10.1074/jbc.M106755200; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SORKIN A, 1993, J CELL PHYSIOL, V156, P373, DOI 10.1002/jcp.1041560221; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Wiseman PW, 1999, BIOPHYS J, V76, P963, DOI 10.1016/S0006-3495(99)77260-7	64	81	83	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37064	37072		10.1074/jbc.M304968200	http://dx.doi.org/10.1074/jbc.M304968200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871957	hybrid			2022-12-25	WOS:000185437200012
J	Tang, ED; Wang, CY; Xiong, Y; Guan, KL				Tang, ED; Wang, CY; Xiong, Y; Guan, KL			A role for NF-kappa B essential modifier/I kappa B kinase-gamma (NEMO/IKK gamma) ubiquitination in the activation of the I kappa B kinase complex by tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE LIVER DEGENERATION; X-LINKED DISORDER; IKK-BETA SUBUNIT; INCONTINENTIA PIGMENTI; ECTODERMAL DYSPLASIA; DEFICIENT MICE; REGULATORY SUBUNIT; CONJUGATING ENZYME; SIGNALING COMPLEX; LIGASE ACTIVITY	NEMO (NF-kappaB essential modifier)/IKKgamma (IkappaB kinase-gamma) is required for the activation of the IkappaB kinase complex (IKK) by inflammatory stimuli such as tumor necrosis factor (TNF-alpha). Here we show that TNF-alpha stimulates the ubiquitination of NEMO in a manner that does not appear to target it for degradation and that is impaired by mutations in the NEMO zinc finger. Mutations of the zinc finger are found in patients with hypohidrotic ectodermal dysplasia with immunodeficiency (HED-ID) and lead to the impairment of TNF-alpha-stimulated IKK phosphorylation and activation. In addition, the ubiquitination of NEMO is mediated by c-IAP1, an inhibitor of apoptosis protein that is a component of the TNF receptor signaling complex. Thus, the ubiquitination of NEMO mediated by c-IAP1 likely plays an important role in the activation of IKK by TNF-alpha. Also, defective NEMO ubiquitination may be responsible for the impaired cellular NF-kappaB signaling found in patients with HED-ID.	Univ Michigan, Sch Dent, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Lab Mol Signaling & Apoptosis, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Inst Gerontol, Ann Arbor, MI 48109 USA; Univ N Carolina, Dept Biochem & Biophys, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of North Carolina; University of North Carolina Chapel Hill	Guan, KL (corresponding author), Univ Michigan, Sch Dent, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Guan, Kun-Liang/ADK-7088-2022					Aradhya S, 2001, AM J HUM GENET, V68, P765, DOI 10.1086/318806; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Furukawa M, 2002, J BIOL CHEM, V277, P15758, DOI 10.1074/jbc.M108565200; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; PICKART CM, 1994, J BIOL CHEM, V269, P7115; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Smahi A, 2000, NATURE, V405, P466; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	53	178	185	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37297	37305		10.1074/jbc.M303389200	http://dx.doi.org/10.1074/jbc.M303389200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867425	Green Published, hybrid			2022-12-25	WOS:000185437200038
J	Boutell, C; Everett, RD				Boutell, C; Everett, RD			The herpes simplex virus type 1 (HSV-1) regulatory protein ICP0 interacts with and ubiquitinates p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME-DEPENDENT DEGRADATION; VIRUS-1-INFECTED CELL PROTEIN-0; TUMOR-SUPPRESSOR; GENE-EXPRESSION; SP100 PROTEINS; DNA-DAMAGE; PML; APOPTOSIS; LIGASE; E3	Herpes simplex virus type 1 regulatory protein ICP0 contains a zinc-binding RING finger and has been shown to induce the proteasome-dependent degradation of a number of cellular proteins in a RING finger-dependent manner during infection. This domain of ICP0 is also required to induce the formation of unanchored polyubiquitin chains in vitro in the presence of ubiquitin-conjugating enzymes UbcH5a and UbcH6. These data indicate that ICP0 has the potential to act as a RING finger ubiquitin ubiquitin-protein isopeptide ligase (E3) and to induce the degradation of certain cellular proteins through ubiquitination and proteasome-mediated degradation. Here we demonstrate that ICP0 is a genuine RING finger ubiquitin E3 ligase that can interact with and mediate the ubiquitination of the major oncoprotein p53 both in vitro and in vivo. Ubiquitination of p53 requires ICP0 to have an intact RING finger domain and occurs independently of its ability to bind to the ubiquitin-specific protease USP7.	MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland		Everett, RD (corresponding author), MRC, Virol Unit, Church St, Glasgow G11 5JR, Lanark, Scotland.	r.everett@vir.gla.ac.uk		Boutell, Chris/0000-0002-2970-7785				Bailey D, 2002, J GEN VIROL, V83, P2951, DOI 10.1099/0022-1317-83-12-2951; Boutell C, 2002, J VIROL, V76, P841, DOI 10.1128/JVI.76.2.841-850.2002; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; Condreay JP, 1999, P NATL ACAD SCI USA, V96, P127, DOI 10.1073/pnas.96.1.127; Everett RD, 2000, J VIROL, V74, P9994, DOI 10.1128/JVI.74.21.9994-10005.2000; EVERETT RD, 1989, J GEN VIROL, V70, P1185, DOI 10.1099/0022-1317-70-5-1185; Everett RD, 1999, EMBO J, V18, P1526, DOI 10.1093/emboj/18.6.1526; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Everett RD, 2000, BIOESSAYS, V22, P761, DOI 10.1002/1521-1878(200008)22:8<761::AID-BIES10>3.0.CO;2-A; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hagglund R, 2002, P NATL ACAD SCI USA, V99, P7889, DOI 10.1073/pnas.122246999; Hagglund R, 2002, P NATL ACAD SCI USA, V99, P631, DOI 10.1073/pnas.022531599; Halford WP, 2001, J VIROL, V75, P6143, DOI 10.1128/JVI.75.13.6143-6153.2001; Halford WP, 2001, J VIROL, V75, P3240, DOI 10.1128/JVI.75.7.3240-3249.2001; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Hobbs WE, 1999, J VIROL, V73, P8245, DOI 10.1128/JVI.73.10.8245-8255.1999; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Kawaguchi Y, 1997, J VIROL, V71, P1019, DOI 10.1128/JVI.71.2.1019-1024.1997; Kawaguchi Y, 1997, J VIROL, V71, P7328, DOI 10.1128/JVI.71.10.7328-7336.1997; Kawaguchi Y, 2001, P NATL ACAD SCI USA, V98, P1877, DOI 10.1073/pnas.041592598; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lomonte P, 1999, J VIROL, V73, P9456, DOI 10.1128/JVI.73.11.9456-9467.1999; Lomonte P, 2001, J BIOL CHEM, V276, P5829, DOI 10.1074/jbc.M008547200; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MEREDITH M, 1995, VIROLOGY, V209, P174, DOI 10.1006/viro.1995.1241; Muller S, 1999, J VIROL, V73, P5137; Parkinson J, 2000, J VIROL, V74, P10006, DOI 10.1128/JVI.74.21.10006-10017.2000; Parkinson J, 1999, J VIROL, V73, P650, DOI 10.1128/JVI.73.1.650-657.1999; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Preston CM, 2000, J GEN VIROL, V81, P1; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; ROIZMAN B, 2001, FIELDS VIROLOGY, V2, P2399; Salomoni P, 2002, NAT CELL BIOL, V4, pE152, DOI 10.1038/ncb0602-e152; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHOWALTER SD, 1981, INFECT IMMUN, V34, P684, DOI 10.1128/IAI.34.3.684-692.1981; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; YAO F, 1995, J VIROL, V69, P6249, DOI 10.1128/JVI.69.10.6249-6258.1995	49	104	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36596	36602		10.1074/jbc.M300776200	http://dx.doi.org/10.1074/jbc.M300776200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855695	hybrid			2022-12-25	WOS:000185318300090
J	Hill, K; Li, YW; Bennett, M; McKay, M; Zhu, XJ; Shern, J; Torre, E; Lah, JJ; Levey, AI; Kahn, RA				Hill, K; Li, YW; Bennett, M; McKay, M; Zhu, XJ; Shern, J; Torre, E; Lah, JJ; Levey, AI; Kahn, RA			Munc18 interacting proteins - ADP-ribosylation factor-dependent coat proteins that regulate the traffic of beta-Alzheimer's precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GOLGI MEMBRANES; PDZ DOMAINS; COMPLEX; BINDING; GTP; CLATHRIN; ARF; RECRUITMENT; RECEPTOR	Coat proteins cycle between soluble and membrane-bound locations at the time of vesicle biogenesis and act to regulate the assembly of the vesicle coat that determines the specificity in cargo selection and the destination of the vesicle. A transmembrane cargo protein, an Arf GTPase, and a coat protein (e.g. COPs, APs, or GGAs) are minimal components required for budding of vesicles. Munc18 interacting proteins (MINTs) are a family of three proteins implicated in the localization of receptors to the plasma membrane. We show that MINTs bind Arfs directly, co-localize with Arf and the Alzheimer's precursor protein (beta-APP) to regions of the Golgi/trans-Golgi network, and can co-immunoprecipitate clathrin. We demonstrate that MINTs bind Arfs through a region of the PTB domain and the PDZ2 domain, and Arf-MINT interaction is necessary for the increased cellular levels of beta-APP produced by MINT overexpression. Knockdown ( small interference RNA) experiments implicate beta-APP as a transmembrane cargo protein that works together with MINTs. We propose that MINTs are a family of Arf-dependent, vesicle-coat proteins that can regulate the traffic of beta-APP.	Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; IGEN Int Corp, Gaithersburg, MD 20877 USA	Emory University; Emory University; Emory University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Ctr Neurodegenerat Dis, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rkahn@emory.edu	Kahn, Richard/ABD-2666-2020; Shern, Jack/V-4002-2019; Levey, Allan/F-2104-2011	Kahn, Richard/0000-0002-0259-0601; Levey, Allan/0000-0002-3153-502X				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Amor JC, 2001, J BIOL CHEM, V276, P42477, DOI 10.1074/jbc.M106660200; Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; Biederer T, 2002, J NEUROSCI, V22, P7340; Boehm M, 2001, EMBO J, V20, P6265, DOI 10.1093/emboj/20.22.6265; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Boman AL, 1999, CELL MOTIL CYTOSKEL, V44, P119, DOI 10.1002/(SICI)1097-0169(199910)44:2<119::AID-CM4>3.3.CO;2-3; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1999, J NEUROSCI, V19, P1307; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Harris BZ, 2002, J BIOL CHEM, V277, P34902, DOI 10.1074/jbc.M205856200; Harris BZ, 2001, J CELL SCI, V114, P3219; Harris BZ, 2001, BIOCHEMISTRY-US, V40, P5921, DOI 10.1021/bi010142l; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787; Ho CS, 2002, J BIOL CHEM, V277, P27021, DOI 10.1074/jbc.M201823200; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kuai J, 2000, J BIOL CHEM, V275, P4022, DOI 10.1074/jbc.275.6.4022; Kuai J, 2000, FEBS LETT, V487, P252, DOI 10.1016/S0014-5793(00)02325-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; Lai A, 1998, J BIOL CHEM, V273, P3732, DOI 10.1074/jbc.273.6.3732; Lau KF, 2000, MOL CELL NEUROSCI, V16, P557, DOI 10.1006/mcne.2000.0898; Lee DS, 2000, J BIOL CHEM, V275, P23134, DOI 10.1074/jbc.C000302200; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; McLoughlin DM, 2001, J BIOL CHEM, V276, P9303, DOI 10.1074/jbc.M010023200; McLoughlin DM, 1996, FEBS LETT, V397, P197; Menetrey J, 2000, NAT STRUCT BIOL, V7, P466; Mueller HT, 2000, J BIOL CHEM, V275, P39302, DOI 10.1074/jbc.M008453200; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Okamoto M, 2001, NEUROSCIENCE, V104, P653, DOI 10.1016/S0306-4522(01)00124-5; Okamoto M, 1998, EUR J CELL BIOL, V77, P161, DOI 10.1016/S0171-9335(98)80103-9; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Riento K, 2000, J BIOL CHEM, V275, P13476, DOI 10.1074/jbc.275.18.13476; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Scheel J, 1997, J CELL BIOL, V137, P319, DOI 10.1083/jcb.137.2.319; Seaman MNJ, 1996, J BIOL CHEM, V271, P25446, DOI 10.1074/jbc.271.41.25446; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Tomita S, 2000, J BIOL CHEM, V275, P13056, DOI 10.1074/jbc.C000019200; Van Valkenburgh H, 2001, J BIOL CHEM, V276, P22826, DOI 10.1074/jbc.M102359200; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141; Zhu XJ, 2000, J BIOL CHEM, V275, P13465, DOI 10.1074/jbc.275.18.13465; Zhu XJ, 2001, J BIOL CHEM, V276, P25014, DOI 10.1074/jbc.M100923200; Zhu YX, 1998, MOL BIOL CELL, V9, P1323, DOI 10.1091/mbc.9.6.1323	72	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36032	36040		10.1074/jbc.M301632200	http://dx.doi.org/10.1074/jbc.M301632200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12842896	hybrid			2022-12-25	WOS:000185318300022
J	Oh, CD; Chun, JS				Oh, CD; Chun, JS			Signaling mechanisms leading to the regulation of differentiation and apoptosis of articular chondrocytes by insulin-like growth factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; OXIDE-INDUCED APOPTOSIS; NITRIC-OXIDE; MESENCHYMAL CELLS; IGF-I; PROTEOGLYCAN SYNTHESIS; SYNOVIAL-FLUID; EXPRESSION; CHONDROGENESIS; CARTILAGE	Cartilage development is initiated by the differentiation of mesenchymal cells into chondrocytes. Differentiated chondrocytes in articular cartilage undergo dedifferentiation and apoptosis during arthritis, in which NO production plays a critical role. Here, we investigated the roles and mechanisms of action of insulin-like growth factor-1 (IGF-1) in the chondrogenesis of mesenchymal cells and the maintenance and survival of differentiated articular chondrocytes. IGF-1 induced chondrogenesis of limb bud mesenchymal cells during micromass culture through the activation of phosphatidylinositol 3-kinase (PI3K) and Akt. PI3K activation is required for the activation of protein kinase C (PKC)-alpha and p38 kinase and inhibition of ERK1/2. These events are necessary for chondrogenesis. The growth factor additionally blocked NO-induced dedifferentiation and apoptosis of primary culture articular chondrocytes. NO production in chondrocytes induced down-regulation of PI3K and Akt activities, which was blocked by IGF-1 treatment. Stimulation of PI3K by IGF-1 resulted in blockage of NO-induced activation of p38 kinase and ERK1/2 and inhibition of PKCalpha and PKCzeta, which in turn suppressed dedifferentiation and apoptosis. Our results collectively indicate that IGF-1 regulates differentiation, maintenance of the differentiated phenotype, and apoptosis of articular chondrocytes via a PI3K pathway that modulates ERK, p38 kinase, and PKC signaling.	Kwangju Inst Sci & Technol, Dept Life Sci, Natl Res Lab, Buk Gu 500712, Gwangju, South Korea	Gwangju Institute of Science & Technology (GIST)	Chun, JS (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Natl Res Lab, Buk Gu 500712, Gwangju, South Korea.	jschun@kjist.ac.kr		Oh, Chundo/0000-0002-5419-8011				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281-199805000-00018; Blanco FJ, 1998, ARTHRITIS RHEUM, V41, P284, DOI 10.1002/1529-0131(199802)41:2<284::AID-ART12>3.0.CO;2-T; Burtscher I, 1999, CANCER RES, V59, P3923; Chang SH, 1998, J BIOL CHEM, V273, P19213, DOI 10.1074/jbc.273.30.19213; Chrysis D, 2001, J NEUROSCI, V21, P1481, DOI 10.1523/JNEUROSCI.21-05-01481.2001; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dealy CN, 1996, DEVELOPMENT, V122, P1323; Dealy CN, 1996, DEV BIOL, V177, P291, DOI 10.1006/dbio.1996.0163; Decraene D, 2002, J BIOL CHEM, V277, P32587, DOI 10.1074/jbc.M111106200; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Fernandes JC, 2002, BIORHEOLOGY, V39, P237; Fortier LA, 2001, J ORTHOPAED RES, V19, P720, DOI 10.1016/S0736-0266(00)00070-X; FOSANG AJ, 1991, MATRIX, V11, P17, DOI 10.1016/S0934-8832(11)80223-4; Fukumoto T, 2003, OSTEOARTHR CARTILAGE, V11, P55, DOI 10.1053/joca.2002.0869; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1266, DOI 10.1002/1529-0131(199807)41:7<1266::AID-ART18>3.0.CO;2-Y; Hidaka K, 2001, INT J BIOCHEM CELL B, V33, P1094, DOI 10.1016/S1357-2725(01)00067-X; Hui W, 2001, CYTOKINE, V16, P31, DOI 10.1006/cyto.2001.0950; Hui W, 2001, ANN RHEUM DIS, V60, P254, DOI 10.1136/ard.60.3.254; Kim B, 2002, J BIOL CHEM, V277, P27393, DOI 10.1074/jbc.M201963200; Kim SJ, 2003, BIOCHEM BIOPH RES CO, V303, P206, DOI 10.1016/S0006-291X(03)00305-X; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Kim SJ, 2002, J BIOL CHEM, V277, P30375, DOI 10.1074/jbc.M205193200; Kolettas E, 2001, RHEUMATOLOGY, V40, P1146, DOI 10.1093/rheumatology/40.10.1146; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Loeser RF, 2000, ARTHRITIS RHEUM, V43, P2110, DOI 10.1002/1529-0131(200009)43:9<2110::AID-ANR23>3.0.CO;2-U; Loeser RF, 2000, ARTHRITIS RHEUM-US, V43, P1552, DOI 10.1002/1529-0131(200007)43:7<1552::AID-ANR20>3.0.CO;2-W; Martel-Pelletier J, 1998, INFLAMM RES, V47, P90, DOI 10.1007/s000110050288; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; McCarthy TL, 2001, GROWTH HORM IGF RES, V11, P213, DOI 10.1054/ghir.2001.0236; McQueeney K, 2001, GROWTH HORM IGF RES, V11, P346, DOI 10.1054/ghir.2001.0250; Mi ZB, 2000, ARTHRITIS RHEUM, V43, P2563, DOI 10.1002/1529-0131(200011)43:11<2563::AID-ANR25>3.0.CO;2-8; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Oh CD, 2001, EUR J PHARMACOL, V427, P175, DOI 10.1016/S0014-2999(01)01241-9; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Poole AR, 1999, FRONT BIOSCI, V4, P662; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Sandell L., 1999, FRONT BIOSCI-LANDMRK, V4, P731; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; SCHALKWIJK J, 1989, ARTHRITIS RHEUM, V32, P66, DOI 10.1002/anr.1780320111; SCHALKWIJK J, 1989, ARTHRITIS RHEUM, V32, P894; Schneiderman R, 1995, ARCH BIOCHEM BIOPHYS, V324, P173, DOI 10.1006/abbi.1995.9913; Shum L, 2002, ARTHRITIS RES, V4, P94, DOI 10.1186/ar396; Tavera C, 1996, OSTEOARTHR CARTILAGE, V4, P263, DOI 10.1016/S1063-4584(05)80104-9; Thimmaiah KN, 2003, CANCER RES, V63, P364; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Yaeger PC, 1997, EXP CELL RES, V237, P318, DOI 10.1006/excr.1997.3781; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Yatsugi N, 2000, J Orthop Sci, V5, P150, DOI 10.1007/s007760050142; Yoon JB, 2003, J BIOL CHEM, V278, P15319, DOI 10.1074/jbc.M212520200; Yoon YM, 2000, J BONE MINER RES, V15, P2197, DOI 10.1359/jbmr.2000.15.11.2197; Yoon YM, 2000, J BIOL CHEM, V275, P12353, DOI 10.1074/jbc.275.16.12353; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200	59	123	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36563	36571		10.1074/jbc.M304857200	http://dx.doi.org/10.1074/jbc.M304857200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12853454	hybrid			2022-12-25	WOS:000185318300086
J	Protchenko, O; Philpott, CC				Protchenko, O; Philpott, CC			Regulation of intracellular heme levels by HMX1, a homologue of heme oxygenase, in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR FACILITATOR SUPERFAMILY; MEDIATED IRON UPTAKE; CORYNEBACTERIUM-DIPHTHERIAE; HMU-O; ENDOPLASMIC-RETICULUM; OXIDATIVE CLEAVAGE; CRYSTAL-STRUCTURE; CANDIDA-ALBICANS; SIDEROPHORE-IRON; YEAST	Saccharomyces cerevisiae responds to iron deprivation by increasing the transcription of genes involved in the uptake of environmental iron and in the mobilization of vacuolar iron stores. HMX1 is also transcribed under conditions of iron deprivation and is under the control of the major iron-dependent transcription factor, Aft1p. Although Hmx1p exhibits limited homology to heme oxygenases, it has not been shown to be enzymatically active. We find that Hmx1p is a resident protein of the endoplasmic reticulum and that isolated yeast membranes contain a heme degradation activity that is dependent on HMX1. Hmx1p facilitates the capacity of cells to use heme as a nutritional iron source. Deletion of HMX1 leads to defects in iron accumulation and to expansion of intracellular heme pools. These alterations in the regulatory pools of iron lead to activation of Aft1p and inappropriate activation of heme-dependent transcription factors. Expression of HmuO, the heme oxygenase from Corynebacterium diphtheriae, restores iron and heme levels, as well as Aft1p- and heme-dependent transcriptional activities, to those of wild type cells, indicating that the heme degradation activity associated with Hmx1p is important in mediating iron and heme homeostasis. Hmx1p promotes both the reutilization of heme iron and the regulation of heme-dependent transcription during periods of iron scarcity.	NIDDK, Liver Dis Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Philpott, CC (corresponding author), NIDDK, Liver Dis Sect, NIH, Bldg 10,Rm 9B-16,10 Ctr Dr,MSC 1800, Bethesda, MD 20892 USA.	carolinep@intra.niddk.nih.gov	Protchenko, Olga/AAU-9237-2021	Protchenko, Olga/0000-0002-4688-4214	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK054507, Z01DK054507] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams Alison, 1997, P123; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Auclair K, 2003, PROTEIN EXPRES PURIF, V28, P340, DOI 10.1016/S1046-5928(02)00699-X; Baxter BK, 1996, MOL CELL BIOL, V16, P6444; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Chu GC, 1999, J BIOL CHEM, V274, P21319, DOI 10.1074/jbc.274.30.21319; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; Cornejo J, 1998, PLANT J, V15, P99, DOI 10.1046/j.1365-313X.1998.00186.x; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Davis SJ, 2001, PLANT PHYSIOL, V126, P656, DOI 10.1104/pp.126.2.656; de Montellano PRO, 2000, CURR OPIN CHEM BIOL, V4, P221; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; GALBRAITH RA, 1985, J BIOL CHEM, V260, P2198; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; GOLLUB EG, 1977, J BIOL CHEM, V252, P2846; Heymann P, 2000, BIOMETALS, V13, P65, DOI 10.1023/A:1009250017785; Heymann P, 1999, BIOMETALS, V12, P301, DOI 10.1023/A:1009252118050; Heymann P, 2000, FEMS MICROBIOL LETT, V186, P221, DOI 10.1016/S0378-1097(00)00152-X; Kwast KE, 1998, J EXP BIOL, V201, P1177; Lange H, 1999, J BIOL CHEM, V274, P18989, DOI 10.1074/jbc.274.27.18989; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Lin SJ, 1997, J BIOL CHEM, V272, P9215; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; Philpott CC, 1998, EMBO J, V17, P5026, DOI 10.1093/emboj/17.17.5026; Portnoy ME, 2002, BIOCHEM J, V362, P119, DOI 10.1042/bj3620119; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Reilly BA, 2001, MOL BIOL CELL, V12, P3783, DOI 10.1091/mbc.12.12.3783; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; Santos R, 2003, MICROBIOL-SGM, V149, P579, DOI 10.1099/mic.0.26108-0; Schneider BL, 1996, YEAST, V12, P129, DOI 10.1002/(SICI)1097-0061(199602)12:2<129::AID-YEA891>3.0.CO;2-O; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Stadler JA, 2002, J BIOL CHEM, V277, P39649, DOI 10.1074/jbc.M203924200; Stearman R, 1998, GENE, V212, P197, DOI 10.1016/S0378-1119(98)00179-6; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Wang JL, 2003, J BIOL CHEM, V278, P20069, DOI 10.1074/jbc.M300989200; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; Weissman Z, 2002, MOL MICROBIOL, V44, P1551, DOI 10.1046/j.1365-2958.2002.02976.x; Wilks A, 2000, J BIOL CHEM, V275, P11686, DOI 10.1074/jbc.275.16.11686; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YOSHIDA T, 1978, J BIOL CHEM, V253, P4230; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709; Yun CW, 2001, J BIOL CHEM, V276, P10218, DOI 10.1074/jbc.M010065200; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000; Zhu WM, 2000, J BACTERIOL, V182, P439, DOI 10.1128/JB.182.2.439-447.2000	56	63	67	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36582	36587		10.1074/jbc.M306584200	http://dx.doi.org/10.1074/jbc.M306584200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12840010	hybrid			2022-12-25	WOS:000185318300088
J	Sanceau, J; Truchet, S; Bauvois, B				Sanceau, J; Truchet, S; Bauvois, B			Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPH-NODE METASTASIS; NECROSIS-FACTOR-ALPHA; E-CADHERIN; MATRIX METALLOPROTEINASES; IV COLLAGENASE; BETA-CATENIN; TISSUE INHIBITORS; CANCER-CELLS; RELATIVE EXPRESSION; SIGNAL-TRANSDUCTION	Enhanced expression of (pro) matrix metalloproteinase-9 (MMP-9) is associated with human tumor invasion and/or metastasis. COH cells derived from a highly invasive and metastatic Ewing's sarcoma constitutively express proMMP-9. Transfection of a double stranded RNA that targets the MMP-9 mRNA into COH cells depleted the corresponding mRNA and protein as demonstrated by reverse transcriptase-PCR, enzyme-linked immunosorbent assay, and gelatin zymography. proMMP-9 extinction resulted in the following: (i) decreased spreading on extracellular matrix (fibronectin, laminin, collagen IV)-coated surfaces, (ii) inhibition of migration toward fibronectin, and (iii) induced aggregation, which was specifically disrupted by a function-blocking E-cadherin antibody. MMP-9 knockdown concomitantly resulted in increased levels of surface E-cadherin, redistribution at the plasma membrane of beta-catenin, and its physical association with E-cadherin. Moreover, induction of E-cadherin-mediated adhesion was associated with RhoA activation and changes in paxillin cytoskeleton. Finally, an inhibitor of gelatinolytic activity of pro-MMP9 did not reduce COH cell migration confirming that the enzymatic property of COH MMP-9 was not required for migration toward fibronectin. Overall, our observations define a novel critical role for proMMP-9 in providing a cellular switch between stationary and migratory cell phases.	Inst Curie, INSERM, U365, F-75248 Paris 05, France; INSERM, Museum Natl Hist Nat, U565,UMR 8646,MNHN, CNRS, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN)	Bauvois, B (corresponding author), Inst Curie, INSERM, U365, 26 Rue Ulm, F-75248 Paris 05, France.	bbauvois@curie.fr	Truchet, Sandrine/O-9067-2017; Truchet, Sandrine/G-9753-2014; Bauvois, Brigitte/F-6776-2013	Truchet, Sandrine/0000-0002-7737-9202; Truchet, Sandrine/0000-0002-7737-9202; Bauvois, Brigitte/0000-0002-1751-6922				Alahari SK, 2002, INT REV CYTOL, V220, P145; Anzai H, 1996, DIFFERENTIATION, V60, P119, DOI 10.1046/j.1432-0436.1996.6020119.x; Ashida N, 2001, J BIOL CHEM, V276, P16555, DOI 10.1074/jbc.M009068200; Bannikov GA, 2002, J BIOL CHEM, V277, P16022, DOI 10.1074/jbc.M110931200; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BAUVOIS B, 1992, J IMMUNOL, V148, P3912; Bauvois B, 2002, LEUKEMIA, V16, P791, DOI 10.1038/sj.leu.2402472; BERNHARD EJ, 1990, CANCER RES, V50, P3872; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; BONFIL RD, 1992, CLIN EXP METASTAS, V10, P211; Bouman L, 2002, BIOCHEM J, V364, P719, DOI 10.1042/BJ20011854; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Brantl S, 2002, BBA-GENE STRUCT EXPR, V1575, P15, DOI 10.1016/S0167-4781(02)00280-4; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; De Arcangelis A, 2001, INT J CANCER, V94, P44, DOI 10.1002/ijc.1444; DeFife KM, 1999, J HISTOCHEM CYTOCHEM, V47, P65, DOI 10.1177/002215549904700107; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; Fiore E, 2002, ONCOGENE, V21, P5213, DOI 10.1038/sj.onc.1205684; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; HAMELIN R, 1994, INT J CANCER, V57, P336, DOI 10.1002/ijc.2910570308; Hua J, 1996, CANCER RES, V56, P5279; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Hummel V, 2001, J NEUROPATH EXP NEUR, V60, P320, DOI 10.1093/jnen/60.4.320; Inoue K, 2002, CLIN CANCER RES, V8, P1863; Janowska-Wieczorek A, 1999, BRIT J HAEMATOL, V105, P402, DOI 10.1046/j.1365-2141.1999.01352.x; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kaihara T, 2001, PATHOBIOLOGY, V69, P172, DOI 10.1159/000048772; Knudsen KA, 1998, J CELL BIOCHEM, P168; Kondraganti S, 2000, CANCER RES, V60, P6851; Kossakowska AE, 2000, LEUKEMIA LYMPHOMA, V39, P485, DOI 10.3109/10428190009113379; Kubota S, 1996, CANCER LETT, V98, P233; Kuniyasu H, 1999, CLIN CANCER RES, V5, P25; Kuniyasu H, 2000, CLIN CANCER RES, V6, P2295; Kupferman ME, 2000, AM J PATHOL, V157, P1777, DOI 10.1016/S0002-9440(10)64815-8; Lakka SS, 2002, ONCOGENE, V21, P8011, DOI 10.1038/sj.onc.1205894; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; Liu SC, 2000, J BIOL CHEM, V275, P22736, DOI 10.1074/jbc.M000388200; Llorens A, 1998, LAB INVEST, V78, P1131; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; MACDOUGALL JR, 1995, EXP CELL RES, V218, P508, DOI 10.1006/excr.1995.1185; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Nakamura K, 2001, ONCOGENE, V20, P2626, DOI 10.1038/sj.onc.1204359; Opdenakker G, 2002, Verh K Acad Geneeskd Belg, V64, P105; Orsulic S, 1999, J CELL SCI, V112, P1237; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Panetti TS, 2002, FRONT BIOSCI-LANDMRK, V7, pD143, DOI 10.2741/panetti; Paulussen M, 2001, ANN ONCOL, V12, P1619, DOI 10.1023/A:1013148730966; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Ridley AJ, 2001, J CELL SCI, V114, P2713; ROY S, 2000, CLIN CANCER RES, V6, P790; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sanceau J, 2002, J BIOL CHEM, V277, P35766, DOI 10.1074/jbc.M202959200; Sato F, 1999, BRIT J CANCER, V80, P1366, DOI 10.1038/sj.bjc.6690530; Slaton JW, 2001, CLIN CANCER RES, V7, P2840; Spessotto P, 2002, J CELL BIOL, V158, P1133, DOI 10.1083/jcb.200202120; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; Tomanek RJ, 2000, ANAT RECORD, V261, P126, DOI 10.1002/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4; Trocme C, 1998, J BIOL CHEM, V273, P20677, DOI 10.1074/jbc.273.32.20677; Truchet S, 2001, MOL REPROD DEV, V60, P319, DOI 10.1002/mrd.1094; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Vizirianakis IS, 2002, INT J ONCOL, V21, P135; WATANABE H, 1993, J CELL SCI, V104, P991; Westphal JR, 2000, INT J CANCER, V86, P768, DOI 10.1002/(SICI)1097-0215(20000615)86:6<768::AID-IJC3>3.3.CO;2-5; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhai Y, 2002, AM J PATHOL, V160, P1229, DOI 10.1016/S0002-9440(10)62550-3; Zhang CH, 1996, J IMMUNOL, V157, P3980	82	103	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36537	36546		10.1074/jbc.M304300200	http://dx.doi.org/10.1074/jbc.M304300200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847101	Green Published, hybrid			2022-12-25	WOS:000185318300083
J	Tate, JJ; Cooper, TG				Tate, JJ; Cooper, TG			Tor1/2 regulation of retrograde gene expression in Saccharomyces cerevisiae derives indirectly as a consequence of alterations in ammonia metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN CATABOLITE REPRESSION; RTG-DEPENDENT MITOCHONDRIA; GLUTAMATE-DEHYDROGENASE; METHIONINE SULFOXIMINE; NUCLEAR-LOCALIZATION; INHIBITION; RAPAMYCIN; YEAST; COMMUNICATION; MECHANISM	Retrograde genes of Saccharomyces cerevisiae encode the enzymes needed to synthesize alpha-ketoglutarate, required for ammonia assimilation, when mitochondria are damaged or non-functional because of glucose fermentation. Therefore, it is not surprising that a close association exists between control of the retrograde regulon and expression of nitrogen catabolic genes. Expression of these latter genes is nitrogen catabolite repression (NCR)-sensitive, i.e. expression is low with good nitrogen sources (e.g. glutamine) and high when only poor (e.g. proline) or limiting nitrogen sources are available. It has been reported recently that both NCR-sensitive and retrograde gene expression is negatively regulated by glutamine and induced by treating cells with the Tor1/2 inhibitor, rapamycin. These conclusions predict that NCR-sensitive and retrograde gene expression should respond in parallel to nitrogen sources, ranging from those that highly repress NCR-sensitive transcription to those that elicit minimal NCR. Because this prediction did not accommodate earlier observations that CIT2 ( a retrograde gene) expression is higher in glutamine than proline containing medium, we investigated retrograde regulation further. We show that (i) retrograde gene expression correlates with intracellular ammonia and alpha-ketoglutarate generated by a nitrogen source rather than the severity of NCR it elicits, and (ii) in addition to its known regulation by NCR, NAD-glutamate dehydrogenase (GDH2) gene expression is down-regulated by ammonia under conditions where NCR is minimal. Therefore, intracellular ammonia plays a pivotal dual role, regulating the interface of nitrogen and carbon metabolism at the level of ammonia assimilation and production. Our results also indicate the effects of rapamycin treatment on CIT2 transcription, and hence Tor1/2 regulation of retrograde gene expression occur indirectly as a consequence of alterations in ammonia and glutamate metabolism.	Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35642, R01 GM035642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; BOSSINGER J, 1975, BIOCHEM BIOPH RES CO, V66, P889, DOI 10.1016/0006-291X(75)90723-8; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CHELSTOWSKA A, 1995, J BIOL CHEM, V270, P18141, DOI 10.1074/jbc.270.30.18141; COOPER AJL, 1976, J BIOL CHEM, V251, P6674; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; Cox KH, 2002, J BIOL CHEM, V277, P37559, DOI 10.1074/jbc.M204879200; Cox KH, 1999, YEAST, V15, P703, DOI 10.1002/(SICI)1097-0061(19990615)15:8<703::AID-YEA413>3.0.CO;2-Z; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; Crespo JL, 2002, P NATL ACAD SCI USA, V99, P6784, DOI 10.1073/pnas.102687599; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; Dilova I, 2002, CURR BIOL, V12, P389, DOI 10.1016/S0960-9822(02)00677-2; DUBOIS E, 1974, EUR J BIOCHEM, V48, P603, DOI 10.1111/j.1432-1033.1974.tb03803.x; Edskes HK, 1999, GENETICS, V153, P585; GRIFFITH OW, 1978, J BIOL CHEM, V253, P2333; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; Liu ZC, 2001, EMBO J, V20, P7209, DOI 10.1093/emboj/20.24.7209; MILLER SM, 1991, MOL CELL BIOL, V11, P6229, DOI 10.1128/MCB.11.12.6229; PETERSEN JGL, 1988, GENETICS, V119, P527; Pierce MM, 2001, P NATL ACAD SCI USA, V98, P13213, DOI 10.1073/pnas.181486098; Rai R, 2003, J BIOL CHEM, V278, P12826, DOI 10.1074/jbc.M212186200; RICHMAN PG, 1973, J BIOL CHEM, V248, P6684; Sekito T, 2000, MOL BIOL CELL, V11, P2103, DOI 10.1091/mbc.11.6.2103; Sekito T, 2002, MOL BIOL CELL, V13, P795, DOI 10.1091/mbc.01-10-0473; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; SUMRADA R, 1976, J BACTERIOL, V125, P1048, DOI 10.1128/JB.125.3.1048-1056.1976; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; TUROSCY V, 1982, J BACTERIOL, V151, P1237, DOI 10.1128/JB.151.3.1237-1246.1982; Velot C, 1996, GENETICS, V144, P893; WATSON TG, 1977, J GEN MICROBIOL, V103, P123, DOI 10.1099/00221287-103-1-123; WATSON TG, 1976, J GEN MICROBIOL, V96, P263, DOI 10.1099/00221287-96-2-263; ZHEGCHANG L, 1999, MOL CELL BIOL, V19, P6720	36	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36924	36933		10.1074/jbc.M301829200	http://dx.doi.org/10.1074/jbc.M301829200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851403	hybrid, Green Accepted			2022-12-25	WOS:000185318300126
J	Li, XH; Ong, DE				Li, XH; Ong, DE			Cellular retinoic acid-binding protein II gene expression is directly induced by estrogen, but not retinoic acid, in rat uterus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; RESPONSIVE ELEMENT; RECEPTOR INTERACTION; MOLECULAR-CLONING; DNA-BINDING; IN-VITRO; CELLS; INDUCTION; ALPHA; 17-BETA-ESTRADIOL	It has been suggested that cellular retinoic acid-binding protein (II) (CRABP(II)) may have a role in the movement of retinoic acid (RA) to its nuclear receptors, thereby enhancing the action of RA in the cells in which it is expressed. RA has also been shown to increase expression of CRABP(II). Previous work from our laboratory has shown that 17beta-estradiol (E-2) administration to prepubertal female rats leads to acquisition of the ability of the lining epithelium to synthesize RA as well as to express CRABP(II). To determine whether this appearance of CRABP(II) was dependent on the production of RA, both E-2 and RA were administered to ovariectomized rats. E-2 administration induced expression of the CRABP(II) gene in the uterus within 4 h, and this induction was not inhibited by prior administration of puromycin, indicating that the induction was direct. In contrast, RA caused no change in CRABP(II) message level, even at times as late as 48 h after administration. Isolation and analysis of 4.5 kb of the 5'-flanking region of the gene revealed no apparent E-2-response element. Using this portion of the gene to drive expression of the luciferase gene in transfected cells allowed identification of a region containing an imperfect estrogen-response element and estrogen-response element half-site, necessary for E-2-driven induction. A possible Sp1 binding site in the 5'-flanking region of the CRABP(II) gene was also required for this induction. The ability of E-2 to induce expression of CRABP(II) suggests that it can enhance the activity of RA, directly affecting expression of retinoid-responsive genes.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA	Vanderbilt University	Ong, DE (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 23rd Ave & Pierce, Nashville, TN 37232 USA.	david.e.ong@vanderbilt.edu		, Xiaohong/0000-0001-5074-193X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025206] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032642, P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68485] Funding Source: Medline; NICHD NIH HHS [HD25206] Funding Source: Medline; NIDDK NIH HHS [DK32642, DK 20593] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASTROM A, 1992, J BIOL CHEM, V267, P25251; ASTROM A, 1991, J BIOL CHEM, V266, P17662; ASTROM A, 1994, J BIOL CHEM, V269, P22334; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; Bastie JN, 2001, FEBS LETT, V507, P67, DOI 10.1016/S0014-5793(01)02938-6; Bucco RA, 1997, BIOCHEMISTRY-US, V36, P4009, DOI 10.1021/bi962094o; Budhu A, 2001, J MOL BIOL, V305, P939, DOI 10.1006/jmbi.2000.4340; Budhu AS, 2002, MOL CELL BIOL, V22, P2632, DOI 10.1128/MCB.22.8.2632-2641.2002; CHAMBON P, 1993, GENE, V135, P223, DOI 10.1016/0378-1119(93)90069-F; Delva L, 1999, MOL CELL BIOL, V19, P7158; Dong D, 1999, J BIOL CHEM, V274, P23695, DOI 10.1074/jbc.274.34.23695; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; Haq R, 1988, Biochem Biophys Res Commun, V156, P712, DOI 10.1016/S0006-291X(88)80901-X; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLINGE CM, 1992, CANCER RES, V52, P1073; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li C, 2001, ENDOCRINOLOGY, V142, P1546, DOI 10.1210/en.142.4.1546; MACGREGOR TM, 1992, J BIOL CHEM, V267, P7777; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; Mira-y-Lopez R, 2000, J CELL PHYSIOL, V185, P302, DOI 10.1002/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#; Nardulli AM, 1996, MOL ENDOCRINOL, V10, P694, DOI 10.1210/me.10.6.694; Qin CH, 1999, ENDOCRINOLOGY, V140, P2501, DOI 10.1210/en.140.6.2501; Rishi AK, 1996, CANCER RES, V56, P5246; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994; Scholz A, 1998, J BIOL CHEM, V273, P4360, DOI 10.1074/jbc.273.8.4360; Vyhlidal C, 2000, J MOL ENDOCRINOL, V24, P329, DOI 10.1677/jme.0.0240329; Wang F, 1997, BIOCHEMISTRY-US, V36, P7793, DOI 10.1021/bi963100j; Wang F, 2002, J CELL BIOCHEM, V84, P156, DOI 10.1002/jcb.1276; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Xing WR, 1998, MOL ENDOCRINOL, V12, P1310, DOI 10.1210/me.12.9.1310; Zheng WL, 1998, BIOL REPROD, V58, P963, DOI 10.1095/biolreprod58.4.963; Zheng WL, 1999, BIOL REPROD, V60, P110, DOI 10.1095/biolreprod60.1.110; Zheng WL, 2000, ENDOCRINOLOGY, V141, P802, DOI 10.1210/en.141.2.802	38	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35819	35825		10.1074/jbc.M302551200	http://dx.doi.org/10.1074/jbc.M302551200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842898	hybrid			2022-12-25	WOS:000185164400131
J	Maeda, N; He, J; Yajima, Y; Mikami, T; Sugahara, K; Yabe, T				Maeda, N; He, J; Yajima, Y; Mikami, T; Sugahara, K; Yabe, T			Heterogeneity of the chondroitin sulfate portion of phosphacan/6B4 proteoglycan regulates its binding affinity for pleiotrophin/heparin binding growth-associated molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE-ZETA/BETA; ZETA/RPTP-BETA; EXTRACELLULAR VARIANT; MONOCLONAL-ANTIBODY; KERATAN SULFATE; FACTOR MIDKINE; CELL-ADHESION; BRAIN; INVOLVEMENT; LIGAND	PTPzeta is a receptor-type protein-tyrosine phosphatase that is synthesized as a chondroitin sulfate proteoglycan and uses pleiotrophin as a ligand. The chondroitin sulfate portion of this receptor is essential for high affinity binding to pleiotrophin. Here, we purified phosphacan, which corresponds to the extracellular domain of PTPzeta, from postnatal day 7 (P7) and P12 rat cerebral cortex (PG-P7 and PG-P12, respectively) and from P20 rat whole brain (PG-P20). The chondroitin sulfate of these preparations displayed immunologically and compositionally different structures. In particular, only PG-P20 reacted with the monoclonal antibody MO-225, which recognizes chondroitin sulfate containing the GlcA(2S)beta1-3GalNAc(6S) disaccharide unit (D unit). Analysis of the chondroitinase digestion products revealed that GlcAbeta1-3GalNAc(4S) disaccharide unit (A unit) was the major component in these preparations and that PG-P20 contained 1.3% D unit, which was not detected in PG-P7 and PG-P12. Interaction analysis using a surface plasmon resonance biosensor indicated that PG-P20 had similar to5-fold stronger affinity for pleiotrophin (dissociation constant (K-D) = 0.14 nM) than PG-P7 and PG-P12, although all these preparations showed similar low affinity binding to pleiotrophin after chondroitinase ABC digestion (K-D = 1.4 similar to 1.6 nM). We also found that shark cartilage chondroitin sulfate D containing similar to20% D unit bound to pleiotrophin with moderate affinity (K-D = 2.7 nM), whereas whale cartilage chondroitin sulfate A showed no binding to this growth factor. These results suggest that variation of chondroitin sulfate plays important roles in the regulation of signal transduction in the brain.	Tokyo Metropolitan Inst Neurosci, Dept Dev Neurosci, Tokyo 1838526, Japan; Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Kobe Pharmaceutical University	Maeda, N (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Dev Neurosci, 2-6 Musashidai, Tokyo 1838526, Japan.	maedan@tmin.ac.jp	Yabe, Tomio/B-5900-2013	Yabe, Tomio/0000-0002-9295-8560				AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Garwood J, 1999, J NEUROSCI, V19, P3888; Hamanaka H, 1997, EUR J NEUROSCI, V9, P2297, DOI 10.1111/j.1460-9568.1997.tb01647.x; Ichijo H, 2001, J NEUROSCI, V21, P9304, DOI 10.1523/JNEUROSCI.21-23-09304.2001; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kurosawa N, 2000, EUR J BIOCHEM, V267, P344, DOI 10.1046/j.1432-1327.2000.01005.x; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; MAEDA N, 1992, DEV BIOL, V151, P564, DOI 10.1016/0012-1606(92)90194-L; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Nishiwaki T, 1998, J BIOCHEM-TOKYO, V123, P458; OOHIRA A, 1994, NEUROSCIENCE, V60, P145, DOI 10.1016/0306-4522(94)90210-0; Peles E, 1998, TRENDS BIOCHEM SCI, V23, P121, DOI 10.1016/S0968-0004(98)01195-5; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Tanaka M, 2003, J NEUROSCI, V23, P2804, DOI 10.1523/jneurosci.23-07-02804.2003; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Vacherot F, 1999, J BIOL CHEM, V274, P7741, DOI 10.1074/jbc.274.12.7741; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4; Zou P, 2003, GLYCOBIOLOGY, V13, P35, DOI 10.1093/glycob/cwg001	35	93	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35805	35811		10.1074/jbc.M305530200	http://dx.doi.org/10.1074/jbc.M305530200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12840014	hybrid			2022-12-25	WOS:000185164400129
J	Henneke, G; Koundrioukoff, S; Hubscher, U				Henneke, G; Koundrioukoff, S; Hubscher, U			Phosphorylation of human Fen1 by cyclin-dependent kinase modulates its role in replication fork regulation	ONCOGENE			English	Article						replication; cell cycle; Fen1; Cdks; phosphorylation	EUKARYOTIC DNA-REPLICATION; HUMAN FLAP ENDONUCLEASE-1; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; CDC2 PHOSPHORYLATION; MOTIF PRESENT; PCNA-BINDING; YEAST; REPAIR; PROTEINS	Cyclin-dependent kinase (Cdk) Cdk1-Cyclin A can phosphorylate Flap endonuclease 1 (Fen1), a key-enzyme of the DNA replication machinery, in late S phase. Cdk1-cyclin A forms a complex in vitro and in vivo with Fen1. Furthermore, Fen1 phosphorylation is detected in vivo and depends upon Cdks activity. As a functional consequence of phosphorylation by Cdk1-Cyclin A in vitro, endo- and exonuclease activities of Fen1 are reduced whereas its DNA binding is not affected. Moreover, phosphorylation of Fen1 by Cdk1-Cyclin A abrogates its proliferating cell nuclear antigen (PCNA) binding thus preventing stimulation of Fen1 by PCNA. Concomitantly, human cells expressing the S187A mutant defective for Cdk1-Cyclin A phosphorylation accumulate in S phase consistent with a failure in cell cycle regulation through DNA replication. Our results suggest a novel regulatory role of Cdks onto the end of S phase by targeting directly a key enzyme involved in DNA replication.	Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	University of Zurich	Hubscher, U (corresponding author), Univ Zurich, Inst Vet Biochem & Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	hubscher@vetbio.unizh.ch		Henneke, Ghislaine/0000-0002-2985-5526				ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Biswas EE, 1997, BIOCHEMISTRY-US, V36, P5955, DOI 10.1021/bi962890u; Brosh RM, 2001, EMBO J, V20, P5791; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Dahm K, 2002, ONCOGENE, V21, P7710, DOI 10.1038/sj.onc.1205872; Donaldson AD, 1999, CURR OPIN GENET DEV, V9, P62, DOI 10.1016/S0959-437X(99)80009-4; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; Fotedar R, 1995, Prog Cell Cycle Res, V1, P73; Frouin I, 2002, EMBO J, V21, P2485, DOI 10.1093/emboj/21.10.2485; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hasan S, 2001, MOL CELL, V7, P1221, DOI 10.1016/S1097-2765(01)00272-6; Henneke G, 2003, EMBO REP, V4, P252, DOI 10.1038/sj.embor.embor774; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Johnston L H, 2000, Prog Cell Cycle Res, V4, P61; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kang HY, 2000, GENETICS, V155, P1055; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Koundrioukoff S, 2000, J BIOL CHEM, V275, P22882, DOI 10.1074/jbc.M001850200; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Lin XH, 1998, P NATL ACAD SCI USA, V95, P14693, DOI 10.1073/pnas.95.25.14693; Matsuzaki Y, 2002, NUCLEIC ACIDS RES, V30, P3273, DOI 10.1093/nar/gkf440; MCVEY D, 1993, J VIROL, V67, P5206, DOI 10.1128/JVI.67.9.5206-5215.1993; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Parenteau J, 1999, MOL CELL BIOL, V19, P4143; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; Schub O, 2001, J BIOL CHEM, V276, P38076; Schurtenberger P, 1998, J MOL BIOL, V275, P123, DOI 10.1006/jmbi.1997.1435; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Storici F, 2002, EMBO J, V21, P5930, DOI 10.1093/emboj/cdf587; Stucki M, 2001, J BIOL CHEM, V276, P7843, DOI 10.1074/jbc.M008829200; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Vas A, 2001, MOL CELL BIOL, V21, P5767, DOI 10.1128/MCB.21.17.5767-5777.2001; Voitenleitner C, 1997, ONCOGENE, V14, P1611, DOI 10.1038/sj.onc.1200975; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	56	83	87	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4301	4313		10.1038/sj.onc.1206606	http://dx.doi.org/10.1038/sj.onc.1206606			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853968				2022-12-25	WOS:000183978900001
J	Steiling, H; Wustefeld, T; Bugnon, P; Brauchle, M; Fassler, R; Teupser, D; Thiery, J; Gordon, JI; Trautwein, C; Werner, S				Steiling, H; Wustefeld, T; Bugnon, P; Brauchle, M; Fassler, R; Teupser, D; Thiery, J; Gordon, JI; Trautwein, C; Werner, S			Fibroblast growth factor receptor signalling is crucial for liver homeostasis and regeneration	ONCOGENE			English	Article						cell cycle; hepatectomy; injury; keratinocyte growth factor; regeneration; steatosis	TARGETED EXPRESSION; TRANSGENIC MICE; DNA-SYNTHESIS; RAT; HEPATOCYTES; PROLIFERATION; MORPHOGENESIS; INITIATION; PROTEIN; FGF	Several growth factors have been suggested to play a crucial role in liver regeneration, but a functional proof is still missing. Since fibroblast growth factors are important for the initiation of mammalian liver development, we determined the roles of these mitogens in liver repair by targeted expression of a dominant-negative fibroblast growth factor receptor (FGFR) in hepatocytes of transgenic mice. The liver of young animals appeared histologically normal, and liver function was not obviously impaired. In aged transgenic mice, the frequency of fatty liver development was strongly increased compared to control animals. Following partial hepatectomy, transgenic mice showed markedly reduced hepatocyte proliferation because of an arrest in the late G(1) phase of the cell cycle. These data demonstrate a key role of FGFR signalling in repair after liver injury.	Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland; Hannover Med Sch, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany; Novatis Pharma AG, CH-4002 Basel, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Klinikum Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, D-04103 Leipzig, Germany; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Hannover Medical School; Max Planck Society; Leipzig University; Washington University (WUSTL)	Werner, S (corresponding author), Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland.	sabine.werner@cell.biol.ethz.ch		Werner, Sabine/0000-0001-7397-8710				Arora V, 2000, J PHARMACOL EXP THER, V292, P921; Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; HOUSLEY RM, 1994, J CLIN INVEST, V94, P1764, DOI 10.1172/JCI117524; HU ZY, 1995, CELL GROWTH DIFFER, V6, P1019; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; KORHONEN J, 1992, INT J DEV BIOL, V36, P323; Loyer P, 1996, Prog Cell Cycle Res, V2, P37; Ludde T, 2001, ONCOGENE, V20, P5264, DOI 10.1038/sj.onc.1204690; MARSDEN ER, 1992, LAB INVEST, V67, P427; NONOGAKI K, 1995, ENDOCRINOLOGY, V136, P4278, DOI 10.1210/en.136.10.4278; Ornitz DM, 2001, GENOME BIOL, V2; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; Senaldi G, 1998, HEPATOLOGY, V27, P1584, DOI 10.1002/hep.510270618; STRAIN AJ, 1994, EXP CELL RES, V210, P253, DOI 10.1006/excr.1994.1037; SUZUKI M, 1993, FEBS LETT, V328, P17, DOI 10.1016/0014-5793(93)80956-U; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; Trautwein C, 1998, J CLIN INVEST, V101, P1960, DOI 10.1172/JCI504; UENO H, 1992, J BIOL CHEM, V267, P1470; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482	27	64	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4380	4388		10.1038/sj.onc.1206499	http://dx.doi.org/10.1038/sj.onc.1206499			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853974				2022-12-25	WOS:000183978900007
J	Crabtree, M; Sieber, OM; Lipton, L; Hodgson, SV; Lamlum, H; Thomas, HJW; Neale, K; Phillips, RKS; Heinimann, K; Tomlinson, IPM				Crabtree, M; Sieber, OM; Lipton, L; Hodgson, SV; Lamlum, H; Thomas, HJW; Neale, K; Phillips, RKS; Heinimann, K; Tomlinson, IPM			Refining the relation between 'first hits' and 'second hits' at the APC locus: the 'loose fit' model and evidence for differences in somatic mutation spectra among patients	ONCOGENE			English	Article						polyposis; APC; colorectal tumours; two-hit hypothesis	FAMILIAL ADENOMATOUS POLYPOSIS; COLORECTAL TUMORS; CLUSTER REGION; GENE; PHENOTYPE; GENOTYPE; GERMLINE; PROTEIN	The site of the 'first hit' in the APC tumour suppressor gene determines the type of the 'second hit', both in familial adenomatous polyposis (FAP) and sporadic colorectal tumours. Mutations near codon 1300 are associated with loss of heterozygosity (LOH) of the wild-type allele; other tumours tend to have two protein-truncating mutations. In this study, we have confirmed and refined the LOH-associated region in colorectal FAP: allelic loss in adenomatous polyps tended to occur when the germline mutation lay in the region of the APC gene between the first and second beta-catenin degradation repeats (codons 1285-1378). LOH generally occurred by mitotic recombination, leaving two identical alleles, each encoding a protein with one remaining beta-catenin degradation repeat. For patients with germline mutations that truncated the protein before the first repeat (codon 1264), LOH was very rare and tumours generally acquired a somatic mutation which left two, or less often one, repeats remaining in the protein. In our sample set, patients with germline mutations after the second beta-catenin degradation repeat tended to have undetectable, presumably cryptic, somatic mutations in their polyps. Exceptions to these rules were, however, not uncommon. Although the site of the germline mutation was the strongest determinant of the somatic mutation in FAP tumours and most patients showed no clear tendency to acquire specific types of truncating 'second hit', a minority of patients did have unusual somatic mutation spectra in their polyps. Thus, some individuals may be predisposed to particular types of 'second hit' (for example, frameshift rather than nonsense changes). Overall, disease severity (polyp number) did not vary with individuals' spectrum of somatic APC mutations, providing no clear evidence for modifier genes that influence disease severity in this fashion. Our data are consistent with the hypothesis that there exists an optimal level of beta-catenin signalling in colorectal tumours and that the APC mutation spectrum principally reflects this fact. The association between 'first hits' and 'second hits' at APC is not, however, so strong as to suggest that tumorigenesis only occurs if the genotype is optimum; we suggest 'relaxed' terminology, the 'loose fit' model, to describe this situation.	Canc Res UK, Mol & Populat Genet Lab, London WC2A 3PX, England; St Marks Hosp, Colorectal Canc Unit, Canc Res UK, Harrow HA1 3UJ, Middx, England; Guys Hosp, Dept Clin Genet, London SE1 9RT, England; St Marks Hosp, Polyposis Registry, Harrow HA1 3UJ, Middx, England; Univ Clin, Res Grp Human Genet, Div Med Genet, CH-4031 Basel, Switzerland	Cancer Research UK; Cancer Research UK; Imperial College London; Guy's & St Thomas' NHS Foundation Trust; Imperial College London	Tomlinson, IPM (corresponding author), Canc Res UK, Mol & Populat Genet Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Sieber, Oliver/M-9473-2015; Sieber, Oliver/ABA-9211-2021	Sieber, Oliver/0000-0001-9480-0786; Sieber, Oliver/0000-0001-9480-0786				Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Crabtree MD, 2002, GUT, V51, P420, DOI 10.1136/gut.51.3.420; Debinski HS, 1996, GASTROENTEROLOGY, V110, P1028, DOI 10.1053/gast.1996.v110.pm8612989; Groves C, 2002, AM J PATHOL, V160, P2055, DOI 10.1016/S0002-9440(10)61155-8; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NUGENT KP, 1994, GUT, V35, P1622, DOI 10.1136/gut.35.11.1622; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rubinfeld B, 1997, CANCER RES, V57, P4624; Sieber OM, 2002, P NATL ACAD SCI USA, V99, P2954, DOI 10.1073/pnas.042699199; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Spink KE, 2001, EMBO J, V20, P6203, DOI 10.1093/emboj/20.22.6203; Wasan HS, 1998, J PATHOL, V185, P246	16	81	84	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4257	4265		10.1038/sj.onc.1206471	http://dx.doi.org/10.1038/sj.onc.1206471			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833148				2022-12-25	WOS:000183979800012
J	Suzuki, R; Tobe, K; Terauchi, Y; Komeda, K; Kubota, N; Eto, K; Yamauchi, T; Azuma, K; Kaneto, H; Taguchi, T; Koga, T; German, MS; Watada, H; Kawamori, R; Wright, CVE; Kajimoto, Y; Kimura, S; Nagai, R; Kadowaki, T				Suzuki, R; Tobe, K; Terauchi, Y; Komeda, K; Kubota, N; Eto, K; Yamauchi, T; Azuma, K; Kaneto, H; Taguchi, T; Koga, T; German, MS; Watada, H; Kawamori, R; Wright, CVE; Kajimoto, Y; Kimura, S; Nagai, R; Kadowaki, T			Pdx1 expression in Irs2-deficient mouse beta-cells is regulated in a strain-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-2; GLUCOSE-INTOLERANCE; MICE LACKING; GENE; DIFFERENTIATION; ACTIVATION; RESISTANCE; DISRUPTION; MUTATIONS; KNOCKOUT	We previously demonstrated that Irs2(-/-) mice develop diabetes due to beta-cell growth failure and insulin resistance; however, glucose-induced insulin secretion was increased in islets isolated from Irs2(-/-) mice. Pdx-1, a transcription factor important for maintenance of the beta-cell function, was recently reported to be severely reduced in Irs2(-/-) murine beta-cells. We report herein that Pdx-1 expression, including the amount of Pdx-1 localized in the nucleus, is not down-regulated in our Irs2(-/-) murine beta-cells with a C57BL/6 background. We have also demonstrated the expression of upstream genes of Pdx-1, such as HNF3beta and HNF1alpha, as well as its downstream genes, including insulin, Glut2, and Nkx6.1, to be well preserved. We have further demonstrated Pdx-1 expression to also be preserved in beta-cells of 30-week-old diabetic Irs2(-/-) mice. In addition, surprisingly, even in Irs2(-/-) mice on a high fat diet with markedly elevated blood glucose, exceeding 400 mg/dl, Pdx-1 expression was not reduced. Furthermore, we found Pdx-1 to be markedly decreased in certain severely diabetic Irs2(-/-) mice with a mixed C57BL/6J x 129Sv background. We conclude that 1) Pdx-1 expression in Irs2(-/-) mice is regulated in a strain-dependent manner, 2) Irs2(-/-) mice develop diabetes associated with beta-cell growth failure even when Pdx1 expression is preserved, and 3) Pdx-1 expression is preserved in severely hyperglycemic Irs2(-/-) mice with a C57BL/6 background on a high fat diet.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol Corp, CREST, Saitama 3320012, Japan; Tokyo Med Univ, Anim Res Ctr, Div Lab Anim Sci, Tokyo 1608402, Japan; Juntendo Univ, Sch Med, Dept Med Metab & Endocrinol, Tokyo 1138421, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan; Sankyo Co Ltd, Biomed Res Labs, Tokyo 1408710, Japan; Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Vanderbilt Univ, Dev Biol Program, Nashville, TN 37232 USA	University of Tokyo; Japan Science & Technology Agency (JST); Tokyo Medical University; Juntendo University; Osaka University; Daiichi Sankyo Company Limited; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Vanderbilt University	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kadowaki-3im@h.u-tokyo.ac.jp	Terauchi, Yasuo/AAO-4347-2020; Suzuki, Ryo/AAA-2736-2019; Kubota, Naoto/N-7892-2015	Suzuki, Ryo/0000-0002-2965-6906; Taguchi, Takashi/0000-0003-1019-2619; Watada, Hirotaka/0000-0001-5961-1816				Accili D, 2001, J CLIN INVEST, V108, P1575, DOI 10.1172/JCI200114454; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI13785; Bonny C, 1997, MOL CELL ENDOCRINOL, V135, P59, DOI 10.1016/S0303-7207(97)00190-1; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Dutta S, 1998, NATURE, V392, P560, DOI 10.1038/33311; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Harmon JS, 1999, DIABETES, V48, P1995, DOI 10.2337/diabetes.48.10.1995; Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791; Huang HP, 2002, MOL ENDOCRINOL, V16, P541, DOI 10.1210/me.16.3.541; Jetton TL, 2001, DIABETOLOGIA, V44, P2056, DOI 10.1007/s001250100011; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kadowaki T, 2000, J CLIN INVEST, V106, P459, DOI 10.1172/JCI10830; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kulkarni RN, 2002, NAT GENET, V31, P111, DOI 10.1038/ng872; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Offield MF, 1996, DEVELOPMENT, V122, P983; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Poitout V, 2002, ENDOCRINOLOGY, V143, P339, DOI 10.1210/en.143.2.339; Qiu J, 2001, ENDOCRINOLOGY, V142, P3421, DOI 10.1210/en.142.8.3421; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Shih DQ, 2002, P NATL ACAD SCI USA, V99, P3818, DOI 10.1073/pnas.062605899; Shih DQ, 2001, P NATL ACAD SCI USA, V98, P14189, DOI 10.1073/pnas.251558998; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Stoffers DA, 1998, J CLIN INVEST, V102, P232, DOI 10.1172/JCI2242; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Sussel L, 1998, DEVELOPMENT, V125, P2213; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Terauchi Y, 2003, J BIOL CHEM, V278, P14284, DOI 10.1074/jbc.M211045200; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wang HY, 2001, J BIOL CHEM, V276, P25279, DOI 10.1074/jbc.M101233200; Watada H, 2000, J BIOL CHEM, V275, P34224, DOI 10.1074/jbc.M004981200; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Watada H, 1996, DIABETES, V45, P1826, DOI 10.2337/diabetes.45.12.1826; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xuan SH, 2002, J CLIN INVEST, V110, P1011, DOI 10.1172/JCI200215276	52	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43691	43698		10.1074/jbc.M307004200	http://dx.doi.org/10.1074/jbc.M307004200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12869553	hybrid			2022-12-25	WOS:000186157000118
J	Blum, G; Gazit, A; Levitzki, A				Blum, G; Gazit, A; Levitzki, A			Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT-NEGATIVE MUTANT; TYROSINE KINASE; ANTISENSE RNA; WILMS-TUMOR; CELLS; EXPRESSION; PHENOTYPE; APOPTOSIS; SUBSTRATE; PATHWAYS	Because insulin-like growth factor-1 (IGF-1) and its receptor play a pivotal role in many cancers, it is an attractive target for the design of inhibitors. Here we present a new family of bioisostere inhibitors, based on the structure of AG 538. AG 538 is a substrate-competitive inhibitor of the IGF-1 receptor (IGF-1R), with an IC50 = 61 nM in a cell-free kinase assay (Blum, G., Gazit, A., and Levitzki, A. ( 2000) Biochemistry 39, 15705 - 15712). AG 538 is a low molecular weight compound containing two catechol rings, which are sensitive to oxidation in cells. We have therefore prepared and examined catechol bioisosteres of AG 538. These AG 538 bioisosteres possess similar biological properties to AG 538; they inhibit IGF-1R by a substrate-competitive mechanism and are non-competitive vis a vis ATP. They inhibit IGF-1R kinase activity in the sub-micromolar concentration range in cell-free assays. IGF-1 induced IGF-1R autophosphorylation; IRS-1 phosphorylation and protein kinase B activation are inhibited at a low micromolar concentration range when applied to intact cells. These inhibitors also block the formation of colonies in soft agar by prostate and breast cancer cells. The ability to replace catechol groups with a moiety that is more stable in cells may aid in developing non-catechol-containing substrate-competitive inhibitors targeted toward IGF-1R and possibly against other protein-tyrosine kinases.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Sect Cellular Signaling, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Chem, Dept Organ Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Sect Cellular Signaling, IL-91904 Jerusalem, Israel.	levitzki@vms.huji.ac.il						AMBROSE D, 1994, J CELL PHYSIOL, V159, P92, DOI 10.1002/jcp.1041590113; ARTEAGA CL, 1989, CANCER RES, V49, P6237; Baserga R, 1997, EXP CELL RES, V236, P1, DOI 10.1006/excr.1997.3732; Ben-Bassat H, 1995, Exp Dermatol, V4, P82, DOI 10.1111/j.1600-0625.1995.tb00227.x; Blum G, 2000, BIOCHEMISTRY-US, V39, P15705, DOI 10.1021/bi001516y; Boney CM, 2001, CELL GROWTH DIFFER, V12, P379; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Carter WG, 1996, BIOCHEMISTRY-US, V35, P14340, DOI 10.1021/bi960732x; DAmbrosio C, 1997, CANCER RES, V57, P3264; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Dunn SE, 1998, CANCER RES, V58, P3353; GANSLER T, 1989, AM J PATHOL, V135, P961; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; Hailey J, 2002, MOL CANCER THER, V1, P1349; Horowitz D, 2000, J IMMUNOL METHODS, V244, P49, DOI 10.1016/S0022-1759(00)00253-2; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; JOHNS IB, 1964, J ORG CHEM, V29, P1970, DOI 10.1021/jo01030a076; Karni R, 2003, FEBS LETT, V537, P47, DOI 10.1016/S0014-5793(03)00069-3; Kurihara S, 2000, ENDOCR J, V47, P739, DOI 10.1507/endocrj.47.739; LEROITH D, 1994, HORM RES, V41, P74, DOI 10.1159/000183964; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; LONG L, 1995, CANCER RES, V55, P1006; MALESKI RJ, 1991, J HETEROCYCLIC CHEM, V28, P1937, DOI 10.1002/jhet.5570280822; Nakamura K, 2000, CANCER RES, V60, P760; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Reiss K, 1998, CLIN CANCER RES, V4, P2647; RESNICOFF M, 1995, CANCER RES, V55, P2463; Reuveni H, 2002, BIOCHEMISTRY-US, V41, P10304, DOI 10.1021/bi0202530; RUBIN R, 1995, LAB INVEST, V73, P311; Schweigert N, 2001, ENVIRON MICROBIOL, V3, P81, DOI 10.1046/j.1462-2920.2001.00176.x; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SZELL T, 1981, J CHEM ENG DATA, V26, P230, DOI 10.1021/je00024a043; Ucar H, 1998, J MED CHEM, V41, P1138, DOI 10.1021/jm970682+; Ucar H, 1998, TETRAHEDRON, V54, P1763, DOI 10.1016/S0040-4020(97)10400-8; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; YOUS S, 1994, J ORG CHEM, V59, P1574, DOI 10.1021/jo00085a052	39	98	111	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40442	40454		10.1074/jbc.M305490200	http://dx.doi.org/10.1074/jbc.M305490200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12869569	hybrid			2022-12-25	WOS:000185847200005
J	Mateo, R; Diaz, A; Baranowski, E; Mateu, MG				Mateo, R; Diaz, A; Baranowski, E; Mateu, MG			Complete alanine scanning of intersubunit interfaces in a foot-and-mouth disease virus capsid reveals critical contributions of many side chains to particle stability and viral function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; AMINO-ACID SUBSTITUTIONS; ICOSAHEDRAL VIRUSES; CELL-CULTURE; MUTATIONAL ANALYSIS; DIMER INTERFACE; COAT PROTEIN; FG LOOP; REPLICATION; RESIDUES	Spherical virus capsids are large, multimeric protein shells whose assembly and stability depend on the establishment of multiple non-covalent interactions between many polypeptide subunits. In a foot-and-mouth disease virus capsid, 42 amino acid side chains per protomer are involved in noncovalent interactions between pentameric subunits that function as assembly/disassembly intermediates. We have individually truncated to alanine these 42 side chains and assessed their relevance for completion of the virus life cycle and capsid stability. Most mutations provoked a drastic reduction in virus yields. Nearly all of these critical mutations led to virions whose thermal inactivation rates differed from that of the parent virus, and many affected also early steps in the viral cycle. Rapid selection of genotypic revertants or variants with forward or compensatory mutations that restored viability was occasionally detected. The results with this model virus indicate the following. (i) Most of the residues at the interfaces between capsid subunits are critically important for viral function, in part but not exclusively because of their involvement in intersubunit recognition. Each hydrogen bond and salt bridge buried at the subunit interfaces may be important for capsid stability. (ii) New mutations able to restore viability may arise frequently at the subunit interfaces during virus evolution. (iii) A few interfacial side chains are functionally tolerant to truncation and may provide adequate mutation sites for the engineering of a thermostable capsid, potentially useful as an improved vaccine.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Mateu, MG (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Baranowski, Eric/I-2655-2013; Mateu, Mauricio/ABF-2146-2021	Mateu, Mauricio/0000-0002-2915-1529; Baranowski, Eric/0000-0003-0660-1854				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; Axblom C, 1998, VIROLOGY, V249, P80, DOI 10.1006/viro.1998.9279; Baker TS, 1999, MICROBIOL MOL BIOL R, V63, P862, DOI 10.1128/MMBR.63.4.862-922.1999; Baranowski E, 1998, J VIROL, V72, P6362, DOI 10.1128/JVI.72.8.6362-6372.1998; Bertolotti-Ciarlet A, 2002, J VIROL, V76, P4044, DOI 10.1128/JVI.76.8.4044-4055.2002; CARRILLO EC, 1984, VIROLOGY, V135, P542, DOI 10.1016/0042-6822(84)90208-3; Chiu W., 1997, STRUCTURAL BIOL VIRU; Chow M., 1997, STRUCTURAL BIOL VIRU, P157; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Curry S, 1996, STRUCTURE, V4, P135, DOI 10.1016/S0969-2126(96)00017-2; Curry S, 1997, J VIROL, V71, P9743, DOI 10.1128/JVI.71.12.9743-9752.1997; Dall'Acqua W, 1998, BIOCHEMISTRY-US, V37, P9266, DOI 10.1021/bi980270i; DIEZ J, 1990, J VIROL, V64, P5519; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; Ellard FM, 1999, J GEN VIROL, V80, P1911, DOI 10.1099/0022-1317-80-8-1911; FILMAN DJ, 1989, EMBO J, V8, P1567, DOI 10.1002/j.1460-2075.1989.tb03541.x; FOGUEL D, 1995, BIOCHEMISTRY-US, V34, P1120, DOI 10.1021/bi00004a003; Fry EE, 1999, EMBO J, V18, P543, DOI 10.1093/emboj/18.3.543; Johnson J. E., 1999, ENCY VIROLOGY, P1946; Johnson JE, 1996, P NATL ACAD SCI USA, V93, P27, DOI 10.1073/pnas.93.1.27; Knipe T, 1997, J VIROL, V71, P2851, DOI 10.1128/JVI.71.4.2851-2856.1997; LAU FTK, 1989, BIOCHEMISTRY-US, V28, P6841, DOI 10.1021/bi00443a010; LEA S, 1994, STRUCTURE, V2, P123, DOI 10.1016/S0969-2126(00)00014-9; LEA S, 1995, STRUCTURE, V3, P571, DOI 10.1016/S0969-2126(01)00191-5; LILJAS L, 1986, PROG BIOPHYS MOL BIO, V48, P1, DOI 10.1016/0079-6107(86)90008-8; Limn CK, 2000, J VIROL, V74, P8658, DOI 10.1128/JVI.74.18.8658-8669.2000; Lu B, 1998, VIROLOGY, V244, P13, DOI 10.1006/viro.1998.9099; MATEU MG, 1994, J VIROL, V68, P1407, DOI 10.1128/JVI.68.3.1407-1417.1994; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; MATEU MG, 1995, VIRUS RES, V38, P1, DOI 10.1016/0168-1702(95)00048-U; Mateu MG, 1996, J BIOL CHEM, V271, P12814, DOI 10.1074/jbc.271.22.12814; McInerney GM, 2000, J GEN VIROL, V81, P1699, DOI 10.1099/0022-1317-81-7-1699; MILLA ME, 1994, NAT STRUCT BIOL, V1, P518, DOI 10.1038/nsb0894-518; MOSSER AG, 1993, J VIROL, V67, P1246, DOI 10.1128/JVI.67.3.1246-1254.1993; Myers DP, 2001, BIOCHEMISTRY-US, V40, P13230, DOI 10.1021/bi0155908; Oliveira AC, 2000, J BIOL CHEM, V275, P16037, DOI 10.1074/jbc.M910145199; Reddy VS, 1998, BIOPHYS J, V74, P546, DOI 10.1016/S0006-3495(98)77813-0; Reddy VS, 2001, J VIROL, V75, P11943, DOI 10.1128/JVI.75.24.11943-11947.2001; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1997, STRUCTURAL BIOL VIRU, P105; Rueckert RR, 1996, VIROLOGY, P609; Ruiz-Jarabo CM, 2000, J VIROL, V74, P3543, DOI 10.1128/JVI.74.8.3543-3547.2000; SAIZ JC, 1994, J VIROL, V68, P4557; Samuel AR, 2001, TRENDS GENET, V17, P421, DOI 10.1016/S0168-9525(01)02374-5; Sastri M, 1999, J MOL BIOL, V289, P905, DOI 10.1006/jmbi.1999.2786; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sengchanthalangsy LL, 1999, J MOL BIOL, V289, P1029, DOI 10.1006/jmbi.1999.2823; SOBRINO F, 1983, VIROLOGY, V128, P310, DOI 10.1016/0042-6822(83)90258-1; Sobrino F, 2001, VET RES, V32, P1, DOI 10.1051/vetres:2001106; Stonehouse NJ, 1996, J MOL BIOL, V256, P330, DOI 10.1006/jmbi.1996.0089; VASQUEZ C, 1979, VIROLOGY, V97, P195, DOI 10.1016/0042-6822(79)90387-8; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wu P, 2000, J VIROL, V74, P8635, DOI 10.1128/JVI.74.18.8635-8647.2000; ZIBERT A, 1990, J VIROL, V64, P2467, DOI 10.1128/JVI.64.6.2467-2473.1990; ZLOTNICK A, 1994, J MOL BIOL, V241, P59, DOI 10.1006/jmbi.1994.1473	55	50	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41019	41027		10.1074/jbc.M304990200	http://dx.doi.org/10.1074/jbc.M304990200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12857761	Green Published, hybrid			2022-12-25	WOS:000185847200076
J	Nicolet, Y; Lockridge, O; Masson, P; Fontecilla-Camps, JC; Nachon, F				Nicolet, Y; Lockridge, O; Masson, P; Fontecilla-Camps, JC; Nachon, F			Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE GORGE; PERIPHERAL SITE; SNAKE-VENOM; ACETYLCHOLINESTERASE; BINDING; FASCICULIN; INHIBITION; MOLSCRIPT; TOXICITY; RESIDUES	Cholinesterases are among the most efficient enzymes known. They are divided into two groups: acetylcholinesterase, involved in the hydrolysis of the neurotransmitter acetylcholine, and butyrylcholinesterase of unknown function. Several crystal structures of the former have shown that the active site is located at the bottom of a deep and narrow gorge, raising the question of how substrate and products enter and leave. Human butyrylcholinesterase (BChE) has attracted attention because it can hydrolyze toxic esters such as cocaine or scavenge organophosphorus pesticides and nerve agents. Here we report the crystal structures of several recombinant truncated human BChE complexes and conjugates and provide a description for mechanistically relevant non-productive substrate and product binding. As expected, the structure of BChE is similar to a previously published theoretical model of this enzyme and to the structure of Torpedo acetylcholinesterase. The main difference between the experimentally determined BChE structure and its model is found at the acyl binding pocket that is significantly bigger than expected. An electron density peak close to the catalytic Ser(198) has been modeled as bound butyrate.	UJF, Cristallog & Cristallogenese Prot Lab, Inst Biol Struct Jean Pierre Ebel, CNRS,CEA, F-38027 Grenoble 1, France; Univ Nebraska, Med Ctr, Eppley Res Inst, Omaha, NE 68198 USA; Serv Sante Armees, Ctr Rech, Unite Enzymol, F-38702 La Tronche, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); University of Nebraska System; University of Nebraska Medical Center	Fontecilla-Camps, JC (corresponding author), UJF, Cristallog & Cristallogenese Prot Lab, Inst Biol Struct Jean Pierre Ebel, CNRS,CEA, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.	juan@lccp.ibs.fr	Yvain, Nicolet/AAP-9763-2020; Masson, Patrick/AAA-7213-2019; Masson, Patrick YM/J-3964-2013	Yvain, Nicolet/0000-0002-4189-7067; Masson, Patrick/0000-0002-7837-3662; Masson, Patrick YM/0000-0002-7837-3662				Allon N, 1998, TOXICOL SCI, V43, P121; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Behra M, 2002, NAT NEUROSCI, V5, P111, DOI 10.1038/nn788; Bourne Y, 1999, J BIOL CHEM, V274, P2963, DOI 10.1074/jbc.274.5.2963; Bourne Y, 2003, EMBO J, V22, P1, DOI 10.1093/emboj/cdg005; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; BROOMFIELD CA, 1991, J PHARMACOL EXP THER, V259, P633; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHATONNET A, 1989, BIOCHEM J, V260, P625, DOI 10.1042/bj2600625; DAWSON RM, 1994, J APPL TOXICOL, V14, P317, DOI 10.1002/jat.2550140502; De Ferrari GV, 2001, J BIOL CHEM, V276, P23282, DOI 10.1074/jbc.M009596200; Enyedy IJ, 1998, J AM CHEM SOC, V120, P8043, DOI 10.1021/ja973131h; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; Harel M, 2000, PROTEIN SCI, V9, P1063, DOI 10.1110/ps.9.6.1063; HARRIS LW, 1966, SCIENCE, V154, P404, DOI 10.1126/science.154.3747.404; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kaplan D, 2001, BIOCHEMISTRY-US, V40, P7433, DOI 10.1021/bi010181x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kryger G, 2000, ACTA CRYSTALLOGR D, V56, P1385, DOI 10.1107/S0907444900010659; Lockridge O, 2000, NEUROTOXICOLOGY, V21, P113; Mack A, 2000, PROG NEUROBIOL, V60, P607, DOI 10.1016/S0301-0082(99)00047-7; Masson P, 2003, EUR J BIOCHEM, V270, P315, DOI 10.1046/j.1432-1033.2003.03388.x; Masson P, 1997, BIOCHEMISTRY-US, V36, P2266, DOI 10.1021/bi962484a; MASSOULIE J, 1993, PROG BRAIN RES, V98, P139; MATTHEWS DA, 1977, J BIOL CHEM, V252, P8875; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; Millard CB, 1999, BIOCHEMISTRY-US, V38, P7032, DOI 10.1021/bi982678l; Nachon F, 1998, BIOCHEMISTRY-US, V37, P10507, DOI 10.1021/bi980536l; Nachon F, 2002, EUR J BIOCHEM, V269, P630, DOI 10.1046/j.0014-2956.2001.02692.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; RAVEH L, 1993, BIOCHEM PHARMACOL, V45, P2465, DOI 10.1016/0006-2952(93)90228-O; ROUSSEL A, 1989, TURBO COMPUTER PROGR; Saxena A, 1997, BIOCHEMISTRY-US, V36, P14642, DOI 10.1021/bi971425+; SIELECKI AR, 1979, J MOL BIOL, V134, P781, DOI 10.1016/0022-2836(79)90486-8; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Szegletes T, 1999, BIOCHEMISTRY-US, V38, P122, DOI 10.1021/bi9813577; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; Weik M, 2000, P NATL ACAD SCI USA, V97, P623, DOI 10.1073/pnas.97.2.623	46	620	632	2	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41141	41147		10.1074/jbc.M210241200	http://dx.doi.org/10.1074/jbc.M210241200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12869558	hybrid			2022-12-25	WOS:000185847200090
J	Conjard, A; Komaty, O; Delage, H; Boghossian, M; Martin, M; Ferrier, B; Baverel, G				Conjard, A; Komaty, O; Delage, H; Boghossian, M; Martin, M; Ferrier, B; Baverel, G			Inhibition of glutamine synthetase in the mouse kidney - A novel mechanism of adaptation to metabolic acidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG RENAL-CORTEX; AMMONIA METABOLISM; RAT NEPHRON; TUBULES; STARVATION; ENZYMES; LIVER; GENE; GLUCONEOGENESIS; DEHYDROGENASE	As part of a study on the regulation of renal ammonia-genesis in the mouse kidney, we investigated the effect of chronic metabolic acidosis on glutamine synthesis by isolated mouse renal proximal tubules. The results obtained reveal that, in tubules from control mice, glutamine synthesis occurred at high rates from glutamate and proline and, to a lesser extent, from ornithine, alanine, and aspartate. A 48 h, metabolic acidosis caused a marked inhibition of glutamine synthesis from near-physiological concentrations of both alanine and proline that were avidly metabolized by the tubules; metabolic acidosis also greatly stimulated glutamine utilization and metabolism. These effects were accompanied by a large increase (i) in alanine, proline, and glutamine gluconeogenesis and (ii) in ammonia accumulation from proline and glutamine. In the renal cortex of acidotic mice, the activity of phosphoenolpyruvate carboxykinase increased 4-fold, but that of glutamate dehydrogenase did not change; in contrast with what is known in the rat renal cortex, metabolic acidosis markedly diminished the glutamine synthetase activity and protein level, but not the glutamine synthetase mRNA level in the mouse renal cortex. These results strongly suggest that, in the mouse kidney, glutamine synthetase is an important regulatory component of the availability of the ammonium ions to be excreted for defending systemic acid-base balance. Furthermore, they show that, in rodents, the regulation of renal glutamine synthetase is species-specific.	Fac Med Laennec, INSERM, U499, Lab Physiopathol Metab & Renale, F-69372 Lyon 08, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Baverel, G (corresponding author), Fac Med Laennec, INSERM, U499, Lab Physiopathol Metab & Renale, Rue G Paradin, F-69372 Lyon 08, France.			Duplany, Agnes/0000-0002-3485-1597				BAVEREL G, 1980, BIOCHEM J, V188, P873, DOI 10.1042/bj1880873; BAVEREL G, 1990, BIOCHEM J, V268, P437, DOI 10.1042/bj2680437; Baverel G, 1984, GLUTAMINE METABOLISM, P187; BERL S, 1984, GLUTAMINE METABOLISM, P223; BURCH HB, 1978, AM J PHYSIOL, V235, pF246, DOI 10.1152/ajprenal.1978.235.3.F246; BURCH HB, 1978, BIOCHEM BIOPH RES CO, V82, P498, DOI 10.1016/0006-291X(78)90902-6; Chauvin MF, 1997, J BIOL CHEM, V272, P4705, DOI 10.1074/jbc.272.8.4705; Conjard A, 2002, J BIOL CHEM, V277, P29444, DOI 10.1074/jbc.M111335200; Conjard A, 2002, BIOCHEM J, V368, P301, DOI 10.1042/BJ20020331; CURTHOYS NP, 1973, J BIOL CHEM, V248, P162; Curthoys NP, 2001, AM J PHYSIOL-RENAL, V281, pF381, DOI 10.1152/ajprenal.2001.281.3.F381; DAMIAN AC, 1970, AM J PHYSIOL, V218, P1249, DOI 10.1152/ajplegacy.1970.218.5.1249; Ferrier B, 1999, BIOCHEM J, V337, P543, DOI 10.1042/0264-6021:3370543; FORISSIER M, 1981, BIOCHEM J, V200, P27, DOI 10.1042/bj2000027; Hallemeesch MM, 2001, LAB ANIM-UK, V35, P101, DOI 10.1258/0023677011911426; HANSON RW, 1997, ANNU REV BIOCHEM, V66, P203; Iyer RK, 2002, MOL CELL BIOL, V22, P4491, DOI 10.1128/MCB.22.13.4491-4498.2002; JANICKI RH, 1969, AM J PHYSIOL, V216, P1107, DOI 10.1152/ajplegacy.1969.216.5.1107; Kew S, 1999, J NUTR, V129, P1524, DOI 10.1093/jn/129.8.1524; KREBS HANS ADOLF, 1935, BIOCHEM JOUR, V29, P1951; KUO CF, 1989, J MOL BIOL, V208, P45, DOI 10.1016/0022-2836(89)90086-7; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMIEUX G, 1976, AM J PHYSIOL, V231, P1068, DOI 10.1152/ajplegacy.1976.231.4.1068; LieVenema H, 1997, BIOCHEM J, V323, P611, DOI 10.1042/bj3230611; NAGAMI GT, 1986, J CLIN INVEST, V78, P124, DOI 10.1172/JCI112540; OWEN EE, 1963, J CLIN INVEST, V42, P263, DOI 10.1172/JCI104713; OWEN OE, 1969, J CLIN INVEST, V48, P574, DOI 10.1172/JCI106016; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; PRUSINER S, 1970, ANAL BIOCHEM, V37, P429, DOI 10.1016/0003-2697(70)90069-2; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; RICHTERICH RW, 1958, AM J PHYSIOL, V195, P316, DOI 10.1152/ajplegacy.1958.195.2.316; SCHOOLWERTH AC, 1994, AM J PHYSIOL, V267, pF400, DOI 10.1152/ajprenal.1994.267.3.F400; TIZIANELLO A, 1980, J CLIN INVEST, V65, P1162, DOI 10.1172/JCI109771; WATFORD M, 1991, CONTRIB NEPHROL, V92, P211; WEIL-MALHERBE HANS, 1935, BIOCHEM JOUR, V29, P2077; WRIGHT PA, 1990, AM J PHYSIOL, V259, pF53, DOI 10.1152/ajprenal.1990.259.1.F53; WU C, 1963, COMP BIOCHEM PHYSIOL, V8, P335, DOI 10.1016/0010-406X(63)90169-5	38	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38159	38166		10.1074/jbc.M302885200	http://dx.doi.org/10.1074/jbc.M302885200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871952	hybrid			2022-12-25	WOS:000185575100010
J	Daiho, T; Yamasaki, K; Wang, GL; Danko, S; Iizuka, H; Suzuki, H				Daiho, T; Yamasaki, K; Wang, GL; Danko, S; Iizuka, H; Suzuki, H			Deletions of any single residues in Glu(40)-Ser(48) loop connecting a domain and the first transmembrane helix of sarcoplasmic reticulum Ca2+-ATPase result in almost complete inhibition of conformational transition and hydrolysis of phosphoenzyme intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; DARIERS-DISEASE; ADENOSINE-TRIPHOSPHATE; ENERGY TRANSDUCTION; CALCIUM-TRANSPORT; ATP2A2 MUTATIONS; CATALYTIC SITE; STEADY-STATE; COS-1 CELLS	Possible roles of the Glu(40)-Ser(48) loop connecting A domain and the first transmembrane helix (M1) in sarcoplasmic reticulum Ca2+-ATPase (SERCA1a) were explored by mutagenesis. Deletions of any single residues in this loop caused almost complete loss of Ca2+-ATPase activity, while their substitutions had no or only slight effects. Single deletions or substitutions in the adjacent N- and C-terminal regions of the loop (His(32)-Asn(39) and Leu(49)-Ile(54)) had no or only slight effects except two specific substitutions of Asn(39) found in SERCA2b in Darier's disease pedigrees. All the single deletion mutants for the Glu(40)-Ser(48) loop and the specific Asn(39) mutants formed phosphoenzyme intermediate (EP) from ATP, but their isomeric transition from ADP-sensitive EP (E1P) to ADP-insensitive EP (E2P) was almost completely or strongly inhibited. Hydrolysis of E2P formed from P-i was also dramatically slowed in these deletion mutants. On the other hand, the rates of the Ca2+-induced enzyme activation and subsequent E1P formation from ATP were not altered by the deletions and substitutions. The results indicate that the Glu(40)-Ser(48) loop, with its appropriate length (but not with specific residues) and with its appropriate junction to A domain, is a critical element for the E1P to E2P transition and formation of the proper structure of E2P, therefore, most likely for the large rotational movement of A domain and resulting in its association with P and N domains. Results further suggest that the loop functions to coordinate this movement of A domain and the unique motion of M1 during the E1P to E2P transition.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College; Asahikawa Medical College	Suzuki, H (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan.	hisuzuki@asahikawa-med.ac.jp						Ahn W, 2003, J BIOL CHEM, V278, P20795, DOI 10.1074/jbc.M301638200; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Clausen JD, 2003, J BIOL CHEM, V278, P20245, DOI 10.1074/jbc.M301122200; Clausen JD, 2003, BIOCHEMISTRY-US, V42, P2585, DOI 10.1021/bi0271897; Daiho T, 1999, J BIOL CHEM, V274, P23910, DOI 10.1074/jbc.274.34.23910; Daiho T, 1999, FEBS LETT, V444, P54, DOI 10.1016/S0014-5793(99)00027-7; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1989, BIOCHIM BIOPHYS ACTA, V973, P333, DOI 10.1016/S0005-2728(89)80440-2; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; IMAMURA Y, 1989, J BIOCHEM-TOKYO, V105, P775, DOI 10.1093/oxfordjournals.jbchem.a122743; INESI G, 1982, Z NATURFORSCH C, V37, P685; Jacobsen NJO, 1999, HUM MOL GENET, V8, P1631, DOI 10.1093/hmg/8.9.1631; Juul B, 2000, INT CONGR SER, V1207, P233; KANAZAWA T, 1970, J BIOCHEM-TOKYO, V67, P693, DOI 10.1093/oxfordjournals.jbchem.a129297; Kato S, 2003, J BIOL CHEM, V278, P9624, DOI 10.1074/jbc.M208861200; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma HL, 2003, J BIOL CHEM, V278, P28938, DOI 10.1074/jbc.M304120200; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; PICK U, 1982, J BIOL CHEM, V257, P6120; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Ringpfeil F, 2001, EXP DERMATOL, V10, P19, DOI 10.1034/j.1600-0625.2001.100103.x; Ruiz-Perez VL, 1999, HUM MOL GENET, V8, P1621, DOI 10.1093/hmg/8.9.1621; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; SUZUKI H, 1987, J BIOL CHEM, V262, P15448; SUZUKI H, 1989, J BIOL CHEM, V264, P920; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WEBER K, 1969, J BIOL CHEM, V244, P4406; ZHANG Z, 1995, J BIOL CHEM, V270, P16283	46	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39197	39204		10.1074/jbc.M305200200	http://dx.doi.org/10.1074/jbc.M305200200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12857730	hybrid			2022-12-25	WOS:000185575100134
J	Hassan, S; Duong, B; Kim, KS; Miles, MF				Hassan, S; Duong, B; Kim, KS; Miles, MF			Pharmacogenomic analysis of mechanisms mediating ethanol regulation of dopamine beta-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; CAMP-RESPONSE ELEMENT; GENE-TRANSCRIPTION; KINASE-A; CREB; EXPRESSION; PHOSPHORYLATION; ADENOSINE; IDENTIFICATION; PROMOTER	We previously showed that ethanol regulates dopamine beta-hydroxylase (DBH) mRNA and protein levels in human neuroblastoma cells (Thibault, C., Lai, C., Wilke, N., Duong, B., Olive, M. F., Rahman, S., Dong, H., Hodge, C. W., Lockhart, D. J., and Miles, M. F. (2000) Mol. Pharmacol. 58, 1593-1600). DBH catalyzes norepinephrine synthesis, and several studies have suggested a role for norepinephrine in ethanol-mediated behaviors. Here, we performed a detailed analysis of mechanism(s) underlying ethanol regulation of DBH expression in SH-SY5Y cells. Transient transfection analysis showed that ethanol (25-200 mM) caused concentration- and time-dependent increases in DBH gene transcription. Progressive deletions identified ethanol-responsive sequences in the -262 to -142 bp region of the DBH gene promoter. Mutagenesis of cAMP-response element (CRE) sequences in this region abolished ethanol responsiveness while maintaining responsiveness to phorbol esters. Co-expression of dominant-negative CRE-binding protein greatly reduced ethanol induction of DBH. Inhibitors of protein kinase A, casein kinase II, and MAPK reduced ethanol induction of DBH promoter activity. Pharmacogenomic studies with microarrays showed that protein kinase A, MEK, and casein kinase II inhibitors blocked induction of DBH and a large subset of ethanol-responsive genes. These genes had diverse functional groupings, including multiple members of the MAPK and phosphatidylinositol signaling cascades. Real-time PCR analysis validated select microarray results. Taken together, these results suggest that ethanol regulation of DBH requires a functional CRE and its binding protein and may require interaction of multiple kinase pathways. This mechanism may also mediate ethanol responsiveness of a complex subset of genes in neural cells. These studies may have implications for behavioral responses to ethanol or mechanisms underlying ethanol-related neurological disease.	Virginia Commonwealth Univ, Dept Pharmacol Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Ctr Study Biol Complex, Richmond, VA 23298 USA; Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Emeryville, CA 94608 USA; Harvard Univ, McLean Hosp, Sch Med, Mol Neurobiol Lab, Belmont, MA 02178 USA	Virginia Commonwealth University; Virginia Commonwealth University; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; Harvard University; McLean Hospital	Miles, MF (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol Toxicol, POB 980599, Richmond, VA 23298 USA.	mfmiles@vcu.edu			NIAAA NIH HHS [AA13200] Funding Source: Medline	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Asher O, 2002, J PHARMACOL EXP THER, V301, P66, DOI 10.1124/jpet.301.1.66; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSSON A, 1973, J PHARM PHARMACOL, V25, P437, DOI 10.1111/j.2042-7158.1973.tb09129.x; Constantinescu A, 2002, J BIOL CHEM, V277, P18810, DOI 10.1074/jbc.M112107200; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; CORRODI H, 1966, J PHARM PHARMACOL, V18, P821, DOI 10.1111/j.2042-7158.1966.tb07817.x; De Cesare D, 1999, TRENDS BIOCHEM SCI, V24, P281, DOI 10.1016/S0968-0004(99)01414-0; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DIAMOND I, 1987, P NATL ACAD SCI USA, V84, P1413, DOI 10.1073/pnas.84.5.1413; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Duman RS, 1997, ARCH GEN PSYCHIAT, V54, P597; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FRIEDMAN S, 1965, J BIOL CHEM, V240, P4763; GAYER GG, 1991, J BIOL CHEM, V266, P22279; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORDON AS, 1986, P NATL ACAD SCI USA, V83, P2105, DOI 10.1073/pnas.83.7.2105; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Hodge CW, 1996, ALCOHOL CLIN EXP RES, V20, P1669, DOI 10.1111/j.1530-0277.1996.tb01714.x; HOFFMAN PL, 1990, FASEB J, V4, P2612, DOI 10.1096/fasebj.4.9.2161371; Hsieh KP, 1996, J BIOL CHEM, V271, P2709, DOI 10.1074/jbc.271.5.2709; HUNT WA, 1974, J NEUROCHEM, V23, P549, DOI 10.1111/j.1471-4159.1974.tb06058.x; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; Ishiguro H, 1995, MOL BRAIN RES, V34, P251, DOI 10.1016/0169-328X(95)00170-W; KAROUM F, 1976, BRIT J PHARMACOL, V56, P403, DOI 10.1111/j.1476-5381.1976.tb07450.x; KIM KS, 1994, J NEUROSCI, V14, P7200; KIRSHNER N, 1957, J BIOL CHEM, V226, P207; Kumari M, 1998, J NEUROCHEM, V70, P1467; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; MHATRE MC, 1992, MOL PHARMACOL, V42, P415; Miles MF, 1995, ALCOHOL HEALTH RES W, V19, P237; MILES MF, 1991, J BIOL CHEM, V266, P2409; MILES MF, 1994, MOL PHARMACOL, V46, P873; MILES MF, 1992, BIOCHIM BIOPHYS ACTA, V1138, P268, DOI 10.1016/0925-4439(92)90003-6; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MONTPIED P, 1991, MOL PHARMACOL, V39, P157; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; Muthusamy N, 1998, J BIOL CHEM, V273, P22841, DOI 10.1074/jbc.273.35.22841; NAGY LE, 1989, MOL PHARMACOL, V36, P744; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Pandey SC, 1998, MOL NEUROBIOL, V17, P1, DOI 10.1007/BF02802021; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; POHORECKY LA, 1975, RES COMMUN CHEM PATH, V12, P433; RABIN RA, 1992, J PHARMACOL EXP THER, V262, P257; Roberson ED, 1999, J NEUROSCI, V19, P4337; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; Saberan-Djoneidi D, 2000, GENE, V248, P223, DOI 10.1016/S0378-1119(00)00116-5; Saeki K, 1999, BIOCHEM J, V338, P49, DOI 10.1042/0264-6021:3380049; SAITO T, 1985, J NEUROCHEM, V44, P1037, DOI 10.1111/j.1471-4159.1985.tb08722.x; SAPRU MK, 1994, J PHARMACOL EXP THER, V271, P542; Schulze PC, 2002, CIRC RES, V91, P689, DOI 10.1161/01.RES.0000037982.55074.F6; Seo HM, 1996, J NEUROSCI, V16, P4102; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; TABAKOFF B, 1988, ALCOHOL CLIN EXP RES, V12, P184, DOI 10.1111/j.1530-0277.1988.tb00157.x; TABAKOFF B, 1988, NEW ENGL J MED, V318, P134, DOI 10.1056/NEJM198801213180302; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Thibault C, 2000, MOL PHARMACOL, V58, P1593, DOI 10.1124/mol.58.6.1593; Thiele TE, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-10-j0003.2000; TREVISAN L, 1994, J NEUROCHEM, V62, P1635; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Waltereit R, 2001, J NEUROSCI, V21, P5484, DOI 10.1523/JNEUROSCI.21-15-05484.2001; Wand G, 2001, J NEUROSCI, V21, P5297, DOI 10.1523/JNEUROSCI.21-14-05297.2001; Weinshenker D, 2000, J NEUROSCI, V20, P3157, DOI 10.1523/JNEUROSCI.20-09-03157.2000; Wilke N, 2000, J PHARMACOL EXP THER, V292, P173; Yalcin A, 2003, J NEUROCHEM, V84, P397, DOI 10.1046/j.1471-4159.2003.01540.x; Yang XJ, 1998, J NEUROCHEM, V70, P224; Yang XJ, 1996, J PHARMACOL EXP THER, V278, P338; Yang XO, 1998, ALCOHOL CLIN EXP RES, V22, P382, DOI 10.1097/00000374-199804000-00014; Yao LN, 2002, CELL, V109, P733, DOI 10.1016/S0092-8674(02)00763-8; Zhang L, 2002, J MOL BIOL, V317, P225, DOI 10.1006/jmbi.2001.5350	81	26	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38860	38869		10.1074/jbc.M305040200	http://dx.doi.org/10.1074/jbc.M305040200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12842874	hybrid			2022-12-25	WOS:000185575100094
J	Jakobi, R; McCarthy, CC; Koeppel, MA; Stringer, DK				Jakobi, R; McCarthy, CC; Koeppel, MA; Stringer, DK			Caspase-activated PAK-2 is regulated by subcellular targeting and proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE GAMMA-PAK; KAPPA-B-ALPHA; MOLECULAR-CLONING; P21-ACTIVATED KINASE; PROTECTS CELLS; CLEAVAGE; AUTOPHOSPHORYLATION; TRANSLOCATION; DEUBIQUITINATION; UBIQUITINATION	p21-activated protein kinases (PAKs) are a family of serine/threonine protein kinases that are activated by binding of the p21 G proteins Cdc42 or Rac. The ubiquitous PAK-2 (gamma-PAK) is unique among the PAK isoforms because it is also activated through proteolytic cleavage by caspases or caspase-like proteases. In response to stress stimulants such as tumor necrosis factor alpha or growth factor withdrawal, PAK-2 is activated as a full-length enzyme and as a proteolytic PAK-2p34 fragment. Activation of full-length PAK-2 stimulates cell survival, whereas proteolytic activation of PAK-2p34 is involved in programmed cell death. Here we provide evidence that the proapoptotic effect of PAK-2p34 is regulated by subcellular targeting and degradation by the proteasome. Full-length PAK-2 is localized in the cytoplasm, whereas the proteolytic PAK-2p34 fragment translocates to the nucleus. Subcellular localization of PAK-2 is regulated by nuclear localization and nuclear export signal motifs. A nuclear export signal motif within the regulatory domain prevents nuclear localization of full-length PAK-2. Proteolytic activation removes most of the regulatory domain and disrupts the nuclear export signal. The activated PAK-2p34 fragment contains a nuclear localization signal and translocates to the nucleus. However, levels of activated PAK-2p34 are tightly regulated through ubiquitination and degradation by the proteasome. Inhibition of degradation by blocking polyubiquitination results in significantly increased levels of PAK-2p34 and as a consequence, in stimulation of programmed cell death. Therefore, nuclear targeting and inhibition of degradation appear to be critical for stimulation of the cell death response by PAK-2p34.	Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Jakobi, R (corresponding author), Univ Hlth Sci, Dept Biochem, 1750 Independence Ave, Kansas City, MO 64106 USA.	rjakobi@uhs.edu						AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chan WH, 1998, J PROTEIN CHEM, V17, P485, DOI 10.1023/A:1022578820147; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; GEY GO, 1952, CANCER RES, V12, P264; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; JAKOBI R, 1992, J BIOL CHEM, V267, P23894; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; Jakobi R, 2002, BIOTECHNIQUES, V33, P1218, DOI 10.2144/02336bm07; Jakobi R, 2001, BIOTECHNIQUES, V30, P476, DOI 10.2144/01303bm02; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Jakobi R, 2000, EUR J BIOCHEM, V267, P4414, DOI 10.1046/j.1432-1327.2000.01488.x; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Roig J, 2001, VITAM HORM, V62, P167, DOI 10.1016/S0083-6729(01)62004-1; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salomoni P, 2002, NAT CELL BIOL, V4, pE152, DOI 10.1038/ncb0602-e152; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schlesinger TK, 2002, J BIOL CHEM, V277, P10283, DOI 10.1074/jbc.M106885200; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Tang TK, 1998, J CELL BIOCHEM, V70, P442, DOI 10.1002/(SICI)1097-4644(19980915)70:4<442::AID-JCB2>3.3.CO;2-N; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200	47	58	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38675	38685		10.1074/jbc.M306494200	http://dx.doi.org/10.1074/jbc.M306494200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12853446	hybrid			2022-12-25	WOS:000185575100072
J	Ng, YP; He, W; Ip, NY				Ng, YP; He, W; Ip, NY			Leukemia inhibitory factor receptor signaling negatively modulates nerve growth factor-induced neurite outgrowth in PC12 cells and sympathetic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; MESSENGER-RNAS; TERMINAL DIFFERENTIATION; RAC1 ACTIVATION; CNTF RECEPTOR; MAH CELLS; EXPRESSION; INTERLEUKIN-6; STAT3; KINASE	Nerve growth factor (NGF) is required for the development of sympathetic neurons and subsets of sensory neurons. Our current knowledge on the molecular mechanisms underlying the biological functions of NGF is in part based on the studies with PC12 rat pheochromocytoma cells, which differentiate into sympathetic neuron-like cells upon NGF treatment. Here we report that the expression of leukemia inhibitory factor receptor (LIFR), one of the signaling molecules shared by several neuropoietic cytokines of the interleukin-6 family, is specifically up-regulated in PC12 cells following treatment with NGF. Attenuation of LIFR signaling through stable transfection of antisense- or dominant negative-LIFR constructs enhances NGF-induced neurite extension in PC12 cells. On the contrary, overexpression of LIFR retards the growth of neurites. More importantly, whereas NGF-induced Rac1 activity is enhanced in antisense- LIFR and dominant negative-LIFR expressing PC12 cells, it is reduced in LIFR expressing PC12 cells. Following combined treatment with NGF and ciliary neurotrophic factor, sympathetic neurons exhibit attenuated neurite growth and branching. On the other hand, in sympathetic neurons lacking LIFR, neurite growth and branching is enhanced when compared with wild type controls. Taken together, our findings demonstrate that LIFR expression can be specifically induced by NGF and, besides its known function in cell survival and phenotype development, activated LIFR signaling can exert negative regulatory effects on neurite extension and branching of sympathetic neurons.	Hong Kong Univ Sci & Technol, Dept Biochem, Biotechnol Res Inst, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Ip, NY (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Biotechnol Res Inst, Clear Water Bay, Hong Kong, Hong Kong, Peoples R China.	BOIP@UST.HK		Ip, Nancy Yuk-Yu/0000-0002-2763-8907				BANNER LR, 1994, P NATL ACAD SCI USA, V91, P7109, DOI 10.1073/pnas.91.15.7109; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; Gallo G, 2000, J NEUROBIOL, V44, P159, DOI 10.1002/1097-4695(200008)44:2<159::AID-NEU6>3.0.CO;2-H; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Guo X, 1999, J NEUROSCI, V19, P2113; Guo X, 1997, DEV BRAIN RES, V104, P101, DOI 10.1016/S0165-3806(97)00142-9; He W, 2002, FEBS LETT, V514, P214, DOI 10.1016/S0014-5793(02)02367-0; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; HUANG EJ, 2003, IN PRESS ANN REV BIO; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Ihara S, 1996, J BIOCHEM, V120, P865; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IP FCF, 1995, J NEUROCHEM, V65, P2393; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; Ip NY, 1996, ANNU REV NEUROSCI, V19, P491; ISHII DN, 1975, J NEUROCHEM, V25, P843, DOI 10.1111/j.1471-4159.1975.tb04416.x; KALMAN D, 1990, NEURON, V4, P355, DOI 10.1016/0896-6273(90)90048-K; Koblar SA, 1998, P NATL ACAD SCI USA, V95, P3178, DOI 10.1073/pnas.95.6.3178; KORSCHING S, 1988, DEV BIOL, V126, P40, DOI 10.1016/0012-1606(88)90236-9; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LEWIS SE, 1994, J NEUROCHEM, V63, P429; Man D, 2003, J BIOL CHEM, V278, P23285, DOI 10.1074/jbc.M301976200; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Moon C, 2002, P NATL ACAD SCI USA, V99, P9015, DOI 10.1073/pnas.132131699; MURPHY M, 1993, DEVELOPMENT, V117, P1173; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; Nusser N, 2002, J BIOL CHEM, V277, P35840, DOI 10.1074/jbc.M203617200; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; Pongrac JL, 1998, MOL BRAIN RES, V62, P25, DOI 10.1016/S0169-328X(98)00215-0; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; REEBEN M, 1995, J NEUROSCI RES, V40, P177, DOI 10.1002/jnr.490400206; Shimazaki T, 2001, J NEUROSCI, V21, P7642, DOI 10.1523/JNEUROSCI.21-19-07642.2001; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Torocsik B, 2002, J NEUROSCI, V22, P8971; Turnley AM, 2000, J NEUROCHEM, V74, P889, DOI 10.1046/j.1471-4159.2000.0740889.x; VERDI JM, 1994, P NATL ACAD SCI USA, V91, P3949, DOI 10.1073/pnas.91.9.3949; WARE CB, 1995, DEVELOPMENT, V121, P1283; WONG VV, 1995, J BIOL CHEM, V270, P313, DOI 10.1074/jbc.270.1.313; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Yasui H, 2001, J BIOL CHEM, V276, P15298, DOI 10.1074/jbc.M008546200; Zaheer A, 1995, NEUROCHEM RES, V20, P1457, DOI 10.1007/BF00970594; Zentrich E, 2002, J BIOL CHEM, V277, P4110, DOI 10.1074/jbc.M107824200	47	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38731	38739		10.1074/jbc.M304623200	http://dx.doi.org/10.1074/jbc.M304623200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871977	hybrid			2022-12-25	WOS:000185575100079
J	Ohtake, S; Kimata, K; Habuchi, O				Ohtake, S; Kimata, K; Habuchi, O			A unique nonreducing terminal modification of chondroitin sulfate by N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT THROMBOMODULIN PROTEOGLYCAN; MOLECULAR-CLONING; GLYCOSAMINOGLYCAN SULFOTRANSFERASES; SQUID CARTILAGE; ACID RESIDUES; EXPRESSION; 6-SULFOTRANSFERASE; PURIFICATION; CLEAVAGE; HEPARIN	N-Acetylgalactosamine 4-sulfate 6-O-sulfotransferase (GalNAc4S-6ST) transfers sulfate from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to position 6 of N-acetylgalactosamine 4-sulfate (GalNAc(4SO(4))). We previously identified human GalNAc4S-6ST cDNA and showed that the recombinant GalNAc4S-6ST could transfer sulfate efficiently to the nonreducing terminal GalNAc(4SO(4)) residues. We here present evidence that GalNAc4S-6ST should be involved in a unique nonreducing terminal modification of chondroitin sulfate A (CSA). From the nonreducing terminal of CS-A, a GlcA-containing oligosaccharide (Oligo I) that could serve as an acceptor for GalNAc4S-6ST was obtained after chondroitinase ACII digestion. Oligo I was found to be GalNAc(4SO(4))-GlcA(2SO(4))-GalNAc(6SO(4)) because GalNAc(4SO(4)) and DeltaHexA(2SO(4))-GalNAc(6SO(4)) were formed after chondroitinase ABC digestion. When Oligo I was used as the acceptor for GalNAc4S-6ST, sulfate was transferred to position 6 of GalNAc(4SO(4)) located at the nonreducing end of Oligo I. Oligo I was much better acceptor for GalNAc4S-6ST than GalNAc(4SO(4))-GlcA-GalNAc(6SO(4)). An oligosaccharide (Oligo II) whose structure is identical to that of the sulfated Oligo I was obtained from CS-A after chondroitinase ACII digestion, indicating that the terminal modification occurs under the physiological conditions. When CS-A was incubated with [S-35]PAPS and GalNAc4S-6ST and the S-35-labeled product was digested with chondroitinase ACII, a S-35-labeled trisaccharide (Oligo III) containing [ 35S] GalNAc(4,6-SO4) residue at the nonreducing end was obtained. Oligo III behaved identically with the sulfated Oligos I and II. These results suggest that GalNAc4S-6ST may be involved in the terminal modification of CS-A, through which a highly sulfated nonreducing terminal sequence is generated.	Aichi Univ Educ, Dept Chem, Aichi 4488542, Japan; Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan	Aichi University Education; Aichi Medical University	Habuchi, O (corresponding author), Aichi Univ Educ, Dept Chem, Igaya Cho, Aichi 4488542, Japan.							BOURIN MC, 1990, BIOCHEM J, V270, P419, DOI 10.1042/bj2700419; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; CONRAD HE, 1980, BIOCHEM J, V191, P355, DOI 10.1042/bj1910355; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; Evers MR, 2001, J BIOL CHEM, V276, P36344, DOI 10.1074/jbc.M105848200; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; Habuchi O, 2002, ANAL BIOCHEM, V310, P129, DOI 10.1016/S0003-2697(02)00277-4; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; HIYAMA K, 1975, J BIOL CHEM, V250, P1824; INOUE H, 1986, J BIOL CHEM, V261, P4460; Ishihara M, 1997, J BIOCHEM-TOKYO, V121, P345; Ito Y, 2000, J BIOL CHEM, V275, P34728, DOI 10.1074/jbc.M909633199; Kang HG, 2002, J BIOL CHEM, V277, P34766, DOI 10.1074/jbc.M204907200; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kitagawa H, 2000, J BIOL CHEM, V275, P21075, DOI 10.1074/jbc.M002101200; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; MIDURA RJ, 1995, J BIOL CHEM, V270, P8009, DOI 10.1074/jbc.270.14.8009; NAKANISHI Y, 1981, J BIOL CHEM, V256, P5443; Ohtake S, 2001, J BIOL CHEM, V276, P43894, DOI 10.1074/jbc.M104922200; OTSU K, 1985, BIOCHEM J, V227, P37, DOI 10.1042/bj2270037; Plaas AHK, 1998, J BIOL CHEM, V273, P12642, DOI 10.1074/jbc.273.20.12642; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; SHAKLEE PN, 1985, J BIOL CHEM, V260, P6064; STROMINGER JL, 1959, J BIOL CHEM, V234, P3263; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; Sugahara K, 1996, EUR J BIOCHEM, V239, P865, DOI 10.1111/j.1432-1033.1996.0865u.x; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Yamauchi S, 1999, J BIOL CHEM, V274, P2456, DOI 10.1074/jbc.274.4.2456; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975	36	40	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38443	38452		10.1074/jbc.M306132200	http://dx.doi.org/10.1074/jbc.M306132200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874280	hybrid			2022-12-25	WOS:000185575100045
J	Rauchenberger, R; Borges, E; Thomassen-Wolf, E; Rom, E; Adar, R; Yaniv, Y; Malka, M; Chumakov, I; Kotzer, S; Resnitzky, D; Knappik, A; Reiffert, S; Prassler, J; Jury, K; Waldherr, D; Bauer, S; Kretzschmar, T; Yayon, A; Rothe, C				Rauchenberger, R; Borges, E; Thomassen-Wolf, E; Rom, E; Adar, R; Yaniv, Y; Malka, M; Chumakov, I; Kotzer, S; Resnitzky, D; Knappik, A; Reiffert, S; Prassler, J; Jury, K; Waldherr, D; Bauer, S; Kretzschmar, T; Yayon, A; Rothe, C			Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREQUENT FGFR3 MUTATIONS; BY-PASSING IMMUNIZATION; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; HIGH-AFFINITY; TYROSINE KINASES; DISPLAY LIBRARY; KINETIC ASPECTS; LIGHT-CHAIN; FULLY HUMAN	The human combinatorial antibody library Fab 1 (HuCAL(R)-Fab 1) was generated by transferring the heavy and light chain variable regions from the previously constructed single-chain Fv library (Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wolle, J., Pluckthun, A., and Virnekas, B. (2000) J. Mol. Biol. 296, 57-86), diversified in both complementarity-determining regions 3 into a novel Fab display vector, yielding 2.1 x 10(10) different antibody fragments. The modularity has been retained in the Fab display and screening plasmids, ensuring rapid conversion into various antibody formats as well as antibody optimization using prebuilt maturation cassettes. HuCAL(R)-Fab 1 was challenged against the human fibroblast growth factor receptor 3, a potential therapeutic antibody target, against which, to the best of our knowledge, no functional antibodies could be generated so far. A unique screening mode was designed utilizing recombinant functional proteins and cell lines differentially expressing fibroblast growth factor receptor isoforms diversified in expression and receptor dependence. Specific Fab fragments with subnanomolar affinities were isolated by selection without any maturation steps as determined by fluorescence flow cytometry. Some of the selected Fab fragments completely inhibit target-mediated cell proliferation, rendering them the first monoclonal antibodies against fibroblast growth factor receptors having significant function blocking activity. This study validates HuCAL(R)-Fab 1 as a valuable source for the generation of target-specific antibodies for therapeutic applications.	ProChon Biotech Ltd, IL-76114 Rehovot, Israel; MorphoSys AG, D-82152 Martinsried, Germany; Weizmann Inst Sci, IL-76100 Rehovot, Israel	MorphoSys; Weizmann Institute of Science	Yayon, A (corresponding author), ProChon Biotech Ltd, Kiryat Weizmann Sci Pk,POB 1482, IL-76114 Rehovot, Israel.	yayon@prochon.co.il; rothe@morphosys.de	Knappik, Achim/D-3677-2011	Knappik, Achim/0000-0002-2693-6750				Adar R, 2002, J BONE MINER RES, V17, P860, DOI 10.1359/jbmr.2002.17.5.860; ALEXANDRU I, 1980, MOL IMMUNOL, V17, P1351, DOI 10.1016/0161-5890(80)90004-8; Ausubel FM, 1998, CURRENT PROTOCOLS MO; AVIVI A, 1991, ONCOGENE, V6, P1089; Baca M, 1997, J BIOL CHEM, V272, P10678; BARBAS CF, 1993, GENE, V137, P57, DOI 10.1016/0378-1119(93)90251-W; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BIGELOW CC, 1974, BIOCHEMISTRY-US, V13, P4602, DOI 10.1021/bi00719a021; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; CHAMOW SM, 1994, J IMMUNOL, V153, P4268; Chellaiah A, 1999, J BIOL CHEM, V274, P34785, DOI 10.1074/jbc.274.49.34785; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; de Haard HJ, 1999, J BIOL CHEM, V274, P18218, DOI 10.1074/jbc.274.26.18218; DEKRUIF J, 1995, J MOL BIOL, V248, P97, DOI 10.1006/jmbi.1995.0204; DUENAS M, 1995, GENE, V158, P61, DOI 10.1016/0378-1119(95)00077-J; Ewert S, 2003, J MOL BIOL, V325, P531, DOI 10.1016/S0022-2836(02)01237-8; GARRARD LJ, 1991, BIO-TECHNOL, V9, P1373, DOI 10.1038/nbt1291-1373; Ge L, 1995, ANTIBODY ENG, P229; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GORDON IL, 1995, CYTOMETRY, V20, P238, DOI 10.1002/cyto.990200307; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HAN IS, 1993, MOL ENDOCRINOL, V7, P889, DOI 10.1210/me.7.7.889; Hanes J, 2000, NAT BIOTECHNOL, V18, P1287, DOI 10.1038/82407; HECHT D, 1995, GROWTH FACTORS, V12, P223, DOI 10.3109/08977199509036882; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; JAFFERS GJ, 1986, TRANSPLANTATION, V41, P572, DOI 10.1097/00007890-198605000-00004; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Jirholt P, 1998, GENE, V215, P471, DOI 10.1016/S0378-1119(98)00317-5; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; KLEIN M, 1979, BIOCHEMISTRY-US, V18, P1473, DOI 10.1021/bi00575a014; KLINT P, 1999, FRONT BIOSCI, V4, P165; Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444; KNAPPIK A, 1993, BIO-TECHNOL, V11, P77, DOI 10.1038/nbt0193-77; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Krebs B, 2001, J IMMUNOL METHODS, V254, P67, DOI 10.1016/S0022-1759(01)00398-2; Kretzschmar T, 2002, CURR OPIN BIOTECH, V13, P598, DOI 10.1016/S0958-1669(02)00380-4; Li ZH, 2001, BLOOD, V97, P2413, DOI 10.1182/blood.V97.8.2413; LOHNING C, 2000, Patent No. 0105950; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MARKS JD, 1993, BIO-TECHNOL, V11, P1145, DOI 10.1038/nbt1093-1145; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; Monsonego-Ornan E, 2000, MOL CELL BIOL, V20, P516, DOI 10.1128/MCB.20.2.516-522.2000; MOVVA NR, 1980, J BIOL CHEM, V255, P27; Nagy ZA, 2002, NAT MED, V8, P801, DOI 10.1038/nm736; NARAMURA M, 1993, CANCER IMMUNOL IMMUN, V37, P343, DOI 10.1007/BF01518458; Naski M.C., 1998, FRONT BIOSCI-LANDMRK, V3, pd781, DOI [10.2741/a321, DOI 10.2741/A321]; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; PERELSON AS, 1989, IMMUNOL REV, V110, P5, DOI 10.1111/j.1600-065X.1989.tb00025.x; PerezCastro AV, 1997, GENOMICS, V41, P10, DOI 10.1006/geno.1997.4616; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PICKEN RN, 1983, INFECT IMMUN, V42, P269, DOI 10.1128/IAI.42.1.269-275.1983; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; Pritchard MP, 1997, ARCH BIOCHEM BIOPHYS, V345, P342, DOI 10.1006/abbi.1997.0265; Robinson D, 1999, CLIN ORTHOP RELAT R, pS163; ROWE ES, 1976, BIOCHEMISTRY-US, V15, P905, DOI 10.1021/bi00649a028; SANNA PP, 1995, P NATL ACAD SCI USA, V92, P6439, DOI 10.1073/pnas.92.14.6439; Sblattero D, 2000, NAT BIOTECHNOL, V18, P75, DOI 10.1038/71958; Schmidt TGM, 1996, J MOL BIOL, V255, P753, DOI 10.1006/jmbi.1996.0061; Sheets MD, 1998, P NATL ACAD SCI USA, V95, P6157, DOI 10.1073/pnas.95.11.6157; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Sibley K, 2002, BRIT J HAEMATOL, V118, P514, DOI 10.1046/j.1365-2141.2002.03618.x; SKERRA A, 1991, PROTEIN ENG, V4, P971, DOI 10.1093/protein/4.8.971; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Sleeman M, 2001, GENE, V271, P171, DOI 10.1016/S0378-1119(01)00518-2; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Soderlind E, 2000, NAT BIOTECHNOL, V18, P852, DOI 10.1038/78458; Stratowa C, 1999, ANTI-CANCER DRUG DES, V14, P393; TAVORMINA PL, 1995, HUM MOL GENET, V4, P2175, DOI 10.1093/hmg/4.11.2175; van Rhijn BWG, 2002, J PATHOL, V198, P245, DOI 10.1002/path.1202; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; VENKATESWARAN S, 1992, HYBRIDOMA, V11, P729, DOI 10.1089/hyb.1992.11.729; VIRNEKAS B, 1994, NUCLEIC ACIDS RES, V22, P5600, DOI 10.1093/nar/22.25.5600; Voss S, 1997, PROTEIN ENG, V10, P975, DOI 10.1093/protein/10.8.975; Wang Q, 2000, MECH DEVELOP, V90, P283, DOI 10.1016/S0925-4773(99)00241-5; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WEIDNER KM, 1992, J BIOL CHEM, V267, P10281; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427; WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102; Yang XD, 1999, CANCER RES, V59, P1236; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	90	99	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38194	38205		10.1074/jbc.M303164200	http://dx.doi.org/10.1074/jbc.M303164200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12842902	hybrid			2022-12-25	WOS:000185575100015
J	Rondon, AG; Jimeno, S; Garcia-Rubio, M; Aguilera, A				Rondon, AG; Jimeno, S; Garcia-Rubio, M; Aguilera, A			Molecular evidence that the eukaryotic THO/TREX complex is required for efficient transcription elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; WHOLE-CELL EXTRACT; SACCHAROMYCES-CEREVISIAE; MITOTIC RECOMBINATION; GENOMIC INSTABILITY; NUCLEAR EXPORT; YEAST HOMOLOG; GENE; SUB2P; HPR1	THO/TREX is a conserved eukaryotic complex formed by the core THO complex plus proteins involved in mRNA metabolism and export such as Sub2 and Yra1. Mutations in any of the THO/TREX structural genes cause pleiotropic phenotypes such as transcription impairment, increased transcription-associated recombination, and mRNA export defects. To assay the relevance of THO/TREX complex in transcription, we performed in vitro transcription elongation assays in mutant cell extracts using supercoiled DNA templates containing two G-less cassettes. With these assays, we demonstrate that hpr1Delta, tho2Delta, and mft1Delta mutants of the THO complex and sub2 mutants show significant reductions in the efficiency of transcription elongation. The mRNA expression defect of hpr1Delta mutants was not due to an increase in mRNA decay, as determined by mRNA half-life measurements and mRNA time course accumulation experiments in the absence of Rrp6p exoribonuclease. This work demonstrates that THO and Sub2 are required for efficient transcription elongation, providing further evidence for the coupling between transcription and mRNA metabolism and export.	Univ Sevilla, Fac Biol, Dept Genet, E-41012 Seville, Spain	University of Sevilla	Aguilera, A (corresponding author), Univ Sevilla, Fac Biol, Dept Genet, Ave Reina Mercedes 6, E-41012 Seville, Spain.		Jimeno González, Sonia/GJM-5073-2022; Rondon, Ana G/C-2102-2017; Jimeno, Sonia/C-2514-2017; Aguilera, Andres/L-1825-2014; Garcia-Rubio, Maria/C-2061-2017	Jimeno González, Sonia/0000-0002-7034-0081; Aguilera, Andres/0000-0003-4782-1714; Garcia-Rubio, Maria/0000-0003-0981-0555; , Ana/0000-0002-9481-1255				Aguilera A, 2002, EMBO J, V21, P195, DOI 10.1093/emboj/21.3.195; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; Chavez S, 2000, EMBO J, V19, P5824, DOI 10.1093/emboj/19.21.5824; Chavez S, 1997, GENE DEV, V11, P3459, DOI 10.1101/gad.11.24.3459; Chavez S, 2001, MOL CELL BIOL, V21, P7054, DOI 10.1128/MCB.21.20.7054-7064.2001; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Fan HY, 2001, MOL CELL BIOL, V21, P5459, DOI 10.1128/MCB.21.16.5459-5470.2001; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Fischer T, 2002, EMBO J, V21, P5843, DOI 10.1093/emboj/cdf590; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; Gallardo M, 2003, J BIOL CHEM, V278, P24225, DOI 10.1074/jbc.M302900200; Gallardo M, 2001, GENETICS, V157, P79; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hartzog GA, 2003, CURR OPIN GENET DEV, V13, P119, DOI 10.1016/S0959-437X(03)00024-8; Jensen TH, 2001, CURR BIOL, V11, P1711, DOI 10.1016/S0960-9822(01)00529-2; Jimeno S, 2002, EMBO J, V21, P3526, DOI 10.1093/emboj/cdf335; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; Lei L, 1999, MOL CELL BIOL, V19, P8372; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Libri D, 2001, GENE DEV, V15, P36, DOI 10.1101/gad.852101; Libri D, 2002, MOL CELL BIOL, V22, P8254, DOI 10.1128/MCB.22.23.8254-8266.2002; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Piruat JI, 1998, EMBO J, V17, P4859, DOI 10.1093/emboj/17.16.4859; Portman DS, 1997, RNA, V3, P527; Prado F, 1997, EMBO J, V16, P2826, DOI 10.1093/emboj/16.10.2826; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Rondon AG, 2003, EMBO J, V22, P612, DOI 10.1093/emboj/cdg047; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; Schneiter R, 1999, MOL CELL BIOL, V19, P3415; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; Shaw RJ, 2000, MOL CELL BIOL, V20, P7427, DOI 10.1128/MCB.20.20.7427-7437.2000; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 2003, ANNU REV BIOCHEM, V72, P693, DOI 10.1146/annurev.biochem.72.121801.161551; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Wada T, 2000, MOL CELL, V5, P1067, DOI 10.1016/S1097-2765(00)80272-5; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zhang M, 2001, GENE DEV, V15, P30, DOI 10.1101/gad.851701	49	91	97	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39037	39043		10.1074/jbc.M305718200	http://dx.doi.org/10.1074/jbc.M305718200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871933	Green Published, hybrid			2022-12-25	WOS:000185575100116
J	Sato, K; Tokmakov, AA; He, CL; Kurokawa, M; Iwasaki, T; Shirouzu, M; Fissore, RA; Yokoyama, S; Fukami, Y				Sato, K; Tokmakov, AA; He, CL; Kurokawa, M; Iwasaki, T; Shirouzu, M; Fissore, RA; Yokoyama, S; Fukami, Y			Reconstitution of Src-dependent phospholipase C gamma phosphorylation and transient calcium release by using membrane rafts and cell-free extracts from Xenopus eggs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; DOMAIN-MEDIATED ACTIVATION; TYROSINE KINASE-ACTIVITY; STARFISH EGGS; GROWTH-FACTOR; PLC-GAMMA; INOSITOL 1,4,5-TRISPHOSPHATE; CA2+ OSCILLATIONS; LIPID RAFTS; MOUSE EGGS	We reported previously that egg membrane rafts serve as a subcellular microdomain for sperm-dependent tyrosine kinase signaling in Xenopus fertilization. Moreover, we demonstrated that raft-associated Src tyrosine kinase was activated by sperm in vitro. Here we show that egg rafts incubated with sperm or hydrogen peroxide (H2O2) can promote Src-dependent phosphorylation of phospholipase Cgamma (PLCgamma) and transient calcium release in the extracts of unfertilized Xenopus eggs. In vivo egg activation by sperm or H2O2 also promotes tyrosine-phosphorylation and raft-translocalization of PLCgamma. Immunodepletion of PLCgamma from the egg extracts inhibits the raft-dependent calcium release. Rafts prepared from H2O2-activated eggs also promote Src-dependent dephosphorylation of p42 mitogen-activated protein kinase and cell cycle transition from metaphase II to interphase in egg extracts. PLCgamma phosphorylation and calcium release in egg extracts can be promoted by rafts prepared from COS-7 cells expressing the Xenopus Src gene. These results demonstrate that the signaling events elicited by fertilization in Xenopus eggs can be reconstituted in vitro. The development of such experimental platforms will allow us to dissect the molecular mechanism of sperm-dependent activation of raft-associated Src and subsequent up-regulation of PLCgamma and egg activation machinery in Xenopus eggs.	Kobe Univ, Fac Sci, Res Ctr Environm Genom, Nada Ku, Kobe, Hyogo 6578501, Japan; Kobe Univ, Fac Sci, Dept Biol, Nada Ku, Kobe, Hyogo 6578501, Japan; RIKEN, Yokohama Inst, Genome Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	Kobe University; Kobe University; RIKEN; University of Massachusetts System; University of Massachusetts Amherst	Sato, K (corresponding author), Kobe Univ, Fac Sci, Res Ctr Environm Genom, Nada Ku, Kobe, Hyogo 6578501, Japan.	kksato@kobe-u.ac.jp	Shirouzu, Mikako/A-6521-2016; Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Kurokawa, Manabu/0000-0002-4138-5934				Abassi YA, 2000, DEV BIOL, V218, P206, DOI 10.1006/dbio.1999.9582; Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Belton RJ, 2001, MOL REPROD DEV, V59, P294, DOI 10.1002/mrd.1034; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Carroll DJ, 1997, J CELL BIOL, V138, P1303, DOI 10.1083/jcb.138.6.1303; Carroll DJ, 1999, DEV BIOL, V206, P232, DOI 10.1006/dbio.1998.9145; Dupont G, 1996, BIOCHEM J, V316, P583, DOI 10.1042/bj3160583; Evans JD, 2001, BIOESSAYS, V23, P62, DOI 10.1002/1521-1878(200101)23:1&lt;62::AID-BIES1008&gt;3.0.CO;2-7; FUKAMI Y, 1993, J BIOL CHEM, V268, P1132; Giusti AF, 2000, J BIOL CHEM, V275, P16788, DOI 10.1074/jbc.M001091200; Giusti AF, 1999, J BIOL CHEM, V274, P29318, DOI 10.1074/jbc.274.41.29318; Glahn D, 1999, DEV BIOL, V205, P171, DOI 10.1006/dbio.1998.9042; Harlow E., 1988, ANTIBODIES LAB MANUA; Kinsey WH, 2000, DEV BIOL, V225, P253, DOI 10.1006/dbio.2000.9830; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SJ, 1998, DEV BIOL, V193, P195, DOI 10.1006/dbio.1997.8792; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Mehlmann LM, 1998, DEV BIOL, V203, P221, DOI 10.1006/dbio.1998.9051; Miller BJ, 2000, J CELL BIOL, V149, P1289, DOI 10.1083/jcb.149.6.1289; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rongish BJ, 1999, DEV BIOL, V215, P147, DOI 10.1006/dbio.1999.9472; Runft LL, 2000, DEVELOPMENT, V127, P3227; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; Runft LL, 1999, DEV BIOL, V214, P399, DOI 10.1006/dbio.1999.9415; Sato K, 1999, DEV BIOL, V209, P308, DOI 10.1006/dbio.1999.9255; Sato K, 1998, FEBS LETT, V424, P113, DOI 10.1016/S0014-5793(98)00123-9; Sato K, 2002, DEVELOPMENT, V129, P885; Sato K, 2001, DEV GROWTH DIFFER, V43, P55; Sato K, 1996, J BIOL CHEM, V271, P13250, DOI 10.1074/jbc.271.22.13250; Sato KI, 2000, DEV BIOL, V224, P453, DOI 10.1006/dbio.2000.9782; Saunders CM, 2002, DEVELOPMENT, V129, P3533; SCHULTZ RM, 1995, CURR TOP DEV BIOL, V30, P21, DOI 10.1016/S0070-2153(08)60563-3; Sette C, 2002, EMBO J, V21, P5386, DOI 10.1093/emboj/cdf553; Shearer J, 1999, DEVELOPMENT, V126, P2273; Shen SS, 1999, DEV GROWTH DIFFER, V41, P345; SHILLING FM, 1994, DEV BIOL, V162, P590, DOI 10.1006/dbio.1994.1112; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STEELE RE, 1989, J BIOL CHEM, V264, P10649; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; Swann K, 2001, REPRODUCTION, V122, P839, DOI 10.1530/reprod/122.6.839; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tokmakov AA, 2002, CELL CALCIUM, V32, P11, DOI 10.1016/S0143-4160(02)00078-7; Tokmakov AA, 2001, J CELL BIOCHEM, V82, P89, DOI 10.1002/jcb.1140.abs; WALKER F, 1993, J BIOL CHEM, V268, P19552; Waltenberger J, 1999, CIRC RES, V85, P12; WHITAKER M, 1993, DEVELOPMENT, V117, P1; Wu H, 2001, BIOL REPROD, V64, P1338, DOI 10.1095/biolreprod64.5.1338; YIM DL, 1994, DEV BIOL, V162, P41, DOI 10.1006/dbio.1994.1065	54	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38413	38420		10.1074/jbc.M302617200	http://dx.doi.org/10.1074/jbc.M302617200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12847104	hybrid			2022-12-25	WOS:000185575100041
J	van Hennik, PB; ten Klooster, JP; Halstead, JR; Voermans, C; Anthony, EC; Divecha, N; Hordijk, PL				van Hennik, PB; ten Klooster, JP; Halstead, JR; Voermans, C; Anthony, EC; Divecha, N; Hordijk, PL			The C-terminal domain of Rac1 contains two motifs that control targeting and signaling specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; RHO GTPASES; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ACTIVATION; MIGRATION; PAK; TRANSFORMATION; ABNORMALITIES; ESTABLISHMENT; ASSOCIATION	Rho-like GTPases control a wide range of cellular functions such as integrin- and cadherin-mediated adhesion, cell motility, and gene expression. The hypervariable C-terminal domain of these GTPases has been implicated in membrane association and effector binding. We found that cell-permeable peptides, encoding the C termini of Rac1, Rac2, RhoA, and Cdc42, interfere with GTPase signaling in a specific fashion in a variety of cellular models. Pull-down assays showed that the C terminus of Rac1 does not associate to either RhoGDI or to Pak. In contrast, the C terminus of Rac1 (but not Rac2 or Cdc42) binds to phosphatidylinositol 4,5-phosphate kinase (PIP5K) via amino acids 185-187 (RKR). Moreover, Rac1 associates to the adapter protein Crk via the N-terminal Src homology 3 (SH3) domain of Crk and the proline-rich stretch in the Rac1 C terminus. These differential interactions mediate Rac1 localization, as well as Rac1 signaling, toward membrane ruffling, cell-cell adhesion, and migration. These data show that the C-terminal, hypervariable domain of Rac1 encodes two distinct binding motifs for signaling proteins and regulates intracellular targeting and differential signaling in a unique and non-redundant fashion.	CLB, Sanquin Res, Dept Expt Immunohematol, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Netherlands Cancer Institute	Hordijk, PL (corresponding author), CLB, Sanquin Res, Dept Expt Immunohematol, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.	p.hordijk@sanquin.nl	Voermans, Carlijn/GPP-3405-2022	Hordijk, Peter/0000-0002-3348-078X; divecha, nullin/0000-0001-9695-6039; ten Klooster, Jean Paul/0000-0002-4979-7482				Alblas J, 2001, MOL BIOL CELL, V12, P2137, DOI 10.1091/mbc.12.7.2137; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Croker BA, 2002, IMMUNOL CELL BIOL, V80, P231, DOI 10.1046/j.1440-1711.2002.01077.x; Croker BA, 2002, J IMMUNOL, V168, P3376, DOI 10.4049/jimmunol.168.7.3376; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; del Pozo MA, 1999, EUR J IMMUNOL, V29, P3609; Divecha N, 2002, CURR BIOL, V12, P582, DOI 10.1016/S0960-9822(02)00769-8; Divecha N, 2000, EMBO J, V19, P5440, DOI 10.1093/emboj/19.20.5440; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Ho A, 2001, CANCER RES, V61, P474; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Insall RH, 2001, DEV CELL, V1, P743, DOI 10.1016/S1534-5807(01)00086-7; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Mayer BJ, 2001, J CELL SCI, V114, P1253; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Nievers MG, 1997, J CELL SCI, V110, P389; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tao W, 2002, BLOOD, V100, P1679, DOI 10.1182/blood.V100.5.1679.h81702001679_1679_1688; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; van Wetering S, 2002, J CELL SCI, V115, P1837; Vastrik I, 1999, CURR BIOL, V9, P991, DOI 10.1016/S0960-9822(99)80447-3; Voermans C, 1999, EXP HEMATOL, V27, P1806, DOI 10.1016/S0301-472X(99)00113-7; Voermans C, 2001, EXP HEMATOL, V29, P1456, DOI 10.1016/S0301-472X(01)00740-8; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	44	86	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39166	39175		10.1074/jbc.M307001200	http://dx.doi.org/10.1074/jbc.M307001200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874273	hybrid			2022-12-25	WOS:000185575100130
J	Webster, JM; Tiwari, S; Weissman, AM; Wojcikiewicz, RJH				Webster, JM; Tiwari, S; Weissman, AM; Wojcikiewicz, RJH			Inositol 1,4,5-trisphosphate receptor ubiquitination is mediated by mammalian Ubc7, a component of the endoplasmic reticulum-associated degradation pathway, and is inhibited by chelation of intracellular Zn2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER-ASSOCIATED DEGRADATION; SH-SY5Y NEUROBLASTOMA-CELLS; MOTILITY FACTOR-RECEPTOR; INDUCED DOWN-REGULATION; ALZHEIMERS-DISEASE; PROTEASOME PATHWAY; CHOLINESTERASE-INHIBITORS; PROTEIN TRANSLOCATION; LIGAND-BINDING; CA2+	In response to activation of certain cell surface receptors, inositol 1,4,5-trisphosphate receptors (InsP(3)Rs), which are located in the endoplasmic reticulum, can be rapidly ubiquitinated and then degraded by the proteasome. Ubiquitination is mediated by the concerted action of ubiquitin-conjugating enzymes (Ubcs or E2s) and ubiquitin-protein ligases (E3s). In the present study we have examined the enzymology of ubiquitination of endogenous InsP(3)Rs in muscarinic agonist-stimulated SH-SY5Y human neuroblastoma cells, focusing our attention on two mammalian E2s, MmUbc6 and MmUbc7, that have been implicated in endoplasmic reticulum-associated degradation (ERAD) and are homologous to the yeast ERAD E2s, Ubc6p and Ubc7p. Analysis of SH-SY5Y cells stably expressing these enzymes and their dominant-negative mutants revealed that MmUbc7 mediates InsP(3)R ubiquitination and down-regulation, but that MmUbc6 does not. These data indicate that InsP(3)Rs are processed by a component of the ERAD pathway and suggest that MmUbc7 may be employed selectively to ubiquitinate proteins, like InsP(3)Rs, that are subject to regulated ERAD. Additional studies showed that the Zn2+ chelator N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine blocked InsP(3)R ubiquitination, suggesting that a RING finger domain- containing E3 is also involved in this process. Finally, muscarinic agonist-induced InsP(3)R ubiquitination was seen in rat brain slices, indicating that the results obtained from SH-SY5Y cells reflect a physiological process.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; NCI, Regulat Prot Funct Lab, Ctr Canc Res, Frederick, MD 21702 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wojcikiewicz, RJH (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	wojcikir@upstate.edu		Webster, Jack/0000-0003-2586-473X	NATIONAL CANCER INSTITUTE [Z01BC009392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049194] Funding Source: NIH RePORTER; NIDDK NIH HHS [5R01DK49194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auld DS, 2002, PROG NEUROBIOL, V68, P209, DOI 10.1016/S0301-0082(02)00079-5; BALDUINI W, 1991, DEV BRAIN RES, V62, P115, DOI 10.1016/0165-3806(91)90196-P; Banki K, 1996, J BIOL CHEM, V271, P32994, DOI 10.1074/jbc.271.51.32994; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Bokkala S, 1997, J BIOL CHEM, V272, P12454, DOI 10.1074/jbc.272.19.12454; Botero D, 2002, MOL ENDOCRINOL, V16, P1999, DOI 10.1210/me.2002-0135; Brind S, 2000, DEV BIOL, V223, P251, DOI 10.1006/dbio.2000.9728; CHALLISS RAJ, 1994, NEUROPHARMACOLOGY, V33, P15, DOI 10.1016/0028-3908(94)90092-2; Chimienti F, 2001, BIOCHEM PHARMACOL, V62, P51, DOI 10.1016/S0006-2952(01)00624-4; da Fonseca PCA, 2003, P NATL ACAD SCI USA, V100, P3936, DOI 10.1073/pnas.0536251100; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Fisher A, 1996, ANN NY ACAD SCI, V777, P189, DOI 10.1111/j.1749-6632.1996.tb34418.x; Fowler CJ, 1996, ANN NY ACAD SCI, V786, P294, DOI 10.1111/j.1749-6632.1996.tb39072.x; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gonen H, 1999, J BIOL CHEM, V274, P14823, DOI 10.1074/jbc.274.21.14823; Grutzendler J, 2001, DRUGS, V61, P41, DOI 10.2165/00003495-200161010-00005; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hamada K, 2002, J BIOL CHEM, V277, P21115, DOI 10.1074/jbc.C200244200; Hampton RY, 2002, ANNU REV CELL DEV BI, V18, P345, DOI 10.1146/annurev.cellbio.18.032002.131219; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jarosch E, 2003, INT REV CYTOL, V223, P39; Jellerette T, 2000, DEV BIOL, V223, P238, DOI 10.1006/dbio.2000.9675; Jiang QX, 2002, EMBO J, V21, P3575, DOI 10.1093/emboj/cdf380; Kaneko M, 2002, FEBS LETT, V532, P147, DOI 10.1016/S0014-5793(02)03660-8; Katsanis N, 1998, GENOMICS, V51, P128, DOI 10.1006/geno.1998.5263; Krall WJ, 1999, ANN PHARMACOTHER, V33, P441, DOI 10.1345/aph.18211; Lenk U, 2002, J CELL SCI, V115, P3007; Lester D, 2000, BIOCHEM BIOPH RES CO, V269, P474, DOI 10.1006/bbrc.2000.2302; Liang JS, 2003, J BIOL CHEM, V278, P23984, DOI 10.1074/jbc.M302683200; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Nadav E, 2003, BIOCHEM BIOPH RES CO, V303, P91, DOI 10.1016/S0006-291X(03)00279-1; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Plemper RK, 1999, MOL BIOL REP, V26, P125, DOI 10.1023/A:1006913215484; Ravid T, 1999, J BIOL CHEM, V274, P29341, DOI 10.1074/jbc.274.41.29341; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; Serysheva II, 2003, J BIOL CHEM, V278, P21319, DOI 10.1074/jbc.C300148200; Sharma K, 2000, AM J PHYSIOL-RENAL, V278, pF1022, DOI 10.1152/ajprenal.2000.278.6.F1022; Sipma H, 1998, CELL CALCIUM, V23, P11, DOI 10.1016/S0143-4160(98)90070-7; Snitsarev VA, 1996, BIOPHYS J, V71, P1048, DOI 10.1016/S0006-3495(96)79305-0; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Soulsby MD, 2002, CELL CALCIUM, V32, P175, DOI 10.1016/S0143416002001525; Tiwari S, 2001, J BIOL CHEM, V276, P16193, DOI 10.1074/jbc.M007640200; Tovey SC, 2001, J CELL SCI, V114, P3979; Walter J, 2001, EMBO J, V20, P3124, DOI 10.1093/emboj/20.12.3124; WARD CL, 1994, J BIOL CHEM, V269, P25710; Webster JM, 2003, EUR J PHARMACOL, V474, P1, DOI 10.1016/S0014-2999(03)02005-3; Willars GB, 2001, J BIOL CHEM, V276, P3123, DOI 10.1074/jbc.M008916200; Wojcikiewicz RJH, 1999, GASTROENTEROLOGY, V116, P1194, DOI 10.1016/S0016-5085(99)70023-5; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 2003, J BIOL CHEM, V278, P940, DOI 10.1074/jbc.M206607200; Wojcikiewicz RJH, 1996, J BIOL CHEM, V271, P16652, DOI 10.1074/jbc.271.28.16652; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOJCIKIEWICZ RJH, 1991, J BIOL CHEM, V266, P22234; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Zhu CC, 1999, J BIOL CHEM, V274, P3476, DOI 10.1074/jbc.274.6.3476; Zhu CC, 2000, BIOCHEM J, V348, P551, DOI 10.1042/0264-6021:3480551	67	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38238	38246		10.1074/jbc.M305600200	http://dx.doi.org/10.1074/jbc.M305600200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12869571	hybrid			2022-12-25	WOS:000185575100020
J	Calero, G; Gupta, P; Nonato, MC; Tandel, S; Biehl, ER; Hofmann, SL; Clardy, J				Calero, G; Gupta, P; Nonato, MC; Tandel, S; Biehl, ER; Hofmann, SL; Clardy, J			The crystal structure of palmitoyl protein thioesterase-2 (PPT2) reveals the basis for divergent substrate specificities of the two lysosomal thioesterases, PPT1 and PPT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; MOLECULAR-CLONING; OPEN CONFORMATION; LIPASE; EXPRESSION; MUTATIONS	Mutations in palmitoyl protein thioesterase-1 (PPT1) have been found to cause the infantile form of neuronal ceroid lipofuscinosis, which is a lysosomal storage disorder characterized by impaired degradation of fatty acid-modified proteins with accumulation of amorphous granular deposits in cortical neurons, leading to mental retardation and death. Palmitoyl protein thioesterase-2 (PPT2) is a second lysosomal hydrolase that shares a 26% identity with PPT1. A previous study had suggested that palmitoyl-CoA was the preferred substrate of PPT2. Furthermore, PPT2 did not hydrolyze palmitate from the several S-palmitoylated protein substrates. Interestingly, PPT2 deficiency in a recent transgenic mouse model is associated with a form of neuronal ceroid lipofuscinosis, suggesting that PPT1 and -2 perform nonredundant roles in lysosomal thioester catabolism. In the current paper, we present the crystal structure of PPT2 at a resolution of 2.7 Angstrom. Comparisons of the structures of PPT1 and - 2 show very similar architectural features; however, conformational differences in helix alpha4 lead to a solvent-exposed lipid-binding groove in PPT1. The limited space between two parallel loops (beta3-alphaA and beta8-alphaF) located immediately above the lipid-binding groove in PPT2 restricts the binding of fatty acids with bulky head groups, and this binding groove is significantly larger in PPT1. This structural difference accounts for the ability of PPT2 to hydrolyze an unbranched structure such as palmitoyl-CoA but not palmitoylcysteine or palmitoylated proteins. Furthermore, differences in fatty acid chain length specificity of PPT1 and - 2, also reported here, are explained by the structure and may provide a biochemical basis for their non-redundant roles.	Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; So Methodist Univ, Dept Chem, Dallas, TX 75275 USA	Cornell University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Southern Methodist University	Clardy, J (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.		Nonato, Maria Cristina C/C-5659-2012	Nonato, Maria Cristina C/0000-0002-4916-1505	NCI NIH HHS [CA59021] Funding Source: Medline; NINDS NIH HHS [NS35323] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035323] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bellizzi JJ, 2000, P NATL ACAD SCI USA, V97, P4573, DOI 10.1073/pnas.080508097; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CHRISTOPHER JA, 1998, SPOCK; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Das AK, 2000, J BIOL CHEM, V275, P23847, DOI 10.1074/jbc.M002758200; Devedjiev Y, 2000, STRUCTURE, V8, P1137, DOI 10.1016/S0969-2126(00)00529-3; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; Gupta P, 2001, P NATL ACAD SCI USA, V98, P13566, DOI 10.1073/pnas.251485198; Hofmann SL, 1999, MOL GENET METAB, V66, P234, DOI 10.1006/mgme.1999.2803; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Knudsen J, 1981, Methods Enzymol, V71 Pt C, P200, DOI 10.1016/0076-6879(81)71028-0; Lang D, 1996, J MOL BIOL, V259, P704, DOI 10.1006/jmbi.1996.0352; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mitchison HM, 1998, HUM MOL GENET, V7, P291, DOI 10.1093/hmg/7.2.291; Nardini M, 2000, J BIOL CHEM, V275, P31219, DOI 10.1074/jbc.M003903200; NOBLE MEM, 1993, FEBS LETT, V331, P123, DOI 10.1016/0014-5793(93)80310-Q; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peltonen L, 2000, CURR OPIN GENET DEV, V10, P299, DOI 10.1016/S0959-437X(00)00086-1; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; Schrag JD, 1997, STRUCTURE, V5, P187, DOI 10.1016/S0969-2126(97)00178-0; Soyombo AA, 1997, J BIOL CHEM, V272, P27456, DOI 10.1074/jbc.272.43.27456; van Diggelen OP, 1999, MOL GENET METAB, V66, P240, DOI 10.1006/mgme.1999.2809; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0	28	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37957	37964		10.1074/jbc.M301225200	http://dx.doi.org/10.1074/jbc.M301225200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855696	hybrid			2022-12-25	WOS:000185437200118
J	Cattaruzza, M; Slodowski, W; Stojakovic, M; Krzesz, R; Hecker, M				Cattaruzza, M; Slodowski, W; Stojakovic, M; Krzesz, R; Hecker, M			Interleukin-10 induction of nitric-oxide synthase expression attenuates CD40-mediated interleukin-12 synthesis in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; INHIBITION; CYTOKINES; IL-10; D-3	Interleukin-10 (IL-10) is a potent anti-inflammatory cytokine in Th1 cell-mediated chronic inflammatory diseases such as, e. g. Crohn's disease. Moreover, IL-10 has been shown to limit the progression of atherosclerosis, presumably by influencing endothelial cell function. Here we demonstrate that under pro-inflammatory conditions expression of the human IL-10 receptor gene is enhanced in endothelial cells in vitro and in vivo. Subsequent exposure to IL-10 results in an up-regulation of both endothelial nitric-oxide synthase (NOS-3) expression and activity. Gel mobility shift analyses and decoy oligonucleotide experiments suggest that this effect of IL-10 is mediated through activation of the transcription factor STAT-3 ( signal transducer and activator of transcription-3). One functional consequence of IL-10 up-regulation of NOS-3 abundance in cultured endothelial cells is the attenuation of CD154-induced IL-12 p40 expression. Moreover, CD154-induced IL-12 p40 expression is enhanced after blockade of NOS-3 activity but attenuated in the presence of exogenous nitric oxide. Increased NOS-3 expression may, thus, be one mechanism by which IL-10 exerts its anti-inflammatory effects in Th1 cell-mediated chronic inflammatory diseases.	Univ Gottingen, Sch Med, Dept Cardiovasc Physiol, D-37073 Gottingen, Germany	University of Gottingen	Hecker, M (corresponding author), Univ Gottingen, Sch Med, Dept Cardiovasc Physiol, Humboldtallee 23, D-37073 Gottingen, Germany.	hecker@veg-physiol.med.uni-goettingen.de						Asadullah K, 1999, ARCH DERMATOL, V135, P187, DOI 10.1001/archderm.135.2.187; Busse R, 1996, J VASC RES, V33, P181, DOI 10.1159/000159147; Cattaruzza M, 2000, BRIT J PHARMACOL, V129, P1155, DOI 10.1038/sj.bjp.0703192; Clark A, 2000, ARTHRITIS RES, V2, P172, DOI 10.1186/ar83; Fedorak RN, 2000, GASTROENTEROLOGY, V119, P1473, DOI 10.1053/gast.2000.20229; Gunnett CA, 2000, AM J PHYSIOL-HEART C, V279, pH1555, DOI 10.1152/ajpheart.2000.279.4.H1555; Harrison DG, 1997, CLIN CARDIOL, V20, P11; HECKER M, 1994, N-S ARCH PHARMACOL, V351, P426; Jirapongsananuruk O, 2000, J ALLERGY CLIN IMMUN, V106, P981, DOI 10.1067/mai.2000.110101; Kelm M, 1999, BBA-BIOENERGETICS, V1411, P273, DOI 10.1016/S0005-2728(99)00020-1; Kinlay S, 2001, CURR OPIN LIPIDOL, V12, P383, DOI 10.1097/00041433-200108000-00003; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Krieglstein CF, 2001, AM J HYPERTENS, V14, p44S, DOI 10.1016/S0895-7061(01)02069-6; Krzesz R, 1999, FEBS LETT, V453, P191, DOI 10.1016/S0014-5793(99)00683-3; Kubes P, 2000, AM J MED, V109, P150, DOI 10.1016/S0002-9343(00)00480-0; Lee TS, 1999, ARTERIOSCL THROM VAS, V19, P734, DOI 10.1161/01.ATV.19.3.734; Libby P, 1995, J CARDIOVASC PHARM, V25, pS9, DOI 10.1097/00005344-199500252-00003; Lienenluke B, 2000, EUR J IMMUNOL, V30, P2864, DOI 10.1002/1521-4141(200010)30:10<2864::AID-IMMU2864>3.0.CO;2-W; Madsen KL, 1999, INFLAMM BOWEL DIS, V5, P262, DOI 10.1097/00054725-199911000-00004; Mallat Z, 1999, CIRC RES, V85, pE17, DOI 10.1161/01.RES.85.8.e17; Michel G, 1997, INFLAMM RES, V46, P32, DOI 10.1007/s000110050042; Morishita R, 1998, CIRC RES, V82, P1023, DOI 10.1161/01.RES.82.10.1023; Romagnani P, 1997, CURR OPIN IMMUNOL, V9, P793, DOI 10.1016/S0952-7915(97)80180-X; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; Shevach EM, 1999, SPRINGER SEMIN IMMUN, V21, P249, DOI 10.1007/s002810050066; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Uyemura K, 1996, J CLIN INVEST, V97, P2130, DOI 10.1172/JCI118650; von der Thusen JH, 2001, FASEB J, V15, P2730, DOI 10.1096/fj.01-0483fje; Wagner AH, 2001, FASEB J, V15, P2121, DOI 10.1096/fj.01-0123com; Wagner AH, 2002, BRIT J PHARMACOL, V136, P143, DOI 10.1038/sj.bjp.0704678	31	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37874	37880		10.1074/jbc.M301670200	http://dx.doi.org/10.1074/jbc.M301670200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857749	hybrid			2022-12-25	WOS:000185437200108
J	Haddad, F; Bodell, PW; Qin, AX; Giger, JM; Baldwin, KM				Haddad, F; Bodell, PW; Qin, AX; Giger, JM; Baldwin, KM			Role of antisense RNA in coordinating cardiac myosin heavy chain gene switching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-MYOSIN; THYROID-HORMONE; MESSENGER-RNA; HUMAN HEART; RAT-HEART; ISOFORM EXPRESSION; SKELETAL-MUSCLE; TRANSGENIC MICE; TRANSCRIPTION; PROMOTER	A novel mechanism of regulation of cardiac alpha and beta myosin heavy chain gene by naturally occurring antisense transcription was elucidated via pre-mRNA analysis. Herein, we report the expression of an antisense beta myosin heavy chain RNA in the normal rodent myocardium. The pattern of expression of the antisense betaMHC RNA (betaRNA) under altered thyroid state and in diabetes directly correlates with that of the alpha pre-mRNA/mRNA, whereas it negatively correlates with the beta mRNA expression. Rapid amplification of the 5' end shows that this antisense transcript originates 2 kb downstream of the beta gene, and it is transcribed across the entire beta gene from the opposite strand. Our results demonstrate that the beta-alpha myosin heavy chain intergenic DNA possesses a bidirectional transcriptional activity, one direction transcribing the beta gene, and the opposite direction transcribing the antisense beta RNA. This process turns on the alpha expression, and it simultaneously turns off that of the beta and thus coordinates alpha and beta expression in an opposite fashion. Comparative analyses of the intergenic DNA sequence across five mammalian species revealed a conserved region that is proposed to be a common regulatory region for the alpha and antisense beta promoter. This finding unravels the mechanism of cardiac alpha-beta gene switching and implicates the role of cardiac myosin gene organization with their function.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Baldwin, KM (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073473] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL73473-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham WT, 2002, MOL MED, V8, P750, DOI 10.1007/BF03402039; ACSADI G, 1991, NEW BIOL, V3, P71; Blanchette M, 2002, GENOME RES, V12, P739, DOI 10.1101/gr.6902; BOHELER KR, 1992, J BIOL CHEM, V267, P12979; Chau YM, 2002, J CLIN ENDOCR METAB, V87, P2674, DOI 10.1210/jc.87.6.2674; CHIZZONITE RA, 1984, J BIOL CHEM, V259, P2628; CLARK WA, 1982, J BIOL CHEM, V257, P5449; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Elferink CJ, 1996, BIOTECHNIQUES, V20, P470; Esser K, 1999, J BIOL CHEM, V274, P12095, DOI 10.1074/jbc.274.17.12095; GULICK J, 1991, J BIOL CHEM, V266, P9180; Haddad F, 1997, J MOL CELL CARDIOL, V29, P559, DOI 10.1006/jmcc.1996.0299; Haddad F, 1997, AM J PHYSIOL-ENDOC M, V272, pE856, DOI 10.1152/ajpendo.1997.272.5.E856; HAMILTON N, 1991, MOL CELL BIOCHEM, V106, P133; Hastings ML, 2000, J BIOL CHEM, V275, P11507, DOI 10.1074/jbc.275.15.11507; Herron TJ, 2002, CIRC RES, V90, P1150, DOI 10.1161/01.RES.0000022879.57270.11; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KNOTTS S, 1995, NUCLEIC ACIDS RES, V23, P3301, DOI 10.1093/nar/23.16.3301; Kramer C, 2003, NATURE, V421, P948, DOI 10.1038/nature01427; Krenz M, 2003, J BIOL CHEM, V278, P17466, DOI 10.1074/jbc.M210804200; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; Lowes BD, 1997, J CLIN INVEST, V100, P2315, DOI 10.1172/JCI119770; Luther HP, 1997, J MOL CELL CARDIOL, V29, P27, DOI 10.1006/jmcc.1996.0248; Luther HP, 1998, J CELL BIOCHEM, V70, P110, DOI 10.1002/(SICI)1097-4644(19980701)70:1<110::AID-JCB11>3.3.CO;2-K; Luther HP, 2001, J CELL BIOCHEM, V80, P596, DOI 10.1002/1097-4644(20010315)80:4<596::AID-JCB1014>3.0.CO;2-Y; MAHDAVI V, 1986, MED SCI SPORTS EXERC, V18, P229; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; Molkentin JD, 1996, J MOL CELL CARDIOL, V28, P1211, DOI 10.1006/jmcc.1996.0112; Morkin E, 2000, MICROSC RES TECHNIQ, V50, P522, DOI 10.1002/1097-0029(20000915)50:6<522::AID-JEMT9>3.0.CO;2-U; Nakao K, 1997, J CLIN INVEST, V100, P2362, DOI 10.1172/JCI119776; O'Sullivan DC, 2002, AM J PHYSIOL-ENDOC M, V283, pE251, DOI 10.1152/ajpendo.00016.2002; Peters DG, 1999, AM J PHYSIOL-CELL PH, V276, pC1218, DOI 10.1152/ajpcell.1999.276.5.C1218; Reiser PJ, 2001, AM J PHYSIOL-HEART C, V280, pH1814, DOI 10.1152/ajpheart.2001.280.4.H1814; RINDT H, 1993, J BIOL CHEM, V268, P5332; Rougeulle C, 2002, TRENDS GENET, V18, P434, DOI 10.1016/S0168-9525(02)02749-X; SAEZ LJ, 1987, NUCLEIC ACIDS RES, V15, P5443, DOI 10.1093/nar/15.13.5443; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; Vanhee-Brossollet C, 1998, GENE, V211, P1, DOI 10.1016/S0378-1119(98)00093-6; Wasserman WW, 1998, J MOL BIOL, V278, P167, DOI 10.1006/jmbi.1998.1700; WEYDERT A, 1985, P NATL ACAD SCI USA, V82, P7183, DOI 10.1073/pnas.82.21.7183; Wright CE, 1999, AM J PHYSIOL-CELL PH, V276, pC883, DOI 10.1152/ajpcell.1999.276.4.C883; Wright CE, 2001, AM J PHYSIOL-CELL PH, V280, pC1262, DOI 10.1152/ajpcell.2001.280.5.C1262; Wu YF, 2000, TRENDS ENDOCRIN MET, V11, P207, DOI 10.1016/S1043-2760(00)00263-0; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	45	76	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37132	37138		10.1074/jbc.M305911200	http://dx.doi.org/10.1074/jbc.M305911200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12851393	hybrid			2022-12-25	WOS:000185437200019
J	Henry, LK; Adkins, EM; Han, Q; Blakely, RD				Henry, LK; Adkins, EM; Han, Q; Blakely, RD			Serotonin and cocaine-sensitive inactivation of human serotonin transporters by methanethiosulfonates targeted to transmembrane domain I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCANNING MUTAGENESIS; DIFFERENTIALLY ALTER; SUBSTRATE TRANSPORT; GAT-1 PLAYS; DOPAMINE; CLONING; CYSTEINE; ACCESSIBILITY; EXPRESSION; RESIDUES	To explore aqueous accessibility and functional contributions of transmembrane domain (TM) 1 in human serotonin transporter (hSERT) proteins, we utilized the largely methanethiosulfonate (MTS) insensitive hSERT C109A mutant and mutated individual residues of hSERT TM1 to Cys followed by tests of MTS inactivation of 5-hydroxytryptamine (5-HT) transport. Residues in TM1 cytoplasmic to Gly-94 were largely unaffected by Cys substitution, whereas the mutation of residues extracellular to Ile-93 variably diminished transport activity. TM1 Cys substitutions displayed differential sensitivity to MTS reagents, with residues more cytoplasmic to Asp-98 being largely insensitive to MTS inactivation. Aminoethylmethanethiosulfonate (MTSEA), [2-(trimethylammonium) ethyl] methanethiosulfonate bromide (MTSET), and sodium (2-sulfonatoethyl)-methanethiosulfonate ( MTSES) similarly and profoundly inactivated 5-HT transport by SERT mutants D98C, G100C, W103C, and Y107C. MTSEA uniquely inactivated transport activity of S91C, G94C, Y95C but increased activity at I108C. MTSEA and MTSET, but not MTSES, inactivated transport function at N101C. Notably, 5-HT provided partial to complete protection from MTSET inactivation for D98C, G100C, N101C, and Y107C. Equivalent blockade of MTSET inactivation at N101C was observed with 5-HT at both room temperature and at 4degreesC, inconsistent with major conformational changes leading to protection. Notably, cocaine also protected MTSET inactivation of G100C and N101C, although MTS incubations with N101C that eliminate 5-HT transport do not preclude cocaine analog binding nor its inhibition by 5-HT. 5-HT modestly enhanced the inactivation by MTSET at I93C and Y95C, whereas cocaine significantly enhanced MTSET sensitivity at Y107C and I108C. In summary, our studies reveal physical differences in TM1 accessibility to externally applied MTS reagents and reveal sites supporting substrate and antagonist modulation of MTS inactivation. Moreover, we identify a limit to accessibility for membrane-impermeant MTS reagents that may reflect aspects of an occluded permeation pathway.	Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Blakely, RD (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Ste 7140 MRBIII, Nashville, TN 37232 USA.	randy.blakely@vanderbilt.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER; NIDA NIH HHS [DA07390] Funding Source: Medline; NIMH NIH HHS [MH12399] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adkins EM, 2001, MOL PHARMACOL, V59, P514, DOI 10.1124/mol.59.3.514; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; Androutsellis-Theotokis A, 2002, J NEUROSCI, V22, P8370; Barker EL, 1999, J NEUROSCI, V19, P4705; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; BARKER EL, 1997, SOC NEUROSCI, V27, P450; Barker Eric L., 1995, P321; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Chang AS, 1996, MOL BRAIN RES, V43, P185, DOI 10.1016/S0169-328X(96)00172-6; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Chen JX, 1998, AM J PHYSIOL-GASTR L, V275, pG433, DOI 10.1152/ajpgi.1998.275.3.G433; Chen NH, 1998, J NEUROSCI, V18, P10257; Chen NH, 2000, J BIOL CHEM, V275, P1608, DOI 10.1074/jbc.275.3.1608; COREY JL, 1994, P NATL ACAD SCI USA, V91, P1188, DOI 10.1073/pnas.91.3.1188; DEMCHYSHYN LL, 1994, P NATL ACAD SCI USA, V91, P5158, DOI 10.1073/pnas.91.11.5158; DORON NK, 1994, J BIOL CHEM, V269, P3063; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; Javitch JA, 1996, MOL PHARMACOL, V49, P692; Javitch JA, 1998, METHOD ENZYMOL, V296, P331; Kanner BI, 2003, J BIOL CHEM, V278, P3705, DOI 10.1074/jbc.M210525200; KAPLAN RS, 2002, TRANSMEMBRANE TRANSP, P125; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; Lee SH, 2000, MOL PHARMACOL, V57, P883; Lin ZC, 2000, FASEB J, V14, P715, DOI 10.1096/fasebj.14.5.715; Madras BK, 1996, SYNAPSE, V24, P340; Meltzer PC, 1997, J MED CHEM, V40, P2661, DOI 10.1021/jm9703045; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mortensen OV, 1999, MOL BRAIN RES, V71, P120, DOI 10.1016/S0169-328X(99)00178-3; Padbury JF, 1997, MOL BRAIN RES, V45, P163, DOI 10.1016/S0169-328X(96)00309-9; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; Petersen CI, 1999, NAT NEUROSCI, V2, P605, DOI 10.1038/10158; Ponce J, 2000, J BIOL CHEM, V275, P13856, DOI 10.1074/jbc.275.18.13856; QIAN Y, 1995, J NEUROSCI, V15, P1261; QUICK MW, 2002, TRANSMEMBRANE TRANSP, pR13; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Ramamoorthy S, 1998, METHOD ENZYMOL, V296, P347; REITH MEA, 1986, BIOCHEM PHARMACOL, V35, P1123, DOI 10.1016/0006-2952(86)90148-6; Reith MEA, 2001, J BIOL CHEM, V276, P29012, DOI 10.1074/jbc.M011785200; Rudnick G., 2002, TRANSMEMBRANE TRANSP, P125; Tatsumi M, 1997, EUR J PHARMACOL, V340, P249, DOI 10.1016/S0014-2999(97)01393-9; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002	52	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37052	37063		10.1074/jbc.M305514200	http://dx.doi.org/10.1074/jbc.M305514200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869570	hybrid			2022-12-25	WOS:000185437200011
J	Keramaris, E; Hirao, A; Slack, RS; Mak, TW; Park, DS				Keramaris, E; Hirao, A; Slack, RS; Mak, TW; Park, DS			Ataxia telangiectasia-mutated protein can regulate p53 and neuronal death independent of Chk2 in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CENTRAL-NERVOUS-SYSTEM; INDUCED CELL-DEATH; CORTICAL-NEURONS; INDUCED PHOSPHORYLATION; CYTOSINE-ARABINOSIDE; IONIZING-RADIATION; TUMOR-SUPPRESSOR; TRANSGENIC MICE; CASPASE 3	DNA damage is a key initiator of neuronal death. We have previously shown that the tumor suppressor p53, in conjunction with cyclin-dependent kinases (CDKs), regulates the mitochondrial pathway of death in neurons exposed to genotoxic agents. However, the mechanisms by which p53 is regulated is unclear. Presently, we show that p53 is phosphorylated on Ser-15 following DNA damage and this occurs independently of the CDK pathway. Instead, we show that p53 phosphorylation, stability, as well as neuronal death is regulated, in part, by the ataxia telangiectasia-mutated (ATM) protein. Previous reports have suggested that ATM regulation of p53 occurs through Chk2. However, in our present paradigms, we show that ATM functions separately from Chk2 to regulate p53 stability and neuronal death. Chk2 deficiency does not affect p53 stability or neuronal death induced by Topoisomerase I or II inhibition. Taken together, our results provide a model by which DNA damage can activate an ATM-dependent, Chk2-independent pathway of p53-mediated neuronal death.	Univ Ottawa, Ottawa Hlth Res Inst, Neurosci Res Program, Ottawa, ON K1H 8M5, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Park, DS (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Neurosci Res Program, Ottawa, ON K1H 8M5, Canada.	dpark@uottawa.ca		Slack, Ruth/0000-0002-1552-2835; Park, David/0000-0002-4490-3784				Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Dumaz N, 2001, BIOCHEM J, V359, P459, DOI 10.1042/0264-6021:3590459; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Ghahremani MH, 2002, J BIOL CHEM, V277, P35586, DOI 10.1074/jbc.M204362200; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Grunewald T, 1999, NAT MED, V5, P1354, DOI 10.1038/70918; Heintz N, 1996, CURR OPIN NEUROL, V9, P137, DOI 10.1097/00019052-199604000-00014; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Johnson MD, 1999, J NEUROSCI, V19, P2996; Keramaris E, 2000, MOL CELL NEUROSCI, V15, P368, DOI 10.1006/mcne.2000.0838; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Liu QH, 2000, GENE DEV, V14, P1448; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; MANSFIELD SH, 1994, AM J NEURORADIOL, V15, P1178; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; McGahan L, 1998, MOL BRAIN RES, V56, P133, DOI 10.1016/S0169-328X(98)00038-2; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; Morrison RS, 1996, J NEUROSCI, V16, P1337; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 1996, J CLIN IMMUNOL, V16, P254, DOI 10.1007/BF01541389; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; Takai H, 2000, GENE DEV, V14, P1439; Trimmer PA, 1996, NEURODEGENERATION, V5, P233, DOI 10.1006/neur.1996.0031; VOGEL H, 1993, CANCER, V71, P1303, DOI 10.1002/1097-0142(19930215)71:4<1303::AID-CNCR2820710422>3.0.CO;2-6; WINKELMAN MD, 1983, ANN NEUROL, V14, P520, DOI 10.1002/ana.410140505; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Xiang H, 1996, J NEUROSCI, V16, P6753; Xiang H, 1998, J NEUROSCI, V18, P1363	49	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37782	37789		10.1074/jbc.M304049200	http://dx.doi.org/10.1074/jbc.M304049200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857758	hybrid			2022-12-25	WOS:000185437200097
J	LaVoie, MJ; Fraering, PC; Ostaszewski, BL; Ye, WJ; Kimberly, WT; Wolfe, MS; Selkoe, DJ				LaVoie, MJ; Fraering, PC; Ostaszewski, BL; Ye, WJ; Kimberly, WT; Wolfe, MS; Selkoe, DJ			Assembly of the gamma-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; BETA-APP; PRESENILIN; ENDOPROTEOLYSIS; PEN-2; ACCUMULATION; TRAFFICKING; INHIBITORS; FRAGMENTS	The gamma-secretase complex is an unusual multimeric protease responsible for the intramembrane cleavage of a variety of type 1 transmembrane proteins, including the beta-amyloid precursor protein and Notch. Genetic and biochemical data have revealed that this protease consists of the presenilin heterodimer, a highly glycosylated form of nicastrin, and the recently identified gene products, Aph-1 and Pen-2. Whereas current evidence supports the notion that presenilin comprises the active site of the protease and that the other three components are members of the active complex required for proteolytic activity, the individual roles of the three co-factors remain unclear. Here, we demonstrate that endogenous Aph-1 interacts with an immature species of nicastrin, forming a stable intermediate early in the assembly of the gamma-secretase complex, prior to the addition of presenilin and Pen-2. Our data suggest 1) that Aph-1 is involved in the early stages of gamma-secretase assembly through the stabilization and perhaps glycosylation of nicastrin and by scaffolding nicastrin to the immature gamma-secretase complex, and 2) that presenilin, and later Pen-2, bind to this intermediate during the formation of the mature protease.	Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Selkoe, DJ (corresponding author), Harvard Inst Med, 77 Ave Louis Pasteur, Boston, MA 02215 USA.	DSelkoe@rics.bwh.harvard.edu		LaVoie, Matthew/0000-0002-2583-1578; Fraering, Patrick/0000-0002-5841-5327	NATIONAL INSTITUTE ON AGING [P01AG015379, R01AG017574] Funding Source: NIH RePORTER; NIA NIH HHS [AG00222, AG15379, AG17574] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; Wolfe MS, 2002, SCIENCE, V296, P2156, DOI 10.1126/science.1073844; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	33	180	190	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37213	37222		10.1074/jbc.M303941200	http://dx.doi.org/10.1074/jbc.M303941200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857757	hybrid			2022-12-25	WOS:000185437200029
J	Lee, JY; Ye, JP; Gao, ZG; Youn, HS; Lee, WH; Zhao, L; Sizemore, N; Hwang, DH				Lee, JY; Ye, JP; Gao, ZG; Youn, HS; Lee, WH; Zhao, L; Sizemore, N; Hwang, DH			Reciprocal modulation of toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MITOGEN-INDUCIBLE CYCLOOXYGENASE; CONFERS LIPOPOLYSACCHARIDE RESPONSIVENESS; ACTIVATED PROTEIN-KINASE; INNATE IMMUNE-RESPONSE; HUMAN COLON-CANCER; ADAPTER PROTEIN; CPG-DNA; TRANSCRIPTIONAL ACTIVITY; RELA/P65 SUBUNIT	Toll-like receptor-4 (TLR4) can be activated by non-bacterial agonists, including saturated fatty acids. However, downstream signaling pathways activated by non-bacterial agonists are not known. Thus, we determined the downstream signaling pathways derived from saturated fatty acid-induced TLR4 activation. Saturated fatty acid (lauric acid)-induced NFkappaB activation was inhibited by a dominant-negative mutant of TLR4, MyD88, IRAK-1, TRAF6, or IkappaBalpha in macrophages (RAW264.7) and 293T cells transfected with TLR4 and MD2. Lauric acid induced the transient phosphorylation of AKT. LY294002, dominant-negative (DN) phosphatidylinositol 3-kinase (PI3K), or AKT(DN) inhibited NFkappaB activation, p65 transactivation, and cyclooxygenase-2 (COX-2) expression induced by lauric acid or constitutively active (CA) TLR4. AKT(DN) blocked MyD88-induced NFkappaB activation, suggesting that AKT is a MyD88-dependent downstream signaling component of TLR4. AKT(CA) was sufficient to induce NFkappaB activation and COX-2 expression. These results demonstrate that NFkappaB activation and COX-2 expression induced by lauric acid are at least partly mediated through the TLR4/PI3K/AKT signaling pathway. In contrast, docosahexaenoic acid (DHA) inhibited the phosphorylation of AKT induced by lipopolysaccharide or lauric acid. DHA also suppressed NFkappaB activation induced by TLR4(CA), but not MyD88(CA) or AKT(CA), suggesting that the molecular targets of DHA are signaling components upstream of MyD88 and AKT. Together, these results suggest that saturated and polyunsaturated fatty acids reciprocally modulate the activation of TLR4 and its downstream signaling pathways involving MyD88/IRAK/TRAF6 and PI3K/AKT and further suggest the possibility that TLR4-mediated target gene expression and cellular responses are also differentially modulated by saturated and unsaturated fatty acids.	ARS, Western Human Nutr Res Ctr, USDA, Davis, CA 95616 USA; Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA	United States Department of Agriculture (USDA); University of California System; University of California Davis; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Cleveland Clinic Foundation	Hwang, DH (corresponding author), ARS, Western Human Nutr Res Ctr, USDA, Meyer Hall,1 Shields Ave, Davis, CA 95616 USA.		Ye, Jianping/N-1998-2017	Ye, Jianping/0000-0003-3875-365X	NCI NIH HHS [CA75613] Funding Source: Medline; NIDDK NIH HHS [DK41868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Byrd-Leifer CA, 2001, EUR J IMMUNOL, V31, P2448, DOI 10.1002/1521-4141(200108)31:8&lt;2448::AID-IMMU2448&gt;3.0.CO;2-N; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du X, 2000, EUR CYTOKINE NETW, V11, P362; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fruman DA, 1999, BIOCHEM SOC T, V27, P624, DOI 10.1042/bst0270624; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; HAZIOT A, 1988, J IMMUNOL, V141, P547; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Ishii KJ, 2002, J EXP MED, V196, P269, DOI 10.1084/jem.20020773; Jefferies CA, 2000, J BIOL CHEM, V275, P3114, DOI 10.1074/jbc.275.5.3114; Jiang QQ, 2000, J IMMUNOL, V165, P3541, DOI 10.4049/jimmunol.165.7.3541; Kaisho T, 2001, J IMMUNOL, V166, P5688, DOI 10.4049/jimmunol.166.9.5688; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; KRAUSS JH, 1989, EUR J BIOCHEM, V180, P519, DOI 10.1111/j.1432-1033.1989.tb14677.x; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Lee JY, 2003, J LIPID RES, V44, P479, DOI 10.1194/jlr.M200361-JLR200; Lee JY, 2001, J BIOL CHEM, V276, P16683, DOI 10.1074/jbc.M011695200; LEE SH, 1992, J BIOL CHEM, V267, P25934; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Manna SK, 2000, FEBS LETT, V473, P113, DOI 10.1016/S0014-5793(00)01501-5; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Monick MM, 2001, J IMMUNOL, V166, P4713, DOI 10.4049/jimmunol.166.7.4713; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Ojaniemi M, 2003, EUR J IMMUNOL, V33, P597, DOI 10.1002/eji.200323376; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Ozes ON, 1999, NATURE, V401, P82; Paik JH, 2000, J BIOL CHEM, V275, P28173; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; QURESHI N, 1991, INFECT IMMUN, V59, P441, DOI 10.1128/IAI.59.1.441-444.1991; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Salh B, 1998, J IMMUNOL, V161, P6947; SANO H, 1995, CANCER RES, V55, P3785; Schnare M, 2000, CURR BIOL, V10, P1139, DOI 10.1016/S0960-9822(00)00700-4; Seki E, 2001, J IMMUNOL, V166, P2651, DOI 10.4049/jimmunol.166.4.2651; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	82	409	431	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37041	37051		10.1074/jbc.M305213200	http://dx.doi.org/10.1074/jbc.M305213200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12865424	hybrid			2022-12-25	WOS:000185437200010
J	Wickham, ME; Culvenor, JG; Cowman, AF				Wickham, ME; Culvenor, JG; Cowman, AF			Selective inhibition of a two-step egress of malaria parasites from the host erythrocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM ANTIGENS; PARASITOPHOROUS VACUOLE; CYSTEINE PROTEASE; RECOMBINANT FALCIPAIN-2; FINE-STRUCTURE; PLASMEPSIN II; FOOD VACUOLE; HEMOGLOBINASE; LOCALIZATION; SCHIZONTS	Escape from the host erythrocyte by the invasive stage of the malaria parasite Plasmodium falciparum is a fundamental step in the pathogenesis of malaria of which little is known. Upon merozoite invasion of the host cell, the parasite becomes enclosed within a parasitophorous vacuole, the compartment in which the parasite undergoes growth followed by asexual division to produce 16-32 daughter merozoites. These daughter cells are released upon parasitophorous vacuole and erythrocyte membrane rupture. To examine the process of merozoite release, we used P. falciparum lines expressing green fluorescent protein-chimeric proteins targeted to the compartments from which merozoites must exit: the parasitophorous vacuole and the host erythrocyte cytosol. This allowed visualization of merozoite release in live parasites. Herein we provide the first evidence in live, untreated cells that merozoite release involves a primary rupture of the parasitophorous vacuole membrane followed by a secondary rupture of the erythrocyte plasma membrane. We have confirmed, with the use of immunoelectron microscopy, that parasitophorous vacuole membrane rupture occurs before erythrocyte plasma membrane rupture in untransfected wild-type parasites. We have also demonstrated selective inhibition of each step in this two-step process of exit using different protease inhibitors, implicating the involvement of distinct proteases in each of these steps. This will facilitate the identification of the parasite and host molecules involved in merozoite release.	Univ Melbourne, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Melbourne, Dept Pathol, Melbourne, Vic 3050, Australia	University of Melbourne; Walter & Eliza Hall Institute; University of Melbourne	Cowman, AF (corresponding author), 1G Royal Parade, Melbourne, Vic 3050, Australia.	cowman@wehi.edu.au	Wickham, Mark/A-1396-2009; Cowman, Alan F/C-7642-2013; Wickham, Mark E/HCI-4959-2022	Wickham, Mark/0000-0002-3473-7196; Cowman, Alan F/0000-0001-5145-9004; Wickham, Mark E/0000-0002-3473-7196	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044008] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI44008] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKAWA M, 1971, EXP PARASITOL, V30, P284, DOI 10.1016/0014-4894(71)90094-4; Ansorge I, 1996, BIOCHEM J, V315, P307, DOI 10.1042/bj3150307; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; BANYAL HS, 1981, J PARASITOL, V67, P623, DOI 10.2307/3280435; CHULAY JD, 1987, J IMMUNOL, V139, P2768; COPPEL RL, 1983, NATURE, V306, P751, DOI 10.1038/306751a0; COWMAN AF, 1985, MODERN APPROACHES VA, P13; DEGUERCY A, 1990, MOL BIOCHEM PARASIT, V38, P233, DOI 10.1016/0166-6851(90)90026-I; DELPLACE P, 1988, BIOL CELL, V64, P215, DOI 10.1016/0248-4900(88)90080-9; DELPLACE P, 1987, MOL BIOCHEM PARASIT, V23, P193, DOI 10.1016/0166-6851(87)90026-0; DHAWAN S, 2003, J BIOL CHEM; Dominguez JN, 1997, J MED CHEM, V40, P2726, DOI 10.1021/jm970266p; Dua M, 2001, MOL BIOCHEM PARASIT, V116, P95, DOI 10.1016/S0166-6851(01)00306-1; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Greenbaum DC, 2002, SCIENCE, V298, P2002, DOI 10.1126/science.1077426; HADLEY T, 1983, EXP PARASITOL, V55, P306, DOI 10.1016/0014-4894(83)90027-9; Hanspal M, 2002, BLOOD, V100, P1048, DOI 10.1182/blood-2002-01-0101; KNAPP B, 1989, MOL BIOCHEM PARASIT, V32, P73, DOI 10.1016/0166-6851(89)90131-X; LANGRETH SG, 1978, J PROTOZOOL, V25, P443, DOI 10.1111/j.1550-7408.1978.tb04167.x; Lauer S, 2000, EMBO J, V19, P3556, DOI 10.1093/emboj/19.14.3556; Le Bonniec S, 1999, J BIOL CHEM, V274, P14218, DOI 10.1074/jbc.274.20.14218; Li J, 2002, MOL BIOCHEM PARASIT, V120, P177, DOI 10.1016/S0166-6851(01)00452-2; LYON JA, 1986, J IMMUNOL, V136, P2245; Miller SK, 2002, J BIOL CHEM, V277, P47524, DOI 10.1074/jbc.M206974200; Moon RP, 1997, EUR J BIOCHEM, V244, P552, DOI 10.1111/j.1432-1033.1997.00552.x; NWAGWU M, 1992, EXP PARASITOL, V75, P399, DOI 10.1016/0014-4894(92)90253-7; Raphael P, 2000, MOL BIOCHEM PARASIT, V110, P259, DOI 10.1016/S0166-6851(00)00283-8; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; RING CS, 1993, P NATL ACAD SCI USA, V90, P3583, DOI 10.1073/pnas.90.8.3583; Rosenthal PJ, 1996, ANTIMICROB AGENTS CH, V40, P1600, DOI 10.1128/AAC.40.7.1600; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; ROSENTHAL PJ, 1993, J CLIN INVEST, V91, P1052, DOI 10.1172/JCI116262; Salmon BL, 2001, P NATL ACAD SCI USA, V98, P271, DOI 10.1073/pnas.011413198; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034; STENZEL DJ, 1989, EUR J CELL BIOL, V49, P311; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; WARD GE, 1993, J CELL SCI, V106, P237; Wickham ME, 2001, EMBO J, V20, P5636, DOI 10.1093/emboj/20.20.5636	40	124	128	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37658	37663		10.1074/jbc.M305252200	http://dx.doi.org/10.1074/jbc.M305252200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857731	hybrid			2022-12-25	WOS:000185437200081
J	Adachi, N; Suzuki, H; Iiizumi, S; Koyama, H				Adachi, N; Suzuki, H; Iiizumi, S; Koyama, H			Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193 - Implications for the repair of topoisomerase II-mediated DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; HOMOLOGOUS RECOMBINATION; LIGASE-IV; V(D)J RECOMBINATION; RANDOM INTEGRATION; REPLICATION FORKS; CELLS DEFICIENT; PROTEIN; YEAST; INHIBITORS	A number of clinically useful anticancer drugs, including etoposide (VP-16), target DNA topoisomerase ( topo) II. These drugs, referred to as topo II poisons, stabilize cleavable complexes, thereby generating DNA double-strand breaks. Bis-2,6-dioxopiperazines such as ICRF-193 also inhibit topo II by inducing a distinct type of DNA damage, termed topo II clamps, which has been believed to be devoid of double-strand breaks. Despite the biological and clinical importance, the molecular mechanisms for the repair of topo II-mediated DNA damage remain largely unknown. Here, we perform genetic analyses using the chicken DT40 cell line to investigate how DNA lesions caused by topo II inhibitors are repaired. Notably, we show that LIG4(-/-) and KU70(-/-) cells, which are defective in nonhomologous DNA end-joining (NHEJ), are extremely sensitive to both VP-16 and ICRF-193. In contrast, RAD54(-/-) cells ( defective in homologous recombination) are much less hypersensitive to VP-16 than the NHEJ mutants and, more importantly, are not hypersensitive to ICRF-193. Our results provide the first evidence that NHEJ is the predominant pathway for the repair of topo II-mediated DNA damage; that is, cleavable complexes and topo II clamps. The outstandingly increased cytotoxicity of topo II inhibitors in the absence of NHEJ suggests that simultaneous inhibition of topo II and NHEJ would provide a powerful protocol in cancer chemotherapy involving topo II inhibitors.	Yokohama City Univ, Kihara Inst Biol Res, Grad Sch Integrated Sci, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan	Yokohama City University	Adachi, N (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Grad Sch Integrated Sci, Totsuka Ku, Maioka Cho 641-12, Yokohama, Kanagawa 2440813, Japan.	nadachi@yokohama-cu.ac.jp						Adachi N, 2000, GENE, V245, P49, DOI 10.1016/S0378-1119(00)00040-8; Adachi N, 2001, P NATL ACAD SCI USA, V98, P12109, DOI 10.1073/pnas.201271098; Akimitsu N, 2003, GENES CELLS, V8, P393, DOI 10.1046/j.1365-2443.2003.00643.x; Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Aratani Y, 1996, MUTAT RES-DNA REPAIR, V362, P181, DOI 10.1016/0921-8777(95)00049-6; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Cline SD, 1999, BIOCHEMISTRY-US, V38, P15500, DOI 10.1021/bi991750s; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Fujimaki K, 1996, SOMAT CELL MOLEC GEN, V22, P279, DOI 10.1007/BF02369567; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Hasinoff BB, 1997, BIOCHEM PHARMACOL, V53, P1843, DOI 10.1016/S0006-2952(97)00013-0; Hong G, 2003, P NATL ACAD SCI USA, V100, P5046, DOI 10.1073/pnas.0835166100; Huang KC, 2001, J BIOL CHEM, V276, P44488, DOI 10.1074/jbc.M104383200; JEGGO PA, 1989, CANCER RES, V49, P7057; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; Jin SF, 1998, CARCINOGENESIS, V19, P965, DOI 10.1093/carcin/19.6.965; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; Kobayashi M, 2001, CANCER LETT, V166, P71, DOI 10.1016/S0304-3835(01)00447-5; Lee KJ, 2000, J BIOL CHEM, V275, P34787, DOI 10.1074/jbc.M004011200; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mao Y, 2001, J BIOL CHEM, V276, P40652, DOI 10.1074/jbc.M104009200; Matsuzaki Y, 2002, NUCLEIC ACIDS RES, V30, P3273, DOI 10.1093/nar/gkf440; Mazin AV, 2003, J BIOL CHEM, V278, P14029, DOI 10.1074/jbc.M212779200; Munoz P, 1998, MOL CELL BIOL, V18, P5797, DOI 10.1128/MCB.18.10.5797; Muris DFR, 1997, CURR GENET, V31, P248, DOI 10.1007/s002940050202; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; POMMIER Y, 1988, CANCER RES, V48, P512; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Sado K, 2001, J BIOL CHEM, V276, P9742, DOI 10.1074/jbc.M010530200; Sigurdsson S, 2002, J BIOL CHEM, V277, P42790, DOI 10.1074/jbc.M208004200; SMITH PJ, 1994, BRIT J CANCER, V70, P914, DOI 10.1038/bjc.1994.420; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; van Hille B, 1999, BRIT J CANCER, V81, P800, DOI 10.1038/sj.bjc.6690767; van Hille B, 1998, CANCER CHEMOTH PHARM, V42, P345, DOI 10.1007/s002800050828; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wilstermann AM, 2001, J BIOL CHEM, V276, P46290, DOI 10.1074/jbc.M105733200; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; Xiao H, 2003, P NATL ACAD SCI USA, V100, P3239, DOI 10.1073/pnas.0736401100; Xiao H, 2003, P NATL ACAD SCI USA, V100, P5205, DOI 10.1073/pnas.0935978100; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430; Yang X, 2000, SCIENCE, V287, P131, DOI 10.1126/science.287.5450.131	57	126	129	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35897	35902		10.1074/jbc.M306500200	http://dx.doi.org/10.1074/jbc.M306500200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12842886	hybrid			2022-12-25	WOS:000185318300006
J	Cok, SJ; Acton, SJ; Morrison, AR				Cok, SJ; Acton, SJ; Morrison, AR			The proximal region of the 3 '-untranslated region of cyclooxygenase-2 is recognized by a multimeric protein complex containing HuR, TIA-1, TIAR, and the heterogeneous nuclear ribonucleoprotein U	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; AU-RICH ELEMENT; CYTOPLASMIC SHUTTLING PROTEIN; BINDING PROTEIN; GENE-EXPRESSION; MESANGIAL CELLS; STABILIZATION; SEQUENCE; DESTABILIZATION; TRISTETRAPROLIN	Cyclooxygenase-2 (COX-2) is an early response gene induced in renal mesangial cells by interleukin-1beta (IL-1beta). The 3'-untranslated region (3'-UTR) of COX-2 mRNA plays an important role in IL-1beta induction by regulating message stability and translational efficiency. The first 60 nucleotides of the 3'-UTR of COX-2 are highly conserved and contain multiple copies of the regulatory sequence AUUUA. Introduction of the 60-nucleotide sequence into the 3'-UTR of a heterologous reporter gene resulted in a 70% decrease in reporter gene expression. Electrophoretic mobility shift assays (EMSAs) demonstrated that mesangial cell nuclear fractions contain a multimeric protein complex that bound this region of COX-2 mRNA in a sequence-specific manner. We identified four members of the protein-RNA complex as HuR, TIA-1, TIAR, and the heterogeneous nuclear ribonucleoprotein U (hnRNP U). Treatment of mesangial cells with IL-1beta caused an increase in cytosolic HuR, which was accompanied by an increase in COX-2 mRNA that co-immunoprecipitated with cytosolic HuR. Therefore, we propose that HuR binds to the proximal region of the 3'-UTR of COX-2 following stimulation by IL-1beta and increases the expression of COX-2 mRNA by facilitating its transport out of the nucleus.	Washington Univ, Sch Med, Wohl Clin, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Morrison, AR (corresponding author), Washington Univ, Sch Med, Wohl Clin, Dept Med, 4940 Parkview Pl,Rm 8843, St Louis, MO 63110 USA.	Morrison@pcg.wustl.edu			NIDDK NIH HHS [DK 59932] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059932] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anant S, 2001, J BIOL CHEM, V276, P47338, DOI 10.1074/jbc.M104911200; Atasoy U, 1998, J CELL SCI, V111, P3145; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Eggert M, 1997, J BIOL CHEM, V272, P28471, DOI 10.1074/jbc.272.45.28471; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gou Q, 1998, BIOCHEM BIOPH RES CO, V242, P508, DOI 10.1006/bbrc.1997.7994; Guan ZH, 1996, AM J PHYSIOL-RENAL, V270, pF634, DOI 10.1152/ajprenal.1996.270.4.F634; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Hamilton BJN, 1997, J BIOL CHEM, V272, P28732, DOI 10.1074/jbc.272.45.28732; Jang BC, 2003, J BIOL CHEM, V278, P2773, DOI 10.1074/jbc.C200620200; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; RZYMKIEWICZ D, 1994, AM J PHYSIOL, V266, pF39, DOI 10.1152/ajprenal.1994.266.1.F39; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SRIVASTAVA SK, 1994, AM J PHYSIOL, V267, pF504, DOI 10.1152/ajprenal.1994.267.3.F504; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Yaman I, 2002, J BIOL CHEM, V277, P41539, DOI 10.1074/jbc.M204850200; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	40	120	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36157	36162		10.1074/jbc.M302547200	http://dx.doi.org/10.1074/jbc.M302547200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855701	hybrid			2022-12-25	WOS:000185318300036
J	Hayashi, I; Ikura, M				Hayashi, I; Ikura, M			Crystal structure of the amino-terminal microtubule-binding domain of end-binding protein 1 (EB1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APC TUMOR-SUPPRESSOR; F-ACTIN; PROGRAM; PLUS; CYTOSKELETON; MAINTENANCE; DYNACTIN; CLIP-170; ENCODES	The end-binding protein 1 (EB1) family is a highly conserved group of proteins that localizes to the plus-ends of microtubules. EB1 has been shown to play an important role in regulating microtubule dynamics and chromosome segregation, but its regulation mechanism is poorly understood. We have determined the 1.45-Angstrom resolution crystal structure of the amino-terminal domain of EB1, which is essential for microtubule binding, and show that it forms a calponin homology ( CH) domain fold that is found in many proteins involved in the actin cytoskeleton. The functional CH domain for actin binding is a tandem pair, whereas EB1 is the first example of a single CH domain that can associate with the microtubule filament. Although our biochemical study shows that microtubule binding of EB1 is electrostatic in part, our mutational analysis suggests that the hydrophobic network, which is partially exposed in our crystal structure, is also important for the association. We propose that, like other actin-binding CH domains, EB1 employs the hydrophobic interaction to bind to microtubules.	Univ Toronto, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Hayashi, I (corresponding author), Univ Toronto, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada.	ihayashi@uhnres.utoronto.ca		Ikura, Mitsuhiko/0000-0002-9524-1303				Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; Barth AIM, 2002, J CELL SCI, V115, P1583; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Bramham J, 2002, STRUCTURE, V10, P249, DOI 10.1016/S0969-2126(02)00703-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; Goldsmith SC, 1997, NAT STRUCT BIOL, V4, P708, DOI 10.1038/nsb0997-708; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Juwana JP, 1999, INT J CANCER, V81, P275, DOI 10.1002/(SICI)1097-0215(19990412)81:2<275::AID-IJC18>3.0.CO;2-Z; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li SL, 2002, J BIOL CHEM, V277, P48596, DOI 10.1074/jbc.M208512200; Ligon LA, 2003, MOL BIOL CELL, V14, P1405, DOI 10.1091/mbc.E02-03-0155; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; Schroer TA, 2001, CURR OPIN CELL BIOL, V13, P92, DOI 10.1016/S0955-0674(00)00179-4; Schuyler SC, 2001, CELL, V105, P421, DOI 10.1016/S0092-8674(01)00364-6; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SU LK, 1995, CANCER RES, V55, P2972; Vaughan KT, 1999, J CELL SCI, V112, P1437	36	134	140	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36430	36434		10.1074/jbc.M305773200	http://dx.doi.org/10.1074/jbc.M305773200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857735	hybrid			2022-12-25	WOS:000185318300071
J	Matsuda, A; Itoh, Y; Koshikawa, N; Akizawa, T; Yana, I; Seiki, M				Matsuda, A; Itoh, Y; Koshikawa, N; Akizawa, T; Yana, I; Seiki, M			Clusterin, an abundant serum factor, is a possible negative regulator of MT6-MMP/MMP-25 produced by neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; C-TERMINAL DOMAIN; CELL-SURFACE; APOLIPOPROTEIN-J; COMPLEMENT; EXPRESSION; PROTEIN; INHIBITOR; BINDS; ACTIVATION	MT6-MMP/MMP-25 is the latest member of the membrane-type matrix metalloproteinase (MT-MMP) subgroup in the MMP family and is expressed in neutrophils and some brain tumors. The proteolytic activity of MT6-MMP has been studied using recombinant catalytic fragments and shown to degrade several components of the extracellular matrix. However, the activity is possibly modulated further by the C-terminal hemopexin- like domain, because some MMPs are known to interact with other proteins through this domain. To explore the possible function of this domain, we purified a recombinant MT6-MMP with the hemopexin- like domain as a soluble form using a Madin-Darby canine kidney cell line as a producer. Mature and soluble MT6-MMP processed at the furin motif was purified as a 45-kDa protein together with a 46-kDa protein having a single cleavage in the hemopexin- like domain. Interestingly, 73- and 70-kDa proteins were co-purified with the soluble MT6-MMP by forming stable complexes. They were identified as clusterin, a major component of serum, by N-terminal amino acid sequencing. MT1-MMP that also has a hemopexin-like domain did not form a complex with clusterin. MT6-MMP forming a complex with clusterin was detected in human neutrophils as well. The enzyme activity of the soluble MT6-MMP was inactive in the clusterin complex. Purified clusterin was inhibitory against the activity of soluble MT6-MMP. On the other hand, it had no effect on the activities of MMP-2 and soluble MT1-MMP. Because clusterin is an abundant protein in the body fluid in tissues, it may act as a negative regulator of MT6-MMP in vivo.	Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, Tokyo 1088639, Japan; Setsunan Univ, Fac Pharmaceut Sci, Dept Analyt Chem, Osaka 5730101, Japan	University of Tokyo; Setsunan University	Seiki, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, 4-6-1 Shirokane Dai, Tokyo 1088639, Japan.	mseiki@ims.u-tokyo.ac.jp	Koshikawa, Naohiko/S-7306-2017; Seiki, Motoharu/K-9443-2015	Koshikawa, Naohiko/0000-0002-4539-888X; Itoh, Yoshifumi/0000-0002-2128-2823				BURKEY BF, 1992, J LIPID RES, V33, P1517; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; English WR, 2001, FEBS LETT, V491, P137, DOI 10.1016/S0014-5793(01)02150-0; FRITZ IB, 1983, BIOL REPROD, V28, P1173, DOI 10.1095/biolreprod28.5.1173; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; HARTMANN K, 1991, J BIOL CHEM, V266, P9924; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; Kang TB, 2001, J BIOL CHEM, V276, P21960, DOI 10.1074/jbc.M007997200; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Liu Z, 2000, CELL, V102, P647, DOI 10.1016/S0092-8674(00)00087-8; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; McHattie S, 1999, BIOCHEM BIOPH RES CO, V259, P336, DOI 10.1006/bbrc.1999.0781; Mclaughlin L, 2000, J CLIN INVEST, V106, P1105, DOI 10.1172/JCI9037; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Michel D, 1997, BIOCHEM J, V328, P45, DOI 10.1042/bj3280045; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; Partridge SR, 1996, INFECT IMMUN, V64, P4324, DOI 10.1128/IAI.64.10.4324-4329.1996; Pei DQ, 1998, PROTEIN EXPRES PURIF, V13, P277, DOI 10.1006/prep.1998.0894; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Rozanov DV, 2002, J BIOL CHEM, V277, P9318, DOI 10.1074/jbc.M110711200; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; SHINOURA N, 1994, CANCER LETT, V86, P143, DOI 10.1016/0304-3835(94)90072-8; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; TSCHOPP J, 1993, J IMMUNOL, V151, P2159; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Velasco G, 2000, CANCER RES, V60, P877; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; Wang X, 1999, FEBS LETT, V462, P261, DOI 10.1016/S0014-5793(99)01534-3; WILSON MR, 1992, BIOCHIM BIOPHYS ACTA, V1159, P319, DOI 10.1016/0167-4838(92)90062-I; Wilson MR, 2000, TRENDS BIOCHEM SCI, V25, P95, DOI 10.1016/S0968-0004(99)01534-0	38	47	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36350	36357		10.1074/jbc.M301509200	http://dx.doi.org/10.1074/jbc.M301509200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860995	hybrid			2022-12-25	WOS:000185318300061
J	Myers, FA; Chong, W; Evans, DR; Thorne, AW; Crane-Robinson, C				Myers, FA; Chong, W; Evans, DR; Thorne, AW; Crane-Robinson, C			Acetylation of histone H2B mirrors that of H4 and H3 at the chicken beta-globin locus but not at housekeeping genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN CHROMATIN-STRUCTURE; DNASE-I SENSITIVITY; CONTROL REGION; PROTEIN; TRANSCRIPTION; ACTIVATION; GAS41; HYPERACETYLATION; BOUNDARIES; INSULATOR	Acetylation of histones H4 and H3 targeted to promoters/ enhancers is linked to the activation of transcription, whereas widespread, long range acetylation of the same histones has been linked to the requirement for open chromatin at transcriptionally active loci and regions of V(D)J recombination. Using affinity-purified polyclonal antibodies to tetra/tri-acetylated histone H2B in chromatin immunoprecipitation (ChIP) assays with mononucleosomes from 15-day chicken embryo erythrocytes, a high resolution distribution of H2B acetylation has been determined and compared with that of H4 and H3 at the same genes/loci. At the beta-globin locus, the H2B acetylation is high throughout and in general mirrors that of H3 and H4, consistent with the observation of co-precipitation of hyperacetylated H4 together with the hyperacetylated H2B. In contrast, at the weakly expressed genes glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and Gas41 ( housekeeping) and carbonic anhydrase ( tissue specific), very little or no hyperacetylated H2B was found despite the presence of acetylated H4 and H3 at their promoters and proximal transcribed sequences. At the inactive lysozyme and ovalbumin genes essentially no acetylation of H2B, H3, or H4 was observed. Acetylation of H2B appears to be principally a feature of only the most actively transcribed genes/loci.	Univ Portsmouth, Fac Sci, Inst Biomed & Biomol Sci, Biophys Labs, Portsmouth PO1 2DT, Hants, England	University of Portsmouth	Crane-Robinson, C (corresponding author), Univ Portsmouth, Fac Sci, Inst Biomed & Biomol Sci, Biophys Labs, Portsmouth PO1 2DT, Hants, England.	colyn.crane-robinson@port.ac.uk	, thorne/AAC-4984-2020	, thorne/0000-0002-8670-2358; Myers, Fiona/0000-0001-5568-1817				Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; BOHM L, 1982, EUR J BIOCHEM, V123, P299, DOI 10.1111/j.1432-1033.1982.tb19767.x; Bonifer C, 1997, J BIOL CHEM, V272, P26075, DOI 10.1074/jbc.272.42.26075; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; Bresnick EH, 1997, P NATL ACAD SCI USA, V94, P4566, DOI 10.1073/pnas.94.9.4566; Bulger M, 2002, CURR OPIN GENET DEV, V12, P170, DOI 10.1016/S0959-437X(02)00283-6; Chong SY, 2002, NUCLEIC ACIDS RES, V30, P463, DOI 10.1093/nar/30.2.463; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Debernardi S, 2002, BLOOD, V99, P275, DOI 10.1182/blood.V99.1.275; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; Elefant F, 2000, J BIOL CHEM, V275, P13827, DOI 10.1074/jbc.275.18.13827; Elefant F, 2000, EMBO J, V19, P6814, DOI 10.1093/emboj/19.24.6814; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; Forsberg EC, 2001, BIOESSAYS, V23, P820, DOI 10.1002/bies.1117; Forsberg EC, 2000, P NATL ACAD SCI USA, V97, P14494, DOI 10.1073/pnas.97.26.14494; Harborth J, 2000, J BIOL CHEM, V275, P31979, DOI 10.1074/jbc.M000994200; HEBBES TR, 1989, MOL IMMUNOL, V26, P865, DOI 10.1016/0161-5890(89)90143-0; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Ho YG, 2002, MOL CELL, V9, P291, DOI 10.1016/S1097-2765(02)00447-1; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Myers FA, 2001, J BIOL CHEM, V276, P20197, DOI 10.1074/jbc.M009472200; Prioleau MN, 1999, EMBO J, V18, P4035, DOI 10.1093/emboj/18.14.4035; Reik A, 1998, MOL CELL BIOL, V18, P5992, DOI 10.1128/MCB.18.10.5992; Saitoh N, 2000, EMBO J, V19, P2315, DOI 10.1093/emboj/19.10.2315; Schubeler D, 2000, GENE DEV, V14, P940; Schubeler D, 2001, P NATL ACAD SCI USA, V98, P11432, DOI 10.1073/pnas.201394698; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; Zimmermann K, 2002, J BIOL CHEM, V277, P18626, DOI 10.1074/jbc.M200572200	34	39	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36315	36322		10.1074/jbc.M305822200	http://dx.doi.org/10.1074/jbc.M305822200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12865423	hybrid			2022-12-25	WOS:000185318300056
J	Perez, A; Barco, R; Fernandez, I; Price-Schiavi, SA; Carraway, KL				Perez, A; Barco, R; Fernandez, I; Price-Schiavi, SA; Carraway, KL			PEA3 transactivates the Muc4/sialomucin complex promoter in mammary epithelial and tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCIN GENE-EXPRESSION; ETS TRANSCRIPTION FACTOR; SURFACE SIALOMUCIN COMPLEX; MOLECULAR-CLONING; HUMAN-BREAST; GLYCOPROTEIN COMPLEX; ADENOCARCINOMA CELLS; MEMBRANE-PROTEIN; MAP KINASE; RAT MUC4	Sialomucin complex (SMC, rat Muc4) is a heterodimeric glycoprotein composed of two subunits, the mucin component ascites sialoglycoprotein ASGP-1 and the transmembrane subunit ASGP-2, which is aberrantly expressed on the surfaces of a variety of tumor cells. Up-regulation of the Muc4/SMC gene in the 13762 sublines of the rat mammary adenocarcinoma correlates with the overexpression of transcription factor PEA3 and the receptor tyrosine kinase ErbB2. Here we report that PEA3 is capable of transactivating the Muc4/ SMC promoter in a dose-dependent manner via direct attachment to a PEA3 binding site. ERM and ER81, the other two members of the PEA3 subfamily of transcription factors, could not transactivate the Muc4/ SMC promoter. Transcriptional activation of Muc4/ SMC by PEA3 is potentiated by Ras and MEKK1 kinases. These data suggest that expression of PEA3 in mammary tumors leads to up-regulation of Muc4/ SMC transcription, the gene product of which may contribute to the metastatic potential of mammary tumors.	Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA	University of Miami	Perez, A (corresponding author), Univ Miami, Sch Med, Dept Cell Biol R124, POB 016960, Miami, FL 33101 USA.	aperez6@med.miami.edu			NCI NIH HHS [CA52498, CA-84178] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA084178, R01CA052498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aslam F, 2001, CANCER RES, V61, P570; AUDIE JP, 1995, HUM REPROD, V10, P98, DOI 10.1093/humrep/10.1.98; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BALAGUE C, 1994, GASTROENTEROLOGY, V106, P1054, DOI 10.1016/0016-5085(94)90767-6; BALAGUE C, 1995, GASTROENTEROLOGY, V109, P953, DOI 10.1016/0016-5085(95)90406-9; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; Bieche I, 1997, CANCER GENET CYTOGEN, V98, P75, DOI 10.1016/S0165-4608(96)00410-4; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; Bolshakov VY, 2000, NAT NEUROSCI, V3, P1107, DOI 10.1038/80624; Brown LA, 1998, ONCOGENE, V17, P93, DOI 10.1038/sj.onc.1201911; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CARRAWAY KL, 1976, J BIOL CHEM, V251, P6173; CARRAWAY KL, 1992, J CELL SCI, V103, P299; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARRAWAY KL, 1986, MOL CELL BIOCHEM, V72, P109; Carraway KL, 2000, FRONT BIOSCI, V5, pD95, DOI 10.2741/Carraway; Cella N, 1996, DIFFERENTIATION, V61, P113, DOI 10.1046/j.1432-0436.1996.6120113.x; Chandrasekera CP, 2003, J BIOL CHEM, V278, P12482, DOI 10.1074/jbc.M212745200; Chen JH, 1996, ONCOGENE, V13, P1667; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; Choudhury A, 2000, J BIOCHEM-TOKYO, V128, P233, DOI 10.1093/oxfordjournals.jbchem.a022746; Choudhury A, 2001, TERATOGEN CARCIN MUT, V21, P83, DOI 10.1002/1520-6866(2001)21:1<83::AID-TCM8>3.0.CO;2-3; Copin MC, 2001, FRONT BIOSCI, V6, pD1264, DOI 10.2741/Copin; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; HOWARD SC, 1980, BIOCHIM BIOPHYS ACTA, V631, P79, DOI 10.1016/0304-4165(80)90055-0; HOWARD SC, 1982, JNCI-J NATL CANCER I, V69, P33; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; Idris N, 1999, BIOL REPROD, V61, P1431, DOI 10.1095/biolreprod61.6.1431; Janknecht R, 1996, ONCOGENE, V13, P1745; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; Jepson S, 2002, ONCOGENE, V21, P7524, DOI 10.1038/sj.onc.1205970; Juang SH, 1996, ONCOGENE, V12, P1033; Kaya M, 1996, ONCOGENE, V12, P221; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 1999, CANCER RES, V59, P2229; LANE EB, 1982, J CELL BIOL, V92, P665, DOI 10.1083/jcb.92.3.665; LEE EYH, 1984, J CELL BIOL, V98, P146, DOI 10.1083/jcb.98.1.146; LENGYEL E, 1995, BBA-MOL CELL RES, V1268, P65, DOI 10.1016/0167-4889(95)00050-3; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Liao J, 2000, BIOTECHNIQUES, V28, P216, DOI 10.2144/00282bm05; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; MONTE D, 1994, ONCOGENE, V9, P1397; Nguyen PL, 1996, TUMOR BIOL, V17, P176, DOI 10.1159/000217980; O'Hagan RC, 1998, ONCOGENE, V16, P301, DOI 10.1038/sj.onc.1201547; OHAGAN RC, 1996, ONCOGENE, V18, P6278; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Petersen H, 1998, EXP CELL RES, V243, P347, DOI 10.1006/excr.1998.4160; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; Price-Schiavi A, 1998, BIOCHEM J, V335, P457, DOI 10.1042/bj3350457; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Price-Schiavi SA, 2002, INT J CANCER, V99, P783, DOI 10.1002/ijc.10410; Price-Schiavi SA, 2000, BIOCHEM J, V349, P641, DOI 10.1042/0264-6021:3490641; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; Scott GK, 2000, ONCOGENE, V19, P6490, DOI 10.1038/sj.onc.1204041; SEELY KA, 1991, J CELL PHYSIOL, V146, P117, DOI 10.1002/jcp.1041460116; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Vandenhaute B, 1997, J HEPATOL, V27, P1057, DOI 10.1016/S0168-8278(97)80150-X; WU K, 1994, J BIOL CHEM, V269, P11950; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Zhu XY, 2000, ONCOGENE, V19, P4354, DOI 10.1038/sj.onc.1203781	82	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36942	36952		10.1074/jbc.M300264200	http://dx.doi.org/10.1074/jbc.M300264200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855694	hybrid			2022-12-25	WOS:000185318300128
J	Saitoh, T; Nakayama, M; Nakano, H; Yagita, H; Yamamoto, N; Yamaoka, S				Saitoh, T; Nakayama, M; Nakano, H; Yagita, H; Yamamoto, N; Yamaoka, S			TWEAK induces NF-kappa B2 p100 processing and long lasting NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; HUMAN BREAST-CANCER; CONSTITUTIVE ACTIVATION; MULTIPLE PATHWAYS; FACTOR FAMILY; CELL-DEATH; KINASE; GENE; TNF; EXPRESSION	Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily that has been shown to induce angiogenesis, apoptosis in tumor cells, and NF-kappaB activation through binding to its receptor, fibroblast growth factor-inducible 14. We have identified TWEAK as an inducer of constitutive NF-kappaB activation by expression cloning, and we report here sequential regulation by TWEAK of two separate signaling cascades for NF-kappaB activation, the NF-kappaB essential modulator-dependent and - independent signaling pathways. Upon TWEAK stimulation, IkappaBalpha is rapidly phosphorylated, generating NF-kappaB DNA-binding complexes containing p50 and RelA in a manner dependent on the canonical IkappaB kinase complex. Unlike TNF-alpha, TWEAK stimulation results in prolonged NF-kappaB activation with a transition of the DNA-binding NF-kappaB components from RelA- to RelB-containing complexes by 8 h, and the latter remained active in binding at least until 24 h post-stimulation. This long lasting activation is accompanied by the proteasome-mediated processing of NF-kappaB2/p100, which does not depend on the NF-kappaB essential modulator but requires IkappaB kinase 1 and functional NF-kappaB-inducing kinase activity. Finally, we show that fibroblast growth factor-inducible 14 with a mutation at its TNF receptor-associated factor ( TRAF)- binding site cannot activate NF-kappaB and that TWEAK fails to induce the p100 processing and IkappaBalpha phosphorylation in cells deficient for TRAF2 and TRAF5. Our results thus identify TWEAK as a novel physiological regulator of the noncanonical pathway for NF-kappaB activation.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Virol, Bunkyo Ku, Tokyo 1138519, Japan; Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Shibuya Ku, Tokyo 1510053, Japan	Tokyo Medical & Dental University (TMDU); Juntendo University; Japan Science & Technology Agency (JST)	Yamaoka, S (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Virol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	shojmmb@tmd.ac.jp		Nakano, Hiroyasu/0000-0003-4843-1427; Nakayama, Masafumi/0000-0002-9839-7143				Ammon C, 2000, BIOCHEM BIOPH RES CO, V268, P99, DOI 10.1006/bbrc.1999.2083; Brown SAN, 2003, BIOCHEM J, V371, P395, DOI 10.1042/BJ20021730; Chiao PJ, 2002, CANCER, V95, P1696, DOI 10.1002/cncr.10829; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Chinanonwait N, 2002, FEBS LETT, V531, P553, DOI 10.1016/S0014-5793(02)03618-9; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; Force WR, 2000, J BIOL CHEM, V275, P11121, DOI 10.1074/jbc.275.15.11121; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hanada K, 1996, J LEUKOCYTE BIOL, V60, P181, DOI 10.1002/jlb.60.2.181; Harada N, 2002, BIOCHEM BIOPH RES CO, V299, P488, DOI 10.1016/S0006-291X(02)02670-0; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Meighan-Mantha RL, 1999, J BIOL CHEM, V274, P33166, DOI 10.1074/jbc.274.46.33166; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Mori N, 2000, BLOOD, V95, P3915; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; Nakayama M, 2003, J IMMUNOL, V170, P341, DOI 10.4049/jimmunol.170.1.341; Nakayama M, 2002, J IMMUNOL, V168, P734, DOI 10.4049/jimmunol.168.2.734; Nakayama M, 2000, J EXP MED, V192, P1373, DOI 10.1084/jem.192.9.1373; NERI A, 1995, BLOOD, V86, P3160, DOI 10.1182/blood.V86.8.3160.bloodjournal8683160; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Onishi M, 1996, EXP HEMATOL, V24, P324; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Saitoh T, 2002, FEBS LETT, V532, P45, DOI 10.1016/S0014-5793(02)03622-0; Schneider P, 1999, EUR J IMMUNOL, V29, P1785, DOI 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Tai DI, 2000, CANCER, V89, P2274, DOI 10.1002/1097-0142(20001201)89:11<2274::AID-CNCR16>3.0.CO;2-2; Tran NL, 2003, AM J PATHOL, V162, P1313, DOI 10.1016/S0002-9440(10)63927-2; Tulin EE, 2001, J BIOL CHEM, V276, P27519, DOI 10.1074/jbc.M101781200; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Weaver KD, 2003, J NEURO-ONCOL, V61, P187, DOI 10.1023/A:1022554824129; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004	56	248	257	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36005	36012		10.1074/jbc.M304266200	http://dx.doi.org/10.1074/jbc.M304266200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12840022	hybrid			2022-12-25	WOS:000185318300018
J	Venkataramaiah, TH; Plapp, BV				Venkataramaiah, TH; Plapp, BV			Formamides mimic aldehydes and inhibit liver alcohol dehydrogenases and ethanol metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID AMIDES; TERNARY COMPLEXES; BINDING; PYRAZOLE; 4-METHYLPYRAZOLE; NICOTINAMIDE; SPECIFICITY; SIMULATION; SULFOXIDES; CATALYSIS	Formamides are unreactive analogues of the aldehyde substrates of alcohol dehydrogenases and are useful for structure-function studies and for specific inhibition of alcohol metabolism. They bind to the enzyme-NADH complex and are uncompetitive inhibitors against varied concentrations of alcohol. Fourteen new branched chain and chiral formamides were prepared and tested as inhibitors of purified Class I liver alcohol dehydrogenases: horse (EqADH E), human (HsADH1C*2), and mouse (MmADH1). In general, larger, substituted formamides, such as N-1-ethylheptylformamide, are better inhibitors of HsADH1C*2 and MmADH1 than of EqADH, reflecting a few differences in amino acid residues that change the sizes of the active sites. In contrast, the linear, alkyl (n-propyl and n-butyl) formamides are better inhibitors of EqADH and MmADH1 than of HsADH1C*2, probably because water disrupts van der Waals interactions. These enzymes are also inhibited strongly by sulfoxides and 4-substituted pyrazoles. The structure of EqADH complexed with NADH and (R)-N-1-methylhexylformamide was determined by x-ray crystallography at 1.6 Angstrom resolution. The structure resembles the expected Michaelis complex with NADH and aldehyde, and shows for the first time that the reduced nicotinamide ring of NADH is puckered, as predicted for the transition state for hydride transfer. Metabolism of ethanol in mice was inhibited by several formamides. The data were fitted with kinetic simulation to a mechanism that describes the non-linear progress curves and yields estimates of the in vivo inhibition constants and the rate constants for elimination of inhibitors. Some small formamides, such as N-isopropylformamide, may be useful inhibitors in vivo.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Plapp, BV (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.	bv-plapp@uiowa.edu	Plapp, Bryce V/F-6353-2010; ID, IMCACAT/D-5867-2014		NIAAA NIH HHS [AA00279] Funding Source: Medline	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALMARSSON O, 1993, J AM CHEM SOC, V115, P2125, DOI 10.1021/ja00059a005; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BEASLEY VR, 1980, VET HUM TOXICOL, V22, P255; BEAVEN GH, 1952, ADV PROTEIN CHEM, V7, P319, DOI 10.1016/S0065-3233(08)60022-4; BOSRON WF, 1980, ENZYMATIC BASIS DETO, V1, P131; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHADHA VK, 1985, J MED CHEM, V28, P36, DOI 10.1021/jm00379a009; CHADHA VK, 1983, J MED CHEM, V26, P916, DOI 10.1021/jm00360a024; Charlier HA, 2000, J BIOL CHEM, V275, P11569, DOI 10.1074/jbc.275.16.11569; Cho H, 1998, BIOCHEMISTRY-US, V37, P4482, DOI 10.1021/bi9727040; Cho H, 1997, BIOCHEMISTRY-US, V36, P382, DOI 10.1021/bi9624604; CHOU JY, 1978, TOXICOL APPL PHARM, V43, P33, DOI 10.1016/S0041-008X(78)80030-1; Cleland W W, 1979, Methods Enzymol, V63, P103; DAHLBOM R, 1974, BIOCHEM BIOPH RES CO, V57, P549, DOI 10.1016/0006-291X(74)90581-6; DAMGAARD SE, 1982, EUR J BIOCHEM, V125, P593, DOI 10.1111/j.1432-1033.1982.tb06724.x; Davis GJ, 1996, J BIOL CHEM, V271, P17057, DOI 10.1074/jbc.271.29.17057; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; Duester G, 1999, BIOCHEM PHARMACOL, V58, P389, DOI 10.1016/S0006-2952(99)00065-9; EDENBERG HJ, 1997, COMPREHENSIVE TOXICO, V3, P119; EKLUND H, 1982, J BIOL CHEM, V257, P4349; EKLUND H, 1982, BIOCHEMISTRY-US, V21, P4858, DOI 10.1021/bi00263a005; FREUDENREICH C, 1984, J AM CHEM SOC, V106, P3344, DOI 10.1021/ja00323a048; HAVRE P, 1977, ARCH BIOCHEM BIOPHYS, V182, P14, DOI 10.1016/0003-9861(77)90278-8; HURLEY TD, 1994, J MOL BIOL, V239, P415, DOI 10.1006/jmbi.1994.1382; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALANT H, 1971, BIOL ALCOHOL, V1, P1; LUMENG L, 1979, BIOCHEM PHARMACOL, V28, P1547, DOI 10.1016/0006-2952(79)90471-4; Luo J, 2001, J AM CHEM SOC, V123, P11952, DOI 10.1021/ja0109747; MCMARTIN KE, 1975, BIOCHEM MED METAB B, V13, P319, DOI 10.1016/0006-2944(75)90171-4; MCMARTIN KE, 1980, ARCH BIOCHEM BIOPHYS, V199, P606, DOI 10.1016/0003-9861(80)90318-5; Meijers R, 2001, J BIOL CHEM, V276, P9316, DOI 10.1074/jbc.M010870200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Niederhut MS, 2001, PROTEIN SCI, V10, P697, DOI 10.1110/ps.45001; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Plapp B V, 1975, Adv Exp Med Biol, V56, P77; PLAPP BV, 1970, J BIOL CHEM, V245, P1727; PLAPP BV, 1995, METHOD ENZYMOL, V249, P91; Plapp BV, 2003, CHEM-BIOL INTERACT, V143, P183, DOI 10.1016/S0009-2797(02)00202-8; PLAPP BV, 1984, ARCH BIOCHEM BIOPHYS, V230, P30, DOI 10.1016/0003-9861(84)90083-3; PLAPP BV, 1975, BIOCH PHARM ETHANOL, P77; PLAPP BV, 1994, MOL BASIS ALCOHOL US, P311; PORTER CC, 1976, LIFE SCI, V18, P953, DOI 10.1016/0024-3205(76)90414-8; Ramaswamy S, 1997, BIOCHEMISTRY-US, V36, P3522, DOI 10.1021/bi962491z; Ramaswamy S, 1999, BIOCHEMISTRY-US, V38, P13951, DOI 10.1021/bi991731i; RAMASWAMY S, 1994, BIOCHEMISTRY-US, V33, P5230, DOI 10.1021/bi00183a028; Rubach JK, 2003, BIOCHEMISTRY-US, V42, P2907, DOI 10.1021/bi0272656; Schindler JF, 1998, J MED CHEM, V41, P1696, DOI 10.1021/jm9707380; SEKHAR VC, 1990, BIOCHEMISTRY-US, V29, P4289, DOI 10.1021/bi00470a005; STONE CL, 1989, J BIOL CHEM, V264, P11112; SUN HW, 1992, J MOL EVOL, V34, P522, DOI 10.1007/BF00160465; WINER AD, 1960, ACTA CHEM SCAND, V14, P1729, DOI 10.3891/acta.chem.scand.14-1729; WU YD, 1995, J AM CHEM SOC, V117, P4100, DOI 10.1021/ja00119a026	53	22	23	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36699	36706		10.1074/jbc.M305419200	http://dx.doi.org/10.1074/jbc.M305419200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855684	hybrid			2022-12-25	WOS:000185318300101
J	Wong, WK; Chen, K; Shih, JC				Wong, WK; Chen, K; Shih, JC			Decreased methylation and transcription repressor Sp3 up-regulated human monoamine oxidase (MAO) B expression during Caco-2 differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR SPECIFICITIES; ACTIVE-SITE; GENES; SUBSTRATE; ASTROCYTES	Monoamine oxidase (MAO) A and B catalyze the oxidative deamination of neuroactive and dietary monoamines such as serotonin, tyramine, and phenylethylamine. Here we show that MAO B, but not MAO A, gene expression was induced during Caco-2 cell differentiation; thus this cell line was used as a model system to study the gene regulation unique for MAO B. Luciferase and gel shift assays showed that transcription factors Sp1 and Sp3 binding to -246 and -99 bp were responsible for the observed gene activation. Overexpression of Sp3 inhibited the induction of MAO B gene by Sp1, and the expression of Sp3 was decreased during Caco-2 cell differentiation. Computer analysis revealed a putative CpG island containing 22 potential CpG methylation sites between -261 and -58 bp. In vitro methylation of MAO B promoter with 5-aza-2'-deoxycytidine, a DNA methyltransferase inhibitor, up-regulated MAO B gene expression in both HeLa and Caco-2 cells. Sodium bisulfite sequencing showed a gradually reduced methylation of the CpG sites during Caco-2 cell differentiation. These results suggested that MAO B gene expression is selectively induced by a decreased Sp3/Sp1 ratio and reduced DNA methylation. This new information may provide insights on the tissue-specific expression of these two isoenzymes.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Shih, JC (corresponding author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, 1985 Zonal Ave,PSC 528, Los Angeles, CA 90089 USA.	jcshih@usc.edu			NIMH NIH HHS [R01 MH37020, R37 MH39085] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037020, R37MH039085] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BOND PA, 1977, CLIN CHIM ACTA, V80, P317, DOI 10.1016/0009-8981(77)90039-0; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; Cesura AM, 1996, EUR J BIOCHEM, V236, P996, DOI 10.1111/j.1432-1033.1996.00996.x; Chen K, 1996, J NEUROCHEM, V66, P797; EGASHIRA T, 1976, JPN J PHARMACOL, V26, P493, DOI 10.1254/jjp.26.493; Geha RM, 2000, J NEUROCHEM, V75, P1304, DOI 10.1046/j.1471-4159.2000.751304.x; Geha RM, 2002, J BIOL CHEM, V277, P17209, DOI 10.1074/jbc.M110920200; Geha RM, 2001, J BIOL CHEM, V276, P9877, DOI 10.1074/jbc.M006972200; Gershon MD, 1999, ALIMENT PHARM THER, V13, P15; Gershon MD, 1998, AM J PHYSIOL-GASTR L, V275, pG869, DOI 10.1152/ajpgi.1998.275.5.G869; Gershon Michael D, 2003, Rev Gastroenterol Disord, V3 Suppl 2, pS25; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; Grimsby J, 1997, NAT GENET, V17, P206, DOI 10.1038/ng1097-206; GRIMSBY J, 1990, J NEUROCHEM, V55, P1166, DOI 10.1111/j.1471-4159.1990.tb03121.x; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Knoll J, 1972, Adv Biochem Psychopharmacol, V5, P393; LAN NC, 1989, GENOMICS, V4, P552, DOI 10.1016/0888-7543(89)90279-6; LEVITT P, 1982, P NATL ACAD SCI-BIOL, V79, P6385, DOI 10.1073/pnas.79.20.6385; Markowitz AJ, 1995, AM J PHYSIOL-GASTR L, V269, pG925, DOI 10.1152/ajpgi.1995.269.6.G925; Oreland L., 1993, MONOAMINE OXIDASE BA, P219; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Pieper RO, 1999, NUCLEIC ACIDS RES, V27, P3229, DOI 10.1093/nar/27.15.3229; Rebrin I, 2001, J BIOL CHEM, V276, P29499, DOI 10.1074/jbc.M100431200; SAURA J, 1994, NEUROSCIENCE, V62, P15, DOI 10.1016/0306-4522(94)90311-5; Shih JC, 1999, AM J HUM GENET, V65, P593, DOI 10.1086/302562; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; TSUGENO Y, 1995, J BIOCHEM-TOKYO, V118, P974, DOI 10.1093/jb/118.5.974; WESTLUND KN, 1985, SCIENCE, V230, P181, DOI 10.1126/science.3875898; WEYLER W, 1985, J BIOL CHEM, V260, P3199; Wong WK, 2002, J BIOL CHEM, V277, P22222, DOI 10.1074/jbc.M202844200; Wong WK, 2001, MOL PHARMACOL, V59, P852, DOI 10.1124/mol.59.4.852; WU HF, 1993, MOL PHARMACOL, V43, P888; Zhou BP, 1998, J BIOL CHEM, V273, P14862, DOI 10.1074/jbc.273.24.14862; ZHU QS, 1994, J NEUROSCI, V14, P7393; ZHU QS, 1992, J NEUROSCI, V12, P4437; ZWEIBAUM A, 1989, ADAPTATION DEV GASTR	38	46	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36227	36235		10.1074/jbc.M305549200	http://dx.doi.org/10.1074/jbc.M305549200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855685	hybrid			2022-12-25	WOS:000185318300044
J	Yoshida, M; Xia, Y				Yoshida, M; Xia, Y			Heat shock protein 90 as an endogenous protein enhancer of inducible nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP90-BASED CHAPERONE SYSTEM; GELDANAMYCIN LEADS; L-ARGININE; HSP90; SUPEROXIDE; GENERATION	Nitric oxide ( NO) generated by inducible NO synthase ( iNOS) plays crucial roles in inflammation and host defense. With an intrinsically bound calmodulin, iNOS is fully active once expressed in cells. Thus, regulation of NO production from iNOS was thought to primarily occur at the enzyme transcriptional level. Here we show that NO synthesis from iNOS can be profoundly modulated by heat shock protein 90 (hsp90) through protein-protein interaction. To study whether hsp90 affects iNOS function, recombinant murine iNOS was purified from an Escherichia coli expression system by affinity chromatography. Hsp90, at physiological concentrations ( 10 - 500 nM), dose-dependently increased iNOS activity. This was a specific effect because neither denatured hsp90 nor irrelevant bovine serum albumin affected iNOS function. Overexpression of hsp90 enhanced NO production in iNOS-transfected cells. On the contrary, hsp90 inhibition dramatically decreased NO formation from iNOS in macrophages. Co-immunoprecipitation studies showed that hsp90 and iNOS associated with each other in cells. Overexpression of iNOS resulted in NO-mediated cellular injury. Hsp90 inhibition markedly attenuated NO formation and prevented cellular injury. These results demonstrated that hsp90 is an allosteric enhancer of iNOS. iNOS is coupled with hsp90 in cells, and this coupling facilitates NO synthesis. In light of the critical role of hsp90 in iNOS-mediated cytotoxic action, modulating the interaction between hsp90 and iNOS may be a new approach to intervene inflammation and immune response.	Ohio State Univ, Davis Heart & Lung Res Inst, Dept Mol & Cellular Biochem, Div Cardiovasc Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Xia, Y (corresponding author), Ohio State Univ, Davis Heart & Lung Res Inst 605, 473 W 12th Ave, Columbus, OH 43210 USA.	xia-3@medctr.osu.edu			NIA NIH HHS [AG00835] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Billecke SS, 2002, J BIOL CHEM, V277, P20504, DOI 10.1074/jbc.M201940200; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Dikalov S, 2002, J BIOL CHEM, V277, P25480, DOI 10.1074/jbc.M203271200; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Fleming I, 2003, AM J PHYSIOL-REG I, V284, pR1, DOI 10.1152/ajpregu.00323.2002; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Papapetropoulos A, 1999, CARDIOVASC RES, V43, P509, DOI 10.1016/S0008-6363(99)00161-3; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Song Y, 2002, BIOCHEMISTRY-US, V41, P10616, DOI 10.1021/bi026060u; Song Y, 2001, BIOCHEM J, V355, P357, DOI 10.1042/0264-6021:3550357; Song Y, 2001, AM J PHYSIOL-CELL PH, V281, pC1819, DOI 10.1152/ajpcell.2001.281.6.C1819; Thykjaer T, 2001, BRIT J CANCER, V85, P568, DOI 10.1054/bjoc.2001.1949; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Wu CQ, 1996, BIOCHEM BIOPH RES CO, V222, P439, DOI 10.1006/bbrc.1996.0763; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; Zimmermann K, 2002, P NATL ACAD SCI USA, V99, P17167, DOI 10.1073/pnas.252345399	36	105	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36953	36958		10.1074/jbc.M305214200	http://dx.doi.org/10.1074/jbc.M305214200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855682	hybrid			2022-12-25	WOS:000185318300129
J	Bitan, G; Vollers, SS; Teplow, DB				Bitan, G; Vollers, SS; Teplow, DB			Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOINDUCED CROSS-LINKING; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; A-BETA; PRECURSOR PROTEIN; CEREBRAL-HEMORRHAGE; DOWNS-SYNDROME; HUMAN BRAIN; IN-VITRO; PEPTIDE	Assembly of monomeric amyloid beta-protein (Abeta) into oligomeric structures is an important pathogenetic feature of Alzheimer's disease. The oligomer size distributions of aggregate-free, low molecular weight Abeta40 and Abeta42 can be assessed quantitatively using the technique of photo-induced cross-linking of unmodified proteins. This approach revealed that low molecular weight Abeta40 is a mixture of monomer, dimer, trimer, and tetramer, in rapid equilibrium, whereas low molecular weight Abeta42 preferentially exists as pentamer/hexamer units ( paranuclei), which self-associate to form larger oligomers. Here, photo-induced cross-linking of unmodified proteins was used to evaluate systematically the oligomerization of 34 physiologically relevant Abeta alloforms, including those containing familial Alzheimer's disease-linked amino acid substitutions, naturally occurring N-terminal truncations, and modifications altering the charge, the hydrophobicity, or the conformation of the peptide. The most important structural feature controlling early oligomerization was the length of the C terminus. Specifically, the side-chain of residue 41 in Abeta42 was important both for effective formation of paranuclei and for self-association of paranuclei into larger oligomers. The side-chain of residue 42, and the C-terminal carboxyl group, affected paranucleus self-association. Abeta40 oligomerization was particularly sensitive to substitutions of Glu(22) or Asp(23) and to truncation of the N terminus, but not to substitutions of Phe(19) or Ala(21). Abeta42 oligomerization, in contrast, was largely unaffected by substitutions at positions 22 or 23 or by N-terminal truncations, but was affected significantly by substitutions of Phe19 or Ala21. These results reveal how specific regions and residues control Abeta oligomerization and show that these controlling elements differ between Abeta40 and Abeta42.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Teplow, DB (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, 77 Ave Louis Pasteur HIM 756, Boston, MA 02115 USA.		Bitan, Gal/U-2204-2019	Bitan, Gal/0000-0001-7046-3754; Vollers, Sabrina/0000-0002-6772-0155	NIA NIH HHS [AG18921] Funding Source: Medline; NINDS NIH HHS [NS38328] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018921] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOP D, 1994, BIOCHEM SOC T, V22, P171, DOI 10.1042/bst0220171; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BEYREUTHER K, 1991, ANN NY ACAD SCI, V640, P129; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; Clements A, 1996, J NEUROCHEM, V66, P740; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; El-Agnaf OMA, 2000, BIOCHEM BIOPH RES CO, V273, P1003, DOI 10.1006/bbrc.2000.3051; Fancy DA, 2000, CHEM BIOL, V7, P697, DOI 10.1016/S1074-5521(00)00020-X; Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020; Fezoui Y, 2000, AMYLOID, V7, P166, DOI 10.3109/13506120009146831; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; GONG YS, 2001, SOC NEUR ABSTR, V27; Grabowski TJ, 2001, ANN NEUROL, V49, P697, DOI 10.1002/ana.1009; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1992, NATURE, V359, P325; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; KAMINO K, 1992, AM J HUM GENET, V51, P998; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; KOTZYBAHIBERT F, 1995, ANGEW CHEM INT EDIT, V34, P1296, DOI 10.1002/anie.199512961; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Larner AJ, 1999, NEUROBIOL AGING, V20, P65; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Liu ST, 1999, BIOCHEMISTRY-US, V38, P9373, DOI 10.1021/bi990205o; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; Massi F, 2001, BIOPHYS J, V80, P31, DOI 10.1016/S0006-3495(01)75993-0; Massi F, 2003, J COMPUT CHEM, V24, P143, DOI 10.1002/jcc.10101; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; Pitschke M, 1998, NAT MED, V4, P832, DOI 10.1038/nm0798-832; Russo C, 1997, FEBS LETT, V409, P411, DOI 10.1016/S0014-5793(97)00564-4; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/0304-3940(96)12970-0; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Tagliavini F., 1999, ALZHEIMERS REP, V2, pS28; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290; Teplow DB, 1997, ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, P311; Teplow DB, 1999, NEUROBIOL AGING, V20, P71; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; Tong LQ, 2001, J BIOL CHEM, V276, P17301, DOI 10.1074/jbc.M010450200; Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200; VANDEWATERBEEMD H, 1994, AMINO ACIDS, V7, P129, DOI 10.1007/BF00814156; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Walsh DM, 2001, BIOCHEM J, V355, P869, DOI 10.1042/bj3550869; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; Ward RV, 2000, BIOCHEM J, V348, P137, DOI 10.1042/0264-6021:3480137; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133; Yang DS, 2000, EUR J BIOCHEM, V267, P6692, DOI 10.1046/j.1432-1327.2000.01767.x; Ye CP, 2003, NEUROBIOL DIS, V13, P177, DOI 10.1016/S0969-9961(03)00068-8	67	250	255	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34882	34889		10.1074/jbc.M300825200	http://dx.doi.org/10.1074/jbc.M300825200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12840029	hybrid			2022-12-25	WOS:000185164400019
J	Danelon, C; Brando, T; Winterhalter, M				Danelon, C; Brando, T; Winterhalter, M			Probing the orientation of reconstituted maltoporin channels at the single-protein level	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI K-12; SUGAR-TRANSPORT; SALMONELLA-TYPHIMURIUM; STRUCTURAL BASIS; LAMB CHANNEL; IN-VITRO; TRANSLOCATION; BINDING; INSERTION	Recently we have shown that maltoporin channels reconstituted into black lipid membranes have pronounced asymmetric properties in both ion conduction and sugar binding. This asymmetry revealed also that maltoporin insertion is directional. However, the orientation in the lipid bilayer remained an open question. To elucidate the orientation, we performed point mutations at each side of the channel and analyzed the ion current fluctuation caused by an asymmetric maltohexaose addition. In a second series we used a chemically modified maltohexaose sugar molecule with inhibited entry possibility from the periplasmic side. In contrast to the natural outer cell wall of bacteria, we found that the maltoporin inserts in artificial lipid bilayer in such a way that the long extracellular loops are exposed to the same side of the membrane than protein addition. Based on this orientation, the directional properties of sugar binding were correlated to physiological conditions. We found that nature has optimized maltoporin channels by lowering the activation barriers at each extremity of the pore to trap sugar molecules from the external medium and eject them most efficiently to the periplasmic side.	Univ Toulouse 3, CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Danelon, C (corresponding author), Univ Toulouse 3, CNRS, Inst Pharmacol & Biol Struct, UMR 5089, 205 Rte Narbonne, F-31077 Toulouse, France.	danelon@ipbs.fr	Danelon, Christophe/AAW-5303-2021	Danelon, Christophe/0000-0002-0961-6640; Winterhalter, Mathias/0000-0002-1604-3318				Andersen C, 2002, J BIOL CHEM, V277, P41318, DOI 10.1074/jbc.M206804200; ANDERSEN C, 1995, J GEN PHYSIOL, V105, P385, DOI 10.1085/jgp.105.3.385; Andersen C, 1999, MOL MICROBIOL, V32, P851, DOI 10.1046/j.1365-2958.1999.01406.x; BENZ R, 1987, J MEMBRANE BIOL, V100, P21, DOI 10.1007/BF02209137; Bezrukov SM, 2000, FEBS LETT, V476, P224, DOI 10.1016/S0014-5793(00)01753-1; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; Brunkhorst C, 1999, J BACTERIOL, V181, P2612, DOI 10.1128/JB.181.8.2612-2619.1999; CHIESA C, 1993, J CHROMATOGR, V645, P337, DOI 10.1016/0021-9673(93)83394-8; deCock H, 1996, EMBO J, V15, P5567, DOI 10.1002/j.1460-2075.1996.tb00941.x; deCock H, 1996, J BIOL CHEM, V271, P12885, DOI 10.1074/jbc.271.22.12885; Dutzler R, 1996, STRUCTURE, V4, P127, DOI 10.1016/S0969-2126(96)00016-0; Dutzler R, 2002, STRUCTURE, V10, P1273, DOI 10.1016/S0969-2126(02)00811-0; Eppens EF, 1997, EMBO J, V16, P4295, DOI 10.1093/emboj/16.14.4295; Hilty C, 2001, PHYS REV LETT, V86, P5624, DOI 10.1103/PhysRevLett.86.5624; Kullman L, 2002, BIOPHYS J, V82, P803, DOI 10.1016/S0006-3495(02)75442-8; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; Meyer JEW, 1997, J MOL BIOL, V266, P761, DOI 10.1006/jmbi.1996.0823; Meyer JEW, 1997, PROTEIN SCI, V6, P1084, DOI 10.1002/pro.5560060515; MILLER DM, 1983, J BIOL CHEM, V258, P3665; Monsarrat B, 1999, GLYCOBIOLOGY, V9, P335, DOI 10.1093/glycob/9.4.335; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; NEKOLLA S, 1994, BIOPHYS J, V66, P1388, DOI 10.1016/S0006-3495(94)80929-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; Orlik F, 2002, BIOPHYS J, V83, P309, DOI 10.1016/S0006-3495(02)75171-0; SCHINDLER H, 1978, P NATL ACAD SCI USA, V75, P3751, DOI 10.1073/pnas.75.8.3751; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Schwarz G, 2003, BIOPHYS J, V84, P2990, DOI 10.1016/S0006-3495(03)70025-3; SEN K, 1988, J BIOL CHEM, V263, P1182; STOCK JB, 1977, J BIOL CHEM, V252, P7850; SURREY T, 1995, J BIOL CHEM, V270, P28199; Surrey T, 1996, BIOCHEMISTRY-US, V35, P2283, DOI 10.1021/bi951216u; Van Gelder P, 2000, BIOPHYS CHEM, V85, P153, DOI 10.1016/S0301-4622(99)00153-2; Van Gelder P, 2000, EUR J BIOCHEM, V267, P79, DOI 10.1046/j.1432-1327.2000.00960.x; Van Gelder P, 2002, J BACTERIOL, V184, P2994, DOI 10.1128/JB.184.11.2994-2999.2002; Wang YF, 1997, J MOL BIOL, V272, P56, DOI 10.1006/jmbi.1997.1224; WARSHEL A, 1989, P NATL ACAD SCI USA, V86, P5820, DOI 10.1073/pnas.86.15.5820; Winterhalter M, 1999, COLLOID SURFACE A, V149, P547, DOI 10.1016/S0927-7757(98)00290-8	39	54	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35542	35551		10.1074/jbc.M305434200	http://dx.doi.org/10.1074/jbc.M305434200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12835320	hybrid			2022-12-25	WOS:000185164400097
J	Gong, F; Jemth, P; Galvis, MLE; Vlodavsky, I; Horner, A; Lindahl, U; Li, JP				Gong, F; Jemth, P; Galvis, MLE; Vlodavsky, I; Horner, A; Lindahl, U; Li, JP			Processing of macromolecular heparin by heparanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K5; MAST-CELLS; MAMMALIAN HEPARANASE; MOUSE MASTOCYTOMA; CAPSULAR POLYSACCHARIDE; EXTRACELLULAR-MATRIX; MOLECULAR-PROPERTIES; CANCER METASTASIS; TUMOR-METASTASIS; URONIC-ACIDS	Heparanase is an endo-glucuronidase expressed in a variety of tissues and cells that selectively cleaves extracellular and cell-surface heparan sulfate. Here we propose that this enzyme is involved also in the processing of serglycin heparin proteoglycan in mouse mast cells. In this process, newly synthesized heparin chains (60-100 kDa) are degraded to fragments (10-20 kDa) similar in size to commercially available heparin (Jacobsson, K. G., and Lindahl, U. (1987) Biochem. J. 246, 409-415). A fraction of these fragments contains the specific pentasaccharide sequence required for high affinity binding to antithrombin implicated with anticoagulant activity. Rat skin heparin, which escapes processing in vivo, was used as a substrate in reaction with recombinant human heparanase. An incubation product of commercial heparin size retained the specific pentasaccharide sequence, although oligosaccharides (3-4 kDa) containing this sequence could be degraded by the same enzyme. Commercial heparin was found to be a powerful inhibitor (I-50 similar to 20 nM expressed as disaccharide unit, similar to0.7 nM polysaccharide) of heparanase action toward antithrombin-binding oligosaccharides. Cells derived from a serglycin-processing mouse mastocytoma expressed a protein highly similar to other mammalian heparanases. These findings strongly suggest that the intracellular processing of the heparin proteoglycan polysaccharide chains is catalyzed by heparanase, which primarily cleaves target structures distinct from the antithrombin-binding sequence.	Univ Uppsala, Dept Med Biochem & Microbiol, Biomed Ctr, SE-75123 Uppsala, Sweden; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A1, Canada	Uppsala University; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Toronto	Li, JP (corresponding author), Univ Uppsala, Dept Med Biochem & Microbiol, Biomed Ctr, Box 582, SE-75123 Uppsala, Sweden.		Galvis, Martha L Escobar/AAD-1998-2019	Escobar Galvis, Martha L/0000-0001-8400-9392				Bai XM, 1997, J BIOL CHEM, V272, P23172, DOI 10.1074/jbc.272.37.23172; Bame KJ, 2002, BIOCHEM J, V364, P265, DOI 10.1042/bj3640265; Bame KJ, 1998, BIOCHEM J, V336, P191, DOI 10.1042/bj3360191; BARNER M, 1987, BLOOD, V70, P551; BASHKIN P, 1990, BLOOD, V75, P2204; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; CASU B, 1994, CARBOHYD RES, V263, P271, DOI 10.1016/0008-6215(94)00172-3; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Hallgren J, 2001, J BIOL CHEM, V276, P42774, DOI 10.1074/jbc.M105531200; HO YC, 1985, ENZYME, V33, P9, DOI 10.1159/000469398; HOOK M, 1977, THROMB RES, V10, P857, DOI 10.1016/0049-3848(77)90143-8; HORNER AA, 1988, BIOCHEM J, V251, P141, DOI 10.1042/bj2510141; HORNER AA, 1971, J BIOL CHEM, V246, P231; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; JACOBSSON KG, 1987, BIOCHEM J, V246, P409, DOI 10.1042/bj2460409; JACOBSSON KG, 1985, J BIOL CHEM, V260, P2154; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; NAKAJIMA M, 1991, J BIOL CHEM, V266, P9661; OGREN S, 1975, J BIOL CHEM, V250, P2690; Okada Y, 2002, J BIOL CHEM, V277, P42488, DOI 10.1074/jbc.M206510200; OLDBERG A, 1980, BIOCHEMISTRY-US, V19, P5755, DOI 10.1021/bi00566a014; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Podyma-Inoue KA, 2002, J BIOL CHEM, V277, P32459, DOI 10.1074/jbc.M203282200; ROBINSON HC, 1978, J BIOL CHEM, V253, P6687; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SMITH I, 1960, CHROMATOGR ELECTROPH, P252; THUNBERG L, 1982, J BIOL CHEM, V257, P278; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; Vlodavsky I, 2002, SEMIN CANCER BIOL, V12, P121, DOI 10.1006/scbi.2001.0420; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Vlodavsky I, 2001, BIOCHIMIE, V83, P831, DOI 10.1016/S0300-9084(01)01318-9; YURT RW, 1977, J BIOL CHEM, V252, P518	46	59	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35152	35158		10.1074/jbc.M300925200	http://dx.doi.org/10.1074/jbc.M300925200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12837765	hybrid			2022-12-25	WOS:000185164400051
J	Srinivasula, SM; Gupta, S; Datta, P; Zhang, ZJ; Hegde, R; Cheong, NE; Fernandes-Alnemri, T; Alnemri, ES				Srinivasula, SM; Gupta, S; Datta, P; Zhang, ZJ; Hegde, R; Cheong, NE; Fernandes-Alnemri, T; Alnemri, ES			Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-DEATH; CASPASE ACTIVATION; IAP PROTEINS; BINDING; HTRA2; MOTIF; XIAP; IDENTIFICATION; INTERACTS; PATHWAY	The mature serine protease Omi/HtrA2 is released from the mitochondria into the cytosol during apoptosis. Suppression of Omi/HtrA2 by RNA interference in human cell lines reduces cell death in response to TRAIL and etoposide. In contrast, ectopic expression of mature wildtype Omi/HtrA2, but not an active site mutant, induces potent caspase activation and apoptosis. In vitro assays demonstrated that Omi/HtrA2 could degrade inhibitor of apoptosis proteins (IAPs). Consistent with this observation, increased expression of Omi/HtrA2 in cells increases degradation of XIAP, while suppression of Omi/HtrA2 by RNA interference has an opposite effect. Combined, our data demonstrate that IAPs are substrates for Omi/HtrA2, and their degradation could be a mechanism by which the mitochondrially released Omi/HtrA2 activates caspases during apoptosis.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,Rm 904,233 S 10th St, Philadelphia, PA 19107 USA.		Alnemri, Emad S/B-4526-2010; Gupta, Sanjeev/AAG-9749-2020; gupta, sanjeev/B-2824-2008	Gupta, Sanjeev/0000-0002-4691-6853; gupta, sanjeev/0000-0002-4691-6853	NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014357] Funding Source: NIH RePORTER; NCI NIH HHS [CA78890] Funding Source: Medline; NIA NIH HHS [AG14357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Martin SJ, 2002, CELL, V109, P793, DOI 10.1016/S0092-8674(02)00802-4; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Maurizi MR, 2002, NAT STRUCT BIOL, V9, P410, DOI 10.1038/nsb0602-410; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shi Y, 2002, CELL DEATH DIFFER, V9, P93, DOI 10.1038/sj/cdd/4400957; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Steller H, 2000, NAT CELL BIOL, V2, pE100, DOI 10.1038/35014093; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903	22	158	169	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31469	31472		10.1074/jbc.C300240200	http://dx.doi.org/10.1074/jbc.C300240200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12835328	hybrid			2022-12-25	WOS:000184782100004
J	Sheu, L; Pasyk, EA; Ji, JZ; Haung, XH; Gao, XD; Varoqueaux, F; Brose, N; Gaisano, HY				Sheu, L; Pasyk, EA; Ji, JZ; Haung, XH; Gao, XD; Varoqueaux, F; Brose, N; Gaisano, HY			Regulation of insulin exocytosis by Munc13-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DENSE-CORE VESICLES; SECRETORY GRANULES; SYNAPTIC-TRANSMISSION; TRANSMITTER RELEASE; PANCREATIC-ISLETS; UNC-13 GENE; BETA-CELLS; GLUCOSE; INHIBITION	The slower kinetics of insulin release from pancreatic islet beta cells, as compared with other regulated secretory processes such as chromaffin granule secretion, can in part be explained by the small number of the insulin granules that are docked to the plasma membrane and readily releasable. In type-2 diabetes, the kinetics of insulin secretion become grossly distorted, and, to therapeutically correct this, it is imperative to elucidate the mechanisms that regulate priming and secretion of insulin secretory granules. Munc13-1, a synaptic protein that regulates SNARE complex assembly, is the major protein determining the priming of synaptic vesicles. Here, we demonstrate the presence of Munc13-1 in human, rat, and mouse pancreatic islet beta cells. Expression of Munc13-1, along with its cognate partners, syntaxin 1a and Munc18a, is reduced in the pancreatic islets of type-2 diabetes non-obese Goto-Kakizaki and obese Zucker fa/fa rats. In insulinoma cells, overexpressed Munc13-1-enhanced green fluorescent protein is translocated to the plasma membrane in a temperature-dependent manner. This, in turn, greatly amplifies insulin exocytosis as determined by patch clamp capacitance measurements and radioimmunoassay of the insulin released. The potentiation of exocytosis by Munc13-1 is dependent on endogenously produced diacylglycerol acting on the overexpressed Munc13-1 because it is blocked by a phospholipase C inhibitor (U73122) and abrogated when the diacylglycerol binding-deficient Munc13-1(H567K) mutant is expressed instead of the wild type protein. Our data demonstrate that Munc13-mediated vesicle priming is not restricted to neurotransmitter release but is also functional in insulin secretion, where it is subject to regulation by the diacylglycerol second messenger pathway. In view of our findings, Munc13-1 is a potential drug target for therapeutic optimization of insulin secretion in diabetes.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Max Planck Inst Expt Med, Dept Mol Neurobiol, D-37075 Gottingen, Germany; Max Planck Inst Expt Med, Ctr Mol Physiol Brain, D-37075 Gottingen, Germany	University of Toronto; University of Toronto; Max Planck Society; Max Planck Society	Gaisano, HY (corresponding author), Univ Toronto, Dept Med, 1 Kings Coll Circle,Rm 7226, Toronto, ON M5S 1A8, Canada.	herbert.gaisano@utoronto.ca	Varoqueaux, Frederique/AAC-1834-2021; Gimenez, Luis E Diaz/D-9291-2011	Varoqueaux, Frederique/0000-0002-3614-3121; 				AbdelHalim SM, 1996, DIABETES, V45, P934, DOI 10.2337/diabetes.45.7.934; AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; Aravamudan B, 1999, NAT NEUROSCI, V2, P965, DOI 10.1038/14764; ARKHAMMAR P, 1994, J BIOL CHEM, V269, P2743; Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; Augustin I, 1999, BIOCHEM J, V337, P363, DOI 10.1042/0264-6021:3370363; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Barg S, 2002, NEURON, V33, P287, DOI 10.1016/S0896-6273(02)00563-9; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; Branstrom R, 1998, J BIOL CHEM, V273, P31395, DOI 10.1074/jbc.273.47.31395; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; Castillo PE, 2002, NATURE, V415, P327, DOI 10.1038/415327a; CERASI E, 1967, ACTA ENDOCRINOL-COP, V55, P278, DOI 10.1530/acta.0.0550278; Chan CB, 1999, DIABETES, V48, P997, DOI 10.2337/diabetes.48.5.997; Daniel S, 1999, DIABETES, V48, P1686, DOI 10.2337/diabetes.48.9.1686; Deeney JT, 1996, J BIOL CHEM, V271, P18154, DOI 10.1074/jbc.271.30.18154; Deeney JT, 2000, J BIOL CHEM, V275, P9363, DOI 10.1074/jbc.275.13.9363; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; Gaisano HY, 2002, ENDOCRINOLOGY, V143, P4218, DOI 10.1210/en.2002-220237; Gromada J, 1999, J PHYSIOL-LONDON, V518, P745, DOI 10.1111/j.1469-7793.1999.0745p.x; Hirose H, 1996, J BIOL CHEM, V271, P5633, DOI 10.1074/jbc.271.10.5633; Huang XH, 2001, AM J PHYSIOL-CELL PH, V281, pC740, DOI 10.1152/ajpcell.2001.281.3.C740; Huang XH, 1998, MOL ENDOCRINOL, V12, P1060, DOI 10.1210/me.12.7.1060; Iezzi M, 2000, FEBS LETT, V474, P66, DOI 10.1016/S0014-5793(00)01572-6; Kang Y, 2002, DIABETOLOGIA, V45, P231, DOI 10.1007/s00125-001-0718-0; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Komatsu M, 1998, DIABETES, V47, P352, DOI 10.2337/diabetes.47.3.352; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; Lackner MR, 1999, NEURON, V24, P335, DOI 10.1016/S0896-6273(00)80848-X; Leung YM, 2002, BIOCHEM BIOPH RES CO, V292, P980, DOI 10.1006/bbrc.2002.6712; Ling ZD, 1996, J CLIN INVEST, V98, P2805, DOI 10.1172/JCI119108; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; Miller KG, 1999, NEURON, V24, P323, DOI 10.1016/S0896-6273(00)80847-8; Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896-6273(00)80835-1; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P3805, DOI 10.1074/jbc.C100712200; OSTENSON CG, 1993, DIABETOLOGIA, V36, P3, DOI 10.1007/BF00399086; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; Plattner H, 1997, J CELL BIOL, V139, P1709, DOI 10.1083/jcb.139.7.1709; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Richmond JE, 1999, NAT NEUROSCI, V2, P959, DOI 10.1038/12160; Sassa T, 1999, J NEUROSCI, V19, P4772; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; Steyer JA, 1997, NATURE, V388, P474, DOI 10.1038/41329; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tang SH, 1998, DIABETES, V47, P905, DOI 10.2337/diabetes.47.6.905; Varoqueaux F, 2002, P NATL ACAD SCI USA, V99, P9037, DOI 10.1073/pnas.122623799; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; WOLF BA, 1989, BIOCHEMISTRY-US, V28, P4291, DOI 10.1021/bi00436a026; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417	61	91	96	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27556	27563		10.1074/jbc.M303203200	http://dx.doi.org/10.1074/jbc.M303203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12871971	hybrid			2022-12-25	WOS:000184242700029
J	Nozell, S; Wu, YJ; McNaughton, K; Liu, G; Willis, A; Paik, JC; Chen, XB				Nozell, S; Wu, YJ; McNaughton, K; Liu, G; Willis, A; Paik, JC; Chen, XB			Characterization of p73 functional domains necessary for transactivation and growth suppression	ONCOGENE			English	Article						p73; p53 family; apoptosis; cell cycle	KINASE C-ABL; DNA-DAMAGE; P53 FAMILY; APOPTOTIC RESPONSE; TRANSCRIPTIONAL ACTIVITY; P53-RELATED PROTEIN; INDUCE APOPTOSIS; TERMINAL DOMAIN; TARGET GENES; TUMOR-CELLS	p73, a p53 family member, is highly similar to p53 in both structure and function. Like p53, the p73 protein contains an N-terminal activation domain, a DNA-binding domain, a tetramerization domain, and several PXXP motifs. Previously, we and others have shown that some functional domains in p53, such as the DNA-binding and tetramerization domains, are required for inducing both cell cycle arrest and apoptosis whereas others, such as the second activation domain, the proline-rich domain, and the C-terminal basic domain, are only required for inducing apoptosis. To determine the activity of p73 functional domains, we have generated stable inducible cell lines that express p73beta and various mutants deficient in one or more functional domains. We found that in addition to the DNA-binding domain, p73-mediated growth suppression requires the N-terminal activation domain and the tetramerization domain. However, unlike p53, p73-mediated apoptosis does not require the region adjacent to the activation domain or the entire C-terminal region. Interestingly, while the N- or the C-terminal PXXP motifs are dispensable for p73 function, deletion of both the Nand the C-terminal PXXP motifs renders p73 inactive in transactivation. In addition, we found that substitution of two conserved tandem hydrophobic residues with two hydrophilic ones, which can abrogate the activity of the first activation domain in p53, has no effect on p73 transcriptional activity. Together, we showed that the p73 protein has its own unique determinants for transactivation and growth suppression.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, MCLM 660,1530 3rd Ave S, Birmingham, AL 35294 USA.	xchen@uab.edu		, Gang/0000-0002-6999-7633; Paik, Jason/0000-0002-9075-4679; Amara, Amy/0000-0003-0762-9656; Liu, Gang/0000-0003-2615-131X	NCI NIH HHS [CA 81237] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081237] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Gong JG, 1999, NATURE, V399, P806; Grimberg A, 2000, MOL GENET METAB, V70, P85, DOI 10.1006/mgme.2000.3008; Inoue T, 2002, J BIOL CHEM, V277, P15053, DOI 10.1074/jbc.M200248200; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishimoto O, 2002, CANCER RES, V62, P636; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LIN JY, 1995, ONCOGENE, V10, P2387; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191; Ozaki T, 1999, CANCER RES, V59, P5902; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Schultz J, 1997, PROTEIN SCI, V6, P249; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CANCER RES, V62, P3598; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Takada N, 1999, CANCER RES, V59, P2810; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu JH, 1998, CANCER RES, V58, P5061	52	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4333	4347		10.1038/sj.onc.1206470	http://dx.doi.org/10.1038/sj.onc.1206470			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853970				2022-12-25	WOS:000183978900003
J	Fajas, L; Egler, V; Reiter, R; Miard, S; Lefebvre, AM; Auwerx, J				Fajas, L; Egler, V; Reiter, R; Miard, S; Lefebvre, AM; Auwerx, J			PPAR gamma controls cell proliferation and apoptosis in an RB-dependent manner	ONCOGENE			English	Article						cancer; cell cycle; colon; nuclear receptor; transcription	ACTIVATED RECEPTOR-GAMMA; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; INDUCE APOPTOSIS; DOWN-REGULATION; MOUSE LENS; DIFFERENTIATION; TRANSCRIPTION; INHIBITION; LIGANDS	The nuclear receptor PPARgamma is implicated in the control of cell proliferation and apoptosis. However, the molecular mechanisms by which it controls these processes remain largely elusive. We show here that PPARgamma activation in the presence of the retinoblastoma protein (RB) results in the arrest of cells at the G1 phase of the cell cycle, whereas in the absence of RB, cells accumulate in G2/M, endoreduplicate, and undergo apoptosis. Through the use of HDAC inhibitors and coimmunoprecipitations, we furthermore demonstrate that the effects of RB on PPARgamma-mediated control of the cell cycle and apoptosis depend on the recruitment of histone deacetylase 3 (HDAC3) to PPARgamma. In combination, these data hence demonstrate that the effects of PPARgamma on cell proliferation and apoptosis are dependent on the presence of an RB-HDAC3 complex.	CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Auwerx, J (corresponding author), CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, France.		Coll, Lluis Fajas/C-8567-2014	Fajas, Lluis/0000-0002-1283-9503; Auwerx, Johan/0000-0002-5065-5393; Lefebvre, Anne-Marie/0000-0001-5644-0441	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059820] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 P01-DK59820-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chang TH, 2000, CANCER RES, V60, P1129; Chang TH, 2002, CLIN CANCER RES, V8, P1206; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fajas L, 2001, J MOL ENDOCRINOL, V27, P1, DOI 10.1677/jme.0.0270001; Fajas L, 2000, P NATL ACAD SCI USA, V97, P7738, DOI 10.1073/pnas.130198397; Guy M, 2001, BRIT J CANCER, V84, P520, DOI 10.1054/bjoc.2000.1635; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Lefebvre AM, 1999, J ENDOCRINOL, V162, P331, DOI 10.1677/joe.0.1620331; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Padilla J, 2000, J IMMUNOL, V165, P6941, DOI 10.4049/jimmunol.165.12.6941; Palakurthi SS, 2001, CANCER RES, V61, P6213; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Rosen ED, 2000, GENE DEV, V14, P1293; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Wakino S, 2000, J BIOL CHEM, V275, P22435, DOI 10.1074/jbc.M910452199; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Yamamoto H, 1999, CLIN CANCER RES, V5, P1805	31	60	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4186	4193		10.1038/sj.onc.1206530	http://dx.doi.org/10.1038/sj.onc.1206530			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833141				2022-12-25	WOS:000183979800005
J	Kool, J; Hamdi, M; Cornelissen-Steijger, P; van der Eb, AJ; Terleth, C; van Dam, H				Kool, J; Hamdi, M; Cornelissen-Steijger, P; van der Eb, AJ; Terleth, C; van Dam, H			Induction of ATF3 by ionizing radiation is mediated via a signaling pathway that includes ATM, Nibrin1, stress-induced MAPkinases and ATF-2	ONCOGENE			English	Article						ionizing radiation; ATM; NBS; ATF3; ATF-2	NIJMEGEN BREAKAGE SYNDROME; CELL-CYCLE CHECKPOINT; MAMMALIAN UV RESPONSE; DNA-DAMAGE RESPONSE; S-PHASE CHECKPOINT; C-JUN INDUCTION; NF-KAPPA-B; ATAXIA-TELANGIECTASIA; GENOTOXIC STRESS; GROWTH-FACTOR	Exposure of human cells to genotoxic agents induces various signaling pathways involved in the execution of stress- and DNA-damage responses. Inappropriate functioning of the DNA-damage response to ionizing radiation (IR) is associated with the human diseases ataxia-telangiectasia (A-T) and Nijmegen Breakage syndrome (NBS). Here, we show that IR efficiently induces Jun/ATF transcription factor activity in normal human diploid fibroblasts, but not in fibroblasts derived from A-T and NBS patients. IR was found to enhance the expression of c-Jun and, in particular, ATF3, but, in contrast to various other stress stimuli, did not induce the expression of c-Fos. Using specific inhibitors, we found that the ATM- and Nibrin1-dependent activation of ATF3 does neither require p53 nor reactive oxygen species, but is dependent on the p38 and JNK MAPkinases. Via these kinases, IR activates ATF-2, one of the transcription factors acting on the atf3 promoter. The activation of ATF-2 by IR resembles ATF-2 activation by certain growth factors, since IR mainly induced the second step of ATF-2 phosphorylation via the stress-inducible MAPkinases, phosphorylation of Thr69. As IR does not enhance ATF-2 phosphorylation in ATM and Nibrin1-deficient cells, both ATF-2 and ATF3 seem to play an important role in the protective response of human cells to IR.	Leiden Univ, Ctr Biomed Genet, Dept Mol Cell Biol, Sect Gene Regulat,Med Ctr, NL-2333 AL Leiden, Netherlands; Leiden Univ, Dept Radiat Genet & Chem Mutagenesis, Med Ctr, NL-2333 AL Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van Dam, H (corresponding author), Leiden Univ, Ctr Biomed Genet, Dept Mol Cell Biol, Sect Gene Regulat,Med Ctr, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.	vdam@lumc.nl		van Dam, Hans/0000-0002-8307-4325				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Bar-Shira A, 2002, ONCOGENE, V21, P849, DOI 10.1038/sj.onc.1205127; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; COFFER PJ, 1995, ONCOGENE, V11, P561; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; Hai T, 1999, GENE EXPRESSION, V7, P321; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; KHANNA KK, 1995, ONCOGENE, V11, P609; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; KLEIN B, 1990, EXP CELL RES, V191, P256, DOI 10.1016/0014-4827(90)90012-Y; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Pfeiffer P, 1996, MUTAT RES-REV GENET, V366, P69, DOI 10.1016/S0165-1110(96)90029-9; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; vanLaar T, 1995, BIOCHEM BIOPH RES CO, V217, P769, DOI 10.1006/bbrc.1995.2839; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yamazaki V, 1998, CANCER RES, V58, P2316; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; ZANDOMENI R, 1982, P NATL ACAD SCI-BIOL, V79, P3167, DOI 10.1073/pnas.79.10.3167; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	57	69	69	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4235	4242		10.1038/sj.onc.1206611	http://dx.doi.org/10.1038/sj.onc.1206611			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833146				2022-12-25	WOS:000183979800010
J	Ward, G; Hadar, Y; Bilkis, I; Dosoretz, CG				Ward, G; Hadar, Y; Bilkis, I; Dosoretz, CG			Mechanistic features of lignin peroxidase-catalyzed oxidation of substituted phenols and 1,2-dimethoxyarenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON REDOX POTENTIALS; HORSERADISH-PEROXIDASE; VERATRYL ALCOHOL; RADICAL-CATION; COMPOUND I; DERIVATIVES; CHRYSOSPORIUM; ANILINES; MEDIATOR; MODELS	The steady state kinetic parameters K-m and k(cat) for the oxidation of phenolic substrates by lignin peroxidase correlated with the presteady state kinetic parameters K-d and k for the reaction of the enzyme intermediate compound II with the substrates, indicating that the latter is the rate-limiting step in the catalytic cycle. ln K-m and ln K-d values for phenolic substrates correlated with redox properties, unlike ln kcat and ln k. This finding suggests that in contrast to horseradish peroxidase, electron transfer is not the rate-limiting step during oxidation by lignin peroxidase compound II. A mechanism is proposed for lignin peroxidase compound II reactions consisting of an equilibrium electron transfer step followed by a subsequent rate-limiting step. Analysis of the correlation coefficients for linear relationships between ln K-d and ln K-m and different calculated redox parameters supports a mechanism in which the acidic forms of phenols are oxidized by lignin peroxidase and electron transfer is coupled with proton transfer. 1,2-Dimethoxyarenes did not comply with the trend for phenolic substrates, which may be a result of more than one substrate binding site on lignin peroxidase and/or alternative binding modes. This behavior was supported by analogue studies with the 1,2-dimethoxyarenes veratric acid and veratryl aldehyde, both of which are not oxidized by lignin peroxidase. Inclusion of either had little effect on the rate of oxidation of phenolic substrates yet resulted in a decrease in the oxidation rate of 1,2-dimethoxyarene substrates, which was considerable for veratryl alcohol and less pronounced for 3,4-dimethoxyphenethylalcohol and 3,4-dimethoxycinnamic acid, in particular in the presence of veratric acid.	Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel; Technion Israel Inst Technol, Fac Civil & Environm Engn, Div Environm Engn & Sci, IL-32000 Haifa, Israel; Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Dept Plant Pathol & Microbiol, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Technion Israel Institute of Technology; Hebrew University of Jerusalem	Bilkis, I (corresponding author), Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel.	bilkis@agri.huji.ac.il	Bilkis, Itzhak/Q-9675-2017	Dosoretz, Carlos G./0000-0002-1759-9203				Baciocchi E, 2002, CHEM COMMUN, P946, DOI 10.1039/b201492k; Baciocchi E, 2001, EUR J ORG CHEM, V2001, P2305; Baciocchi E, 2000, CHEM COMMUN, P393, DOI 10.1039/a908394d; Baciocchi E, 2000, EUR J BIOCHEM, V267, P2705, DOI 10.1046/j.1432-1327.2000.01293.x; Banci L, 1999, BIOCHEMISTRY-US, V38, P3205, DOI 10.1021/bi982139g; Bietti M, 1998, J PHYS CHEM A, V102, P7337, DOI 10.1021/jp9812482; Blodig W, 2001, J MOL BIOL, V305, P851, DOI 10.1006/jmbi.2000.4346; CAI DY, 1993, J BIOTECHNOL, V30, P79, DOI 10.1016/0168-1656(93)90029-M; Candeias LP, 1996, BIOCHEMISTRY-US, V35, P102, DOI 10.1021/bi9514424; Candeias LP, 1997, BIOCHEMISTRY-US, V36, P7081, DOI 10.1021/bi970384e; Choinowski T, 1999, J MOL BIOL, V286, P809, DOI 10.1006/jmbi.1998.2507; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; Doyle WA, 1998, BIOCHEMISTRY-US, V37, P15097, DOI 10.1021/bi981633h; Folkes LK, 1997, FEBS LETT, V412, P305, DOI 10.1016/S0014-5793(97)00792-8; GOODWIN DC, 1995, BIOCHEMISTRY-US, V34, P5060, DOI 10.1021/bi00015a017; HARVEY PJ, 1986, FEBS LETT, V195, P242, DOI 10.1016/0014-5793(86)80168-5; HARVEY PJ, 1995, BIOCHEM SOC T, V23, P262, DOI 10.1042/bst0230262; HARVEY PJ, 1992, BIOCHEM SOC T, V20, P345, DOI 10.1042/bst0200345; Hilal SH, 1995, QUANT STRUCT-ACT REL, V14, P348, DOI 10.1002/qsar.19950140405; Joshi DK, 1996, EUR J BIOCHEM, V237, P45, DOI 10.1111/j.1432-1033.1996.0045n.x; JOVANOVIC SV, 1994, J AM CHEM SOC, V116, P4846, DOI 10.1021/ja00090a032; JOVANOVIC SV, 1991, J PHYS CHEM-US, V95, P10824, DOI 10.1021/j100179a054; KERSTEN PJ, 1990, BIOCHEM J, V268, P475, DOI 10.1042/bj2680475; KHODPE SM, 2000, BIOPHYS CHEM, V88, P103; KODURI RS, 1995, J BIOL CHEM, V270, P22254, DOI 10.1074/jbc.270.38.22254; KODURI RS, 1994, BIOCHEMISTRY-US, V33, P4225, DOI 10.1021/bi00180a016; Li C, 1999, J PHYS CHEM B, V103, P6653, DOI 10.1021/jp983819w; Lin WZ, 1998, RADIAT PHYS CHEM, V53, P425, DOI 10.1016/S0969-806X(97)00318-6; LIND J, 1990, J AM CHEM SOC, V112, P479, DOI 10.1021/ja00158a002; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Park JW, 1999, ENVIRON SCI TECHNOL, V33, P2028, DOI 10.1021/es9810787; Piontek K, 2001, BIOCHEM SOC T, V29, P111, DOI 10.1042/BST0290111; Priyadarsini KI, 1998, FREE RADICAL BIO MED, V24, P933, DOI 10.1016/S0891-5849(97)00382-1; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; Rothschild N, 1997, APPL ENVIRON MICROB, V63, P857, DOI 10.1128/AEM.63.3.857-861.1997; SAKURADA J, 1990, BIOCHEMISTRY-US, V29, P4093, DOI 10.1021/bi00469a011; Schlegel HB., 2009, GAUSSIAN 09 REVISION; Schoemaker H E, 1994, Bioorg Med Chem, V2, P509, DOI 10.1016/0968-0896(94)80021-9; SEGEL HM, 1975, ENZYME KINETICS, P727; STEENKEN S, 1982, J PHYS CHEM-US, V86, P3661, DOI 10.1021/j100215a033; STEENKEN S, 1979, J PHYS CHEM-US, V83, P1134, DOI 10.1021/j100472a005; Teunissen PJM, 1998, ARCH BIOCHEM BIOPHYS, V360, P233, DOI 10.1006/abbi.1998.0940; TIEN M, 1988, METHOD ENZYMOL, V161, P238; TIEN M, 1986, J BIOL CHEM, V261, P1687; Van Haandel MJH, 1999, BBA-PROTEIN STRUCT M, V1435, P22, DOI 10.1016/S0167-4838(99)00199-5; vanHaandel MJH, 1996, J BIOL INORG CHEM, V1, P460, DOI 10.1007/s007750050079; Ward G, 2002, ENZYME MICROB TECH, V30, P490, DOI 10.1016/S0141-0229(01)00526-9; Ward G, 2001, J BIOL CHEM, V276, P18734, DOI 10.1074/jbc.M009785200; Ward G, 2001, ENZYME MICROB TECH, V29, P34, DOI 10.1016/S0141-0229(01)00336-2; WARDMAN P, 1989, J PHYS CHEM REF DATA, V18, P1637, DOI 10.1063/1.555843	51	23	25	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39726	39734		10.1074/jbc.M303918200	http://dx.doi.org/10.1074/jbc.M303918200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12857756	hybrid			2022-12-25	WOS:000185713800058
J	Barabas, O; Rumlova, M; Erdei, A; Pongracz, V; Pichova, I; Vertessy, BG				Barabas, O; Rumlova, M; Erdei, A; Pongracz, V; Pichova, I; Vertessy, BG			dUTPase and nucleocapsid polypeptides of the Mason-Pfizer monkey virus form a fusion protein in the virion with homotrimeric organization and low catalytic efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; INFECTIOUS-ANEMIA VIRUS; HIGH-LEVEL EXPRESSION; 3 ACTIVE FORMS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; NUCLEOTIDE-SEQUENCE; IN-VITRO; BINDING; GAG	Betaretroviruses encode dUTPase, an essential factor in DNA metabolism and repair, in the pro open reading frame located between gag and pol. Ribosomal frame-shifts during expression of retroviral proteins provide a unique possibility for covalent joining of nucleocapsid (NC) and dUTPase within Gag-Pro polyproteins. By developing an antibody against the prototype betaretrovirus Mason-Pfizer monkey virus dUTPase, we demonstrate that i) the NC-dUTPase fusion protein exists both within the virions and infected cells providing the only form of dUTPase, and ii) the retroviral protease does not cleave NC-dUTPase either in the virion or in vitro. We show that recombinant betaretroviral NC-dUTPase and dUTPase are both inefficient catalysts compared with all other dUTPases. Dynamic light scattering and gel filtration confirm that the homotrimeric organization, common among dUTPases, is retained in the NC-dUTPase fusion protein. The betaretroviral dUTPase has been crystallized and single crystals contain homotrimers. Oligonucleotide and Zn2+ binding is well retained in the fusion protein, which is the first example of acquisition of a functional nucleic acid binding module by the DNA repair factor dUTPase. Binding of the hexanucleotide ACTGCC or the octanucleotide (TG)(4) to NC-dUTPase modulates enzymatic function, indicating that the low catalytic activity may be compensated by adequate localization.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary; Eotvos Lorand Univ, Dept Theoret Chem, H-1518 Budapest, Hungary; Acad Sci Czech Republ, Inst Organ Chem & Biochem, Prague, Czech Republic; Eotvos Lorand Univ, Dept Immunol, Budapest, Hungary; Inst Chem Technol, Dept Biochem & Microbiol, CR-16628 Prague, Czech Republic	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; Czech Academy of Sciences; Institute of Organic Chemistry & Biochemistry of the Czech Academy of Sciences; Eotvos Lorand University; University of Chemistry & Technology, Prague	Vertessy, BG (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, POB 7, H-1518 Budapest, Hungary.	vertessy@enzim.hu	Barabas, Orsolya/F-3961-2012; Vertessy, Beata G/H-6202-2012; Rumlova, Michaela/G-9142-2018; Erdei, Anna/AAN-5988-2020; Rumlova, Michaela/G-6140-2014; Pichova, Iva/G-7917-2014	Barabas, Orsolya/0000-0002-2873-5872; Rumlova, Michaela/0000-0002-5645-8227; Vertessy, Beata G./0000-0002-1288-2982; Erdei, Anna/0000-0002-3622-6680				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldo AM, 1999, J VIROL, V73, P7710, DOI 10.1128/JVI.73.9.7710-7721.1999; BERGMAN AC, 1994, VIROLOGY, V204, P420, DOI 10.1006/viro.1994.1547; BERGMAN AC, 1995, PROTEIN EXPRES PURIF, V6, P379, DOI 10.1006/prep.1995.1050; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dauter Z, 1999, J MOL BIOL, V285, P655, DOI 10.1006/jmbi.1998.2332; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; ELDER JH, 1992, J VIROL, V66, P1791, DOI 10.1128/JVI.66.3.1791-1794.1992; ELHAJJ HH, 1988, J BACTERIOL, V170, P1069, DOI 10.1128/jb.170.3.1069-1075.1988; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; Fiser A, 2000, BIOCHEM BIOPH RES CO, V279, P534, DOI 10.1006/bbrc.2000.3994; Fisher RJ, 1998, J VIROL, V72, P1902, DOI 10.1128/JVI.72.3.1902-1909.1998; FITZGERALD DW, 1991, BIOCHEMISTRY-US, V30, P5195, DOI 10.1021/bi00235a012; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; Gao Y, 1998, PROTEIN SCI, V7, P2265, DOI 10.1002/pro.5560071104; Goulian M, 1986, Adv Exp Med Biol, V195 Pt B, P89; GREEN LM, 1990, P NATL ACAD SCI USA, V87, P6403, DOI 10.1073/pnas.87.16.6403; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Harris JM, 1999, J MOL BIOL, V288, P275, DOI 10.1006/jmbi.1999.2680; HRUSKOVAHEIDINGSFELDOVA O, 1995, J BIOL CHEM, V270, P15053, DOI 10.1074/jbc.270.25.15053; JACKS T, 1987, P NATL ACAD SCI USA, V84, P4298, DOI 10.1073/pnas.84.12.4298; KOPPE B, 1994, J VIROL, V68, P2313; Larsson G, 1996, J BIOL CHEM, V271, P24010, DOI 10.1074/jbc.271.39.24010; Larsson G, 1996, NAT STRUCT BIOL, V3, P532, DOI 10.1038/nsb0696-532; LERNER DL, 1995, P NATL ACAD SCI USA, V92, P7480, DOI 10.1073/pnas.92.16.7480; LESLIE AGW, 1992, NEWSLETTER PROTEIN C, V26; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCCLURE MA, 1987, P NATL ACAD SCI USA, V84, P2693, DOI 10.1073/pnas.84.9.2693; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; Morellet N, 1998, J MOL BIOL, V283, P419, DOI 10.1006/jmbi.1998.2098; MORRISON ID, 1985, LANGMUIR, V1, P496, DOI 10.1021/la00064a016; OMICHINSKI JG, 1991, FEBS LETT, V292, P25, DOI 10.1016/0014-5793(91)80825-N; Pearl LH, 1996, NAT STRUCT BIOL, V3, P485, DOI 10.1038/nsb0696-485; Persson R, 2002, PREP BIOCHEM BIOTECH, V32, P157, DOI 10.1081/PB-120004128; Pichova I, 1998, ADV EXP MED BIOL, V436, P105; Prasad GS, 1996, PROTEIN SCI, V5, P2429, DOI 10.1002/pro.5560051205; Prasad GS, 2000, ACTA CRYSTALLOGR D, V56, P1100, DOI 10.1107/S0907444900009197; PYLES RB, 1992, J VIROL, V66, P6706, DOI 10.1128/JVI.66.11.6706-6713.1992; Rumlova M, 2003, VIROLOGY, V310, P310, DOI 10.1016/S0042-6822(03)00128-4; Sambrook J, 2001, MOL CLONING LAB MANU; SONIGO P, 1986, CELL, V45, P375, DOI 10.1016/0092-8674(86)90323-5; STEAGALL WK, 1995, VIROLOGY, V210, P302, DOI 10.1006/viro.1995.1347; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUROVOY A, 1993, J MOL BIOL, V229, P94, DOI 10.1006/jmbi.1993.1011; THREADGILL DS, 1993, J VIROL, V67, P2592, DOI 10.1128/JVI.67.5.2592-2600.1993; Turelli P, 1997, J VIROL, V71, P4522, DOI 10.1128/JVI.71.6.4522-4530.1997; Urbaneja MA, 2000, J BIOL CHEM, V275, P10394, DOI 10.1074/jbc.275.14.10394; Vertessy BG, 1996, BIOCHEM BIOPH RES CO, V219, P294, DOI 10.1006/bbrc.1996.0226; VERTESSY BG, 1994, BBA-PROTEIN STRUCT M, V1205, P146, DOI 10.1016/0167-4838(94)90103-1; Vertessy BG, 1997, PROTEINS, V28, P568, DOI 10.1002/(SICI)1097-0134(199708)28:4<568::AID-PROT10>3.0.CO;2-E; Vuilleumier C, 1999, BIOCHEMISTRY-US, V38, P16816, DOI 10.1021/bi991145p; Wang Y, 2002, RNA, V8, P981, DOI 10.1017/S1355838202024044; Zabransky A, 1998, VIROLOGY, V245, P250, DOI 10.1006/viro.1998.9173	57	21	22	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38803	38812		10.1074/jbc.M306967200	http://dx.doi.org/10.1074/jbc.M306967200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12869552	hybrid			2022-12-25	WOS:000185575100088
J	Johnson, JL; Cusack, B; Hughes, TF; McCullough, EH; Fauq, A; Romanovskis, P; Spatola, AF; Rosenberry, TL				Johnson, JL; Cusack, B; Hughes, TF; McCullough, EH; Fauq, A; Romanovskis, P; Spatola, AF; Rosenberry, TL			Inhibitors tethered near the acetylcholinesterase active site serve as molecular rulers of the peripheral and acylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; BINDING-SITE; RECEPTOR; SPECIFICITY; FASCICULIN; PROPIDIUM; CYSTEINES; PROTEINS; REVEALS; REAGENT	The acetylcholinesterase (AChE) active site consists of a narrow gorge with two separate ligand binding sites: an acylation site (or A-site) at the bottom of the gorge where substrate hydrolysis occurs and a peripheral site (or P-site) at the gorge mouth. AChE is inactivated by organo-phosphates as they pass through the P-site and phosphorylate the catalytic serine in the A-site. One strategy to protect against organophosphate inactivation is to design cyclic ligands that will bind specifically to the P-site and block the passage of organophosphates but not acetylcholine. To accelerate the process of identifying cyclic compounds with high affinity for the AChE P-site, we introduced a cysteine residue near the rim of the P-site by site-specific mutagenesis to generate recombinant human H287C AChE. Compounds were synthesized with a highly reactive methanethiosulfonyl substituent and linked to this cysteine through a disulfide bond. The advantages of this tethering were demonstrated with H287C AChE modified with six compounds, consisting of cationic trialkyl-ammonium, acridinium, and tacrine ligands with tethers of varying length. Modification by ligands with short tethers had little effect on catalytic properties, but longer tethering resulted in shifts in substrate hydrolysis profiles and reduced affinity for acridinium affinity resin. Molecular modeling calculations indicated that cationic ligands with tethers of intermediate length bound to the P-site, whereas those with long tethers reached the A-site. These binding locations were confirmed experimentally by measuring competitive inhibition constants K-I2 for propidium and tacrine, inhibitors specific for the P- and A-sites, respectively. Values of K-I2 for propidium increased 30- to 100-fold when ligands had either intermediate or long tethers. In contrast, the value of K-I2 for tacrine increased substantially only when ligands had long tethers. These relative changes in propidium and tacrine affinities thus provided a sensitive molecular ruler for assigning the binding locations of the tethered cations.	Mayo Clin Jacksonville, Mayo Fdn Med Educ & Res, Dept Pharmacol, Jacksonville, FL 32224 USA; Mayo Clin Jacksonville, Mayo Fdn Med Educ & Res, Dept Neurosci, Jacksonville, FL 32224 USA; Univ Louisville, Dept Chem, Louisville, KY 40292 USA	Mayo Clinic; Mayo Clinic; University of Louisville	Rosenberry, TL (corresponding author), Mayo Clin Jacksonville, Mayo Fdn Med Educ & Res, Dept Pharmacol, 4500 San Pablo Rd,Birdsall Bldg, Jacksonville, FL 32224 USA.		Cusack, Bernadette/D-4606-2013					Aldridge WN, 1972, FRONTIERS BIOL, V26; [Anonymous], ENZYMES 3E; Bourne Y, 2003, EMBO J, V22, P1, DOI 10.1093/emboj/cdg005; Boyd AE, 2000, J BIOL CHEM, V275, P22401, DOI 10.1074/jbc.M000606200; Bruice T.W., 1982, J PROTEIN CHEM, V1, P47, DOI DOI 10.1007/BF01025550; BURGEN ASV, 1949, BRIT J PHARM CHEMOTH, V4, P219, DOI 10.1111/j.1476-5381.1949.tb00540.x; Carlier PR, 1999, BIOORGAN MED CHEM, V7, P351, DOI 10.1016/S0968-0896(98)00213-2; De Ferrari GV, 2001, J BIOL CHEM, V276, P23282, DOI 10.1074/jbc.M009596200; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Erlanson DA, 2000, P NATL ACAD SCI USA, V97, P9367, DOI 10.1073/pnas.97.17.9367; Foong LY, 1997, BIOCHEMISTRY-US, V36, P1343, DOI 10.1021/bi9624907; HAAS R, 1985, ANAL BIOCHEM, V148, P154, DOI 10.1016/0003-2697(85)90640-2; HAAS R, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P131; Haldane J. B. S., 1930, ENZYMES, P84; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; Incardona JP, 1996, MOL BIOL CELL, V7, P613, DOI 10.1091/mbc.7.4.613; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; Li LT, 2001, CHEM BIOL, V8, P47, DOI 10.1016/S1074-5521(00)00055-7; Mallender WD, 2000, BIOCHEMISTRY-US, V39, P7753, DOI 10.1021/bi000210o; Mallender WD, 1999, J BIOL CHEM, V274, P8491, DOI 10.1074/jbc.274.13.8491; Mallender WD, 2001, MOL PHARMACOL, V59, P619, DOI 10.1124/mol.59.3.619; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; Raves ML, 1997, NAT STRUCT BIOL, V4, P57, DOI 10.1038/nsb0197-57; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROSENBERRY TL, 1979, BIOPHYS J, V26, P263, DOI 10.1016/S0006-3495(79)85249-2; ROSENBERRY TL, 1984, J BIOL CHEM, V259, P5643; ROSENBERRY TL, 1982, METHOD ENZYMOL, V82, P325; Rosenberry TL, 1975, ADV ENZYMOLOGY, P43; SILMAN I, 1969, SCIENCE, V164, P1420, DOI 10.1126/science.164.3886.1420; SPATOLA AF, 1993, METHODS NEUROSCIENCE, V13, P19; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Szegletes T, 1999, BIOCHEMISTRY-US, V38, P122, DOI 10.1021/bi9813577; Szegletes T, 1998, BIOCHEMISTRY-US, V37, P4206, DOI 10.1021/bi972158a; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; WILSON IB, 1955, BIOCHIM BIOPHYS ACTA, V18, P168, DOI 10.1016/0006-3002(55)90040-8; WILSON IB, 1951, J BIOL CHEM, V190, P111	39	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38948	38955		10.1074/jbc.M304797200	http://dx.doi.org/10.1074/jbc.M304797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12851386	hybrid			2022-12-25	WOS:000185575100105
J	Ni, DTN; Matthews, SP; Antoniou, AN; Mazzeo, D; Watts, C				Ni, DTN; Matthews, SP; Antoniou, AN; Mazzeo, D; Watts, C			Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR PROCESSING ENZYME; HUMAN PROCATHEPSIN-B; CLASS-II COMPLEXES; DENDRITIC CELLS; SCHISTOSOMA-MANSONI; MAMMALIAN LEGUMAIN; CRYSTAL-STRUCTURE; GENE-EXPRESSION; SERIAL ANALYSIS; ACTIVATION	Mammalian asparaginyl endopeptidase (AEP) or legumain is a recently discovered lysosomal cysteine protease that specifically cleaves after asparagine residues. How this unusually specific lysosomal protease is itself activated is not fully understood. Using purified recombinant pro-enzyme, we show that activation is autocatalytic, requires sequential removal of C- and N-terminal pro-peptides at different pH thresholds, and is bimolecular. Removal of the N-terminal propeptide requires cleavage after aspartic acid rather than asparagine. Cellular processing, either of exogenously added AEP precursor or of pulse-labeled endogenous precursor, introduces at least one further cleavage to yield the final mature lysosomal enzyme. We also provide evidence that in living cells, there is clear compartmental heterogeneity in terms of AEP activation status. Moreover, we show that human monocyte-derived dendritic cells harbor inactive proforms of AEP that become activated upon maturation of dendritic cells with lipopolysaccharide.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland	University of Dundee	Watts, C (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland.	c.watts@dundee.ac.uk		Antoniou, Antony/0000-0002-6536-7781; Watts, Colin/0000-0001-6183-2087; Matthews, Stephen/0000-0003-3556-962X				Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; Anderton SM, 2002, NAT IMMUNOL, V3, P175, DOI 10.1038/ni756; Antoniou AN, 2000, IMMUNITY, V12, P391, DOI 10.1016/S1074-7613(00)80191-0; Beck H, 2001, EUR J IMMUNOL, V31, P3726, DOI 10.1002/1521-4141(200112)31:12<3726::AID-IMMU3726>3.0.CO;2-O; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Caffrey CR, 2000, FEBS LETT, V466, P244, DOI 10.1016/S0014-5793(99)01798-6; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Chen JM, 1998, FEBS LETT, V441, P361, DOI 10.1016/S0014-5793(98)01574-9; Chen JM, 2001, BIOL CHEM, V382, P777, DOI 10.1515/BC.2001.093; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Chen JM, 2000, BIOCHEM J, V352, P327, DOI 10.1042/0264-6021:3520327; Choi SJ, 1999, J BIOL CHEM, V274, P27747, DOI 10.1074/jbc.274.39.27747; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; Dalton JP, 1995, PARASITOLOGY, V111, P575, DOI 10.1017/S0031182000077052; Dando PM, 1999, BIOCHEM J, V339, P743, DOI 10.1042/0264-6021:3390743; Ding SH, 1997, ARCH BIOCHEM BIOPHYS, V348, P403, DOI 10.1006/abbi.1997.0405; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Halfon S, 1998, FEBS LETT, V438, P114, DOI 10.1016/S0014-5793(98)01281-2; HARANISHIMURA I, 1993, PLANT CELL, V5, P1651, DOI 10.1105/tpc.5.11.1651; Hashimoto S, 1999, BLOOD, V94, P837, DOI 10.1182/blood.V94.3.837.413k02_837_844; Hashimoto S, 1999, BLOOD, V94, P845, DOI 10.1182/blood.V94.3.845.415k09_845_852; Hiraiwa N, 1999, FEBS LETT, V447, P213, DOI 10.1016/S0014-5793(99)00286-0; Inaba K, 2000, J EXP MED, V191, P927, DOI 10.1084/jem.191.6.927; Johansen HT, 1999, ANAL BIOCHEM, V273, P278, DOI 10.1006/abio.1999.4221; KAUFMAN RJ, 1978, J BIOL CHEM, V253, P5852; KEMBHAVI AA, 1993, ARCH BIOCHEM BIOPHYS, V303, P208, DOI 10.1006/abbi.1993.1274; KLINKERT MQ, 1989, MOL BIOCHEM PARASIT, V33, P113, DOI 10.1016/0166-6851(89)90025-X; Kuroyanagi M, 2002, PLANT CELL PHYSIOL, V43, P143, DOI 10.1093/pcp/pcf035; LaLonde JM, 1999, BIOCHEMISTRY-US, V38, P862, DOI 10.1021/bi9822271; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; Lennon-Dumenil AM, 2002, CURR OPIN IMMUNOL, V14, P15, DOI 10.1016/S0952-7915(01)00293-X; MACH L, 1994, J BIOL CHEM, V269, P13030; Manoury B, 2003, IMMUNITY, V18, P489, DOI 10.1016/S1074-7613(03)00085-2; Manoury B, 2002, NAT IMMUNOL, V3, P169, DOI 10.1038/ni754; Manoury B, 1998, NATURE, V396, P695, DOI 10.1038/25379; Mathieu MA, 2002, MOL BIOCHEM PARASIT, V121, P99, DOI 10.1016/S0166-6851(02)00026-9; Menard R, 1998, J BIOL CHEM, V273, P4478, DOI 10.1074/jbc.273.8.4478; Mikolajczyk J, 2003, J BIOL CHEM, V278, P10458, DOI 10.1074/jbc.M210564200; Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0; Podobnik M, 1997, J MOL BIOL, V271, P774, DOI 10.1006/jmbi.1997.1218; Quraishi O, 2001, J BIOL CHEM, V276, P8118, DOI 10.1074/jbc.M005851200; ROME LH, 1979, P NATL ACAD SCI USA, V76, P2331, DOI 10.1073/pnas.76.5.2331; Rozman J, 1999, FEBS LETT, V459, P358, DOI 10.1016/S0014-5793(99)01302-2; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sarandeses CS, 2003, J BIOL CHEM, V278, P13286, DOI 10.1074/jbc.M213005200; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; Shirahama-Noda K, 2003, J BIOL CHEM, V278, P33194, DOI 10.1074/jbc.M302742200; SHUTOV A D, 1982, Biokhimiya, V47, P814; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Villadangos JA, 2001, IMMUNITY, V14, P739, DOI 10.1016/S1074-7613(01)00148-0; Waizenegger IC, 2002, CURR BIOL, V12, P1368, DOI 10.1016/S0960-9822(02)01073-4; Yamada K, 1999, J BIOL CHEM, V274, P2563, DOI 10.1074/jbc.274.4.2563	56	138	139	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38980	38990		10.1074/jbc.M305930200	http://dx.doi.org/10.1074/jbc.M305930200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12860980	hybrid			2022-12-25	WOS:000185575100109
J	Blocker, D; Pohlmann, K; Haug, G; Bachmeyer, C; Benz, R; Aktories, K; Barth, H				Blocker, D; Pohlmann, K; Haug, G; Bachmeyer, C; Benz, R; Aktories, K; Barth, H			Clostridium botulinum C2 toxin - Low pH-induced pore formation is required for translocation of the enzyme component C2I into the cytosol of host cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTHRAX PROTECTIVE ANTIGEN; LIPID BILAYER-MEMBRANES; PERFRINGENS IOTA-TOXIN; CHANNEL FUNCTION; DELIVERY SYSTEM; BINARY TOXIN; ACTIN; PURIFICATION; INHIBITION; PROTEINS	The binary Clostridium botulinum C2 toxin consists of two individual proteins, the transport component C2II ( 80 kDa) and the enzyme component C2I, which ADP-ribosylates G-actin in the cytosol of cells. Trypsin-activated C2II (C2IIa) forms heptamers that bind to the cell receptor and mediate translocation of C2I from acidic endosomes into the cytosol of target cells. Here, we report that translocation of C2I across cell membranes is accompanied by pore formation of C2IIa. We used a radioactive rubidium release assay to detect C2IIa pores in the membranes of Chinese hamster ovary cells. Pore formation by C2IIa was dependent on the cellular C2 toxin receptor and an acidic pulse. Pores were formed when C2IIa was bound to cells at neutral pH and when cells were subsequently shifted to acidic medium ( pH less than or equal to 5.5), but no pores were detected when C2IIa was added to cells directly in acidic medium. Most likely, acidification induces a change from "pre-pore" to "pore" conformation of C2IIa, and formation of the pore conformation before membrane binding precludes insertion into membranes. When C2I was present during binding of C2IIa to cells prior to the acidification step, C2IIa-mediated rubidium release was decreased, suggesting that C2I interacted with the lumen of the C2IIa pore. A decrease of rubidium efflux was also detected when C2I was added to C2IIa-treated cells after the acidification step, suggesting that C2I interacted with C2IIa in its pore conformation. Moreover, C2I also interacted with C2IIa channels in artificial lipid membranes and blocked them partially. C2I was only translocated across the cell membrane when C2IIa plus C2I were bound to cells at neutral pH and subsequently shifted to acidic pH. When cell-bound C2IIa was exposed to acidic pH prior to C2I addition, only residual intoxication of cells was observed at high toxin concentrations, and binding of C2I to C2IIa was slightly decreased. Overall, C2IIa pores were essential but not sufficient for translocation of C2I. Intoxication of target cells with C2 toxin requires a strictly coordinated pH-dependent sequence of binding, pore formation by C2IIa, and translocation of C2I.	Univ Freiburg, Inst Expt, D-79104 Freiburg, Germany; Univ Freiburg, Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany; Univ Wurzburg, Biozentrum, Theodor Boveri Inst, D-97074 Wurzburg, Germany	University of Freiburg; University of Freiburg; University of Wurzburg	Barth, H (corresponding author), Univ Freiburg, Inst Expt, Albertstr 25,Otto Krayer Haus, D-79104 Freiburg, Germany.	Holger.Barth@pharmakol.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022; Barth, Holger/E-7920-2013	Aktories, Klaus/0000-0002-5397-0436; Benz, Roland/0000-0002-9510-9265				AKTORIES K, 1992, MOL MICROBIOL, V6, P2905, DOI 10.1111/j.1365-2958.1992.tb01749.x; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; Bachmeyer C, 2001, FASEB J, V15, P1658, DOI 10.1096/fj.00-0671fje; Barth H, 2000, J BIOL CHEM, V275, P18704, DOI 10.1074/jbc.M000596200; Barth H, 2002, N-S ARCH PHARMACOL, V366, P501, DOI 10.1007/s00210-002-0626-y; Barth H, 1998, J BIOL CHEM, V273, P29506, DOI 10.1074/jbc.273.45.29506; Barth H, 2002, J BIOL CHEM, V277, P5074, DOI 10.1074/jbc.M109167200; Barth H, 2001, J BIOL CHEM, V276, P10670, DOI 10.1074/jbc.M009445200; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; Eckhardt M, 2000, J BIOL CHEM, V275, P2328, DOI 10.1074/jbc.275.4.2328; FRITZ G, 1995, INFECT IMMUN, V63, P2334, DOI 10.1128/IAI.63.6.2334-2340.1995; Han S, 1999, NAT STRUCT BIOL, V6, P932, DOI 10.1038/13300; Haug G, 2003, J BIOL CHEM, V278, P32266, DOI 10.1074/jbc.M303980200; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Knapp O, 2002, J BIOL CHEM, V277, P6143, DOI 10.1074/jbc.M103939200; Leppla S. H., 1995, Bacterial toxins and virulence factors in disease., P543; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Mourez M, 2002, TRENDS MICROBIOL, V10, P287, DOI 10.1016/S0966-842X(02)02369-7; OHISHI I, 1990, J BIOCHEM-TOKYO, V107, P420, DOI 10.1093/oxfordjournals.jbchem.a123060; OHISHI I, 1987, INFECT IMMUN, V55, P1461, DOI 10.1128/IAI.55.6.1461-1465.1987; OHISHI I, 1980, INFECT IMMUN, V30, P668; Ohishi I, 2000, HANDB EXP PHARM, V145, P253; Olsnes S, 2000, HANDB EXP PHARM, V145, P1; PERELLE S, 1995, INFECT IMMUN, V63, P4967, DOI 10.1128/IAI.63.12.4967-4967.1995; POPOFF MR, 1988, INFECT IMMUN, V56, P2299, DOI 10.1128/IAI.56.9.2299-2306.1988; POPOFF MR, 1988, BIOCHEM BIOPH RES CO, V152, P1361, DOI 10.1016/S0006-291X(88)80435-2; SCHMID A, 1994, J BIOL CHEM, V269, P16706; Sellman BR, 2001, J BIOL CHEM, V276, P8371, DOI 10.1074/jbc.M008309200; SIMPSON LI, 1989, J PHARMACOL EXP THER, V251, P1223; STILES BG, 1986, INFECT IMMUN, V54, P683, DOI 10.1128/IAI.54.3.683-688.1986	32	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37360	37367		10.1074/jbc.M305849200	http://dx.doi.org/10.1074/jbc.M305849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869543	hybrid			2022-12-25	WOS:000185437200046
J	Georlette, D; Damien, B; Blaise, V; Depiereux, E; Uversky, VN; Gerday, C; Feller, G				Georlette, D; Damien, B; Blaise, V; Depiereux, E; Uversky, VN; Gerday, C; Feller, G			Structural and functional adaptations to extreme temperatures in psychrophilic, mesophilic, and thermophilic DNA ligases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD ADAPTATION; CONFORMATIONAL FLEXIBILITY; ALPHA-AMYLASE; IN-VITRO; STABILITY; PROTEINS; ENZYMES; EXTREMOPHILES; DEHYDROGENASE; FLUCTUATIONS	Psychrophiles, host of permanently cold habitats, display metabolic fluxes comparable to those exhibited by mesophilic organisms at moderate temperatures. These organisms have evolved by producing, among other peculiarities, cold-active enzymes that have the properties to cope with the reduction of chemical reaction rates induced by low temperatures. The emerging picture suggests that these enzymes display a high catalytic efficiency at low temperatures through an improved flexibility of the structural components involved in the catalytic cycle, whereas other protein regions, if not implicated in catalysis, may be even more rigid than their mesophilic counterparts. In return, the increased flexibility leads to a decreased stability of psychrophilic enzymes. In order to gain further advances in the analysis of the activity/flexibility/stability concept, psychrophilic, mesophilic, and thermophilic DNA ligases have been compared by three-dimensional-modeling studies, as well as regards their activity, surface hydrophobicity, structural permeability, conformational stabilities, and irreversible thermal unfolding. These data show that the cold-adapted DNA ligase is characterized by an increased activity at low and moderate temperatures, an overall destabilization of the molecular edifice, especially at the active site, and a high conformational flexibility. The opposite trend is observed in the mesophilic and thermophilic counterparts, the latter being characterized by a reduced low temperature activity, high stability and reduced flexibility. These results strongly suggest a complex relationship between activity, flexibility and stability. In addition, they also indicate that in cold-adapted enzymes, the driving force for denaturation is a large entropy change.	Univ Liege, Biochem Lab, Inst Chem B6, B-4000 Liege, Belgium; Fac Univ Notre Dame Paix, Dept Biol, Unite Biol Mol, B-5000 Namur, Belgium; Russian Acad Sci, Inst Biol Instrumentat, Pushchino 142290, Moscow Region, Russia; Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	University of Liege; University of Namur; Russian Academy of Sciences; University of California System; University of California Santa Cruz	Feller, G (corresponding author), Univ Liege, Biochem Lab, Inst Chem B6, B-4000 Liege, Belgium.	gfeller@ulg.ac.be	Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857				Blochl E, 1997, EXTREMOPHILES, V1, P14; Cavicchioli R, 2002, CURR OPIN BIOTECH, V13, P253, DOI 10.1016/S0958-1669(02)00317-8; Chakravarty S, 2002, BIOCHEMISTRY-US, V41, P8152, DOI 10.1021/bi025523t; Ciardiello MA, 2000, BBA-PROTEIN STRUCT M, V1543, P11, DOI 10.1016/S0167-4838(00)00186-2; Collins T, 2003, J MOL BIOL, V328, P419, DOI 10.1016/S0022-2836(03)00287-0; D'Amico S, 2003, J BIOL CHEM, V278, P7891, DOI 10.1074/jbc.M212508200; D'Amico S, 2002, PHILOS T R SOC B, V357, P917, DOI 10.1098/rstb.2002.1105; Deming JW, 2002, CURR OPIN MICROBIOL, V5, P301, DOI 10.1016/S1369-5274(02)00329-6; Demirjian DC, 2001, CURR OPIN CHEM BIOL, V5, P144, DOI 10.1016/S1367-5931(00)00183-6; Feller G, 1999, BIOCHEMISTRY-US, V38, P4613, DOI 10.1021/bi982650+; Fields PA, 1998, P NATL ACAD SCI USA, V95, P11476, DOI 10.1073/pnas.95.19.11476; Fields PA, 2001, COMP BIOCHEM PHYS A, V129, P417, DOI 10.1016/S1095-6433(00)00359-7; Fitter J, 2000, BIOPHYS J, V79, P1629, DOI 10.1016/S0006-3495(00)76413-7; Georlette D, 2000, EUR J BIOCHEM, V267, P3502, DOI 10.1046/j.1432-1327.2000.01377.x; Gerday C, 1997, BBA-PROTEIN STRUCT M, V1342, P119, DOI 10.1016/S0167-4838(97)00093-9; Goldberg, 1995, Fold Des, V1, P21; Hernandez G, 2000, P NATL ACAD SCI USA, V97, P3166, DOI 10.1073/pnas.040569697; Hochachka P.W., 1984, BIOCHEMICAL ADAPTATI, P355; Kumar S, 2002, BIOCHEMISTRY-US, V41, P5359, DOI 10.1021/bi012154c; Kumar S, 2001, PROTEINS, V43, P433, DOI 10.1002/prot.1056; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; Levy M, 1998, P NATL ACAD SCI USA, V95, P7933, DOI 10.1073/pnas.95.14.7933; Lonhienne T, 2000, BBA-PROTEIN STRUCT M, V1543, P1, DOI 10.1016/S0167-4838(00)00210-7; MATOUSCHEK A, 1994, PROTEIN ENG, V7, P1089, DOI 10.1093/protein/7.9.1089; Miyazaki K, 2000, J MOL BIOL, V297, P1015, DOI 10.1006/jmbi.2000.3612; Pace C N, 1986, Methods Enzymol, V131, P266; Russell N J, 1998, Adv Biochem Eng Biotechnol, V61, P1; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Siddiqui KS, 2002, EXTREMOPHILES, V6, P143, DOI 10.1007/s007920100237; Smalas A O, 2000, Biotechnol Annu Rev, V6, P1, DOI 10.1016/S1387-2656(00)06018-X; Sriskanda V, 1999, NUCLEIC ACIDS RES, V27, P3953, DOI 10.1093/nar/27.20.3953; Sriskanda V, 2002, J BIOL CHEM, V277, P9695, DOI 10.1074/jbc.M111164200; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Svingor A, 2001, J BIOL CHEM, V276, P28121, DOI 10.1074/jbc.M104432200; THORBJARNARDOTTIR SH, 1995, GENE, V161, P1, DOI 10.1016/0378-1119(95)00286-F; Timson DJ, 1999, J MOL BIOL, V285, P73, DOI 10.1006/jmbi.1998.2302; Vanhove M, 1997, BIOCHEM J, V321, P413, DOI 10.1042/bj3210413; Wintrode PL, 2000, J BIOL CHEM, V275, P31635, DOI 10.1074/jbc.M004503200	40	125	137	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37015	37023		10.1074/jbc.M305142200	http://dx.doi.org/10.1074/jbc.M305142200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857762	hybrid, Green Published			2022-12-25	WOS:000185437200007
J	Piri, N; Yamashita, CK; Shih, J; Akhmedov, NB; Farber, DB				Piri, N; Yamashita, CK; Shih, J; Akhmedov, NB; Farber, DB			Differential expression of rod photoreceptor cGMP-phosphodiesterase alpha and beta subunits - mRNA and protein levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; AUG INITIATOR CODON; GENE-EXPRESSION; RETINAL DEGENERATION; OUTER SEGMENTS; TRANSLATION; CELLS; TRANSCRIPTION; QUANTITATION; NUCLEOTIDES	The catalytic core of photoreceptor-specific cGMP-phosphodiesterase (PDE) consists of two subunits, PDEalpha and PDEbeta, that are homologous and have similar domain organization but are encoded by different genes. We have examined the PDEalpha and PDEbeta mRNA steady-state and protein levels as well as the biosynthesis rate of these proteins in developing and fully differentiated retinas. We have also determined the translational efficiency of PDE subunits and the role of their mRNA structures in regulating protein synthesis. In mature retinas, PDEalpha and PDEbeta are represented by similar to1.5 x 10(8) and 7.5 x 10(8) copies/mug retinal mRNA, respectively. The levels of these transcripts in developing photoreceptors (P10) are approximately 75% of those at P30. Quantification of protein concentration indicated that PDEalpha and PDEbeta are equally expressed in developing and fully differentiated photoreceptors. Furthermore, the PDEalpha/PDEbeta ratios obtained throughout a 2-h pulse-chase period revealed a similar turnover rate for both subunits. The observed discordance between the mRNA and protein levels of PDEalpha and PDEbeta suggested post-transcriptional regulation of their expression. We found that PDEalpha mRNA is translated more efficiently than either of the two PDEbeta transcripts expressed in retina. Therefore, the lower level of PDEalpha mRNA is compensated by its more efficient translation to achieve equimolar expression with PDEbeta. We also analyzed the effect of PDEalpha and PDEbeta mRNA 5'- and 3'-untranslated regions as well as that of their coding regions on protein synthesis. We determined that the PDE-coding regions play a critical role in the differential translation of these subunits.	Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Piri, N (corresponding author), Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA.	piri@jsei.ucla.edu; farber@jsei.ucla.edu		Farber, Debora/0000-0002-3207-697X	NEI NIH HHS [EY02651] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY002651, R01EY002651] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Artemyev NO, 1996, J BIOL CHEM, V271, P25382, DOI 10.1074/jbc.271.41.25382; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Day DA, 1998, J ENDOCRINOL, V157, P361, DOI 10.1677/joe.0.1570361; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; DiPolo A, 1996, INVEST OPHTH VIS SCI, V37, P551; DIPOLO A, 1995, P NATL ACAD SCI USA, V92, P4016, DOI 10.1073/pnas.92.9.4016; FARBER DB, 1988, EXP EYE RES, V46, P363, DOI 10.1016/S0014-4835(88)80026-5; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; JANSEN M, 1995, PEDIATR RES, V37, P681, DOI 10.1203/00006450-199506000-00001; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P7134, DOI 10.1073/pnas.92.15.7134; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lerner LE, 2002, J BIOL CHEM, V277, P25877, DOI 10.1074/jbc.M201407200; Lerner LE, 2001, J BIOL CHEM, V276, P34999, DOI 10.1074/jbc.M103301200; LIEBHABER SA, 1992, J MOL BIOL, V226, P609, DOI 10.1016/0022-2836(92)90619-U; MENZO S, 1992, J CLIN MICROBIOL, V30, P1752, DOI 10.1128/JCM.30.7.1752-1757.1992; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Phelan JK, 2000, EXP EYE RES, V71, P119, DOI 10.1006/exer.2000.0861; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; RIEDY MC, 1995, BIOTECHNIQUES, V18, P70; STROOP SD, 1992, ADV SEC MESS PHOSPH, V25, P55; Stuart JJ, 2000, BIOCHEM BIOPH RES CO, V274, P641, DOI 10.1006/bbrc.2000.3189; THEODORAKIS NG, 1988, J BIOL CHEM, V263, P14579; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsang SH, 1996, SCIENCE, V272, P1026, DOI 10.1126/science.272.5264.1026; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4	37	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					36999	37005		10.1074/jbc.M303710200	http://dx.doi.org/10.1074/jbc.M303710200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871955	hybrid			2022-12-25	WOS:000185437200005
J	Chong, HR; Guan, KL				Chong, HR; Guan, KL			Regulation of Raf through phosphorylation and N terminus-C terminus interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL-ACTIVITY; V-RAF; ACTIVATION; PROTEIN; MEMBRANE; DEFINITION; ONCOGENE; DELETION; DOMAIN; PAK1	Raf kinase is a key component in regulating the MAPK pathway. B-Raf has been reported as an oncogene and is mutated in 60% of human melanomas. The main focus of Raf regulation studies has been on phosphorylation, dephosphorylation, and scaffolding proteins; however, Raf also has its own auto-regulatory domain. Removal of the N-terminal regulatory domain, initially discovered in the viral Raf oncogene (v-Raf), results in a kinase domain with high basal activity independent of Ras activation. In this report, we show that activating phosphorylations are still required for activity of the truncated C-terminal kinase domain (called 22W). The interaction between the N-terminal regulatory domain and the C-terminal kinase domain is disrupted by activated Ras. Mutations in the Ras binding domain, cysteine-rich domain, or S259A do not affect the inhibition of 22W by the N-terminal domain. When phosphomimetic residues are substituted at the activating sites (DDED) in 22W, this results in a higher basal activity that is no longer inhibited by expression of the N-terminal domain, although binding to the N-terminal domain still occurs. Although the interaction between 22W/DDED and the N-terminal domain may be in a different conformation, the interaction is still disrupted by activated Ras. These data demonstrate that N-terminal domain binding to the kinase domain inhibits the activity of the kinase domain. However, this inhibition is relieved when the C-terminal kinase domain is activated by phosphorylation.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guan, KL (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.	kunliang@umich.edu		Kopera, Huira/0000-0002-8347-5567	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000114] Funding Source: NIH RePORTER; NIA NIH HHS [T32-AG00114-18] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07544] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mineo C, 1997, J BIOL CHEM, V272, P10345; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	30	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36269	36276		10.1074/jbc.M212803200	http://dx.doi.org/10.1074/jbc.M212803200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12865432	hybrid			2022-12-25	WOS:000185318300050
J	Zhuang, SG; Ouedraogo, GD; Kochevar, IE				Zhuang, SG; Ouedraogo, GD; Kochevar, IE			Downregulation of epidermal growth factor receptor signaling by singlet oxygen through activation of caspase-3 and protein phosphatases	ONCOGENE			English	Article						apoptosis; epidermal growth factor receptor; caspase; keratinocyte; protein phosphatase; singlet oxygen	RABBIT SKELETAL-MUSCLE; REVERSIBLE INACTIVATION; ULTRAVIOLET-LIGHT; OXIDATIVE STRESS; EGF RECEPTOR; APOPTOSIS; CLEAVAGE; INHIBITION; INDUCTION; ACID	Downregulation of survival signaling pathways contributes to the cytotoxicity of reactive oxygen species (ROS) and may underlie certain therapies for hyperproliferative diseases. We have investigated the role of singlet oxygen, an ROS formed by photosensitization, in the regulation of survival signaling via the epidermal growth factor receptor (EGFR). Exposure of human keratinocytes to singlet oxygen resulted in rapid loss of EGFR, which was not blocked by either inhibition of receptor internalization or by interrupting the major proteolytic pathways (proteasome, lysosome or calpain). However, pretreatment with a caspase-3 inhibitor, DEVD-FMK, inhibited EGFR degradation. Caspase-3 cleavage was detected as early as 5 min after singlet oxygen treatment, and recombinant active caspase-3 completely cleaved EGFR in a keratinocyte membrane fraction. The singlet oxygen-induced loss of EGFR was accompanied by dephosphorylation of EGFR as well as of Akt and extracellular signal-regulated kinase 1/2 (ERK)1/2. Singlet oxygen-induced protein dephosphorylation was not dependent on activation of caspase-3. In contrast, inhibition of protein phosphatases (PPs) with okadaic acid completely blocked dephosphorylation of EGFR, ERK1/2 and Akt as well as degradation of EGFR. These results indicate that the oxidative stress produced by singlet oxygen rapidly disrupts EGFR-mediated signaling by decreasing both the protein level and its phosphorylation. These responses depended on intertwined activation of caspase-3 and PPs.	Harvard Univ, Sch Med, Wellman Labs Photomed, Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Kochevar, IE (corresponding author), Harvard Univ, Sch Med, Wellman Labs Photomed, Massachusetts Gen Hosp, WEL-224,55 Fruit St, Boston, MA 02114 USA.	kochevar@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030755] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30755] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad N, 2001, ONCOGENE, V20, P2314, DOI 10.1038/sj.onc.1204313; An B, 1996, FEBS LETT, V399, P158, DOI 10.1016/S0014-5793(96)01311-7; Authier F, 1999, J BIOL CHEM, V274, P33723, DOI 10.1074/jbc.274.47.33723; Bae SS, 2001, FEBS LETT, V491, P16, DOI 10.1016/S0014-5793(01)02167-6; BAKER A, 1992, PHOTOCHEM PHOTOBIOL, V55, P523, DOI 10.1111/j.1751-1097.1992.tb04273.x; BARSAGI D, 1988, J CELL BIOL, V106, P1649, DOI 10.1083/jcb.106.5.1649; Boulougouris P, 2001, ANTICANCER RES, V21, P2769; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CAYLA X, 1994, J BIOL CHEM, V269, P15668; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Fladmark KE, 1999, CELL DEATH DIFFER, V6, P1099, DOI 10.1038/sj.cdd.4400590; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GREGORIOU M, 1994, EUR J BIOCHEM, V223, P455, DOI 10.1111/j.1432-1033.1994.tb19013.x; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Hunter I, 2001, J BONE MINER RES, V16, P466, DOI 10.1359/jbmr.2001.16.3.466; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kamata H, 2000, EUR J BIOCHEM, V267, P1933, DOI 10.1046/j.1432-1327.2000.01194.x; KATOH S, 1994, BIOL PHARM BULL, V17, P1003; Kessel D, 2001, PHOTOCHEM PHOTOBIOL, V74, P318, DOI 10.1562/0031-8655(2001)074<0318:ETBITT>2.0.CO;2; Kidd VJ, 2000, SEMIN CELL DEV BIOL, V11, P191, DOI 10.1006/scdb.2000.0165; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; KRUEGER JG, 1990, J INVEST DERMATOL, V94, pS135, DOI 10.1111/1523-1747.ep12876121; LASKIN JD, 1986, P NATL ACAD SCI USA, V83, P8211, DOI 10.1073/pnas.83.21.8211; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; Lin CP, 2000, EXP CELL RES, V259, P351, DOI 10.1006/excr.2000.4979; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; Maziere C, 2001, BIOCHEM BIOPH RES CO, V281, P289, DOI 10.1006/bbrc.2001.4348; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; Posmantur R, 1997, J NEUROCHEM, V68, P2328; Ravid T, 2002, J BIOL CHEM, V277, P31214, DOI 10.1074/jbc.M204677200; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Scheving LA, 1998, AM J PHYSIOL-CELL PH, V274, pC1363, DOI 10.1152/ajpcell.1998.274.5.C1363; Schutze S, 1999, J BIOL CHEM, V274, P10203, DOI 10.1074/jbc.274.15.10203; Separovic D, 1998, PHOTOCHEM PHOTOBIOL, V68, P101, DOI 10.1111/j.1751-1097.1998.tb03259.x; SILBERMAN SR, 1984, J BIOL CHEM, V259, P2913; SONG QZ, 1993, BIOCHEM BIOPH RES CO, V190, P47, DOI 10.1006/bbrc.1993.1009; Spizz G, 1997, J BIOL CHEM, V272, P23833, DOI 10.1074/jbc.272.38.23833; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1046/j.1365-2613.2000.00169.x; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Yarden Y, 2001, EUR J CANCER, V37, pS3; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200; Zhuang SG, 1999, EXP CELL RES, V250, P203, DOI 10.1006/excr.1999.4501	60	41	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4413	4424		10.1038/sj.onc.1206604	http://dx.doi.org/10.1038/sj.onc.1206604			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853978				2022-12-25	WOS:000183978900011
J	Hernandez, AI; Blace, N; Crary, JF; Serrano, PA; Leitges, M; Libien, JM; Weinstein, G; Tcherapanov, A; Sacktor, TC				Hernandez, AI; Blace, N; Crary, JF; Serrano, PA; Leitges, M; Libien, JM; Weinstein, G; Tcherapanov, A; Sacktor, TC			Protein kinase M zeta synthesis from a brain mRNA encoding an independent protein kinase C zeta catalytic domain - Implications for the molecular mechanism of memory	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; RAT-BRAIN; SYNAPTIC PLASTICITY; POLYMERASE-II; PKC-ZETA; EXPRESSION; ISOFORM; ACTIVATION; GENE; MAINTENANCE	Protein kinase Mzeta (PKMzeta) is a newly described form of PKC that is necessary and sufficient for the maintenance of hippocampal long term potentiation (LTP) and the persistence of memory in Drosophila. PKMzeta is the independent catalytic domain of the atypical PKCzeta isoform and produces long term effects at synapses because it is persistently active, lacking autoinhibition from the regulatory domain of PKCzeta. PKM has been thought of as a proteolytic fragment of PKC. Here we report that brain PKMzeta is a new PKC isoform, synthesized from a PKMzeta mRNA encoding a PKCzeta catalytic domain without a regulatory domain. Multiple zeta-specific antisera show that PKMzeta is expressed in rat forebrain as the major form of zeta in the near absence of full-length PKCzeta. A PKCzeta knockout mouse, in which the regulatory domain was disrupted and catalytic domain spared, still expresses brain PKMzeta, indicating that this form of PKM is not a PKCzeta proteolytic fragment. Furthermore, the distribution of brain PKMzeta does not correlate with PKCzeta mRNA but instead with an alternate zeta RNA transcript thought incapable of producing protein. In vitro translation of this RNA, however, generates PKMzeta of the same molecular weight as that in brain. Metabolic labeling of hippocampal slices shows increased de novo synthesis of PKMzeta in LTP. Because PKMzeta is a kinase synthesized in an autonomously active form and is necessary and sufficient for maintaining LTP, it serves as an example of a link coupling gene expression directly to synaptic plasticity.	SUNY Downstate Med Ctr, Dept Pharmacol, Brooklyn, NY 11203 USA; SUNY Downstate Med Ctr, Dept Physiol, Brooklyn, NY 11203 USA; SUNY Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA; SUNY Downstate Med Ctr, Grad Program Neural & Behav Sci, Brooklyn, NY 11203 USA; Max Planck Inst Expt Endokrinol, D-30625 Hannover, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Max Planck Society	Sacktor, TC (corresponding author), SUNY Downstate Med Ctr, Dept Pharmacol, Box 29,450 Clarkson Ave, Brooklyn, NY 11203 USA.		Leitges, Michael/AAN-1953-2021	Leitges, Michael/0000-0003-4203-6995; Blace, Nancy/0000-0002-6174-6004; Libien, Jenny/0000-0001-6291-4391	NIMH NIH HHS [MH53576, MH057068] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053576, R01MH057068, R29MH053576] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ANDREA JE, 1995, BIOCHEM J, V310, P835, DOI 10.1042/bj3100835; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; Drier EA, 2002, NAT NEUROSCI, V5, P316, DOI 10.1038/nn820; Dyer JR, 2003, NAT NEUROSCI, V6, P219, DOI 10.1038/nn1018; Farese RV, 2002, AM J PHYSIOL-ENDOC M, V283, pE1, DOI 10.1152/ajpendo.00045.2002; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; Grunbaum L, 1998, J NEUROSCI, V18, P4384; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; KIKKAWA U, 1987, FEBS LETT, V223, P212, DOI 10.1016/0014-5793(87)80291-0; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; Klann E, 1999, PROG NEURO-PSYCHOPH, V23, P359, DOI 10.1016/S0278-5846(99)00002-0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAND M, 1994, J BIOL CHEM, V269, P14820; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Ling DSF, 2002, NAT NEUROSCI, V5, P295, DOI 10.1038/nn829; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; Marshall BS, 2000, DNA CELL BIOL, V19, P707, DOI 10.1089/104454900750058071; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; MARUYAMA K, 1994, GENE, V138, P171; Merlo E, 2002, NEUROSCIENCE, V112, P161, DOI 10.1016/S0306-4522(02)00049-0; Naik MU, 2000, J COMP NEUROL, V426, P243, DOI 10.1002/1096-9861(20001016)426:2<243::AID-CNE6>3.0.CO;2-8; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Niino YS, 2001, J BIOL CHEM, V276, P36711, DOI 10.1074/jbc.M104348200; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; Osten P, 1996, J NEUROSCI, V16, P2444; Otmakhov N, 1997, J NEUROSCI, V17, P5357; POWELL CM, 1994, J BIOL CHEM, V269, P27958; POWELL CT, 1994, CELL GROWTH DIFFER, V5, P143; Roberson ED, 1999, LEARN MEMORY, V6, P381; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; Sanes JR, 1999, NAT NEUROSCI, V2, P597, DOI 10.1038/10154; SCHWARTZ JH, 1993, P NATL ACAD SCI USA, V90, P8310, DOI 10.1073/pnas.90.18.8310; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SUBLETTE E, 1993, NEUROSCI LETT, V159, P175, DOI 10.1016/0304-3940(93)90827-8; Suzuki Y, 2000, GENOMICS, V64, P286, DOI 10.1006/geno.2000.6076; Suzuki Y, 2001, EMBO REP, V2, P388, DOI 10.1093/embo-reports/kve085; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; VANDERKLISH P, 1995, MOL BRAIN RES, V32, P25, DOI 10.1016/0169-328X(95)00057-Y; Wooten MW, 2000, MOL CELL BIOL, V20, P4494, DOI 10.1128/MCB.20.13.4494-4504.2000; Yeh SH, 2002, J BIOL CHEM, V277, P46720, DOI 10.1074/jbc.M206258200; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; ZHOU GS, 1994, EXP CELL RES, V214, P1, DOI 10.1006/excr.1994.1227	53	216	229	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40305	40316		10.1074/jbc.M307065200	http://dx.doi.org/10.1074/jbc.M307065200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12857744	hybrid			2022-12-25	WOS:000185713800123
J	Xu, DZ; Kyriakis, JM				Xu, DZ; Kyriakis, JM			Phosphatidylinositol 3 '-kinase-dependent activation of renal mesangial cell Ki-Ras and ERK by advanced glycation end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; SIGNALING PATHWAYS; RECEPTOR; STRESS; RAGE; INDUCTION; GROWTH; DOMAIN	Advanced glycation end products (AGEs) are produced by the non-enzymatic glycation of proteins and lipids. AGE levels are pathologically elevated in a number of inflammatory diseases and in diabetes mellitus. There is evidence that AGEs, acting through the receptor for AGEs, contribute to diabetic complications. Nephropathy is a major complication of diabetes mellitus. However, the initiating molecular events that trigger diabetic renal disease are unknown. Renal mesangial cells produce excess extracellular matrix in response to treatment with transforming growth factor-beta, and excess mesangial cell matrix production, by impairing glomerular filtration, contributes to diabetic nephropathy. AGEs are known to trigger the autocrine production and release of transforming growth factor-beta. However, it is unclear how AGEs signal in mesangial cells. Here we show that treatment of mesangial cells with AGEs and with the receptor for AGEs agonist S100 triggers activation of the extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3'-kinase (PI3K) pathways. AGEs trigger the GTP loading of mesangial cell Ras, and AGE activation of ERK requires Ras. We observe that Ki-Ras, but not Ha-Ras, is the target of AGE action. Surprisingly, inhibition of PI3K blocks both ERK and Ki-Ras activation. We also observe that activation of ERK and the PI3K target kinase protein kinase-B is blocked with free radical scavengers, indicating a role for reactive oxygen species in AGE recruitment of PI3K. Thus, AGEs signal to Ki-Ras and ERK through reactive oxygen species-dependent activation of PI3K.	Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Kyriakis, JM (corresponding author), Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, 750 Washington St,Box 8486, Boston, MA 02111 USA.	jkyriakis@tufts-nemc.org		Xu, Dazhong/0000-0001-9264-3342	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK062680, R01DK041513] Funding Source: NIH RePORTER; NIDDK NIH HHS [R02-DK41513, F32-DK62680] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bar-Sagi D, 2001, MOL CELL BIOL, V21, P1441, DOI 10.1128/MCB.21.5.1441-1443.2001; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chen S, 2001, KIDNEY INT, V59, P673, DOI 10.1046/j.1523-1755.2001.059002673.x; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Esposito F, 2003, J BIOL CHEM, V278, P20828, DOI 10.1074/jbc.M211841200; Goruppi S, 2002, EMBO J, V21, P5427, DOI 10.1093/emboj/cdf535; GREWAL IS, 1999, AM J PHYSIOL, V276, pF922; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Heidland A, 2001, AM J KIDNEY DIS, V38, pS100, DOI 10.1053/ajkd.2001.27414; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Huang JS, 1999, BIOCHEM J, V342, P231, DOI 10.1042/0264-6021:3420231; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Jacob A, 2002, J BIOL CHEM, V277, P23420, DOI 10.1074/jbc.M202485200; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; KREISBERG JI, 1986, AM J PHYSIOL, V251, pC505, DOI 10.1152/ajpcell.1986.251.4.C505; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 2000, FR MOLEC B, V29, P40; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; O'Neill LA, 2000, SCI STKE; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Wautier JL, 2001, DIABETES METAB, V27, P535; Wautier MP, 2001, AM J PHYSIOL-ENDOC M, V280, pE685, DOI 10.1152/ajpendo.2001.280.5.E685; Wolf G, 1999, KIDNEY INT, V56, P393, DOI 10.1046/j.1523-1755.1999.00590.x; Yamagishi S, 2001, CONTRIB NEPHROL, V134, P30; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004	38	50	52	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39349	39355		10.1074/jbc.M302771200	http://dx.doi.org/10.1074/jbc.M302771200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12871951	hybrid			2022-12-25	WOS:000185713800012
J	Kanamori, M; Sandy, P; Marzinotto, S; Benetti, R; Kai, C; Hayashizaki, Y; Schneider, C; Suzuki, H				Kanamori, M; Sandy, P; Marzinotto, S; Benetti, R; Kai, C; Hayashizaki, Y; Schneider, C; Suzuki, H			The PDZ protein tax-interacting protein-1 inhibits beta-catenin transcriptional activity and growth of colorectal cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL MODULES; C-TERMINUS; COMPLEX; DOMAIN; ICAT; ACTIVATION; NUCLEUS; BINDING; ARREST; APC	Wnt signaling is essential during development while deregulation of this pathway frequently leads to the formation of various tumors including colorectal carcinomas. A key component of the pathway is beta-catenin that, in association with TCF-4, directly regulates the expression of Wnt-responsive genes. To identify novel binding partners of beta-catenin that may control its transcriptional activity, we performed a mammalian two-hybrid screen and isolated the Tax-interacting protein (TIP-1). The in vivo complex formation between beta-catenin and TIP-1 was verified by coimmunoprecipitation, and a direct physical association was revealed by glutathione S-transferase pull-down experiments in vitro. By using a panel of deletion mutants of both proteins, we demonstrate that the interaction is mediated by the PDZ (PSD-95/DLG/ZO-1 homology) domain of TIP-1 and requires primarily the last four amino acids of beta-catenin. TIP-1 overexpression resulted in a dose-dependent decrease in the transcriptional activity of beta-catenin when tested on the TOP/FOPFLASH reporter system. Conversely, siRNA-mediated knock-down of endogenous TIP-1 slightly increased endogenous beta-catenin transactivation function. Moreover, we show that overexpression of TIP-1 reduced the proliferation and anchorage-independent growth of colorectal cancer cells. These data suggest that TIP-1 may represent a novel regulatory element in the Wnt/beta-catenin signaling pathway.	RIKEN, Genom Sci Ctr, Lab Genome Explorat Res Grp, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; RIKEN, Genome Sci Lab, Wako, Saitama 3510198, Japan; Lab Nazl Concorzio Interuniv Biotecnol, I-34012 Trieste, Italy	RIKEN; RIKEN	Suzuki, H (corresponding author), RIKEN, Genom Sci Ctr, Lab Genome Explorat Res Grp, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.		Hayashizaki, Yoshihide/N-6590-2015; Suzuki, Harukazu/N-9553-2015	Suzuki, Harukazu/0000-0002-8087-0836; BENETTI, Roberta/0000-0001-8863-0821				BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Bienz M, 2003, NAT CELL BIOL, V5, P179, DOI 10.1038/ncb0303-179; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Daniels DL, 2002, MOL CELL, V10, P573, DOI 10.1016/S1097-2765(02)00631-7; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; Harris BZ, 2001, J CELL SCI, V114, P3219; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kanamori M, 2002, FEBS LETT, V532, P241, DOI 10.1016/S0014-5793(02)03688-8; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Monte M, 2003, J BIOL CHEM, V278, P30356, DOI 10.1074/jbc.M302902200; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Olalla L, 2002, J BIOL CHEM, V277, P38939, DOI 10.1074/jbc.C200373200; Olalla L, 2001, FEBS LETT, V488, P116, DOI 10.1016/S0014-5793(00)02373-5; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Perego C, 2000, EMBO J, V19, P3978, DOI 10.1093/emboj/19.15.3978; Polakis P, 2000, GENE DEV, V14, P1837; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; Riefler GM, 2001, J BIOL CHEM, V276, P48262, DOI 10.1074/jbc.M106503200; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Sandy P, 2000, ONCOGENE, V19, P188, DOI 10.1038/sj.onc.1203250; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Sekiya T, 2002, CANCER RES, V62, P3322; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Suzuki H, 2001, GENOME RES, V11, P1758, DOI 10.1101/gr.180101; Tago K, 2000, GENE DEV, V14, P1741; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Traweger A, 2003, J BIOL CHEM, V278, P2692, DOI 10.1074/jbc.M206821200	40	63	75	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38758	38764		10.1074/jbc.M306324200	http://dx.doi.org/10.1074/jbc.M306324200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874278	hybrid			2022-12-25	WOS:000185575100082
J	Longobardi, E; Blasi, F				Longobardi, E; Blasi, F			Overexpression of PREP-1 in F9 teratocarcinoma cells leads to a functionally relevant increase of PBX-2 by preventing its degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOPERATIVE DNA-BINDING; NUCLEAR-LOCALIZATION; HOMEODOMAIN PROTEINS; HOMEOBOX GENES; RETINOIC ACID; HOX; HINDBRAIN; EXTRADENTICLE; HOMOTHORAX; FAMILY	To bind DNA and to be retained in the nucleus, PBX proteins must form heterodimeric complexes with members of the MEINOX family. Therefore the balance between PBX and MEINOX must be an important regulatory feature. We show that overexpression of PREP-1 influences the level of PBX-2 protein maintaining the PREP-1-PBX balance. This effect has important functional consequences. F9 teratocarcinoma cells stably transfected with PREP-1 had an increased DNA binding activity to a PREP-PBX-responsive element. Because PREP-1 binds DNA efficiently only when dimerized to PBX, the increased DNA binding activity suggests that the level of PBX might also have increased. Indeed PREP-1-overexpressing cells had a higher level of PBX-2 and PBX-1b proteins. PBX-2 increase did not depend on increased mRNA level or a higher rate of translation but rather because of a protein stabilization process. Indeed, PBX-2 level drastically decreased after 3 h of cycloheximide treatment in control but not in PREP-1-overexpressing cells and the proteasome inhibitor MG132 prevented PBX-2 decay in control cells. Hence, dimerization with PREP-1 appears to decrease proteasomal degradation of PBX-2. Retinoic acid induces differentiation of F9 teratocarcinoma cells with a cascade synthesis of HOX proteins. In PREP-1-overexpressing cells, HOXb1 induction was more sustained (3 days versus 1 day) and the induced level of MEIS-1b, another TALE (three amino acid loop extension) protein involved in embryonal development, was higher. Thus an increase in PREP-1 leads to changes in the fate-determining HOXb1 and has therefore important functional consequences.	Univ Vita Salute San Raffaele, Dept Mol Biol & Funct Genom, Mol Genet Unit, I-20132 Milan, Italy; DIBIT, I-20132 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); Vita-Salute San Raffaele University	Blasi, F (corresponding author), Univ Vita Salute San Raffaele, Dept Mol Biol & Funct Genom, Mol Genet Unit, Via Olgettina 58, I-20132 Milan, Italy.	blasi.francesco@hsr.it		Blasi, Francesco/0000-0001-9406-1784	Telethon [GGP02031] Funding Source: Medline	Telethon(Fondazione Telethon)		Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; Berthelsen J, 1998, GENOMICS, V47, P323, DOI 10.1006/geno.1997.5086; Berthelsen J, 1996, J BIOL CHEM, V271, P3822; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Calvo KR, 1999, ONCOGENE, V18, P8033, DOI 10.1038/sj.onc.1203377; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chen HM, 1997, GENOMICS, V41, P193, DOI 10.1006/geno.1997.4632; Dibner C, 2001, DEVELOPMENT, V128, P3415; DiMartino JF, 2001, BLOOD, V98, P618, DOI 10.1182/blood.V98.3.618; Ferretti E, 2000, DEVELOPMENT, V127, P155; Fognani C, 2002, NUCLEIC ACIDS RES, V30, P2043, DOI 10.1093/nar/30.9.2043; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Jaw TJ, 2000, MECH DEVELOP, V91, P279, DOI 10.1016/S0925-4773(99)00316-0; Kilstrup-Nielsen C, 2003, EMBO J, V22, P89, DOI 10.1093/emboj/cdg010; Kim SK, 2002, NAT GENET, V30, P430, DOI 10.1038/ng860; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Knoepfler PS, 1997, MECH DEVELOP, V63, P5, DOI 10.1016/S0925-4773(97)00669-2; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kurant E, 1998, DEVELOPMENT, V125, P1037; Kurant E, 2001, GENETICS, V157, P689; Lin L, 1996, MOL CELL BIOL, V16, P2248; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Moens CB, 2002, DEV DYNAM, V224, P1, DOI 10.1002/dvdy.10086; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; PSPPERL H, 2000, MOL CELL, V6, P255; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; Salzberg A, 1999, MECH DEVELOP, V80, P3, DOI 10.1016/S0925-4773(98)00187-7; Sanchez-Font MF, 2003, NUCLEIC ACIDS RES, V31, P2769, DOI 10.1093/nar/gkg396; Selleri L, 2001, DEVELOPMENT, V128, P3543; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Steeman S, 1997, GENOME RES, V7, P142, DOI 10.1101/gr.7.2.142; Studer M, 1996, NATURE, V384, P630, DOI 10.1038/384630a0; Studer M, 1998, DEVELOPMENT, V125, P1025; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Vlachakis N, 2001, DEVELOPMENT, V128, P1299; Wagner K, 2001, MECH DEVELOP, V103, P127, DOI 10.1016/S0925-4773(01)00349-5; Waskiewicz AJ, 2001, DEVELOPMENT, V128, P4139; Waskiewicz AJ, 2002, DEV CELL, V3, P723, DOI 10.1016/S1534-5807(02)00319-2	49	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39235	39241		10.1074/jbc.M304704200	http://dx.doi.org/10.1074/jbc.M304704200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871956	hybrid			2022-12-25	WOS:000185575100138
J	Yoo, YG; Oh, SH; Park, ES; Cho, H; Lee, N; Park, H; Kim, DK; Yu, DY; Seong, JK; Lee, MO				Yoo, YG; Oh, SH; Park, ES; Cho, H; Lee, N; Park, H; Kim, DK; Yu, DY; Seong, JK; Lee, MO			Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1 alpha through activation of mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HEPATOCELLULAR-CARCINOMA; FACTOR 1-ALPHA; HBX PROTEIN; FACTOR GENE; SIGNAL-TRANSDUCTION; TUMOR ANGIOGENESIS; INDUCED EXPRESSION; DNA-BINDING; ALPHA	Hepatitis B virus X protein (HBx) of the hepatitis B virus was strongly implicated in angiogenesis and metastasis during hepatocarcinogenesis. Here, we explored the possibility of cross-talk between HBx and hypoxia-inducible factor-1alpha (HIF-1alpha), a potent transcriptional inducer of angiogenic factors. First, we showed that stability of HIF-1alpha protein was increased by HBx in HBx-inducible Chang liver cells as well as in transient HBx expression system of non-hepatic cells. Immunofluorescence studies revealed that the HBx-induced HIF-1alpha was partially translocated into the nucleus in majority of cells while additional CoCl2-induced hypoxic condition caused complete nuclear translocation. Second, HBx induced both phosphorylation of HIF-1alpha and activation of p42/p44 mitogen-activated protein kinases (MAPKs), which were synergistically enhanced in the presence of CoCl2. Furthermore, HBx enhanced transcriptional activity of HIF-1alpha in the reporter genes encoding hypoxia response element or VEGF promoter. Either treatment of MEK inhibitor PD98059 or coexpression of dominant-negative MAPK mutants abolished the HBx-induced transcriptional activity and protein stability as well as nuclear translocation of HIF-1alpha, suggesting that HBx activates HIF-1alpha through MAPK pathway. Third, the association of HIF-1alpha with von Hippel-Lindau was decreased but the association with CREB-binding protein was enhanced in the presence of HBx, suggesting the molecular mechanism by which HBx enhances the protein stability and transactivation function of HIF-1alpha. Finally, we demonstrated that expression of HIF-1alpha and vascular endothelial growth factor was increased in the liver of HBx-transgenic mice, suggesting that the cross-talk between HIF-1alpha and HBx may lead to transcriptional activation of HIF-1alpha target genes, which play a critical role in hepatocarcinogenesis.	Seoul Natl Univ, Coll Vet Med, Lab Dev Biol & Genom, Seoul 150742, South Korea; Sejong Univ, Dept Biosci & Biotechnol, Seoul 140747, South Korea; Ajou Univ, Coll Med, Dept Biochem, Suwon 442749, South Korea; Univ Seoul, Dept Life Sci, Seoul 130743, South Korea; Chung Ang Univ, Coll Pharm, Seoul 156756, South Korea; Korea Res Inst Biosci & Biotechnol, Taejon 305600, South Korea	Seoul National University (SNU); Sejong University; Ajou University; University of Seoul; Chung Ang University; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Seong, JK (corresponding author), Seoul Natl Univ, Coll Vet Med, Lab Dev Biol & Genom, Seoul 150742, South Korea.	snumouse@snu.ac.kr; molee@sejong.ac.kr						Bae MH, 1998, CANCER LETT, V128, P41, DOI 10.1016/S0304-3835(98)00044-5; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Blancher C, 1998, CANCER METAST REV, V17, P187, DOI 10.1023/A:1006002419244; Catalano A, 2002, ONCOGENE, V21, P2896, DOI 10.1038/sj.onc.1205382; Cho S, 2001, FEBS LETT, V498, P62, DOI 10.1016/S0014-5793(01)02499-1; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cromlish JA, 1996, TRENDS MICROBIOL, V4, P270, DOI 10.1016/0966-842X(96)10046-9; Dachs GU, 2000, EUR J CANCER, V36, P1649, DOI 10.1016/S0959-8049(00)00159-3; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; KIM KW, 1998, CANCER RES, V58, P48; Kim YB, 2001, HISTOPATHOLOGY, V38, P160, DOI 10.1046/j.1365-2559.2001.01064.x; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lara-Pezzi E, 2001, HEPATOLOGY, V33, P1270, DOI 10.1053/jhep.2001.1270; Lara-Pezzi E, 2001, J HEPATOL, V34, P409, DOI 10.1016/S0168-8278(00)00090-8; Lee MO, 2002, J HEPATOL, V37, P380, DOI 10.1016/S0168-8278(02)00181-2; Lee MO, 2001, BIOCHEM BIOPH RES CO, V288, P1162, DOI 10.1006/bbrc.2001.5910; Lee SW, 2000, BIOCHEM BIOPH RES CO, V268, P456, DOI 10.1006/bbrc.2000.2093; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Lin Y, 1997, CANCER RES, V57, P5137; Lopez-Ocejo O, 2000, ONCOGENE, V19, P4611, DOI 10.1038/sj.onc.1203817; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Schraml P, 2002, J PATHOL, V196, P186, DOI 10.1002/path.1034; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Sodhi A, 2000, CANCER RES, V60, P4873; Sun X, 2001, GENE THER, V8, P638, DOI 10.1038/sj.gt.3301388; Suzuki H, 1999, INT J ONCOL, V14, P1087; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Toi M, 2001, LANCET ONCOL, V2, P667, DOI 10.1016/S1470-2045(01)00556-3; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wiesener MS, 2001, CANCER RES, V61, P5215; Yoong KF, 1999, AM J PATHOL, V154, P693, DOI 10.1016/S0002-9440(10)65316-3; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Yun C, 2002, CANCER LETT, V184, P97, DOI 10.1016/S0304-3835(02)00187-8; Yun CW, 2000, ONCOGENE, V19, P5163, DOI 10.1038/sj.onc.1203896; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang ZS, 2000, J BIOL CHEM, V275, P15157, DOI 10.1074/jbc.M910378199; Zhong H, 1998, CANCER RES, V58, P5280	55	134	154	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39076	39084		10.1074/jbc.M305101200	http://dx.doi.org/10.1074/jbc.M305101200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12855680	hybrid			2022-12-25	WOS:000185575100121
J	Caricasole, A; Ferraro, T; Iacovelli, L; Barletta, E; Caruso, A; Melchiorri, D; Terstappen, GC; Nicoletti, F				Caricasole, A; Ferraro, T; Iacovelli, L; Barletta, E; Caruso, A; Melchiorri, D; Terstappen, GC; Nicoletti, F			Functional characterization of WNT7A signaling in PC12 cells - Interaction with a FZD5 center dot LRP6 receptor complex and modulation by dickkopf proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TCF TRANSCRIPTION FACTORS; WNT/BETA-CATENIN; BETA-CATENIN; GENE-EXPRESSION; WNT-7A; INDUCTION; HOMOLOG; LITHIUM; PATHWAY; FAMILY	WNT factors represent key mediators of many processes in animal development and homeostasis and act through a receptor complex comprised of members of the Frizzled and low density lipoprotein-related receptors (LRP). In mammals, 19 genes encoding Wingless and Int-related factor (WNTs), 10 encoding Frizzled, and 2 encoding LRP proteins have been identified, but little is known of the identities of individual Frizzled-LRP combinations mediating the effects of specific WNT factors. Additionally, several secreted modulators of WNT signaling have been identified, including at least three members of the Dickkopf family. WNT7A is a WNT family member expressed in the vertebrate central nervous system capable of modulating aspects of neuronal plasticity. Gene knock-out models in the mouse have revealed that WNT7A plays a role in cerebellar maturation, although its function in the development of distal limb structures and of the reproductive tract have been more intensely studied. To identify a receptor complex for this WNT family member, we have analyzed the response of the rat pheochromocytoma cell line PC12 to WNT7A. We find that PC12 cells are capable of responding to WNT7A as measured by increased beta-catenin stability and activation of a T-cell factor-based luciferase reporter construct and that these cells express three members of the Frizzled family (Frizzled-2, -5, and -7) and LRP6. Our functional analysis indicates that WNT7A can specifically act via a Frizzled-5.LRP6 receptor complex in PC12 cells and that this activity can be antagonized by Dickkopf-1 and Dickkopf-3.	Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, I-00185 Rome, Italy; SienaBiotech, I-53100 Siena, Italy; UCL, Wellcome Lab Mol Pharmacol, London WC1E 6BT, England; Ist Ricovero & Cura Carattere Sci, Ist Neurol Mediterraneo Neuromed, I-86077 Pozzilli, Italy	Sapienza University Rome; Siena Biotech; University of London; University College London; IRCCS Neuromed	Caricasole, A (corresponding author), Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	acaricasole@sienabiotech.it	Nicoletti, Ferdinando/K-4410-2016; Nicoletti, Ferdinando/T-4898-2019; Nicoletti, Ferdinando/A-2446-2010	NICOLETTI, Ferdinando/0000-0003-3366-7269; Nicoletti, Ferdinando/0000-0003-0917-443X				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Bettini E, 2002, NEUROSCI LETT, V317, P50, DOI 10.1016/S0304-3940(01)02405-3; Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002; Caricasole A, 2002, GENE, V288, P147, DOI 10.1016/S0378-1119(02)00467-5; Caricasole A, 2000, BBA-GENE STRUCT EXPR, V1517, P63, DOI 10.1016/S0167-4781(00)00260-8; Chou AH, 2000, MOL BRAIN RES, V77, P232, DOI 10.1016/S0169-328X(00)00058-9; Dahmen RP, 2001, CANCER RES, V61, P7039; Dale TC, 1998, BIOCHEM J, V329, P209; Dickinson ME, 1992, CURR OPIN GENET DEV, V2, P562, DOI 10.1016/S0959-437X(05)80172-8; Eickholt BJ, 2002, J CELL BIOL, V157, P211, DOI 10.1083/jcb.200201098; Erdreich-Epstein A, 1998, GROWTH FACTORS, V15, P149, DOI 10.3109/08977199809117190; Gan DD, 2001, ONCOGENE, V20, P4864, DOI 10.1038/sj.onc.1204670; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Giarre M, 1998, ANN NY ACAD SCI, V857, P43, DOI 10.1111/j.1749-6632.1998.tb10106.x; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Holmen SL, 2002, J BIOL CHEM, V277, P34727, DOI 10.1074/jbc.M204989200; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Iacovelli L, 2002, J NEUROCHEM, V82, P216, DOI 10.1046/j.1471-4159.2002.00929.x; Ishikawa T, 2001, DEVELOPMENT, V128, P25; Issack PS, 1998, CELL GROWTH DIFFER, V9, P827; Karasawa T, 2002, J BIOL CHEM, V277, P37479, DOI 10.1074/jbc.M205658200; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Koch A, 2001, INT J CANCER, V93, P445, DOI 10.1002/ijc.1342; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Lucas FR, 1997, DEV BIOL, V192, P31, DOI 10.1006/dbio.1997.8734; Lucas FR, 1998, J CELL SCI, V111, P1351; Malbon CC, 2001, BIOCHEM BIOPH RES CO, V287, P589, DOI 10.1006/bbrc.2001.5630; Manji HK, 2000, J CLIN PSYCHIAT, V61, P82; Manji HK, 1999, BIOL PSYCHIAT, V46, P929, DOI 10.1016/S0006-3223(99)00165-1; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Millar JBA, 2002, GENOME BIOL, V3; Miller C, 1998, DEVELOPMENT, V125, P3201; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nusse R, 2001, NATURE, V411, P254, DOI 10.1038/35077199; Parr BA, 1998, DEV BIOL, V202, P228, DOI 10.1006/dbio.1998.9007; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Patapoutian A, 2000, CURR OPIN NEUROBIOL, V10, P392, DOI 10.1016/S0959-4388(00)00100-8; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Rees S, 1996, BIOTECHNIQUES, V20, P102; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Sala CF, 2000, BIOCHEM BIOPH RES CO, V273, P27, DOI 10.1006/bbrc.2000.2882; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Winklbauer R, 2001, NATURE, V413, P856, DOI 10.1038/35101621; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WOODGETT JR, 2001, SCI STKE; Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Zorn AM, 2001, CURR BIOL, V11, pR592, DOI 10.1016/S0960-9822(01)00360-8	62	111	114	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37024	37031		10.1074/jbc.M300191200	http://dx.doi.org/10.1074/jbc.M300191200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857724	hybrid			2022-12-25	WOS:000185437200008
J	Cheng, JB; Motola, DL; Mangelsdorf, DJ; Russell, DW				Cheng, JB; Motola, DL; Mangelsdorf, DJ; Russell, DW			De-orphanization of cytochrome P450 2R1 - A microsomal vitamin D 25-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID SYNTHESIS; MOLECULAR-CLONING; HUMAN-LIVER; D-RECEPTOR; RAT; EXPRESSION; CDNA; GENE; CHOLESTEROL; METABOLITE	The conversion of vitamin D into an active ligand for the vitamin D receptor requires 25-hydroxylation in the liver and 1alpha-hydroxylation in the kidney. Mitochondrial and microsomal vitamin D 25-hydroxylase enzymes catalyze the first reaction. The mitochondrial activity is associated with sterol 27-hydroxylase, a cytochrome P450 (CYP27A1); however, the identity of the microsomal enzyme has remained elusive. A cDNA library prepared from hepatic mRNA of sterol 27-hydroxylase-deficient mice was screened with a ligand activation assay to identify an evolutionarily conserved microsomal cytochrome P450 (CYP2R1) with vitamin D 25-hydroxylase activity. Expression of CYP2R1 in cells led to the transcriptional activation of the vitamin D receptor when either vitamin D-2 or D-3 was added to the medium. Thin layer chromatography and radioimmunoassays indicated that the secosteroid product of CYP2R1 was 25-hydroxyvitamin D-3. Co-expression of CYP2R1 with vitamin D 1alpha-hydroxylase (CYP27B1) elicited additive activation of vitamin D-3, whereas co-expression with vitamin D 24-hydroxylase (CYP24A1) caused inactivation. CYP2R1 mRNA is abundant in the liver and testis, and present at lower levels in other tissues. The data suggest that CYP2R1 is a strong candidate for the microsomal vitamin D 25-hydroxylase.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mangelsdorf, DJ (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	davo.mango@utsouthwestern.edu; david.russell@utsouthwestern.edu		Russell, David/0000-0002-0277-403X; Mangelsdorf, David/0000-0002-4355-0796	NHLBI NIH HHS [P01 HL020948, HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1983, J BIOL CHEM, V258, P6777; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDERSSON S, 1986, J BIOL CHEM, V261, P6932; Barletta F, 2002, MOL ENDOCRINOL, V16, P301, DOI 10.1210/me.16.2.301; BHATTACHARYYA MH, 1974, ARCH BIOCHEM BIOPHYS, V160, P58, DOI 10.1016/S0003-9861(74)80008-1; BJORKHEM I, 1978, J BIOL CHEM, V253, P842; BJORKHEM I, 1980, J BIOL CHEM, V255, P5244; BJORKHEM I, 2001, METABOLIC MOL BASES, P2961; BLUNT JW, 1968, BIOCHEMISTRY-US, V7, P3317, DOI 10.1021/bi00850a001; CALI JJ, 1991, J BIOL CHEM, V266, P7779; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; Choi M, 2003, CHEM BIOL, V10, P261, DOI 10.1016/S1074-5521(03)00050-4; DAHLBACK H, 1988, BIOCHEM J, V252, P207, DOI 10.1042/bj2520207; EDELSON PJ, 1975, J EXP MED, V142, P1150, DOI 10.1084/jem.142.5.1150; FRASER DR, 1970, NATURE, V228, P764, DOI 10.1038/228764a0; FUKUSHIMA M, 1976, FEBS LETT, V65, P211, DOI 10.1016/0014-5793(76)80482-6; Graham SE, 2002, METHOD ENZYMOL, V357, P15; GUO YD, 1993, P NATL ACAD SCI USA, V90, P8668, DOI 10.1073/pnas.90.18.8668; HAUSSLER MR, 1968, J BIOL CHEM, V243, P4055; HAUSSLER MR, 1969, P NATL ACAD SCI USA, V62, P155, DOI 10.1073/pnas.62.1.155; HOLICK MF, 1971, BIOCHEMISTRY-US, V10, P2799; HOLMBERG I, 1986, SCAND J CLIN LAB INV, V46, P785, DOI 10.3109/00365518609084051; Hosseinpour F, 2000, J BIOL CHEM, V275, P34650, DOI 10.1074/jbc.M004185200; ITOH S, 1995, BBA-GENE STRUCT EXPR, V1264, P26, DOI 10.1016/0167-4781(95)00147-9; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; KAWAUCHI H, 1994, BBA-GENE STRUCT EXPR, V1219, P179, DOI 10.1016/0167-4781(94)90266-6; Kleene KC, 2001, MECH DEVELOP, V106, P3, DOI 10.1016/S0925-4773(01)00413-0; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316; MADHOK TC, 1979, BIOCHEM J, V184, P491, DOI 10.1042/bj1840491; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; MASUMOTO O, 1988, J BIOL CHEM, V263, P14256; MCDONNELL DP, 1987, SCIENCE, V235, P1214, DOI 10.1126/science.3029866; Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7; Nelson DR, 2003, ARCH BIOCHEM BIOPHYS, V409, P18, DOI 10.1016/S0003-9861(02)00553-2; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; Peterson JA, 1998, STRUCTURE, V6, P1079, DOI 10.1016/S0969-2126(98)00109-9; PONCHON G, 1969, J CLIN INVEST, V48, P2032, DOI 10.1172/JCI106168; PONCHON G, 1969, J CLIN INVEST, V48, P1273, DOI 10.1172/JCI106093; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; SAAREM K, 1985, BIOCHIM BIOPHYS ACTA, V840, P117, DOI 10.1016/0304-4165(85)90168-0; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SETCHELL BP, 1975, HDB PHYSL, V5; Simoni RD, 2002, J BIOL CHEM, V277, P9623; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; Touchstone J. C., 1992, PRACTICE THIN LAYER; USUI E, 1990, FEBS LETT, V262, P135, DOI 10.1016/0014-5793(90)80172-F; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033	52	281	294	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38084	38093		10.1074/jbc.M307028200	http://dx.doi.org/10.1074/jbc.M307028200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867411	Green Accepted, hybrid			2022-12-25	WOS:000185437200130
J	Contreras, FX; Villar, AV; Alonso, A; Kolesnick, RN; Goni, FM				Contreras, FX; Villar, AV; Alonso, A; Kolesnick, RN; Goni, FM			Sphingomyelinase activity causes transbilayer lipid translocation in model and cell membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GH3 PITUITARY-CELLS; PHOSPHOLIPASE-C; LIPOSOME FUSION; PHORBOL ESTERS; HL-60 CELLS; CERAMIDE; APOPTOSIS; DIFFERENTIATION; VESICLES	Ceramide is known to induce structural rearrangements in membrane bilayers, including the formation of ceramide-rich and -poor domains and the efflux of aqueous solutes. This report describes a novel effect of ceramide, namely the induction of transbilayer lipid movements. This effect was demonstrated in both model (large unilamellar vesicles) and cell (erythrocyte ghost) membranes in which ceramide generation took place in situ through the action of an externally added sphingomyelinase. Two different novel assays were developed to detect transbilayer lipid movement. One of the assays required the preparation of vesicles containing a ganglioside only in the outer monolayer and entrapped neuraminidase. Sphingomyelinase activity induced ganglioside hydrolysis under conditions in which no neuraminidase was released from the vesicles. The second assay involved the preparation of liposomes or erythrocyte ghosts labeled with a fluorescent energy donor in their inner leaflets. Sphingomyelin hydrolysis was accompanied by fluorescence energy transfer to an impermeable acceptor in the outer aqueous medium. Ceramide-induced transbilayer lipid movement is explained in terms of another well known property of ceramide, namely the facilitation of lamellar to non-lamellar lipid-phase transitions. Thus, sphingomyelinase generates ceramide on one side of the membrane; ceramide then induces the transient formation of non-lamellar structural intermediates, which cause the loss of lipid asymmetry in the bilayer, i.e. the transbilayer movement of ceramide together with other lipids. As direct targets for ceramide tend to be intracellular, these observations may be relevant to the mechanism of transmembrane signaling by means of the sphingomyelin pathway.	Univ Basque Country, Unidad Biofis, Ctr Mixto CSIC UPV EHU, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Memorial Sloan Kettering Cancer Center	Goni, FM (corresponding author), Univ Basque Country, Unidad Biofis, Ctr Mixto CSIC UPV EHU, E-48080 Bilbao, Spain.	gbpgourf@lg.ehu.es	Goni, Felix M/M-5425-2015; Villar, Ana/I-5190-2015; Contreras, Xabier/AAA-8885-2019; Alonso, Alicia/E-5310-2012	Goni, Felix M/0000-0001-6270-9216; Villar, Ana/0000-0003-4588-9598; Alonso, Alicia/0000-0002-2730-7470; Contreras, Xabier/0000-0003-0875-634X				Bai JN, 1997, BIOCHEMISTRY-US, V36, P8840, DOI 10.1021/bi970145r; Basanez G, 1997, BIOPHYS J, V72, P2630, DOI 10.1016/S0006-3495(97)78906-9; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P31, DOI 10.1016/0005-2736(78)90109-8; Dekkers DWC, 2002, BIOCHEM J, V362, P741, DOI 10.1042/0264-6021:3620741; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; Goni FM, 2000, BIOSCIENCE REP, V20, P443, DOI 10.1023/A:1010450702670; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Gulbins Erich, 2002, Subcell Biochem, V36, P229; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Harlow E., 1988, ANTIBODIES LAB MANUA; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; IKEZAWA H, 1978, BIOCHIM BIOPHYS ACTA, V528, P247; Kamp D, 2001, BIOCHEMISTRY-US, V40, P9438, DOI 10.1021/bi0107492; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; Lin CC, 2000, AM J CHINESE MED, V28, P87, DOI 10.1142/S0192415X00000118; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Luberto C, 2002, NEUROCHEM RES, V27, P609, DOI 10.1023/A:1020267831851; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Mattjus P, 2002, J BIOL CHEM, V277, P19476, DOI 10.1074/jbc.M201305200; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Montes LR, 2002, J BIOL CHEM, V277, P11788, DOI 10.1074/jbc.M111568200; NIEVA JL, 1989, BIOCHEMISTRY-US, V28, P7364, DOI 10.1021/bi00444a032; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Ruiz-Arguello MB, 1998, J BIOL CHEM, V273, P22977, DOI 10.1074/jbc.273.36.22977; RuizArguello MB, 1996, J BIOL CHEM, V271, P26616, DOI 10.1074/jbc.271.43.26616; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Steck T L, 1974, Methods Enzymol, V31, P172; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; Villar AV, 1999, FEBS LETT, V457, P71, DOI 10.1016/S0014-5793(99)01010-8; Wybenga LE, 1996, BIOCHEMISTRY-US, V35, P9513, DOI 10.1021/bi9606152; Yan F, 2001, CANCER RES, V61, P963; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zhou M, 2002, J MOL BIOL, V315, P435, DOI 10.1006/jmbi.2001.5263	54	98	99	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37169	37174		10.1074/jbc.M303206200	http://dx.doi.org/10.1074/jbc.M303206200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855704	hybrid			2022-12-25	WOS:000185437200024
J	Murakami, M; Nakashima, K; Kamei, D; Masuda, S; Ishikawa, Y; Ishii, T; Ohmiya, Y; Watanabe, K; Kudo, I				Murakami, M; Nakashima, K; Kamei, D; Masuda, S; Ishikawa, Y; Ishii, T; Ohmiya, Y; Watanabe, K; Kudo, I			Cellular prostaglandin E-2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); H SYNTHASE-1; INTESTINAL POLYPOSIS; GENE DISRUPTION; DEFICIENT MICE; POTENTIAL ROLE; KNOCKOUT MICE; UP-REGULATION; EXPRESSION; RECEPTOR	Current evidence suggests that two forms of prostaglandin (PG) E synthase (PGES), cytosolic PGES and membrane-bound PGES (mPGES) -1, preferentially lie downstream of cyclooxygenase (COX) -1 and -2, respectively, in the PGE(2) biosynthetic pathway. In this study, we examined the expression and functional aspects of the third PGES enzyme, mPGES-2, in mammalian cells and tissues. mPGES-2 was synthesized as a Golgi membrane-associated protein, and spontaneous cleavage of the N-terminal hydrophobic domain led to the formation of a truncated mature protein that was distributed in the cytosol with a trend to be enriched in the perinuclear region. In several cell lines, mPGES-2 promoted PGE2 production via both COX-1 and COX-2 in the immediate and delayed responses with modest COX-2 preference. In contrast to the marked inducibility of mPGES-1, mPGES-2 was constitutively expressed in various cells and tissues and was not increased appreciably during tissue inflammation or damage. Interestingly, a considerable elevation of mPGES-2 expression was observed in human colorectal cancer. Collectively, mPGES-2 is a unique PGES that can be coupled with both COXs and may play a role in the production of the PGE(2) involved in both tissue homeostasis and disease.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Toho Univ, Sch Med, Dept Pathol, Ohta Ku, Tokyo 1438540, Japan; AIST, Cell Dynam Res Grp, Special Div Human Life Technol, Osaka 5638577, Japan; Univ E Asia, Grad Sch Integrated Sci & Art, Div Life Sci, Yamaguchi 7518503, Japan	Showa University; National Institute of Advanced Industrial Science & Technology (AIST)	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	kudo@pharm.showa-u.ac.jp	Ohmiya, Yoshihiro/J-7143-2013	Ohmiya, Yoshihiro/0000-0002-4944-509X				Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Begay CK, 2003, TOXICOLOGY, V185, P79, DOI 10.1016/S0300-483X(02)00594-2; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; Bensen W, 2002, RHEUMATOLOGY, V41, P1008, DOI 10.1093/rheumatology/41.9.1008; Callejas NA, 2001, HEPATOLOGY, V33, P860, DOI 10.1053/jhep.2001.23002; Camitta MGW, 2001, CIRCULATION, V104, P2453, DOI 10.1161/hc4401.098429; Cheng JD, 2002, HEPATOL RES, V23, P185, DOI 10.1016/S1386-6346(01)00177-2; Claveau D, 2003, J IMMUNOL, V170, P4738, DOI 10.4049/jimmunol.170.9.4738; de Ledinghen V, 2002, CARCINOGENESIS, V23, P73, DOI 10.1093/carcin/23.1.73; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Filion F, 2001, J BIOL CHEM, V276, P34323, DOI 10.1074/jbc.M103709200; Gotta Alexander W, 2002, Curr Opin Investig Drugs, V3, P240; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; Hu JB, 2002, J BIOL CHEM, V277, P30253, DOI 10.1074/jbc.M202679200; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kamei D, 2003, J BIOL CHEM, V278, P19396, DOI 10.1074/jbc.M213290200; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Langenbach R, 1999, ANN NY ACAD SCI, V889, P52, DOI 10.1111/j.1749-6632.1999.tb08723.x; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Liou JY, 2000, J BIOL CHEM, V275, P15314, DOI 10.1074/jbc.275.20.15314; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Loftin CD, 2002, PROSTAG OTH LIPID M, V68-9, P177, DOI 10.1016/S0090-6980(02)00028-X; Loftin CD, 2001, P NATL ACAD SCI USA, V98, P1059, DOI 10.1073/pnas.031573498; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; MARNETT LJ, 1992, CANCER RES, V52, P5575; Matsumoto AK, 2002, J RHEUMATOL, V29, P1623; Matsumoto H, 2002, J BIOL CHEM, V277, P29260, DOI 10.1074/jbc.M203996200; MEHINDATE K, 1995, J IMMUNOL, V155, P3570; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Morita I, 2002, PROSTAG OTH LIPID M, V68-9, P165, DOI 10.1016/S0090-6980(02)00029-1; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Murakami M, 2002, PROSTAG OTH LIPID M, V68-9, P383, DOI 10.1016/S0090-6980(02)00043-6; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2003, J BIOL CHEM, V278, P10657, DOI 10.1074/jbc.M211325200; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Mutoh M, 2002, CANCER RES, V62, P28; Myers LK, 2000, ARTHRITIS RHEUM-US, V43, P2687, DOI 10.1002/1529-0131(200012)43:12<2687::AID-ANR8>3.0.CO;2-9; Naraba H, 2002, J BIOL CHEM, V277, P28601, DOI 10.1074/jbc.M203618200; Nguyen MT, 1997, NATURE, V390, P78, DOI 10.1038/36342; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; RAO CV, 1995, CANCER RES, V55, P1464; Rudnick DA, 2001, P NATL ACAD SCI USA, V98, P8885, DOI 10.1073/pnas.151217998; Shinmura K, 2000, P NATL ACAD SCI USA, V97, P10197, DOI 10.1073/pnas.97.18.10197; Siegle I, 1998, ARTHRITIS RHEUM-US, V41, P122, DOI 10.1002/1529-0131(199801)41:1<122::AID-ART15>3.3.CO;2-#; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Smith WL, 2002, PROSTAG OTH LIPID M, V68-9, P115, DOI 10.1016/S0090-6980(02)00025-4; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Tanioka T, 2003, BIOCHEM BIOPH RES CO, V303, P1018, DOI 10.1016/S0006-291X(03)00470-4; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Thoren S, 2003, J BIOL CHEM, V278, P22199, DOI 10.1074/jbc.M303227200; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; Vane JR, 1998, INFLAMM RES, V47, pS78; Watanabe K, 1999, BBA-MOL CELL BIOL L, V1439, P406, DOI 10.1016/S1388-1981(99)00084-0; Watanabe K, 1999, CANCER RES, V59, P5093; Watanabe K, 2003, BIOCHEM BIOPH RES CO, V306, P577, DOI 10.1016/S0006-291X(03)01025-8; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001; Yoshimatsu K, 2001, CLIN CANCER RES, V7, P3971; Yoshimatsu K, 2001, CLIN CANCER RES, V7, P2669	72	278	295	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37937	37947		10.1074/jbc.M305108200	http://dx.doi.org/10.1074/jbc.M305108200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12835322	hybrid			2022-12-25	WOS:000185437200116
J	Sage, EH; Reed, M; Funk, SE; Truong, T; Steadele, M; Puolakkainen, P; Maurice, DH; Bassuk, JA				Sage, EH; Reed, M; Funk, SE; Truong, T; Steadele, M; Puolakkainen, P; Maurice, DH; Bassuk, JA			Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL PROLIFERATION; SMOOTH-MUSCLE CELLS; EXTRACELLULAR-MATRIX; ESCHERICHIA-COLI; CHORIOALLANTOIC MEMBRANE; SECRETED PROTEIN; FOLLISTATIN-LIKE; BINDING-SITES; DNA-SYNTHESIS; GROWTH-FACTOR	SPARC, a matricellular protein that affects cellular adhesion and proliferation, is produced in remodeling tissue and in pathologies involving fibrosis and angiogenesis. In this study we have asked whether peptides generated from cleavage of SPARC in the extracellular milieu can regulate angiogenesis. Matrix metalloproteinase (MMP)-3, but not MMP-1 or 9, showed significant activity toward SPARC. Limited digestion of recombinant human (rhu) SPARC with purified catalytic domain of rhuMMP-3 produced three major fragments, which were sequenced after purification by HPLC. Three synthetic peptides (Z-1, Z-2, and Z-3) representing motifs from each fragment were tested in distinct assays of angiogenesis. Peptide Z-1 (3.9 kDa, containing a Cu2+-binding sequence KHGK) exhibited a biphasic effect on [H-3] thymidine incorporation by cultured endothelial cells and stimulated vascular growth in the chick chorioallantoic membrane ( CAM). In contrast, peptides Z-2 (6.1 kDa, containing Ca2+-binding EF hand-1) and Z-3 (2.2 kDa, containing neither Cu2+-binding motifs nor EF hands), inhibited cell proliferation in a concentration-dependent manner and exhibited no effects on vessel growth in the CAM. Reciprocal results were obtained in a migration assay in native collagen gels: peptide Z-1 was ineffective over a range of concentrations, whereas Z-2 or Z-3 stimulated cell migration. Therefore, proteolysis of SPARC by MMP-3 produced peptides that regulate endothelial cell proliferation and/or migration in vitro in a mutually exclusive manner. One of these peptides containing KHGK also demonstrated a concentration-dependent effect on angiogenesis.	Hope Heart Inst, Dept Vasc Biol, Seattle, WA 98104 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Urol, Seattle, WA 98195 USA; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Queens University - Canada	Sage, EH (corresponding author), Hope Heart Inst, Dept Vasc Biol, 1124 Columbia St,Suite 723, Seattle, WA 98104 USA.	hsage@hopeheart.org	Maurice, Donald/AAE-9332-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040711] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59475] Funding Source: Medline; NIDDK NIH HHS [P50 DK47659] Funding Source: Medline; NIGMS NIH HHS [GM40711] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agnihotri R, 2001, J BIOL CHEM, V276, P28261, DOI 10.1074/jbc.M103608200; Bassuk JA, 1996, ARCH BIOCHEM BIOPHYS, V325, P8, DOI 10.1006/abbi.1996.0002; Bassuk JA, 1996, INT J BIOCHEM CELL B, V28, P1031, DOI 10.1016/1357-2725(96)00036-2; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Bradshaw AD, 2003, J INVEST DERMATOL, V120, P949, DOI 10.1046/j.1523-1747.2003.12241.x; Bradshaw AD, 2003, P NATL ACAD SCI USA, V100, P6045, DOI 10.1073/pnas.1030790100; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken Rolf A., 2001, Matrix Biology, V19, P816; Busch E, 2000, J BIOL CHEM, V275, P25508, DOI 10.1074/jbc.M001770200; Colman RW, 2000, BLOOD, V95, P543, DOI 10.1182/blood.V95.2.543; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; Gilles C, 1998, CANCER RES, V58, P5529; Hashimoto G, 2002, J BIOL CHEM, V277, P36288, DOI 10.1074/jbc.M201674200; HOFFMAN BJ, 1995, PROTEIN EXPRES PURIF, V6, P646, DOI 10.1006/prep.1995.1085; Hohenester E, 1997, EMBO J, V16, P3778, DOI 10.1093/emboj/16.13.3778; IRUELAARISPE ML, 1995, MOL BIOL CELL, V6, P327, DOI 10.1091/mbc.6.3.327; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE TF, 1994, J CELL BIOL, V125, P929, DOI 10.1083/jcb.125.4.929; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Lijnen HR, 2002, ARTERIOSCL THROM VAS, V22, P374, DOI 10.1161/hq0302.104522; Lymn JS, 2002, J CELL SCI, V115, P4353, DOI 10.1242/jcs.00119; MAQUART FX, 1993, J CLIN INVEST, V92, P2368, DOI 10.1172/JCI116842; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; Maurer P, 1997, CELL MOL LIFE SCI, V53, P478, DOI 10.1007/s000180050059; Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106; Parsons-Wingerter P, 1998, MICROVASC RES, V55, P201, DOI 10.1006/mvre.1998.2073; Pike SE, 1999, BLOOD, V94, P2461, DOI 10.1182/blood.V94.7.2461.419a26_2461_2468; Ponce ML, 1999, CIRC RES, V84, P688, DOI 10.1161/01.RES.84.6.688; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; Puolakkainen P, 1999, DIGEST DIS SCI, V44, P1554, DOI 10.1023/A:1026602708263; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; SAGE EH, 1995, J CELL BIOCHEM, V57, P127, DOI 10.1002/jcb.240570113; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; Sage EH, 2001, J CLIN INVEST, V107, P781, DOI 10.1172/JCI12683; SAGE H, 1984, J BIOL CHEM, V259, P3993; Sasaki T, 1997, J BIOL CHEM, V272, P9237; Sasaki T, 1999, MATRIX BIOL, V18, P499, DOI 10.1016/S0945-053X(99)00041-4; Shankavaram UT, 1997, J CELL PHYSIOL, V173, P327, DOI 10.1002/(SICI)1097-4652(199712)173:3<327::AID-JCP4>3.3.CO;2-R; Silence J, 2001, ARTERIOSCL THROM VAS, V21, P1440, DOI 10.1161/hq0901.097004; St Croix B, 2000, SCIENCE, V289, P1197; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Suzuki K, 1998, BIOL CHEM, V379, P185, DOI 10.1515/bchm.1998.379.2.185; TREMBLE PM, 1993, J CELL BIOL, V121, P1433, DOI 10.1083/jcb.121.6.1433; Vernon RB, 1999, MICROVASC RES, V57, P118, DOI 10.1006/mvre.1998.2122; YOST JC, 1993, J BIOL CHEM, V268, P25790	53	131	139	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37849	37857		10.1074/jbc.M302946200	http://dx.doi.org/10.1074/jbc.M302946200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867428	hybrid			2022-12-25	WOS:000185437200105
J	Saito, S; Yamaguchi, H; Higashimoto, Y; Chao, C; Xu, Y; Fornace, AJ; Appella, E; Anderson, CW				Saito, S; Yamaguchi, H; Higashimoto, Y; Chao, C; Xu, Y; Fornace, AJ; Appella, E; Anderson, CW			Phosphorylation site interdependence of human p53 post-translational modifications in response to stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; IONIZING-RADIATION; UBIQUITIN SYSTEM; GAMMA-RADIATION; UV-RADIATION; MURINE P53; IN-VITRO; ACTIVATION; ATM	Modification-specific antibodies were used to characterize the phosphorylation and acetylation of human p53 in response to genotoxic (UV, IR, and adriamycin) and non-genotoxic (PALA, taxol, nocodazole) stress in cultured human cells at 14 known modification sites. In A549 cells, phosphorylation or acetylation was induced at most sites by the three DNA damage-inducing agents, but significant differences between agents were observed. IR-induced phosphorylation reached a maximum 2 h after treatment and returned to near pretreatment levels by 72 h; UV light and adriamycin induced a less rapid but more robust and prolonged p53 phosphorylation, which reached a maximum between 8 and 24 h, but persisted ( UV) even 96 h after treatment. Ser(33), Ser(37), Ser(46), and Ser(392) were more efficiently phosphorylated after exposure to UV light than after IR. The non-genotoxic agents PALA, taxol and nocodazole induced p53 accumulation and phosphorylation at Ser(6), Ser(33), Ser(46), and Ser(392). Some phosphorylation at Ser(15) also was observed. Modifications occurred similarly in the HCT116 human colon carcinoma cell line. Analysis of single site mutant p53s indicated clear interdependences between N-terminal phosphorylation sites, which could be classified in four clusters: Ser(6) and Ser(9); Ser(9), Ser(15), Thr(18) and Ser(20); Ser(33) and Ser(37); and Ser(46). We suggest that p53 phosphorylation is regulated through a double cascade involving both the activation of secondary, effector protein kinases as well as intermolecular phosphorylation site interdependencies that check inappropriate p53 inactivation while allowing for signal amplification and the integration of signals from multiple stress pathways.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Basic Res Lab, NIH, Bethesda, MD 20892 USA; Univ Calif San Diego, Mol Biol Sect, Div Biol, La Jolla, CA 92093 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego	Anderson, CW (corresponding author), Brookhaven Natl Lab, Dept Biol, 50 Bell Ave, Upton, NY 11973 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Xu, Yang/0000-0001-5574-921X; Higashimoto, Yuichiro/0000-0003-1382-8598				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ANDERSON CW, 2003, HDB CELL SIGNALING, V3, P237; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; Damia G, 2001, NEOPLASIA, V3, P10, DOI 10.1038/sj.neo.7900122; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Gatti A, 2000, BIOCHEMISTRY-US, V39, P9837, DOI 10.1021/bi992454i; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hofseth LJ, 2003, P NATL ACAD SCI USA, V100, P143, DOI 10.1073/pnas.0237083100; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Kishi H, 2001, J BIOL CHEM, V276, P39115, DOI 10.1074/jbc.M105134200; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Meyer KM, 1999, ONCOGENE, V18, P5795, DOI 10.1038/sj.onc.1202977; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stewart ZA, 2001, ONCOGENE, V20, P113, DOI 10.1038/sj.onc.1204060; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002	51	196	204	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37536	37544		10.1074/jbc.M305135200	http://dx.doi.org/10.1074/jbc.M305135200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12860987	hybrid			2022-12-25	WOS:000185437200067
J	Tee, AR; Anjum, R; Blenis, J				Tee, AR; Anjum, R; Blenis, J			Inactivation of the tuberous sclerosis complex-1 and-2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEINS; RIBOSOMAL S6 KINASE-2; CELL-GROWTH; MAMMALIAN TARGET; MULTIPLE SITES; TSC2; MTOR; INSULIN; ACTIVATION; RHEB	The tuberous sclerosis complex (TSC) is a genetic disorder that is caused through mutations in either one of the two tumor suppressor genes, TSC1 and TSC2, that encode hamartin and tuberin, respectively. Interaction of hamartin with tuberin forms a heterodimer that inhibits signaling by the mammalian target of rapamycin to its downstream targets: eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase 1 (S6K1). During mitogenic sufficiency, the phosphoinositide 3-kinase (PI3K)/Akt pathway phosphorylates tuberin on Ser-939 and Thr-1462 that inhibits the tumor suppressor function of the TSC complex. Here we show that tuberin-hamartin heterodimers block protein kinase C (PKC)/MAPK- and phosphatidic acid-mediated signaling toward mammalian target of rapamycin-dependent targets. We also show that two TSC2 mutants derived from TSC patients are defective in repressing phorbol 12-myristate 13-acetate-induced 4E-BP1 phosphorylation. PKC/MAPK signaling leads to phosphorylation of tuberin at sites that overlap with and are distinct from Akt phosphorylation sites. Phosphorylation of tuberin by phorbol 12-myristate 13-acetate was reduced by treatment of cells with either bisindolylmaleimide I or UO126, inhibitors of PKC and MAPK/MEK (MAPK/ERK kinase), respectively, but not by wortmannin ( an inhibitor of PI3K). This work reveals that both PI3K-independent and - dependent mechanisms modulate tuberin phosphorylation in vivo.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.			Tee, Andrew/0000-0002-5577-4631	NIGMS NIH HHS [GM51405] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLENIS J, 1986, P NATL ACAD SCI USA, V83, P1733, DOI 10.1073/pnas.83.6.1733; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; GREEN AJ, 1994, HUM MOL GENET, V3, P1833, DOI 10.1093/hmg/3.10.1833; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Liu MY, 2002, CANCER RES, V62, P6475; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Martin KA, 2001, J BIOL CHEM, V276, P7884, DOI 10.1074/jbc.M006969200; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Park IH, 2002, J BIOL CHEM, V277, P31423, DOI 10.1074/jbc.M204080200; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Rousseau D, 1996, ONCOGENE, V13, P2415; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shumway SD, 2003, J BIOL CHEM, V278, P2089, DOI 10.1074/jbc.C200499200; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	43	171	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37288	37296		10.1074/jbc.M303257200	http://dx.doi.org/10.1074/jbc.M303257200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867426	hybrid			2022-12-25	WOS:000185437200037
J	Wonerow, P; Pearce, AC; Vaux, DJ; Watson, SP				Wonerow, P; Pearce, AC; Vaux, DJ; Watson, SP			A critical role for phospholipase C gamma 2 in alpha(IIb)beta(3)-mediated platelet spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-GAMMA-CHAIN; GLYCOPROTEIN IB-ALPHA; TYROSINE PHOSPHORYLATION; COLLAGEN RECEPTOR; INTEGRIN ALPHA(IIB)BETA(3); OUTSIDE-IN; SIGNALING PATHWAY; CALCIUM SIGNALS; KINASE SYK; T-CELLS	The interaction of fibrinogen with the integrin alpha(IIb)beta(3) plays a crucial role in platelet adhesion and platelet activation leading to the generation of intracellular signals that nucleate the reorganization of the cytoskeleton. Presently, we have only a limited understanding of the signaling cascades and effector proteins through which changes in the cytoskeletal architecture are mediated. The present study identifies phospholipase Cgamma2 (PLCgamma2) as an important target of the Src-dependent signaling cascade regulated by alpha(IIb)beta(3). Real time phase-contrast microscopy is used to show that formation of filopodia and lamellapodia in murine platelets on a fibrinogen surface is dramatically inhibited in the absence of PLCgamma2. Significantly, the formation of these structures is mediated by Ca2+ elevation and activation of protein kinase C, both directly regulated by PLC activity. With the involvement of Syk, SLP-76, and Btk, alpha(IIb)beta(3)-induced PLCgamma2 activation partly overlaps with the pathway used by the collagen receptor glycoprotein VI. Important differences, however, exist between the two signaling cascades in that activation of PLCgamma2 by alpha(IIb)beta(3) is unaltered in murine platelets, which lack the FcR gamma-chain or the adaptor LAT, but is abolished in the presence of cytochalasin D. Therefore, PLCgamma2 plays not only a crucial role in activation of alpha(IIb)beta(3) by collagen receptors but also in alpha(IIb)beta(3)-mediated responses.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Birmingham Sch Med, Div Med Sci, Birmingham B15 2TT, W Midlands, England	University of Oxford; University of Oxford; University of Birmingham	Wonerow, P (corresponding author), Aventis Pharma, DG Thrombot Degenerat Joint Dis, Ind Pk Hochst,Bldg H824, D-65926 Frankfurt, Germany.		Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423; Vaux, David/0000-0002-4901-9795				Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Griffiths EK, 2002, CURR OPIN IMMUNOL, V14, P317, DOI 10.1016/S0952-7915(02)00334-5; Gross BS, 1999, EUR J BIOCHEM, V263, P612, DOI 10.1046/j.1432-1327.1999.00560.x; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Hellberg C, 1996, BIOCHEM J, V317, P403, DOI 10.1042/bj3170403; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Judd BA, 2000, P NATL ACAD SCI USA, V97, P12056, DOI 10.1073/pnas.97.22.12056; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; Lockhart LK, 1999, J PHARMACOL EXP THER, V289, P721; Marshall SJ, 2002, BIOCHEM J, V361, P297, DOI 10.1042/0264-6021:3610297; Mazzucato M, 2002, BLOOD, V100, P2793, DOI 10.1182/blood-2002-02-0514; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Navdaev A, 2002, J BIOL CHEM, V277, P45928, DOI 10.1074/jbc.M206129200; Nesbitt WS, 2002, J BIOL CHEM, V277, P2965, DOI 10.1074/jbc.M110070200; Obergfell A, 2002, BLOOD, V100, p122A; Obergfell A, 2001, J BIOL CHEM, V276, P5916, DOI 10.1074/jbc.M010639200; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Ozdener F, 2002, MOL PHARMACOL, V62, P672, DOI 10.1124/mol.62.3.672; PARK SY, 1995, EUR J IMMUNOL, V25, P2107, DOI 10.1002/eji.1830250746; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Pasquet JM, 1999, BIOCHEM J, V342, P171, DOI 10.1042/0264-6021:3420171; Payrastre B, 2000, BIOCHEM PHARMACOL, V60, P1069, DOI 10.1016/S0006-2952(00)00417-2; Phillips DR, 2001, THROMB HAEMOSTASIS, V86, P246; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Quek LS, 2000, BLOOD, V96, P4246; Ricard I, 1997, EUR J IMMUNOL, V27, P1530, DOI 10.1002/eji.1830270632; Schottelndreier H, 2001, CELL SIGNAL, V13, P895, DOI 10.1016/S0898-6568(01)00225-X; Shattil SJ, 1999, THROMB HAEMOSTASIS, V82, P318; Suzuki-Inoue K, 2003, BLOOD, V102, P1367, DOI 10.1182/blood-2003-01-0029; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Wonerow P, 2002, BIOCHEM J, V364, P755, DOI 10.1042/BJ20020128; Wrenn RW, 1996, BIOCHEM BIOPH RES CO, V226, P876, DOI 10.1006/bbrc.1996.1443; Yap CL, 2002, BLOOD, V99, P151, DOI 10.1182/blood.V99.1.151; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	41	113	114	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37520	37529		10.1074/jbc.M305077200	http://dx.doi.org/10.1074/jbc.M305077200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12832411	hybrid			2022-12-25	WOS:000185437200065
J	Hanson, PK; Malone, L; Birchmore, JL; Nichols, JW				Hanson, PK; Malone, L; Birchmore, JL; Nichols, JW			Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIVISION-CYCLE; P-TYPE ATPASES; NBD-LABELED PHOSPHATIDYLCHOLINE; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; PHOSPHOLIPID TRANSLOCATION; DIFFERENTIALLY AFFECTS; ET-18-OCH3 EDELFOSINE; PHENOTYPIC ANALYSIS; GENE DELETION	The alkylphosphocholine class of drugs, including edelfosine and miltefosine, has recently shown promise in the treatment of protozoal and fungal diseases, most notably, leishmaniasis. One of the major barriers to successful treatment of these infections is the development of drug resistance. To understand better the mechanisms underlying the development of drug resistance, we performed a combined mutant selection and screen in Saccharomyces cerevisiae, designed to identify genes that confer resistance to the alkylphosphocholine drugs by inhibiting their transport across the plasma membrane. Mutagenized cells were first selected for resistance to edelfosine, and the initial collection of mutants was screened a second time for defects in internalization of a short chain, fluorescent (7-nitrobenz-2-oxa-1,3-diazol-4-yl (NBD))-labeled phosphatidylcholine reporter. This approach identified mutations in a single gene, YNL323W/LEM3, that conferred resistance to alkylphosphocholine drugs and inhibited internalization of NBD-labeled phosphatidylcholine. Loss of YNL323W/ LEM3 does not confer resistance to N-nitroquinilone N-oxide or ketoconazole and actually increases sensitivity to cycloheximide. The defect in internalization is specific to NBD-labeled phosphatidylcholine and phosphatidylethanolamine. Labeled phosphatidylserine is internalized at normal levels in lem3 strains. LEM3 is a member of an evolutionarily conserved family and has two homologues in S. cerevisiae. Single point mutations that produce resistance to alkylphosphocholine drugs and inhibition of NBD-labeled phosphatidylcholine internalization were identified in several highly conserved domains. These data demonstrate a requirement for Lem3p expression for normal phosphatidylcholine and alkylphosphocholine drug transport across the plasma membrane of yeast.	Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA	Emory University	Nichols, JW (corresponding author), Emory Univ, Sch Med, Dept Physiol, 605G Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	wnichols@physio.emory.edu		Hanson, Pamela/0000-0002-9312-1682	NIGMS NIH HHS [GM64770] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064770] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS A, 1997, METHODS YEAST GENETI, P15; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; BRACHWITZ H, 1995, PHARMACOL THERAPEUT, V66, P39, DOI 10.1016/0163-7258(95)00001-W; COLLART MA, 1993, EMBO J, V12, P177, DOI 10.1002/j.1460-2075.1993.tb05643.x; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; Croft SL, 1996, J ANTIMICROB CHEMOTH, V38, P1041, DOI 10.1093/jac/38.6.1041; CROFT SL, 1987, BIOCHEM PHARMACOL, V36, P2633, DOI 10.1016/0006-2952(87)90543-0; Daleke DL, 2000, BBA-MOL CELL BIOL L, V1486, P108, DOI 10.1016/S1388-1981(00)00052-4; DIOMEDE L, 1993, INT J CANCER, V53, P124, DOI 10.1002/ijc.2910530123; Escobar P, 2002, ACTA TROP, V81, P151, DOI 10.1016/S0001-706X(01)00197-8; Grant AM, 2001, TRAFFIC, V2, P37, DOI 10.1034/j.1600-0854.2001.020106.x; Hampton RY, 2002, ANNU REV CELL DEV BI, V18, P345, DOI 10.1146/annurev.cellbio.18.032002.131219; Hanson PK, 2002, J CELL SCI, V115, P2725; Hanson PK, 2001, J BIOL CHEM, V276, P9861, DOI 10.1074/jbc.M009065200; Herwaldt BL, 1999, NEW ENGL J MED, V341, P1840, DOI 10.1056/NEJM199912093412411; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hua ZL, 2002, MOL BIOL CELL, V13, P3162, DOI 10.1091/mbc.E02-03-0172; Jha TK, 1999, NEW ENGL J MED, V341, P1795, DOI 10.1056/NEJM199912093412403; Kato U, 2002, J BIOL CHEM, V277, P37855, DOI 10.1074/jbc.M205564200; KEAN LS, 1993, J CELL BIOL, V123, P1403, DOI 10.1083/jcb.123.6.1403; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; Konstantinov SM, 1997, ACTA TROP, V64, P145, DOI 10.1016/S0001-706X(96)00628-6; KUHLENCORD A, 1992, ANTIMICROB AGENTS CH, V36, P1630, DOI 10.1128/AAC.36.8.1630; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOPES MD, 1990, MOL CELL BIOL, V10, P2966, DOI 10.1128/MCB.10.6.2966; Lux H, 2000, MOL BIOCHEM PARASIT, V111, P1, DOI 10.1016/S0166-6851(00)00278-4; Maftahi M, 1998, YEAST, V14, P271, DOI 10.1002/(SICI)1097-0061(199802)14:3<271::AID-YEA218>3.0.CO;2-Y; Misu K, 2003, MOL BIOL CELL, V14, P730, DOI 10.1091/mbc.E02-06-0314; MOIR D, 1982, GENETICS, V100, P547; Mollinedo F, 1997, CANCER RES, V57, P1320; Muren E, 2001, YEAST, V18, P163, DOI 10.1002/1097-0061(20010130)18:2<163::AID-YEA659>3.0.CO;2-#; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Oberholzer U, 1998, GENE, V207, P61, DOI 10.1016/S0378-1119(97)00605-7; Perez-Victoria JM, 2001, ANTIMICROB AGENTS CH, V45, P2468, DOI 10.1128/AAC.45.9.2468-2474.2001; Pomorski T, 2003, MOL BIOL CELL, V14, P1240, DOI 10.1091/mbc.E02-08-0501; Pomorski T, 1999, BIOCHEMISTRY-US, V38, P142, DOI 10.1021/bi981244n; Prinz WA, 2000, J CELL BIOL, V150, P461, DOI 10.1083/jcb.150.3.461; Radji M, 2001, YEAST, V18, P195, DOI 10.1002/1097-0061(200102)18:3<195::AID-YEA660>3.0.CO;2-L; Raggers RJ, 2000, TRAFFIC, V1, P226, DOI 10.1034/j.1600-0854.2000.010305.x; REED SI, 1980, GENETICS, V95, P579; Rieger KJ, 1997, YEAST, V13, P1547, DOI 10.1002/(SICI)1097-0061(199712)13:16<1547::AID-YEA230>3.3.CO;2-P; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Ruetz S, 1997, BIOCHEMISTRY-US, V36, P8180, DOI 10.1021/bi970564o; SHERMAN F, 1986, METHODS YEAST GENETI, P181; Sitcheran R, 2000, GENETICS, V156, P963; SLEIGHT RG, 1989, J CELL SCI, V93, P363; Soto J, 2001, CLIN INFECT DIS, V33, pE57, DOI DOI 10.1086/322689; Sundar S, 1998, LANCET, V352, P1821, DOI 10.1016/S0140-6736(98)04367-0; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; van den Hazel HB, 1999, J BIOL CHEM, V274, P1934, DOI 10.1074/jbc.274.4.1934; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	53	93	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36041	36050		10.1074/jbc.M305263200	http://dx.doi.org/10.1074/jbc.M305263200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12842877	hybrid			2022-12-25	WOS:000185318300023
J	Matsukawa, J; Nakayama, K; Nagao, T; Ichijo, H; Urushidani, T				Matsukawa, J; Nakayama, K; Nagao, T; Ichijo, H; Urushidani, T			Role of ADP-ribosylation factor 6 (ARF6) in gastric acid secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-GAMMA-S; PARIETAL-CELLS; MEMBRANE; ACTIVATION; EXPRESSION; PHOSPHATIDYLINOSITOL; STIMULATION; GLANDS	ADP-ribosylation factor (ARF) proteins are monomeric GTPases that are essential for membrane transport and exocytosis in a number of secretory cells. We investigated ARF6, the activation of which is insensitive to brefeldin A, to determine whether it regulates membrane traffic in gastric parietal cells. ARF6 translocated from cytosol to tubulovesicle in the presence of GTPgammaS, a potential inhibitor of acid secretion in permeabilized cells, whereas under the Mg2+-chelated condition where activity of ARF-GTPase activating protein is inhibited, ARF6 translocated to the apical secretory membrane. Immunohistochemical examination revealed that ARF6 mainly located in parietal cell within the gastric glands, and it translocated from the cytosol to the intracellular canaliculi when the glands were stimulated. These results indicated that the distribution of ARF6 between cytosol and the two different membranes was regulated by its GTPase activity. In cultured gastric glands infected with adenovirus expressing ARF6 Q67L, a mutant lacking GTP hydrolysis activity, gastric acid secretion was inhibited. These results suggest that ARF6 regulates gastric acid secretion in parietal cell and that the GTP hydrolysis cycle of ARF6 is essential for the activation pathway.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Cell Signaling, Tokyo 1130033, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Kyoto 6068501, Japan; Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan	University of Tokyo; Kyoto University; National Institute of Health Sciences - Japan	Urushidani, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Cell Signaling, Tokyo 1130033, Japan.	urusidani@nihs.go.jp	Nakayama, Kazuhisa/ABF-2924-2020; Matsukawa, Jun/R-4972-2019	Matsukawa, Jun/0000-0001-9457-3683; Nakayama, Kazuhisa/0000-0001-7701-7183; Ichijo, Hidenori/0000-0002-5005-6438				Akagi K, 2001, J BIOL CHEM, V276, P28171, DOI 10.1074/jbc.M101190200; Akagi K, 1999, AM J PHYSIOL-GASTR L, V277, pG736, DOI 10.1152/ajpgi.1999.277.3.G736; BERGLINDH T, 1990, METHOD ENZYMOL, V192, P93; Calhoun BC, 1998, AM J PHYSIOL-CELL PH, V275, pC163, DOI 10.1152/ajpcell.1998.275.1.C163; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; CHEW CS, 1989, AM J PHYSIOL, V256, pG254, DOI 10.1152/ajpgi.1989.256.1.G254; Dana RR, 2000, J BIOL CHEM, V275, P32566, DOI 10.1074/jbc.M005406200; Dohke Y, 1998, ARCH BIOCHEM BIOPHYS, V357, P147, DOI 10.1006/abbi.1998.0793; Duman JG, 1999, AM J PHYSIOL-CELL PH, V277, pC361, DOI 10.1152/ajpcell.1999.277.3.C361; Gaschet J, 1999, J BIOL CHEM, V274, P20040, DOI 10.1074/jbc.274.28.20040; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; Jones AT, 1999, J CELL SCI, V112, P3477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Miller MD, 1996, AM J PHYSIOL-GASTR L, V270, pG962, DOI 10.1152/ajpgi.1996.270.6.G962; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Muto Y, 2001, AM J PHYSIOL-CELL PH, V280, pC155, DOI 10.1152/ajpcell.2001.280.1.C155; Okamoto CT, 2001, J PHYSIOL-LONDON, V532, P287, DOI 10.1111/j.1469-7793.2001.0287f.x; Omi N, 2001, AM J PHYSIOL-GASTR L, V281, pG786, DOI 10.1152/ajpgi.2001.281.3.G786; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TASHIRO K, 2003, IN PRESS J CELL PHYS; Toda K, 1999, FEBS LETT, V442, P221, DOI 10.1016/S0014-5793(98)01646-9; URUSHIDANI T, 1987, AM J PHYSIOL, V252, pG458, DOI 10.1152/ajpgi.1987.252.4.G458; Urushidani T, 1997, J MEMBRANE BIOL, V159, P99, DOI 10.1007/s002329900274; Vitale N, 2002, J CELL BIOL, V159, P79, DOI 10.1083/jcb.200203027; WALKER MW, 1992, J BIOL CHEM, V267, P3230; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	30	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36470	36475		10.1074/jbc.M305444200	http://dx.doi.org/10.1074/jbc.M305444200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860984	hybrid			2022-12-25	WOS:000185318300075
J	Misawa, K; Horiba, T; Arimura, N; Hirano, Y; Inoue, J; Emoto, N; Shimano, H; Shimizu, M; Sato, R				Misawa, K; Horiba, T; Arimura, N; Hirano, Y; Inoue, J; Emoto, N; Shimano, H; Shimizu, M; Sato, R			Sterol regulatory element-binding protein-2 interacts with hepatocyte nuclear factor-4 to enhance sterol isomerase gene expression in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; TRANSGENIC MICE; CHOLESTEROL-SYNTHESIS; RECEPTOR; LIVER; ACTIVATION; MUTATIONS; ACID; BIOSYNTHESIS; TAMOXIFEN	In the course of an effort to identify unknown targets genes for sterol regulatory element-binding proteins (SREBPs) by PCR, the gene for ATP citrate-lyase was determined to be one such gene. (Sato, R., Okamoto, A., Inoue, J., Miyamoto, W., Sakai, Y., Emoto, N., Shimano, H., and Maeda, M. (2000) J. Biol. Chem. 275, 12497-12502). We here report that gene expression of sterol Delta(8)-isomerase (SI), which catalyzes the conversion of the 8-ene isomer into the 7-ene isomer in the last steps of the cholesterol biosynthetic pathway, is regulated by SREBPs, mainly by SREBP-2. Luciferase assays using the promoter of the human SI gene revealed that a 200-base pair segment upstream region from the transcription start site contains functional elements required for the activity of the SREBPs, Sp1 and NF-Y. Interestingly, SI gene expression was well regulated by sterols in Caco-2 and HepG2 cells, in contrast with HEK293 and HeLa cells. Overexpression of hepatocyte nuclear factor (HNF)-4 in HEK293 cells augmented expression of SREBP-responsive genes including the SI gene, whereas inactivation of HNF-4 by small interfering RNAs in HepG2 cells reduced the SI gene promoter activity. The in vitro pull-down and in vivo co-immunoprecipitation experiments showed the direct interaction between SREBP-2 and HNF-4. These data provide a novel pathway by which HNF-4 potentiates the SREBP functions and stimulates expression of SREBP-responsive genes in enterohepatic cells.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan; Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc & Resp Med, Kobe, Hyogo 6500017, Japan; Univ Tsukuba, Inst Clin Med, Dept Internal Med, Div Endocrinol & Metab, Tsukuba, Ibaraki 3058575, Japan	University of Tokyo; Kobe University; University of Tsukuba	Sato, R (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan.	aroysato@mail.ecc.u-tokyo.ac.jp	Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020; INOUE, Jun/O-7352-2016	Shimano, Hitoshi/0000-0002-5562-5572; INOUE, Jun/0000-0003-4145-3754; Misawa, Koichi/0000-0002-0317-0609; Emoto, Noriaki/0000-0001-6673-2616				Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Bae SH, 2001, BIOCHEM J, V353, P689, DOI 10.1042/0264-6021:3530689; Braverman N, 1999, NAT GENET, V22, P291, DOI 10.1038/10357; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; De Fabiani E., 2001, J BIOL CHEM, V276, P30708; Derry JMJ, 1999, NAT GENET, V22, P286, DOI 10.1038/10350; Ericsson J, 1998, J BIOL CHEM, V273, P17865, DOI 10.1074/jbc.273.28.17865; Guan GM, 1997, J BIOL CHEM, V272, P10295; HANNER M, 1995, J BIOL CHEM, V270, P7551, DOI 10.1074/jbc.270.13.7551; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Holleran AL, 1998, METABOLISM, V47, P1504, DOI 10.1016/S0026-0495(98)90078-6; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Inoue J, 1998, J BIOCHEM-TOKYO, V123, P1191; Jiang GQ, 1997, ARCH BIOCHEM BIOPHYS, V340, P1, DOI 10.1006/abbi.1997.9914; Louet JF, 2002, J BIOL CHEM, V277, P37991, DOI 10.1074/jbc.M205087200; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Nakahara M, 2002, J BIOL CHEM, V277, P37229, DOI 10.1074/jbc.M206749200; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Paul R, 1998, J PHARMACOL EXP THER, V285, P1296; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Sakakura Y, 2001, BIOCHEM BIOPH RES CO, V286, P176, DOI 10.1006/bbrc.2001.5375; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SATO R, 1994, J BIOL CHEM, V269, P17267; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Silve S, 1996, J BIOL CHEM, V271, P22434, DOI 10.1074/jbc.271.37.22434; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Stroup D, 2000, J LIPID RES, V41, P1; Vidal-Puig A, 2001, NATURE, V413, P125, DOI 10.1038/35093198; Yabe D, 2002, P NATL ACAD SCI USA, V99, P16672, DOI 10.1073/pnas.262669399; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Yin LY, 2002, J BIOL CHEM, V277, P19554, DOI 10.1074/jbc.M111771200	38	60	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36176	36182		10.1074/jbc.M302387200	http://dx.doi.org/10.1074/jbc.M302387200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855700	hybrid			2022-12-25	WOS:000185318300039
J	Polly, P; Haddadi, LM; Issa, LL; Subramaniam, N; Palmer, SJ; Tay, ESE; Hardeman, EC				Polly, P; Haddadi, LM; Issa, LL; Subramaniam, N; Palmer, SJ; Tay, ESE; Hardeman, EC			hMusTRD1 alpha 1 represses MEF2 activation of the Troponin I slow enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; TRANSCRIPTION FACTOR MEF2C; FIBER-TYPE; TFII-I; TRANSGENIC MICE; GENE-EXPRESSION; HISTONE DEACETYLASE; SOLEUS MUSCLE; BINDING PROTEIN; THYROID-HORMONE	The novel transcription factor hMusTRD1alpha1 ( human muscle TFII-I repeat domain-containing protein 1alpha1; previously named MusTRD1; O'Mahoney, J.V., Guven, K. L., Lin, J., Joya, J. E., Robinson, C. S., Wade, R. P., and Hardeman, E. C. (1998) Mol. Cell. Biol. 18, 6641-6652) was identified in a yeast one-hybrid screen as a protein that binds within an upstream enhancer-containing region of the skeletal muscle-specific gene, TNNI1 ( human troponin I slow; hTnI(slow)). It has been proposed that hMusTRD1alpha1 may play an important role in fiber-specific muscle gene expression by virtue of its ability to bind to an Inr-like element (nucleotides -977 to -960) within the hTnI(slow) upstream enhancer-containing region that is necessary for slow fiber-specific expression. In this study we demonstrate that both MEF2C, a known regulator of slow fiber-specific genes, and hMusTRD1alpha1 regulate hTnIslow through the Inr-like element. Co-transfection assays in C2C12 cells and Cos-7 cells demonstrate that hMusTRD1alpha1 represses hTnI(slow) transcription and prevents MEF2C-mediated activation of hTnI(slow) transcription. Gel shift analysis shows that hMusTRD1alpha1 can abrogate MEF2C binding to its cognate site in the hTnI(slow) enhancer. Glutathione S-transferase pull-down assays demonstrate that hMusTRD1alpha1 can interact with both MEF2C and the nuclear receptor co-repressor. The data support the role of hMusTRD1alpha1 as a repressor of slow fiber-specific transcription through mechanisms involving direct interactions with MEF2C and the nuclear receptor co-repressor.	Childrens Med Res Inst, Muscle Dev Unit, Wentworthville, NSW 2145, Australia	Children's Medical Research Institute - Australia	Hardeman, EC (corresponding author), Childrens Med Res Inst, Muscle Dev Unit, Locked Bag 23, Wentworthville, NSW 2145, Australia.	ehardeman@cmri.usyd.edu.au	Hardeman, Edna C/F-8872-2012; Palmer, Stephen/F-2822-2013	Palmer, Stephen/0000-0002-4907-4719; Hardeman, Edna/0000-0003-1649-7712				Bayarsaihan D, 2000, P NATL ACAD SCI USA, V97, P7342, DOI 10.1073/pnas.97.13.7342; Bigard AX, 2000, PFLUG ARCH EUR J PHY, V440, pR259; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Calvo S, 1999, MOL CELL BIOL, V19, P515; Calvo S, 2001, MOL CELL BIOL, V21, P8490, DOI 10.1128/MCB.21.24.8490-8503.2001; CAMPIONE M, 1993, J APPL PHYSIOL, V74, P1156, DOI 10.1152/jappl.1993.74.3.1156; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CORIN SJ, 1995, P NATL ACAD SCI USA, V92, P6185, DOI 10.1073/pnas.92.13.6185; Criswell DS, 1998, J APPL PHYSIOL, V84, P1083, DOI 10.1152/jappl.1998.84.3.1083; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Dunn SE, 2001, J BIOL CHEM, V276, P45243, DOI 10.1074/jbc.M105445200; Esser K, 1999, J BIOL CHEM, V274, P12095, DOI 10.1074/jbc.274.17.12095; ESSER K, 1993, DEV BIOL, V159, P173, DOI 10.1006/dbio.1993.1231; ESSER KA, 1995, AM J PHYSIOL-CELL PH, V268, pC466, DOI 10.1152/ajpcell.1995.268.2.C466; Giger JM, 2000, AM J PHYSIOL-CELL PH, V278, pC1153, DOI 10.1152/ajpcell.2000.278.6.C1153; GUNNING P, 1991, FASEB J, V5, P3064, DOI 10.1096/fasebj.5.15.1835946; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HAUSCHKA SD, 2001, MYOLOGY; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Hughes SM, 1999, J CELL BIOL, V145, P633, DOI 10.1083/jcb.145.3.633; Hughes SM, 1997, MECH DEVELOP, V61, P151, DOI 10.1016/S0925-4773(96)00631-4; Hughes SM, 1999, CURR OPIN NEUROBIOL, V9, P54, DOI 10.1016/S0959-4388(99)80007-5; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; LEVITT LK, 1995, DNA CELL BIOL, V14, P599, DOI 10.1089/dna.1995.14.599; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; MCLENNAN IS, 1994, PROG NEUROBIOL, V44, P119, DOI 10.1016/0301-0082(94)90035-3; Murgia M, 2000, NAT CELL BIOL, V2, P142, DOI 10.1038/35004013; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Naya FJ, 1999, DEVELOPMENT, V126, P2045; Nikovits W, 2001, DEVELOPMENT, V128, P2537; O'Mahoney JV, 1998, MOL CELL BIOL, V18, P6641, DOI 10.1128/MCB.18.11.6641; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Spitz F, 1998, J BIOL CHEM, V273, P14975, DOI 10.1074/jbc.273.24.14975; SUTHERLAND CJ, 1993, DEV DYNAM, V196, P25, DOI 10.1002/aja.1001960104; Tassabehji M, 1999, EUR J HUM GENET, V7, P737, DOI 10.1038/sj.ejhg.5200396; TAY ES, 2003, IN PRESS BIOCH J; Tussie-Luna MI, 2001, P NATL ACAD SCI USA, V98, P7789, DOI 10.1073/pnas.141222298; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Washabaugh CH, 1998, DEV DYNAM, V211, P177, DOI 10.1002/(SICI)1097-0177(199802)211:2<177::AID-AJA6>3.0.CO;2-E; Wen YD, 2003, J BIOL CHEM, V278, P1841, DOI 10.1074/jbc.M206528200; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Wu H, 2002, J CLIN INVEST, V109, P1327, DOI 10.1172/JCI200215417; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yan XM, 2000, BIOCHEM J, V345, P749, DOI 10.1042/0264-6021:3450749; Zhao M, 1999, MOL CELL BIOL, V19, P21; ZHU L, 1995, DEV BIOL, V169, P487, DOI 10.1006/dbio.1995.1163	59	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36603	36610		10.1074/jbc.M212814200	http://dx.doi.org/10.1074/jbc.M212814200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857748	hybrid			2022-12-25	WOS:000185318300091
J	Goncalves, I; Hughan, SC; Schoenwaelder, SM; Yap, CL; Yuan, YP; Jackson, SP				Goncalves, I; Hughan, SC; Schoenwaelder, SM; Yap, CL; Yuan, YP; Jackson, SP			Integrin alpha(IIb)beta(3)-dependent calcium signals regulate platelet-fibrinogen interactions under flow - Involvement of phospholipase C gamma 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; VON-WILLEBRAND-FACTOR; FURA-2-LOADED HUMAN PLATELETS; SURFACE-BOUND FIBRINOGEN; REAL-TIME ANALYSIS; THROMBUS FORMATION; TYROSINE PHOSPHORYLATION; VONWILLEBRAND-FACTOR; OUTSIDE-IN; ADHESION	Platelet adhesion to fibrinogen is important for platelet aggregation and thrombus growth. In this study we have examined the mechanisms regulating platelet adhesion on immobilized fibrinogen under static and shear conditions. We demonstrate that integrin alpha(IIb)beta(3) engagement of immobilized fibrinogen is sufficient to induce an oscillatory calcium response, necessary for lamellipodial formation and platelet spreading. Released ADP increases the proportion of platelets exhibiting a cytosolic calcium response but is not essential for calcium signaling or lamellipodial extension. Pretreating platelets with the Src kinase inhibitor PP2, the inositol 1,4,5-trisphosphate (IP3) receptor antagonist 2-aminoethoxydiphenyl borate (APB-2), or the phospholipase C ( PLC) inhibitor U73122 abolished calcium signaling and platelet spreading, suggesting a major role for Src kinase-regulated PLC isoforms in these processes. Analysis of PLCgamma2(-/-) mouse platelets revealed a major role for this isoform in regulating cytosolic calcium flux and platelet spreading on fibrinogen. Under flow conditions, platelets derived from PLCgamma2(-/-) mice formed less stable adhesive interactions with fibrinogen, particularly in the presence of ADP antagonists. Our studies define an important role for PLCgamma2 in integrin alpha(IIb)beta(3)-dependent calcium flux, necessary for stable platelet adhesion and spreading on fibrinogen. Furthermore, they establish an important cooperative signaling role for PLCgamma2 and ADP in regulating platelet adhesion efficiency on fibrinogen.	Monash Univ, Dept Med, Australian Ctr Blood Dis, Box Hill Hosp, Box Hill, Vic 3128, Australia	Box Hill Hospital; Monash University	Jackson, SP (corresponding author), Monash Univ, Dept Med, Australian Ctr Blood Dis, Box Hill Hosp, Box Hill, Vic 3128, Australia.	shaun.jackson@med.monash.edu.au	Goncalves, Isaac/AAO-8371-2020; Schoenwaelder, Simone/E-9506-2011	Schoenwaelder, Simone/0000-0003-0465-5840; Jackson, Shaun/0000-0002-4750-1991				ALEVRIADOU BR, 1993, BLOOD, V81, P1263; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Cowan KJ, 2000, J BIOL CHEM, V275, P36423, DOI 10.1074/jbc.M004068200; Goto S, 1998, J CLIN INVEST, V101, P479, DOI 10.1172/JCI973; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HEEMSKERK JWM, 1993, J BIOL CHEM, V268, P356; HEEMSKERK JWM, 1992, BIOCHEM J, V283, P379, DOI 10.1042/bj2830379; Heemskerk JWM, 2001, J PHYSIOL-LONDON, V535, P625, DOI 10.1111/j.1469-7793.2001.00625.x; Heraud JM, 1998, J BIOL CHEM, V273, P17817, DOI 10.1074/jbc.273.28.17817; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; JAKOBSEN E, 1974, THROMB RES, V4, P499, DOI 10.1016/0049-3848(74)90227-8; Jen CJ, 1996, BLOOD, V87, P3775, DOI 10.1182/blood.V87.9.3775.bloodjournal8793775; Lee SB, 1996, BLOOD, V88, P1684; LINDON JN, 1986, BLOOD, V68, P355; Mangin P, 2003, FEBS LETT, V542, P53, DOI 10.1016/S0014-5793(03)00337-5; Mazzucato M, 2002, BLOOD, V100, P2793, DOI 10.1182/blood-2002-02-0514; Melford SK, 1997, J BIOL CHEM, V272, P27539, DOI 10.1074/jbc.272.44.27539; Moog S, 2001, BLOOD, V98, P1038, DOI 10.1182/blood.V98.4.1038; Nesbitt WS, 2002, J BIOL CHEM, V277, P2965, DOI 10.1074/jbc.M110070200; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; Ni HY, 2003, P NATL ACAD SCI USA, V100, P2415, DOI 10.1073/pnas.2628067100; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; Sage SO, 2000, CELL CALCIUM, V28, P119, DOI 10.1054/ceca.2000.0139; SALZMAN EW, 1987, ANN NY ACAD SCI, V516, P184, DOI 10.1111/j.1749-6632.1987.tb33040.x; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1995, J BIOL CHEM, V270, P28812, DOI 10.1074/jbc.270.48.28812; Shattil SJ, 1999, THROMB HAEMOSTASIS, V82, P318; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Tsuji S, 1999, BLOOD, V94, P968, DOI 10.1182/blood.V94.3.968.415a13_968_975; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7; Wonerow P, 2002, BIOCHEM J, V364, P755, DOI 10.1042/BJ20020128; Woodside DG, 2001, CURR BIOL, V11, P1799, DOI 10.1016/S0960-9822(01)00565-6; Yap CL, 2000, J BIOL CHEM, V275, P41377, DOI 10.1074/jbc.M005590200; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847; Zaffran Y, 2000, J BIOL CHEM, V275, P16779, DOI 10.1074/jbc.275.22.16779; Zaidi TN, 1996, BLOOD, V88, P2967, DOI 10.1182/blood.V88.8.2967.bloodjournal8882967	45	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34812	34822		10.1074/jbc.M306504200	http://dx.doi.org/10.1074/jbc.M306504200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832405	hybrid			2022-12-25	WOS:000185164400012
J	Calderwood, MS; Gannoun-Zaki, L; Wellems, TE; Deitsch, KW				Calderwood, MS; Gannoun-Zaki, L; Wellems, TE; Deitsch, KW			Plasmodium falciparum var genes are regulated by two regions with separate promoters, one upstream of the coding region and a second within the intron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGENIC VARIATION; MALARIA PARASITES; BINDING-PROTEIN; NUCLEAR-MATRIX; DNA-REPLICATION; IN-VIVO; TRANSCRIPTION; EXPRESSION; INSULATORS; BOUNDARIES	Antigenic variation in Plasmodium falciparum malaria parasites results from switches in expression among members of the multicopy var gene family. This family is subject to allelic exclusion by which particular genes are expressed while the rest of the family remains transcriptionally silent. Evidence from reporter constructs indicates that var gene silencing involves a cooperative interaction between the var intron and an upstream element and requires transition of the parasites through S-phase of the cell cycle. These findings implicate chromatin assembly in the process of regulating var gene expression and antigenic variation. Here we characterize the var intron and the elements within it that are necessary for var transcriptional silencing. Alignments of var introns show a highly conserved structure that consists of three discreet regions with distinct base pair compositions. The middle region is highly AT-rich and is sufficient to silence an associated var promoter. Constructs that include a typical var intron upstream of a reporter gene or drug-selectable marker reveal that the intron also possesses promoter activity, presumably providing an explanation for the origin of the previously described var "sterile" transcripts. Deletions that disable the promoter activity of the intron also eliminate its ability to function as a silencer. These findings suggest that interactions between the regions of these two promoters and the generation of the sterile transcripts play a significant role in regulating var gene expression.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Deitsch, KW (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, 1300 York Ave,W-704,Box 62, New York, NY 10021 USA.	kwd2001@med.cornell.edu		Gannoun, Laila/0000-0002-9644-1083	NIAID NIH HHS [AI 52390] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000483, R01AI052390, Z01AI000483] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEY SB, 1984, J EXP MED, V160, P1585, DOI 10.1084/jem.160.5.1585; Arnot DE, 1998, ANN TROP MED PARASIT, V92, P361, DOI 10.1080/00034989859357; Avramova Z, 1999, TRENDS GENET, V15, P138, DOI 10.1016/S0168-9525(99)01712-6; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Bi X, 2001, CURR OPIN GENET DEV, V11, P199, DOI 10.1016/S0959-437X(00)00179-9; Bischoff E, 2000, MOL MICROBIOL, V35, P1005, DOI 10.1046/j.1365-2958.2000.01788.x; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Borst P, 2002, CELL, V109, P5, DOI 10.1016/S0092-8674(02)00711-0; Cai HNN, 2001, DEVELOPMENT, V128, P4339; Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; Deitsch KW, 1999, MOL BIOCHEM PARASIT, V101, P107, DOI 10.1016/S0166-6851(99)00062-6; Deitsch KW, 2001, NATURE, V412, P875, DOI 10.1038/35091146; Deitsch KW, 2001, NUCLEIC ACIDS RES, V29, P850, DOI 10.1093/nar/29.3.850; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Duffy MF, 2002, MOL MICROBIOL, V43, P1285, DOI 10.1046/j.1365-2958.2002.02822.x; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Fourel G, 2001, EMBO REP, V2, P124, DOI 10.1093/embo-reports/kve024; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gerasimova TI, 2001, ANNU REV GENET, V35, P193, DOI 10.1146/annurev.genet.35.102401.090349; Girard F, 1998, EMBO J, V17, P2079, DOI 10.1093/emboj/17.7.2079; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; Hall N, 2002, NATURE, V419, P527, DOI 10.1038/nature01095; Ikeda S, 2000, BIOCHEM BIOPH RES CO, V273, P1063, DOI 10.1006/bbrc.2000.3071; Kawai Y, 2003, BBA-GENE STRUCT EXPR, V1625, P246, DOI 10.1016/S0167-4781(02)00627-9; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; Kyes S, 2000, MOL BIOCHEM PARASIT, V105, P311, DOI 10.1016/S0166-6851(99)00193-0; Kyes S, 2001, ANNU REV MICROBIOL, V55, P673, DOI 10.1146/annurev.micro.55.1.673; Kyes SA, 2003, MOL MICROBIOL, V48, P1339, DOI 10.1046/j.1365-2958.2003.03505.x; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; LIAO WC, 1994, GENE, V146, P183, DOI 10.1016/0378-1119(94)90291-7; Liston DR, 1999, MOL CELL BIOL, V19, P2380; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; Mongelard F, 2001, NAT STRUCT BIOL, V8, P192, DOI 10.1038/84905; Morisawa G, 2000, PLANT CELL, V12, P1903, DOI 10.1105/tpc.12.10.1903; Nash TE, 2002, MOL MICROBIOL, V45, P585, DOI 10.1046/j.1365-2958.2002.03029.x; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3454310; Sabatino DE, 1998, MOL CELL BIOL, V18, P6634, DOI 10.1128/MCB.18.11.6634; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; Serizawa S, 2000, NAT NEUROSCI, V3, P687, DOI 10.1038/76641; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Taylor HM, 2000, MOL BIOCHEM PARASIT, V105, P13, DOI 10.1016/S0166-6851(99)00159-0; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	50	140	143	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34125	34132		10.1074/jbc.M213065200	http://dx.doi.org/10.1074/jbc.M213065200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12832422	Green Published, hybrid			2022-12-25	WOS:000185047500065
J	De Maria, F; Pedersen, JZ; Caccuri, AM; Antonini, G; Turella, P; Stella, L; Lo Bello, M; Federici, G; Ricci, G				De Maria, F; Pedersen, JZ; Caccuri, AM; Antonini, G; Turella, P; Stella, L; Lo Bello, M; Federici, G; Ricci, G			The specific interaction of dinitrosyl-diglutathionyl-iron complex, a natural NO carrier, with the glutathione transferase superfamily - Suggestion for an evolutionary pressure in the direction of the storage of nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; SULFATE-BINDING POCKET; PROTEUS-MIRABILIS; CRYSTAL-STRUCTURE; S-TRANSFERASES; ACTIVE-SITE; BIOCHEMICAL PATHWAYS; CATALYTIC ACTIVITY; MOLECULAR-CLONING; SUBSTRATE-BINDING	The interaction of dinitrosyl-diglutathionyl-iron complex (DNDGIC), a natural carrier of nitric oxide, with representative members of the human glutathione transferase (GST) superfamily, i.e. GSTA1-1, GSTM2-2, GSTP1-1, and GSTT2-2, has been investigated by means of pre-steady and steady state kinetics, fluorometry, electron paramagnetic resonance, and radiometric experiments. This complex binds with extraordinary affinity to the active site of all these dimeric enzymes; GSTA1-1 shows the strongest interaction (K-D congruent to 10(-10) M), whereas GSTM2-2 and GSTP1-1 display similar and slightly lower affinities (K-D congruent to 10(-9) M). Binding of the complex to GSTA1-1 triggers structural intersubunit communication, which lowers the affinity for DNDGIC in the vacant subunit and also causes a drastic loss of enzyme activity. Negative cooperativity is also found in GSTM2-2 and GSTP1-1, but it does not affect the catalytic competence of the second subunit. Stopped-flow and fluorescence data fit well to a common minimal binding mechanism, which includes an initial interaction with GSH and a slower bimolecular interaction of DNDGIC with one high and one low affinity binding site. Interestingly, the Theta class GSTT2-2, close to the ancestral precursor of GSTs, shows very slow binding kinetics and hundred times lowered affinity (K-D congruent to 10(-7) M), whereas the bacterial GSTB1-1 is not inhibited by DNDGIC. Molecular modeling and EPR data reveal structural details that may explain the observed kinetic data. The optimized interaction with this NO carrier, developed in the more recently evolved GSTs, may be related to the acquired capacity to utilize NO as a signal messenger.	Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Rome Roma Tre, Dept Biol, I-00146 Rome, Italy; Childrens Hosp IRCCS Bambin Gesu, I-00165 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; Roma Tre University; IRCCS Bambino Gesu	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Chem Sci & Technol, Via Ric Sci, I-00133 Rome, Italy.	riccig@uniroma2.it	Stella, Lorenzo/A-7996-2010; CACCURI, ANNA MARIA/AFU-2643-2022	Stella, Lorenzo/0000-0002-5489-7381; Antonini, Giovanni/0000-0002-2115-8961; Ricci, Giorgio/0000-0002-7108-2846; CACCURI, ANNA MARIA/0000-0002-3756-4163				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BOARD PG, 1987, BIOCHEM J, V248, P937, DOI 10.1042/bj2480937; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; Caccuri AM, 1999, J BIOL CHEM, V274, P19276, DOI 10.1074/jbc.274.27.19276; Caccuri AM, 2002, BIOCHEMISTRY-US, V41, P4686, DOI 10.1021/bi0158425; Caccuri AM, 2002, J BIOL CHEM, V277, P18777, DOI 10.1074/jbc.M201137200; Caccuri AM, 2001, J BIOL CHEM, V276, P5427, DOI 10.1074/jbc.M002819200; Caccuri AM, 2001, J BIOL CHEM, V276, P5432, DOI 10.1074/jbc.M002818200; Caccuri AM, 1999, BIOCHEM J, V344, P419, DOI 10.1042/0264-6021:3440419; Casalone E, 1998, FEBS LETT, V423, P122, DOI 10.1016/S0014-5793(98)00080-5; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Flanagan JU, 1999, PROTEIN SCI, V8, P2205, DOI 10.1110/ps.8.10.2205; Giannone G, 2000, J PHYSIOL-LONDON, V529, P735, DOI 10.1111/j.1469-7793.2000.00735.x; GILLHAM B, 1971, BIOCHEM J, V121, P667, DOI 10.1042/bj1210667; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; Lo Bello M, 2001, J BIOL CHEM, V276, P42138; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; Malyshev IY, 1999, NITRIC OXIDE-BIOL CH, V3, P105, DOI 10.1006/niox.1999.0213; Malysheva IY, 1996, FEBS LETT, V391, P21, DOI 10.1016/0014-5793(96)00691-6; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MANNERVIK B, 1986, CHEM SCRIPTA, V26B, P281; Manukhina E B, 1998, Biull Eksp Biol Med, V125, P30; MCDONALD CC, 1965, J AM CHEM SOC, V87, P3319, DOI 10.1021/ja01093a007; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; Mendes P, 1998, BIOINFORMATICS, V14, P869, DOI 10.1093/bioinformatics/14.10.869; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; Muller B, 1996, BRIT J PHARMACOL, V119, P1281, DOI 10.1111/j.1476-5381.1996.tb16034.x; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; MULSCH A, 1993, BIOCHEM BIOPH RES CO, V196, P1303, DOI 10.1006/bbrc.1993.2394; Mulsch A., 1994, DRUG RES, V44, P408; PEDERSEN JZ, 1988, J MAGN RESON, V77, P369, DOI 10.1016/0022-2364(88)90186-2; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; Perito B, 1996, BIOCHEM J, V318, P157, DOI 10.1042/bj3180157; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; ROSS VL, 1993, BIOCHEM J, V294, P373, DOI 10.1042/bj2940373; Rossjohn J, 1998, STRUCTURE, V6, P309, DOI 10.1016/S0969-2126(98)00034-3; Tan KL, 1996, BIOCHEM J, V319, P315, DOI 10.1042/bj3190315; Turella P, 2003, J BIOL CHEM, V278, P42294, DOI 10.1074/jbc.M305569200; Ueno T, 2000, JPN J PHARMACOL, V82, P95, DOI 10.1254/jjp.82.95; Vanin AF, 1997, NITRIC OXIDE-BIOL CH, V1, P191, DOI 10.1006/niox.1997.0122; VANIN AF, 1991, FEBS LETT, V289, P1, DOI 10.1016/0014-5793(91)80894-9; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; Wilce MCJ, 1994, BIOCHIM BIOPHYS ACTA, V205, P1	54	52	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42283	42293		10.1074/jbc.M305568200	http://dx.doi.org/10.1074/jbc.M305568200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12871945	hybrid			2022-12-25	WOS:000185989500088
J	Girardin, SE; Travassos, LH; Herve, M; Blanot, D; Boneca, IG; Philpott, DJ; Sansonetti, PJ; Mengin-Lecreulx, D				Girardin, SE; Travassos, LH; Herve, M; Blanot, D; Boneca, IG; Philpott, DJ; Sansonetti, PJ; Mengin-Lecreulx, D			Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ALANINE AMIDASE; N-ACETYLMURAMIC ACID; ESCHERICHIA-COLI; DIAMINOPIMELIC ACID; CELL-WALL; BACTERIAL PEPTIDOGLYCAN; SHIGELLA-FLEXNERI; HOST RECOGNITION; CROHNS-DISEASE; KAPPA-B	Nod1 and Nod2 are mammalian proteins implicated in the intracellular detection of pathogen-associated molecular patterns. Recently, naturally occurring peptidoglycan ( PG) fragments were identified as the microbial motifs sensed by Nod1 and Nod2. Whereas Nod2 detects GlcNAc-MurNAc dipeptide (GM-Di), Nod1 senses a unique diaminopimelate-containing GlcNAc-MurNAc tripeptide muropeptide (GM-Tri(DAP)) found mostly in Gram-negative bacterial PGs. Because Nod1 and Nod2 detect similar yet distinct muropeptides, we further analyzed the molecular sensing specificity of Nod1 and Nod2 toward PG fragments. Using a wide array of natural or modified muramyl peptides, we show here that Nod1 and Nod2 have evolved divergent strategies to achieve PG sensing. By defining the PG structural requirements for Nod1 and Nod2 sensing, this study reveals how PG processing and modifications, either by host or bacterial enzymes, may affect innate immune responses.	Inst Pasteur, INSERM, U389, Unite Pathogenie Microbienne Mol, F-75724 Paris 15, France; Inst Pasteur, Grp Immun Innee & Signalisat, F-75724 Paris, France; Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris 15, France; Univ Paris 11, CNRS, UMR 8619, Inst Biochim & Biophys Mol & Cellulaire, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Girardin, SE (corresponding author), Inst Pasteur, INSERM, U389, Unite Pathogenie Microbienne Mol, 28 Rue Dr Roux, F-75724 Paris 15, France.		Boneca, Ivo G/H-1677-2014; Travassos, Leonardo/G-1925-2012	Boneca, Ivo G/0000-0001-8122-509X; Travassos, Leonardo/0000-0003-1323-3797; MENGIN-LECREULX, Dominique/0000-0003-3205-0275				Atrih A, 1999, J BACTERIOL, V181, P3956, DOI 10.1128/JB.181.13.3956-3966.1999; AUGER G, 1995, J PRAK CHEM-CHEM ZTG, V337, P351, DOI 10.1002/prac.19953370176; Auger G, 1998, PROTEIN EXPRES PURIF, V13, P23, DOI 10.1006/prep.1997.0850; Bartoleschi C, 2002, CELL MICROBIOL, V4, P613, DOI 10.1046/j.1462-5822.2002.00216.x; BERGES DA, 1986, J MED CHEM, V29, P89, DOI 10.1021/jm00151a015; Bertrand JA, 1999, J MOL BIOL, V289, P579, DOI 10.1006/jmbi.1999.2800; BLANOT D, 1994, CARBOHYD RES, V252, P107; Chamaillard M, 2003, P NATL ACAD SCI USA, V100, P3455, DOI 10.1073/pnas.0530276100; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; Gelius E, 2003, BIOCHEM BIOPH RES CO, V306, P988, DOI 10.1016/S0006-291X(03)01096-9; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; MENGINLECREULX D, 1988, J BACTERIOL, V170, P2031, DOI 10.1128/jb.170.5.2031-2039.1988; MENGINLECREULX D, 1994, J BACTERIOL, V176, P4321, DOI 10.1128/jb.176.14.4321-4327.1994; MICHAUD C, 1987, EUR J BIOCHEM, V166, P631, DOI 10.1111/j.1432-1033.1987.tb13560.x; MOLLNER S, 1984, ARCH MICROBIOL, V140, P171, DOI 10.1007/BF00454921; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; RICHAUD C, 1993, J BIOL CHEM, V268, P26827; SACHS H, 1953, J AM CHEM SOC, V75, P4608, DOI 10.1021/ja01114a528; Templin MF, 1999, EMBO J, V18, P4108, DOI 10.1093/emboj/18.15.4108; VANHEIJENOORT J, 1969, B SOC CHIM FR, P2743; VANHEIJENOORT J, 1968, B SOC CHIM FR, P2828; VANHEIJENOORT J, 1975, EUR J BIOCHEM, V58, P611	31	499	533	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41702	41708		10.1074/jbc.M307198200	http://dx.doi.org/10.1074/jbc.M307198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12871942	hybrid			2022-12-25	WOS:000185989500020
J	Liu, Q; Huang, QQ; Teng, MK; Weeks, CM; Jelsch, C; Zhang, RG; Niu, LW				Liu, Q; Huang, QQ; Teng, MK; Weeks, CM; Jelsch, C; Zhang, RG; Niu, LW			The crystal structure of a novel, inactive, lysine 49 PLA2 from Agkistrodon acutus venom - An ultrahigh resolution, ab initio structure determination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY-DIFFRACTION DATA; X-RAY; PHOSPHOLIPASE A(2); CHARGE-DENSITY; ELECTRON-DENSITY; MYOTOXIN-II; PROTEINS; IMPLEMENTATION; REFINEMENT; PARAMETERS	The crystal structure of acutohaemolysin, a lysine 49 phospholipase A2 protein with 1010 non-hydrogen protein atoms and 232 water molecules, has been determined ab initio using the program SnB at an ultrahigh resolution of 0.8 Angstrom. The lack of catalytic activity appears to be related to the presence of Phe(102), which prevents the access of substrate to the active site. The substitution of tryptophan for leucine at residue 10 interferes with dimer formation and may be responsible for the additional loss of hemolytic activity. The ultrahigh resolution of the experimental diffraction data permits alternative conformations to be modeled for disordered residues, many hydrogen atoms to be located, the protonation of the Nepsilon2 atom in the catalytic residue His(48) to be observed experimentally, and the density of the bonding electrons to be analyzed in detail.	Chinese Acad Sci, Key Lab Struct Biol, Hefei 230026, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Dept Mol & Cell Biol, Hefei 230026, Anhui, Peoples R China; Hauptman Woodward Med Res Inst, Buffalo, NY 14203 USA; Fac Sci, CNRS, Lab Cristallog & Modelisat Mat Mineraux & Biol, F-54506 Vandoeuvre Les Nancy, France; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA	Chinese Academy of Sciences; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Hauptman Woodward Medical Research Institute; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; United States Department of Energy (DOE); Argonne National Laboratory	Niu, LW (corresponding author), Chinese Acad Sci, Key Lab Struct Biol, 96 Jinzhai Rd, Hefei 230026, Anhui, Peoples R China.	lwniu@ustc.edu.cn	Liu, Qun/A-8757-2011	Liu, Qun/0000-0002-1179-290X; jelsch, christian/0000-0002-2655-0313	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P01EB002057] Funding Source: NIH RePORTER; NIBIB NIH HHS [EB-002057] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Arni RK, 1999, ARCH BIOCHEM BIOPHYS, V366, P177, DOI 10.1006/abbi.1999.1210; Blessing RH, 1996, ACTA CRYSTALLOGR D, V52, P257, DOI 10.1107/S0907444995014053; Coppens P, 1998, ACTA CRYSTALLOGR A, V54, P779, DOI 10.1107/S0108767398008575; COPPENS P, 1997, XRAY CHARGE DENSITIE, P233; Dauter Z, 1997, CURR OPIN STRUC BIOL, V7, P681, DOI 10.1016/S0959-440X(97)80078-4; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fan CY, 1999, GENET ANAL-BIOMOL E, V15, P15, DOI 10.1016/S1050-3862(98)00033-3; FRANCIS B, 1991, ARCH BIOCHEM BIOPHYS, V284, P352, DOI 10.1016/0003-9861(91)90307-5; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; Guillot B, 2001, J APPL CRYSTALLOGR, V34, P214, DOI 10.1107/S0021889801001753; GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z; HANSEN NK, 1978, ACTA CRYSTALLOGR A, V34, P909, DOI 10.1107/S0567739478001886; Harris TK, 2002, IUBMB LIFE, V53, P85, DOI 10.1080/15216540211468; HOLLAND DR, 1990, J BIOL CHEM, V265, P17649; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Housset D, 2000, ACTA CRYSTALLOGR D, V56, P151, DOI 10.1107/S0907444999014948; Huang QQ, 2000, ACTA CRYSTALLOGR D, V56, P907, DOI 10.1107/S0907444900005643; Jelsch C, 2000, P NATL ACAD SCI USA, V97, P3171, DOI 10.1073/pnas.97.7.3171; Jelsch C, 1998, PROTEINS, V31, P320, DOI 10.1002/(SICI)1097-0134(19980515)31:3<320::AID-PROT8>3.0.CO;2-M; Jelsch C, 1998, ACTA CRYSTALLOGR D, V54, P1306, DOI 10.1107/S0907444998004466; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kuhn P, 1998, BIOCHEMISTRY-US, V37, P13446, DOI 10.1021/bi9813983; Kumar S, 1999, J MOL BIOL, V293, P1241, DOI 10.1006/jmbi.1999.3218; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LECOMTE C, 1986, J AM CHEM SOC, V108, P6942, DOI 10.1021/ja00282a019; Lee WH, 2001, BIOCHEMISTRY-US, V40, P28, DOI 10.1021/bi0010470; Merritt EA, 1999, ACTA CRYSTALLOGR D, V55, P1109, DOI 10.1107/S0907444999003789; MILLER R, 1994, J APPL CRYSTALLOGR, V27, P613, DOI 10.1107/S0021889894000191; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ownby CL, 1999, TOXICON, V37, P411, DOI 10.1016/S0041-0101(98)00188-3; PEDERSEN JZ, 1995, BIOCHEMISTRY-US, V34, P4670, DOI 10.1021/bi00014a021; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; RENETSEDER R, 1985, J BIOL CHEM, V260, P1627; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; Sheldrick G.M., 1997, SHELX 97 MANUAL; SHIMOHIGASHI Y, 1995, J BIOCHEM-TOKYO, V118, P1037, DOI 10.1093/jb/118.5.1037; Spackman MA, 1996, ACTA CRYSTALLOGR B, V52, P1023, DOI 10.1107/S0108768196008294; STEWART RF, 1993, BIOPHYS J, V65, P998, DOI 10.1016/S0006-3495(93)81142-1; Svergun DI, 1998, P NATL ACAD SCI USA, V95, P2267, DOI 10.1073/pnas.95.5.2267; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ward RJ, 1998, TOXICON, V36, P1623, DOI 10.1016/S0041-0101(98)00155-X; Ward RJ, 1998, PROTEIN ENG, V11, P285, DOI 10.1093/protein/11.4.285; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; WEEKS CM, 1994, ACTA CRYSTALLOGR A, V50, P210, DOI 10.1107/S0108767393008992; Yamaguchi Y, 1997, BIOCHEM MOL BIOL INT, V43, P19	47	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41400	41408		10.1074/jbc.M305210200	http://dx.doi.org/10.1074/jbc.M305210200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12871974	hybrid			2022-12-25	WOS:000185847200120
J	Oishi, K; Miyazaki, K; Kadota, K; Kikuno, R; Nagase, T; Atsumi, G; Ohkura, N; Azama, T; Mesaki, M; Yukimasa, S; Kobayashi, H; Iitaka, C; Umehara, T; Horikoshi, M; Kudo, T; Shimizu, Y; Yano, M; Monden, M; Machida, K; Matsuda, J; Horie, S; Todo, T; Ishida, N				Oishi, K; Miyazaki, K; Kadota, K; Kikuno, R; Nagase, T; Atsumi, G; Ohkura, N; Azama, T; Mesaki, M; Yukimasa, S; Kobayashi, H; Iitaka, C; Umehara, T; Horikoshi, M; Kudo, T; Shimizu, Y; Yano, M; Monden, M; Machida, K; Matsuda, J; Horie, S; Todo, T; Ishida, N			Genome-wide expression analysis of mouse liver reveals CLOCK-regulated circadian output genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; MUTANT MICE; TRANSCRIPTION; RHYTHMICITY; INCREASE; MUTATION; PROTEIN; PERIOD; MPER2; MODEL	CLOCK is a positive component of a transcription/ translation-based negative feedback loop of the central circadian oscillator in the suprachiasmatic nucleus in mammals. To examine CLOCK-regulated circadian transcription in peripheral tissues, we performed microarray analyses using liver RNA isolated from Clock mutant mice. We also compared expression profiles with those of Cryptochromes (Cry1 and Cry2) double knockout mice. We identified more than 100 genes that fluctuated from day to night and of which expression levels were decreased in Clock mutant mice. In Cry-deficient mice, the expression levels of most CLOCK-regulated genes were elevated to the upper range of normal oscillation. Most of the screened genes had a CLOCK/BMAL1 binding site (E box) in the 5'-flanking region. We found that CLOCK was absolutely concerned with the circadian transcription of one type of liver genes ( such as DBP, TEF, and Usp2) and partially with another ( such as mPer1, mPer2, mDec1, Nocturnin, P450 oxidoreductase, and FKBP51) because the latter were damped but remained rhythmic in the mutant mice. Our results showed that CLOCK and CRY proteins are involved in the transcriptional regulation of many circadian output genes in the mouse liver. In addition to being a core component of the negative feedback loop that drives the circadian oscillator, CLOCK also appears to be involved in various physiological functions such as cell cycle, lipid metabolism, immune functions, and proteolysis in peripheral tissues.	Natl Inst Adv Ind Sci & Technol, Clock Cell Biol Grp, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan; Natl Inst Adv Ind Sci & Technol, Computat Biol Res Ctr, Koto Ku, Tokyo 1350064, Japan; Kazusa DNA Res Inst, Dept Human Gene Res, Lab Human Gene Res 1, Chiba 2920818, Japan; Teikyo Univ, Fac Pharmaceut Sci, Kanagawa 1990195, Japan; Osaka Univ, Grad Sch Med, Dept Surg & Clin Oncol, Osaka 5650871, Japan; Waseda Univ, Sch Human Sci, Dept Hyg & Publ Hlth, Tokorozawa, Saitama 3591192, Japan; Tokyo Inst Technol, Dept Biomol Engn, Kanagawa 2268501, Japan; Japan Sci & Technol Corp, Exploratory Res Adv Technol, Horikoshi Gene Selector Project, Tsukuba, Ibaraki 3002635, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058502, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Dev Biol Lab, Bunkyo Ku, Tokyo 1130032, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); Kazusa DNA Research Institute; Teikyo University; Osaka University; Waseda University; Tokyo Institute of Technology; Japan Science & Technology Agency (JST); Kyoto University; University of Tsukuba; University of Tokyo	Ishida, N (corresponding author), Natl Inst Adv Ind Sci & Technol, Clock Cell Biol Grp, Inst Biol Resources & Funct, Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	n.ishida@aist.go.jp	Jansen, Heiko T./A-5770-2008; Kadota, Koji/C-9168-2011; Kobayashi, Hisato/AAP-7910-2020; Miyazaki, Koyomi/L-6539-2018; Umehara, Takashi/N-5683-2015; , Kadota/AAP-2804-2020; Oishi, Katsutaka/L-6906-2018; Umehara, Takashi/AHB-1730-2022; Kinoshita, Chisato/AAW-5116-2020	Jansen, Heiko T./0000-0003-0178-396X; Kadota, Koji/0000-0002-3907-4336; Miyazaki, Koyomi/0000-0002-5464-1095; Umehara, Takashi/0000-0003-3464-2960; , Kadota/0000-0002-3907-4336; Oishi, Katsutaka/0000-0002-4870-0837; Umehara, Takashi/0000-0003-3464-2960; Kinoshita, Chisato/0000-0001-5877-0196; Kobayashi, Hisato/0000-0003-3800-4691				Akhtar RA, 2002, CURR BIOL, V12, P540, DOI 10.1016/S0960-9822(02)00759-5; Baggs JE, 2003, CURR BIOL, V13, P189, DOI 10.1016/S0960-9822(03)00014-9; Cassone VM, 2002, NUTRITION, V18, P814, DOI 10.1016/S0899-9007(02)00937-1; Cha JY, 2001, EXP MOL MED, V33, P59, DOI 10.1038/emm.2001.11; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Debeljak N, 2003, ARCH BIOCHEM BIOPHYS, V409, P159, DOI 10.1016/S0003-9861(02)00418-6; Delaunay F, 2002, TRENDS GENET, V18, P595, DOI 10.1016/S0168-9525(02)02794-4; Desai UJ, 2001, DIABETES, V50, P2287, DOI 10.2337/diabetes.50.10.2287; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Humphries A, 2002, J NEUROENDOCRINOL, V14, P101, DOI 10.1046/j.0007-1331.2001.00738.x; Katzenberg D, 1998, SLEEP, V21, P569, DOI 10.1093/sleep/21.6.569; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lavery DJ, 1999, MOL CELL BIOL, V19, P6488; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Matsuzaka T, 2002, J LIPID RES, V43, P911; Nakamura W, 2002, NAT NEUROSCI, V5, P399, DOI 10.1038/nn843; Oishi K, 2002, BIOCHEM BIOPH RES CO, V298, P198, DOI 10.1016/S0006-291X(02)02427-0; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; PANDO MP, 2001, SCI STKE; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Rouyer F, 1997, EMBO J, V16, P3944, DOI 10.1093/emboj/16.13.3944; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Sei H, 2003, NEUROSCIENCE, V117, P785, DOI 10.1016/S0306-4522(02)00909-0; Sei H, 2001, NEUROREPORT, V12, P1461, DOI 10.1097/00001756-200105250-00033; Sommer D, 2002, ARCH BIOCHEM BIOPHYS, V404, P271, DOI 10.1016/S0003-9861(02)00242-4; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Travnickova-Bendova Z, 2002, P NATL ACAD SCI USA, V99, P7728, DOI 10.1073/pnas.102075599; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; Vermeer H, 2003, J CLIN ENDOCR METAB, V88, P277, DOI 10.1210/jc.2002-020354; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Wang Y, 2001, BMC Dev Biol, V1, P9, DOI 10.1186/1471-213X-1-9; Wilsbacher LD, 2002, P NATL ACAD SCI USA, V99, P489, DOI 10.1073/pnas.012248599; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301	45	271	281	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41519	41527		10.1074/jbc.M304564200	http://dx.doi.org/10.1074/jbc.M304564200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12865428	hybrid			2022-12-25	WOS:000185847200132
J	Gobeil, F; Bernier, SG; Vazquez-Tello, A; Brault, S; Beauchamp, MH; Quiniou, C; Marrache, AM; Checchin, D; Sennlaub, F; Hou, X; Nader, M; Bkaily, G; Ribeiro-da-Silva, A; Goetzl, EJ; Chemtob, S				Gobeil, F; Bernier, SG; Vazquez-Tello, A; Brault, S; Beauchamp, MH; Quiniou, C; Marrache, AM; Checchin, D; Sennlaub, F; Hou, X; Nader, M; Bkaily, G; Ribeiro-da-Silva, A; Goetzl, EJ; Chemtob, S			Modulation of pro-inflammatory gene expression by nuclear lysophosphatidic acid receptor type-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR RECEPTOR; SMOOTH-MUSCLE-CELLS; SPHINGOSINE 1-PHOSPHATE; PHOSPHOLIPASE A(2); CEREBRAL-CORTEX; RAT-LIVER; ENDOTHELIAL-CELLS; HYDROGEN-PEROXIDE	Lysophosphatidic acid (LPA) is a bioactive molecule involved in inflammation, immunity, wound healing, and neoplasia. Its pleiotropic actions arise presumably by interaction with their cell surface G protein-coupled receptors. Herein, the presence of the specific nuclear lysophosphatidic acid receptor-1 (LPA(1)R) was revealed in unstimulated porcine cerebral microvascular endothelial cells (pCMVECs), LPA(1)R stably transfected HTC4 rat hepatoma cells, and rat liver tissue using complementary approaches, including radioligand binding experiments, electron- and cryomicroscopy, cell fractionation, and immunoblotting with three distinct antibodies. Co-immunoprecipitation studies in enriched plasmalemmal fractions of unstimulated pCMVEC showed that LPA(1)Rs are dually sequestrated in caveolin-1 and clathrin sub-compartments, whereas in nuclear fractions LPA1R appeared primarily in caveolae. Immunofluorescent assays using a cell-free isolated nuclear system confirmed LPA1R and caveolin-1 co-localization. In pCMVEC, LPA-stimulated increases in cyclooxygenase-2 and inducible nitric-oxide synthase RNA and protein expression were insensitive to caveolea-disrupting agents but sensitive to LPA-generating phospholipase A(2) enzyme and tyrosine kinase inhibitors. Moreover, LPA-induced increases in Ca2+ transients and/or iNOS expression in highly purified rat liver nuclei were prevented by pertussis toxin, phosphoinositide 3-kinase/Akt inhibitor wortmannin and Ca2+ chelator and channel blockers EGTA and SK&F96365, respectively. This study describes for the first time the nucleus as a potential organelle for LPA intracrine signaling in the regulation of pro-inflammatory gene expression.	Univ Sherbrooke, Dept Anat & Cell Biol, Sherbrooke, PQ J1H 5N4, Canada; Hop St Justine, Ctr Rech, Dept Pediat, Montreal, PQ H3T 1C5, Canada; Hop St Justine, Ctr Rech, Dept Ophthalmol, Montreal, PQ H3T 1C5, Canada; Hop St Justine, Ctr Rech, Dept Pharmacol, Montreal, PQ H3T 1C5, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Univ Calif San Francisco, Dept Med Microbiol Immunol, San Francisco, CA 94143 USA	University of Sherbrooke; Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; University of California System; University of California San Francisco	Gobeil, F (corresponding author), Univ Sherbrooke, Dept Pharmacol, 3001,12th North Ave, Sherbrooke, PQ J1H 5N4, Canada.	Fernand.Gobeil@USherbrooke.ca	Ribeiro-da-Silva, Alfredo/K-4783-2012; Sennlaub, Florian/F-2756-2017	Ribeiro-da-Silva, Alfredo/0000-0002-4125-0255; Sennlaub, Florian/0000-0003-4412-1341; Nader, Moni/0000-0003-2138-5213	NHLBI NIH HHS [HL-31809] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allard J, 1998, EUR J NEUROSCI, V10, P1045, DOI 10.1046/j.1460-9568.1998.00117.x; An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Baker RR, 1999, BBA-MOL CELL BIOL L, V1438, P253, DOI 10.1016/S1388-1981(99)00057-8; Baker RR, 2000, BBA-MOL CELL BIOL L, V1483, P58, DOI 10.1016/S1388-1981(99)00185-7; Banning AP, 1999, ATHEROSCLEROSIS, V145, P17, DOI 10.1016/S0021-9150(99)00010-6; Bkaily G, 1997, MOL CELL BIOCHEM, V172, P171, DOI 10.1023/A:1006840228104; BOYER CS, 1995, BIOCHEM PHARMACOL, V50, P753, DOI 10.1016/0006-2952(95)00195-6; Bratt T, 2000, BBA-PROTEIN STRUCT M, V1482, P318, DOI 10.1016/S0167-4838(00)00154-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Cussac D, 2002, J BIOL CHEM, V277, P19882, DOI 10.1074/jbc.M110142200; D'Santos CS, 1998, BBA-MOL CELL BIOL L, V1436, P201, DOI 10.1016/S0005-2760(98)00146-5; DAHAN S, 1994, J CELL BIOL, V127, P1859, DOI 10.1083/jcb.127.6.1859; Dumont I, 1999, J PHARMACOL EXP THER, V291, P627; Fayard JM, 1998, J CELL SCI, V111, P985; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; Gobeil F, 2003, CAN J PHYSIOL PHARM, V81, P196, DOI 10.1139/Y02-163; Gobeil F, 2002, CIRC RES, V90, P682, DOI 10.1161/01.RES.0000013303.17964.7A; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Goetzl EJ, 2000, J IMMUNOL, V164, P4996, DOI 10.4049/jimmunol.164.10.4996; Goetzl EJ, 1999, CANCER RES, V59, P4732; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hahn A, 2002, BIOCHEM J, V362, P33, DOI 10.1042/0264-6021:3620033; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Ikeda H, 1998, BIOCHEM BIOPH RES CO, V248, P436, DOI 10.1006/bbrc.1998.8983; Im DS, 1997, AM J PHYSIOL-GASTR L, V272, pG1091, DOI 10.1152/ajpgi.1997.272.5.G1091; Isenovic E, 2000, HYPERTENSION, V35, P249, DOI 10.1161/01.HYP.35.1.249; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Kohno T, 2002, FASEB J, V16, P983, DOI 10.1096/fj.01-0809com; Le PU, 2002, J BIOL CHEM, V277, P3371, DOI 10.1074/jbc.M111240200; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; Miralles C, 2000, FEBS LETT, V476, P253, DOI 10.1016/S0014-5793(00)01748-8; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Nanji AA, 1997, J PHARMACOL EXP THER, V282, P1037; NATARAJAN V, 1993, J BIOL CHEM, V268, P930; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Pages C, 2001, PROSTAG OTH LIPID M, V64, P1, DOI 10.1016/S0090-6980(01)00110-1; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Re R, 1999, HYPERTENSION, V34, P534, DOI 10.1161/01.HYP.34.4.534; Reiser COA, 1998, BIOCHEM J, V330, P1107; RIBEIRODASILVA A, 1993, IMMUNOHISTOCHEMISTRY, V2, P182; Sadir R, 2001, CYTOKINE, V14, P19, DOI 10.1006/cyto.2000.0854; Sarret P, 1999, J BIOL CHEM, V274, P19294, DOI 10.1074/jbc.274.27.19294; Sautin YY, 2001, AM J PHYSIOL-CELL PH, V281, pC2010, DOI 10.1152/ajpcell.00077.2001; Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.0.CO;2-L; Shin I, 1999, MOL CELLS, V9, P292; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Subramaniam PS, 2002, J IMMUNOL, V169, P1959, DOI 10.4049/jimmunol.169.4.1959; Tabuchi S, 2000, NEUROCHEM RES, V25, P573, DOI 10.1023/A:1007542532395; THOMSON FJ, 1994, MOL PHARMACOL, V45, P718; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; Tiruppathi C, 1996, P NATL ACAD SCI USA, V93, P250, DOI 10.1073/pnas.93.1.250; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Voisin L, 2002, AM J PHYSIOL-CELL PH, V283, pC446, DOI 10.1152/ajpcell.00261.2001; Wheatley M, 1999, HUM REPROD UPDATE, V5, P356, DOI 10.1093/humupd/5.4.356; Zheng YH, 2001, J IMMUNOL, V166, P2317, DOI 10.4049/jimmunol.166.4.2317	67	117	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38875	38883		10.1074/jbc.M212481200	http://dx.doi.org/10.1074/jbc.M212481200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12847111	hybrid			2022-12-25	WOS:000185575100096
J	Kelm, RJ; Wang, SX; Polikandriotis, JA; Strauch, AR				Kelm, RJ; Wang, SX; Polikandriotis, JA; Strauch, AR			Structure/function analysis of mouse Pur beta, a single-stranded DNA-binding repressor of vascular smooth muscle alpha-actin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; MYOFIBROBLAST DIFFERENTIATION; TRANSGENIC MICE; MCAT ENHANCER; CARG ELEMENTS; NIH3T3 CELLS; IN-VITRO; PROMOTER; PROTEIN; EXPRESSION	Plasticity of smooth muscle alpha-actin gene expression in fibroblasts and vascular smooth muscle cells is mediated by opposing effects of transcriptional activators and repressors. Among these factors, three single-stranded DNA-binding proteins, Puralpha, Purbeta, and MSY1, have been implicated as coregulators of a cryptic 5'-enhancer module. In this study, a molecular analysis of Purbeta, the least well characterized member of this group, was conducted. Southwestern and Northwestern blotting of purified Purbeta deletion mutants using smooth muscle alpha-actin-derived probes mapped the minimal single-stranded DNA/RNA-binding domain to a conserved region spanning amino acids 37-263. Quantitative binding assays indicated that the relative affinity and specificity of Purbeta for single-stranded DNA were influenced by purine/pyrimidine content; by non-conserved regions outside amino acids 37-263; and by cell-derived proteins, specifically MSY1. When overexpressed in A7r5 vascular smooth muscle cells, Purbeta (but not Puralpha) inhibited transcription of a smooth muscle-specific mouse alpha-actin promoter transgene. Structural domains required for Purbeta repressor activity included the minimal DNA-binding region and a C-terminal domain required for stabilizing high affinity protein and nucleic acid interactions. Purbeta inhibitory activity in transfected A7r5 cells was potentiated by MSY1, but antagonized by serum response factor, reinforcing the idea that interplay among activators and repressors may account for phenotypic changes in smooth muscle alpha-actin-expressing cell types.	Univ Vermont, Dept Med, Colchester Res Facil, Coll Med, Colchester 05446, Essex, England; Ohio State Univ, Coll Med & Publ Hlth, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Kelm, RJ (corresponding author), Univ Vermont, Dept Med, Colchester Res Facil, Coll Med, 208 S Pk Dr, Colchester 05446, Essex, England.	robert.kelm@uvm.edu			NHLBI NIH HHS [HL54281, HL60876] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054281, R01HL060876] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barr SM, 2001, J CELL BIOCHEM, V81, P621, DOI 10.1002/jcb.1099; Becker NA, 2000, J BIOL CHEM, V275, P15384, DOI 10.1074/jbc.M909687199; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; Carlini LE, 2002, J BIOL CHEM, V277, P8682, DOI 10.1074/jbc.M109754200; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; Cogan JG, 2002, J BIOL CHEM, V277, P36433, DOI 10.1074/jbc.M203232200; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; Darbinian N, 1999, ONCOGENE, V18, P6398, DOI 10.1038/sj.onc.1203011; Darbinian N, 2001, J NEUROIMMUNOL, V121, P3, DOI 10.1016/S0165-5728(01)00372-1; Darbinian N, 2001, J CELL BIOCHEM, V80, P589, DOI 10.1002/1097-4644(20010315)80:4<589::AID-JCB1013>3.0.CO;2-0; Darbinian N, 2001, J CELL PHYSIOL, V189, P334, DOI 10.1002/jcp.10029; Ding Y, 1997, NEUROCHEM INT, V31, P45, DOI 10.1016/S0197-0186(96)00127-1; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; Feugate JE, 2002, J CELL BIOL, V156, P161, DOI 10.1083/jcb.200103062; Firulli AB, 1998, IN VITRO CELL DEV-AN, V34, P217; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; Gallia GL, 1999, J CELL BIOCHEM, V74, P334, DOI 10.1002/(SICI)1097-4644(19990901)74:3<334::AID-JCB3>3.0.CO;2-O; Gallia GL, 2000, NUCLEIC ACIDS RES, V28, P3197, DOI 10.1093/nar/28.17.3197; Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10; Herring BP, 2001, J BIOL CHEM, V276, P14482, DOI 10.1074/jbc.M011585200; Hinz B, 2002, J CELL BIOL, V157, P657, DOI 10.1083/jcb.200201049; Itoh H, 1998, CELL GROWTH DIFFER, V9, P651; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; Kelm RJ, 1999, J BIOL CHEM, V274, P38268, DOI 10.1074/jbc.274.53.38268; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Lasham A, 2000, GENE, V252, P1, DOI 10.1016/S0378-1119(00)00220-1; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Liu H, 2002, NUCLEIC ACIDS RES, V30, P2417, DOI 10.1093/nar/30.11.2417; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; Mack CP, 1999, CIRC RES, V84, P852; Majesky MW, 2003, CIRC RES, V92, P824, DOI 10.1161/01.RES.0000071525.18323.4C; Manabe I, 2001, CIRC RES, V88, P1127, DOI 10.1161/hh1101.091339; MIN BH, 1990, J BIOL CHEM, V265, P16667; Muralidharan V, 1997, J CELL BIOCHEM, V66, P524, DOI 10.1002/(SICI)1097-4644(19970915)66:4<524::AID-JCB11>3.0.CO;2-B; Nakamura M, 2001, J BIOL CHEM, V276, P18313, DOI 10.1074/jbc.M101127200; Nishida W, 2002, J BIOL CHEM, V277, P7308, DOI 10.1074/jbc.M111824200; Ogut O, 2003, J MOL CELL CARDIOL, V35, P347, DOI 10.1016/S0022-2828(03)00045-2; Phiel CJ, 2001, J BIOL CHEM, V276, P34637, DOI 10.1074/jbc.M105826200; Regan CP, 2000, J CLIN INVEST, V106, P1139, DOI 10.1172/JCI10522; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Safak R, 1999, MOL CELL BIOL, V19, P2712; Sartore S, 2001, CIRC RES, V89, P1111, DOI 10.1161/hh2401.100844; Shelley CS, 2002, J IMMUNOL, V168, P3887, DOI 10.4049/jimmunol.168.8.3887; Shelley CS, 2001, BRIT J HAEMATOL, V115, P159, DOI 10.1046/j.1365-2141.2001.03066.x; Stacey DW, 1999, ONCOGENE, V18, P4254, DOI 10.1038/sj.onc.1202795; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; STRAUCH AR, 1999, EXPERT OPIN THER TAR, V3, P279; Subramanian SV, 2002, CARDIOVASC RES, V54, P539, DOI 10.1016/S0008-6363(02)00270-5; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; Tretiakova A, 1999, J CELL PHYSIOL, V181, P160, DOI 10.1002/(SICI)1097-4652(199910)181:1<160::AID-JCP17>3.0.CO;2-H; Tretiakova A, 1998, J BIOL CHEM, V273, P22241, DOI 10.1074/jbc.273.35.22241; TRINKLE LA, 1992, AM J PHYSIOL, V262, pC828, DOI 10.1152/ajpcell.1992.262.4.C828; Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Zhang MY, 2002, J BIOL CHEM, V277, P21285, DOI 10.1074/jbc.M112082200	61	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38749	38757		10.1074/jbc.M306163200	http://dx.doi.org/10.1074/jbc.M306163200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874279	hybrid			2022-12-25	WOS:000185575100081
J	Ragona, L; Fogolari, F; Catalano, M; Ugolini, R; Zetta, L; Molinari, H				Ragona, L; Fogolari, F; Catalano, M; Ugolini, R; Zetta, L; Molinari, H			EF loop conformational change triggers ligand binding in beta-lactoglobulins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; ELECTROSTATIC PROPERTIES; RUMINANT; LIPASE; LIPOCALIN; STABILITY; ALBUMIN; PROTEIN; TOOL	beta-Lactoglobulins, belonging to the lipocalin family, are a widely studied group of proteins, characterized by the ability to solubilize and transport hydrophobic ligands, especially fatty acids. Despite many reports, the mechanism of ligand binding and the functional role of these proteins is still unclear, and many contradicting concepts are often encountered in the literature. In the present paper the comparative analysis of the binding properties of beta-lactoglobulins has been performed using sequence-derived information, structure-based electrostatic calculations, docking simulations, and NMR experiments. Our results reveal for the first time the mechanism of beta-lactoglobulin ligand binding, which is completely determined by the opening-closing of EF loop, triggered by Glu(89) protonation. The alkaline shift observed for Glu(89) pK(alpha) in porcine beta-lactoglobulin (pK(alpha) 9.7) with respect to the bovine species (pK(a) 5.5) depends upon the interplay of electrostatic effects of few nearby key residues. Porcine protein is therefore able to bind fatty acids provided that the appropriate pH solution conditions are met (pH > 8.6), where the EF loop conformational change can take place. The unusually high pH of binding detected for porcine beta-lactoglobulin seems to be functional to lipases activity. Theoretical pK(alpha) calculations extended to representative beta-lactoglobulins allowed the identification of key residues involved in structurally and functionally important electrostatic interactions. The results presented here provide a strong indication that the described conformational change is a common feature of all beta-lactoglobulins.	Dipartimento Sci & Tecnol, I-37134 Verona, Italy; CNR, Ist Macromol, Lab Risonanza Magnet Nucl, I-20133 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR)	Molinari, H (corresponding author), Dipartimento Sci & Tecnol, Strada Le Grazie 15, I-37134 Verona, Italy.	molinari@sci.univr.it	Molinari, Henriette/A-1695-2008; Ragona, Laura/AAB-9691-2020; molinari, henriette/ABE-9775-2021	Molinari, Henriette/0000-0002-3678-130X; Ragona, Laura/0000-0003-3893-7117; Fogolari, Federico/0000-0001-9862-250X				ANTOSIEWICZ J, 1994, J MOL BIOL, V238, P415, DOI 10.1006/jmbi.1994.1301; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Burova TV, 2002, EUR J BIOCHEM, V269, P3958, DOI 10.1046/j.1432-1033.2002.03081.x; Collini M, 2003, PROTEIN SCI, V12, P1596, DOI 10.1110/ps.0304403; Fogolari F, 2000, PROTEINS, V39, P317, DOI 10.1002/(SICI)1097-0134(20000601)39:4<317::AID-PROT50>3.0.CO;2-W; Fogolari F, 2002, J MOL RECOGNIT, V15, P377, DOI 10.1002/jmr.577; FRAPIN D, 1994, BIOCHIM BIOPHYS ACTA, V1205, P105; Gasymov OK, 2001, BIOCHEMISTRY-US, V40, P14754, DOI 10.1021/bi0110342; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Herrgard S, 2000, BIOCHEMISTRY-US, V39, P2921, DOI 10.1021/bi9916980; Kastenholz MA, 2000, J MED CHEM, V43, P3033, DOI 10.1021/jm000934y; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; MADURA JD, 1995, COMPUT PHYS COMMUN, V91, P57, DOI 10.1016/0010-4655(95)00043-F; Narayan M, 1997, BIOCHEMISTRY-US, V36, P1906, DOI 10.1021/bi9621526; PEREZ MD, 1992, BIOCHIM BIOPHYS ACTA, V1123, P151, DOI 10.1016/0005-2760(92)90105-5; PEREZ MD, 1993, J DAIRY RES, V60, P55, DOI 10.1017/S0022029900027345; PEREZ MD, 1989, J BIOCHEM-TOKYO, V106, P1094, DOI 10.1093/oxfordjournals.jbchem.a122971; Qin BY, 1998, BIOCHEMISTRY-US, V37, P14014, DOI 10.1021/bi981016t; Ragona L, 2000, PROTEIN SCI, V9, P1347, DOI 10.1110/ps.9.7.1347; Sawyer L, 2000, BBA-PROTEIN STRUCT M, V1482, P136, DOI 10.1016/S0167-4838(00)00160-6; TANFORD C, 1959, J BIOL CHEM, V234, P2874; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ugolini R, 2001, EUR J BIOCHEM, V268, P4477, DOI 10.1046/j.1432-1327.2001.02371.x; Uhrinova S, 2000, BIOCHEMISTRY-US, V39, P3565, DOI 10.1021/bi992629o; VERGER R, 1976, J BIOL CHEM, V251, P3128; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wu SY, 1999, J BIOL CHEM, V274, P170, DOI 10.1074/jbc.274.1.170	28	64	64	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38840	38846		10.1074/jbc.M306269200	http://dx.doi.org/10.1074/jbc.M306269200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12857741	hybrid			2022-12-25	WOS:000185575100092
J	Ciani, B; Layfield, R; Cavey, JR; Sheppard, PW; Searle, MS				Ciani, B; Layfield, R; Cavey, JR; Sheppard, PW; Searle, MS			Structure of the ubiquitin-associated domain of p62 (SQSTM1) and implications for mutations that cause Paget's disease of bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN P62; UBA DOMAINS; 26S PROTEASOME; SEQUESTOSOME; PROTEOLYSIS; INTERACT; CHAINS; SIGNAL; SMART	The p62 protein ( also known as SQSTM1) mediates diverse cellular functions including control of NFkappaB signaling and transcriptional activation. p62 binds non-covalently to ubiquitin and co-localizes with ubiquitylated inclusions in a number of human protein aggregation diseases. Mutations in the gene encoding p62 cause Paget's disease of bone ( PDB), a common disorder of the elderly characterized by excessive bone resorption and formation. All of the p62 PDB mutations identified to date cluster within the C-terminal region of the protein, which shows low sequence identity to previously characterized ubiquitin-associated (UBA) domains. We report the first NMR structure of a recombinant polypeptide that contains the C-terminal UBA domain of the human p62 protein ( residues 387 - 436). This sequence, which confers multiubiquitin chain binding, forms a compact three-helix bundle with a structure analogous to the UBA domains of HHR23A but with differences in the loop regions connecting helices that may be involved in binding accessory proteins. We show that the Pro(392) --> Leu PDB substitution mutation modifies the structure of the UBA domain by extending the N terminus of helix 1. In contrast to the p62 PDB deletion mutations that remove the UBA domain and ablate multiubiquitin chain binding, the Pro392 3 Leu substitution does not affect interaction of the UBA domain with multiubiquitin chains. Thus, phenotypically identical substitution and deletion mutations do not appear to predispose to PDB through a mechanism dependent on a common loss of ubiquitin chain binding by p62.	Univ Nottingham, Sch Med, Sch Biomed Sci, Nottingham NG7 2UH, England; Sch Chem, Nottingham NG7 2RD, England; Affiniti Res Prod Ltd, Exeter EX2 8NL, Devon, England	University of Nottingham	Layfield, R (corresponding author), Univ Nottingham, Sch Med, Sch Biomed Sci, Nottingham NG7 2UH, England.	robert.layfield@nottingham.ac.uk; mark.searle@nottingham.ac.uk	Ciani, Barbara/A-1679-2012	Ciani, Barbara/0000-0001-7223-4154; Cavey, James/0000-0003-4515-0515; Searle, Mark/0000-0001-8387-9978; Layfield, Robert/0000-0003-0702-3259				Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; BRUNGER AT, 1992, XPLOR VERSION 3 1; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Geetha T, 2002, FEBS LETT, V512, P19, DOI 10.1016/S0014-5793(02)02286-X; Hartmann-Petersen R, 2003, TRENDS BIOCHEM SCI, V28, P26, DOI 10.1016/S0968-0004(02)00002-6; Hocking LJ, 2002, HUM MOL GENET, V11, P2735, DOI 10.1093/hmg/11.22.2735; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667; Kanis J., 1998, PATHOPHYSIOLOGY TREA, VSecond; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laurin N, 2002, AM J HUM GENET, V70, P1582, DOI 10.1086/340731; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shin J, 1998, ARCH PHARM RES, V21, P629, DOI 10.1007/BF02976748; Stumptner C, 2002, HEPATOLOGY, V35, P1053, DOI 10.1053/jhep.2002.32674; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Withers-Ward ES, 2000, BIOCHEMISTRY-US, V39, P14103, DOI 10.1021/bi0017071; Wuthrich K, 1986, NMR NUCL ACIDS PROTE	31	104	108	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37409	37412		10.1074/jbc.M307416200	http://dx.doi.org/10.1074/jbc.M307416200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857745	hybrid			2022-12-25	WOS:000185437200052
J	da Costa, CA; Masliah, E; Checler, F				da Costa, CA; Masliah, E; Checler, F			beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation - Cross-talk with alpha-synuclein and implication for Parkinson's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRESYNAPTIC PROTEIN; LEWY BODIES; WILD-TYPE; NEURODEGENERATIVE DISORDERS; NACP/ALPHA-SYNUCLEIN; APOPTOTIC STIMULI; HUMAN BRAIN; P53; AGGREGATION	We have established stable transfectants expressing beta-synuclein in TSM1 neurons. We show that in basal and staurosporine-induced conditions the number of terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling (TUNEL)- positive beta-synuclein-expressing neurons was drastically lower than in mock-transfected TSM1 cells. This was accompanied by a lower DNA fragmentation as evidenced by the reduction of propidium iodide incorporation measured by fluorescence-activated cell sorter analysis. beta-Synuclein strongly reduces staurosporine-induced caspase 3 activity and immunoreactivity. We establish that beta-synuclein triggers a drastic reduction of p53 expression and transcriptional activity. This was accompanied by increased Mdm2 immunoreactivity while p38 expression appeared enhanced, indicating that beta-synuclein-induced p53 downregulation likely occurs at a post-transcriptional level. We showed previously that alpha-synuclein displays an antiapoptotic function that was abolished by the dopaminergic derived toxin 6-hydroxydopamine (6OHDA). Interestingly, beta-synuclein retains its ability to protect TSM1 neurons even after 6OHDA treatment. Furthermore, beta-synuclein restores the antiapoptotic function of alpha-synuclein in 6OHDA-treated neurons. Altogether, our data document for the first time that beta-synuclein protects neurons from staurosporine and 6OHDA-stimulated caspase activation in a p53-dependent manner. Our observation that beta-synuclein contributes to restoration of the alpha-synuclein antiapoptotic function abolished by 6OHDA may have direct implications for Parkinson's disease pathology. In this context, the cross-talk between these two parent proteins is discussed.	CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097, F-06560 Valbonne, France; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of California System; University of California San Diego	Checler, F (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097, 660 Route Lucioles, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr	da Costa, Cristine Alves/G-8075-2011; Checler, Frederic/C-1241-2009	da Costa, Cristine Alves/0000-0002-7777-005X; Checler, Frederic/0000-0003-2098-1750	NATIONAL INSTITUTE ON AGING [R37AG018440, R01AG018440] Funding Source: NIH RePORTER; NIA NIH HHS [AG18440] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ancolio K, 2000, NEUROSCI LETT, V285, P79, DOI 10.1016/S0304-3940(00)01049-1; Baba M, 1998, AM J PATHOL, V152, P879; Barzilai A, 2003, TRENDS MOL MED, V9, P126, DOI 10.1016/S1471-4914(03)00020-0; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; CURTIUS HC, 1974, J CHROMATOGR, V99, P529, DOI 10.1016/S0021-9673(00)90882-3; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2003, CURR MOL MED, V3, P17, DOI 10.2174/1566524033361690; da Costa CA, 2003, J BIOL CHEM, V278, P12064, DOI 10.1074/jbc.M212379200; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; El-Agnaf OMA, 2000, J STRUCT BIOL, V130, P300, DOI 10.1006/jsbi.2000.4262; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Ferrigno P, 2000, NEURON, V26, P9, DOI 10.1016/S0896-6273(00)81132-0; Fratiglioni L, 2000, NEUROLOGY, V54, pS10; Giampaoli S, 2000, AGING CLIN EXP RES, V12, P93, DOI 10.1007/BF03339896; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; Hashimoto M, 1999, BRAIN PATHOL, V9, P707; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hirata H, 1997, J NEUROCHEM, V69, P780; Irwin I, 1995, ETIOLOGY PARKINSONS, P153; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; Iwai A, 2000, BBA-MOL BASIS DIS, V1502, P95, DOI 10.1016/S0925-4439(00)00036-3; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jellinger K, 1995, J NEURAL TRANSM-SUPP, P297; JENSEN PH, 1995, BIOCHEM J, V310, P91, DOI 10.1042/bj3100091; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Masliah E, 1996, AM J PATHOL, V148, P201; NAKAJO S, 1993, EUR J BIOCHEM, V217, P1057, DOI 10.1111/j.1432-1033.1993.tb18337.x; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Paitel E, 2003, J BIOL CHEM, V278, P10061, DOI 10.1074/jbc.M211580200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rockenstein E, 2001, BRAIN RES, V914, P48, DOI 10.1016/S0006-8993(01)02772-X; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takeda A, 1998, AM J PATHOL, V152, P367; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Windisch M, 2002, J MOL NEUROSCI, V19, P63, DOI 10.1007/s12031-002-0012-8; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P793, DOI 10.1001/archneur.57.6.793; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	54	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37330	37335		10.1074/jbc.M306083200	http://dx.doi.org/10.1074/jbc.M306083200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867415	hybrid			2022-12-25	WOS:000185437200042
J	Dupont, JL; Karas, M; LeRoith, D				Dupont, JL; Karas, M; LeRoith, D			The cyclin-dependent kinase inhibitor p21C(IP/WAF) is a positive regulator of insulin-like growth factor I-induced cell proliferation in MCF-7 human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CDK INHIBITORS; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR MECHANISMS; SIGNAL-TRANSDUCTION; P21; P21(WAF1/CIP1); RECEPTOR; P21(CIP1/WAF1); EXPRESSION	To study the role of IGF-I receptor signaling on cell cycle events we utilized MCF-7 breast cancer cells. IGF-I at physiological concentrations increased the level of p21(CIP/WAF) mRNA after 4 h as well as protein after 8 h by 10- and 6-fold, respectively, in MCF-7 cells. This IGF-1 effect was reduced by 50% in MCF-7-derived cells (SX13), which exhibit a 50% reduction in IGF-1R expression, demonstrating that IGF-1 receptor activation was involved in this process. Preincubation with the ERK1/2 inhibitor U0126 significantly reduced the IGF-1 effect on the amount of p21(CIP/WAF) protein in MCF-7 cells. These results were confirmed by the expression of a dominant negative construct for MEK-1 suggesting that the increase of the abundance of p21(CIP/WAF) in response to IGF-1 occurs via the ERK1/2 mitogen-activated protein kinase pathway. Using an antisense strategy, we demonstrated that abolition of p21(CIP/WAF) expression decreased by 2-fold the IGF-1 effect on cell proliferation in MCF-7. This latter result is explained by a delay in G(1) to S cell cycle progression due partly to a reduction in the activation of some components of cell cycle including the induction of cyclin D1 expression in response to IGF-1. MCF-7 cells transiently overexpressing p21 showed increased basal and IGF-I-induced thymidine incorporation. Taken together, these results define p21(CIP/WAF) as a positive regulator in the cell proliferation induced by IGF-1 in MCF-7 cells.	NIDDK, Sect Mol & Cellular Physiol, Diabet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	LeRoith, D (corresponding author), NIDDK, Sect Mol & Cellular Physiol, Diabet Branch, NIH, Rm 8D12,Bldg 10, Bethesda, MD 20892 USA.							ARTEAGA CL, 1989, CANCER RES, V49, P6237; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bearss DJ, 2002, CANCER RES, V62, P2077; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Braun SE, 1998, BLOOD CELL MOL DIS, V24, P138, DOI 10.1006/bcmd.1998.0181; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN XB, 1995, CANCER RES, V55, P4257; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Dupont J, 2000, J BIOL CHEM, V275, P35893, DOI 10.1074/jbc.M006741200; Erber R, 1997, INT J CANCER, V74, P383, DOI 10.1002/(SICI)1097-0215(19970822)74:4<383::AID-IJC4>3.0.CO;2-R; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Fukuchi K, 2000, BBA-MOL CELL RES, V1496, P207, DOI 10.1016/S0167-4889(00)00018-5; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GRANA X, 1995, ONCOGENE, V11, P211; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Johannessen LE, 1999, BIOCHEM J, V337, P599, DOI 10.1042/0264-6021:3370599; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; JUNG J, 1995, ONCOGENE, V11, P201; Kanter-Lewensohn L, 2000, GROWTH FACTORS, V17, P193, DOI 10.3109/08977190009001068; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Kivinen L, 1999, CELL GROWTH DIFFER, V10, P621; Kleinman D, 1996, ENDOCRINOLOGY, V137, P1089, DOI 10.1210/en.137.3.1089; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Liu Y, 1996, CANCER RES, V56, P31; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Marches R, 1999, P NATL ACAD SCI USA, V96, P8711, DOI 10.1073/pnas.96.15.8711; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; MOUSSES S, 1995, HUM MOL GENET, V4, P1089, DOI 10.1093/hmg/4.6.1089; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; Nolan MK, 1997, INT J CANCER, V72, P828, DOI 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3; Parry D, 1999, MOL CELL BIOL, V19, P1775; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; QUELLE DE, 1995, ONCOGENE, V11, P635; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Russell A, 1999, ONCOGENE, V18, P6454, DOI 10.1038/sj.onc.1203030; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Skildum AJ, 2002, J BIOL CHEM, V277, P5145, DOI 10.1074/jbc.M109179200; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Weiss RH, 2000, J BIOL CHEM, V275, P10285, DOI 10.1074/jbc.275.14.10285; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	59	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37256	37264		10.1074/jbc.M302355200	http://dx.doi.org/10.1074/jbc.M302355200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867429	hybrid, Green Submitted			2022-12-25	WOS:000185437200034
J	Kazerounian, S; Aho, S				Kazerounian, S; Aho, S			Characterization of periphilin, a widespread, highly insoluble nuclear protein and potential constituent of the keratinocyte cornified envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLAKIN FAMILY; CELL-ENVELOPE; TISSUE TRANSGLUTAMINASE; INTERMEDIATE-FILAMENTS; DESMOSOMAL PLAQUE; EPITHELIAL-CELLS; PERIPLAKIN; COMPLEXES; ENVOPLAKIN; BINDING	While keratinocytes go through the terminal differentiation and move toward the outer layers of epidermis, multiple proteins become sequentially incorporated into the cornified cell envelope. We have identified through yeast two-hybrid screening a novel protein, periphilin, interacting with periplakin, which is known as a precursor of the cornified cell envelope. Periphilin gene at chromosome 12q12 gives rise to multiple alternatively spliced transcripts. A monoclonal antibody detected the keratinocyte-specific periphilin isoform in undifferentiated keratinocytes in speckle-type nuclear granules and at the nuclear membrane, but in differentiated keratinocytes periphilin localized to the cell periphery and at cell-cell junctions, colocalizing there with periplakin. From cultured keratinocytes, periphilin was solubilized only after urea extraction, indicating the highly insoluble character of this protein. The nuclear localization, mediated through the N-terminal sequences of periphilin protein, is a prerequisite for the formation of insoluble complexes. Although the globular N terminus of periphilin was necessary for the interaction with the periplakin tail, the keratinocyte-specific C terminus was responsible for the homodimerization. The C-terminal helical domain, composed of multiple heptad repeats, serves as a substrate for cross-linking by transglutaminases but also was specifically cleaved by caspase-5 in vitro. In conclusion, the localization pattern and insolubility of periphilin indicate that this novel protein is potentially involved in epithelial differentiation and contributes to epidermal integrity and barrier formation.	Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA	Jefferson University	Aho, S (corresponding author), Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, 233 S 10th St,BLSB 422, Philadelphia, PA 19107 USA.	Sirpa.Aho@jefferson.edu			PHS HHS [R01-33588] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aho S, 1997, ANAL BIOCHEM, V253, P270, DOI 10.1006/abio.1997.2394; Aho S, 2000, J CELL BIOL, V148, P1165, DOI 10.1083/jcb.148.6.1165; Brandner JM, 1998, EUR J CELL BIOL, V75, P295, DOI 10.1016/S0171-9335(98)80063-0; Brandner JM, 1997, DIFFERENTIATION, V62, P119, DOI 10.1046/j.1432-0436.1997.6230119.x; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; Chen XY, 2002, J BIOL CHEM, V277, P10512, DOI 10.1074/jbc.M108765200; DiColandrea T, 2000, J CELL BIOL, V151, P573, DOI 10.1083/jcb.151.3.573; Fricker M, 1997, J CELL BIOL, V136, P531, DOI 10.1083/jcb.136.3.531; Goepfert TM, 2002, CANCER RES, V62, P4115; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; HARE JF, 1994, J BIOL CHEM, V269, P5981; Hofmann I, 2002, MOL BIOL CELL, V13, P1665, DOI 10.1091/mbc.01-12-0567; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; Karashima T, 2002, J CELL SCI, V115, P5027, DOI 10.1242/jcs.00191; Kazerounian S, 2002, EXP DERMATOL, V11, P428, DOI 10.1034/j.1600-0625.2002.110506.x; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; Kim JH, 2001, ANN NY ACAD SCI, V928, P65; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Ku NO, 1997, J BIOL CHEM, V272, P33197, DOI 10.1074/jbc.272.52.33197; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; Lesort M, 1998, J BIOL CHEM, V273, P11991, DOI 10.1074/jbc.273.20.11991; Line A, 2002, BRIT J CANCER, V86, P1824, DOI 10.1038/sj.bjc.6600321; MA ASP, 1986, J CELL BIOL, V103, P41, DOI 10.1083/jcb.103.1.41; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; Marekov LN, 1998, J BIOL CHEM, V273, P17763, DOI 10.1074/jbc.273.28.17763; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; Mertens C, 2001, P NATL ACAD SCI USA, V98, P7795, DOI 10.1073/pnas.141219498; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; MOIR RD, 1994, J CELL BIOL, V125, P1201, DOI 10.1083/jcb.125.6.1201; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nikolic B, 1996, J CELL BIOL, V134, P1455, DOI 10.1083/jcb.134.6.1455; OUYANG P, 1996, J CELL BIOL, P1027; Ruchaud S, 2002, EMBO J, V21, P1967, DOI 10.1093/emboj/21.8.1967; Ruhrberg C, 1997, J CELL BIOL, V139, P1835, DOI 10.1083/jcb.139.7.1835; Ruhrberg C, 1997, CURR OPIN GENET DEV, V7, P392, DOI 10.1016/S0959-437X(97)80154-2; Schmidt A, 1997, CELL TISSUE RES, V290, P481, DOI 10.1007/s004410050956; Solomon KR, 1998, BIOCHEM J, V334, P325, DOI 10.1042/bj3340325; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; STORCH S, 1999, THESIS G AUGUST U GO; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; Tan JH, 2000, MOL BIOL CELL, V11, P1547, DOI 10.1091/mbc.11.5.1547; van den Heuvel APJ, 2002, J CELL SCI, V115, P3957, DOI 10.1242/jcs.00069; Verderio E, 1998, EXP CELL RES, V239, P119, DOI 10.1006/excr.1997.3874; Wang P, 2002, BIOCHEM BIOPH RES CO, V294, P448, DOI 10.1016/S0006-291X(02)00495-3; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596	47	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36707	36717		10.1074/jbc.M303896200	http://dx.doi.org/10.1074/jbc.M303896200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12853457	hybrid			2022-12-25	WOS:000185318300102
J	Linster, CL; Van Schaftingen, E				Linster, CL; Van Schaftingen, E			Rapid stimulation of free glucuronate formation by non-glucuronidable xenobiotics in isolated rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ASCORBIC-ACID; FRUCTOSE 2,6-BISPHOSPHATE; METABOLISM; PYROPHOSPHATASE; DEHYDROGENASE; BIOSYNTHESIS; PURIFICATION; TRANSFERASE; MECHANISM; REDUCTASE	Vitamin C synthesis in rat liver is enhanced by several xenobiotics, including aminopyrine and chloretone. The effect of these agents has been linked to induction of enzymes potentially involved in the formation of glucuronate, a precursor of vitamin C. Using isolated rat hepatocytes as a model, we show that a series of agents ( aminopyrine, antipyrine, chloretone, clotrimazole, metyrapone, proadifen, and barbital) induced in a few minutes an up to 15-fold increase in the formation of glucuronate, which was best observed in the presence of sorbinil, an inhibitor of glucuronate reductase. They also caused an similar to2-fold decrease in the concentration of UDP-glucuronate but little if any change in the concentration of UDP-glucose. Depletion of UDP-glucuronate with resorcinol or D-galactosamine markedly decreased the formation of glucuronate both in the presence and in the absence of aminopyrine, confirming the precursor-product relationship between UDP-glucuronate and free glucuronate. Most of the agents did not induce the formation of detectable amounts of glucuronides, indicating that the formation of glucuronate is not due to a glucuronidation-deglucuronidation cycle. With the exception of barbital ( which inhibits glucuronate reductase), all of the above mentioned agents also caused an increase in the concentration of ascorbic acid. They had little effect on glutathione concentration, and their effect on glucuronate and vitamin C formation was not mimicked by glutathione-depleting agents such as diamide and buthionine sulfoximine. It is concluded that the stimulation of vitamin C synthesis exerted by some xenobiotics is mediated through a rapid increase in the conversion of UDP-glucuronate to glucuronate, which does not apparently involve a glucuronidation-deglucuronidation cycle.	Catholic Univ Louvain, Physiol Chem Lab, B-1200 Brussels, Belgium; Christian de Duve Inst Cellular Pathol, B-1200 Brussels, Belgium	Universite Catholique Louvain	Van Schaftingen, E (corresponding author), Catholic Univ Louvain, Physiol Chem Lab, B-1200 Brussels, Belgium.	vanschaftingen@bchm.ucl.ac.be	Van+Schaftingen, Emile/AAF-5532-2020	Linster, Carole/0000-0001-7143-0719; Van Schaftingen, Emile/0000-0002-6199-7647				ASHWELL G, 1960, J BIOL CHEM, V235, P1559; BARTRONS R, 1983, BIOCHEM J, V214, P829, DOI 10.1042/bj2140829; Braun L, 1996, FEBS LETT, V388, P173, DOI 10.1016/0014-5793(96)00548-0; BURNS JJ, 1956, J BIOL CHEM, V223, P897; BURNS JJ, 1957, J BIOL CHEM, V227, P785; EVANS C, 1960, BIOCHIM BIOPHYS ACTA, V41, P9, DOI 10.1016/0006-3002(60)90362-0; GINSBURG V, 1958, BIOCHIM BIOPHYS ACTA, V28, P649, DOI 10.1016/0006-3002(58)90538-9; GRIFFITH OW, 1990, METHOD ENZYMAT AN, V8, P521; HIATT HH, 2001, METABOLIC MOL BASES, V1, P1589; HICKMAN J, 1960, J BIOL CHEM, V235, P1566; HOCHMAN Y, 1984, J BIOL CHEM, V259, P5521; HOLLMANN S, 1962, BIOCHIM BIOPHYS ACTA, V62, P338, DOI 10.1016/0006-3002(62)90048-3; HORIO F, 1993, J NUTR, V123, P2075; HORIO F, 1983, J NUTR SCI VITAMINOL, V29, P233, DOI 10.3177/jnsv.29.233; Horio F, 1997, BIOSCI BIOTECH BIOCH, V61, P109, DOI 10.1271/bbb.61.109; IYANAGI T, 1989, J BIOL CHEM, V264, P21302; KEPPLER DOR, 1970, EUR J BIOCHEM, V17, P246, DOI 10.1111/j.1432-1033.1970.tb01160.x; LEWIS DF, 2001, GUIDE CYTOCHROMES P4, P118; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Margolis JJ, 1929, AM J MED SCI, V177, P348, DOI 10.1097/00000441-192903000-00005; Omaye S T, 1979, Methods Enzymol, V62, P3, DOI 10.1016/0076-6879(79)62181-X; POGELL BM, 1961, J BIOL CHEM, V236, P293; PUHAKAINEN E, 1976, EUR J BIOCHEM, V61, P165, DOI 10.1111/j.1432-1033.1976.tb10007.x; Radominska-Pandya A, 1999, DRUG METAB REV, V31, P817, DOI 10.1081/DMR-100101944; RODRIGUES AD, 1987, BIOCHEM PHARMACOL, V36, P4277, DOI 10.1016/0006-2952(87)90670-8; SATO K, 1993, ARCH BIOCHEM BIOPHYS, V307, P286, DOI 10.1006/abbi.1993.1591; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Smirnoff N, 2001, VITAM HORM, V61, P241; SRIVASTAVA SK, 1982, CURR EYE RES, V2, P407, DOI 10.3109/02713688209000786; Tanaka E, 1997, J CLIN PHARM THER, V22, P237, DOI 10.1046/j.1365-2710.1997.10875108.x; Trautschold I., 1985, METHODS ENZYMATIC AN, V3rd, P346; VANSCHAFTINGEN E, 1995, EUR J BIOCHEM, V234, P301; VANSCHAFTINGEN E, 1987, EUR J BIOCHEM, V166, P653	33	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36328	36333		10.1074/jbc.M306593200	http://dx.doi.org/10.1074/jbc.M306593200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12865420	Green Published, hybrid			2022-12-25	WOS:000185318300058
J	Wang, W; Loh, HH; Law, PY				Wang, W; Loh, HH; Law, PY			The intracellular trafficking of opioid receptors directed by carboxyl tail and a di-leucine motif in Neuro2A cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; C-TERMINAL TAIL; AGONIST-SPECIFIC REGULATION; INDUCED DOWN-REGULATION; NG108-15 HYBRID-CELLS; BETA-ARRESTIN; MEDIATED ENDOCYTOSIS; BETA(2)-ADRENERGIC RECEPTOR; OPIATE RECEPTOR; ALPHA(2)-ADRENERGIC RECEPTORS	The mu- and delta-opioid receptors (MOR and DOR) differ significantly in their intracellular trafficking. MORs recycle back to the cell surface upon agonist treatment, whereas most internalized DORs are targeted to lysosomes for degradation. By exchanging the carboxyl tail domains of MOR and DOR and expressing the receptor chimeras in mouse neuroblastoma Neuro2A cells, it could be demonstrated that the carboxyl tail domain is not the sole determinant in directing the intracellular trafficking in these Neuro2A cells. Deletion of the dileucine motif ( Leu(245)-Leu(246)) within the third intracellular loop of DOR or the mutation of Leu(245) to Met slowed the lysosomal targeting of these delta-opioid receptors. Meanwhile the mutation of Met(264) to Leu increased the rate of agonist-induced receptor internalization and the lysosomal targeting of the wild type and the delta-opioid receptor carboxyl tail chimera of the mu-opioid receptor. These studies suggest interplay between a di-leucine motif and the carboxyl tail in the lysosomal targeting of the receptor.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Law, PY (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	lawxx001@umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NATIONAL INSTITUTE ON DRUG ABUSE [K05DA000513, P50DA011806, R01DA007339] Funding Source: NIH RePORTER; NIDA NIH HHS [K05 DA00513, K05 DA70544, DA11806, DA07339] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Afify EA, 1998, MOL BRAIN RES, V54, P24, DOI 10.1016/S0169-328X(97)00315-X; Bohn LM, 2000, J NEUROCHEM, V74, P574, DOI 10.1046/j.1471-4159.2000.740574.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; Cen B, 2001, MOL PHARMACOL, V59, P758, DOI 10.1124/mol.59.4.758; Cen B, 2001, J NEUROCHEM, V76, P1887, DOI 10.1046/j.1471-4159.2001.00204.x; Chaipatikul V, 2003, J PHARMACOL EXP THER, V305, P909, DOI 10.1124/jpet.102.046219; CHANG KJ, 1982, NATURE, V296, P446, DOI 10.1038/296446a0; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; DeGraff JL, 2002, J BIOL CHEM, V277, P43247, DOI 10.1074/jbc.M207495200; El Kouhen R, 2001, J BIOL CHEM, V276, P12774, DOI 10.1074/jbc.M009571200; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Georgoussi Z, 1997, BBA-MOL CELL RES, V1359, P263, DOI 10.1016/S0167-4889(97)00097-9; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Johnson AO, 2001, MOL BIOL CELL, V12, P367, DOI 10.1091/mbc.12.2.367; Jones SM, 2002, AM J PHYSIOL-CELL PH, V282, pC420, DOI 10.1152/ajpcell.00253.2001; Ko JL, 1999, MOL BRAIN RES, V69, P171, DOI 10.1016/S0169-328X(99)00094-7; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; LAW PY, 1982, MOL PHARMACOL, V22, P1; LAW PY, 1984, J BIOL CHEM, V259, P4096; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Merkouris M, 1996, MOL PHARMACOL, V50, P985; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Moore RH, 1999, J CELL SCI, V112, P329; Mundell SJ, 1998, BRIT J PHARMACOL, V125, P1594, DOI 10.1038/sj.bjp.0702234; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Nakamura K, 1999, MOL PHARMACOL, V56, P728; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; Neilan CL, 1999, BRIT J PHARMACOL, V128, P556, DOI 10.1038/sj.bjp.0702816; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Preisser L, 1999, FEBS LETT, V460, P303, DOI 10.1016/S0014-5793(99)01360-5; Roth BL, 1998, DRUG ALCOHOL DEPEN, V51, P73, DOI 10.1016/S0376-8716(98)00067-2; SADEE W, 1995, ADV EXP MED BIOL, V373, P85; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; Sandoval IV, 2000, J BIOL CHEM, V275, P39874, DOI 10.1074/jbc.M006261200; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Setaluri V, 2000, PIGM CELL RES, V13, P128, DOI 10.1034/j.1600-0749.2000.130302.x; Simmen T, 1999, J CELL SCI, V112, P45; Smythies J, 2000, P ROY SOC B-BIOL SCI, V267, P1363, DOI 10.1098/rspb.2000.1151; Tang BL, 1999, FEBS LETT, V446, P211, DOI 10.1016/S0014-5793(99)00195-7; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; Wang HL, 1999, J NEUROCHEM, V72, P1307, DOI 10.1046/j.1471-4159.1999.0721307.x; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 2001, J BIOL CHEM, V276, P34331, DOI 10.1074/jbc.M104627200; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Wolf R, 1999, MOL PHARMACOL, V55, P263, DOI 10.1124/mol.55.2.263; ZADINA JE, 1993, J PHARMACOL EXP THER, V265, P254; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1999, J RECEPT SIGNAL TR R, V19, P301, DOI 10.3109/10799899909036653; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	72	37	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36848	36858		10.1074/jbc.M301540200	http://dx.doi.org/10.1074/jbc.M301540200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851402	hybrid			2022-12-25	WOS:000185318300118
J	Grabar, TB; Cain, BD				Grabar, TB; Cain, BD			Integration of b subunits of unequal lengths into F1F0-ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ATP SYNTHASE; ESCHERICHIA-COLI; DELTA-SUBUNIT; EPSILON-SUBUNIT; 2ND STALK; DIMERIZATION DOMAIN; MUTAGENIC ANALYSIS; TERMINAL REGION; ALPHA-SUBUNIT; F-0 PARTS	In Escherichia coli the peripheral stalk of F1F0-ATP synthase consists of a parallel dimer of identical b subunits. However, the length of the two b subunits need not be fixed. This led us to ask whether it is possible for two b subunits of unequal length to dimerize in a functional enzyme complex. A two-plasmid expression system has been developed that directs production of b subunits of unequal lengths in the same cell. Two b subunits differing in length have been expressed with either a histidine or V5 epitope tag to facilitate nickel-affinity resin purification ( Ni-resin) and Western blot analysis. The epitope tags did not materially affect enzyme function. The system allowed us to determine whether the different b subunits segregate to form homodimers or, conversely, whether a heterodimer consisting of both the shortened and lengthened b subunits can occur in an intact enzyme complex. Experiments expressing different b subunits lengthened and shortened by up to 7 amino acids were detected in the same enzyme complex. The V5-tagged b subunit shortened by 7 amino acids (b(Delta7-V5)) was detected in Ni-resin-purified membrane preparations only when coexpressed with a histidine-tagged b subunit in the same cell. The results demonstrate that the enzyme complex can tolerate a size difference between the two b subunits of up to 14 amino acids. Moreover, the experiments demonstrated the feasibility of constructing enzyme complexes with non-identical b subunits that will be valuable for research requiring specific chemical modification of a single b subunit.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Cain, BD (corresponding author), Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043495] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM43495] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altendorf K, 2000, J EXP BIOL, V203, P19; ARIS JP, 1985, J BIOL CHEM, V260, P1207; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Cipriano DJ, 2002, J BIOL CHEM, V277, P16782, DOI 10.1074/jbc.M201349200; DECKERSHEBESTREIT G, 1992, J BIOL CHEM, V267, P12364; DECKERSHEBESTREIT G, 1986, EUR J BIOCHEM, V161, P225, DOI 10.1111/j.1432-1033.1986.tb10146.x; Del Rizzo PA, 2002, BIOCHEMISTRY-US, V41, P6875, DOI 10.1021/bi025736i; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Dunn SD, 2000, J BIOENERG BIOMEMBR, V32, P347, DOI 10.1023/A:1005571818730; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Fillingame RH, 1999, NOVART FDN SYMP, V221, P218; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; Greie JC, 2000, EUR J BIOCHEM, V267, P3040, DOI 10.1046/j.1432-1327.2000.01327.x; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCORMICK KA, 1993, J BIOL CHEM, V268, P24683; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; Nath Sunil, 2002, Adv Biochem Eng Biotechnol, V74, P65; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P325, DOI 10.1023/A:1005594800983; Prescott M, 2003, J BIOL CHEM, V278, P251, DOI 10.1074/jbc.M204556200; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sawada K, 1997, J BIOL CHEM, V272, P30047, DOI 10.1074/jbc.272.48.30047; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; Sorgen PL, 1999, J BIOL CHEM, V274, P36261, DOI 10.1074/jbc.274.51.36261; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; TAKEYAMA M, 1988, J BIOL CHEM, V263, P16106; TAMARAPPOO BK, 1992, J BIOL CHEM, V267, P2370; Turina P, 2000, J BIOENERG BIOMEMBR, V32, P373, DOI 10.1023/A:1005528003709; Weber J, 2003, J BIOL CHEM, V278, P13409, DOI 10.1074/jbc.M212037200; Weber J, 2003, J BIOL CHEM, V278, P13623, DOI 10.1074/jbc.C300061200; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; Wilkens S, 1998, BBA-BIOENERGETICS, V1365, P93, DOI 10.1016/S0005-2728(98)00048-6; Wilkens S, 2000, J BIOENERG BIOMEMBR, V32, P333, DOI 10.1023/A:1005567717821	44	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34751	34756		10.1074/jbc.M303361200	http://dx.doi.org/10.1074/jbc.M303361200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842903	hybrid			2022-12-25	WOS:000185164400005
J	Hanson, JL; Anest, V; Reuther-Madrid, J; Baldwin, AS				Hanson, JL; Anest, V; Reuther-Madrid, J; Baldwin, AS			Oncoprotein suppression of tumor necrosis factor-induced NF kappa B activation is independent of Raf-controlled pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL-MEDIATED TRANSFORMATION; TRANSCRIPTIONAL ACTIVITY; RELA/P65 SUBUNIT; ONCOGENIC RAS; P65 SUBUNIT; DNA-BINDING; APOPTOSIS; KINASE; PHOSPHORYLATION; EXPRESSION	Extensive data indicate that the transcription factor NFkappaB is activated by signals downstream of oncoproteins such as Ras or breakpoint cluster region (BCR)-ABL. Consistent with this, evidence has been presented that NFkappaB activity is required for Ras and BCR-ABL to transform cells. However, it remains unclear whether these oncoproteins activate a full spectrum of NFkappaB-dependent gene expression or whether they may augment or interfere with other stimuli that activate NFkappaB. The data presented here indicate that BCR-ABL expression in 32D myeloid cells or oncogenic Ras expression in murine fibroblasts blocks the ability of tumor necrosis factor (TNF) to activate NFkappaB. This suppression of NFkappaB is manifested by an inhibition of TNF-induced inhibitor of NFkappaB (IKK) activity and NFkappaB DNA binding potential but not by blocking TNF-induced nuclear accumulation of NFkappaB/p65. The inhibition of NFkappaB is not observed in oncogenic Raf-expressing cells and is not fully restored by the suppression of PI3-kinase or MEK pathways. Oncogenic Ras suppresses the ability of TNF to activate the expression of NFkappaB-dependent genes, such as iNOS ( inducible nitric oxide synthase) and RANTES ( regulated on activation normal T-cell expressed and secreted). These studies suggest that the ability of Ras and BCR-ABL to activate NFkappaB involves an uncharacterized pathway that does not involve classic IKK activity and that suppresses the TNF-induced IKK pathway through a Raf/MEK/Erk-independent mechanism.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA073756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER; NCI NIH HHS [CA73756] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; EHRLICH T, 1993, IMMUNOL LETT, V39, P3, DOI 10.1016/0165-2478(93)90156-V; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Jeay S, 2003, MOL CELL BIOL, V23, P2251, DOI 10.1128/MCB.23.7.2251-2263.2003; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LI CCH, 1994, J BIOL CHEM, V269, P30089; Liu Qingyan, 2001, Molecular Cell Biology Research Communications, V4, P381, DOI 10.1006/mcbr.2001.0304; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Millan O, 2003, ONCOGENE, V22, P477, DOI 10.1038/sj.onc.1206179; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Perez P, 2000, MOL CARCINOGEN, V27, P272, DOI 10.1002/(SICI)1098-2744(200004)27:4<272::AID-MC5>3.0.CO;2-P; Rees RC, 1999, CANCER IMMUNOL IMMUN, V48, P374, DOI 10.1007/s002620050589; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297; SOLANA R, 1992, INVAS METAST, V12, P210; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	46	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34910	34917		10.1074/jbc.M304189200	http://dx.doi.org/10.1074/jbc.M304189200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12851413	Green Published, hybrid			2022-12-25	WOS:000185164400022
J	Hirayama, J; Nakamura, H; Ishikawa, T; Kobayashi, Y; Todo, T				Hirayama, J; Nakamura, H; Ishikawa, T; Kobayashi, Y; Todo, T			Functional and structural analyses of cryptochrome - Vertebrate cry regions responsible for interaction with the CLOCK : BMAL1 heterodimer and its nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN CIRCADIAN CLOCK; DNA PHOTOLYASE; MOLECULAR ANALYSIS; CRYSTAL-STRUCTURE; DROSOPHILA CLOCK; ZEBRAFISH; TIMELESS; PROTEIN; PERIOD; PHOTORECEPTOR	Mouse mCRY1 and zebrafish zCRY1a and zCRY3 belong to the DNA photolyase/Cryptochrome family. mCRY1 and zCRY1a repress CLOCK: BMAL1-mediated transcription, whereas zCRY3 does not. Reciprocal chimeras between zCRY1a and zCRY3 were generated to determine the zCRY1a regions responsible for nuclear translocation, interaction with the CLOCK: BMAL1 heterodimer, and repression of CLOCK: BMAL1-mediated transcription. Three regions, RD-2a-(126-196), RD-1( 197 - 263), and RD- 2b-( 264 - 293), were identified. Proteins in this family consist of an N- terminal alpha/beta domain and a C-terminal helical domain connected by an interdomain loop. RD-2a is within this loop, RD- 1 is at the N- terminal 50 amino acids, and RD- 2b at the following 31 amino acid residues of the helical domain. Either RD- 2a or RD- 1 is required for interaction with the CLOCK: BMAL1 heterodimer, and either RD- 1 or RD- 2b is required for the nuclear translocation of CRY. Both of these functions are prerequisites for the transcriptional repressor activity. The functional nuclear localizing signal in the RD- 2b region also was identified. The sequence is well conserved among repressor-type CRYs, including mCRY1. Mutations in the nuclear localizing signal of mCRY1 reduce the extent of its nuclear localization. These findings show that both nuclear localization and interaction with the CLOCK: BMAL heterodimer are essential for transcriptional repression by CRY.	Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan; Osaka Univ, Inst Prot Res, Res Ctr Struct Biol, Lab Prot Informat, Suita, Osaka 5650871, Japan	Kyoto University; Osaka University	Todo, T (corresponding author), Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Yoshidakonoe Cho, Kyoto 6068501, Japan.			Hirayama, Jun/0000-0002-8485-3320				Brudler R, 2003, MOL CELL, V11, P59, DOI 10.1016/S1097-2765(03)00008-X; Cahill GM, 2002, CELL TISSUE RES, V309, P27, DOI 10.1007/s00441-002-0570-7; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Cermakian N, 2000, P NATL ACAD SCI USA, V97, P4339, DOI 10.1073/pnas.97.8.4339; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Hirayama J, 2003, NUCLEIC ACIDS RES, V31, P935, DOI 10.1093/nar/gkg174; Hitomi K, 2001, J BIOL CHEM, V276, P10103, DOI 10.1074/jbc.M008828200; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; Ishikawa T, 1999, GENES CELLS, V4, P57, DOI 10.1046/j.1365-2443.1999.00237.x; Ishikawa T, 2002, GENES CELLS, V7, P1073, DOI 10.1046/j.1365-2443.2002.00579.x; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; Kobayashi Y, 2000, GENES CELLS, V5, P725, DOI 10.1046/j.1365-2443.2000.00364.x; Komori H, 2001, P NATL ACAD SCI USA, V98, P13560, DOI 10.1073/pnas.241371398; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lin FJ, 2001, MOL CELL BIOL, V21, P7287, DOI 10.1128/MCB.21.21.7287-7294.2001; MORIKAMI K, 1992, COMPUT CHEM, V16, P243, DOI 10.1016/0097-8485(92)80010-W; NAKAMURA H, 1991, NUCLEIC ACIDS RES, V19, P1817, DOI 10.1093/nar/19.8.1817; Pando MP, 2001, P NATL ACAD SCI USA, V98, P10178, DOI 10.1073/pnas.181228598; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Rosato E, 2001, CURR BIOL, V11, P909, DOI 10.1016/S0960-9822(01)00259-7; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sancar A, 2000, ANNU REV BIOCHEM, V69, P31, DOI 10.1146/annurev.biochem.69.1.31; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; TANIMURA R, 1994, PROTEIN SCI, V3, P2358, DOI 10.1002/pro.5560031220; Todo T, 1999, MUTAT RES-DNA REPAIR, V434, P89, DOI 10.1016/S0921-8777(99)00013-0; Todo T, 1997, MUTAT RES-DNA REPAIR, V384, P195, DOI 10.1016/S0921-8777(97)00032-3; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Yamamoto K, 2001, NEUROSCI LETT, V313, P13, DOI 10.1016/S0304-3940(01)02227-3	42	45	46	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35620	35628		10.1074/jbc.M305028200	http://dx.doi.org/10.1074/jbc.M305028200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832412	hybrid			2022-12-25	WOS:000185164400106
J	Reuter, G; Janvilisri, T; Venter, H; Shahi, S; Balakrishnan, L; van Veen, HW				Reuter, G; Janvilisri, T; Venter, H; Shahi, S; Balakrishnan, L; van Veen, HW			The ATP binding cassette multidrug transporter LmrA and lipid transporter MsbA have overlapping substrate Specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MDR3 P-GLYCOPROTEIN; ESCHERICHIA-COLI; LACTOCOCCUS-LACTIS; PLASMA-MEMBRANE; PHOSPHATIDYLCHOLINE TRANSLOCASE; CYTOPLASMIC MEMBRANE; ABC TRANSPORTERS; CELL-SURFACE; RESISTANCE; PROTEINS	LmrA is an ATP binding cassette (ABC) multidrug transporter in Lactococcus lactis that is a structural and functional homologue of the human multidrug resistance P-glycoprotein MDR1 (ABCB1). LmrA is also homologous to MsbA, an essential ABC transporter in Escherichia coli involved in the trafficking of lipids, including Lipid A. We have compared the substrate specificities of LmrA and MsbA in detail. Surprisingly, LmrA was able to functionally substitute for a temperature-sensitive mutant MsbA in E. coli WD2 at non-permissive temperatures, suggesting that LmrA could transport Lipid A. LmrA also exhibited a Lipid A-stimulated, vanadate-sensitive ATPase activity. Reciprocally, the expression of MsbA conferred multidrug resistance on E. coli. Similar to LmrA, MsbA interacted with photoactivatable substrate [H-3] azidopine, displayed a daunomycin, vinblastine, and Hoechst 33342-stimulated vanadate- sensitive ATPase activity, and mediated the transport of ethidium from cells and Hoechst 33342 in proteoliposomes containing purified and functionally reconstituted protein. Taken together, these data demonstrate that MsbA and LmrA have overlapping substrate specificities. Our observations imply the presence of structural elements in the recently published crystal structures of MsbA in E. coli and Vibrio cholera (Chang, G., and Roth, C. B. (2001) Science 293, 1793 - 1800; Chang, G. (2003) J. Mol. Biol. 330, 419 - 430) that support drug-protein interactions and suggest a possible role for LmrA in lipid trafficking in L. lactis.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	van Veen, HW (corresponding author), Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England.		Janvilisri, Tavan/O-6679-2019; van Veen, Hendrik W./A-4162-2008; Janvilisri, Tavan/C-8391-2015; Venter, Rietie/E-4795-2013	Janvilisri, Tavan/0000-0002-6376-5575; van Veen, Hendrik W./0000-0002-9658-8077; Janvilisri, Tavan/0000-0002-6376-5575; Venter, Rietie/0000-0001-5569-7755				Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Andersen C, 2000, EMBO REP, V1, P313, DOI 10.1093/embo-reports/kvd075; BAYER MH, 1982, J BACTERIOL, V149, P758, DOI 10.1128/JB.149.2.758-767.1982; Blackmore CG, 2001, MOL MEMBR BIOL, V18, P97, DOI 10.1080/09687680010030200; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Janvilisri T, 2003, J BIOL CHEM, V278, P20645, DOI 10.1074/jbc.M301358200; Johnstone RW, 2000, TRENDS BIOCHEM SCI, V25, P1, DOI 10.1016/S0968-0004(99)01493-0; Lomovskaya O, 2002, NAT BIOTECHNOL, V20, P1210, DOI 10.1038/nbt1202-1210; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Nikaido H, 2001, SEMIN CELL DEV BIOL, V12, P215, DOI 10.1006/scdb.2000.0247; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qu Q, 2002, BIOCHEMISTRY-US, V41, P4744, DOI 10.1021/bi0120897; Raggers RJ, 1999, J CELL SCI, V112, P415; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Schouten A, 2002, EMBO J, V21, P2117, DOI 10.1093/emboj/21.9.2117; Shapiro AB, 1997, EUR J BIOCHEM, V250, P122, DOI 10.1111/j.1432-1033.1997.00122.x; Smith AJ, 2000, J BIOL CHEM, V275, P23530, DOI 10.1074/jbc.M909002199; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; van Helvoort A, 1997, J CELL SCI, V110, P75; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; van Veen HW, 2001, SEMIN CELL DEV BIOL, V12, P239, DOI 10.1006/scdb.2000.0249; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	36	129	130	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35193	35198		10.1074/jbc.M306226200	http://dx.doi.org/10.1074/jbc.M306226200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842882	hybrid			2022-12-25	WOS:000185164400055
J	Zhou, RH; Cao, XW; Watson, C; Miao, Y; Guo, Z; Forte, JG; Yao, XB				Zhou, RH; Cao, XW; Watson, C; Miao, Y; Guo, Z; Forte, JG; Yao, XB			Characterization of protein kinase A-mediated phosphorylation of ezrin in gastric parietal cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; F-ACTIN BINDING; RHO-ASSOCIATED KINASE; ERM PROTEINS; TYROSINE PHOSPHORYLATION; THREONINE 558; POLARIZED DISTRIBUTION; 80-KDA PHOSPHOPROTEIN; RECYCLING HYPOTHESIS; PLATELET MOESIN	Gastric ezrin was initially identified as a phosphoprotein associated with parietal cell activation. To explore the nature of ezrin phosphorylation, proteins from resting and secreting gastric glands were subjected to two-dimensional SDS-PAGE. Histamine triggers acid secretion and a series of acidic isoforms of ezrin on two-dimensional SDS-PAGE. Mass spectrometric analysis of these acidic ezrin spots induced by stimulation suggests that Ser(66) is phosphorylated. To determine whether Ser(66) is a substrate of protein kinase A (PKA), recombinant proteins of ezrin, both wild type and S66A mutant, were incubated with the catalytic subunit of PKA and [P-32] ATP. Incorporation of P-32 into wild type but not the mutant ezrin verified that Ser(66) is a substrate of PKA. In addition, expression of S66A mutant ezrin in cultured parietal cells attenuates the dilation of apical vacuolar membrane associated with stimulation by histamine, indicating that PKA-mediated phosphorylation of ezrin is necessary for acid secretion. In fact, expression of phosphorylation-like S66D mutant in parietal cells mimics histamine-stimulated apical vacuole remodeling. Further examination of H, K-ATPase distribution revealed a blockade of stimulation-induced proton pump mobilization in S66A but not S66D ezrin-expressing parietal cells. These data suggest that PKA-mediated phosphorylation of ezrin plays an important role in mediating the remodeling of the apical membrane cytoskeleton associated with acid secretion in parietal cells.	Univ Sci & Technol China, Sch Life Sci, Lab Cell Dynam, Hefei 230027, Peoples R China; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Chinese Academy of Sciences; University of Science & Technology of China, CAS; University of California System; University of California Berkeley	Yao, XB (corresponding author), Univ Sci & Technol China, Sch Life Sci, Lab Cell Dynam, Hefei 230027, Peoples R China.		MIAO, YONG/D-4244-2015; Cao, Xinwang/W-2883-2019; Yao, Xuebiao/P-5771-2014	cao, xinwang/0000-0002-8052-7333	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR012961, P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056292, R37DK010141, R01DK010141] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01614, RR12961] Funding Source: Medline; NIDDK NIH HHS [DK-56292, DK-10141] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agnew BJ, 1999, J CELL SCI, V112, P2639; Ammar DA, 2002, AM J PHYSIOL-GASTR L, V282, pG23, DOI 10.1152/ajpgi.00277.2002; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BLACK JA, 1982, GASTROENTEROLOGY, V83, P595; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; CHEN J, 1995, P NATL ACAD SCI USA, V92, P7495, DOI 10.1073/pnas.92.16.7495; CHOW DC, 1993, AM J PHYSIOL, V265, pC1562, DOI 10.1152/ajpcell.1993.265.6.C1562; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; FAZIOLI F, 1993, ONCOGENE, V8, P1335; Forte JG, 1996, TRENDS CELL BIOL, V6, P45, DOI 10.1016/0962-8924(96)81009-9; FORTE TM, 1977, GASTROENTEROLOGY, V73, P941; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HANZEL DK, 1989, AM J PHYSIOL, V256, pG1082, DOI 10.1152/ajpgi.1989.256.6.G1082; Hishiya A, 1999, J BIOL CHEM, V274, P26705, DOI 10.1074/jbc.274.38.26705; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Nakamura F, 1999, MOL BIOL CELL, V10, P2669, DOI 10.1091/mbc.10.8.2669; Nakamura F, 1996, BIOCHEM BIOPH RES CO, V226, P650, DOI 10.1006/bbrc.1996.1410; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; URUSHIDANI T, 1987, BIOCHIM BIOPHYS ACTA, V930, P209, DOI 10.1016/0167-4889(87)90033-4; URUSHIDANI T, 1989, AM J PHYSIOL, V256, pG1070, DOI 10.1152/ajpgi.1989.256.6.G1070; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435; Yao XB, 2003, ANNU REV PHYSIOL, V65, P103, DOI 10.1146/annurev.physiol.65.072302.114200; YAO XB, 1993, AM J PHYSIOL, V265, pC36, DOI 10.1152/ajpcell.1993.265.1.C36; Yao XB, 1996, J BIOL CHEM, V271, P7224, DOI 10.1074/jbc.271.12.7224; YAO XB, 1995, MOL BIOL CELL, V6, P541, DOI 10.1091/mbc.6.5.541; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497; Zhou RH, 2003, MOL BIOL CELL, V14, P1097, DOI 10.1091/mbc.E02-07-0425	42	71	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35651	35659		10.1074/jbc.M303416200	http://dx.doi.org/10.1074/jbc.M303416200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12840026	hybrid			2022-12-25	WOS:000185164400110
J	Park, JI; Lee, MG; Cho, KC; Park, BJ; Chae, KS; Byun, DS; Ryu, BK; Park, YK; Chi, SG				Park, JI; Lee, MG; Cho, KC; Park, BJ; Chae, KS; Byun, DS; Ryu, BK; Park, YK; Chi, SG			Transforming growth factor-beta 1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappa B, JNK, and Ras signaling pathways	ONCOGENE			English	Article						IL-6; TGF-beta 1; Smad; nuclear factor-kappa B; c-Jun; prostate cancer	GROWTH-FACTOR-BETA; MESSENGER-RNA STABILITY; NF-KAPPA-B; PROTEIN-KINASE PATHWAY; TGF-BETA; GENE-EXPRESSION; TERMINAL KINASE; NEUROENDOCRINE DIFFERENTIATION; IL-6 FUNCTIONS; RICH ELEMENTS	Transforming growth factor (TGF)-beta1 acts as a potent growth inhibitor of prostate epithelial cells, and aberrant function of its receptor type I and II correlates with tumor aggressiveness. However, intracellular and serum TGF-beta1 levels are elevated in prostate cancer patients and further increased in patients with metastatic carcinoma, suggesting the oncogenic switch of TGF-beta1 role in prostate tumorigenesis. Recently, we reported the mitogenic conversion of TGF-beta1 effect by oncogenic Ha-Ras in prostate cancer cells. Here, we show that TGF-beta1 activates interleukin (IL)-6, which has been implicated in the malignant progression of prostate cancers, via multiple signaling pathways including Smad2, nuclear factor-kappaB (NF-kappaB), JNK, and Ras. TGF-beta1-induced IL-6 gene expression was strongly inhibited by DN-Smad2 but not by DN-Smad3 while it was further activated by wild-type Smad2 transfection. IL-6 activation by TGF-beta1 was accompanied by nuclear translocation of NF-kappaB, which was blocked by the p38 inhibitors SB202190 and SB203580 or by IkappaBalphaDeltaN transfection, indicating the crucial role for the p38-NF-kappaB signaling in TGF-beta1 induction of IL-6. TGF-beta1 activated c-Jun phosphorylation, and IL-6 induction by TGF-beta1 was severely impeded by DN-c-Jun and DN-JNK or AP-1 inhibitor curcumin, showing that the JNK-c-Jun-AP-1 signaling plays a pivotal role in TGF-beta1 stimulation of IL-6. It was also found that the Ras-Raf-MEK1 cascade is activated by TGF-beta1 and participates in the TGF-beta1 induction of IL-6 in an AP-1-dependent manner. Cotransfection assays demonstrated that TGF-beta1 stimulation of IL-6 results from the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK-c-Jun-AP-1, or Ras-Raf-MEK1 cascades. In addition, a time course IL-6 decay revealed that mRNA stability of IL-6 is modestly increased by TGF-beta1, indicating that TGF-beta1 also regulates IL-6 at the post-transcriptional level. Intriguingly, IL-6 inactivation restored the sensitivity to TGF-beta1-mediated growth arrest and apoptosis, suggesting that elevated IL-6 in advanced prostate tumors might act as a resistance factor against TGF-beta1. Collectively, our data demonstrate that IL-6 expression is stimulated by tumor-producing TGF-beta1 in human prostate cancer cells through multiple signaling pathways including Smad2, p38, JNK, and Ras, and enhanced expression of IL-6 could contribute to the oncogenic switch of TGF-beta1 role for prostate tumorigenesis, in part by counteracting its growth suppression function.	Kyung Hee Univ, Dept Pathol, Coll Med, Seoul 130701, South Korea; Korea Univ, Grad Sch Life Sci & Biotechnol, Seoul 136701, South Korea	Kyung Hee University; Korea University	Chi, SG (corresponding author), Kyung Hee Univ, Dept Pathol, Coll Med, Seoul 130701, South Korea.	sgchi@khu.ac.kr	park, jaeil/AAS-5894-2021	PARK, JAE-IL/0000-0002-0737-2654				Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Akira S, 1992, Semin Cancer Biol, V3, P17; Asschert JGW, 1999, INT J CANCER, V82, P244, DOI 10.1002/(SICI)1097-0215(19990719)82:2<244::AID-IJC15>3.0.CO;2-N; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Barrack ER, 1997, PROSTATE, V31, P61; BORSELLINO N, 1995, CANCER RES, V55, P4633; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN PH, 1994, ONCOGENE, V9, P791; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chi SG, 1997, CLIN CANCER RES, V3, P1889; Chung TDK, 2000, PROSTATE, V42, P1; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Drachenberg DE, 1999, PROSTATE, V41, P127, DOI 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H; EASTHAM JA, 1995, LAB INVEST, V73, P628; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; EUSTACE D, 1993, GYNECOL ONCOL, V50, P15, DOI 10.1006/gyno.1993.1156; Franchimont N, 1999, J BIOL CHEM, V274, P6783, DOI 10.1074/jbc.274.10.6783; Franchimont N, 2000, BONE, V26, P249, DOI 10.1016/S8756-3282(99)00275-6; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Junn E, 2000, J IMMUNOL, V165, P2190, DOI 10.4049/jimmunol.165.4.2190; Kim IY, 1998, CLIN CANCER RES, V4, P1625; Kim IY, 1996, CANCER RES, V56, P44; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; Kossakowska AE, 1999, BLOOD, V94, P2080, DOI 10.1182/blood.V94.6.2080.418k30_2080_2089; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mazzarelli P, 1998, J NEUROIMMUNOL, V87, P185, DOI 10.1016/S0165-5728(98)00110-6; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Montero L, 1999, CANCER RES, V59, P5286; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Nabors LB, 2001, CANCER RES, V61, P2154; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Oka M, 1996, CANCER RES, V56, P2776; Okamoto M, 1997, CANCER RES, V57, P141; Okamoto M, 1998, PROSTATE, V35, P255, DOI 10.1002/(SICI)1097-0045(19980601)35:4<255::AID-PROS4>3.0.CO;2-F; Park BJ, 2000, CANCER RES, V60, P3031; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Riggins GJ, 1997, CANCER RES, V57, P2578; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; Sehgal I, 1996, CANCER RES, V56, P3359; Seymour JF, 1997, AM J MED, V102, P21; SIEGALL CB, 1990, CANCER RES, V50, P7786; SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022-5347(17)35267-9; St-Arnaud Rene, 1998, Frontiers in Bioscience, V3, pD838; Stearns ME, 1999, CLIN CANCER RES, V5, P711; Troppmair J, 1998, ONCOGENE, V17, P685, DOI 10.1038/sj.onc.1201981; TRUONG LD, 1993, HUM PATHOL, V24, P4, DOI 10.1016/0046-8177(93)90055-L; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Williams RH, 1996, CLIN CANCER RES, V2, P635; Wong C, 1999, MOL CELL BIOL, V19, P1821; Yakymovych I, 2002, BIOCHEMISTRY-US, V41, P11000, DOI 10.1021/bi025936u; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhao Y, 1996, J BIOL CHEM, V271, P2369, DOI 10.1074/jbc.271.5.2369; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	83	164	171	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4314	4332		10.1038/sj.onc.1206478	http://dx.doi.org/10.1038/sj.onc.1206478			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853969				2022-12-25	WOS:000183978900002
J	Ragab, A; Bodin, S; Viala, C; Chap, H; Payrastre, B; Ragab-Thomas, J				Ragab, A; Bodin, S; Viala, C; Chap, H; Payrastre, B; Ragab-Thomas, J			The tyrosine phosphatase 1B regulates linker for activation of T-cell phosphorylation and platelet aggregation upon Fc gamma RIIa cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-INDUCED THROMBOCYTOPENIA; THROMBIN-STIMULATED PLATELETS; RECEPTOR GLYCOPROTEIN VI; PHOSPHOLIPASE C-GAMMA-2; MEDIATED ACTIVATION; INSULIN-RECEPTOR; IMMUNOGLOBULIN-G; PROTEIN; COLLAGEN; INTEGRIN	Human platelets express the receptor for immunoglobulin G, FcgammaRIIa, that triggers cell aggregation upon interaction with immune complexes. Here, we report that the rapid tyrosine phosphorylation of the Linker for Activation of T-cell (LAT) in human platelets stimulated by FcgammaRIIa cross-linking was followed by its complete dephosphorylation in an alphaIIb/beta3 integrin-dependent manner. Concomitant to LAT dephosphorylation, the protein tyrosine phosphatase 1B (PTP1B) was activated through a mechanism involving its proteolysis by calpains downstream of integrins. Both PTP1B and LAT were associated with the actin cytoskeleton complex formed during platelet aggregation. Moreover, phospho-LAT appeared as a good substrate of activated PTP1B in vitro and these two proteins interacted upon platelet activation by FcgammaRIIa cross-linking. The permeant substrate-trapping PTP1B (TAT-PTP1B D181A) partly inhibited LAT dephosphorylation in human platelets, strongly suggesting that this tyrosine phosphatase was involved in this regulatory pathway. Using a pharmacological inhibitor, we provide evidence that PTP1B activation and LAT dephosphorylation processes were required for irreversible platelet aggregation. Altogether, our results demonstrate that PTP1B plays an important role in the integrin-mediated dephosphorylation of LAT in human platelets and is involved in the control of irreversible aggregation upon FcgammaRIIa stimulation.	Univ Toulouse 3, Hop Purpan, INSERM,U563,Ctr Physiopathol Toulouse Purpan, Inst Federat Rech 30, F-31059 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Ragab, A (corresponding author), Univ Toulouse 3, Hop Purpan, INSERM,U563,Ctr Physiopathol Toulouse Purpan, Inst Federat Rech 30, Bat C, F-31059 Toulouse, France.			, Bernard/0000-0002-8693-0190				Adachi M, 1996, CELL, V85, P15; ANDERSON CL, 1995, SEMIN THROMB HEMOST, V21, P1, DOI 10.1055/s-2007-1000374; Arabaci G, 1999, J AM CHEM SOC, V121, P5085, DOI 10.1021/ja9906756; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Bodin S, 2001, BIOCHEMISTRY-US, V40, P15290, DOI 10.1021/bi0109313; Buckley DA, 2002, MOL CELL BIOL, V22, P1998, DOI 10.1128/MCB.22.7.1998-2010.2002; BURRIDGE K, 1995, ANAL BIOCHEM, V232, P56, DOI 10.1006/abio.1995.9961; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; Cicmil M, 2002, BLOOD, V99, P137, DOI 10.1182/blood.V99.1.137; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; Dadke S, 2000, J BIOL CHEM, V275, P23642, DOI 10.1074/jbc.M001063200; Edmead CE, 1999, FEBS LETT, V459, P27, DOI 10.1016/S0014-5793(99)01209-0; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Gates RE, 1996, ANAL BIOCHEM, V237, P208, DOI 10.1006/abio.1996.0231; Gibbins JM, 1998, J BIOL CHEM, V273, P34437, DOI 10.1074/jbc.273.51.34437; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; Gross BS, 1999, EUR J BIOCHEM, V263, P612, DOI 10.1046/j.1432-1327.1999.00560.x; Ibarrola I, 1997, BBA-MOL CELL RES, V1357, P348, DOI 10.1016/S0167-4889(97)00034-7; Johnson TO, 2002, NAT REV DRUG DISCOV, V1, P696, DOI 10.1038/nrd895; KappersKlunne MC, 1997, BRIT J HAEMATOL, V96, P442, DOI 10.1046/j.1365-2141.1997.d01-2056.x; Kralisz U, 2000, IUBMB LIFE, V49, P33, DOI 10.1080/713803580; Li RY, 1997, THROMB HAEMOSTASIS, V77, P150; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; LI RY, 1994, FEBS LETT, V343, P89, DOI 10.1016/0014-5793(94)80613-6; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; MYERS MP, 2001, J BIOL CHEM, V1, P1; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Newman PM, 2000, BLOOD, V96, P182, DOI 10.1182/blood.V96.1.182.013k18_182_187; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Osdoit S, 2001, J BIOL CHEM, V276, P6703, DOI 10.1074/jbc.M008945200; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Rendu F, 1996, PLATELETS, V7, P361; ROSENFELD SI, 1985, J CLIN INVEST, V76, P2317, DOI 10.1172/JCI112242; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Tobin JF, 2002, CURR OPIN DRUG DISC, V5, P500; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	53	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40923	40932		10.1074/jbc.M303602200	http://dx.doi.org/10.1074/jbc.M303602200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12857726	hybrid			2022-12-25	WOS:000185847200064
J	Ben-Zaken, O; Tzaban, S; Tal, Y; Horonchik, L; Esko, JD; Vlodavsky, I; Taraboulos, A				Ben-Zaken, O; Tzaban, S; Tal, Y; Horonchik, L; Esko, JD; Vlodavsky, I; Taraboulos, A			Cellular heparan sulfate participates in the metabolism of prions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; GPI-ANCHORED PROTEINS; BETA-D-XYLOSIDES; CULTURED-CELLS; SCRAPIE ISOFORM; SPONGIFORM ENCEPHALOPATHY; EXTRACELLULAR-MATRIX; INCUBATION PERIOD; AMYLOID PLAQUES; PRP	During prion diseases, the host protein PrPC is refolded into an abnormal conformer "prion" PrPSc. Histological and pharmacological data have suggested that glycosaminoglycans may be involved in the development of prion diseases. Here we present the first direct evidence that cellular glycosaminoglycans play a role in the biogenesis of PrPSc in prion-infected ScN2a cells. When ScN2a cells were incubated with estradiol beta-D-xyloside to inhibit the glycosylation of proteoglycans, PrPSc was vastly reduced. Treating ScN2a-M cells with heparinase III, but not with heparinase I or chondroitinase ABC, caused a profound reduction of PrPSc. In contrast, neither the amount of PrPC nor its subcellular distribution were affected as assayed by immunofluorescence microscopy and flotation procedures. In vitro treatment of ScN2a membranes with heparinase III at either neutral or acidic pH did not reduce the level of protease-resistant PrPSc. The inhibitor of sulfation, sodium chlorate, vastly reduces PrPSc in ScN2a cells (Gabizon, R., Meiner, Z., Halimi, M., and Ben-Sasson, S. A. ( 1993) J. Cell. Physiol. 157, 319-325). Both soluble heparan sulfate and chondroitin sulfate partially restored the level of PrPSc in chlorate-treated cells. We conclude that heparinase III-sensitive, presumably undersulfated, cellular heparan sulfate plays a significant role in the biogenesis of PrPSc in ScN2a cells.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of California System; University of California San Diego; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Taraboulos, A (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel.				NATIONAL CANCER INSTITUTE [R01CA046462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063, R37GM033063] Funding Source: NIH RePORTER; NCI NIH HHS [CA46462] Funding Source: Medline; NIGMS NIH HHS [GM33063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVIEZER D, 1994, J BIOL CHEM, V269, P114; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Birkett CR, 2001, EMBO J, V20, P3351, DOI 10.1093/emboj/20.13.3351; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Cohlberg JA, 2002, BIOCHEMISTRY-US, V41, P1502, DOI 10.1021/bi011711s; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; Diaz-Nido J, 2002, PEPTIDES, V23, P1323, DOI 10.1016/S0196-9781(02)00068-2; EHLERS B, 1984, J GEN VIROL, V65, P1325, DOI 10.1099/0022-1317-65-8-1325; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; GIBBS CJ, 1969, SCIENCE, V165, P1023, DOI 10.1126/science.165.3897.1023; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; Graner E, 2000, MOL BRAIN RES, V76, P85, DOI 10.1016/S0169-328X(99)00334-4; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; LADOGANA A, 1992, J GEN VIROL, V73, P661, DOI 10.1099/0022-1317-73-3-661; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; McBride PA, 1998, EXP NEUROL, V149, P447, DOI 10.1006/exnr.1997.6740; MCKINLEY MP, 1991, LAB INVEST, V65, P622; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; NADER HB, 1990, J BIOL CHEM, V265, P16807; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; ROGERS M, 1991, J IMMUNOL, V147, P3568; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; SCHWARTZ NB, 1974, P NATL ACAD SCI USA, V71, P4047, DOI 10.1073/pnas.71.10.4047; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; Shaked GM, 2001, J BIOL CHEM, V276, P14324, DOI 10.1074/jbc.M007815200; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; SNOW AD, 1989, ACTA NEUROPATHOL, V77, P337, DOI 10.1007/BF00687367; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Tkachenko E, 2002, J BIOL CHEM, V277, P19946, DOI 10.1074/jbc.M200841200; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Tzaban S, 2002, BIOCHEMISTRY-US, V41, P12868, DOI 10.1021/bi025958g; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1999, CURRENT PROTOCOLS CE, V1; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; WILESMITH JW, 1988, VET REC, V123, P638; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Yamada S, 2002, J BIOL CHEM, V277, P31877, DOI 10.1074/jbc.M205078200; Yanai A, 1999, FEBS LETT, V460, P11, DOI 10.1016/S0014-5793(99)01316-2; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325	74	116	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40041	40049		10.1074/jbc.M301152200	http://dx.doi.org/10.1074/jbc.M301152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12871949	hybrid			2022-12-25	WOS:000185713800094
J	Mould, AP; Symonds, EJH; Buckley, PA; Grossmann, JG; McEwan, PA; Barton, SJ; Askari, JA; Craig, SE; Bella, J; Humphries, MJ				Mould, AP; Symonds, EJH; Buckley, PA; Grossmann, JG; McEwan, PA; Barton, SJ; Askari, JA; Craig, SE; Bella, J; Humphries, MJ			Structure of an integrin-ligand complex deduced from solution x-ray scattering and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-ANGLE SCATTERING; CRYSTAL-STRUCTURE; CELL-ADHESION; CONFORMATIONAL-CHANGES; EXTRACELLULAR SEGMENT; FIBRONECTIN DEPENDS; LOW-RESOLUTION; BINDING-SITES; SYNERGY SITE; A-DOMAIN	The structural basis of the interaction of integrin heterodimers with their physiological ligands is poorly understood. We have used solution x-ray scattering to visualize the head region of integrin alpha(5)beta(1) in an inactive (Ca2+-occupied) state, and in complex with a fragment of fibronectin containing the RGD and synergy recognition sequences. Shape reconstructions of the data have been interpreted in terms of appropriate molecular models. The scattering data suggest that the head region undergoes no gross conformational changes upon ligand binding but do lend support to a proposed outward movement of the hybrid domain in the beta subunit. Fibronectin is observed to bind across the top of the head region, which contains an alpha subunit beta-propeller and a beta subunit vWF type A domain. The model of the complex indicates that the synergy region binds on the side of the beta-propeller domain. In support of this suggestion, mutagenesis of a prominent loop region on the side of the propeller identifies two residues (Tyr(208) and Ile(210)) involved in recognition of the synergy region. Our data provide the first view of a complex between an integrin and a macromolecular ligand in solution, at a nominal resolution of similar to10 Angstrom.	Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Sch Biol Sci, Manchester M13 9PT, Lancs, England; CLRC, Daresbury Lab, Synchrotron Radiat Dept, Warrington WA4 4AD, Cheshire, England	University of Manchester; STFC Daresbury Laboratory	Mould, AP (corresponding author), Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Sch Biol Sci, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Bella, Jordi/F-3794-2018	Bella, Jordi/0000-0003-0443-4562; Humphries, Martin/0000-0002-4331-6967; Mould, Paul/0000-0003-0076-6228; mcewan, paul/0000-0001-6097-1528				AKIYAMA SK, 1995, CELL ADHES COMMUN, V3, P13, DOI 10.3109/15419069509081275; Altroff H, 2001, J BIOL CHEM, V276, P38885, DOI 10.1074/jbc.M105868200; Altroff H, 2003, J BIOL CHEM, V278, P491, DOI 10.1074/jbc.M209992200; AOTA S, 1994, J BIOL CHEM, V269, P24756; Arnaout MA, 2002, IMMUNOL REV, V186, P125, DOI 10.1034/j.1600-065X.2002.18612.x; Baker TS, 1996, CURR OPIN STRUC BIOL, V6, P585, DOI 10.1016/S0959-440X(96)80023-6; Baneres JL, 2000, J BIOL CHEM, V275, P5888, DOI 10.1074/jbc.275.8.5888; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burrows L, 1999, BIOCHEM J, V344, P527, DOI 10.1042/0264-6021:3440527; Chen J, 1996, CELL ADHES COMMUN, V4, P237, DOI 10.3109/15419069609010769; Coe APF, 2001, J BIOL CHEM, V276, P35854, DOI 10.1074/jbc.M103639200; Copie V, 1998, J MOL BIOL, V277, P663; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; Garcia AJ, 2002, BIOCHEMISTRY-US, V41, P9063, DOI 10.1021/bi025752f; Grossmann JG, 2002, BIOCHEMISTRY-US, V41, P3613, DOI 10.1021/bi015955o; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; Hantgan RR, 2001, PROTEIN SCI, V10, P1614, DOI 10.1110/ps.3001; Humphries MJ, 2003, TRENDS BIOCHEM SCI, V28, P313, DOI 10.1016/S0968-0004(03)00112-9; Humphries MJ, 2003, CURR OPIN STRUC BIOL, V13, P236, DOI 10.1016/S0959-440X(03)00035-6; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kamata T, 2001, J BIOL CHEM, V276, P44275, DOI 10.1074/jbc.M107021200; Kolatkar PR, 1999, EMBO J, V18, P6249, DOI 10.1093/emboj/18.22.6249; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; Lee C, 2001, IBM SYST J, V40, P592, DOI 10.1147/sj.402.0592; Li FY, 2003, BIOPHYS J, V84, P1252, DOI 10.1016/S0006-3495(03)74940-6; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Loftus JC, 1997, J CLIN INVEST, V100, pS77; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Mousa SA, 2002, CURR OPIN CHEM BIOL, V6, P534, DOI 10.1016/S1367-5931(02)00350-2; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945-053X(00)00065-2; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 2002, CURR OPIN STRUC BIOL, V12, P654, DOI 10.1016/S0959-440X(02)00363-9; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Tani PH, 2002, BIOCHEM J, V365, P287, DOI 10.1042/BJ20020067; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Witty M, 2002, EMBO J, V21, P4207, DOI 10.1093/emboj/cdf417; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040	50	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39993	39999		10.1074/jbc.M304627200	http://dx.doi.org/10.1074/jbc.M304627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12871973	hybrid			2022-12-25	WOS:000185713800088
J	Kwasnicka, DA; Krakowiak, A; Thacker, C; Brenner, C; Vincent, SR				Kwasnicka, DA; Krakowiak, A; Thacker, C; Brenner, C; Vincent, SR			Coordinate expression of NADPH-dependent flavin reductase, Fre-1, and Hint-related 7meGMP-directed hydrolase, DCS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE SYNTHASE REDUCTASE; HUMAN TUMOR-SUPPRESSOR; MESSENGER-RNA; SCHIZOSACCHAROMYCES-POMBE; CAENORHABDITIS-ELEGANS; ENZYMATIC-SYNTHESIS; PROTEIN; FHIT; CLONING; GENE	A novel human cytosolic flavin reductase, Nr1, was recently described that contains FMN, FAD, and NADPH cofactors. Though the targets of the related NADPH-dependent flavoprotein reductases, cytochrome P450 reductase, methionine synthase reductase, and nitric oxide synthase, are known, the cellular function of Nr1 is not clear. To explore expression and regulation of Nr1, we cloned fre-1, the Caenorhabditis elegans ortholog of Nr1, and discovered that it is transcribed as a bicistronic pre-mRNA together with dcs-1, the ortholog of the recently described scavenger mRNA decapping enzyme. We used the novel substrate, 7meGpppBODIPY, to demonstrate that DCS-1 has low micromolar specificity for guanine ribonucleotides with the 7me modification, whereas trimethylated G substrates are poor competitors. Contrary to earlier classification, DCS-1 is not a pyrophosphatase but a distant member of the Hint branch of the histidine triad superfamily of nucleotide hydrolases and transferases. These observations are consistent with the hypothesis that DCS-1 homologs may function in the metabolism of capped oligonucleotides generated following exosome-dependent degradation of short-lived mRNA transcripts. We find that fre-1 and dcs-1 are coordinately expressed through worm development, are induced by heat shock, and have a nearly identical expression profile in human tissues. Furthermore, immunocytochemical analysis of the endogenous proteins in COS cells indicates that both are present in the nucleus and concentrated in a distinct perinuclear structure. Though no connection between these enzymes had been anticipated, our data and data from global expression and protein association studies suggest that the two enzymes jointly participate in responses to DNA damage, heat shock, and other stresses.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Kimmel Canc Ctr, Struct Biol & Bioinformat Program, Philadelphia, PA 19107 USA	University of British Columbia; University of British Columbia; University of British Columbia; Jefferson University	Vincent, SR (corresponding author), Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 1Z3, Canada.	svincent@interchange.ubc.ca	Vincent, Steven R/D-2996-2012; Brenner, Charles/D-6339-2014; Krakowiak, Agnieszka/ABC-8848-2020	Brenner, Charles/0000-0002-4955-3226; Krakowiak, Agnieszka/0000-0002-0273-2972	NCI NIH HHS [CA75954, R01 CA075954-07, R01 CA075954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Blumenthal Thomas, 2003, Nature Reviews Genetics, V4, P112; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; BRENNER S, 1974, GENETICS, V77, P71; BUCZYNSKI G, 1990, BIOCHIM BIOPHYS ACTA, V1041, P296, DOI 10.1016/0167-4838(90)90288-Q; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; DIGNAM JD, 1975, BIOCHEM BIOPH RES CO, V63, P845, DOI 10.1016/0006-291X(75)90644-0; Ding S, 2001, BIOCHEM J, V356, P613, DOI 10.1042/0264-6021:3560613; Draganescu A, 2000, J BIOL CHEM, V275, P4555, DOI 10.1074/jbc.275.7.4555; FERNANDES M, 1994, NUCLEIC ACIDS RES, V22, P167, DOI 10.1093/nar/22.2.167; Ghosh S, 1996, GENE, V176, P249, DOI 10.1016/0378-1119(96)00260-0; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huang T, 2001, MOL CELL BIOL, V21, P1111, DOI 10.1128/MCB.21.4.1111-1120.2001; Huang Y, 1995, BIOCHEM J, V312, P925, DOI 10.1042/bj3120925; Ingelfinger D, 2002, RNA, V8, P1489, DOI 10.1017/S1355838202021726; Kemmeren P, 2002, MOL CELL, V9, P1133, DOI 10.1016/S1097-2765(02)00531-2; Lazarowski ER, 1996, BRIT J PHARMACOL, V117, P203, DOI 10.1111/j.1476-5381.1996.tb15175.x; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; Lima CD, 1997, STRUCTURE, V5, P763, DOI 10.1016/S0969-2126(97)00231-1; Liu HD, 2002, EMBO J, V21, P4699, DOI 10.1093/emboj/cdf448; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller DM, 1999, BIOTECHNIQUES, V26, P914, DOI 10.2144/99265rr01; Moteki S, 2002, MOL CELL, V10, P599, DOI 10.1016/S1097-2765(02)00660-3; Mouaikel J, 2002, MOL CELL, V9, P891, DOI 10.1016/S1097-2765(02)00484-7; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pace HC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r18; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Pace HC, 2000, CURR BIOL, V10, P907, DOI 10.1016/S0960-9822(00)00621-7; Paine MJI, 2000, J BIOL CHEM, V275, P1471, DOI 10.1074/jbc.275.2.1471; Salehi Z, 2002, MOL MICROBIOL, V46, P49, DOI 10.1046/j.1365-2958.2002.03151.x; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Steiger M, 2003, RNA, V9, P231, DOI 10.1261/rna.2151403; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; VANDOREN K, 1990, MOL CELL BIOL, V10, P1769, DOI 10.1128/MCB.10.4.1769; Verheggen C, 2002, EMBO J, V21, P2736, DOI 10.1093/emboj/21.11.2736; VINCENT S, 1995, NITRIC OXIDE NERVOUS; Wilson A, 1999, MOL GENET METAB, V67, P317, DOI 10.1006/mgme.1999.2879; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	48	33	40	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39051	39058		10.1074/jbc.M306355200	http://dx.doi.org/10.1074/jbc.M306355200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871939	hybrid, Green Accepted			2022-12-25	WOS:000185575100118
J	Lasorsa, FM; Pinton, P; Palmieri, L; Fiermonte, G; Rizzuto, R; Palmieri, F				Lasorsa, FM; Pinton, P; Palmieri, L; Fiermonte, G; Rizzuto, R; Palmieri, F			Recombinant expression of the Ca2+-sensitive aspartate/glutamate carrier increases mitochondrial ATP production in agonist-stimulated chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALATE ASPARTATE SHUTTLE; RAT-LIVER MITOCHONDRIA; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; MAMMALIAN MITOCHONDRIA; ENDOPLASMIC-RETICULUM; CALCIUM; CA2+; METABOLISM; ACTIVATION; SECRETION	The Ca2+-sensitive dehydrogenases of the mitochondrial matrix are, so far, the only known effectors to allow Ca2+ signals to couple the activation of plasma membrane receptors to the stimulation of aerobic metabolism. In this study, we demonstrate a novel mechanism, based on Ca2+- sensitive metabolite carriers of the inner membrane. We expressed in Chinese hamster ovary cells aralar1 and citrin, aspartate/glutamate exchangers that have Ca2+- binding sites in their sequence, and measured mitochondrial Ca2+ and ATP levels as well as cytosolic Ca2+ concentration with targeted recombinant probes. The increase in mitochondrial ATP levels caused by cell stimulation with Ca2+- mobilizing agonists was markedly larger in cells expressing aralar and citrin ( but not truncated mutants lacking the Ca2+-binding site) than in control cells. Conversely, the cytosolic and the mitochondrial Ca2+ signals were the same in control cells and cells expressing the different aralar1 and citrin variants, thus ruling out an indirect effect through the Ca2+- sensitive dehydrogenases. Together, these data show that the decoding of Ca2+ signals in mitochondria depends on the coordinate activity of mitochondrial enzymes and carriers, which may thus represent useful pharmacological targets in this process of major pathophysiological interest.	Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44110 Ferrara, Italy; Univ Ferrara, ICSI, I-44110 Ferrara, Italy; Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy; CNR, Inst Biomembranes & Bioenerget, I-70125 Bari, Italy	University of Ferrara; University of Ferrara; Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR)	Palmieri, F (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44110 Ferrara, Italy.		Pinton, Paolo/J-8025-2012; Fiermonte, Giuseppe/D-3680-2018; Fiermonte, Giuseppe/F-3159-2010; lasorsa, francesco massimo m/B-7931-2008; Rizzuto, Rosario/B-6312-2008	Pinton, Paolo/0000-0001-7108-6508; Fiermonte, Giuseppe/0000-0002-6764-9395; lasorsa, francesco massimo m/0000-0001-8418-5222; Rizzuto, Rosario/0000-0001-7044-5097	Telethon [GTF01011] Funding Source: Medline	Telethon(Fondazione Telethon)		Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; BROWN GC, 1992, BIOCHEM J, V284, P1; BROWN LJ, 1994, J BIOL CHEM, V269, P14363; Budd SL, 1996, J NEUROCHEM, V67, P2282; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; Civelek VN, 1996, BIOCHEM J, V318, P615, DOI 10.1042/bj3180615; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; del Arco A, 2000, BIOCHEM J, V345, P725, DOI 10.1042/0264-6021:3450725; del Arco A, 1998, J BIOL CHEM, V273, P23327, DOI 10.1074/jbc.273.36.23327; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; FRIEL DD, 1994, J NEUROSCI, V14, P4007; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANSFORD RG, 1991, J BIOENERG BIOMEMBR, V23, P823, DOI 10.1007/BF00786004; ICHAS F, 1997, CELL, V891, P145; Iijima M, 2001, ADV ENZYME REGUL, V41, P325, DOI 10.1016/S0065-2571(00)00022-4; INDIVERI C, 1987, J BIOL CHEM, V262, P15979; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Kennedy ED, 1998, DIABETES METAB, V24, P15; Kobayashi K, 1999, NAT GENET, V22, P159, DOI 10.1038/9667; KOBAYASHI K, 2000, CALCIUM MOL BASIS CA, P557; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; LANOUE KF, 1974, ARCH BIOCHEM BIOPHYS, V161, P544, DOI 10.1016/0003-9861(74)90337-3; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; LEVERVE XM, 1986, EUR J BIOCHEM, V155, P551, DOI 10.1111/j.1432-1033.1986.tb09523.x; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MCCORMACK JG, 1980, BIOCHEM J, V190, P95, DOI 10.1042/bj1900095; MEIJER AJ, 1978, J BIOL CHEM, V253, P2308; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PALMIERI F, 1972, EUR J BIOCHEM, V29, P408, DOI 10.1111/j.1432-1033.1972.tb02003.x; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; Papa S, 2002, BBA-BIOENERGETICS, V1555, P147, DOI 10.1016/S0005-2728(02)00270-0; Patterson GH, 2000, P NATL ACAD SCI USA, V97, P5203, DOI 10.1073/pnas.090098797; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; RUTTER GA, 1992, BIOCHIM BIOPHYS ACTA, V1175, P107, DOI 10.1016/0167-4889(92)90016-5; SCADUTO RC, 1994, EUR J BIOCHEM, V223, P751, DOI 10.1111/j.1432-1033.1994.tb19049.x; Schonau W, 2000, JAHRB INT GERMAN, V32, P10; Simpson PB, 1997, J BIOL CHEM, V272, P22654, DOI 10.1074/jbc.272.36.22654; STERNICZUK A, 1991, EUR J BIOCHEM, V196, P143, DOI 10.1111/j.1432-1033.1991.tb15797.x; STRZELECKI T, 1988, ARCH BIOCHEM BIOPHYS, V264, P310, DOI 10.1016/0003-9861(88)90599-1; SUGANO T, 1988, ARCH BIOCHEM BIOPHYS, V264, P144, DOI 10.1016/0003-9861(88)90579-6; Williamson J. R., 1976, GLUCONEOGENESIS ITS, P165; Zara V, 2003, J MOL BIOL, V325, P399, DOI 10.1016/S0022-2836(02)01236-6; ZARA V, 1992, J BIOL CHEM, V267, P12077	55	115	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38686	38692		10.1074/jbc.M304988200	http://dx.doi.org/10.1074/jbc.M304988200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12851387	hybrid, Green Published			2022-12-25	WOS:000185575100073
J	Pettus, BJ; Bielawska, A; Spiegel, S; Roddy, P; Hannun, YA; Chalfant, CE				Pettus, BJ; Bielawska, A; Spiegel, S; Roddy, P; Hannun, YA; Chalfant, CE			Ceramide kinase mediates cytokine- and calcium ionophore-induced arachidonic acid release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); INTESTINAL POLYPOSIS; PHOSPHATASE-ACTIVITY; MOLECULAR-CLONING; KNOCKOUT MICE; LIPID KINASE; CELLS; PHOSPHORYLATION; TRANSLOCATION; 1-PHOSPHATE	Despite the importance of prostaglandins, little is known about the regulation of prostanoid synthesis proximal to the activation of cytosolic phospholipase A(2), the initial rate-limiting step. In this study, ceramide-1-phosphate (C-1-P) was shown to be a specific and potent inducer of arachidonic acid (AA) and prostanoid synthesis in cells. This study also demonstrates that two well established activators of AA release and prostanoid synthesis, the cytokine, interleukin-1beta (IL-1beta), and the calcium ionophore, A23187, induce an increase in C-1-P levels within the relevant time-frame of AA release. Furthermore, the enzyme responsible for the production of C-1-P in mammalian cells, ceramide kinase, was activated in response to IL-1beta and A23187. RNA interference targeted to ceramide kinase specifically down-regulated ceramide kinase mRNA and activity with a concomitant decrease of AA release in response to IL-1beta and A23187. Down-regulation of ceramide kinase had no effect on AA release induced by exogenous C-1-P. Collectively, these results indicate that ceramide kinase, via the formation of C-1-P, is an upstream modulator of phospholipase A(2) activation. This study identifies previously unknown roles for ceramide kinase and its product, C-1-P, in AA release and production of eicosanoids and provides clues for potential new targets to block inflammatory responses.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA 23249 USA	Virginia Commonwealth University; Medical University of South Carolina; Hunter Holmes McGuire Veterinary Affairs Medical Center	Chalfant, CE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Rm 2-003,Sanger Hall,1101 E Marshall St,POB 98061, Richmond, VA 23298 USA.	cechalfant@vcu.edu			NCI NIH HHS [CA87584] Funding Source: Medline; NIGMS NIH HHS [GM43825, GM43880, GM08716] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880, R37GM043825, R01GM043825, R01GM043880] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold R E, 1976, JACEP, V5, P262, DOI 10.1016/S0361-1124(76)80005-6; Bajjalieh S, 2000, METHOD ENZYMOL, V311, P207; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; Balsinde J, 2000, J IMMUNOL, V164, P5398, DOI 10.4049/jimmunol.164.10.5398; BOUDKER O, 1993, J BIOL CHEM, V268, P22150; Brinckmann R, 1996, BIOCHEM J, V318, P305, DOI 10.1042/bj3180305; CARBONARO PA, 1995, CUTIS, V56, P256; Carpio LC, 1999, PROSTAG LEUKOTR ESS, V61, P267, DOI 10.1054/plef.1999.0100; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Feldhaus MJ, 2002, J BIOL CHEM, V277, P4285, DOI 10.1074/jbc.M106653200; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GomezMunoz A, 1997, BIOCHEM J, V325, P435, DOI 10.1042/bj3250435; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; Gordon RD, 1996, EUR J BIOCHEM, V238, P690, DOI 10.1111/j.1432-1033.1996.0690w.x; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hinkovska-Galcheva VT, 1998, J BIOL CHEM, V273, P33203, DOI 10.1074/jbc.273.50.33203; Hogback S, 2003, BIOCHEM J, V370, P111, DOI 10.1042/bj20020970; Kitatani K, 2000, ARCH BIOCHEM BIOPHYS, V382, P296, DOI 10.1006/abbi.2000.2028; Klapisz E, 2000, J LIPID RES, V41, P1680; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; KURPIEWSKI G, 1981, BIOCHIM BIOPHYS ACTA, V678, P467, DOI 10.1016/0304-4165(81)90128-8; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; REES RS, 1988, TOXICON, V26, P1035, DOI 10.1016/0041-0101(88)90202-4; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; Rile G, 2003, ACTA HAEMATOL-BASEL, V109, P76, DOI 10.1159/000068491; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHINGHAL R, 1993, J NEUROCHEM, V61, P2279, DOI 10.1111/j.1471-4159.1993.tb07470.x; Sugiura M, 2002, J BIOL CHEM, V277, P23294, DOI 10.1074/jbc.M201535200; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; TAY A, 1995, GENOMICS, V26, P138, DOI 10.1016/0888-7543(95)80093-2; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yamane M, 2000, J BIOCHEM-TOKYO, V128, P827, DOI 10.1093/oxfordjournals.jbchem.a022821; Yamauchi T, 2003, ANTICANCER RES, V23, P245; Zhou HP, 2003, AM J PHYSIOL-GASTR L, V284, pG472, DOI 10.1152/ajpgi.00345.2002	48	184	189	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38206	38213		10.1074/jbc.M304816200	http://dx.doi.org/10.1074/jbc.M304816200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12855693	hybrid			2022-12-25	WOS:000185575100016
J	Toustrup-Jensen, M; Vilsen, B				Toustrup-Jensen, M; Vilsen, B			Functional consequences of alterations to Ile(279), Ile(283), Glu(284), His(285), Phe(286), and His(288) in the NH2-terminal part of transmembrane helix M3 of the Na+, K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY NA+,K+-ATPASE; NA,K-ATPASE ALPHA-SUBUNIT; SITE-DIRECTED MUTAGENESIS; SARCOPLASMIC-RETICULUM CA2+-ATPASE; CATION-BINDING POCKET; RENAL NA,K-ATPASE; CONFORMATIONAL-CHANGES; SODIUM-PUMP; SEGMENT M3; COORDINATING RESIDUES	Mutations Ile(279) --> Ala, Ile(283) --> Ala, Glu(284) --> Ala, His(285) --> Ala, His(285) --> Lys, His(285) --> Glu, Phe(286) --> Ala, and His(288) --> Ala in transmembrane helix M3 of the Na+, K+-ATPase were studied. Except for His(285) --> Ala, these mutations were compatible with cell viability, permitting analysis of their effects on the overall and partial reactions of the Na+, K+-transport cycle. In Ile(279) --> Ala and Ile(283) --> Ala, the E-1 form accumulated, whereas in His(285) --> Lys and His(285) --> Glu, E1P accumulated. Phe(286) --> Ala displaced the conformational equilibria of dephosphoenzyme and phosphoenzyme in parallel in favor of E-2 and E2P, respectively, and showed a unique enhancement of the E1P --> E2P transition rate. These effects suggest that M3 undergoes significant rearrangements in relation to E-1 - E-2 and E1P - E2P conformational changes. Because the E-1 - E-2 and E1P - E2P conformational equilibria were differentially affected by some of the mutations, the phosphorylated conformations seem to differ significantly from the dephospho forms in the M3 region. Mutation of His(285) furthermore increased the Na+-activated ATPase activity in the absence of K+ ("Na+-ATPase activity"). Ile(279) --> Ala, Ile(283) --> Ala, and His(288)-->Ala showed reduced Na+ affinity of the E-1 form. The rate of Na+-activated phosphorylation from ATP was reduced in Ile(279) --> Ala and Ile(283) --> Ala, and these mutants showed evidence similar to Glu(329) --> Gln of destabilization of the Na+-occluded state.	Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark	Aarhus University	Vilsen, B (corresponding author), Aarhus Univ, Dept Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	bv@fi.au.dk		Toustrup-Jensen, Mads Schak/0000-0003-2064-5861; Vilsen, Bente/0000-0002-4727-9382				ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Babes A, 2000, BIOPHYS J, V79, P2557, DOI 10.1016/S0006-3495(00)76496-4; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Clausen JD, 2003, BIOCHEMISTRY-US, V42, P2585, DOI 10.1021/bi0271897; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1993, J PHYSIOL-LONDON, V462, P1; GLYNN IM, 1976, J PHYSIOL-LONDON, V256, P465, DOI 10.1113/jphysiol.1976.sp011333; Goldshleger R, 1999, J BIOL CHEM, V274, P16213, DOI 10.1074/jbc.274.23.16213; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KARLISH SJD, 1985, J PHYSIOL-LONDON, V359, P119, DOI 10.1113/jphysiol.1985.sp015578; KLODOS I, 1994, J BIOL CHEM, V269, P1734; Koenderink JB, 2000, BIOCHEMISTRY-US, V39, P9959, DOI 10.1021/bi0001168; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; POST RL, 1972, J BIOL CHEM, V247, P6530; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; Skou J. C, 1991, SODIUM PUMP RECENT D, P317; Strock C, 1998, J BIOL CHEM, V273, P15104, DOI 10.1074/jbc.273.24.15104; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Tal DM, 2001, BIOCHEMISTRY-US, V40, P12505, DOI 10.1021/bi011167n; Toustrup-Jensen M, 2002, J BIOL CHEM, V277, P38607, DOI 10.1074/jbc.M203665200; Toustrup-Jensen M, 2001, BIOCHEMISTRY-US, V40, P5521, DOI 10.1021/bi002367m; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vilsen B, 1999, BIOCHEMISTRY-US, V38, P11389, DOI 10.1021/bi990951t; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7; VILSEN B, 1995, FEBS LETT, V363, P179, DOI 10.1016/0014-5793(95)00313-X; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; Vilsen B, 1997, ANN NY ACAD SCI, V834, P297, DOI 10.1111/j.1749-6632.1997.tb52260.x	44	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38653	38664		10.1074/jbc.M305521200	http://dx.doi.org/10.1074/jbc.M305521200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12847095	hybrid			2022-12-25	WOS:000185575100070
J	Belham, C; Roig, J; Caldwell, JA; Aoyama, Y; Kemp, BE; Comb, M; Avruch, J				Belham, C; Roig, J; Caldwell, JA; Aoyama, Y; Kemp, BE; Comb, M; Avruch, J			A mitotic cascade of NIMA family kinases - Nercc1/Nek9 activates the Nek6 and Nek7 kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; PROTEIN-KINASE; ASPERGILLUS-NIDULANS; S6 KINASE; SUBSTRATE-SPECIFICITY; MASS-SPECTROMETRY; KIDNEY-DISEASE; AUTOPHOSPHORYLATION; PHOSPHORYLATION; REGULATOR	The Nek family of protein kinases in humans is composed of 11 members that share an amino-terminal catalytic domain related to NIMA, an Aspergillus kinase involved in the control of several aspects of mitosis, and divergent carboxyl-terminal tails of varying length. Nek6 (314AA) and Nek7 (303AA), 76% identical, have little noncatalytic sequence but bind to the carboxyl-terminal noncatalytic tail of Nercc1/Nek9, a NIMA family protein kinase that is activated in mitosis. Microinjection of anti-Nercc1 antibodies leads to spindle abnormalities and prometaphase arrest or chromosome missegregation. Herein we show that Nek6 is increased in abundance and activity during mitosis; activation requires the phosphorylation of Ser(206) on the Nek6 activation loop. This phosphorylation and the activity of recombinant Nek6 is stimulated by coexpression with an activated mutant of Nercc1. Moreover, Nercc1 catalyzes the direct phosphorylation of prokaryotic recombinant Nek6 at Ser(206) in vitro concomitant with 20-25-fold activation of Nek6 activity; Nercc1 activates Nek7 in vitro in a similar manner. Nercc1/Nek9 is likely to be responsible for the activation of Nek6 during mitosis and probably participates in the regulation of Nek7 as well. These findings support the conclusion that Nercc1/Nek9 and Nek6 represent a novel cascade of mitotic NIMA family protein kinases whose combined function is important for mitotic progression.	Massachusetts Gen Hosp, Dept Mol Biol & Med Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; Pharmacia Italia SpA, Dept Biol, I-20014 Milan, Italy; MDS Proteom, Charlottesville, VA 22911 USA; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Cell Signaling Technol, Beverly, MA 01915 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Pfizer; St. Vincent's Institute of Medical Research	Avruch, J (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol & Med Serv, Boston, MA 02114 USA.	avruch@helix.mgh.harvard.edu	Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019; Roig, Joan/E-2836-2017	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082; Roig, Joan/0000-0002-3872-4712	NIDDK NIH HHS [DK17776, R37 DK017776] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017776, R01DK017776] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Di Agostino S, 2002, DEVELOPMENT, V129, P1715; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Holland PM, 2002, J BIOL CHEM, V277, P16229, DOI 10.1074/jbc.M108662200; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Kandli M, 2000, GENOMICS, V68, P187, DOI 10.1006/geno.2000.6293; Lies CM, 1998, J CELL SCI, V111, P1453; Liu SM, 2002, DEVELOPMENT, V129, P5839, DOI 10.1242/dev.00173; Lizcano JM, 2002, J BIOL CHEM, V277, P27839, DOI 10.1074/jbc.M202042200; Logarinho E, 1998, J CELL SCI, V111, P2897; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; LU KP, 1993, J BIOL CHEM, V268, P8769; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Martin SE, 2000, ANAL CHEM, V72, P4266, DOI 10.1021/ac000497v; Noguchi K, 2002, J BIOL CHEM, V277, P39655, DOI 10.1074/jbc.M204599200; O'Connell MJ, 2003, TRENDS CELL BIOL, V13, P221, DOI 10.1016/S0962-8924(03)00056-4; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; Osmani SA, 1996, BIOCHEM J, V317, P633, DOI 10.1042/bj3170633; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; PU RT, 1995, J BIOL CHEM, V270, P18110, DOI 10.1074/jbc.270.30.18110; Roig J, 2002, GENE DEV, V16, P1640, DOI 10.1101/gad.972202; SOTIRELLIS N, 1995, J BIOL CHEM, V270, P29773; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; Upadhya P, 2000, P NATL ACAD SCI USA, V97, P217, DOI 10.1073/pnas.97.1.217; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x	36	124	129	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34897	34909		10.1074/jbc.M303663200	http://dx.doi.org/10.1074/jbc.M303663200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12840024	Green Published, hybrid			2022-12-25	WOS:000185164400021
J	Song, LX; Turkson, J; Karras, JG; Jove, R; Haura, EB				Song, LX; Turkson, J; Karras, JG; Jove, R; Haura, EB			Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells	ONCOGENE			English	Article						STAT proteins; lung cancer; Src; IL-6; HGF; EGF receptor; tyrosine kinase inhibitors	EPIDERMAL-GROWTH-FACTOR; LUNG-CANCER; CONSTITUTIVE ACTIVATION; SRC KINASES; FACTOR-I; DIFFERENTIAL EXPRESSION; TRANSCRIPTION FACTORS; FACTOR-ALPHA; INHIBITOR; APOPTOSIS	Overexpression of receptor tyrosine kinases including the epidermal growth factor receptor (EGF-R) as well as nonreceptor tyrosine kinases, such as Src, have been implicated in the formation of human lung cancers. In addition, cytokines like interleukin-6 (IL-6) have been demonstrated to modulate lung cancer cell growth and elevated levels of IL-6 have been shown to be an adverse prognostic factor for patients with lung cancer. Despite a large body of evidence pointing to their potential importance, few direct studies into the role of signal transducers and activators of transcription (STAT) pathways in human lung cancer have been undertaken. Here we demonstrate that multiple nonsmall cell lung cancer cell lines demonstrate constitutive Stat3 DNA-binding activity. Stat3 DNA-binding activity is specifically upregulated by the addition of epidermal growth factor (EGF), IL-6, and hepatocyte-derived growth factor (HGF). Furthermore, the stimulation of Stat3 DNA-binding activity by EGF requires the activity of EGF-R tyrosine kinase as well as Src-kinase, while the upregulation of Stat3 activity by IL-6 or HGF requires only Src-kinase activity. Treatment of A549 lung cancer cells with PD180970 or SU6656, both pharmacological inhibitors of Src-kinase, resulted in reduced Src and Stat3 activity, cell cycle arrest in G2, and reduced viability of cells accompanied by induction of apoptosis. Treatment of Stat3-positive A549 and H358 cells with antisense Stat3 oligonucleotides results in complete loss of Stat3 DNA-binding activity and apoptosis, while Stat3-positive H1299 cells remained healthy. Finally, an adenoviral vector expressing a dominant-negative Stat3 isoform results in loss of Stat3 DNA-binding activity, apoptosis, and reduced cellular viability. These results demonstrate a role of Stat3 in transducing survival signals downstream of tyrosine kinases such as Src, EGF-R, and c-Met, as well as cytokines such as IL-6, in human nonsmall cell lung cancers.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Expt Therapeut Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Isis Pharmaceuticals Inc	Haura, EB (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Expt Therapeut Program, MRC3 E,Room 3056,12902 Magnolia Dr, Tampa, FL 33612 USA.	hauraeb@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [P01CA082533] Funding Source: NIH RePORTER; NCI NIH HHS [CA82533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTI W, 1995, BRIT MED J, V311, P899; ANKRAPP DP, 1993, CANCER RES, V53, P3399; ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P3942, DOI 10.1073/pnas.89.9.3942; Bihl M, 1998, AM J RESP CELL MOL, V19, P606, DOI 10.1165/ajrcmb.19.4.3247; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bowman, 1999, Cancer Control, V6, P615; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brabender J, 2001, CLIN CANCER RES, V7, P1850; Brognard J, 2001, CANCER RES, V61, P3986; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BUDDE RJA, 1994, CANCER BIOCHEM BIOPH, V14, P171; Carbone DP, 1997, SEMIN ONCOL, V24, P388; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Doucet C, 2000, ONCOGENE, V19, P5898, DOI 10.1038/sj.onc.1203933; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Fang K, 1999, INT J CANCER, V81, P471; FAVONI RE, 1994, INT J CANCER, V56, P858, DOI 10.1002/ijc.2910560618; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, LARYNGOSCOPE, V110, P868, DOI 10.1097/00005537-200005000-00016; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hallek M, 1997, EXP HEMATOL, V25, P1367; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hitt DC, 2000, MOL BIOTECHNOL, V14, P197, DOI 10.1385/MB:14:3:197; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200; Ichimura E, 1996, JPN J CANCER RES, V87, P1063, DOI 10.1111/j.1349-7006.1996.tb03111.x; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Jiang YX, 1999, ONCOGENE, V18, P6071, DOI 10.1038/sj.onc.1202984; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kawai T, 1997, LAB INVEST, V77, P431; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kopantzev Y, 2002, ONCOGENE, V21, P6791, DOI 10.1038/sj.onc.1205815; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Krystal GW, 1998, CANCER RES, V58, P4660; LEE M, 1992, JNCI-J NATL CANCER I, V13, P117; Lei WD, 1998, BIOCHEM BIOPH RES CO, V245, P939, DOI 10.1006/bbrc.1998.8552; Lei WD, 1999, ANTICANCER RES, V19, P221; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Ling YH, 2000, ANTICANCER RES, V20, P693; Liu JB, 2002, AM J RESP CELL MOL, V27, P306, DOI 10.1165/rcmb.4850; Martin F, 1999, CYTOKINE, V11, P80, DOI 10.1006/cyto.1998.0398; MAZURENKO NN, 1992, EUR J CANCER, V28A, P372, DOI 10.1016/S0959-8049(05)80056-5; Moasser MM, 1999, CANCER RES, V59, P6145; MONIA BP, 1993, J BIOL CHEM, V268, P14514; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Norman P, 2001, Curr Opin Investig Drugs, V2, P428; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Olivero M, 1996, BRIT J CANCER, V74, P1862, DOI 10.1038/bjc.1996.646; RABIASZ GJ, 1992, BRIT J CANCER, V66, P254, DOI 10.1038/bjc.1992.253; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; RUSCH V, 1993, CANCER RES, V53, P2379; Rusch V, 1997, CLIN CANCER RES, V3, P515; Schaeffer M, 2001, MOL CELL BIOL, V21, P8068, DOI 10.1128/MCB.21.23.8068-8081.2001; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Siegfried JM, 1998, ANN THORAC SURG, V66, P1915, DOI 10.1016/S0003-4975(98)01165-5; Siegfried JM, 1997, CANCER RES, V57, P433; Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Takahashi T, 1999, CIRC RES, V85, P884; TAKANAMI I, 1995, J SURG ONCOL, V58, P40, DOI 10.1002/jso.2930580109; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tsao MS, 1998, LUNG CANCER, V20, P1, DOI 10.1016/S0169-5002(98)00007-5; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; YANAGAWA H, 1995, BRIT J CANCER, V71, P1095, DOI 10.1038/bjc.1995.212; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang YW, 2002, ONCOGENE, V21, P217, DOI 10.1038/sj/onc/1205004; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	89	315	347	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4150	4165		10.1038/sj.onc.1206479	http://dx.doi.org/10.1038/sj.onc.1206479			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833138				2022-12-25	WOS:000183979800002
J	Madi, L; Bar-Yehuda, S; Barer, F; Ardon, E; Ochaion, A; Fishman, P				Madi, L; Bar-Yehuda, S; Barer, F; Ardon, E; Ochaion, A; Fishman, P			A3 adenosine receptor activation in melanoma cells - Association between receptor fate and tumor growth inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BIOCHEMICAL-CHARACTERIZATION; INTERNALIZATION; DESENSITIZATION; APOPTOSIS; ROLES	Activation of the G(i) protein-coupled A3 adenosine receptor (A3AR) has been implicated in the inhibition of melanoma cell growth by deregulating protein kinase A and key components of the Wnt signaling pathway. Receptor activation results in internalization/recycling events that play an important role in turning on/off receptor-mediated signal transduction pathways. Thus, we hereby examined the association between receptor fate, receptor functionality, and tumor growth inhibition upon activation with the agonist 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purine-9-yl]-N-methyl-beta-D-ribofuranuronamide (IB-MECA). Results showed that melanoma cells highly expressed A3AR on the cell surface, which was rapidly internalized to the cytosol and "sorted" to the endosomes for recycling and to the lysosomes for degradation. Receptor distribution in the lysosomes was consistent with the down-regulation of receptor protein expression and was followed by mRNA and protein resynthesis. At each stage, receptor functionality was evidenced by the modulation in cAMP level and the downstream effectors protein kinase A, glycogen synthase kinase-3beta, c-Myc, and cyclin D1. The A3AR antagonist MRS 1523 counteracted the internalization process as well as the modulation in the expression of the signaling proteins, demonstrating that the responses are A3AR-mediated. Supporting this notion are the in vivo studies showing tumor growth inhibition upon IB-MECA treatment and reverse of this response when IB-MECA was given in combination with MRS 1523. In addition, in melanoma tumor lesions derived from IB-MECA-treated mice, the expression level A3AR and the downstream key signaling proteins were modulated in the same pattern as was seen in vitro. Altogether, our observations tie the fate of A3AR to modulation of downstream molecular mechanisms leading to tumor growth inhibition both in vitro and in vivo.	Can Fite BioPharma Ltd, IL-49170 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr,Felsenstein Med Res Ctr, Lab Clin & Tumor Immunol, IL-49100 Petah Tiqwa, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Fishman, P (corresponding author), Can Fite BioPharma Ltd, IL-49170 Petah Tiqwa, Israel.	pfishman@post.tau.ac.il						Appel E, 2001, J MOL NEUROSCI, V17, P285, DOI 10.1385/JMN:17:3:285; Bonvini P, 2000, BBA-MOL CELL RES, V1495, P308, DOI 10.1016/S0167-4889(99)00162-7; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Ferguson G, 2002, BIOCHEMISTRY-US, V41, P14748, DOI 10.1021/bi0262911; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Fishman P, 2003, CURR TOP MED CHEM, V3, P463, DOI 10.2174/1568026033392147; Fishman P, 2002, ONCOGENE, V21, P4060, DOI 10.1038/sj.onc.1205531; Fishman P, 2001, EXP CELL RES, V269, P230, DOI 10.1006/excr.2001.5327; Gessi S, 2001, BRIT J PHARMACOL, V134, P116, DOI 10.1038/sj.bjp.0704254; Kim SG, 2002, BIOCHEM PHARMACOL, V63, P871, DOI 10.1016/S0006-2952(02)00839-0; Merighi S, 2001, BRIT J PHARMACOL, V134, P1215, DOI 10.1038/sj.bjp.0704352; Merimsky O, 2003, DRUG DEVELOP RES, V58, P386, DOI 10.1002/ddr.10182; Montesinos MC, 2003, ARTHRITIS RHEUM-US, V48, P240, DOI 10.1002/art.10712; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Ohana G, 2001, J CELL PHYSIOL, V186, P19, DOI 10.1002/1097-4652(200101)186:1<19::AID-JCP1011>3.0.CO;2-3; Olah ME, 2000, PHARMACOL THERAPEUT, V85, P55, DOI 10.1016/S0163-7258(99)00051-0; Parrella P, 2001, INVEST OPHTH VIS SCI, V42, P1679; Petrou C, 1997, J BIOL CHEM, V272, P2326; Poulsen SA, 1998, BIOORGAN MED CHEM, V6, P619, DOI 10.1016/S0968-0896(98)00038-8; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; Suh BC, 2001, BRIT J PHARMACOL, V134, P132, DOI 10.1038/sj.bjp.0704218; Trincavelli ML, 2002, MOL PHARMACOL, V62, P1373, DOI 10.1124/mol.62.6.1373; Trincavelli ML, 2000, J NEUROCHEM, V75, P1493, DOI 10.1046/j.1471-4159.2000.0751493.x	28	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42121	42130		10.1074/jbc.M301243200	http://dx.doi.org/10.1074/jbc.M301243200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12865431	hybrid			2022-12-25	WOS:000185989500070
J	Nagae, M; Nozawa, A; Koizumi, N; Sano, H; Hashimoto, H; Sato, M; Shimizu, T				Nagae, M; Nozawa, A; Koizumi, N; Sano, H; Hashimoto, H; Sato, M; Shimizu, T			The crystal structure of the novel calcium-binding protein AtCBL2 from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; SIGNAL-TRANSDUCTION; ABSCISIC-ACID; PLANT-CELLS; KINASE; SALT; CALCINEURIN; SENSOR; MYRISTOYLATION; TRANSCRIPTS	Arabidopsis thaliana calcineurin B-like protein (AtCBL2) is a member of a recently identified family of calcineurin B-like calcium-binding proteins in A. thaliana. The crystal structure of AtCBL2 has been determined at 2.1 Angstrom resolution. The protein forms a compact alpha-helical structure with two pairs of EF-hand motifs. The structure is similar in overall folding topology to the structures of calcineurin B and neuronal calcium sensor 1, but differs significantly in local conformation. The two calcium ions are coordinated in the first and fourth EF-hand motifs, whereas the second and third EF-hand motifs are maintained in the open form by internal hydrogen bonding without coordination of calcium ions. Both a possible site and a possible mechanism for the target binding to AtCBL2 are discussed based on the three-dimensional structure.	Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Lab Plant Mol Breeding, Nara 6300192, Japan	Yokohama City University; Nara Institute of Science & Technology	Shimizu, T (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, 1-7-29 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	shimizu@tsurumi.yokohama-cu.ac.jp		Nozawa, Akira/0000-0003-4886-0213; Hashimoto, Hiroshi/0000-0003-1503-6789; Nagae, Masamichi/0000-0002-5470-3807				Albrecht V, 2001, EMBO J, V20, P1051, DOI 10.1093/emboj/20.5.1051; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Benson LM, 2003, RAPID COMMUN MASS SP, V17, P267, DOI 10.1002/rcm.903; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; Chikano H, 2001, MOL GEN GENET, V264, P674, DOI 10.1007/s004380000354; FINN BE, 1995, NAT STRUCT BIOL, V2, P777, DOI 10.1038/nsb0995-777; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guo Y, 2002, DEV CELL, V3, P233, DOI 10.1016/S1534-5807(02)00229-0; Guo Y, 2001, PLANT CELL, V13, P1383, DOI 10.1105/tpc.13.6.1383; Halfter U, 2000, P NATL ACAD SCI USA, V97, P3735, DOI 10.1073/pnas.040577697; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Ishitani M, 2000, PLANT CELL, V12, P1667, DOI 10.1105/tpc.12.9.1667; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim KN, 2003, PLANT CELL, V15, P411, DOI 10.1105/tpc.006858; Kim KN, 2000, PLANT PHYSIOL, V124, P1844, DOI 10.1104/pp.124.4.1844; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; Kudla J, 1999, P NATL ACAD SCI USA, V96, P4718, DOI 10.1073/pnas.96.8.4718; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu JP, 2000, P NATL ACAD SCI USA, V97, P3730, DOI 10.1073/pnas.060034197; Liu JP, 1998, SCIENCE, V280, P1943, DOI 10.1126/science.280.5371.1943; Luan S, 2002, PLANT CELL, V14, pS389, DOI 10.1105/tpc.001115; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagae M, 2003, ACTA CRYSTALLOGR D, V59, P1079, DOI 10.1107/S0907444903007029; Nakayama N, 2000, TOP BIOL INORG CHEM, V3, P29; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nozawa A, 2001, PLANT CELL PHYSIOL, V42, P976, DOI 10.1093/pcp/pce126; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Shi JR, 1999, PLANT CELL, V11, P2393, DOI 10.1105/tpc.11.12.2393; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Trewavas AJ, 1998, CURR OPIN PLANT BIOL, V1, P428, DOI 10.1016/S1369-5266(98)80268-9; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Xiong LM, 2002, PLANT CELL, V14, pS165, DOI 10.1105/tpc.000596; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; Zhu JK, 2002, ANNU REV PLANT BIOL, V53, P247, DOI 10.1146/annurev.arplant.53.091401.143329; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	49	90	111	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42240	42246		10.1074/jbc.M303630200	http://dx.doi.org/10.1074/jbc.M303630200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12871972	hybrid			2022-12-25	WOS:000185989500083
J	de Graffenried, CL; Bertozzi, CR				de Graffenried, CL; Bertozzi, CR			Golgi localization of carbohydrate sulfotransferases is a determinant of L-selectin ligand biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE 2 BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE; ENDOTHELIAL-DERIVED LIGAND; SIALYL-LEWIS-X; CELL-LINE; GLCNAC 6-O-SULFOTRANSFERASE; LINKED OLIGOSACCHARIDES; VASCULAR ADDRESSIN; KIN RECOGNITION; BREFELDIN-A; HELA-CELLS	Sulfation of endothelial glycoproteins by the sulfotransferase GlcNAc6ST-2 is a regulatory modification that promotes binding of the leukocyte adhesion molecule L-selectin. GlcNAc6ST-2 is a member of a family of related enzymes that act on similar carbohydrate substrates in vitro but discrete glycoproteins in vivo. We demonstrate that GlcNAc6ST-1, -2, and -3 have <LF>distinct Golgi distributions, with GlcNAc6ST-1 confined to the trans-Golgi network, GlcNAc6ST-3 confined to the early secretory pathway, and GlcNAc6ST-2 distributed throughout the Golgi. Their localization was correlated with preferred activity on either N-linked or O-linked glycoproteins. A chimera comprising the localization domain of GlcNAc6ST-1 fused to the catalytic domain of GlcNAc6ST-2 was confined to the trans-Golgi network and adopted the substrate preference of GlcNAc6ST-1. We propose a model in which Golgi enzyme localization and competition orchestrate the biosynthesis of L-selectin ligands.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Bertozzi, CR (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	bertozzi@cchem.berkeley.edu	de Graffenried, Christopher/I-6172-2019	de Graffenried, Christopher/0000-0003-3386-6487	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059907] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59907] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akama TO, 2001, J BIOL CHEM, V276, P16271, DOI 10.1074/jbc.M009995200; Andre P, 2000, P NATL ACAD SCI USA, V97, P3400, DOI 10.1073/pnas.040569797; Aplin JD, 1998, GLYCOBIOLOGY, V8, P269, DOI 10.1093/glycob/8.3.269; Baekkevold ES, 1999, LAB INVEST, V79, P327; Banting G, 1997, BBA-MOL CELL RES, V1355, P209, DOI 10.1016/S0167-4889(96)00146-2; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; Beum PV, 1999, J BIOL CHEM, V274, P24641, DOI 10.1074/jbc.274.35.24641; Bieberich E, 2002, BIOCHEMISTRY-US, V41, P11479, DOI 10.1021/bi0259958; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; Bowman KG, 2001, BIOCHEMISTRY-US, V40, P5382, DOI 10.1021/bi001750o; BROWN GM, 1994, EUR J BIOCHEM, V224, P281, DOI 10.1111/j.1432-1033.1994.00281.x; CAMPBELL C, 1984, J BIOL CHEM, V259, P1208; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; Chen SQ, 1999, J CELL BIOL, V144, P185, DOI 10.1083/jcb.144.1.185; Cole NB, 1998, J CELL BIOL, V140, P1, DOI 10.1083/jcb.140.1.1; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Dalziel M, 2001, J BIOL CHEM, V276, P11007, DOI 10.1074/jbc.M006523200; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; Elhammer AP, 1999, GLYCOCONJUGATE J, V16, P171, DOI 10.1023/A:1026465232149; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; Giraudo CG, 2001, P NATL ACAD SCI USA, V98, P1625, DOI 10.1073/pnas.031458398; Gleeson PA, 1998, HISTOCHEM CELL BIOL, V109, P517, DOI 10.1007/s004180050252; Grabenhorst E, 1999, J BIOL CHEM, V274, P36107, DOI 10.1074/jbc.274.51.36107; Grunwell JR, 2002, BIOCHEMISTRY-US, V41, P15590, DOI 10.1021/bi0269557; Hauri HP, 2000, J CELL SCI, V113, P587; Hemmerich S, 2001, DRUG DISCOV TODAY, V6, P27, DOI 10.1016/S1359-6446(00)01581-6; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; Hemmerich S, 2001, GLYCOBIOLOGY, V11, P75, DOI 10.1093/glycob/11.1.75; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Hooper LV, 2001, GLYCOBIOLOGY, V11, p1R, DOI 10.1093/glycob/11.2.1R; Ikehara Y, 1999, GLYCOBIOLOGY, V9, P1213, DOI 10.1093/glycob/9.11.1213; IMAI Y, 1993, NATURE, V361, P555; KAMERLING JP, 1988, FEBS LETT, V241, P246, DOI 10.1016/0014-5793(88)81070-6; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; Lawrence MB, 1999, CURR OPIN CHEM BIOL, V3, P659, DOI 10.1016/S1367-5931(99)00023-X; Lee JK, 2003, GLYCOBIOLOGY, V13, P245, DOI 10.1093/glycob/cwg018; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; Lippincott-Schwartz J, 1998, TRENDS CELL BIOL, V8, P16, DOI 10.1016/S0962-8924(97)01199-9; Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Marsh BJ, 2001, P NATL ACAD SCI USA, V98, P2399, DOI 10.1073/pnas.051631998; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; MICHIE SA, 1993, AM J PATHOL, V143, P1688; Miles S, 2001, J CELL BIOL, V155, P543, DOI 10.1083/jcb.200103104; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NOGUCHI S, 1992, EUR J BIOCHEM, V209, P883, DOI 10.1111/j.1432-1033.1992.tb17361.x; NOVIKOFF PM, 1983, P NATL ACAD SCI-BIOL, V80, P4364, DOI 10.1073/pnas.80.14.4364; O'Riordan CR, 2000, GLYCOBIOLOGY, V10, P1225, DOI 10.1093/glycob/10.11.1225; Opat AS, 2001, BIOCHIMIE, V83, P763, DOI 10.1016/S0300-9084(01)01312-8; Opat AS, 2001, BIOCHEM J, V358, P33, DOI 10.1042/0264-6021:3580033; Osman N, 1996, J BIOL CHEM, V271, P33105, DOI 10.1074/jbc.271.51.33105; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Pinhal MAS, 2001, P NATL ACAD SCI USA, V98, P12984, DOI 10.1073/pnas.241175798; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; Roth J, 2002, CHEM REV, V102, P285, DOI 10.1021/cr000423j; Rottger S, 1998, J CELL SCI, V111, P45; Sanders WJ, 1999, J BIOL CHEM, V274, P5271, DOI 10.1074/jbc.274.9.5271; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Seko A, 2002, GLYCOBIOLOGY, V12, P379, DOI 10.1093/glycob/12.6.379; SHILATIFARD A, 1993, J VIROL, V67, P943, DOI 10.1128/JVI.67.2.943-952.1993; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; STANLEY P, 1995, FASEB J, V9, P1436, DOI 10.1096/fasebj.9.14.7589985; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Tsuboi S, 2001, BIOESSAYS, V23, P46, DOI 10.1002/1521-1878(200101)23:1<46::AID-BIES1006>3.3.CO;2-V; Uchimura K, 2002, J BIOL CHEM, V277, P3979, DOI 10.1074/jbc.M106587200; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Varki A, 1998, TRENDS CELL BIOL, V8, P34, DOI 10.1016/S0962-8924(97)01198-7; Walcheck B, 2002, BLOOD, V99, P4063, DOI 10.1182/blood-2001-12-0265; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4; Zerfaoui M, 2002, GLYCOBIOLOGY, V12, P15, DOI 10.1093/glycob/12.1.15	87	25	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40282	40295		10.1074/jbc.M304928200	http://dx.doi.org/10.1074/jbc.M304928200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12855678	hybrid			2022-12-25	WOS:000185713800121
J	Merckx, A; Le Roch, K; Nivez, MP; Dorin, D; Alano, P; Gutierrez, GJ; Nebreda, AR; Goldring, D; Whittle, C; Patterson, S; Chakrabarti, D; Doerig, C				Merckx, A; Le Roch, K; Nivez, MP; Dorin, D; Alano, P; Gutierrez, GJ; Nebreda, AR; Goldring, D; Whittle, C; Patterson, S; Chakrabarti, D; Doerig, C			Identification and initial characterization of three novel cyclin-related proteins of the human malaria parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; CELL-CYCLE; KINASE; EXPRESSION; GENOME; SEQUENCE; ANTIGEN; CLONING	The molecular mechanisms regulating cell proliferation and development during the life cycle of malaria parasites remain to be elucidated. The peculiarities of the cell cycle organization during Plasmodium falciparum schizogony suggest that the modalities of cell cycle control in this organism may differ from those in other eukaryotes. Indeed, existing data concerning Plasmodium cell cycle regulators such as cyclin-dependent kinases reveal structural and functional properties that are divergent from those of their homologues in other systems. The work presented here lies in the context of the exploitation of the recently available P. falciparum genome sequence toward the characterization of putative cell cycle regulators. We describe the in silico identification of three open reading frames encoding proteins with maximal homology to various members of the cyclin family and demonstrate that the corresponding polypeptides are expressed in the erythrocytic stages of the infection. We present evidence that these proteins possess cyclin activity by demonstrating either their association with histone H1 kinase activity in parasite extracts or their ability to activate PfPK5, a P. falciparum cyclin-dependent kinase homologue, in vitro. Furthermore, we show that RINGO, a protein with no sequence homology to cyclins but that is nevertheless a strong activator of mammalian CDK1/2, is also a strong activator of PfPK5 in vitro. This raises the possibility that "cryptic" cell cycle regulators may be found among the 50% of the open reading frames in the P. falciparum genome that display no homology to any known proteins.	Anderson Coll, INSERM, U511 Team, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland; Ist Super Sanita, I-00161 Rome, Italy; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ KwaZulu Natal, Sch Mol & Cellular Biosci, ZA-3209 Scottsville, South Africa; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Glasgow; Istituto Superiore di Sanita (ISS); European Molecular Biology Laboratory (EMBL); University of Kwazulu Natal; State University System of Florida; University of Central Florida	Doerig, C (corresponding author), Anderson Coll, INSERM, U511 Team, Wellcome Ctr Mol Parasitol, 56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.	cdoer001@udcf.gla.ac.uk	ALANO, PIETRO/C-2946-2016; Doerig, Christian/Q-9900-2019; Gutierrez, Gustavo/AAO-9957-2021; Nebreda, Angel Rodriguez/R-9594-2019; Gutierrez, Gustavo/B-6771-2013	ALANO, PIETRO/0000-0003-0092-9840; Gutierrez, Gustavo/0000-0001-8652-972X; Gutierrez, Gustavo/0000-0003-4133-5002; Doerig, Christian/0000-0002-3188-094X; Merckx, Anais/0000-0002-9756-7980; Goldring, James Philip Dean/0000-0001-6713-9515	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048036] Funding Source: NIH RePORTER; NIAID NIH HHS [AI48036, R01 AI048036-03, R01 AI048036] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALANO P, 1995, EXP PARASITOL, V81, P227, DOI 10.1006/expr.1995.1112; Alano P, 1995, MOL BIOCHEM PARASIT, V74, P143, DOI 10.1016/0166-6851(95)02491-3; Arnot DE, 1998, ANN TROP MED PARASIT, V92, P361, DOI 10.1080/00034989859357; Cross FR, 2000, MOL CELL BIOL, V20, P4782, DOI 10.1128/MCB.20.13.4782-4790.2000; Cross FR, 1999, MOL CELL, V4, P11, DOI 10.1016/S1097-2765(00)80183-5; Doerig C, 2000, Prog Cell Cycle Res, V4, P163; DOERIG C, 1995, MOL BIOCHEM PARASIT, V70, P167, DOI 10.1016/0166-6851(95)00033-W; Doerig C, 2002, INT J PARASITOL, V32, P1575, DOI 10.1016/S0020-7519(02)00186-8; DOERIG C, 2004, IN PRESS PLASMODIUM; Ferby I, 1999, GENE DEV, V13, P2177, DOI 10.1101/gad.13.16.2177; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gomez EB, 2001, MOL BIOCHEM PARASIT, V113, P97, DOI 10.1016/S0166-6851(00)00382-0; HALDAR K, 1985, J BIOL CHEM, V260, P4969; Holder AA, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P409; Honey S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.4.e24; Horrocks P, 2000, MOL BIOCHEM PARASIT, V105, P115, DOI 10.1016/S0166-6851(99)00174-7; Irniger S, 2002, FEBS LETT, V532, P7, DOI 10.1016/S0014-5793(02)03657-8; Karaiskou A, 2001, J BIOL CHEM, V276, P36028, DOI 10.1074/jbc.M104722200; Kele Z, 1998, RAPID COMMUN MASS SP, V12, P1564, DOI 10.1002/(SICI)1097-0231(19981030)12:20<1564::AID-RCM351>3.0.CO;2-T; Kissinger JC, 2002, NATURE, V419, P490, DOI 10.1038/419490a; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; Koski LB, 2001, J MOL EVOL, V52, P540, DOI 10.1007/s002390010184; Kumar Rajinder, 2002, Malar J, V1, P5, DOI 10.1186/1475-2875-1-5; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Le Roch K, 2000, J BIOL CHEM, V275, P8952, DOI 10.1074/jbc.275.12.8952; Li JL, 1996, EUR J BIOCHEM, V241, P805, DOI 10.1111/j.1432-1033.1996.00805.x; Li ZY, 2001, BIOCHEM BIOPH RES CO, V288, P1207, DOI 10.1006/bbrc.2001.5920; Malhotra P, 2002, MOL MICROBIOL, V45, P1245, DOI 10.1046/j.1365-2958.2002.03105.x; McRobert L, 2002, MOL BIOCHEM PARASIT, V119, P273, DOI 10.1016/S0166-6851(01)00429-7; Nairn AC, 2001, NEURON, V32, P174, DOI 10.1016/S0896-6273(01)00469-X; POLSON A, 1985, IMMUNOL INVEST, V14, P323, DOI 10.3109/08820138509022667; READ M, 1993, PARASITOLOGY, V106, P223, DOI 10.1017/S0031182000075041; Ridley RG, 2002, NATURE, V415, P686, DOI 10.1038/415686a; ROSSMACDONALD PB, 1994, EUR J BIOCHEM, V220, P693, DOI 10.1111/j.1432-1033.1994.tb18670.x; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Trembley JH, 2002, J BIOL CHEM, V277, P2589, DOI 10.1074/jbc.M109755200; Umeda M, 1999, MOL GEN GENET, V262, P230, DOI 10.1007/s004380051079; Van Hellemond JJ, 2000, J BIOL CHEM, V275, P8315, DOI 10.1074/jbc.275.12.8315; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; Wirth DF, 2002, NATURE, V419, P495, DOI 10.1038/419495a; Zhang SW, 2002, J BIOL CHEM, V277, P35314, DOI 10.1074/jbc.M202179200	43	61	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39839	39850		10.1074/jbc.M301625200	http://dx.doi.org/10.1074/jbc.M301625200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869562	Green Published, hybrid			2022-12-25	WOS:000185713800070
J	Mignen, O; Thompson, JL; Shuttleworth, TJ				Mignen, O; Thompson, JL; Shuttleworth, TJ			Calcineurin directs the reciprocal regulation of calcium entry pathways in nonexcitable cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ ENTRY; T-LYMPHOCYTES; NUCLEAR IMPORT; HEK293 CELLS; CHANNELS; OSCILLATIONS; ACTIVATION; RECEPTOR; RELEASE; IMMUNOSUPPRESSANT	The reciprocal regulation of noncapacitative and capacitative (or store-operated) Ca2+ entry in nonexcitable cells (Mignen, O., Thompson, J. L., and Shuttleworth, T. J. (2001) J. Biol. Chem. 276, 35676-35683) represents a switching between two distinct Ca2+-selective channels: the noncapacitative arachidonate-regulated Ca2+ channels (ARC channels) and the store- operated Ca2+ channels (SOC channels). This switch is directly associated with the change from oscillatory to sustained Ca2+ signals as agonist concentrations increase and involves a Ca2+-dependent inhibition of the ARC channels. Here we show that this process is mediated via a calcineurin-dependent inhibition of the noncapacitative ARC channels. Pharmacological and molecular inhibition of calcineurin activity (using cyclosporin or the FK506 analogue ascomycin, and a transfected C-terminal domain of the calcineurin inhibitory protein CAIN, respectively) results in a complete reversal of the Ca2+-dependent inhibition of the ARC channels. Agonist concentrations that result in oscillatory Ca2+ signals and specifically activate Ca2+ entry through the ARC channels fail to increase calcineurin activity. However, agonist concentrations that activate the store- operated Ca2+ channels and produce prolonged increases in cytosolic Ca2+ concentrations increase calcineurin activity. Thus, calcineurin is the key mediator of the reciprocal regulation of these co-existing channels, allowing each to play a unique and non-overlapping role in Ca2+ signaling.	Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester	Shuttleworth, TJ (corresponding author), Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Box 711,601 Elmwood Ave, Rochester, NY 14642 USA.	trevor_shuttleworth@urmc.rochester.edu	MIGNEN, Olivier/M-3258-2019	MIGNEN, Olivier/0000-0001-7913-6119	NIGMS NIH HHS [GM40457] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Broad LM, 1999, J BIOL CHEM, V274, P32881, DOI 10.1074/jbc.274.46.32881; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hartzell HC, 1997, MOL PHARMACOL, V51, P683, DOI 10.1124/mol.51.4.683; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MACKINTOSH C, 1990, FEBS LETT, V277, P137, DOI 10.1016/0014-5793(90)80828-7; Mignen O, 2003, J BIOL CHEM, V278, P10174, DOI 10.1074/jbc.M212536200; Mignen O, 2001, J BIOL CHEM, V276, P21365, DOI 10.1074/jbc.M102311200; Mignen O, 2001, J BIOL CHEM, V276, P35676, DOI 10.1074/jbc.M105626200; Mignen O, 2000, J BIOL CHEM, V275, P9114, DOI 10.1074/jbc.275.13.9114; Peterson LB, 1998, TRANSPLANTATION, V65, P10, DOI 10.1097/00007890-199801150-00004; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; Schuhmann K, 1997, J GEN PHYSIOL, V110, P503, DOI 10.1085/jgp.110.5.503; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; Shuttleworth TJ, 1996, BIOCHEM J, V313, P815, DOI 10.1042/bj3130815; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	43	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40088	40096		10.1074/jbc.M306365200	http://dx.doi.org/10.1074/jbc.M306365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12874277	hybrid			2022-12-25	WOS:000185713800100
J	Deleris, P; Bacqueville, D; Gayral, S; Carrez, L; Salles, JP; Perret, B; Breton-Douillon, M				Deleris, P; Bacqueville, D; Gayral, S; Carrez, L; Salles, JP; Perret, B; Breton-Douillon, M			SHIP-2 and PTEN are expressed and active in vascular smooth muscle cell nuclei, but only SHIP-2 is associated with nuclear speckles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID PHOSPHATASE-ACTIVITY; TUMOR-SUPPRESSOR PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; GLIOBLASTOMA CELLS; SIGNALING PATHWAYS; CYCLE ARREST; PC12 CELLS; IN-VITRO; KINASE	Recently, the control of phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3)-dependant signaling by phosphatases has emerged, but there is a shortage of information on intranuclear PtdIns(3,4,5)P-3 phosphatases. Therefore, we investigated the dephosphorylation of [P-32]PtdIns(3,4,5)P-3 specifically labeled on the D-3 position of the inositol ring in membrane-free nuclei isolated from pig aorta vascular smooth muscle cells (VSMCs). In vitro PtdIns(3,4,5)P-3 phosphatase assays revealed the production of both [P-32]PtdIns(3,4)P-2 and inorganic phosphate, demonstrating the presence of PtdIns(3,4,5)P-3 5- and 3-phosphatase activities inside the VSMC nucleus, respectively. Both activities presented the same potency in cellular lysates, whereas the nuclear PtdIns(3,4,5)P-3 5- phosphatase activity appeared to be the most efficient. Immunoblot experiments showed for the first time the expression of the 5- phosphatase SHIP-2 (src homology 2 domain-containing inositol phosphatase) as well as the 3-phosphatase PTEN (phosphatase and tensin homolog deleted on chromosome 10) in VSMC nuclei. In addition, immunoprecipitations from nuclear fractions indicated a [P-32]PtdIns(3,4,5)P-3 dephosphorylation by both SHIP-2 and PTEN. Moreover, confocal microscopy analyses demonstrated that SHIP-2 but not PTEN colocalized with a speckle-specific component, the SC35 splicing factor. These results suggest that SHIP-2 may be the primary enzyme for metabolizing PtdIns(3,4,5)P-3 into PtdIns(3,4)P-2 within the nucleus, thus producing another second messenger, whereas PTEN could down-regulate nuclear phosphoinositide 3-kinase signaling. Finally, intranuclear PtdIns(3,4,5)P-3 phosphatases might be involved in the control of VSMC proliferation and the pathogenesis of vascular proliferative disorders.	Hop Purpan, Dept LML, INSERM,U563, Ctr Physiopathol Toulouse Purpan, F-31059 Toulouse, France; INSERM, U469, F-34094 Montpellier 5, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Breton-Douillon, M (corresponding author), Hop Purpan, Dept LML, INSERM,U563, Ctr Physiopathol Toulouse Purpan, Pl Dr Baylac, F-31059 Toulouse, France.		SALLES, Jean Pierre/K-2998-2014	Gayral, Stephanie/0000-0001-6276-3917; Bertrand, PERRET/0000-0001-7568-445X				Bacqueville D, 1998, BIOCHEM BIOPH RES CO, V244, P630, DOI 10.1006/bbrc.1997.7885; Bacqueville D, 2001, J BIOL CHEM, V276, P22170, DOI 10.1074/jbc.M011572200; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Braun-Dullaeus RC, 2001, ARTERIOSCL THROM VAS, V21, P1152, DOI 10.1161/hq0701.092104; BRETON M, 1986, EXP CELL RES, V166, P416, DOI 10.1016/0014-4827(86)90487-8; Calcerrada MC, 2002, FEBS LETT, V514, P361, DOI 10.1016/S0014-5793(02)02401-8; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; Downes CP, 2001, BIOCHEM SOC T, V29, P846, DOI 10.1042/BST0290846; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Ginisty H, 1999, J CELL SCI, V112, P761; Ginn-Pease ME, 2003, CANCER RES, V63, P282; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Huang JH, 2002, ARTERIOSCL THROM VAS, V22, P745, DOI 10.1161/01.ATV.0000016358.05294.8D; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Lu PJ, 1998, BIOCHEMISTRY-US, V37, P5738, DOI 10.1021/bi972551g; Marchisio M, 1998, BIOCHEM BIOPH RES CO, V253, P346, DOI 10.1006/bbrc.1998.9787; Martelli AM, 2001, FEBS LETT, V505, P1, DOI 10.1016/S0014-5793(01)02752-1; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Metjian A, 1999, J BIOL CHEM, V274, P27943, DOI 10.1074/jbc.274.39.27943; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; Osborne SL, 2001, J CELL SCI, V114, P2501; PAYRASTRE B, 1994, FEBS LETT, V341, P113, DOI 10.1016/0014-5793(94)80251-3; Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Scheid MP, 2002, J BIOL CHEM, V277, P9027, DOI 10.1074/jbc.M106755200; Schwartzbauer G, 2001, J BIOL CHEM, V276, P35786, DOI 10.1074/jbc.M102479200; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yu HY, 1998, EUR J BIOCHEM, V251, P281, DOI 10.1046/j.1432-1327.1998.2510281.x; Zheng WH, 2000, J BIOL CHEM, V275, P39152, DOI 10.1074/jbc.M002417200	51	75	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38884	38891		10.1074/jbc.M300816200	http://dx.doi.org/10.1074/jbc.M300816200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12847108	hybrid			2022-12-25	WOS:000185575100097
J	Smith, SB; Gasa, R; Watada, H; Wang, JH; Griffen, SC; German, MS				Smith, SB; Gasa, R; Watada, H; Wang, JH; Griffen, SC; German, MS			Neurogenin3 and hepatic nuclear factor 1 cooperate in activating pancreatic expression of Pax4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; RECOMBINANT ADENOVIRUS; ALPHA-CELLS; BETA-CELLS; GENE; DIFFERENTIATION; PROMOTER; HOMEOPROTEIN; SYNERGY; HOMEODOMAIN	During fetal development, paired/homeodomain transcription factor Pax4 controls the formation of the insulin-producing beta cells and the somatostatin-producing delta cells in the islets of Langerhans in the pancreas. Targeting of Pax4 expression to the islet lineage in the fetal pancreas depends on a short sequence located similar to2 kb upstream of the transcription initiation site of the PAX4 gene. This short sequence contains binding sites for homeodomain transcription factors PDX1 and hepatic nuclear factor (HNF)1, nuclear receptor HNF4alpha, and basic helix-loop-helix factor Neurogenin3. In the current study we demonstrate that the HNF1alpha and Neurogenin3 binding sites are critical for activity of the region through synergy between the two proteins. Synergy involves a physical interaction between the factors and requires the activation domains of both factors. Furthermore, exogenous expression of Neurogenin3 is sufficient to induce expression of the endogenous pax4 gene in the mouse pancreatic ductal cell line mPAC, which already expresses HNF1alpha, whereas expression of both Neurogenin3 and HNF1alpha are necessary to activate the pax4 gene in the fibroblast cell line NIH3T3. These data demonstrate how Neurogenin3 and HNF1alpha activate the pax4 gene during the cascade of gene expression events that control pancreatic endocrine cell development.	Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	German, MS (corresponding author), Univ Calif San Francisco, Ctr Diabet, 513 Parnassus Ave,Rm HSW1090, San Francisco, CA 94143 USA.			Watada, Hirotaka/0000-0001-5961-1816	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK021344, R01DK021344, R37DK021344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK553401, DK21344, R01 DK021344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antes TJ, 2001, DNA CELL BIOL, V20, P67, DOI 10.1089/104454901750070265; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BECKER TC, 1994, J BIOL CHEM, V269, P21234; Brink C, 2001, MECH DEVELOP, V100, P37, DOI 10.1016/S0925-4773(00)00500-1; Coffinier C, 1999, DEVELOPMENT, V126, P4785; Coffinier C, 1999, MECH DEVELOP, V89, P211, DOI 10.1016/S0925-4773(99)00221-X; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Edlund H, 1999, CURR OPIN CELL BIOL, V11, P663, DOI 10.1016/S0955-0674(99)00033-2; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Lechner J, 1997, J BIOL CHEM, V272, P20954, DOI 10.1074/jbc.272.33.20954; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; PEERS B, 1995, MOL CELL BIOL, V15, P7091; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Sander M, 2000, DEVELOPMENT, V127, P5533; Sander M, 1998, P NATL ACAD SCI USA, V95, P11572, DOI 10.1073/pnas.95.20.11572; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Smith SB, 1999, MOL CELL BIOL, V19, P8272; Smith SB, 2000, J BIOL CHEM, V275, P36910, DOI 10.1074/jbc.M005202200; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Vaxillaire M, 1999, J BIOL CHEM, V274, P35639, DOI 10.1074/jbc.274.50.35639; Wilson ME, 2003, MECH DEVELOP, V120, P65, DOI 10.1016/S0925-4773(02)00333-7; Xu WZ, 2000, MOL CELL ENDOCRINOL, V170, P79, DOI 10.1016/S0303-7207(00)00329-4; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8	32	92	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38254	38259		10.1074/jbc.M302229200	http://dx.doi.org/10.1074/jbc.M302229200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12837760	hybrid			2022-12-25	WOS:000185575100022
J	Dementiev, A; Simonovic, M; Volz, K; Gettins, PGW				Dementiev, A; Simonovic, M; Volz, K; Gettins, PGW			Canonical inhibitor-like interactions explain reactivity of alpha(1)-proteinase inhibitor Pittsburgh and antithrombin with proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTER LOOP; CONFORMATIONAL-CHANGE; HEPARIN ACCELERATION; MECHANISM; THROMBIN; SERPIN; COMPLEX; ALPHA(1)-ANTITRYPSIN; ACTIVATION; TRYPSIN	The serpin antithrombin is a slow thrombin inhibitor that requires heparin to enhance its reaction rate. In contrast, alpha(1)-proteinase inhibitor (alpha(1)PI) Pittsburgh (P1 Met --> Arg natural variant) inhibits thrombin 17 times faster than pentasaccharide heparin-activated antithrombin. We present here x-ray structures of free and S195A trypsin-bound alpha(1)PI Pittsburgh, which show that the reactive center loop (RCL) possesses a canonical conformation in the free serpin that does not change upon binding to S195A trypsin and that contacts the proteinase only between P2 and P2'. By inference from the structure of heparin cofactor II bound to S195A thrombin, this RCL conformation is also appropriate for binding to thrombin. Reaction rates of trypsin and thrombin with alpha(1)PI Pittsburgh and antithrombin and their P2 variants show that the low antithrombin-thrombin reaction rate results from the antithrombin RCL sequence at P2 and implies that, in solution, the antithrombin RCL must be in a similar canonical conformation to that found here for alpha(1)PI Pittsburgh, even in the nonheparin-activated state. This suggests a general, limited, canonical-like interaction between serpins and proteinases in their Michaelis complexes.	Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Volz, K (corresponding author), Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60607 USA.			Simonovic, Miljan/0000-0002-1576-2222	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049234, R37HL049234, P01HL064013] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007739] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64013, HL49234] Funding Source: Medline; NIDDK NIH HHS [T32 DK07739] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Bianchini EP, 2002, J BIOL CHEM, V277, P20527, DOI 10.1074/jbc.M201139200; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Futamura A, 2001, BIOCHEMISTRY-US, V40, P6680, DOI 10.1021/bi0029346; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; Peterson FC, 2000, BIOCHEMISTRY-US, V39, P11884, DOI 10.1021/bi001152+; Peterson FC, 2001, BIOCHEMISTRY-US, V40, P6275, DOI 10.1021/bi0100992; Simonovic M, 2001, P NATL ACAD SCI USA, V98, P11131, DOI 10.1073/pnas.211268598; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; TRAVIS J, 1986, BIOL CHEM H-S, V367, P853, DOI 10.1515/bchm3.1986.367.2.853; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977; Ye S, 2001, NAT STRUCT BIOL, V8, P979, DOI 10.1038/nsb1101-979; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	25	72	75	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37881	37887		10.1074/jbc.M305195200	http://dx.doi.org/10.1074/jbc.M305195200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12860985	hybrid			2022-12-25	WOS:000185437200109
J	Lacour, S; Kolb, A; Landini, P				Lacour, S; Kolb, A; Landini, P			Nucleotides from-16 to-12 determine specific promoter recognition by bacterial sigma(S)-RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; GENERAL STRESS-RESPONSE; SIGMA SUBUNIT SYNTHESIS; ESCHERICHIA-COLI; ADAPTIVE RESPONSE; TRANSCRIPTION INITIATION; INTRACELLULAR LEVELS; ADA PROTEIN; REGION 2.5; DNA	The alternative sigma factor sigma(S), mainly active in stationary phase of growth, recognizes in vitro a -10 promoter sequence almost identical to the one for the main sigma factor, sigma(70), thus raising the problem of how specific promoter recognition by sigmaS-RNA polymerase (Esigma(S)) is achieved in vivo. We investigated the promoter features involved in selective recognition by Esigma(S) at the strictly sigma(S)-dependent aidB promoter. We show that the presence of a C nucleotide as first residue of the aidB -10 sequence (-12C), instead of the T nucleotide canonical for sigma(70)-dependent promoters, is the major determinant for selective recognition by Esigma(S). The presence of the -12C does not allow formation of an open complex fully proficient in transcription initiation by Esigma(70). The role of -12C as specific determinant for promoter recognition by Esigma(S) was confirmed by sequence analysis of known Esigma(S)-dependent promoters as well as site-directed mutagenesis at the promoters of the csgB and sprE genes. We propose that Esigma(S), unlike Esigma(70), can recognize both C and T as the first nucleotide in the -10 sequence. Additional promoter features such as the presence of a C nucleotide at position -13, contributing to open complex formation by Esigma(S), and a TG motif found at the unusual -16/-15 location, possibly contributing to initial binding to the promoter, also represent important factors for sigma(S)-dependent transcription. We propose a new sequence, TG(N)(0-2)CCATA(c/a)T, as consensus -10 sequence for promoters exclusively recognized by Esigma(S).	Swiss Fed Inst Environm Technol, EAWAG, CH-8600 Dubendorf, Switzerland; Inst Pasteur, Dept Microbiol Fondamentale & Med, CNRS, URA 1773,Unite Regulat Transcript, F-75724 Paris 15, France	Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Landini, P (corresponding author), Swiss Fed Inst Environm Technol, EAWAG, Uberlandstr 133, CH-8600 Dubendorf, Switzerland.	landini@eawag.ch	Landini, Paolo/B-7859-2017	Landini, Paolo/0000-0003-0999-426X; Lacour, Stephan/0000-0002-6066-4189				Barne KA, 1997, EMBO J, V16, P4034, DOI 10.1093/emboj/16.13.4034; Becker G, 2001, MOL MICROBIOL, V39, P1153, DOI 10.1046/j.1365-2958.2001.02313.x; Bordes P, 2000, MOL MICROBIOL, V35, P845, DOI 10.1046/j.1365-2958.2000.01758.x; Bown JA, 1999, J BIOL CHEM, V274, P2263, DOI 10.1074/jbc.274.4.2263; Burr T, 2000, NUCLEIC ACIDS RES, V28, P1864, DOI 10.1093/nar/28.9.1864; Colland F, 1999, EMBO J, V18, P4049, DOI 10.1093/emboj/18.14.4049; Colland F, 2002, GENES CELLS, V7, P233, DOI 10.1046/j.1365-2443.2002.00517.x; Colland F, 2000, EMBO J, V19, P3028, DOI 10.1093/emboj/19.12.3028; EspinosaUrgel M, 1996, MOL MICROBIOL, V21, P657; Gaal T, 2001, MOL MICROBIOL, V42, P939, DOI 10.1046/j.1365-2958.2001.02703.x; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; Hengge-Aronis R, 2002, CURR OPIN MICROBIOL, V5, P591, DOI 10.1016/S1369-5274(02)00372-7; Hengge-Aronis R, 1999, CURR OPIN MICROBIOL, V2, P148, DOI 10.1016/S1369-5274(99)80026-5; Hengge-Aronis R, 2002, J MOL MICROB BIOTECH, V4, P341; Hiratsu K, 1995, MOL MICROBIOL, V18, P841, DOI 10.1111/j.1365-2958.1995.18050841.x; Ishihama A, 2000, ANNU REV MICROBIOL, V54, P499, DOI 10.1146/annurev.micro.54.1.499; Jishage M, 1996, J BACTERIOL, V178, P5447, DOI 10.1128/jb.178.18.5447-5451.1996; JISHAGE M, 1995, J BACTERIOL, V177, P6832, DOI 10.1128/jb.177.23.6832-6835.1995; KEILTY S, 1987, J BIOL CHEM, V262, P6389; KUMAR A, 1993, J MOL BIOL, V232, P406, DOI 10.1006/jmbi.1993.1400; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lacour S, 2002, BIOCHEM BIOPH RES CO, V292, P922, DOI 10.1006/bbrc.2002.6744; Landini P, 1998, J BIOL CHEM, V273, P13307, DOI 10.1074/jbc.273.21.13307; LANDINI P, 1994, J BACTERIOL, V176, P6583, DOI 10.1128/JB.176.21.6583-6589.1994; LANDINI P, 1995, J BIOL CHEM, V270, P8285, DOI 10.1074/jbc.270.14.8285; Landini P, 2000, J BACTERIOL, V182, P6543, DOI 10.1128/JB.182.23.6543-6549.2000; Landini P, 1996, MOL MICROBIOL, V20, P947, DOI 10.1111/j.1365-2958.1996.tb02536.x; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; Lee SJ, 2001, J BIOL CHEM, V276, P30064, DOI 10.1074/jbc.M102886200; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Maeda H, 2000, NUCLEIC ACIDS RES, V28, P3497, DOI 10.1093/nar/28.18.3497; Marschall C, 1998, J MOL BIOL, V276, P339, DOI 10.1006/jmbi.1997.1533; Matlock DL, 2000, BIOCHEMISTRY-US, V39, P12274, DOI 10.1021/bi001433h; MINCHIN S, 1993, BIOCHEM J, V289, P771, DOI 10.1042/bj2890771; PONNAMBALAM S, 1986, J BIOL CHEM, V261, P6043; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; TANAKA K, 1995, NUCLEIC ACIDS RES, V23, P827, DOI 10.1093/nar/23.5.827; TANAKA K, 1993, P NATL ACAD SCI USA, V90, P3511, DOI 10.1073/pnas.90.8.3511; Vicente M, 1999, MOL MICROBIOL, V33, P8, DOI 10.1046/j.1365-2958.1999.01445.x; VOLKERT MR, 1986, GENETICS, V112, P11; VOLKERT MR, 1994, J BACTERIOL, V176, P7638, DOI 10.1128/JB.176.24.7638-7645.1994; Volkert MR, 2001, CURR OPIN MICROBIOL, V4, P178, DOI 10.1016/S1369-5274(00)00186-7; Wise A, 1996, J BACTERIOL, V178, P2785, DOI 10.1128/jb.178.10.2785-2793.1996; Yang CH, 2002, MOL PLANT MICROBE IN, V15, P472, DOI 10.1094/MPMI.2002.15.5.472	45	30	30	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37160	37168		10.1074/jbc.M305281200	http://dx.doi.org/10.1074/jbc.M305281200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12853450	Green Published, hybrid			2022-12-25	WOS:000185437200023
J	Lee, JM; Shih, AY; Murphy, TH; Johnson, JA				Lee, JM; Shih, AY; Murphy, TH; Johnson, JA			NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT-RESPONSIVE ELEMENT; NRF2 TRANSCRIPTION FACTOR; HUMAN NEUROBLASTOMA-CELLS; SUBUNIT GENE-EXPRESSION; HEME OXYGENASE-1 GENE; PARKINSONS-DISEASE; OXIDATIVE STRESS; OLIGONUCLEOTIDE MICROARRAY; GLUTATHIONE-PEROXIDASE; CONFERRING PROTECTION	NF-E2-related factor-2 (Nrf2) regulates the gene expression of phase II detoxification enzymes and antioxidant proteins through an enhancer sequence referred to as the antioxidant-responsive element ( ARE). In this study, we demonstrate that Nrf2 protects neurons in mixed primary neuronal cultures containing both astrocytes (similar to 10%) and neurons (similar to 90%) through coordinate up-regulation of ARE- driven genes. Nrf2(-/-) neurons in this mixed culture system were more sensitive to mitochondrial toxin ( 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine or rotenone)-induced apoptosis compared with Nrf2(+/+) neurons. To understand the underlying mechanism of this observed differential sensitivity, we compared the gene expression profiles using oligonucleotide microarrays. Microarray data showed that Nrf2(+/+) neuronal cultures had higher expression levels of genes encoding detoxification enzymes, antioxidant proteins, calcium homeostasis proteins, growth factors, neuron-specific proteins, and signaling molecules compared with Nrf2(-/-) neuronal cultures. As predicted from the microarray data, Nrf2(-/-) neurons were indeed more vulnerable to the cytotoxic effects of ionomycin- and 2,5-di( t-butyl)-1,4-hydroquinone-induced increases in intracellular calcium. Finally, adenoviral vector-mediated overexpression of Nrf2 recovered ARE- driven gene expression in Nrf2(-/-) neuronal cultures and rescued Nrf2(+/+) neurons from rotenone- or ionomycin- induced cell death. Taken together, these findings suggest that Nrf2 plays an important role in protecting neurons from toxic insult.	Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA; Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53705 USA; Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Univ Wisconsin, Ctr Neurosci, Madison, WI 53705 USA; Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Physiol, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1Z3, Canada	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of British Columbia; University of British Columbia	Johnson, JA (corresponding author), Univ Wisconsin, Sch Pharm, 6125 Rennebohm Hall,777 Highland Ave, Madison, WI 53705 USA.		Murphy, Timothy H/I-4982-2014; Murphy, Timothy/AAW-1975-2021	Murphy, Timothy H/0000-0002-0093-4490; Murphy, Timothy/0000-0002-0093-4490	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES008089, P30ES009090, R01ES010042, R01ES008089] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES09090, ES10042, ES08089] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams JD, 2001, CURR MED CHEM, V8, P809, DOI 10.2174/0929867013372995; Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Aschner M, 2000, NEUROTOXICOLOGY, V21, P1101; Beal MF, 1998, BRAIN RES, V783, P109, DOI 10.1016/S0006-8993(97)01192-X; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bharath S, 2002, BIOCHEM PHARMACOL, V64, P1037, DOI 10.1016/S0006-2952(02)01174-7; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; DEXTER DT, 1990, J NEUROCHEM, V55, P16, DOI 10.1111/j.1471-4159.1990.tb08814.x; Duffy S, 1998, J NEUROCHEM, V71, P69; Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099; Figueredo-Cardenas G, 1998, EXP NEUROL, V149, P356, DOI 10.1006/exnr.1997.6724; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; Johnson DA, 2002, J NEUROCHEM, V81, P1233, DOI 10.1046/j.1471-4159.2002.00913.x; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; Klivenyi P, 2000, J NEUROSCI, V20, P1; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Li J, 2002, J BIOL CHEM, V277, P388, DOI 10.1074/jbc.M109380200; MANN VM, 1994, ANN NEUROL, V36, P876, DOI 10.1002/ana.410360612; Mercer EA, 2000, EMBO J, V19, P3597, DOI 10.1093/emboj/19.14.3597; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MOUNT HTJ, 1995, P NATL ACAD SCI USA, V92, P9092, DOI 10.1073/pnas.92.20.9092; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nakamura K, 1997, J NEUROCHEM, V69, P1850; Offen D, 1998, P NATL ACAD SCI USA, V95, P5789, DOI 10.1073/pnas.95.10.5789; PROCHASKA HJ, 1988, ANAL BIOCHEM, V169, P328, DOI 10.1016/0003-2697(88)90292-8; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Sherer TB, 2002, J NEUROSCI, V22, P7006; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Zhang J, 2000, J NEUROPATH EXP NEUR, V59, P53, DOI 10.1093/jnen/59.1.53	45	253	264	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37948	37956		10.1074/jbc.M305204200	http://dx.doi.org/10.1074/jbc.M305204200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12842875	hybrid			2022-12-25	WOS:000185437200117
J	Szentirmay, MN; Yang, HX; Pawar, SA; Vinson, C; Sawadogo, M				Szentirmay, MN; Yang, HX; Pawar, SA; Vinson, C; Sawadogo, M			The IGF2 receptor is a USF2-specific target in nontumorigenic mammary epithelial cells but not in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; TRANSCRIPTION FACTOR USF; FACTOR TYPE-2 RECEPTOR; TUMOR-SUPPRESSOR GENE; PERINATAL LETHALITY; M6P/IGF2 RECEPTOR; PROMOTER ELEMENTS; FETAL OVERGROWTH; BINDING-PROTEINS; CARCINOMA-CELLS	The antiproliferative activities of the USF proteins and the frequent loss of USF function in cancer cells suggest a role for these ubiquitous transcription factors in tumor suppression. However, the cellular targets that mediate the effects of USF on cellular proliferation and transformation remain uncharacterized. IGF2R, with multiple functions in both normal growth and cancer, was investigated here as a possible USF target in both nontumorigenic and tumorigenic breast cell lines. The 5'-flanking sequences of the human IGF2R gene contain multiple, highly conserved E boxes almost identical to the consensus USF DNA-binding sequence. These E boxes were found to be essential for IGF2R promoter activity in the nontumorigenic mammary epithelial cell line MCF-10A. USF1 and USF2 bound the IGF2R promoter in vitro, and both USF1 and USF2, but not c-Myc, were present within the IGF2R promoter-associated chromatin in vivo. Overexpressed USF2, but not USF1, transactivated the IGF2R promoter, and IGF2R mRNA was markedly decreased by expression of a USF-specific dominant negative mutant, identifying IGF2R as a USF2 target. IGF2R promoter-driven expression was USF-independent in both MCF-7 and MDA-MB-231 breast cancer cell lines, suggesting that a defect in USF function may contribute to down-regulation of IGF2R expression in cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sawadogo, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.		Pawar, Snehalata/ABD-4557-2020	Pawar, Snehalata/0000-0003-3992-2494	NCI NIH HHS [CA79578] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079578, Z01BC005271, ZIABC005271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Berthe ML, 2003, EUR J CANCER, V39, P635, DOI 10.1016/S0959-8049(02)00627-5; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; DeBleser PJ, 1996, HEPATOLOGY, V23, P1530; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; Hankins GR, 1996, ONCOGENE, V12, P2003; Hassan AB, 2003, AM J PATHOL, V162, P3, DOI 10.1016/S0002-9440(10)63791-1; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Ismail PM, 1999, ONCOGENE, V18, P5582, DOI 10.1038/sj.onc.1202932; Jaiswal AS, 2001, J CELL BIOCHEM, V81, P262, DOI 10.1002/1097-4644(20010501)81:2<262::AID-JCB1041>3.0.CO;2-R; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; KEISS W, 1996, GROWTH REGULAT, V6, P66; Killian JK, 1999, MAMM GENOME, V10, P74, DOI 10.1007/s003359900947; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; Latil A, 2001, CANCER RES, V61, P1919; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LIU ZY, 1995, MOL ENDOCRINOL, V9, P1477, DOI 10.1210/me.9.11.1477; Lorenzo K, 2000, CANCER RES, V60, P4070; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luo X, 1996, MOL CELL BIOL, V16, P1367; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; O'Gorman DB, 1999, CANCER RES, V59, P5692; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Roy RN, 1999, MOL CELL ENDOCRINOL, V153, P19, DOI 10.1016/S0303-7207(99)00092-1; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Szutorisz H, 2001, ONCOGENE, V20, P2600, DOI 10.1038/sj.onc.1204346; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; Weiner JK, 1998, J BIOL CHEM, V273, P15913, DOI 10.1074/jbc.273.26.15913; Wu K, 2000, J BIOL CHEM, V275, P35548, DOI 10.1074/jbc.M004390200; XING W, 1980, MOL ENDOCRINOL, V12, P1310; Young LE, 2001, NAT GENET, V27, P153, DOI 10.1038/84769; Zavras AI, 2003, CANCER RES, V63, P296	48	33	34	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37231	37240		10.1074/jbc.M305791200	http://dx.doi.org/10.1074/jbc.M305791200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857727	hybrid			2022-12-25	WOS:000185437200031
J	Tisdale, EJ; Wang, J; Silver, RB; Artalejo, CR				Tisdale, EJ; Wang, J; Silver, RB; Artalejo, CR			Atypical protein kinase C plays a critical role in protein transport from pre-Golgi intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; VESICULAR TRANSPORT; PHOSPHORYLATION; RAB2; PSEUDOSUBSTRATE; ER; INHIBITION; ACTIVATION; ISOENZYMES	The small GTPase Rab2 requires atypical protein kinase C iota/lambda (PKC iota/lambda) kinase activity to promote vesicle budding from normal rat kidney cell microsomes (Tisdale, E. J. (2000) Traffic 1, 702 - 712). The released vesicles lack anterograde-directed cargo but contain coat protein I ( COPI) and the recycling protein p53/p58, suggesting that the vesicles traffic in the retrograde pathway. In this study, we have directly characterized the role of PKC iota/lambda in the early secretory pathway. A peptide corresponding to the unique PKC iota/lambda pseudosubstrate domain was introduced into an in vitro assay that efficiently reconstitutes transport of vesicular stomatitis virus glycoprotein from the endoplasmic reticulum to the cis-medial Golgi compartments. This peptide blocked transport in a dose-dependent manner. Moreover, normal rat kidney cells incubated with Rab2 and the pseudosubstrate peptide displayed abundant swollen or dilated vesicles that contained Rab2, PKC iota/lambda, beta-COP, and p53/p58. Because Rab2, beta-COP, and p53/p58 are marker proteins for pre-Golgi intermediates ( vesicular tubular clusters, VTCs), most probably the swollen vesicles are derived from VTCs. Similar results were obtained when the assays were supplemented with kinase-dead PKC iota/lambda (W274K). Both the pseudosubstrate peptide and kinase-dead PKC iota/lambda in tandem with Rab2 caused sustained membrane association of PKC iota/lambda, suggesting that reverse translocation was inhibited. Importantly, the inhibitory phenotype of kinase-dead PKC iota/lambda was reversed by PKC iota/lambda wild type. These combined results indicate that PKC iota/lambda is essential for protein transport in the early secretory pathway and suggest that PKC iota/lambda kinase activity is required to promote Rab2-mediated vesicle budding at a VTC subcompartment enriched in recycling cargo.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Tisdale, EJ (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 6374 Scott Hall,540 E Canfield Ave, Detroit, MI 48201 USA.	etisdale@med.wayne.edu			NIDDK NIH HHS [R01 DK058921, DK58921] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058921] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER DR, 1989, BIOCHEM J, V260, P893, DOI 10.1042/bj2600893; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Blobe GC, 1996, CANCER SURV, V27, P213; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; EICHHOLTZ T, 1990, FEBS LETT, V261, P147, DOI 10.1016/0014-5793(90)80657-5; Farese RV, 2002, AM J PHYSIOL-ENDOC M, V283, pE1, DOI 10.1152/ajpendo.00045.2002; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; Horstmann H, 2002, J CELL SCI, V115, P4263, DOI 10.1242/jcs.00115; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; SARASTE J, 1991, J CELL SCI, V100, P415; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; Signorelli P, 2001, FASEB J, V15, P2401, DOI 10.1096/fj.01-0244com; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tisdale EJ, 2000, TRAFFIC, V1, P702, DOI 10.1034/j.1600-0854.2000.010903.x; Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Tisdale EJ, 2002, J BIOL CHEM, V277, P3334, DOI 10.1074/jbc.M109744200; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; Tisdale EJ, 2001, J BIOL CHEM, V276, P2480, DOI 10.1074/jbc.M007567200; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020; Wooten MW, 1999, J NEUROSCI RES, V58, P607, DOI 10.1002/(SICI)1097-4547(19991201)58:5<607::AID-JNR1>3.0.CO;2-M	39	7	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38015	38021		10.1074/jbc.M305381200	http://dx.doi.org/10.1074/jbc.M305381200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871960	hybrid			2022-12-25	WOS:000185437200123
J	Wang, LB; Atkinson, D; Small, DM				Wang, LB; Atkinson, D; Small, DM			Interfacial properties of an amphipathic alpha-helix consensus peptide of exchangeable apolipoproteins at air/water and oil/water interfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; A-I; SURFACE-ACTIVITIES; LIPID-COMPOSITION; ADSORPTION; PACKING	Amphipathic alpha-helices are the main structure and the major lipid binding motif of exchangeable apolipoproteins. To understand how these apolipoproteins behave at an hydrophobic lipoprotein interface, the interfacial properties of a consensus sequence peptide (CSP) derived from three exchangeable apolipoproteins (A-I, A-IV, and E) were studied using an oil drop tensiometer at air/water (A/W) and dodecane/water (DD/W) interfaces. CSP ((PLAEELRARLRAQLEELRERLG) 2-NH2) contains two 22-amino acid tandem repeat sequences that form amphipathic alpha-helices. CSP, when added into the aqueous phase, lowered the interfacial tension (gamma) of A/W and DD/W in a concentration-dependant fashion. The gamma(A/W) was lowered similar to 24 mN/m, and gamma(DD/W) similar to 31 mN/m, indicating a greater affinity of CSP for DD/W. Using the Gibbs equation for surface, the surface area per CSP molecule was estimated at similar to 702 Angstrom(2) (similar to 16 Angstrom(2)/amino acid) on A/W and similar to 622 Angstrom(2) on DD/W (similar to 14 Angstrom(2)/amino acid) suggesting that adsorbed CSP lies flat with alpha-helices in the plane of both interfaces. At equilibrium gamma, CSP desorbed from the interface when compressed and re-adsorbed when expanded. The adsorption rate was concentration-dependant, but the desorption rate was not. Less CSP desorbed from DD/W than A/W indicating that CSP has higher affinity for DD/W. Dynamic analysis of elasticity shows that the faster the oscillation period (4, 8 s) and the lower the oscillation amplitude the more elastic the surfaces. CSP can be compressed 6 - 12% while remaining on the surface, but large increases in pressure eject it from the surface. We suggest that surface pressure-mediated desorption and readsorption of amphipathic alpha-helices provide lipoprotein stability during remodeling reactions in plasma.	Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA	Boston University	Small, DM (corresponding author), Boston Univ, Sch Med, Dept Physiol & Biophys, 715 Albany St,W-302, Boston, MA 02118 USA.	dmsmall@bu.edu		Atkinson, David/0000-0002-4796-7396; Small, Donald/0000-0002-3072-243X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL026335] Funding Source: NIH RePORTER; NHLBI NIH HHS [2P01 HL26335-21] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM NK, 1941, PHYSICS CHEM SURFACE, P107; ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; Benjamins J, 1996, COLLOID SURFACE A, V114, P245, DOI 10.1016/0927-7757(96)03533-9; Benjamins J, 1998, STUD INTERF SCI, V7, P341, DOI 10.1016/S1383-7303(98)80056-2; Bos MA, 2001, ADV COLLOID INTERFAC, V91, P437; BOURILETTE CG, 2001, BIOCHIM BIOPHYS ACTA, V1531, P4; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; CHAO Y, 2002, THESIS BOSTON U SCH; Datta G, 2001, J LIPID RES, V42, P1096; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; IBDAH JA, 1989, BIOCHEMISTRY-US, V28, P1126, DOI 10.1021/bi00429a029; IBDAH JA, 1988, BIOCHEMISTRY-US, V27, P7155, DOI 10.1021/bi00418a073; IBDAH JA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P300, DOI 10.1016/0005-2760(89)90077-5; KREBS KE, 1988, BIOCHIM BIOPHYS ACTA, V959, P229, DOI 10.1016/0005-2760(88)90195-6; KREBS KE, 1983, BIOCHIM BIOPHYS ACTA, V751, P470, DOI 10.1016/0005-2760(83)90308-9; LABOURDENNE S, 1994, CHEM PHYS LIPIDS, V71, P163, DOI 10.1016/0009-3084(94)90068-X; Lucassen-Reynders EH, 2001, COLLOID SURFACE A, V186, P63, DOI 10.1016/S0927-7757(01)00483-6; McNamara JR, 1996, J LIPID RES, V37, P1924; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; NOLTE RT, 1994, THESIS BOSTON U SCH; PHILLIPS MC, 1986, METHOD ENZYMOL, V128, P387; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; POWNALL HJ, 1979, BIOCHEMISTRY-US, V18, P574, DOI 10.1021/bi00571a004; RITTER MC, 1977, J BIOL CHEM, V252, P1208; RITTER MC, 1979, J BIOL CHEM, V254, P2517; SCANU AM, 1972, BIOCHIM BIOPHYS ACTA, V265, P471, DOI 10.1016/0304-4157(72)90006-8; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; Segrest JP, 2001, J LIPID RES, V42, P1346; SEGREST JP, 1992, J LIPID RES, V33, P141; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHEN BW, 1980, BIOCHEMISTRY-US, V19, P3643, DOI 10.1021/bi00557a001; TALL AR, 1977, J BIOL CHEM, V252, P4701; WANG L, 2002, BIOPHYS J, P149; WEINBERG RB, 1992, J BIOL CHEM, V267, P8977; Weinberg RB, 2000, J LIPID RES, V41, P1419	36	32	32	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37480	37491		10.1074/jbc.M303133200	http://dx.doi.org/10.1074/jbc.M303133200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12842901	hybrid			2022-12-25	WOS:000185437200061
J	Bohan, A; Chen, WS; Denson, LA; Held, MA; Boyer, JL				Bohan, A; Chen, WS; Denson, LA; Held, MA; Boyer, JL			Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE-ASSOCIATED PROTEIN-3; BILE-SALT; EXPRESSION; CYTOKINES; MRP3	Mrp3(Abcc3) is markedly induced following bile duct ligation (BDL) in the rat and in some human cholestatic liver diseases and is believed to ameliorate liver injury in this setting. Recently, the orphan nuclear receptor fetoprotein transcription factor/cholesterol-7alpha-hydroxylase promoter factor (CPF/FTF/Lrh-1) has been shown to activate Mrp3 expression. However, whether inflammatory cytokines or elevated bile acid levels increased Lrh1/Mrp3 expression in obstructive cholestasis was not known. We hypothesized that induction of Mrp3 would be associated with Lrh-1 up-regulation and would require intact cytokine signaling. Male tumor necrosis factor (Tnf) receptor I (Tnfr-/-) mice and C57BLJ wild type (WT) controls were subjected to sham surgery or bile duct ligation. HepG2 cells were treated with bile acids or cytokines. Immunoblot assay and real time reverse transcriptase-PCR were used to determine expression of MRP3/Mrp3, CPF/Lrh-1, Mrp2, and Bsep. CPF/Lrh-1 DNA binding to the MRP3/Mrp3 promoter was assessed using electrophoretic mobility shift assay, and promoter activity was determined by luciferase assay. Total bile acids and lactate dehydrogenase were measured using colorimetric assays, and cytokine abundance was determined by enzyme-linked immunosorbent assay. Lrh-1 and Mrp3 were significantly induced after BDL in WT but not Tnfr-/- mice. This was associated with more severe hepatocellular necrosis in Tnfr-/- mice. Lrh-1 binding to the Mrp3 promoter increased after BDL in WT but not in Tnfr-/- mice. Tnfalpha treatment of HepG2 cells also up-regulated CPF and MRP3, increased CPF binding to the MRP3 promoter, and up-regulated MRP3 promoter activity. These results indicate that induction of Mrp3 after BDL is due to Tnfalpha-dependent up-regulation of Lrh-1. They provide strong evidence that induction of Mrp3 plays a significant role in hepatocyte protection during obstructive cholestasis.	Yale Univ, Sch Med, Dept Internal Med,Yale Liver Ctr, Sect Digest Dis,Liver Ctr, New Haven, CT 06520 USA; Yale Univ, Sch Med, Yale Child Hlth Res Ctr, New Haven, CT 06520 USA	Yale University; Yale University	Boyer, JL (corresponding author), Yale Univ, Sch Med, Dept Internal Med,Yale Liver Ctr, Sect Digest Dis,Liver Ctr, 1080 LMP,POB 208019, New Haven, CT 06520 USA.	james.boyer@yale.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK002700, R37DK002700] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25606, DK02700] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEMELMANS MHA, 1992, HEPATOLOGY, V15, P1132, DOI 10.1002/hep.1840150626; Bohan A, 2001, HEPATOLOGY, V34, p261A; Bradford BU, 2001, HEPATOLOGY, V34, p378A; De Meo M, 1998, AM J GASTROENTEROL, V93, P967, DOI 10.1111/j.1572-0241.1998.00289.x; Denson LA, 2000, J BIOL CHEM, V275, P8835, DOI 10.1074/jbc.275.12.8835; Denson LA, 2002, GASTROENTEROLOGY, V123, P599, DOI 10.1053/gast.2002.34758; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Inokuchi A, 2001, J BIOL CHEM, V276, P46822, DOI 10.1074/jbc.M104612200; JACOBS E, 1996, CLIN BIOCHEM, V19, P183; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; JANSEN PL, 2000, BALLIERES BEST PRACT, V41, P571; Kiuchi Y, 1998, FEBS LETT, V433, P149, DOI 10.1016/S0014-5793(98)00899-0; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Lee JM, 2000, GASTROENTEROLOGY, V118, P163, DOI 10.1016/S0016-5085(00)70425-2; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; *NIH, 1985, PUBL NIH, V8623; Ogawa K, 2000, AM J PHYSIOL-GASTR L, V278, pG438, DOI 10.1152/ajpgi.2000.278.3.G438; Pare JF, 2001, J BIOL CHEM, V276, P13136, DOI 10.1074/jbc.M010737200; PETERS TJ, 1975, CLIN SCI MOL MED, V48, P307, DOI 10.1042/cs0480307; Plebani M, 1999, CLIN EXP PHARMACOL P, V26, P358, DOI 10.1046/j.1440-1681.1999.03042.x; Scheffer GL, 2002, LAB INVEST, V82, P193, DOI 10.1038/labinvest.3780411; Shoda J, 2001, AM J GASTROENTEROL, V96, P3368; SHWUJEN T, 2002, BIOCHEM BIOPH RES CO, V291, P270; Soroka CJ, 2001, HEPATOLOGY, V33, P783, DOI 10.1053/jhep.2001.23501; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Stonans I, 1999, CYTOKINE, V11, P151, DOI 10.1006/cyto.1998.0366; TSUKUI T, 1994, EXP CELL RES, V210, P172, DOI 10.1006/excr.1994.1026; UCHIUMI T, 1998, BIOCHEM BIOPH RES CO, V9, P1332	28	128	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36688	36698		10.1074/jbc.M304011200	http://dx.doi.org/10.1074/jbc.M304011200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12837754	hybrid			2022-12-25	WOS:000185318300100
J	Lee, KH; Kim, SJ; Lee, YJ; Jin, JB; Hwang, I				Lee, KH; Kim, SJ; Lee, YJ; Jin, JB; Hwang, I			The M domain of atToc159 plays an essential role in the import of proteins into chloroplasts and chloroplast biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO IMPORT; TRANSIT PEPTIDE; ENVELOPE MEMBRANE; OUTER ENVELOPE; RECEPTOR; IDENTIFICATION; TRAFFICKING; TRANSLOCON; PRECURSOR; COMPONENT	Toc159, a protein located in the outer envelope membrane and the cytosol, is an important component of the receptor complex for nuclear-encoded chloroplast proteins. We investigated the molecular mechanism of protein import into chloroplasts by atToc159 using the ppi2 mutant, which has a T-DNA insertion at atToc159, shows an albino phenotype, and does not survive beyond the seedling stage due to a defect in protein import into chloroplasts. First we established that transiently expressing atToc159 in protoplasts obtained from the white leaf tissues of ppi2 plants complements the protein import defect into chloroplasts. Using this transient expression approach and a series of deletion mutants, we demonstrated that the C-terminal membrane-anchored ( M) domain is targeted to the chloroplast envelope membrane in ppi2 protoplasts, and is sufficient to complement the defect in protein import. The middle GTPase ( G) domain plays an additional critical role in protein import: the atToc159[S/N] and atToc159[D/L] mutants, which have a mutation at the first and second GTP-binding motifs, respectively, do not support protein import into chloroplasts. Leaf cells of transgenic plants expressing the M domain in a ppi2 background contained nearly fully developed chloroplasts with respect to size and density of thylakoid membranes, and displayed about half as much chlorophyll as wild-type cells. In transgenic plants, the isolated M domain localized to the envelope membrane of chloroplasts but not the cytosol. Based on these results, we propose that the M domain is the minimal structure required to support protein import into chloroplasts, while the G domain plays a regulatory role.	Pohang Univ Sci & Technol, Ctr Plant Intracellular Trafficking, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Hwang, I (corresponding author), Pohang Univ Sci & Technol, Ctr Plant Intracellular Trafficking, Pohang 790784, South Korea.	ihhwang@postech.ac.kr						Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; Bauer J, 2002, J CELL BIOL, V159, P845, DOI 10.1083/jcb.200208018; Bauer J, 2001, CELL MOL LIFE SCI, V58, P420, DOI 10.1007/PL00000867; Bruce BD, 1998, PLANT MOL BIOL, V38, P223, DOI 10.1023/A:1006094308805; Chen XJ, 1999, TRENDS CELL BIOL, V9, P222, DOI 10.1016/S0962-8924(99)01554-8; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; Gutensohn M, 2000, PLANT J, V23, P771, DOI 10.1046/j.1365-313x.2000.00849.x; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; Hinnah SC, 2002, BIOPHYS J, V83, P899, DOI 10.1016/S0006-3495(02)75216-8; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Jarvis P, 1998, SCIENCE, V282, P100, DOI 10.1126/science.282.5386.100; JARVIS P, 2000, BIOCHIM BIOPHYS ACTA, V1541, P64; Jin JB, 2001, PLANT CELL, V13, P1511, DOI 10.1105/tpc.13.7.1511; Keegstra K, 1999, CURR OPIN PLANT BIOL, V2, P471, DOI 10.1016/S1369-5266(99)00021-7; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kim YW, 2001, PLANT PHYSIOL, V127, P1243, DOI 10.1104/pp.010450; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; Lee KH, 2002, MOL CELLS, V14, P388; Lee YJ, 2001, PLANT CELL, V13, P2175, DOI 10.1105/tpc.13.10.2175; Niwa Y, 1999, PLANT J, V18, P455, DOI 10.1046/j.1365-313X.1999.00464.x; Rensink WA, 1998, PLANT PHYSIOL, V118, P691, DOI 10.1104/pp.118.2.691; Schleiff E, 2003, J CELL BIOL, V160, P541, DOI 10.1083/jcb.200210060; Schleiff E, 2000, PLANTA, V211, P449, DOI 10.1007/s004250000357; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SERRA EC, 1995, J BIOL CHEM, V270, P19930, DOI 10.1074/jbc.270.34.19930; Sheen J, 2001, PLANT PHYSIOL, V127, P1466, DOI 10.1104/pp.010820; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; Smith MD, 2002, J CELL BIOL, V159, P833, DOI 10.1083/jcb.200208017; Sohn EJ, 2003, PLANT CELL, V15, P1057, DOI 10.1105/tpc.009779; Sohrt K, 2000, J CELL BIOL, V148, P1213, DOI 10.1083/jcb.148.6.1213; Surpin M, 2002, PLANT CELL, V14, pS327, DOI 10.1105/tpc.010446; VANTHOF R, 1995, J BIOL CHEM, V270, P22368, DOI 10.1074/jbc.270.38.22368; VANTHOF R, 1993, J BIOL CHEM, V268, P4037	38	55	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36794	36805		10.1074/jbc.M304457200	http://dx.doi.org/10.1074/jbc.M304457200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12853455	hybrid			2022-12-25	WOS:000185318300112
J	Liu, J; DeYoung, SM; Hwang, JB; O'Leary, EE; Saltiel, AR				Liu, J; DeYoung, SM; Hwang, JB; O'Leary, EE; Saltiel, AR			The roles of Cbl-b and c-Cbl in insulin-stimulated glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE ACTIVITY; ACTIVATED T-CELLS; TYROSINE PHOSPHORYLATION; GLUT4 TRANSLOCATION; 3T3-L1 ADIPOCYTES; NEGATIVE REGULATION; COMPLEX-FORMATION; PROTEIN; RECEPTOR; DOMAIN	Previous studies suggest that the stimulation of glucose transport by insulin involves the tyrosine phosphorylation of c-Cbl and the translocation of the c-Cbl/CAP complex to lipid raft subdomains of the plasma membrane. We now demonstrate that Cbl-b also undergoes tyrosine phosphorylation and membrane translocation in response to insulin in 3T3-L1 adipocytes. Ectopic expression of APS facilitated insulin-stimulated phosphorylation of tyrosines 665 and 709 in Cbl-b. The phosphorylation of APS produced by insulin drove the translocation of both c-Cbl and Cbl-b to the plasma membrane. Like c-Cbl, Cbl-b associates constitutively with CAP and interacts with Crk upon insulin stimulation. Cbl proteins formed homo- and heterodimers in vivo, which required the participation of a conserved leucine zipper domain. A Cbl mutant incapable of dimerization failed to interact with APS and to undergo tyrosine phosphorylation in response to insulin, indicating an essential role of Cbl dimerization in these processes. Thus, both c-Cbl and Cbl-b can initiate a phosphatidylinositol 3-kinase/protein kinase B-independent signaling pathway critical to insulin-stimulated GLUT4 translocation.	Univ Michigan, Med Ctr, Inst Life Sci, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Inst Life Sci, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Saltiel, AR (corresponding author), Univ Michigan, Med Ctr, Inst Life Sci, Dept Internal Med, MSRB 1,Rm 4520C,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	saltiel@umich.edu	Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NIDDK NIH HHS [DK61618, DK60591, 5F32 DK61188-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060591, F32DK061188, R01DK061618] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed Z, 2000, FEBS LETT, V475, P31, DOI 10.1016/S0014-5793(00)01621-5; Andoniou CE, 1996, ONCOGENE, V12, P1981; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Elly C, 1999, ONCOGENE, V18, P1147, DOI 10.1038/sj.onc.1202411; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; Hwang JB, 1999, J BIOL CHEM, V274, P22813, DOI 10.1074/jbc.274.32.22813; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Lavagna-Sevenier C, 1998, J BIOL CHEM, V273, P14962, DOI 10.1074/jbc.273.24.14962; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu J, 2002, MOL CELL BIOL, V22, P3599, DOI 10.1128/MCB.22.11.3599-3609.2002; Liu J, 2000, BIOCHEM J, V346, P77, DOI 10.1042/0264-6021:3460077; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Moodie SA, 1999, J BIOL CHEM, V274, P11186, DOI 10.1074/jbc.274.16.11186; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Yasuda T, 2002, J EXP MED, V196, P51, DOI 10.1084/jem.20020068	33	66	76	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36754	36762		10.1074/jbc.M300664200	http://dx.doi.org/10.1074/jbc.M300664200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12842890	hybrid			2022-12-25	WOS:000185318300108
J	Molinas, SM; Altabe, SG; Opperdoes, FR; Rider, MH; Michels, PAM; Uttaro, AD				Molinas, SM; Altabe, SG; Opperdoes, FR; Rider, MH; Michels, PAM; Uttaro, AD			The multifunctional isopropyl alcohol dehydrogenase of Phytomonas sp could be the result of a horizontal gene transfer from a bacterium to the trypanosomatid lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED ALDEHYDE REDUCTASE; CARBOHYDRATE-METABOLISM; MITOCHONDRIAL; EUPHORBIA; PURIFICATION; EXPRESSION; CRITHIDIA; PROTEINS; CLONING; PLANT	Isopropyl alcohol dehydrogenase (iPDH) is a dimeric mitochondrial alcohol dehydrogenase (ADH), so far detected within the Trypanosomatidae only in the genus Phytomonas. The cloning, sequencing, and heterologous expression of the two gene alleles of the enzyme revealed that it is a zinc-dependent medium-chain ADH. Both polypeptides have 361 amino acids. A mitochondrial targeting sequence was identified. The mature proteins each have 348 amino acids and a calculated molecular mass of 37 kDa. They differ only in one amino acid, which can explain the three isoenzymes and their respective isoelectric points previously found. A phylogenetic analysis locates iPDH within a cluster with fermentative ADHs from bacteria, sharing 74% similarity and 60% identity with Ralstonia eutropha ADH. The characterization of the two bacterially expressed Phytomonas enzymes and the comparison of their kinetic properties with those of the wild-type iPDH and of the R. eutropha ADH strongly support the idea of a horizontal gene transfer event from a bacterium to a trypanosomatid to explain the origin of the iPDH in Phytomonas. Phytomonas iPDH and R. eutropha ADH are able to use a wide range of substrates with similar K-m values such as primary and secondary alcohols, diols, and aldehydes, as well as ketones such as acetone, diacetyl, and acetoin. We speculate that, as for R. eutropha ADH, Phytomonas iPDH acts as a safety valve for the release of excess reducing power.	Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Microbiol,Inst Biol Mol & Celular Rosario, Consejo Nacl Invest Cient & Tecn, RA-2000 Rosario, Santa Fe, Argentina; Catholic Univ Louvain, Christian de Duve Inst Cellular Pathol, Hormone Metab Res Unit, Trop Dis Res Unit, B-1200 Brussels, Belgium	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario; Universite Catholique Louvain	Uttaro, AD (corresponding author), Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Microbiol,Inst Biol Mol & Celular Rosario, Consejo Nacl Invest Cient & Tecn, Suipacha 531, RA-2000 Rosario, Santa Fe, Argentina.	toniuttaro@yahoo.com.ar	Opperdoes, Frederik R/C-8897-2018; Opperdoes, Fred/N-9922-2019; Michels, Paul A/A-5637-2009; Molinas, Sara María/AAA-2490-2022	Opperdoes, Frederik R/0000-0003-1984-3764; Opperdoes, Fred/0000-0003-1984-3764; Michels, Paul A/0000-0003-3726-6104; 				ALLERT S, 1991, EUR J BIOCHEM, V200, P19, DOI 10.1111/j.1432-1033.1991.tb21043.x; ARAUZO S, 1989, FEMS MICROBIOL LETT, V58, P283, DOI 10.1111/j.1574-6968.1989.tb03060.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Branden C.-I., 1975, ENZYMES, V11, P103; CAZZULO JJ, 1985, COMP BIOCHEM PHYS B, V81, P1019, DOI 10.1016/0305-0491(85)90106-3; CHAUMONT F, 1994, MOL BIOCHEM PARASIT, V67, P321, DOI 10.1016/0166-6851(94)00141-3; Chua N. H, 1980, METHOD ENZYMOL, V69, P434; DOLLET M, 1982, CR ACAD SCI III-VIE, V295, P547; Duester G, 1999, BIOCHEM PHARMACOL, V58, P389, DOI 10.1016/S0006-2952(99)00065-9; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; FERREYRA RG, 1993, J BACTERIOL, V175, P1514, DOI 10.1128/JB.175.5.1514-1523.1993; Hausler T, 1997, EUR J CELL BIOL, V73, P240; KEEGAN FP, 1995, J EUKARYOT MICROBIOL, V42, P255, DOI 10.1111/j.1550-7408.1995.tb01575.x; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Korkhin Y, 1998, J MOL BIOL, V278, P967, DOI 10.1006/jmbi.1998.1750; Maslov DA, 1999, MOL BIOCHEM PARASIT, V99, P207, DOI 10.1016/S0166-6851(99)00028-6; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; PERSSON B, 1994, EUR J BIOCHEM, V226, P15, DOI 10.1111/j.1432-1033.1994.tb20021.x; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; RIDER MH, 1995, EUR J BIOCHEM, V230, P258; ROSSI DA, 1938, ARCH SCI BIOL-BOLOGN, V24, P73; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCHEZMORENO M, 1992, MOL BIOCHEM PARASIT, V54, P185, DOI 10.1016/0166-6851(92)90111-V; Shafqat J, 1996, P NATL ACAD SCI USA, V93, P5595, DOI 10.1073/pnas.93.11.5595; STEINBUCHEL A, 1984, EUR J BIOCHEM, V141, P555, DOI 10.1111/j.1432-1033.1984.tb08229.x; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uttaro AD, 1997, MOL BIOCHEM PARASIT, V90, P337, DOI 10.1016/S0166-6851(97)00142-4; Uttaro AD, 1997, MOL BIOCHEM PARASIT, V85, P213, DOI 10.1016/S0166-6851(97)02830-2; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	32	13	13	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36169	36175		10.1074/jbc.M305666200	http://dx.doi.org/10.1074/jbc.M305666200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12853449	hybrid			2022-12-25	WOS:000185318300038
J	Ryu, KS; Lee, KJ; Bae, SH; Kim, BK; Kim, KA; Choi, BS				Ryu, KS; Lee, KJ; Bae, SH; Kim, BK; Kim, KA; Choi, BS			Binding surface mapping of intra- and interdomain interactions among hHR23B, ubiquitin, and polyubiquitin binding site 2 of S5a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBA DOMAINS; SACCHAROMYCES-CEREVISIAE; MULTIUBIQUITIN CHAINS; REPAIR PROTEIN; RAD23; PROTEASOME; PROTEOLYSIS; SUBUNIT; DEFECTS; COMPLEX	hHR23B is the human homologue of the yeast protein RAD23 and is known to participate in DNA repair by stabilizing xeroderma pigmentosum group C protein. However, hHR23B and RAD23 also have many important functions related to general proteolysis. hHR23B consists of N-terminal ubiquitin-like (UbL), ubiquitin association 1 (UBA1), xeroderma pigmentosum group C binding, and UBA2 domains. The UBA domains interact with ubiquitin (Ub) and inhibit the assembly of polyubiquitin. On the other hand, the UbL domain interacts with the poly-Ub binding site 2 (PUbS2) domain of the S5a protein, which can carry polyubiquitinated substrates into the proteasome. We calculated the NMR structure of the UbL domain of hHR23B and determined binding surfaces of UbL and Ub to UBA1, UBA2, of hHR23B and PUbS2 of S5a by using chemical shift perturbation. Interestingly, the surfaces of UbL and Ub that bind to UBA1, UBA2, and PUbS2 are similar, consisting of five beta-strands and their connecting loops. This is the first report that an intramolecular interaction between UbL and UBA domains is possible, and this interaction could be important for the control of proteolysis by hHR23B. The binding specificities of UbL and Ub for PUbS1, PUbS2, and general ubiquitin-interacting motifs, which share the LALA motif, were evaluated. The UBA domains bind to the surface of Ub including Lys-48, which is required for multiubiquitin assembly, possibly explaining the observed inhibition of multiubiquitination by hHR23B. The UBA domains bind to UbL through electrostatic interactions supported by hydrophobic interactions and to Ub mainly through hydrophobic interactions supported by electrostatic interactions.	Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Choi, BS (corresponding author), Korea Adv Inst Sci & Technol, Dept Chem, Gusong Dong 373-1, Taejon 305701, South Korea.	byongseok.choi@webmail.kaist.ac.kr	Bae, Sung-Ho/AAK-7350-2020; Choi, Byong-Seok/C-1937-2011					Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bertolaet BL, 2001, J MOL BIOL, V313, P955, DOI 10.1006/jmbi.2001.5105; Case D. A., 2002, AMBER 7; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Clarke DJ, 2001, MOL CELL BIOL, V21, P1997, DOI 10.1128/MCB.21.6.1997-2007.2001; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cornilescu G, 1998, J AM CHEM SOC, V120, P6836, DOI 10.1021/ja9812610; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; GODDARD TD, SPARK 7; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lambertson D, 1999, GENETICS, V153, P69; Lambertson D, 2003, CURR GENET, V42, P199, DOI 10.1007/s00294-002-0350-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lommel L, 2002, CURR GENET, V42, P9, DOI 10.1007/s00294-002-0332-9; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Masutani C, 1997, MOL CELL BIOL, V17, P6915, DOI 10.1128/MCB.17.12.6915; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Ng JMY, 2002, MOL CELL BIOL, V22, P1233, DOI 10.1128/MCB.22.4.1233-1245.2002; Permi P, 2000, J BIOMOL NMR, V16, P29, DOI 10.1023/A:1008343926502; Phillips CL, 2001, ACTA CRYSTALLOGR D, V57, P341, DOI 10.1107/S090744490001800X; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Shekhtman A, 2002, BIOCHEM BIOPH RES CO, V296, P1222, DOI 10.1016/S0006-291X(02)02006-5; Sugasawa K, 1997, MOL CELL BIOL, V17, P6924, DOI 10.1128/MCB.17.12.6924; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; Sweder K., 2002, Journal of Biomedicine & Biotechnology, V2, P94, DOI 10.1155/S1110724302205033; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	47	94	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36621	36627		10.1074/jbc.M304628200	http://dx.doi.org/10.1074/jbc.M304628200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12832454	hybrid			2022-12-25	WOS:000185318300093
J	Yasutake, Y; Watanabe, S; Yao, M; Takada, Y; Fukunaga, N; Tanaka, I				Yasutake, Y; Watanabe, S; Yao, M; Takada, Y; Fukunaga, N; Tanaka, I			Crystal structure of the monomeric isocitrate dehydrogenase in the presence of NADP(+) - Insight into the cofactor recognition, catalysis, and evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN ABE-1; NICOTINAMIDE ADENINE-DINUCLEOTIDE; 3-ISOPROPYLMALATE DEHYDROGENASE; THERMUS-THERMOPHILUS; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; PSYCHROPHILIC BACTERIUM; AZOTOBACTER-VINELANDII; ANGSTROM RESOLUTION; PROTEIN-STRUCTURE	NADP(+)-dependent monomeric isocitrate dehydrogenase (IDH) from the nitrogen-fixing bacterium Azotobacter vinelandii (AvIDH) is one of members of the beta-decarboxylating dehydrogenase family and catalyzes the dehydration and decarboxylation of isocitrate to yield 2-oxoglutrate and CO2 in the Krebs cycle. We solved the crystal structure of the AvIDH in complex with cofactor NADP(+) (AvIDH-NADP(+) complex). The final refined model shows the closed form that has never been detected in any previously solved structures of beta-decarboxylating dehydrogenases. The structure also reveals all of the residues that interact with NADP(+). The structure-based sequence alignment reveals that these residues were not conserved in any other dimeric NADP(+)-dependent IDHs. Therefore the NADP(+) specificity of the monomeric and dimeric IDHs was independently acquired through the evolutional process. The AvIDH was known to show an exceptionally high turnover rate. The structure of the AvIDH-NADP(+) complex indicates that one loop, which is not present in the Escherichia coli IDHs, reliably stabilizes the conformation of the nicotinamide mononucleotide of the bound NADP(+) by forming a few hydrogen bonds, and such interactions are considered to be important for the monomeric enzyme to initiate the hydride transfer reaction immediately. Finally, the structure of the AvIDH is compared with that of other dimeric NADP-IDHs. Several structural features demonstrate that the monomeric IDHs are structurally more related to the eukaryotic dimeric IDHs than to the bacterial dimeric IDHs.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Kita Ku, Sapporo, Hokkaido 0600810, Japan	Hokkaido University	Tanaka, I (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Kita Ku, Kita 10,Nishi 8, Sapporo, Hokkaido 0600810, Japan.	tanaka@castor.sci.hokudai.ac.jp	Yasutake, Yoshiaki/H-8079-2018; yao, min/F-5287-2011	Yasutake, Yoshiaki/0000-0002-4521-7516; yao, min/0000-0003-1687-5904				Bahnson BJ, 1997, P NATL ACAD SCI USA, V94, P12797, DOI 10.1073/pnas.94.24.12797; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARRERA C R, 1970, Biochimica et Biophysica Acta, V220, P416, DOI 10.1016/0005-2744(70)90273-1; BODOR N, 1990, THEOCHEM-J MOL STRUC, V65, P315; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ceccarelli C, 2002, J BIOL CHEM, V277, P43454, DOI 10.1074/jbc.M207306200; CHEN RD, 1990, PLANT PHYSIOL BIOCH, V28, P411; Chen RD, 2000, PROTEIN SCI, V9, P2344, DOI 10.1110/ps.9.12.2344; Chen RD, 2000, ARCH BIOCHEM BIOPHYS, V383, P238, DOI 10.1006/abbi.2000.2082; Cherbavaz DB, 2000, J MOL BIOL, V295, P377, DOI 10.1006/jmbi.1999.3195; CHUNG A E, 1970, Archives of Biochemistry and Biophysics, V141, P416, DOI 10.1016/0003-9861(70)90157-8; CHUNG AE, 1969, BIOCHEMISTRY-US, V8, P3175, DOI 10.1021/bi00836a007; Dean AM, 1997, P NATL ACAD SCI USA, V94, P3104, DOI 10.1073/pnas.94.7.3104; Doyle SA, 2001, BIOCHEMISTRY-US, V40, P4234, DOI 10.1021/bi002533q; DUGGLEBY RG, 1970, J BIOL CHEM, V245, P3751; EHRLICH RS, 1990, BIOCHEMISTRY-US, V29, P5179, DOI 10.1021/bi00473a026; EHRLICH RS, 1983, J BIOL CHEM, V258, P7079; FinerMoore J, 1997, BIOCHEMISTRY-US, V36, P13890, DOI 10.1021/bi9711691; Fudou R, 2002, INT J SYST EVOL MICR, V52, P1127, DOI [10.1099/ijs.0.02086-0, 10.1099/00207713-52-4-1127]; Hermoso JA, 2002, J MOL BIOL, V319, P1133, DOI 10.1016/S0022-2836(02)00388-1; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Howell DM, 2000, J BACTERIOL, V182, P5013, DOI 10.1128/JB.182.17.5013-5016.2000; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; HURLEY JH, 1994, STRUCTURE, V2, P1007, DOI 10.1016/S0969-2126(94)00104-9; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; IMADA K, 1991, J MOL BIOL, V222, P725, DOI 10.1016/0022-2836(91)90508-4; Imada K, 1998, STRUCTURE, V6, P971, DOI 10.1016/S0969-2126(98)00099-9; ISHII A, 1987, J BIOCHEM, V102, P1489, DOI 10.1093/oxfordjournals.jbchem.a122196; ISHII A, 1993, J BACTERIOL, V175, P6873, DOI 10.1128/jb.175.21.6873-6880.1993; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KADONO S, 1995, J BIOCHEM-TOKYO, V118, P745, DOI 10.1093/oxfordjournals.jbchem.a124975; Kawamoto M, 2001, NUCL INSTRUM METH A, V467, P1375, DOI 10.1016/S0168-9002(01)00672-6; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB, P26; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; Miyazaki J, 2003, J BIOL CHEM, V278, P1864, DOI 10.1074/jbc.M205133200; MIYAZAKI K, 1993, FEBS LETT, V332, P35, DOI 10.1016/0014-5793(93)80477-C; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Singh SK, 2001, J BIOL CHEM, V276, P26154, DOI 10.1074/jbc.M101191200; Steen IH, 2001, J BIOL CHEM, V276, P43924, DOI 10.1074/jbc.M105999200; Steen IH, 1997, ARCH MICROBIOL, V168, P412, DOI 10.1007/s002030050516; Stoddard BL, 1998, NAT STRUCT BIOL, V5, P891, DOI 10.1038/2331; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9310, DOI 10.1021/bi00087a008; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9317, DOI 10.1021/bi00087a009; SUZUKI M, 1995, J BACTERIOL, V177, P2138, DOI 10.1128/jb.177.8.2138-2142.1995; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wallon G, 1997, J MOL BIOL, V266, P1016, DOI 10.1006/jmbi.1996.0797; WICKEN JS, 1972, BIOCHEMISTRY-US, V11, P4766, DOI 10.1021/bi00775a021; WU YD, 1991, J AM CHEM SOC, V113, P2353, DOI 10.1021/ja00007a002; Yasutake Y, 2002, STRUCTURE, V10, P1637, DOI 10.1016/S0969-2126(02)00904-8; Yasutake Y, 2001, ACTA CRYSTALLOGR D, V57, P1682, DOI 10.1107/S0907444901012823; ZHANG T, 1995, PROTEIN SCI, V4, P84	63	39	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36897	36904		10.1074/jbc.M304091200	http://dx.doi.org/10.1074/jbc.M304091200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855708	hybrid			2022-12-25	WOS:000185318300123
J	Abassi, YA; Rehn, M; Ekman, N; Alitalo, K; Vuori, K				Abassi, YA; Rehn, M; Ekman, N; Alitalo, K; Vuori, K			p130(Cas) couples the tyrosine kinase Bmx/Etk with regulation of the actin cytoskeleton and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SIGNALING COMPLEX-FORMATION; PLECKSTRIN-HOMOLOGY DOMAIN; CRK-ASSOCIATED SUBSTRATE; SRC FAMILY KINASES; EXTRACELLULAR-MATRIX; DEPENDENT MANNER; DIRECT BINDING; CANCER CELLS; SH3 DOMAINS	Bmx/Etk, a member of the Tec/Btk family of nonreceptor kinases, has recently been shown to mediate cell motility in signaling pathways that become activated upon integrin-mediated cell adhesion ( Chen, R., Kim, O., Li, M., Xiong, X., Guan, J. L., Kung, H. J., Chen, H., Shimizu, Y., and Qiu, Y. ( 2001) Nat Cell Biol. 3, 439 - 444). The molecular mechanisms of Bmx-induced cell motility have so far remained unknown. Previous studies by us and others have demonstrated that a complex formation between the docking protein p130(Cas) (Cas) and the adapter protein Crk is instrumental in connecting several stimuli to the regulation of actin cytoskeleton and cell motility. We demonstrate here that expression of Bmx leads to an interaction between Bmx and Cas at membrane ruffles, which are sites of active actin remodeling in motile cells. Expression of Bmx also enhances tyrosine phosphorylation of Cas and Cas . Crk complex formation, and coexpression of Bmx with Cas results in an enhanced membrane ruffling and haptotactic cell migration. Importantly, a mutant form of Bmx that fails to interact with Cas also fails to induce cell migration. Furthermore, expression of a dominant-negative form of Cas that is incapable of interacting with Crk inhibits Bmx-induced membrane ruffling and cell migration. These studies suggest that Bmx-Cas interaction, phosphorylation of Cas by Bmx, and subsequent Cas . Crk complex formation functionally couple Bmx to the regulation of actin cytoskeleton and cell motility.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland	Sanford Burnham Prebys Medical Discovery Institute; University of Helsinki	Vuori, K (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	kvuori@burnham.org	Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902				Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CARY LA, 1999, FRONT BIOSCI, V4, P102; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Ekman N, 2000, ONCOGENE, V19, P4151, DOI 10.1038/sj.onc.1203763; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; ILLC D, 1995, NATURE, V377, P539; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Owen JD, 1999, MOL CELL BIOL, V19, P4806; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; Saharinen P, 1997, BLOOD, V90, P4341; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stupack DG, 2000, IMMUNOL RES, V21, P83, DOI 10.1385/IR:21:2-3:83; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	66	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35636	35643		10.1074/jbc.M306438200	http://dx.doi.org/10.1074/jbc.M306438200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832404	hybrid			2022-12-25	WOS:000185164400108
J	Zhang, XH; Ma, L; Enkemann, SA; Pledger, WJ				Zhang, XH; Ma, L; Enkemann, SA; Pledger, WJ			Role of Gadd45 alpha in the density-dependent G1 arrest induced by p27(Kip1)	ONCOGENE			English	Article						Gadd45 alpha; p27(Kip1); culture density	MESSENGER-RNA EXPRESSION; KINASE INHIBITOR; GROWTH ARREST; MAMMALIAN-CELLS; P53-REGULATED PROTEIN; T-LYMPHOCYTES; MICE LACKING; GENES; TRANSCRIPTION; FIBROBLASTS	p27(Kip1), an inhibitor of cyclin-dependent kinases, is an important regulator of cell cycle progression. We have previously shown that p27(Kip1) inhibits the G0 to S transition when ectopically expressed in p27-47 mouse fibroblasts arrested at high but not low densities. In the study described here, we identify Gadd45alpha, a member of the growth arrest- and DNA damage-inducible family of proteins, as a potential mediator of the density-dependent effects of p27(Kip1) on cell proliferation. Gadd45alpha mRNA and protein were more abundant in p27-47 cells arrested at high densities than at low densities. Amounts of both decreased and remained low when cells arrested at high densities were exposed to mitogens in the absence, but not in the presence, of ectopically expressed p27(Kip1). Importantly, enforced expression of Gadd45alpha prevented density-arrested mouse fibroblasts from initiating DNA synthesis in response to mitogens. We suggest that amounts of Gadd45alpha above a certain threshold are growth inhibitory and that such amounts are achieved in cells arrested at high but not low densities. For cultures arrested at high densities, the resumption of cell cycle traverse requires a sustained reduction in Gadd45alpha abundance, a process that is induced by mitogens and inhibited by p27(Kip1).	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Pledger, WJ (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA67370] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abcouwer SF, 1999, J BIOL CHEM, V274, P28645, DOI 10.1074/jbc.274.40.28645; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; Carrier F, 1999, MOL CELL BIOL, V19, P1673; CARRIER F, 1994, J BIOL CHEM, V269, P32672; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; Fan W, 1999, ONCOGENE, V18, P6573, DOI 10.1038/sj.onc.1203054; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Fong WF, 2001, BBA-GENE STRUCT EXPR, V1517, P250, DOI 10.1016/S0167-4781(00)00287-6; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kettenhofen R, 2001, CELL SIGNAL, V13, P787, DOI 10.1016/S0898-6568(01)00198-X; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Miskimins R, 2002, J NEUROSCI RES, V67, P100, DOI 10.1002/jnr.10080.abs; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PESTOV DG, 1994, P NATL ACAD SCI USA, V91, P12549, DOI 10.1073/pnas.91.26.12549; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang W, 2001, INT J ONCOL, V18, P749; Zhang XH, 2000, MOL BIOL CELL, V11, P2117, DOI 10.1091/mbc.11.6.2117	52	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4166	4174		10.1038/sj.onc.1206599	http://dx.doi.org/10.1038/sj.onc.1206599			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833139				2022-12-25	WOS:000183979800003
J	Dias-Baruffi, M; Zhu, H; Cho, MJ; Karmakar, S; McEver, RP; Cummings, RD				Dias-Baruffi, M; Zhu, H; Cho, MJ; Karmakar, S; McEver, RP; Cummings, RD			Dimeric galectin-1 induces surface exposure of phosphatidylserine and phagocytic recognition of leukocytes without inducing apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; MEMBRANE PHOSPHOLIPID ASYMMETRY; ANTICOAGULANT PROTEIN-I; HUMAN-ENDOTHELIAL-CELLS; PLASMA-MEMBRANE; FAS LIGAND; HUMAN NEUTROPHILS; CYSTIC-FIBROSIS; GENERAL FEATURE; T-CELLS	We report that human galectin-1 (dGal-1), a small dimeric beta-galactoside-binding protein, induces phosphatidylserine ( PS) exposure, measured by Annexin V staining, on human promyelocytic HL-60 cells, T leukemic MOLT-4 cells, and fMet-Leu-Phe-activated, but not resting, human neutrophils. This effect of dGal-1 on HL-60 and MOLT-4 cells is enhanced by pretreatment of the cells with neuraminidase, but treatment of resting neutrophils with neuraminidase does not enhance their sensitivity to dGal-1. Although the induction of staining with Annexin V is often associated with apoptosis, the dGal-1-treated HL-60 cells, MOLT-4 cells, and activated neutrophils do not undergo apoptosis, and there is no detectable DNA fragmentation. HL-60 and MOLT-4 cells treated with dGal-1 continue to grow normally. By contrast, camptothecin-treated HL-60 cells, etoposide-treated MOLT-4 cells, and anti-Fas-treated neutrophils exhibit extensive DNA fragmentation and/or cell death. Lactose inhibits the dGal-1-induced effects, indicating that dGal-1-induced signaling requires binding to cell surface beta-galactosides. The dimeric form of Gal-1 is required for signaling, because a monomeric mutant form of Gal-1, termed mGal-1, binds to cells but does not cause these effects. Importantly, dGal-1, but not mGal-1, treatment of HL-60 cells and activated human neutrophils significantly promotes their phagocytosis by activated mouse macrophages. These dGal-1-induced effects are distinguishable from apoptosis, but like apoptotic agents, prepare cells for phagocytic removal. Such effects of dGal-1 may contribute to leukocyte homeostasis.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto SP, BR-14015900 Sao Paulo, Brazil; Jeju Natl Univ, Sch Med, Dept Biochem, Cheju 690756, South Korea	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; Universidade de Sao Paulo; Jeju National University	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 975 NE 10th St,BRC417, Oklahoma City, OK 73104 USA.	richard-cummings@ouhsc.edu	Baruffi, Marcelo D/I-7199-2015	Baruffi, Marcelo D/0000-0002-2039-1884	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015577] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034363, R37HL034363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048075] Funding Source: NIH RePORTER; NCRR NIH HHS [RR15577] Funding Source: Medline; NHLBI NIH HHS [HL34363] Funding Source: Medline; NIAID NIH HHS [AI48075] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams L, 1996, BBA-MOL CELL RES, V1312, P137, DOI 10.1016/0167-4889(96)00031-6; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; ALLEN HJ, 1991, TUMOR BIOL, V12, P52, DOI 10.1159/000217688; BAUM LG, 1995, GLYCOCONJUGATE J, V12, P63, DOI 10.1007/BF00731870; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; Brown SB, 2000, J BIOL CHEM, V275, P5987, DOI 10.1074/jbc.275.8.5987; Cho M, 1996, BIOCHEMISTRY-US, V35, P13081, DOI 10.1021/bi961181d; CHO MJ, 1995, J BIOL CHEM, V270, P5198, DOI 10.1074/jbc.270.10.5198; Colnot C, 1998, IMMUNOLOGY, V94, P290, DOI 10.1046/j.1365-2567.1998.00517.x; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; CROSS AS, 1991, J CLIN INVEST, V88, P2067, DOI 10.1172/JCI115536; Del Giudice E, 2001, EUR CYTOKINE NETW, V12, P510; Dillon SR, 2000, J IMMUNOL, V164, P1322, DOI 10.4049/jimmunol.164.3.1322; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P504, DOI 10.1006/bbrc.1999.1820; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fecho K, 1998, J LEUKOCYTE BIOL, V64, P373, DOI 10.1002/jlb.64.3.373; Fecho K, 1998, CELL IMMUNOL, V188, P19, DOI 10.1006/cimm.1998.1339; Galvan M, 2000, J BIOL CHEM, V275, P16730, DOI 10.1074/jbc.M001117200; Hammill AK, 1999, EXP CELL RES, V251, P16, DOI 10.1006/excr.1999.4581; HASLETT C, 1989, CURR OPIN IMMUNOL, V2, P10, DOI 10.1016/0952-7915(89)90091-5; HASLETT C, 1994, PHILOS T ROY SOC B, V345, P327, DOI 10.1098/rstb.1994.0113; HIRABAYASHI J, 1989, FEBS LETT, V250, P161, DOI 10.1016/0014-5793(89)80711-2; Hohlbaum AM, 2001, J IMMUNOL, V167, P6217, DOI 10.4049/jimmunol.167.11.6217; Homburg C H, 1996, Curr Opin Hematol, V3, P94; HOMBURG CHE, 1995, BLOOD, V85, P532; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; IWAI K, 1994, BLOOD, V84, P1201; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Kopitz J, 2001, J BIOL CHEM, V276, P35917, DOI 10.1074/jbc.M105135200; Krahling S, 1999, CELL DEATH DIFFER, V6, P183, DOI 10.1038/sj.cdd.4400473; Kuypers FA, 1996, BLOOD, V87, P1179, DOI 10.1182/blood.V87.3.1179.bloodjournal8731179; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; LOTAN R, 1994, GLYCOCONJUGATE J, V11, P462, DOI 10.1007/BF00731282; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Misawa R, 2001, APOPTOSIS, V6, P411, DOI 10.1023/A:1012406121993; OFFNER H, 1990, J NEUROIMMUNOL, V28, P177, DOI 10.1016/0165-5728(90)90032-I; OUTENREATH RL, 1992, J NEUROCYTOL, V21, P788, DOI 10.1007/BF01237904; Pace KE, 1999, J IMMUNOL, V163, P3801; Pace KE, 2000, J IMMUNOL, V165, P2331, DOI 10.4049/jimmunol.165.5.2331; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; PITTS MJ, 1981, BIOCHEM J, V195, P435, DOI 10.1042/bj1950435; POIRIER F, 1993, DEVELOPMENT, V119, P1229; Puche AC, 1996, DEV BIOL, V179, P274, DOI 10.1006/dbio.1996.0257; Rabinovich G, 1999, J EXP MED, V190, P385, DOI 10.1084/jem.190.3.385; Razi N, 1999, GLYCOBIOLOGY, V9, P1225, DOI 10.1093/glycob/9.11.1225; Rimon G, 1997, J NEUROSCI RES, V48, P563, DOI 10.1002/(SICI)1097-4547(19970615)48:6<563::AID-JNR9>3.0.CO;2-8; SANFORD GL, 1990, FASEB J, V4, P2912, DOI 10.1096/fasebj.4.11.2379767; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Schlegel RA, 1996, ADV EXP MED BIOL, V406, P21; Shi JL, 2001, BLOOD, V98, P1226, DOI 10.1182/blood.V98.4.1226; Shiratsuchi A, 1998, BIOCHEM BIOPH RES CO, V246, P549, DOI 10.1006/bbrc.1998.8663; Shudo K, 2001, EUR J IMMUNOL, V31, P2504, DOI 10.1002/1521-4141(200108)31:8<2504::AID-IMMU2504>3.0.CO;2-C; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; Stahnke K, 1998, EXP HEMATOL, V26, P844; TAIT JF, 1989, J BIOL CHEM, V264, P7944; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Tyurina YY, 2000, TOXICOLOGY, V148, P93, DOI 10.1016/S0300-483X(00)00199-2; Vandivier RW, 2002, CHEST, V121, p89S, DOI 10.1378/chest.121.3_suppl.89S; Vandivier RW, 2002, J CLIN INVEST, V109, P661, DOI 10.1172/JCI200213572; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; vanEngeland M, 1997, EXP CELL RES, V235, P421, DOI 10.1006/excr.1997.3738; Varki A., 1999, ESSENTIALS GLYCOBIOL; Vespa GNR, 1999, J IMMUNOL, V162, P799; Walzel H, 2000, GLYCOBIOLOGY, V10, P131, DOI 10.1093/glycob/10.2.131; WANG WC, 1988, J BIOL CHEM, V263, P4576; WASANO K, 1990, CELL TISSUE RES, V259, P43, DOI 10.1007/BF00571428; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; Williamson P, 2001, BIOCHEMISTRY-US, V40, P8065, DOI 10.1021/bi001929z; Zhao J, 1998, J BIOL CHEM, V273, P6603, DOI 10.1074/jbc.273.12.6603; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628; Zimmerman GA, 1996, J CLIN INVEST, V98, P1699, DOI 10.1172/JCI118967; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	86	139	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41282	41293		10.1074/jbc.M306624200	http://dx.doi.org/10.1074/jbc.M306624200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12853445	hybrid			2022-12-25	WOS:000185847200107
J	Travaglini-Allocatelli, C; Gianni, S; Morea, V; Tramontano, A; Soulimane, T; Brunori, M				Travaglini-Allocatelli, C; Gianni, S; Morea, V; Tramontano, A; Soulimane, T; Brunori, M			Exploring the cytochrome c folding mechanism - Cytochrome c(552) from Thermus thermophilus folds through an on-pathway intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSTATIC INTERACTIONS; GUANIDINE-HYDROCHLORIDE; PSEUDOMONAS-AERUGINOSA; KINETIC ROLE; STATE; PROTEINS; ACID; COLLAPSE	Understanding the role of partially folded intermediate states in the folding mechanism of a protein is a crucial yet very difficult problem. We exploited a kinetic approach to demonstrate that a transient intermediate of a thermostable member of the widely studied cytochrome c family (cytochrome c(552) from Thermus thermophilus) is indeed on-pathway. This is the first clear indication of an obligatory intermediate in the folding mechanism of a cytochrome c. The fluorescence properties of this intermediate demonstrate that the relative position of the heme and of the only tryptophan residue cannot correspond to their native orientation. Based on an analysis of the three-dimensional structure of cytochrome c(552), we propose an interpretation of the data which explains the residual fluorescence of the intermediate and is consistent with the established role played by some conserved interhelical interactions in the folding of other members of this family. A limited set of topologically conserved contacts may guide the folding of evolutionary distant cytochromes c through the same partially structured state, which, however, can play different kinetic roles, acting either as an intermediate or a transition state.	Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, Ist Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, Consiglio Nazl Ric, Ist Biol & Patol Mol, I-00185 Rome, Italy; Paul Scherrer Inst, CH-5232 Villigen, Switzerland	Fondazione Cenci Bolognetti; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Brunori, M (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, Ist Pasteur Fdn Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	maurizio.brunori@uniroma1.it	Tramontano, anna/D-5378-2009; gianni, stefano/C-8536-2009; Morea, Veronica/AAS-6881-2020	Tramontano, anna/0000-0002-5610-3338; Morea, Veronica/0000-0003-2566-3049; Brunori, Maurizio/0000-0002-7795-1635; Travaglini-Allocatelli, Carlo/0000-0001-8735-1126; Gianni, Stefano/0000-0003-1653-1925				Bai YW, 1999, P NATL ACAD SCI USA, V96, P477, DOI 10.1073/pnas.96.2.477; BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brockwell DJ, 2000, CURR OPIN STRUC BIOL, V10, P16, DOI 10.1016/S0959-440X(99)00043-3; Capaldi AP, 2001, NAT STRUCT BIOL, V8, P68; Capaldi AP, 2002, NAT STRUCT BIOL, V9, P209, DOI 10.1038/nsb757; Cavagnero S, 1998, BIOCHEMISTRY-US, V37, P3369, DOI 10.1021/bi9721795; Chan CK, 1997, P NATL ACAD SCI USA, V94, P1779, DOI 10.1073/pnas.94.5.1779; Colon W, 1996, BIOCHEMISTRY-US, V35, P5538, DOI 10.1021/bi960052u; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; Fersht AR, 2000, P NATL ACAD SCI USA, V97, P14121, DOI 10.1073/pnas.260502597; Gianni S, 2001, J MOL BIOL, V309, P1177, DOI 10.1006/jmbi.2001.4728; Hagen SJ, 2000, J MOL BIOL, V301, P1019, DOI 10.1006/jmbi.2000.3969; HONNAMI K, 1979, BIOCHEMISTRY-US, V18, P5693, DOI 10.1021/bi00592a027; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIEFHABER T, 1995, P NATL ACAD SCI USA, V92, P9029, DOI 10.1073/pnas.92.20.9029; MARMORINO JL, 1995, BIOCHEMISTRY-US, V34, P3140, DOI 10.1021/bi00010a002; Ogasahara K, 1998, BIOCHEMISTRY-US, V37, P17537, DOI 10.1021/bi9814585; Pace CN, 2000, PROTEINS, P1; Ptitsyn OB, 1998, J MOL BIOL, V278, P655, DOI 10.1006/jmbi.1997.1620; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; Rumbley J, 2001, P NATL ACAD SCI USA, V98, P105, DOI 10.1073/pnas.98.1.105; Sanchez IE, 2003, J MOL BIOL, V325, P367, DOI 10.1016/S0022-2836(02)01230-5; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Sauder JM, 1996, BIOCHEMISTRY-US, V35, P16852, DOI 10.1021/bi961976k; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764; Soulimane T, 1997, BIOCHEM BIOPH RES CO, V237, P572, DOI 10.1006/bbrc.1997.7041; Takahashi S, 1997, NAT STRUCT BIOL, V4, P44, DOI 10.1038/nsb0197-44; Than ME, 1997, J MOL BIOL, V271, P629, DOI 10.1006/jmbi.1997.1181; Travaglini-Allocatelli C, 1999, J MOL BIOL, V289, P1459, DOI 10.1006/jmbi.1999.2852; Wagner C, 1999, P NATL ACAD SCI USA, V96, P6716, DOI 10.1073/pnas.96.12.6716; Yeh SR, 1998, NAT STRUCT BIOL, V5, P222, DOI 10.1038/nsb0398-222; YOSHIDA T, 1984, J BIOL CHEM, V259, P112	33	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41136	41140		10.1074/jbc.M303990200	http://dx.doi.org/10.1074/jbc.M303990200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12842869	hybrid			2022-12-25	WOS:000185847200089
J	Baars, S; Bachmann, A; Levitzki, A; Rosl, F				Baars, S; Bachmann, A; Levitzki, A; Rosl, F			Tyrphostin AG 555 inhibits bovine papillomavirus transcription by changing the ratio between E2 transactivator/repressor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; EARLY GENE-EXPRESSION; OPEN READING FRAME; FACTOR-I RECEPTOR; TRANSFORMING PROTEIN; SIGNAL-TRANSDUCTION; MESSENGER-RNAS; TYPE-16 DNA; CELLS	The tyrosine kinase inhibitor ( tyrphostin) AG 555 selectively interferes with viral transcription in bovine papillomavirus type 1 (BPV-1)-transformed fibroblasts and induces suppression of cyclin-dependent kinase activity and cell cycle arrest. Concomitant with inhibition of viral transcription, c-Jun was strongly up-regulated, which was consistent with the observation that AG 555 treatment also led to an activation of the mitogen-activated protein kinase pathway by enhancing phosphorylation of JNK and p38. Increased JNK and p38 activity resulted in higher phosphorylation of the AP-1 family members c-Jun and activating transcription factor 2. Scanning the BPV-1 genome for potential binding sequences, an intragenic AP-1 site (BAP-1) within the E7 open reading frame was detected. Enhanced dimerization of phosphorylated activating transcription factor 2 together with c-Jun and binding to BAP-1 seem to be responsible for viral dysregulation because both suppression of BPV-1 and induction of c-Jun mRNA could be almost entirely abrogated by simultaneous treatment with SB 203580, an inhibitor of p38 mitogen-activated protein kinase activity. Moreover, dissecting the complex transcriptional pattern of episomal BPV-1 with specific primer sets for reverse transcription-PCR analysis, the repressive effect could be attributed to a selective down-regulation of the mRNA encoding the E2 transactivator function in favor of the E2 repressor, whose mRNA level remained constant during AG 555 treatment. These data indicate that tyrphostin AG 555 disturbs the balance of negative and positive regulatory factors necessary to maintain the homeostasis of a virus-transformed phenotype.	Deutsch Krebsforschungszentrum, Abt Virale Transformat Mech, Forsch Schwerpunkt Angew Tumorvirol, D-69120 Heidelberg, Germany; Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel	Helmholtz Association; German Cancer Research Center (DKFZ); Hebrew University of Jerusalem	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Abt Virale Transformat Mech, Forsch Schwerpunkt Angew Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	f.roesl@dkfz.de	Bachmann, Anastasia/F-8419-2014					Abroi A, 1996, J VIROL, V70, P6169, DOI 10.1128/JVI.70.9.6169-6179.1996; Alazawi W, 2002, CANCER RES, V62, P6959; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAKER CC, 1987, EMBO J, V6, P1027, DOI 10.1002/j.1460-2075.1987.tb04855.x; BARKSDALE SK, 1993, J VIROL, V67, P5605, DOI 10.1128/JVI.67.9.5605-5616.1993; Ben-Bassat H, 1999, J PHARMACOL EXP THER, V290, P1442; Ben-Bassat H, 1995, Exp Dermatol, V4, P82, DOI 10.1111/j.1600-0625.1995.tb00227.x; BenBassat H, 1997, CANCER RES, V57, P3741; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenner T, 1998, EXP NEUROL, V154, P489, DOI 10.1006/exnr.1998.6971; CHEN EY, 1982, NATURE, V299, P529, DOI 10.1038/299529a0; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; Choi CY, 1997, J BIOL CHEM, V272, P16934, DOI 10.1074/jbc.272.27.16934; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crusius K, 1997, ONCOGENE, V15, P1437, DOI 10.1038/sj.onc.1201312; DEAN PN, 1974, J CELL BIOL, V60, P523, DOI 10.1083/jcb.60.2.523; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Eyers PA, 1999, FEBS LETT, V451, P191, DOI 10.1016/S0014-5793(99)00552-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HERMONAT PL, 1988, EMBO J, V7, P2815, DOI 10.1002/j.1460-2075.1988.tb03137.x; HUBBERT NL, 1988, P NATL ACAD SCI USA, V85, P5864, DOI 10.1073/pnas.85.16.5864; HUMMEL M, 1992, J VIROL, V66, P6070, DOI 10.1128/JVI.66.10.6070-6080.1992; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Kabsch K, 2002, J VIROL, V76, P12162, DOI 10.1128/JVI.76.23.12162-12172.2002; Kansra SV, 1999, PHARMACOL RES, V39, P21, DOI 10.1006/phrs.1998.0402; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARLEN S, 1993, J VIROL, V67, P4296, DOI 10.1128/JVI.67.7.4296-4306.1993; KHANDJIAN EW, 1986, ANAL BIOCHEM, V159, P227, DOI 10.1016/0003-2697(86)90332-5; Kim KY, 2003, J MED VIROL, V69, P122, DOI 10.1002/jmv.10256; Klein O, 1999, J VIROL, V73, P3264, DOI 10.1128/JVI.73.4.3264-3272.1999; Kleinberger-Doron N, 1998, EXP CELL RES, V241, P340, DOI 10.1006/excr.1998.4061; KLEINER E, 1986, EMBO J, V5, P1945, DOI 10.1002/j.1460-2075.1986.tb04448.x; LAMBERT PF, 1990, J VIROL, V64, P950, DOI 10.1128/JVI.64.2.950-956.1990; LARSEN JK, 1986, CYTOMETRY, V7, P54, DOI 10.1002/cyto.990070108; LAW MF, 1981, P NATL ACAD SCI-BIOL, V78, P2727, DOI 10.1073/pnas.78.5.2727; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; Lipson KE, 1998, J PHARMACOL EXP THER, V285, P844; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MARUO T, 1992, CANCER, V69, P1182; Mathur SP, 2000, AM J REPROD IMMUNOL, V44, P222, DOI 10.1111/j.8755-8920.2000.440406.x; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; Nakamura K, 2000, CANCER RES, V60, P760; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Powell TJ, 1999, BRIT J DERMATOL, V141, P802, DOI 10.1046/j.1365-2133.1999.03152.x; RABSON MS, 1986, J VIROL, V60, P626, DOI 10.1128/JVI.60.2.626-634.1986; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROSL F, 1991, MOL CARCINOGEN, V4, P248, DOI 10.1002/mc.2940040312; ROSL F, 1986, J VIROL, V58, P500; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Soto U, 2000, INT J CANCER, V86, P811, DOI 10.1002/(SICI)1097-0215(20000615)86:6<811::AID-IJC9>3.0.CO;2-J; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; SPALHOLZ BA, 1991, J VIROL, V65, P743, DOI 10.1128/JVI.65.2.743-753.1991; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; SZYMANSKI P, 1991, J VIROL, V65, P5710, DOI 10.1128/JVI.65.11.5710-5720.1991; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WINOKUR PL, 1992, EMBO J, V11, P4111, DOI 10.1002/j.1460-2075.1992.tb05504.x; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	72	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37306	37313		10.1074/jbc.M304449200	http://dx.doi.org/10.1074/jbc.M304449200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867421	hybrid			2022-12-25	WOS:000185437200039
J	Buerger, C; Nagel-Wolfrum, K; Kunz, C; Wittig, I; Butz, K; Hoppe-Seyler, F; Groner, B				Buerger, C; Nagel-Wolfrum, K; Kunz, C; Wittig, I; Butz, K; Hoppe-Seyler, F; Groner, B			Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; ERBB SIGNALING NETWORK; ADAPTER PROTEIN SHC; KINASE C-SRC; EGF RECEPTOR; IN-VITRO; CELLULAR UPTAKE; A431 CELLS; CANCER; DELIVERY	Receptor tyrosine kinases of the epidermal growth factor (EGF) receptor family regulate essential cellular functions such as proliferation, survival, migration, and differentiation but also play central roles in the etiology and progression of tumors. We have identified short peptide sequences from a random peptide library integrated into the thioredoxin scaffold protein, which specifically bind to the intracellular domain of the EGF receptor ( EGFR). These molecules have the potential to selectively inhibit specific aspects of EGF receptor signaling and might become valuable as anticancer agents. Intracellular expression of the aptamer encoding gene construct KDI1 or introduction of bacterially expressed KDI1 via a protein transduction domain into EGFR-expressing cells results in KDI1 . EGF receptor complex formation, a slower proliferation, and reduced soft agar colony formation. Aptamer KDI1 did not summarily block the EGF receptor tyrosine kinase activity but selectively interfered with the EGF-induced phosphorylation of the tyrosine residues 845, 1068, and 1148 as well as the phosphorylation of tyrosine 317 of p46 Shc. EGF-induced phosphorylation of Stat3 at tyrosine 705 and Stat3-dependent transactivation were also impaired. Transduction of a short synthetic peptide aptamer sequence not embedded into the scaffold protein resulted in the same impairment of EGF-induced Stat3 activation.	Georg Speyer Haus, Biomed Res Inst, D-60596 Frankfurt, Germany; Deutsch Krebsforschungszentrum, Angew Tumorvirol, D-69120 Heidelberg, Germany	Octapharma; Helmholtz Association; German Cancer Research Center (DKFZ)	Groner, B (corresponding author), Georg Speyer Haus, Biomed Res Inst, Paul Ehrlich Str 42, D-60596 Frankfurt, Germany.		Buerger, Claudia/AAE-4685-2019; Nagel-Wolfrum, Kerstin/AAX-6477-2020	Hoppe-Seyler, Felix/0000-0002-1864-300X; Buerger, Claudia/0000-0002-7838-197X				Baselga J, 2002, ONCOLOGIST, V7, P2; BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Butz K, 2001, ONCOGENE, V20, P6579, DOI 10.1038/sj.onc.1204805; Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 2000, CURR OPIN CHEM BIOL, V4, P54, DOI 10.1016/S1367-5931(99)00051-4; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; Hynes NE, 2000, BREAST CANCER RES, V2, P154, DOI 10.1186/bcr48; Klapper LN, 2000, ADV CANCER RES, V77, P25; Klevenz B, 2002, CELL MOL LIFE SCI, V59, P1993, DOI 10.1007/PL00012521; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; Lydon NB, 1998, INT J CANCER, V76, P154, DOI 10.1002/(SICI)1097-0215(19980330)76:1<154::AID-IJC24>3.0.CO;2-B; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; Mi ZB, 2000, MOL THER, V2, P339, DOI 10.1006/mthe.2000.0137; Niesner U, 2002, BIOCONJUGATE CHEM, V13, P729, DOI 10.1021/bc025517+; Norman TC, 1999, SCIENCE, V285, P591, DOI 10.1126/science.285.5427.591; Normanno N, 2003, J CELL PHYSIOL, V194, P13, DOI 10.1002/jcp.10194; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Olayioye MA, 2001, EXP CELL RES, V267, P81, DOI 10.1006/excr.2001.5242; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; Sato K, 2000, GENES CELLS, V5, P749, DOI 10.1046/j.1365-2443.2000.00358.x; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; Schmidt M, 1999, ONCOGENE, V18, P1711, DOI 10.1038/sj.onc.1202489; Schmidt S, 2002, FEBS LETT, V523, P35, DOI 10.1016/S0014-5793(02)02928-9; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Xu CW, 2002, ONCOGENE, V21, P5753, DOI 10.1038/sj.onc.1205680; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	48	76	89	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37610	37621		10.1074/jbc.M301629200	http://dx.doi.org/10.1074/jbc.M301629200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12842895	hybrid			2022-12-25	WOS:000185437200076
J	Guillas, I; Jiang, JC; Vionnet, C; Roubaty, C; Uldry, D; Chuard, R; Wang, JQ; Jazwinski, SM; Conzelmann, A				Guillas, I; Jiang, JC; Vionnet, C; Roubaty, C; Uldry, D; Chuard, R; Wang, JQ; Jazwinski, SM; Conzelmann, A			Human homologues of LAG1 reconstitute acyl-CoA-dependent ceramide synthesis in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEINS; SPHINGOLIPIDS; LONGEVITY; BIOSYNTHESIS; SYNTHASE; DOMAINS; FAMILY; LAC1P	Lag1p and Lac1p are two highly homologous membrane proteins of the endoplasmic reticulum. lag1Delta lac1Delta double mutants in Saccharomyces cerevisiae lack an acyl-CoA-dependent ceramide synthase and are either very sick or nonviable, depending on the genetic background. LAG1 and LAC1 are members of a large eukaryotic gene family that shares the Lag1 motif, and some members of this family additionally contain a DNA-binding HOX homeodomain. Here we show that several human LAG1 homologues can rescue the viability of lag1Delta lac1Delta yeast cells and restore acyl-CoA-dependent ceramide and sphingolipid biosynthesis. When tested in a microsomal assay, Lac1p and Lag1p had a strong preference for C26:0-CoA over C24:0-CoA, C20-CoA, and C16-CoA, whereas some human homologues preferred C24:0-CoA and CoA derivatives with shorter fatty acids. This suggests that LAG1 proteins are related to substrate recognition and to the catalytic activity of ceramide synthase enzymes. CLN8, another human LAG1 homologue implicated in ceroid lipofuscinosis, could not restore viability to lag1Delta lac1Delta yeast mutants.	Univ Fribourg, Dept Med, Div Biochem, CH-1700 Fribourg, Switzerland; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA	University of Fribourg; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Conzelmann, A (corresponding author), Univ Fribourg, Dept Med, Div Biochem, Rte Musee 5, CH-1700 Fribourg, Switzerland.			Guillas, Isabelle/0000-0002-6073-0529				Barz WP, 1999, MOL BIOL CELL, V10, P1043, DOI 10.1091/mbc.10.4.1043; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; Flury I, 2000, J BIOL CHEM, V275, P24458, DOI 10.1074/jbc.M003844200; Funato K, 2003, J BIOL CHEM, V278, P7325, DOI 10.1074/jbc.M209925200; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; Jiang JC, 1998, GENOME RES, V8, P1259, DOI 10.1101/gr.8.12.1259; Kirchman PA, 1999, GENETICS, V152, P179; Lonka L, 2000, HUM MOL GENET, V9, P1691, DOI 10.1093/hmg/9.11.1691; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; MORELL P, 1970, J BIOL CHEM, V245, P342; OBRIEN JS, 1964, J LIPID RES, V5, P339; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; Reggiori F, 1997, EMBO J, V16, P3506, DOI 10.1093/emboj/16.12.3506; ROBSON KJ, 1994, J LIPID RES, V35, P2060; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; SMITH SW, 1974, J BIOL CHEM, V249, P3395; ULLMAN MD, 1972, ARCH BIOCHEM BIOPHYS, V152, P767, DOI 10.1016/0003-9861(72)90272-X; Venkataraman K, 2002, FEBS LETT, V528, P3, DOI 10.1016/S0014-5793(02)03248-9; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Wang E, 2000, METHOD ENZYMOL, V311, P15; WERTZ PW, 1989, COMP BIOCHEM PHYS B, V93, P265, DOI 10.1016/0305-0491(89)90080-1; Winter E, 2002, TRENDS BIOCHEM SCI, V27, P381, DOI 10.1016/S0968-0004(02)02154-0	30	76	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37083	37091		10.1074/jbc.M307554200	http://dx.doi.org/10.1074/jbc.M307554200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869556	hybrid			2022-12-25	WOS:000185437200014
J	Hiriart, E; Bardouillet, L; Manet, E; Gruffat, H; Penin, F; Montserret, R; Farjot, G; Sergeant, A				Hiriart, E; Bardouillet, L; Manet, E; Gruffat, H; Penin, F; Montserret, R; Farjot, G; Sergeant, A			A region of the Epstein-Barr virus (EBV) mRNA export factor EB2 containing an arginine-rich motif mediates direct binding to RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXON-EXON JUNCTIONS; REV RESPONSIVE ELEMENT; NUCLEAR EXPORT; PROTEIN INTERACTIONS; HUMAN HOMOLOG; IN-VIVO; TRANSCRIPTION; INTERACTS; GENE; PEPTIDE	The Epstein-Barr virus (EBV) protein EB2 (also called Mta, SM, or BMLF1) has properties in common with mRNA export factors and is essential for the production of EBV infectious virions. However, to date no RNA-binding motif essential for EB2-mediated mRNA export has been located in the protein. We show here by Northwestern blot analysis that the EB2 protein purified from mammalian cells binds directly to RNA. Furthermore, using overlapping glutathione S-transferase (GST)-EB2 peptides, we have, by RNA electrophoretic mobility shift assays (REMSAs) and Northwestern blotting, located an RNA-binding motif in a 33-amino acid segment of EB2 that has structural features of the arginine-rich RNA-binding motifs (ARMs) also found in many RNA-binding proteins. A synthetic peptide (called Da), which contains this EB2 ARM, bound RNA in REMSA. A GST-Da fusion protein also bound RNA in REMSA without apparent RNA sequence specificity, because similar to10 GST-Da molecules bound at multiple sites on a 180-nucleotide RNA fragment. Importantly, a short deletion in the ARM region impaired both EB2 binding to RNA in vivo and in vitro and EB2-mediated mRNA export without affecting the shuttling of EB2 between the nucleus and the cytoplasm. Moreover, ectopic expression of ARM-deleted EB2 did not rescue the production of infectious virions by 293 cells carrying an EBVDeltaEB2 genome, which suggests that the binding of EB2 to RNA plays an essential role in the EBV productive cycle.	INSERM, U412, Virol Lab, Ens Lyon, F-69364 Lyon 07, France; CNRS, F-75700 Paris, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)	Sergeant, A (corresponding author), INSERM, U412, Virol Lab, Ens Lyon, 46 Allee Italie, F-69364 Lyon 07, France.		MANET, Evelyne/G-5644-2019; Gruffat, Henri/I-2407-2016; PENIN, Francois/A-7315-2008	MANET, Evelyne/0000-0001-7619-9982; Gruffat, Henri/0000-0002-4735-6894; Hiriart, Eneko/0000-0003-4379-3672				BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; Buisson M, 1999, J VIROL, V73, P4090, DOI 10.1128/JVI.73.5.4090-4100.1999; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; COUNTRYMAN J, 1987, J VIROL, V61, P3672, DOI 10.1128/JVI.61.12.3672-3679.1987; Delecluse HJ, 1999, P NATL ACAD SCI USA, V96, P5188, DOI 10.1073/pnas.96.9.5188; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Farjot G, 2000, J VIROL, V74, P6068, DOI 10.1128/JVI.74.13.6068-6076.2000; Feederle R, 2000, EMBO J, V19, P3080, DOI 10.1093/emboj/19.12.3080; Gatfield D, 2002, J CELL BIOL, V159, P579, DOI 10.1083/jcb.200207128; Gruffat H, 2002, J VIROL, V76, P9635, DOI 10.1128/JVI.76.19.9635-9644.2002; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Hieronymus H, 2003, NAT GENET, V33, P155, DOI 10.1038/ng1080; Hiriart E, 2003, J BIOL CHEM, V278, P335, DOI 10.1074/jbc.M208656200; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Janz A, 2000, J VIROL, V74, P10142, DOI 10.1128/JVI.74.21.10142-10152.2000; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; Koffa MD, 2001, EMBO J, V20, P5769, DOI 10.1093/emboj/20.20.5769; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2000, GENE DEV, V14, P1098; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; RODRIGUEZ PL, 1994, BIOTECHNIQUES, V17, P702; ROLLER RJ, 1990, J VIROL, V64, P3463, DOI 10.1128/JVI.64.7.3463-3470.1990; ROONEY CM, 1989, J VIROL, V63, P3109, DOI 10.1128/JVI.63.7.3109-3116.1989; Ruvolo V, 1998, P NATL ACAD SCI USA, V95, P8852, DOI 10.1073/pnas.95.15.8852; Ruvolo V, 2001, J VIROL, V75, P6033, DOI 10.1128/JVI.75.13.6033-6041.2001; Sandri-Goldin RM, 1998, GENE DEV, V12, P868, DOI 10.1101/gad.12.6.868; Sciabica KS, 2003, EMBO J, V22, P1608, DOI 10.1093/emboj/cdg166; Semmes OJ, 1998, J VIROL, V72, P9526, DOI 10.1128/JVI.72.12.9526-9534.1998; Smith CA, 2000, MOL CELL, V6, P1067, DOI 10.1016/S1097-2765(00)00105-2; Soliman TM, 2000, J VIROL, V74, P2814, DOI 10.1128/JVI.74.6.2814-2825.2000; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160; Zolotukhin AS, 2002, J BIOL CHEM, V277, P3935, DOI 10.1074/jbc.M107598200; Zuker M., 1999, V70, P11	56	59	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37790	37798		10.1074/jbc.M305925200	http://dx.doi.org/10.1074/jbc.M305925200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857728				2022-12-25	WOS:000185437200098
J	Hughey, RP; Mueller, GM; Bruns, JB; Kinlough, CL; Poland, PA; Harkleroad, KL; Carattino, MD; Kleyman, TR				Hughey, RP; Mueller, GM; Bruns, JB; Kinlough, CL; Poland, PA; Harkleroad, KL; Carattino, MD; Kleyman, TR			Maturation of the epithelial Na+ channel involves proteolytic processing of the alpha- and gamma-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; CLATHRIN-MEDIATED ENDOCYTOSIS; SODIUM-CHANNEL; MEMBRANE TOPOLOGY; A6 CELLS; SERINE PROTEASES; COLLECTING DUCT; XENOPUS-OOCYTES; ENAC; BIOSYNTHESIS	The epithelial Na+ channel (ENaC) is a tetramer of two alpha-, one beta-, and one gamma-subunit, but little is known about its assembly and processing. Because co-expression of mouse ENaC subunits with three different carboxyl-terminal epitope tags produced an amiloride-sensitive sodium current in oocytes, these tagged subunits were expressed in both Chinese hamster ovary or Madin-Darby canine kidney type 1 epithelial cells for further study. When expressed alone alpha- (95 kDa), beta- ( 96 kDa), and gamma-subunits ( 93 kDa) each produced a single band on SDS gels by immunoblotting. However, co-expression of alphabetagamma ENaC subunits revealed a second band for each subunit (65 kDa for alpha, 110 kDa for beta, and 75 kDa for gamma) that exhibited N-glycans that had been processed to complex type based on sensitivity to treatment with neuraminidase, resistance to cleavage by endoglycosidase H, and GalNAc-independent labeling with [H-3]Gal in glycosylation-defective Chinese hamster ovary cells (1d1D). The smaller size of the processed alpha- and gamma-subunits is also consistent with proteolytic cleavage. By using alpha- and gamma-subunits with epitope tags at both the amino and carboxyl termini, proteolytic processing of the alpha- and gamma-subunits was confirmed by isolation of an additional epitope-tagged fragment from the amino terminus (30 kDa for alpha and 18 kDa for gamma) consistent with cleavage within the extracellular loop. The fragments remain stably associated with the channel as shown by immunoblotting of co-immunoprecipitates, suggesting that proteolytic cleavage represents maturation rather than degradation of the channel.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kleyman, TR (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA.	kleyman@pitt.edu			NIDDK NIH HHS [DK54787, DK51391, DK54354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051391, R01DK054787, R37DK051391, R01DK054354] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; Bridges RJ, 2001, AM J PHYSIOL-LUNG C, V281, pL16, DOI 10.1152/ajplung.2001.281.1.L16; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Cheng C, 1998, J BIOL CHEM, V273, P22693, DOI 10.1074/jbc.273.35.22693; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Guipponi M, 2002, HUM MOL GENET, V11, P2829, DOI 10.1093/hmg/11.23.2829; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hell JW, 1996, P NATL ACAD SCI USA, V93, P3362, DOI 10.1073/pnas.93.8.3362; JEROME KR, 1991, CANCER RES, V51, P2908; Jovov B, 2002, J BIOL CHEM, V277, P4134, DOI 10.1074/jbc.M108354200; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Kubodera T, 2003, NEUROSCI LETT, V341, P74, DOI 10.1016/S0304-3940(03)00156-3; Li JQ, 2003, J BIOL CHEM, V278, P13867, DOI 10.1074/jbc.M300149200; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; May A, 1997, J AM SOC NEPHROL, V8, P1813; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Prince LS, 1998, BIOCHEM J, V336, P705, DOI 10.1042/bj3360705; Puliyanda DP, 2003, BIOCHEM BIOPH RES CO, V303, P52, DOI 10.1016/S0006-291X(03)00215-8; RamseyEwing A, 1996, J BIOL CHEM, V271, P16962, DOI 10.1074/jbc.271.28.16962; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; Sheng SH, 2001, J BIOL CHEM, V276, P44091, DOI 10.1074/jbc.M108522200; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Vallet VR, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133588; Vuagniaux G, 2000, J AM SOC NEPHROL, V11, P828, DOI 10.1681/ASN.V115828; Vuagniaux G, 2002, J GEN PHYSIOL, V120, P191, DOI 10.1085/jgp.20028598; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; WEISZ OA, 1994, METHOD CELL BIOL, V43, P137	43	220	220	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37073	37082		10.1074/jbc.M307003200	http://dx.doi.org/10.1074/jbc.M307003200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871941	hybrid			2022-12-25	WOS:000185437200013
J	Crist, SA; Griffith, TS; Ratliff, TL				Crist, SA; Griffith, TS; Ratliff, TL			Structure/function analysis of the murine CD95L promoter reveals the identification of a novel transcriptional repressor and functional CD28 response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-LIGAND EXPRESSION; INDUCED CELL-DEATH; T-CELLS; COSTIMULATORY SIGNAL; INDUCED APOPTOSIS; UP-REGULATION; C-FLIPSHORT; IN-VIVO; ACTIVATION; TCR	CD28 costimulation, an important second signal for antigen-mediated T cell activation, is known to enhance expression of several genes important for the regulation of CD4+ T cell effector function including interleukin-2 and CD154. Previous studies demonstrate CD28-mediated enhancement of the transcription and expression of Fas ligand (CD95L) in T cell lines, suggesting a regulatory link between CD28 and CD95L expression. These results served as the basis for structure/function analysis of the CD95L promoter to elucidate the mechanism for CD28-mediated enhancement of CD95L. In this report, we describe a novel response element, located at - 210 to - 201 bp upstream of the transcription start site, that confers CD28 responsiveness to the CD95L gene. This response element is homologous to the CD28 response element (CD28RE) previously identified in the IL-2 promoter and bears structural similarities to a newly identified CD28RE in the CD154 promoter. We further demonstrate that CD28-mediated enhancement of promoter activity correlates with enhanced expression of CD95L mRNA, cell surface expression of CD95L protein, and increased apoptosis of CD95+ target cells. These results demonstrate a direct transcriptional regulatory role for CD28 in CD95L-mediated functional activity in CD4+ T cells. Mutational analysis of the CD95L promoter also reveals a novel transcriptional repressor element located similar to 60 bp 5' of the CD28RE. The repressor element bears sequence homology to an activator protein-1 element, constitutively binds c-Fos but not c-Jun, and is activation-independent.	Univ Iowa, Dept Urol, Iowa City, IA 52242 USA; Univ Iowa, Interdisciplinary Grad Program Immunol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Ratliff, TL (corresponding author), Dept Urol, 3206 MERF, Iowa City, IA 52245 USA.	Tim-Ratliff@uiowa.edu						ALI SA, 1995, BIOTECHNIQUES, V18, P746; Appleman LJ, 2000, J IMMUNOL, V164, P144, DOI 10.4049/jimmunol.164.1.144; Bruder JM, 1996, MOL ENDOCRINOL, V10, P35, DOI 10.1210/me.10.1.35; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; Brunner T, 1996, Behring Inst Mitt, P161; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Diehn M, 2002, P NATL ACAD SCI USA, V99, P11796, DOI 10.1073/pnas.092284399; ELKHATIB M, 1995, CELL IMMUNOL, V163, P237, DOI 10.1006/cimm.1995.1122; ETTINGER R, 1995, J IMMUNOL, V154, P4302; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074/jbc.273.39.25185; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Latinis KM, 1997, J IMMUNOL, V158, P4602; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Li-Weber M, 1998, EUR J IMMUNOL, V28, P2373, DOI 10.1002/(SICI)1521-4141(199808)28:08<2373::AID-IMMU2373>3.0.CO;2-T; Lindgren H, 2001, J IMMUNOL, V166, P4578, DOI 10.4049/jimmunol.166.7.4578; Maggirwar SB, 1997, MOL CELL BIOL, V17, P2605, DOI 10.1128/MCB.17.5.2605; Matsui K, 2000, J IMMUNOL, V164, P3002, DOI 10.4049/jimmunol.164.6.3002; Matsui K, 1998, J IMMUNOL, V161, P3469; Michel F, 2000, J IMMUNOL, V165, P3820, DOI 10.4049/jimmunol.165.7.3820; Michel F, 2001, IMMUNITY, V15, P935, DOI 10.1016/S1074-7613(01)00244-8; Nagel T, 2000, EUR J IMMUNOL, V30, P1632, DOI 10.1002/1521-4141(200006)30:6<1632::AID-IMMU1632>3.0.CO;2-Q; Norian LA, 1998, J IMMUNOL, V161, P1078; Norian LA, 2000, J IMMUNOL, V164, P4471, DOI 10.4049/jimmunol.164.9.4471; Parra E, 2001, J IMMUNOL, V166, P2437, DOI 10.4049/jimmunol.166.4.2437; Riley JL, 2002, P NATL ACAD SCI USA, V99, P11790, DOI 10.1073/pnas.162359999; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Sabelko-Downes KA, 1999, J NEUROIMMUNOL, V100, P42, DOI 10.1016/S0165-5728(99)00191-5; Sabelko-Downes KA, 1999, J EXP MED, V189, P1195, DOI 10.1084/jem.189.8.1195; Sabelko-Downes KA, 2000, CURR OPIN IMMUNOL, V12, P330, DOI 10.1016/S0952-7915(00)00095-9; Shea-Eaton W, 2002, MOL CELL ENDOCRINOL, V188, P161, DOI 10.1016/S0303-7207(01)00715-8; STALDER T, 1994, J IMMUNOL, V152, P1127; Thilenius ARB, 1999, J IMMUNOL, V162, P643; Villalba M, 1999, J IMMUNOL, V163, P5813; Wang JKM, 1997, CELL IMMUNOL, V179, P153, DOI 10.1006/cimm.1997.1159; Wang JKM, 2000, EUR J IMMUNOL, V30, P931; Wang RD, 1996, J IMMUNOL, V157, P2961; Xiao S, 1999, EUR J IMMUNOL, V29, P3456, DOI 10.1002/(SICI)1521-4141(199911)29:11<3456::AID-IMMU3456>3.3.CO;2-2; Zhang J, 1999, J BIOL CHEM, V274, P26537, DOI 10.1074/jbc.274.37.26537; Zhang J, 2000, BBA-GENE STRUCT EXPR, V1490, P291, DOI 10.1016/S0167-4781(99)00212-2	51	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35950	35958		10.1074/jbc.M306220200	http://dx.doi.org/10.1074/jbc.M306220200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855690	hybrid			2022-12-25	WOS:000185318300012
J	Hussain, I; Hawkins, J; Shikotra, A; Riddell, DR; Faller, A; Dingwall, C				Hussain, I; Hawkins, J; Shikotra, A; Riddell, DR; Faller, A; Dingwall, C			Characterization of the ectodomain shedding of the beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-ALPHA; CELL-SURFACE; ALZHEIMERS-DISEASE; CONVERTING-ENZYME; MEMBRANE-PROTEINS; SECRETASE CLEAVAGE; DISINTEGRIN; METALLOPROTEINASE; ACTIVATION	Generation of the amyloid peptide through proteolytic processing of the amyloid precursor protein by beta- and gamma-secretases is central to the etiology of Alzheimer's disease. beta-secretase, known more widely as the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), has been identified as a transmembrane aspartic proteinase, and its ectodomain has been reported to be cleaved and secreted from cells in a soluble form. The extracellular domains of many diverse proteins are known to be cleaved and secreted from cells by a process known as ectodomain shedding. Here we confirm that the ectodomain of BACE1 is secreted from cells and that this processing is up-regulated by agents that activate protein kinase C. A metalloproteinase is involved in the cleavage of BACE1 as hydroxamic acid-based metalloproteinase inhibitors abolish the release of shed BACE1. Using potent and selective inhibitors, we demonstrate that ADAM10 is a strong candidate for the BACE1 sheddase. In addition, we show that the BACE1 sheddase is distinct from alpha-secretase and, importantly, that inhibition of BACE1 shedding does not influence amyloid precursor protein processing at the beta-site.	GlaxoSmithKline Res & Dev Ltd, Neurol & Gastrointestinal Ctr Excellence Drug Dis, Harlow CM19 5AW, Essex, England	GlaxoSmithKline	Hussain, I (corresponding author), GlaxoSmithKline Res & Dev Ltd, Neurol & Gastrointestinal Ctr Excellence Drug Dis, New Frontiers Sci Pk,3rd Ave, Harlow CM19 5AW, Essex, England.	Ishrut_2_Hussain@gsk.com						Amit T, 2001, J ENDOCRINOL, V169, P397, DOI 10.1677/joe.0.1690397; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bodendorf U, 2002, J NEUROCHEM, V80, P799, DOI 10.1046/j.0022-3042.2002.00770.x; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Condon TP, 2001, ANTISENSE NUCLEIC A, V11, P107, DOI 10.1089/108729001750171353; Deng P, 1996, J BIOL CHEM, V271, P16338, DOI 10.1074/jbc.271.27.16338; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hotoda N, 2002, BIOCHEM BIOPH RES CO, V293, P800, DOI 10.1016/S0006-291X(02)00302-9; Howlett DR, 2000, TRENDS NEUROSCI, V23, P565, DOI 10.1016/S0166-2236(00)01647-7; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Moss ML, 2002, ESSAYS BIOCHEM, V38, P141, DOI 10.1042/bse0380141; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; TEIXIDO J, 1990, J BIOL CHEM, V265, P6410; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; YOSHIDA K, 1992, P NATL ACAD SCI USA, V89, P6443, DOI 10.1073/pnas.89.14.6443	36	50	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36264	36268		10.1074/jbc.M304186200	http://dx.doi.org/10.1074/jbc.M304186200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857759	hybrid			2022-12-25	WOS:000185318300049
J	Lees, MJ; Peet, DJ; Whitelaw, ML				Lees, MJ; Peet, DJ; Whitelaw, ML			Defining the role for XAP2 in stabilization of the dioxin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; PEPTIDYLPROLYL ISOMERASE DOMAIN; HEAT-SHOCK-PROTEIN; AH RECEPTOR; SUBCELLULAR-LOCALIZATION; LIGAND-BINDING; GLUCOCORTICOID-RECEPTOR; MOLECULAR CHAPERONES; NUCLEAR-LOCALIZATION; DYNEIN INTERACTION	The dioxin receptor (DR) is a ligand-activated transcription factor that is activated upon binding of dioxins or structurally related forms of xenobiotics. Upon binding ligand the DR translocates from the cytoplasm to the nucleus where it complexes with the partner protein Arnt to form a DNA binding heterodimer, which activates transcription of target genes involved in xenobiotic metabolism. Latency of the DR signaling pathway is maintained by association of the DR with a number of molecular chaperones including the 90-kDa heat shock protein (hsp90), the hepatitis B virus X-associated protein (XAP2), and the 23-kDa heat shock protein (p23). Here we investigated the role of XAP2 in DR signaling and demonstrated that reduced levels of XAP2 labilize the DR, arguing for a function of XAP2 beyond its reported role as a cytoplasmic retention factor. In addition, we showed that a constitutively nuclear DR is degraded in the nucleus and does not require nuclear export for efficient degradation. We also provided evidence implicating the ubiquitin ligase protein C-terminal hsp70-interacting protein ( CHIP) in the degradation of the DR, and we demonstrated that this degradation can be overcome by overexpression of XAP2. XAP2 protection of CHIP-mediated degradation is dependent on the tetratricopeptide repeat domain of XAP2 and suggests a mechanism whereby competition for the C-terminal tetratricopeptide repeat acceptor site of hsp90 guides the protein triage decision, the point of determination for either maturation of DR folding or DR degradation.	Univ Adelaide, Sch Mol & Biomed Sci Biochem, Adelaide, SA 5005, Australia; Univ Adelaide, Ctr Mol Genet & Dev, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Whitelaw, ML (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci Biochem, Mol Life Sci Bldg, Adelaide, SA 5005, Australia.	murray.whitelaw@adelaide.edu.au	Peet, Daniel/AAE-6698-2020	Peet, Daniel/0000-0002-6085-8936				Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bell DR, 2000, J BIOL CHEM, V275, P36407, DOI 10.1074/jbc.M004236200; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CARVER LA, 1994, J BIOL CHEM, V269, P30109; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; COUMAILLEAU P, 1995, J BIOL CHEM, V270, P25291, DOI 10.1074/jbc.270.42.25291; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; Ikuta T, 2000, J BIOCHEM, V127, P503, DOI 10.1093/oxfordjournals.jbchem.a022633; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kashuba E, 2000, ONCOGENE, V19, P1801, DOI 10.1038/sj.onc.1203501; Kazlauskas A, 2002, J BIOL CHEM, V277, P11795, DOI 10.1074/jbc.M200053200; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lando D, 2000, J BIOL CHEM, V275, P4618, DOI 10.1074/jbc.275.7.4618; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; Lees MJ, 1999, MOL CELL BIOL, V19, P5811; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; Ma Q, 1997, J BIOL CHEM, V272, P8878; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8; PERDEW GH, 1991, ARCH BIOCHEM BIOPHYS, V291, P284, DOI 10.1016/0003-9861(91)90136-7; Petrulis JR, 2000, J BIOL CHEM, V275, P37448, DOI 10.1074/jbc.M006873200; Petrulis JR, 2003, J BIOL CHEM, V278, P2677, DOI 10.1074/jbc.M209331200; Pollenz RS, 2000, MOL CELL BIOL, V20, P6095, DOI 10.1128/MCB.20.16.6095-6104.2000; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; REXIN M, 1991, J BIOL CHEM, V266, P24601; Richter CA, 2001, ARCH BIOCHEM BIOPHYS, V389, P207, DOI 10.1006/abbi.2001.2339; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Singh SS, 1996, ARCH BIOCHEM BIOPHYS, V329, P47, DOI 10.1006/abbi.1996.0190; Song ZJ, 2002, MOL PHARMACOL, V62, P806, DOI 10.1124/mol.62.4.806; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	63	64	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35878	35888		10.1074/jbc.M302430200	http://dx.doi.org/10.1074/jbc.M302430200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12837759	hybrid			2022-12-25	WOS:000185318300004
J	Mikami, T; Mizumoto, S; Kago, N; Kitagawa, H; Sugahara, K				Mikami, T; Mizumoto, S; Kago, N; Kitagawa, H; Sugahara, K			Specificities of three distinct human chondroitin/dermatan N-acetylgalactosamine 4-O-sulfotransferases demonstrated using partially desulfated dermatan sulfate as an acceptor - Implication of differential roles in dermatan sulfate biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-COFACTOR-II; MOLECULAR-CLONING; STRUCTURAL-ANALYSIS; EXPRESSION CLONING; TRANSFERS SULFATE; BOVINE SERUM; ACID; SULFOTRANSFERASE; PROTEOGLYCANS; MIGRATION	4-O-Sulfation of GalNAc is a high frequency modification of chondroitin sulfate and dermatan sulfate (DS), and three major GalNAc 4-O-sulfotransferases including dermatan 4-O-sulfotransferase-1 (D4ST-1) and chondroitin 4-O-sulfotransferases-1 and -2 (C4ST-1 and -2) have been identified. 4-O-Sulfation of GalNAc during DS biosynthesis had long been postulated to be a prerequisite for iduronic acid (IdoUA) formation by C5-epimerization of GlcUA. This hypothesis has recently been argued based on enzymological studies using microsomes that C5-epimerization precedes 4-O-sulfation, which was further supported by the specificity of the cloned D4ST-1 with predominant preference for IdoUA-GalNAc flanked by GlcUA-GalNAc over IdoUA-GalNAc flanked by IdoUA-GalNAc in exhaustively desulfated dermatan. Whereas the counterproposal explains the initial reactions, apparently it cannot rationalize the synthetic mechanism of IdoUA-GalNAc(4-O-sulfate)-rich clusters typical of mature DS chains. In this study, we examined detailed specificities of the three recombinant human 4-O-sulfotransferases using partially desulfated DS as an acceptor. Enzymatic analysis of the transferase reaction products showed that D4ST-1 far more efficiently transferred sulfate to GalNAc residues in -IdoUA-GalNAc-IdoUA- than in -GlcUA-GalNAc-GlcUA-sequences. In contrast, C4ST-1 showed the opposite preference, and C4ST-2 used GalNAc residues in both sequences to comparable degrees, being consistent with its phylogenetic relations to D4ST-1 and C4ST-1. Structural analysis of the oligosaccharides, which were isolated after chondroitinase AC-I digestion of the S-35-labeled transferase reaction products, revealed for the first time that D4ST-1, as compared with C4ST-1 and C4ST-2, most efficiently utilized GalNAc residues located not only in the sequence -IdoUA-GalNAc-IdoUA- but also in -GlcUA-GalNAc-IdoUA- and -IdoUA-GalNAc-GlcUA-. The isolated oligosaccharide structures also suggest that 4-O-sulfation promotes subsequent 4-O-sulfation of GalNAc in the neighboring disaccharide unit.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Kobe Pharmaceutical University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp	Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; BAO X, 2003, IN PRESS SEIKAGAKU; Burge CB, 1998, CURR OPIN STRUC BIOL, V8, P346, DOI 10.1016/S0959-440X(98)80069-9; CHENG F, 1994, GLYCOBIOLOGY, V4, P685, DOI 10.1093/glycob/4.5.685; Eklund E, 2000, ARCH BIOCHEM BIOPHYS, V383, P171, DOI 10.1006/abbi.2000.2043; Elefteriou F, 2001, FEBS LETT, V495, P44, DOI 10.1016/S0014-5793(01)02361-4; Evers MR, 2001, J BIOL CHEM, V276, P36344, DOI 10.1074/jbc.M105848200; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; Fansson LA, 2000, MATRIX BIOL, V19, P367, DOI 10.1016/S0945-053X(00)00083-4; GATTI G, 1979, CARBOHYD RES, V68, pC3, DOI 10.1016/S0008-6215(00)84070-7; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; Habuchi O, 2000, SEIKAGAKU, V72, P427; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hiraoka N, 2001, GLYCOBIOLOGY, V11, P495, DOI 10.1093/glycob/11.6.495; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kang HG, 2002, J BIOL CHEM, V277, P34766, DOI 10.1074/jbc.M204907200; Kang HG, 2001, J BIOL CHEM, V276, P10861, DOI 10.1074/jbc.M011560200; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kinsella MG, 1997, J BIOL CHEM, V272, P318; KITAGAWA H, 1995, J BIOCHEM-TOKYO, V117, P1083, DOI 10.1093/oxfordjournals.jbchem.a124810; Kitagawa H, 2001, J BIOL CHEM, V276, P4834, DOI 10.1074/jbc.C000835200; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; LAFONT F, 1992, DEVELOPMENT, V114, P17; LEWANDOWSKA K, 1999, J BIOL CHEM, V274, P11431; Liaw PCY, 2001, J BIOL CHEM, V276, P20959, DOI 10.1074/jbc.M010584200; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MALMSTRO.A, 1971, EUR J BIOCHEM, V18, P431, DOI 10.1111/j.1432-1033.1971.tb01260.x; MALMSTROM A, 1975, J BIOL CHEM, V250, P3419; MALMSTROM A, 1984, J BIOL CHEM, V259, P161; Merle B, 1999, J CELL BIOCHEM, V75, P538; Nadanaka S, 1999, FEBS LETT, V452, P185, DOI 10.1016/S0014-5793(99)00597-9; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; NANDINI CD, 2003, IN PRESS SEIKAGAKU; Okuda T, 2000, J BIOCHEM, V128, P763, DOI 10.1093/oxfordjournals.jbchem.a022813; Okuda T, 2000, J BIOL CHEM, V275, P40605, DOI 10.1074/jbc.M007983200; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SILBERT JE, 1986, J BIOL CHEM, V261, P3397; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; Sugahara K, 1996, EUR J BIOCHEM, V239, P871, DOI 10.1111/j.1432-1033.1996.0871u.x; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; SUGAHARA K, 2003, 17 INT S GLYC BANG I; Sugiyama E, 1997, GLYCOBIOLOGY, V7, P719, DOI 10.1093/glycob/7.5.719; Tiedemann K, 2001, ARCH BIOCHEM BIOPHYS, V391, P65, DOI 10.1006/abbi.2001.2376; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200; Yamada S, 1998, EUR J BIOCHEM, V258, P775, DOI 10.1046/j.1432-1327.1998.2580775.x; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yamauchi S, 1999, J BIOL CHEM, V274, P2456, DOI 10.1074/jbc.274.4.2456; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	64	90	96	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36115	36127		10.1074/jbc.M306044200	http://dx.doi.org/10.1074/jbc.M306044200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847091	hybrid			2022-12-25	WOS:000185318300032
J	Murakami, E; Feng, JY; Lee, H; Hanes, J; Johnson, KA; Anderson, KS				Murakami, E; Feng, JY; Lee, H; Hanes, J; Johnson, KA; Anderson, KS			Characterization of novel reverse transcriptase and other RNA-associated catalytic activities by human DNA polymerase gamma - Importance in mitochondrial DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY SUBUNIT; R-LOOP; FIDELITY; PROCESSIVITY; MAINTENANCE; INITIATION; MECHANISM; TOXICITY; CLEAVES; ORIGIN	During mitochondrial DNA ( mtDNA) replication, DNA/RNA heteroduplex intermediates are formed. To understand how and why ribonucleotides are involved in mtDNA replication, we have studied the novel RNA-associated activities of human mitochondrial DNA polymerase (Pol gamma), including reverse transcription, RNA-directed 3' --> 5' DNA excision, RNA-primed DNA synthesis, and ribonucleotide incorporation. Remarkably, Pol gamma catalyzes reverse transcription with a slightly higher efficiency than HIV-1 reverse transcriptase, suggesting that the activity may be physiologically significant, and furthermore, proofreading activity with an RNA template was also observed. RNA-primed DNA synthesis activity is required for initiation of mtDNA replication, and we have found that Pol gamma holoenzyme is capable of performing this reaction at a physiologically relevant rate and that the accessory subunit plays an essential role in the initiation steps. Single ribonucleotides have been found scattered in the mtDNA genome, although their role and significance are not yet defined. Our finding that Pol gamma also incorporates ribonucleotide triphosphates into a DNA primer offers a plausible enzymatic pathway for the origin of the RNA-containing mtDNA genome.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	Yale University; University of Texas System; University of Texas Austin	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	karen.anderson@yale.edu			NIGMS NIH HHS [GM 044613, GM 49551] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049551, R01GM044613] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257; Carrodeguas JA, 2002, J BIOL CHEM, V277, P50008, DOI 10.1074/jbc.M207030200; Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039; Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Fan L, 1999, P NATL ACAD SCI USA, V96, P9527, DOI 10.1073/pnas.96.17.9527; Fan L, 2001, BIOCHEMISTRY-US, V40, P4780, DOI 10.1021/bi010102h; Feng JY, 2001, J BIOL CHEM, V276, P23832, DOI 10.1074/jbc.M101156200; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; GALLO RC, 1970, NATURE, V228, P927, DOI 10.1038/228927a0; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1; Iyengar B, 2002, P NATL ACAD SCI USA, V99, P4483, DOI 10.1073/pnas.072664899; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38097; Johnson AA, 2001, J BIOL CHEM, V276, P38090; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14056, DOI 10.1021/bi971385+; Lee DY, 1998, J BIOL CHEM, V273, P30614, DOI 10.1074/jbc.273.46.30614; Lee DY, 1997, GENE DEV, V11, P582, DOI 10.1101/gad.11.5.582; Lewis W, 2001, LAB INVEST, V81, P777, DOI 10.1038/labinvest.3780288; Pinz KG, 2000, J BIOL CHEM, V275, P12509, DOI 10.1074/jbc.275.17.12509; RICCHETTI M, 1993, EMBO J, V12, P387, DOI 10.1002/j.1460-2075.1993.tb05670.x; ROBERTGUROFF M, 1977, BIOCHEMISTRY-US, V16, P2866, DOI 10.1021/bi00632a010; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; WONG TW, 1985, CELL, V42, P951, DOI 10.1016/0092-8674(85)90291-0; Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9	30	38	39	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36403	36409		10.1074/jbc.M306236200	http://dx.doi.org/10.1074/jbc.M306236200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857740	hybrid			2022-12-25	WOS:000185318300068
J	Nyunoya, T; Powers, LS; Yarovinsky, TO; Butler, NS; Monick, MM; Hunninghake, GW				Nyunoya, T; Powers, LS; Yarovinsky, TO; Butler, NS; Monick, MM; Hunninghake, GW			Hyperoxia induces macrophage cell cycle arrest by adhesion-dependent induction of p21(Cip1) and activation of the retinoblastoma protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH ARREST; EPITHELIAL-CELLS; ALVEOLAR MACROPHAGES; OXIDATIVE STRESS; CDK INHIBITORS; LUNG INJURY; DNA-DAMAGE; KINASE; EXPRESSION; P21(WAF1/CIP1)	Hyperoxia induces growth arrest, apoptosis, necrosis, and morphological changes (spreading and adhesion) in various types of cells. The mechanism of hyperoxia-induced cell growth arrest has not been well elucidated, especially in macrophages. One possible mechanism is a role of cell adhesion in hyperoxia-induced cell cycle arrest. To evaluate this finding, macrophages were cultured in normoxia (21% O-2) or hyperoxia (95% O-2) in adhesion or low adhesion conditions. Incubation of macrophages in hyperoxia induced cell cycle arrest. The hyperoxia-induced cell cycle arrest was prevented by low adhesion conditions. To evaluate pathways potentially involved in hyperoxia-induced growth arrest, we measured extracellular regulated kinase and retinoblastoma protein activation and p21(Cip1) and p53 accumulation. Hyperoxia strongly induced activation of extracellular regulated kinase and retinoblastoma protein as well as up-regulation of p21(Cip1). These effects of hyperoxia were attenuated under low adhesion conditions, suggesting a role for integrin-dependent signaling. The induction of p21(Cip1) and activation of retinoblastoma protein occurred via a p53-independent mechanism. These results suggest that adhesion-dependent pathways are required for hyperoxia-induced cell cycle arrest in macrophages.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Div Pulm Crit Care & Occupat Med, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Nyunoya, T (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Div Pulm Crit Care & Occupat Med, 100 Ekstein Med Res Bldg, Iowa City, IA 52242 USA.	toru-nyunoya@uiowa.edu	NYUNOYA, TORU/AAX-1482-2021	NYUNOYA, TORU/0000-0002-0688-4607; Butler, Noah/0000-0002-1429-0796	NCRR NIH HHS [RR00059] Funding Source: Medline; NHLBI NIH HHS [HL-60316] Funding Source: Medline; NIEHS NIH HHS [ES-09607] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000059] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009607] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bai FL, 1998, FEBS LETT, V437, P61, DOI 10.1016/S0014-5793(98)01198-3; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BOWLES AL, 1979, AM REV RESPIR DIS, V120, P541; CACCIUTTOLO MA, 1993, FREE RADICAL BIO MED, V14, P267, DOI 10.1016/0891-5849(93)90023-N; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; COALSON JJ, 1989, J APPL PHYSIOL, V67, P346, DOI 10.1152/jappl.1989.67.1.346; Corroyer S, 1997, ENDOCRINOLOGY, V138, P3677, DOI 10.1210/en.138.9.3677; Corroyer S, 1996, J BIOL CHEM, V271, P25117, DOI 10.1074/jbc.271.41.25117; DAVIS WB, 1983, NEW ENGL J MED, V309, P878, DOI 10.1056/NEJM198310133091502; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Desmarquest P, 1998, RESP MED, V92, P951, DOI 10.1016/S0954-6111(98)90195-0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Helt CE, 2001, TOXICOL SCI, V63, P214, DOI 10.1093/toxsci/63.2.214; JUNOD AF, 1987, J APPL PHYSIOL, V62, P10, DOI 10.1152/jappl.1987.62.1.10; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li YC, 1997, J BIOL CHEM, V272, P20646, DOI 10.1074/jbc.272.33.20646; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARTIN WJ, 1989, J LAB CLIN MED, V113, P413; Marwick JA, 2002, ANN NY ACAD SCI, V973, P278, DOI 10.1111/j.1749-6632.2002.tb04649.x; McGrath SA, 1998, AM J RESP CELL MOL, V18, P179, DOI 10.1165/ajrcmb.18.2.2964m; Monick MM, 2002, AM J PHYSIOL-LUNG C, V283, pL390, DOI 10.1152/ajplung.00437.2001; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NERURKAR LS, 1988, ANN ALLERGY, V61, P344; O'Reilly MA, 1998, AM J RESP CELL MOL, V19, P777, DOI 10.1165/ajrcmb.19.5.3200; O'Reilly MA, 2003, AM J PHYSIOL-LUNG C, V284, pL368, DOI 10.1152/ajplung.00299.2002; O'Reilly MA, 2001, AM J RESP CELL MOL, V24, P703, DOI 10.1165/ajrcmb.24.6.4355; O'Reilly PJ, 2003, AM J RESP CELL MOL, V28, P443, DOI 10.1165/rcmb.2002-0153OC; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Petrache I, 1999, AM J PHYSIOL-LUNG C, V277, pL589, DOI 10.1152/ajplung.1999.277.3.L589; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Rancourt RC, 2002, J CELL PHYSIOL, V193, P26, DOI 10.1002/jcp.10146; Rancourt RC, 2001, AM J PHYSIOL-LUNG C, V280, pL617, DOI 10.1152/ajplung.2001.280.4.L617; SCHOONEN WGEJ, 1990, MUTAT RES, V237, P173; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shenberger JS, 1999, AM J RESP CELL MOL, V21, P395, DOI 10.1165/ajrcmb.21.3.3604; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SUTTORP N, 1983, AM REV RESPIR DIS, V128, P486, DOI 10.1164/arrd.1983.128.3.486; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xue LZ, 2000, J BIOL CHEM, V275, P8817, DOI 10.1074/jbc.275.12.8817; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	54	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36099	36106		10.1074/jbc.M304370200	http://dx.doi.org/10.1074/jbc.M304370200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847100	hybrid			2022-12-25	WOS:000185318300030
J	Yun, JH; Chae, HD; Choi, TS; Kim, EH; Bang, YJ; Chung, JK; Choi, KS; Mantovani, R; Shin, DY				Yun, JH; Chae, HD; Choi, TS; Kim, EH; Bang, YJ; Chung, JK; Choi, KS; Mantovani, R; Shin, DY			Cdk2-dependent phosphorylation of the NF-Y transcription factor and its involvement in the p53-p21 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CCAAT-BINDING PROTEIN; CELL-CYCLE; MACROPHAGE DIFFERENTIATION; IN-VIVO; COMPLEX; CDC2; P53; REPRESSION; GENE	Recent studies have suggested that the NF-Y transcription factor is involved in transcription repression of the cell cycle regulatory genes in a response to p53 induction or DNA damage. Here we demonstrate the cdk2-dependent phosphorylation of NF-Y and its involvement in transcription repression by the p53-p21 signaling pathway. Cdk2 phosphorylates two serine residues near the DNA-binding domain of the YA subunit of NF-Y. Cyclin A-cdk2 appears to associate with NF-Y both in vitro and in vivo. Furthermore, YA protein is phosphorylated in parallel with a cell cycle-dependent activation of cdk2 kinase and cyclin A expression. YA phosphorylation is unnecessary for heterotrimer formation with the YB-YC dimer. However, NF-Y containing a phosphorylation-deficient mutant form of YA, YA-aa, has its DNA binding activity impaired. Consistently, YA-aa inhibits transcription activation of a NF-Y target promoter, cdc2, by cdk2. These results facilitate the elucidation of the regulatory mechanisms of cell cycle progression involving the p21-cdk2-NF-Y signaling pathway.	Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab, Cheonan 330714, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305333, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110799, South Korea; Ajou Univ, Coll Med, Inst Med Sci, Suwon 442749, South Korea; Univ Modena & Reggio Emilia, Dipartimento Biol Anim, I-41100 Modena, Italy	Dankook University; Korea Advanced Institute of Science & Technology (KAIST); Seoul National University (SNU); Ajou University; Universita di Modena e Reggio Emilia	Shin, DY (corresponding author), Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab, Cheonan 330714, South Korea.	dreamer@dku.edu	Chae, Hee-Don/D-2620-2011; Kim, Eunhee/Q-9162-2016; Bang, Yung Jue/J-2759-2012; Kim, Eunhee/AAK-3650-2020	Kim, Eunhee/0000-0001-7143-7769; Bang, Yung Jue/0000-0001-6000-4597; Choi, Kyeong Sook/0000-0003-2331-0856				BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Currie RA, 1998, J BIOL CHEM, V273, P18220, DOI 10.1074/jbc.273.29.18220; de Borja PF, 2001, EMBO J, V20, P5737; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Dieffenbach C.W., 1995, PCR PRIMER LAB MANUA; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; LI XY, 1992, J BIOL CHEM, V267, P8984; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Marziali G, 1999, BLOOD, V93, P519, DOI 10.1182/blood.V93.2.519.402a01_519_526; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; PANG JH, 1993, J BIOL CHEM, V268, P2909; Park M, 2000, CANCER RES, V60, P542; PARK SP, 2001, CANC RES TREAT, V33, P236; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sinha S, 1996, MOL CELL BIOL, V16, P328; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	40	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36966	36972		10.1074/jbc.M305178200	http://dx.doi.org/10.1074/jbc.M305178200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857729	hybrid, Green Published			2022-12-25	WOS:000185318300131
J	Kwok, SC; Hodges, RS				Kwok, SC; Hodges, RS			Clustering of large hydrophobes in the hydrophobic core of two-stranded alpha-helical coiled-coils controls protein folding and stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; SIDE-CHAIN PACKING; DE-NOVO DESIGN; OLIGOMERIZATION STATE; HEAT-CAPACITY; LEUCINE-ZIPPER; REVERSED-PHASE; TROPOMYOSIN; SEQUENCE; MODEL	The de novo design and biophysical characterization of two 60-residue peptides that dimerize to fold as parallel coiled-coils with different hydrophobic core clustering is described. Our goal was to investigate whether designing coiled-coils with identical hydrophobicity but with different hydrophobic clustering of non-polar core residues ( each contained 6 Leu, 3 Ile, and 7 Ala residues in the hydrophobic core) would affect helical content and protein stability. The disulfide-bridged P3 and P2 differed dramatically in alpha-helical structure in benign conditions. P3 with three hydrophobic clusters was 98% alpha-helical, whereas P2 was only 65% alpha-helical. The stability profiles of these two analogs were compared, and the enthalpy and heat capacity changes upon denaturation were determined by measuring the temperature dependence by circular dichroism spectroscopy and confirmed by differential scanning calorimetry. The results showed that P3 assembled into a stable alpha-helical two-stranded coiled-coil and exhibited a native protein-like cooperative two-state transition in thermal melting, chemical denaturation, and calorimetry experiments. Although both peptides have identical inherent hydrophobicity ( the hydrophobic burial of identical non-polar residues in equivalent heptad coiled-coil positions), we found that the context dependence of an additional hydrophobic cluster dramatically increased stability of P3 (DeltaT(m) approximate to 18 degreesC and Delta[urea](1/2) approximate to 1.5 M) as compared with P2. These results suggested that hydrophobic clustering significantly stabilized the coiled-coil structure and may explain how long fibrous proteins like tropomyosin maintain chain integrity while accommodating polar or charged residues in regions of the protein hydrophobic core.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Alberta	Hodges, RS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.				NIGMS NIH HHS [R01GM 61855] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061855] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Araya E, 2002, J STRUCT BIOL, V137, P176, DOI 10.1006/jsbi.2002.4463; Betz SF, 1997, BIOCHEMISTRY-US, V36, P2450, DOI 10.1021/bi961704h; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chana M, 2002, J STRUCT BIOL, V137, P206, DOI 10.1006/jsbi.2002.4446; Colon W, 1996, BIOCHEMISTRY-US, V35, P5538, DOI 10.1021/bi960052u; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; Dill KA, 1999, PROTEIN SCI, V8, P1166, DOI 10.1110/ps.8.6.1166; Durr E, 2000, BIOCHEMISTRY-US, V39, P4472, DOI 10.1021/bi992948f; Gee M, 1998, EUR BIOPHYS J BIOPHY, V27, P466, DOI 10.1007/s002490050157; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GOMEZ J, 1995, PROTEINS, V22, P404, DOI 10.1002/prot.340220410; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P1011, DOI 10.1038/nsb1296-1011; HODGES R S, 1990, Peptide Research, V3, P123; HODGES R S, 1988, Peptide Research, V1, P19; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; Kohn WD, 1997, J MOL BIOL, V267, P1039, DOI 10.1006/jmbi.1997.0930; Kwok SC, 2002, PROTEIN SCI, V11, P1519, DOI 10.1110/ps.4170102; LAU SYM, 1984, J CHROMATOGR, V317, P129, DOI 10.1016/S0021-9673(01)91653-X; LAVIGNE P, 1995, J MOL BIOL, V254, P505, DOI 10.1006/jmbi.1995.0634; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Mant CT, 1997, METHOD ENZYMOL, V289, P426; McClain DL, 2001, J MOL BIOL, V313, P371, DOI 10.1006/jmbi.2001.5044; Merrifield B, 1997, METHOD ENZYMOL, V289, P3; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Pace C N, 1986, Methods Enzymol, V131, P266; Privalov P L, 1986, Methods Enzymol, V131, P4; PRIVALOV PL, 1990, J MOL BIOL, V213, P385, DOI 10.1016/S0022-2836(05)80198-6; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SEREDA TJ, 1993, J CHROMATOGR, V646, P17, DOI 10.1016/S0021-9673(99)87003-4; SHORTLE D, 1989, J BIOL CHEM, V264, P5315; Shortle D, 2001, SCIENCE, V293, P487, DOI 10.1126/science.1060438; SODEK J, 1972, P NATL ACAD SCI USA, V69, P3800, DOI 10.1073/pnas.69.12.3800; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; Sosnick TR, 1996, PROTEINS, V24, P427; Suarez MC, 2001, BIOCHEMISTRY-US, V40, P1300, DOI 10.1021/bi0020978; THOMASIN AS, 2002, J STRUCT BIOL, V137, P128; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; Tripet B, 2002, J STRUCT BIOL, V137, P220, DOI 10.1006/jsbi.2002.4475; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; Vallee RB, 1998, TRENDS CELL BIOL, V8, P490, DOI 10.1016/S0962-8924(98)01379-8; Wagschal K, 1999, J MOL BIOL, V285, P785, DOI 10.1006/jmbi.1998.2284; Wagschal K, 1999, PROTEIN SCI, V8, P2312; XIE D, 1994, J MOL BIOL, V242, P62, DOI 10.1006/jmbi.1994.1557; Yao J, 2001, BIOCHEMISTRY-US, V40, P3561, DOI 10.1021/bi002776i; ZHOU NE, 1993, BIOCHEMISTRY-US, V32, P6190, DOI 10.1021/bi00075a011; ZHOU NE, 1992, BIOPOLYMERS, V32, P419, DOI 10.1002/bip.360320419	51	43	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35248	35254		10.1074/jbc.M305306200	http://dx.doi.org/10.1074/jbc.M305306200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842878	hybrid			2022-12-25	WOS:000185164400062
J	Schmechel, A; Zentgraf, H; Scheuermann, S; Fritz, G; Pipkorn, RD; Reed, J; Beyreuther, K; Bayer, TA; Multhaup, G				Schmechel, A; Zentgraf, H; Scheuermann, S; Fritz, G; Pipkorn, RD; Reed, J; Beyreuther, K; Bayer, TA; Multhaup, G			Alzheimer beta-amyloid homodimers facilitate A beta fibrillization and the generation of conformational antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN; SECONDARY STRUCTURE; SENILE PLAQUES; IN-VITRO; DISEASE; FIBRILS; PEPTIDE; DIMER; OLIGOMERS; MODEL	We reported previously that stabilized beta-amyloid peptide dimers were derived from mutant amyloid precursor protein with a single cysteine in the ectodomain juxtamembrane position. In vivo studies revealed that two forms of SDS-stable Abeta homodimers exist, species ending at Abeta40 and Abeta42. The phenomenon of the transformation of the initially deposited 42-residue beta-amyloid peptide into the amyloid fibrils of Alzheimer's disease plaques remains to be explained in physical terms, i.e. energetically and structurally. We therefore performed spectroscopic analyses revealing that engineered dimeric peptides ending at residue 42 displayed a much more pronounced beta-structural transition than corresponding monomers. Specifically, the single chemically induced dimerization of Abeta peptides significantly increased the beta-sheet content by a factor of 2. The C-terminal residues Ile-41 and Ala-42 of dimeric forms further increased the beta-sheet content by roughly one-third. In contrast to Abeta42, the beta-sheet content of the alpha- and gamma-secretase-generated p3 fragments did not necessarily correlate with the tendency to form fibrils, although p3/17-42 had a pronounced thread forming character with fibril lengths of up to 2.5 mum. Electron microscopic images show that forms of p3/17-42 generated smaller granular particles than forms ending at residue 40. We discuss these findings in terms of Abeta1-42 dimers representing paranuclei, which self-aggregate into ribbon-like ordered fibrils by elongation. Based on Abeta42 dimer-specific titers of a polyclonal antiserum we propose that the Abeta homodimer represents a nidus for plaque formation and a well defined novel therapeutic target.	Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany; Heidelberg Univ, Ctr Mol Biol, ZMBH, D-69120 Heidelberg, Germany; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Univ Saarland, Med Ctr, Dept Psychiat, Div Neurobiol, D-66421 Homburg, Germany	Free University of Berlin; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Zurich; Saarland University	Multhaup, G (corresponding author), Free Univ Berlin, Inst Chem Biochem, Thielallee 63, D-14195 Berlin, Germany.	multhaup@chemie.fu-berlin.de	Fritz, Guenter/E-2933-2013	Fritz, Guenter/0000-0002-4571-8812				Antzutkin ON, 2002, BIOCHEMISTRY-US, V41, P15436, DOI 10.1021/bi0204185; Benzinger TLS, 2000, BIOCHEMISTRY-US, V39, P3491, DOI 10.1021/bi991527v; Benzinger TLS, 1998, P NATL ACAD SCI USA, V95, P13407, DOI 10.1073/pnas.95.23.13407; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Enya M, 1999, AM J PATHOL, V154, P271, DOI 10.1016/S0002-9440(10)65273-X; Garzon-Rodriguez W, 2000, J BIOL CHEM, V275, P22645, DOI 10.1074/jbc.M000756200; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Haass C, 1996, EUR ARCH PSY CLIN N, V246, P118, DOI 10.1007/BF02189111; HAASS M, 1992, N-S ARCH PHARMACOL, V346, P410; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Iwata K, 2001, J AM CHEM SOC, V123, P6728, DOI 10.1021/ja015735y; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kuo YM, 1998, BBA-MOL BASIS DIS, V1406, P291, DOI 10.1016/S0925-4439(98)00014-3; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Li LP, 1999, BIOPHYS J, V76, P2871, DOI 10.1016/S0006-3495(99)77442-4; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; Ma BY, 2002, P NATL ACAD SCI USA, V99, P14126, DOI 10.1073/pnas.212206899; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NASLUND J, 1994, BIOCHEM BIOPH RES CO, V204, P780, DOI 10.1006/bbrc.1994.2527; Nichols MR, 2002, BIOCHEMISTRY-US, V41, P6115, DOI 10.1021/bi015985r; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; Reed J, 1997, ANAL BIOCHEM, V254, P36, DOI 10.1006/abio.1997.2355; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIEBERT F, 1995, METHOD ENZYMOL, V246, P501; Simons A, 2002, BIOCHEMISTRY-US, V41, P9310, DOI 10.1021/bi0258647; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Town T, 2001, NEUROSCI LETT, V307, P101, DOI 10.1016/S0304-3940(01)01951-6; Van Nostrand WE, 2002, J BIOL CHEM, V277, P36392, DOI 10.1074/jbc.M204676200; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wei WL, 2002, BRAIN, V125, P2036, DOI 10.1093/brain/awf205; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208	44	65	69	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35317	35324		10.1074/jbc.M303547200	http://dx.doi.org/10.1074/jbc.M303547200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12840025	hybrid			2022-12-25	WOS:000185164400071
J	Castro, AF; Rebhun, JF; Clark, GJ; Quilliam, LA				Castro, AF; Rebhun, JF; Clark, GJ; Quilliam, LA			Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; TUMOR-SUPPRESSOR PROTEINS; TUBEROUS-SCLEROSIS; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; CELL-GROWTH; FARNESYLTRANSFERASE INHIBITORS; SCHIZOSACCHAROMYCES-POMBE; 3-KINASE/AKT PATHWAY; FISSION YEAST; GENE-PRODUCT	Recently the tuberous sclerosis complex 2 (TSC2) tumor suppressor gene product has been identified as a negative regulator of protein synthesis upstream of the mTOR and ribosomal S6 kinases. Because of the homology of TSC2 with GTPase-activating proteins for Rap1, we examined whether a Ras/Rap-related GTPase might be involved in this process. TSC2 was found to bind to Rheb-GTP in vitro and to reduce Rheb GTP levels in vivo. Over-expression of Rheb but not Rap1 promoted the activation of S6 kinase in a rapamycin-dependent manner, suggesting that Rheb acts upstream of mTOR. The ability of Rheb to induce S6 phosphorylation was also inhibited by a farnesyl transferase inhibitor, suggesting that Rheb may be responsible for the Ras-independent anti-neoplastic properties of this drug.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; NCI, Dept Cell & Canc Biol, NIH, Rockville, MD 20850 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Castro, AF (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 35 barnhill Dr,MS-4053, Indianapolis, IN 46202 USA.	acastro@iupui.edu	Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019; Rebhun, John F/H-7235-2019	Rebhun, John F/0000-0002-0764-5210				Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471-4892(02)00181-9; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Dasgupta B, 2003, CURR OPIN GENET DEV, V13, P20, DOI 10.1016/S0959-437X(02)00015-1; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Gutmann D H, 1998, Semin Pediatr Neurol, V5, P276, DOI 10.1016/S1071-9091(98)80006-5; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Law BK, 2000, J BIOL CHEM, V275, P10796, DOI 10.1074/jbc.275.15.10796; Mach KE, 2000, GENETICS, V155, P611; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Matsumoto S, 2002, GENETICS, V161, P1053; Momose S, 2002, HUM MOL GENET, V11, P2997, DOI 10.1093/hmg/11.24.2997; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Prendergast GC, 2001, EXPERT OPIN INV DRUG, V10, P2105, DOI 10.1517/13543784.10.12.2105; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sato T, 2002, J HUM GENET, V47, P20, DOI 10.1007/s10038-002-8651-8; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Sullivan EJ, 1998, CHEST, V114, P1689, DOI 10.1378/chest.114.6.1689; Tamanoi F, 2001, J CELL BIOCHEM, V84, P64, DOI 10.1002/jcb.10067; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Yang WL, 2001, MOL MICROBIOL, V41, P1339, DOI 10.1046/j.1365-2958.2001.02599.x; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	45	292	300	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32493	32496		10.1074/jbc.C300226200	http://dx.doi.org/10.1074/jbc.C300226200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12842888	hybrid			2022-12-25	WOS:000184901800003
J	Sreenivasan, Y; Sarkar, A; Manna, SK				Sreenivasan, Y; Sarkar, A; Manna, SK			Mechanism of cytosine arabinoside-mediated apoptosis: role of Rel A (p65) dephosphorylation	ONCOGENE			English	Article						NF-kappa B; araC; apoptosis; phosphatase; p65	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; MYELOID-LEUKEMIA CELLS; TNF-INDUCED ACTIVATION; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CONSTITUTIVE ACTIVATION; MULTIDRUG-RESISTANCE; LIPID-PEROXIDATION	Nuclear transcription factor kappa B (NF-kappaB) has been shown both to block apoptosis and to promote cell proliferation, and hence has been considered an important target for anticancer drug development. The pyrimidine analogue cytosine arabinoside (araC) is among the most effective agents used in the treatment of acute leukemia, and we demonstrate in this study that its chemotherapeutic activity may be mediated by its inhibition of NF-kappaB. We found that in Jurkat cells, although tumor necrosis factor (TNF), araC, or ceramide induced NF-kappaB, the induction was only transient in the case of araC. In both HuT-78 and serum-activated LPS-stimulated Jurkat (SA-LPS/Jkt) cells that expressed NF-kappaB, TNF or ceramide treatments did not affect the NF-kappaB expression whereas araC downregulated it. AraC, but not TNF or ceramide was able to induce apoptosis in these cells as detected by assays for lipid peroxidation, reactive oxygen intermediates generation, caspase activation, cytotoxicity, Bcl-2 degradation, and DNA fragmentation. AraC also potentiated apoptosis mediated by cis-platin, etoposide, or taxol in these cells. AraC was able to induce protein phosphatases (PP) 2A and 2B-A, and phosphorylation of p65 subunit of NF-kappaB in the HuT-78 and SA-LPS/Jkt cells was downregulated by araC treatment. Furthermore, calyculin A, a specific phospho-serine/phospho-threonine phosphatase inhibitor, protected HuT-78 and SA-LPS/Jkt cells from araC-mediated NF-kappaB downregulation and apoptosis. These observations collectively suggest that araC induces apoptosis in NF-kappaB-expressing cells by dephosphorylating the p65 subunit of NF-kappaB.	Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD)	Manna, SK (corresponding author), Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India.	manna@www.cdfd.org.in						Badrichani AZ, 1999, J CLIN INVEST, V103, P543, DOI 10.1172/JCI2517; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELLAMY WT, 1994, ADV CLIN CHEM, V31, P1, DOI 10.1016/S0065-2423(08)60332-7; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; BRACH MA, 1992, BLOOD, V79, P728; BRACH MA, 1992, MOL PHARMACOL, V41, P60; Braess J, 1999, BRIT J HAEMATOL, V105, P388, DOI 10.1111/j.1365-2141.1999.01338.x; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DOU QP, 1995, CANCER RES, V55, P5222; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; HARRISON DJ, 1995, J PATHOL, V175, P7, DOI 10.1002/path.1711750103; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Izban KF, 2000, HUM PATHOL, V31, P1482, DOI 10.1053/hupa.2000.20370; Jarvis WD, 1998, MOL PHARMACOL, V54, P844, DOI 10.1124/mol.54.5.844; KHARBANDA S, 1994, MOL PHARMACOL, V46, P67; Kochetkova M, 1997, J CLIN INVEST, V99, P3000, DOI 10.1172/JCI119495; Lee JI, 1998, J CLIN PHARMACOL, V38, P981, DOI 10.1177/009127009803801101; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, J IMMUNOL, V162, P1510; Manna SK, 1999, J IMMUNOL, V163, P6800; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nutku E, 2001, J IMMUNOL, V167, P1039, DOI 10.4049/jimmunol.167.2.1039; Perez C, 1997, J CELL SCI, V110, P337; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Rajkumar SV, 2002, J CLIN ONCOL, V20, P4319, DOI 10.1200/JCO.2002.02.116; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SUGANUMA M, 1990, CANCER RES, V50, P3521; Terada R, 2002, HEPATO-GASTROENTEROL, V49, P1545; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; VAN AD, 1996, SCIENCE, V274, P787; Waddick KG, 1999, BIOCHEM PHARMACOL, V57, P9, DOI 10.1016/S0006-2952(98)00224-X; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang RH, 2001, ONCOGENE, V20, P6111, DOI 10.1038/sj.onc.1204829	52	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4356	4369		10.1038/sj.onc.1206486	http://dx.doi.org/10.1038/sj.onc.1206486			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853972				2022-12-25	WOS:000183978900005
J	Matushansky, I; Radparvar, F; Skoultchi, AI				Matushansky, I; Radparvar, F; Skoultchi, AI			CDK6 blocks differentiation: coupling cell proliferation to the block to differentiation in leukemic cells	ONCOGENE			English	Article						cyclin-dependent kinase 6; PU. 1; erythroleukemia; proliferation; differentiation	CYCLIN-DEPENDENT KINASE-6; PU.1 TRANSCRIPTION FACTOR; ERYTHROLEUKEMIA-CELLS; ERYTHROID-DIFFERENTIATION; TERMINAL DIFFERENTIATION; FRIEND-ERYTHROLEUKEMIA; EXPRESSION; GENE; DISRUPTION; REGULATORS	Cell proliferation and differentiation are highly coordinated during normal development. Many tumor cells exhibit both uncontrolled proliferation and a block to terminal differentiation. To understand the mechanisms coordinating these two processes, we have investigated the relation between cyclin-dependent kinase (CDK) activities and the block to differentiation in murine erythroleukemia (MEL) cells. We found that CDK6 (but not CDK4) is rapidly downregulated as MEL cells are induced to re-enter erythroid differentiation and that maintenance of CDK6 (but not CDK4) activity by transfection blocks differentiation. Moreover, we found that PU.1, an Ets transcription factor that is oncogenic in erythroid cells and also can block their differentiation, controls the synthesis of CDK6 mRNA. These results suggest a mechanism for coupling proliferation and the block to differentiation in these leukemic cells through the action of an oncogenic transcription factor (PU.1) on a key cell cycle regulator (CDK6). Our findings suggest that studying the relative roles of CDK6 and CDK4 in other types of malignant cells will be important in designing approaches for cell cycle inhibition and differentiation therapy in cancer.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Skoultchi, AI (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	skoultch@aecom.yu.edu			NATIONAL CANCER INSTITUTE [R37CA016368, P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000194] Funding Source: NIH RePORTER; NCI NIH HHS [5R37CA16368, 2P30CA13330] Funding Source: Medline; NIA NIH HHS [5T32AG00194] Funding Source: Medline; NIGMS NIH HHS [5T32GM07288-25] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chilosi M, 1998, AM J PATHOL, V152, P209; Corcoran MM, 1999, ONCOGENE, V18, P6271, DOI 10.1038/sj.onc.1203033; Costello JF, 1997, CANCER RES, V57, P1250; DellaRagione F, 1997, BIOCHEM BIOPH RES CO, V231, P73, DOI 10.1006/bbrc.1997.5938; Easton J, 1998, CANCER RES, V58, P2624; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; LEVENSON R, 1979, J CELL BIOL, V82, P715, DOI 10.1083/jcb.82.3.715; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MARKS PA, 1987, ANN NY ACAD SCI, V511, P246, DOI 10.1111/j.1749-6632.1987.tb36252.x; Matushansky I, 2000, BLOOD, V96, P2755, DOI 10.1182/blood.V96.8.2755.h8002755_2755_2764; Matushansky I, 2000, P NATL ACAD SCI USA, V97, P14317, DOI 10.1073/pnas.250488697; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rifkind RA, 1996, PHARMACOL THERAPEUT, V69, P97, DOI 10.1016/0163-7258(95)02044-6; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Senderowicz AM, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	34	70	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4143	4149		10.1038/sj.onc.1206484	http://dx.doi.org/10.1038/sj.onc.1206484			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833137				2022-12-25	WOS:000183979800001
J	Bose, S; French, S; Evans, FJ; Joubert, F; Balaban, RS				Bose, S; French, S; Evans, FJ; Joubert, F; Balaban, RS			Metabolic network control of oxidative phosphorylation - Multiple roles of inorganic phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREATINE-KINASE; MITOCHONDRIAL RESPIRATION; MATHEMATICAL-MODEL; OXYGEN-CONSUMPTION; ENERGY-METABOLISM; ISOLATED HEART; RABBIT HEARTS; DEHYDROGENASE; HEMOGLOBIN; TRANSPORT	Phosphate (P-i) is a putative cytosolic signaling molecule in the regulation of oxidative phosphorylation. Here, by using a multiparameter monitoring system, we show that P-i controls oxidative phosphorylation in a balanced fashion, modulating both the generation of useful potential energy and the formation of ATP by F1F0-ATPase in heart and skeletal muscle mitochondria. In these studies the effect of P-i was determined on the mitochondria [NADH], NADH generating capacity, matrix pH, membrane potential, oxygen consumption, and cytochrome reduction level. P-i enhanced NADH generation and was obligatory for electron flow under uncoupled conditions. P-i oxidized cytochrome b (cyto-b) and reduced cytochrome c (cyto-c), potentially improving the coupling between the NADH free energy and the proton motive force. The apparent limitation in reducing equivalent flow between cyto-b and cyto-c in the absence of P-i was confirmed in the intact heart by using optical spectroscopic techniques under conditions with low cytosolic [P-i]. These results demonstrate that P-i signaling results in the balanced modulation of oxidative phosphorylation, by influencing both DeltaG(H+) generation and ATP production, which may contribute to the energy metabolism homeostasis observed in intact systems.	NHLBI, Cardiac Energet Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Balaban, RS (corresponding author), NHLBI, Cardiac Energet Lab, NIH, Dept Hlth & Human Serv, Bldg 10,Rm BID-161, Bethesda, MD 20892 USA.		Balaban, Robert S/A-7459-2009	Balaban, Robert S/0000-0003-4086-0948; Joubert, Frederic/0000-0003-0239-1052	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004601, Z01HL004601] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aliev MK, 1998, MOL CELL BIOCHEM, V184, P209, DOI 10.1023/A:1006871903596; AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; Balaban RS, 1996, ANAL BIOCHEM, V237, P274, DOI 10.1006/abio.1996.0239; BALABAN RS, 1980, AM J PHYSIOL, V238, pF50, DOI 10.1152/ajprenal.1980.238.1.F50; BALABAN RS, 1990, AM J PHYSIOL, V258, pC377, DOI 10.1152/ajpcell.1990.258.3.C377; Balaban RS, 2002, J MOL CELL CARDIOL, V34, P1259, DOI 10.1006/jmcc.2002.2082; BALABAN RS, 1986, SCIENCE, V232, P1121, DOI 10.1126/science.3704638; BAYSAL K, 1991, ARCH BIOCHEM BIOPHYS, V291, P383, DOI 10.1016/0003-9861(91)90150-H; BLONDE DJ, 1967, CAN J BIOCHEM CELL B, V45, P641, DOI 10.1139/o67-075; BRAND MD, 1995, BIOCHEM SOC T, V23, P371, DOI 10.1042/bst0230371; BROWN GC, 1992, BIOCHEM J, V284, P1; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHANCE B, 1981, P NATL ACAD SCI-BIOL, V78, P6714, DOI 10.1073/pnas.78.11.6714; Combs CA, 2001, BIOPHYS J, V80, P2018, DOI 10.1016/S0006-3495(01)76172-3; ERNSTER L, 1966, BIOCH MITOCHONDRIA, P29; French SA, 1998, AM J PHYSIOL-CELL PH, V275, pC900, DOI 10.1152/ajpcell.1998.275.3.C900; GARD JK, 1985, BIOPHYS J, V48, P803, DOI 10.1016/S0006-3495(85)83839-X; GARLICK PB, 1992, AM J PHYSIOL, V263, pH497, DOI 10.1152/ajpheart.1992.263.2.H497; GARLID KD, 1980, J BIOL CHEM, V255, P1273; GORMAN MW, 1992, CIRC RES, V70, P1146, DOI 10.1161/01.RES.70.6.1146; GUNTER TE, 1988, AM J PHYSIOL, V255, pC304, DOI 10.1152/ajpcell.1988.255.3.C304; HALESTRAP AP, 1994, BIOCHEM SOC T, V22, P522, DOI 10.1042/bst0220522; HANSFORD RG, 1968, BIOCHEM BIOPH RES CO, V30, P643, DOI 10.1016/0006-291X(68)90561-5; HANSFORD RG, 1972, BIOCHEM J, V127, P271, DOI 10.1042/bj1270271; HARPER ME, 1993, J BIOL CHEM, V268, P14850; HEINEMAN FW, 1992, AM J PHYSIOL, V262, pH255, DOI 10.1152/ajpheart.1992.262.1.H255; Hoffmann J, 1998, PHYS MED BIOL, V43, P3571, DOI 10.1088/0031-9155/43/12/014; IZZARD S, 1973, ARCH BIOCHEM BIOPHYS, V154, P527, DOI 10.1016/0003-9861(73)90005-2; IZZARD S, 1970, P NATL ACAD SCI USA, V67, P702, DOI 10.1073/pnas.67.2.702; JOUBERT FFH, 2004, IN PRESS BIOPHYS J; Jung DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1194, DOI 10.1152/ajpcell.1999.277.6.C1194; JUNG DW, 1990, BIOCHEMISTRY-US, V29, P4121, DOI 10.1021/bi00469a015; KATZ LA, 1989, AM J PHYSIOL, V256, pH265, DOI 10.1152/ajpheart.1989.256.1.H265; KATZ LA, 1988, AM J PHYSIOL, V255, pH189, DOI 10.1152/ajpheart.1988.255.1.H189; Kushnareva YE, 1999, ARCH BIOCHEM BIOPHYS, V363, P155, DOI 10.1006/abbi.1998.1039; LARDY HA, 1952, J BIOL CHEM, V195, P215; MEYER RA, 1984, AM J PHYSIOL, V242, P1; Rodriguez-Zavala JS, 2000, ARCH BIOCHEM BIOPHYS, V379, P78, DOI 10.1006/abbi.2000.1856; ROTTENBERG H, 1974, BIOCHEMISTRY-US, V13, P4811, DOI 10.1021/bi00720a020; SAKS VA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P134, DOI 10.1016/0005-2728(93)90166-D; Spindler M, 2002, AM J PHYSIOL-HEART C, V283, pH680, DOI 10.1152/ajpheart.00800.2001; TAGER JM, 1983, FEBS LETT, V151, P1, DOI 10.1016/0014-5793(83)80330-5; Territo PR, 2000, AM J PHYSIOL-CELL PH, V278, pC423, DOI 10.1152/ajpcell.2000.278.2.C423; Territo PR, 2000, ANAL BIOCHEM, V286, P156, DOI 10.1006/abio.2000.4774; Territo PR, 2001, J BIOL CHEM, V276, P2586, DOI 10.1074/jbc.M002923200; Vicini P, 2000, AM J PHYSIOL-CELL PH, V279, pC213, DOI 10.1152/ajpcell.2000.279.1.C213; WOHLRAB H, 1986, BIOCHIM BIOPHYS ACTA, V853, P115, DOI 10.1016/0304-4173(86)90007-8; ZHANG JY, 1995, AM J PHYSIOL-HEART C, V268, pH1891, DOI 10.1152/ajpheart.1995.268.5.H1891	48	172	172	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39155	39165		10.1074/jbc.M306409200	http://dx.doi.org/10.1074/jbc.M306409200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871940	hybrid			2022-12-25	WOS:000185575100129
J	Piontek, J; Brandt, R				Piontek, J; Brandt, R			Differential and regulated binding of cAMP-dependent protein kinase and protein kinase C isoenzymes to gravin in human model neurons - Evidence that gravin provides a dynamic platform for the localization of kinases during neuronal development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; SUBSTRATE; TAU; PHOSPHORYLATION; CELLS; MICROTUBULE; EXPRESSION; COMPLEXES; SCAFFOLD; SYSTEM	The membrane cortex has an important role in generating and maintaining spatially and functionally distinct domains in neurons. As a tool to functionally characterize molecules of the membrane cortex, we generated novel monoclonal antibodies against a fraction enriched for components of the neuronal membrane skeleton. We obtained two antibodies against the kinase-anchoring protein gravin. Gravin was strongly up-regulated during differentiation of human model neurons (NT2-N neurons) and was enriched at the inner peripheral cortex in close proximity to the plasma membrane where its localization primarily depended on association with membranes. In differentiated neurons, gravin colocalized in putative signaling complexes with protein kinase C (PKCbetaII) and partially with PKCalpha and cAMP-dependent protein kinase (PKA). Colocalization with PKCepsilon was not observed. PKCbetaII, PKCalpha, and PKA but not PKCepsilon coprecipitated with gravin indicating physical interaction. Binding of gravin to PKCalpha required the presence of Ca2+ and was increased after inhibition of PKC. In contrast, binding of PKCbetaII and PKA were independent of Ca2+ and PKC inhibition. Activation of PKC decreased binding of PKCalpha to gravin, decreased its association with the plasma membrane, and reduced the mean size of gravin particles. Taken together the data suggest that gravin provides a dynamic platform to localize kinases in an isoenzyme-specific and activation-dependent manner at specific sites in neurons.	Univ Osnabruck, Dept Neurobiol, D-49076 Osnabruck, Germany; Heidelberg Univ, IZN, Dept Neurobiol, INF 345, D-69120 Heidelberg, Germany	University Osnabruck; Ruprecht Karls University Heidelberg	Brandt, R (corresponding author), Univ Osnabruck, Dept Neurobiol, Barbarastr 11, D-49076 Osnabruck, Germany.	Brandt@biologie.uni-osnabrueck.de	Piontek, Joerg/F-8549-2011; Piontek, Joerg/K-6305-2013	Piontek, Joerg/0000-0002-0880-8915; Brandt, Roland/0000-0003-0101-1257				Audesirk G, 1997, DEV BRAIN RES, V102, P247, DOI 10.1016/S0165-3806(97)00100-4; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIEDLER JL, 1978, CANCER RES, V38, P3751; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; BRANDT R, 1993, J BIOL CHEM, V268, P3414; CABELL L, 1993, INT J DEV NEUROSCI, V11, P357, DOI 10.1016/0736-5748(93)90007-Z; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; Fan GF, 2001, J BIOL CHEM, V276, P24005, DOI 10.1074/jbc.M011199200; Faux MC, 1999, BIOCHEM J, V343, P443, DOI 10.1042/0264-6021:3430443; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Gelman IH, 1998, CELL MOTIL CYTOSKEL, V41, P1; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; GORDON T, 1992, J CLIN INVEST, V90, P992, DOI 10.1172/JCI115976; GROVE BD, 1994, ANAT REC, V239, P231, DOI 10.1002/ar.1092390302; Grove BD, 2001, J VASC RES, V38, P163, DOI 10.1159/000051043; Harlow E., 1988, ANTIBODIES LAB MANUA; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Kempf M, 1996, J NEUROSCI, V16, P5583; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Maas T, 2000, J BIOL CHEM, V275, P15733, DOI 10.1074/jbc.M000389200; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Nelson PJ, 1999, J CELL SCI, V112, P361; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Paterlini M, 1998, NEUROSCI LETT, V243, P77, DOI 10.1016/S0304-3940(98)00087-1; Piontek J, 1999, J NEUROCHEM, V73, P139, DOI 10.1046/j.1471-4159.1999.0730139.x; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; Sato N, 1998, J BIOCHEM-TOKYO, V123, P1119; Schneider S, 2001, J NEUROSCI, V21, P920, DOI 10.1523/JNEUROSCI.21-03-00920.2001; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Sinha P, 2001, PROTEOMICS, V1, P835, DOI 10.1002/1615-9861(200107)1:7<835::AID-PROT835>3.3.CO;2-U; WALAAS SI, 1991, PHARMACOL REV, V43, P299	42	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38970	38979		10.1074/jbc.M306749200	http://dx.doi.org/10.1074/jbc.M306749200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12857743	hybrid			2022-12-25	WOS:000185575100108
J	Tsuruta, D; Hopkinson, SB; Lane, KD; Werner, ME; Cryns, VL; Jones, JCR				Tsuruta, D; Hopkinson, SB; Lane, KD; Werner, ME; Cryns, VL; Jones, JCR			Crucial role of the specificity-determining loop of the integrin beta(4) subunit in the binding of cells to laminin-5 and outside-in signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; ALPHA(6)BETA(4) INTEGRIN; ENDOTHELIAL-CELLS; ALPHA-6-BETA-4 INTEGRIN; CYTOPLASMIC DOMAIN; HEMIDESMOSOMES; ADHESION; CYTOSKELETON; ASSOCIATION; ABSENCE	Within each hemidesmosome, alpha(6)beta(4) integrin plays a crucial role in hemidesmosome assembly by binding to laminin-5 in the basement membrane zone of epithelial tissue. Recent analyses have implicated "specificity-determining loops" (SDLs) in the I-like domain of beta integrin in regulating ligand binding. Here, we investigated the function of an SDL-like motif within the extracellular I-like domain of beta(4) integrin. We generated point mutations within the SDL of beta(4) integrin tagged with green fluorescent protein (GFP-beta(4)K150A and GFP-beta(4)Q155L). We also generated a mutation within the I-like domain of the beta(4) integrin, lying outside the SDL region (GFP- beta(4)V284E). We transfected constructs encoding the mutated beta(4) integrins and a GFP-conjugated wild type beta(4) integrin ( GFP- beta(4)WT) into 804G cells, which assemble hemidesmosomes, and human endothelial cells, which express little endogenous beta(4) integrin. In transfected 804G cells, GFP- beta(4)WT and GFP- beta(4)V284E colocalize with hemidesmosome proteins, whereas hemidesmosomal components in cells expressing GFP- beta(4)K150A and GFP- beta(4)Q155L are aberrantly localized. In endothelial cells, GFP- beta(4)WT and mutant proteins are co-expressed at the cell surface with alpha(6) integrin. When transfected endothelial cells are plated onto laminin-5 matrix, GFP-beta(4)WT and GFP- beta(4)V284E localize with laminin-5, whereas GFP-beta(4)K150A and GFP-beta(4)Q155L do not. GFP-beta(4)WT and GFPbeta(4)V284E expressed in endothelial cells associate with the adaptor protein Shc when the cells are stimulated with laminin-5. However, GFP-beta(4)K150A and GFPbeta(4)Q155L fail to associate with Shc even when laminin-5 is present, thus impacting downstream signaling. These results provide evidence that the SDL segment of the beta(4) integrin subunit is required for ligand binding and is involved in outside-in signaling.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Jones, JCR (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Morton 4-616,303 E Chicago Ave, Chicago, IL 60611 USA.		Jones, Jonathan C R/T-9467-2017	Jones, Jonathan C R/0000-0002-1496-4922	NIDDK NIH HHS [R01(24) DK60589] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060589] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker SE, 1996, J CELL SCI, V109, P2509; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Gonzalez AM, 2002, P NATL ACAD SCI USA, V99, P16075, DOI 10.1073/pnas.252649399; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; Homan SM, 2002, EXP CELL RES, V281, P107, DOI 10.1006/excr.2002.5643; Homan SM, 1998, J CELL SCI, V111, P2717; HOPKINSON SB, 1995, J CELL BIOL, V130, P117, DOI 10.1083/jcb.130.1.117; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; Jones JCR, 1998, BIOESSAYS, V20, P488, DOI 10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO;2-I; Kamata T, 2002, J IMMUNOL, V168, P2296, DOI 10.4049/jimmunol.168.5.2296; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGHOFER M, 1993, J CELL SCI, V105, P753; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Martin KH, 2002, SCIENCE, V296, P1652, DOI 10.1126/science.296.5573.1652; Nievers MG, 1998, J CELL SCI, V111, P1659; Nievers MG, 2000, J CELL SCI, V113, P963; RIDDELLE KS, 1992, J CELL SCI, V103, P475; RIDDELLE KS, 1991, J CELL BIOL, V112, P159, DOI 10.1083/jcb.112.1.159; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Schweitzer KM, 1997, LAB INVEST, V76, P25; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2002, BIOCHEMISTRY-US, V41, P4339, DOI 10.1021/bi016047u; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Tsuruta D, 2003, CELL MOTIL CYTOSKEL, V54, P122, DOI 10.1002/cm.10089; Tsuruta D, 2002, FASEB J, V16, P866, DOI 10.1096/fj.01-0878fje; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535	38	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38707	38714		10.1074/jbc.M301637200	http://dx.doi.org/10.1074/jbc.M301637200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12867433	hybrid			2022-12-25	WOS:000185575100076
J	Esteve, E; Smida-Rezgui, S; Sarkozi, S; Szegedi, C; Regaya, I; Chen, LL; Altafaj, X; Rochat, H; Allen, P; Pessah, IN; Marty, I; Sabatier, JM; Jona, I; De Waard, M; Ronjat, M				Esteve, E; Smida-Rezgui, S; Sarkozi, S; Szegedi, C; Regaya, I; Chen, LL; Altafaj, X; Rochat, H; Allen, P; Pessah, IN; Marty, I; Sabatier, JM; Jona, I; De Waard, M; Ronjat, M			Critical amino acid residues determine the binding affinity and the Ca2+ release efficacy of maurocalcine in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-III-LOOP; DIHYDROPYRIDINE RECEPTOR; RYANODINE RECEPTOR; SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; CA2+-RELEASE CHANNEL; PANDINUS-IMPERATOR; SCORPION TOXIN; PEPTIDE; ACTIVATOR	Maurocalcine (MCa) is a 33 amino acid residue peptide toxin isolated from the scorpion Scorpio maurus palmatus. MCa and mutated analogues were chemically synthesized, and their interaction with the skeletal muscle ryanodine receptor (RyR1) was studied on purified RyR1, sarcoplasmic reticulum (SR) vesicles, and cultured myotubes. MCa strongly potentiates [H-3] ryanodine binding on SR vesicles (7-fold at pCa 5) with an apparent EC50 of 12 nM. MCa decreases the sensitivity of [H-3] ryanodine binding to inhibitory high Ca2+ concentrations and increases it to the stimulatory low Ca2+ concentrations. In the presence of MCa, purified RyR1 channels show long-lasting openings characterized by a conductance equivalent to 60% of the full conductance. This effect correlates with a global increase in Ca2+ efflux as demonstrated by MCa effects on Ca2+ release from SR vesicles. In addition, we show for the first time that external application of MCa to cultured myotubes produces a cytosolic Ca2+ increase due to Ca2+ release from 4-chloro-m-cresol-sensitive intracellular stores. Using various MCa mutants, we identified a critical role of Arg(24) for MCa binding onto RyR1. All of the other MCa mutants are still able to modify [H-3] ryanodine binding although with a decreased EC50 and a lower stimulation efficacy. All of the active mutants produce both the appearance of a subconductance state and Ca2+ release from SR vesicles. Overall, these data identify some amino acid residues of MCa that support the effect of this toxin on ryanodine binding, RyR1 biophysical properties, and Ca2+ release from SR.	CEA, CIS, INSERM, EMI 9931, F-38054 Grenoble 09, France; Brigham & Womens Hosp, Dept Anesthesia, Boston, MA 02115 USA; Univ Calif Davis, Grad Program Neurosci, Davis, CA 95616 USA; Univ Calif Davis, Dept Mol Biosci, Davis, CA 95616 USA; Fac Med Nord, CNRS UMR 6560, F-13916 Marseille 20, France; Univ Debrecen, Sch Med, Dept Physiol, H-4012 Debrecen, Hungary	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Harvard University; Brigham & Women's Hospital; University of California System; University of California Davis; University of California System; University of California Davis; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Debrecen	Ronjat, M (corresponding author), CEA, CIS, INSERM, EMI 9931, 17 Rue Martyrs, F-38054 Grenoble 09, France.	mronjat@cea.fr	Altafaj, Xavier/K-9257-2014; ESTEVE, Eric/M-7490-2014; Marty, Isabelle/N-7114-2017; Pessah, Isaac N/K-7985-2017; De Waard, Michel/G-7406-2014; Marty, Isabelle/ABF-5362-2020; Regaya, Imed/L-7899-2018	Altafaj, Xavier/0000-0002-7595-0647; Pessah, Isaac N/0000-0002-8149-588X; De Waard, Michel/0000-0002-2782-9615; Marty, Isabelle/0000-0003-3625-913X; Regaya, Imed/0000-0001-8671-5186; ESTEVE, Eric/0000-0002-4548-9140; Ronjat, Michel/0000-0002-9728-6425; SABATIER, Jean-Marc/0000-0002-9040-5647	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011269] Funding Source: NIH RePORTER; NIAMS NIH HHS [2P01 AR17605] Funding Source: Medline; NIEHS NIH HHS [1P01 ES11269] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahern CA, 2001, BIOPHYS J, V81, P3294, DOI 10.1016/S0006-3495(01)75963-2; Chen L, 2003, J BIOL CHEM, V278, P16095, DOI 10.1074/jbc.M209501200; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P28696, DOI 10.1074/jbc.270.48.28696; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Fajloun Z, 2000, FEBS LETT, V469, P179, DOI 10.1016/S0014-5793(00)01239-4; Green D, 2003, BIOCHEM J, V370, P517, DOI 10.1042/BJ20021488; Gschwend MH, 1999, PFLUG ARCH EUR J PHY, V438, P101, DOI 10.1007/s004240050885; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; HerrmannFrank A, 1996, BBA-GEN SUBJECTS, V1289, P31, DOI 10.1016/0304-4165(95)00131-X; Jona I, 2001, PFLUG ARCH EUR J PHY, V441, P729, DOI 10.1007/s004240000484; KIM DH, 1983, J BIOL CHEM, V258, P9662; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; Marty I, 2000, J BIOL CHEM, V275, P8206, DOI 10.1074/jbc.275.11.8206; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; Mosbah A, 2000, PROTEINS, V40, P436, DOI 10.1002/1097-0134(20000815)40:3&lt;436::AID-PROT90&gt;3.0.CO;2-9; O'Reilly FM, 2002, BIOPHYS J, V82, P145, DOI 10.1016/S0006-3495(02)75381-2; PALADE P, 1987, J BIOL CHEM, V262, P6142; Proenza C, 2000, J BIOL CHEM, V275, P29935, DOI 10.1074/jbc.C000464200; Simeoni I, 2001, FEBS LETT, V508, P5, DOI 10.1016/S0014-5793(01)03013-7; VALDIVIA HH, 1992, P NATL ACAD SCI USA, V89, P12185, DOI 10.1073/pnas.89.24.12185; Zamudio FZ, 1997, FEBS LETT, V405, P385, DOI 10.1016/S0014-5793(97)00227-5; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192	26	36	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37822	37831		10.1074/jbc.M305798200	http://dx.doi.org/10.1074/jbc.M305798200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869557	hybrid			2022-12-25	WOS:000185437200102
J	Gober, MD; Smith, CC; Ueda, K; Toretsky, JA; Aurelian, L				Gober, MD; Smith, CC; Ueda, K; Toretsky, JA; Aurelian, L			Forced expression of the H11 heat shock protein can be regulated by DNA methylation and trigger apoptosis in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA CELLS; N-TERMINAL KINASE; HIPPOCAMPAL-NEURONS; SIGNAL-TRANSDUCTION; SURVIVAL PATHWAY; CYTOCHROME-C; ACTIVATION; DEATH; INHIBITOR; GROWTH	H11, the eukaryotic homologue of a herpes simplex virus protein, has the crystallin motif of heat shock proteins (Hsp), but it differs from canonical family members in that mRNA and protein levels were reduced in various tumor tissues and cell lines ( viz. melanoma, prostate cancer and sarcoma) relative to their normal counterparts. In these cells, expression was not restored by heat shock, but rather by the demethylating agent 5-aza-2'-deoxycytidine (Aza-C). Forced H11 expression by Aza-C treatment, transient transfection with H11 expression vectors, or retrovirus-mediated delivery of H11 under the control of a tetracycline-sensitive promoter triggered apoptosis. This is evidenced by a significant ( p < 0.001) increase in the percentage of cells positive for terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling ( TUNEL) and for activation of caspase-3 and p38MAPK and by the co-localization of TUNEL+ nuclei with increased H11 levels. Apoptosis was partially inhibited by the pancaspase inhibitor benzyloxycarbonyl-Val- Ala-Asp-fluoromethyl ketone or the p38MAPK inhibitor SB203580. It was abrogated by co-treatment with both inhibitors, suggesting that H11-triggered apoptosis is both caspase- and p38MAPK-dependent. A single site mutant (H11-W51C) had cytoprotective activity related to MEK/ERK activation, and it blocked H11-induced apoptosis in co-transfected and Aza-C-treated cells, indicating that it is a dominant negative mutant. This is the first report of a heat shock protein with proapoptotic activity.	Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Aurelian, L (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St, Baltimore, MD 21201 USA.				NATIONAL CANCER INSTITUTE [R01CA075453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042647] Funding Source: NIH RePORTER; NCI NIH HHS [CA75453] Funding Source: Medline; NIAMS NIH HHS [AR42647] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aurelian L, 2001, J INVEST DERMATOL, V116, P286, DOI 10.1046/j.1523-1747.2001.00191.x; Beere HM, 2001, SCI STKE, V93, P1; Benndorf R, 2001, J BIOL CHEM, V276, P26753, DOI 10.1074/jbc.M103001200; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blackburn RV, 1997, MOL CELL BIOCHEM, V170, P31, DOI 10.1023/A:1006810005545; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Casaccia-Bonnefil P, 1999, MICROSC RES TECHNIQ, V45, P217, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<217::AID-JEMT5>3.0.CO;2-5; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512290-00014; Condorelli G, 2002, J BIOL CHEM, V277, P11013, DOI 10.1074/jbc.M110934200; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Depre C, 2002, CIRC RES, V91, P1007, DOI 10.1161/01.RES.0000044380.54893.4B; Deschesnes RG, 2001, MOL BIOL CELL, V12, P1569, DOI 10.1091/mbc.12.6.1569; Drujan D, 1999, SHOCK, V12, P443, DOI 10.1097/00024382-199912000-00005; Ehses JA, 2002, J BIOL CHEM, V277, P37088, DOI 10.1074/jbc.M205055200; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gabai VL, 2000, MOL CELL BIOL, V20, P6826, DOI 10.1128/MCB.20.18.6826-6836.2000; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hur J, 2001, FEBS LETT, V507, P157, DOI 10.1016/S0014-5793(01)02975-1; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kappe G, 2001, BBA-GENE STRUCT EXPR, V1520, P1, DOI 10.1016/S0167-4781(01)00237-8; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Perkins D, 2003, J VIROL, V77, P1292, DOI 10.1128/JVI.77.2.1292-1305.2003; Perkins D, 2002, J VIROL, V76, P1435, DOI 10.1128/JVI.76.3.1435-1449.2002; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Smith CC, 2000, J BIOL CHEM, V275, P25690, DOI 10.1074/jbc.M002140200; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Yu YX, 2001, INT J ONCOL, V18, P905	46	61	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37600	37609		10.1074/jbc.M303834200	http://dx.doi.org/10.1074/jbc.M303834200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12832417	hybrid			2022-12-25	WOS:000185437200075
J	Leissring, MA; Lu, A; Condron, MM; Teplow, DB; Stein, RL; Farris, W; Selkoe, DJ				Leissring, MA; Lu, A; Condron, MM; Teplow, DB; Stein, RL; Farris, W; Selkoe, DJ			Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; IN-VIVO; NEPRILYSIN; PEPTIDES; BRAINS	Proteases that degrade the amyloid beta-protein (Abeta) are important regulators of brain Abeta levels in health and in Alzheimer's disease, yet few practical methods exist to study their detailed kinetics. Here, we describe robust and quantitative Abeta degradation assays based on the novel substrate, fluorescein-Abeta- (1-40)-Lys-biotin (FAbetaB). Liquid chromatography/ mass spectrometric analysis shows that FAbetaB is hydrolyzed at closely similar sites as wild-type Abeta by neprilysin and insulin-degrading enzyme, the two most widely studied Abeta-degrading proteases. The derivatized peptide is an avid substrate and is suitable for use with biological samples and in high throughput compound screening. The assays we have developed are easily implemented and are particularly useful for the generation of quantitative kinetic data, as we demonstrate by determining the kinetic parameters of FAbetaB degradation by several Abeta-degrading proteases, including plasmin, which has not previously been characterized. The use of these assays should yield additional new insights into the biology of Abeta-degrading proteases and facilitate the identification of activators and inhibitors of such enzymes.	Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Ctr Neurodegenerat & Repair, Lab Drug Discovery Neurodegenerat, Cambridge, MA 02135 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University	Selkoe, DJ (corresponding author), Harvard Inst Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.		LEISSRING, MALCOLM/AAW-5361-2021	LEISSRING, MALCOLM/0000-0001-7185-4255				Ait-Ghezala G, 2002, NEUROSCI LETT, V325, P87, DOI 10.1016/S0304-3940(02)00243-4; Beaulieu H, 1999, BIOCHEM J, V340, P813, DOI 10.1042/0264-6021:3400813; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; Chesneau V, 2000, BIOCHEM J, V351, P509, DOI 10.1042/0264-6021:3510509; Chesneau V, 2000, PROTEIN EXPRES PURIF, V19, P91, DOI 10.1006/prep.2000.1217; Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P16263, DOI 10.1021/bi005122i; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Karlstrom H, 2002, J BIOL CHEM, V277, P6763, DOI 10.1074/jbc.C100649200; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Li YJ, 2002, AM J HUM GENET, V70, P985, DOI 10.1086/339815; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Morelli L, 2003, J BIOL CHEM, V278, P23221, DOI 10.1074/jbc.M300276200; Mukherjee A, 2000, J NEUROSCI, V20, P8745; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Vekrellis K, 2000, J NEUROSCI, V20, P1657; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	24	95	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37314	37320		10.1074/jbc.M305627200	http://dx.doi.org/10.1074/jbc.M305627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867419	hybrid			2022-12-25	WOS:000185437200040
J	Wilcox, HM; Berg, LJ				Wilcox, HM; Berg, LJ			Itk phosphorylation sites are required for functional activity in primary T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; TEC FAMILY KINASES; B-CELL; SH3 DOMAIN; REGULATORY DOMAINS; HOMOLOGY DOMAIN; CROSS-LINKING; RECEPTOR; ACTIVATION; ANTIGEN	The Tec family kinase Itk plays a critical role in signal transduction downstream of the T cell antigen receptor and has been implicated in the activation of phospholipase C-gamma1, a key regulator of calcium mobilization and extracellular signal-regulated kinase (ERK) activation. We have shown previously that Itk is regulated by an activating transphosphorylation event in which Tyr-511 in the kinase domain is phosphorylated by Lck (Heyeck, S. D., Wilcox, H. M., Bunnell, S. C., and Berg, L. J. (1997) J. Biol. Chem. 272, 25401-25408). In this study, we present evidence for another mode of regulation for Itk, the autophosphorylation of Tyr-180 in the Src homology 3 (SH3) domain. To investigate the role of Itk trans- and autophosphorylation in T cell signaling, a retroviral transduction system was used to introduce different versions of Itk into Itk-deficient primary T cells. We report that Itk mutated at either the trans- or the autophosphorylation site is unable to fully restore cytokine production and ERK activation in the Itk-deficient cells; Itk-Y511F is severely defective, whereas Itk-Y180F has partial activity. Because phosphorylation at Tyr-180 is predicted to interfere with ligand binding by the SH3 domain, an SH3 point mutant that cannot bind ligand was also examined and found to be unable to restore function to the Itk(-/-) cells. These data provide new insights into the complex regulation of Itk in primary T cells.	Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA; Harvard Univ, Div Med Sci, Cambridge, MA USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University	Berg, LJ (corresponding author), Univ Massachusetts, Sch Med, Dept Pathol, 55 Lake Ave N, Worcester, MA 01655 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037584] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37584] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Afar DEH, 1996, MOL CELL BIOL, V16, P3465; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Brazin KN, 2000, J MOL BIOL, V302, P607, DOI 10.1006/jmbi.2000.4091; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Ching KA, 2000, J IMMUNOL, V165, P256, DOI 10.4049/jimmunol.165.1.256; Ebinu JO, 2000, BLOOD, V95, P3199; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; Gibson S, 1996, J IMMUNOL, V156, P2716; Hansson H, 1998, BIOCHEMISTRY-US, V37, P2912, DOI 10.1021/bi972409f; Hansson H, 2001, FEBS LETT, V489, P67, DOI 10.1016/S0014-5793(00)02438-8; Hao SL, 2002, FEBS LETT, V525, P53, DOI 10.1016/S0014-5793(02)03066-1; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; Heyeck SD, 1997, J BIOL CHEM, V272, P25401, DOI 10.1074/jbc.272.40.25401; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; Laederach A, 2002, PROTEIN SCI, V11, P36, DOI 10.1110/ps.ps.26702; Larson SM, 2000, PROTEIN SCI, V9, P2170, DOI 10.1110/ps.9.11.2170; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; Liu KQ, 1998, J EXP MED, V187, P1721, DOI 10.1084/jem.187.10.1721; Lucas JA, 2002, J IMMUNOL, V168, P6142, DOI 10.4049/jimmunol.168.12.6142; Miller AT, 2002, J IMMUNOL, V168, P2163, DOI 10.4049/jimmunol.168.5.2163; Nisitani S, 2000, P NATL ACAD SCI USA, V97, P2737, DOI 10.1073/pnas.050583597; Nisitani S, 1999, P NATL ACAD SCI USA, V96, P2221, DOI 10.1073/pnas.96.5.2221; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Pinschewer DD, 1999, EUR J IMMUNOL, V29, P2981, DOI 10.1002/(SICI)1521-4141(199909)29:09<2981::AID-IMMU2981>3.0.CO;2-Y; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RIGLEY KP, 1989, EUR J IMMUNOL, V19, P2081, DOI 10.1002/eji.1830191117; Satterthwaite AB, 1997, P NATL ACAD SCI USA, V94, P13152, DOI 10.1073/pnas.94.24.13152; Schaeffer EM, 2000, CURR OPIN IMMUNOL, V12, P282, DOI 10.1016/S0952-7915(00)00088-1; Schaeffer EM, 2000, J EXP MED, V192, P987, DOI 10.1084/jem.192.7.987; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shan XC, 1999, J BIOL CHEM, V274, P29323, DOI 10.1074/jbc.274.41.29323; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Thomis DC, 1997, J EXP MED, V185, P197, DOI 10.1084/jem.185.2.197; Tzeng SR, 2000, J BIOMOL NMR, V16, P303, DOI 10.1023/A:1008376624863; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Yamadori T, 1999, P NATL ACAD SCI USA, V96, P6341, DOI 10.1073/pnas.96.11.6341; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	48	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37112	37121		10.1074/jbc.M304811200	http://dx.doi.org/10.1074/jbc.M304811200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12842872	hybrid			2022-12-25	WOS:000185437200017
J	Grimm, DH; Cai, YQ; Chauvet, V; Rajendran, V; Zeltner, R; Geng, L; Avner, ED; Sweeney, W; Somlo, S; Caplan, MJ				Grimm, DH; Cai, YQ; Chauvet, V; Rajendran, V; Zeltner, R; Geng, L; Avner, ED; Sweeney, W; Somlo, S; Caplan, MJ			Polycystin-1 distribution is modulated by polycystin-2 expression in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY-DISEASE GENE; CATION CHANNEL; PRODUCT; PKD1; PROTEIN; LOCALIZATION; MICE; IDENTIFICATION; ACTIVATION; INTERACTS	Mutations in PKD1 and PKD2, the genes that encode polycystin-1 and polycystin-2 respectively, account for almost all cases of autosomal dominant polycystic kidney disease. Although the polycystins are believed to interact in vivo, the two proteins often display dissimilar patterns and gradients of expression during development. In an effort to understand this apparent discrepancy, we investigated how changes in polycystin-2 expression can affect the subcellular localization of polycystin-1. We show that, when polycystin-1 is expressed alone in a PKD2 null cell line, it localizes to the cell surface, as well as to the endoplasmic reticulum. When co-expressed with polycystin-2, however, polycystin-1 is not seen at the cell surface and co-localizes completely with polycystin-2 in the endoplasmic reticulum. The localization of a polycystin-1 fusion protein was similarly affected by changes in its level of expression relative to that of polycystin-2. This phenomenon was observed in populations as well as in individual COS-7 cells. Our data suggest that the localization of polycystin-1 can be regulated via the relative expression level of polycystin-2 in mammalian cells. This mechanism may help to explain the divergent patterns and levels of expression observed for the polycystins, and may provide clues as to how the function of these two proteins are regulated during development.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	Yale University; Yale University; Yale University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University	Caplan, MJ (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06510 USA.	michael.caplan@yale.edu		Caplan, Michael/0000-0001-5768-4405	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK057328] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 57328] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnaout MA, 2001, ANNU REV MED, V52, P93, DOI 10.1146/annurev.med.52.1.93; Arnould T, 1999, MOL CELL BIOL, V19, P3423; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Barr MM, 2001, CURR BIOL, V11, P1341, DOI 10.1016/S0960-9822(01)00423-7; Boletta A, 2000, MOL CELL, V6, P1267, DOI 10.1016/S1097-2765(00)00123-4; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Geng L, 1996, J CLIN INVEST, V98, P2674, DOI 10.1172/JCI119090; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Griffin MD, 1996, P ASSOC AM PHYSICIAN, V108, P185; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Hateboer N, 1999, LANCET, V353, P103, DOI 10.1016/S0140-6736(98)03495-3; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Ibraghimov-Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Luo Y, 2003, MOL CELL BIOL, V23, P2600, DOI 10.1128/MCB.23.7.2600-2607.2003; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Newby LJ, 2002, J BIOL CHEM, V277, P20763, DOI 10.1074/jbc.M107788200; Nickel C, 2002, J CLIN INVEST, V109, P481, DOI 10.1172/JC1200212867; Ong ACM, 2000, EXP NEPHROL, V8, P208; Palsson R, 1996, MOL MED, V2, P702, DOI 10.1007/BF03401654; Pazour GJ, 2002, CURR BIOL, V12, pR378, DOI 10.1016/S0960-9822(02)00877-1; Peters DJM, 1999, J PATHOL, V188, P439, DOI 10.1002/(SICI)1096-9896(199908)188:4<439::AID-PATH367>3.0.CO;2-P; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; Pritchard L, 2000, HUM MOL GENET, V9, P2617, DOI 10.1093/hmg/9.18.2617; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Sweeney WE, 1998, AM J PHYSIOL-RENAL, V275, pF387, DOI 10.1152/ajprenal.1998.275.3.F387; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; VANADELSBERG J, 1989, AM J PHYSIOL, V256, pC1004, DOI 10.1152/ajpcell.1989.256.5.C1004; vanAdelsberg J, 1997, AM J PHYSIOL-RENAL, V272, pF602, DOI 10.1152/ajprenal.1997.272.5.F602; Vandorpe DH, 2001, J BIOL CHEM, V276, P4093, DOI 10.1074/jbc.M006252200; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; Xu GM, 2001, J BIOL CHEM, V276, P46544, DOI 10.1074/jbc.M107828200; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25	40	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36786	36793		10.1074/jbc.M306536200	http://dx.doi.org/10.1074/jbc.M306536200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12840011	hybrid			2022-12-25	WOS:000185318300111
J	Rocic, P; Seshiah, P; Griendling, KK				Rocic, P; Seshiah, P; Griendling, KK			Reactive oxygen species sensitivity of angiotensin II-dependent translation initiation in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR 4E PHOSPHORYLATION; JURKAT T-CELLS; 4E-BINDING PROTEIN-1; PHOSPHATASE 2A; PHAS-I; PHOSPHATIDYLINOSITOL 3-KINASE; STIMULATES PHOSPHORYLATION; INDUCED HYPERTROPHY; CRITICAL COMPONENT	Translation initiation, the rate-limiting step in protein synthesis, is a key event in vascular smooth muscle cell growth, a major component of vascular disease. Translation initiation is regulated by interaction between PHAS-I and the eukaryotic initiation factor 4E (eIF4E). Although angiotensin II (Ang II)-induced vascular smooth muscle cell hypertrophy requires the generation of reactive oxygen species (ROS), the ROS sensitivity of these events and their upstream activators remain unclear. Here, we investigated the role of ROS in the regulation of PHAS-I phosphorylation on Thr-70 and Ser-65, an event required for the release of eIF4E from PHAS-I. Ang II-induced Ser-65 phosphorylation was ROS-dependent as assessed by pretreatment with ebselen (3.6 +/- 0.2 versus 1.1 +/- 0.2), diphenylene iodonium (3.6 +/- 0.2 versus 1.0 +/- 0.1), and N-acetyl cysteine (3.6 +/- 0.2 versus 1.2 +/- 0.1), but Ang II-stimulated phosphorylation of Thr-70 was ROS-insensitive. Although phosphatidyl-inositol 3-kinase pathway inhibition by LY294004 blocked both Ser-65 and Thr-70 phosphorylation (3.8 +/- 0.1 versus 0.8 +/- 0.1 and 3.2 +/- 0.2 versus 1.0 +/- 0.01, respectively), protein phosphatase 2A inhibition by okadaic acid selectively increased (3.3 +/- 0.1 versus 5.2 +/- 0.1) and p38 mitogen-activated protein kinase inhibition by SB203580 selectively decreased (3.8 +/- 0.1 versus 1.4 +/- 0.3) Ser-65 phosphorylation. Dominant negative Akt adenovirus also inhibited only Ser-65 phosphorylation (3.7 +/- 0.1 versus 1.0 +/- 0.03). These results demonstrate a unique differential ROS sensitivity of two separate residues on PHAS-I, which seems to be explained by the selective involvement of distinct signaling pathways in the regulation of these phosphorylation events.	Emory Univ, Div Cardiol, Atlanta, GA 30322 USA	Emory University	Griendling, KK (corresponding author), Emory Univ, Div Cardiol, 319 WMB,1639 Pierce Dr, Atlanta, GA 30322 USA.	kgriend@emory.edu		Rocic, Petra/0000-0002-5781-3075; Griendling, Kathy/0000-0002-9456-8582	NHLBI NIH HHS [HL58000, HL38206] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038206, R01HL038206, P01HL058000, R37HL038206] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aronica SM, 1997, BLOOD, V89, P3582, DOI 10.1182/blood.V89.10.3582.3582_3582_3595; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BU X, 1992, FEBS LETT, V301, P15, DOI 10.1016/0014-5793(92)80200-Z; Coffer PJ, 1998, BIOCHEM J, V335, P1; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Diggle TA, 1996, BIOCHEM J, V316, P447, DOI 10.1042/bj3160447; Duncan RF, 2003, BIOCHEM J, V369, P213, DOI 10.1042/BJ20020435; Fleurent M, 1997, J BIOL CHEM, V272, P4006, DOI 10.1074/jbc.272.7.4006; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Go YM, 2001, J APPL PHYSIOL, V91, P1574, DOI 10.1152/jappl.2001.91.4.1574; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Heesom KJ, 1999, FEBS LETT, V457, P489, DOI 10.1016/S0014-5793(99)01094-7; Lin TA, 1997, DIABETOLOGIA, V40, pS18, DOI 10.1007/s001250051391; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Liu GM, 2002, J BIOL CHEM, V277, P8810, DOI 10.1074/jbc.M110477200; MAKKINJE A, 1995, J BIOL CHEM, V270, P14824, DOI 10.1074/jbc.270.24.14824; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MOHAZZABH KM, 1994, AM J PHYSIOL, V266, pH2568, DOI 10.1152/ajpheart.1994.266.6.H2568; Morley SJ, 1997, FEBS LETT, V418, P327, DOI 10.1016/S0014-5793(97)01405-1; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; RAO GN, 1994, J BIOL CHEM, V269, P7180; Rao GN, 2000, J BIOL CHEM, V275, P16993, DOI 10.1074/jbc.275.22.16993; Rao GN, 1999, J BIOL CHEM, V274, P12925, DOI 10.1074/jbc.274.18.12925; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; REURENT M, 1997, J BIOL CHEM, V272, P4006; Rocic P, 2001, AM J PHYSIOL-CELL PH, V280, pC90, DOI 10.1152/ajpcell.2001.280.1.C90; Rybkin II, 2000, J BIOL CHEM, V275, P5460, DOI 10.1074/jbc.275.8.5460; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Vary TC, 2000, AM J PHYSIOL-ENDOC M, V278, pE58, DOI 10.1152/ajpendo.2000.278.1.E58; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488	43	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36973	36979		10.1074/jbc.M302099200	http://dx.doi.org/10.1074/jbc.M302099200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860993	hybrid			2022-12-25	WOS:000185318300132
J	Selivanova, OM; Shiryaev, VM; Tiktopulo, EI; Potekhin, SA; Spirin, AS				Selivanova, OM; Shiryaev, VM; Tiktopulo, EI; Potekhin, SA; Spirin, AS			Compact globular structure of Thermus thermophilus ribosomal protein S1 in solution - Sedimentation and calorimetric study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BINDING-SITE	Ribosomal protein S1 of Thermus thermophilus overexpressed in Escherichia coli cells has been isolated and subjected to studies by analytical sedimentation and differential scanning microcalorimetry techniques. It has been demonstrated that the protein of 60 kDa sediments at s(20,w)(0) = 4.6 S and has the diffusion coefficient D-20,w(0) = 6.7 x 10(-7) cm(2)/s in 25 mM HEPES-NaOH buffer, pH 7.5 (similarly to bovine serum albumin of 66 kDa that sediments at s(20,w)(0) = 4.4 S and D-20,w(0) = 6.0 x 10(-7) cm(2)/s), indicating its compact globular conformation under these conditions. The microcalorimetry study has shown the presence of a cooperative tertiary structure melting at 90 degreesC, but with several (probably three) independent cooperative domains. In the presence of 100 mM NaCl the protein becomes more asymmetric (s(20,w)(0) = 3.1 S) but does not lose its cooperativity and thermostability, this suggesting just the weakening of interdomain ionic interactions. The compact globular conformation of protein S1 seems to be most likely within the ribosome.	Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia	Russian Academy of Sciences	Spirin, AS (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia.	spirin@vega.protres.ru	Potekhin, Sergey A/M-8274-2015; Spirin, Alexander/A-7307-2016; Selivanova, Olga/M-3184-2015					BERESTOWSKAYA NH, 1988, FEBS LETT, V228, P263, DOI 10.1016/0014-5793(88)80012-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; DRAPER DE, 1978, J MOL BIOL, V122, P321, DOI 10.1016/0022-2836(78)90193-6; GIORGINIS S, 1980, J MOL BIOL, V141, P393, DOI 10.1016/0022-2836(80)90253-3; GIRI L, 1977, FEBS LETT, V81, P199, DOI 10.1016/0014-5793(77)80958-7; GRIBSKOV M, 1992, GENE, V119, P107, DOI 10.1016/0378-1119(92)90073-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUGHREA M, 1977, J MOL BIOL, V112, P399, DOI 10.1016/S0022-2836(77)80189-7; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; ODOM OW, 1984, ARCH BIOCHEM BIOPHYS, V230, P178, DOI 10.1016/0003-9861(84)90099-7; Privalov P L, 1986, Methods Enzymol, V131, P4; Schachman H.K., 1959, ULTRACENTRIFUGATION; Senin AA, 2000, J THERM ANAL CALORIM, V62, P153, DOI 10.1023/A:1010171013669; Shiryaev VM, 2002, FEBS LETT, V525, P88, DOI 10.1016/S0014-5793(02)03092-2; Sorensen MA, 1998, J MOL BIOL, V280, P561, DOI 10.1006/jmbi.1998.1909; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; YOKOTA T, 1979, J BIOCHEM, V86, P1725, DOI 10.1093/oxfordjournals.jbchem.a132693; [No title captured]	19	12	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36311	36314		10.1074/jbc.M304713200	http://dx.doi.org/10.1074/jbc.M304713200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860989	hybrid			2022-12-25	WOS:000185318300055
J	Dobrosotskaya, IY; Goldstein, JL; Brown, MS; Rawson, RB				Dobrosotskaya, IY; Goldstein, JL; Brown, MS; Rawson, RB			Reconstitution of sterol-regulated endoplasmic reticulum-to-Golgi transport of SREBP-2 in insect cells by co-expression of mammalian SCAP and Insigs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE-ACTIVATING PROTEIN; ELEMENT-BINDING PROTEINS; BOUND TRANSCRIPTION FACTOR; CHOLESTEROL-METABOLISM; LIPID-SYNTHESIS; MEMBRANE; ER; PATHWAY; PROTEOLYSIS; DROSOPHILA	In mammalian cells, membrane-bound sterol regulatory element-binding proteins (SREBPs) are transported from ER to Golgi where they are processed proteolytically to generate soluble transcription factors that activate lipid synthesis. ER-to-Golgi transport requires SCAP, a sterol-regulated escort protein. In sterol-treated cells, the SCAP/SREBP complex binds to Insig-1 or Insig-2, which retains the complex in the ER, blocking SREBP processing and decreasing lipid synthesis. In Drosophila cells, the endogenous SCAP/SREBP complex is transported to Golgi, but transport is blocked by phosphatidylethanolamine instead of sterols. Here, we show that mammalian SREBP-2 is not transported to Golgi when expressed in Drosophila cells. Transport requires co-expression of mammalian SCAP. Sterols block transport of the mammalian SCAP/SREBP-2 complex, but only when mammalian Insig-1 or -2 is co-expressed. These reconstitution studies define SCAP and Insig as the minimal requirements for sterol-regulated transport of SREBPs from ER to Golgi. They indicate that insect cells can respond to sterols when proper regulatory proteins are expressed.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Goldstein, JL (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd,Rm L5-238, Dallas, TX 75390 USA.				NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CLARK AJ, 1959, J BIOL CHEM, V234, P2578; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Espenshade PJ, 2002, P NATL ACAD SCI USA, V99, P11694, DOI 10.1073/pnas.182412799; Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Seegmiller AC, 2002, DEV CELL, V2, P229, DOI 10.1016/S1534-5807(01)00119-8; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Yabe D, 2002, P NATL ACAD SCI USA, V99, P16672, DOI 10.1073/pnas.262669399; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	22	29	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35837	35843		10.1074/jbc.M306476200	http://dx.doi.org/10.1074/jbc.M306476200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842885	hybrid			2022-12-25	WOS:000185164400133
J	Hatsell, S; Medina, L; Merola, J; Haltiwanger, R; Cowin, P				Hatsell, S; Medina, L; Merola, J; Haltiwanger, R; Cowin, P			Plakoglobin is O-glycosylated close to the N-terminal destruction box	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME SYSTEM; JUNCTIONAL PLAQUE PROTEIN; ESTROGEN-RECEPTOR-BETA; APC TUMOR-SUPPRESSOR; MUTATIONAL HOT-SPOT; CELL-CELL ADHESION; E-CADHERIN; GENE-PRODUCT; NUCLEOCYTOPLASMIC PROTEINS; TYROSINE PHOSPHORYLATION	Plakoglobin provides a key linkage in protein chains that connect desmosomal and classical cadherins to the cytoskeleton. It is also present in a significant cytosolic pool that has the capacity to impact on canonical Wnt signaling by competing for interaction with partner proteins of beta-catenin. The closely related protein, beta-catenin, is rapidly targeted for proteasomal degradation by phosphorylation of a "destruction box" within the N-terminal domain. Inhibition of this process forms the basis of Wnt signaling. This destruction box is also found in the N-terminal domain of plakoglobin. We report that plakoglobin is modified by the addition of O-GlcNAc at a single site in close proximity to the destruction box. O-GlcNAc modification has been proposed to counteract phosphorylation, provide protection from proteasomal degradation, mediate signal transduction, silence transcription, and regulate multimolecular protein assembly. This finding has potential implications for understanding the roles of plakoglobin.	NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	New York University; New York University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Cowin, P (corresponding author), NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA.			Merola, Joseph/0000-0001-6514-4353; Cowin, Pamela/0000-0002-1827-1154; Hatsell, Sarah/0000-0003-1103-6087	NIGMS NIH HHS [GM47429] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047429] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Bierkamp C, 1996, DEV BIOL, V180, P780, DOI 10.1006/dbio.1996.0346; Bornslaeger EA, 2001, J CELL SCI, V114, P727; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; Castano J, 2002, J BIOL CHEM, V277, P31541, DOI 10.1074/jbc.M204376200; Chan SK, 2002, CELL, V111, P265, DOI 10.1016/S0092-8674(02)01037-1; Charpentier E, 2000, J CELL BIOL, V149, P503, DOI 10.1083/jcb.149.2.503; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; Cheng XG, 2001, J BIOL CHEM, V276, P10570, DOI 10.1074/jbc.M010411200; Chitaev NA, 1996, J CELL BIOL, V133, P359, DOI 10.1083/jcb.133.2.359; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; Cox RT, 1999, GENETICS, V153, P319; Dong DLY, 1996, J BIOL CHEM, V271, P20845, DOI 10.1074/jbc.271.34.20845; DONG DLY, 1993, J BIOL CHEM, V268, P16679; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; GELDERLOOS JA, 1997, CYTOSKELETAL MEMBRAN; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Haltiwanger RS, 1997, J BIOL CHEM, V272, P8752, DOI 10.1074/jbc.272.13.8752; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; KAPPRELL HP, 1987, EUR J BIOCHEM, V166, P505, DOI 10.1111/j.1432-1033.1987.tb13543.x; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; Klymkowsky MW, 1999, MOL BIOL CELL, V10, P3151, DOI 10.1091/mbc.10.10.3151; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; Kolligs FT, 2000, GENE DEV, V14, P1319; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Kowalczyk AP, 1998, J CELL SCI, V111, P3045; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; KU NO, 1995, J BIOL CHEM, V270, P11820, DOI 10.1074/jbc.270.20.11820; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; MATHUR M, 1994, J BIOL CHEM, V269, P14075; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; McKoy G, 2000, LANCET, V355, P2119, DOI 10.1016/S0140-6736(00)02379-5; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Miravet S, 2002, J BIOL CHEM, V277, P1884, DOI 10.1074/jbc.M110248200; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NIEHRS C, 1992, J BIOL CHEM, V267, P15938; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Park WS, 1999, CANCER RES, V59, P4257; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Ruiz P, 1996, J CELL BIOL, V135, P215, DOI 10.1083/jcb.135.1.215; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; SCHMELZ M, 1993, EUR J CELL BIOL, V61, P274; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; SHIBATA T, 1994, BIOCHEM BIOPH RES CO, V203, P519, DOI 10.1006/bbrc.1994.2213; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; Vallorosi CJ, 2000, J BIOL CHEM, V275, P3328, DOI 10.1074/jbc.275.5.3328; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van de Wetering M, 2002, CELL, V109, pS13, DOI 10.1016/S0092-8674(02)00709-2; van Noort M, 2002, EXP CELL RES, V276, P264, DOI 10.1006/excr.2002.5520; Vosseller K, 2002, CURR OPIN CHEM BIOL, V6, P851, DOI 10.1016/S1367-5931(02)00384-8; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Wahl JK, 2000, J CELL SCI, V113, P1737; Wahl JK, 1996, J CELL SCI, V109, P1143; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Williams BO, 2000, ONCOGENE, V19, P5720, DOI 10.1038/sj.onc.1203921; Witcher LL, 1996, J BIOL CHEM, V271, P10904, DOI 10.1074/jbc.271.18.10904; WITCHER LW, 2000, THESIS NEW YORK U; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999; Zhurinsky J, 2000, J CELL SCI, V113, P3127; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	95	32	34	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37745	37752		10.1074/jbc.M301346200	http://dx.doi.org/10.1074/jbc.M301346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12847106	hybrid			2022-12-25	WOS:000185437200092
J	Pelicano, H; Feng, L; Zhou, Y; Carew, JS; Hileman, EO; Plunkett, W; Keating, MJ; Huang, P				Pelicano, H; Feng, L; Zhou, Y; Carew, JS; Hileman, EO; Plunkett, W; Keating, MJ; Huang, P			Inhibition of mitochondrial respiration - A novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; PERSISTENT OXIDATIVE STRESS; ARSENIC TRIOXIDE AS2O3; CYTOCHROME-C RELEASE; SUPEROXIDE-DISMUTASE; FIBROBLAST PROLIFERATION; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; DNA FRAGMENTATION	Cancer cells are under intrinsic increased oxidative stress and vulnerable to free radical-induced apoptosis. Here, we report a strategy to hinder mitochondrial electron transport and increase superoxide (O-2(radical anion)) radical generation in human leukemia cells as a novel mechanism to enhance apoptosis induced by anticancer agents. This strategy was first tested in a proof-of-principle study using rotenone, a specific inhibitor of mitochondrial electron transport complex I. Partial inhibition of mitochondrial respiration enhances electron leakage from the transport chain, leading to an increase in O-2(radical anion). generation and sensitization of the leukemia cells to anticancer agents whose action involve free radical generation. Using leukemia cells with genetic alterations in mitochondrial DNA and biochemical approaches, we further demonstrated that As2O3, a clinically active anti-leukemia agent, inhibits mitochondrial respiratory function, increases free radical generation, and enhances the activity of another O-2(radical anion) generating agent against cultured leukemia cells and primary leukemia cells isolated from patients. Our study shows that interfering mitochondrial respiration is a novel mechanism by which As2O3 increases generation of free radicals. This novel mechanism of action provides a biochemical basis for developing new drug combination strategies using As2O3 to enhance the activity of anticancer agents by promoting generation of free radicals.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Huang, P (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd,Box 89, Houston, TX 77030 USA.	phuang@mdanderson.org		Hileman, Elizabeth/0000-0001-6822-9571	NCI NIH HHS [CA100428, CA77339, CA81534, CA85563] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA077339, R01CA100428, R01CA085563, P01CA081534, P20CA081534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chan TS, 2002, FREE RADICAL RES, V36, P421, DOI 10.1080/10715760290021270; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chen GQ, 1996, BLOOD, V88, P1052; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; CHESON BD, 1988, AM J HEMATOL, V29, P152, DOI 10.1002/ajh.2830290307; Devi GS, 2000, CLIN CHIM ACTA, V293, P53, DOI 10.1016/S0009-8981(99)00222-3; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; Fang J, 2002, CANCER RES, V62, P3138; Fantin VR, 2002, CANCER CELL, V2, P29, DOI 10.1016/S1535-6108(02)00082-X; Fujimura M, 1999, J NEUROSCI, V19, P3414; Gao CF, 2001, EXP CELL RES, V265, P145; Golab J, 2003, J BIOL CHEM, V278, P407, DOI 10.1074/jbc.M209125200; Hail N, 2001, CANCER RES, V61, P6698; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hileman E. O., 2001, EXPERT OPIN THER TAR, V5, P679; Huang P, 2000, LEUKEMIA, V14, P1405, DOI 10.1038/sj.leu.2401845; Huang P, 1995, CLIN CANCER RES, V1, P1005; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Iwama K, 2001, INT J CANCER, V92, P518, DOI 10.1002/ijc.1220; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Kondo S, 1999, FREE RADICAL BIO MED, V27, P401, DOI 10.1016/S0891-5849(99)00087-8; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Martin KR, 2002, HUM EXP TOXICOL, V21, P71, DOI 10.1191/0960327102ht213oa; MCCORD JM, 1995, P SOC EXP BIOL MED, V209, P112; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NICOTERA TM, 1994, CANCER RES, V54, P3884; Nishimura G, 2001, FEBS LETT, V505, P399, DOI 10.1016/S0014-5793(01)02859-9; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Preeta R, 1999, J MOL CELL CARDIOL, V31, P1573, DOI 10.1006/jmcc.1999.0994; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; ROBERTSON LE, 1993, BLOOD, V81, P143; Saybasili H, 2001, ANTIOXID REDOX SIGN, V3, P1099, DOI 10.1089/152308601317203602; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Smith TAD, 2000, BRIT J BIOMED SCI, V57, P170; Staniek K, 2002, FREE RADICAL RES, V36, P381, DOI 10.1080/10715760290021225; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Toyokuni S, 1998, BIOTHERAPY, V11, P147, DOI 10.1023/A:1007934229968; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Wang TS, 1996, J CELL PHYSIOL, V169, P256, DOI 10.1002/(SICI)1097-4652(199611)169:2<256::AID-JCP5>3.0.CO;2-N; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wei YH, 1996, ANN NY ACAD SCI, V786, P24, DOI 10.1111/j.1749-6632.1996.tb39049.x; Wood L, 2001, ANTI-CANCER DRUG DES, V16, P209; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhou Y, 2003, BLOOD, V101, P4098, DOI 10.1182/blood-2002-08-2512	52	397	415	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37832	37839		10.1074/jbc.M301546200	http://dx.doi.org/10.1074/jbc.M301546200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12853461	hybrid			2022-12-25	WOS:000185437200103
J	Zou, H; Lee, J; Umamoto, S; Kilani, AF; Kim, J; Trang, P; Zhou, TH; Liu, FY				Zou, H; Lee, J; Umamoto, S; Kilani, AF; Kim, J; Trang, P; Zhou, TH; Liu, FY			Engineered RNase P ribozymes are efficient in cleaving a human cytomegalovirus mRNA in vitro and are effective in inhibiting viral gene expression and growth in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-P; SUBSTRATE-BINDING; ESCHERICHIA-COLI; HAMMERHEAD RIBOZYMES; PROTEIN COFACTOR; ENZYME; SELECTION; CLEAVAGE; INVITRO; SUBUNIT	By using an in vitro selection procedure, we have previously isolated RNase P ribozyme variants that efficiently cleave an mRNA sequence in vitro. In this study, a ribozyme variant was used to target the overlapping region of the mRNAs encoding human cytomegalovirus ( HCMV) major transcription regulatory proteins IE1 and IE2. The variant is about 90 times more efficient in cleaving the IE1/IE2 mRNA sequence in vitro than the ribozyme derived from the wild type RNase P ribozyme. Our results provide the first direct evidence that a point mutation at nucleotide position 80 of RNase P catalytic RNA from Escherichia coli (U-80-->C-80) increases the rate of chemical cleavage, and another mutation at nucleotide position 188 (C-188-->U-188) enhances substrate binding of the ribozyme. Moreover, the variant is more effective in inhibiting viral IE1 and IE2 expression and growth in HCMV-infected cells than the wild type ribozyme. A reduction of about 99% in the expression level of IE1 and IE2 and a reduction of 10,000-fold in viral growth were observed in cells that expressed the variant. In contrast, a reduction of less than 10% in IE1/IE2 expression and viral growth was observed in cells that either did not express the ribozyme or produced a catalytically inactive ribozyme mutant. Thus, engineered RNase P ribozyme variants are highly effective in inhibiting HCMV gene expression and growth. These results also demonstrate the feasibility of engineering highly effective RNase P ribozymes for gene targeting applications, including anti-HCMV gene therapy.	Univ Calif Berkeley, Sch Publ Hlth, Program Infect Dis & Immun, Program Comparat Biochem, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Liu, FY (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Program Infect Dis & Immun, Program Comparat Biochem, 140 Warren Hall, Berkeley, CA 94720 USA.	liu_fy@uclink4.berkeley.edu		Lee, Jarone/0000-0002-4532-8523	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054815] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41927] Funding Source: Medline; NIGMS NIH HHS [GM54815] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman S., 1999, RNA WORLD, P351; ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; BERTRAND EL, 1994, EMBO J, V13, P2904, DOI 10.1002/j.1460-2075.1994.tb06585.x; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; Chen JL, 1998, EMBO J, V17, P1515, DOI 10.1093/emboj/17.5.1515; Cobaleda C, 2000, BLOOD, V95, P731, DOI 10.1182/blood.V95.3.731.003k28_731_737; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; FRANK DN, 1994, BIOCHEMISTRY-US, V33, P10800, DOI 10.1021/bi00201a030; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; Gold L., 1993, RNA WORLD, P497; Greaves RF, 1998, J VIROL, V72, P366, DOI 10.1128/JVI.72.1.366-379.1998; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; Haas ES, 1998, NUCLEIC ACIDS RES, V26, P4093, DOI 10.1093/nar/26.18.4093; HAAS ES, 1994, P NATL ACAD SCI USA, V91, P2527, DOI 10.1073/pnas.91.7.2527; Hsu AW, 2000, NUCLEIC ACIDS RES, V28, P3105, DOI 10.1093/nar/28.16.3105; JOYCE GF, 1992, SCI AM, V267, P90, DOI 10.1038/scientificamerican1292-90; Kawa D, 1998, RNA, V4, P1397, DOI 10.1017/S1355838298980918; Kilani AF, 1999, RNA, V5, P1235, DOI 10.1017/S1355838299990672; Kilani AF, 2000, J BIOL CHEM, V275, P10611, DOI 10.1074/jbc.275.14.10611; Kim JJ, 1997, RNA, V3, P613; Krasilnikov AS, 2003, NATURE, V421, P760, DOI 10.1038/nature01386; Lan N, 1998, SCIENCE, V280, P1593, DOI 10.1126/science.280.5369.1593; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; LIU FY, 1995, GENE DEV, V9, P471, DOI 10.1101/gad.9.4.471; Marchini A, 2001, J VIROL, V75, P1870, DOI 10.1128/JVI.75.4.1870-1878.2001; Massire C, 1998, J MOL BIOL, V279, P773, DOI 10.1006/jmbi.1998.1797; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mocarski E.S., 2001, FIELDS VIROLOGY, V4th Edn, P2629; NAKAMAYE KL, 1994, BIOCHEMISTRY-US, V33, P1271, DOI 10.1021/bi00171a030; PASS RF, 2001, FIELDS VIROLOGY, P2675; Putlitz JZ, 1999, J VIROL, V73, P4188, DOI 10.1128/JVI.73.5.4188-4196.1999; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; Rossi JJ, 1999, CHEM BIOL, V6, pR33, DOI 10.1016/S1074-5521(99)80001-5; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; SMITH D, 1992, J BIOL CHEM, V267, P2429; STENBERG RM, 1989, J VIROL, V63, P2699, DOI 10.1128/JVI.63.6.2699-2708.1989; STENBERG RM, 1985, J VIROL, V56, P665, DOI 10.1128/JVI.56.3.665-675.1985; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; Tang J, 1997, RNA, V3, P914; Trang P, 1999, NUCLEIC ACIDS RES, V27, P4590, DOI 10.1093/nar/27.23.4590; Trang P, 2000, P NATL ACAD SCI USA, V97, P5812, DOI 10.1073/pnas.100101797; Tsai HY, 2003, J MOL BIOL, V325, P661, DOI 10.1016/S0022-2836(02)01267-6; Wong-Staal F, 1998, HUM GENE THER, V9, P2407, DOI 10.1089/hum.1998.9.16-2407; YU M, 1993, P NATL ACAD SCI USA, V90, P6340, DOI 10.1073/pnas.90.13.6340; YUAN Y, 1992, P NATL ACAD SCI USA, V89, P8006, DOI 10.1073/pnas.89.17.8006; ZAUG AJ, 1995, RNA, V1, P363; Zhu H, 1997, P NATL ACAD SCI USA, V94, P13985, DOI 10.1073/pnas.94.25.13985	54	14	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37265	37274		10.1074/jbc.M303531200	http://dx.doi.org/10.1074/jbc.M303531200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867424	hybrid			2022-12-25	WOS:000185437200035
J	Kato-Yamada, Y; Yoshida, M				Kato-Yamada, Y; Yoshida, M			Isolated epsilon subunit of thermophilic F-1-ATPase binds ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-BINDING; ENDOGENOUS INHIBITOR; BETA-SUBUNITS; IN-SITU; SYNTHASE; F1-ATPASE; COMPLEX; PURIFICATION; RESOLUTION	F-1-ATPase, a soluble part of the F0F1-ATP synthase, has subunit structure alpha(3)beta(3)gammadeltaepsilon in which nucleotide-binding sites are located in the alpha and beta subunits and, as believed, in none of the other subunits. However, we report here that the isolated epsilon subunit of F-1-ATPase from thermophilic Bacillus strain PS3 can bind ATP. The binding was directly demonstrated by isolating the epsilon subunit-ATP complex with gel filtration chromatography. The binding was not dependent on Mg2+ but was highly specific for ATP; however, ADP, GTP, UTP, and CTP failed to bind. The epsilon subunit lacking the C-terminal helical hairpin was unable to bind ATP. Although ATP binding to the isolated epsilon subunits from other organisms has not been detected under the same conditions, a possibility emerges that the epsilon subunit acts as a built in cellular ATP level sensor of F0F1-ATP synthase.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, R-1,4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Gruber G, 1996, J BIOL CHEM, V271, P32623, DOI 10.1074/jbc.271.51.32623; Hara KY, 2001, J BIOL CHEM, V276, P23969, DOI 10.1074/jbc.M009303200; HASHIMOTO T, 1990, J BIOENERG BIOMEMBR, V22, P27, DOI 10.1007/BF00762843; HISABORI T, 1992, J BIOL CHEM, V267, P4551; Hisabori T, 1997, EUR J BIOCHEM, V247, P1158, DOI 10.1111/j.1432-1033.1997.01158.x; Johnson EA, 2002, BIOCHEMISTRY-US, V41, P2446, DOI 10.1021/bi011939f; Kato Y, 1997, J BIOL CHEM, V272, P24906, DOI 10.1074/jbc.272.40.24906; Kato-Yamada Y, 1999, J BIOL CHEM, V274, P33991, DOI 10.1074/jbc.274.48.33991; Kato-Yamada Y, 2000, J BIOL CHEM, V275, P35746, DOI 10.1074/jbc.M006575200; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAGET PP, 1979, ARCH BIOCHEM BIOPHYS, V197, P83, DOI 10.1016/0003-9861(79)90222-4; NELSON N, 1972, J BIOL CHEM, V247, P7657; ORT DR, 1992, ANNU REV PLANT PHYS, V43, P269, DOI 10.1146/annurev.pp.43.060192.001413; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Schulenberg B, 1999, J BIOL CHEM, V274, P28351, DOI 10.1074/jbc.274.40.28351; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; SMITH JB, 1975, J SUPRAMOL STR CELL, V3, P248, DOI 10.1002/jss.400030307; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; WEBER J, 1994, J BIOL CHEM, V269, P11261; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	32	62	66	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36013	36016		10.1074/jbc.M306140200	http://dx.doi.org/10.1074/jbc.M306140200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12837747	hybrid			2022-12-25	WOS:000185318300019
J	Wu, XL; Chen, JJ				Wu, XL; Chen, JJ			Autophosphorylation of checkpoint kinase 2 at serine 516 is required for radiation-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; ATAXIA-TELANGIECTASIA; TUMOR-SUPPRESSOR; CDS1 CHK2; PHOSPHORYLATION; ACTIVATION; ATM; P53; THREONINE-68; RESPONSES	In response to ionizing radiation, checkpoint kinase 2 (Chk2) is activated in an ataxia telangiectasia mutation-dependent manner and induces either cell cycle arrest or apoptosis. Chk2 is also autophosphorylated following DNA damage. It is proposed that autophosphorylation of Chk2 may contribute to Chk2 activation. To fully understand the regulation of Chk2, we mapped an in vitro Chk2 autophosphorylation site at C-terminal serine 516 site (Ser-516). Ser-516 of Chk2 is phosphorylated following radiation in vivo, and this phosphorylation depends on the kinase activity of Chk2. Mutation of this autophosphorylation site (S516A) results in reduced Chk2 kinase activity, suggesting that Chk2 autophosphorylation is required for full kinase activation following DNA damage. Moreover, the S516A mutant of Chk2 is defective in ionizing radiation-induced apoptosis, suggesting that Chk2 autophosphorylation is critical for Chk2 function following DNA damage.	Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA	Mayo Clinic	Chen, JJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA.	chen.junjie@mayo.edu			NCI NIH HHS [R01 CA92312] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092312] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN J, 2002, J BIOL CHEM, V16, P16; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Curman D, 2001, J BIOL CHEM, V276, P17914, DOI 10.1074/jbc.M100728200; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; MEYN MS, 1995, CANCER RES, V55, P5991; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Shieh SY, 2000, GENE DEV, V14, P289; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xu JH, 2001, FEBS LETT, V508, P394, DOI 10.1016/S0014-5793(01)03103-9; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; YANG S, 2002, NAT CELL BIOL, V28, P28; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	31	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36163	36168		10.1074/jbc.M303795200	http://dx.doi.org/10.1074/jbc.M303795200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855706	hybrid			2022-12-25	WOS:000185318300037
J	Ammanamanchi, S; Freeman, JW; Brattain, MG				Ammanamanchi, S; Freeman, JW; Brattain, MG			Acetylated Sp3 is a transcriptional activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RECEPTOR GENE; HISTONE DEACETYLASE INHIBITOR; COLON-CARCINOMA CELLS; FACTOR-BETA RECEPTORS; HUMAN GASTRIC-CANCER; TGF-BETA; EXPRESSION; PROMOTER; REPRESSION; RESISTANCE	Sp3 transcription factor can either activate or repress target gene expression. However, the molecular event that controls this dual function is unclear. We previously reported (Ammanamanchi, S., and Brattain, M. G. (2001) J. Biol. Chem. 276, 3348-3352) that unmodified Sp3 acts as a transcriptional repressor of transforming growth factor-beta receptors in MCF-7L breast cancer cells. We now report that histone deacetylase inhibitor trichostatin A (TSA) induces acetylation of Sp3, which acts as a transcriptional activator of transforming growth factor-beta receptor type II (RII) in MCF-7L cells. Mutation analysis indicated the TSA response is mediated through a GC box located on the RII promoter, which was previously identified as an Sp1/Sp3-binding site that was critical for RII promoter activity. Ectopic Sp3 expression in Sp3-deficient MCF-7E breast cancer cells repressed RII promoter activity in the absence of TSA. However, in the TSA-treated MCF-7E cells ectopic Sp3 activated RII promoter. Histone acetyltransferase p300 was shown to acetylate Sp3. Sp3-mediated RII promoter activity was stimulated by wild type p300 but not the histone acetyltransferase domain-deleted mutant p300 in MCF-7L cells, suggesting the positive effect of p300 acetylase activity on Sp3. Consequently, the results presented in this manuscript demonstrate that acetylation acts as a switch that controls the repressor and activator role of Sp3.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA	Roswell Park Cancer Institute; University of Texas System; University of Texas Health San Antonio	Brattain, MG (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.				NATIONAL CANCER INSTITUTE [R01CA050457, R56CA069122, R37CA038173, R01CA072001, R01CA069122, R01CA038173] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50457, CA 72001, CA 38173, CA 69122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Ammanamanchi S, 2001, J BIOL CHEM, V276, P32854, DOI 10.1074/jbc.M103951200; Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Jennings R, 2001, ONCOGENE, V20, P6899, DOI 10.1038/sj.onc.1204808; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Kim DH, 1997, J BIOL CHEM, V272, P688; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, GENE DEV, V14, P627; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Periyasamy S, 2000, ONCOGENE, V19, P4660, DOI 10.1038/sj.onc.1203822; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Venkatasubbarao K, 2001, CANCER RES, V61, P6239; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200	26	107	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35775	35780		10.1074/jbc.M305961200	http://dx.doi.org/10.1074/jbc.M305961200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12837748	hybrid			2022-12-25	WOS:000185164400125
J	Toda, H; Tsuji, M; Nakano, I; Kobuke, K; Hayashi, T; Kasahara, H; Takahashi, J; Mizoguchi, A; Houtani, T; Sugimoto, T; Hashimoto, N; Palmer, TD; Honjo, T; Tashiro, K				Toda, H; Tsuji, M; Nakano, I; Kobuke, K; Hayashi, T; Kasahara, H; Takahashi, J; Mizoguchi, A; Houtani, T; Sugimoto, T; Hashimoto, N; Palmer, TD; Honjo, T; Tashiro, K			Stem cell-derived neural stem/progenitor cell supporting factor is an autocrine/paracrine survival factor for adult neural stem/progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; SIGNAL SEQUENCE TRAP; CAENORHABDITIS-ELEGANS; SECRETED PROTEINS; PROGENITOR CELLS; NERVOUS-SYSTEM; DENTATE GYRUS; BRAIN; PROLIFERATION; RAT	Recent evidence suggests that adult neural stem/progenitor cells (ANSCs) secrete autocrine/paracrine factors and that these intrinsic factors are involved in the maintenance of adult neurogenesis. We identified a novel secretory molecule, stem cell-derived neural stem/ progenitor cell supporting factor (SDNSF), from adult hippocampal neural stem/ progenitor cells by using the signal sequence trap method. The expression of SDNSF in adult central nervous system was localized to hippocampus including dentate gyrus, where the neurogenesis persists throughout life. In induced neurogenesis status seen in ischemically treated hippocampus, the expression of SDNSF was up-regulated. As functional aspects, SDNSF protein provided a dose-dependent survival effect for ANSC following basic fibroblast growth factor 2 (FGF-2) withdrawal. ANSCs treated by SDNSF also retain self-renewal potential and multipotency in the absence of FGF-2. However, SDNSF did not have mitogenic activity, nor was it a cofactor that promoted the mitogenic effects of FGF-2. These data suggested an important role of SDNSF as an autocrine/paracrine factor in maintaining stem cell potential and lifelong neurogenesis in adult central nervous system.	Kyoto Univ, Grad Sch Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Neurosurg, Sakyo Ku, Kyoto 6068507, Japan; Mie Univ, Sch Med, Dept Anat, Tsu, Mie 5148507, Japan; Kansai Med Univ, Dept Anat & Brain Sci, Osaka 5708506, Japan; Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; Kyoto Univ, Grad Sch Med, Ctr Mol Biol & Genet, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Mie University; Kansai Medical University; Stanford University; Kyoto University	Tashiro, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med Chem, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.		Palmer, Theo/GSI-6635-2022; Nakano, Ichiro/F-2076-2014; Nakano, Ichiro/AAR-9562-2020; Honjo, Tasuku/N-4470-2016; Toda, Hiroki/C-6932-2016	Nakano, Ichiro/0000-0002-6734-3468; Nakano, Ichiro/0000-0002-0916-3207; Toda, Hiroki/0000-0002-1596-4131; Palmer, Theo/0000-0002-6266-1862				ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; Arsenijevic Y, 2001, J NEUROSCI, V21, P7194, DOI 10.1523/JNEUROSCI.21-18-07194.2001; BAYER SA, 1982, EXP BRAIN RES, V46, P315; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BLOCHBERGER TC, 1989, J BIOL CHEM, V264, P20718; BOOHER J, 1972, Neurobiology (Copenhagen), V2, P97; Ciccolini F, 1998, J NEUROSCI, V18, P7869; DERIDDER LI, 1987, ACTA NEUROPATHOL, V72, P207, DOI 10.1007/BF00691091; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gritti A, 1996, J NEUROSCI, V16, P1091; Herrera DG, 1999, ANN NEUROL, V46, P867, DOI 10.1002/1531-8249(199912)46:6<867::AID-ANA9>3.0.CO;2-Z; Houtani T, 2000, J COMP NEUROL, V424, P489; Jacobs KA, 1997, GENE, V198, P289, DOI 10.1016/S0378-1119(97)00330-2; Jones SJM, 2001, GENOME RES, V11, P1346, DOI 10.1101/gr.184401; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; Kato K, 2000, BLOOD, V96, P362, DOI 10.1182/blood.V96.1.362.013k23_362_364; Kobuke K, 2001, J BIOL CHEM, V276, P34105, DOI 10.1074/jbc.M105293200; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Liu JL, 1998, J NEUROSCI, V18, P7768; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Martens DJ, 2000, J NEUROSCI, V20, P1085, DOI 10.1523/JNEUROSCI.20-03-01085.2000; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MAURER P, 1995, J MOL BIOL, V253, P347, DOI 10.1006/jmbi.1995.0557; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1235, DOI 10.1006/bbrc.1994.2063; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nakamura T, 1998, GENOMICS, V54, P89, DOI 10.1006/geno.1998.5571; Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476; Nakashiba T, 2000, J NEUROSCI, V20, P6540, DOI 10.1523/JNEUROSCI.20-17-06540.2000; NAKAYAMA H, 1992, NUCLEIC ACIDS RES, V20, P4939, DOI 10.1093/nar/20.18.4939; Okada A, 1999, EXP NEUROL, V156, P394, DOI 10.1006/exnr.1999.7033; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Palmer TD, 1999, J NEUROSCI, V19, P8487; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Sambrook J., 2002, MOL CLONING LAB MANU; Scherer PE, 1996, J CELL BIOL, V133, P257, DOI 10.1083/jcb.133.2.257; SMITH ML, 1984, ACTA NEUROL SCAND, V69, P385, DOI 10.1111/j.1600-0404.1984.tb07822.x; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; Takahashi J, 1999, J NEUROBIOL, V38, P65, DOI 10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.3.CO;2-H; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; Tashiro K, 1999, METHOD ENZYMOL, V303, P479; Taupin P, 2000, NEURON, V28, P385, DOI 10.1016/S0896-6273(00)00119-7; Terami H, 1999, J CELL BIOL, V146, P193, DOI 10.1083/jcb.146.1.193; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Yabe D, 1997, J BIOL CHEM, V272, P18232, DOI 10.1074/jbc.272.29.18232	50	42	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35491	35500		10.1074/jbc.M305342200	http://dx.doi.org/10.1074/jbc.M305342200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832409	hybrid			2022-12-25	WOS:000185164400091
J	Jandt, E; Denner, K; Kovalenko, M; Ostman, A; Bohmer, FD				Jandt, E; Denner, K; Kovalenko, M; Ostman, A; Bohmer, FD			The protein-tyrosine phosphatase DEP-1 modulates growth factor-stimulated cell migration and cell-matrix adhesion	ONCOGENE			English	Article						protein-tyrosine phosphatase; DEP-1; growth factor; cell migration; cell-matrix adhesion	SRC FAMILY KINASES; PDGF BETA-RECEPTOR; SITE-SELECTIVE DEPHOSPHORYLATION; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; IN-VIVO; CD148; ACTIVATION; CHEMOTAXIS; PHOSPHORYLATION	Density-enhanced protein-tyrosine phosphatase-1 (DEP-1 also CD148) is a transmembrane molecule with a single intracellular PTP domain. It has recently been proposed to function as a tumor suppressor. We have previously shown that DEP-1 dephosphorylates the activated platelet-derived growth factor (PDGF) beta-receptor in a site-selective manner (Kovalenko et al. (2000). J. Biol. Chem. 275, 16219-16226). We analysed cell lines with inducible DEP-1 expression for cellular functions of DEP-1. Several aspects of PDGFbeta-receptor signaling were negatively affected by DEP-1 expression. These include PDGF-stimulated activation of inositol trisphosphate formation, Erk1/2, p21Ras, and Src. Activation of receptor-associated phosphoinositide-3 kinase activity and of Akt/PKB were weakly attenuated at early time points of stimulation. Inhibition of PDGF-stimulated signaling depended on DEP-1 catalytic activity. Importantly, DEP-1 inhibited PDGF-stimulated cell migration. The catalytically inactive DEP-1 C1239S variant enhanced cell migration and PDGF-stimulated Erk1/2 activation, suggesting a dominant negative interference with endogenous DEP-1. In contrast to cell migration, cell-substrate adhesion was promoted by active DEP-1 and delayed or suppressed by DEP-1 C1239S, correlating with positive effects of DEP-1 on adhesion-stimulated Src kinase. We propose that negative regulation of growth-factor stimulated cell migration and promotion of cell-matrix adhesion may be related to the function of DEP-1 as tumor suppressor.	Univ Jena, Res Unit Mol Cell Biol, Fac Med, D-07747 Jena, Germany; Ludwig Inst Canc Res, Uppsala Branch, S-75123 Uppsala, Sweden	Friedrich Schiller University of Jena; Ludwig Institute for Cancer Research	Bohmer, FD (corresponding author), Univ Jena, Res Unit Mol Cell Biol, Fac Med, Drackendorfer Str 1, D-07747 Jena, Germany.							ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; Autschbach F, 1999, TISSUE ANTIGENS, V54, P485, DOI 10.1034/j.1399-0039.1999.540506.x; Baker JE, 2001, MOL CELL BIOL, V21, P2393, DOI 10.1128/MCB.21.7.2393-2403.2001; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Borges LG, 1996, CIRC RES, V79, P570, DOI 10.1161/01.RES.79.3.570; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; Chiarugi P, 2002, J CELL SCI, V115, P2219; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; de la Fuente-Garcia MA, 1998, BLOOD, V91, P2800, DOI 10.1182/blood.V91.8.2800.2800_2800_2809; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Graness A, 1997, BIOCHEM J, V327, P147, DOI 10.1042/bj3270147; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Hundt M, 1997, EUR J IMMUNOL, V27, P3532, DOI 10.1002/eji.1830271255; Iuliano R, 2003, CANCER RES, V63, P882; Iuliano R, 2001, FEBS LETT, V500, P41, DOI 10.1016/S0014-5793(01)02580-7; Jallal B, 1997, J BIOL CHEM, V272, P12158, DOI 10.1074/jbc.272.18.12158; Keane MM, 1996, CANCER RES, V56, P4236; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; KOVALENKO M, 1994, CANCER RES, V54, P6106; Mahboobi S, 2002, J MED CHEM, V45, P1002, DOI 10.1021/jm010988n; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Persson C, 2002, FEBS LETT, V517, P27, DOI 10.1016/S0014-5793(02)02570-X; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Ronnstrand L, 1999, J BIOL CHEM, V274, P22089, DOI 10.1074/jbc.274.31.22089; RONNSTRAND L, 1988, J BIOL CHEM, V263, P10429; Ronnstrand L, 2001, INT J CANCER, V91, P757, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1136>3.0.CO;2-J; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Schraven B, 2000, J BIOL REG HOMEOS AG, V14, P220; Sorby M, 2001, ONCOGENE, V20, P5219, DOI 10.1038/sj.onc.1204581; Takahashi T, 1999, J AM SOC NEPHROL, V10, P2135; Takahashi T, 2003, MOL CELL BIOL, V23, P1817, DOI 10.1128/MCB.23.5.1817-1831.2003; Tangye SG, 1998, J IMMUNOL, V161, P3249; Tangye SG, 1998, J IMMUNOL, V161, P3803; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; Venable CL, 2000, J BIOL CHEM, V275, P18318, DOI 10.1074/jbc.M908392199; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659	51	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4175	4185		10.1038/sj.onc.1206652	http://dx.doi.org/10.1038/sj.onc.1206652			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833140				2022-12-25	WOS:000183979800004
J	Tosha, T; Yoshioka, S; Takahashi, S; Ishimori, K; Shimada, H; Morishima, I				Tosha, T; Yoshioka, S; Takahashi, S; Ishimori, K; Shimada, H; Morishima, I			NMR study on the structural changes of cytochrome P450cam upon the complex formation with putidaredoxin - Functional significance of the putidaredoxin-induced structural changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; SITE-DIRECTED MUTAGENESIS; ELECTRON-TRANSFER COMPLEX; HEME PROXIMAL SITE; CRYSTAL-STRUCTURE; REDUCED PUTIDAREDOXIN; OXIDIZED PUTIDAREDOXIN; SURFACE RESIDUES; H-1-NMR SPECTRA	We investigated putidaredoxin-induced structural changes in carbonmonoxy P450cam by using NMR spectroscopy. The resonance from the beta-proton of the axial cysteine was upfield shifted by 0.12 ppm upon the putidaredoxin binding, indicating that the axial cysteine approaches to the heme-iron by about 0.1 Angstrom. The approach of the axial cysteine to the heme-iron would enhance the electronic donation from the axial thiolate to the heme-iron, resulting in the enhanced heterolysis of the dioxygen bond. In addition to the structural perturbation on the axial ligand, the structural changes in the substrate and ligand binding site were observed. The resonances from the 5-exo- and 9-methyl-protons of d-camphor, which were newly identified in this study, were upfield shifted by 1.28 and 0.20 ppm, respectively, implying that d-camphor moves to the heme-iron by 0.15-0.7 Angstrom. Based on the radical rebound mechanism, the approach of d-camphor to the heme-iron could promote the oxygen transfer reaction. On the other hand, the downfield shift of the resonance from the gamma-methyl group of Thr-252 reflects the movement of the side chain away from the heme-iron by similar to0.25 Angstrom. Because Thr-252 regulates the heterolysis of the dioxygen bond, the positional rearrangement of Thr-252 might assist the scission of the dioxygen bond. We, therefore, conclude that putidaredoxin induces the specific heme environmental changes of P450cam, which would facilitate the oxygen activation and the oxygen transfer reaction.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan; Keio Univ, Sch Med, Dept Biochem, Tokyo 1608582, Japan	Kyoto University; Keio University	Morishima, I (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan.	morisima@mds.moleng.kyoto-u.ac.jp	Tosha, Takehiko/AAR-2404-2020; Ishimori, Koichiro/AAQ-4434-2021; Ishimori, Koichiro/S-1247-2016	Tosha, Takehiko/0000-0002-8971-0759; Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462				Aoki M, 1998, BBA-PROTEIN STRUCT M, V1386, P157, DOI 10.1016/S0167-4838(98)00094-6; Aoki M, 1998, BBA-PROTEIN STRUCT M, V1384, P180, DOI 10.1016/S0167-4838(98)00017-X; Aoki M, 1998, INORG CHIM ACTA, V272, P80, DOI 10.1016/S0020-1693(97)05946-X; ATKINS WM, 1987, J AM CHEM SOC, V109, P3754, DOI 10.1021/ja00246a038; ATKINS WM, 1988, BIOCHEMISTRY-US, V27, P1610, DOI 10.1021/bi00405a033; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERZINIS AP, 1979, BIOCHEM BIOPH RES CO, V87, P229, DOI 10.1016/0006-291X(79)91670-X; BREWER CB, 1988, J BIOL CHEM, V263, P791; BREWER CB, 1986, ARCH BIOCHEM BIOPHYS, V249, P515, DOI 10.1016/0003-9861(86)90029-9; Case DA, 1995, J BIOMOL NMR, V6, P341; CRULL GB, 1989, J BIOL CHEM, V264, P2649; DALVIT C, 1985, BIOCHEMISTRY-US, V24, P3398, DOI 10.1021/bi00335a003; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; Franzen S, 2001, J AM CHEM SOC, V123, P12578, DOI 10.1021/ja0108988; Furukawa Y, 2000, BIOCHEMISTRY-US, V39, P10996, DOI 10.1021/bi000874y; Furukawa Y, 2001, J BIOL CHEM, V276, P12983, DOI 10.1074/jbc.M010217200; GRIFFIN BW, 1972, BIOCHEMISTRY-US, V11, P4740, DOI 10.1021/bi00775a017; GROVES JT, 1981, J AM CHEM SOC, V103, P2884, DOI 10.1021/ja00400a075; Gunsalus I C, 1978, Methods Enzymol, V52, P166; Hata M, 2001, J AM CHEM SOC, V123, P6410, DOI 10.1021/ja000908p; HINTZ MJ, 1981, J BIOL CHEM, V256, P6721; HINTZ MJ, 1982, J BIOL CHEM, V257, P4324; Hishiki T, 2000, J BIOCHEM, V128, P965, DOI 10.1093/oxfordjournals.jbchem.a022848; Holden M, 1997, J BIOL CHEM, V272, P21720, DOI 10.1074/jbc.272.35.21720; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; JOHNSON CE, 1958, J CHEM PHYS, V29, P1012, DOI 10.1063/1.1744645; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Lian L. Y., 1993, NMR MACROMOLECULES P, P153; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; MABBUTT BC, 1985, BIOCHIM BIOPHYS ACTA, V832, P175, DOI 10.1016/0167-4838(85)90329-2; Makino R., 1984, Proceedings of the IXth International Conference on Raman Spectroscopy (papers in summary form only received), P492; Makino R., 1982, OXYGENASES OXYGEN ME, P467; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; Mouro C, 1999, FEBS LETT, V455, P302, DOI 10.1016/S0014-5793(99)00898-4; Mouro C, 1997, FEBS LETT, V414, P203, DOI 10.1016/S0014-5793(97)00995-2; OGG RJ, 1994, J MAGN RESON SER B, V104, P1, DOI 10.1006/jmrb.1994.1048; Pochapsky SS, 2003, BIOCHEMISTRY-US, V42, P5649, DOI 10.1021/bi034263s; Pochapsky TC, 1996, BIOCHIMIE, V78, P723, DOI 10.1016/S0300-9084(97)82530-8; POCHAPSKY TC, 1994, BIOCHEMISTRY-US, V33, P6424, DOI 10.1021/bi00187a006; Pochapsky TC, 1999, BIOCHEMISTRY-US, V38, P4681, DOI 10.1021/bi983030b; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RAAG R, 1989, BIOCHEMISTRY-US, V28, P917, DOI 10.1021/bi00428a077; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Roitberg AE, 1998, J AM CHEM SOC, V120, P8927, DOI 10.1021/ja9739906; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Shimada H, 2001, J INORG BIOCHEM, V83, P255, DOI 10.1016/S0162-0134(00)00173-2; Shimada H, 1999, J BIOL CHEM, V274, P9363, DOI 10.1074/jbc.274.14.9363; SHIRO Y, 1989, J AM CHEM SOC, V111, P7707, DOI 10.1021/ja00202a007; SHULMAN RG, 1970, J MOL BIOL, V53, P143, DOI 10.1016/0022-2836(70)90050-1; Sjodin T, 2001, BIOCHEMISTRY-US, V40, P6852, DOI 10.1021/bi002510b; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; STAYTON PS, 1989, BIOCHEMISTRY-US, V28, P8201, DOI 10.1021/bi00446a035; STAYTON PS, 1990, BIOCHEMISTRY-US, V29, P7381, DOI 10.1021/bi00484a005; Tosha T, 2002, BIOCHEMISTRY-US, V41, P13883, DOI 10.1021/bi0261037; Ueno T, 1998, J AM CHEM SOC, V120, P12264, DOI 10.1021/ja980016d; Unno M, 1997, J AM CHEM SOC, V119, P6614, DOI 10.1021/ja963785a; Unno M, 2002, J BIOL CHEM, V277, P2547, DOI 10.1074/jbc.M108917200; Unno M, 1996, J BIOL CHEM, V271, P17869, DOI 10.1074/jbc.271.30.17869; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; Wuthrich K, 1998, NAT STRUCT BIOL, V5, P492, DOI 10.1038/728; Yoshioka S, 2002, J AM CHEM SOC, V124, P14571, DOI 10.1021/ja0265409; Yoshioka S, 2001, EUR J BIOCHEM, V268, P252, DOI 10.1046/j.1432-1033.2001.01872.x; Yoshioka S, 2000, J INORG BIOCHEM, V81, P141, DOI 10.1016/S0162-0134(00)00097-0; Yoshizawa K, 2001, J AM CHEM SOC, V123, P9806, DOI 10.1021/ja010593t	71	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39809	39821		10.1074/jbc.M304265200	http://dx.doi.org/10.1074/jbc.M304265200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12842870	hybrid			2022-12-25	WOS:000185713800067
J	Haase, I; Fischer, M; Bacher, A; Schramek, N				Haase, I; Fischer, M; Bacher, A; Schramek, N			Temperature-dependent presteady state kinetics of lumazine synthase from the hyperthermophilic eubacterium Aquifex aeolicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY RIBOFLAVIN SYNTHASE; CRYSTAL-STRUCTURE ANALYSIS; BACILLUS-SUBTILIS; 6,7-DIMETHYL-8-RIBITYLLUMAZINE SYNTHASE; ANGSTROM RESOLUTION; BIOSYNTHESIS; PURIFICATION; MECHANISM; CATALYSIS; REVEALS	6,7-Dimethyl-8-ribityllumazine synthase (lumazine synthase) catalyzes the condensation of 5-amino-6-ribitylamino- 2,4(1H, 3H)-pyrimidinedione and 3,4-dihydroxy-2- butanone 4-phosphate. Presteady state kinetic experiments using the enzyme from the hyperthermophilic bacterium Aquifex aeolicus were monitored by multiwavelength photometry. An early optical transient absorbing around 330 nm is interpreted as a Schiff base intermediate obtained by reaction of the position 5 amino group of the heterocyclic substrate with the carbonyl group of 3,4-dihydroxy-2-butanone 4-phosphate. A second transient with an absorption maximum at 445 nm represents an intermediate resulting from the elimination of orthophosphate from the Schiff base. The rate-determining step is the subsequent formation of the 7-exomethylene type anion of 6,7-dimethyl-8-ribityllumazine. The rate constants for the three partial reactions identified by the stopped flow experiments show linear Arrhenius relations in the temperature range of 15 - 70 degreesC.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Schramek, N (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Fischer, Markus/H-2870-2012; Fischer, Markus/AFT-1856-2022; Fischer, Markus J./G-9477-2012	Fischer, Markus/0000-0001-7243-4199; 				BACHER A, 1986, METHOD ENZYMOL, V122, P192; BACHER A, 1980, J BIOL CHEM, V255, P632; BACHER A, 1986, J MOL BIOL, V187, P75, DOI 10.1016/0022-2836(86)90407-9; Bacher A., 1980, P 6 INT S, P579; BACHER A, 1991, CHEM BIOCH FLAVOPROT, V1, P293; BEACH RL, 1971, J ORG CHEM, V36, P3937, DOI 10.1021/jo00824a020; BOWN DH, 1986, J ORG CHEM, V51, P2461, DOI 10.1021/jo00363a011; CRESSWELL RM, 1960, J CHEM SOC, P4768, DOI 10.1039/jr9600004768; Fischer M, 2003, J MOL BIOL, V326, P783, DOI 10.1016/S0022-2836(02)01473-0; Fischer M, 2002, EUR J BIOCHEM, V269, P519, DOI 10.1046/j.0014-2956.2001.02674.x; Haase I, 2003, EUR J BIOCHEM, V270, P1025, DOI 10.1046/j.1432-1033.2003.03478.x; KIS K, 1995, J BIOL CHEM, V270, P16788, DOI 10.1074/jbc.270.28.16788; KIS K, 1995, BIOCHEMISTRY-US, V34, P2883, DOI 10.1021/bi00009a019; KISTIAKOWSKY GB, 1949, J AM CHEM SOC, V71, P2006, DOI 10.1021/ja01174a029; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LADENSTEIN R, 1983, J BIOL CHEM, V258, P1981; MASSEY V, 1966, J BIOL CHEM, V241, P2347; Meining W, 2000, J MOL BIOL, V299, P181, DOI 10.1006/jmbi.2000.3742; Mortl S, 1996, J BIOL CHEM, V271, P33201, DOI 10.1074/jbc.271.52.33201; NEUBERGER G, 1986, BIOCHEM BIOPH RES CO, V139, P1111, DOI 10.1016/S0006-291X(86)80292-3; Persson K, 1999, PROTEIN SCI, V8, P2355; PFLEIDERER W, 1966, CHEM BER-RECL, V99, P3503, DOI 10.1002/cber.19660991117; Richter G, 1997, METHOD ENZYMOL, V280, P374; RITSERT K, 1995, J MOL BIOL, V253, P151, DOI 10.1006/jmbi.1995.0542; Schramek N, 2003, J AM CHEM SOC, V125, P4460, DOI 10.1021/ja028226k; VOLK R, 1990, J BIOL CHEM, V265, P19479; Zhang XF, 2003, J MOL BIOL, V328, P167, DOI 10.1016/S0022-2836(03)00186-4; Zhang XF, 2001, J MOL BIOL, V306, P1099, DOI 10.1006/jmbi.2000.4435; Zheng YJ, 2000, BIOORG CHEM, V28, P89, DOI 10.1006/bioo.2000.1163	29	15	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37909	37915		10.1074/jbc.M303090200	http://dx.doi.org/10.1074/jbc.M303090200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867427	hybrid			2022-12-25	WOS:000185437200113
J	Weibel, P; Hiltbrunner, A; Brand, L; Kessler, F				Weibel, P; Hiltbrunner, A; Brand, L; Kessler, F			Dimerization of Toc-GTPases at the chloroplast protein import machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROTEIN RECEPTOR; OUTER ENVELOPE; MEMBRANE; GTP; MECHANISM; BINDING; DOMAIN; IDENTIFICATION; TRANSLOCATION; BIOGENESIS	Import of chloroplast precursor proteins is controlled by the coordinate action of two homologous GTPases, Toc159 and Toc33, located at the cytosol-outer membrane interface. Recent studies in Arabidopsis showed that the cytosolic form of the precursor binding protein Toc159 is targeted to its receptor at the import machinery, Toc33, via heterodimerization of their GTP-binding domains. Toc33 may also form GDP-bound homodimers, as suggested by the crystal structure of its pea ortholog. Moreover, the structural data suggested that arginine 130 ( Arg(130)) of Arabidopsis Toc33 may function as a GTPase-activating "arginine-finger" at the other monomer in the Toc33 dimer. Here, we demonstrate that Arg(130) of Toc33 does not function as an Arginine-finger. A mutant, Toc33-R130A, binds and hydrolyzes GTP like the wild type. However, we demonstrate that Arg(130) is involved in both homodimerization of Toc33 and in heterodimerization with the GTP-binding domain of Toc159. The dependence of Toc33 homodimerization on Arg(130) is mutual, requiring the presence of Arg(130) at both monomers. As the GTPase is not activated by dimerization, it may be activated independently at either monomer, possibly even before dimerization. Independent regulation of GTPase activity may serve to coordinate the interactions of the GTPases during the import of proteins into the chloroplast.	Univ Neuchatel, Inst Bot, Lab Physiol Vegetale, CH-2007 Neuchatel, Switzerland; ETH, Inst Plant Sci, Plant Physiol & Biochem Grp, CH-8092 Zurich, Switzerland	University of Neuchatel; Swiss Federal Institutes of Technology Domain; ETH Zurich	Kessler, F (corresponding author), Univ Neuchatel, Inst Bot, Lab Physiol Vegetale, Rue Emile Argand 11, CH-2007 Neuchatel, Switzerland.		Kessler, Felix Henrique/AAO-1722-2020	Hiltbrunner, Andreas/0000-0003-0438-5297; Kessler, Felix/0000-0001-6409-5043				Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; Bauer J, 2002, J CELL BIOL, V159, P845, DOI 10.1083/jcb.200208018; Bauer J, 2001, CELL MOL LIFE SCI, V58, P420, DOI 10.1007/PL00000867; Bolter B, 1998, P NATL ACAD SCI USA, V95, P15831, DOI 10.1073/pnas.95.26.15831; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen K, 2000, BIOCHEM SOC T, V28, P485, DOI 10.1042/0300-5127:0280485; Cline K, 2000, NATURE, V403, P148, DOI 10.1038/35003082; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; HILTBRUNNER A, 2001, BIOCH CELL BIOL, V79, P1; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Jackson-Constan D, 2001, PLANT PHYSIOL, V125, P1567, DOI 10.1104/pp.125.4.1567; Jarvis P, 2002, BBA-MOL CELL RES, V1590, P177, DOI 10.1016/S0167-4889(02)00176-3; Jelic M, 2003, BIOCHEMISTRY-US, V42, P5906, DOI 10.1021/bi034001q; Kessler F, 2002, NAT STRUCT BIOL, V9, P81, DOI 10.1038/nsb0202-81; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; Liang ZM, 2000, BIOCHEM J, V346, P501, DOI 10.1042/0264-6021:3460501; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; Reumann S, 1999, P NATL ACAD SCI USA, V96, P784, DOI 10.1073/pnas.96.2.784; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schleiff E, 2003, P NATL ACAD SCI USA, V100, P4604, DOI 10.1073/pnas.0730860100; Schleiff E, 2002, BIOCHEMISTRY-US, V41, P1934, DOI 10.1021/bi011361+; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; Smith MD, 2002, J CELL BIOL, V159, P833, DOI 10.1083/jcb.200208017; Sun YJ, 2002, NAT STRUCT BIOL, V9, P95, DOI 10.1038/nsb744; Sveshnikova N, 2000, P NATL ACAD SCI USA, V97, P4973, DOI 10.1073/pnas.080491597; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	31	42	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37321	37329		10.1074/jbc.M305946200	http://dx.doi.org/10.1074/jbc.M305946200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869544	Green Submitted, hybrid			2022-12-25	WOS:000185437200041
J	Beck, J; Nassal, M				Beck, J; Nassal, M			Efficient hsp90-independent in vitro activation by Hsc70 and Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION INITIATION COMPLEX; RNA ENCAPSIDATION SIGNAL; STEM-LOOP STRUCTURE; HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE; ATPASE ACTIVITY; TYROSINE RESIDUE; DNAJ; BINDING; HSP70	Hsp90 is a specialized chaperone that controls the activity of many key regulator proteins such as steroid hormone receptors (SHRs). Hormone binding, and therefore SHR activation, requires Hsp90, which is loaded onto the receptors by a series of events involving Hsp70, Hsp40, Hop, and p23. The reverse transcriptase (RT) of hepatitis B viruses, small DNA-containing viruses that replicate via an RNA intermediate, has been reported to depend similarly on Hsp90 for enzymatic activity. Using an in vitro reconstitution system consisting of recombinant duck hepatitis B virus RT, purified chaperones, and the authentic RNA template Depsilon, we demonstrate here that this RT can be activated efficiently by just Hsp40 and Hsc70 plus energy, without the need for Hsp90 or other cofactors. The reaction appears to proceed selectively with the Hdj1 variant of Hsp40 but not Hdj2 or its yeast homolog Ydj1. The primary reaction product is a metastable, RNA binding-competent intermediate that decays quickly in the absence of its cognate RNA but, in its presence, accumulates in an initiation-competent form over several hours. Because deletion of the RNase H domain rendered the protein partly chaperone-independent, the chaperones may be needed indirectly to relieve occlusion of the RNA binding site by this domain. Our results do not exclude that other factors contribute to RT activation in vivo, but they challenge a fundamental SHR-like dependence on Hsp90. Thus Hsc70, mostly known for its role in general protein folding, is able to effect activation of a highly specialized target protein.	Univ Hosp freiburg, Dept Internal Med Mol Biol 2, D-79106 Freiburg, Germany	University of Freiburg	Nassal, M (corresponding author), Univ Hosp freiburg, Dept Internal Med Mol Biol 2, Hugstetter Str 55, D-79106 Freiburg, Germany.	nassal2@ukl.uni-freiburg.de	Nassal, Michael/U-4529-2019	Nassal, Michael/0000-0003-2204-9158; Beck, Jurgen/0000-0001-8794-9320				BARTENSCHLAGER R, 1992, EMBO J, V11, P3413, DOI 10.1002/j.1460-2075.1992.tb05420.x; Beck J, 1998, MOL CELL BIOL, V18, P6265, DOI 10.1128/MCB.18.11.6265; Beck J, 1997, VIROLOGY, V227, P500, DOI 10.1006/viro.1996.8329; Beck J, 2001, J VIROL, V75, P7410, DOI 10.1128/JVI.75.16.7410-7419.2001; Beerens N, 2001, J BIOL CHEM, V276, P31247, DOI 10.1074/jbc.M102441200; Blumberg BS, 1997, P NATL ACAD SCI USA, V94, P7121, DOI 10.1073/pnas.94.14.7121; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; Buchner J, 1998, METHOD ENZYMOL, V290, P409, DOI 10.1016/S0076-6879(98)90034-9; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; Davis GD, 1999, BIOTECHNOL BIOENG, V65, P382, DOI 10.1002/(SICI)1097-0290(19991120)65:4<382::AID-BIT2>3.3.CO;2-9; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Eickbush Thomas H., 1994, P121; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; Fliss AE, 1999, J BIOL CHEM, V274, P34045, DOI 10.1074/jbc.274.48.34045; Forsythe HL, 2001, J BIOL CHEM, V276, P15571, DOI 10.1074/jbc.C100055200; Gao BC, 1996, J BIOL CHEM, V271, P16792, DOI 10.1074/jbc.271.28.16792; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; Hu JM, 2002, J VIROL, V76, P269, DOI 10.1128/JVI.76.1.269-279.2002; Hu JM, 2000, J VIROL, V74, P11447, DOI 10.1128/JVI.74.24.11447-11455.2000; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; Kanelakis KC, 1999, J BIOL CHEM, V274, P34134, DOI 10.1074/jbc.274.48.34134; Kanelakis KC, 2000, BIOCHEMISTRY-US, V39, P14314, DOI 10.1021/bi001671c; King C, 1999, BIOCHEMISTRY-US, V38, P12452, DOI 10.1021/bi9902788; KNAUS T, 1993, NUCLEIC ACIDS RES, V21, P3967, DOI 10.1093/nar/21.17.3967; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Lanford RE, 1999, J VIROL, V73, P1885, DOI 10.1128/JVI.73.3.1885-1893.1999; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LOEB DD, 1995, J VIROL, V69, P6886, DOI 10.1128/JVI.69.11.6886-6891.1995; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; Murphy PJM, 2001, J BIOL CHEM, V276, P30092, DOI 10.1074/jbc.M103773200; Nassal M, 1996, J VIROL, V70, P2764, DOI 10.1128/JVI.70.5.2764-2773.1996; Nassal M, 1999, INTERVIROLOGY, V42, P100, DOI 10.1159/000024970; NASSAL M, 2000, FRONTIERS MOL BIOL D, V26, P1; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; POLLACK JR, 1993, J VIROL, V67, P3254, DOI 10.1128/JVI.67.6.3254-3263.1993; POLLACK JR, 1994, J VIROL, V68, P5579, DOI 10.1128/JVI.68.9.5579-5587.1994; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Schaaf SG, 1999, J BIOL CHEM, V274, P37787, DOI 10.1074/jbc.274.53.37787; SCHAAF SG, 1998, THESIS U HEIDELBERG; Schiene-Fischer C, 2002, NAT STRUCT BIOL, V9, P419, DOI 10.1038/nsb804; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; Tavis JE, 1998, J VIROL, V72, P5789, DOI 10.1128/JVI.72.7.5789-5796.1998; WANG GH, 1993, J VIROL, V67, P6507, DOI 10.1128/JVI.67.11.6507-6512.1993; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; Wang XT, 2002, J VIROL, V76, P5857, DOI 10.1128/JVI.76.12.5857-5865.2002; WEBER M, 1994, J VIROL, V68, P2994, DOI 10.1128/JVI.68.5.2994-2999.1994; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; ZOULIM F, 1994, J VIROL, V68, P6, DOI 10.1128/JVI.68.1.6-13.1994	66	78	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36128	36138		10.1074/jbc.M301069200	http://dx.doi.org/10.1074/jbc.M301069200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851401	hybrid			2022-12-25	WOS:000185318300033
J	Kovacs, KA; Steinmann, M; Magistretti, PJ; Halfon, O; Cardinaux, JR				Kovacs, KA; Steinmann, M; Magistretti, PJ; Halfon, O; Cardinaux, JR			CCAAT/enhancer-binding protein family members recruit the coactivator CREB-binding protein and trigger its phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL INHIBITORY PROTEIN; RNA-POLYMERASE-II; C/EBP-BETA; GENE-EXPRESSION; DEPENDENT KINASES; MAMMALIAN-CELLS; CBP; ALPHA; P300; ACTIVATION	CCAAT/enhancer-binding protein (C/EBP) family members are transcription factors involved in important physiological processes, such as cellular proliferation and differentiation, regulation of energy homeostasis, inflammation, and hematopoiesis. Transcriptional activation by C/EBPalpha and C/EBPbeta involves the coactivators CREB-binding protein (CBP) and p300, which promote transcription by acetylating histones and recruiting basal transcription factors. In this study, we show that C/EBPdelta is also using CBP as a coactivator. Based on sequence homology with C/EBPalpha and -beta, we identify in C/EBPalpha two conserved amino acid segments that are necessary for the physical interaction with CBP. Using reporter gene assays, we demonstrate that mutation of these residues prevents CBP recruitment and diminishes the transactivating potential of C/EBPdelta. In addition, our results indicate that C/EBP family members not only recruit CBP but specifically induce its phosphorylation. We provide evidence that CBP phosphorylation depends on its interaction with C/EBPdelta and define point mutations within one of the two conserved amino acid segments of C/EBPdelta that abolish CBP phosphorylation as well as transcriptional activation, suggesting that this new mechanism could be important for C/EBP-mediated transcription.	Univ Lausanne, Dept Child Adolescent Psychiat, CH-1005 Lausanne, Switzerland; Univ Lausanne, Ctr Psychiat Neurosci, Dept Psychiat, CH-1005 Lausanne, Switzerland; Univ Lausanne, Inst Physiol, CH-1005 Lausanne, Switzerland	University of Lausanne; University of Lausanne; University of Lausanne	Cardinaux, JR (corresponding author), Ctr Neurosci Psychiat, 1er Etage,Site Cery, CH-1008 Prilly, Switzerland.	Jean-Rene.Cardinaux@hospvd.ch	Cardinaux, Jean-René/G-5391-2012	Cardinaux, Jean-René/0000-0001-6423-0014; Magistretti, Pierre Julius/0000-0002-6678-320X; Kovacs, Krisztian/0000-0001-6251-1007				Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; BANERJEE AC, 1994, ONCOGENE, V9, P1733; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Cardinaux JR, 1997, MOL BRAIN RES, V51, P220, DOI 10.1016/S0169-328X(97)00241-6; Cardinaux JR, 1996, J NEUROSCI, V16, P919; Cardinaux JR, 2000, GLIA, V29, P91, DOI 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.0.CO;2-I; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chan HM, 2001, J CELL SCI, V114, P2363; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cohen LE, 1999, J CLIN INVEST, V104, P1123, DOI 10.1172/JCI7308; Colangelo AM, 1998, P NATL ACAD SCI USA, V95, P10920, DOI 10.1073/pnas.95.18.10920; Cortes-Canteli M, 2002, J BIOL CHEM, V277, P5460, DOI 10.1074/jbc.M108761200; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Cruzalegui FH, 1999, EMBO J, V18, P1335, DOI 10.1093/emboj/18.5.1335; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; Darlington GJ, 1999, CURR OPIN CELL BIOL, V11, P678, DOI 10.1016/S0955-0674(99)00035-6; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Goodman RH, 2000, GENE DEV, V14, P1553; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Jurado LA, 2002, J BIOL CHEM, V277, P27606, DOI 10.1074/jbc.M201429200; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kievit P, 2001, MOL ENDOCRINOL, V15, P614, DOI 10.1210/me.15.4.614; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Liu YZ, 1999, NEUROREPORT, V10, P1239, DOI 10.1097/00001756-199904260-00016; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; LORIAUX MM, 1994, J BIOL CHEM, V269, P28839; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MCKNIGHT SL, 1991, SCI AM, V264, P54, DOI 10.1038/scientificamerican0491-54; Menard C, 2002, NEURON, V36, P597, DOI 10.1016/S0896-6273(02)01026-7; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; NATSUKA S, 1992, BLOOD, V79, P460; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; SCOTT LM, 1992, BLOOD, V80, P1725; Taubenfeld SM, 2001, NAT NEUROSCI, V4, P813, DOI 10.1038/90520; Taubenfeld SM, 2001, J NEUROSCI, V21, P84, DOI 10.1523/JNEUROSCI.21-01-00084.2001; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wilson HL, 2002, MOL CELL ENDOCRINOL, V188, P15, DOI 10.1016/S0303-7207(01)00754-7; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; Yuan LW, 2002, BBA-MOL CELL RES, V1592, P205, DOI 10.1016/S0167-4889(02)00327-0; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200; Yukawa K, 1998, J BIOL CHEM, V273, P31345, DOI 10.1074/jbc.273.47.31345; Zanger K, 1999, MOL ENDOCRINOL, V13, P268, DOI 10.1210/me.13.2.268	72	129	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36959	36965		10.1074/jbc.M303147200	http://dx.doi.org/10.1074/jbc.M303147200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857754	hybrid			2022-12-25	WOS:000185318300130
J	Medici, MA; Sciortino, MT; Perri, D; Amici, C; Avitabile, E; Ciotti, M; Balestrieri, E; De Smaele, E; Franzoso, G; Mastino, A				Medici, MA; Sciortino, MT; Perri, D; Amici, C; Avitabile, E; Ciotti, M; Balestrieri, E; De Smaele, E; Franzoso, G; Mastino, A			Protection by herpes simplex virus glycoprotein D against Fas-mediated apoptosis - Role of nuclear factor kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOCKS APOPTOSIS; MONOCLONAL-ANTIBODIES; FUNCTIONAL REGION; PROTEIN-KINASE; CELLS; TYPE-1; ACTIVATION; TNF; INDUCTION; ENTRY	Signals involved in protection against apoptosis by herpes simplex virus 1 (HSV-1) were investigated. Using U937 monocytoid cells as an experimental model, we have demonstrated that HSV-1 rendered these cells resistant to Fas-induced apoptosis promptly after infection. UV-inactivated virus as well as the envelope glycoprotein D (gD) of HSV-1, by itself, exerted a protective effect on Fas-induced apoptosis. NF-kappaB was activated by gD, and protection against Fas-mediated apoptosis by gD was abolished in cells stably transfected with a dominant negative mutant I-kappaBalpha, indicating that NF-kappaB activation plays a role in the antiapoptotic activity of gD in our experimental model. Moreover, NF-kappaB-dependent protection against Fas-mediated apoptosis was associated with decreased levels of caspase-8 activity and with the up-regulation of intracellular antiapoptotic proteins.	Univ Messina, Dept Microbiol Genet & Mol Sci, I-98166 Messina, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Bologna, Dept Expt Pathol, Sect Microbiol & Virol, I-40126 Bologna, Italy; Univ Roma Tor Vergata, Tor Vergata Univ Hosp, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA	University of Messina; University of Rome Tor Vergata; University of Bologna; University of Rome Tor Vergata; Policlin Tor Vergata; University of Chicago	Mastino, A (corresponding author), Univ Messina, Dept Microbiol Genet & Mol Sci, Salita Sperone 31, I-98166 Messina, Italy.	mastino@med.uniroma2.it	Sciortino, Maria Teresa/B-9425-2012; Mastino, Antonio/A-4686-2008; Franzoso, Guido/GRR-8628-2022; De Smaele, Enrico/C-1124-2013	Sciortino, Maria Teresa/0000-0002-8519-7724; Mastino, Antonio/0000-0002-0338-6450; De Smaele, Enrico/0000-0003-4524-4423; AVITABILE, ELISA/0000-0003-0328-2544; balestrieri, emanuela/0000-0001-5906-5907; Franzoso, Guido/0000-0002-0778-988X				Amici C, 2001, J BIOL CHEM, V276, P28759, DOI 10.1074/jbc.M103408200; Aubert M, 1999, J VIROL, V73, P2803, DOI 10.1128/JVI.73.4.2803-2813.1999; Aubert M, 1999, J VIROL, V73, P10359, DOI 10.1128/JVI.73.12.10359-10370.1999; Aubert M, 2001, J VIROL, V75, P1013, DOI 10.1128/JVI.75.2.1013-1030.2001; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barry M, 1998, CURR OPIN IMMUNOL, V10, P422, DOI 10.1016/S0952-7915(98)80116-7; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Clarke P, 2003, J BIOL CHEM, V278, P18092, DOI 10.1074/jbc.M300265200; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; Everett H, 1999, TRENDS MICROBIOL, V7, P160, DOI 10.1016/S0966-842X(99)01487-0; FEI S, 2002, NATURE, V419, P634; FEI S, 2001, J VIROL, V75, P215; Galvan V, 2000, J VIROL, V74, P1931, DOI 10.1128/JVI.74.4.1931-1938.2000; Galvan V, 1999, J VIROL, V73, P3219, DOI 10.1128/JVI.73.4.3219-3226.1999; Galvan V, 1998, P NATL ACAD SCI USA, V95, P3931, DOI 10.1073/pnas.95.7.3931; HIGHLANDER SL, 1987, J VIROL, V61, P3356, DOI 10.1128/JVI.61.11.3356-3364.1987; Hikichi Y, 2001, BIOCHEM BIOPH RES CO, V289, P670, DOI 10.1006/bbrc.2001.6039; Ito M, 1997, J INFECT DIS, V175, P1220, DOI 10.1086/593672; Jerome KR, 1999, J VIROL, V73, P8950, DOI 10.1128/JVI.73.11.8950-8957.1999; Jerome KR, 2001, J IMMUNOL, V167, P3928, DOI 10.4049/jimmunol.167.7.3928; Jerome KR, 1998, J VIROL, V72, P436, DOI 10.1128/JVI.72.1.436-441.1998; Kagi D, 1996, ANNU REV IMMUNOL, V14, P207, DOI 10.1146/annurev.immunol.14.1.207; Kieff E, 1998, SEMIN VIROL, V8, P471, DOI 10.1006/smvy.1998.0151; Koyama AH, 1997, J GEN VIROL, V78, P2909, DOI 10.1099/0022-1317-78-11-2909; Koyama AH, 1997, J VIROL, V71, P2567, DOI 10.1128/JVI.71.3.2567-2571.1997; Krummenacher C, 1998, J VIROL, V72, P7064, DOI 10.1128/JVI.72.9.7064-7074.1998; Leopardi R, 1997, P NATL ACAD SCI USA, V94, P7891, DOI 10.1073/pnas.94.15.7891; Leopardi R, 1996, P NATL ACAD SCI USA, V93, P9583, DOI 10.1073/pnas.93.18.9583; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Mastino A, 1997, CELL DEATH DIFFER, V4, P629, DOI 10.1038/sj.cdd.4400289; Matteucci C, 1999, CYTOMETRY, V35, P145, DOI 10.1002/(SICI)1097-0320(19990201)35:2<145::AID-CYTO6>3.0.CO;2-2; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicola AV, 1998, J VIROL, V72, P3595, DOI 10.1128/JVI.72.5.3595-3601.1998; Nicola AV, 1996, J VIROL, V70, P3815, DOI 10.1128/JVI.70.6.3815-3822.1996; O'Brien V, 1998, J GEN VIROL, V79, P1833, DOI 10.1099/0022-1317-79-8-1833; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pan JB, 2001, J GEN VIROL, V82, P171, DOI 10.1099/0022-1317-82-1-171; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; Patel A, 1998, VIROLOGY, V247, P212, DOI 10.1006/viro.1998.9243; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; RONG BL, 1992, VIROLOGY, V189, P750, DOI 10.1016/0042-6822(92)90599-K; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Rux AH, 1998, J VIROL, V72, P7091, DOI 10.1128/JVI.72.9.7091-7098.1998; SABBIONI S, 1995, ARCH VIROL, V140, P335, DOI 10.1007/BF01309866; Sciortino MT, 2000, VIROLOGY, V277, P27, DOI 10.1006/viro.2000.0575; SERAFINICESSI F, 1988, J GEN VIROL, V69, P869, DOI 10.1099/0022-1317-69-4-869; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Tamada K, 2000, J IMMUNOL, V164, P4105, DOI 10.4049/jimmunol.164.8.4105; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Zachos G, 2001, J VIROL, V75, P2710, DOI 10.1128/JVI.75.6.2710-2728.2001; Zhou GY, 2001, J VIROL, V75, P6166, DOI 10.1128/JVI.75.13.6166-6172.2001; Zhou GY, 2000, J VIROL, V74, P11782, DOI 10.1128/JVI.74.24.11782-11791.2000; Zhou GY, 2000, J VIROL, V74, P9048, DOI 10.1128/JVI.74.19.9048-9053.2000	60	81	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36059	36067		10.1074/jbc.M306198200	http://dx.doi.org/10.1074/jbc.M306198200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12844494	hybrid, Green Published			2022-12-25	WOS:000185318300025
J	Chalifour, RJ; McLaughlin, RW; Lavoie, L; Morissette, C; Tremblay, N; Boule, M; Sarazin, P; Stea, D; Lacombe, D; Tremblay, P; Gervais, F				Chalifour, RJ; McLaughlin, RW; Lavoie, L; Morissette, C; Tremblay, N; Boule, M; Sarazin, P; Stea, D; Lacombe, D; Tremblay, P; Gervais, F			Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; FIBRIL FORMATION; APOLIPOPROTEIN-E; AMINO-ACIDS; PROTEIN; LIGANDS; A-BETA(1-42); TOXICITY; MODEL; FIBRILLOGENESIS	Residues 16 - 20 of the beta-amyloid peptide (Abeta) function as a self-recognition element during Abeta assembly into fibers. Peptides containing this motif retain the ability to interact with Abeta and, in some cases, potently inhibit its assembly. Replacing L- with D-amino acids could stabilize such peptides and permit their evaluation as therapeutic agents for Alzheimer's disease. Here we have assessed the effect that such a chiral reversal has on inhibitory potency. D-enantiomers of five peptides, KLVFFA, KKLVFFA, KFVFFA, KIVFFA, and KVVFFA, were unexpectedly more active as inhibitors in an in vitro fibrillogenesis assay. Circular dichroism showed that D-KLVFFA more effectively prevented Abeta adopting the beta-sheet secondary structure correlated with fibrillogenesis. Electron microscopy showed that fiber formation was also more strongly inhibited by D-KLVFFA. Heterochiral inhibition was confirmed using D-Abeta, on the principle that enantiomeric proteins exhibit reciprocal chiral biochemical interactions. With D-Abeta, L-KLVFFA was the more potent inhibitor, rather than D-KLVFFA. Most significantly, D-peptides were more potent at reducing the toxicity of both Abeta(1-40) and Abeta(1-42) toward neuronal cells in culture. This unforeseen heterochiral stereoselectivity of Abeta for D-peptide inhibitors should be considered during future design of peptide-based inhibitors of Abeta neurotoxicity and fibrillogenesis.	Neurochem Inc, St Laurent, PQ H4S 2A1, Canada		Gervais, F (corresponding author), Neurochem Inc, 7220 Frederick Bldg,Suite 100, St Laurent, PQ H4S 2A1, Canada.			Tremblay, Nadine/0000-0003-3011-030X				Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Colon W, 1999, METHOD ENZYMOL, V309, P605; CORIGLIANOMURPHY MA, 1985, INT J PEPT PROT RES, V25, P225; Esler WP, 1996, BIOCHEMISTRY-US, V35, P13914, DOI 10.1021/bi961302+; Esler WP, 1999, BIOPOLYMERS, V49, P505, DOI 10.1002/(SICI)1097-0282(199905)49:6<505::AID-BIP8>3.0.CO;2-I; Feifel B, 1998, J BIOL CHEM, V273, P11999, DOI 10.1074/jbc.273.20.11999; Findeis MA, 1999, BIOCHEMISTRY-US, V38, P6791, DOI 10.1021/bi982824n; Ghanta J, 1996, J BIOL CHEM, V271, P29525, DOI 10.1074/jbc.271.47.29525; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gordon DJ, 2001, BIOCHEMISTRY-US, V40, P8237, DOI 10.1021/bi002416v; Hasegawa K, 1999, BIOCHEMISTRY-US, V38, P15514, DOI 10.1021/bi991161m; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; Janek K, 2001, BIOCHEMISTRY-US, V40, P5457, DOI 10.1021/bi002005e; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kuner P, 2000, J BIOL CHEM, V275, P1673, DOI 10.1074/jbc.275.3.1673; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lowe TL, 2001, BIOCHEMISTRY-US, V40, P7882, DOI 10.1021/bi002734u; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; McLaurin J, 1999, EUR J BIOCHEM, V266, P1101, DOI 10.1046/j.1432-1327.1999.00957.x; McLaurin J, 2000, J BIOL CHEM, V275, P18495, DOI 10.1074/jbc.M906994199; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Pritsker M, 1998, P NATL ACAD SCI USA, V95, P7287, DOI 10.1073/pnas.95.13.7287; Reed J, 1997, ANAL BIOCHEM, V254, P36, DOI 10.1006/abio.1997.2355; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tjernberg LO, 1997, J BIOL CHEM, V272, P12601, DOI 10.1074/jbc.272.19.12601; Wall J, 1999, BIOCHEMISTRY-US, V38, P14101, DOI 10.1021/bi991131j; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; Yang DS, 2001, AMYLOID, V8, P10	38	131	138	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34874	34881		10.1074/jbc.M212694200	http://dx.doi.org/10.1074/jbc.M212694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12840031	hybrid			2022-12-25	WOS:000185164400018
J	Console, S; Marty, C; Garcia-Echeverria, C; Schwendener, R; Ballmer-Hofer, K				Console, S; Marty, C; Garcia-Echeverria, C; Schwendener, R; Ballmer-Hofer, K			Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR DELIVERY; PENETRATING PEPTIDES; BASIC DOMAIN; INTERNALIZATION; LIPOSOMES; MEMBRANE; HEPARIN; OLIGOSACCHARIDES; PROTEOGLYCANS; BIOSYNTHESIS	Protein transduction domains (PTDs) are short basic peptide sequences present in many cellular and viral proteins that mediate translocation across cellular membranes. PTDs have become widely used as tools for the delivery of high M-r polypetides, polynucleotides, or nanoparticles to cells in culture; and even the transfer of cargo molecules to the tissue of live animals has been reported. These cell-permeable peptides are functional when fused in-frame to recombinant polypeptides or when chemically coupled to their cargo. The mechanism responsible for PTD-mediated membrane translocation is controversially discussed and may vary among the various PTDs reported in the literature. Thus direct physical interaction with membrane lipids resulting in vectorial delivery to cells has been proposed for the Antennapedia (Antp) PTD, whereas uptake by the retroviral TAT ( transactivator of transcription) protein PTD seems to require cell surface-expressed glycosaminoglycans. The view that PTD-mediated cellular uptake is energy-independent has been dismissed recently as an artifact resulting from fixation of cells. The data reported here agree with and further extend this work. They support the idea that certain PTDs promote cellular uptake via endocytosis and require the expression of negatively charged glycosaminoglycans on the surface of the target cells. Uptake of Antp PTD conjugates or peptide-derivatized liposomes was blocked by heparan sulfate proteoglycans, whereas TAT-mediated uptake was inhibited by both heparin and dextran sulfate. Mutant cells defective for glycosaminoglycan synthesis showed dramatically reduced Antp- or TAT-mediated transmembrane transport confirming the role of these complex polysaccharides in PTD-mediated cellular uptake. The fact that PTDs selectively interact with distinct glycosaminoglycan species has implications for therapeutic applications and may allow targeting of selective tissues that differ in their surface-expressed glycosaminoglycan patterns.	Paul Scherrer Inst, CH-5232 Villigen, Switzerland; Novartis Pharma Inc, CH-4002 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Novartis	Ballmer-Hofer, K (corresponding author), Paul Scherrer Inst, CH-5232 Villigen, Switzerland.		Schwendener, Reto A/F-6373-2011	Ballmer-Hofer, Kurt/0000-0002-3800-9129				Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Fischer PM, 2001, BIOCONJUGATE CHEM, V12, P825, DOI 10.1021/bc0155115; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Garcia-Echeverria C, 2001, BIOORG MED CHEM LETT, V11, P1363, DOI 10.1016/S0960-894X(01)00208-6; GarciaEcheverria C, 1997, LETT PEPT SCI, V4, P49; GarciaEcheverria C, 1996, BIOORG MED CHEM LETT, V6, P229, DOI 10.1016/0960-894X(96)00009-1; Hausser H, 1999, BIOCHEM J, V344, P827, DOI 10.1042/0264-6021:3440827; Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Lundberg M, 2001, NAT BIOTECHNOL, V19, P713, DOI 10.1038/90741; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Marty C, 2002, BRIT J CANCER, V87, P106, DOI 10.1038/sj.bjc.6600423; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Rusnati M, 2001, J BIOL CHEM, V276, P22420, DOI 10.1074/jbc.M010779200; Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377	29	348	386	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35109	35114		10.1074/jbc.M301726200	http://dx.doi.org/10.1074/jbc.M301726200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12837762	hybrid, Green Accepted			2022-12-25	WOS:000185164400046
J	Ito, T; Okazawa, H; Maruyama, K; Tomizawa, K; Motegi, S; Ohnishi, H; Kuwano, H; Kosugi, A; Matozaki, T				Ito, T; Okazawa, H; Maruyama, K; Tomizawa, K; Motegi, S; Ohnishi, H; Kuwano, H; Kosugi, A; Matozaki, T			Interaction of SAP-1, a transmembrane-type protein-tyrosine phosphatase, with the tyrosine kinase Lck - Roles in regulation of T cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; CYTOPLASMIC DOMAINS; NEGATIVE REGULATION; MOLECULAR-CLONING; DOCKING PROTEIN; ACTIVATION; INHIBITION; EXPRESSION; MIGRATION	SAP-1 is a transmembrane-type protein-tyrosine phosphatase that is expressed in most tissues but whose physiological functions remain unknown. The cytoplasmic region of SAP-1 has now been shown to bind directly the tyrosine kinase Lck. Overexpression of wild-type SAP-1, but not that of a catalytically inactive mutant of SAP-1, inhibited both the basal and the T cell antigen receptor (TCR)-stimulated activity of Lck in human Jurkat T cell lines. Lck served as a direct substrate for dephosphorylation by SAP-1 in vitro. Overexpression of wild-type SAP-1 in Jurkat cells also: (i) inhibited both the activation of mitogen-activated protein kinase and the increase in cell surface expression of CD69 induced by TCR stimulation; (ii) reduced the extent of the TCR-induced increase in the tyrosine phosphorylation of ZAP-70 or that of LAT; (iii) reduced both the basal level of tyrosine phosphorylation of p62(dok), as well as the increase in the phosphorylation of this protein induced by CD2 stimulation; and (iv) inhibited cell migration. These results thus suggest that the direct interaction of SAP-1 with Lck results in inhibition of the kinase activity of the latter and a consequent negative regulation of T cell function.	Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, Gunma 3718512, Japan; Osaka Univ, Fac Med, Sch Allied Hlth Sci, Suita, Osaka 5650871, Japan; Gunma Univ, Grad Sch Med, Dept Gen Surg Sci Surg 1, Gunma 3718511, Japan	Gunma University; Osaka University; Gunma University	Matozaki, T (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, 3-39-15 Showa Machi, Gunma 3718512, Japan.		Okazawa, Hideki/E-3055-2010; Okazawa, Hideki/C-3836-2011					Baker JE, 2001, MOL CELL BIOL, V21, P2393, DOI 10.1128/MCB.21.7.2393-2403.2001; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; Davidson D, 2001, EMBO J, V20, P3414, DOI 10.1093/emboj/20.13.3414; de la Fuente-Garcia MA, 1998, BLOOD, V91, P2800, DOI 10.1182/blood.V91.8.2800.2800_2800_2809; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; Hata Y, 1996, J NEUROSCI, V16, P2488; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; HONDA H, 1994, BLOOD, V84, P4186, DOI 10.1182/blood.V84.12.4186.bloodjournal84124186; Hosooka T, 2001, MOL CELL BIOL, V21, P5437, DOI 10.1128/MCB.21.16.5437-5446.2001; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Inngjerdingen M, 2002, BLOOD, V99, P4318, DOI 10.1182/blood.V99.12.4318; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Johnson KG, 1999, J IMMUNOL, V162, P3802; Kosugi A, 2001, IMMUNITY, V14, P669, DOI 10.1016/S1074-7613(01)00146-7; Martelli MP, 2001, J BIOL CHEM, V276, P45654, DOI 10.1074/jbc.M105777200; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nemorin JG, 2000, J BIOL CHEM, V275, P14590, DOI 10.1074/jbc.275.19.14590; Nemorin JG, 2001, J IMMUNOL, V166, P4408, DOI 10.4049/jimmunol.166.7.4408; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; Noguchi T, 2001, J BIOL CHEM, V276, P15216, DOI 10.1074/jbc.M007208200; OHTA M, 1990, JPN J CANCER RES, V81, P440, DOI 10.1111/j.1349-7006.1990.tb02588.x; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; RYAN TC, 1995, J BIOL CHEM, V270, P17081, DOI 10.1074/jbc.270.29.17081; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; Sattler M, 2001, J BIOL CHEM, V276, P2451, DOI 10.1074/jbc.M006250200; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seo Y, 1997, BIOCHEM BIOPH RES CO, V231, P705, DOI 10.1006/bbrc.1997.6139; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Takada T, 2002, J BIOL CHEM, V277, P34359, DOI 10.1074/jbc.M206541200; Tangye SG, 1998, J IMMUNOL, V161, P3803; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; Weber KSC, 2001, MOL BIOL CELL, V12, P3074, DOI 10.1091/mbc.12.10.3074; Wills Z, 1999, NEURON, V22, P301, DOI 10.1016/S0896-6273(00)81091-0; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yamasaki S, 2001, J BIOL CHEM, V276, P45175, DOI 10.1074/jbc.M105384200; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264	57	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34854	34863		10.1074/jbc.M300648200	http://dx.doi.org/10.1074/jbc.M300648200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12837766	hybrid			2022-12-25	WOS:000185164400016
J	Ueki, N; Hayman, MJ				Ueki, N; Hayman, MJ			Direct interaction of Ski with either Smad3 or Smad4 is necessary and sufficient for Ski-mediated repression of transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; CO-REPRESSOR; DNA-BINDING; ONCOPROTEIN; RECEPTOR; CELLS; ALPHA; ACTS; MAD	The oncoprotein Ski represses transforming growth factor (TGF)-beta signaling in an N-CoR-independent manner. However, the molecular mechanism(s) underlying this event has not been elucidated. Here, we identify an additional domain in Ski that mediates interaction with Smad3 which is important for this repression. This domain is distinct from the previously reported N-terminal Smad3 binding domain in Ski. Individual alanine substitution of several residues in the domain significantly affected Ski-Smad3 interaction. Furthermore, combined mutations within this domain, together with those in the previously identified Smad3 binding domain, can completely abolish the interaction of Ski with Smad3, while mutation in each domain alone retained partial interaction. By introducing those mutations that abolish direct interaction with Smad3 or Smad4 individually, or in combination, we show that interaction of Ski with either Smad3 or Smad4 is sufficient for Ski-mediated repression of TGF-beta signaling. Furthermore our results clearly demonstrate that Ski does not disrupt Smad3-Smad4 heteromer formation, and recruitment of Ski to the Smad3/4 complex through binding to either Smad3 or Smad4 is both necessary and sufficient for repression.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [R01CA042573] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Jepsen K, 2002, J CELL SCI, V115, P689; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kim SS, 2002, STRUCTURE, V10, P787, DOI 10.1016/S0969-2126(02)00769-4; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mizuide M, 2003, J BIOL CHEM, V278, P531, DOI 10.1074/jbc.C200596200; Nicol R, 1999, CELL GROWTH DIFFER, V10, P243; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Ueki N, 2003, J BIOL CHEM, V278, P24858, DOI 10.1074/jbc.M303447200; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zheng GX, 1997, J BIOL CHEM, V272, P31855, DOI 10.1074/jbc.272.50.31855	18	40	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32489	32492		10.1074/jbc.C300276200	http://dx.doi.org/10.1074/jbc.C300276200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12857746	hybrid			2022-12-25	WOS:000184901800002
J	Li, XH; Zhao, QP; Liao, R; Sun, PQ; Wu, XH				Li, XH; Zhao, QP; Liao, R; Sun, PQ; Wu, XH			The SCFSkp2 ubiquitin ligase complex interacts with the human replication licensing factor Cdt1 and regulates Cdt1 degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; S-PHASE; CELL-CYCLE; BUDDING YEAST; MCM PROTEINS; SACCHAROMYCES-CEREVISIAE; DEPENDENT DEGRADATION; MEDIATED DEGRADATION; CDK PHOSPHORYLATION; PROTEASOME PATHWAY	DNA replication initiation is tightly controlled so that each origin only fires once per cell cycle. Cell cycle-dependent Cdt1 degradation plays an essential role in DNA replication control, as overexpression of Cdt1 leads to re-replication. In this study, we investigated the mechanisms of Cdt1 degradation in mammalian cells. We showed that the F-box protein Skp2 specifically interacted with human Cdt1 in a phosphorylation-dependent manner. The SCFSkp2 complex ubiquitinated Cdt1 both in vivo and in vitro. Down-regulation of Skp2 or disruption of the interaction between Cdt1 and Skp2 resulted in a stabilization and accumulation of Cdt1. These results suggest that the SCFSkp2-mediated ubiquitination pathway may play an important role in the cell cycle-dependent Cdt1 degradation in mammalian cells.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Wu, XH (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Baum B, 1998, EMBO J, V17, P5689, DOI 10.1093/emboj/17.19.5689; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coverley D, 2000, J CELL SCI, V113, P1929; Devault A, 2002, CURR BIOL, V12, P689, DOI 10.1016/S0960-9822(02)00768-6; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Lei M, 2001, J CELL SCI, V114, P1447; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Seki T, 2000, P NATL ACAD SCI USA, V97, P14115, DOI 10.1073/pnas.97.26.14115; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	49	191	195	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30854	30858		10.1074/jbc.C300251200	http://dx.doi.org/10.1074/jbc.C300251200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12840033	hybrid			2022-12-25	WOS:000184658800056
J	Gasteier, JE; Madrid, R; Krautkramer, E; Schroder, S; Muranyi, W; Benichou, S; Fackler, OT				Gasteier, JE; Madrid, R; Krautkramer, E; Schroder, S; Muranyi, W; Benichou, S; Fackler, OT			Activation of the Rac-binding partner FHOD1 induces actin stress fibers via a ROCK-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIAPHANOUS-RELATED FORMIN; SERUM RESPONSE FACTOR; SRC TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; CYTOSKELETAL CONTROL; FAMILY PROTEINS; ARP2/3 COMPLEX; RHO GTPASES; LIM KINASE; DYNAMICS	Diaphanous related formins (DRFs) are part of the formin protein family that control morphogenesis, embryonic differentiation, cytokinesis, and cell polarity. DRFs organize the cytoskeleton in eukaryotic cells via the interaction with specific members of the Rho family of small GTPases including Rho, Rac, and Cdc42. This is best understood for Rho, which transmits signals to the actin cytoskeleton through the cooperation of its DRF effector mDia with ROCK (Rho-associated kinase). Here, we show that a constitutive active form of the Rac-interacting DRF FHOD1 (formin homology 2 domain containing 1) associates with F-actin in NIH3T3 cells, resulting in the formation of thick actin fibers. Cytoskeletal changes induced by FHOD1 correlated with the induction of serum response element transcription and were mediated by formin homology domains 1 and 2 of FHOD1. FHOD1-induced effects required the activity of the Rho-ROCK cascade that is targeted at a level downstream of Rho by the DRF. However, when the functional interaction of FHOD1 with individual GTPases was addressed, Rac but not Rho or Cdc42 bound to FHOD1 in cells and induced its recruitment to actin filaments and lamellipodia/membrane ruffles. Furthermore, activated FHOD1 interfered with lamellipodia formation. These results indicate that FHOD1 acts as an effector of Rac in actin rearrangements and transcriptional regulation and may provide a link for the Rac-dependent activation of the Rho cascade.	Univ Heidelberg, Dept Virol, Inst Hyg, INF 324, D-69120 Heidelberg, Germany; Univ Paris 05, Dept Infect Dis, Inst Cochin, CNRS,UMR 8104,INSERM,U567, F-75014 Paris, France	Ruprecht Karls University Heidelberg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Fackler, OT (corresponding author), Univ Heidelberg, Dept Virol, Inst Hyg, INF 324, D-69120 Heidelberg, Germany.			Benichou, Serge/0000-0003-3602-3530; Madrid Gonzalez, Ricardo/0000-0002-1350-9864; Fackler, Oliver Till/0000-0003-2982-4209				Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bierne H, 2001, J CELL BIOL, V155, P101, DOI 10.1083/jcb.200104037; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Evangelista M, 2002, NAT CELL BIOL, V4, P41; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; FRAZIER JA, 1997, CURR BIOL, V7, P414; Gasman S, 2003, NAT CELL BIOL, V5, P195, DOI 10.1038/ncb935; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Koka S, 2003, J CELL SCI, V116, P1745, DOI 10.1242/jcs.00386; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; Pollard TD, 2002, NAT CELL BIOL, V4, pE191, DOI 10.1038/ncb0802-e191a; Pollard TD, 2001, J CELL SCI, V114, P3; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, DEV CELL, V1, P160, DOI 10.1016/S1534-5807(01)00029-6; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; Schafer DA, 1998, J CELL BIOL, V143, P1919, DOI 10.1083/jcb.143.7.1919; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tanaka K, 2000, BIOCHEM BIOPH RES CO, V267, P479, DOI 10.1006/bbrc.1999.1707; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Westendorf JJ, 1999, GENE, V232, P173, DOI 10.1016/S0378-1119(99)00127-4; Westendorf JJ, 2001, J BIOL CHEM, V276, P46453, DOI 10.1074/jbc.M105162200; Yayoshi-Yamamoto S, 2000, MOL CELL BIOL, V20, P6872, DOI 10.1128/MCB.20.18.6872-6881.2000; Zhou Z, 2001, DEV CELL, V1, P477, DOI 10.1016/S1534-5807(01)00058-2	47	75	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38902	38912		10.1074/jbc.M306229200	http://dx.doi.org/10.1074/jbc.M306229200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12857739	hybrid			2022-12-25	WOS:000185575100099
J	Noe, V; MacKenzie, S; Ciudad, CJ				Noe, V; MacKenzie, S; Ciudad, CJ			An intron is required for dihydrofolate reductase protein stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSENSE-MEDIATED DECAY; MATERNAL MESSENGER-RNA; GENE-EXPRESSION; ADENINE PHOSPHORIBOSYLTRANSFERASE; TRANSLATION INITIATION; MAMMALIAN-CELLS; NUCLEOCYTOPLASMIC TRANSPORT; INTERVENING SEQUENCES; NUCLEAR HISTORY; XENOPUS-OOCYTES	We compared the expression of dihydrofolate reductase minigenes with and without an intron. The levels of protein were significantly higher in the presence of dihydrofolate reductase intron 1. However, mRNA levels in both constructs were comparable. In addition, the RNA transcribed from either construct was correctly polyadenylated and exported to the cytoplasm. The intron-mediated increase in dihydrofolate reductase protein levels was position-independent and was also observed when dihydrofolate reductase intron 1 was replaced by heterologous introns. The translational rate of dihydrofolate reductase protein was increased in transfectants from the intron-containing minigene. In addition, the protein encoded by the intronless construct was unstable and subject to lysosomal degradation, thus showing a shorter half-life than the protein encoded by the intron-containing minigene. We conclude that an intron is required for the translation and stability of dihydrofolate reductase protein.	Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Autonomous Univ Barcelona, Sch Sci, Dept Cellular Biol Physiol & Immunol, E-08193 Barcelona, Spain	University of Barcelona; Autonomous University of Barcelona	Noe, V (corresponding author), Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, Av Diagonal 643, E-08028 Barcelona, Spain.		MacKenzie, Simon/Q-2362-2019; Noe, Veronique/K-3615-2014; Ciudad, Carlos J./D-7917-2014	MacKenzie, Simon/0000-0003-1845-6826; Noe, Veronique/0000-0001-7937-8038; Ciudad, Carlos J./0000-0002-7855-392X				BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BRADDOCK M, 1994, NUCLEIC ACIDS RES, V22, P5255, DOI 10.1093/nar/22.24.5255; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; Brocke KS, 2002, HUM MOL GENET, V11, P331, DOI 10.1093/hmg/11.3.331; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P4395, DOI 10.1128/MCB.8.10.4395; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; Cooke C, 1999, MOL CELL BIOL, V19, P4971; CROUSE GF, 1988, NUCLEIC ACIDS RES, V16, P7025, DOI 10.1093/nar/16.14.7025; de Moor CH, 2001, INT REV CYTOL, V203, P567; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; GASSER CS, 1982, P NATL ACAD SCI-BIOL, V79, P6522, DOI 10.1073/pnas.79.21.6522; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; HAMM J, 1989, EMBO J, V8, P4153; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; Huang YQ, 1996, MOL CELL BIOL, V16, P1534; KESSLER O, 1993, MOL CELL BIOL, V13, P6211, DOI 10.1128/MCB.13.10.6211; Kessler O, 1996, MOL CELL BIOL, V16, P4426; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; Lu SH, 2003, RNA, V9, P618, DOI 10.1261/rna.5260303; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; LUSKY M, 1984, CELL, V36, P391, DOI 10.1016/0092-8674(84)90232-0; Maquat LE, 2001, RNA, V7, P445, DOI 10.1017/S1355838201002229; Matsumoto K, 1998, EMBO J, V17, P2107, DOI 10.1093/emboj/17.7.2107; Meric F, 1996, J BIOL CHEM, V271, P30804, DOI 10.1074/jbc.271.48.30804; Moriyama T, 1998, J BIOL CHEM, V273, P22037, DOI 10.1074/jbc.273.34.22037; Muckenthaler M, 1997, RNA, V3, P983; NESIC D, 1994, GENE DEV, V8, P363, DOI 10.1101/gad.8.3.363; NESIC D, 1993, MOL CELL BIOL, V13, P3359, DOI 10.1128/MCB.13.6.3359; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE EXPRESSION, V1, P5; Noe V, 1998, ONCOGENE, V16, P1931, DOI 10.1038/sj.onc.1201718; Noe V, 1999, J BIOL CHEM, V274, P27807, DOI 10.1074/jbc.274.39.27807; Nott A, 2003, RNA, V9, P607, DOI 10.1261/rna.5250403; PANDEY NB, 1990, NUCLEIC ACIDS RES, V18, P3161, DOI 10.1093/nar/18.11.3161; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; Preiss T, 1998, RNA, V4, P1321, DOI 10.1017/S1355838298980669; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; RYU WS, 1989, J VIROL, V63, P4386, DOI 10.1128/JVI.63.10.4386-4394.1989; Salles FJ, 1999, METHODS, V17, P38, DOI 10.1006/meth.1998.0705; Salvador N, 2000, J BIOL CHEM, V275, P27447; SEGLEN PO, 1979, EUR J BIOCHEM, V95, P215, DOI 10.1111/j.1432-1033.1979.tb12956.x; STANDART N, 1994, CURR BIOL, V4, P939, DOI 10.1016/S0960-9822(00)00212-8; Sun XL, 2000, EMBO J, V19, P4734, DOI 10.1093/emboj/19.17.4734; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; VENOLIA L, 1987, SOMAT CELL MOLEC GEN, V13, P491, DOI 10.1007/BF01534491; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Zhang J, 1998, RNA, V4, P801, DOI 10.1017/S1355838298971849	60	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38292	38300		10.1074/jbc.M212746200	http://dx.doi.org/10.1074/jbc.M212746200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12865433	hybrid			2022-12-25	WOS:000185575100027
J	Fusetti, F; Pijning, T; Kalk, KH; Bos, E; Dijkstra, BW				Fusetti, F; Pijning, T; Kalk, KH; Bos, E; Dijkstra, BW			Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY RHEUMATOID-ARTHRITIS; SERUM YKL-40; HUMAN CHITOTRIOSIDASE; GLUCOSAMINE RESIDUES; PERIPHERAL-BLOOD; SYNOVIAL-CELLS; HC GP-39; PROTEIN; CHITINASE; FAMILY	The human cartilage glycoprotein-39 (HCgp-39 or YKL40) is expressed by synovial cells and macrophages during inflammation. Its precise physiological role is unknown. However, it has been proposed that HCgp-39 acts as an autoantigen in rheumatoid arthritis, and high expression levels have been associated with cancer development. HCgp-39 shares high sequence homology with family 18 chitinases, and although it binds to chitin it lacks enzymatic activity. The crystal structure of HCgp-39 shows that the protein displays a (beta/alpha)(8)-barrel fold with an insertion of an alpha + beta domain. A 43-Angstrom long carbohydrate-binding cleft is present at the C-terminal side of the beta-strands in the (beta/alpha)(8) barrel. Binding of chitin fragments of different lengths identified nine sugar-binding subsites in the groove. Protein-carbohydrate interactions are mainly mediated by stacking of side chains of aromatic amino acid residues. Surprisingly, the specificity of chitin binding to HCgp-39 depends on the length of the oligosaccharide. Although chitin disaccharides tend to occupy the distal subsites, longer chains bind preferably to the central subsites in the groove. Despite the absence of enzymatic activity, long chitin fragments are distorted upon binding, with the GlcNAc at subsite -1 in a boat conformation, similar to what has been observed in chitinases. The presence of chitin in the human body has never been documented so far. However, the binding features observed in the complex structures suggest that either chitin or a closely related oligosaccharide could act as the physiological ligand for HCgp-39.	Univ Groningen, Dept Chem, Cent Lab Biophys, NL-9747 AG Groningen, Netherlands; NV Organon, NL-5340 BH Oss, Netherlands	University of Groningen	Dijkstra, BW (corresponding author), Univ Groningen, Dept Chem, Cent Lab Biophys, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	bauke@chem.rug.nl	Pijning, Tjaard/ABA-2929-2021; Dijkstra, Bauke W./H-4308-2019; Pijning, Tjaard/HDO-3704-2022	Pijning, Tjaard/0000-0003-4107-3663; Dijkstra, Bauke W./0000-0001-9731-6586; 				Baeten D, 2000, ARTHRITIS RHEUM, V43, P1233, DOI 10.1002/1529-0131(200006)43:6<1233::AID-ANR6>3.0.CO;2-9; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buhi WC, 2002, REPRODUCTION, V123, P355, DOI 10.1530/rep.0.1230355; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Chang NCA, 2001, J BIOL CHEM, V276, P17497, DOI 10.1074/jbc.M010417200; Cintin C, 1999, BRIT J CANCER, V79, P1494, DOI 10.1038/sj.bjc.6690238; Connor JR, 2000, OSTEOARTHR CARTILAGE, V8, P87, DOI 10.1053/joca.1999.0276; Conrozier T, 2000, ANN RHEUM DIS, V59, P828, DOI 10.1136/ard.59.10.828; Cope AP, 1999, ARTHRITIS RHEUM, V42, P1497, DOI 10.1002/1529-0131(199907)42:7<1497::AID-ANR25>3.0.CO;2-#; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DeLano W. L., 2002, PYMOL MOL GRAPHIC SY; Drenth J., 2010, PRINCIPLES PROTEIN C, V3rd; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; FORD LO, 1974, J MOL BIOL, V88, P349, DOI 10.1016/0022-2836(74)90487-2; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Fusetti F, 2002, J BIOL CHEM, V277, P25537, DOI 10.1074/jbc.M201636200; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; Johansen JS, 2000, J HEPATOL, V32, P911, DOI 10.1016/S0168-8278(00)80095-1; JOHANSEN JS, 1995, EUR J CANCER, V31A, P1437, DOI 10.1016/0959-8049(95)00196-P; Johansen JS, 1996, BRIT J RHEUMATOL, V35, P553; JOHANSEN JS, 1993, BRIT J RHEUMATOL, V32, P949; Johansen JS, 2001, SCAND J RHEUMATOL, V30, P297; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kavanaugh A, 2003, J RHEUMATOL, V30, P449; Kawamura K, 1999, DEVELOPMENT, V126, P211; Kirkpatrick RB, 1997, EXP CELL RES, V237, P46, DOI 10.1006/excr.1997.3764; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; Mohanty AK, 2003, J BIOL CHEM, V278, P14451, DOI 10.1074/jbc.M208967200; Mueller A, 2003, P NATL ACAD SCI USA, V100, P1292, DOI 10.1073/pnas.242741699; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; NYIRKOS P, 1990, BIOCHEM J, V269, P265, DOI 10.1042/bj2690265; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papanikolau Y, 2001, BIOCHEMISTRY-US, V40, P11338, DOI 10.1021/bi010505h; Peltomaa R, 2001, RHEUMATOL INT, V20, P192, DOI 10.1007/s002960100115; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Recklies AD, 2002, BIOCHEM J, V365, P119, DOI 10.1042/BJ20020075; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; Sun YJ, 2001, J BIOL CHEM, V276, P17507, DOI 10.1074/jbc.M010416200; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; Tsark EC, 2002, J IMMUNOL, V169, P6625, DOI 10.4049/jimmunol.169.11.6625; Tsuji T, 2002, SPINE, V27, P732, DOI 10.1097/00007632-200204010-00010; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; van Aalten DMF, 2000, P NATL ACAD SCI USA, V97, P5842, DOI 10.1073/pnas.97.11.5842; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; Varela PF, 2002, J BIOL CHEM, V277, P13229, DOI 10.1074/jbc.M110502200; Verheijden GFM, 1997, ARTHRITIS RHEUM, V40, P1115, DOI 10.1002/art.1780400616; Vos K, 2000, ANN RHEUM DIS, V59, P544, DOI 10.1136/ard.59.7.544; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Westling C, 2002, J BIOL CHEM, V277, P49247, DOI 10.1074/jbc.M209139200	61	146	155	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37753	37760		10.1074/jbc.M303137200	http://dx.doi.org/10.1074/jbc.M303137200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12851408	hybrid, Green Published			2022-12-25	WOS:000185437200093
J	Hansen, U; Bruckner, P				Hansen, U; Bruckner, P			Macromolecular specificity of collagen fibrillogenesis - Fibrils of collagens I and XI contain a heterotypic alloyed core and a collagen I sheath	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V COLLAGEN; INTERMEDIATE-FILAMENTS; EXTRACELLULAR-MATRIX; INTERVERTEBRAL DISCS; SMALL PROTEOGLYCAN; MOLECULAR PACKING; CARTILAGE FIBRILS; ARP2/3 COMPLEX; TRIPLE-HELIX; III COLLAGEN	Suprastructures of the extracellular matrix, such as banded collagen fibrils, microfibrils, filaments, or networks, are composites comprising more than one type of macromolecule. The suprastructural diversity reflects tissue-specific requirements and is achieved by formation of macromolecular composites that often share their main molecular components alloyed with minor components. Both, the mechanisms of formation and the final macromolecular organizations depend on the identity of the components and their quantitative contribution. Collagen I is the predominant matrix constituent in many tissues and aggregates with other collagens and/or fibril-associated macromolecules into distinct types of banded fibrils. Here, we studied co-assembly of collagens I and XI, which co-exist in fibrils of several normal and pathologically altered tissues, including fibrous cartilage and bone, or osteoarthritic joints. Immediately upon initiation of fibrillogenesis, the proteins co-assembled into alloy-like stubby aggregates that represented efficient nucleation sites for the formation of composite fibrils. Propagation of fibrillogenesis occurred by exclusive accretion of collagen I to yield composite fibrils of highly variable diameters. Therefore, collagen I/XI fibrils strikingly differed from the homogeneous fibrillar alloy generated by collagens II and XI, although the constituent polypeptides of collagens I and II are highly homologous. Thus, the mode of aggregation of collagens into vastly diverse fibrillar composites is finely tuned by subtle differences in molecular structures through formation of macromolecular alloys.	Univ Klinikum Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany	University of Munster	Bruckner, P (corresponding author), Univ Klinikum Munster, Inst Physiol Chem & Pathobiochem, Waldeyerstr 15, D-48149 Munster, Germany.	peter.bruckner@uni-muenster.de	Bruckner, Peter/F-4817-2019	Bruckner, Peter/0000-0002-5566-5611				ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; Aszodi A, 1998, J CELL BIOL, V143, P1399, DOI 10.1083/jcb.143.5.1399; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; Birk DE, 2001, MICRON, V32, P223, DOI 10.1016/S0968-4328(00)00043-3; BIRK DE, 1990, J CELL SCI, V95, P649; Blaschke UK, 2000, J BIOL CHEM, V275, P10370, DOI 10.1074/jbc.275.14.10370; Bos KJ, 2001, J MOL BIOL, V306, P1011, DOI 10.1006/jmbi.2000.4429; BRODSKY B, 1980, BIOCHIM BIOPHYS ACTA, V621, P162, DOI 10.1016/0005-2795(80)90072-0; BRODSKY B, 1985, BIOL CHEM PATHOLOGY, P73; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; Chakravarti S, 2000, INVEST OPHTH VIS SCI, V41, P3365; Coulombe PA, 2001, J CELL SCI, V114, P4345; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; EIKENBERRY EF, 1984, J MOL BIOL, V176, P261, DOI 10.1016/0022-2836(84)90424-8; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; Eyre D, 2002, ARTHRITIS RES, V4, P30, DOI 10.1186/ar380; Eyre D, 1987, STRUCTURE FUNCTION C, P261; Ezura Y, 2000, J CELL BIOL, V151, P779, DOI 10.1083/jcb.151.4.779; FRASER RDB, 1987, J MOL BIOL, V193, P115, DOI 10.1016/0022-2836(87)90631-0; GELMAN RA, 1979, J BIOL CHEM, V254, P180; Hagg R, 1998, J CELL BIOL, V142, P285, DOI 10.1083/jcb.142.1.285; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HENKEL W, 1982, EUR J BIOCHEM, V122, P205, DOI 10.1111/j.1432-1033.1982.tb05868.x; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P59, DOI 10.1177/39.1.1983874; Kinoshita K, 2002, TRENDS CELL BIOL, V12, P267, DOI 10.1016/S0962-8924(02)02295-X; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; LI SW, 1995, GENE DEV, V9, P2821, DOI 10.1101/gad.9.22.2821; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MIOSGE N, 1994, HISTOCHEM J, V26, P939; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; NAH HD, 1992, J BIOL CHEM, V267, P22581; Nerlich AG, 1998, VIRCHOWS ARCH, V432, P67, DOI 10.1007/s004280050136; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; Oosawa F., 1975, THERMODYNAMICS POLYM; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; PIHLAJANIEMI T, 1984, J BIOL CHEM, V259, P2941; Pollard TD, 2002, CURR OPIN STRUC BIOL, V12, P768, DOI 10.1016/S0959-440X(02)00396-2; Rousseau JC, 1996, J BIOL CHEM, V271, P23743, DOI 10.1074/jbc.271.39.23743; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; Sherratt MJ, 2001, MICRON, V32, P185, DOI 10.1016/S0968-4328(99)00082-7; SILVER D, 1992, P NATL ACAD SCI USA, V89, P9860, DOI 10.1073/pnas.89.20.9860; Strelkov SV, 2003, BIOESSAYS, V25, P243, DOI 10.1002/bies.10246; THOM JR, 1991, J BIOL CHEM, V266, P7262; TIMPL R, 1982, METHOD ENZYMOL, V82, P472; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Wess TJ, 1998, J STRUCT BIOL, V122, P92, DOI 10.1006/jsbi.1998.3991; Wiberg C, 2002, J BIOL CHEM, V277, P49120, DOI 10.1074/jbc.M206891200; Wiberg C, 2001, J BIOL CHEM, V276, P18947, DOI 10.1074/jbc.M100625200; WU JJ, 1995, J BIOL CHEM, V270, P18865, DOI 10.1074/jbc.270.32.18865; YARKER YE, 1984, CONNECT TISSUE RES, V12, P337, DOI 10.3109/03008208409013695; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	57	61	63	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37352	37359		10.1074/jbc.M304325200	http://dx.doi.org/10.1074/jbc.M304325200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869566	hybrid			2022-12-25	WOS:000185437200045
J	Merkulova-Rainon, T; England, P; Ding, SL; Demerens, C; Tobelem, R				Merkulova-Rainon, T; England, P; Ding, SL; Demerens, C; Tobelem, R			The N-terminal domain of hepatocyte growth factor inhibits the angiogenic behavior of endothelial cells independently from binding to the c-met receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; IN-VIVO; BIOLOGICAL-ACTIVITY; HEPARIN-BINDING; FACTOR GENE; FACTOR/SCATTER FACTOR; TUMOR ANGIOGENESIS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; TYROSINE KINASE	Hepatocyte growth factor ( HGF) is a pleiotropic factor that plays an important role in complex biological processes such as embryogenesis, tissue regeneration, cancerogenesis, and angiogenesis. HGF promotes cell proliferation, survival, motility, and morphogenesis through binding to its receptor, a transmembrane tyrosine kinase encoded by the MET proto-oncogene (c-met). Structurally speaking, HGF is a polypeptide related to the enzymes of the blood coagulation cascade. Thus, it comprises kringle domains that in some other proteins have been shown to be responsible for the anti-angiogenic activity. To check whether the isolated kringles of HGF were able to inhibit angiogenesis, we produced them as recombinant proteins and compared their biological activity with that of the recombinant HGF N-terminal domain (N). We showed that (i) none of the isolated HGF kringle exhibits an anti-angiogenic activity; (ii) N is a new anti-angiogenic polypeptide; (iii) the inhibitory action of N is not specific toward HGF, because it antagonized the angiogenic activity of other growth factors, such as fibroblast growth factor-2 and vascular endothelial growth factor; and (iv) in contrast with full-length HGF, N does not bind to the c-met receptor in vitro, but fully retains its heparin-binding capacity. Our results suggest that N inhibits angiogenesis not by disrupting the HGF/c-met interaction but rather by interfering with the endothelial glycosaminoglycans, which are the secondary binding sites of HGF.	Hop Lariboisiere, Assoc Claude Bernard, Ctr Rech, Inst Vaisseaux & Sang, F-75475 Paris 10, France; Inst Pasteur, F-75724 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Merkulova-Rainon, T (corresponding author), Hop Lariboisiere, Assoc Claude Bernard, Ctr Rech, Inst Vaisseaux & Sang, 8 Rue Guy Patin, F-75475 Paris 10, France.	tatiana.merkoulova-rainon@lrb.ap-hop-paris.fr	; Demerens de Chappedelaine, Corinne/H-1648-2017	ENGLAND, Patrick/0000-0001-6410-5918; Demerens de Chappedelaine, Corinne/0000-0003-3651-0646; Merkulova-Rainon, Tatyana/0000-0002-1142-2749				Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bulteau AL, 2001, J BIOL CHEM, V276, P45662, DOI 10.1074/jbc.M105374200; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cai WY, 2000, INVEST OPHTH VIS SCI, V41, P1885; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Carey DJ, 1997, BIOCHEM J, V327, P1; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Date K, 1997, FEBS LETT, V420, P1, DOI 10.1016/S0014-5793(97)01475-0; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Hayashi K, 2000, GENE THER, V7, P1664, DOI 10.1038/sj.gt.3301284; Hendrix MJC, 1998, AM J PATHOL, V152, P855; Horiguchi N, 2002, ONCOGENE, V21, P1791, DOI 10.1038/sj.onc.1205248; IKEO K, 1995, J MOL EVOL, V40, P331, DOI 10.1007/BF00163238; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jakubczak JL, 1998, MOL CELL BIOL, V18, P1275, DOI 10.1128/MCB.18.3.1275; Jiang WG, 1999, CLIN CANCER RES, V5, P3695; Kuba K, 2000, CANCER RES, V60, P6737; Kumar R, 1998, INT J ONCOL, V12, P749; Lee TH, 1998, J BIOL CHEM, V273, P28805, DOI 10.1074/jbc.273.44.28805; Lietha D, 2001, EMBO J, V20, P5543, DOI 10.1093/emboj/20.20.5543; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; LOKKER NA, 1994, PROTEIN ENG, V7, P895, DOI 10.1093/protein/7.7.895; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Lyon M, 2002, J BIOL CHEM, V277, P1040, DOI 10.1074/jbc.M107506200; Matsumoto K, 1997, CIBA F SYMP, V212, P198; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; Nagashima M, 2001, J RHEUMATOL, V28, P1772; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Nguyen TH, 1998, HUM GENE THER, V9, P2469, DOI 10.1089/10430349850019319; Ono K, 1999, GLYCOBIOLOGY, V9, P705, DOI 10.1093/glycob/9.7.705; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Otsuka T, 2000, MOL CELL BIOL, V20, P2055, DOI 10.1128/MCB.20.6.2055-2065.2000; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Rosen EM, 1997, CIBA F SYMP, V212, P215; Rubin JS, 2001, J BIOL CHEM, V276, P32977, DOI 10.1074/jbc.M105486200; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmidt NO, 1999, INT J CANCER, V84, P10, DOI 10.1002/(SICI)1097-0215(19990219)84:1<10::AID-IJC3>3.3.CO;2-C; SHIMA N, 1994, BIOCHEM BIOPH RES CO, V200, P808, DOI 10.1006/bbrc.1994.1523; SILVAGNO F, 1995, ARTERIOSCL THROM VAS, V15, P1857, DOI 10.1161/01.ATV.15.11.1857; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Taniyama Y, 2001, CIRCULATION, V104, P2344, DOI 10.1161/hc4401.098470; Taniyama Y, 2001, GENE THER, V8, P181, DOI 10.1038/sj.gt.3301379; Trieu VN, 1999, BIOCHEM BIOPH RES CO, V257, P714, DOI 10.1006/bbrc.1999.0519; Van Belle E, 1998, CIRCULATION, V97, P381; Wagatsuma S, 1998, CANCER, V82, P520, DOI 10.1002/(SICI)1097-0142(19980201)82:3<520::AID-CNCR14>3.0.CO;2-3; Yang S, 1999, AM J PATHOL, V155, P887, DOI 10.1016/S0002-9440(10)65188-7; YU Q, 1995, BIOTECHNIQUES, V19, P122; Zhou HJ, 1998, STRUCTURE, V6, P109, DOI 10.1016/S0969-2126(98)00012-4	60	20	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37400	37408		10.1074/jbc.M212768200	http://dx.doi.org/10.1074/jbc.M212768200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12847110	hybrid, Green Published			2022-12-25	WOS:000185437200051
J	Wickstrom, SA; Alitalo, K; Keski-Oja, J				Wickstrom, SA; Alitalo, K; Keski-Oja, J			Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL APOPTOSIS; GPI-ANCHORED PROTEINS; FOCAL ADHESIONS; STRESS FIBERS; TUMOR-GROWTH; SIGNAL-TRANSDUCTION; CAVEOLAE MEMBRANE; GENE-TRANSFER; MDCK CELLS; IN-VIVO	Endostatin, the C-terminal fragment of collagen XVIII, is a potent inhibitor of angiogenesis. Observations that endostatin inhibits endothelial cell migration and induces disassembly of the actin cytoskeleton provide putative cellular mechanisms for this effect. To understand the mechanisms of endostatin-induced intracellular signaling, we analyzed the association of recombinant endostatin with endothelial cell lipid rafts and the roles of its heparin- and integrin-binding properties in this interaction. We observed that a fraction of cell surface-bound endostatin partitioned in low density membrane raft fractions together with caveolin-1. Heparinase treatment of cells prevented the recruitment of endostatin to the lipid rafts but did not affect the association of endostatin with the non-raft fraction, whereas preincubation of endostatin with soluble alpha(5)beta(1) integrin prevented the association of endostatin with the endothelial cell membrane. Endostatin treatment induced recruitment of alpha(5)beta(1) integrin into the raft fraction via a heparan sulfate proteoglycan-dependent mechanism. Subsequently, through alpha(5)beta(1) integrin, heparan sulfate, and lipid raft-mediated interactions, endostatin induced Src-dependent activation of p190RhoGAP with concomitant decrease in RhoA activity and disassembly of actin stress fibers and focal adhesions. These observations provide a cell biological mechanism, which plausibly explains the anti-angiogenic mechanisms of endostatin in vivo.	Univ Helsinki, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Virol, FIN-00014 Helsinki, Finland; Univ Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Ludwig Inst Canc Res, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Biomedicum Helsinki, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Keski-Oja, J (corresponding author), Univ Helsinki, Biomedicum Helsinki, Cell Biol Lab, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Wickstrom, Sara/0000-0001-6383-6292				Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carey DJ, 1996, J BIOL CHEM, V271, P15253, DOI 10.1074/jbc.271.25.15253; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHANG JH, 1993, ONCOGENE, V8, P959; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Dixelius J, 2002, CANCER RES, V62, P1944; Feldman AL, 2001, J NATL CANCER I, V93, P1014, DOI 10.1093/jnci/93.13.1014; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pande G, 2000, CURR OPIN CELL BIOL, V12, P569, DOI 10.1016/S0955-0674(00)00133-2; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Santos MF, 1997, J CLIN INVEST, V100, P216, DOI 10.1172/JCI119515; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Sauter BV, 2000, P NATL ACAD SCI USA, V97, P4802, DOI 10.1073/pnas.090065597; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sudhakar A, 2003, P NATL ACAD SCI USA, V100, P4766, DOI 10.1073/pnas.0730882100; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; Tkachenko E, 2002, J BIOL CHEM, V277, P19946, DOI 10.1074/jbc.M200841200; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Wickstrom SA, 2001, CANCER RES, V61, P6511; Wickstrom SA, 2002, CANCER RES, V62, P5580; Yoon SS, 1999, CANCER RES, V59, P6251	55	103	115	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37895	37901		10.1074/jbc.M303569200	http://dx.doi.org/10.1074/jbc.M303569200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12851410	hybrid			2022-12-25	WOS:000185437200111
J	Katz, FS; Bryant, FR				Katz, FS; Bryant, FR			Three-strand exchange by the Escherichia coli RecA protein using ITP as a nucleotide cofactor - Mechanistic parallels with the ATP-dependent reaction of the RecA protein from Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SSB PROTEIN; BINDING PROTEIN; NTP HYDROLYSIS; FILAMENTS; KINETICS	The RecA protein from Escherichia coli promotes an ATP-dependent three-strand exchange reaction between a circular single-stranded DNA (ssDNA) and a homologous linear double-stranded ( dsDNA). We have now found that under certain conditions, the RecA protein is also able to promote the three-strand exchange reaction using the structurally related nucleoside triphosphate, ITP, as the nucleotide cofactor. However, although both reactions are stimulated by single-stranded DNA-binding (SSB) protein, the ITP-dependent reaction differs from the ATP-dependent reaction in that it is observed only at low SSB protein concentrations, whereas the ATP-dependent reaction proceeds efficiently even at high SSB protein concentrations. Moreover, the circular ssDNA-dependent ITP hydrolysis activity of the RecA protein is strongly inhibited by SSB protein ( suggesting that SSB protein displaces RecA protein from ssDNA when ITP is present), whereas the ATP hydrolysis activity is uninhibited even at high SSB protein concentrations ( because RecA protein is resistant to displacement by SSB protein when ATP is present). These results suggest that SSB protein does not stimulate the ITP-dependent strand exchange reaction presynaptically ( by facilitating the binding of RecA protein to the circular ssDNA substrate) but may act postsynaptically ( by binding to the displaced strand that is generated when the circular ssDNA invades the linear dsDNA substrate). Interestingly, the mechanistic characteristics of the ITP-dependent strand exchange reaction of the E. coli RecA protein are similar to those of the ATP-dependent strand exchange reaction of the RecA protein from Streptococcus pneumoniae. These findings are discussed in terms of the relationship between the dynamic state of the RecA-ssDNA filament and the mechanism of the SSB protein-stimulated three-strand exchange reaction.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bryant, FR (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA.	fbryant@jhsph.edu	Katz, Francine/AAE-8953-2022		NIGMS NIH HHS [GM36516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Bork JM, 2001, J BIOL CHEM, V276, P45740, DOI 10.1074/jbc.M109247200; COTTERILL SM, 1982, BIOCHEMISTRY-US, V21, P4332, DOI 10.1021/bi00261a023; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; Katz FS, 2001, BIOCHEMISTRY-US, V40, P11082, DOI 10.1021/bi011030x; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; MENGE KL, 1992, BIOCHEMISTRY-US, V31, P5151, DOI 10.1021/bi00137a009; Nayak S, 1999, J BIOL CHEM, V274, P25979, DOI 10.1074/jbc.274.37.25979; Steffen SE, 2002, J BIOL CHEM, V277, P14493, DOI 10.1074/jbc.M112444200; Stole E, 1996, J BIOL CHEM, V271, P18326, DOI 10.1074/jbc.271.31.18326; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126	17	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35889	35896		10.1074/jbc.M305470200	http://dx.doi.org/10.1074/jbc.M305470200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12842880	hybrid			2022-12-25	WOS:000185318300005
J	Wakasugi, K; Nakano, T; Morishima, I				Wakasugi, K; Nakano, T; Morishima, I			Oxidized human neuroglobin acts as a heterotrimeric G alpha protein guanine nucleotide dissociation inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; CRYSTAL-STRUCTURE; DISULFIDE BOND; NITRIC-OXIDE; OXYGEN; HEMOGLOBIN; STABILIZATION; MYOGLOBIN; EXCHANGE; G-ALPHA(O)	Neuroglobin (Ngb) is a newly discovered vertebrate heme protein that is expressed in the brain and can reversibly bind oxygen. It has been reported that Ngb expression levels increase in response to oxygen deprivation and that it protects neurons from hypoxia in vitro and in vivo. However, the mechanism of this neuroprotection remains unclear. In the present study, we tried to clarify the neuroprotective role of Ngb under oxidative stress in vitro. By surface plasmon resonance, we found that ferric Ngb, which is generated spontaneously as a result of the rapid autoxidation, binds exclusively to the GDP-bound form of the alpha subunit of heterotrimeric G protein (Galpha(i)). In GDP dissociation assays or guanosine 5'-O-(3-thio) triphosphate binding assays, ferric Ngb behaved as a guanine nucleotide dissociation inhibitor (GDI), inhibiting the rate of exchange of GDP for GTP. The interaction of GDP-bound Galpha(i) with ferric Ngb will liberate Gbetagamma, leading to protection against neuronal death. In contrast, ferrous ligand-bound Ngb under normoxia did not have GDI activities. Taken together, we propose that human Ngb may be a novel oxidative stress-responsive sensor for signal transduction in the brain.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan; Japan Sci & Technol Corp, Precursory Res Embry Sci & Technol, Kyoto 6158510, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Wakasugi, K (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan.	kei@wakasugi.mbox.media.kyoto-u.ac.jp	Wakasugi, Keisuke/AAQ-1642-2020	Wakasugi, Keisuke/0000-0002-8408-5616				Awenius C, 2001, BIOCHEM BIOPH RES CO, V287, P418, DOI 10.1006/bbrc.2001.5614; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P209, DOI 10.1016/S0968-0004(01)01824-2; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; de Alba E, 1999, J MOL BIOL, V291, P927, DOI 10.1006/jmbi.1999.2989; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Erecinska M, 2001, RESP PHYSIOL, V128, P263, DOI 10.1016/S0034-5687(01)00306-1; Esplugues JV, 2002, BRIT J PHARMACOL, V135, P1079, DOI 10.1038/sj.bjp.0704569; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HUBBARD SR, 1990, J MOL BIOL, V213, P215, DOI 10.1016/S0022-2836(05)80181-0; Joshi MS, 2002, P NATL ACAD SCI USA, V99, P10341, DOI 10.1073/pnas.152149699; KANAYA S, 1991, J BIOL CHEM, V266, P6038; Kawada N, 2001, J BIOL CHEM, V276, P25318, DOI 10.1074/jbc.M102630200; Kriegl JM, 2002, P NATL ACAD SCI USA, V99, P7992, DOI 10.1073/pnas.082244399; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Mammen PPA, 2002, J HISTOCHEM CYTOCHEM, V50, P1591, DOI 10.1177/002215540205001203; Natochin M, 2002, BIOCHEMISTRY-US, V41, P258, DOI 10.1021/bi015708k; Natochin M, 2001, BIOCHEMISTRY-US, V40, P5322, DOI 10.1021/bi015505w; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Nishida M, 2002, J BIOL CHEM, V277, P9036, DOI 10.1074/jbc.M107392200; Ouellett H, 2002, P NATL ACAD SCI USA, V99, P5902, DOI 10.1073/pnas.092017799; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; PERRY LJ, 1984, SCIENCE, V226, P555, DOI 10.1126/science.6387910; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Sowa AW, 1998, P NATL ACAD SCI USA, V95, P10317, DOI 10.1073/pnas.95.17.10317; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trent JT, 2001, BIOCHEMISTRY-US, V40, P6155, DOI 10.1021/bi0100790; Trevaskis B, 1997, P NATL ACAD SCI USA, V94, P12230, DOI 10.1073/pnas.94.22.12230; Uchida T, 1997, BIOCHEMISTRY-US, V36, P324, DOI 10.1021/bi960591z; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wieland T, 1999, N-S ARCH PHARMACOL, V360, P14, DOI 10.1007/s002109900031; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; Zhang CG, 2002, BIOCHEM BIOPH RES CO, V290, P1411, DOI 10.1006/bbrc.2002.6360; Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968-0004(99)01474-7	56	168	187	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36505	36512		10.1074/jbc.M305519200	http://dx.doi.org/10.1074/jbc.M305519200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860983	hybrid			2022-12-25	WOS:000185318300079
J	Ladd, PA; Du, LP; Capdevila, JH; Mernaugh, R; Keeney, DS				Ladd, PA; Du, LP; Capdevila, JH; Mernaugh, R; Keeney, DS			Epoxyeicosatrienoic acids activate transglutaminases in situ and induce cornification of epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNIFIED CELL-ENVELOPE; CROSS-LINKING ENZYMES; ARACHIDONIC-ACID; TISSUE TRANSGLUTAMINASE; FUNCTIONAL-PROPERTIES; LAMELLAR ICHTHYOSIS; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; MAMMALIAN-CELLS; K+-CHANNEL	The cytochrome P450 CYP2B19 is a keratinocyte-specific arachidonic acid epoxygenase expressed in the granular cell layer of mouse epidermis. In cultured keratinocytes, CYP2B19 mRNAs are up-regulated coordinately with those of profilaggrin, another granular cell-specific marker. We investigated effects of the CYP2B19 metabolites 11,12- and 14,15-epoxyeicosatrienoic acids (EETs) on keratinocyte transglutaminase activities and cornified cell envelope formation. Keratinocytes were differentiated in vitro in the presence of biotinylated cadaverine. Transglutaminases cross-linked this substrate into endogenous proteins in situ; an enzyme-linked immunosorbent assay was used to quantify the biotinylated proteins. Exogenously added or endogenously formed 14,15-EET increased transglutaminase cross-linking activities in cultured human and mouse epidermal keratinocytes in a modified in situ assay. Transglutaminase activities increased similar to8-fold ( p less than or equal to 0.02 versus mock control) in human keratinocytes transduced with adenovirus particles expressing a 14S, 15R-EET epoxygenase ( P450 BM3v). The physiological transglutaminase substrate involucrin was preferentially biotinylated in situ, determined by immunoblotting and mass spectrometry. P450 BM3v-induced transglutaminase activation was associated with increased 14,15-EET formation ( p = 0.002) and spontaneous cell cornification ( p less than or equal to 0.001). Preferential involucrin biotinylation and the increased cornified cell envelope formation provided evidence that transglutaminases mediated the P450 BM3v-induced cross-linking activities. These results support a physiological role for 14,15-EET epoxygenases in regulating epidermal cornification, and they have important implications for epidermal barrier functions in vivo.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Div Dermatol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Div Nephrol, Nashville, TN 37212 USA; Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Keeney, DS (corresponding author), Vanderbilt Univ, Dept Med Dermatol & Biochem, 607 Light Hall, Nashville, TN 37232 USA.	diane.keeney@vanderbilt.edu			NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041943, R01AR045603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA68485] Funding Source: Medline; NIAMS NIH HHS [P30 AR41943, AR45603] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [GM37922] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baron A, 1997, J PHYSIOL-LONDON, V504, P537, DOI 10.1111/j.1469-7793.1997.537bd.x; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BURNS KD, 1995, AM J PHYSIOL-CELL PH, V269, pC831, DOI 10.1152/ajpcell.1995.269.4.C831; Candi E, 1998, J BIOL CHEM, V273, P13693, DOI 10.1074/jbc.273.22.13693; Candi E, 2001, J BIOL CHEM, V276, P35014, DOI 10.1074/jbc.M010157200; Capdevila JH, 2000, J LIPID RES, V41, P163; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; Cartlidge P, 2000, Semin Neonatol, V5, P273, DOI 10.1053/siny.2000.0013; Chen JK, 1999, J BIOL CHEM, V274, P4764, DOI 10.1074/jbc.274.8.4764; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Chen JK, 1998, J BIOL CHEM, V273, P29254, DOI 10.1074/jbc.273.44.29254; Davies P J, 1988, Adv Exp Med Biol, V250, P391; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; ETOH Y, 1986, BIOCHEM BIOPH RES CO, V136, P51, DOI 10.1016/0006-291X(86)90875-2; Gibson DFC, 1996, J INVEST DERMATOL, V106, P154, DOI 10.1111/1523-1747.ep12329856; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GrahamLorence S, 1997, J BIOL CHEM, V272, P1127, DOI 10.1074/jbc.272.2.1127; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAAKE AR, 1993, J INVEST DERMATOL, V101, P107, DOI 10.1111/1523-1747.ep12363594; HAWEL L, 1994, J BIOL CHEM, V269, P7412; Hiiragi T, 1999, J BIOL CHEM, V274, P34148, DOI 10.1074/jbc.274.48.34148; Hohl D, 1998, J INVEST DERMATOL, V110, P268, DOI 10.1046/j.1523-1747.1998.00132.x; HOLTZMAN MJ, 1989, J CLIN INVEST, V84, P1446, DOI 10.1172/JCI114319; HU SL, 1993, EUR J PHARMACOL, V230, P215, DOI 10.1016/0014-2999(93)90805-R; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; Ishida-Yamamoto A, 1998, EXP DERMATOL, V7, P1, DOI 10.1111/j.1600-0625.1998.tb00295.x; IshidaYamamoto A, 1996, J HISTOCHEM CYTOCHEM, V44, P167, DOI 10.1177/44.2.8609373; Jeon JH, 2003, FEBS LETT, V534, P180, DOI 10.1016/S0014-5793(02)03836-X; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; Keeney DS, 1998, J BIOL CHEM, V273, P32071, DOI 10.1074/jbc.273.48.32071; Keeney DS, 1998, J BIOL CHEM, V273, P9279, DOI 10.1074/jbc.273.15.9279; Keeney DS, 1998, GENOMICS, V53, P417, DOI 10.1006/geno.1998.5533; KVEDAR JC, 1992, BIOCHEMISTRY-US, V31, P49, DOI 10.1021/bi00116a009; Lajemi M, 1997, HISTOCHEM J, V29, P593, DOI 10.1023/A:1026484227851; Lesort M, 1998, J BIOL CHEM, V273, P11991, DOI 10.1074/jbc.273.20.11991; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1979, BIOCHEMISTRY-US, V18, P1756, DOI 10.1021/bi00576a019; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; MARCELO CL, 1994, J INVEST DERMATOL, V103, P564, DOI 10.1111/1523-1747.ep12396864; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; MAURO T, 1995, J INVEST DERMATOL, V105, P203, DOI 10.1111/1523-1747.ep12317130; Meguro S, 2000, ARCH DERMATOL RES, V292, P463, DOI 10.1007/s004030000160; Menon GK, 2003, J INVEST DERMATOL, V120, pXV, DOI 10.1046/j.1523-1747.2003.12117.x; MICHEL S, 1988, J INVEST DERMATOL, V90, P472, DOI 10.1111/1523-1747.ep12460922; Nemes Z, 1999, J BIOL CHEM, V274, P11013, DOI 10.1074/jbc.274.16.11013; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Ohtsuka T, 2000, J AGR FOOD CHEM, V48, P6230, DOI 10.1021/jf000302k; PARK MH, 1981, P NATL ACAD SCI-BIOL, V78, P2869, DOI 10.1073/pnas.78.5.2869; PIACENTINI M, 1988, J BIOL CHEM, V263, P3790; Raghunath M, 1998, ARCH DERMATOL RES, V290, P621, DOI 10.1007/s004030050362; Rice RH., 1994, KERATINOCYTE METHODS, P157; SCHRODE J, 1979, J BIOL CHEM, V254, P653; SIEFRING GE, 1978, BIOCHEMISTRY-US, V17, P2598, DOI 10.1021/bi00606a022; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1996, BIOCHEM BIOPH RES CO, V221, P101, DOI 10.1006/bbrc.1996.0552; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; Sundberg J., 2000, SYSTEMATIC APPROACH; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; Uddin MR, 1998, HYPERTENSION, V31, P242, DOI 10.1161/01.HYP.31.1.242; Wertz PW, 1998, CHEM PHYS LIPIDS, V91, P85, DOI 10.1016/S0009-3084(97)00108-4; YAFFE MB, 1992, J BIOL CHEM, V267, P12233; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288; ZHANG WW, 1995, BIOTECHNIQUES, V18, P444	67	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35184	35192		10.1074/jbc.M301666200	http://dx.doi.org/10.1074/jbc.M301666200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12840027	hybrid			2022-12-25	WOS:000185164400054
J	Campbell, RB; Liu, FH; Ross, AH				Campbell, RB; Liu, FH; Ross, AH			Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; PHOSPHOINOSITIDE PHOSPHATASES; MYOTUBULARIN; SPECIFICITY; LIPIDS; CELLS	Phosphatase and tensin homologue deleted on chromosome 10 ( PTEN) is a tumor suppressor that is lost in many human tumors and encodes a phosphatidylinositol phosphate phosphatase specific for the 3-position of the inositol ring. Here we report a novel mechanism of PTEN regulation. Binding of di-C8-phosphatidylinositol 4,5-P-2 (PI(4,5) P-2) to PTEN enhances phosphatase activity for monodispersed substrates, PI(3,4,5) P-3 and PI(3,4) P-2. PI(5) P also is an activator, but PI(4) P, PI(3,4) P-2, and PI(3,5) P-2 do not activate PTEN. Activation by exogenous PI(4,5) P-2 is more apparent with PI(3,4) P-2 as a substrate than with PI(3,4,5) P-3, probably because hydrolysis of PI(3,4) P-2 yields PI(4) P, which is not an activator. In contrast, hydrolysis of PI(3,4,5) P-3 yields a potent activator, PI( 4,5) P-2, creating a positive feedback loop. In addition, neither di-C4-PI(4,5) P-2 nor inositol trisphosphate-activated PTEN. Hence, the interaction between PI(4,5) P-2 and PTEN requires specific, ionic interactions with the phosphate groups on the inositol ring as well as hydrophobic interactions with the fatty acid chains, likely mimicking the physiological interactions that PTEN has with the polar surface head groups and the hydrophobic core of phospholipid membranes. Mutations of the apparent PI(4,5) P-2-binding motif in the PTEN N terminus severely reduced PTEN activity. In contrast, mutation of the C2 phospholipid-binding domain had little effect on PTEN activation. These results suggest a model in which a PI(4,5) P-2 monomer binds to PTEN, initiates an allosteric conformational change and, thereby, activates PTEN independent of membrane binding.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Ross, AH (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, 364 Plantat St,Rm 364, Worcester, MA 01605 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021716] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS21716] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Furnari FB, 1998, CANCER RES, V58, P5002; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Kleinschmidt JH, 2002, BIOPHYS J, V83, P994, DOI 10.1016/S0006-3495(02)75225-9; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li L, 2002, MOL CELL NEUROSCI, V20, P21, DOI 10.1006/mcne.2002.1115; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; McConnachie G, 2003, BIOCHEM J, V371, P947, DOI 10.1042/BJ20021848; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; REBECCHI MJ, 1993, J BIOL CHEM, V268, P1735; ROSEN MJ, 1984, ACS S SERIES, V23; Schaletzky J, 2003, CURR BIOL, V13, P504, DOI 10.1016/S0960-9822(03)00132-5; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0	22	162	164	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33617	33620		10.1074/jbc.C300296200	http://dx.doi.org/10.1074/jbc.C300296200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12857747	hybrid			2022-12-25	WOS:000185047500003
J	Derry, JJ; Prins, GS; Ray, V; Tyner, AL				Derry, JJ; Prins, GS; Ray, V; Tyner, AL			Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells	ONCOGENE			English	Article						prostate cancer; BRK; Sik; tyrosine kinase; Sam68; PTK6	GASTROINTESTINAL-TRACT; GROWTH-FACTORS; SAM68; CANCER; EXPRESSION; RNA; BRK; PHOSPHORYLATION; INHIBITION; SUBSTRATE	Breast tumor kinase (BRK) is an intracellular tyrosine kinase expressed in differentiating epithelial cells of the gastrointestinal tract and skin, and in several epithelial cancers including carcinomas of the breast and colon. We examined expression of BRK and its mouse ortholog Src-related intestinal kinase (Sik) in prostate tissues and detected it in the nuclei of normal luminal prostate epithelial cells. BRK localization was then examined in 58 human prostate biopsy samples representing various grades of prostate cancer. While nuclear localization of BRK was present in well-differentiated tumors, it was absent in poorly differentiated tumors. However localization of Sam68, a nuclear substrate of BRK/Sik, was unaltered in all prostate tumors examined. Consistent with these results, nuclear BRK was detected in the more differentiated androgen-responsive LNCaP human prostate cancer cell line that is poorly tumorigenic in host animals, but it was primarily cytoplasmic in the undifferentiated androgen-unresponsive PC3 prostate cancer cell line that forms aggressive tumors. While PC3 cells expressed higher levels of endogenous BRK than LNCaP cells, BRK was less active in these cells. Our data suggest that BRK plays a role in differentiation of prostate epithelial cells. Altered BRK localization and/or activity may provide a prognostic indicator for prostate tumor progression and be a potential target for therapeutic intervention.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Urol, Chicago, IL 60607 USA; Provident Hosp Cook Cty, Dept Pathol, Chicago, IL 60615 USA; Univ Illinois, Dept Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Tyner, AL (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.	atyner@uic.edu		Tyner, Angela/0000-0001-7448-8625	NIDDK NIH HHS [R01 DK040890, DK44525, R01 DK044525-09, R01 DK044525] Funding Source: Medline; PHS HHS [40890] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044525, R01DK040890, R01DK044525] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; Denegri M, 2001, MOL BIOL CELL, V12, P3502, DOI 10.1091/mbc.12.11.3502; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Djakiew D, 2000, PROSTATE, V42, P150, DOI 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Hellawell GO, 2002, BJU INT, V89, P230, DOI 10.1046/j.1464-4096.2001.001067.x; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; KAIGHN ME, 1979, INVEST UROL, V17, P16; LEE ST, 1993, ONCOGENE, V8, P3403; LIM DJ, 1993, PROSTATE, V22, P109, DOI 10.1002/pros.2990220203; Llor X, 1999, CLIN CANCER RES, V5, P1767; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; Soros VB, 2001, J VIROL, V75, P8203, DOI 10.1128/JVI.75.17.8203-8215.2001; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9	29	103	109	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4212	4220		10.1038/sj.onc.1206465	http://dx.doi.org/10.1038/sj.onc.1206465			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833144				2022-12-25	WOS:000183979800008
J	Ho, SM; Lau, KM; Mok, SCH; Syed, V				Ho, SM; Lau, KM; Mok, SCH; Syed, V			Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells	ONCOGENE			English	Article						cDNA microarray; hormonal carcinogenesis; gene expression; GTPase activating protein (rap1GAP); neogenin; restin	REED-STERNBERG CELLS; HEAT-SHOCK PROTEINS; LUTEINIZING-HORMONE; CDNA MICROARRAY; CALORIC RESTRICTION; HODGKINS-DISEASE; BREAST-CANCER; RNA HELICASES; RECEPTOR; GONADOTROPINS	Epidemiological data have implicated the pituitary gonadotropin follicle stimulating hormone (FSH) as both a risk factor for and a protective agent against epithelial ovarian cancer. Yet, little is known about how this hormone could play such opposing roles in ovarian carcinogenesis. Complementary DNA microarrays containing 2400 named genes were used to examine FSH-induced gene expression changes in ovarian cancer (OC) and immortalized normal human ovarian surface epithelial (HOSE) cell lines. Two-way t-statistics analyses of array data identified two distinct sets of FSH-regulated genes in HOSE and in established OC cell lines established from patients (OVCA cell tines). Among the HOSE cell lines, FSH increased expression of 57% of the 312 genes and downregulated 43%. In contrast, FSH diminished expression of 92% of the 177 genes in the OVCA cell lines. All but 18 of the genes affected by FSH in HOSE cell lines were different from those altered in OVCA cell lines. Among the 18 overlapping genes, nine genes exhibited the same direction of change following FSH challenge, while the other nine showed discordance in response between HOSE and OVCA cell tines. The FSH-induced differential expression of seven out of nine genes was confirmed by real-time RT-PCR. Gene-specific antisense otigonuleotides (ODNs) were used to inhibit the expression of genes encoding GTPase activating protein (rap1GAP), neogenin, and restin in HOSE and OVCA cells. Antisense ODNs to neogenin and restin, but not an antisense ODN to rap1GAP, were effective in inhibiting OVCA cell growth, diminishing proliferating cell nuclear antigen expression, and increasing caspase 3 activities. Furthermore, the ODN to rap1GAP was further shown to be ineffective in altering migration properties of OVCA cell lines. HOSE cell proliferation was not affected by treatment with any of the antisense ODNs. In summary, gene profiling data reveal for the first time that FSH may exert different biological actions on OVCA cells than on HOSE cells, by differential regulation of a set of putative oncogenes/tumor suppressors. Specifically, neogenin and restin were found to exhibit proproliferation/survival action on OC cells.	Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Cell Biol & Physiol, Worcester, MA 01605 USA; Harvard Univ, Brigham & Womens Hosp,Sch Med, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Boston, MA 02115 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Syed, V (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, 364 Plantat St,5th Floor, Worcester, MA 01605 USA.	Viqar.Syed@umassmed.edu			NATIONAL CANCER INSTITUTE [R01CA094221, R03CA091250] Funding Source: NIH RePORTER; NCI NIH HHS [CA091250, CA94221] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ala-Fossi SL, 1999, ANTICANCER RES, V19, P4289; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BILBE G, 1992, EMBO J, V11, P2103, DOI 10.1002/j.1460-2075.1992.tb05269.x; Callow ME, 2000, APPL ENVIRON MICROB, V66, P3249, DOI 10.1128/AEM.66.8.3249-3254.2000; Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Conroy SE, 1996, BRIT J CANCER, V74, P717, DOI 10.1038/bjc.1996.427; Cramer DW, 1998, FERTIL STERIL, V70, P371, DOI 10.1016/S0015-0282(98)00153-8; Dujardin D, 1998, J CELL BIOL, V141, P849, DOI 10.1083/jcb.141.4.849; Emons G, 1996, CANCER, V78, P1452; ERICKSON GF, 1994, ENDOCRINOLOGY, V134, P1365, DOI 10.1210/en.134.3.1365; Feeley KM, 2001, HISTOPATHOLOGY, V38, P87, DOI 10.1046/j.1365-2559.2001.01042.x; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; FUQUA SAW, 1994, BREAST CANCER RES TR, V32, P67, DOI 10.1007/BF00666207; GILLETT WR, 1991, HUM REPROD, V6, P645, DOI 10.1093/oxfordjournals.humrep.a137398; GODWIN AK, 1993, CANCER-AM CANCER SOC, V71, P530; Halperin R, 1999, INT J GYNECOL CANCER, V9, P502, DOI 10.1046/j.1525-1438.1999.99075.x; HAMILTON TC, 1992, CURR PROB CANCER, V16, P5, DOI 10.1016/0147-0272(92)90047-R; HEIZISOUER KJ, 1995, JAMA-J AM MED ASSOC, V274, P1926; HILLIKER C, 1994, CYTOGENET CELL GENET, V65, P172, DOI 10.1159/000133625; Hofstra LS, 1999, ANTICANCER RES, V19, P3627; Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S; Hough CD, 2001, CANCER RES, V61, P3869; Ismail RS, 2000, CANCER RES, V60, P6744; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Ivarsson K, 2001, HUM REPROD, V16, P18, DOI 10.1093/humrep/16.1.18; Konishi I, 1999, ONCOLOGY-BASEL, V57, P45, DOI 10.1159/000055274; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee HM, 2001, MECH AGEING DEV, V122, P355, DOI 10.1016/S0047-6374(00)00254-2; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Mandai M, 1997, EUR J CANCER, V33, P1501, DOI 10.1016/S0959-8049(97)00166-4; MARIMOTO RI, 1994, BIOL HEAT SHOCK PROT; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Meyerhardt JA, 1997, ONCOGENE, V14, P1129, DOI 10.1038/sj.onc.1200935; Mukherjee A, 1998, MOL ENDOCRINOL, V12, P785, DOI 10.1210/me.12.6.785; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; Ono K, 2000, CANCER RES, V60, P5007; Parrott JA, 2001, MOL CELL ENDOCRINOL, V172, P213, DOI 10.1016/S0303-7207(00)00340-3; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; Rauh-Adelmann C, 2000, MOL CARCINOGEN, V28, P236, DOI 10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H; Rickard JE, 1996, TRENDS CELL BIOL, V6, P178, DOI 10.1016/0962-8924(96)10017-9; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Shridhar V, 2001, CANCER RES, V61, P5895; Shushan A, 1996, FERTIL STERIL, V65, P13, DOI 10.1016/S0015-0282(16)58020-0; Syed V, 2001, CANCER RES, V61, P6768; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Venema J, 1997, MOL CELL BIOL, V17, P3398, DOI 10.1128/MCB.17.6.3398; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wang C, 2000, J PHARMACOL EXP THER, V294, P287; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Wani MA, 1997, SOMAT CELL MOLEC GEN, V23, P123, DOI 10.1007/BF02679971; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; WERA S, 1994, BIOCHEM J, V311, P17; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zheng WX, 1996, AM J PATHOL, V148, P47; Zheng WX, 2000, GYNECOL ONCOL, V76, P80, DOI 10.1006/gyno.1999.5628	68	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4243	4256		10.1038/sj.onc.1206437	http://dx.doi.org/10.1038/sj.onc.1206437			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833147	Bronze			2022-12-25	WOS:000183979800011
J	Su, CL; Sztalryd, C; Contreras, JA; Holm, C; Kimmel, AR; Londos, C				Su, CL; Sztalryd, C; Contreras, JA; Holm, C; Kimmel, AR; Londos, C			Mutational analysis of the hormone-sensitive lipase translocation reaction in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION; LIPOLYSIS; PERILIPIN; SERINE; SITES	Lipolysis in adipocytes governs the release of fatty acids for the supply of energy to various tissues of the body. This reaction is mediated by hormone-sensitive lipase (HSL), a cytosolic enzyme, and perilipin, which coats the lipid droplet surface in adipocytes. Both HSL and perilipin are substrates for polyphosphorylation by protein kinase A (PKA), and phosphorylation of perilipin is required to induce HSL to translocate from the cytosol to the surface of the lipid droplet, a critical step in the lipolytic reaction (Sztalryd C., Xu, G., Dorward, H., Tansey, J.T., Contreras, J.A, Kimmel, A. R., and Londos, C. (2003) J. Cell Biol. 161, 1093-1103). In the present paper we demonstrate that phosphorylation at one of the two more recently discovered PKA sites within HSL, serines 659 and 660, is also required to effect the translocation reaction. Translocation does not occur when these serines residues are mutated simultaneously to alanines. Also, mutation of the catalytic Ser-423 eliminates HSL translocation, showing that the inactive enzyme does not migrate to the lipid droplet upon PKA activation. Thus, HSL translocation requires the phosphorylation of both HSL and perilipin.	NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; Lund Univ, Dept Cell & Mol Biol, Sect Mol Signaling, SE-22184 Lund, Sweden	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Lund University	Londos, C (corresponding author), Bldg 50,Rm 3140,MSC-8028, Bethesda, MD 20892 USA.	DeanL@intra.niddk.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015503] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; HOLM C, 1994, PROTEIN ENG, V7, P537, DOI 10.1093/protein/7.4.537; HOLM C, 1994, FEBS LETT, V344, P234, DOI 10.1016/0014-5793(94)00403-X; Holm C, 1997, METHOD ENZYMOL, V284, P272; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; HOPP TP, 2002, BIOTECHNOLOGY, V6, P1204; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Lucas S, 2003, J LIPID RES, V44, P154, DOI 10.1194/jlr.M200250-JLR200; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Peters GH, 1998, BIOCHEMISTRY-US, V37, P12375, DOI 10.1021/bi972883l; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169	18	111	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43615	43619		10.1074/jbc.M301809200	http://dx.doi.org/10.1074/jbc.M301809200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12832420	hybrid			2022-12-25	WOS:000186157000109
J	Suetsugu, S; Takenawa, T				Suetsugu, S; Takenawa, T			Translocation of N-WASP by nuclear localization and export signals into the nucleus modulates expression of HSP90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH-SYNDROME; ACTIN-DEPOLYMERIZING PROTEIN; ARP2/3 COMPLEX; TYROSINE KINASE; FAMILY; SRC; ACTIVATION; FILAMENTS; VIRUS; WAVE	N-WASP regulates the actin cytoskeleton through activation of the Arp2/3 complex. N-WASP localizes at the cell periphery, where it controls actin polymerization downstream of signal molecules such as adapter proteins, Cdc42, Src family kinases, and phosphoinositides. N-WASP also localizes in the nucleus; however, the role of N-WASP in the nucleus is unclear. Here, we show that localization of N-WASP is controlled through phosphorylation by Src family kinases in which phosphorylated N-WASP is exported from the nucleus in a nuclear export signal (NES) and leptomycin B-dependent manner. N-WASP had nuclear localization signal (NLS) at its basic region and NES close to the phosphorylation site by Src family kinases, indicating that phosphorylation controls the accessibility to the NES through conformational changes. Increased levels of unphosphorylated N-WASP in the nucleus suppressed expression of HSP90 and transcription from a heat shock element (HSE). N-WASP bound heat shock transcription factor (HSTF) and enhanced the HSTF association with HSE. In addition, nuclear N-WASP was present in the protein complex that associates with HSE, suggesting that N-WASP participates in suppression of HSP90 transcription. Increased levels of unphosphorylated N-WASP also decreased the activities of Src family kinases in cells but not in experiments in vitro with pure N-WASP and Fyn. Because HSP90 is essential for the activities of Src family kinases, these results suggest that localization of N-WASP modulates Src kinase activity by regulating HSP90 expression.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokane Dai, Tokyo 1088639, Japan.		Suetsugu, Shiro/AAF-4427-2019; Suetsugu, Shiro/ABB-6033-2020; Suetsugu, Shiro/B-3300-2010	Suetsugu, Shiro/0000-0002-4612-0628; Suetsugu, Shiro/0000-0002-4612-0628				Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cairns BR, 1998, MOL CELL, V2, P639, DOI 10.1016/S1097-2765(00)80162-8; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Fukami K, 2000, EUR J BIOCHEM, V267, P28, DOI 10.1046/j.1432-1327.2000.00943.x; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Nakai A, 2001, EMBO J, V20, P2885, DOI 10.1093/emboj/20.11.2885; Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557; Peterson CL, 1998, J BIOL CHEM, V273, P23641, DOI 10.1074/jbc.273.37.23641; Phimister B, 1999, NAT GENET, V22, P318, DOI 10.1038/11880; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Suetsugu S, 2002, CELL MOTIL CYTOSKEL, V51, P113, DOI 10.1002/cm.10020; Suetsugu S, 2001, J CELL SCI, V114, P4533; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Takenawa T, 2001, J CELL SCI, V114, P1801; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; Vetterkind S, 2002, J BIOL CHEM, V277, P87, DOI 10.1074/jbc.M104555200; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608	31	45	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42515	42523		10.1074/jbc.M302177200	http://dx.doi.org/10.1074/jbc.M302177200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12871950	hybrid			2022-12-25	WOS:000185989500116
J	Innis, CA; Hyvonen, M				Innis, CA; Hyvonen, M			Crystal structures of the heparan sulfate-binding domain of follistatin - Insights into ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; FOLLICLE-STIMULATING-HORMONE; ACTIVIN-BINDING; PROTEIN STRUCTURES; XENOPUS EMBRYO; EXPRESSION; REFINEMENT; COMPLEX; PROGRAM; CELL	Follistatin associates with transforming growth factor-beta-like growth factors such as activin or bone morphogenetic proteins to form an inactive complex, thereby regulating processes as diverse as embryonic development and cell secretion. Although an interaction between heparan sulfate chains present at the cell surface and follistatin has been recorded, the impact of this binding reaction on the follistatin-mediated inhibition of transforming growth factor-beta-like signaling remains unclear. To gain a structural insight into this interaction, we have solved the crystal structure of the presumed heparan sulfate-binding domain of follistatin, both alone and in complex with the small heparin analogs sucrose octasulfate and D-myo-inositol hexasulfate. In addition, we have confirmed the binding of the sucrose octasulfate and D-myo-inositol hexasulfate molecules to this follistatin domain and determined the association constants and stoichiometries of both interactions in solution using isothermal titration calorimetry. Overall, our results shed light upon the structure of this follistatin domain and reveal a novel conformation for a hinge region connecting epidermal growth factor-like and Kazal-like subdomains compared with the follistatin-like domain found in the extracellular matrix protein BM-40. Moreover, the crystallographic analysis of the two protein-ligand complexes mentioned above leads us to propose a potential location for the heparan sulfate-binding site on the surface of follistatin and to suggest the involvement of residues Asn(80) and Arg(86) in such a follistatin-heparin interaction.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Cambridge	Hyvonen, M (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.		Innis, Axel/A-5927-2009; Innis, Axel/P-9863-2019	Innis, Axel/0000-0003-3153-9490; Innis, Axel/0000-0003-3153-9490				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BODE W, 1985, EUR J BIOCHEM, V147, P387, DOI 10.1111/j.1432-1033.1985.tb08762.x; BOLOGNESI M, 1982, J MOL BIOL, V162, P839, DOI 10.1016/0022-2836(82)90550-2; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Denzer AJ, 1998, EMBO J, V17, P335, DOI 10.1093/emboj/17.2.335; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ESCH FS, 1987, MOL ENDOCRINOL, V1, P849, DOI 10.1210/mend-1-11-849; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Guzman-Casado M, 2000, EUR J BIOCHEM, V267, P3477, DOI 10.1046/j.1432-1327.2000.01371.x; Hashimoto O, 1997, J BIOL CHEM, V272, P13835, DOI 10.1074/jbc.272.21.13835; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; Hohenester E, 1997, EMBO J, V16, P3778, DOI 10.1093/emboj/16.13.3778; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; INOUYE S, 1991, ENDOCRINOLOGY, V129, P815, DOI 10.1210/endo-129-2-815; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; Phillips DJ, 1998, FRONT NEUROENDOCRIN, V19, P287, DOI 10.1006/frne.1998.0169; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROBERTSON DM, 1987, BIOCHEM BIOPH RES CO, V149, P744, DOI 10.1016/0006-291X(87)90430-X; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SHIMASAKI S, 1989, MOL ENDOCRINOL, V3, P651, DOI 10.1210/mend-3-4-651; SUGINO K, 1993, J BIOL CHEM, V268, P15579; SUMITOMO S, 1995, BIOCHEM BIOPH RES CO, V208, P1, DOI 10.1006/bbrc.1995.1297; TASHIRO K, 1991, BIOCHEM BIOPH RES CO, V174, P1022, DOI 10.1016/0006-291X(91)91521-D; Uchida T, 1999, BIOCHEM BIOPH RES CO, V266, P593, DOI 10.1006/bbrc.1999.1873; UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282; Ullman CG, 1997, BIOCHEM J, V326, P939, DOI 10.1042/bj3260929v; VANDELOCHT A, 1995, EMBO J, V14, P5149, DOI 10.1002/j.1460-2075.1995.tb00199.x; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang QF, 2000, ENDOCRINOLOGY, V141, P3183, DOI 10.1210/en.141.9.3183; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Yamane Y, 1998, J BIOL CHEM, V273, P7375, DOI 10.1074/jbc.273.13.7375	49	43	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39969	39977		10.1074/jbc.M211284200	http://dx.doi.org/10.1074/jbc.M211284200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12867435	hybrid			2022-12-25	WOS:000185713800085
J	Lang, SH; Palmer, M				Lang, SH; Palmer, M			Characterization of Streptococcus agalactiae CAMP factor as a pore-forming toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; GLUTATHIONE-S-TRANSFERASE; GROUP-B STREPTOCOCCI; ESCHERICHIA-COLI; STREPTOLYSIN-O; FACTOR GENE; EXPRESSION; PURIFICATION; MECHANISM	A recombinant form of CAMP factor of Streptococcus agalactiae has been expressed as glutathione S-transferase-CAMP fusion protein in Escherichia coli. After thrombin cleavage of the fusion protein, the recombinant CAMP factor exhibited hemolytic activity comparable with that of the native form. Osmotic protection experiments with polyethylene glycols show that CAMP factor forms discrete transmembrane pores with a diameter upward of 1.6 nm on susceptible membranes; electron microscopy reveals circular membrane lesions of heterogeneous size, up to 12-15 nm in diameter. Liposome permeabilization studies show that pore formation is a highly cooperative process, which suggests that it involves the oligomerization of CAMP factor. Chemical cross-linking experiments also support an oligomeric mode of action.	Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada	University of Waterloo	Palmer, M (corresponding author), Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada.							Aronson AI, 1999, APPL ENVIRON MICROB, V65, P2503; BERNHEIMER AW, 1979, INFECT IMMUN, V23, P838, DOI 10.1128/IAI.23.3.838-844.1979; BHAKDI S, 1984, J IMMUNOL, V133, P1453; BHAKDI S, 1985, INFECT IMMUN, V47, P52; Christie R. N. E. Atkins, 1944, AUSTRALIAN JOUR EXP BIOL AND MED SCI, V22, P197; Deamer DW, 1983, LIPOSOMES, P27; FEHRENBACH FJ, 1984, BACTERIAL PROTEIN TO, P317; Gase K, 1999, INFECT IMMUN, V67, P4725, DOI 10.1128/IAI.67.9.4725-4731.1999; GHOSH P, 1993, J MEMBRANE BIOL, V134, P85; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HIDER RC, 1983, BIOCHIM BIOPHYS ACTA, V728, P206, DOI 10.1016/0005-2736(83)90473-X; Jiang M, 1996, MICROB PATHOGENESIS, V20, P297, DOI 10.1006/mpat.1996.0028; JURGENS D, 1985, J CHROMATOGR, V348, P363, DOI 10.1016/S0021-9673(01)92474-4; JURGENS D, 1987, J EXP MED, V165, P720, DOI 10.1084/jem.165.3.720; KUGA S, 1981, J CHROMATOGR, V206, P449, DOI 10.1016/S0021-9673(00)88914-1; Lobley A, 2001, BIOPHYS J, V80, p373A; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; NELSON GJ, 1967, BIOCHIM BIOPHYS ACTA, V144, P221, DOI 10.1016/0005-2760(67)90152-X; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; PODBIELSKI A, 1994, MED MICROBIOL IMMUN, V183, P239, DOI 10.1007/BF00198458; RUHLMANN J, 1988, FEBS LETT, V235, P262, DOI 10.1016/0014-5793(88)81275-4; RYGUS T, 1991, APPL MICROBIOL BIOT, V35, P594; SAUER H, 1991, BIOCHEM J, V276, P395, DOI 10.1042/bj2760395; SCHNEEWIND O, 1988, INFECT IMMUN, V56, P2174, DOI 10.1128/IAI.56.8.2174-2179.1988; SKALKA B, 1981, ZBL BAKT-INT J MED M, V249, P190; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soberon M, 2000, FEMS MICROBIOL LETT, V191, P221, DOI 10.1016/S0378-1097(00)00394-3; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sterzik B., 1984, Bacterial protein toxins, P195; STERZIK B, 1985, J GEN MICROBIOL, V131, P817; WAYS P, 1964, J LIPID RES, V5, P318	32	83	89	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38167	38173		10.1074/jbc.M303544200	http://dx.doi.org/10.1074/jbc.M303544200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12835325	hybrid			2022-12-25	WOS:000185575100011
J	Matthews, V; Schuster, B; Schutze, S; Bussmeyer, I; Ludwig, A; Hundhausen, C; Sadowski, T; Saftig, P; Hartmann, D; Kallen, KJ; Rose-John, S				Matthews, V; Schuster, B; Schutze, S; Bussmeyer, I; Ludwig, A; Hundhausen, C; Sadowski, T; Saftig, P; Hartmann, D; Kallen, KJ; Rose-John, S			Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ALPHA-CONVERTING-ENZYME; HUMAN IL-6 RECEPTOR; KINASE-C-DELTA; PLASMA-MEMBRANE; SOLUBLE RECEPTOR; T-CELL; FLUORESCENCE POLARIZATION; LEUKOCYTE RECRUITMENT; PRECURSOR PROTEIN	Interleukin-6 (IL-6) activates cells by binding to the membrane-bound IL-6 receptor (IL-6R) and subsequent formation of a glycoprotein 130 homodimer. Cells that express glycoprotein 130, but not the IL-6R, can be activated by IL-6 and the soluble IL-6R which is generated by shedding from the cell surface or by alternative splicing. Here we show that cholesterol depletion of cells with methyl-beta-cyclodextrin increases IL-6R shedding independent of protein kinase C activation and thus differs from phorbol ester-induced shedding. Contrary to cholesterol depletion, cholesterol enrichment did not increase IL-6R shedding. Shedding of the IL-6R because of cholesterol depletion is highly dependent on the metalloproteinase ADAM17 (tumor necrosis factor-alpha-converting enzyme), and the related ADAM10, which is identified here for the first time as an enzyme involved in constitutive and induced shedding of the human IL-6R. When combined with protein kinase C inhibition by staurosporine or rottlerin, breakdown of plasma membrane sphingomyelin or enrichment of the plasma membrane with ceramide also increased IL-6R shedding. The effect of cholesterol depletion was confirmed in human THP-1 and Hep3B cells and in primary human peripheral blood monocytes, which naturally express the IL-6R. For decades, high cholesterol levels have been considered harmful. This study indicates that low cholesterol levels may play a role in shedding of the membrane-bound IL-6R and thereby in the immuno-pathogenesis of human diseases.	Univ Kiel, Inst Biochem, D-24098 Kiel, Germany; Univ Kiel, Inst Immunol, D-24105 Kiel, Germany; Leuven & Flanders Interuniv, Ctr Human Genet, B-3000 Louvain, Belgium	University of Kiel; University of Kiel; KU Leuven	Rose-John, S (corresponding author), Univ Kiel, Inst Biochem, Olshaussenstr 40, D-24098 Kiel, Germany.		Ludwig, Andreas/I-5685-2012; Rose-John, Stefan/A-7998-2010; Hundhausen, Christian/F-2539-2011; Saftig, Paul/A-7966-2010; Schuster, Bjorn/G-6339-2014; Schütze, Stefan/C-8596-2011	Ludwig, Andreas/0000-0001-8536-4986; Rose-John, Stefan/0000-0002-7519-3279; 				Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Althoff K, 2001, BIOCHEM J, V353, P663, DOI 10.1042/0264-6021:3530663; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bourbon NA, 2002, J BIOL CHEM, V277, P3286, DOI 10.1074/jbc.M110541200; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Garton KJ, 2001, J BIOL CHEM, V276, P37993; GEARING DP, 1991, CELL, V66, P9, DOI 10.1016/0092-8674(91)90131-H; Grotzinger J, 1999, BIOL CHEM, V380, P803, DOI 10.1515/BC.1999.100; GROUP HPS, 2002, LANCET, V360, P7; Hansen HP, 2000, J IMMUNOL, V165, P6703, DOI 10.4049/jimmunol.165.12.6703; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Heinz D, 2001, J VIRAL HEPATITIS, V8, P186, DOI 10.1046/j.1365-2893.2001.00281.x; Herget T, 2000, J BIOL CHEM, V275, P30344, DOI 10.1074/jbc.M000714200; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Jones SA, 2001, FASEB J, V15, P43, DOI 10.1096/fj.99-1003rev; Kallen K J, 1999, Expert Opin Investig Drugs, V8, P1327, DOI 10.1517/13543784.8.9.1327; Kallen KJ, 2002, BBA-MOL CELL RES, V1592, P323, DOI 10.1016/S0167-4889(02)00325-7; KALLEN KJ, 1993, BIOCHEM J, V289, P307, DOI 10.1042/bj2890307; KALLEN KJ, 1994, BBA-BIOMEMBRANES, V1191, P52, DOI 10.1016/0005-2736(94)90232-1; KALLEN KJ, 1993, BIOCHIM BIOPHYS ACTA, V1166, P305, DOI 10.1016/0005-2760(93)90111-L; Klouche M, 1999, J IMMUNOL, V163, P4583; Klouche M, 1998, ARTERIOSCL THROM VAS, V18, P1376, DOI 10.1161/01.ATV.18.9.1376; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Ludewig B, 2001, J IMMUNOL, V166, P3369, DOI 10.4049/jimmunol.166.5.3369; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MULLBERG J, 1995, J IMMUNOL, V155, P5198; MULLBERG J, 1992, BIOCHEM BIOPH RES CO, V189, P794, DOI 10.1016/0006-291X(92)92272-Y; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Peters M, 1998, BLOOD, V92, P3495, DOI 10.1182/blood.V92.10.3495.422k47_3495_3504; Podar K, 2003, J BIOL CHEM, V278, P5794, DOI 10.1074/jbc.M208636200; PORN MI, 1995, BIOCHEM J, V308, P269; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Scalia R, 2001, CIRCULATION, V103, P2598; Schatz IJ, 2001, LANCET, V358, P351, DOI 10.1016/S0140-6736(01)05553-2; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schuster B, 2003, FEBS LETT, V538, P113, DOI 10.1016/S0014-5793(03)00154-6; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; Shoenfeld Yehuda, 2001, Trends in Immunology, V22, P293, DOI 10.1016/S1471-4906(01)01922-6; Signorelli P, 2001, FASEB J, V15, P2401, DOI 10.1096/fj.01-0244com; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Sparrow CP, 2001, ARTERIOSCL THROM VAS, V21, P115, DOI 10.1161/01.ATV.21.1.115; Taubes G, 2001, SCIENCE, V291, P2536, DOI 10.1126/science.291.5513.2536; Thabard W, 2001, BIOCHEM J, V358, P193, DOI 10.1042/0264-6021:3580193; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; VANBLITTERSWIJK WJ, 1981, BIOCHIM BIOPHYS ACTA, V644, P323, DOI 10.1016/0005-2736(81)90390-4; VANBLITTERSWIJK WJ, 1987, BIOCHEMISTRY-US, V26, P1746, DOI 10.1021/bi00380a038; Vincent B, 2001, J BIOL CHEM, V276, P37743; Vollmer P, 1999, EUR J BIOCHEM, V263, P438, DOI 10.1046/j.1432-1327.1999.00511.x; Walev I, 2000, J LEUKOCYTE BIOL, V68, P865; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wolozin B, 2001, P NATL ACAD SCI USA, V98, P5371, DOI 10.1073/pnas.101123198	71	308	312	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38829	38839		10.1074/jbc.M210584200	http://dx.doi.org/10.1074/jbc.M210584200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12832423	hybrid			2022-12-25	WOS:000185575100091
J	Sakaue, H; Nishizawa, A; Ogawa, W; Teshigawara, K; Mori, T; Takashima, Y; Noda, T; Kasuga, M				Sakaue, H; Nishizawa, A; Ogawa, W; Teshigawara, K; Mori, T; Takashima, Y; Noda, T; Kasuga, M			Requirement for 3-phosphoinositide-dependent kinase-1 (PDK-1) in insulin-induced glucose uptake in immortalized brown adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; 3T3-L1 ADIPOCYTES; RECEPTOR SUBSTRATE-1; GLUT4 TRANSLOCATION; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE; SIGNALING PATHWAY; C-LAMBDA; ACTIVATION	To provide insight into the physiological importance of 3-phosphoinositide-dependent kinase-1 (PDK-1) in the metabolic actions of insulin, we have generated mice that harbor a PDK-1 gene containing LoxP sites (PDK1(lox/lox) mice) and established immortalized brown preadipocyte cell lines both from these animals and from wild-type mice. Exposure to appropriate hormonal inducers resulted in the differentiation of > 80% of the immortalized brown preadipocytes derived from both types of mice into mature adipocytes. Introduction of the Cre recombinase with the use of adenovirus-mediated gene transfer induced a dose-dependent decrease in the abundance of PDK-1 in PDK-1(lox/lox) adipocytes but not in the wild-type cells. In Cre-expressing PDK-1(lox/lox) adipocytes in which the abundance of PDK-1 was reduced by similar to85%, the insulin-induced phosphorylation both of Akt on threonine 308 and of p70 S6 kinase on threonine-389 was markedly inhibited. The phosphorylation both of Akt on serine 473 and of p42 and p44 isoforms of mitogen-activated protein kinase induced by insulin was not affected by Cre expression, indicating that the latter specifically inhibits PDK-1-dependent signaling. Both glucose uptake and the translocation of glucose transporter 4 to the plasma membrane induced by insulin as well as glucose uptake induced by a constitutively active form of phosphoinositide 3-kinase were also greatly inhibited by Cre expression in PDK1(lox/lox) adipocytes. Phosphorylation of AMP- activated protein kinase and glucose uptake induced by 5-aminoimidazole-4- carboxamide ribonucleoside (AICAR) were not affected by Cre expression in PDK-1(lox/lox) adipocytes. These results indicate that PDK-1 is essential for insulin-induced glucose uptake in adipocytes.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis,Chuo Ku, Kobe, Hyogo 6500017, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Tokyo 1708455, Japan; Tohoku Univ, Sch Med, Dept Mol Genet, Sendai, Miyagi 9808574, Japan	Kobe University; Japanese Foundation for Cancer Research; Tohoku University	Ogawa, W (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	ogawa@med.kobe-u.ac.jp	OGAWA, Wataru/AAQ-9586-2020; Noda, Tetsuo/B-1667-2016; Sakaue, Hiroshi/ABE-2337-2021	Sakaue, Hiroshi/0000-0002-2468-2363; Takashima, Yasuhiro/0000-0003-0126-7260				Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, MOL ENDOCRINOL, V13, P1766, DOI 10.1210/me.13.10.1766; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Egawa K, 2002, J BIOL CHEM, V277, P38863, DOI 10.1074/jbc.M203132200; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Grillo S, 1999, FEBS LETT, V461, P277, DOI 10.1016/S0014-5793(99)01472-6; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klein J, 2002, BIOESSAYS, V24, P382, DOI 10.1002/bies.10058; Klein J, 1999, J BIOL CHEM, V274, P34795, DOI 10.1074/jbc.274.49.34795; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Matsumoto M, 2002, DIABETES, V51, P1672, DOI 10.2337/diabetes.51.6.1672; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Miyake K, 2002, J CLIN INVEST, V110, P1483, DOI 10.1172/JCI200215880; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Sakaue H, 1998, J BIOL CHEM, V273, P28945, DOI 10.1074/jbc.273.44.28945; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Wick MJ, 2002, J BIOL CHEM, V277, P16632, DOI 10.1074/jbc.M112402200; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yamada T, 2002, AM J PHYSIOL-ENDOC M, V282, pE1385, DOI 10.1152/ajpendo.00486.2001	39	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38870	38874		10.1074/jbc.M306151200	http://dx.doi.org/10.1074/jbc.M306151200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12855688	hybrid			2022-12-25	WOS:000185575100095
J	Chen, CC; Ghole, M; Majumder, A; Wang, ZJ; Chandana, S; Wu, HY				Chen, CC; Ghole, M; Majumder, A; Wang, ZJ; Chandana, S; Wu, HY			LeuO-mediated transcriptional derepression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LEU-500 PROMOTER; DNA CONFORMATION; ILVYC OPERON; EXPRESSION; GENE; BOUNDARIES; ACTIVATION; MECHANISM; UPSTREAM	To understand the coordination of gene expression in the Salmonella typhimurium ilvIH-leuO-leuABCD gene cluster, we had previously identified a 72-bp AT-rich (78% A+T) DNA sequence element, AT4, which was capable of silencing transcription in a promoter nonspecific manner. LeuO protein provided in trans relieved (derepressed) AT4-mediated gene silencing (transcriptional repression), but underlying mechanisms remained unclear. In the present communication, the 72-bp DNA sequence element is further dissected into two functional elements, AT7 and AT8. LeuO binds to the 25-bp AT7, which lies closest to the leuO promoter in the AT4 DNA. After deletion of the AT7 DNA sequence responsible for LeuO binding from AT4, the remaining 47-bp AT-rich (85% A+T) DNA sequence, termed AT8, retains the full bi-directional gene-silencing activity, which is no longer relieved by LeuO. LeuO-mediated transcriptional derepression is restored when the LeuO binding site, AT7, is placed within close proximity to the gene silencer AT8. As a pair of functionally coupled transcription elements, the presence of an equal copy number of AT7 and AT8 within proximity is important for the transcription control. The characterization provides clues for future elucidation of the molecular details whereby LeuO negates the gene-silencing activity.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Wu, HY (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave, Detroit, MI 48201 USA.	haiwu@med.wayne.edu			NIGMS NIH HHS [GM-53617] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053617, R29GM053617] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Chen CC, 2001, J BIOL CHEM, V276, P9478, DOI 10.1074/jbc.M010501200; Chen Chien-Chung, 2003, Frontiers in Bioscience, V8, P430; Dai X, 1999, CURR OPIN MICROBIOL, V2, P126, DOI 10.1016/S1369-5274(99)80022-8; Fang M, 1998, J BIOL CHEM, V273, P29929, DOI 10.1074/jbc.273.45.29929; Fang M, 2000, BIOCHEM BIOPH RES CO, V276, P64, DOI 10.1006/bbrc.2000.3440; Fang M, 1998, J BACTERIOL, V180, P626, DOI 10.1128/JB.180.3.626-633.1998; HAUGHN GW, 1986, J BACTERIOL, V166, P1113, DOI 10.1128/jb.166.3.1113-1117.1986; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; Levens D, 1997, CURR TOP MICROBIOL, V224, P33; Lissemore JL, 2000, BIOTECHNIQUES, V28, P82, DOI 10.2144/00281st02; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Majumder A, 2001, J BIOL CHEM, V276, P19046, DOI 10.1074/jbc.M100945200; MARGOLIN P, 1985, P NATL ACAD SCI USA, V82, P5437, DOI 10.1073/pnas.82.16.5437; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; Miller J. H., 1972, EXPT MOL GENETICS, P431; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; Opel ML, 2001, MOL MICROBIOL, V39, P1109, DOI 10.1046/j.1365-2958.2001.02309.x; Opel ML, 2001, MOL MICROBIOL, V39, P191, DOI 10.1046/j.1365-2958.2001.02249.x; Repoila F, 2001, J BACTERIOL, V183, P4012, DOI 10.1128/JB.183.13.4012-4023.2001; Rhee KY, 1999, P NATL ACAD SCI USA, V96, P14294, DOI 10.1073/pnas.96.25.14294; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Sun FL, 1999, CELL, V99, P459, DOI 10.1016/S0092-8674(00)81534-2; SZOKE PA, 1987, BIOCHEMISTRY-US, V26, P6188, DOI 10.1021/bi00393a035; TAN JY, 1994, J BACTERIOL, V176, P1077, DOI 10.1128/JB.176.4.1077-1086.1994; TRUCKSIS M, 1981, J BACTERIOL, V147, P679, DOI 10.1128/JB.147.2.679-681.1981; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; WU HY, 1995, CELL, V82, P445, DOI 10.1016/0092-8674(95)90433-6; WU HY, 1991, J MOL BIOL, V219, P615, DOI 10.1016/0022-2836(91)90658-S; Wu HY, 2003, PROG NUCLEIC ACID RE, V73, P43, DOI 10.1016/S0079-6603(03)01002-X; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	33	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38094	38103		10.1074/jbc.M300461200	http://dx.doi.org/10.1074/jbc.M300461200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871947	hybrid			2022-12-25	WOS:000185437200131
J	Cortez, D				Cortez, D			Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; EARLY EMBRYONIC LETHALITY; CELL-CYCLE REGULATION; S-PHASE CHECKPOINT; INDUCED G2 ARREST; RADIOSENSITIZING AGENT; XANTHINE DERIVATIVES; DOWNSTREAM EFFECTOR; MAMMALIAN-CELLS; IN-VITRO	The ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) kinases regulate cell cycle checkpoints by phosphorylating multiple substrates including the CHK1 and -2 protein kinases and p53. Caffeine has been widely used to study ATM and ATR signaling because it inhibits these kinases in vitro and overcomes cell cycle checkpoint responses in vivo. Thus, caffeine has been thought to overcome the checkpoint through its ability to prevent phosphorylation of ATM and ATR substrates. Surprisingly, I have found that multiple ATM- ATR substrates including CHK1 and -2 are hyperphosphorylated in cells treated with caffeine and genotoxic agents such as hydroxyurea or ionizing radiation. ATM autophosphorylation in cells is also increased when caffeine is used in combination with inhibitors of replication suggesting that ATM activity is not inhibited in vivo by caffeine. Furthermore, CHK1 hyperphosphorylation induced by caffeine in combination with hydroxyurea is ATR-dependent suggesting that ATR activity is stimulated by caffeine. Finally, the G(2)/M checkpoint in response to ionizing radiation or hydroxyurea is abrogated by caffeine treatment without a corresponding decrease in ATM-ATR-dependent signaling. This data suggests that although caffeine is an inhibitor of ATM- ATR kinase activity in vitro, it can block checkpoints without inhibiting ATM- ATR activation in vivo.	Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Cortez, D (corresponding author), Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA.				NCI NIH HHS [K01 CA093701, K01 CA093701-03] Funding Source: Medline; PHS HHS [KO193701] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA093701] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BEAVO JA, 1970, MOL PHARMACOL, V6, P597; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; DOMON M, 1970, INT J RADIAT BIOL RE, V17, P395, DOI 10.1080/09553007014550481; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kozlov S, 2003, J BIOL CHEM, V278, P9309, DOI 10.1074/jbc.M300003200; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Nishijima H, 2003, GENES CELLS, V8, P423, DOI 10.1046/j.1365-2443.2003.00644.x; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Poon RYC, 1997, CANCER RES, V57, P5168; POWELL SN, 1995, CANCER RES, V55, P1643; ROWLEY R, 1988, RADIAT RES, V113, P58, DOI 10.2307/3577180; ROWLEY R, 1992, RADIAT RES, V129, P224, DOI 10.2307/3578161; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SELBY CP, 1990, P NATL ACAD SCI USA, V87, P3522, DOI 10.1073/pnas.87.9.3522; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; TORNALETTI S, 1989, BIOCHIM BIOPHYS ACTA, V1007, P112, DOI 10.1016/0167-4781(89)90138-3; Tsuchida R, 2002, RADIAT RES, V158, P195, DOI 10.1667/0033-7587(2002)158[0195:DOAGMI]2.0.CO;2; WELLS JN, 1988, METHOD ENZYMOL, V159, P489; WHARTON W, 1979, BIOCHEM PHARMACOL, V28, P763, DOI 10.1016/0006-2952(79)90356-3; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	50	123	128	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37139	37145		10.1074/jbc.M307088200	http://dx.doi.org/10.1074/jbc.M307088200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12847089	hybrid			2022-12-25	WOS:000185437200020
J	Delacour, D; Gouyer, V; Leteurtre, E; Ait-Slimane, T; Drobecq, H; Lenoir, C; Moreau-Hannedouche, O; Trugnan, G; Huet, G				Delacour, D; Gouyer, V; Leteurtre, E; Ait-Slimane, T; Drobecq, H; Lenoir, C; Moreau-Hannedouche, O; Trugnan, G; Huet, G			1-benzyl-2-acetamido-2-deoxy-alpha-D-galactopyranoside blocks the apical biosynthetic pathway in polarized HT-29 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DETERGENT-INSOLUBLE COMPLEXES; INTRACELLULAR-TRANSPORT; ANNEXIN XIIIB; SUCRASE-ISOMALTASE; PLASMA-MEMBRANE; O-GLYCOSYLATION; GLYCANS MEDIATE; SYNTAXIN 3; N-GLYCANS; TRAFFICKING	In previous work we reported that long term treatment of polarized HT-29 cells by 1-benzyl-2-acetamido-2-deoxy-alpha-D-galactopyranoside (GalNAcalpha-O-bn) induced undersialylation and intracellular distribution of apical glycoproteins such as dipeptidyl peptidase IV (DPP-IV), and we suggested therefore that sialylation could act as an apical targeting signal. In this work, the apical direct biosynthetic route was studied after transfection of polarized enterocyte-like HT-29 5M12 cloned cells with a murine cDNA coding for a soluble form of DPP-IV, which was secreted into the apical medium. A 24-h treatment of transfected cells by GalNAcalpha-O-bn markedly inhibited the apical secretion and the sialylation of this soluble murine DPP-IV, which became blocked inside the cell. A similar short GalNAcalpha-O-bn treatment also induced an intracellular distribution of both endogenous transmembrane DPP-IV and proteins involved in the regulation of the apical trafficking such as the apical t-SNARE syntaxin-3 and the raft-associated protein annexin XIIIb, whereas the basolateral t-SNARE syntaxin-4 kept its normal localization. These apical membrane proteins moved efficiently from trans-Golgi network to apical carrier vesicles but failed to be transported from carrier vesicles to the apical plasma membrane. Isolation of membrane microdomains showed that GalNAcalpha-O-bn induced the formation of abnormal lipid-rich microdomains in comparison to normal rafts, as shown by their lower buoyant density and their depletion in annexin XIIIb. In conclusion, GalNAcalpha-O-bn blocks the anterograde traffic to the apical surface of polarized HT-29 cells at the transport level or docking/fusion level of carrier vesicles.	INSERM, Unite 560, F-59045 Lille, France; INSERM, Unite 538, F-75571 Paris, France; Inst Biol Lille, CNRS UMR 8525, F-59019 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Huet, G (corresponding author), INSERM, Unite 560, Pl Verdun, F-59045 Lille, France.	huet@lille.inserm.fr	Gouyer, Valérie/R-4984-2018	Gouyer, Valérie/0000-0002-4223-7060; Delacour, Delphine/0000-0001-8202-4425; AIT SLIMANE, Tounsia/0000-0002-7459-859X; Drobecq, Herve/0000-0002-4081-1575				AITSLIMANE T, 2000, EXP CELL RES, V258, P184; Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Breuza L, 2000, AM J PHYSIOL-CELL PH, V279, pC1239, DOI 10.1152/ajpcell.2000.279.4.C1239; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BYRD JC, 1995, EUR J CANCER, V31A, P1498, DOI 10.1016/0959-8049(95)00248-H; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; Delannoy P, 1996, GLYCOCONJUGATE J, V13, P717, DOI 10.1007/BF00702335; Delgrossi MH, 1997, J CELL SCI, V110, P2207; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; Gouyer V, 2001, J CELL SCI, V114, P1455; Gouyer V, 2001, FRONT BIOSCI, V6, pD1235, DOI 10.2741/gouyer; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; Hennebicq-Reig S, 1998, BIOCHEM J, V334, P283, DOI 10.1042/bj3340283; HUANG J, 1992, ONCOL RES, V4, P507; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lafont F, 1998, J CELL BIOL, V142, P1413, DOI 10.1083/jcb.142.6.1413; Lecat S, 2000, J CELL SCI, V113, P2607; Lesuffleur T, 1998, INT J CANCER, V76, P383, DOI 10.1002/(SICI)1097-0215(19980504)76:3<383::AID-IJC16>3.3.CO;2-M; Leteurtre E, 2003, J HISTOCHEM CYTOCHEM, V51, P349, DOI 10.1177/002215540305100310; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; MARGUET D, 1992, J BIOL CHEM, V267, P2200; Mirre C, 1996, AM J PHYSIOL-CELL PH, V271, pC887, DOI 10.1152/ajpcell.1996.271.3.C887; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; Noda Y, 2001, J CELL BIOL, V155, P77, DOI 10.1083/jcb.200108042; Riento K, 2000, J BIOL CHEM, V275, P13476, DOI 10.1074/jbc.275.18.13476; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; Spodsberg N, 2001, J BIOL CHEM, V276, P23506, DOI 10.1074/jbc.C100219200; Ulloa F, 2003, J BIOL CHEM, V278, P12374, DOI 10.1074/jbc.M211909200; Ulloa F, 2000, J BIOL CHEM, V275, P18785, DOI 10.1074/jbc.M000510200; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WEISZ OA, 1992, J BIOL CHEM, V267, P22282; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Zanetta JP, 2000, GLYCOBIOLOGY, V10, P565, DOI 10.1093/glycob/10.6.565	50	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37799	37809		10.1074/jbc.M305755200	http://dx.doi.org/10.1074/jbc.M305755200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855686	hybrid			2022-12-25	WOS:000185437200099
J	Walmsley, AR; Zeng, F; Hooper, NM				Walmsley, AR; Zeng, F; Hooper, NM			The N-terminal region of the prion protein ectodomain contains a lipid raft targeting determinant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; AMYLOID PRECURSOR PROTEIN; GPI-ANCHORED PROTEINS; CELLULAR PRION; MEMBRANE DOMAINS; TRANSMEMBRANE DOMAIN; SUBCELLULAR TRAFFICKING; RENAL DIPEPTIDASE; EPITHELIAL-CELLS; SCRAPIE ISOFORM	The association of the prion protein (PrP) with sphingolipid- and cholesterol-rich lipid rafts is instrumental in the pathogenesis of the neurodegenerative prion diseases. Although the glycosylphosphatidylinositol (GPI) anchor is an exoplasmic determinant of raft association, PrP remained raft-associated in human neuronal cells even when the GPI anchor was deleted or substituted for a transmembrane anchor indicating that the ectodomain contains a raft localization signal. The raft association of transmembrane-anchored PrP occurred independently of Cu(II) binding as it failed to be abolished by either deletion of the octapeptide repeat region ( residues 51 - 90) or treatment of cells with a Cu( II) chelator. Raft association of transmembrane-anchored PrP was only abolished by the deletion of the N-terminal region ( residues 23 - 90) of the ectodomain. This region was sufficient to confer raft localization when fused to the N terminus of a non-raft transmembrane-anchored protein and suppressed the clathrin-coated pit localization signal in the cytoplasmic domain of the amyloid precursor protein. These data indicate that the N-terminal region of PrP acts as a cellular raft targeting determinant and that residues 23 - 90 of PrP represent the first proteinaceous raft targeting signal within the ectodomain of a GPI-anchored protein.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Hooper, NM (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.			Hooper, Nigel/0000-0002-5811-3484				Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; Baron GS, 2003, J BIOL CHEM, V278, P14883, DOI 10.1074/jbc.M210840200; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bock J, 2003, FEBS LETT, V534, P169, DOI 10.1016/S0014-5793(02)03784-5; BREWIS IA, 1995, J BIOL CHEM, V270, P22946, DOI 10.1074/jbc.270.39.22946; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; HOOPER NM, 1987, BIOCHEM J, V244, P465, DOI 10.1042/bj2440465; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Ledesma MD, 2000, EMBO REP, V1, P530; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LITTLEWOOD GM, 1989, BIOCHEM J, V257, P361, DOI 10.1042/bj2570361; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Martin-Belmonte F, 2000, J BIOL CHEM, V275, P41074, DOI 10.1074/jbc.M005429200; McMahon HEM, 2001, J BIOL CHEM, V276, P2286, DOI 10.1074/jbc.M007243200; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nunziante M, 2003, J BIOL CHEM, V278, P3726, DOI 10.1074/jbc.M206313200; Pang S, 2001, BIOCHEM J, V358, P185, DOI 10.1042/0264-6021:3580185; Parham SN, 2001, EMBO J, V20, P2111, DOI 10.1093/emboj/20.9.2111; Parkin ET, 1999, BIOCHEM J, V344, P23, DOI 10.1042/0264-6021:3440023; Parkin ET, 1996, BIOCHEM J, V319, P887, DOI 10.1042/bj3190887; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Perera WSS, 1999, FEBS LETT, V463, P273, DOI 10.1016/S0014-5793(99)01648-8; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Tatulian SA, 2000, BIOCHEMISTRY-US, V39, P496, DOI 10.1021/bi991594p; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Viles JH, 2001, BIOCHEMISTRY-US, V40, P2743, DOI 10.1021/bi002898a; Walmsley AR, 2001, EMBO J, V20, P703, DOI 10.1093/emboj/20.4.703; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591; WILLIAMS TA, 1992, BIOCHEM J, V288, P875, DOI 10.1042/bj2880875; Yamabhai M, 2002, J BIOL CHEM, V277, P24843, DOI 10.1074/jbc.C200277200; Yamazaki T, 1996, J CELL SCI, V109, P999; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325	57	91	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37241	37248		10.1074/jbc.M302036200	http://dx.doi.org/10.1074/jbc.M302036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12865430	hybrid			2022-12-25	WOS:000185437200032
J	Wang, JH; Barke, RA; Charboneau, R; Loh, HH; Roy, S				Wang, JH; Barke, RA; Charboneau, R; Loh, HH; Roy, S			Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-OPIOID RECEPTOR; NF-KAPPA-B; SIGNALING PATHWAYS; NUCLEAR-FACTOR; TRANSCRIPTION FACTORS; ADENYLATE-CYCLASE; LOCUS COERULEUS; PROTEIN-KINASES; GENE-EXPRESSION; AP-1 ACTIVITY	To explore the mechanism by which morphine promotes the incidence of HIV infection, we evaluated the regulatory role of morphine on the interferon-gamma (IFN-gamma) promoter in activated T cells from wild type and mu-opioid receptor knockout mice. Our results show that morphine inhibited anti-CD3/CD28-stimulated IFN-gamma promoter activity in a dose-dependent manner. Chronic morphine treatment of T cells increased intracellular cAMP. To evaluate the role of cAMP in morphine's modulatory function, the effects of dibutyryl cyclic AMP and forskolin were investigated. Both dibutyryl cyclic AMP and forskolin treatment inhibited IFN-gamma promoter activity. Treatment with pertussis toxin, but not with a protein kinase A inhibitor, antagonized morphine's inhibitory effects. Morphine inhibited phosphorylation of ERK1/2 and p38 MAPK; in addition, morphine treatment in the presence of either ERK1/2 or p38 MAPK inhibitor (PD98059 or SB203580) resulted in an additive inhibition of IFN-gamma promoter activity. The transcription factor activator protein-1, NF-kappaB, and nuclear factor of activated T cells ( NFAT) were negatively regulated by morphine. Overexpression of NF-kappaB p65 rescued the inhibitory effect of morphine on IFN-gamma promoter activity. However, only when NFATc1 was co-overexpressed with c-fos was the inhibitory effect of morphine on IFN-gamma promoter counteracted. The inhibitory effects of morphine were not observed in T cells obtained from mu-opioid receptor knockout mice, suggesting that morphine modulation of IFN-gamma promoter activity is mediated through the mu-opioid receptor. In summary, our data indicate that morphine modulation of IFN-gamma promoter activity is mediated through two distinct cAMP-dependent pathways, the NF-kappaB signaling pathway and the ERK1/2, p38 MAPK, AP-1/NFAT pathway.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Vet Affairs Med Ctr, Dept Surg, Minneapolis, MN 55417 USA; N Mem Med Ctr, Robbinsdale, MN 55422 USA	University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Roy, S (corresponding author), Univ Minnesota, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.				NIDA NIH HHS [P50 DA 11806, R0-1 DA12104, KO-2 DA015349] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806, R01DA012104, K02DA015349] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Barbulescu K, 1997, EUR J IMMUNOL, V27, P1098, DOI 10.1002/eji.1830270509; Barbulescu K, 1998, J IMMUNOL, V160, P3642; BRETTLE RP, 1992, INT J STD AIDS, V2, P96; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; Chuang LF, 1997, J BIOL CHEM, V272, P26815, DOI 10.1074/jbc.272.43.26815; Cippitelli M, 1996, J BIOL CHEM, V271, P26783, DOI 10.1074/jbc.271.43.26783; DUMAN RS, 1988, J PHARMACOL EXP THER, V246, P1033; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Grader-Beck T, 2003, BLOOD, V101, P998, DOI 10.1182/blood-2002-06-1665; Gunzer M, 2001, J IMMUNOL METHODS, V258, P55, DOI 10.1016/S0022-1759(01)00466-5; HARAGUCHI S, 1995, IMMUNOL TODAY, V16, P595, DOI 10.1016/0167-5699(95)80083-2; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jimenez JL, 2001, J PHARMACOL EXP THER, V299, P753; Kaminuma O, 2002, FEBS LETT, V514, P153, DOI 10.1016/S0014-5793(02)02316-5; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kiani A, 2001, BLOOD, V98, P1480, DOI 10.1182/blood.V98.5.1480; Law PY, 1999, J PHARMACOL EXP THER, V289, P607; LOH HH, 1990, ANNU REV PHARMACOL, V30, P123; Malmberg KJ, 2001, J IMMUNOL, V167, P2595, DOI 10.4049/jimmunol.167.5.2595; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; NESTLER EJ, 1988, MOL PHARMACOL, V33, P127; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; Penix LA, 1996, J BIOL CHEM, V271, P31964, DOI 10.1074/jbc.271.50.31964; PETERSON PK, 1989, J INFECT DIS, V159, P480, DOI 10.1093/infdis/159.3.480; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Reuben JM, 2002, J ALLERGY CLIN IMMUN, V110, P255, DOI 10.1067/mai.2002.125979; Risdahl JM, 1998, J NEUROIMMUNOL, V83, P4, DOI 10.1016/S0165-5728(97)00216-6; Roy S, 1998, MOL BRAIN RES, V61, P190, DOI 10.1016/S0169-328X(98)00212-5; Roy S, 2001, SURGERY, V130, P304, DOI 10.1067/msy.2001.116033; Roy S, 1998, BIOCHEM BIOPH RES CO, V245, P392, DOI 10.1006/bbrc.1998.8415; Roy S, 1999, SURGERY, V126, P239, DOI 10.1067/msy.1999.98252; Rozenfeld-Granot G, 2002, EXP HEMATOL, V30, P473, DOI 10.1016/S0301-472X(02)00786-5; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; Sweetser MT, 1998, J BIOL CHEM, V273, P34775, DOI 10.1074/jbc.273.52.34775; Tamir A, 1996, J IMMUNOL, V157, P1514; Torgersen KM, 2002, CELL SIGNAL, V14, P1, DOI 10.1016/S0898-6568(01)00214-5; Wang JH, 2002, J LEUKOCYTE BIOL, V71, P782; Wang JH, 2001, J LEUKOCYTE BIOL, V70, P527; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q; YU VC, 1990, J NEUROCHEM, V55, P1390, DOI 10.1111/j.1471-4159.1990.tb03151.x; Zhang F, 1998, J IMMUNOL, V161, P6105; Zhang J, 1999, J IMMUNOL, V162, P3819	50	73	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37622	37631		10.1074/jbc.M301224200	http://dx.doi.org/10.1074/jbc.M301224200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12842891	hybrid			2022-12-25	WOS:000185437200077
J	Qiu, Y; Law, PY; Loh, HH				Qiu, Y; Law, PY; Loh, HH			mu-opioid receptor desensitization - Role of receptor phosphorylation, internalization, and resensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; AGONIST-INDUCED DESENSITIZATION; INDUCED DOWN-REGULATION; BETA-ARRESTIN; AMINO-ACIDS; HOMOLOGOUS DESENSITIZATION; MEDIATED ENDOCYTOSIS; TERMINAL TAIL; KINASES; IDENTIFICATION	It is generally accepted that the internalization and desensitization of mu-opioid receptor (MOR) involves receptor phosphorylation and beta-arrestin recruitment. However, a mutant MOR, which is truncated after the amino acid residue Ser(363) (MOR363D), was found to undergo phosphorylation-independent internalization and desensitization. As expected, MOR363D, missing the putative agonist-induced phosphorylation sites, did not exhibit detectable agonist-induced phosphorylation. MOR363D underwent slower internalization as reflected in the attenuation of membrane translocation of beta-arrestin 2 when compared with wild type MOR, but the level of receptor being internalized was similar to that of wild type MOR after 4 h of etorphine treatment. Furthermore, MOR363D was observed to desensitize faster than that of wild type MOR upon agonist activation. Surface biotinylation assay demonstrated that the wild type receptors recycled back to membrane after agonist-induced internalization, which contributed to the receptor resensitization and thus partially reversed the receptor desensitization. On the contrary, MOR363D did not recycle after internalization. Hence, MOR desensitization is controlled by the receptor internalization and the recycling of internalized receptor to cell surface in an active state. Taken together, our data indicated that receptor phosphorylation is not absolutely required in the internalization, but receptor phosphorylation and subsequent beta-arrestin recruitment play important roles in the resensitization of internalized receptors.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Qiu, Y (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	qiuxx014@umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHS [DA0564, K05 DA00513, DA11806, K05 DA70544, DA07339] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA000564, R01DA007339, K05DA000513, P50DA011806, R56DA000564] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Afify EA, 1998, MOL BRAIN RES, V54, P24, DOI 10.1016/S0169-328X(97)00315-X; Allouche S, 1999, EUR J PHARMACOL, V371, P235, DOI 10.1016/S0014-2999(99)00180-6; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Baratti-Elbaz C, 1999, MOL ENDOCRINOL, V13, P1751, DOI 10.1210/me.13.10.1751; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Brasselet S, 2002, FEBS LETT, V516, P124, DOI 10.1016/S0014-5793(02)02517-6; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; Celver JP, 2001, J BIOL CHEM, V276, P4894, DOI 10.1074/jbc.M007437200; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Deng HB, 2000, BIOCHEMISTRY-US, V39, P5492, DOI 10.1021/bi991938b; Deng HB, 2001, BRAIN RES, V898, P204, DOI 10.1016/S0006-8993(01)02179-5; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; El Kouhen R, 1999, J BIOL CHEM, V274, P9207, DOI 10.1074/jbc.274.14.9207; El Kouhen R, 2001, J BIOL CHEM, V276, P12774, DOI 10.1074/jbc.M009571200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Kishi M, 2001, MOL ENDOCRINOL, V15, P1624, DOI 10.1210/me.15.9.1624; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Kovoor A, 1998, MOL PHARMACOL, V54, P704; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Olivares-Reyes JA, 2001, J BIOL CHEM, V276, P37761; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Richardson MD, 2003, J NEUROCHEM, V84, P854, DOI 10.1046/j.1471-4159.2003.01577.x; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Wang HL, 2002, BIOCHEM PHARMACOL, V64, P257, DOI 10.1016/S0006-2952(02)01114-0; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449	39	62	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36733	36739		10.1074/jbc.M305857200	http://dx.doi.org/10.1074/jbc.M305857200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860981	hybrid			2022-12-25	WOS:000185318300105
J	Han, JW; Rose, DM; Woodside, DG; Goldfinger, LE; Ginsberg, MH				Han, JW; Rose, DM; Woodside, DG; Goldfinger, LE; Ginsberg, MH			Integrin alpha(4)beta(1)-dependent T cell migration requires both phosphorylation and dephosphorylation of the alpha(4) cytoplasmic domain to regulate the reversible binding of paxillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN PAXILLIN; ASSOCIATION; MODULATION; ACTIVATION; MOTILITY; MOUSE; MOTIF; SRC	alpha(4) integrins mediate increased cell migration and decreased cell spreading because the alpha(4) cytoplasmic domain ( tail) binds tightly to paxillin, a signaling adaptor protein. Paxillin binding to the alpha(4) tail is blocked by alpha(4) phosphorylation at Ser(988). To establish the biological role of alpha(4) phosphorylation, we reconstituted alpha(4)-deficient Jurkat T cells with phosphorylation-mimicking (alpha(4)(S988D)) or non-phosphorylatable (alpha(4)(S988A)) mutants. alpha(4)(S988D) disrupted paxillin binding and also inhibited cell migration and promoted cell spreading. In contrast, the non-phosphorylatable alpha(4)( S988A) resulted in a further reduction in cell spreading; however, this mutation led to an unexpected suppression of cell migration. The suppression of cell migration by alpha(4)( S988A) was ascribable to enhanced alpha(4)-paxillin association, because enforced association by an alpha(4)-paxillin fusion led to a phenotype similar to that of the non-phosphorylatable alpha(4)(S988A) mutant. These data establish that optimal alpha(4)-mediated cell migration requires both phosphorylation and dephosphorylation of the alpha(4) cytoplasmic domain to regulate the reversible binding of paxillin.	Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ginsberg@scripps.edu						Calderwood DA, 2001, NAT CELL BIOL, V3, P1060, DOI 10.1038/ncb1201-1060; Cary LA, 1996, J CELL SCI, V109, P1787; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Han JW, 2001, J BIOL CHEM, V276, P40903, DOI 10.1074/jbc.M102665200; HEMLER ME, 1992, COLD SPRING HARB SYM, V57, P213, DOI 10.1101/SQB.1992.057.01.026; Huttenlocher A, 1998, J CELL BIOL, V141, P515, DOI 10.1083/jcb.141.2.515; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ILLC D, 1995, NATURE, V377, P539; Jongewaard IN, 1996, CELL ADHES COMMUN, V3, P487, DOI 10.3109/15419069609081025; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Li S, 2002, P NATL ACAD SCI USA, V99, P3546, DOI 10.1073/pnas.052018099; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Liu SC, 2000, J BIOL CHEM, V275, P22736, DOI 10.1074/jbc.M000388200; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rose DM, 2002, IMMUNOL REV, V186, P118, DOI 10.1034/j.1600-065X.2002.18611.x; Rose DM, 2003, J IMMUNOL, V170, P5912, DOI 10.4049/jimmunol.170.12.5912; Rose DM, 2001, J IMMUNOL, V167, P2824, DOI 10.4049/jimmunol.167.5.2824; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Sakai T, 2001, P NATL ACAD SCI USA, V98, P3808, DOI 10.1073/pnas.240456398; Sakai T, 1998, J BIOL CHEM, V273, P19378, DOI 10.1074/jbc.273.31.19378; Salgia R, 1999, ONCOGENE, V18, P67, DOI 10.1038/sj.onc.1202273; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; TAPLEY P, 1989, ONCOGENE, V4, P325; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Zhang XA, 2001, MOL BIOL CELL, V12, P351, DOI 10.1091/mbc.12.2.351	35	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34845	34853		10.1074/jbc.M304691200	http://dx.doi.org/10.1074/jbc.M304691200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12837751	hybrid			2022-12-25	WOS:000185164400015
J	Steinert, PM; Parry, DAD; Marekov, LN				Steinert, PM; Parry, DAD; Marekov, LN			Trichohyalin mechanically strengthens the hair follicle - Multiple cross-bridging roles in the inner root sheath	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNIFIED CELL-ENVELOPE; KERATIN INTERMEDIATE-FILAMENTS; PROLINE-RICH PROTEINS; PEPTIDYLARGININE DEIMINASE; STRUCTURAL FEATURES; GENE FAMILY; CITRULLINE; MOUSE; TRANSGLUTAMINASE; DIFFERENTIATION	Trichohyalin is expressed in specialized epithelia that are unusually mechanically strong, such as the inner root sheath cells of the hair follicle. We have previously shown that trichohyalin is sequentially subjected to post-synthetic modifications by peptidylarginine deaminases, which convert many of its arginines to citrullines, and by transglutaminases, which introduce intra- and interprotein chain cross-links. Here we have characterized in detail the proteins to which it becomes crosslinked in vivo in the inner root sheath of the mouse hair follicle. We suggest that it has three principal roles. First, it serves as an interfilamentous matrix protein by becoming cross-linked both to itself and to the head and tail end domains of the inner root sheath keratin intermediate filament chains. A new antibody reveals that arginines of the tail domains of the keratins are modified to citrullines before cross-linking, which clarifies previous studies. Second, trichohyalin serves as a cross-bridging reinforcement protein of the cornified cell envelope of the inner root sheath cells by becoming crosslinked to several known or novel barrier proteins, including involucrin, small proline-rich proteins, repetin, and epiplakin. Third, it coordinates linkage between the keratin filaments and cell envelope to form a seamless continuum. Together, our new data document that trichohyalin is a multi-functional cross-bridging protein that functions in the inner root sheath and perhaps in other specialized epithelial tissues by conferring to and coordinating mechanical strength between their peripheral cell envelope barrier structures and their cytoplasmic keratin filament networks.	NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; Massey Univ, Inst Fundamental Sci, Palmerston North, New Zealand	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Massey University	Marekov, LN (corresponding author), NIAMS, Skin Biol Lab, NIH, Bldt 50,Rm 1531, Bethesda, MD 20892 USA.	marekovl@mail.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041084] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aoki N, 2001, J INVEST DERMATOL, V116, P359, DOI 10.1046/j.1523-1747.2001.01226.x; AUBER L., 1952, TRANS ROY SOC EDINBURGH, V62, P191; Bawden CS, 2001, J INVEST DERMATOL, V116, P157, DOI 10.1046/j.1523-1747.2001.00215.x; Candi E, 1998, P NATL ACAD SCI USA, V95, P2067, DOI 10.1073/pnas.95.5.2067; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; FIETZ MJ, 1993, J CELL BIOL, V121, P855, DOI 10.1083/jcb.121.4.855; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; Fraser R.D.B., 1972, KERATINS THEIR COMPO; Fujiwara S, 2001, J BIOL CHEM, V276, P13340, DOI 10.1074/jbc.M011386200; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAMILTON EH, 1991, J INVEST DERMATOL, V96, P666, DOI 10.1111/1523-1747.ep12470590; HARDING HWJ, 1972, BIOCHEMISTRY-US, V11, P2858, DOI 10.1021/bi00765a019; HARDING HWJ, 1976, BIOCHIM BIOPHYS ACTA, V427, P315, DOI 10.1016/0005-2795(76)90307-X; HARDING HWJ, 1971, BIOCHEMISTRY-US, V10, P624, DOI 10.1021/bi00780a013; Hesse M, 2001, J CELL SCI, V114, P2569; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; HOHL D, 1991, J BIOL CHEM, V266, P6626; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; Kanno T, 2000, J INVEST DERMATOL, V115, P813, DOI 10.1046/j.1523-1747.2000.00131.x; Kim SY, 2002, NEUROCHEM INT, V40, P85, DOI 10.1016/S0197-0186(01)00064-X; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; Krieg P, 1997, GENOMICS, V43, P339, DOI 10.1006/geno.1997.4818; LEE SC, 1993, J BIOL CHEM, V268, P12164; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MANABE M, 1994, DIFFERENTIATION, V58, P65, DOI 10.1046/j.1432-0436.1994.5810065.x; Marshall D, 2001, P NATL ACAD SCI USA, V98, P13031, DOI 10.1073/pnas.231489198; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; OGUIN WM, 1992, J INVEST DERMATOL, V98, P24, DOI 10.1111/1523-1747.ep12494172; OGUIN WM, 1991, ANN NY ACAD SCI, V642, P51; OKEEFE EJ, 1993, J INVEST DERMATOL, V101, pS65, DOI 10.1111/1523-1747.ep12362866; PARENTEAU NL, 1986, DIFFERENTIATION, V33, P130, DOI 10.1111/j.1432-0436.1986.tb00418.x; Parry DAD, 1999, Q REV BIOPHYS, V32, P99, DOI 10.1017/S0033583500003516; Pearton DJ, 2002, J INVEST DERMATOL, V119, P661, DOI 10.1046/j.1523-1747.2002.01831.x; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; Rogers G, 1997, J INVEST DERMATOL, V108, P700, DOI 10.1111/1523-1747.ep12292083; ROGERS GE, 1962, NATURE, V194, P1149, DOI 10.1038/1941149a0; ROGERS GE, 1963, J HISTOCHEM CYTOCHEM, V11, P700, DOI 10.1177/11.6.700; ROGERS GE, 1983, NORMAL ABNORMAL EPID, P171; ROTHNAGEL JA, 1986, J CELL BIOL, V102, P1419, DOI 10.1083/jcb.102.4.1419; Sato H, 1999, GENOMICS, V56, P303, DOI 10.1006/geno.1998.5721; Shirai H, 2001, TRENDS BIOCHEM SCI, V26, P465, DOI 10.1016/S0968-0004(01)01906-5; Song HJ, 1999, GENOMICS, V55, P28, DOI 10.1006/geno.1998.5607; STEINERT P, 1982, METHOD CELL BIOL, V24, P399; Steinert PM, 2000, J CELL BIOL, V151, pF5, DOI 10.1083/jcb.151.2.F5; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; STEINERT PM, 1978, BIOCHEMISTRY-US, V17, P5045, DOI 10.1021/bi00616a029; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEINERT PM, 1971, J INVEST DERMATOL, V56, P49, DOI 10.1111/1523-1747.ep12291902; TAKAHARA H, 1983, J BIOCHEM, V94, P1945, DOI 10.1093/oxfordjournals.jbchem.a134548; TAKAHARA H, 1989, J BIOL CHEM, V264, P13361; TAMADA Y, 1995, ACTA DERM-VENEREOL, V75, P190; Tarcsa E, 1997, J BIOL CHEM, V272, P27893, DOI 10.1074/jbc.272.44.27893; Tarcsa E, 1996, J BIOL CHEM, V271, P30709, DOI 10.1074/jbc.271.48.30709; TERAKAWA H, 1991, J BIOCHEM, V110, P661, DOI 10.1093/oxfordjournals.jbchem.a123636; Tobin DJ, 2002, AM J PATHOL, V160, P1807, DOI 10.1016/S0002-9440(10)61127-3; VORNER H, 1903, DERMATOL Z BERLIN, V10, P357; WATANABE K, 1988, BIOCHIM BIOPHYS ACTA, V966, P375, DOI 10.1016/0304-4165(88)90088-8; Watts NR, 2002, J STRUCT BIOL, V137, P109, DOI 10.1006/jsbi.2002.4469; WEINBERG WC, 1993, J INVEST DERMATOL, V100, P229, DOI 10.1111/1523-1747.ep12468971; Zhao XP, 1997, GENOMICS, V45, P250, DOI 10.1006/geno.1997.4952	60	93	94	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41409	41419		10.1074/jbc.M302037200	http://dx.doi.org/10.1074/jbc.M302037200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12853460	hybrid			2022-12-25	WOS:000185847200121
J	Kovacs, M; Wang, F; Hu, AH; Zhang, Y; Sellers, JR				Kovacs, M; Wang, F; Hu, AH; Zhang, Y; Sellers, JR			Functional divergence of human cytoplasmic myosin II - Kinetic characterization of the non-muscle IIA isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADENOSINE-TRIPHOSPHATASE; SKELETAL-MUSCLE MYOSIN; HEAVY-CHAIN; DIFFERENTIAL LOCALIZATION; ACTOMYOSIN SUBFRAGMENT-1; FLUORESCENT-PROBE; NEURITE OUTGROWTH; SMOOTH-MUSCLE; RELEASE STEPS; LIGHT-CHAINS	Cytoplasmic (or non-muscle) myosin II isoforms are widely expressed molecular motors playing essential cellular roles in cytokinesis and cortical tension maintenance. Two of the three human non-muscle myosin II isoforms (IIA and IIB) have been investigated at the protein level. Transient kinetics of non-muscle myosin IIB showed that this motor has a very high actomyosin ADP affinity and slow ADP release. Here we report the kinetic characterization of the non-muscle myosin IIA isoform. Similar to non-muscle myosin IIB, non-muscle myosin IIA shows high ADP affinity and little enhancement of the ADP release rate by actin. The ADP release rate constant, however, is more than an order of magnitude higher than the steady-state ATPase rate. This implies that non-muscle myosin IIA spends only a small fraction of its ATPase cycle time in strongly actin-bound states, which is in contrast to non-muscle myosin IIB. Non-muscle myosin II isoforms thus appear to have distinct enzymatic properties that may be of importance in carrying out their cellular functions.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sellers, JR (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202, Bethesda, MD 20892 USA.		Kovacs, Mihaly/A-6841-2011	Kovacs, Mihaly/0000-0002-1200-4741	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL001786, Z01HL001786] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Bridgman PC, 2001, J NEUROSCI, V21, P6159, DOI 10.1523/JNEUROSCI.21-16-06159.2001; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Cremo CR, 2001, J BIOL CHEM, V276, P41465, DOI 10.1074/jbc.M107103200; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; HARRIS DE, 1993, J BIOL CHEM, V268, P14764; Hu AH, 2002, J BIOL CHEM, V277, P46512, DOI 10.1074/jbc.M208506200; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; Kong HH, 2002, J CELL SCI, V115, P4993, DOI 10.1242/jcs.00159; KONISHI K, 2001, J BIOCHEM-TOKYO, P365; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; Malnasi-Csizmadia A, 2001, BIOCHEMISTRY-US, V40, P12727, DOI 10.1021/bi010963q; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; MAUPIN P, 1994, J CELL SCI, V107, P3077; MILLAR NC, 1983, FEBS LETT, V160, P141, DOI 10.1016/0014-5793(83)80954-5; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; Reggiani C, 2000, NEWS PHYSIOL SCI, V15, P26; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; ROCHLIN MW, 1995, J CELL SCI, V108, P3661; Saitoh T, 2001, FEBS LETT, V509, P365, DOI 10.1016/S0014-5793(01)03186-6; Sellers J. R., 1999, MYOSINS; SELLERS JR, 1993, METHOD CELL BIOL, V39, P23, DOI 10.1016/S0091-679X(08)60159-4; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SLEEP JA, 1976, BIOCHEMISTRY-US, V15, P5813, DOI 10.1021/bi00671a019; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; Tullio AN, 2001, J COMP NEUROL, V433, P62, DOI 10.1002/cne.1125; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; VERKHOVSKY AB, 1995, J CELL BIOL, V131, P989, DOI 10.1083/jcb.131.4.989; WAGNER PD, 1981, J BIOL CHEM, V256, P2493; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wang F, 2000, BIOCHEMISTRY-US, V39, P5555, DOI 10.1021/bi000133x; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Wylie SR, 1998, P NATL ACAD SCI USA, V95, P12967, DOI 10.1073/pnas.95.22.12967; Wylie SR, 2001, NAT CELL BIOL, V3, P88, DOI 10.1038/35050613	46	181	186	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38132	38140		10.1074/jbc.M305453200	http://dx.doi.org/10.1074/jbc.M305453200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12847096	hybrid			2022-12-25	WOS:000185575100007
J	Pile, LA; Spellman, PT; Katzenberger, RJ; Wassarman, DA				Pile, LA; Spellman, PT; Katzenberger, RJ; Wassarman, DA			The SIN3 deacetylase complex represses genes encoding mitochondrial proteins - Implications for the regulation of energy metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; DROSOPHILA DEVELOPMENT; MOLECULAR ANALYSIS; HISTONE; EXPRESSION; IDENTIFICATION; TRANSCRIPTION; COMPONENTS; SEQUENCE	Deacetylation of histones by the SIN3 complex is a major mechanism utilized in eukaryotic organisms to repress transcription. Presumably, developmental and cellular phenotypes resulting from mutations in SIN3 are a consequence of altered transcription of SIN3 target genes. Therefore, to understand the molecular mechanisms underlying SIN3 mutant phenotypes in Drosophila, we used full-genome oligonucleotide microarrays to compare gene expression levels in wild type Drosophila tissue culture cells versus SIN3-deficient cells generated by RNA interference. Of the 13,137 genes tested, 364 were induced and 35 were repressed by loss of SIN3. The similar to10-fold difference between the number of induced and repressed genes suggests that SIN3 plays a direct role in regulating these genes. The identified genes are distributed throughout euchromatic regions but are preferentially excluded from heterochromatic regions of Drosophila chromosomes suggesting that the SIN3 complex can only access particular chromatin structures. A number of cell cycle regulators were repressed by loss of SIN3, and functional studies indicate that repression of string, encoding the Drosophila homologue of the yeast CDC25 phosphatase, contributes to the G(2) cell cycle delay of SIN3-deficient cells. Unexpectedly, a substantial fraction of genes induced by loss of SIN3 is involved in cytosolic and mitochondrial energy-generating pathways and other genes encode components of the mitochondrial translation machinery. Increased expression of mitochondrial proteins in SIN3-deficient cells is manifested in an increase in mitochondrial mass. Thus, SIN3 may play an important role in regulating mitochondrial respiratory activity.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; NICHD, NIH, Cell Biol & Metab Branch, Bethesda, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Wassarman, DA (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	dawassarman@facstaff.wisc.edu						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Al-Feel W, 2003, P NATL ACAD SCI USA, V100, P3095, DOI 10.1073/pnas.0538069100; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Berg J. M., 2002, BIOCHEMISTRY, V5th, P425; Berg RW, 2001, J PHARMACOL EXP THER, V298, P477; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Camarero N, 2003, NUCLEIC ACIDS RES, V31, P1693, DOI 10.1093/nar/gkg262; CHERBAS L, 1981, ADV CELL CULT, V1, P91; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DEZELEE S, 1989, EMBO J, V8, P3437, DOI 10.1002/j.1460-2075.1989.tb08508.x; Dubrovsky EB, 2000, DEV BIOL, V224, P486, DOI 10.1006/dbio.2000.9800; Fazzio TG, 2001, MOL CELL BIOL, V21, P6450, DOI 10.1128/MCB.21.19.6450-6460.2001; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Fleischer TC, 2003, MOL CELL BIOL, V23, P3456, DOI 10.1128/MCB.23.10.3456-3467.2003; HUDAK KA, 1994, GENETICS, V136, P475; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; IRIZARRY RA, 2002, IN PRESS BIOSTATISTI; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson RE, 2003, GENE DEV, V17, P77, DOI 10.1101/gad.1048303; Jones DC, 2002, J BIOL CHEM, V277, P6838, DOI 10.1074/jbc.M106908200; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Lamb TM, 2001, GENETICS, V157, P545; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Meertens LM, 1998, EMBO J, V17, P6972, DOI 10.1093/emboj/17.23.6972; Neufeld TP, 1998, GENETICS, V148, P277; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Orr WC, 1996, ARCH BIOCHEM BIOPHYS, V330, P251, DOI 10.1006/abbi.1996.0250; Pavlidis P, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-10-research0042; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; Pile LA, 2000, EMBO J, V19, P6131, DOI 10.1093/emboj/19.22.6131; Pile LA, 2002, MOL CELL BIOL, V22, P4965, DOI 10.1128/MCB.22.14.4965-4976.2002; Radyuk SN, 2000, ARCH INSECT BIOCHEM, V45, P79, DOI 10.1002/1520-6327(200010)45:2&lt;79::AID-ARCH4&gt;3.0.CO;2-Y; REED BH, 1995, BIOESSAYS, V17, P553, DOI 10.1002/bies.950170613; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Scaerou F, 1999, J CELL SCI, V112, P3757; Schoderbock P, 1996, APPL SURF SCI, V93, P109, DOI 10.1016/0169-4332(95)00327-4; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SINGH KK, 1998, MITOCHONDRIAL DNA MU; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; Sweet S, 1999, J CELL PHYSIOL, V180, P91, DOI 10.1002/(SICI)1097-4652(199907)180:1<91::AID-JCP10>3.0.CO;2-6; Torroja L, 1998, J CELL BIOL, V141, P1009, DOI 10.1083/jcb.141.4.1009; VIDAL M, 1995, P NATL ACAD SCI USA, V92, P2370, DOI 10.1073/pnas.92.6.2370; WATSON JD, 1987, MOL BIOL GENET, P411; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200	52	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37840	37848		10.1074/jbc.M305996200	http://dx.doi.org/10.1074/jbc.M305996200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12865422	hybrid			2022-12-25	WOS:000185437200104
J	Walther, RF; Lamprecht, C; Ridsdale, A; Groulx, I; Lee, S; Lefebvre, YA; Hache, RJG				Walther, RF; Lamprecht, C; Ridsdale, A; Groulx, I; Lee, S; Lefebvre, YA; Hache, RJG			Nuclear export of the glucocorticoid receptor is accelerated by cell fusion-dependent release of calreticulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; MOLECULAR CHAPERONES; GENE-EXPRESSION; SUBNUCLEAR TRAFFICKING; PROGESTERONE-RECEPTOR; TRANSCRIPTION FACTORS; LOCALIZATION; SIGNAL; IMPORT; IDENTIFICATION	Nucleocytoplasmic exchange of nuclear hormone receptors is hypothesized to allow for rapid and direct interactions with cytoplasmic signaling factors. In addition to recycling between a naive, chaperone-associated cytoplasmic complex and a liganded chaperone-free nuclear form, the glucocorticoid receptor (GR) has been observed to shuttle between nucleus and cytoplasm. Nuclear export of GR and other nuclear receptors has been proposed to depend on direct interactions with calreticulin, which is predominantly localized to the lumen of the endoplasmic reticulum. We show that rapid calreticulin-mediated nuclear export of GR is a specific response to transient disruption of the endoplasmic reticulum that occurs during polyethylene glycol-mediated cell fusion. Using live and digitonin-permeabilized cells we demonstrate that, in the absence of cell fusion, GR nuclear export occurs slowly over a period of many hours independent of direct interaction with calreticulin. Our findings temper expectations that nuclear receptors respond rapidly and directly to cytoplasmic signals in the absence of additional regulatory control. These results highlight the importance of verifying findings of nucleocytoplasmic trafficking using techniques in addition to heterokaryon cell fusion.	Univ Ottawa, Ottawa Hlth Res Inst, Hormones Growth & Dev Program, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Kidney Res Ctr, Ottawa, ON K1H 8M5, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Hache, RJG (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Hormones Growth & Dev Program, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.							Baumann CT, 2001, J BIOL CHEM, V276, P11237, DOI 10.1074/jbc.M011112200; Black BE, 2001, CURR BIOL, V11, P1749, DOI 10.1016/S0960-9822(01)00537-1; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; DeFranco DB, 2000, KIDNEY INT, V57, P1241, DOI 10.1046/j.1523-1755.2000.00957.x; Du XB, 1998, J CELL BIOL, V141, P585, DOI 10.1083/jcb.141.3.585; Freeman BC, 2000, GENE DEV, V14, P422; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Groulx I, 2000, J BIOL CHEM, V275, P8991, DOI 10.1074/jbc.275.12.8991; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; Holaska JM, 2002, MOL CELL BIOL, V22, P6286, DOI 10.1128/MCB.22.17.6286-6297.2002; Holaska JM, 1998, P NATL ACAD SCI USA, V95, P14739, DOI 10.1073/pnas.95.25.14739; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Lee S, 1999, MOL CELL BIOL, V19, P1486; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; MADAN AP, 1993, P NATL ACAD SCI USA, V90, P3588, DOI 10.1073/pnas.90.8.3588; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; Nakamura K, 2001, J CELL BIOL, V154, P961, DOI 10.1083/jcb.200102073; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Prufer K, 2002, MOL ENDOCRINOL, V16, P1738, DOI 10.1210/me.2001-0345; Prufer K, 2000, J BIOL CHEM, V275, P41114, DOI 10.1074/jbc.M003791200; Prymakowska-Bosak M, 2002, MOL CELL BIOL, V22, P6809, DOI 10.1128/MCB.22.19.6809-6819.2002; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; Savory JGA, 2001, MOL CELL BIOL, V21, P781, DOI 10.1128/MCB.21.3.781-793.2001; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yang J, 1997, J CELL BIOL, V137, P523, DOI 10.1083/jcb.137.3.523	50	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37858	37864		10.1074/jbc.M306356200	http://dx.doi.org/10.1074/jbc.M306356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869547	hybrid			2022-12-25	WOS:000185437200106
J	Gregory, PA; Gardner-Stephen, DA; Lewinsky, RH; Duncliffe, KN; Mackenzie, PI				Gregory, PA; Gardner-Stephen, DA; Lewinsky, RH; Duncliffe, KN; Mackenzie, PI			Cloning and characterization of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 gene promoters - Differential regulation through an initiator-like region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION; BINDING PROTEIN; HUMAN BILIRUBIN; HUMAN LIVER; TATA-LESS; EXPRESSION; ELEMENTS; ACTIVATION; RECEPTOR; SUBUNIT	The human UDP-glucuronosyltransferases, UGT1A8, 1A9, and 1A10, are closely related in sequence and have a major role in the elimination of lipophilic chemicals by glucuronidation. UGT1A8 and 1A10 are expressed exclusively in the gastrointestinal tract, whereas UGT1A9 is expressed mainly in the liver and kidneys. To determine the factors contributing to the extrahepatic expression of these UDP-glucuronosyltransferases, we have cloned and characterized the promoters of the UGT1A8, 1A9, and 1A10 genes and studied their regulation in the colon cell line, Caco2. Their transcription start sites were mapped, and a functional overlapping Sp1/initiator-like site was identified which strongly contributed to UGT1A8 and 1A10 promoter activity. The high promoter activity of UGT1A8 and 1A10 correlated with the binding of nuclear proteins ( complex B) to this region. Two-bp differences in the corresponding site in the UGT1A9 promoter prevented the binding of complex B and reduced promoter activity. Although Sp1 was able to bind to the Sp1/initiator-like site, its binding was dispensable for promoter activity. However, the binding of Sp1 to a second Sp1 site 30 bp 5' to the Sp1/initiator-like site greatly enhanced the activity of the UGT1A8 and 1A10 promoters. These results provide evidence that the UGT1A8, 1A9, and 1A10 genes are differentially regulated through an initiator element in their 5'-flanking regions.	Flinders Univ S Australia, Sch Med, Med Ctr, Dept Clin Pharmacol, Bedford Pk, SA 5042, Australia	Flinders University South Australia	Mackenzie, PI (corresponding author), Flinders Univ S Australia, Sch Med, Med Ctr, Dept Clin Pharmacol, Bedford Pk, SA 5042, Australia.	Peter.Mackenzie@flinders.edu.au	Gregory, Philip/F-4089-2013	Gregory, Philip/0000-0002-0999-0632; Mackenzie, Peter/0000-0002-0697-6878				Barbier O, 2003, J BIOL CHEM, V278, P13975, DOI 10.1074/jbc.M300749200; BASU A, 1993, J BIOL CHEM, V268, P4188; Bellorini M, 1996, MOL CELL BIOL, V16, P503; Bernard P, 1999, MOL PHARMACOL, V56, P526, DOI 10.1124/mol.56.3.526; Beutler E, 1998, P NATL ACAD SCI USA, V95, P8170, DOI 10.1073/pnas.95.14.8170; Breen GAM, 1998, GENE EXPRESSION, V7, P163; Brierley CH, 1996, ADV ENZYME REGUL, V36, P85, DOI 10.1016/0065-2571(95)00006-2; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; Cheng ZQ, 1998, ARCH BIOCHEM BIOPHYS, V356, P301, DOI 10.1006/abbi.1998.0781; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; Dutton G.F., 1980, GLUCURONIDATION DRUG; Emi Y, 1996, J BIOL CHEM, V271, P3952, DOI 10.1074/jbc.271.7.3952; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; Metz RP, 1998, J BIOL CHEM, V273, P5607, DOI 10.1074/jbc.273.10.5607; Mojarrabi B, 1996, BIOCHEM BIOPH RES CO, V225, P785, DOI 10.1006/bbrc.1996.1251; Mojarrabi B, 1998, BIOCHEM BIOPH RES CO, V247, P704, DOI 10.1006/bbrc.1998.8843; MONAGHAN G, 1994, GENOMICS, V23, P496, DOI 10.1006/geno.1994.1531; Munzel PA, 1998, ARCH BIOCHEM BIOPHYS, V350, P72, DOI 10.1006/abbi.1997.0485; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; RITTER JK, 1992, J BIOL CHEM, V267, P3257; RITTER JK, 1991, J BIOL CHEM, V266, P1043; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Strassburg CP, 1997, MOL PHARMACOL, V52, P212, DOI 10.1124/mol.52.2.212; Strassburg CP, 1998, MOL PHARMACOL, V54, P647; Strassburg CP, 1998, J BIOL CHEM, V273, P8719, DOI 10.1074/jbc.273.15.8719; Strassburg CP, 2000, J BIOL CHEM, V275, P36164, DOI 10.1074/jbc.M002180200; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Tukey RH, 2001, MOL PHARMACOL, V59, P405, DOI 10.1124/mol.59.3.405; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Turgeon D, 2000, J MOL BIOL, V295, P489, DOI 10.1006/jmbi.1999.3374; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; WANG JC, 1993, BIOCHIM BIOPHYS ACTA, V1216, P73, DOI 10.1016/0167-4781(93)90039-G; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Yu M, 1997, J BIOL CHEM, V272, P29060, DOI 10.1074/jbc.272.46.29060	57	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36107	36114		10.1074/jbc.M305565200	http://dx.doi.org/10.1074/jbc.M305565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847094	hybrid			2022-12-25	WOS:000185318300031
J	Mulder, H; Sorhede-Winzell, M; Contreras, JA; Fex, M; Strom, K; Ploug, T; Galbo, H; Arner, P; Lundberg, C; Sundler, F; Ahren, B; Holm, C				Mulder, H; Sorhede-Winzell, M; Contreras, JA; Fex, M; Strom, K; Ploug, T; Galbo, H; Arner, P; Lundberg, C; Sundler, F; Ahren, B; Holm, C			Hormone-sensitive lipase null mice exhibit signs of impaired insulin sensitivity whereas insulin secretion is intact	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-TISSUE; LIPOPROTEIN-LIPASE; GLUCOSE-TRANSPORT; PROTEIN-KINASE; FATTY-ACIDS; EXPRESSION; LIPOLYSIS; GENE; LIPOTOXICITY; PATHOGENESIS	Lipid metabolism plays an important role in glucose homeostasis under normal and pathological conditions. In adipocytes, skeletal muscle, and pancreatic beta-cells, lipids are mobilized from acylglycerides by the hormone-sensitive lipase (HSL). Here, the consequences of a targeted disruption of the HSL gene for glucose homeostasis were examined. HSL null mice were slightly hyperglycemic in the fasted, but not fed state, which was accompanied by moderate hyperinsulinemia. During glucose challenges, however, disposal of the sugar was not affected in HSL null mice, presumably because of release of increased amounts of insulin. Impaired insulin sensitivity was further indicated by retarded glucose disposal during an insulin tolerance test. A euglycemic hyperinsulinemic clamp revealed that hepatic glucose production was insufficiently blocked by insulin in HSL null mice. In vitro, insulin-stimulated glucose uptake into soleus muscle, and lipogenesis in adipocytes were moderately reduced, suggesting additional sites of insulin resistance. Morphometric analysis of pancreatic islets revealed a doubling of beta-cell mass in HSL null mice, which is consistent with an adaptation to insulin resistance. Insulin secretion in vitro, examined by perifusion of isolated islets, was not impacted by HSL deficiency. Thus, HSL deficiency results in a moderate impairment of insulin sensitivity in multiple target tissues of the hormone but is compensated by hyperinsulinemia.	Lund Univ, Dept Cell & Mol Biol, Sect Mol Signaling, SE-22184 Lund, Sweden; Lund Univ, Dept Physiol Sci, SE-22184 Lund, Sweden; Lund Univ, Dept Med, SE-22184 Lund, Sweden; Huddinge Univ Hosp, Dept Med, SE-14186 Stockholm, Sweden; Univ Copenhagen, Panum Inst, Copenhagen Muscle Res Ctr, DK-2200 Copenhagen, Denmark	Lund University; Lund University; Lund University; Karolinska Institutet; University of Copenhagen	Mulder, H (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Mol Signaling, BMC C11, SE-22184 Lund, Sweden.	hindrik.mulder@medkem.lu.se	Mulder, Hindrik/E-1045-2012	Lundberg, Cecilia/0000-0002-6959-2564; Ploug, Thorkil/0000-0002-5375-6595; Arner, Peter/0000-0002-6208-6220; Fex, Malin/0000-0003-0675-7576; Mulder, Hindrik/0000-0002-6593-8417				Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; ELKS ML, 1993, ENDOCRINOLOGY, V133, P208, DOI 10.1210/en.133.1.208; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Grober J, 2003, J BIOL CHEM, V278, P6510, DOI 10.1074/jbc.M208513200; Haemmerle G, 2002, J BIOL CHEM, V277, P12946, DOI 10.1074/jbc.M108640200; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; HELLMER J, 1989, ANAL BIOCHEM, V177, P132, DOI 10.1016/0003-2697(89)90027-4; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; Ihlemann J, 1999, AM J PHYSIOL-ENDOC M, V277, pE208, DOI 10.1152/ajpendo.1999.277.2.E208; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; Langfort J, 1999, BIOCHEM J, V340, P459, DOI 10.1042/0264-6021:3400459; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Levin K, 2001, DIABETOLOGIA, V44, P824; Mayerson AB, 2002, DIABETES, V51, P797, DOI 10.2337/diabetes.51.3.797; McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130; Medvedev AV, 2002, J BIOL CHEM, V277, P42639, DOI 10.1074/jbc.M208645200; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; MULDER H, 1993, CELL TISSUE RES, V274, P467, DOI 10.1007/BF00314543; Mulder H, 1999, DIABETES, V48, P228, DOI 10.2337/diabetes.48.1.228; Okazaki H, 2002, DIABETES, V51, P3368, DOI 10.2337/diabetes.51.12.3368; ORCI L, 1990, P NATL ACAD SCI USA, V87, P9953, DOI 10.1073/pnas.87.24.9953; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Pacini G, 2001, AM J PHYSIOL-ENDOC M, V281, pE693, DOI 10.1152/ajpendo.2001.281.4.E693; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; RODBELL M, 1964, J BIOL CHEM, V239, P375; Roduit R, 2001, DIABETES, V50, P1970, DOI 10.2337/diabetes.50.9.1970; Sekar N, 1998, ENDOCRINOLOGY, V139, P2514, DOI 10.1210/en.139.5.2514; SKOGLUND G, 1988, ACTA PHYSIOL SCAND, V132, P289, DOI 10.1111/j.1748-1716.1988.tb08332.x; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Talts JF, 1999, METH MOL B, V129, P153; TORNQVIST H, 1978, J LIPID RES, V19, P654; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Yaney GC, 2001, DIABETES, V50, P56, DOI 10.2337/diabetes.50.1.56	49	93	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36380	36388		10.1074/jbc.M213032200	http://dx.doi.org/10.1074/jbc.M213032200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12835327	hybrid			2022-12-25	WOS:000185318300065
J	Cook, JA; Albacker, L; August, A; Henderson, AJ				Cook, JA; Albacker, L; August, A; Henderson, AJ			CD28-dependent HIV-1 transcription is associated with Vav, Rac, and NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL-ACTIVATION; CD28 CYTOPLASMIC TAIL; LONG TERMINAL REPEAT; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; COSTIMULATION; PROTEIN; TCR	Activation of HIV-1-infected T cells through the T cell receptor and costimulatory molecule CD28 induces proviral transcription; however, the mechanism behind this enhanced virus expression is unknown. Jurkat T cells and primary CD4(+) T cells expressing a CD8alpha/CD28 chimeric receptor containing a mutation at tyrosine 200 in the cytoplasmic tail were unable to fully induce HIV-1 proviral transcription in response to CD8alpha/28 receptor cross-linking in comparison to CD28 costimulation. The loss of transactivation seen with the mutant chimeric receptor correlated with a decrease in Vav tyrosine phosphorylation. CD28-dependent activation of HIV-1 transcription also required the GTPase activity of Rac1, which was not activated during costimulation with the mutated receptor. Furthermore, the mutated receptor was unable to induce NF-kappaB DNA binding or transactivation, as demonstrated by electromobility shift assays and HIV-1 long terminal repeat and NF-kappaB-dependent reporter constructs. These studies show that signaling events initiated by tyrosine 200 of CD28 are required for efficient expression of HIV-1 transcription in activated T cells.	Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Grad Program Biochem Microbiol & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Henderson, AJ (corresponding author), Penn State Univ, Dept Vet Sci, 115 Henning Bldg, University Pk, PA 16802 USA.	ajh6@psu.edu		Henderson, Andrew/0000-0002-9299-5302	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051626, R01AI046261] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46261, AI051626] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUGUST A, 1994, INT IMMUNOL, V6, P769, DOI 10.1093/intimm/6.5.769; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Barker E, 1998, J IMMUNOL, V161, P6223; Bartz SR, 1997, METHODS, V12, P337, DOI 10.1006/meth.1997.0487; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; CALVERT I, 1991, GENE, V101, P171, DOI 10.1016/0378-1119(91)90408-4; Carroll RG, 1997, SCIENCE, V276, P273, DOI 10.1126/science.276.5310.273; Chen BK, 1996, J VIROL, V70, P6044, DOI 10.1128/JVI.70.9.6044-6053.1996; Cook JA, 2002, J IMMUNOL, V169, P254, DOI 10.4049/jimmunol.169.1.254; CROOKS MEC, 1995, MOL CELL BIOL, V15, P6820; Dienz O, 2000, J BIOL CHEM, V275, P24547, DOI 10.1074/jbc.C000177200; Ellis JH, 2000, J IMMUNOL, V164, P5805, DOI 10.4049/jimmunol.164.11.5805; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; Herndon TM, 2001, J IMMUNOL, V166, P5654, DOI 10.4049/jimmunol.166.9.5654; HUTCHCROFT JE, 1995, P NATL ACAD SCI USA, V92, P8808, DOI 10.1073/pnas.92.19.8808; Kaga S, 1998, J IMMUNOL, V160, P4182; Kane LP, 2002, TRENDS IMMUNOL, V23, P413, DOI 10.1016/S1471-4906(02)02264-0; Kim HH, 1998, J BIOL CHEM, V273, P296, DOI 10.1074/jbc.273.1.296; King PD, 1997, J IMMUNOL, V158, P580; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Klasen S, 1998, INT IMMUNOL, V10, P481, DOI 10.1093/intimm/10.4.481; Levine BL, 1996, SCIENCE, V272, P1939, DOI 10.1126/science.272.5270.1939; LI YC, 1994, J BIOL CHEM, V269, P30616; LU YL, 1995, EUR J IMMUNOL, V25, P533, DOI 10.1002/eji.1830250234; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Maniatis T., 1982, MOL CLONING; Marinari B, 2002, EUR J IMMUNOL, V32, P447, DOI 10.1002/1521-4141(200202)32:2<447::AID-IMMU447>3.0.CO;2-5; Marti F, 2001, J IMMUNOL, V166, P197, DOI 10.4049/jimmunol.166.1.197; Michel F, 2000, J IMMUNOL, V165, P3820, DOI 10.4049/jimmunol.165.7.3820; Okkenhaug K, 2001, NAT IMMUNOL, V2, P325, DOI 10.1038/86327; Pages F, 1996, J BIOL CHEM, V271, P9403, DOI 10.1074/jbc.271.16.9403; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Raab M, 2001, IMMUNITY, V15, P921, DOI 10.1016/S1074-7613(01)00248-5; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Rameil P, 2000, ONCOGENE, V19, P2086, DOI 10.1038/sj.onc.1203542; Riley JL, 1998, J VIROL, V72, P8273, DOI 10.1128/JVI.72.10.8273-8280.1998; Sadra A, 1999, J IMMUNOL, V162, P1966; Salojin KV, 1999, J IMMUNOL, V163, P844; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Secchiero P, 2000, J IMMUNOL, V164, P4018, DOI 10.4049/jimmunol.164.8.4018; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SMITHGALL MD, 1995, AIDS RES HUM RETROV, V11, P885, DOI 10.1089/aid.1995.11.885; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; Tao L, 2002, BIOCHEM J, V363, P175, DOI 10.1042/0264-6021:3630175; Teng JMC, 1996, TISSUE ANTIGENS, V48, P255, DOI 10.1111/j.1399-0039.1996.tb02643.x; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; WARD SG, 1995, EUR J IMMUNOL, V25, P526, DOI 10.1002/eji.1830250233; Ward SG, 1996, BIOCHEM J, V318, P361, DOI 10.1042/bj3180361; Wong JGP, 1997, IMMUNOLOGY, V90, P281, DOI 10.1046/j.1365-2567.1997.00147.x; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yoon K, 1999, J GEN VIROL, V80, P2951, DOI 10.1099/0022-1317-80-11-2951; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	54	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35812	35818		10.1074/jbc.M302878200	http://dx.doi.org/10.1074/jbc.M302878200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842899	hybrid			2022-12-25	WOS:000185164400130
J	Ganesan, LP; Fang, HQ; Marsh, CB; Tridandapani, S				Ganesan, LP; Fang, HQ; Marsh, CB; Tridandapani, S			The protein-tyrosine phosphatase SHP-1 associates with the phosphorylated immunoreceptor tyrosine-based activation motif of Fc gamma RIIa to modulate signaling events in myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; NEGATIVE REGULATION; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; IMMUNODEFICIENT MUTANT; CYTOPLASMIC DOMAIN; CRYSTAL-STRUCTURE; HUMAN MONOCYTES; KINASE; SYK	FcgammaRIIa is a low affinity IgG receptor uniquely expressed in human cells that promotes phagocytosis of immune complexes and induces inflammatory cytokine gene transcription. Recent studies have revealed that phagocytosis initiated by FcgammaRIIa is tightly controlled by the inositol phosphatase SHIP-1, and the protein-tyrosine phosphatase SHP-1. Whereas the molecular nature of SHIP-1 involvement with FcgammaRIIa has been well studied, it is not clear how SHP-1 is activated by FcgammaRIIa to mediate its regulatory effect. Here we report that FcgammaRIIa clustering induces SHP-1 phosphatase activity in THP-1 cells. Using synthetic phosphopeptides, and stable transfectants expressing immunoreceptor tyrosine-based activation motif ( ITAM) tyrosine mutants of FcgammaRIIa, we demonstrate that SHP-1 associates with the phosphorylated amino-terminal ITAM tyrosine of FcgammaRIIa, whereas the tyrosine kinase Syk associates with the carboxyl-terminal ITAM tyrosine. Association of SHP-1 with FcgammaRIIa ITAM appears to suppress total cellular tyrosine phosphorylation. Furthermore, FcgammaRIIa clustering results in the association of SHP-1 with key signaling molecules such as Syk, p85 subunit of PtdIns 3-kinase, and p62dok, suggesting that these molecules may be substrates of SHP-1 in this system. Finally, overexpression of wild-type SHP-1 but not catalytically deficient SHP-1 led to a down-regulation of NFkappaB-dependent gene transcription in THP-1 cells activated by clustering FcgammaRIIa.	Ohio State Univ, Dept Internal Med, Div Pulm & Crit Care Med, Dorthy M Davis Heart & Lung Inst, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Tridandapani, S (corresponding author), 405B HLRI,473 W 12th Ave, Columbus, OH 43210 USA.	tridandapani.2@osu.edu	Tridandapani, Susheela/E-4209-2011		NATIONAL CANCER INSTITUTE [P01CA095426, P30CA016058] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063800, P01HL070294] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA095426, P30 CA16058] Funding Source: Medline; NHLBI NIH HHS [HL6176, HL63800, HL70294] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Berg KL, 1999, J BIOL CHEM, V274, P35855, DOI 10.1074/jbc.274.50.35855; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179; Cooney DS, 2001, J IMMUNOL, V167, P844, DOI 10.4049/jimmunol.167.2.844; Cox D, 1996, J BIOL CHEM, V271, P16597, DOI 10.1074/jbc.271.28.16597; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Cox D, 2001, J EXP MED, V193, P61, DOI 10.1084/jem.193.1.61; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Dustin LB, 1999, J IMMUNOL, V162, P2717; EDBERG JC, 1995, J BIOL CHEM, V270, P22301, DOI 10.1074/jbc.270.38.22301; Futterer K, 1998, J MOL BIOL, V281, P523, DOI 10.1006/jmbi.1998.1964; Galandrini R, 2001, EUR J IMMUNOL, V31, P2016, DOI 10.1002/1521-4141(200107)31:7<2016::AID-IMMU2016>3.0.CO;2-W; GHAZIZADEH S, 1995, BIOCHEM J, V305, P669, DOI 10.1042/bj3050669; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; Gibbins JM, 1998, J BIOL CHEM, V273, P34437, DOI 10.1074/jbc.273.51.34437; GREEN MC, 1975, J HERED, V66, P250, DOI 10.1093/oxfordjournals.jhered.a108625; Kant AM, 2002, BLOOD, V100, P1852; KIENER PA, 1993, J BIOL CHEM, V268, P24442; Kim MK, 2001, CLIN IMMUNOL, V98, P125, DOI 10.1006/clim.2000.4955; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; Krugmann S, 1998, CURR BIOL, V8, pR828; Lowry MB, 1998, J BIOL CHEM, V273, P24513, DOI 10.1074/jbc.273.38.24513; MITCHELL MA, 1994, BLOOD, V84, P1753; Nadler MJS, 1997, J BIOL CHEM, V272, P20038, DOI 10.1074/jbc.272.32.20038; Nakamura K, 2002, BLOOD, V100, P3374, DOI 10.1182/blood-2002-03-0787; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Pani G, 1997, CLIN IMMUNOL IMMUNOP, V84, P1, DOI 10.1006/clin.1996.4326; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Pengal RA, 2003, J BIOL CHEM, V278, P22657, DOI 10.1074/jbc.M302907200; Phee H, 2001, MOL CELL BIOL, V21, P8615, DOI 10.1128/MCB.21.24.8615-8625.2001; Pricop L, 2001, J IMMUNOL, V166, P531, DOI 10.4049/jimmunol.166.1.531; Sanchez-Mejorada G, 1998, J BIOL CHEM, V273, P27610, DOI 10.1074/jbc.273.42.27610; Sanchez-Mejorada G, 1998, J LEUKOCYTE BIOL, V63, P521, DOI 10.1002/jlb.63.5.521; SHULTZ LD, 1976, J IMMUNOL, V116, P936; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Tridandapani S, 2002, J BIOL CHEM, V277, P5082, DOI 10.1074/jbc.M110277200; Tridandapani S, 2002, J IMMUNOL, V169, P4370, DOI 10.4049/jimmunol.169.8.4370; Tridandapani S, 2000, J BIOL CHEM, V275, P20480, DOI 10.1074/jbc.M909462199; VANDENHERIKOUDIJK IE, 1995, BLOOD, V85, P2202, DOI 10.1182/blood.V85.8.2202.bloodjournal8582202; VANDENHERIKOUDIJK IE, 1994, J IMMUNOL, V152, P574; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; Vely F, 1997, HYBRIDOMA, V16, P519, DOI 10.1089/hyb.1997.16.519; Worth RG, 2003, P NATL ACAD SCI USA, V100, P4533, DOI 10.1073/pnas.0836650100; Worth RG, 2001, BLOOD, V98, P3429, DOI 10.1182/blood.V98.12.3429; Xie ZH, 2000, J IMMUNOL, V164, P1521, DOI 10.4049/jimmunol.164.3.1521; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; Zhang JS, 2002, J BIOL CHEM, V277, P44660, DOI 10.1074/jbc.M203584200; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223	54	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35710	35717		10.1074/jbc.M305078200	http://dx.doi.org/10.1074/jbc.M305078200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832410	hybrid			2022-12-25	WOS:000185164400117
J	Miyakawa, K; Imamura, T				Miyakawa, K; Imamura, T			Secretion of FGF-16 requires an uncleaved bipartite signal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; FACTOR FAMILY; NUCLEOTIDE-SEQUENCE; HYDROPHOBIC REGION; PROTEIN; IDENTIFICATION; BINDING; TRANSLOCATION; RECOGNITION; EFFICIENCY	Fibroblast growth factor (FGF)- 16 is one of the rare secreted proteins that do not possess a cleavable signal sequence. Here we describe our examination of the mechanism and structural requirements for the secretion of FGF-16 from COS-1 transfectants. Inhibition of its secretion by brefeldin A and identification of an N-glycan on the secreted form confirmed that FGF-16 is secreted by means of the endoplasmic reticulum and Golgi apparatus, as are secreted proteins having a conventional cleavable signal sequence. Deletion of its N terminus abolished secretion of FGF- 16. When chimerized with prolactin, however, the N- terminal sequence of FGF- 16 was not able to mediate secretion of the chimera. Point mutations that made the N terminus less hydrophobic had little effect on secretion of FGF- 16, whereas making the central hydrophobic region less hydrophobic abolished secretion. Within cells, an unsecretable FGF- 16 N- terminal deletion mutant was distributed in the perinuclear region and overlapped the distribution of the Golgi apparatus. Mutants with less hydrophobic central regions were distributed evenly throughout the cytosol. Collectively, these results indicate that FGF- 16 employs a unique bipartite signal sequence ( i. e. both the N- terminal region and central hydrophobic region) that is not cleaved, although it shares the same secretory machinery used by secreted proteins with cleavable signal sequences.	Nat Inst Adv Ind Sci & Technol, Age Dimens Res Ctr, Tsukuba, Ibaraki 3058566, Japan; Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Tsukuba	Imamura, T (corresponding author), Nat Inst Adv Ind Sci & Technol, Age Dimens Res Ctr, Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	imamura-toru@aist.go.jp						ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BAIRD A, 1991, FIBROBLAST GROWTH FA, V638; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; Bellovino D, 2001, J BIOL CHEM, V276, P13949, DOI 10.1074/jbc.M006779200; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; Hatsuzawa K, 1997, J BIOCHEM-TOKYO, V121, P270; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1988, BIOCHEM BIOPH RES CO, V155, P583, DOI 10.1016/S0006-291X(88)80534-5; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Jeffers M, 2001, CANCER RES, V61, P3131; Keenan RJ, 1998, CELL, V94, P181, DOI 10.1016/S0092-8674(00)81418-X; Konishi M, 2000, J BIOL CHEM, V275, P12119, DOI 10.1074/jbc.275.16.12119; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Li AJ, 1999, EUR J NEUROSCI, V11, P1362, DOI 10.1046/j.1460-9568.1999.00546.x; LINGAPPA VR, 1979, NATURE, V281, P117, DOI 10.1038/281117a0; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; Miyakawa K, 1999, J BIOL CHEM, V274, P29352, DOI 10.1074/jbc.274.41.29352; Miyake A, 1998, BIOCHEM BIOPH RES CO, V243, P148, DOI 10.1006/bbrc.1998.8073; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ornitz DM, 2001, GENOME BIOL, V2; Revest JM, 2000, J BIOL CHEM, V275, P8083, DOI 10.1074/jbc.275.11.8083; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; Suzuki S, 2000, J INVEST DERMATOL, V114, P456, DOI 10.1046/j.1523-1747.2000.00912.x; TABE L, 1984, J MOL BIOL, V180, P645, DOI 10.1016/0022-2836(84)90031-7; Urban A, 1997, NUCLEIC ACIDS RES, V25, P2227, DOI 10.1093/nar/25.11.2227; Uruno T, 1999, GROWTH FACTORS, V17, P93, DOI 10.3109/08977199909103519; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	39	33	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35718	35724		10.1074/jbc.M300690200	http://dx.doi.org/10.1074/jbc.M300690200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12851399	hybrid			2022-12-25	WOS:000185164400118
J	Sreedhar, AS; Mihaly, K; Pato, B; Schnaider, T; Stetak, A; Kis-Petik, K; Fidy, J; Simonics, T; Maraz, A; Csermely, P				Sreedhar, AS; Mihaly, K; Pato, B; Schnaider, T; Stetak, A; Kis-Petik, K; Fidy, J; Simonics, T; Maraz, A; Csermely, P			Hsp90 inhibition accelerates cell lysis - Anti-Hsp90 ribozyme reveals a complex mechanism of Hsp90 inhibitors involving both superoxide- and Hsp90-dependent events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE; MEMBRANE FLUIDITY; ATP-BINDING; GENERATION; HEAT-SHOCK-PROTEIN-90; ACTIVATION; STRESS; RADICICOL	The 90 kDa heat shock protein, Hsp90, is an abundant molecular chaperone participating in the cytoprotection of eukaryotic cells. Here we analyzed the involvement of Hsp90 in the maintenance of cellular integrity using partial cell lysis as a measure. Inhibition of Hsp90 by geldanamycin, radicicol, cisplatin, and novobiocin induced a significant acceleration of detergent- and hypotonic shock-induced cell lysis. The concentration and time dependence of cell lysis acceleration was in agreement with the Hsp90 inhibition characteristics of the N-terminal inhibitors, geldanamycin and radicicol. Glutathione and other reducing agents partially blocked geldanamycin-induced acceleration of cell lysis but were largely ineffective with other inhibitors. Indeed, geldanamycin treatment led to superoxide production and a change in membrane fluidity. When Hsp90 content was diminished using anti-Hsp90 hammerhead ribozymes, an accelerated cell lysis was also observed. Hsp90 inhibition-induced cell lysis was more pronounced in eukaryotic ( yeast, mouse red blood, and human T-lymphoma) cells than in bacteria. Our results indicate that besides the geldanamycin-induced superoxide production, and a consequent increase in cell lysis, inhibition or lack of Hsp90 alone can also compromise cellular integrity. Moreover, cell lysis after hypoxia and complement attack was also enhanced by any type of Hsp90 inhibition used, which shows that the maintenance of cellular integrity by Hsp90 is important in physiologically relevant lytic conditions of tumor cells.	Semmelweis Univ, Dept Med Chem, H-1088 Budapest, Hungary; Semmelweis Univ, Dept Biophys, H-1088 Budapest, Hungary; St Istvan Univ, Dept Microbiol & Biotechnol, H-1118 Budapest, Hungary	Semmelweis University; Semmelweis University; Hungarian University of Agriculture & Life Sciences	Csermely, P (corresponding author), Semmelweis Univ, Dept Med Chem, POB 260, H-1444 Budapest 8, Hungary.	csermely@puskin.sote.hu	Kis-Petik, Katalin/AAA-8948-2019; Csermely, Peter/J-2067-2017	Csermely, Peter/0000-0001-9234-0659; Maraz, Anna/0000-0002-8122-158X				Asamoto Y, 2001, BIOCHEM J, V359, P605, DOI 10.1042/0264-6021:3590605; Billecke SS, 2002, J BIOL CHEM, V277, P20504, DOI 10.1074/jbc.M201940200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; CARRAWAY KL, 1982, J CELL BIOL, V94, P624, DOI 10.1083/jcb.94.3.624; Chiosis G, 2003, MOL CANCER THER, V2, P123; Chiosis G, 2002, BIOORGAN MED CHEM, V10, P3555, DOI 10.1016/S0968-0896(02)00253-5; CLEGG JS, 1988, BIOCHEM J, V255, P335; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Csermely P, 2001, NEWS PHYSIOL SCI, V16, P123; Czar MJ, 1996, EUR J CELL BIOL, V70, P322; de Sampaio G, 1999, MOL MICROBIOL, V34, P247, DOI 10.1046/j.1365-2958.1999.01585.x; Dikalov S, 2002, J BIOL CHEM, V277, P25480, DOI 10.1074/jbc.M203271200; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; HEADS RJ, 1995, J MOL CELL CARDIOL, V27, P1669, DOI 10.1016/S0022-2828(95)90722-X; Itoh H, 1999, BIOCHEM J, V343, P697, DOI 10.1042/0264-6021:3430697; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; Kabakov A. E., 1997, HEAT SHOCK PROTEINS; KELLERMAYER MSZ, 1995, BIOCHEM BIOPH RES CO, V211, P166, DOI 10.1006/bbrc.1995.1792; Ki SW, 2000, J BIOL CHEM, V275, P39231, DOI 10.1074/jbc.M006192200; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; Krishnaswamy G, 2001, FRONT BIOSCI-LANDMRK, V6, pD1109, DOI 10.2741/krishnas; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDENEV AN, 1986, BIOCHEM INT, V13, P391; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; LubyPhelps K, 1996, COMP BIOCHEM PHYS B, V115, P295, DOI 10.1016/S0305-0491(96)00176-9; Manzo G, 1998, MED HYPOTHESES, V51, P5, DOI 10.1016/S0306-9877(98)90246-8; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; MINAMIDE Y, 1992, LIPIDS, V27, P354, DOI 10.1007/BF02536150; MISETA A, 1991, J CELL PHYSIOL, V146, P394, DOI 10.1002/jcp.1041460309; OSBORN M, 1977, CELL, V12, P561, DOI 10.1016/0092-8674(77)90257-4; Ou J, 2003, FREE RADICAL BIO MED, V34, P269, DOI 10.1016/S0891-5849(02)01299-6; PATEL JM, 1986, AM REV RESPIR DIS, V134, P1196; PATO B, 2001, EUR J BIOCHEM, V268, pS107; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; REVATHI CJ, 1994, BIOCHEM MOL BIOL INT, V32, P1392; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schnaider T, 2000, CELL STRESS CHAPERON, V5, P52, DOI 10.1379/1466-1268(2000)005<0052:THSIGS>2.0.CO;2; Schulz A, 1997, J BACTERIOL, V179, P3103, DOI 10.1128/jb.179.10.3103-3109.1997; SCOTT JE, 1995, CELL IMMUNOL, V163, P296, DOI 10.1006/cimm.1995.1129; Shah M, 2002, J BIOL CHEM, V277, P45662, DOI 10.1074/jbc.M205935200; SHERTZER HG, 1992, BIOCHEM PHARMACOL, V43, P2135, DOI 10.1016/0006-2952(92)90172-F; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; Song Y, 2002, BIOCHEMISTRY-US, V41, P10616, DOI 10.1021/bi026060u; Soti C, 2003, AGING CELL, V2, P39, DOI 10.1046/j.1474-9728.2003.00031.x; Soti C, 2002, J BIOL CHEM, V277, P7066, DOI 10.1074/jbc.M105568200; Sreedhar AS, 2002, J CELL BIOCHEM, V86, P154, DOI 10.1002/jcb.10204; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; Suttitanamongkol S, 2000, BIOCHEM J, V345, P307, DOI 10.1042/0264-6021:3450307; Tanaka Y, 1998, J ANTIBIOT, V51, P451, DOI 10.7164/antibiotics.51.451; Verkman AS, 2002, TRENDS BIOCHEM SCI, V27, P27, DOI 10.1016/S0968-0004(01)02003-5; Waczulikova I, 2002, BIOELECTROCHEMISTRY, V55, P53, DOI 10.1016/S1567-5394(01)00134-7; Waheed AA, 2002, J BIOL CHEM, V277, P32409, DOI 10.1074/jbc.C200383200; Wang GC, 2000, NUCLEIC ACIDS RES, V28, P2135, DOI 10.1093/nar/28.10.2135; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210; Xie YW, 1996, CIRCULATION, V94, P2580, DOI 10.1161/01.CIR.94.10.2580; YAHARA I, 1986, CELL STRUCT FUNCT, V11, P65, DOI 10.1247/csf.11.65; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	62	81	84	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35231	35240		10.1074/jbc.M301371200	http://dx.doi.org/10.1074/jbc.M301371200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842893	hybrid			2022-12-25	WOS:000185164400060
J	Pirkmaier, A; Dow, R; Ganiatsas, S; Waring, P; Warren, K; Thompson, A; Hendley, J; Germain, D				Pirkmaier, A; Dow, R; Ganiatsas, S; Waring, P; Warren, K; Thompson, A; Hendley, J; Germain, D			Alternative mammary oncogenic pathways are induced by D-type cyclins; MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma	ONCOGENE			English	Article						MMTV; D-type cyclins; squamous differentiation	ESTROGEN-RECEPTOR; BREAST CANCERS; P27(KIP1); PROLIFERATION; ACTIVATION; GLAND; TRANSDIFFERENTIATION; DIFFERENTIATION; SEQUESTRATION; PROGRESSION	The three human D-type cyclins, cyclin D1, D2 and D3 share the ability to bind to and activate cdk4 and 6. MMTV-cyclin D1 transgenic mice develop mainly adenocarcinoma, while MMTV-cyclin D2 mice show a lack of alveologenesis during pregnancy and only develop carcinoma at low frequency. The effect of cyclin D3 overexpression in mammary glands remains hitherto unknown. We generated MMTV-cyclin D3 transgenic mice and report here that they develop exclusively squamous cell carcinoma. We show that although cyclin D3 transgene expression was detected early in puberty, postnatal development and mammary gland proliferation were normal in virgin animals. In contrast, multiparous mice develop multiple foci of abnormal growth that correspond to various stages of squamous metaplasia. Therefore, our results support a role for cyclin D3 in squamous differentiation. In addition, we found that p16 expression during involution is abolished, while p27 expression increased in MMTV-cyclin D3 mice, two modifications that have been reported in the other MMTV-D-type cyclin transgenic models. Our observations indicate that despite biochemical redundancy in vitro and in vivo, D-type cyclins promote distinct oncogenic pathways.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3002, Australia; Peter MacCallum Canc Inst, Dept Pathol, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne	Germain, D (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, St Andrews Pl, Melbourne, Vic 3002, Australia.							Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Evron E, 2001, CANCER RES, V61, P2782; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; Gadd M, 2001, CANCER RES, V61, P8811; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; Kong G, 2002, ONCOGENE, V21, P7214, DOI 10.1038/sj.onc.1205895; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sicinski P, 1997, J MAMMARY GLAND BIOL, V2, P335, DOI 10.1023/A:1026391128117; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Tong W, 2001, MOL CELL BIOL, V21, P1319, DOI 10.1128/MCB.21.4.1319-1328.2001; TOYASHIMA H, 1994, CELL, V78, P67; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wong SCC, 2001, J PATHOL, V194, P35, DOI 10.1002/path.838; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	31	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	2003	22	28					4425	4433		10.1038/sj.onc.1206488	http://dx.doi.org/10.1038/sj.onc.1206488			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853979				2022-12-25	WOS:000183978900012
J	Rutter, JL; Goldstein, AM; Davila, MR; Tucker, MA; Struewing, JP				Rutter, JL; Goldstein, AM; Davila, MR; Tucker, MA; Struewing, JP			CDKN2A point mutations D153spl(c.457G > T) and IVS2+1G > T result in aberrant splice products affecting both p16(INK4a) and p14(ARF)	ONCOGENE			English	Article						melanoma; RT-PCR; alternate reading frame; cryptic splice site	CELL-CYCLE ARREST; PRONE FAMILIES; MELANOMA; P19(ARF); GENE; INHIBITION; LOCUS; MDM2; P53	The CDKN2A gene, which encodes the proteins p16(INK4a) and p14(ARF), is located on chromosome 9p21. Germline mutations at this locus increase susceptibility to cutaneous malignant melanoma (CMM). In general, missense and nonsense mutations are primarily responsible for defective p16(INK4a) and possibly p14(ARF) protein function and account for similar to20% of inherited CMM cases. We report a G>T transversion mutation in the last nucleotide of exon 2, affecting the aspartic acid residue at position 153 of CDKN2A-p16(INK4a) in a proband with melanoma. If splicing were unaffected, this mutation would change Asp to Tyr. RT-PCR analysis, however, revealed that this mutation, which we have termed D153spl(c.457G>T), and a previously described mutation at the next nucleotide, IVS2 + 1G > T, result in identical aberrant splicing affecting both p16(INK4a) and p14(ARF). The two main alternate splice products for each of the two normal transcripts includes a 74 bp deletion in exon 2, revealing a cryptic splice site, and the complete skipping of exon 2. The dual inactivation of p16(INK4a), and p14(ARF) may contribute to the CMM in these families.	NCI, Lab Populat Genet, NIH, DHHS,Ctr Canc Res, Bethesda, MD 20892 USA; NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Struewing, JP (corresponding author), NCI, Lab Populat Genet, NIH, DHHS,Ctr Canc Res, Bldg 41,Room D702,41 Library Dr,MSC 5060, Bethesda, MD 20892 USA.		Struewing, Jeffery P/C-3221-2008; Tucker, Margaret A/B-4297-2015; Struewing, Jeffery P/I-7502-2013	Struewing, Jeffery P/0000-0002-4848-3334; Rutter, Joni/0000-0002-6502-2361				Goldstein AM, 2000, J NATL CANCER I, V92, P1006, DOI 10.1093/jnci/92.12.1006; Goldstein AM, 2001, ARCH DERMATOL, V137, P1493; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Harland M, 2001, HUM MOL GENET, V10, P2679, DOI 10.1093/hmg/10.23.2679; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kefford RF, 1999, J CLIN ONCOL, V17, P3245, DOI 10.1200/JCO.1999.17.10.3245; KRAWCZAK M, 1992, HUM GENET, V90, P41; Lynch HT, 2002, CANCER-AM CANCER SOC, V94, P84, DOI 10.1002/cncr.10159; Moskaluk C A, 1998, Hum Mutat, V12, P70; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Pesole G, 1999, NUCLEIC ACIDS RES, V27, P188, DOI 10.1093/nar/27.1.188; Petronzelli F, 2001, GENE CHROMOSOME CANC, V31, P398, DOI 10.1002/gcc.1159; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Rizos H, 1997, ONCOGENE, V15, P515, DOI 10.1038/sj.onc.1201217; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	21	21	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	2003	22	28					4444	4448		10.1038/sj.onc.1206564	http://dx.doi.org/10.1038/sj.onc.1206564			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853981				2022-12-25	WOS:000183978900014
J	Bonnal, S; Schaeffer, C; Creancier, L; Clamens, S; Moine, H; Prats, AC; Vagner, S				Bonnal, S; Schaeffer, C; Creancier, L; Clamens, S; Moine, H; Prats, AC; Vagner, S			A single internal ribosome entry site containing a G quartet RNA structure drives fibroblast growth factor 2 gene expression at four alternative translation initiation codons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; MESSENGER-RNA; IRES ELEMENTS; C-MYC; VIRUS-RNA; PROTEIN; BINDING; REGION; GROWTH-FACTOR-2; TETRAPLEX	The 484-nucleotide (nt) alternatively translated region (ATR) of the human fibroblast growth factor 2 (FGF-2) mRNA contains four CUG and one AUG translation initiation codons. Although the 5'-end proximal CUG codon is initiated by a cap-dependent translation process, the other four initiation codons are initiated by a mechanism of internal entry of ribosomes. We undertook here a detailed analysis of the cis-acting elements defining the FGF-2 internal ribosome entry site (IRES). A thorough deletion analysis study within the 5'-ATR led us to define a 176-nt region as being necessary and sufficient for IRES function at four codons present in a downstream 308-nt RNA segment. Unexpectedly, a single IRES module is therefore responsible for translation initiation at four distantly localized codons. The determination of the FGF-2 5'-ATR RNA secondary structure by enzymatic and chemical probing experiments showed that the FGF-2 IRES contained two stem-loop regions and a G quartet motif that constitute novel structural determinants of IRES function.	CHU Rangueil, Inst Louis Bugnard, INSERM, U589, F-31403 Toulouse 04, France; CNRS, UPR 9002, F-67084 Strasbourg, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Vagner, S (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U589, F-31403 Toulouse 04, France.		Schaeffer, Celine/AAC-5208-2022; Prats, Anne-Catherine/E-5051-2016; Schaeffer, Celine/AAU-5713-2020; Vagner, Stephan/G-3664-2013; Moine, Herve/Q-2328-2016	Schaeffer, Celine/0000-0001-5883-3951; Prats, Anne-Catherine/0000-0002-5282-3776; Schaeffer, Celine/0000-0001-5883-3951; Moine, Herve/0000-0002-6250-7902; vagner, stephan/0000-0003-1452-7164				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BELSHAM GJ, 1992, EMBO J, V11, P1105, DOI 10.1002/j.1460-2075.1992.tb05150.x; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bonnal S, 2003, NUCLEIC ACIDS RES, V31, P427, DOI 10.1093/nar/gkg003; Brunel C, 2000, METHOD ENZYMOL, V318, P3; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hu MCY, 1999, P NATL ACAD SCI USA, V96, P1339, DOI 10.1073/pnas.96.4.1339; Hudder A, 2000, J BIOL CHEM, V275, P34586, DOI 10.1074/jbc.M005199200; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Kanamori Y, 2001, RNA, V7, P266, DOI 10.1017/S1355838201001741; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; LAUGHLAN G, 1994, SCIENCE, V265, P520, DOI 10.1126/science.8036494; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; Martinez-Salas E, 2002, BIOCHIMIE, V84, P755, DOI 10.1016/S0300-9084(02)01408-6; Miyashiro KY, 2003, NEURON, V37, P417, DOI 10.1016/S0896-6273(03)00034-5; Nanbru C, 2001, ONCOGENE, V20, P4270, DOI 10.1038/sj.onc.1204548; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Oliver AW, 2000, J MOL BIOL, V301, P575, DOI 10.1006/jmbi.2000.3991; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Robertson MEM, 1999, RNA, V5, P1167, DOI 10.1017/S1355838299990301; Ryabova LA, 2002, PROG NUCLEIC ACID RE, V72, P1, DOI 10.1016/S0079-6603(02)72066-7; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; Sella O, 1999, MOL CELL BIOL, V19, P5429; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, J BIOL CHEM, V270, P20376, DOI 10.1074/jbc.270.35.20376; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; WANG CY, 1995, RNA, V1, P526; Wilson JE, 2000, MOL CELL BIOL, V20, P4990, DOI 10.1128/MCB.20.14.4990-4999.2000; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; ZUKER M, 1991, NUCLEIC ACIDS RES, V19, P2707, DOI 10.1093/nar/19.10.2707	42	133	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39330	39336		10.1074/jbc.M305580200	http://dx.doi.org/10.1074/jbc.M305580200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12857733	Green Accepted, hybrid, Green Submitted			2022-12-25	WOS:000185713800010
J	Meng, GX; Grabiec, A; Vallon, M; Ebe, B; Hampel, S; Bessler, W; Wagner, H; Kirschning, CJ				Meng, GX; Grabiec, A; Vallon, M; Ebe, B; Hampel, S; Bessler, W; Wagner, H; Kirschning, CJ			Cellular recognition of Tri-/Di-palmitoylated peptides is independent from a domain encompassing the N-terminal seven leucine-rich repeat (LRR)/LRR-like motifs of TLR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; BACTERIAL CPG-DNA; KAPPA-B; CUTTING EDGE; ACTIVATION; LIPOPOLYSACCHARIDE; EXPRESSION; PROTEINS; CELLS; RESPONSIVENESS	Toll-like receptors (TLRs) mediate microbial pattern recognition in vertebrates. A broad variety of agonists has been attributed to TLR2 and three TLRs, TLR4, TLR2, and TLR5, have been demonstrated to bind microbial products. Distinct agonists might interact with different subdomains of the TLR2 extracellular domain. The TLR2 extracellular domain sequence includes 10 canonical leucine-rich repeat (LRR) motifs and 8-10 additional and potentially functionally relevant LRR-like motifs. Thus, the transfection of TLR2 LRR/LRR-like motif deletion constructs in human embryonic kidney 293 cells and primary TLR2-deficient mouse fibroblasts was performed for analysis of the role of the regarding domains in specific pattern recognition. Preparations applied as agonists were highly purified soluble peptidoglycan, lipoteichoic acid, outer surface protein A from Borrelia burgdorferi, synthetic mycoplasmal macrophage-activating lipoprotein-2, tripalmitoyl-cysteinylseryl-(lysyl)3-lysine (P3CSK4), dipalmitoyl-CSK4 (P-2-CSK4), and monopalmitoyl-CSK4 (PCSK4) as well as lipopolysaccharide and inactivated bacteria. We found that a block of the N-terminal seven LRR/LRR-like motifs was not involved in TLR2-mediated cell activation by P3CSK4 and P2CSK4 ligands mimicking triacylated and diacylated bacterial polypeptides, respectively. In contrast, the integrity of the TLR2 holoprotein was compulsory for effective cellular recognition of other TLR2 agonists applied, including PCSK4. The formation of a functionally relevant subdomain by a region including the N-terminal seven LRR/LRR-like motifs rather than by single LRRs is suggested by our results. They further imply that TLR2 contains multiple binding domains for ligands that may contribute to the characterization of its promiscuous molecular pattern recognition.	Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany; Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany	Technical University of Munich; University of Freiburg	Kirschning, CJ (corresponding author), Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Trogerstr 4A, D-81675 Munich, Germany.	carsten.kirschning@lrz.tum.de		孟, 广勋/0000-0002-4253-9675				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732; BESSLER WG, 1992, RES IMMUNOL, V143, P548, DOI 10.1016/0923-2494(92)80067-U; BESSLER WG, 1980, INFECT IMMUN, V28, P818; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Bochud PY, 2003, J IMMUNOL, V170, P3451, DOI 10.4049/jimmunol.170.7.3451; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; da Costa CP, 2002, EUR J IMMUNOL, V32, P2460, DOI 10.1002/1521-4141(200209)32:9<2460::AID-IMMU2460>3.0.CO;2-M; Dunn J J, 1990, Protein Expr Purif, V1, P159, DOI 10.1016/1046-5928(90)90011-M; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; FRED MA, 1990, CURRENT PROTOCOLS MO; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Heine H, 1999, J IMMUNOL, V162, P6971; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Iwaki D, 2002, J BIOL CHEM, V277, P24315, DOI 10.1074/jbc.M107057200; Kajava AV, 2002, PROTEIN SCI, V11, P1082, DOI 10.1110/ps.4010102; Kirschning CJ, 2002, CURR TOP MICROBIOL, V270, P121; LATZ E, 2002, J BIOL CHEM, V24, P24; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Mitsuzawa H, 2001, J BIOL CHEM, V276, P41350, DOI 10.1074/jbc.M104177200; MIZEL SB, 2003, J BIOL CHEM, V23, P23; Morath S, 2001, J EXP MED, V193, P393, DOI 10.1084/jem.193.3.393; Morr M, 2002, EUR J IMMUNOL, V32, P3337, DOI 10.1002/1521-4141(2002012)32:12<3337::AID-IMMU3337>3.0.CO;2-I; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Nagai Y, 2002, BLOOD, V99, P1699, DOI 10.1182/blood.V99.5.1699; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schubert WD, 2002, CELL, V111, P825, DOI 10.1016/S0092-8674(02)01136-4; Shoham S, 2001, J IMMUNOL, V166, P4620, DOI 10.4049/jimmunol.166.7.4620; Sing A, 2002, J EXP MED, V196, P1017, DOI 10.1084/jem.20020908; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354	44	66	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39822	39829		10.1074/jbc.M304766200	http://dx.doi.org/10.1074/jbc.M304766200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12860988	hybrid			2022-12-25	WOS:000185713800068
J	Baardsnes, J; Kuiper, MJ; Davies, PL				Baardsnes, J; Kuiper, MJ; Davies, PL			Antifreeze protein dimer - When two ice-binding faces are better than one	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III ANTIFREEZE; THERMAL HYSTERESIS; GROWTH-INHIBITION; STRUCTURAL BASIS; SURFACE; FISHES; IDENTIFICATION; MECHANISMS; ADSORPTION; RESIDUES	A naturally occurring tandem duplication of the 7-kDa type III antifreeze protein from Antarctic eel pout (Lycodichthys dearborni) is twice as active as the monomer in depressing the freezing point of a solution. We have investigated the basis for this enhanced activity by producing recombinant analogues of the linked dimer that assess the effects of protein size and the number and area of the ice-binding site(s). The recombinant dimer connected by a peptide linker had twice the activity of the monomer. When one of the two ice-binding sites was inactivated by site-directed mutagenesis, the linked dimer was only 1.2 times more effective than the monomer. When the two monomers were linked through a C-terminal disulfide bond in such a way that their two ice-binding sites were opposite each other and unable to engage the same ice surface simultaneously, the dimer was again only 1.2 times as active as the monomer. We conclude from these analyses that the enhanced activity of the dimer stems from the two ice-binding sites being able to engage to ice at the same time, effectively doubling the area of the ice-binding site.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Davies, PL (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.							Antson AA, 2001, J MOL BIOL, V305, P875, DOI 10.1006/jmbi.2000.4336; Baardsnes J, 1999, FEBS LETT, V463, P87, DOI 10.1016/S0014-5793(99)01588-4; Baardsnes J, 2002, BBA-PROTEINS PROTEOM, V1601, P49, DOI 10.1016/S1570-9639(02)00431-4; CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; Chao H, 1996, PROTEIN SCI, V5, P1150; CHAO H, 1993, PROTEIN SCI, V2, P1411, DOI 10.1002/pro.5560020906; CHAO H, 1994, PROTEIN SCI, V3, P1760, DOI 10.1002/pro.5560031016; Chen GJ, 1999, BIOPHYS J, V77, P1602, DOI 10.1016/S0006-3495(99)77008-6; Cheng C.C., 1991, P1; Davies PL, 1997, CURR OPIN STRUC BIOL, V7, P828, DOI 10.1016/S0959-440X(97)80154-6; DeLuca CI, 1998, BIOPHYS J, V74, P1502, DOI 10.1016/S0006-3495(98)77862-2; DeLuca CI, 1996, BIOPHYS J, V71, P2346, DOI 10.1016/S0006-3495(96)79476-6; DEVRIES AL, 1982, COMP BIOCHEM PHYS A, V73, P627, DOI 10.1016/0300-9629(82)90270-5; DEVRIES AL, 1983, ANNU REV PHYSIOL, V45, P245, DOI 10.1146/annurev.ph.45.030183.001333; Ewart KV, 1999, CELL MOL LIFE SCI, V55, P271, DOI 10.1007/s000180050289; Fletcher GL, 2001, ANNU REV PHYSIOL, V63, P359, DOI 10.1146/annurev.physiol.63.1.359; Graether SP, 1999, J BIOL CHEM, V274, P11842, DOI 10.1074/jbc.274.17.11842; GRIFFITH M, 1995, BIOTECHNOL ADV, V13, P375, DOI 10.1016/0734-9750(95)02001-J; Harding MM, 1999, EUR J BIOCHEM, V264, P653, DOI 10.1046/j.1432-1327.1999.00617.x; Jia ZC, 1996, NATURE, V384, P285, DOI 10.1038/384285a0; JIA ZC, 1995, PROTEIN SCI, V4, P1236, DOI 10.1002/pro.5560040621; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; Ko TP, 2003, BIOPHYS J, V84, P1228, DOI 10.1016/S0006-3495(03)74938-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leinala EK, 2002, J BIOL CHEM, V277, P33349, DOI 10.1074/jbc.M205575200; Miura K, 2001, J BIOL CHEM, V276, P1304, DOI 10.1074/jbc.M007902200; Nishimiya Y, 2003, J BIOL CHEM, V278, P32307, DOI 10.1074/jbc.M304390200; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; Sambrook J., 2002, MOL CLONING LAB MANU; Sonnichsen FD, 1996, STRUCTURE, V4, P1325, DOI 10.1016/S0969-2126(96)00140-2; WANG X, 1995, BBA-PROTEIN STRUCT M, V1247, P163, DOI 10.1016/0167-4838(94)00205-U; WILSON PW, 1993, CRYO-LETT, V14, P31; Yang DSC, 1998, BIOPHYS J, V74, P2142, DOI 10.1016/S0006-3495(98)77923-8; Yeh Y, 1996, CHEM REV, V96, P601, DOI 10.1021/cr950260c; Zachariassen KE, 1999, BIOTECHNOLOGICAL APPLICATIONS OF COLD-ADAPTED ORGANISMS, P319	36	41	51	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38942	38947		10.1074/jbc.M306776200	http://dx.doi.org/10.1074/jbc.M306776200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12869550	hybrid			2022-12-25	WOS:000185575100104
J	Leverrier, Y; Okkenhaug, K; Sawyer, C; Bilancio, A; Vanhaesebroeck, B; Ridley, AJ				Leverrier, Y; Okkenhaug, K; Sawyer, C; Bilancio, A; Vanhaesebroeck, B; Ridley, AJ			Class I phosphoinositide 3-kinase p110 beta is required for apoptotic cell and Fc gamma receptor-mediated phagocytosis by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPAIRED B-CELL; PHOSPHATIDYLINOSITOL 3-KINASE; EMBRYONIC LETHALITY; DNA-SYNTHESIS; PI 3-KINASE; RHO GTPASES; T-CELLS; ACTIVATION; SUBUNIT; MICE	Phosphoinositide 3-kinases (PI3Ks) play an important role in a variety of cellular functions, including phagocytosis. PI3Ks are activated during phagocytosis induced by several receptors and have been shown to be required for phagocytosis through the use of inhibitors such as wortmannin and LY294002. Mammalian cells have multiple isoforms of PI3K, and the role of the individual isoforms during phagocytosis has not been addressed. The class I PI3Ks consist of a catalytic p110 isoform associated with a regulatory subunit. Mammals have three genes for the class IA p110 subunits encoding p110alpha, p110beta, and p110delta and one gene for the class IB p110 subunit encoding p110gamma. Here we report a specific recruitment of p110beta and p110delta (but not p110alpha) isoforms to the nascent phagosome during apoptotic cell phagocytosis by fibroblasts. By microinjecting inhibitory antibodies specific to class IA p110 subunits, we have shown that p110beta is the major isoform required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by primary mouse macrophages. Macrophages from mice expressing a catalytically inactive form of p110delta showed no defect in the phagocytosis of apoptotic cells and IgG-opsonized particles, confirming the lack of a major role for p110delta in this process. Similarly, p110gamma-deficient macrophages phagocytosed apoptotic cells normally. Our findings demonstrate that p110beta is the major class I catalytic isoform required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by primary macrophages.	Ludwig Inst Canc Res, Royal Free & Univ Coll Med Sch Branch, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Ridley, AJ (corresponding author), Ludwig Inst Canc Res, Royal Free & Univ Coll Med Sch Branch, 91 Riding House St, London W1W 7BS, England.	anne@ludwig.ucl.ac.uk	Okkenhaug, Klaus/H-3154-2019; Okkenhaug, Klaus/D-5149-2012; LEVERRIER, Yann/M-3767-2014	Okkenhaug, Klaus/0000-0002-9432-4051; Okkenhaug, Klaus/0000-0002-9432-4051; LEVERRIER, Yann/0000-0002-4227-5446; Ridley, Anne/0000-0001-8186-5708; BILANCIO, Antonio/0000-0002-5118-3359; Box, Carol/0000-0002-8919-8724				Albert ML, 2001, NAT IMMUNOL, V2, P1010, DOI 10.1038/ni722; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Benistant C, 2000, ONCOGENE, V19, P5083, DOI 10.1038/sj.onc.1203871; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bi L, 2002, MAMM GENOME, V13, P169, DOI 10.1007/s00335-001-2123-x; Booth JW, 2001, SEMIN IMMUNOL, V13, P357, DOI 10.1006/smim.2001.0332; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Cox D, 2001, J EXP MED, V193, P61, DOI 10.1084/jem.193.1.61; Cox D, 2002, NAT CELL BIOL, V4, P469, DOI 10.1038/ncb805; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; Ellson CD, 2001, CURR BIOL, V11, P1631, DOI 10.1016/S0960-9822(01)00447-X; FADOK VA, 1992, J IMMUNOL, V149, P4029; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Hill KM, 2001, J BIOL CHEM, V276, P16374, DOI 10.1074/jbc.M006985200; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Hooshmand-Rad R, 2000, J CELL SCI, V113, P207; Hu B, 2002, J LEUKOCYTE BIOL, V71, P881; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kurosu H, 2001, J BIOCHEM-TOKYO, V130, P73, DOI 10.1093/oxfordjournals.jbchem.a002964; Leverrier Y, 2001, J IMMUNOL, V166, P4831, DOI 10.4049/jimmunol.166.8.4831; Leverrier Y, 2001, CURR BIOL, V11, P195, DOI 10.1016/S0960-9822(01)00047-1; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Lu-Kuo JM, 2000, J BIOL CHEM, V275, P6022, DOI 10.1074/jbc.275.8.6022; Marshall JG, 2001, J CELL BIOL, V153, P1369, DOI 10.1083/jcb.153.7.1369; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Okkenhaug K, 2002, SCIENCE, V297, P1031; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Roberts RL, 2000, J LEUKOCYTE BIOL, V68, P627; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sawyer C, 2003, CANCER RES, V63, P1667; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Swanson JA, 1999, J CELL SCI, V112, P307; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081	45	76	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38437	38442		10.1074/jbc.M306649200	http://dx.doi.org/10.1074/jbc.M306649200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12869549	hybrid			2022-12-25	WOS:000185575100044
J	Murray, J; Taylor, SW; Zhang, B; Ghosh, SS; Capaldi, RA				Murray, J; Taylor, SW; Zhang, B; Ghosh, SS; Capaldi, RA			Oxidative damage to mitochondrial complex I due to peroxynitrite - Identification of reactive tyrosines by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; NITRIC-OXIDE; PROTEIN IDENTIFICATION; PERSISTENT INHIBITION; SELECTIVE NITRATION; SUBUNIT COMPOSITION; BRAIN MITOCHONDRIA; HYDROGEN-PEROXIDE; SUBSTANTIA-NIGRA; GLUTATHIONE	There is growing evidence that oxidative phosphorylation (OXPHOS) generates reactive oxygen and nitrogen species within mitochondria as unwanted byproducts that can damage OXPHOS enzymes with subsequent enhancement of free radical production. The accumulation of this oxidative damage to mitochondria in brain is thought to lead to neuronal cell death resulting in neurodegeneration. The predominant reactive nitrogen species in mitochondria are nitric oxide and peroxynitrite. Here we show that peroxynitrite reacts with mitochondrial membranes from bovine heart to significantly inhibit the activities of complexes I, II, and V ( 50 - 80%) but with less effect upon complex IV and no significant inhibition of complex III. Because inhibition of complex I activity has been a reported feature of Parkinson's disease, we undertook a detailed analysis of peroxynitrite-induced modifications to proteins from an enriched complex I preparation. Immunological and mass spectrometric approaches coupled with two-dimensional PAGE have been used to show that peroxynitrite modification resulting in a 3-nitrotyrosine signature is predominantly associated with the complex I subunits, 49-kDa subunit (NDUFS2), TYKY (NDUFS8), B17.2 ( 17.2-kDa differentiation associated protein), B15 (NDUFB4), and B14 (NDUFA6). Nitration sites and estimates of modification yields were deduced from MS/MS fragmentograms and extracted ion chromatograms, respectively, for the last three of these subunits as well as for two co-purifying proteins, the beta and the d subunits of the F1F0-ATP synthase. Subunits B15 ( NDUFB4) and B14 ( NDUFA6) contained the highest degree of nitration. The most reactive site in subunit B14 was Tyr(122), while the most reactive region in B15 contained 3 closely spaced tyrosines Tyr(46), Tyr(50), and Tyr(51). In addition, a site of oxidation of tryptophan was detected in subunit B17.2 adding to the number of post-translationally modified tryptophans we have detected in complex I subunits ( Taylor, S. W., Fahy, E., Murray, J., Capaldi, R. A., and Ghosh, S. S. (2003) J. Biol. Chem. 278, 19587 - 19590). These sites of oxidation and nitration may be useful biomarkers for assessing oxidative stress in neurodegenerative disorders.	Univ Oregon, Dept Mol Biol, Eugene, OR 97403 USA; MitoKor, San Diego, CA 92121 USA	University of Oregon	Capaldi, RA (corresponding author), Univ Oregon, Dept Mol Biol, Eugene, OR 97403 USA.	rcapaldi@oregon.uoregon.edu						Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4; Borutaite V, 2000, BBA-BIOENERGETICS, V1459, P405, DOI 10.1016/S0005-2728(00)00178-X; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brookes PS, 1998, J NEUROCHEM, V70, P2195; BROWN GC, 1995, FEBS LETT, V369, P136, DOI 10.1016/0014-5793(95)00763-Y; Byun J, 1999, BIOCHEMISTRY-US, V38, P2590, DOI 10.1021/bi9822980; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Ferrante RJ, 1999, BRAIN RES, V823, P177, DOI 10.1016/S0006-8993(99)01166-X; Field HI, 2002, PROTEOMICS, V2, P36, DOI 10.1002/1615-9861(200201)2:1<36::AID-PROT36>3.0.CO;2-W; FINEL M, 1994, EUR J BIOCHEM, V226, P237, DOI 10.1111/j.1432-1033.1994.tb20046.x; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Hanson BJ, 2001, ELECTROPHORESIS, V22, P950, DOI 10.1002/1522-2683()22:5<950::AID-ELPS950>3.0.CO;2-D; Heales SJR, 2002, NEUROCHEM INT, V40, P469, DOI 10.1016/S0197-0186(01)00117-6; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jha N, 2000, J BIOL CHEM, V275, P26096, DOI 10.1074/jbc.M000120200; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P976; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; Maneiro E, 2003, ARTHRITIS RHEUM, V48, P700, DOI 10.1002/art.10837; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; Murray J, 2003, J BIOL CHEM, V278, P13619, DOI 10.1074/jbc.C300064200; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Orsi A, 2000, BIOCHEM J, V346, P407, DOI 10.1042/0264-6021:3460407; Pennathur S, 1999, J BIOL CHEM, V274, P34621, DOI 10.1074/jbc.274.49.34621; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; RICHMAN PG, 1978, BIOCHEMISTRY-US, V17, P928, DOI 10.1021/bi00598a029; Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Sharov VS, 2002, ANAL BIOCHEM, V308, P328, DOI 10.1016/S0003-2697(02)00261-0; Sherer TB, 2002, NEUROSCIENTIST, V8, P192, DOI 10.1177/1073858402008003004; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; SINGER TP, 1990, FEBS LETT, V274, P1, DOI 10.1016/0014-5793(90)81315-F; Skehel JM, 1998, FEBS LETT, V438, P301, DOI 10.1016/S0014-5793(98)01317-9; Smallwood HS, 2003, CHEM RES TOXICOL, V16, P95, DOI 10.1021/tx025566a; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; SOFIC E, 1992, NEUROSCI LETT, V142, P128, DOI 10.1016/0304-3940(92)90355-B; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Taylor SW, 2002, J PROTEOME RES, V1, P451, DOI 10.1021/pr025533g; TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169; Triepels RH, 2001, J BIOL CHEM, V276, P8892, DOI 10.1074/jbc.M009903200; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Yamamoto T, 2002, J NEURAL TRANSM, V109, P1, DOI 10.1007/s702-002-8232-1	57	262	266	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37223	37230		10.1074/jbc.M305694200	http://dx.doi.org/10.1074/jbc.M305694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857734	hybrid			2022-12-25	WOS:000185437200030
J	Wolins, NE; Skinner, JR; Schoenfish, MJ; Tzekov, A; Bensch, KG; Bickel, PE				Wolins, NE; Skinner, JR; Schoenfish, MJ; Tzekov, A; Bensch, KG; Bickel, PE			Adipocyte protein S3-12 coats nascent lipid droplets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; DIFFERENTIATION-RELATED PROTEIN; NECROSIS-FACTOR-ALPHA; A-MEDIATED LIPOLYSIS; FATTY-ACID UPTAKE; PERILIPIN-A; 3T3-L1 ADIPOCYTES; STORAGE DROPLET; ACYL-COA; GLUCOSE-TRANSPORT	Most animals store lipid intracellularly in protein-coated droplets. The protein coat usually contains at least one member of the PAT (perilipin, adipose differentiation-related protein, and TIP47) family. Evidence suggests that PAT proteins control access to the lipid they enclose. The protein S3-12, which has sequence similarity to the PAT proteins, was found in a screen for adipocyte-specific proteins. The adipocyte expression of S3-12 and its similarity to the PAT proteins suggest that S3-12 is involved in adipocyte lipid storage. To test this hypothesis, we supplemented 3T3-L1 adipocytes with fatty acids and assessed the distribution of S3-12 by immunofluorescence microscopy. Prior to fatty acid incubation, S3-12 was distributed diffusely throughout the cytoplasm on punctate structures of heterogeneous size. After 10 min of lipid loading, S3-12 localized to 500-nm structures concentrated at the adipocyte periphery. After longer incubations, S3-12 coated the surface of lipid droplets up to several micrometers in diameter. Initially, these droplets were distinct from those droplets surrounded by perilipin; but by 240 min, most perilipin-coated droplets had some S3-12 on the surface as well. We additionally report that the formation of S3-12-coated droplets 1) required glucose and fatty acids that can be incorporated into triacylglycerol, 2) was blocked by an inhibitor of triacylglycerol synthesis, and 3) was insulin-dependent. This study reports for the first time the early morphological events in the genesis and maturation of adipocyte lipid droplets.	Washington Univ, Dept Med, Sch Med, Div Endocrinol Metab & Lipid Res, St Louis, MO 63110 USA; Washington Univ, Dept Cell Biol & Physiol, Sch Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Bickel, PE (corresponding author), Washington Univ, Dept Med, Sch Med, Div Endocrinol Metab & Lipid Res, 660 S Euclid Ave,Campus Box 8127, St Louis, MO 63110 USA.		Bickel, Perry/Q-9185-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574, P30DK056341, T32DK007120] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK07120, P30 DK56341, P30 DK52574] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bonifacino J. S., 2003, CURRENT PROTOCOLS CE; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; Buhman KK, 2001, J BIOL CHEM, V276, P40369, DOI 10.1074/jbc.R100050200; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; FROST SC, 1985, J BIOL CHEM, V260, P2646; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; Guo W, 2000, BIOCHEM J, V349, P463, DOI 10.1042/0264-6021:3490463; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; Imamura M, 2002, AM J PHYSIOL-ENDOC M, V283, pE775, DOI 10.1152/ajpendo.00040.2002; Khelef N, 2000, ARTERIOSCL THROM VAS, V20, P1769; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Meegalla RL, 2002, BIOCHEM BIOPH RES CO, V298, P317, DOI 10.1016/S0006-291X(02)02466-X; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Mora S, 2002, DIABETES-METAB RES, V18, P345, DOI 10.1002/dmrr.321; SADUR CN, 1982, J CLIN INVEST, V69, P1119, DOI 10.1172/JCI110547; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Spector A A, 1980, Prog Lipid Res, V19, P155; Stahl A, 2002, DEV CELL, V2, P477, DOI 10.1016/S1534-5807(02)00143-0; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; WEINER FR, 1991, J BIOL CHEM, V266, P23525; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200	36	169	175	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37713	37721		10.1074/jbc.M304025200	http://dx.doi.org/10.1074/jbc.M304025200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12840023	hybrid			2022-12-25	WOS:000185437200088
J	Arias, DA; Navenot, JM; Zhang, WB; Broach, J; Peiper, SC				Arias, DA; Navenot, JM; Zhang, WB; Broach, J; Peiper, SC			Constitutive activation of CCR5 and CCR2 induced by conformational changes in the conserved TXP motif in transmembrane helix 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AMINO-TERMINAL DOMAIN; MACROPHAGE-TROPIC HIV; CHEMOKINE-RECEPTOR; ENVELOPE GLYCOPROTEIN; C5A RECEPTOR; N-TERMINUS; CORECEPTOR; BINDING; RESIDUES	CCR5 is a G protein-coupled receptor for RANTES, MIP-1alpha, MIP-1beta, and MCP-2 that functions as the front line coreceptor for human immunodeficiency virus type 1 infection. To elucidate the mechanism for CCR5 activation, this coreceptor was expressed in yeast coupled to the pheromone response pathway and a constitutively active mutant (CAM) was derived by random mutagenesis. Conversion of Thr-82 in the highly conserved TXP motif in transmembrane helix 2 to Pro, His, Tyr, Arg, or Lys conferred autonomous signaling activity in yeast and mammalian cells. This substitution also imparted constitutive signaling to CCR2 in yeast and mammalian cells, but not CCR1, CCR3, CCR4, CXCR2, or CXCR4. The CCR5-CAM, but not the CCR2-CAM had a reduction in ligand binding affinity. Whereas the amplitude of calcium mobilization induced by RANTES stimulation was lower in the CCR5-CAM than the wild-type (WT) receptor, MCP-1 induced a higher signal in the CCR2-CAM than in CCR2-WT. The chemotactic response of CCR5-CAM(T82P) to RANTES was similar to that of CCR5-WT, but CCR5-CAM(T82K) was dramatically decreased. The chemotactic response of CCR2-WT and CCR2-CAM(T94K) were similar. These findings extend insight into the role of the TXP motif in the mechanism for CCR5 signaling. CCR2, the receptor most closely genetically related to CCR5, shared a similar signaling mechanism, but other receptors containing the TXP motif did not. The expression of CCR5 and CCR2 in yeast and the availability of variants with autonomous signaling represent critical tools for characterizing receptor antagonists and developing approaches to block their role in human diseases.	Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA; Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	University System of Georgia; Augusta University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Princeton University	Peiper, SC (corresponding author), Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA.	speiper@mail.mcg.edu		Broach, James/0000-0003-1197-0312	NIAID NIH HHS [R01 AI41346] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041346] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Arthos J, 2000, J VIROL, V74, P6418, DOI 10.1128/JVI.74.14.6418-6424.2000; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Blanpain C, 2003, J BIOL CHEM, V278, P5179, DOI 10.1074/jbc.M205684200; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Carrington M, 1997, AM J HUM GENET, V61, P1261, DOI 10.1086/301645; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Cicala C, 1999, J IMMUNOL, V163, P420; Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762; Del Carmine R, 2002, BRIT J PHARMACOL, V135, P1715, DOI 10.1038/sj.bjp.0704622; Doranz BJ, 1997, J VIROL, V71, P6305, DOI 10.1128/JVI.71.9.6305-6314.1997; Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Farzan M, 2000, J BIOL CHEM, V275, P33516, DOI 10.1074/jbc.M007228200; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; Govaerts C, 2003, J BIOL CHEM, V278, P1892, DOI 10.1074/jbc.M205685200; Govaerts C, 2001, J BIOL CHEM, V276, P13217, DOI 10.1074/jbc.M011670200; Ho HH, 2001, J BIOL CHEM, V276, P1376, DOI 10.1074/jbc.M007885200; Howard OMZ, 1999, J BIOL CHEM, V274, P16228, DOI 10.1074/jbc.274.23.16228; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; Lee B, 1999, P NATL ACAD SCI USA, V96, P5215, DOI 10.1073/pnas.96.9.5215; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Miura S, 2003, J BIOL CHEM, V278, P3720, DOI 10.1074/jbc.M211338200; Miura S, 2002, J BIOL CHEM, V277, P24299, DOI 10.1074/jbc.M202743200; Mueller A, 2002, BRIT J PHARMACOL, V135, P1033, DOI 10.1038/sj.bjp.0704540; Navenot JM, 2001, J MOL BIOL, V313, P1181, DOI 10.1006/jmbi.2001.5086; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parnot C, 2000, P NATL ACAD SCI USA, V97, P7615, DOI 10.1073/pnas.110142297; Rana S, 1997, J VIROL, V71, P3219, DOI 10.1128/JVI.71.4.3219-3227.1997; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Siciliano SJ, 1999, J BIOL CHEM, V274, P1905, DOI 10.1074/jbc.274.4.1905; Sommers CM, 2000, BIOCHEMISTRY-US, V39, P6898, DOI 10.1021/bi992616a; Thomas WG, 2000, J BIOL CHEM, V275, P2893, DOI 10.1074/jbc.275.4.2893; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wang ZX, 1999, J BIOL CHEM, V274, P28413, DOI 10.1074/jbc.274.40.28413; Weissman D, 1997, NATURE, V389, P981, DOI 10.1038/40173; Whistler JL, 2002, TRAFFIC, V3, P866, DOI 10.1034/j.1600-0854.2002.31203.x; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zhang WB, 2002, J BIOL CHEM, V277, P24515, DOI 10.1074/jbc.M200889200	49	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36513	36521		10.1074/jbc.M303739200	http://dx.doi.org/10.1074/jbc.M303739200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12837756	hybrid			2022-12-25	WOS:000185318300080
J	Dai, SH; Petruccelli, S; Ordiz, MI; Zhang, ZH; Chen, SY; Beachy, RN				Dai, SH; Petruccelli, S; Ordiz, MI; Zhang, ZH; Chen, SY; Beachy, RN			Functional analysis of RF2a, a rice transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUNGRO BACILLIFORM VIRUS; TATA-BINDING PROTEIN; IN-VITRO TRANSCRIPTION; VP16 ACTIVATION DOMAIN; GENE-EXPRESSION; DNA-BINDING; PROMOTER; SPECIFICITY; ELONGATION; INTERACTS	RF2a is a bZIP transcription factor that regulates expression of the promoter of rice tungro bacilliform badnavirus. RF2a is predicted to include three domains that contribute to its function. The results of transient assays with mutants of RF2a from which one or more domains were removed demonstrated that the acidic domain was essential for the activation of gene expression, although the proline-rich and glutamine-rich domains each played a role in this function. Studies using fusion proteins of different functional domains of RF2a with the 2C7 synthetic zinc finger DNA-binding domain showed that the acidic region is a relatively strong activation domain, the function of which is dependent on the context in which the domain is placed. Data from transgenic plants further supported the conclusion that the acidic domain was important for maintaining the biological function of RF2a. RF2a and TBP (TATA-binding protein) synergistically activate transcription in vitro (Zhu, Q., Ordiz, M. I., Dabi, T., Beachy, R. N., and Lamb, C. (2002) Plant Cell 14, 795 - 803). In vitro and in vivo assays showed that RF2a interacts with TBP through the glutamine-rich domain but not the acidic domain. Functional analysis of such interactions indicates that the acidic domain activates transcription through mechanisms other than via the direct recruitment of TBP.	Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; Chinese Acad Sci, Inst Genet, Beijing 100101, Peoples R China	Donald Danforth Plant Science Center; Chinese Academy of Sciences	Beachy, RN (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	rnbeachy@danforthcenter.org	Petruccelli, Silvana/A-3083-2012; Petruccelli, Silvana/AAC-6826-2019	Petruccelli, Silvana/0000-0002-7072-0076; Petruccelli, Silvana/0000-0002-7072-0076				Bean TL, 1997, NUCLEIC ACIDS RES, V25, P2509, DOI 10.1093/nar/25.12.2509; BHATTACHARYYAPAKRASI M, 1993, PLANT J, V4, P71, DOI 10.1046/j.1365-313X.1993.04010071.x; Fujii Y, 2000, NAT STRUCT BIOL, V7, P889; Fukazawa J, 2000, PLANT CELL, V12, P901, DOI 10.1105/tpc.12.6.901; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HAAS NB, 1995, MOL CELL BIOL, V15, P1923; Hall DB, 2002, J BIOL CHEM, V277, P46043, DOI 10.1074/jbc.M208911200; Hayashi F, 1998, BIOCHEMISTRY-US, V37, P7941, DOI 10.1021/bi9801098; He XY, 2000, J BIOL CHEM, V275, P11799, DOI 10.1074/jbc.275.16.11799; Hoffmann N, 1988, PLANT MOL BIOL MANUA, pA5 1; Holmes MC, 2000, SCIENCE, V288, P867, DOI 10.1126/science.288.5467.867; Jakoby M, 2002, TRENDS PLANT SCI, V7, P106, DOI 10.1016/S1360-1385(01)02223-3; JEFFERSON RA, 1987, EMBO J, V6, P3901; KATAGIRI F, 1992, MOL CELL BIOL, V12, P4809, DOI 10.1128/MCB.12.11.4809; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; Meshi T, 1995, PLANT CELL PHYSIOL, V36, P1405; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Olive M, 1996, J BIOL CHEM, V271, P2040, DOI 10.1074/jbc.271.4.2040; Ordiz MI, 2002, P NATL ACAD SCI USA, V99, P13290, DOI 10.1073/pnas.202471899; Petruccelli S, 2001, P NATL ACAD SCI USA, V98, P7635, DOI 10.1073/pnas.121186398; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; Reindl A, 1998, FEBS LETT, V436, P318, DOI 10.1016/S0014-5793(98)01152-1; Ringli C, 1998, PLANT MOL BIOL, V37, P977, DOI 10.1023/A:1006030007333; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; TRUANT R, 1993, J BIOL CHEM, V268, P2284; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WATANABE Y, 1987, FEBS LETT, V219, P65, DOI 10.1016/0014-5793(87)81191-2; Xie YQ, 2000, J BIOL CHEM, V275, P31914, DOI 10.1074/jbc.M003760200; Xie YQ, 2000, J BIOL CHEM, V275, P40797, DOI 10.1074/jbc.M007019200; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; Yin YH, 1997, EMBO J, V16, P5247, DOI 10.1093/emboj/16.17.5247; Yin YH, 1997, PLANT J, V12, P1179, DOI 10.1046/j.1365-313X.1997.12051179.x; YIN YH, 1995, PLANT J, V7, P969, DOI 10.1046/j.1365-313X.1995.07060969.x; ZHU Q, 1995, PLANT J, V7, P1021, DOI 10.1046/j.1365-313X.1995.07061021.x; Zhu Q, 2002, PLANT CELL, V14, P795, DOI 10.1105/tpc.010364	43	26	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36396	36402		10.1074/jbc.M304862200	http://dx.doi.org/10.1074/jbc.M304862200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855676	hybrid, Green Published			2022-12-25	WOS:000185318300067
J	Walter, W; Kireeva, ML; Studitsky, VM; Kashlev, M				Walter, W; Kireeva, ML; Studitsky, VM; Kashlev, M			Bacterial polymerase and yeast polymerase II use similar mechanisms for transcription through nucleosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-DNA HYBRID; ESCHERICHIA-COLI; ELONGATION COMPLEX; STRUCTURAL BASIS; HISTONE OCTAMER; SITE; INITIATION; STABILITY; BARRIER; CORE	We have previously shown that nucleosomes act as a strong barrier to yeast RNA polymerase II (Pol II) in vitro and that transcription through the nucleosome results in the loss of an H2A/H2B dimer. Here, we demonstrate that Escherichia coli RNA polymerase (RNAP), which never encounters chromatin in vivo, behaves similarly to Pol II in all aspects of transcription through the nucleosome in vitro. The nucleosome-specific pausing pattern of RNAP is comparable with that of Pol II. At physiological ionic strength or lower, the nucleosome blocks RNAP progression along the template, but this barrier can be relieved at higher ionic strength. Transcription through the nucleosome by RNAP results in the loss of an H2A/H2B dimer, and the histones that remain in the hexasome retain their original positions on the DNA. The results were similar for elongation complexes that were assembled from components (oligonucleotides and RNAP) and elongation complexes obtained by initiation from the promoter. The data suggest that eukaryotic Pol II and E. coli RNAP utilize very similar mechanisms for transcription through the nucleosome. Thus, bacterial RNAP can be used as a suitable model system to study general aspects of chromatin transcription by Pol II. Furthermore, the data argue that the general elongation properties of polymerases may determine the mechanism used for transcription through the nucleosome.	Wayne State Univ, Sch Med, Dept Biochem, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA; NCI, Ctr Canc Res, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA	Wayne State University; Wayne State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Studitsky, VM (corresponding author), Univ Med & Dent New Jersey, Dept Pharmacol, 675 Hoes Lane,Rm 405, Piscataway, NJ 08854 USA.	vstudit@med.wayne.edu; mkashlev@mail.ncifcrf.gov	Kireeva, Maria/B-4391-2018; Studitsky, Vasily/A-9382-2014	Kireeva, Maria/0000-0003-0527-3182; 	DIVISION OF BASIC SCIENCES - NCI [Z01BC010343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058650] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58650] Funding Source: Medline	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDELEBEN C, 1994, J MOL BIOL, V235, P1193, DOI 10.1006/jmbi.1994.1073; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bednar J, 1999, MOL CELL, V4, P377, DOI 10.1016/S1097-2765(00)80339-1; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; BONNER G, 1994, J BIOL CHEM, V269, P25120; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; Chang CH, 1997, J BIOL CHEM, V272, P23427, DOI 10.1074/jbc.272.37.23427; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; CLARK DJ, 1995, NUCLEUS, V1, P207; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DIMAURO E, 1969, NATURE, V222, P533, DOI 10.1038/222533a0; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; Ebright RH, 2000, J MOL BIOL, V304, P687, DOI 10.1006/jmbi.2000.4309; Fu JH, 1999, CELL, V98, P799, DOI 10.1016/S0092-8674(00)81514-7; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; Kashlev M, 1996, METHOD ENZYMOL, V274, P326; Kireeva ML, 2000, J BIOL CHEM, V275, P6530, DOI 10.1074/jbc.275.9.6530; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Kireeva ML, 2000, J MOL BIOL, V299, P325, DOI 10.1006/jmbi.2000.3755; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Korzheva N, 2001, CURR OPIN MICROBIOL, V4, P119, DOI 10.1016/S1369-5274(00)00176-4; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; Landick R, 2001, CELL, V105, P567, DOI 10.1016/S0092-8674(01)00381-6; Lopez PJ, 1998, J MOL BIOL, V276, P861, DOI 10.1006/jmbi.1997.1576; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LUSE D, 1995, CHROMATIN STRUCTURE, P104; Mote J, 1998, J BIOL CHEM, V273, P16843, DOI 10.1074/jbc.273.27.16843; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Palangat M, 2001, J MOL BIOL, V311, P265, DOI 10.1006/jmbi.2001.4842; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; Protacio RU, 1997, J MOL BIOL, V274, P708, DOI 10.1006/jmbi.1997.1440; RANDALL SK, 1992, J BIOL CHEM, V267, P14259; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; ROUVIEREYANIV J, 1979, CELL, V17, P265, DOI 10.1016/0092-8674(79)90152-1; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Studitsky VM, 1999, METH MOL B, V119, P17; Ubukata T, 2003, J BIOL CHEM, V278, P8580, DOI 10.1074/jbc.M211384200; Walter W, 2001, J BIOL CHEM, V276, P29104, DOI 10.1074/jbc.M103704200; WHITE RJ, 2000, RNA POLYM 3 TRANSCRI; YAGER TD, 1984, J BIOL CHEM, V259, P4212	51	40	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36148	36156		10.1074/jbc.M305647200	http://dx.doi.org/10.1074/jbc.M305647200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851391	hybrid			2022-12-25	WOS:000185318300035
J	Cipres, A; Carrasco, S; Merino, E; Diaz, E; Krishna, UM; Falck, JR; Martinez, C; Merida, I				Cipres, A; Carrasco, S; Merino, E; Diaz, E; Krishna, UM; Falck, JR; Martinez, C; Merida, I			Regulation of diacylglycerol kinase alpha by phosphoinositide 3-kinase lipid products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHATIDIC-ACID; TYROSINE KINASES; BETA-CHAIN; T-CELLS; PHOSPHATIDYLINOSITOL; ACTIVATION; INTERLEUKIN-2-RECEPTOR; DOMAIN; RECRUITMENT	Diacylglycerol kinase alpha (DAGKalpha), like all type I DAGKs, has calcium regulatory motifs that act as negative regulators of enzyme activity and localization. Accordingly, DAGKalpha is activated by phospholipase C-coupled receptors in a calcium-dependent manner. One of the first functions attributed to DAGKalpha in lymphocytes was that of regulating interleukin 2-induced cell cycle entry. Interleukin-2 nonetheless exerts its action in the absence of cytosolic calcium increase. We have studied alternative receptor-derived signals to explain calcium-independent DAGKalpha activation, and show that DAGKalpha is stimulated by Src-like kinase-dependent phosphoinositide 3 kinase (PI3K) activation in lymphocytes. Our results demonstrate that, in vivo, the increase in cellular levels of PI3K products is sufficient to induce DAGKalpha activation, allowing DAGKalpha relocation to the intact lymphocyte plasma membrane. This activation is isoform-specific, because other type I DAGKs are not subject to this type of regulation. These studies are the first to describe a pathway in which, in the absence of receptorregulated calcium increase, DAGKalpha activation and membrane localization is a direct consequence of PI3K activation.	CSIC, Natl Biotechnol Ctr, Dept Immunol & Oncol, E-28049 Madrid, Spain; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	Consejo Superior de Investigaciones Cientificas (CSIC); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Merida, I (corresponding author), CSIC, Natl Biotechnol Ctr, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.	imerida@cnb.uam.es	Ciprés, Ángel/ABH-6863-2020; Merida, Isabel/A-9713-2014	Merida, Isabel/0000-0003-2762-6241; Cipres, Angel/0000-0001-7086-2704; Falck, John/0000-0002-9219-7845	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31278] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Caricasole A, 2002, J BIOL CHEM, V277, P4790, DOI 10.1074/jbc.M110249200; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Flores I, 1999, J IMMUNOL, V163, P708; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; GonzalezGarcia A, 1997, J BIOL CHEM, V272, P10220; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jiang Y, 2000, J BIOL CHEM, V275, P34092, DOI 10.1074/jbc.M004914200; Jones DR, 1999, J BIOL CHEM, V274, P18407, DOI 10.1074/jbc.274.26.18407; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; MERIDA I, 1993, J BIOL CHEM, V268, P6765; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; MILLS GB, 1985, J IMMUNOL, V134, P2431; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Sakane F, 1996, BIOCHEM J, V318, P583, DOI 10.1042/bj3180583; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Santos T, 2002, J BIOL CHEM, V277, P30300, DOI 10.1074/jbc.M200999200; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; Taniguchi T, 1995, ANN NY ACAD SCI, V766, P235, DOI 10.1111/j.1749-6632.1995.tb26671.x; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447	33	45	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35629	35635		10.1074/jbc.M305635200	http://dx.doi.org/10.1074/jbc.M305635200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832407	hybrid			2022-12-25	WOS:000185164400107
J	Umehara, T; Horikoshi, M				Umehara, T; Horikoshi, M			Transcription initiation factor IID-interactive histone chaperone CIA-II implicated in mammalian spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN ASSEMBLY FACTORS; RNA-POLYMERASE-II; FACTOR S-II; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; BINDING PROTEIN; DNA-REPLICATION; CELL-DEATH; IN-VITRO; EXPRESSION	Histones are thought to have specific roles in mammalian spermatogenesis, because several subtypes of histones emerge that are post-translationally modified during spermatogenesis. Though regular assembly of nucleosome is guaranteed by histone chaperones, their involvement in spermatogenesis is yet to be characterized. Here we identified a histone chaperone-related factor, which we designated as CCG1-interacting factor A-II (CIA-II), through interaction with bromodomains of TAF(II)250/CCG1, which is the largest subunit of human transcription initiation factor IID ( TFIID). We found that human CIA-II ( hCIA-II) localizes in HeLa nuclei and is highly expressed in testis and other proliferating cell-containing tissues. Expression of mouse CIA-II ( mCIAII) does not occur in the germ cell-lacking testes of adult WBB6F1-W/W-v mutant mice, indicating its expression in testis to be specific to germ cells. Fractionation of testicular germ cells revealed that mCIA-II transcripts accumulate in pachytene spermatocytes but not in spermatids. In addition, the mCIA-II transcripts in testis were present as early as 4 days after birth and decreased at 56 days after birth. These findings indicate that mCIA-II expression in testis is restricted to premeiotic to meiotic stages during spermatogenesis. Also, we found that hCIA-II interacts with histone H3 in vivo and with histones H3/H4 in vitro and that it facilitates supercoiling of circular DNA when it is incubated with core histones and topoisomerase I in vitro. These data suggest that CIA-II is a histone chaperone and is implicated in the regulation of mammalian spermatogenesis.	Univ Tokyo, Inst Mol & Cellular Biosci, Dev Biol Lab, Bunkyo Ku, Tokyo 1130032, Japan; Japan Sci & Technol Corp, Exploratory Res Adv Technol, Horikoshi Gene Selector Project, Tsukuba, Ibaraki 3002635, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Horikoshi, M (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Dev Biol Lab, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.		Umehara, Takashi/AHB-1730-2022; Umehara, Takashi/N-5683-2015	Umehara, Takashi/0000-0003-3464-2960; Umehara, Takashi/0000-0003-3464-2960				Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; ALFONSO PJ, 1993, BIOL REPROD, V48, P522, DOI 10.1095/biolreprod48.3.522; Bando M, 1997, J BIOCHEM-TOKYO, V121, P591; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Blanco-Rodriguez J, 1998, INT J ANDROL, V21, P236; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; Chimura T, 2002, P NATL ACAD SCI USA, V99, P9334, DOI 10.1073/pnas.142627899; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Doenecke D, 1997, ADV EXP MED BIOL, V424, P37; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HEIDARAN MA, 1987, J BIOL CHEM, V262, P13309; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; KIERSZENBAUM AL, 1978, FED PROC, V37, P2512; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Lahn BT, 2002, P NATL ACAD SCI USA, V99, P8707, DOI 10.1073/pnas.082248899; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; Le SY, 1997, YEAST, V13, P1029, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1029::AID-YEA160>3.0.CO;2-1; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Matangkasombut O, 2000, GENE DEV, V14, P951; MATSUMOTO K, 1993, J BIOL CHEM, V268, P10582; MEISTRICH ML, 1977, DEV BIOL, V60, P428, DOI 10.1016/0012-1606(77)90140-3; MEISTRICH ML, 1985, DEV BIOL, V112, P230, DOI 10.1016/0012-1606(85)90137-X; MEISTRICH ML, 1978, FED PROC, V37, P2522; Munakata T, 2000, GENES CELLS, V5, P221, DOI 10.1046/j.1365-2443.2000.00319.x; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; NEBEL BR, 1961, SCIENCE, V134, P832, DOI 10.1126/science.134.3482.832; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Rogner UC, 2000, NAT GENET, V25, P431, DOI 10.1038/78124; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAUNDERS PTK, 1992, MOL REPROD DEV, V33, P385, DOI 10.1002/mrd.1080330404; Schnieders F, 1996, HUM MOL GENET, V5, P1801, DOI 10.1093/hmg/5.11.1801; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; Shen HH, 2001, GENOMICS, V71, P21, DOI 10.1006/geno.2000.6397; Sillje HHW, 2001, CURR BIOL, V11, P1068, DOI 10.1016/S0960-9822(01)00298-6; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; Singer MS, 1998, GENETICS, V150, P613; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TROSTLEWEIGE PK, 1984, J BIOL CHEM, V259, P8769; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Umehara T, 1997, J BIOCHEM-TOKYO, V121, P598, DOI 10.1093/oxfordjournals.jbchem.a021627; Umehara T, 1995, GENE, V167, P297, DOI 10.1016/0378-1119(95)00634-6; Umehara T, 2002, GENES CELLS, V7, P59, DOI 10.1046/j.1356-9597.2001.00493.x; WOLFE SA, 1989, BIOCHIM BIOPHYS ACTA, V1007, P140, DOI 10.1016/0167-4781(89)90032-8; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yamaki M, 2001, GENES CELLS, V6, P1043, DOI 10.1046/j.1365-2443.2001.00487.x; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; YELICK P C, 1989, Molecular Reproduction and Development, V1, P193, DOI 10.1002/mrd.1080010307; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689	63	29	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35660	35667		10.1074/jbc.M303549200	http://dx.doi.org/10.1074/jbc.M303549200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842904	hybrid			2022-12-25	WOS:000185164400111
J	Wiebe, EM; Stafford, AR; Fredenburgh, JC; Weitz, JI				Wiebe, EM; Stafford, AR; Fredenburgh, JC; Weitz, JI			Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT HEPARINS; FACTOR-X ACTIVATION; SYNTHETIC PENTASACCHARIDE; PROTEASE DOMAIN; VENOUS THROMBOEMBOLISM; PROTEINASE REACTIONS; BLOOD-COAGULATION; HIP-REPLACEMENT; BINDING EXOSITE; CALCIUM-BINDING	Because of the homology between factor IXa and factor Xa (f.IXa and f.Xa, respectively), and the critical upstream position of f.IXa in the coagulation cascade, the contribution of the heparin-derived pentasaccharide to antithrombin-mediated inhibition of f.IXa was investigated. Pentasaccharide promotes inhibition of both f.IXa and f.Xa generated in recalcified plasma. This result demonstrates that antithrombin is the predominant inhibitor of f.IXa in plasma, and that the activity of antithrombin is promoted by pentasaccharide. Kinetic experiments reveal that pentasaccharide increases the rates of antithrombin-mediated inhibition of both f.IXa and f.Xa by 2 orders of magnitude. These findings indicate that pentasaccharide-induced conformational changes in antithrombin enhance its capacity to inhibit both f.IXa and f.Xa. In the presence of Ca2+, full-length heparin produces an additional similar to10-fold increase in the rates of inhibition of both enzymes, consistent with a template role of heparin. Heparin binding to f.Xa was previously shown to be promoted in the presence of Ca2+. Binding studies with f.IXa reveal a 10-fold higher affinity for heparin in the presence of Ca2+ compared with its absence. Thus, Ca2+ promotes heparin-catalyzed inhibition of f.IXa and f.Xa by antithrombin by augmenting the template mechanism. These results indicate that heparin-mediated catalysis of f.IXa inhibition by antithrombin reflects both pentasaccharide-induced conformational changes and heparin-mediated bridging of antithrombin to f.IXa. Furthermore, our data suggest that the efficacy of pentasaccharide for prevention and treatment of thrombotic disorders may reflect its action at two sites in the coagulation system.	Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Hamilton, ON L8V 1C3, Canada	McMaster University	Weitz, JI (corresponding author), Henderson Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				Anderson JAM, 2001, J BIOL CHEM, V276, P9755, DOI 10.1074/jbc.M010048200; ASTERMARK J, 1994, J BIOL CHEM, V269, P3682; Badellino KO, 2001, BIOCHEMISTRY-US, V40, P7569, DOI 10.1021/bi0027433; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; Bauer KA, 2002, CARDIOVASC DRUG REV, V20, P37; Bedsted T, 2003, BIOCHEMISTRY-US, V42, P8143, DOI 10.1021/bi034363y; Bock SC, 2001, HEMOSTASIS THROMBOSI, V4th, P321; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Brufatto N, 2001, J BIOL CHEM, V276, P17663, DOI 10.1074/jbc.M011586200; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Colman RWCA, 2001, HEMOSTASIS THROMBOSI, P3; Eriksson BI, 2001, NEW ENGL J MED, V345, P1298, DOI 10.1056/NEJMoa011100; FUCHS HE, 1984, J CLIN INVEST, V73, P1696, DOI 10.1172/JCI111377; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; HAMAGUCHI N, 1994, THROMB HAEMOSTASIS, V72, P856; Herault JP, 2002, THROMB HAEMOSTASIS, V88, P432; Herbert JM, 1996, CIRC RES, V79, P590, DOI 10.1161/01.RES.79.3.590; HIRSH J, 1992, BLOOD, V79, P1; Hockin MF, 2002, J BIOL CHEM, V277, P18322, DOI 10.1074/jbc.M201173200; HOLMER E, 1981, BIOCHEM J, V193, P395, DOI 10.1042/bj1930395; HOYLAERTS M, 1984, J BIOL CHEM, V259, P5670; Huntington JA, 2000, J BIOL CHEM, V275, P15377, DOI 10.1074/jbc.275.20.15377; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KURACHI K, 1976, BIOCHEMISTRY-US, V15, P373, DOI 10.1021/bi00647a021; Lassen MR, 2002, LANCET, V359, P1715, DOI 10.1016/S0140-6736(02)08652-X; Lin PH, 2001, BBA-GEN SUBJECTS, V1526, P105, DOI 10.1016/S0304-4165(01)00117-9; LOLLAR P, 1984, BLOOD, V63, P1303; *MAT INV, 2002, BLOOD, V100, pA83; Mathur A, 1997, J BIOL CHEM, V272, P23418, DOI 10.1074/jbc.272.37.23418; Mauray S, 1998, BBA-PROTEIN STRUCT M, V1387, P184, DOI 10.1016/S0167-4838(98)00120-4; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OSTERUD B, 1976, THROMB HAEMOSTASIS, V35, P295, DOI 10.1055/s-0038-1647922; Petitou M, 1999, NATURE, V398, P417, DOI 10.1038/18877; PIETERS J, 1988, J BIOL CHEM, V263, P15313; PIETERS J, 1990, BLOOD, V76, P549; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P12083, DOI 10.1021/bi0011126; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; Rezaie AR, 2001, BLOOD, V97, P2308, DOI 10.1182/blood.V97.8.2308; STREUSAND VJ, 1995, J BIOL CHEM, V270, P9043, DOI 10.1074/jbc.270.16.9043; STUBBS MT, 1994, CURR OPIN STRUC BIOL, V4, P823, DOI 10.1016/0959-440X(94)90263-1; Sturzebecher J, 1997, FEBS LETT, V412, P295, DOI 10.1016/S0014-5793(97)00811-9; Turpie AGG, 2001, NEW ENGL J MED, V344, P619, DOI 10.1056/NEJM200103013440901; Underwood MC, 2000, J BIOL CHEM, V275, P36876, DOI 10.1074/jbc.M001386200; WALENGA JM, 1988, THROMB RES, V51, P23, DOI 10.1016/0049-3848(88)90279-4; WALENGA JM, 1991, THROMB HAEMORR DIS, V3, P53; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; Yang LK, 2002, J BIOL CHEM, V277, P50756, DOI 10.1074/jbc.M208485200	50	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35767	35774		10.1074/jbc.M304803200	http://dx.doi.org/10.1074/jbc.M304803200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832413	hybrid			2022-12-25	WOS:000185164400124
J	Yamasaki, M; Takahashi, N; Hirose, M				Yamasaki, M; Takahashi, N; Hirose, M			Crystal structure of S-ovalbumin as a non-loop-inserted thermostabilized serpin form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACHAIN DISULFIDE BOND; DENATURED STATE; REACTIVE CENTER; HEN OVALBUMIN; TRANSFORMATION; UREA; EGG; SUPERFAMILY; CONVERSION; MECHANISM	Ovalbumin, a non-inhibitory member of serine proteinase inhibitors ( serpin), is transformed into a heatstabilized form, S-ovalbumin, under elevated pH conditions. The structural mechanism for the S-ovalbumin formation has long been a puzzling question in food science and serpin structural biology. On the basis of the commonly observed serpin thermostabilization by insertion of the reactive center loop into the proximal beta-sheet, the most widely accepted hypothetical model has included partial loop insertion. Here we demonstrate, for the first time, the crystal structure of S-ovalbumin at 1.9-Angstrom resolution. This structure unequivocally excludes the partial loop insertion mechanism; the overall structure, including the reactive center loop structure, is almost the same as that of native ovalbumin, except for the significant motion of the preceding loop of strand 1A away from strand 2A. The most striking finding is that Ser-164, Ser-236, and Ser-320 take the D-amino acid residue configuration. These chemical inversions can be directly related to the irreversible and stepwise nature of the transformation from native ovalbumin to S-ovalbumin. As conformational changes of the side chains, significant alternations are found in the values of the chi(1) of Phe-99 and the chi(3) of Met-241. The former conformational change leads to the decreased solvent accessibility of the hydrophobic core around Phe-99, which includes Phe-180 and Phe-378, the highly conserved residues in serpin. This may give a thermodynamic advantage to the structural stability of S-ovalbumin.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6110011, Japan	Kyoto University	Hirose, M (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6110011, Japan.	hirose@kais.kyoto-u.ac.jp		Hirose, Masaaki/0000-0003-2672-4384				Arii Y, 1999, BIOSCI BIOTECH BIOCH, V63, P1392, DOI 10.1271/bbb.63.1392; Bada J.L, 1985, CHEM BIOCH AMINO ACI, P399; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; GOUX WJ, 1986, BIOCHEMISTRY-US, V25, P84, DOI 10.1021/bi00349a013; Hatta H, 2001, BIOSCI BIOTECH BIOCH, V65, P2021, DOI 10.1271/bbb.65.2021; Hubbard SJ, 1993, NACCESS COMPUTER PRO; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; HUNTINGTON JA, 1995, PROTEIN SCI, V4, P613; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Huntington JA, 2001, J CHROMATOGR B, V756, P189, DOI 10.1016/S0378-4347(01)00108-6; Im H, 2000, PROTEIN SCI, V9, P1497, DOI 10.1110/ps.9.8.1497; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; KINT S, 1979, BIOPOLYMERS, V18, P1073, DOI 10.1002/bip.1979.360180505; KITABATAKE N, 1988, AGR BIOL CHEM TOKYO, V52, P967; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAKAMURA R, 1981, AGR BIOL CHEM TOKYO, V45, P2775, DOI 10.1080/00021369.1981.10864966; NAKAMURA R, 1981, AGR BIOL CHEM TOKYO, V45, P1653, DOI 10.1080/00021369.1981.10864762; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Onda M, 1997, J BIOCHEM-TOKYO, V122, P83; Onda M, 1997, J BIOL CHEM, V272, P3973, DOI 10.1074/jbc.272.7.3973; Onda M, 2003, J BIOL CHEM, V278, P23600, DOI 10.1074/jbc.M300295200; PAINTER PC, 1976, BIOPOLYMERS, V15, P2155, DOI 10.1002/bip.1976.360151105; Saxena I, 1997, CELL MOL LIFE SCI, V53, P13, DOI 10.1007/PL00000575; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SHITAMORI S, 1984, AGR BIOL CHEM TOKYO, V48, P1539, DOI 10.1080/00021369.1984.10866350; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SMITH MB, 1962, NATURE, V193, P878, DOI 10.1038/193878a0; SMITH MB, 1965, AUST J BIOL SCI, V18, P365, DOI 10.1071/BI9650365; SORENSEN SPL, 1915, COMPT REND TRAV LAB, V12, P12; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; Sugimoto Y, 1999, J BIOL CHEM, V274, P11030, DOI 10.1074/jbc.274.16.11030; TAKAHASHI N, 1992, J BIOL CHEM, V267, P11565; TAKAHASHI N, 1991, J BIOCHEM-TOKYO, V109, P846, DOI 10.1093/oxfordjournals.jbchem.a123469; Takahashi N, 1996, BIOSCI BIOTECH BIOCH, V60, P1464, DOI 10.1271/bbb.60.1464; TANI F, 1995, J AGR FOOD CHEM, V43, P2325, DOI 10.1021/jf00057a003; Tani F, 1997, PROTEIN SCI, V6, P1491, DOI 10.1002/pro.5560060713; TATSUMI E, 1994, J BIOL CHEM, V269, P28062; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; Yamamoto H, 2003, BIOSCI BIOTECH BIOCH, V67, P830, DOI 10.1271/bbb.67.830; Yamasaki M, 2002, J MOL BIOL, V315, P113, DOI 10.1006/jmbi.2001.5056; Ye S, 2001, NAT STRUCT BIOL, V8, P979, DOI 10.1038/nsb1101-979	49	70	73	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35524	35530		10.1074/jbc.M305926200	http://dx.doi.org/10.1074/jbc.M305926200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12840013	hybrid			2022-12-25	WOS:000185164400095
J	Knauf, JA; Kuroda, H; Basu, S; Fagin, JA				Knauf, JA; Kuroda, H; Basu, S; Fagin, JA			RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase	ONCOGENE			English	Article						thyroid; RET/PTC; differentiation; RAS; MEK	TISSUE-SPECIFIC EXPRESSION; RECEPTOR TYROSINE KINASE; SODIUM/IODIDE SYMPORTER GENE; TRANSCRIPTION FACTOR PAX8; PAPILLARY CARCINOMAS; EPITHELIAL-CELLS; AUTOPHOSPHORYLATION SITES; ONCOGENE ACTIVATION; UPSTREAM ENHANCER; MAMMALIAN-CELLS	Constitutive activation of the RET proto-oncogene in papillary thyroid carcinomas results from rearrangements linking the promoter(s) and N-terminal domains of unrelated genes to the C-terminus of RET tyrosine kinase (RET/PTC). RET/PTC expression has been demonstrated to inhibit transcription of thyroid-specific genes. To study the signal transduction pathways responsible for this, we generated PCCL3 thyroid cells with doxycycline-inducible expression of RET/PTC3, RET/PTC3(Y541F), or PTC2/PDZ. Acute expression of RET/PTCY541F appropriately interacted with She, an intermediate in the activation of the Ras pathway, but failed to activate PLCgamma. By contrast, PTC2/PDZ failed to bind She, but interacted normally with PLCgamma. Acute expression of RET/PTC3 or RET/PTC3Y541F, but not PTC2/PDZ, inhibited TSH-induced Tg and NIS expression, suggesting that activation of Shc-Ras, but not PLCgamma, is required for RET/PTC-induced dedifferentiation. Accordingly, acute expression of H-Ras(V12) or of a constitutively active MEK1 also blocked TSH-induced expression of Tg and NIS. Moreover, MEK inhibitors restored Tg and NIS levels. In conclusion, activation of the Ras/Raf/MEK/MAPK pathway through She mediates RET/PTC-induced thyroid cell dedifferentiation. This suggests that inhibition of this pathway may promote redifferentiation in poorly differentiated thyroid carcinomas with constitutive activation of either Ras or RET/PTC.	Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Knauf, JA (corresponding author), Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Mail Locat 0547, Cincinnati, OH 45267 USA.			Knauf, Jeffrey/0000-0003-4456-8792	NATIONAL CANCER INSTITUTE [R01CA050706, R29CA050706, R01CA072597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002781] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA050706, R01 CA072597, CA72597, CA50706] Funding Source: Medline; NIDDK NIH HHS [KO1DK02781] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Bounacer A, 1997, BIOCHIMIE, V79, P619, DOI 10.1016/S0300-9084(97)82012-3; Chun JT, 2001, EXP CLIN ENDOCR DIAB, V109, P23, DOI 10.1055/s-2001-11021; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; De Vita G, 1998, CELL GROWTH DIFFER, V9, P97; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; FABBRO D, 1994, CANCER RES, V54, P4744; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gire V, 2000, ONCOGENE, V19, P737, DOI 10.1038/sj.onc.1203399; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOSSEN M, 1993, NUCLEIC ACIDS RES, V21, P4411, DOI 10.1093/nar/21.18.4411; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; ITO T, 1993, CANCER RES, V53, P2940; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Jhiang SM, 1998, RECENT RES CANCER, V154, P265; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Mascia A, 2002, J ENDOCRINOL, V172, P163, DOI 10.1677/joe.0.1720163; Medina DL, 2000, THYROID, V10, P295, DOI 10.1089/thy.2000.10.295; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Mercalli E, 2001, ONCOGENE, V20, P3475, DOI 10.1038/sj.onc.1204462; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; Missero C, 1998, MOL CELL ENDOCRINOL, V140, P37, DOI 10.1016/S0303-7207(98)00027-6; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; Mizuno T, 1997, ONCOGENE, V15, P1455, DOI 10.1038/sj.onc.1201313; Mizuno T, 2000, ONCOGENE, V19, P438, DOI 10.1038/sj.onc.1203343; Nikiforov YE, 1997, CANCER RES, V57, P1690; Ohno M, 1999, MOL CELL BIOL, V19, P2051; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Powell DJ, 1998, CANCER RES, V58, P5523; Puxeddu E, 2001, ENDOCRIN METAB CLIN, V30, P493, DOI 10.1016/S0889-8529(05)70196-1; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; Santoro M, 2000, BRIT J CANCER, V82, P315, DOI 10.1054/bjoc.1999.0921; Santoro M, 2002, ANN NY ACAD SCI, V963, P116, DOI 10.1111/j.1749-6632.2002.tb04102.x; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Santoro M, 1996, ONCOGENE, V12, P1821; Schmitt TL, 2002, THYROID, V12, P273, DOI 10.1089/10507250252949388; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; SINCLAIR AJ, 1990, EUR J BIOCHEM, V193, P311, DOI 10.1111/j.1432-1033.1990.tb19339.x; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Trapasso F, 1999, EUR J ENDOCRINOL, V140, P447, DOI 10.1530/eje.0.1400447; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Vecchio G, 2000, CLIN CHEM LAB MED, V38, P113, DOI 10.1515/CCLM.2000.017; Velasco JA, 1998, ENDOCRINOLOGY, V139, P2796, DOI 10.1210/en.139.6.2796; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	55	130	136	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	2003	22	28					4406	4412		10.1038/sj.onc.1206602	http://dx.doi.org/10.1038/sj.onc.1206602			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853977				2022-12-25	WOS:000183978900010
J	Simberg, D; Weisman, S; Talmon, Y; Faerman, A; Shoshani, T; Barenholz, Y				Simberg, D; Weisman, S; Talmon, Y; Faerman, A; Shoshani, T; Barenholz, Y			The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE-TRANSFER; DNA LPD COMPLEXES; IN-VIVO; PLASMID DNA; CATIONIC LIPOSOMES; TRANSFECTION EFFICIENCY; PHASE-BEHAVIOR; DELIVERY; EXPRESSION; LIPIDS	Following intravenous administration of cationic lipid-DNA complexes (lipoplexes) into mice, transfection (lipofection) occurs predominantly in the lungs. This was attributed to high entrapment of lipoplexes in the extended lung vascular tree. To determine whether lipofection in other organs could be enhanced by increasing the degree of vascularization, we used a transgenic mouse model with tissue-specific angiogenesis in liver. Tail vein injection of N-(1-(2,3-dioleoyloxy)propyl)-N, N,N-trimethylammonium chloride (DOTAP)/cholesterol lipoplexes resulted in increased lipoplex entrapment in hypervascularized liver but did not boost luciferase expression, suggesting that lipoplex delivery is not a sufficient condition for efficient organ lipofection. Because the intravenously injected lipoplexes migrated within seconds to lungs, we checked whether the effects of immediate contact with serum correlate with lung lipofection efficiency of different DOTAP-based formulations. Under conditions mimicking the injection environment, the lipoplex-serum interaction was strongly dependent on helper lipid and ionic strength: lipoplexes prepared in 150 mM NaCl or lipoplexes with high (>33 mol%) cholesterol were found to aggregate immediately. This aggregation process was irreversible and was inversely correlated with the percentage of lung cells that took up lipoplexes and with the efficiency of lipofection. No other structural changes in serum were observed for cholesterol-based lipoplexes. Dioleoyl phosphatidylethanolamine-based lipoplexes were found to give low expression, apparently because of an immediate loss of integrity in serum, without lipid-DNA dissociation. Our study suggests that efficient in vivo lipofection is the result of cross-talk between lipoplex composition, interaction with serum, hemodynamics, and target tissue "susceptibility" to transfection.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, Lab Membrane & Lipsome Res, IL-91120 Jerusalem, Israel; Technion Israel Inst Technol, Dept Chem Engn, IL-32000 Haifa, Israel; Quark Biotech Inc, Cleveland, OH 44106 USA	Hebrew University of Jerusalem; Technion Israel Institute of Technology	Barenholz, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, Lab Membrane & Lipsome Res, POB 12272, IL-91120 Jerusalem, Israel.		Weisman, Sarah/B-5091-2009; Talmon, Yeshayahu/N-1076-2019	Talmon, Yeshayahu/0000-0002-9854-3972				Audouy S, 2001, MOL MEMBR BIOL, V18, P129, DOI 10.1080/713816122; Barron LG, 1999, HUM GENE THER, V10, P1683, DOI 10.1089/10430349950017680; Dass CR, 2002, INT J PHARMACEUT, V241, P1, DOI 10.1016/S0378-5173(02)00194-1; DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122; Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939; Eliyahu H, 2002, GENE THER, V9, P850, DOI 10.1038/sj.gt.3301705; Escriou V, 1998, BBA-BIOMEMBRANES, V1368, P276, DOI 10.1016/S0005-2736(97)00194-6; Even-Chen S, 2000, BBA-BIOMEMBRANES, V1509, P176, DOI 10.1016/S0005-2736(00)00292-3; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; Hirsch-Lerner D, 1999, BBA-BIOMEMBRANES, V1461, P47, DOI 10.1016/S0005-2736(99)00145-5; Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X; Hui SW, 1996, BIOPHYS J, V71, P590, DOI 10.1016/S0006-3495(96)79309-8; Hwang SH, 2001, GENE THER, V8, P1276, DOI 10.1038/sj.gt.3301510; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; KUMAR VV, 1991, P NATL ACAD SCI USA, V88, P444, DOI 10.1073/pnas.88.2.444; Lagane B, 2002, BIOPHYS CHEM, V95, P7, DOI 10.1016/S0301-4622(01)00235-6; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; LAVNIKOVA N, 1993, AM J RESP CELL MOL, V8, P384, DOI 10.1165/ajrcmb/8.4.384; Li S, 1999, GENE THER, V6, P585, DOI 10.1038/sj.gt.3300865; Li S, 1998, GENE THER, V5, P930, DOI 10.1038/sj.gt.3300683; Li S, 1997, GENE THER, V4, P891, DOI 10.1038/sj.gt.3300482; Liu F, 2002, J CONTROL RELEASE, V78, P259, DOI 10.1016/S0168-3659(01)00494-1; Liu F, 1997, GENE THER, V4, P517, DOI 10.1038/sj.gt.3300424; Mahato RI, 1998, HUM GENE THER, V9, P2083, DOI 10.1089/hum.1998.9.14-2083; Niven R, 1998, J PHARM SCI, V87, P1292, DOI 10.1021/js980087a; OSTROWSKY N, 1993, CHEM PHYS LIPIDS, V64, P45, DOI 10.1016/0009-3084(93)90057-A; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Sakurai F, 2001, GENE THER, V8, P677, DOI 10.1038/sj.gt.3301460; SHMEEDA H, 1995, AM J PHYSIOL-HEART C, V268, pH759, DOI 10.1152/ajpheart.1995.268.2.H759; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Simberg D, 2001, J BIOL CHEM, V276, P47453, DOI 10.1074/jbc.M105588200; Simberg D, 2000, J LIPOSOME RES, V10, P1, DOI 10.3109/08982100009031091; Smith JG, 1998, PHARMACEUT RES, V15, P1356, DOI 10.1023/A:1011937218418; Song YK, 1998, GENE THER, V5, P1531, DOI 10.1038/sj.gt.3300770; Song YK, 1997, HUM GENE THER, V8, P1585, DOI 10.1089/hum.1997.8.13-1585; Yang JW, 2001, HEPATOLOGY, V33, P848, DOI 10.1053/jhep.2001.23438; Zelphati O, 1998, BBA-LIPID LIPID MET, V1390, P119, DOI 10.1016/S0005-2760(97)00169-0; Zuhorn IS, 2002, BIOPHYS J, V83, P2096, DOI 10.1016/S0006-3495(02)73970-2; Zuidam NJ, 1999, BBA-BIOMEMBRANES, V1419, P207, DOI 10.1016/S0005-2736(99)00069-3; Zuidam NJ, 1998, BBA-BIOMEMBRANES, V1368, P115, DOI 10.1016/S0005-2736(97)00187-9; Zuidam NJ, 1997, BBA-BIOMEMBRANES, V1329, P211, DOI 10.1016/S0005-2736(97)00110-7	41	79	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39858	39865		10.1074/jbc.M302232200	http://dx.doi.org/10.1074/jbc.M302232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869564	hybrid			2022-12-25	WOS:000185713800072
J	Bookout, AL; Finney, AE; Guo, RS; Peppel, K; Koch, WJ; Daaka, Y				Bookout, AL; Finney, AE; Guo, RS; Peppel, K; Koch, WJ; Daaka, Y			Targeting G beta gamma signaling to inhibit prostate tumor formation and growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; ANDROGEN RECEPTOR; CANCER; KINASE; ACTIVATION; EXPRESSION; PROLIFERATION; GENE	Prostate cancer starts as androgen-dependent malignancy and responds initially to androgen ablative therapy. Beneficial effects of androgen ablation, however, are often temporary and the cancer reappears as androgen-independent tumor, suggesting the existence of additional factors responsible for progression of the disease. Attention has focused on receptor tyrosine kinases as the growth mediators of androgen-independent prostate cancer; overexpression of epidermal growth factor receptors or their ligand heparin-bound epidermal growth factor, for example, promotes transition to androgen independence. Emerging data demonstrate involvement of another class of cell membrane-anchored receptors, the heterotrimeric guanine-binding ( G) protein-coupled receptors (GPCRs) in prostate cancer. In vitro, stimulation of many endogenous GPCRs induces mitogenic signaling and growth of prostate cancer cells. The GPCRs transduce mitogenic signals via activated G proteins in the form of Galpha-GTP and Gbetagamma subunits. Here, we show that expression of a Gbetagamma inhibitor peptide derived from carboxy terminus of G protein-coupled receptor kinase 2 obliterates serum-regulated prostate cancer cell growth in vitro and prevents prostate tumor formation in vivo. We also demonstrate that inhibition of Gbetagamma signaling retards growth of existing prostate tumors by inducing cell death. These data establish a central role for heterotrimeric G proteins in prostate cancer and suggest targeted inhibition of Gbetagamma signaling may serve as specific molecular therapy tool to limit pathologic growth of advanced prostate cancer.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol Canc Biol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Daaka, Y (corresponding author), Duke Univ, Med Ctr, Dept Surg, Box 2607, Durham, NC 27710 USA.	daaka001@mc.duke.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017952] Funding Source: NIH RePORTER; NIA NIH HHS [AG17952] Funding Source: Medline; NIDDK NIH HHS [DK60917] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam RM, 2002, ENDOCRINOLOGY, V143, P4599, DOI 10.1210/en.2002-220561; Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Barki-Harrington L, 2001, J UROLOGY, V165, P2121, DOI 10.1016/S0022-5347(05)66305-7; Barki-Harrington L, 2003, BIOCHEM J, V371, P581, DOI 10.1042/BJ20021708; BOSTWICK DG, 1989, UROLOGY, V34, P16; Calvo BF, 2003, CLIN CANCER RES, V9, P1087; Chodak GW, 2002, UROLOGY, V60, P201, DOI 10.1016/S0090-4295(02)01677-1; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Daaka Y, 2002, BBA-MOL CELL BIOL L, V1582, P265, DOI 10.1016/S1388-1981(02)00180-4; Djakiew D, 2000, PROSTATE, V42, P150, DOI 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H; Drazner MH, 1997, J CLIN INVEST, V99, P288, DOI 10.1172/JCI119157; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; George DJ, 2002, UROLOGY, V60, P115, DOI 10.1016/S0090-4295(02)01589-3; Gioeli D, 1999, CANCER RES, V59, P279; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Gutkind J. S., 2000, SCI STKE, pre1, DOI DOI 10.1126/STKE.2000.40.RE1; Iaccarino G, 1999, P NATL ACAD SCI USA, V96, P3945, DOI 10.1073/pnas.96.7.3945; Isaacs W, 2002, CANCER CELL, V2, P113, DOI 10.1016/S1535-6108(02)00103-4; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kue PF, 2000, J UROLOGY, V164, P2162, DOI 10.1016/S0022-5347(05)66990-X; Kue PF, 2002, INT J CANCER, V102, P572, DOI 10.1002/ijc.10734; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Peppel K, 2000, CIRCULATION, V102, P793, DOI 10.1161/01.CIR.102.7.793; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Porter AT, 2001, UROL ONCOL, V6, P131, DOI 10.1016/S1078-1439(00)00124-1; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; Taub JS, 2003, CANCER RES, V63, P2037; Xu LL, 2000, CANCER RES, V60, P6568; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yowell Charles W, 2002, Clin Prostate Cancer, V1, P177, DOI 10.3816/CGC.2002.n.020	37	62	64	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37569	37573		10.1074/jbc.M306276200	http://dx.doi.org/10.1074/jbc.M306276200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869546	hybrid			2022-12-25	WOS:000185437200071
J	Li, HY; Pajor, AM				Li, HY; Pajor, AM			Serines 260 and 288 are involved in sulfate transport by hNaSi-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONALLY SENSITIVE RESIDUES; NA+/DICARBOXYLATE COTRANSPORTER; DICARBOXYLATE COTRANSPORTER; FUNCTIONAL-CHARACTERIZATION; SUBSTRATE; PROTEIN; CATION; SODIUM; NA+; CYSTEINE	The low affinity Na+/sulfate cotransporter, NaSi-1, belongs to the SLC13 family that also includes the Na+/ dicarboxylate cotransporters, NaDC. Two serine residues in hNaSi-1, at positions 260 and 288, are conserved in all of the sulfate transporters in the family whereas the NaDC contain alanine or threonine at those positions. Therefore, the functional roles of serines 260 and 288 in substrate and cation binding by hNaSi-1 were investigated. These two serine residues were first mutated to alanine and the mutants were characterized in Xenopus oocytes. Alanine substitution of Ser-260 resulted in increased Km values for both substrate and Na+ whereas alanine replacement at Ser-288 resulted in a broadened cation selectivity, indicating that these two serines might play important roles in cation and/or substrate binding of hNaSi-1. The two serines and 12 surrounding residues were further mutated to cysteine and studied using a thiol-reactive compound, [2-(trimethylammonium) ethyl] methane-thiosulfonate ( MTSET). Four mutants surrounding Ser-260 (T257C, T259C, T261C, and L263C) were sensitive to MTSET inhibition. The sensitivity to MTSET was dependent on the presence of substrate, suggesting that the accessibility of these substituted cysteines depends on the conformational state of the transporter. Because the four residues are located in transmembrane domain 5, this transmembrane domain is likely to participate in the conformational movements during the transport cycle of hNaSi-1.	Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Pajor, AM (corresponding author), Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046269] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46269] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHEARN GA, 1984, J MEMBRANE BIOL, V78, P177, DOI 10.1007/BF01925966; Beck L, 2001, KIDNEY INT, V59, P835, DOI 10.1046/j.1523-1755.2001.00566.x; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; Burgess KSD, 1999, J NEUROCHEM, V73, P656, DOI 10.1046/j.1471-4159.1999.0730656.x; BUSCH AE, 1994, J BIOL CHEM, V269, P12407; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; Griffith DA, 1999, BIOCHEMISTRY-US, V38, P7524, DOI 10.1021/bi990076b; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Kahn ES, 1999, BIOCHEMISTRY-US, V38, P6151, DOI 10.1021/bi9827722; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee A, 2000, GENOMICS, V70, P354, DOI 10.1006/geno.2000.6404; Markovich D, 2001, PHYSIOL REV, V81, P1499, DOI 10.1152/physrev.2001.81.4.1499; Morris ME, 2001, J MEMBRANE BIOL, V181, P1; Pajor AM, 1999, BIOCHEM J, V344, P205, DOI 10.1042/0264-6021:3440205; Pajor AM, 1998, BBA-BIOMEMBRANES, V1370, P98, DOI 10.1016/S0005-2736(97)00249-6; Pajor AM, 2000, J MEMBRANE BIOL, V175, P1, DOI 10.1007/s002320001049; Pajor AM, 1996, AM J PHYSIOL-RENAL, V271, pF1093, DOI 10.1152/ajprenal.1996.271.5.F1093; Pajor AM, 1996, AM J PHYSIOL-CELL PH, V271, pC1808, DOI 10.1152/ajpcell.1996.271.6.C1808; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; Pajor AM, 2001, J BIOL CHEM, V276, P29961, DOI 10.1074/jbc.M011387200; SEGEL IH, 1975, ENZYME KINETICS, P125; Wang J, 1999, J BIOL CHEM, V274, P2298, DOI 10.1074/jbc.274.4.2298; Wu JH, 1998, J MOL BIOL, V282, P959, DOI 10.1006/jmbi.1998.2065; Yao XZ, 2002, BIOCHEMISTRY-US, V41, P1083, DOI 10.1021/bi0156761; Zhang FF, 2001, BBA-BIOMEMBRANES, V1511, P80, DOI 10.1016/S0005-2736(00)00385-0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710	26	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37204	37212		10.1074/jbc.M305465200	http://dx.doi.org/10.1074/jbc.M305465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857732	hybrid			2022-12-25	WOS:000185437200028
J	May, P; Bock, HH; Nimpf, J; Herz, J				May, P; Bock, HH; Nimpf, J; Herz, J			Differential glycosylation regulates processing of lipoprotein receptors by gamma-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E RECEPTOR-2; AMYLOID PRECURSOR PROTEIN; O-LINKED GLYCOSYLATION; LDL-RECEPTOR; TYROSINE PHOSPHORYLATION; DEFICIENT MUTANT; VARIANT LACKING; MESSENGER-RNA; IN-VITRO; NOTCH	The low density lipoprotein (LDL) receptor-related protein 1 (LRP1) belongs to a growing number of cell surface proteins that undergo regulated proteolytic processing that culminates in the release of their intracellular domain (ICD) by the intramembranous protease gamma-secretase. Here we show that LRP1 is differentially glycosylated in a tissue-specific manner and that carbohydrate addition reduces proteolytic cleavage of the extracellular domain and, concomitantly, ICD release. The apolipoprotein E ( apoE) receptor-2 (apoER2), another member of the LDL receptor family with functions in cellular signal transmission, also undergoes sequential proteolytic processing, resulting in intracellular domain release into the cytoplasm. The penultimate processing step also involves cleavage of the apoER2 extracellular domain. The rate at which this cleavage step occurs is determined by the glycosylation state of the receptor, which in turn is regulated by the alternative splicing of an exon encoding several O-linked sugar attachment sites. These findings suggest a role for differential and tissue-specific glycosylation as a physiological switch that modulates the diverse biological functions of these receptors in a cell-type specific manner.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Vienna, Dept Mol Genet, A-1030 Vienna, Austria	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Vienna	May, P (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Bock, Hans/AAF-2635-2021	Nimpf, Johannes/0000-0002-9273-3492	NHLBI NIH HHS [R37 HL063762, HL20948, HL63762] Funding Source: Medline; NINDS NIH HHS [NS43408] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063762, R37HL063762, P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Blobel CP, 2002, INFLAMM RES, V51, P83, DOI 10.1007/BF02684007; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Brandes C, 2001, J BIOL CHEM, V276, P22160, DOI 10.1074/jbc.M102662200; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Chen JH, 2001, P NATL ACAD SCI USA, V98, P13716, DOI 10.1073/pnas.241398098; Clatworthy AE, 1999, NEUROSCIENCE, V90, P903, DOI 10.1016/S0306-4522(98)00489-8; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Galbete JL, 2000, BIOCHEM J, V348, P307, DOI 10.1042/0264-6021:3480307; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Iijima H, 1998, J BIOCHEM-TOKYO, V124, P747, DOI 10.1093/oxfordjournals.jbchem.a022175; Jones C, 2003, J BIOL CHEM, V278, P29024, DOI 10.1074/jbc.M304855200; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KINGSLEY DM, 1986, J CELL BIOL, V102, P1576, DOI 10.1083/jcb.102.5.1576; Koch S, 2002, EMBO J, V21, P5996, DOI 10.1093/emboj/cdf599; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Magrane J, 1999, FEBS LETT, V451, P56, DOI 10.1016/S0014-5793(99)00494-9; Martensen PM, 1997, EUR J BIOCHEM, V248, P583, DOI 10.1111/j.1432-1033.1997.00583.x; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Nakamura Y, 1998, BRAIN RES, V793, P47, DOI 10.1016/S0006-8993(98)00112-7; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Sun XM, 1999, EUR J BIOCHEM, V262, P230, DOI 10.1046/j.1432-1327.1999.00394.x; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	38	120	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37386	37392		10.1074/jbc.M305858200	http://dx.doi.org/10.1074/jbc.M305858200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871934	hybrid			2022-12-25	WOS:000185437200049
J	Isshiki, S; Kudo, T; Nishihara, S; Ikehara, Y; Togayachi, A; Furuya, A; Shitara, K; Kubota, T; Watanabe, M; Kitajima, M; Narimatsu, H				Isshiki, S; Kudo, T; Nishihara, S; Ikehara, Y; Togayachi, A; Furuya, A; Shitara, K; Kubota, T; Watanabe, M; Kitajima, M; Narimatsu, H			Lewis type 1 antigen synthase (beta 3Gal-T5) is transcriptionally regulated by homeoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE NUCLEAR FACTOR-1-ALPHA; HOMEODOMAIN PROTEIN CDX2; COLONIC ADENOCARCINOMA CELLS; LACTASE-PHLORHIZIN HYDROLASE; DIPEPTIDYL PEPTIDASE IV; GENE-TRANSCRIPTION; INTESTINAL METAPLASIA; HOMEOBOX GENE; CACO-2 CELLS; ENTEROCYTIC DIFFERENTIATION	The type 1 carbohydrate chain, Galbeta1-3GlcNAc, is synthesized by UDP-galactose:beta-N-acetylglucosamine beta1,3-galactosyltransferase (beta3Gal-T). Among six beta3Gal-Ts cloned to date, beta3Gal-T5 is an essential enzyme for the synthesis of type 1 chain in epithelium of digestive tracts or pancreatic tissue. It forms the type 1 structure on glycoproteins produced from such tissues. In the present study, we found that the transcriptional regulation of the beta3Gal-T5 gene is controlled by homeoproteins, i.e. members of caudal-related homeobox protein (Cdx) and hepatocyte nuclear factor (HNF) families. We found an important region (-151 to -121 from the transcription initiation site), named the beta3Gal-T5 control element (GCE), for the promoter activity. GCE contained the consensus sequences for members of the Cdx and HNF families. Mutations introduced into this sequence abolished the transcriptional activity. Four factors, Cdx1, Cdx2, HNF1alpha, and HNF1beta, could bind to GCE and transcriptionally activate the beta3Gal-T5 gene. Transcriptional regulation of the beta3Gal-T5 gene was consistent with that of members of the Cdx and HNF1 families in two in vivo systems. 1) During in vitro differentiation of Caco-2 cells, transcriptional up-regulation of beta3Gal-T5 was observed in correlation with the increase in transcripts for Cdx2 and HNF1alpha. 2) Both transcript and protein levels of beta3Gal-T5 were determined to be significantly reduced in colon cancer. This down-regulation was correlated with the decrease of Cdx1 and HNF1beta expression in cancer tissue. This is the first finding that a glycosyltransferase gene is transcriptionally regulated under the control of homeoproteins in a tissue-specific manner. beta3Gal-T5, controlled by the intestinal homeoproteins, may play an important role in the specific function of intestinal cells by modifying the carbohydrate structure of glycoproteins.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Glycogene Funct Team, Open Space Lab, Tsukuba, Ibaraki 3058568, Japan; Soka Univ, Inst Life Sci, Div Cell Biol, Tokyo 1928577, Japan; Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Tokyo 1608582, Japan; Aichi Canc Ctr, Res Inst, Div Oncol Pathol, Chikusa Ku, Nagoya, Aichi 4640021, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 1948533, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Soka University; Keio University; Aichi Cancer Center; Kyowa Kirin Ltd	Narimatsu, H (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Glycogene Funct Team, Open Space Lab, Cent 2,1-1-1 Umoezono, Tsukuba, Ibaraki 3058568, Japan.	h.narimatsu@aist.go.jp	Ikehara, yuzuru/L-7696-2018; Narimatsu, Hisashi/M-4757-2018; Ikehara, yuzuru/R-2239-2019; Togayachi, Akira/M-4144-2018	Ikehara, yuzuru/0000-0002-1915-9172; Narimatsu, Hisashi/0000-0002-8402-133X; Ikehara, yuzuru/0000-0002-1915-9172; Togayachi, Akira/0000-0003-3600-9149; Nishihara, Shoko/0000-0002-1668-2603				Amano J, 2001, ARCH BIOCHEM BIOPHYS, V395, P191, DOI 10.1006/abbi.2001.2572; Amano J, 1999, J BIOL CHEM, V274, P21209, DOI 10.1074/jbc.274.30.21209; Bai YQ, 2002, CANCER LETT, V176, P47, DOI 10.1016/S0304-3835(01)00753-4; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Boudreau F, 2001, J BIOL CHEM, V276, P32122, DOI 10.1074/jbc.M102002200; BROCKHAUSEN I, 1991, CANCER RES, V51, P3136; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Domon-Dell C, 2002, GUT, V50, P525, DOI 10.1136/gut.50.4.525; Eda A, 2002, J GASTROENTEROL, V37, P94, DOI 10.1007/s005350200002; Erickson RH, 2000, BIOCHEM BIOPH RES CO, V270, P235, DOI 10.1006/bbrc.2000.2420; Erickson RH, 1999, BIOCHEM J, V338, P91, DOI 10.1042/0264-6021:3380091; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; Ichikawa T, 1999, J HISTOCHEM CYTOCHEM, V47, P1593, DOI 10.1177/002215549904701211; Ikehara Y, 1998, GLYCOCONJUGATE J, V15, P799; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; Laurent-Puig P, 2003, GASTROENTEROLOGY, V124, P1311, DOI 10.1016/S0016-5085(03)00268-3; MAGNANI JL, 1983, CANCER RES, V43, P5489; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Mitchelmore C, 2000, BIOCHEM J, V346, P529, DOI 10.1042/0264-6021:3460529; MIYAKE M, 1989, CANCER RES, V49, P5689; Sakaguchi T, 2002, J BIOL CHEM, V277, P21361, DOI 10.1074/jbc.M110261200; Salvini R, 2001, J BIOL CHEM, V276, P3564, DOI 10.1074/jbc.M006662200; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seko A, 1996, CANCER RES, V56, P3468; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Spodsberg N, 1999, GASTROENTEROLOGY, V116, P842, DOI 10.1016/S0016-5085(99)70067-3; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; WU GD, 1994, J BIOL CHEM, V269, P17080; YOUAKIM A, 1989, CANCER RES, V49, P6889; Zhou DP, 1999, EUR J BIOCHEM, V263, P571, DOI 10.1046/j.1432-1327.1999.00541.x	38	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36611	36620		10.1074/jbc.M302681200	http://dx.doi.org/10.1074/jbc.M302681200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855703	hybrid			2022-12-25	WOS:000185318300092
J	Song, JY; Lim, JW; Kim, H; Morio, T; Kim, KH				Song, JY; Lim, JW; Kim, H; Morio, T; Kim, KH			Oxidative stress induces nuclear loss of DNA repair proteins Ku70 and Ku80 and apoptosis in pancreatic acinar AR42J cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-INDUCED APOPTOSIS; KINASE CATALYTIC SUBUNIT; FOCAL CEREBRAL-ISCHEMIA; NF-KAPPA-B; HYDROGEN-PEROXIDE; TRANSPORT FACTORS; EARLY DECREASE; REDOX CYCLE; HL-60 CELLS; LINE AR42J	Cell death linked to oxidative DNA damage has been implicated in acute pancreatitis. The severe DNA damage, which is beyond the capacity of the DNA repair proteins, triggers apoptosis. It has been hypothesized that oxidative stress may induce a decrease in the Ku70 and Ku80 levels and apoptosis in pancreatic acinar cells. In this study, it was found that oxidative stress caused by glucose oxidase (GO) acting on beta-D-glucose, glucose/glucose oxidase (G/GO), induced slight changes in cytoplasmic Ku70 and Ku80 but drastically induced a decrease in nuclear Ku70 and Ku80 both time- and concentration-dependently in AR42J cells. G/GO induced apoptosis determined by poly(ADP-ribose) polymerase cleavage, an increase in expression of p53 and Bax, and a decrease in Bcl-2 expression. G/GO-induced apoptosis was in parallel with the loss of nuclear Ku proteins in AR42J cells. Caspase-3 inhibitor prevented G/GO-induced nuclear Ku loss and cell death. G/GO did not induce apoptosis in the cells transfected with either the Ku70 or Ku80 expression gene but increased apoptosis in those transfected with the Ku dominant negative mutant. Pulse and pulse-chase results show that G/GO induced Ku70 and Ku80 syntheses, even though Ku70 and Ku80 were degraded both in cytoplasm and nucleus. G/GO-induced decrease in Ku binding to importin alpha and importin beta reflects possible modification of nuclear import of Ku proteins. The importin beta level was not changed by G/GO. These results demonstrate that nuclear decrease in Ku70 and Ku80 may result from the decrease in Ku binding to nuclear transporter importins and the degradation of Ku proteins. The nuclear loss of Ku proteins may underlie the mechanism of apoptosis in pancreatic acinar cells after oxidative stress.	Yonsei Univ, Coll Med, Dept Pharmacol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Inst Gastroenterol, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Tokyo Med & Dent Univ, Sch Med, Dept Gen Med, Tokyo 1138519, Japan	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Tokyo Medical & Dental University (TMDU)	Kim, H (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, Seoul 120752, South Korea.	kim626@yumc.yonsei.ac.kr		Morio, Tomohiro/0000-0002-9259-1025; Kim, Hyeyoung/0000-0002-7019-917X				AHO HJ, 1982, ACTA PATH MICRO IM A, V90, P367; AJMANI AK, 1995, J EXP MED, V181, P2049, DOI 10.1084/jem.181.6.2049; Arrington ED, 2000, FREE RADICAL BIO MED, V29, P1166, DOI 10.1016/S0891-5849(00)00439-1; BALKWILL FR, 1989, IMMUNOL TODAY, V10, P299, DOI 10.1016/0167-5699(89)90085-6; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bjork J, 1982, Agents Actions Suppl, V11, P63; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chechlacz M, 2001, J NEUROCHEM, V78, P141, DOI 10.1046/j.1471-4159.2001.00380.x; CHRISTOPHE J, 1994, AM J PHYSIOL, V266, pG963, DOI 10.1152/ajpgi.1994.266.6.G963; Cohen MC, 1996, AM J CLIN PATHOL, V105, P589; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Emanuele S, 2002, INT J ONCOL, V21, P857; Endoh D, 2001, RADIAT RES, V155, P320, DOI 10.1667/0033-7587(2001)155[0320:HTIRIN]2.0.CO;2; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Ferrando-May E, 2001, CELL DEATH DIFFER, V8, P495, DOI 10.1038/sj.cdd.4400837; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fujimura M, 1999, STROKE, V30, P2456, DOI 10.1161/01.STR.30.11.2456; Fujimura M, 1999, J CEREBR BLOOD F MET, V19, P495, DOI 10.1097/00004647-199905000-00003; GUICE KS, 1989, ANN SURG, V210, P740, DOI 10.1097/00000658-198912000-00008; Gukovsaya AS, 1996, GASTROENTEROLOGY, V110, P875, DOI 10.1053/gast.1996.v110.pm8608898; Gukovskaya AS, 1997, J CLIN INVEST, V100, P1853, DOI 10.1172/JCI119714; GUYAN PM, 1990, FREE RADICAL BIO MED, V8, P347, DOI 10.1016/0891-5849(90)90100-W; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; HARLAN JM, 1984, J CLIN INVEST, V73, P706, DOI 10.1172/JCI111263; HIRAISHI H, 1991, AM J PHYSIOL, V261, pG921, DOI 10.1152/ajpgi.1991.261.6.G921; Holstein SA, 2002, J BIOL CHEM, V277, P10678, DOI 10.1074/jbc.M111369200; HU JJ, 1995, MUTAT RES-DNA REPAIR, V336, P193, DOI 10.1016/0921-8777(94)00054-A; Jang MH, 2002, NEUROSCI LETT, V329, P177, DOI 10.1016/S0304-3940(02)00644-4; Kaiser AM, 1996, AM J PHYSIOL-CELL PH, V271, pC982, DOI 10.1152/ajpcell.1996.271.3.C982; KAISER AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1295, DOI 10.1152/ajpcell.1995.269.5.C1295; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim SH, 1999, CANCER RES, V59, P4012; Kimura K, 1998, GASTROENTEROLOGY, V114, P372, DOI 10.1016/S0016-5085(98)70490-1; Klein A, 2000, LEUKEMIA, V14, P40, DOI 10.1038/sj.leu.2401636; Koike M, 1999, ONCOGENE, V18, P7495, DOI 10.1038/sj.onc.1203247; Koike M, 1999, EXP CELL RES, V250, P401, DOI 10.1006/excr.1999.4507; Koike M, 1999, J CELL SCI, V112, P4031; Li G, 2002, P NATL ACAD SCI USA, V99, P832, DOI 10.1073/pnas.022649699; Li JJ, 1997, CANCER RES, V57, P3569; Lim JW, 2002, J BIOL CHEM, V277, P46093, DOI 10.1074/jbc.M206603200; Mandal M, 1999, BIOCHEM BIOPH RES CO, V260, P775, DOI 10.1006/bbrc.1999.0966; Marangoni E, 2000, NUCLEIC ACIDS RES, V28, P4778, DOI 10.1093/nar/28.23.4778; Masamune A, 2001, PANCREAS, V22, P75, DOI 10.1097/00006676-200101000-00014; Matsura T, 1999, FREE RADICAL RES, V30, P73, DOI 10.1080/10715769900300081; McConnell KR, 1997, J IMMUNOL, V158, P2083; MIYASHITA T, 1995, CELL, V80, P293; Mizutani H, 2002, J BIOL CHEM, V277, P30684, DOI 10.1074/jbc.M204353200; Morio T, 1999, IMMUNITY, V11, P339, DOI 10.1016/S1074-7613(00)80109-0; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicke B, 1999, AM J PHYSIOL-GASTR L, V276, pG499, DOI 10.1152/ajpgi.1999.276.2.G499; Nonaka A, 1990, Nihon Geka Gakkai Zasshi, V91, P169; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Osipovich O, 1997, J BIOL CHEM, V272, P27259, DOI 10.1074/jbc.272.43.27259; PETRONE WF, 1980, P NATL ACAD SCI-BIOL, V77, P1159, DOI 10.1073/pnas.77.2.1159; Piiper A, 2001, BIOCHEM BIOPH RES CO, V287, P746, DOI 10.1006/bbrc.2001.5651; Pucci S, 2001, ONCOGENE, V20, P739, DOI 10.1038/sj.onc.1204148; Ramadani M, 2001, PANCREAS, V22, P383, DOI 10.1097/00006676-200105000-00008; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; Saitoh H, 1996, MOL BIOL CELL, V7, P1319, DOI 10.1091/mbc.7.9.1319; Sandoval D, 1996, GASTROENTEROLOGY, V111, P1081, DOI 10.1016/S0016-5085(96)70077-X; SANFEY H, 1985, ANN SURG, V201, P633, DOI 10.1097/00000658-198505000-00013; Sata N, 1997, PANCREAS, V15, P278, DOI 10.1097/00006676-199710000-00010; SCEMAMA JL, 1987, GUT, V28, P233, DOI 10.1136/gut.28.Suppl.233; SCHOENBERG MH, 1995, PANCREAS, V10, P36, DOI 10.1097/00006676-199501000-00005; SCHOENBERG MH, 1988, BRIT J SURG, V75, P1254; SCHOENBERG MH, 1995, AM J CLIN NUTR, V62, P1306, DOI 10.1093/ajcn/62.6.1306S; SCOTT P, 1993, BRIT J SURG, V80, P750, DOI 10.1002/bjs.1800800632; Shackelford DA, 1999, J NEUROSCI, V19, P4727; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Takuma K, 2002, BRAIN RES, V946, P232, DOI 10.1016/S0006-8993(02)02888-3; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA, P121; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Teoh G, 1998, J CLIN INVEST, V101, P1379; Teraoka H, 1996, FEBS LETT, V393, P1, DOI 10.1016/0014-5793(96)00842-3; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; Velez-Pardo C, 2002, NEUROTOXICOLOGY, V23, P351, DOI 10.1016/S0161-813X(02)00081-5; WISNER J, 1988, GUT, V29, P1516, DOI 10.1136/gut.29.11.1516; Xie YT, 2002, CANCER RES, V62, P3861; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; Yu JH, 2002, LAB INVEST, V82, P1359, DOI 10.1097/01.LAB.0000032377.09626.C7	89	90	91	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36676	36687		10.1074/jbc.M303692200	http://dx.doi.org/10.1074/jbc.M303692200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12867423	hybrid			2022-12-25	WOS:000185318300099
J	Delisle, BP; Anderson, CL; Balijepalli, RC; Anson, BD; Kamp, TJ; January, CT				Delisle, BP; Anderson, CL; Balijepalli, RC; Anson, BD; Kamp, TJ; January, CT			Thapsigargin selectively rescues the trafficking defective LQT2 channels G601S and F805C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; FIBROSIS EPITHELIAL-CELLS; SODIUM 4-PHENYLBUTYRATE; SURFACE EXPRESSION; CARDIAC-ARRHYTHMIA; POTASSIUM CHANNEL; HERG; MUTATIONS; CALCIUM; PROTEIN	Several mutations in the human ether-a-go-go-related K+ channel gene (HERG or KCNH2) cause long QT syndrome (LQT2) by reducing the intracellular transport (trafficking) of the channel protein to the cell surface. Drugs that bind to and block HERG channels (i.e. E4031) rescue the surface expression of some trafficking defective LQT2 mutations. Because these drugs potently block HERG current, their ability to correct congenital LQT is confounded by their risk of causing acquired LQT. We tested the hypothesis that pharmacological rescue can occur without HERG channel block. Thapsigargin (1 muM), a sarcoplasmic/endoplasmic reticulum Ca2+-ATPase inhibitor, rescued the surface expression of G601S, and it did so without blocking current. Thapsigargin-induced rescue and E4031-induced rescue caused complex glycosylation that was evident within 3 h of drug exposure. Disruption of the Golgi apparatus with brefeldin A prevented thapsigargin- and E4031-induced rescue of I-G01S. Confocal imaging showed that G601S protein is predominantly "trapped" intracellularly and that both thapsigargin and E4031 promote its relocation to the surface membrane. We also studied two other trafficking defective LQT2 mutations. Thapsigargin rescued the C terminus mutation F805C but not N470D, whereas E4031 rescued N470D but not F805C. Other sarcoplasmic/endoplasmic reticulum Ca2+-ATPase inhibitors did not rescue G601S or F805C. This study 1) supports the hypothesis that the LQT2 trafficking defective phenotype can be reversed without blocking the channel; 2) demonstrates pharmacological rescue of a C terminus LQT2 mutation; and 3) shows that thapsigargin can correct trafficking defective phenotypes in more than one channel type and disease (i.e. LQT2 and cystic fibrosis).	Univ Wisconsin, Dept Med Cardiol, Madison, WI 53706 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	January, CT (corresponding author), Univ Wisconsin Hosp, Cardiol Sect, Rm H6-354,600 Highland Ave, Madison, WI 53792 USA.	ctj@medicine.wisc.edu	Anderson, Corey/AGM-2386-2022; Kamp, Timothy/ABD-1343-2020	Kamp, Timothy/0000-0003-2103-7876; Delisle, Brian/0000-0002-2146-327X	NHLBI NIH HHS [R01 HL60723, F32 HL07146-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060723, F32HL007146] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akimoto K, 1998, HUM MUTAT, pS184; BRODSKY F, 2001, AM J PHYSIOL, V281, pL39; Choo-Kang LR, 2001, AM J PHYSIOL-LUNG C, V281, pL58, DOI 10.1152/ajplung.2001.281.1.L58; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Delisle BP, 2000, BIOPHYS J, V78, P1895, DOI 10.1016/S0006-3495(00)76738-5; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; Egan ME, 2002, NAT MED, V8, P485, DOI 10.1038/nm0502-485; Ficker E, 2002, J BIOL CHEM, V277, P4989, DOI 10.1074/jbc.M107345200; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; Gong QM, 2002, AM J PHYSIOL-HEART C, V283, pH77, DOI 10.1152/ajpheart.00008.2002; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; January CT, 2000, J CARDIOVASC ELECTR, V11, P1413, DOI 10.1046/j.1540-8167.2000.01413.x; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Lees-Miller JP, 2000, MOL PHARMACOL, V57, P367; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497; Paulussen A, 2002, J BIOL CHEM, V277, P48610, DOI 10.1074/jbc.M206569200; POWELL K, 2002, ADV DRUG DELIVERY RE, V110, P1591; Rajamani S, 2002, CIRCULATION, V105, P2830, DOI 10.1161/01.CIR.0000019513.50928.74; Rubenstein RC, 2001, AM J PHYSIOL-LUNG C, V281, pL43, DOI 10.1152/ajplung.2001.281.1.L43; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	27	74	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35749	35754		10.1074/jbc.M305787200	http://dx.doi.org/10.1074/jbc.M305787200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12837749	hybrid			2022-12-25	WOS:000185164400122
J	Lasham, A; Moloney, S; Hale, T; Homer, C; Zhang, YF; Murison, JG; Braithwaite, AW; Watson, J				Lasham, A; Moloney, S; Hale, T; Homer, C; Zhang, YF; Murison, JG; Braithwaite, AW; Watson, J			The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; NUCLEAR EXPRESSION; GELATINASE-A; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; P-GLYCOPROTEIN; FACTOR YB-1; MDR1 GENE; PROMOTER; APOPTOSIS	The p53 tumor suppressor plays a major role in preventing tumor development by transactivating genes to remove or repair potentially tumorigenic cells. Here we show that the Y-box-binding protein, YB1, acts as a negative regulator of p53. Using reporter assays we show that YB1 represses transcription of the p53 promoter in a sequence-specific manner. We also show that YB1 reduces endogenous levels of p53, which in turn reduces p53 activity. Conversely, inhibiting YB1 in a variety of tumor cell lines induces p53 activity, resulting in significant apoptosis via a p53-dependent pathway. These data suggest that YB1 may, in some situations, protect cells from p53-mediated apoptosis, indicating that YB1 may be a good target for the development of new therapeutics.	Univ Otago, Dunedin Sch Med, Dept Pathol, Cell Transformat Grp, Dunedin 9001, New Zealand; Genesis Res & Dev Corp Ltd, Auckland 1001, New Zealand	University of Otago	Braithwaite, AW (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, Cell Transformat Grp, Box 913, Dunedin 9001, New Zealand.	antony.braithwaite@stonebow.otago.ac.nz						Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HALE TK, 1995, NUCLEIC ACIDS RES, V23, P663, DOI 10.1093/nar/23.4.663; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; JANSENDURR P, 1992, NUCLEIC ACIDS RES, V20, P1243, DOI 10.1093/nar/20.6.1243; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lasham A, 2000, GENE, V252, P1, DOI 10.1016/S0378-1119(00)00220-1; LEACH FS, 1993, CANCER RES, V53, P2231; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; MIYASHITA T, 1995, CELL, V80, P293; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; NEGOESCU A, 1997, BIOCHEMICA, V2, P12; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Oda Y, 2003, J PATHOL, V199, P251, DOI 10.1002/path.1282; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Park YG, 1999, J BIOL CHEM, V274, P1573, DOI 10.1074/jbc.274.3.1573; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Raffetseder U, 2003, J BIOL CHEM, V278, P18241, DOI 10.1074/jbc.M212518200; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Safak R, 1999, MOL CELL BIOL, V19, P2712; SAKURA H, 1988, GENE, V73, P499; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shibahara K, 2001, CLIN CANCER RES, V7, P3151; Shibao K, 1999, INT J CANCER, V83, P732; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; TAMURA T, 1995, ONCOGENE, V11, P1939; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; WEEKS DL, 1983, MOL CELL BIOL, V3, P1222, DOI 10.1128/MCB.3.7.1222; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357	58	86	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35516	35523		10.1074/jbc.M303920200	http://dx.doi.org/10.1074/jbc.M303920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12835324	hybrid			2022-12-25	WOS:000185164400094
J	Ma, YJ; Hendershot, LM				Ma, YJ; Hendershot, LM			Delineation of a negative feedback regulatory loop that controls protein translation during endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED GENE-EXPRESSION; TRANSCRIPTION FACTOR; ER STRESS; MESSENGER-RNA; MAMMALIAN-CELLS; INDUCIBLE PROTEIN; ENTRY SITE; INITIATION; EIF2-ALPHA; KINASE	Transient protein synthesis inhibition is an important protective mechanism used by cells during various stress conditions including endoplasmic reticulum ( ER) stress. This response centers on the phosphorylation state of eukaryotic initiation factor (eIF)-2alpha, which is induced by kinases like protein kinase R-like ER kinase ( PERK) and GCN2 to suppress translation and is later reversed so translation resumes. GADD34 was recently identified as the factor that activates the type 1 protein serine/threonine phosphatase (PP1), which dephosphorylates eIF-2alpha during cellular stresses. Our study delineates a negative feedback regulatory loop in which the eIF-2alpha-controlled inhibition of protein translation leads to GADD34 induction, which promotes translational recovery. We show that activating transcription factor-4 (ATF4), which is paradoxically translated during the eIF-2alpha-mediated translational block, is required for the transactivation of the GADD34 promoter in response to ER stress and amino acid deprivation. ATF4 directly binds to and trans-activates a conserved ATF site in the GADD34 promoter during ER stress. Examination of ATF4-/- MEFs revealed an absence of GADD34 induction, prolonged eIF-2alpha phosphorylation, delayed protein synthesis recovery, and diminished translational upregulation of BiP during ER stress. These studies demonstrate the essential role of GADD34 in the resumption of protein synthesis, define the pathway for its induction, and reveal that cytoprotective unfolded protein response targets like BiP are sensitive to the eIF-2alpha-mediated block in translation.	St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Hendershot, LM (corresponding author), St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.	linda.hendershot@stjude.org	Hendershot, Linda/N-8124-2018	Hendershot, Linda/0000-0002-5473-0274	NATIONAL CANCER INSTITUTE [P01CA023099, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054068] Funding Source: NIH RePORTER; NCI NIH HHS [CA23099, CA21765] Funding Source: Medline; NIGMS NIH HHS [GM54068] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brewer JW, 1997, EMBO J, V16, P7207, DOI 10.1093/emboj/16.23.7207; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; HENDERSHOT LM, 1995, MOL BIOL CELL, V6, P283, DOI 10.1091/mbc.6.3.283; Hettmann T, 2000, DEV BIOL, V222, P110, DOI 10.1006/dbio.2000.9699; HINNEBUSCH AG, 1993, MOL MICROBIOL, V10, P215, DOI 10.1111/j.1365-2958.1993.tb01947.x; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Lawson B, 1998, J CELL PHYSIOL, V174, P170, DOI 10.1002/(SICI)1097-4652(199802)174:2<170::AID-JCP4>3.3.CO;2-A; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Tanaka T, 1998, GENES CELLS, V3, P801, DOI 10.1046/j.1365-2443.1998.00230.x; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; van Huizen R, 2003, J BIOL CHEM, V278, P15558, DOI 10.1074/jbc.M212074200; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001	47	333	344	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34864	34873		10.1074/jbc.M301107200	http://dx.doi.org/10.1074/jbc.M301107200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12840028	hybrid			2022-12-25	WOS:000185164400017
J	Ng, CC; Arakawa, H; Fukuda, S; Kondoh, H; Nakamura, Y				Ng, CC; Arakawa, H; Fukuda, S; Kondoh, H; Nakamura, Y			p53RFP, a p53-inducible RING-finger protein, regulates the stability of p21(WAF1)	ONCOGENE			English	Article						p53RFP; p53-inducible gene; IBR domain	CYCLIN-DEPENDENT KINASES; P53-DEPENDENT APOPTOSIS; UBIQUITIN LIGASE; BINDING-SITE; HUMAN CANCER; PROTEASOME; DEGRADATION; GENES; PATHWAY; P21	The mechanisms by which p53 prevents development of cancer are much more complicated than previously thought. Under normal conditions, p53 is involved in cell-cycle arrest, apoptosis, DNA repair, and inhibition of angiogenesis; it also promotes degradation of proteins through transcriptional regulation of certain target genes. Here we report the isolation of a novel transcriptional target of p53, designated p53RFP (p53-inducible RING-finger protein), whose product has E3 ubiquitin ligase activity. Its expression was negatively correlated to that of p21(WAF1) protein; p53RFP is likely to play a role in the regulation of this protein, probably through interaction with, and ubiquitination of, p21(WAF1). p53RFP appears to represent the second known example, the first being MDM2, of an E3 ubiquitin ligase as a p53 target. Our results further suggest that p53 might regulate the stability of p21(WAF1) through transcriptional regulation of p53RFP, and this feature may represent a novel mechanism for a p53-dependent cell-cycle checkpoint.	Univ Tokyo, Mol Med Lab, Ctr Human Genet, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan	University of Tokyo; Osaka University	Nakamura, Y (corresponding author), Univ Tokyo, Mol Med Lab, Ctr Human Genet, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	NG, CHING CHING/B-9221-2010; Arakawa, Hirofumi/L-3459-2013	Arakawa, Hirofumi/0000-0001-6077-0638				Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fukuchi K, 1999, BBA-MOL CELL RES, V1451, P206, DOI 10.1016/S0167-4889(99)00081-6; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Marin I, 2002, MOL BIOL EVOL, V19, P2039, DOI 10.1093/oxfordjournals.molbev.a004029; Matsuda N, 2001, J CELL SCI, V114, P1949; Mimnaugh EG, 1999, ELECTROPHORESIS, V20, P418, DOI 10.1002/(SICI)1522-2683(19990201)20:2<418::AID-ELPS418>3.0.CO;2-N; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhao RB, 2000, GENE DEV, V14, P981	27	38	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4449	4458		10.1038/sj.onc.1206586	http://dx.doi.org/10.1038/sj.onc.1206586			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853982				2022-12-25	WOS:000183978900015
J	Lim, D; Ercolano, E; Kyozuka, K; Nusco, GA; Moccia, F; Lange, K; Santella, L				Lim, D; Ercolano, E; Kyozuka, K; Nusco, GA; Moccia, F; Lange, K; Santella, L			The M-phase-promoting factor modulates the sensitivity of the Ca2+ stores to inositol 1,4,5-trisphosphate via the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; INDUCED CALCIUM OSCILLATIONS; STARFISH OOCYTE MATURATION; MEIOSIS REINITIATION; NUCLEAR TRANSLOCATION; GERMINAL VESICLE; PROTEIN-KINASE; FROG OOCYTES; HELA-CELLS; FERTILIZATION	The resumption of the meiotic cycle ( maturation) induced by 1-methyladenine in prophase-arrested starfish oocytes is indicated by the breakdown of the germinal vesicle and is characterized by the increased sensitivity of the Ca2+ stores to inositol 1,4,5-trisphosphate (InsP(3)) to InsP(3) starting at the animal hemisphere ( where the germinal vesicle was originally located) and propagating along the animal/vegetal axis of the oocyte. This initiates Ca2+ signals around the germinal vesicle before nuclear envelope breakdown. Previous studies have suggested that the final activation of the maturation-promoting factor (MPF), a cyclin-dependent kinase, which is the major element controlling the entry of eukaryotic cells into the M phase, occurs in the nucleus. MPF is then exported to the cytoplasm where its activity is autocatalytically amplified following a similar animal/ vegetal spatial pattern. We have investigated whether activated MPF was involved in the increased sensitivity of the Ca2+ response to InsP(3). We have found that the development of increased sensitivity of the Ca2+ stores to InsP(3) receptors together with the Ca2+ signals in the perinuclear region was blocked in oocytes treated with the specific MPF inhibitor roscovitine. That the nuclear MPF activation is indeed required for changes of the InsP(3) receptors sensitivity was shown by enucleating or by dissecting oocytes into vegetal and animal hemispheres prior to the addition of 1-MA. MPF activity 50 min after 1-methyladenine addition was much lower in the enucleated oocytes and in the vegetal hemisphere, which did not contain the germinal vesicle, as compared with the animal hemisphere, which did contain it. The Ca2+ increase induced by InsP(3) under these experimental conditions correlated with the changes in actin cytoskeleton induced by MPF.	Staz Zool Anton Dohrn, Cell Biol Lab, I-80121 Naples, Italy; Asamushi Marine Biol Stn, Aomori 0393501, Japan	Stazione Zoologica Anton Dohrn di Napoli	Santella, L (corresponding author), Staz Zool Anton Dohrn, Cell Biol Lab, I-80121 Naples, Italy.	santella@szn.it	Moccia, Francesco/AAX-6447-2020; Lim, Dmitry/H-9101-2012; Santella, Luigia/AAM-3524-2020	Moccia, Francesco/0000-0003-0010-0098; Santella, Luigia/0000-0001-7159-0499				Beckhelling C, 2000, BIOL CELL, V92, P245, DOI 10.1016/S0248-4900(00)01067-4; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; Carroll J, 1996, Rev Reprod, V1, P137, DOI 10.1530/ror.0.0010137; CHIBA K, 1990, DEV BIOL, V140, P300, DOI 10.1016/0012-1606(90)90080-3; Deng MQ, 2000, BIOL REPROD, V62, P873, DOI 10.1095/biolreprod62.4.873; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; Gall L, 2002, MOL REPROD DEV, V62, P4, DOI 10.1002/mrd.10117; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; Iwasaki H, 2002, J BIOL CHEM, V277, P2763, DOI 10.1074/jbc.M108839200; KANATANI H, 1969, NATURE, V221, P273, DOI 10.1038/221273a0; Kishimoto T, 1999, DEV BIOL, V214, P1, DOI 10.1006/dbio.1999.9393; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; KURAISHI R, 1989, DEV BIOL, V136, P304, DOI 10.1016/0012-1606(89)90257-1; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; Levasseur M, 2000, DEVELOPMENT, V127, P631; Lim D, 2002, FASEB J, V16, P1050, DOI 10.1096/fj.02-0021com; Lim D, 2001, FASEB J, V15, P2257, DOI 10.1096/fj.01-0157com; MASUI Y, 1972, J EXP ZOOL, V179, P365, DOI 10.1002/jez.1401790308; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MEIJER L, 1984, INT REV CYTOL, V86, P129, DOI 10.1016/S0074-7696(08)60179-5; MEIJER L, 1987, DEV BIOL, V121, P306, DOI 10.1016/0012-1606(87)90166-7; MOREAU M, 1978, NATURE, V272, P251, DOI 10.1038/272251a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NEMOTO SI, 1983, EXP CELL RES, V145, P226, DOI 10.1016/S0014-4827(83)80025-1; NURSE P, 1980, GENETICS, V96, P627; Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; Patel R, 1999, J BIOL CHEM, V274, P7958, DOI 10.1074/jbc.274.12.7958; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Picard A, 1998, BIOL CELL, V90, P487, DOI 10.1016/S0248-4900(99)80007-0; PICARD A, 1984, DEV BIOL, V104, P357, DOI 10.1016/0012-1606(84)90091-5; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Santella L, 1997, EUR J BIOCHEM, V246, P602, DOI 10.1111/j.1432-1033.1997.t01-1-00602.x; SANTELLA L, 1994, BIOCHEM BIOPH RES CO, V203, P674, DOI 10.1006/bbrc.1994.2235; STRICKER SA, 1995, DEV BIOL, V170, P496, DOI 10.1006/dbio.1995.1232; Torok K, 1998, CURR BIOL, V8, P692, DOI 10.1016/S0960-9822(98)70275-1; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Wang Y, 2002, J NEUROCHEM, V82, P945, DOI 10.1046/j.1471-4159.2002.01059.x; Wilding M, 1996, J CELL BIOL, V135, P191, DOI 10.1083/jcb.135.1.191	42	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42505	42514		10.1074/jbc.M301851200	http://dx.doi.org/10.1074/jbc.M301851200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12867432	hybrid			2022-12-25	WOS:000185989500115
J	Anderson, AA; Treves, S; Biral, D; Betto, R; Sandona, D; Ronjat, M; Zorzato, F				Anderson, AA; Treves, S; Biral, D; Betto, R; Sandona, D; Ronjat, M; Zorzato, F			The novel skeletal muscle sarcoplasmic reticulum JP-45 protein - Molecular cloning, tissue distribution, developmental expression, and interaction with alpha 1.1 subunit of the voltage-gated calcium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL-FACE MEMBRANE; CA2+ RELEASE CHANNELS; RYANODINE RECEPTOR; TERMINAL CISTERNAE; DIHYDROPYRIDINE RECEPTOR; MALIGNANT HYPERTHERMIA; CALSEQUESTRIN; BINDING	JP-45 is a novel integral protein constituent of the skeletal muscle sarcoplasmic reticulum junctional face membrane. We identified its primary structure from a cDNA clone isolated from a mouse skeletal muscle cDNA library. Mouse skeletal muscle JP-45 displays over 86 and 50% identity with two hypothetical NCBI data base protein sequences from mouse tongue and human muscle, respectively. JP-45 is predicted to have a cytoplasmic domain, a single transmembrane segment followed by an intralumenal domain enriched in positively charged amino acids. Northern and Western blot analyses reveal that the protein is mainly expressed in skeletal muscle. The mRNA encoding JP-45 appears in 17-day-old mouse embryos; expression of the protein peaks during the second month of postnatal development and then decreases similar to3-fold during aging. Double immunofluorescence of adult skeletal muscle fibers demonstrates that JP-45 co-localizes with the sarcoplasmic reticulum calcium release channel. Co-immunoprecipitation experiments with a monoclonal antibody against JP-45 show that JP-45 interacts with the alpha1.1 subunit voltage-gated calcium channel and calsequestrin. These results are consistent with the localization of JP-45 in the junctional sarcoplasmic reticulum and with its involvement in the molecular mechanism underlying skeletal muscle excitation-contraction coupling.	Kantonsspital Basel, Zentrum Lehr & Forsch, Dept Anesthesia, CH-4031 Basel, Switzerland; Kantonsspital Basel, Zentrum Lehr & Forsch, Dept Res, CH-4031 Basel, Switzerland; CNR, Inst Neurosci, Unit Muscle Biol & Physiopathol, F-38054 Grenoble 9, France; CEA, INSERM, Lab Canaux Ion & Signalisat, F-38054 Grenoble 9, France; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Gen Pathol Sect, I-44100 Ferrara, Italy	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Padua; University of Ferrara	Zorzato, F (corresponding author), Kantonsspital Basel, Zentrum Lehr & Forsch, Dept Anesthesia, Hebelstr 20, CH-4031 Basel, Switzerland.	fzorzato@uhbs.ch	sandona, dorianna/AAB-9480-2020	Ronjat, Michel/0000-0002-9728-6425; Treves, Susan/0000-0002-0007-9631	Telethon [1259] Funding Source: Medline	Telethon(Fondazione Telethon)		Biral D, 1996, J MUSCLE RES CELL M, V17, P523, DOI 10.1007/BF00124352; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; Damiani E, 1997, CELL CALCIUM, V22, P129, DOI 10.1016/S0143-4160(97)90113-5; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Hamilton SL, 2000, NEWS PHYSIOL SCI, V15, P281; IKEMOTO N, 1994, BIOCHEMISTRY-US, V33, P10961, DOI 10.1021/bi00202a015; Jurkat-Rott K, 2000, MUSCLE NERVE, V23, P4, DOI 10.1002/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; LAMB GD, 1990, J PHYSIOL-LONDON, V423, P519, DOI 10.1113/jphysiol.1990.sp018037; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; Marks AR, 2002, TRENDS CARDIOVAS MED, V12, P166, DOI 10.1016/S1050-1738(02)00156-1; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nishi M, 1999, J CELL BIOL, V147, P1473, DOI 10.1083/jcb.147.7.1473; Pan Z, 2002, NAT CELL BIOL, V4, P379, DOI 10.1038/ncb788; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Sacchetto R, 2001, J MUSCLE RES CELL M, V22, P545, DOI 10.1023/A:1015010914328; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SILVER M, 1995, MOUSE GENETIC; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TREVES S, 1992, BIOCHEM J, V283, P767, DOI 10.1042/bj2830767; Treves S, 2000, J BIOL CHEM, V275, P39555, DOI 10.1074/jbc.M005473200; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; Zorzato F, 2000, BIOCHEM J, V351, P537, DOI 10.1042/0264-6021:3510537	31	32	35	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39987	39992		10.1074/jbc.M305016200	http://dx.doi.org/10.1074/jbc.M305016200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12871958	hybrid			2022-12-25	WOS:000185713800087
J	Lee, MH; Rapti, M; Murphy, G				Lee, MH; Rapti, M; Murphy, G			Unveiling the surface Epitopes that render tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; MATRIX-METALLOPROTEINASE; TIMP-1; PROGELATINASE; STROMELYSIN-1; ACTIVATION; (TIMP)-3	Membrane type 1-matrix metalloproteinase (MT1-MMP) is a zinc-dependent, membrane-associated endoproteinase of the metzincin family. The enzyme regulates extracellular matrix remodeling and is capable of cleaving a wide variety of transmembrane proteins. The enzymatic activity of MT1-MMP is regulated by endogenous inhibitors, the tissue inhibitor of metalloproteinases (TIMP). To date, four variants of mammalian TIMP have been identified. Whereas TIMP-2-4 are potent inhibitors against MT1-MMP, TIMP-1 displays negligible inhibitory activity against the enzyme. The rationale for such selectivity is hitherto unknown. Here we identify the surface epitopes that render TIMP-1 inactive against MT1-MMP. We show that TIMP-1 can be transformed into an active inhibitor against MT1-MMP by the mutation of a single residue, namely threonine 98 to leucine (T98L). The resultant mutant displayed inhibitory characteristics of a typical slow, tight binding inhibitor. The potency of the mutant could be further enhanced by the introduction of valine 4 to alanine (V4A) and proline 6 to valine (P6V) mutations. Indeed, the inhibitory profile of the triple mutant (V4A/P6V/T98L) is indistinguishable from those of other TIMPs. Our findings suggest that threonine 98 is critical in initiating MMP binding and complex stabilization. Our findings also provide a potential mechanistic explanation for MMP-TIMP selectivity.	Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of Cambridge	Murphy, G (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust MRC Bldg, Cambridge CB2 2XY, England.	gm290@cam.ac.uk						Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Bode W, 2000, METH MOL B, V151, P45, DOI 10.1385/1-59259-046-2:045; Bode W, 1999, ANN NY ACAD SCI, V878, P73, DOI 10.1111/j.1749-6632.1999.tb07675.x; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Galvez BG, 2001, J BIOL CHEM, V276, P37491, DOI 10.1074/jbc.M104094200; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Lee MH, 2002, PROTEIN SCI, V11, P2493, DOI 10.1110/ps.0216202; Lee MH, 2002, BIOCHEM J, V364, P227, DOI 10.1042/bj3640227; Lee MH, 2001, BIOCHEM BIOPH RES CO, V280, P945, DOI 10.1006/bbrc.2000.4192; MORRISON JF, 1995, METHOD ENZYMOL, V248, P201; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Nagase H, 1999, ANN NY ACAD SCI, V878, P1, DOI 10.1111/j.1749-6632.1999.tb07670.x; Nagase H, 2002, ARTHRITIS RES THER, V4, pS51, DOI 10.1186/ar573; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Tuuttila A, 1998, J MOL BIOL, V284, P1133, DOI 10.1006/jmbi.1998.2223; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wei S, 2003, J BIOL CHEM, V278, P9831, DOI 10.1074/jbc.M211793200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; Williamson RA, 2001, J BIOL CHEM, V276, P32966, DOI 10.1074/jbc.M101843200	28	57	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40224	40230		10.1074/jbc.M305678200	http://dx.doi.org/10.1074/jbc.M305678200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869573	hybrid			2022-12-25	WOS:000185713800115
J	Liu, YY; Schultz, JJ; Brent, GA				Liu, YY; Schultz, JJ; Brent, GA			A thyroid hormone receptor alpha gene mutation (P398H) is associated with visceral adiposity and impaired catecholamine-stimulated lipolysis in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT-NEGATIVE MUTATION; BETA-ADRENERGIC-RECEPTOR; RETINOID-X-RECEPTOR; FAT-CELL FUNCTION; INSULIN-RESISTANCE; DEFICIENT MICE; POSTNATAL-DEVELOPMENT; COREPRESSOR RELEASE; EXPRESSION; TISSUE	Thyroid hormone has profound effects on metabolic homeostasis, regulating both lipogenesis and lipolysis, primarily by modulating adrenergic activity. We generated mice with a point mutation in the thyroid hormone receptor alpha (TRalpha) gene producing a dominant-negative TRalpha mutant receptor with a proline to histidine substitution (P398H). The heterozygous P398H mutant mice had a 3.4-fold (p < 0.02) increase in serum thyrotropin (TSH) levels. Serum triiodothyronine (T3) and thyroxine (T4) concentrations were slightly elevated compared with wild-type mice. The P398H mice had a 4.4-fold increase in body fat (as a fraction of total body weight) (p < 0.001) and a 5-fold increase in serum leptin levels (p < 0.005) compared with wild-type mice. A 3-fold increase in serum fasting insulin levels (p < 0.002) and a 55% increase in fasting glucose levels (p < 0.01) were observed in P398H compared with wild-type mice. There was a marked reduction in norepinephrine-induced lipolysis, as reflected in reduced glycerol release from white adipose tissue isolated from P398H mice. Heart rate and cold-induced adaptive thermogenesis, mediated by thyroid hormone-catecholamine interaction, were also reduced in P398H mice. In conclusion, the TR&alpha; P398H mutation is associated with visceral adiposity and insulin resistance primarily due to a marked reduction in catecholamine-stimulated lipolysis. The observed phenotype in the TR&alpha; P398H mouse is likely due to interference with TR&alpha; action as well as influence on other metabolic signaling pathways. The physiologic significance of these findings will ultimately depend on understanding the full range of actions of this mutation.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med,Mol Endocrinol Lab, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol,Mol Endocrinol Lab, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Brent, GA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med,Mol Endocrinol Lab, Vet Affairs Greater Los Angeles Healthcare Syst, Bldg 114,Rm 230,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.				NCI NIH HHS [CA-89364] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089364] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate N, 2002, J CLIN ENDOCR METAB, V87, P4522, DOI 10.1210/jc.2002-020567; BERLAN M, 1985, EUR J CLIN INVEST, V15, P341, DOI 10.1111/j.1365-2362.1985.tb00282.x; Bernal J, 2002, J ENDOCRINOL INVEST, V25, P268, DOI 10.1007/BF03344003; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; BILZEKIAN JP, 1983, ENDOCR REV, V4, P378; Brent G A, 2000, Rev Endocr Metab Disord, V1, P27, DOI 10.1023/A:1010056202122; Buzzard JJ, 2000, BIOL REPROD, V62, P664, DOI 10.1095/biolreprod62.3.664; Cai Y, 2003, ENDOCRINOLOGY, V144, P2311, DOI 10.1210/en.2002-0129; CHATTERJEE VKK, 1992, CANCER SURV, V14, P147; Chiellini G, 2002, BIOORGAN MED CHEM, V10, P333, DOI 10.1016/S0968-0896(01)00284-X; Clifton-Bligh RJ, 1998, MOL ENDOCRINOL, V12, P609, DOI 10.1210/me.12.5.609; Costet P, 2000, J BIOL CHEM, V275, P28240; Endre T, 1996, J HUM HYPERTENS, V10, P755; ENGFELDT P, 1982, J CLIN ENDOCR METAB, V54, P625, DOI 10.1210/jcem-54-3-625; ENGFELDT P, 1988, J BIOL CHEM, V263, P15553; FAIN JN, 1983, J LIPID RES, V24, P945; Flier JS, 2000, J CLIN INVEST, V105, P859, DOI 10.1172/JCI9725; Forrest D, 1996, NAT GENET, V13, P354, DOI 10.1038/ng0796-354; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; GIUDICELLI Y, 1978, BIOCHEM J, V176, P1007, DOI 10.1042/bj1761007; Gong DW, 1998, DNA CELL BIOL, V17, P301, DOI 10.1089/dna.1998.17.301; Gothe S, 1999, GENE DEV, V13, P1329, DOI 10.1101/gad.13.10.1329; Gullberg H, 2000, MOL ENDOCRINOL, V14, P1739, DOI 10.1210/me.14.11.1739; HAFFNER SM, 1994, DIABETES, V43, P212, DOI 10.2337/diabetes.43.2.212; Hellstrom L, 1997, J CLIN ENDOCR METAB, V82, P159, DOI 10.1210/jc.82.1.159; Huber BR, 2003, MOL ENDOCRINOL, V17, P107, DOI 10.1210/me.2002-0097; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P9913, DOI 10.1073/pnas.171319498; Jequier E, 2002, ANN NY ACAD SCI, V967, P379, DOI 10.1111/j.1749-6632.2002.tb04293.x; Kaneshige M, 2001, P NATL ACAD SCI USA, V98, P15095, DOI 10.1073/pnas.261565798; Kim MS, 2000, J CLIN INVEST, V105, P1005, DOI 10.1172/JCI8857; Kreier F, 2002, J CLIN INVEST, V110, P1243, DOI 10.1172/JCI200215736; LAFONTAN M, 1982, EUR J PHARMACOL, V82, P107, DOI 10.1016/0014-2999(82)90562-3; LAFONTAN M, 1993, J LIPID RES, V34, P1057; LAFONTAN M, 1995, ENDOCR REV, V16, P716, DOI 10.1210/er.16.6.716; LANGIN D, 1991, EUR J PHARMACOL, V199, P291, DOI 10.1016/0014-2999(91)90492-9; Liu YY, 2002, ENDOCRINOLOGY, V143, P2664, DOI 10.1210/en.143.7.2664; LONNQVIST F, 1992, J CLIN INVEST, V90, P2175, DOI 10.1172/JCI116103; Makowski A, 2003, MOL ENDOCRINOL, V17, P273, DOI 10.1210/me.2002-0310; MALBON CC, 1984, J BIOL CHEM, V259, P3254; MAUTIEGE P, 1987, EUR CLIN INVEST, V17, P156; Nishizawa H, 2002, DIABETES, V51, P2734, DOI 10.2337/diabetes.51.9.2734; Pohlenz J, 1999, THYROID, V9, P1265, DOI 10.1089/thy.1999.9.1265; Privalsky ML, 2000, MOL CELL ENDOCRINOL, V159, P109, DOI 10.1016/S0303-7207(99)00201-4; Ribeiro MO, 2001, J CLIN INVEST, V108, P97, DOI 10.1172/JCI12584; RICHELSEN B, 1987, METABOLISM, V36, P1031, DOI 10.1016/0026-0495(87)90022-9; RODBELL M, 1964, J BIOL CHEM, V239, P375; Romero R, 2000, J ENDOCRINOL, V164, P187, DOI 10.1677/joe.0.1640187; RUFFOLO RR, 1994, PHARMACOL THERAPEUT, V61, P1, DOI 10.1016/0163-7258(94)90058-2; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; Tinnikov A, 2002, EMBO J, V21, P5079, DOI 10.1093/emboj/cdf523; Trost SU, 2000, ENDOCRINOLOGY, V141, P3057, DOI 10.1210/en.141.9.3057; Viguerie N, 2002, J CLIN ENDOCR METAB, V87, P630, DOI 10.1210/jc.87.2.630; WAHRENBERG H, 1986, J CLIN ENDOCR METAB, V63, P631, DOI 10.1210/jcem-63-3-631; WAHRENBERG H, 1989, J CLIN INVEST, V84, P458, DOI 10.1172/JCI114187; WAHRENBERG H, 1994, J CLIN ENDOCR METAB, V78, P898, DOI 10.1210/jc.78.4.898; Weiss RE, 1998, ENDOCRINOLOGY, V139, P4945, DOI 10.1210/en.139.12.4945; Weiss RE, 2002, J ENDOCRINOL, V172, P177, DOI 10.1677/joe.0.1720177; Wikstrom L, 1998, EMBO J, V17, P455, DOI 10.1093/emboj/17.2.455; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; ZAVACKI AM, 1993, MOL ENDOCRINOL, V7, P1319, DOI 10.1210/me.7.10.1319	62	125	128	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38913	38920		10.1074/jbc.M306120200	http://dx.doi.org/10.1074/jbc.M306120200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12869545	hybrid			2022-12-25	WOS:000185575100100
J	Strubing, C; Krapivinsky, G; Krapivinsky, L; Clapham, DE				Strubing, C; Krapivinsky, G; Krapivinsky, L; Clapham, DE			Formation of novel TRPC channels by complex subunit interactions in embryonic brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-PERMEABLE CATION CHANNEL; TRANSIENT RECEPTOR; STORE DEPLETION; FUNCTIONAL-CHARACTERIZATION; ACTIVATION; CELLS; DIACYLGLYCEROL; STIMULATION; ASSOCIATION; EXPRESSION	Mammalian short TRP channels (TRPCs) are putative receptor- and store-operated cation channels that play a fundamental role in the regulation of cellular Ca2+ homeostasis. Assembly of the seven TRPC homologs (TRPC1-7) into homo- and heteromers can create a large variety of different channels. However, the compositions as well as the functional properties of native TRPC complexes are largely undefined. We performed a systematic biochemical study of TRPC interactions in mammalian brain and identified previously unrecognized channel heteromers composed of TRPC1, TRPC4, or TRPC5 and the diacylglycerol-activated TRPC3 or TRPC6 subunits. The novel TRPC heteromers were found exclusively in embryonic brain. In heterologous systems, we demonstrated that assembly of these novel heteromers required the combination of TRPC1 plus TRPC4 or TRPC5 subunits along with diacylglycerol-sensitive subunits in the channel complexes. Functional interaction of the TRPC subunits was verified using a dominant negative TRPC5 mutant (TRPC5(DN)). Co-expression of TRPC5(DN) suppressed currents through TRPC5- and TRPC4-containing complexes; TRPC3-associated currents were unaffected by TRPC5(DN) unless TRPC1 was also co-expressed. This complex assembly mechanism increases the diversity of TRPC channels in mammalian brain and may generate novel heteromers that have specific roles in the developing brain.	Childrens Hosp, Howard Hughes Med Inst, Dept Cardiovasc Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Clapham, DE (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Dept Cardiovasc Res, Enders 1309,320 Longwood Ave, Boston, MA 02115 USA.	dclapham@enders.tch.harvard.edu	Clapham, David/S-1123-2019; Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; 				Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Congar P, 1997, J NEUROSCI, V17, P5366; Estacion M, 2001, J PHYSIOL-LONDON, V530, P1, DOI 10.1111/j.1469-7793.2001.0001m.x; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Greka A, 2003, NAT NEUROSCI, V6, P837, DOI 10.1038/nn1092; Haj-Dahmane S, 1999, EUR J NEUROSCI, V11, P1973, DOI 10.1046/j.1460-9568.1999.00612.x; HajDahmane S, 1996, J NEUROSCI, V16, P3848; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Montell C., 2001, SCI STKE; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Putney JW, 1999, BIOESSAYS, V21, P38; Riccio A, 2002, MOL BRAIN RES, V109, P95, DOI 10.1016/S0169-328X(02)00527-2; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	29	327	343	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39014	39019		10.1074/jbc.M306705200	http://dx.doi.org/10.1074/jbc.M306705200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12857742	hybrid			2022-12-25	WOS:000185575100113
J	Hoff, KG; Cupp-Vickery, JR; Vickery, LE				Hoff, KG; Cupp-Vickery, JR; Vickery, LE			Contributions of the LPPVK motif of the iron-sulfur template protein IscU to interactions with the Hsc66-Hsc20 chaperone system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING DOMAIN; ESCHERICHIA-COLI; EXTINCTION COEFFICIENTS; AZOTOBACTER-VINELANDII; MOLECULAR CHAPERONES; CLUSTER BIOSYNTHESIS; HSP70 CHAPERONES; GENE-CLUSTER; DNAK; HSC66	Hsc66 (HscA) and Hsc20 ( HscB) from Escherichia coli comprise a specialized chaperone system that selectively binds the iron-sulfur cluster template protein IscU. Hsc66 interacts with peptides corresponding to a discrete region of IscU including residues 99 - 103 (LPPVK), and a peptide containing residues 98 - 106 stimulates Hsc66 ATPase activity in a manner similar to IscU. To determine the relative contributions of individual residues in the LPPVK motif to Hsc66 binding and regulation, we have carried out an alanine mutagenesis scan of this motif in the Glu(98) - Cys(106) peptide and the IscU protein. Alanine substitutions in the Glu(98) - Cys(106) peptide resulted in decreased ATPase stimulation (2 -10-fold) because of reduced binding affinity, with peptide( P101A) eliciting < 10% of the parent peptide stimulation. Alanine substitutions in the IscU protein also revealed lower activities resulting from decreased apparent binding affinity, with the greatest changes in K-m observed for the Pro(101) (77-fold), Val(102) (4-fold), and Lys(103) (15-fold) mutants. Calorimetric studies of the binding of IscU mutants to the Hsc66 &BULL; ADP complex showed that the P101A and K103A mutants also exhibit decreased binding affinity for the ADP-bound state. When ATPase stimulatory activity was assayed in the presence of the co-chaperone Hsc20, each of the mutants displayed enhanced binding affinity, but the P101A and V102A mutants exhibited decreased ability to maximally simulate Hsc66 ATPase. A charge mutant containing the motif sequence of NifU, IscU( V102E), did not bind the ATP or ADP states of Hsc66 but did bind Hsc20 and weakly stimulated Hsc66 ATPase in the presence of the co-chaperone. These results indicate that residues in the LPPVK motif are important for IscU interactions with Hsc66 but not for the ability of Hsc20 to target IscU to Hsc66. The results are discussed in the context of a structural model based on the crystallographic structure of the DnaK peptide-binding domain.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Vickery, LE (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.				NIGMS NIH HHS [GM54264] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Atherton E., 1990, SOLID PHASE PEPTIDE; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; James P, 1997, SCIENCE, V275, P387, DOI 10.1126/science.275.5298.387; KAWULA TH, 1994, J BACTERIOL, V176, P610, DOI 10.1128/jb.176.3.610-619.1994; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; LANDRY SL, 1992, NATURE, V355, P4455; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Rudiger S, 2000, J MOL BIOL, V304, P245, DOI 10.1006/jmbi.2000.4193; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; SEATON BL, 1994, P NATL ACAD SCI USA, V91, P2066, DOI 10.1073/pnas.91.6.2066; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	40	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37582	37589		10.1074/jbc.M305292200	http://dx.doi.org/10.1074/jbc.M305292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871959	hybrid			2022-12-25	WOS:000185437200073
J	Kalinichenko, VV; Gusarova, GA; Tan, YJ; Wang, IC; Major, ML; Wang, XH; Yoder, HM; Costal, RH				Kalinichenko, VV; Gusarova, GA; Tan, YJ; Wang, IC; Major, ML; Wang, XH; Yoder, HM; Costal, RH			Ubiquitous expression of the Forkhead Box M1B transgene accelerates proliferation of distinct pulmonary cell types following lung injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR HFH-11B; BUTYLATED HYDROXYTOLUENE; LIVER DEVELOPMENT; HEPATOCYTE ENTRY; S-PHASE; MICE; PROTEIN; REGENERATION; BINDING; GENE	The delayed early transcription factor Forkhead Box M1B (FoxM1B) is expressed in proliferating cells, but its expression is extinguished in cells undergoing terminal differentiation. Liver regeneration studies with genetically altered mice that either prematurely expressed FoxM1B in hepatocytes or contained a hepatocyte-specific deletion of the Foxm1b allele demonstrated that FoxM1B is critical for regulating the expression of cell cycle genes required for hepatocyte proliferation. Furthermore, preventing the decline in hepatocyte FoxM1B levels during aging was sufficient to increase regenerating hepatocyte proliferation and expression of cell cycle genes to levels found in young regenerating mouse liver. Although these liver regeneration studies demonstrated that FoxM1B is required for hepatocyte proliferation, whether FoxM1B regulates proliferation of cell types other than hepatocytes remains to be determined. Here, we developed a new TG mouse line in which the - 800-base pair Rosa26 promoter was used to drive expression of the FoxM1B transgene in all mouse tissues and found that Rosa26-FoxM1B TG mice were healthy, displaying no developmental defects. We used butylated hydroxytoluene (BHT) lung injury to demonstrate that premature expression of the FoxM1B transgene protein accelerated proliferation of different lung cell types, including alveolar type II epithelial cells, bronchial epithelial and smooth muscle cells, and endothelial cells of pulmonary capillaries and arteries. This was associated with the earlier expression of the cell cycle promoting cyclin A2, cyclin E, cyclin B1, cyclin F, and cyclin dependent kinase-1 (Cdk1) genes and diminished protein levels of Cdk inhibitor p21(Cip1). Taken together, these results suggest that increasing FoxM1B levels is an effective means to stimulate cellular proliferation during aging and in lung diseases such as emphysema.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Costal, RH (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, M-C 669,900 S Ashland Ave,Rm 2220 MBRB, Chicago, IL 60607 USA.			Wang, I-Ching/0000-0003-4398-2975	NIA NIH HHS [R01 AG 21842-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK 54687-05] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021842] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMSON IYR, 1977, LAB INVEST, V36, P26; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; Duncan SA, 2000, DEV DYNAM, V219, P131, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1051>3.3.CO;2-E; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hawke TJ, 2003, J BIOL CHEM, V278, P4015, DOI 10.1074/jbc.M209200200; Kaestner KH, 2000, TRENDS ENDOCRIN MET, V11, P281, DOI 10.1016/S1043-2760(00)00271-X; Kaestner KH, 2000, GENE DEV, V14, P142; Kalinichenko VV, 2002, AM J PHYSIOL-LUNG C, V282, pL1253, DOI 10.1152/ajplung.00463.2001; Kalinichenko VV, 2001, DEV BIOL, V235, P489, DOI 10.1006/dbio.2001.0322; Kalinichenko VV, 2001, AM J PHYSIOL-LUNG C, V280, pL695, DOI 10.1152/ajplung.2001.280.4.L695; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kisseberth WC, 1999, DEV BIOL, V214, P128, DOI 10.1006/dbio.1999.9417; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; MARINO AA, 1972, P SOC EXP BIOL MED, V140, P122, DOI 10.3181/00379727-140-36407; Marsden I, 1998, J MOL BIOL, V278, P293, DOI 10.1006/jmbi.1998.1703; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; SHAPIRO SD, 1994, AM J RESP CRIT CARE, V150, pS160, DOI 10.1164/ajrccm/150.6_Pt_2.S160; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Wang XH, 2002, J BIOL CHEM, V277, P44310, DOI 10.1074/jbc.M207510200; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; Wang XH, 2001, HEPATOLOGY, V33, P1404, DOI 10.1053/jhep.2001.24666; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zaret KS, 2002, NAT REV GENET, V3, P499, DOI 10.1038/nrg837	42	85	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37888	37894		10.1074/jbc.M305555200	http://dx.doi.org/10.1074/jbc.M305555200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867420	hybrid			2022-12-25	WOS:000185437200110
J	Molinier-Frenkel, V; Prevost-Blondel, A; Hong, SS; Lengagne, R; Boudaly, S; Magnusson, MK; Boulanger, P; Guillet, JG				Molinier-Frenkel, V; Prevost-Blondel, A; Hong, SS; Lengagne, R; Boudaly, S; Magnusson, MK; Boulanger, P; Guillet, JG			The maturation of murine dendritic cells induced by human adenovirus is mediated by the fiber knob domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; NF-KAPPA-B; RECOMBINANT ADENOVIRUS; IMMUNE-RESPONSES; GENE-THERAPY; IN-VIVO; CELLULAR RECEPTOR; CYSTIC-FIBROSIS; BINDING SITE; PENTON BASE	We investigated the mechanism of adenovirus serotype 5 (Ad5)-mediated maturation of bone marrow-derived murine dendritic cells (DC) using (i) Ad5 vectors with wildtype capsid (AdE1degrees, AdGFP); (ii) Ad5 vector mutant deleted of the fiber C-terminal knob domain (AdGFPDeltaknob); and (iii) capsid components isolated from Ad5-infected cells or expressed as recombinant proteins, hexon, penton, penton base, full-length fiber, fiber knob, and fiber mutants. We found that penton capsomer (penton base linked to its fiber projection), full-length fiber protein, and its isolated knob domain were all capable of inducing DC maturation, whereas no significant DC maturation was observed for hexon or penton base alone. This capacity was severely reduced for AdGFPDeltaknob and for fiber protein deletion mutants lacking the beta-stranded region F of the knob (residues Leu-485-Thr-486). The DC maturation effect was fully retained in a recombinant fiber protein deleted of the HI loop (FiDeltaHI), a fiber (Fi) deletion mutant that failed to trimerize, suggesting that the fiber knob-mediated DC activation did not depend on the integrity of the HI loop and on the trimeric status of the fiber. Interestingly, peptide-pulsed DC that had been stimulated with Ad5 knob protein induced a potent CD8(+) T cell response in vivo.	Fac Med RTH Laennec, CNRS UMR 5537, Lab Virol & Pathogenese Virale, F-69372 Lyon 08, France; Univ Paris 05, Lab Membre Inst Federatif Rech 116, CNRS UMR 8104, Dept Immunol,Inst Cochin,INSERM,U567, F-75014 Paris, France; Hop St Vincent de Paul, INSERM, U342, Lab Pathol Metab & Hormonale Dev, F-75014 Paris, France; Got A Gene AB, Stena Ctr 1B, SE-41292 Gothenburg, Sweden	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Boulanger, P (corresponding author), Fac Med RTH Laennec, CNRS UMR 5537, Lab Virol & Pathogenese Virale, 7 Rue Guillaume Paradin, F-69372 Lyon 08, France.		Prevost-Blondel, Armelle/N-7643-2017; Molinier-Frenkel, Valérie/Q-2852-2018; Hong, Saw See/M-9818-2017	Hong, Saw See/0000-0001-8871-0901; Molinier-Frenkel, Valerie/0000-0002-7250-7295; Prevost-Blondel, Armelle/0000-0002-7268-5905; Magnusson, Maria/0000-0002-8888-4968				Akira S, 2003, CURR OPIN IMMUNOL, V15, P238, DOI 10.1016/S0952-7915(03)00005-0; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; Borgland SL, 2000, J VIROL, V74, P3941, DOI 10.1128/JVI.74.9.3941-3947.2000; Bruder JT, 1997, J VIROL, V71, P398, DOI 10.1128/JVI.71.1.398-404.1997; Gaden F, 2002, AM J RESP CELL MOL, V27, P628, DOI 10.1165/rcmb.4841; Gahery-Segard H, 1998, J VIROL, V72, P2388; GaherySegard H, 1997, J CLIN INVEST, V100, P2218, DOI 10.1172/JCI119759; Hirschowitz EA, 2000, GENE THER, V7, P1112, DOI 10.1038/sj.gt.3301210; Hong SS, 2003, MOL THER, V7, P692, DOI 10.1016/S1525-0016(03)00067-4; Hong SS, 1997, EMBO J, V16, P2294, DOI 10.1093/emboj/16.9.2294; Jeannin P, 2000, NAT IMMUNOL, V1, P502, DOI 10.1038/82751; KARAYAN L, 1994, VIROLOGY, V202, P782, DOI 10.1006/viro.1994.1400; Kirby I, 2000, J VIROL, V74, P2804, DOI 10.1128/JVI.74.6.2804-2813.2000; Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807; Legrand V, 1999, J VIROL, V73, P907, DOI 10.1128/JVI.73.2.907-919.1999; Lusky M, 1998, J VIROL, V72, P2022, DOI 10.1128/JVI.72.3.2022-2032.1998; Luster AD, 2002, CURR OPIN IMMUNOL, V14, P129, DOI 10.1016/S0952-7915(01)00308-9; Magnusson MK, 2002, J GENE MED, V4, P356, DOI 10.1002/jgm.285; Magnusson MK, 2001, J VIROL, V75, P7280, DOI 10.1128/JVI.75.16.7280-7289.2001; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; Mercier S, 2002, J VIROL, V76, P2899, DOI 10.1128/JVI.76.6.2899-2911.2002; Molinier-Frenkel V, 2000, J VIROL, V74, P7678, DOI 10.1128/JVI.74.16.7678-7682.2000; Molinier-Frenkel V, 2002, J VIROL, V76, P127, DOI 10.1128/JVI.76.1.127-135.2002; Morelli AE, 2000, J VIROL, V74, P9617, DOI 10.1128/JVI.74.20.9617-9628.2000; Muruve DA, 1999, HUM GENE THER, V10, P965, DOI 10.1089/10430349950018364; NOVELLI A, 1991, VIROLOGY, V185, P365, DOI 10.1016/0042-6822(91)90784-9; Oehen S, 1997, J IMMUNOL METHODS, V207, P33, DOI 10.1016/S0022-1759(97)00089-6; Okada N, 2001, BIOCHEM BIOPH RES CO, V282, P173, DOI 10.1006/bbrc.2001.4527; Rea D, 1999, J VIROL, V73, P10245, DOI 10.1128/JVI.73.12.10245-10253.1999; Rea D, 2001, J IMMUNOL, V166, P5236, DOI 10.4049/jimmunol.166.8.5236; Ribas A, 1997, CANCER RES, V57, P2865; Roelvink PW, 1999, SCIENCE, V286, P1568, DOI 10.1126/science.286.5444.1568; Roth MD, 2002, J IMMUNOL, V169, P4651, DOI 10.4049/jimmunol.169.8.4651; Rouard H, 2000, J IMMUNOL METHODS, V241, P69, DOI 10.1016/S0022-1759(00)00214-3; Santis G, 1999, J GEN VIROL, V80, P1519, DOI 10.1099/0022-1317-80-6-1519; Sarukhan A, 2001, J VIROL, V75, P269, DOI 10.1128/JVI.75.1.269-277.2001; Steitz J, 2001, GENE THER, V8, P1255, DOI 10.1038/sj.gt.3301521; Suomalainen M, 2001, EMBO J, V20, P1310, DOI 10.1093/emboj/20.6.1310; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Worgall S, 1997, HUM GENE THER, V8, P37, DOI 10.1089/hum.1997.8.1-37; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; YANG YP, 1995, NAT MED, V1, P890, DOI 10.1038/nm0995-890; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; Zabner J, 1996, J CLIN INVEST, V97, P1504, DOI 10.1172/JCI118573	46	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37175	37182		10.1074/jbc.M303496200	http://dx.doi.org/10.1074/jbc.M303496200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855705	hybrid			2022-12-25	WOS:000185437200025
J	Natochin, M; Gasimov, KG; Moussaif, M; Artemyev, NO				Natochin, M; Gasimov, KG; Moussaif, M; Artemyev, NO			Rhodopsin determinants for transducin activation - A gain-of-function approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE SUBSTITUTION MUTANTS; PROTEIN-COUPLED RECEPTORS; COVALENT CROSS-LINKING; 4TH CYTOPLASMIC LOOP; BOVINE RHODOPSIN; SULFHYDRYL REACTIVITY; TERTIARY STRUCTURE; CRYSTAL-STRUCTURE; LIGHT-ACTIVATION; VISUAL PIGMENTS	Three cytoplasmic loops in the G protein-coupled receptor rhodopsin, C2, C3, and C4, have been implicated as key sites for binding and activation of the visual G protein transducin. Non-helical portions of the C2- and C3-loops and the cytoplasmic helix-8 from the C4 loop were targeted for a "gain-of-function" mutagenesis to identify rhodopsin residues critical for transducin activation. Mutant opsins with residues 140 - 148 ( C2- loop), 229 - 244 ( C3-loop), or 310 - 320 ( C4-loop) substituted by poly-Ala sequences of equivalent lengths served as templates for mutagenesis. The template mutants with poly-Ala substitutions in the C2- and C3-loops formed the 500-nm absorbing pigments but failed to activate transducin. Reverse substitutions of the Ala residues by rhodopsin residues have been generated in each of the templates. Significant (similar to 50%) restoration of the rhodopsin/ transducin coupling was achieved with re-introduction of residues Cys(140)/Lys(141) and Arg(147)/Phe(148) into the C2 template. The reverse substitutions of the C3-loop residues Thr(229)/Val(230) and Ser(240)/Thr(242)/Thr(243)/Gln(244) produced a pigment with a full capacity for transducin activation. The C4 template mutant was unable to bind 11-cis-retinal, and the presence of Asn(310)/Lys(311) was required for correct folding of the protein. Subsequent mutagenesis of the C4-loop revealed the role of Phe(313) and Met(317). On the background of Asn(310)/Lys(311), the inclusion of Phe313 and Met317 produced a mutant pigment with the potency of transducin activation equal to that of the wild-type rhodopsin. Overall, our data support the role of the three cytoplasmic loops of rhodopsin and suggest that residues adjacent to the transmembrane helices are most important for transducin activation.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA.			Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [EY-12682] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012682] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; Kazmi MA, 1996, BIOTECHNIQUES, V21, P304; Klein-Seetharaman J, 1999, BIOCHEMISTRY-US, V38, P7938, DOI 10.1021/bi990013t; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Marin EP, 2002, BIOCHEMISTRY-US, V41, P6988, DOI 10.1021/bi025514k; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OSAWA S, 1994, MOL PHARMACOL, V46, P1036; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RESEK JF, 1994, P NATL ACAD SCI USA, V91, P7643, DOI 10.1073/pnas.91.16.7643; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; Stenkamp RE, 2002, BBA-BIOMEMBRANES, V1565, P168, DOI 10.1016/S0005-2736(02)00567-9; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011; Yamashita T, 2000, J BIOL CHEM, V275, P34272, DOI 10.1074/jbc.M002954200; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; Yeagle PL, 2003, BIOCHEMISTRY-US, V42, P1365, DOI 10.1021/bi0270539	40	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37574	37581		10.1074/jbc.M305136200	http://dx.doi.org/10.1074/jbc.M305136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12860986	hybrid			2022-12-25	WOS:000185437200072
J	Panda, K; Adak, S; Aulak, KS; Santolini, J; McDonald, JF; Stuehr, DJ				Panda, K; Adak, S; Aulak, KS; Santolini, J; McDonald, JF; Stuehr, DJ			Distinct influence of N-terminal elements on neuronal nitric-oxide synthase structure and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-TURNOVER CONDITIONS; STOPPED-FLOW ANALYSIS; ARGININE BINDING; TETRAHYDROBIOPTERIN INTERACTION; MOLECULAR-MECHANISMS; SUBUNIT DIMERIZATION; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; ELECTRON-TRANSFER; OXYGENASE DOMAIN	Nitric oxide (NO) is a signal molecule produced in animals by three different NO synthases. Of these, only NOS I (neuronal nitric-oxide synthase; nNOS) is expressed as catalytically active N-terminally truncated forms that are missing either an N-terminal leader sequence required for protein-protein interactions or are missing the leader sequence plus three core structural motifs that in other NOS are required for dimer assembly and catalysis. To understand how the N-terminal elements impact nNOS structure-function, we generated, purified, and extensively characterized variants that were missing the N-terminal leader sequence (Delta296nNOS) or missing the leader sequence plus the three core motifs (Delta349nNOS). Eliminating the leader sequence had no impact on nNOS structure or catalysis. In contrast, additional removal of the core elements weakened but did not destroy the dimer interaction, slowed ferric heme reduction and reactivity of a heme-dioxy intermediate, and caused a 10-fold poorer affinity toward substrate L-arginine. This created an nNOS variant with slower and less coupled NO synthesis that is predisposed to generate reactive oxygen species along with NO. Our findings help justify the existence of nNOS N-terminal splice variants and identify specific catalytic changes that create functional differences among them.	Cleveland Clin, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stuehr, DJ (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.		; Panda, Koustubh/E-5273-2017	Santolini, Jerome/0000-0001-8919-112X; Panda, Koustubh/0000-0002-4783-2221	NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Abu-Soud HM, 1999, BIOCHEMISTRY-US, V38, P12446, DOI 10.1021/bi990698x; ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Adak S, 2000, J BIOL CHEM, V275, P17434, DOI 10.1074/jbc.M000846200; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 2001, J INORG BIOCHEM, V83, P301, DOI 10.1016/S0162-0134(00)00176-8; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bender AT, 2000, J BIOL CHEM, V275, P26018, DOI 10.1074/jbc.275.34.26018; Bird LE, 2002, STRUCTURE, V10, P1687, DOI 10.1016/S0969-2126(02)00911-5; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; Boyhan A, 1997, BIOCHEM J, V323, P131, DOI 10.1042/bj3230131; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; Couture M, 2001, J BIOL CHEM, V276, P38280; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Dawson VL, 1998, PROG BRAIN RES, V118, P215; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Ghosh S, 1999, J BIOL CHEM, V274, P24100, DOI 10.1074/jbc.274.34.24100; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; Hemmens B, 1998, METH MOL B, V100, P1; Hemmens B, 1998, FEBS LETT, V430, P397, DOI 10.1016/S0014-5793(98)00704-2; Hemmens B, 2000, J BIOL CHEM, V275, P35786, DOI 10.1074/jbc.M005976200; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Komeima K, 2000, J BIOL CHEM, V275, P28139; Lee MA, 1997, J CLIN INVEST, V100, P1507, DOI 10.1172/JCI119673; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Martasek P, 1998, J BIOL CHEM, V273, P34799, DOI 10.1074/jbc.273.52.34799; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Panda K, 2002, J BIOL CHEM, V277, P31020, DOI 10.1074/jbc.M203749200; Panda K, 2001, J BIOL CHEM, V276, P23349, DOI 10.1074/jbc.M100687200; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Rodriguez-Crespo I, 1999, J BIOL CHEM, V274, P21617, DOI 10.1074/jbc.274.31.21617; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Scheele JS, 2001, J BIOL CHEM, V276, P4733, DOI 10.1074/jbc.M007461200; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; STANKOVICH MT, 1980, ANAL BIOCHEM, V109, P295, DOI 10.1016/0003-2697(80)90652-1; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Wang Y, 1997, J BIOL CHEM, V272, P11392; Wang Y, 1999, CRIT REV NEUROBIOL, V13, P21, DOI 10.1615/CritRevNeurobiol.v13.i1.20; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Wang Y, 1995, Adv Pharmacol, V34, P71; Wang ZQ, 2001, BIOCHEMISTRY-US, V40, P12819, DOI 10.1021/bi011182s; Zanelli SA, 2002, NEUROSCIENCE, V112, P869, DOI 10.1016/S0306-4522(02)00141-0	71	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37122	37131		10.1074/jbc.M304456200	http://dx.doi.org/10.1074/jbc.M304456200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12847099	hybrid			2022-12-25	WOS:000185437200018
J	Rao, GSJ; Coleman, DE; Karsten, WE; Cook, PF; Harris, BG				Rao, GSJ; Coleman, DE; Karsten, WE; Cook, PF; Harris, BG			Crystallographic studies on Ascaris suum NAD-malic enzyme bound to reduced cofactor and identification of an effector site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; ELECTRON-DENSITY MAPS; CRYSTAL-STRUCTURE; OXIDATIVE DECARBOXYLASES; REGULATORY PROPERTIES; ANGSTROM RESOLUTION; MECHANISM; DEHYDROGENASE; MOLSCRIPT; SEQUENCE	The crystal structure of the mitochondrial NAD-malic enzyme from Ascaris suum, in a quaternary complex with NADH, tartronate, and magnesium has been determined to 2.0-Angstrom resolution. The structure closely resembles the previously determined structure of the same enzyme in binary complex with NAD. However, a significant difference is observed within the coenzyme-binding pocket of the active site with the nicotinamide ring of NADH molecule rotating by 198degrees over the C-1 - N-1 bond into the active site without causing significant movement of the other catalytic residues. The implications of this conformational change in the nicotinamide ring to the catalytic mechanism are discussed. The structure also reveals a binding pocket for the divalent metal ion in the active site and a binding site for tartronate located in a highly positively charged environment within the subunit interface that is distinct from the active site. The tartronate binding site, presumably an allosteric site for the activator fumarate, shows striking similarities and differences with the activator site of the human NAD-malic enzyme that has been reported recently. Thus, the structure provides additional insights into the catalytic as well as the allosteric mechanisms of the enzyme.	Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of North Texas System; University of North Texas Health Science Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Oklahoma System; University of Oklahoma - Norman	Harris, BG (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA.				NHLBI NIH HHS [HR 990217] Funding Source: Medline; NIAID NIH HHS [AI41552, AI24155] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041552, R21AI041552, R01AI024155] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS MJ, 1994, STRUCTURE, V2, P651, DOI 10.1016/S0969-2126(00)00066-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Coleman DE, 2002, BIOCHEMISTRY-US, V41, P6928, DOI 10.1021/bi0255120; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; HALL MD, 1993, J MOL BIOL, V232, P213, DOI 10.1006/jmbi.1993.1377; Hammen PK, 2002, BIOCHEMISTRY-US, V41, P7156, DOI 10.1021/bi012197t; HLAVATY J, 1997, BIOCHEMISTRY-US, V39, P3389; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARSTEN WE, 1994, BIOCHEMISTRY-US, V33, P2096, DOI 10.1021/bi00174a016; Karsten WE, 2000, PROTEIN PEPTIDE LETT, V7, P281; Karsten WE, 1999, BIOCHEMISTRY-US, V38, P10527, DOI 10.1021/bi9906165; KIICK DM, 1986, BIOCHEMISTRY-US, V25, P227, DOI 10.1021/bi00349a032; Komuniecki Richard, 1995, P49, DOI 10.1016/B978-012473345-9/50005-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KULKARNI G, 1993, ARCH BIOCHEM BIOPHYS, V300, P231, DOI 10.1006/abbi.1993.1032; LAI CJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P214, DOI 10.1016/0003-9861(92)90266-Y; LANDSPERGER WJ, 1976, J BIOL CHEM, V251, P3599; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu D, 2000, BIOCHEMISTRY-US, V39, P11955, DOI 10.1021/bi000790p; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOREADITH RW, 1984, J BIOL CHEM, V259, P6222; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK SH, 1986, BIOCHEMISTRY-US, V25, P3752, DOI 10.1021/bi00361a004; Rao GSJ, 2000, PROTEIN PEPTIDE LETT, V7, P297; SAUER LA, 1973, BIOCHEM BIOPH RES CO, V50, P524, DOI 10.1016/0006-291X(73)90871-1; SAUER LA, 1973, FEBS LETT, V33, P251, DOI 10.1016/0014-5793(73)80205-4; SAZ HJ, 1981, ANNU REV PHYSIOL, V43, P323, DOI 10.1146/annurev.ph.43.030181.001543; VINCENT JFS, 1994, P NATL ACAD SCI USA, P4383; WEISS PM, 1991, BIOCHEMISTRY-US, V30, P5755, DOI 10.1021/bi00237a018; Xu YW, 1999, STRUCT FOLD DES, V7, P877, DOI 10.1016/S0969-2126(99)80115-4; Yang ZR, 2000, NAT STRUCT BIOL, V7, P251; Yang ZR, 2002, STRUCTURE, V10, P951, DOI 10.1016/S0969-2126(02)00788-8	33	30	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38051	38058		10.1074/jbc.M305145200	http://dx.doi.org/10.1074/jbc.M305145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12853453	hybrid			2022-12-25	WOS:000185437200127
J	Tsurupa, G; Ho-Tin-Noe, B; Angles-Cano, E; Medved, L				Tsurupa, G; Ho-Tin-Noe, B; Angles-Cano, E; Medved, L			Identification and characterization of novel lysine-independent apolipoprotein(a)-binding sites in fibrin(ogen) alpha C-domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSING HUMAN APOLIPOPROTEIN(A); MEDIATED PLASMINOGEN ACTIVATION; CORONARY-HEART-DISEASE; BINDING-SITE; TRANSGENIC RABBITS; FIBRINOGEN BINDING; RECOMBINANT APOLIPOPROTEIN(A); ATHEROSCLEROTIC LESIONS; IMMOBILIZED FIBRINOGEN; MONOCLONAL-ANTIBODY	Accumulation of lipoprotein(a) (Lp(a)) in atherosclerotic plaques is mediated through interaction of fibrin-(ogen) deposits with the apolipoprotein(a) (apo(a)) moiety of Lp(a). It was suggested that because apo(a) competes with plasminogen for binding to fibrin, causing inhibition of fibrinolysis, it could also promote atherothrombosis. Because the fibrin(ogen) alphaC-domains bind plasminogen and tissue-type plasminogen activator with high affinity in a Lys-dependent manner, we hypothesized that they could also bind apo(a). To test this hypothesis, we studied the interaction between the recombinant apo(a) A10 isoform and the recombinant alphaC-fragment (Aalpha-(221-610)) corresponding to the alphaC-domain by enzyme-linked immunosorbent assay and surface plasmon resonance. Both methods revealed a high affinity interaction (K-d = 19-21 nM) between the immobilized alphaC-fragment and apo(a), indicating that the former contains an apo(a)-binding site. This affinity was comparable to that of apo(a) for fibrin. At the same time, no interaction was observed between soluble fibrinogen and immobilized apo(a), suggesting that, in the former, this and other apo(a)-binding sites are cryptic. Further experiments with truncated recombinant variants of the alphaC-fragment allowed localization of the apo(a)-binding site to the Aalpha-(392-610) region. The presence of epsilon-aminocaproic acid only slightly inhibited binding of apo(a) to the alphaC-fragment, indicating the Lys-independent nature of their interaction. In agreement, the influence of plasminogen or tissue-type plasminogen activator on binding of apo(a) to the alphaC-fragment was minimal. These results indicate that the alphaC-domains contain novel high affinity apo(a)-binding sites that may provide a Lys-independent mechanism for bringing Lp(a) to places of fibrin deposition such as injured vessels or atherosclerotic lesions.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Rockville, MD 20855 USA; CHU Bichat, INSERM, U460, F-75877 Paris 18, France	American Red Cross; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Medved, L (corresponding author), Amer Red Cross, Jerome H Holland Lab Biomed Sci, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.		Ho-Tin-Noé, Benoit/U-8059-2018; ANGLES-CANO, Eduardo/G-2311-2012; ANGLES-CANO, Eduardo/ABA-1739-2020	Ho-Tin-Noé, Benoit/0000-0002-7428-1760; ANGLES-CANO, Eduardo/0000-0001-7891-3975; ANGLES-CANO, Eduardo/0000-0001-7891-3975; Medved, Leonid/0000-0002-3665-9849	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056051] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56051, R01 HL056051] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angles-Cano E, 1999, J LIPID RES, V40, P354; Angles-Cano E, 2001, ANN NY ACAD SCI, V936, P261; BAS LC, 1992, THROMB HAEMOSTASIS, V68, P185; BINI A, 1995, ANN NY ACAD SCI, V748, P461; Boonmark NW, 1997, J CLIN INVEST, V100, P558, DOI 10.1172/JCI119565; BROWN MS, 1987, NATURE, V330, P113, DOI 10.1038/330113a0; Danesh J, 2000, CIRCULATION, V102, P1082, DOI 10.1161/01.CIR.102.10.1082; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Dominguez M, 2001, BBA-PROTEIN STRUCT M, V1548, P72, DOI 10.1016/S0167-4838(01)00215-1; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; ELLIS V, 1993, J BIOL CHEM, V268, P4806; Fan JL, 2001, ARTERIOSCL THROM VAS, V21, P88, DOI 10.1161/01.ATV.21.1.88; Gorgani NN, 1999, J BIOL CHEM, V274, P29633, DOI 10.1074/jbc.274.42.29633; GUEVARA J, 1993, ARTERIOSCLER THROMB, V13, P758, DOI 10.1161/01.ATV.13.5.758; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; Henschen A., 1986, BLOOD COAGULATION, V171, P241; HERVIO L, 1995, BIOCHEMISTRY-US, V34, P13353, DOI 10.1021/bi00041a011; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; HUBY T, 1995, BIOCHEMISTRY-US, V34, P7385, DOI 10.1021/bi00022a011; Ichikawa T, 2002, AM J PATHOL, V160, P227, DOI 10.1016/S0002-9440(10)64366-0; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Kang C, 2002, ARTERIOSCL THROM VAS, V22, P1232, DOI 10.1161/01.ATV.0000021144.87870.C8; Klezovitch O, 1996, ARTERIOSCL THROM VAS, V16, P392, DOI 10.1161/01.ATV.16.3.392; Klezovitch O, 1996, J CLIN INVEST, V98, P185, DOI 10.1172/JCI118765; Klose R, 2000, J BIOL CHEM, V275, P38206, DOI 10.1074/jbc.M003640200; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; Lawn RM, 1996, J BIOL CHEM, V271, P31367, DOI 10.1074/jbc.271.49.31367; Lishko VK, 2002, BIOCHEMISTRY-US, V41, P12942, DOI 10.1021/bi026324c; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; Lou XJ, 1998, P NATL ACAD SCI USA, V95, P12591, DOI 10.1073/pnas.95.21.12591; Makogonenko E, 2002, BIOCHEMISTRY-US, V41, P7907, DOI 10.1021/bi025770x; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; Medved L, 2003, THROMB HAEMOSTASIS, V89, P409; Medved L, 1997, BIOCHEMISTRY-US, V36, P4685, DOI 10.1021/bi962795l; Medved L, 2001, ANN NY ACAD SCI, V936, P185; Moskowitz KA, 1998, THROMB HAEMOSTASIS, V79, P824, DOI 10.1055/s-0037-1615072; Nieuwenhuizen W, 2001, ANN NY ACAD SCI, V936, P237; PRIVALOV PL, 1982, J MOL BIOL, V159, P665, DOI 10.1016/0022-2836(82)90107-3; ROUY D, 1992, BIOCHEMISTRY-US, V31, P6333, DOI 10.1021/bi00142a024; ROUY D, 1992, ARTERIOSCLER THROMB, V12, P146, DOI 10.1161/01.ATV.12.2.146; Sangrar W, 2000, BIOCHEM CELL BIOL, V78, P519, DOI 10.1139/bcb-78-4-519; Schuck P, 1996, TRENDS BIOCHEM SCI, V21, P458, DOI 10.1016/S0968-0004(96)20025-8; SHIBA E, 1991, AM PHYSL SOC, V260, P965; Sun HJ, 2002, J BIOL CHEM, V277, P47486, DOI 10.1074/jbc.M205814200; Tsurupa G, 2002, BIOCHEMISTRY-US, V41, P6449, DOI 10.1021/bi025584r; Tsurupa G, 2001, BIOCHEMISTRY-US, V40, P801, DOI 10.1021/bi001789t; VERHEIJEN JH, 1982, THROMB RES, V27, P377, DOI 10.1016/0049-3848(82)90055-X; Weisel JW, 2001, ANN NY ACAD SCI, V936, P312; WIMAN B, 1978, NATURE, V272, P549, DOI 10.1038/272549a0; WIMAN B, 1977, THROMB RES, V10, P213, DOI 10.1016/0049-3848(77)90003-2; Xue S, 2001, THROMB HAEMOSTASIS, V86, P1229, DOI 10.1055/s-0037-1616056	53	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37154	37159		10.1074/jbc.M305154200	http://dx.doi.org/10.1074/jbc.M305154200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12853452	hybrid			2022-12-25	WOS:000185437200022
J	Fang, M; Tao, YX; He, FH; Zhang, MJ; Levine, CF; Mao, PZ; Tao, F; Chou, CL; Sadegh-Nasseri, S; Johns, RA				Fang, M; Tao, YX; He, FH; Zhang, MJ; Levine, CF; Mao, PZ; Tao, F; Chou, CL; Sadegh-Nasseri, S; Johns, RA			Synaptic PDZ domain-mediated protein interactions are disrupted by inhalational anesthetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR SUBUNITS; LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; GENERAL-ANESTHETICS; VOLATILE ANESTHETICS; NEUROPATHIC PAIN; ACID RECEPTOR; BINDING; HALOTHANE; PSD-95	Anesthetics exert multiple effects on the central nervous system through altering synaptic transmission, but the mechanisms for this process are poorly understood. PDZ domain-mediated protein interactions play a central role in organizing signaling complexes around synaptic receptors for efficient signal transduction. We report here that clinically relevant concentrations of inhalational anesthetics dose-dependently and specifically inhibit the PDZ domain-mediated protein interaction between PSD-95 or PSD-93 and the N-methyl-D-aspartate receptor or neuronal nitric-oxide synthase. These inhibitory effects are immediate, potent, and reversible and occur at a hydrophobic peptide-binding groove on the surface of the second PDZ domain of PSD-95 in a manner relevant to anesthetic action. These findings reveal the PDZ domain as a new molecular target for inhalational anesthetics.	Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Johns Hopkins University; Johns Hopkins University; Hong Kong University of Science & Technology	Johns, RA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Ross 361,720 Rutland Ave, Baltimore, MD 21205 USA.	Rajohns@jhmi.edu	Tao, Feng/Q-7827-2016; He, Fahu/I-9060-2012; He, Fahu/N-1442-2014	Tao, Feng/0000-0002-0623-6298; Sadegh-Nasseri, Scheherazade/0000-0002-8127-1720; Zhang, Mingjie/0000-0001-9404-0190	NIGMS NIH HHS [GM49111] Funding Source: Medline; NINDS NIH HHS [NS 44219] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044219] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; ALLOTT PR, 1971, BRIT J ANAESTH, V43, P913, DOI 10.1093/bja/43.10.913; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Cheng G, 2000, ANESTHESIOLOGY, V93, P1075, DOI 10.1097/00000542-200010000-00032; Chou CL, 2000, J EXP MED, V192, P1697, DOI 10.1084/jem.192.12.1697; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; COHEN NA, 2000, NEURON, V17, P739; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DANIELS S, 1993, BRIT J ANAESTH, V71, P59, DOI 10.1093/bja/71.1.59; de Sousa SLM, 2000, ANESTHESIOLOGY, V92, P1055, DOI 10.1097/00000542-200004000-00024; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Eckenhoff MF, 1998, J PHARMACOL EXP THER, V285, P371; Eckenhoff R G, 2001, Mol Interv, V1, P258; Eckenhoff RG, 1997, PHARMACOL REV, V49, P343; ELMAGHRABI EA, 1992, P NATL ACAD SCI USA, V89, P4329, DOI 10.1073/pnas.89.10.4329; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; Jenkins A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-06-j0002.2001; Johansson JS, 2000, BIOPHYS J, V78, P982, DOI 10.1016/S0006-3495(00)76656-2; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kudo M, 2001, ANESTHESIOLOGY, V95, P756, DOI 10.1097/00000542-200109000-00031; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Miller KW, 2002, BRIT J ANAESTH, V89, P17, DOI 10.1093/bja/aef167; Ming Z, 2002, ANESTHESIOLOGY, V97, P856, DOI 10.1097/00000542-200210000-00017; NELSON RJ, 1995, NATURE, V378, P383, DOI 10.1038/378383a0; Niethammer M, 1996, J NEUROSCI, V16, P2157; Nishikawa K, 2000, ANESTHESIOLOGY, V92, P228, DOI 10.1097/00000542-200001000-00035; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Roche KW, 1999, J NEUROSCI, V19, P3926; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; Tao F, 2003, NEUROSCIENCE, V117, P731, DOI 10.1016/S0306-4522(02)00801-1; Tao F, 2001, NEUROREPORT, V12, P3251, DOI 10.1097/00001756-200110290-00022; Tao YX, 2000, NEUROSCIENCE, V98, P201, DOI 10.1016/S0306-4522(00)00193-7; Tao YX, 2001, ANESTHESIOLOGY, V94, P1010, DOI 10.1097/00000542-200106000-00015; Tochio H, 2000, J MOL BIOL, V303, P359, DOI 10.1006/jmbi.2000.4148; Tochio H, 2000, J MOL BIOL, V295, P225, DOI 10.1006/jmbi.1999.3350; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WAKAMORI M, 1991, J NEUROPHYSIOL, V66, P2014, DOI 10.1152/jn.1991.66.6.2014; Woodward JJ, 2000, CRIT REV NEUROBIOL, V14, P69; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545	60	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36669	36675		10.1074/jbc.M303520200	http://dx.doi.org/10.1074/jbc.M303520200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12853458	hybrid			2022-12-25	WOS:000185318300098
J	Shanmugam, N; Kim, YS; Lanting, L; Natarajan, R				Shanmugam, N; Kim, YS; Lanting, L; Natarajan, R			Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BINDING-PROTEIN-BETA; GENE-EXPRESSION; NITRIC-OXIDE; INSULIN-SECRETION; NUCLEAR-FACTOR; MESSENGER-RNA; GLUCOSE; ACTIVATION; INDUCTION	Cyclooxygenase-2 (COX-2) enzyme and its inflammatory products such as prostaglandin E-2 (PGE(2)) have been implicated in the pathogenesis of several inflammatory diseases. However their role in diabetic vascular disease is unclear. Advanced glycation end products (AGEs) act via their receptor, RAGE, to play a major role in diabetic complications. In this study, we investigated the effect of AGEs and S100b, a specific RAGE ligand, on the expression of COX-2 and the molecular mechanisms involved in cultured THP-1 monocytes and human peripheral blood monocytes. S100b treatment of THP-1 cells led to a significant 3-5-fold induction of COX-2 mRNA ( p < 0.001). COX-2 protein and its product PGE(2) were also increased, whereas COX-1 expression was unaffected. In vitro prepared AGE also induced COX-2 mRNA. S100b-induced COX-2 mRNA was blocked by an anti-RAGE antibody and by inhibitors of NF-kappa B ( Bay11-7082), oxidant stress, protein kinase C, ERK, and p38 MAPKs. S100b (4-h treatment) significantly increased transcription from a human COX-2 promoter-luciferase construct (4-fold, p < 0.001). Promoter deletion analyses and inhibition of transcription by an NF-kappaB superrepressor mutant confirmed NF-kappaB involvement. This was further supported by inhibition of S100b-induced PGE(2) by Bay11-7082. Additionally, S100b-induced adherence of THP-1 monocytes to vascular smooth muscle cells was blocked by the COX-2 inhibitor NS-398, Bay11-7082, inhibitors of ERK and p38 MAPK, and protein kinase C thereby indicating functional relevance. S100b also increased COX-2 mRNA expression in human peripheral blood monocytes from healthy donors. Moreover, COX-2 mRNA levels were clearly evident in monocytes obtained from diabetic patients but not from normal subjects. These results show for the first time that AGEs can augment inflammatory responses by up-regulating COX-2 via RAGE and multiple signaling pathways, thereby leading to monocyte activation and vascular cell dysfunction.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Diabet, Gonda Diabet Res Ctr, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Natarajan, R (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Diabet, Gonda Diabet Res Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA.	rnatarajan@coh.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065073] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL55798] Funding Source: Medline; NIDDK NIH HHS [R01 DK065073, R01DK65073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Bucciarelli LG, 2002, CIRCULATION, V106, P2827, DOI 10.1161/01.CIR.0000039325.03698.36; Burleigh ME, 2002, CIRCULATION, V105, P1816, DOI 10.1161/01.CIR.0000014927.74465.7F; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Cho YH, 2003, MOL PHARMACOL, V63, P512, DOI 10.1124/mol.63.3.512; COHEN RA, 1995, PROG CARDIOVASC DIS, V38, P105, DOI 10.1016/S0033-0620(05)80002-7; Cosentino F, 2003, CIRCULATION, V107, P1017, DOI 10.1161/01.CIR.0000051367.92927.07; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; Fitzgerald GA, 2002, AM J CARDIOL, V89, p26D; Freshwater JD, 2002, DIABETES, V51, P2249, DOI 10.2337/diabetes.51.7.2249; FU JY, 1990, J BIOL CHEM, V265, P16737; Guha M, 2000, J BIOL CHEM, V275, P17728, DOI 10.1074/jbc.275.23.17728; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1993, ANN NY ACAD SCI, V696, P197; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Huang JS, 1999, BIOCHEM J, V342, P231, DOI 10.1042/0264-6021:3420231; Jabbour HN, 2002, PROSTAG LEUKOTR ESS, V67, P357, DOI 10.1054/plef.2002.0442; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; Kwon G, 1998, DIABETES, V47, P583, DOI 10.2337/diabetes.47.4.583; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Lee SH, 2000, LIFE SCI, V68, P57, DOI 10.1016/S0024-3205(00)00920-6; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Maedler K, 2002, J CLIN INVEST, V110, P851, DOI 10.1172/JCI200215318; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; McDaniel ML, 1996, P SOC EXP BIOL MED, V211, P24; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; METZ SA, 1981, DIABETES, V30, P551, DOI 10.2337/diabetes.30.7.551; MOROHOSHI M, 1995, ANN NY ACAD SCI, V748, P562; Nakao S, 2002, MOL CELL BIOCHEM, V238, P11, DOI 10.1023/A:1019927616000; NATARAJAN R, 1993, P NATL ACAD SCI USA, V90, P4947, DOI 10.1073/pnas.90.11.4947; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Pontsler AV, 2002, J BIOL CHEM, V277, P13029, DOI 10.1074/jbc.M109546200; Pratico D, 2001, P NATL ACAD SCI USA, V98, P3358, DOI 10.1073/pnas.061607398; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Robertson RP, 1998, DIABETES, V47, P1379, DOI 10.2337/diabetes.47.9.1379; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; Schonbeck U, 1999, AM J PATHOL, V155, P1281, DOI 10.1016/S0002-9440(10)65230-3; Shanmugam N, 2003, DIABETES, V52, P1256, DOI 10.2337/diabetes.52.5.1256; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Singh B, 2002, J SURG RES, V108, P173, DOI 10.1006/jsre.2002.6532; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Tabatabaie T, 2000, BIOCHEM BIOPH RES CO, V273, P699, DOI 10.1006/bbrc.2000.2959; Tamura M, 2002, J CLIN ENDOCR METAB, V87, P3263, DOI 10.1210/jc.87.7.3263; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tran POT, 1999, J BIOL CHEM, V274, P31245, DOI 10.1074/jbc.274.44.31245; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Vlassara H, 2001, DIABETES-METAB RES, V17, P436, DOI 10.1002/dmrr.233; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; Wadleigh DJ, 1999, BIOCHEM BIOPH RES CO, V264, P865, DOI 10.1006/bbrc.1999.1606; Wang CY, 2002, BIOCHEM PHARMACOL, V64, P177, DOI 10.1016/S0006-2952(02)01106-1; Westwood ME, 1996, IMMUNOL LETT, V50, P17, DOI 10.1016/0165-2478(96)02496-0; Yang XH, 1997, BBA-GENE STRUCT EXPR, V1350, P287, DOI 10.1016/S0167-4781(96)00225-4	60	151	155	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34834	34844		10.1074/jbc.M302828200	http://dx.doi.org/10.1074/jbc.M302828200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12837757	hybrid			2022-12-25	WOS:000185164400014
J	Tahtaoui, C; Balestre, MN; Klotz, P; Rognan, D; Barberis, C; Mouillac, B; Hibert, M				Tahtaoui, C; Balestre, MN; Klotz, P; Rognan, D; Barberis, C; Mouillac, B; Hibert, M			Identification of the binding sites of the SR49059 nonpeptide antagonist into the V-1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OXYTOCIN RECEPTOR; AROMATIC RESIDUES; AGONIST; PEPTIDE; V1A; DOMAINS; HYPERTENSION; EXPRESSION; BUTYRATE; DOCKING	To identify the binding site of the human V-1a vasopressin receptor for the selective nonpeptide antagonist SR49059, we have developed a site-directed irreversible labeling strategy that combines mutagenesis of the receptor and use of sulfydryl-reactive ligands. Based on a three-dimensional model of the antagonist docked into the receptor, hypothetical ligand-receptor interactions were investigated by replacing the residues potentially involved in the binding of the antagonist into cysteines and designing analogues of SR49059 derivatized with isothiocyanate or alpha-chloroacetamide moieties. The F225C, F308C, and K128C mutants of the V-1a receptor were expressed in COS-7 or Chinese hamster ovary cells, and their pharmacological properties toward SR49059 and its sulfydryl-reactive analogues were analyzed. We demonstrated that treatment of the F225C mutant with the isothiocyanate-derivative compound led to dose-dependent inhibition of the residual binding of the radiolabeled antagonist [I-125]HO-LVA. This inhibition is probably the consequence of a covalent irreversible chemical modification, which is only possible when close contacts and optimal orientations exist between reactive groups created both on the ligand and the receptor. This result validated the three-dimensional model hypothesis. Thus, we propose that residue Phe(225), located in transmembrane domain V, directly participates in the binding of the V-1a-selective nonpeptide antagonist SR49059. This conclusion is in complete agreement with all our previous data on the definition of the agonist/antagonist binding to members of the oxytocin/vasopressin receptor family.	CNRS, Fac Pharm Strasbourg, UMR 7081, Lab Pharmacochim Commun Cellulaire, F-67401 Illkirch Graffenstaden, France; INSERM, U469, F-34094 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Hibert, M (corresponding author), CNRS, Fac Pharm Strasbourg, UMR 7081, Lab Pharmacochim Commun Cellulaire, 74 Route Rhin,BP 24, F-67401 Illkirch Graffenstaden, France.	mhibert@pharma.u-strasbg.fr	Rognan, Didier/B-9939-2014; MOUILLAC, Bernard/M-3896-2014	MOUILLAC, Bernard/0000-0002-3906-8673				Attwood TK, 2001, TRENDS PHARMACOL SCI, V22, P162, DOI 10.1016/S0165-6147(00)01658-8; BARBERIS C, 1995, NEUROENDOCRINOLOGY, V62, P135, DOI 10.1159/000126998; Breton C, 2001, J BIOL CHEM, V276, P26931, DOI 10.1074/jbc.M102073200; Brouard R, 1998, ADV EXP MED BIOL, V449, P455; BURRELL LM, 1994, HYPERTENSION, V23, P737, DOI 10.1161/01.HYP.23.6.737; CASE DA, 1997, AMBER 5 0 COMPUTER P; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; Chini B, 1996, FEBS LETT, V397, P201, DOI 10.1016/S0014-5793(96)01135-0; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Cotte N, 2000, EUR J BIOCHEM, V267, P4253, DOI 10.1046/j.1432-1033.2000.01472.x; COWLEY AW, 1982, INT REV PHYSIOL, V26, P189; Foucaud B, 2001, TRENDS PHARMACOL SCI, V22, P170, DOI 10.1016/S0165-6147(00)01674-6; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gieldon A, 2001, J COMPUT AID MOL DES, V15, P1085, DOI 10.1023/A:1015905822671; GOLDSMITH SR, 1987, AM J MED, V82, P1213, DOI 10.1016/0002-9343(87)90228-2; Hawtin SR, 2002, MOL ENDOCRINOL, V16, P600, DOI 10.1210/me.16.3.600; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Hibert M, 1999, J RECEPT SIGNAL TR R, V19, P589, DOI 10.3109/10799899909036674; JARD S, 1988, INT CONGR SER, V799, P1183; JOHNSTON CI, 1985, J HYPERTENS, V3, P557, DOI 10.1097/00004872-198512000-00001; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; KASSIS S, 1984, J BIOL CHEM, V259, P4910; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Malta Di, 1995, [No title captured], Patent No. [EP 0636608, 0636608]; Marjamaki A, 1998, MOL PHARMACOL, V53, P370, DOI 10.1124/mol.53.3.370; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OKADA H, 1994, AM J PHYSIOL-REG I, V267, pR1467, DOI 10.1152/ajpregu.1994.267.6.R1467; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Park C, 1996, BIOCHEMISTRY-US, V35, P9807, DOI 10.1021/bi9602223; Perret P, 1999, J BIOL CHEM, V274, P25350, DOI 10.1074/jbc.274.36.25350; Phalipou S, 1999, J BIOL CHEM, V274, P23316, DOI 10.1074/jbc.274.33.23316; Phalipou S, 1997, J BIOL CHEM, V272, P26536, DOI 10.1074/jbc.272.42.26536; Rognan D, 2001, J COMPUT AID MOL DES, V15, P103, DOI 10.1023/A:1008145813315; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; SHARE L, 1988, PHYSIOL REV, V68, P1248, DOI 10.1152/physrev.1988.68.4.1248; SLADEK CD, 1988, HYPERTENSION, V12, P506, DOI 10.1161/01.HYP.12.5.506; STRADER CD, 1987, J BIOL CHEM, V262, P16439; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; Thibonnier M, 2000, J PHARMACOL EXP THER, V294, P195; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Weber R, 1997, HYPERTENSION, V30, P1121, DOI 10.1161/01.HYP.30.5.1121; YAMAMURA Y, 1991, SCIENCE, V252, P572, DOI 10.1126/science.1850553; Yatsu T, 1997, EUR J PHARMACOL, V321, P225, DOI 10.1016/S0014-2999(96)00940-5	47	46	46	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40010	40019		10.1074/jbc.M301128200	http://dx.doi.org/10.1074/jbc.M301128200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869559	hybrid			2022-12-25	WOS:000185713800090
J	Honnappa, S; Cutting, B; Jahnke, W; Seelig, J; Steinmetz, MO				Honnappa, S; Cutting, B; Jahnke, W; Seelig, J; Steinmetz, MO			Thermodynamics of the Op18/stathmin-tubulin interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-REGULATING ACTIVITIES; TERNARY COMPLEX; TUBULIN; STATHMIN; PHOSPHORYLATION; DYNAMICS; PROTEIN; BINDING; FAMILY; PHOSPHOPROTEIN	Op18/stathmin (stathmin) is an intrinsically disordered protein involved in the regulation of the microtubule filament system. One function of stathmin is to sequester tubulin dimers into assembly incompetent complexes, and recent studies revealed two tubulin binding sites per stathmin molecule. Using high sensitivity isothermal titration calorimetry, we document that at 10 degreesC and under the conditions of 80 mM PIPES, pH 6.8, 1 mM EGTA, 1 mM MgCl2, 1 mM GTP these two binding sites are of equal affinity with an equilibrium binding constant of K-0 = 6.0 x 10(6) M-1. The obtained large negative molar heat capacity change of DeltaC(p)(0) = -860 cal mol(-1) K-1 (referring to tubulin) for the tubulin-stathmin binding equilibrium suggests that the hydrophobic effect is the major driving force of the binding reaction. Replacing GTP by GDP on beta-tubulin had no significant effect on the thermodynamic parameters of the tubulin-stathmin binding equilibrium. The proposed pH-sensitive dual function of stathmin was further evaluated by circular dichroism spectroscopy and nuclear magnetic resonance. At low temperatures, stathmin was found to be extensively helical but devoid of any stable tertiary structure. However, in complex with two tubulin subunits stathmin adopts a stable conformation. Both the stability and conformation of the individual proteins and complexes were not significantly affected by small changes in pH. A 4-fold decrease in affinity of stathmin for tubulin was revealed at pH 7.5 compared with pH 6.8. This decrease could be attributed to a weaker binding of the C terminus of stathmin. These findings do not support the view that stathmin works as a pH-sensitive protein.	Paul Scherrer Inst, CH-5232 Villigen, Switzerland; Novartis Pharma AG, Cent Technol, CH-4002 Basel, Switzerland; Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Novartis; University of Basel	Steinmetz, MO (corresponding author), Paul Scherrer Inst, CH-5232 Villigen, Switzerland.		Steinmetz, Michel O/AAA-3349-2022	Steinmetz, Michel O/0000-0001-6157-3687				Amayed P, 2000, BIOCHEMISTRY-US, V39, P12295, DOI 10.1021/bi000279w; Amayed P, 2002, J BIOL CHEM, V277, P22718, DOI 10.1074/jbc.M111605200; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Arnal I, 2000, J CELL BIOL, V149, P767, DOI 10.1083/jcb.149.4.767; Baker BM, 1998, METHOD ENZYMOL, V295, P294; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; Brannstrom K, 2003, J BIOL CHEM, V278, P16651, DOI 10.1074/jbc.M300131200; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; Cantor C. R., 1980, PART CONFORMATION BI, P279; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Charbaut E, 2001, J BIOL CHEM, V276, P16146, DOI 10.1074/jbc.M010637200; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DOYE V, 1990, J BIOL CHEM, V265, P11650; FOWLER WE, 1983, J ULTRA MOL STRUCT R, V83, P319, DOI 10.1016/S0022-5320(83)90139-9; Gavet O, 1998, J CELL SCI, V111, P3333; Gigant B, 2000, CELL, V102, P809, DOI 10.1016/S0092-8674(00)00069-6; Holmfeldt P, 2001, MOL BIOL CELL, V12, P73, DOI 10.1091/mbc.12.1.73; HOWARD WD, 1986, BIOCHEMISTRY-US, V25, P8292, DOI 10.1021/bi00373a025; Howell B, 1999, J CELL SCI, V112, P3713; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Larsson NL, 1999, MOL CELL BIOL, V19, P2242; Lawler S, 1998, CURR BIOL, V8, pR212, DOI 10.1016/S0960-9822(98)70128-9; MAUCUER A, 1990, FEBS LETT, V264, P275, DOI 10.1016/0014-5793(90)80266-L; Melhem R, 1997, LEUKEMIA, V11, P1690, DOI 10.1038/sj.leu.2400792; Meurer-Grob P, 2001, BIOCHEMISTRY-US, V40, P8000, DOI 10.1021/bi010343p; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Muller DR, 2001, ANAL CHEM, V73, P1927, DOI 10.1021/ac001379a; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Ozon S, 2002, MOL BIOL CELL, V13, P698, DOI 10.1091/mbc.01-07-0362; Redeker V, 2000, J BIOL CHEM, V275, P6841, DOI 10.1074/jbc.275.10.6841; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; Seelig J, 1997, BBA-REV BIOMEMBRANES, V1331, P103, DOI 10.1016/S0304-4157(97)00002-6; Segerman B, 2000, J BIOL CHEM, V275, P35759, DOI 10.1074/jbc.M005875200; Segerman B, 2003, J CELL SCI, V116, P197, DOI 10.1242/jcs.00205; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Steinmetz MO, 2000, EMBO J, V19, P572, DOI 10.1093/emboj/19.4.572; Steinmetz MO, 2001, EMBO REP, V2, P505, DOI 10.1093/embo-reports/kve105; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; VANHOLDE KE, 1998, PRINCIPLES PHYSICAL; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; Wallon G, 2000, EMBO J, V19, P213, DOI 10.1093/emboj/19.2.213; Wiltscheck R, 1997, PROTEIN SCI, V6, P1734, DOI 10.1002/pro.5560060814; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110	48	40	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38926	38934		10.1074/jbc.M305546200	http://dx.doi.org/10.1074/jbc.M305546200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12860982	hybrid, Green Published			2022-12-25	WOS:000185575100102
J	Reinelt, S; Hofmann, E; Gerharz, T; Bott, M; Madden, DR				Reinelt, S; Hofmann, E; Gerharz, T; Bott, M; Madden, DR			The structure of the periplasmic ligand-binding domain of the sensor kinase CitA reveals the first extracellular PAS domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC CITRATE METABOLISM; PLANT PHOTORECEPTOR DOMAIN; CRYSTAL-STRUCTURE; TRANSPORT-SYSTEM; DIFFRACTION DATA; PROTEIN; MECHANISM; RECEPTOR; OXYGEN; CRYSTALLIZATION	The integral membrane sensor kinase CitA of Klebsiella pneumoniae is part of a two-component signal transduction system that regulates the transport and metabolism of citrate in response to its environmental concentration. Two-component systems are widely used by bacteria for such adaptive processes, but the stereochemistry of periplasmic ligand binding and the mechanism of signal transduction across the membrane remain poorly understood. The crystal structure of the CitAP periplasmic sensor domain in complex with citrate reveals a PAS fold, a versatile ligand-binding structural motif that has not previously been observed outside the cytoplasm or implicated in the transduction of conformational signals across the membrane. Citrate is bound in a pocket that is shared among many PAS domains but that shows structural variation according to the nature of the bound ligand. In CitAP, some of the citrate contact residues are located in the final strand of the central beta-sheet, which is connected to the C-terminal transmembrane helix. These secondary structure elements thus provide a potential conformational link between the periplasmic ligand binding site and the cytoplasmic signaling domains of the receptor.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Max Planck Inst Med Res, Ion Channel Struct Grp, D-69120 Heidelberg, Germany; Ruhr Univ Bochum, Lehrstuhl Biophys, D-44780 Bochum, Germany; Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany	Dartmouth College; Max Planck Society; Ruhr University Bochum; Helmholtz Association; Research Center Julich	Madden, DR (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	dean.madden@dartmouth.edu	Hofmann, Eckhard/GPF-5024-2022; Bott, Michael/E-8004-2011	Bott, Michael/0000-0002-4701-8254; Hofmann, Eckhard/0000-0003-4874-372X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amezcua CA, 2002, STRUCTURE, V10, P1349, DOI 10.1016/S0969-2126(02)00857-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bott M, 1997, ARCH MICROBIOL, V167, P78, DOI 10.1007/s002030050419; BOTT M, 1995, MOL MICROBIOL, V18, P533, DOI 10.1111/j.1365-2958.1995.mmi_18030533.x; BRESE NE, 1991, ACTA CRYSTALLOGR B, V47, P192, DOI 10.1107/S0108768190011041; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; CEDERGRENZEPPEZAUER ES, 1994, J MOL BIOL, V240, P459, DOI 10.1006/jmbi.1994.1461; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; Crosson S, 2003, BIOCHEMISTRY-US, V42, P2, DOI 10.1021/bi026978l; Crosson S, 2002, PLANT CELL, V14, P1067, DOI 10.1105/tpc.010475; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Falke JJ, 2002, P NATL ACAD SCI USA, V99, P6530, DOI 10.1073/pnas.112214199; Fedorov R, 2003, BIOPHYS J, V84, P2474, DOI 10.1016/S0006-3495(03)75052-8; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Gerharz T, 2003, BIOCHEMISTRY-US, V42, P5917, DOI 10.1021/bi0340595; Gili P, 1999, INORG CHIM ACTA, V295, P106, DOI 10.1016/S0020-1693(99)00329-1; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HARLE C, 1995, EMBO J, V14, P1430, DOI 10.1002/j.1460-2075.1995.tb07129.x; Harrison DHT, 1997, BIOCHEMISTRY-US, V36, P16134, DOI 10.1021/bi9717136; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kaspar S, 1999, MOL MICROBIOL, V33, P858, DOI 10.1046/j.1365-2958.1999.01536.x; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Lin AP, 2001, BIOCHEMISTRY-US, V40, P14291, DOI 10.1021/bi0111707; Lloyd SJ, 1999, PROTEIN SCI, V8, P2655, DOI 10.1110/ps.8.12.2655; Luft JR, 2001, J CRYST GROWTH, V232, P591, DOI 10.1016/S0022-0248(01)01206-4; Mayer SM, 2002, J BIOL CHEM, V277, P35263, DOI 10.1074/jbc.M205888200; Meller J, 2001, PROTEINS, V45, P241, DOI 10.1002/prot.1145; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Parac TN, 2001, J BIOMOL NMR, V19, P91, DOI 10.1023/A:1008301425100; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Regelmann AG, 2002, J BACTERIOL, V184, P5468, DOI 10.1128/JB.184.19.5468-5478.2002; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; Robinson VL, 2000, NAT STRUCT BIOL, V7, P626, DOI 10.1038/77915; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; VANDERREST ME, 1992, J BIOL CHEM, V267, P8971; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Vannini A, 2002, EMBO J, V21, P4393, DOI 10.1093/emboj/cdf459; Vreede J, 2003, J BIOL CHEM, V278, P18434, DOI 10.1074/jbc.M301701200; Waldburger CD, 1996, J BIOL CHEM, V271, P26630, DOI 10.1074/jbc.271.43.26630; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yamamoto H, 2000, MOL MICROBIOL, V37, P898, DOI 10.1046/j.1365-2958.2000.02055.x; Zhang RG, 2002, J BIOL CHEM, V277, P19183, DOI 10.1074/jbc.M112171200; Zhou ZH, 2000, INORG CHEM, V39, P59, DOI 10.1021/ic990042s; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	57	122	124	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39189	39196		10.1074/jbc.M305864200	http://dx.doi.org/10.1074/jbc.M305864200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12867417	Green Published, hybrid			2022-12-25	WOS:000185575100133
J	Harris, CL; Hughes, CE; Williams, AS; Goodfellow, I; Evans, DJ; Caterson, B; Morgan, BP				Harris, CL; Hughes, CE; Williams, AS; Goodfellow, I; Evans, DJ; Caterson, B; Morgan, BP			Generation of anti-complement "prodrugs" - Cleavable reagents for specific delivery of complement regulators to disease sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE CLEAVAGE; INTERGLOBULAR DOMAIN; SYNOVIAL-FLUID; CARTILAGE PROTEOGLYCAN; SEGMENTAL FLEXIBILITY; MONOCLONAL-ANTIBODIES; RHEUMATOID-ARTHRITIS; RECOMBINANT AGGRECAN; CHIMERIC HUMAN; CATABOLISM	Expression of biologically active molecules as fusion proteins with antibody Fc can substantially extend the plasma half-life of the active agent but may also influence function. We have previously generated a number of fusion proteins comprising a complement regulator coupled to Fc and shown that the hybrid molecule has a long plasma half-life and retains biological activity. However, several of the fusion proteins generated had substantially reduced biological activity when compared with the native regulator or regulator released from the Fc following papain cleavage. We have taken advantage of this finding to engineer a prodrug with low complement regulatory activity that is cleaved at sites of inflammation to release active regulator. Two model prodrugs, comprising, respectively, the four short consensus repeats of human decay accelerating factor (CD55) linked to IgG(4) Fc and the three NH2-terminal short consensus repeats of human decay accelerating factor linked to IgG(2) Fc have been developed. In each, specific cleavage sites for matrix metalloproteinases and/or aggrecanases have been incorporated between the complement regulator and the Fc. These prodrugs have markedly decreased complement inhibitory activity when compared with the parent regulator in vitro. Exposure of the prodrugs to the relevant enzymes, either purified, or in supernatants of cytokine-stimulated chondrocytes or in synovial fluid, efficiently cleaved the prodrug, releasing active regulator. Such agents, having negligible systemic effects but active at sites of inflammation, represent a paradigm for the next generation of anti-C therapeutics.	Cardiff Univ, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales; Cardiff Univ, Dept Rheumatol, Cardiff CF14 4XN, S Glam, Wales; Cardiff Univ, Cardiff Sch Biosci, Connect Tissue Biol Labs, Cardiff CF10 3US, S Glam, Wales; Univ Glasgow, Fac Biomed & Life Sci, Div Virol, Glasgow G11 5JR, Lanark, Scotland	Cardiff University; Cardiff University; Cardiff University; University of Glasgow	Harris, CL (corresponding author), Cardiff Univ, Dept Med Biochem & Immunol, Tenovus Bldg,Heath Pk, Cardiff CF14 4XX, S Glam, Wales.	HarrisCL@cardiff.ac.uk	Caterson, Bruce/A-8085-2010; Hughes, Clare E/A-4526-2010; Evans, David/C-7553-2012	Morgan, Paul/0000-0003-4075-7676; Evans, David J./0000-0002-1315-4258; Hughes, Clare/0000-0003-4726-5877; Goodfellow, Ian/0000-0002-9483-510X; Caterson, Bruce/0000-0001-6016-0661				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; BREKKE OH, 1995, IMMUNOL TODAY, V16, P85, DOI 10.1016/0167-5699(95)80094-8; BRODEUR JP, 1991, ARTHRITIS RHEUM, V34, P1531; Buttner FH, 1998, BIOCHEM J, V333, P159, DOI 10.1042/bj3330159; Caterson B, 2000, MATRIX BIOL, V19, P333, DOI 10.1016/S0945-053X(00)00078-0; Caterson B, 1995, ACTA ORTHOP SCAND, V66, P121, DOI 10.3109/17453679509157666; CHARREAU B, 1994, TRANSPLANTATION, V58, P1222, DOI 10.1097/00007890-199412150-00015; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; Daniels GL, 1998, TRANSFUSION, V38, P332, DOI 10.1046/j.1537-2995.1998.38498257370.x; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FOSANG AJ, 1991, MATRIX, V11, P17, DOI 10.1016/S0934-8832(11)80223-4; Goodfellow RM, 2000, CLIN EXP IMMUNOL, V119, P210, DOI 10.1046/j.1365-2249.2000.01129.x; Goodfellow RM, 1997, CLIN EXP IMMUNOL, V110, P45; Harris CL, 2002, BIOCHEM SOC T, V30, P1019, DOI 10.1042/bst0301019; Harris CL, 2002, CLIN EXP IMMUNOL, V129, P198, DOI 10.1046/j.1365-2249.2002.01924.x; Harris CL, 2002, J IMMUNOL METHODS, V268, P245, DOI 10.1016/S0022-1759(02)00207-7; Horber C, 2000, MATRIX BIOL, V19, P533, DOI 10.1016/S0945-053X(00)00113-X; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; Hughes CE, 1997, J BIOL CHEM, V272, P20269, DOI 10.1074/jbc.272.32.20269; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Hughes CE, 1998, J BIOL CHEM, V273, P30576, DOI 10.1074/jbc.273.46.30576; Ishiguro N, 2001, ARTHRITIS RHEUM, V44, P2503, DOI 10.1002/1529-0131(200111)44:11<2503::AID-ART430>3.0.CO;2-P; Lea SM, 1998, J BIOL CHEM, V273, P30443, DOI 10.1074/jbc.273.46.30443; Little CB, 1999, BIOCHEM J, V344, P61, DOI 10.1042/0264-6021:3440061; Little CB, 2002, MATRIX BIOL, V21, P271, DOI 10.1016/S0945-053X(02)00004-5; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Matsuno H, 2001, J RHEUMATOL, V28, P22; Mercuri FA, 2000, J BIOL CHEM, V275, P33038, DOI 10.1074/jbc.275.42.33038; MORGAN BP, 1988, CLIN EXP IMMUNOL, V73, P473; MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366; Morgan BP., 1999, COMPLEMENT REGULATOR; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; NIEDZWIECKI L, 1992, BIOCHEMISTRY-US, V31, P12618, DOI 10.1021/bi00165a011; OLEESKY DA, 1991, CLIN EXP IMMUNOL, V84, P250; Powell RM, 1997, J VIROL, V71, P9306, DOI 10.1128/JVI.71.12.9306-9312.1997; Quigg RJ, 1998, J IMMUNOL, V160, P4553; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Rioux P, 2001, Curr Opin Investig Drugs, V2, P364; TAN LK, 1990, P NATL ACAD SCI USA, V87, P162, DOI 10.1073/pnas.87.1.162; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; van Meurs JBJ, 1999, ARTHRITIS RHEUM, V42, P1128, DOI 10.1002/1529-0131(199906)42:6<1128::AID-ANR9>3.0.CO;2-2	44	22	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36068	36076		10.1074/jbc.M306351200	http://dx.doi.org/10.1074/jbc.M306351200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12842884	Green Accepted, hybrid			2022-12-25	WOS:000185318300026
J	Horton, JD; Shimomura, I; Ikemoto, S; Bashmakov, Y; Hammer, RE				Horton, JD; Shimomura, I; Ikemoto, S; Bashmakov, Y; Hammer, RE			Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEIN; COENZYME-A SYNTHETASE; ACYL-COA SYNTHETASE; TRANSGENIC MICE; DIABETES-MELLITUS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; INSULIN-RESISTANCE; NUCLEAR SREBP-1C; CULTURED-CELLS	Sterol regulatory element-binding proteins (SREBPs) are a family of membrane-bound transcription factors that regulate cholesterol and fatty acid homeostasis. In mammals, three SREBP isoforms designated SREBP-1a, SREBP-1c, and SREBP-2 have been identified. SREBP-1a and SREBP-1c are derived from the same gene by virtue of alternatively spliced first exons. SREBP-1a has a longer transcriptional activation domain and is a more potent transcriptional activator than SREBP-1c in cultured cells and liver. Here, we describe the physiologic consequences of overexpressing the nuclear form of SREBP-1a (nSREBP-1a) in adipocytes of mice using the adipocyte-specific aP2 promoter (aP2-nSREBP-1a). The transgenic aP2-nSREBP-1a mice developed markedly enlarged white and brown adipocytes that were fully differentiated. Adipocytes isolated from aP2-nSREBP-1a mice had significantly increased rates of fatty acid synthesis and enhanced fatty acid secretion. The increased production and release of fatty acids from adipocytes led, in turn, to a fatty liver. Overexpression of the alternative SREBP-1 isoform, nSREBP-1c, in adipose tissue inhibits adipocyte differentiation; as a result, the transgenic nSREBP-1c mice develop a syndrome resembling human lipodystrophy, which includes a loss of peripheral white adipose tissue, diabetes, and fatty livers (Shimomura, I., Hammer, R. E., Richardson, J. A., Ikemoto, S., Bashmakov, Y., Goldstein, J. L., and Brown, M. S. ( 1998) Genes Dev. 12, 3182-3194). In striking contrast, nSREBP-1a overexpression in fat resulted in the hypertrophy of fully differentiated adipocytes, no diabetes, and mild hepatic steatosis. These results suggest that nSREBP-1a and nSREBP-1c have distinct roles in adipocyte fat metabolism in vivo.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hammer, RE (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Robert.hammer@utsouthwestern.edu		Hammer, Robert E./0000-0001-5487-7551; Ikemoto, Shinji/0000-0002-2291-2735	NHLBI NIH HHS [HL-20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; BARTANA J, 1971, BIOCHEM J, V122, P353, DOI 10.1042/bj1220353; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Fajas L, 1999, MOL CELL BIOL, V19, P5495; HOFMANN SL, 1988, SCIENCE, V239, P1277, DOI 10.1126/science.3344433; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Miller CW, 1996, P NATL ACAD SCI USA, V93, P9443, DOI 10.1073/pnas.93.18.9443; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Sambrook J, 2001, MOL CLONING LAB MANU; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1997, P NATL ACAD SCI USA, V94, P12354, DOI 10.1073/pnas.94.23.12354; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	35	159	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36652	36660		10.1074/jbc.M306540200	http://dx.doi.org/10.1074/jbc.M306540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855691	hybrid			2022-12-25	WOS:000185318300096
J	Johanson, K; Hoang, T; Sheth, M; Hyman, LE				Johanson, K; Hoang, T; Sheth, M; Hyman, LE			GRS1, a yeast tRNA synthetase with a role in mRNA 3 ' end formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II; POLY(A) SIGNAL; SACCHAROMYCES-CEREVISIAE; EM VISUALIZATION; TRANSCRIPTION; TERMINATION; PROTEIN; ELONGATION; SEQUENCE; COMPLEX	Transcription termination and 3' end formation are essential processes necessary for gene expression. However, the specific mechanisms responsible for these events remain elusive. A screen designed to identify trans-acting factors involved in these mechanisms in Saccharomyces cerevisiae identified a temperature-sensitive mutant that displayed phenotypes consistent with a role in transcription termination. The complementing gene was identified as GRS1, which encodes the S. cerevisiae glycyl-tRNA synthetase. This result, although unusual, is not unprecedented given that the involvement of tRNA synthetases in a variety of cellular processes other than translation has been well established. A direct role for the synthetase in transcription termination was determined through several in vitro assays using purified wild type and mutant enzyme. First, binding to two well characterized yeast mRNA 3' ends was demonstrated by cross-linking studies. In addition, it was found that all three substrates compete with each other for binding to GlyRS enzyme. Next, the affinity of the synthetase for the two mRNA 3' ends was found to be similar to that of its "natural" substrate, glycine tRNA in a nitrocellulose filter binding assay. The effect of the grs1-1 mutation was also examined and found to significantly reduce the affinity of the enzyme for the three RNA substrates. Taken together, these data indicate that not only does this synthetase interact with several different RNA substrates, but also that these substrates bind to the same site. These results establish a direct role for GRS1 in mRNA 3' end formation.	Tulane Univ, Hlth Sci Ctr, Dept Biochem, New Orleans, LA 70112 USA	Tulane University	Hyman, LE (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Biochem SL43, 1430 Tulane Ave, New Orleans, LA 70112 USA.	lhyman@tulane.edu		Hyman, Linda/0000-0002-2511-2928				Alen C, 2002, MOL CELL, V10, P1441, DOI 10.1016/S1097-2765(02)00778-5; Austin J, 2002, J BIOL CHEM, V277, P14812, DOI 10.1074/jbc.M103396200; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Azad AK, 2001, MOL BIOL CELL, V12, P1381, DOI 10.1091/mbc.12.5.1381; Birse CE, 1998, SCIENCE, V280, P298, DOI 10.1126/science.280.5361.298; CAREY J, 1983, BIOCHEMISTRY-US, V22, P4723, DOI 10.1021/bi00289a017; CHEN S, 1998, THESIS TULANE U NEW; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; Francklyn C, 2002, RNA, V8, P1363, DOI 10.1017/S1355838202021180; GALLIE DR, 1990, GENE DEV, V4, P1149, DOI 10.1101/gad.4.7.1149; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Guthrie C, 1991, GUIDE YEAST GENETICS; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Howe KJ, 2002, BBA-GENE STRUCT EXPR, V1577, P308, DOI 10.1016/S0167-4781(02)00460-8; HYMAN LE, 1991, MOL CELL BIOL, V11, P2004, DOI 10.1128/MCB.11.4.2004; KERN D, 1977, BIOCHIMIE, V59, P453, DOI 10.1016/S0300-9084(77)80050-3; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Komissarova N, 2002, MOL CELL, V10, P1151, DOI 10.1016/S1097-2765(02)00738-4; Lechler A, 1998, J MOL BIOL, V278, P897, DOI 10.1006/jmbi.1998.1744; LOGAN DT, 1995, EMBO J, V14, P4156, DOI 10.1002/j.1460-2075.1995.tb00089.x; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; Magrath C, 1999, GENETICS, V152, P129; MAGRATH C, 1999, THESIS TULANE U NEW; Martinis Susan A., 1999, EMBO (European Molecular Biology Organization) Journal, V18, P4591, DOI 10.1093/emboj/18.17.4591; Miller CA, 1998, NUCLEIC ACIDS RES, V26, P3577, DOI 10.1093/nar/26.15.3577; Morris DP, 1999, J BIOL CHEM, V274, P31583, DOI 10.1074/jbc.274.44.31583; Orozco IJ, 2002, J BIOL CHEM, V277, P42899, DOI 10.1074/jbc.M207415200; Osheim YN, 2002, CHROMOSOMA, V111, P1, DOI 10.1007/s00412-002-0183-7; Osheim YN, 1999, MOL CELL, V3, P379, DOI 10.1016/S1097-2765(00)80465-7; PAN T, 1991, SCIENCE, V254, P1361, DOI 10.1126/science.1720569; Rho SB, 2000, RNA, V6, P1882, DOI 10.1017/S1355838200001254; Sherman F, 1986, LAB COURSE MANUAL ME; TAKAHASHI A, 1994, CANCER RES, V54, P4233; Tran DP, 2001, MOL CELL BIOL, V21, P7495, DOI 10.1128/MCB.21.21.7495-7508.2001; Turner RJ, 2000, J BIOL CHEM, V275, P27681; Voet D, 1999, FUNDAMENTALS BIOCH; YAGER TD, 1987, CELLULAR MOL BIOL, P1241; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	38	11	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35923	35930		10.1074/jbc.M304978200	http://dx.doi.org/10.1074/jbc.M304978200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855679	hybrid			2022-12-25	WOS:000185318300009
J	Mishima, M; Takayama, S; Sasaki, K; Jee, J; Kojima, C; Isogai, A; Shirakawa, M				Mishima, M; Takayama, S; Sasaki, K; Jee, J; Kojima, C; Isogai, A; Shirakawa, M			Structure of the male determinant factor for Brassica self-incompatibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-LOCUS; PROTEIN; POLLEN; RECOGNITION; GENE; GLYCOPROTEINS; HAPLOTYPE; SEQUENCES; ALIGNMENT; BINDING	Many flowering plants possess a self-incompatibility system to prevent inbreeding. In Brassica rapa, self/ non-self recognition in mating is established through S-haplotype-specific interactions between stigma receptors and S-locus protein 11 (SP11, also called S-locus cysteine-rich protein) that is encoded at the highly polymorphic S-locus. Here we describe the solution structure of the SP11 protein of the S-8-haplotype ( S-8-SP11), which specifically binds to the stigma factor of the same haplotype. It folds into an alpha/beta sandwich structure that resembles those of plant defensins. Residues important for structural integrity are highly conserved among the allelic SP11s, suggesting the existence of a common folding pattern. Structure-based sequence alignment and homology modeling of allelic SP11 identified a hypervariable (HV) region, which is thought to form a loop that bulges out from the body of the protein that is amenable to solvent exposure. We suggest that the HV region could serve as a specific binding site for the stigma receptor.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma 6300101, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Div Mol Biophys, Yokohama, Kanagawa 2300045, Japan; RIKEN, Genom Sci Ctr, Kanagawa 2300045, Japan	Nara Institute of Science & Technology; Yokohama City University; RIKEN	Kojima, C (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Ikoma 6300101, Japan.	kojima@bs.aist-nara.ac.jp; shirakawa@tsurumi.yokohama-cu.ac.jp	Kojima, Chojiro/AFV-4592-2022; Swaibu, Ramadhani A/H-3164-2011; Isogai, Akira/O-8897-2017	Isogai, Akira/0000-0001-8095-0441; Kojima, Chojiro/0000-0003-2723-8249				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRUIX M, 1993, BIOCHEMISTRY-US, V32, P715, DOI 10.1021/bi00053a041; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Doughty J, 1998, PLANT CELL, V10, P1333, DOI 10.1105/tpc.10.8.1333; Fant F, 1998, J MOL BIOL, V279, P257, DOI 10.1006/jmbi.1998.1767; GODDARD TD, 1999, SPARKY3; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Iwano M, 2003, PLANT CELL PHYSIOL, V44, P428, DOI 10.1093/pcp/pcg056; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kusaba M, 2001, PLANT CELL, V13, P627, DOI 10.1105/tpc.13.3.627; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; McCubbin AG, 2000, ANNU REV CELL DEV BI, V16, P333, DOI 10.1146/annurev.cellbio.16.1.333; NASRALLAH JB, 1987, NATURE, V326, P617, DOI 10.1038/326617a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schopfer CR, 1999, SCIENCE, V286, P1697, DOI 10.1126/science.286.5445.1697; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4298, DOI 10.1073/pnas.71.11.4298; SHARON J, 1990, P NATL ACAD SCI USA, V87, P4814, DOI 10.1073/pnas.87.12.4814; Shiu S.H., 2001, SCI STKE, pre22; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; Suzuki G, 1997, GENE, V199, P133, DOI 10.1016/S0378-1119(97)00358-2; Suzuki G, 1999, GENETICS, V153, P391; Takasaki T, 2000, NATURE, V403, P913, DOI 10.1038/35002628; Takayama S, 2003, J EXP BOT, V54, P149, DOI 10.1093/jxb/54.380.149; TAKAYAMA S, 1987, NATURE, V326, P102, DOI 10.1038/326102a0; Takayama S, 2000, P NATL ACAD SCI USA, V97, P1920, DOI 10.1073/pnas.040556397; Takayama S, 2002, CURR OPIN PLANT BIOL, V5, P382, DOI 10.1016/S1369-5266(02)00284-4; Takayama S, 2001, NATURE, V413, P534, DOI 10.1038/35097104; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Watanabe M, 2000, FEBS LETT, V473, P139, DOI 10.1016/S0014-5793(00)01514-3; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712	41	44	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36389	36395		10.1074/jbc.M305305200	http://dx.doi.org/10.1074/jbc.M305305200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12835321	hybrid			2022-12-25	WOS:000185318300066
J	Nagahama, M; Hayashi, S; Morimitsu, S; Sakurai, J				Nagahama, M; Hayashi, S; Morimitsu, S; Sakurai, J			Biological activities and pore formation of Clostridium perfringens beta toxin in HL 60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DETERGENT-INSOLUBLE MICRODOMAINS; STAPHYLOCOCCAL ALPHA-HEMOLYSIN; LIPID RAFTS; MEMBRANE; BINDING; FORMS; CHANNEL; ASSOCIATION; MUTAGENESIS; RECEPTORS	Clostridium perfringens beta toxin is an important agent of necrotic enteritis. Of the 10 cell lines tested, only the HL 60 cell line was susceptible to beta toxin. The toxin induced swelling and lysis of the cell. Treatment of the cells with the toxin resulted in K+ efflux from the cells and Ca2+, Na+, and Cl- influxes. These events reached a maximum just before the cells were lysed by the toxin. Incubation of the cells with the toxin showed the formation of toxin complexes of about 191 and 228 kDa, which were localized in the domains that fulfilled the criteria of lipid rafts. The complex of 228 kDa was observed until 30 min after incubation, and only the complex of 191 kDa remained after 60 min. Treatment of the cells with methyl-beta-cyclodextrin or cholesterol oxidase blocked binding of the toxin to the rafts and the toxin-induced K+ efflux and swelling. The toxin-induced Ca2+ influx and morphological changes were inhibited by an increase in the hydrodynamic diameter of polyethylene glycols from 200 to 400 and markedly or completely inhibited by polyethylene glycol 600 and 1000. However, these polyethylene glycols had no effect on the toxin-induced K+ efflux. The toxin induced carboxyfluorescein release from phosphatidylcholine-cholesterol liposomes containing carboxyfluorescein and formed an oligomer with 228 kDa in a dose-dependent manner but did not form an oligomer with the 191-kDa complex. We conclude that the toxin acts on HL 60 cells by binding to lipid rafts and forming a functional oligomer with 228 kDa.	Tokushima Bunri Univ, Fac Pharmaceut Sci, Dept Microbiol, Yamashiro, Tokushima 7708514, Japan	Tokushima Bunri University	Sakurai, J (corresponding author), Tokushima Bunri Univ, Fac Pharmaceut Sci, Dept Microbiol, Yamashiro, Tokushima 7708514, Japan.	sakurai@ph.bunri-u.ac.jp						Duncan MJ, 2002, CELL MICROBIOL, V4, P783, DOI 10.1046/j.1462-5822.2002.00230.x; Falguieres T, 2001, MOL BIOL CELL, V12, P2453, DOI 10.1091/mbc.12.8.2453; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Gibert M, 1997, GENE, V203, P65, DOI 10.1016/S0378-1119(97)00493-9; Gordon VM, 1999, J BIOL CHEM, V274, P27274, DOI 10.1074/jbc.274.38.27274; Herreros J, 2001, MOL BIOL CELL, V12, P2947, DOI 10.1091/mbc.12.10.2947; HUNTER SEC, 1993, INFECT IMMUN, V61, P3958, DOI 10.1128/IAI.61.9.3958-3965.1993; Katagiri YU, 1999, J BIOL CHEM, V274, P35278, DOI 10.1074/jbc.274.49.35278; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Miyata S, 2002, J BIOL CHEM, V277, P39463, DOI 10.1074/jbc.M206731200; Nagahama M, 1999, BBA-MOL BASIS DIS, V1454, P97, DOI 10.1016/S0925-4439(99)00026-5; Nagahama M, 2003, BRIT J PHARMACOL, V138, P23, DOI 10.1038/sj.bjp.0705022; Nagahama M, 2002, INFECT IMMUN, V70, P1909, DOI 10.1128/IAI.70.4.1909-1914.2002; Nagahama M, 1996, BBA-BIOMEMBRANES, V1280, P120, DOI 10.1016/0005-2736(95)00288-X; Petit L, 2001, J BIOL CHEM, V276, P15736, DOI 10.1074/jbc.M010412200; SABIROV RZ, 1993, GEN PHYSIOL BIOPHYS, V12, P95; SAKURAI J, 1987, TOXICON, V25, P1301, DOI 10.1016/0041-0101(87)90008-0; Sakurai J, 1997, J TOXICOL-TOXIN REV, V16, P195, DOI 10.3109/15569549709016456; SAKURAI J, 1980, MICROBIOL IMMUNOL, V24, P595, DOI 10.1111/j.1348-0421.1980.tb02862.x; SAKURAI J, 1992, TOXICON, V30, P323, DOI 10.1016/0041-0101(92)90872-3; SAKURAI J, 1977, INFECT IMMUN, V18, P741, DOI 10.1128/IAI.18.3.741-745.1977; SCHERRER R, 1971, J BACTERIOL, V107, P718, DOI 10.1128/JB.107.3.718-735.1971; Schraw W, 2002, J BIOL CHEM, V277, P34642, DOI 10.1074/jbc.M203466200; Shatursky O, 2000, INFECT IMMUN, V68, P5546, DOI 10.1128/IAI.68.10.5546-5551.2000; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Steinthorsdottir V, 1998, FEMS MICROBIOL LETT, V158, P17, DOI 10.1016/S0378-1097(97)00470-9; Steinthorsdottir V, 2000, MICROB PATHOGENESIS, V28, P45, DOI 10.1006/mpat.1999.0323; TOMITA T, 1992, J BIOL CHEM, V267, P13391; Tweten RK, 2001, VET MICROBIOL, V82, P1, DOI 10.1016/S0378-1135(01)00372-8; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065	33	78	79	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36934	36941		10.1074/jbc.M306562200	http://dx.doi.org/10.1074/jbc.M306562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851396	hybrid			2022-12-25	WOS:000185318300127
J	Cardinali, B; Carissimi, C; Gravina, P; Pierandrei-Amaldi, P				Cardinali, B; Carissimi, C; Gravina, P; Pierandrei-Amaldi, P			La protein is associated with terminal oligopyrimidine mRNAs in actively translating polysomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS; TRANSCRIPTION TERMINATION; PYRIMIDINE TRACT; IN-VITRO; 5 UTR; AUTOANTIGEN; BINDING; IDENTIFICATION; REGION; CDNA	La is an abundant, mostly nuclear, RNA-binding protein that interacts with regions rich in pyrimidines. In the nucleus it has a role in the metabolism of several small RNAs. A number of studies, however, indicate that La protein is also implicated in cytoplasmic functions such as translation. The association of La in vivo with endogenous mRNAs engaged with polysomes would support this role, but this point has never been addressed yet. Terminal oligopyrimidine (TOP) mRNAs, which code for ribosomal proteins and other components of the translational apparatus, bear a TOP stretch at the 5' end, which is necessary for the regulation of their translation. La protein can bind the TOP sequence in vitro and activates TOP mRNA translation in vivo. Here we have quantified La protein in the cytoplasm of Xenopus oocytes and embryo cells and have shown in embryo cells that it is associated with actively translating polysomes. Disruption of polysomes by EDTA treatment displaces La in messenger ribonucleoprotein complexes sedimenting at 40-60 S. The results of polysome treatment with either low concentrations of micrococcal nuclease or with high concentrations of salt indicate, respectively, that La association with polysomes is mediated by mRNA and that it is not an integral component of ribosomes. Moreover, the analysis of messenger ribonucleoprotein complexes dissociated from translating polysomes shows that La protein associates with TOP mRNAs in vivo when they are translated, in line with a positive role of La in the translation of this class of mRNAs previously observed in cultured cells.	CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy	Consiglio Nazionale delle Ricerche (CNR)	Cardinali, B (corresponding author), CNR, Ist Biol Cellulare, Via Ramarini 32, I-00016 Monterotondo, Italy.	bcardinali@ibc.cnr.it	carissimi, claudia/AAU-7414-2021; Cardinali, Beatrice/M-8862-2015	carissimi, claudia/0000-0002-9885-2855; Cardinali, Beatrice/0000-0002-3333-3384				Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; AMALDI F, 1989, TRENDS BIOCHEM SCI, V14, P175, DOI 10.1016/0968-0004(89)90269-7; Amaldi F, 1997, Prog Mol Subcell Biol, V18, P1; AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; Belsham GJ, 2000, TRENDS MICROBIOL, V8, P330, DOI 10.1016/S0966-842X(00)01788-1; BOELENS WC, 1995, RNA, V1, P273; Brooks S A, 2000, Nucleic Acids Res, V28, pE49, DOI 10.1093/nar/28.10.e49; Cardinali B, 1999, J VIROL, V73, P7070, DOI 10.1128/JVI.73.8.7070-7076.1999; CARDINALI B, 1993, NUCLEIC ACIDS RES, V21, P2301, DOI 10.1093/nar/21.10.2301; Carter MS, 2000, J BIOL CHEM, V275, P28301; Ceman S, 1999, MOL CELL BIOL, V19, P7925; CHANG YN, 1994, J VIROL, V68, P7008, DOI 10.1128/JVI.68.11.7008-7020.1994; Crosio C, 2000, NUCLEIC ACIDS RES, V28, P2927, DOI 10.1093/nar/28.15.2927; De Dominicis A, 2000, GENE, V241, P35, DOI 10.1016/S0378-1119(99)00471-0; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; GEYER PK, 1982, MOL CELL BIOL, V2, P685, DOI 10.1128/MCB.2.6.685; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; Grimm C, 1997, EMBO J, V16, P793, DOI 10.1093/emboj/16.4.793; GURDON JB, 1974, CONTROL GENE EXPRESS; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; KASPAR RL, 1992, J BIOL CHEM, V267, P508; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Khandjian EW, 1996, NAT GENET, V12, P91, DOI 10.1038/ng0196-91; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; Kim YK, 2001, NUCLEIC ACIDS RES, V29, P5009, DOI 10.1093/nar/29.24.5009; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; Lin-Marq N, 1998, EMBO J, V17, P2033, DOI 10.1093/emboj/17.7.2033; LORENI F, 1992, EUR J BIOCHEM, V205, P1027, DOI 10.1111/j.1432-1033.1992.tb16870.x; LORENI F, 1985, EMBO J, V4, P3483, DOI 10.1002/j.1460-2075.1985.tb04107.x; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; MARIOTTINI P, 1990, MOL CELL BIOL, V10, P816, DOI 10.1128/MCB.10.2.816; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Meyuhas O, 2000, COLD SPRING HARBOR M, V39, P671; Meyuhas Oded, 1996, V30, P363; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Peek R, 1996, EUR J BIOCHEM, V236, P649, DOI 10.1111/j.1432-1033.1996.0649d.x; Pellizzoni L, 1996, J MOL BIOL, V259, P904, DOI 10.1006/jmbi.1996.0368; Pellizzoni L, 1997, J MOL BIOL, V267, P264, DOI 10.1006/jmbi.1996.0888; Pellizzoni L, 1998, J MOL BIOL, V281, P593, DOI 10.1006/jmbi.1998.1961; PELLIZZONI L, 1995, GENE, V154, P145, DOI 10.1016/0378-1119(94)00834-F; PIERANDREIAMALDI P, 1982, CELL, V30, P163, DOI 10.1016/0092-8674(82)90022-8; PIERANDREIAMALDI P, 1980, EUR J BIOCHEM, V106, P603, DOI 10.1111/j.1432-1033.1980.tb04608.x; Rouault TA, 2000, COLD SPRING HARBOR M, V39, P655; RUSCONI S, 1981, P NATL ACAD SCI-BIOL, V78, P5051, DOI 10.1073/pnas.78.8.5051; Sambrook J., 2001, MOL CLONING; Schlatter S, 2003, BIOTECHNOL BIOENG, V83, P210, DOI 10.1002/bit.10662; SHIOKAWA K, 1985, J EXP ZOOL, V235, P227, DOI 10.1002/jez.1402350209; Shiroki K, 1999, J VIROL, V73, P2193, DOI 10.1128/JVI.73.3.2193-2200.1999; Simons FHM, 1996, EXP CELL RES, V224, P224, DOI 10.1006/excr.1996.0132; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; VANVENROOIJ WJ, 1993, MOL BIOL REP, V18, P113, DOI 10.1007/BF00986765; VANVENROOIJ WJ, 1981, EXP CELL RES, V135, P79, DOI 10.1016/0014-4827(81)90301-3; WARDEN CH, 1994, GENOMICS, V24, P14, DOI 10.1006/geno.1994.1576; WEDLICH D, 1988, CELL TISSUE RES, V254, P295; WEISS IM, 1995, MOL CELL BIOL, V15, P2457; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2; Zhu JF, 2001, BBA-GENE STRUCT EXPR, V1521, P19, DOI 10.1016/S0167-4781(01)00277-9	65	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35145	35151		10.1074/jbc.M300722200	http://dx.doi.org/10.1074/jbc.M300722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12840030	hybrid			2022-12-25	WOS:000185164400050
J	Thomas, JL; Duax, WL; Addlagatta, A; Brandt, S; Fuller, RR; Norris, W				Thomas, JL; Duax, WL; Addlagatta, A; Brandt, S; Fuller, RR; Norris, W			Structure/function relationships responsible for coenzyme specificity and the isomerase activity of human type 1 3 beta-hydroxysteroid dehydrogenase/isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL 3-BETA-HYDROXY-5-ENE-STEROID DEHYDROGENASE; UDP-GALACTOSE 4-EPIMERASE; CANCER CELL-LINES; STEROID 5->4-ENE-ISOMERASE; ESCHERICHIA-COLI; EPITHELIAL-CELLS; PURIFICATION; RESIDUES; INTERLEUKIN-4; MUTAGENESIS	Human type 1 3beta-hydroxysteroid dehydrogenase/ isomerase (3beta-HSD/isomerase) catalyzes the two sequential enzyme reactions on a single protein that converts dehydroepiandrosterone or pregnenolone to androstenedione or progesterone, respectively, in placenta, mammary gland, breast tumors, prostate, prostate tumors, and other peripheral tissues. Our earlier studies show that the two enzyme reactions are linked by the coenzyme product, NADH, of the 3beta-HSD activity. NADH activates the isomerase activity by inducing a time-dependent conformational change in the enzyme protein. The current study tested the hypothesis that the 3beta-HSD and isomerase activities shared a common coenzyme domain, and it characterized key amino acids that participated in coenzyme binding and the isomerase reaction. Homology modeling with UDP-galactose-4-epimerase predicts that Asp(36) is responsible for the NAD(H) specificity of human 3beta-HSD/isomerase and identifies the Rossmann-fold coenzyme domain at the amino terminus. The D36A/K37R mutant in the potential coenzyme domain and the D241N, D257L, D258L, and D265N mutants in the potential isomerase domain ( previously identified by affinity labeling) were created, expressed, and purified. The D36A/K37R mutant shifts the cofactor preference of both 3beta-HSD and isomerase from NAD(H) to NADP( H), which shows that the two activities utilize a common coenzyme domain. The D257L and D258L mutations eliminate isomerase activity, whereas the D241N and D265N mutants have nearly full isomerase activity. Kinetic analyses and pH dependence studies showed that either Asp(257) or Asp(258) plays a catalytic role in the isomerization reaction. These observations further characterize the structure/function relationships of human 3beta-HSD/isomerase and bring us closer to the goal of selectively inhibiting the type 1 enzyme in placenta ( to control the timing of labor) or in hormone-sensitive breast tumors ( to slow their growth).	Mercer Univ, Sch Med, Div Basic Med Sci, Macon, GA 31207 USA; Mercer Univ, Sch Med, Dept Obstet Gynecol, Macon, GA 31207 USA; Hauptman Woodward Med Res Inst, Buffalo, NY 14203 USA; SUNY Buffalo, Buffalo, NY 14203 USA; Univ Oregon, Howard Hughes Med Inst, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Phys, Eugene, OR 97403 USA	Mercer University; Mercer University; Hauptman Woodward Medical Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Howard Hughes Medical Institute; University of Oregon; University of Oregon	Thomas, JL (corresponding author), Mercer Univ, Sch Med, Div Basic Med Sci, 1550 Coll St, Macon, GA 31207 USA.		Addlagatta, Anthony/AAW-2675-2020; Addlagatta, Anthony/B-1101-2010		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026546, R37DK026546] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD020055, HD20055] Funding Source: Medline; NIDDK NIH HHS [DK26546] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Borman S, 2000, CHEM ENG NEWS, V78, P31, DOI 10.1021/cen-v078n031.p031; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; DUAX WL, 2003, IN PRESS PROTEINS ST; GELDOF AA, 1995, ANTICANCER RES, V15, P1349; Gerratana B, 2001, BIOCHEMISTRY-US, V40, P9187, DOI 10.1021/bi0108249; Gingras S, 1999, MOL ENDOCRINOL, V13, P66, DOI 10.1210/me.13.1.66; Gingras S, 1999, ENDOCRINOLOGY, V140, P4573, DOI 10.1210/en.140.10.4573; Huang YW, 2001, MOL ENDOCRINOL, V15, P2010, DOI 10.1210/me.15.11.2010; KACSOH B, 2000, ENDOCRINE PHYSL, P566; KULIOPULOS A, 1990, BIOCHEMISTRY-US, V29, P10271, DOI 10.1021/bi00496a017; Lund O, 1997, PROTEIN ENG, V10, P1241, DOI 10.1093/protein/10.11.1241; Mason JI, 1998, ENDOCR RES, V24, P549, DOI 10.3109/07435809809032644; McKeever BM, 2002, BBA-PROTEINS PROTEOM, V1601, P29, DOI 10.1016/S1570-9639(02)00434-X; Nayar S, 2001, INDIAN J BIOCHEM BIO, V38, P353; Rainey WE, 2002, TRENDS ENDOCRIN MET, V13, P234, DOI 10.1016/S1043-2760(02)00609-4; RHEAUME E, 1991, MOL ENDOCRINOL, V5, P1147, DOI 10.1210/mend-5-8-1147; Sali A, 2001, NAT STRUCT BIOL, V8, P482, DOI 10.1038/88529; Schlegel BP, 1998, BIOCHEMISTRY-US, V37, P3538, DOI 10.1021/bi9723055; SEGEL IH, 1975, ENZYME KINETICS, P109; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; THOMAS JL, 1988, J STEROID BIOCHEM, V31, P785, DOI 10.1016/0022-4731(88)90287-7; Thomas JL, 1998, J STEROID BIOCHEM, V66, P327, DOI 10.1016/S0960-0760(98)00058-2; THOMAS JL, 1989, J STEROID BIOCHEM, V33, P209, DOI 10.1016/0022-4731(89)90296-3; Thomas JL, 1997, BIOCHEMISTRY-US, V36, P9029, DOI 10.1021/bi9710378; Thomas JL, 2002, J BIOL CHEM, V277, P42795, DOI 10.1074/jbc.M208537200; THOMAS JL, 1995, J BIOL CHEM, V270, P21003, DOI 10.1074/jbc.270.36.21003; Thomas JL, 2001, J MOL ENDOCRINOL, V27, P77, DOI 10.1677/jme.0.0270077; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vitkup D, 2001, NAT STRUCT BIOL, V8, P559, DOI 10.1038/88640; XUE L, 1991, BIOCHEMISTRY-US, V30, P4991, DOI 10.1021/bi00234a022	33	57	60	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35483	35490		10.1074/jbc.M304752200	http://dx.doi.org/10.1074/jbc.M304752200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832414	hybrid			2022-12-25	WOS:000185164400090
J	Yang, H; Shelat, AA; Guy, RK; Gopinath, VS; Ma, TH; Du, K; Lukacs, GL; Taddei, A; Folli, C; Pedemonte, N; Galietta, LJV; Verkman, AS				Yang, H; Shelat, AA; Guy, RK; Gopinath, VS; Ma, TH; Du, K; Lukacs, GL; Taddei, A; Folli, C; Pedemonte, N; Galietta, LJV; Verkman, AS			Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS MUTATION; EPITHELIAL-CELLS; PROTEIN; ACTIVATORS; PHENOTYPE; KINETICS; DRUG	Deletion of Phe-508 (DeltaF508) is the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) causing cystic fibrosis. DeltaF508-CFTR has defects in both channel gating and endoplasmic reticulum-to-plasma membrane processing. We identified six novel classes of high affinity potentiators of defective DeltaF508-CFTR Cl- channel gating by screening 100,000 diverse small molecules. Compounds were added 15 min prior to assay of iodide uptake in epithelial cells co-expressing DeltaF508-CFTR and a high sensitivity halide indicator (YFP-H148Q/I152L) in which DeltaF508-CFTR was targeted to the plasma membrane by culture at 27 degreesC for 24 h. Thirty-two compounds with submicromolar activating potency were identified; most had tetrahydrobenzothiophene, benzofuran, pyramidinetrione, dihydropyridine, and anthraquinone core structures (360-480 daltons). Further screening of > 1000 structural analogs revealed tetrahydrobenzothiophenes that activated DeltaF508-CFTR Cl- conductance reversibly with K-d < 100 nM. Single-cell voltage clamp analysis showed characteristic CFTR currents after &UDelta;F508-CFTR activation. Activation required low concentrations of a cAMP agonist, thus mimicking the normal physiological response. A Bayesian computational model was developed using tetrahydrobenzothiophene structure-activity data, yielding insight into the physical character and structural features of active and inactive potentiators and successfully predicting the activity of structural analogs. Efficient potentiation of defective &UDelta;F508-CFTR gating was also demonstrated in human bronchial epithelial cells from a &UDelta;F508 cystic fibrosis subject after 27 &DEG;C temperature rescue. In conjunction with correctors of defective &UDelta;F508-CFTR processing, small molecule potentiators of defective &UDelta;F508-CFTR gating may be useful for therapy of cystic fibrosis caused by the &UDelta;F508 mutation.	Univ Calif San Francisco, Dept Physiol & Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Chem Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Hosp Sick Children, Res Inst, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada; Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Genoa; IRCCS Istituto Giannina Gaslini	Verkman, AS (corresponding author), Univ Calif San Francisco, Dept Physiol & Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.		Guy, Rodney/J-7107-2013; Galietta, Luis JV/HCG-8692-2022; Pedemonte, Nicoletta/B-3607-2010; Shelat, Anang/J-4995-2013	Guy, Rodney/0000-0002-9638-2060; Pedemonte, Nicoletta/0000-0002-5161-1720; Shelat, Anang/0000-0002-6266-2910; Lukacs, Gergely/0000-0003-0900-0675; Ma, Tonghui/0000-0001-9338-1030; Galietta, Luis/0000-0001-8686-3461	NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; Telethon [GP0296Y01] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, R01HL073856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bobadilla JL, 2002, HUM MUTAT, V19, P575, DOI 10.1002/humu.10041; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; Egan ME, 2002, NAT MED, V8, P485, DOI 10.1038/nm0502-485; Galietta LJV, 1998, AM J PHYSIOL-LUNG C, V275, pL917, DOI 10.1152/ajplung.1998.275.5.L917; Galietta LJV, 2001, J BIOL CHEM, V276, P19723, DOI 10.1074/jbc.M101892200; Galietta LJV, 2001, FEBS LETT, V499, P220, DOI 10.1016/S0014-5793(01)02561-3; GEWALD K, 1966, CHEM BER-RECL, V99, P94, DOI 10.1002/cber.19660990116; Haws CM, 1996, AM J PHYSIOL-CELL PH, V270, pC1544, DOI 10.1152/ajpcell.1996.270.5.C1544; HWANG TC, 1997, AM J PHYSIOL, V273, P988; Kang HL, 2002, P NATL ACAD SCI USA, V99, P838, DOI 10.1073/pnas.022631999; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; Ma TH, 2002, J BIOL CHEM, V277, P37235, DOI 10.1074/jbc.M205932200; Rubenstein RC, 2000, AM J PHYSIOL-CELL PH, V278, pC259, DOI 10.1152/ajpcell.2000.278.2.C259; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Wang F, 2000, J PHYSIOL-LONDON, V524, P637, DOI 10.1111/j.1469-7793.2000.00637.x	21	191	203	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35079	35085		10.1074/jbc.M303098200	http://dx.doi.org/10.1074/jbc.M303098200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832418	hybrid			2022-12-25	WOS:000185164400042
J	Zhang, C; Dowd, DR; Staal, A; Gu, C; Lian, JB; van Wijnen, AJ; Stein, GS; MacDonald, PN				Zhang, C; Dowd, DR; Staal, A; Gu, C; Lian, JB; van Wijnen, AJ; Stein, GS; MacDonald, PN			Nuclear coactivator-62 kDa/Ski-interacting protein is a nuclear matrix-associated coactivator that may couple vitamin D receptor-mediated transcription and RNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; POLYMERASE-II; IN-VIVO; ESTROGEN-RECEPTOR; SCAFFOLD PROTEIN; BINDING-PROTEIN; CROSS-LINKING; SNRNP PROTEIN; ACTIVATION; HORMONE	Nuclear coactivator-62 kDa/Ski-interacting protein (NCoA62/SKIP) is a putative vitamin D receptor (VDR) and nuclear receptor coactivator protein that is unrelated to other VDR coactivators such as those in the steroid receptor coactivator ( SRC) family. The mechanism through which NCoA62/SKIP functions in VDR-activated transcription is unknown. In the present study, we identified a nuclear localization sequence in the COOH terminus of NCoA62/SKIP and showed that NCoA62/SKIP was targeted to nuclear matrix subdomains. Chromatin immunoprecipitation studies revealed that endogenous NCoA62/SKIP associated in a 1,25-dihydroxyvitamin D-3-dependent manner with VDR target genes in ROS17/2.8 osteosarcoma cells. A cyclic pattern of promoter occupancy by VDR, SRC-1, and NCoA62/SKIP was observed, with NCoA62/SKIP entering these promoter complexes after SRC-1. These studies provide strong support for the proposed role of NCoA62/SKIP as a VDR transcriptional coactivator, and they indicate that key mechanistic differences probably exist between NCoA62/SKIP and SRC coactivators. To explore potential mechanisms, NCoA62/SKIP-interacting proteins were purified from HeLa cell nuclear extracts and identified by mass spectrometry. The identified proteins represent components of the spliceosome as well as other nuclear matrix-associated proteins. Here, we show that a dominant negative inhibitor of NCoA62/SKIP (dnNCoA62/SKIP) interfered with appropriate splicing of transcripts derived from 1,25-dihydroxyvitamin D-3-induced expression of a growth hormone minigene cassette. Taken together, these data show that NCoA62/SKIP has properties that are consistent with those of nuclear receptor coactivators and with RNA spliceosome components, thus suggesting a potential role for NCoA62/SKIP in coupling VDR-mediated transcription to RNA splicing.	Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	Case Western Reserve University; University of Massachusetts System; University of Massachusetts Worcester	MacDonald, PN (corresponding author), Case Western Reserve Univ, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.		van Wijnen, Andre J./AAG-3578-2019; Zhang, Chi/K-4467-2012	van Wijnen, Andre J./0000-0002-4458-0946; 	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053980] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR049069] Funding Source: Medline; NIDDK NIH HHS [DK53980] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Achsel T, 1998, MOL CELL BIOL, V18, P6756, DOI 10.1128/MCB.18.11.6756; Albers M, 2003, RNA, V9, P138, DOI 10.1261/rna.2119903; Ambrozkova M, 2001, BIOCHEM BIOPH RES CO, V284, P1148, DOI 10.1006/bbrc.2001.5108; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Barry JB, 2003, J BIOL CHEM, V278, P8224, DOI 10.1074/jbc.C200712200; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; BELGRADER P, 1991, J BIOL CHEM, V266, P9893; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Dahl R, 1998, ONCOGENE, V16, P1579, DOI 10.1038/sj.onc.1201687; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hibino Y, 2000, BIOCHEM BIOPH RES CO, V279, P282, DOI 10.1006/bbrc.2000.3938; Hirose Y, 2000, GENE DEV, V14, P1415; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; Jurutka P W, 2001, Rev Endocr Metab Disord, V2, P203, DOI 10.1023/A:1010062929140; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; Kraichely DM, 1999, J BIOL CHEM, V274, P14352, DOI 10.1074/jbc.274.20.14352; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Laggerbauer B, 1996, NUCLEIC ACIDS RES, V24, P868, DOI 10.1093/nar/24.5.868; Laggerbauer B, 1998, P NATL ACAD SCI USA, V95, P4188, DOI 10.1073/pnas.95.8.4188; Liu ZR, 1997, RNA, V3, P1207; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Makarov EM, 2002, SCIENCE, V298, P2205, DOI 10.1126/science.1077783; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; Mintz PJ, 1999, EMBO J, V18, P4308, DOI 10.1093/emboj/18.15.4308; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; ONATE SA, 1995, SCIENCE, V270, P1354; ORGRYZKO VV, 1996, CELL, V87, P953; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shopland LS, 2000, J CELL BIOL, V150, pF1, DOI 10.1083/jcb.150.1.F1; SMITH HC, 1986, MOL CELL BIOCHEM, V70, P151; Stein GS, 2000, J CELL SCI, V113, P2527; Sutton ALM, 2003, MOL ENDOCRINOL, V17, P777, DOI 10.1210/me.2002-0363; TEIGELKAMP S, 1995, NUCLEIC ACIDS RES, V23, P320, DOI 10.1093/nar/23.3.320; TERPENING CM, 1991, MOL ENDOCRINOL, V5, P373, DOI 10.1210/mend-5-3-373; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; TSUTSUI K, 1993, J BIOL CHEM, V268, P12886; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; VONKRIES JP, 1994, NUCLEIC ACIDS RES, V22, P1215, DOI 10.1093/nar/22.7.1215; Wei XY, 1999, J CELL BIOL, V146, P543, DOI 10.1083/jcb.146.3.543; XING YG, 1991, J CELL BIOL, V112, P1055, DOI 10.1083/jcb.112.6.1055; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zaidi SK, 2001, J CELL SCI, V114, P3093; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zhang C, 2001, J BIOL CHEM, V276, P40614, DOI 10.1074/jbc.M106263200; Zhang Z, 2001, CELL, V106, P465, DOI 10.1016/S0092-8674(01)00466-4	68	122	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35325	35336		10.1074/jbc.M305191200	http://dx.doi.org/10.1074/jbc.M305191200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12840015	hybrid			2022-12-25	WOS:000185164400072
J	Norris, EH; Giasson, BI; Ischiropoulos, H; Lee, VMY				Norris, EH; Giasson, BI; Ischiropoulos, H; Lee, VMY			Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; PARKINSONS-DISEASE; LEWY BODIES; IN-VITRO; NEURODEGENERATIVE DISEASES; ALZHEIMERS-DISEASE; FIBRIL FORMATION; NITRIC-OXIDE; AGGREGATION; PARAQUAT	Filamentous inclusions of alpha-synuclein protein are hallmarks of neurodegenerative diseases collectively known as synucleinopathies. Previous studies have shown that exposure to oxidative and nitrative species stabilizes alpha-synuclein filaments in vitro, and this stabilization may be due to dityrosine cross-linking. To test this hypothesis, we mutated tyrosine residues to phenylalanine and generated recombinant wild type and mutant alpha-synuclein proteins. alpha-Synuclein proteins lacking some or all tyrosine residues form fibrils to the same extent as the wild type protein. Tyrosine residues are not required for protein cross-linking or filament stabilization resulting from transition metal-mediated oxidation, because higher M-r SDS-resistant oligomers and filaments stable to chaotropic agents are detected using all Tyr --> Phe alpha-synuclein mutants. By contrast, cross-linking resulting from exposure to nitrating agents required the presence of one or more tyrosine residues. Furthermore, tyrosine cross-linking is involved in filament stabilization, because nitrating agent-exposed assembled wild type, but not mutant alpha-synuclein lacking all tyrosine residues, was stable to chaotropic treatment. In addition, the formation of stable alpha-synuclein inclusions in intact cells after exposure to oxidizing and nitrating species requires tyrosine residues. These findings demonstrate that nitrative and/or oxidative stress results in distinct mechanisms of alpha-synuclein protein modifications that can influence the formation of stable alpha-synuclein fibrils.	Univ Penn, Med Ctr, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Childrens Hosp Philadelphia, Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Lee, VMY (corresponding author), Hosp Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, 3600 Spruce St,Maloney 3, Philadelphia, PA 19104 USA.			Norris, Erin/0000-0002-4522-3537	NATIONAL INSTITUTE ON AGING [P01AG009215] Funding Source: NIH RePORTER; NIA NIH HHS [AG 09215] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baba M, 1998, AM J PATHOL, V152, P879; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Brooks AI, 1999, BRAIN RES, V823, P1, DOI 10.1016/S0006-8993(98)01192-5; Chen T., 1997, J EPIDEMIOL BIOSTAT, P9; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; CLEJAN L, 1989, BIOCHEM PHARMACOL, V38, P1779, DOI 10.1016/0006-2952(89)90412-7; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Fitzhugh AL, 2000, FREE RADICAL BIO MED, V28, P1463, DOI 10.1016/S0891-5849(00)00251-3; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 1998, BIOCHEM SOC T, V26, P463, DOI 10.1042/bst0260463; Gow AJ, 2000, AM J PHYSIOL-CELL PH, V278, pC1099, DOI 10.1152/ajpcell.2000.278.6.C1099; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jakes R, 1999, NEUROSCI LETT, V269, P13, DOI 10.1016/S0304-3940(99)00411-5; Krishnan S, 2003, BIOCHEMISTRY-US, V42, P829, DOI 10.1021/bi026528t; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Paik SR, 2000, ARCH BIOCHEM BIOPHYS, V378, P269, DOI 10.1006/abbi.2000.1822; Paik SR, 1999, BIOCHEM J, V340, P821, DOI 10.1042/0264-6021:3400821; Papadimitriou A, 1999, NEUROLOGY, V52, P651, DOI 10.1212/WNL.52.3.651; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takahashi T, 2002, BRAIN RES, V938, P73, DOI 10.1016/S0006-8993(02)02498-8; Thiruchelvam M, 2000, J NEUROSCI, V20, P9207; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Uversky VN, 2002, FEBS LETT, V517, P239, DOI 10.1016/S0014-5793(02)02638-8; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	45	139	143	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27230	27240		10.1074/jbc.M212436200	http://dx.doi.org/10.1074/jbc.M212436200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12857790	hybrid			2022-12-25	WOS:000184155700119
J	Chen, DY; Xu, LG; Chen, L; Li, LX; Zhai, ZH; Shu, HB				Chen, DY; Xu, LG; Chen, L; Li, LX; Zhai, ZH; Shu, HB			NIK is a component of the EGF/heregulin receptor signaling complexes	ONCOGENE			English	Article						NIK; EGF; Grb7; NF-kappa B; signaling	NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; LYMPHOTOXIN-BETA-RECEPTOR; FOCAL ADHESION KINASE; SRC HOMOLOGY 2; ADAPTER PROTEIN; INTERACTING PROTEIN; BINDING-PROTEIN; GRB7 FAMILY; ACTIVATION	Nuclear factor kappaB-inducing kinase (NIK) is a member of the MAP kinase kinase kinase family that was first identified as a component of the TNF-R1-induced NF-kappaB activation pathway (TNF, tumor necrosis factor; nuclear factor kappaB, NF-kappaB). Gene knockout study, however, suggests that NIK is dispensable for TNF-R1- but required for lymphotoxin-beta receptor-induced NF-kappaB activation. A NIK kinase inactive mutant is a potent inhibitor of NF-kappaB activation triggered by various stimuli, suggesting that NIK is involved in a broad range of NF-kappaB activation pathways. To unambiguously identify signaling pathways that NIK participates in, we screened antibody arrays for proteins that are associated with NIK. This effort identified ErbB4, one of the EGF/heregulin receptors, and Grb7, an adapter protein associated with ErbB4 (ErbB, epidermal growth factor receptor family protein; EGF, epidermal growth factor; Grb, growth factor receptor bound). Coimmunoprecipitation experiments demonstrated that NIK interacted with Grb7, as well as Grb10 and Grb14, but not Grb2. Domain mapping experiments indicated that the central GM domain of Grb7 was sufficient for its interaction with NIK. Coimmunoprecipitation experiments also indicated that Grb7 and NIK could be simultaneously recruited into signaling complexes of all known EGF/heregulin receptors, including EGFR, ErbB2, ErbB3, and ErbB4. In reporter gene assays, NIK could potentiate Grb7, ErbB2/ErbB4, and EGF-induced NF-kappaB activation. A NIK kinase inactive mutant could block ErbB2/ErbB4 and EGF-induced NF-kappaB activation. Moreover, EGF/heregulin receptors activated NF-kappaB in wild-type, but not NIK-/- embryonic fibroblasts. Our findings suggest that NIK is a component of the EGF/heregulin receptor signaling complexes and involved in NF-kappaB activation triggered by these receptors.	Univ Colorado, Hlth Sci Ctr, Dept Immunol, Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Peking Univ, Dept Cell Biol & Genet, Coll Life Sci, Beijing 100871, Peoples R China	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Peking University	Shu, HB (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Immunol, Natl Jewish Med & Res Ctr, 1400 Jackson St,K516C, Denver, CO 80206 USA.	shuh@njc.org		Xu, Liangguo/0000-0003-1991-2889	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049992] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI49992-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akiyama N, 1997, CANCER RES, V57, P3548; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Forster RE, 1998, P NATL ACAD SCI USA, V95, P15815, DOI 10.1073/pnas.95.26.15815; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hoffmann M, 1998, CANCER IMMUNOL IMMUN, V47, P167, DOI 10.1007/s002620050517; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; JANES PW, 1997, J BIOL CHEM, V274, P30896; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Nantel A, 1999, J BIOL CHEM, V274, P35719, DOI 10.1074/jbc.274.50.35719; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; OOI J, 1995, ONCOGENE, V10, P1621; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; Tanaka S, 1997, CANCER RES, V57, P28; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vayssiere B, 2000, FEBS LETT, V467, P91, DOI 10.1016/S0014-5793(99)01530-6; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453	41	32	36	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4348	4355		10.1038/sj.onc.1206532	http://dx.doi.org/10.1038/sj.onc.1206532			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853971				2022-12-25	WOS:000183978900004
J	Baron, V; De Gregorio, G; Krones-Herzig, A; Virolle, T; Calogero, A; Urcis, R; Mercola, D				Baron, V; De Gregorio, G; Krones-Herzig, A; Virolle, T; Calogero, A; Urcis, R; Mercola, D			Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo	ONCOGENE			English	Article						prostate cancer; Egr-1; antisense oligonucleotide; TRAMP mouse	TRANSCRIPTION FACTOR EGR-1; GROWTH-FACTOR; ANTISENSE OLIGONUCLEOTIDES; GENE-EXPRESSION; UP-REGULATION; INVOLVEMENT; INDUCTION; APOPTOSIS; BINDING; PROTEIN	Transcription factor early growth response-1 (Egr-1) is a crucial regulator of cell growth, differentiation and survival. Several observations suggest that Egr-1 is growth promoting in prostate cancer cells and that blocking its function may impede cancer progression. To test this hypothesis, we developed phosphorothioate antisense oligonucleotides that efficiently inhibit Egr-1 expression without altering the expression of other family members Egr-2, Egr-3 and Egr-4. In TRAMP mouse-derived prostate cancer cell lines, our optimal antisense oligonucleotide decreased the expression of the Egr-1 target gene transforming growth factor-beta1 whereas a control oligonucleotide had no effect, indicating that the antisense blocked Egr-1 function as a transcription factor. The antisense oligonucleotide deregulated cell cycle progression and decreased proliferation of the three TRAMP cell lines by an average of 54+/-3%. Both colony formation and growth in soft agar were inhibited by the antisense oligonucleotide. When TRAMP mice were treated systemically for 10 weeks, the incidence of palpable tumors at 32 weeks of age in untreated mice or mice injected with the control scramble oligonucleotide was 87%, whereas incidence of tumors in antisense-Egr-1-treated mice was significantly reduced to 37% (P=0.026). Thus, Egr-1 plays a functional role in the transformed phenotype and may represent a valid target for prostate cancer therapy.	Sidnet Kimmel Canc Ctr, San Diego, CA 92121 USA; Inst Ricovero & Cura Carattere Sci, I-86077 Pozzilli, Italy; Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Baron, V (corresponding author), Sidnet Kimmel Canc Ctr, 10835 Altman Row, San Diego, CA 92121 USA.	vbaron@skcc.org; danmercola@skcc.org	mercola, dan/L-4182-2013; calogero, antonella/U-5418-2019; Virolle, Thierry/E-5838-2016	mercola, dan/0000-0002-0281-9840; calogero, antonella/0000-0002-3322-2916	NATIONAL CANCER INSTITUTE [R01CA084107, R01CA076173] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76173, CA 84107] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Arai M, 2000, CIRC RES, V86, P8, DOI 10.1161/01.RES.86.1.8; BERUBE NG, 1994, CANCER RES, V54, P3077; Bost F, 2000, METHOD ENZYMOL, V314, P342; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; Eid MA, 1998, CANCER RES, V58, P2461; Foster BA, 1997, CANCER RES, V57, P3325; Galderisi U, 1999, J CELL PHYSIOL, V181, P251, DOI 10.1002/(SICI)1097-4652(199911)181:2<251::AID-JCP7>3.0.CO;2-D; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Gousseva N, 2001, J CELL BIOCHEM, V81, P523, DOI 10.1002/1097-4644(20010601)81:3<523::AID-JCB1066>3.0.CO;2-E; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hofer G, 1996, J BIOL CHEM, V271, P28306, DOI 10.1074/jbc.271.45.28306; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; HUANG RP, 1995, CANCER RES, V55, P5054; IRVING SG, 1989, MOL CELL BIOL, V9, P1034, DOI 10.1128/MCB.9.3.1034; Jackson MW, 2002, CANCER RES, V62, P854; KINANE TB, 1994, J BIOL CHEM, V269, P27503; Kroon ME, 2001, J CELL SCI, V114, P825; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1998, CANCER GENE THER, V5, P3; McMenamin ME, 1999, CANCER RES, V59, P4291; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; Muthukkumar S, 1997, J BIOL CHEM, V272, P27987, DOI 10.1074/jbc.272.44.27987; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Nishi H, 2002, CANCER RES, V62, P827; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Okada M, 2001, FASEB J, V15, P2757, DOI 10.1096/fj.01-0490fje; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; Russell PJ, 1998, CLIN CHEM, V44, P705; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; Stein CA, 2001, J CLIN INVEST, V108, P641, DOI 10.1172/JCI13885; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181	48	90	97	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4194	4204		10.1038/sj.onc.1206560	http://dx.doi.org/10.1038/sj.onc.1206560			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833142				2022-12-25	WOS:000183979800006
J	Snijders, AM; Nowee, ME; Fridlyand, J; Piek, JMJ; Dorsman, JC; Jain, AN; Pinkel, D; van Diest, PJ; Verheijen, RHM; Albertson, DG				Snijders, AM; Nowee, ME; Fridlyand, J; Piek, JMJ; Dorsman, JC; Jain, AN; Pinkel, D; van Diest, PJ; Verheijen, RHM; Albertson, DG			Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in Fallopian tube carcinoma	ONCOGENE			English	Article						array CGH; CCNE1; AKT2; fallopian tube cancer	CYCLIN-E GENE; OVARIAN-CANCER; C-MYC; SOLID TUMORS; AMPLIFICATION; OVEREXPRESSION; ONCOGENE; MICROARRAYS; CDK2; AKT2	Fallopian tube carcinoma (FTC) is a rare, poorly studied and aggressive cancer, associated with poor survival. Since tumorigenesis is related to the acquisition of genetic changes, we used genome-wide array comparative genomic hybridization to analyse copy number aberrations occurring in FTC in order to obtain a better understanding of FTC carcinogenesis and to identify prognostic events and targets for therapy. We used arrays of 2464 genomic clones, providing similar to 1.4 Mb resolution across the genome to map genomic DNA copy number aberrations quantitatively from 14 FTC onto the human genome sequence. All tumors showed a high frequency of copy number aberrations with recurrent gains on 3q, 6p, 7q, 8q, 12p, 17q, 19 and 20q, and losses involving chromosomes 4, 5q, 8p, 16q, 17p, 18q and X. Recurrent regions of amplification included 1p34, 8p11-q11, 8q24, 12p, 17p13, 17q12-q21, 19p13, 19q12-q13 and 19q13. Candidate, known oncogenes mapping to these amplicons included CMYC (8q24), CCNE1 (19q12-q21) and AKT2 (19q13), whereas PIK3CA and KRAS, previously suggested to be candidate driver genes for amplification, mapped outside copy number maxima on 3q and 12p, respectively. The FTC were remarkably homogeneous, with some recurrent aberrations occurring in more than 70% of samples, which suggests a stereotyped pattern of tumor evolution.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; VU Univ, Dept Obstet & Gynaecol, Med Ctr, Amsterdam, Netherlands; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; VU Univ, Dept Pathol, Med Ctr, Amsterdam, Netherlands	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Vrije Universiteit Amsterdam; University of California System; University of California San Francisco; Vrije Universiteit Amsterdam	Albertson, DG (corresponding author), Univ Calif San Francisco, Canc Res Inst, Box 0808, San Francisco, CA 94143 USA.		Piek, Jurgen Martinus Johannes/AAX-2108-2021	Piek, Jurgen Martinus Johannes/0000-0002-0487-0631	NATIONAL CANCER INSTITUTE [R01CA083040, R33CA094407] Funding Source: NIH RePORTER; NCI NIH HHS [CA83040, CA94407] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Aziz S, 2001, GYNECOL ONCOL, V80, P341, DOI 10.1006/gyno.2000.6095; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Caduff RF, 1998, AM J SURG PATHOL, V22, P319, DOI 10.1097/00000478-199803000-00006; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheung VG, 2001, NATURE, V409, P953, DOI 10.1038/35057192; Chung TKH, 2000, GYNECOL OBSTET INVES, V49, P47, DOI 10.1159/000010212; DUTRILLAUX B, 1986, INT J CANCER, V38, P475, DOI 10.1002/ijc.2910380404; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HELLSTROM AC, 1994, INT J GYNECOL CANCER, V4, P408, DOI 10.1046/j.1525-1438.1994.04060408.x; Heselmeyer K, 1998, INT J GYNECOL PATHOL, V17, P245, DOI 10.1097/00004347-199807000-00009; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Karhu R, 1997, CYTOMETRY, V28, P198, DOI 10.1002/(SICI)1097-0320(19970701)28:3<198::AID-CYTO3>3.0.CO;2-A; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; Knight SJL, 2000, AM J HUM GENET, V67, P320, DOI 10.1086/302998; Leeper K, 2002, GYNECOL ONCOL, V87, P52, DOI 10.1006/gyno.2002.6779; Lin L, 2000, CANCER RES, V60, P7021; Manavi M, 1998, GYNECOL ONCOL, V71, P165, DOI 10.1006/gyno.1998.5084; Marone M, 1998, INT J CANCER, V75, P34, DOI 10.1002/(SICI)1097-0215(19980105)75:1<34::AID-IJC6>3.0.CO;2-2; MIZUUCHI H, 1995, CANCER, V76, P86, DOI 10.1002/1097-0142(19950701)76:1<86::AID-CNCR2820760112>3.0.CO;2-L; MONK BJ, 1994, AM J OBSTET GYNECOL, V171, P1193, DOI 10.1016/0002-9378(94)90131-7; Pere H, 1998, CANCER RES, V58, P4274; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; SNIJDERS AM, 2003, IN PRESS ONCOGENE; SolinasToldo S, 1996, CANCER RES, V56, P3803; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sun PC, 2001, GENOMICS, V75, P17, DOI 10.1006/geno.2001.6587; Wang ZR, 1999, EXP MOL PATHOL, V66, P140, DOI 10.1006/exmp.1999.2259; Weiss MM, 1999, J CLIN PATHOL-MOL PA, V52, P243; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598; Zweemer RP, 2000, GYNECOL ONCOL, V76, P45, DOI 10.1006/gyno.1999.5623; Zweemer RP, 2001, LAB INVEST, V81, P1363, DOI 10.1038/labinvest.3780350	39	48	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4281	4286		10.1038/sj.onc.1206621	http://dx.doi.org/10.1038/sj.onc.1206621			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833150				2022-12-25	WOS:000183979800014
J	Hartmann, J; Scepek, S; Hafez, I; Lindau, M				Hartmann, J; Scepek, S; Hafez, I; Lindau, M			Differential regulation of exocytotic fusion and granule-granule fusion in eosinophils by Ca2(+) and GTP analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPOUND EXOCYTOSIS; SCHISTOSOMA-MANSONI; CAPACITANCE MEASUREMENTS; GUANINE-NUCLEOTIDES; RAT EOSINOPHILS; CELLS; SECRETION; DEGRANULATION; MECHANISM; EVENTS	Dynamics of degranulation was studied in horse eosinophils by patch clamp capacitance measurements. Degranulation was stimulated by intracellular application of calcium, and GTPgammaS or guanosine 5'-(beta,gamma-imido)-triphosphate at different concentrations via the patch pipette. Degranulation was quantified by measuring the delay time between the beginning of intracellular perfusion and the first exocytotic event, determining the distribution of time intervals between fusion events and the capacitance step size distributions under the different conditions. The degranulation dynamics could be well reproduced using a computer model assuming three independent rate constants for granule-plasma membrane fusion, granule fusion with already exocytosed granules, and intracellular granule-granule fusion. The rate of granule-plasma membrane fusion is sensitive to both, the GTP analog and [Ca2+]i. The rate of granule-exocytosed granule fusion is sensitive to [Ca2+](i) but insensitive to the GTP analogs, and the rate of granule-to-granule fusion is sensitive to the GTP analog but insensitive to [Ca2+](i). Granule fusions with the three different target compartments thus involve different regulatory mechanisms.	Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA; Univ Munich, Inst Physiol, D-80336 Munich, Germany	Cornell University; University of Munich	Lindau, M (corresponding author), Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA.	ml95@cornell.edu	Hartmann, Jana/C-1024-2008; Lindau, Manfred/ABD-3449-2021	Lindau, Manfred/0000-0002-5722-9557; Hartmann, Jana/0000-0002-1033-7104	NINDS NIH HHS [R01 NS38200, R01 NS038200-01A2, R01 NS038200-03, R01 NS038200, R01 NS038200-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038200] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angleson JK, 1999, NAT NEUROSCI, V2, P440, DOI 10.1038/8107; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; Bokvist K, 2000, PFLUG ARCH EUR J PHY, V439, P634, DOI 10.1007/s004240050987; Butterworth A E, 1977, Curr Top Microbiol Immunol, V77, P127; Cochilla AJ, 2000, J CELL BIOL, V150, P839, DOI 10.1083/jcb.150.4.839; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; FIDLER N, 1989, BIOPHYS J, V56, P1153, DOI 10.1016/S0006-3495(89)82762-6; GLAUERT AM, 1978, J CELL SCI, V34, P173, DOI 10.1007/BF01944659; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; Hansen NJ, 1999, J BIOL CHEM, V274, P22871, DOI 10.1074/jbc.274.32.22871; Hartmann J, 2003, J BIOL CHEM, V278, P44929, DOI 10.1074/jbc.M306014200; HARTMANN J, 1995, J PHYSIOL-LONDON, V483, P201, DOI 10.1113/jphysiol.1995.sp020578; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; LINDAU M, 1994, ANN NY ACAD SCI, V710, P232, DOI 10.1111/j.1749-6632.1994.tb26631.x; LINDAU M, 1994, ADV SEC MESS PHOSPH, V29, P173; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; Lollike K, 2002, J LEUKOCYTE BIOL, V71, P973; Mair N, 1999, AM J PHYSIOL-LUNG C, V276, pL376, DOI 10.1152/ajplung.1999.276.2.L376; MCLAREN DJ, 1978, PARASITOLOGY, V77, P313, DOI 10.1017/S0031182000050277; MCLAREN DJ, 1977, CLIN EXP IMMUNOL, V30, P105; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; NUSSE O, 1990, J EXP MED, V171, P775, DOI 10.1084/jem.171.3.775; NUSSE O, 1988, J CELL BIOL, V107, P2117, DOI 10.1083/jcb.107.6.2117; NUSSE O, 1993, CELL CALCIUM, V14, P255, DOI 10.1016/0143-4160(93)90047-A; Parsons TD, 2003, NEURON, V37, P379, DOI 10.1016/S0896-6273(03)00062-X; PFEUFFER T, 1976, FEBS LETT, V67, P354, DOI 10.1016/0014-5793(76)80563-7; SCEPEK S, 1993, EMBO J, V12, P1811, DOI 10.1002/j.1460-2075.1993.tb05829.x; SCEPEK S, 1994, PARASITOL TODAY, V10, P276, DOI 10.1016/0169-4758(94)90146-5; Scepek S, 1997, BLOOD, V89, P510, DOI 10.1182/blood.V89.2.510; TAI PC, 1981, BRIT J HAEMATOL, V49, P219, DOI 10.1111/j.1365-2141.1981.tb07218.x; VOGEL SS, 1992, P NATL ACAD SCI USA, V89, P4749, DOI 10.1073/pnas.89.10.4749; YAMANAKA G, 1986, BIOCHEMISTRY-US, V25, P6149, DOI 10.1021/bi00368a048; Zimmerli S, 1996, J CELL BIOL, V132, P49, DOI 10.1083/jcb.132.1.49	35	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44929	44934		10.1074/jbc.M306014200	http://dx.doi.org/10.1074/jbc.M306014200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12853448	hybrid, Green Published			2022-12-25	WOS:000186306700129
J	Abdelmohsen, K; Gerber, PA; von Montfort, C; Sies, H; Klotz, LO				Abdelmohsen, K; Gerber, PA; von Montfort, C; Sies, H; Klotz, LO			Epidermal growth factor receptor is a common mediator of quinone-induced signaling leading to phosphorylation of connexin-43 - Role of glutathione and tyrosine phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; REGULATED KINASE; VITAMIN-K; RAT-LIVER; ACTIVATION; CELLS; PATHWAY; EGF; IDENTIFICATION; COMMUNICATION	Rat liver epithelial cells were exposed to three quinones with different properties: menadione (2-methyl-1,4-lnaphthoquinone, vitamin K-3), an alkylating as well as redox-cycling quinone, the strongly alkylating p-benzoquinone (BQ), and the non-arylating redox-cycler, 2,3-dimethoxy-1,4-naphthoquinone (DMNQ). All three quinones induced the activation of extracellular signal-regulated kinase (ERK) 1 and ERK 2 via the activation of epidermal growth factor receptor (EGFR) and MAPK/ERK kinases (MEK) 1/2. ERK activation resulted in phosphorylation at Ser-279 and Ser-282 of the gap junctional protein, connexin-43, known to result in the loss of gap junctional intercellular communication. Another EGFR-dependent pathway was stimulated, leading to the activation of the antiapoptotic kinase Akt via phosphoinositide 3-kinase. The activation of EGFR-dependent signaling by these quinones was by different mechanisms: (i) menadione, but not BQ or DMNQ, inhibited a protein-tyrosine phosphatase regulating the EGFR, as concluded from an EGFR dephosphorylation assay; (ii) although menadione-induced activation of ERK was unimpaired by pretreatment of cells with N-acetyl cysteine, activation by BQ and DMNQ was prevented; (iii) cellular glutathione (GSH) levels were strongly depleted by BQ. The mere depletion of GSH by application of diethyl maleate EGFR-dependently activated ERK and Akt, thus mimicking BQ effects. GSH levels were only moderately decreased by menadione and not affected by DMNQ. In summary, EGFR-dependent signaling was mediated by protein-tyrosine phosphatase inactivation (menadione), GSH depletion (BQ), and redox-cycling (DMNQ), funneling into the same signaling pathway.	Univ Dusseldorf, Inst Biochem & Mol Biol 1, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Klotz, LO (corresponding author), Univ Dusseldorf, Inst Biochem & Mol Biol 1, Univ Str 1,Geb 22-03,Ebene 2, D-40225 Dusseldorf, Germany.	LarsOliver.Klotz@uni-duesseldorf.de	Sies, Helmut/ABE-7355-2020; Abdelmohsen, Kotb/AAX-4191-2020; Gerber, Peter Arne/M-2746-2013; Klotz, Lars Oliver/AAC-5051-2019; Sies, Helmut/B-7266-2008; Gerber, Peter Arne/C-2000-2009	Abdelmohsen, Kotb/0000-0001-6240-5810; Gerber, Peter Arne/0000-0003-1657-1863; Klotz, Lars Oliver/0000-0002-1261-8911; Sies, Helmut/0000-0002-1000-3198; 				ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; BELLOMO G, 1987, BIOCHEM PHARMACOL, V36, P1313, DOI 10.1016/0006-2952(87)90087-6; Benhar M, 2002, ONCOGENE, V21, P8723, DOI 10.1038/sj.onc.1205980; Boatman RJ, 2000, CHEM RES TOXICOL, V13, P853, DOI 10.1021/tx000037x; Bolton JL, 2000, CHEM RES TOXICOL, V13, P135, DOI 10.1021/tx9902082; BRUNMARK A, 1989, FREE RADICAL BIO MED, V7, P435, DOI 10.1016/0891-5849(89)90126-3; Cameron SJ, 2003, J BIOL CHEM, V278, P18682, DOI 10.1074/jbc.M213283200; Carr BI, 2002, J CELL PHYSIOL, V193, P263, DOI 10.1002/jcp.10171; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Coleman WB, 1997, AM J PATHOL, V151, P353; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Hargreaves RHJ, 2000, FRONT BIOSCI-LANDMRK, V5, pE172, DOI 10.2741/hargreav; Herrlich P, 2000, BIOCHEM PHARMACOL, V59, P35, DOI 10.1016/S0006-2952(99)00298-1; Kim DY, 1999, J BIOL CHEM, V274, P5581, DOI 10.1074/jbc.274.9.5581; Klotz LO, 2000, BIOCHEM J, V352, P219, DOI 10.1042/0264-6021:3520219; Klotz LO, 2002, CANCER RES, V62, P4922; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Knebel A, 2000, METHOD ENZYMOL, V319, P255; Kolmodin K, 2001, FEBS LETT, V498, P208, DOI 10.1016/S0014-5793(01)02479-6; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; LAU SS, 1988, MOL PHARMACOL, V34, P829; Leykauf K, 2003, CELL TISSUE RES, V311, P23, DOI 10.1007/s00441-002-0645-5; Li XA, 2001, J SURG RES, V100, P197, DOI 10.1006/jsre.2001.6238; Mahns A, 2003, FREE RADICAL RES, V37, P391, DOI 10.1080/1071576031000064702; MASUI H, 1993, J CELL BIOL, V120, P85, DOI 10.1083/jcb.120.1.85; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; Vine AL, 2002, CANCER METAST REV, V21, P199, DOI 10.1023/A:1021250624933; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wang ZQ, 2002, J BIOL CHEM, V277, P19470, DOI 10.1074/jbc.M201097200; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; Wu RC, 1998, ONCOGENE, V17, P357, DOI 10.1038/sj.onc.1201930; Wu WD, 1999, AM J PHYSIOL-LUNG C, V277, pL924, DOI 10.1152/ajplung.1999.277.5.L924	34	93	98	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38360	38367		10.1074/jbc.M306785200	http://dx.doi.org/10.1074/jbc.M306785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874275	hybrid			2022-12-25	WOS:000185575100035
J	Klumpp, LM; Mackey, AT; Farrell, CM; Rosenberg, JM; Gilbert, SP				Klumpp, LM; Mackey, AT; Farrell, CM; Rosenberg, JM; Gilbert, SP			A kinesin switch I arginine to lysine mutation rescues microtubule function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP HYDROLYSIS; MOLECULAR MOTOR; DIMERIC KINESIN; SALT-BRIDGE; CONFORMATIONAL-CHANGE; DICTYOSTELIUM MYOSIN; CRYSTAL-STRUCTURE; EPR SPECTROSCOPY; BRAIN KINESIN; ADP RELEASE	Switch I and II are key active site structural elements of kinesins, myosins, and G-proteins. Our analysis of a switch I mutant (R210A) in Drosophila melanogaster kinesin showed a reduction in microtubule affinity, a loss in cooperativity between the motor domains, and an ATP hydrolysis defect leading to aberrant detachment from the microtubule. To investigate the conserved arginine in switch I further, a lysine substitution mutant was generated. The R210K dimeric motor has lost the ability to hydrolyze ATP; however, it has rescued microtubule function. Our results show that R210K has restored microtubule association kinetics, microtubule affinity, ADP release kinetics, and motor domain cooperativity. Moreover, the active site at head 1 is able to distinguish ATP, ADP, and AMP-PNP to signal head 2 to bind the microtubule and release mantADP with kinetics comparable with wild-type. Therefore, the structural pathway of communication from head 1 to head 2 is restored, and head 2 can respond to this signal by binding the microtubule and releasing mantADP. Structural modeling revealed that lysine could retain some of the hydrogen bonds made by arginine but not all, suggesting a structural hypothesis for the ability of lysine to rescue microtubule function in the Arg210 mutant.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gilbert, SP (corresponding author), Univ Pittsburgh, Dept Biol Sci, 518 Langley Hall, Pittsburgh, PA 15260 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR047841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054141, R01GM054141] Funding Source: NIH RePORTER; NIAMS NIH HHS [K02-AR47841, K02 AR047841, K02 AR047841-01A1, K02 AR047841-02] Funding Source: Medline; NIGMS NIH HHS [R01 GM054141-04, R01 GM054141-06, R01 GM054141-05, GM54141, R01 GM054141, R37 GM054141, R01 GM054141-07] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brendza KM, 1999, J BIOL CHEM, V274, P31506, DOI 10.1074/jbc.274.44.31506; Brendza KM, 2000, J BIOL CHEM, V275, P22187, DOI 10.1074/jbc.M001124200; Case RB, 2000, CURR BIOL, V10, P157, DOI 10.1016/S0960-9822(00)00316-X; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; Crevel I, 1999, EMBO J, V18, P5863, DOI 10.1093/emboj/18.21.5863; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; Farrell CM, 2002, J BIOL CHEM, V277, P17079, DOI 10.1074/jbc.M108793200; Foster KA, 1998, J BIOL CHEM, V273, P35307, DOI 10.1074/jbc.273.52.35307; Foster KA, 2001, J BIOL CHEM, V276, P19259, DOI 10.1074/jbc.M008347200; Furch M, 1999, J MOL BIOL, V290, P797, DOI 10.1006/jmbi.1999.2921; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Gilbert SP, 2000, METHODS, V22, P337, DOI 10.1006/meth.2000.1086; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; Hackney DD, 2002, BIOCHEMISTRY-US, V41, P4437, DOI 10.1021/bi0159229; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Kliche W, 2001, EMBO J, V20, P40, DOI 10.1093/emboj/20.1.40; Klumpp LM, 2003, BIOCHEMISTRY-US, V42, P2595, DOI 10.1021/bi026715r; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 2002, J CELL SCI, V115, P15; Kull FJ, 1998, J MUSCLE RES CELL M, V19, P877, DOI 10.1023/A:1005489907021; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Mackey AT, 2000, BIOCHEMISTRY-US, V39, P1346, DOI 10.1021/bi991918+; Mandelkow E, 1998, TRENDS BIOCHEM SCI, V23, P429, DOI 10.1016/S0968-0004(98)01278-X; Minehardt TJ, 2001, BIOPHYS J, V80, P1151, DOI 10.1016/S0006-3495(01)76092-4; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; MOYER ML, 1998, THESIS PENNSYLVANIA; Muller J, 1999, BIOL CHEM, V380, P981, DOI 10.1515/BC.1999.122; Naber N, 2003, BIOPHYS J, V84, P3190, DOI 10.1016/S0006-3495(03)70043-5; Onishi H, 1998, P NATL ACAD SCI USA, V95, P6653, DOI 10.1073/pnas.95.12.6653; Onishi H, 2002, P NATL ACAD SCI USA, V99, P15339, DOI 10.1073/pnas.242604099; Pate E, 1997, BIOCHEMISTRY-US, V36, P12155, DOI 10.1021/bi970996z; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rosenfeld SS, 2002, J BIOL CHEM, V277, P36731, DOI 10.1074/jbc.M205261200; Rosenfeld SS, 2001, J BIOL CHEM, V276, P40167, DOI 10.1074/jbc.M103899200; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Sack S, 1999, EUR J BIOCHEM, V262, P1, DOI 10.1046/j.1432-1327.1999.00341.x; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; Schnitzer MJ, 2000, NAT CELL BIOL, V2, P718, DOI 10.1038/35036345; Shimada T, 1997, BIOCHEMISTRY-US, V36, P14037, DOI 10.1021/bi971837i; Sindelar CV, 2002, NAT STRUCT BIOL, V9, P844, DOI 10.1038/nsb852; Skiniotis G, 2003, EMBO J, V22, P1518, DOI 10.1093/emboj/cdg164; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Song YH, 2001, EMBO J, V20, P6213, DOI 10.1093/emboj/20.22.6213; Sosa H, 2001, NAT STRUCT BIOL, V8, P540, DOI 10.1038/88611; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; Tomishige M, 2000, J CELL BIOL, V151, P1081, DOI 10.1083/jcb.151.5.1081; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Wriggers W, 1998, BIOPHYS J, V75, P646, DOI 10.1016/S0006-3495(98)77555-1; Yun MY, 2001, EMBO J, V20, P2611, DOI 10.1093/emboj/20.11.2611	63	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39059	39067		10.1074/jbc.M304250200	http://dx.doi.org/10.1074/jbc.M304250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12860992	Green Accepted, hybrid			2022-12-25	WOS:000185575100119
J	Kupke, T; Hernandez-Acosta, P; Culianez-Macia, FA				Kupke, T; Hernandez-Acosta, P; Culianez-Macia, FA			4 '-phosphopantetheine and coenzyme A biosynthesis in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANTOTHENATE KINASE GENE; BACTERIAL DFP FLAVOPROTEINS; ESCHERICHIA-COLI; MOLECULAR CHARACTERIZATION; ARABIDOPSIS-THALIANA; PHOSPHOPANTETHEINE ADENYLYLTRANSFERASE; PHOSPHOPANTOTHENOYLCYSTEINE SYNTHETASE; CRYSTAL-STRUCTURE; COA SYNTHASE; 4'-PHOSPHOPANTOTHENOYLCYSTEINE	Coenzyme A is required for many synthetic and degradative reactions in intermediary metabolism and is the principal acyl carrier in prokaryotic and eukaryotic cells. Coenzyme A is synthesized in five steps from pantothenate, and recently the CoaA biosynthetic genes in bacteria and human have all been identified and characterized. Coenzyme A biosynthesis in plants is not fully understood, and to date only the AtHAL3a (AtCoaC) gene of Arabidopsis thaliana has been cloned and identified as 4'-phosphopantothenoylcysteine (PPC) decarboxylase (Kupke, T., Hernandez-Acosta, P., Steinbacher, S., and Culianez-Macia, F. A. (2001) J. Biol. Chem. 276, 19190-19196). Here, we demonstrate the cloning of the four missing genes, purification of the enzymes, and identification of their functions. In contrast to bacterial PPC synthetases, the plant synthetase is not CTP- but ATP-dependent. The complete biosynthetic pathway from pantothenate to coenzyme A was reconstituted in vitro by adding the enzymes pantothenate kinase (AtCoaA), 4'-phosphopantothenoylcysteine synthetase (AtCoaB), 4'-phosphopantothenoylcysteine decarboxylase (AtCoaC), 4'-phosphopantetheine adenylyltransferase (AtCoaD), and dephospho-coenzyme A kinase (AtCoaE) to a mixture containing pantothenate, cysteine, ATP, dithiothreitol, and Mg2+.	Univ Tubingen, Lehrstuhl Mikrobielle Genet, D-72076 Tubingen, Germany; Univ Politecn Valencia, CSIC, Inst Biol Mol & Celular Plantas, E-46022 Valencia, Spain	Eberhard Karls University of Tubingen; Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP)	Kupke, T (corresponding author), Univ Tubingen, Lehrstuhl Mikrobielle Genet, Morgenstelle 15,Verfugungsgebaude, D-72076 Tubingen, Germany.	thomas.kupke@t-online.de; faculia@ibmcp.upv.es	Zhang, Ning/F-1387-2014	Kupke, Thomas/0000-0003-2341-1710				Abiko Y., 1975, Metabolism of sulphur compounds., P1; ABIKO Y, 1968, J BIOCHEM-TOKYO, V64, P115, DOI 10.1093/oxfordjournals.jbchem.a128855; ABIKO Y, 1967, J BIOCHEM-TOKYO, V61, P309, DOI 10.1093/oxfordjournals.jbchem.a128549; Aghajanian S, 2002, BIOCHEM J, V365, P13, DOI 10.1042/BJ20020569; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Begley TP, 2001, VITAM HORM, V61, P157; Blaesse M, 2000, EMBO J, V19, P6299, DOI 10.1093/emboj/19.23.6299; BROWN GM, 1959, J BIOL CHEM, V234, P370; Calder RB, 1999, J BIOL CHEM, V274, P2014, DOI 10.1074/jbc.274.4.2014; Choudhry AE, 2003, ANTIMICROB AGENTS CH, V47, P2051, DOI 10.1128/AAC.47.6.2051-2055.2003; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; Daugherty M, 2002, J BIOL CHEM, V277, P21431, DOI 10.1074/jbc.M201708200; DICOMO CJ, 1995, GENETICS, V139, P95; Espinosa-Ruiz A, 1999, PLANT J, V20, P529, DOI 10.1046/j.1365-313X.1999.00626.x; FALK KL, 1993, ARCH BIOCHEM BIOPHYS, V301, P424, DOI 10.1006/abbi.1993.1166; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; Geerlof A, 1999, J BIOL CHEM, V274, P27105, DOI 10.1074/jbc.274.38.27105; Gerdes SY, 2002, J BACTERIOL, V184, P4555, DOI 10.1128/JB.184.16.4555-4572.2002; HELDT HW, 1997, PLANT BIOCH MOL BIOL, P124; Hernandez-Acosta P, 2002, J BIOL CHEM, V277, P20490, DOI 10.1074/jbc.M201557200; JACKOWSKI S, 1996, ESCHERICHIA COLI SAL, V1, P687; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kleinkauf Horst, 2000, Biofactors, V11, P91; Kupke T, 2000, J BIOL CHEM, V275, P31838, DOI 10.1074/jbc.M004273200; Kupke T, 2002, J BIOL CHEM, V277, P36137, DOI 10.1074/jbc.M206188200; Kupke T, 2001, J BIOL CHEM, V276, P19190, DOI 10.1074/jbc.M100776200; Kupke T, 2001, J BIOL CHEM, V276, P27597, DOI 10.1074/jbc.M103342200; LYNEN F, 1973, NOBEL LECTURES 1963, P103; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mishra PK, 2001, J BACTERIOL, V183, P2774, DOI 10.1128/JB.183.9.2774-2778.2001; Ni XH, 2002, INT J BIOCHEM CELL B, V34, P109, DOI 10.1016/S1357-2725(01)00114-5; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; Steinbacher S, 2003, J MOL BIOL, V327, P193, DOI 10.1016/S0022-2836(03)00092-5; Strauss E, 2001, J AM CHEM SOC, V123, P6449, DOI 10.1021/ja016020y; Strauss E, 2001, J BIOL CHEM, V276, P13513, DOI 10.1074/jbc.C100033200; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Zhao LH, 2003, EUR J MED CHEM, V38, P345, DOI 10.1016/S0223-5234(03)00047-3; Zhou B, 2001, NAT GENET, V28, P345, DOI 10.1038/ng572; Zhyvoloup A, 2002, J BIOL CHEM, V277, P22107, DOI 10.1074/jbc.C200195200	42	48	59	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38229	38237		10.1074/jbc.M306321200	http://dx.doi.org/10.1074/jbc.M306321200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12860978	hybrid			2022-12-25	WOS:000185575100019
J	Pop, OI; Westermann, M; Volkmer-Engert, R; Schulz, D; Lemke, C; Schreiber, S; Gerlach, R; Wetzker, R; Muller, JP				Pop, OI; Westermann, M; Volkmer-Engert, R; Schulz, D; Lemke, C; Schreiber, S; Gerlach, R; Wetzker, R; Muller, JP			Sequence-specific binding of prePhoD to soluble TatA(d) indicates protein-mediated targeting of the Tat export in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE TRANSLOCATION PATHWAY; ESCHERICHIA-COLI; SIGNAL PEPTIDE; ALKALINE-PHOSPHATASE; THYLAKOID MEMBRANES; PRECURSOR PROTEINS; CONSENSUS MOTIF; SEC; SYSTEM; COMPLEX	The Tat (twin-arginine protein translocation) system initially discovered in the thylakoid membrane of chloroplasts has been described recently for a variety of eubacterial organisms. Although in Escherichia coli four Tat proteins with calculated membrane spanning domains have been demonstrated to mediate Tat-dependent transport, a specific transport system for twin-arginine signal peptide containing phosphodiesterase PhoD of Bacillus subtilis consists of one TatA/TatC (TatA(d)/TatC(d)) pair of proteins. Here, we show that TatA(d) was found beside its membrane-integrated localization in the cytosol were it interacted with prePhoD. prePhoD was efficiently co-immunoprecipitated by TatA(d). Inefficient co-immunoprecipitation of mature PhoD and missing interaction to Sec-dependent and cytosolic peptides by TatA(d) demonstrated a particular role of the twin-arginine signal peptide for this interaction. Affinity of prePhoD to TatA(d) was interfered by peptides containing the twin-arginine motif but remained active when the arginine residues were substituted. The selective binding of TatA(d) to peptides derived from the signal peptide of PhoD elucidated the function of the twin-arginine motif as a target site for pre-protein TatA(d) interaction. Substitution of the binding motif demonstrated the pivotal role of basic amino acid residues for TatA binding. These features suggest that TatA interacts prior to membrane integration with its pre-protein substrate and could therefore assist targeting of twin-arginine pre-proteins.	Univ Jena, Inst Mol Biol, D-07745 Jena, Germany; Univ Jena Klinikum, Inst Ultrastrukturforsch, D-07743 Jena, Germany; Charite, Abt Mol Bibliotheken, D-10117 Berlin, Germany; Univ Jena, Inst Anat 1, D-07743 Jena, Germany; Univ Jena Klinikum, Arbeitsgrp Mol Zellbiol, D-07747 Jena, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Muller, JP (corresponding author), Univ Jena, Inst Mol Biol, Hans Knoll Str 2, D-07745 Jena, Germany.		Wetzker, Reinhard/AAD-8713-2019	Gerlach, Roman/0000-0002-5718-4758; Volkmer, Rudolf/0000-0003-4710-1143				Alami M, 2002, J BIOL CHEM, V277, P20499, DOI 10.1074/jbc.M201711200; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Bolhuis A, 2000, FEBS LETT, V472, P88, DOI 10.1016/S0014-5793(00)01428-9; Bruser T, 2003, EUR J BIOCHEM, V270, P1211, DOI 10.1046/j.1432-1033.2003.03481.x; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; CLINE K, 1992, J BIOL CHEM, V267, P2688; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; De Leeuw E, 2001, FEBS LETT, V506, P143, DOI 10.1016/S0014-5793(01)02904-0; DELISA MP, 2002, J BIOL CHEM; Dilks K, 2003, J BACTERIOL, V185, P1478, DOI 10.1128/JB.185.4.1478-1483.2003; Dreusch A, 1997, BBA-BIOENERGETICS, V1319, P311, DOI 10.1016/S0005-2728(96)00174-0; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Economou A, 1999, TRENDS MICROBIOL, V7, P315, DOI 10.1016/S0966-842X(99)01555-3; Eder S, 1996, MICROBIOL-SGM, V142, P2041, DOI 10.1099/13500872-142-8-2041; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Fujimoto K, 1997, HISTOCHEM CELL BIOL, V107, P87, DOI 10.1007/s004180050092; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gerharz CD, 2001, UROLOGY, V58, P821, DOI 10.1016/S0090-4295(01)01371-1; Gouffi K, 2002, FEBS LETT, V525, P65, DOI 10.1016/S0014-5793(02)03069-7; Gross R, 1999, ARCH MICROBIOL, V172, P227, DOI 10.1007/s002030050764; Halbig D, 1999, EUR J BIOCHEM, V263, P543, DOI 10.1046/j.1432-1327.1999.00536.x; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; Hinsley AP, 2001, FEBS LETT, V497, P45, DOI 10.1016/S0014-5793(01)02428-0; HULETT FM, 1990, J BACTERIOL, V172, P735, DOI 10.1128/jb.172.2.735-740.1990; Jongbloed JDH, 2002, J BIOL CHEM, V277, P44068, DOI 10.1074/jbc.M203191200; Jongbloed JDH, 2000, J BIOL CHEM, V275, P41350, DOI 10.1074/jbc.M004887200; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leenhouts K, 1998, APPL MICROBIOL BIOT, V49, P417, DOI 10.1007/s002530051192; LEGRICE SFJ, 1990, METHOD ENZYMOL, V185, P201; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; MULLER J, 1992, MOL GEN GENET, V235, P89, DOI 10.1007/BF00286185; Muller JP, 1999, FEMS MICROBIOL LETT, V180, P287; Muller JP, 1997, MICROBIOL-SGM, V143, P947, DOI 10.1099/00221287-143-3-947; Muller JP, 2000, BIOCHEM J, V348, P367, DOI 10.1042/0264-6021:3480367; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Oresnik IJ, 2001, MOL MICROBIOL, V40, P323, DOI 10.1046/j.1365-2958.2001.02391.x; Pop O, 2002, J BIOL CHEM, V277, P3268, DOI 10.1074/jbc.M110829200; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rivas S, 2002, PLANT CELL, V14, P689, DOI [10.1105/tpc.010357, 10.​1105/​tpc.​010357]; Robinson C, 1997, TRENDS PLANT SCI, V2, P431, DOI 10.1016/S1360-1385(97)90027-3; Robinson C, 2001, NAT REV MOL CELL BIO, V2, P350, DOI 10.1038/35073038; Robinson C, 2000, BIOL CHEM, V381, P89, DOI 10.1515/BC.2000.013; Rodrigue A, 1999, J BIOL CHEM, V274, P13223, DOI 10.1074/jbc.274.19.13223; Sambrook J., 2002, MOL CLONING LAB MANU; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Sargent F, 2001, TRENDS MICROBIOL, V9, P196, DOI 10.1016/S0966-842X(01)02017-0; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Settles AM, 1998, TRENDS CELL BIOL, V8, P494, DOI 10.1016/S0962-8924(98)01387-7; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Steinmetzer K, 1997, J MOL BIOL, V269, P684, DOI 10.1006/jmbi.1997.1083; Takizawa T, 2000, HISTOL HISTOPATHOL, V15, P515, DOI 10.14670/HH-15.515; Thomas JD, 2001, MOL MICROBIOL, V39, P47, DOI 10.1046/j.1365-2958.2001.02253.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T; Westermarck J, 2002, EMBO J, V21, P451, DOI 10.1093/emboj/21.3.451; Wu LF, 2000, J MOL MICROB BIOTECH, V2, P179; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472; YAMANE K, 1978, J BACTERIOL, V134, P108, DOI 10.1128/JB.134.1.108-114.1978; Yen MR, 2002, ARCH MICROBIOL, V177, P441, DOI 10.1007/s00203-002-0408-4	71	52	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38428	38436		10.1074/jbc.M306516200	http://dx.doi.org/10.1074/jbc.M306516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12867413	hybrid			2022-12-25	WOS:000185575100043
J	Ying, SX; Hussain, ZJ; Zhang, YE				Ying, SX; Hussain, ZJ; Zhang, YE			Smurf1 facilitates myogenic differentiation and antagonizes the bone morphogenetic protein-2-induced osteoblast conversion by targeting Smad5 for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; TGF-BETA RECEPTOR; E3 UBIQUITIN LIGASE; SIGNAL-TRANSDUCTION; C2C12 MYOBLASTS; I RECEPTORS; CELL-LINE; EXPRESSION; MUSCLE; SUPERFAMILY	Controlled proteolysis mediated by Smad ubiquitination regulatory factors (Smurfs) plays a crucial role in modulating cellular responses to signaling of the transforming growth factor-beta (TGF-beta) superfamily. However, it is not clear what influences the selectivity of Smurfs in the individual signaling pathway, nor is it clear the biological function of Smurfs in vivo. Using a mouse C2C12 myoblast cell differentiation system, which is subject to control by both TGF-beta and bone morphogenetic protein (BMP), here we examine the role of Smurf1 in myogenic differentiation. We show that increased expression of Smurf1 promotes myogenic differentiation of C2C12 cells and blocks the BMP-induced osteogenic conversion but has no effect on the TGF-beta-induced differentiation arrest. Consistent with an inhibitory role in the BMP signaling pathway, the elevated Smurf1 markedly reduces the level of endogenous Smad5, whereas it leaves unaltered that of Smad2, Smad3, and Smad7, which are components of the TGF-beta pathway. Adding back Smad5 from a different source to the Smurf1-overexpressing cells restores the BMP-mediated osteoblast conversion. Finally, by depletion of the endogenous Smurf1 through small interfering RNA-mediated RNA interference, we demonstrate that Smurf1 is required for the myogenic differentiation of C2C12 cells and plays an important regulatory role in the BMP-2-mediated osteoblast conversion.	NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhang, YE (corresponding author), NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bldg 37,Rm 1C27, Bethesda, MD 20892 USA.		Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	Intramural NIH HHS [Z01 BC010419-08, ZIA BC011168-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010419] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki H, 2001, J CELL SCI, V114, P1483; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Faure S, 2000, DEVELOPMENT, V127, P2917; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moustakas A, 2001, J CELL SCI, V114, P4359; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	37	70	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39029	39036		10.1074/jbc.M301193200	http://dx.doi.org/10.1074/jbc.M301193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871975	hybrid, Green Accepted			2022-12-25	WOS:000185575100115
J	Harwood, HJ; Petras, SF; Shelly, LD; Zaccaro, LM; Perry, DA; Makowski, MR; Hargrove, DM; Martin, KA; Tracey, WR; Chapman, JG; Magee, WP; Dalvie, DK; Soliman, VF; Martin, WH; Mularski, CJ; Eisenbeis, SA				Harwood, HJ; Petras, SF; Shelly, LD; Zaccaro, LM; Perry, DA; Makowski, MR; Hargrove, DM; Martin, KA; Tracey, WR; Chapman, JG; Magee, WP; Dalvie, DK; Soliman, VF; Martin, WH; Mularski, CJ; Eisenbeis, SA			Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; INSULIN-RESISTANCE; MUSCLE; PURIFICATION; SECRETION; MECHANISM; CLONING; BETA; IDENTIFICATION; ACTIVATION	Inhibition of acetyl-CoA carboxylase (ACC), with its resultant inhibition of fatty acid synthesis and stimulation of fatty acid oxidation, has the potential to favorably affect the multitude of cardiovascular risk factors associated with the metabolic syndrome. To achieve maximal effectiveness, an ACC inhibitor should inhibit both the lipogenic tissue isozyme (ACC1) and the oxidative tissue isozyme (ACC2). Herein, we describe the biochemical and acute physiological properties of CP-610431, an isozyme-nonselective ACC inhibitor identified through high throughput inhibition screening, and CP-640186, an analog with improved metabolic stability. CP-610431 inhibited ACC1 and ACC2 with IC(50)s of similar to50 nM. Inhibition was reversible, uncompetitive with respect to ATP, and non-competitive with respect to bicarbonate, acetyl-CoA, and citrate, indicating interaction with the enzymatic carboxyl transfer reaction. CP-610431 also inhibited fatty acid synthesis, triglyceride (TG) synthesis, TG secretion, and apolipoprotein B secretion in HepG2 cells ( ACC1) with EC(50)s of 1.6, 1.8, 3.0, and 5.7 muM, without affecting either cholesterol synthesis or apolipoprotein CIII secretion. CP-640186, also inhibited both isozymes with IC(50)s of similar to55 nM but was 2-3 times more potent than CP-610431 in inhibiting HepG2 cell fatty acid and TG synthesis. CP-640186 also stimulated fatty acid oxidation in C2C12 cells ( ACC2) and in rat epitrochlearis muscle strips with EC(50)s of 57 nM and 1.3 muM. In rats, CP-640186 lowered hepatic, soleus muscle, quadriceps muscle, and cardiac muscle malonyl-CoA with ED(50)s of 55, 6, 15, and 8 mg/kg. Consequently, CP-640186 inhibited fatty acid synthesis in rats, CD1 mice, and ob/ob mice with ED(50)s of 13, 11, and 4 mg/kg, and stimulated rat whole body fatty acid oxidation with an ED50 of similar to30 mg/kg. Taken together, These observations indicate that isozyme-nonselective ACC inhibition has the potential to favorably affect risk factors associated with the metabolic syndrome.	Pfizer Inc, Pfizer Global Res & Dev, Groton Labs, Dept Cardiovasc & Metab Dis, Groton, CT 06340 USA	Pfizer	Harwood, HJ (corresponding author), Pfizer Inc, Pfizer Global Res & Dev, Groton Labs, Dept Cardiovasc & Metab Dis, Groton, CT 06340 USA.	h_james_harwood@groton.pfizer.com						Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; AbuElheiga L, 1997, J BIOL CHEM, V272, P10669; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; ALFEEL W, 1992, P NATL ACAD SCI USA, V89, P4534, DOI 10.1073/pnas.89.10.4534; ARBEENY CM, 1992, J LIPID RES, V33, P843; Bai YL, 1996, J BIOL CHEM, V271, P13939, DOI 10.1074/jbc.271.24.13939; BEATY NB, 1982, J BIOL CHEM, V257, P924; BIANCHI A, 1990, J BIOL CHEM, V265, P1502; Bjorntorp Per, 1994, Current Opinion in Lipidology, V5, P166, DOI 10.1097/00041433-199405030-00003; Brun T, 1996, DIABETES, V45, P190, DOI 10.2337/diabetes.45.2.190; BUCKLEY MG, 1987, BIOCHEM J, V243, P437, DOI 10.1042/bj2430437; CHEN SY, 1994, DIABETES, V43, P878, DOI 10.2337/diabetes.43.7.878; Chien D, 2000, AM J PHYSIOL-ENDOC M, V279, pE259, DOI 10.1152/ajpendo.2000.279.2.E259; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; CREPALDI G, 1995, ATHEROSCLEROSIS, V10, P511; Despres Jean-Pierre, 1994, Current Opinion in Lipidology, V5, P274, DOI 10.1097/00041433-199408000-00006; FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; FUKUDA N, 1984, J LIPID RES, V25, P831; Grundy SM, 1999, AM J CARDIOL, V83, p25F; Ha J, 1996, P NATL ACAD SCI USA, V93, P11466, DOI 10.1073/pnas.93.21.11466; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; Haghpassand M, 1996, J LIPID RES, V37, P1468; HAGHPASSAND M, 1995, ATHEROSCLEROSIS, V117, P199, DOI 10.1016/0021-9150(95)05572-E; Harwood HJ, 1997, BIOCHEM PHARMACOL, V53, P839, DOI 10.1016/S0006-2952(96)00892-1; HARWOOD HJ, 1990, BIOCHEM PHARMACOL, V40, P1281, DOI 10.1016/0006-2952(90)90394-Z; HASHIMOT.T, 1971, EUR J BIOCHEM, V18, P319, DOI 10.1111/j.1432-1033.1971.tb01247.x; HOWARD BV, 1995, ATHEROSCLEROSIS, V10, P516; Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683; IVERSON AJ, 1990, BIOCHEM J, V269, P365, DOI 10.1042/bj2690365; KEMPEN HJ, 1995, J LIPID RES, V36, P1796; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; MCCUNE SA, 1979, J BIOL CHEM, V254, P95; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MCGARRY JD, 1978, J BIOL CHEM, V253, P8291; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Munday MR, 1999, ADV ENZYME REGUL, V39, P205, DOI 10.1016/S0065-2571(98)00016-8; OGIWARA H, 1978, EUR J BIOCHEM, V89, P33, DOI 10.1111/j.1432-1033.1978.tb20893.x; PARKER RA, 1977, J MED CHEM, V20, P781, DOI 10.1021/jm00216a009; Petras SF, 1999, J LIPID RES, V40, P24; Rasmussen BB, 2002, J CLIN INVEST, V110, P1687, DOI 10.1172/JCI200215715; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SAHA AK, 1995, AM J PHYSIOL-ENDOC M, V269, pE283, DOI 10.1152/ajpendo.1995.269.2.E283; Tanabe T, 1981, Methods Enzymol, V71 Pt C, P5; THAMPY KG, 1985, J BIOL CHEM, V260, P6318; Trevisan M, 1998, AM J EPIDEMIOL, V148, P958; TRISCARI J, 1984, INT J OBESITY, V8, P227; TRUMBLE GE, 1995, EUR J BIOCHEM, V231, P192, DOI 10.1111/j.1432-1033.1995.tb20686.x; WHITTINGTON FM, 1987, INT J OBESITY, V11, P619; Widmer J, 1996, BIOCHEM J, V316, P915, DOI 10.1042/bj3160915; WINDER WW, 1990, AM J PHYSIOL, V259, pE266, DOI 10.1152/ajpendo.1990.259.2.E266	56	199	227	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37099	37111		10.1074/jbc.M304481200	http://dx.doi.org/10.1074/jbc.M304481200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12842871	hybrid			2022-12-25	WOS:000185437200016
J	Lookene, A; Zhang, LY; Tougu, V; Olivecrona, G				Lookene, A; Zhang, LY; Tougu, V; Olivecrona, G			1,1 '-bis(anilino)-4-,4 '-bis(naphtalene)-8,8 '-disulfonate acts as an inhibitor of lipoprotein lipase and competes for binding with apolipoprotein CII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-II; CONFORMATIONAL-CHANGES; CATALYZED HYDROLYSIS; ENERGY-METABOLISM; PANCREATIC LIPASE; COFACTOR-BINDING; HEPARIN-BINDING; MOLTEN GLOBULE; HEPATIC LIPASE; PROTEIN	Lipoprotein lipase (LPL) is dependent on apolipoprotein CII (apoCII), a component of plasma lipoproteins, for function in vivo. The hydrophobic fluorescent probe 1,1'-bis(anilino)-4,4'-bis(naphthalene)-8,8'-disulfonate (bis-ANS) was found to be a potent inhibitor of LPL. ApoCII prevented the inhibition by bis-ANS, and was also able to restore the activity of inhibited LPL in a competitive manner, but only with triacylglycerols with acyl chains longer than three carbons. Studies of fluorescence and surface plasmon resonance indicated that LPL has an exposed hydrophobic site for binding of bis-ANS. The high affinity interaction was characterized by an equilibrium constant K-d of 0.10-0.26 muM and by a relatively high on rate constant k(as)s = 2.0 x 10(4) M-1 s(-1) and a slow off-rate with a dissociation rate constant k(diss) = 1.2 x 10(-4) s(-1). The high affinity binding of bis-ANS did not influence interaction of LPL with heparin or with lipid/water interfaces and did not dissociate the active LPL dimer into monomers. Analysis of fragments of LPL after photoincorporation of bis-ANS indicated that the high affinity binding site was located in the middle part of the N-terminal folding domain. We propose that bis-ANS binds to an exposed hydrophobic area that is located close to the active site. This area may be the binding site for individual substrate molecules and also for apoCII.	Umea Univ, Dept Med Biosci, SE-90187 Umea, Sweden; Tallinn Univ Technol, Dept Gene Technol, EE-19086 Tallinn, Estonia; NICPB, EE-12618 Tallinn, Estonia	Umea University; Tallinn University of Technology; National Institute of Chemical Physics & Biophysics (NICPB)	Olivecrona, G (corresponding author), Umea Univ, Dept Med Biosci, Bldg 6M,3rd Floor, SE-90187 Umea, Sweden.	Gunilla.Olivecrona@medbio.umu.se	Tõugu, Vello/B-4462-2019	Tougu, Vello/0000-0002-6271-7993				BENGTSSON G, 1980, EUR J BIOCHEM, V106, P549, DOI 10.1111/j.1432-1033.1980.tb04602.x; BENGTSSON G, 1980, EUR J BIOCHEM, V106, P557, DOI 10.1111/j.1432-1033.1980.tb04603.x; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; BENGTSSONOLIVECRONA G, 1986, EUR J BIOCHEM, V161, P281, DOI 10.1111/j.1432-1033.1986.tb10444.x; BENGTSSONOLIVECRONA G, 1985, BIOCHEM J, V226, P409, DOI 10.1042/bj2260409; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; Carneiro FA, 2001, J BIOL CHEM, V276, P62, DOI 10.1074/jbc.M008753200; Chakraborty S, 1999, BBA-PROTEIN STRUCT M, V1432, P350, DOI 10.1016/S0167-4838(99)00110-7; Chapeaurouge A, 2002, J BIOL CHEM, V277, P16478, DOI 10.1074/jbc.M105232200; CHAPUS C, 1981, EUR J BIOCHEM, V115, P99; Chatterjee S, 2002, PROTEINS, V49, P554, DOI 10.1002/prot.10236; Davis TM, 2000, ANAL BIOCHEM, V284, P348, DOI 10.1006/abio.2000.4726; EDWARDS K, 1994, BIOCHEMISTRY-US, V33, P13304, DOI 10.1021/bi00249a017; GARNER CW, 1972, J BIOL CHEM, V247, P561; Gaspar LP, 1997, J MOL BIOL, V273, P456, DOI 10.1006/jmbi.1997.1299; Goldberg IJ, 2001, FRONT BIOSCI-LANDMRK, V6, pD388, DOI 10.2741/Goldberg; Hill JS, 1998, J BIOL CHEM, V273, P30979, DOI 10.1074/jbc.273.47.30979; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; Joniau M, 2001, PROTEINS, V44, P1, DOI 10.1002/prot.1065; KINNUNEN PKJ, 1977, P NATL ACAD SCI USA, V74, P4848, DOI 10.1073/pnas.74.11.4848; Kobayashi Y, 2002, EUR J BIOCHEM, V269, P4701, DOI 10.1046/j.1432-1033.2002.03179.x; LAROSA JC, 1970, BIOCHEM BIOPH RES CO, V41, P57, DOI 10.1016/0006-291X(70)90468-7; Lichtarge O, 2002, CURR OPIN STRUC BIOL, V12, P21, DOI 10.1016/S0959-440X(02)00284-1; LOOKENE A, 1993, EUR J BIOCHEM, V213, P185, DOI 10.1111/j.1432-1033.1993.tb17747.x; Lookene A, 1997, BIOCHEMISTRY-US, V36, P5267, DOI 10.1021/bi962699k; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; LOOKENE A, 1994, EUR J BIOCHEM, V222, P395, DOI 10.1111/j.1432-1033.1994.tb18878.x; LYCKSELL PO, 1992, EUR J BIOCHEM, V205, P223, DOI 10.1111/j.1432-1033.1992.tb16772.x; McIlhargey TL, 2003, J BIOL CHEM, V278, P23027, DOI 10.1074/jbc.M300315200; MCLEAN LR, 1985, BIOCHEMISTRY-US, V24, P4196, DOI 10.1021/bi00336a057; Moore SA, 2001, J MOL BIOL, V312, P511, DOI 10.1006/jmbi.2001.4979; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; Olivecrona G, 1997, METHOD ENZYMOL, V286, P102; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PETERSON J, 1990, P NATL ACAD SCI USA, V87, P909, DOI 10.1073/pnas.87.3.909; Preiss-Landl K, 2002, CURR OPIN LIPIDOL, V13, P471, DOI 10.1097/00041433-200210000-00002; Primm TP, 2001, J BIOL CHEM, V276, P281, DOI 10.1074/jbc.M007670200; RAPP D, 1978, EUR J BIOCHEM, V91, P379, DOI 10.1111/j.1432-1033.1978.tb12690.x; Razzaghi H, 2001, J MOL GRAPH MODEL, V19, P487, DOI 10.1016/S1093-3263(00)00096-6; Seale JW, 1998, METHOD ENZYMOL, V290, P318, DOI 10.1016/S0076-6879(98)90028-3; Shen Y, 2002, J BIOL CHEM, V277, P4334, DOI 10.1074/jbc.M105421200; SHI L, 1994, BIOCHEMISTRY-US, V33, P7536, DOI 10.1021/bi00190a006; SHINOMIYA M, 1983, BIOCHEM BIOPH RES CO, V113, P811, DOI 10.1016/0006-291X(83)91071-9; SHINOMIYA M, 1984, J BIOL CHEM, V259, P8724; SKOTTOVA N, 1995, J LIPID RES, V36, P1334; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; WHITE ZW, 1995, J BIOL CHEM, V270, P20404, DOI 10.1074/jbc.270.35.20404; Wong H, 2002, J LIPID RES, V43, P993, DOI 10.1194/jlr.R200007-JLR200; Wong H, 1997, P NATL ACAD SCI USA, V94, P5594, DOI 10.1073/pnas.94.11.5594; Zdunek J, 2003, BIOCHEMISTRY-US, V42, P1872, DOI 10.1021/bi0267184	53	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37183	37194		10.1074/jbc.M303894200	http://dx.doi.org/10.1074/jbc.M303894200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855707	hybrid			2022-12-25	WOS:000185437200026
J	Wen, YF; Caffrey, TC; Wheelock, MJ; Johnson, KR; Hollingsworth, MA				Wen, YF; Caffrey, TC; Wheelock, MJ; Johnson, KR; Hollingsworth, MA			Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA-ASSOCIATED ANTIGEN; CANCER CELL-LINE; GROWTH-FACTOR RECEPTOR; E-SELECTIN BINDING; CYCLIN D1; SIGNAL-TRANSDUCTION; LEUKOCYTE ADHESION; TUMOR-SUPPRESSOR; GAMMA-CATENIN; BREAST-CANCER	MUC1, an integral membrane mucin associated with the metastatic phenotype, is overexpressed by most human carcinoma cells. The MUC1 cytoplasmic tail (CT) is postulated to function in morphogenetic signal transduction via interactions with Grb2/Sos, c-Src, and beta-catenin. We investigated intracellular trafficking of the MUC1 CT, using epitope-tagged constructs that were overexpressed in human pancreatic cancer cell lines S2-013 and Panc-1. The MUC1 CT was detected at the inner cell surface, in the cytosol, and in the nucleus of cells overexpressing MUC1. Fragments of the MUC1 CT were associated with beta-catenin in both cytoplasm and nuclei. Overexpression of MUC1 increased steady state levels of nuclear beta-catenin but decreased nuclear levels of plakoglobin (gamma-catenin). There was no detectable association between plakoglobin and the MUC1 CT. Coimmunoprecipitation experiments revealed that the cytoplasmic and nuclear association of MUC1 CT and beta-catenin was not affected by disruption of Ca2+-dependent intercellular cadherin interactions. These results demonstrate nuclear localization of fragments of MUC1 CT in association with beta-catenin and raise the possibility that overexpression of the MUC1 CT stabilizes beta-catenin and enhances levels of nuclear beta-catenin during disruption of cadherin-mediated cell-cell adhesion.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Oral Biol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Hollingsworth, MA (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst, 986805 NE Med Ctr, Omaha, NE 68198 USA.	mahollin@unmc.edu			NATIONAL CANCER INSTITUTE [P30CA036727, P50CA072712, R01CA057362] Funding Source: NIH RePORTER; NCI NIH HHS [CA36727, CA72712, CA57362] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal B, 1998, MOL MED TODAY, V4, P397, DOI 10.1016/S1357-4310(98)01322-7; BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537; Barker N, 2000, ADV CANCER RES, V77, P1; BATRA SK, 1991, J CELL SCI, V100, P841; BATRA SK, 1992, INT J PANCREATOL, V12, P271; Ben-Ze'Ev A, 1999, ANN NY ACAD SCI, V886, P37, DOI 10.1111/j.1749-6632.1999.tb09398.x; Beum PV, 1999, J BIOL CHEM, V274, P24641, DOI 10.1074/jbc.274.35.24641; BOSHELL M, 1992, BIOCHEM BIOPH RES CO, V185, P1, DOI 10.1016/S0006-291X(05)80946-5; Burdick MD, 1997, J BIOL CHEM, V272, P24198, DOI 10.1074/jbc.272.39.24198; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; De Strooper B, 2001, J CELL BIOL, V152, pF17, DOI 10.1083/jcb.152.4.F17; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Durum SK, 2003, CANCER BIOL THER, V2, P194, DOI 10.4161/cbt.2.2.351; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; Gradl D, 1999, MOL CELL BIOL, V19, P5576; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Hagen T, 2002, J BIOL CHEM, V277, P23330, DOI 10.1074/jbc.M201364200; Hayashi T, 2001, DIGESTION, V63, P87, DOI 10.1159/000051917; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; HOLLINGSWORTH MA, 1994, NUCLEIC ACIDS RES, V22, P1138, DOI 10.1093/nar/22.7.1138; IWAMURA T, 1992, J GASTROEN HEPATOL, V7, P512, DOI 10.1111/j.1440-1746.1992.tb01030.x; IWAMURA T, 1987, JPN J CANCER RES, V78, P54; Jaiswal AS, 2002, ONCOGENE, V21, P8414, DOI 10.1038/sj.onc.1205947; Kandikonda S, 1996, CELL ADHES COMMUN, V4, P13, DOI 10.3109/15419069609010760; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kohlgraf KG, 2003, CANCER RES, V63, P5011; Kolligs FT, 2000, GENE DEV, V14, P1319; LAN MS, 1990, J BIOL CHEM, V265, P15294; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, BIOCHEM BIOPH RES CO, V281, P440, DOI 10.1006/bbrc.2001.4383; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Liao J, 2000, BIOTECHNIQUES, V28, P216, DOI 10.2144/00282bm05; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; Lillehoj EP, 2001, AM J PHYSIOL-LUNG C, V280, pL181, DOI 10.1152/ajplung.2001.280.1.L181; Ling YH, 2001, MOL PHARMACOL, V59, P593, DOI 10.1124/mol.59.3.593; McDermott KM, 2001, INT J CANCER, V94, P783, DOI 10.1002/ijc.1554; Munne A, 1999, J HISTOCHEM CYTOCHEM, V47, P1089; PANDEY P, 1995, CANCER RES, V55, P4000; Parry S, 2001, BIOCHEM BIOPH RES CO, V283, P715, DOI 10.1006/bbrc.2001.4775; Pollice AA, 2000, CYTOMETRY, V42, P347, DOI 10.1002/1097-0320(20001215)42:6<347::AID-CYTO1001>3.0.CO;2-A; Regimbald LH, 1996, CANCER RES, V56, P4244; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; SAWADA T, 1994, INT J CANCER, V57, P901, DOI 10.1002/ijc.2910570621; Schroeder JA, 2002, J BIOL CHEM, V277, P22692, DOI 10.1074/jbc.M201975200; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Silverman HS, 2001, GLYCOBIOLOGY, V11, P459, DOI 10.1093/glycob/11.6.459; SPICER AP, 1991, J BIOL CHEM, V266, P15099; SPICER AP, 1995, MAMM GENOME, V6, P885, DOI 10.1007/BF00292441; STROOPER BD, 2001, NAT CELL BIOL, V3, P221; STROUT HV, 1988, BIOCHEM BIOPH RES CO, V151, P633, DOI 10.1016/S0006-291X(88)80328-0; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Venkiteswaran K, 2002, AM J PHYSIOL-CELL PH, V283, pC811, DOI 10.1152/ajpcell.00417.2001; VISHWANATHA JK, 1992, J CELL SCI, V101, P25; Wang HLL, 2002, INT J CANCER, V101, P301, DOI 10.1002/ijc.10630; Wei Q, 2002, MOL BIOL CELL, V13, P683, DOI 10.1091/mbc.01-07-0358; WOLFF DJ, 1981, J BIOL CHEM, V256, P1846; Wu R, 2001, CANCER RES, V61, P8247; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; YONEZAWA S, 1991, BIOCHEM J, V276, P599, DOI 10.1042/bj2760599; Zhang K, 1996, J CELL BIOCHEM, V60, P538, DOI 10.1002/(SICI)1097-4644(19960315)60:4<538::AID-JCB10>3.3.CO;2-A; Zhang K, 1997, TUMOR BIOL, V18, P175, DOI 10.1159/000218028	72	142	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38029	38039		10.1074/jbc.M304333200	http://dx.doi.org/10.1074/jbc.M304333200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12832415	hybrid			2022-12-25	WOS:000185437200125
J	Boucard, AA; Roy, M; Beaulieu, ME; Lavigne, P; Escher, E; Guillemette, G; Leduc, R				Boucard, AA; Roy, M; Beaulieu, ME; Lavigne, P; Escher, E; Guillemette, G; Leduc, R			Constitutive activation of the angiotensin II type 1 receptor alters the spatial proximity of transmembrane 7 to the ligand-binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2) ADRENERGIC-RECEPTOR; MEMBRANE-SPANNING SEGMENT; LIGHT-DEPENDENT CHANGES; AMINO-ACID-RESIDUES; AT(1) RECEPTOR; CONFORMATIONAL-CHANGES; EXTRACELLULAR DOMAINS; SIGNAL-TRANSDUCTION; CYTOPLASMIC END	Activation of G protein-coupled receptors by agonists involves significant movement of transmembrane domains (TM) following binding of agonist. The underlying structural mechanism by which receptor activation takes place is largely unknown but can be inferred by detecting variability within the environment of the ligand-binding pocket, which constitutes a water-accessible crevice surrounded by the seven TM helices. Using the substituted cysteine accessibility method, we initially identified those residues within the seventh transmembrane domain (TM7) of wild type angiotensin II type 1 (AT(1)) receptor that contribute to forming the binding site pocket. We have substituted successively TM7 residues ranging from Ile(276) to Tyr(302) to cysteine. Treatment of A277C, V280C, T282C, A283C, I286C, A291C, and F301C mutant receptors with the charged sulfhydryl-specific alkylating agent MTSEA significantly inhibited ligand binding, which suggests that these residues orient themselves within the water-accessible binding pocket of the AT(1) receptor. Interestingly, this pattern of acquired MTSEA sensitivity was greatly reduced for TM7 reporter cysteines engineered in a constitutively active mutant of the AT(1) receptor. Our data suggest that upon activation, TM7 of the AT(1) receptor goes through a pattern of helical movements that results in its distancing from the binding pocket per se. These studies support accumulating evidence whereby elements of TM7 of class A GPCRs promote activation of the receptor through structural rearrangements.	Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Leduc, R (corresponding author), Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada.	Richard.Leduc@USherbrooke.ca	Boucard, Antony/CAJ-3093-2022; Boucard, Antony/ABA-9769-2020	Escher, Emanuel/0000-0001-6601-987X; BOUCARD, Antony Jr/0000-0002-5538-0464; Beaulieu, Marie-Eve/0000-0001-5224-8436				Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Boucard AA, 2000, BIOCHEMISTRY-US, V39, P9662, DOI 10.1021/bi000597v; Boucard AA, 2003, BIOCHEM J, V370, P829, DOI 10.1042/BJ20021566; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; Dawson ES, 2001, MOL PHARMACOL, V59, P1187, DOI 10.1124/mol.59.5.1187; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Feng YH, 1999, J BIOL CHEM, V274, P35546, DOI 10.1074/jbc.274.50.35546; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; Gales C, 2000, J BIOL CHEM, V275, P17321, DOI 10.1074/jbc.M909801199; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Hamdan FF, 2002, BIOCHEMISTRY-US, V41, P7647, DOI 10.1021/bi016029c; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; Hunyady L, 1998, MOL PHARMACOL, V54, P427, DOI 10.1124/mol.54.2.427; Hunyady L, 1996, TRENDS PHARMACOL SCI, V17, P135, DOI 10.1016/0165-6147(96)81588-4; Inoue Y, 1997, J HYPERTENS, V15, P703, DOI 10.1097/00004872-199715070-00001; Javitch JA, 2002, METHOD ENZYMOL, V343, P137; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P10355, DOI 10.1073/pnas.91.22.10355; JOSEPH MP, 1995, J PROTEIN CHEM, V14, P381, DOI 10.1007/BF01886795; Laporte SA, 1996, MOL PHARMACOL, V49, P89; Le MT, 2002, J BIOL CHEM, V277, P23107, DOI 10.1074/jbc.C200201200; MARIE J, 1994, J BIOL CHEM, V269, P20815; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; Miura S, 2003, J BIOL CHEM, V278, P3720, DOI 10.1074/jbc.M211338200; Miura S, 2002, J BIOL CHEM, V277, P24299, DOI 10.1074/jbc.M202743200; Noda K, 1996, BIOCHEMISTRY-US, V35, P16435, DOI 10.1021/bi961593m; OHYAMA K, 1995, REGUL PEPTIDES, V57, P141, DOI 10.1016/0167-0115(95)00030-F; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perodin J, 2002, BIOCHEMISTRY-US, V41, P14348, DOI 10.1021/bi0258602; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0	41	56	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36628	36636		10.1074/jbc.M305952200	http://dx.doi.org/10.1074/jbc.M305952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12842881	hybrid			2022-12-25	WOS:000185318300094
J	Callebaut, I; Curcio-Morelli, C; Mornon, JP; Gereben, B; Buettner, C; Huang, S; Castro, B; Fonseca, TL; Harney, JW; Larsen, PR; Bianco, AC				Callebaut, I; Curcio-Morelli, C; Mornon, JP; Gereben, B; Buettner, C; Huang, S; Castro, B; Fonseca, TL; Harney, JW; Larsen, PR; Bianco, AC			The iodothyronine selenodeiodinases are thioredoxin-fold family proteins containing a glycoside hydrolase clan GH-A-like structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC CLUSTER-ANALYSIS; ANGSTROM RESOLUTION; DEIODINASE; ENVIRONMENT; MEMBRANE; IDENTIFICATION; SUBSTITUTION; RECOGNITION; EXPRESSION; CATALYSIS	The three iodothyronine selenodeiodinases catalyze the initiation and termination of thyroid hormone effects in vertebrates. Structural analyses of these proteins have been hindered by their integral membrane nature and the inefficient eukaryotic-specific pathway for selenoprotein synthesis. Hydrophobic cluster analysis used in combination with Position-specific Iterated BLAST reveals that their extramembrane portion belongs to the thioredoxin-fold superfamily for which experimental structure information exists. Moreover, a large deiodinase region imbedded in the thioredoxin fold shares strong similarities with the active site of iduronidase, a member of the clan GH-A-fold of glycoside hydrolases. This model can explain a number of results from previous mutagenesis analyses and permits new verifiable insights into the structural and functional properties of these enzymes.	Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA; Univ Paris 06, CNRS, UMR 7590, Lab Mineral Cristallog Paris, F-75252 Paris 05, France; Univ Paris 07, CNRS, UMR 7590, Lab Mineral Cristallog Paris, F-75252 Paris 05, France; Hungarian Acad Sci, Inst Expt Med, Dept Endocrine & Behav Neurobiol, H-1083 Budapest, Hungary; Harvard Univ, Sch Med, Boston, MA 02115 USA; Sanofi Synthelabo, F-94255 Gentilly, France	Harvard University; Brigham & Women's Hospital; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; Harvard University; Harvard Medical School; Sanofi-Aventis; Sanofi France	Bianco, AC (corresponding author), Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, 77 Ave Louis Pasteur,HIM Bldg 643, Boston, MA 02115 USA.	abianco@partners.org	Bianco, Antonio/AAK-6336-2020; Bianco, Antonio C/A-4965-2008; Buettner, Christoph/F-5793-2013	Bianco, Antonio/0000-0001-7737-6813; Bianco, Antonio C/0000-0001-7737-6813; Buettner, Christoph/0000-0003-0412-4062	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036256, R01DK058538] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58538, DK 36256] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baqui M, 2003, J BIOL CHEM, V278, P1206, DOI 10.1074/jbc.M210266200; Baqui MMA, 2000, ENDOCRINOLOGY, V141, P4309, DOI 10.1210/en.141.11.4309; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BERRY MJ, 1992, J BIOL CHEM, V267, P18055; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Brooks DA, 2001, GLYCOBIOLOGY, V11, P741, DOI 10.1093/glycob/11.9.741; Buettner C, 2000, ENDOCRINOLOGY, V141, P4606, DOI 10.1210/en.141.12.4606; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Callebaut I, 2000, ANN NY ACAD SCI, V923, P90; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Capitani G, 2001, J MOL BIOL, V311, P1037, DOI 10.1006/jmbi.2001.4913; COUTINHO PM, 1999, CARBOHYDRATE ACTIVE; CROTEAU W, 1995, J BIOL CHEM, V270, P16569, DOI 10.1074/jbc.270.28.16569; Curcio-Morelli C, 2003, ENDOCRINOLOGY, V144, P937, DOI 10.1210/en.2002-220960; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P1926, DOI 10.1021/bi972162m; Durand P, 1997, GLYCOBIOLOGY, V7, P277, DOI 10.1093/glycob/7.2.277; Edeling MA, 2002, STRUCTURE, V10, P973, DOI 10.1016/S0969-2126(02)00794-3; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Huang SA, 2002, J CLIN ENDOCR METAB, V87, P4457, DOI 10.1210/jc.2002-020627; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kinch LN, 2002, CURR OPIN STRUC BIOL, V12, P400, DOI 10.1016/S0959-440X(02)00338-X; Kohrle J, 1984, Horm Metab Res Suppl, V14, P42; Kuiper GGJM, 2002, ENDOCRINOLOGY, V143, P1190, DOI 10.1210/en.143.4.1190; Leonard JL, 1986, THYROID HORMONE META, P189; Lo Conte L, 2002, NUCLEIC ACIDS RES, V30, P264; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Newman J, 1999, BIOCHEMISTRY-US, V38, P16105, DOI 10.1021/bi9913855; OTTEN MH, 1983, SCIENCE, V221, P81, DOI 10.1126/science.6857270; SALVATORE D, 1995, J CLIN INVEST, V96, P2421, DOI 10.1172/JCI118299; Salvatore D, 1996, ENDOCRINOLOGY, V137, P3308, DOI 10.1210/en.137.8.3308; Sanders JP, 1997, ENDOCRINOLOGY, V138, P5153, DOI 10.1210/en.138.12.5153; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Sun BC, 1997, ENDOCRINOLOGY, V138, P5452, DOI 10.1210/en.138.12.5452; TOYODA N, 1995, J BIOL CHEM, V270, P12310, DOI 10.1074/jbc.270.20.12310; TOYODA N, 1994, J BIOL CHEM, V269, P20329; Trifonov EN, 2003, CURR OPIN STRUC BIOL, V13, P110, DOI 10.1016/S0959-440X(03)00005-8; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	42	106	108	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36887	36896		10.1074/jbc.M305725200	http://dx.doi.org/10.1074/jbc.M305725200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847093	hybrid			2022-12-25	WOS:000185318300122
J	Gonzalez-Martinez, MT				Gonzalez-Martinez, MT			Induction of a sodium-dependent depolarization by external calcium removal in human sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SPERM; ACROSOME REACTION; HUMAN-SPERMATOZOA; EGG ZP3; PROGESTERONE; CHANNELS; HYPERPOLARIZATION; MOTILITY; CA2+; CAPACITATION	Removal of external calcium with EGTA (from 2.5 mM to nanomolar levels) caused a remarkable depolarization in human sperm. This depolarization was initially fast. It was followed by a slow phase that brought the V-m to values of over 0 mV in 1 - 2 min. The slow and sustained phase correlated with a sustained decrease in intracellular calcium. However, calcium removal still induced depolarization in sperm with enhanced intracellular calcium ( induced by progesterone), indicating that the sustained depolarization was not caused by a sustained intracellular calcium decrease. The depolarization was reduced as the external sodium content was substituted with choline, indicating that it was due to a sodium current, and was observed in lithium but not in tetramethylammonium-containing medium. In low sodium medium, the addition of sodium after calcium removal induced depolarization to the extent of which slightly increased in 2 min. The depolarization was completely inhibited by external magnesium (K-i = 1.16 mM). The addition of calcium or magnesium to calcium removal-induced depolarized sperm induced hyperpolarization that was inhibited by ouabain and was also prevented in medium without potassium, suggesting that the activity of the electrogenic Na+, K+-ATPase was involved. The conductance activated by calcium removal might unveil the presence of a calcium channel that in the absence of external calcium allows sodium permeation and that in normal conditions might contribute to the resting intracellular calcium concentration.	Univ Nacl Autonoma Mexico, Fac Med, Dept Farmacol, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Gonzalez-Martinez, MT (corresponding author), Univ Nacl Autonoma Mexico, Fac Med, Dept Farmacol, Ciudad Univ,Apartado Postal 70-297, Mexico City 04510, DF, Mexico.	tuliog@servidor.unam.mx						Arnoult C, 1999, P NATL ACAD SCI USA, V96, P6757, DOI 10.1073/pnas.96.12.6757; Bakowski D, 2002, PFLUG ARCH EUR J PHY, V443, P892, DOI 10.1007/s00424-001-0775-8; BALDI E, 1991, J ANDROL, V12, P323; BLACKMORE PF, 1993, CELL CALCIUM, V14, P53, DOI 10.1016/0143-4160(93)90018-2; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; Brewis IA, 2000, J ANDROL, V21, P238; Carbone E, 1997, J PHYSIOL-LONDON, V504, P1, DOI 10.1111/j.1469-7793.1997.001bf.x; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; De Blas G, 2002, J BIOL CHEM, V277, P49326, DOI 10.1074/jbc.M208587200; EDES I, 1998, CELL PHYSL SOURCE BO, P225; ESPINOSA F, 1995, FEBS LETT, V372, P119, DOI 10.1016/0014-5793(95)00962-9; FORESTA C, 1993, BIOCHEM J, V294, P279, DOI 10.1042/bj2940279; Gonzalez-Martinez MT, 2002, ARCH BIOCHEM BIOPHYS, V408, P205, DOI 10.1016/S0003-9861(02)00587-8; Guzman-Grenfell AM, 2000, BBA-BIOMEMBRANES, V1464, P188, DOI 10.1016/S0005-2736(99)00247-3; HONG CY, 1983, BRIT J CLIN PHARMACO, V16, P487, DOI 10.1111/j.1365-2125.1983.tb02204.x; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; LINARESHERNANDE.L, 1988, BIOCHIM BIOPHYS ACTA, V1372, P1; MAKLER A, 1992, ARCH ANDROLOGY, V29, P255, DOI 10.3109/01485019208987733; MENDOZA C, 1993, FEBS LETT, V330, P57, DOI 10.1016/0014-5793(93)80919-L; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; Patrat C, 2000, BIOL REPROD, V62, P1380, DOI 10.1095/biolreprod62.5.1380; Quill TA, 2001, P NATL ACAD SCI USA, V98, P12527, DOI 10.1073/pnas.221454998; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; ROBINSON JD, 1979, BIOCHIM BIOPHYS ACTA, V549, P145, DOI 10.1016/0304-4173(79)90013-2; SUAREZ SS, 1986, GAMETE RES, V14, P107, DOI 10.1002/mrd.1120140203; WAGGONER AS, 1979, ANNU REV BIOPHYS BIO, V8, P47, DOI 10.1146/annurev.bb.08.060179.000403; WALENSKY LD, 1995, J CELL BIOL, V130, P857, DOI 10.1083/jcb.130.4.857; ZENG Y, 1995, DEV BIOL, V171, P554, DOI 10.1006/dbio.1995.1304	30	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36304	36310		10.1074/jbc.M304479200	http://dx.doi.org/10.1074/jbc.M304479200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860990	hybrid			2022-12-25	WOS:000185318300054
J	Lee, L; Sadowski, PD				Lee, L; Sadowski, PD			Identification of Cre residues involved in synapsis, isomerization, and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; LOXP SITE; LAMBDA-INTEGRASE; HOLLIDAY STRUCTURES; DNA RECOMBINATION; CRYSTAL-STRUCTURE; MECHANISM; CLEAVAGE; PROTEIN; FAMILY	The Cre protein of bacteriophage P1 is a tyrosine recombinase and catalyzes recombination via formation of a covalent protein-DNA complex and a Holliday junction intermediate. Several co-crystal structures of Cre bound to its target lox site have provided novel insights into its biochemical activities. We have used these structures to guide the mutagenesis of several Cre residues that contact the lox spacer region and/or are involved in intersubunit protein-protein interactions. None of the mutant proteins had significant defects in DNA binding, DNA bending, or strand-specific initiation of recombination. We have identified novel functions of several amino acids that are involved in three aspects of the Cre reaction. 1) Single mutation of several NH2-terminal basic residues that contact the spacer region of loxP caused the accumulation of Holliday junction (HJ) intermediates but only a modest impairment of recombination. These residues may be involved in the isomerization of the Holliday intermediate. 2) We identified three new residues (Arg-118, Lys-122, and Glu-129) that are involved in synapsis. Cre R118A, K122A, and E129Q were catalytically competent. 3) Mutations E129R, Q133H, and K201A inactivated catalysis by the protein. The function of these Cre residues in recombination is discussed.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto	Sadowski, PD (corresponding author), Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada.	p.sadowski@utoronto.ca						ABREMSKI K, 1988, J MOL BIOL, V202, P59, DOI 10.1016/0022-2836(88)90518-9; ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; Aihara H, 2003, MOL CELL, V12, P187, DOI 10.1016/S1097-2765(03)00268-5; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao YH, 1999, J MOL BIOL, V289, P517, DOI 10.1006/jmbi.1999.2793; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; DIXON JE, 1994, J MOL BIOL, V243, P199, DOI 10.1006/jmbi.1994.1647; EHEN Y, 2003, IN PRESS J BIOL CHEM, V27; Ferreira H, 2001, J MOL BIOL, V312, P45, DOI 10.1006/jmbi.2001.4940; Gopaul Deshmukh N., 1999, Current Opinion in Structural Biology, V9, P14, DOI 10.1016/S0959-440X(99)80003-7; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HOESS R, 1984, COLD SPRING HARB SYM, V49, P761, DOI 10.1101/SQB.1984.049.01.086; HOESS R, 1987, P NATL ACAD SCI USA, V84, P6840, DOI 10.1073/pnas.84.19.6840; HOESS RH, 1985, J MOL BIOL, V181, P351, DOI 10.1016/0022-2836(85)90224-4; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; HOESS RH, 1990, STRUCTURE METHODS, V1, P203; Jayaram M., 2002, MOBILE DNA, P192; Kamadurai HB, 2003, PROTEIN SCI, V12, P620, DOI 10.1110/ps.0234303; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; Lee G, 1998, GENE, V216, P55, DOI 10.1016/S0378-1119(98)00325-4; Lee L, 2003, J BIOL CHEM, V278, P23118, DOI 10.1074/jbc.M302272200; Lee L, 2003, J MOL BIOL, V326, P397, DOI 10.1016/S0022-2836(02)01429-8; Lee L, 2001, J BIOL CHEM, V276, P31092, DOI 10.1074/jbc.M103739200; MACK A, 1992, NUCLEIC ACIDS RES, V20, P4451, DOI 10.1093/nar/20.17.4451; Martin SS, 2002, J MOL BIOL, V319, P107, DOI 10.1016/S0022-2836(02)00246-2; MEYERLEON L, 1990, MOL CELL BIOL, V10, P235, DOI 10.1128/MCB.10.1.235; MIRZABEKOV AD, 1979, P NATL ACAD SCI USA, V76, P1118, DOI 10.1073/pnas.76.3.1118; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Shaikh AC, 2000, J BIOL CHEM, V275, P30186, DOI 10.1074/jbc.M005256200; Shaikh AC, 2000, J MOL BIOL, V302, P27, DOI 10.1006/jmbi.2000.3967; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; SHAIKH AC, 2000, THESIS U TORONTO; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; Strauss JK, 1996, P NATL ACAD SCI USA, V93, P9515, DOI 10.1073/pnas.93.18.9515; Subramaniam S, 2003, J MOL BIOL, V329, P423, DOI 10.1016/S0022-2836(03)00469-8; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Van Duyne GD, 2001, ANNU REV BIOPH BIOM, V30, P87, DOI 10.1146/annurev.biophys.30.1.87; WIERZBICKI A, 1987, J MOL BIOL, V195, P785, DOI 10.1016/0022-2836(87)90484-0; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	50	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36905	36915		10.1074/jbc.M305464200	http://dx.doi.org/10.1074/jbc.M305464200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851389	hybrid			2022-12-25	WOS:000185318300124
J	Bertinato, J; L'Abbe, MR				Bertinato, J; L'Abbe, MR			Copper modulates the degradation of copper chaperone for Cu,Zn superoxide dismutase by the 26 S proteosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON-DISEASE PROTEIN; HUMAN T-LYMPHOCYTES; MENKES-DISEASE; BIOCHEMICAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; REGULATED TRAFFICKING; GENE; DEFICIENCY; PROTEASOME; ATPASE	Copper chaperones are copper-binding proteins that directly insert copper into specific targets, preventing the accumulation of free copper ions that can be toxic to the cell. Despite considerable advances in the understanding of copper transfer from copper chaperones to their target, to date, there is no information regarding how the activity of these proteins is regulated in higher eukaryotes. The insertion of copper into the antioxidant enzyme Cu,Zn superoxide dismutase (SOD1) depends on the copper chaperone for SOD1 (CCS). We have recently reported that CCS protein is increased in tissues of rats fed copper-deficient diets suggesting that copper may regulate CCS expression. Here we show that whereas copper deficiency increased CCS protein in rats, mRNA level was unaffected. Rodent and human cell lines cultured in the presence of the specific copper chelator 2,3,2-tetraamine displayed a dose-dependent increase in CCS protein that could be reversed with the addition of copper but not iron or zinc to the cells. Switching cells from copper-deficient to copper-rich medium promoted the rapid degradation of CCS, which could be blocked by the proteosome inhibitors MG132 and lactacystin but not a cysteine protease inhibitor or inhibitors of the lysosomal degradation pathway. In addition, CCS degradation was slower in copper-deficient cells than in cells cultured in copper-rich medium. Together, these data show that copper regulates CCS expression by modulating its degradation by the 26 S proteosome and suggest a novel role for CCS in prioritizing the utilization of copper when it is scarce.	Hlth Canada, Banting Res Ctr 2203C, Hlth Prod & Food Branch, Food Directorate,Nutr Res Div, Ottawa, ON K1A 0L2, Canada	Health Canada	L'Abbe, MR (corresponding author), Hlth Canada, Banting Res Ctr 2203C, Hlth Prod & Food Branch, Food Directorate,Nutr Res Div, PL AL 2202C,Ross Ave, Ottawa, ON K1A 0L2, Canada.	mary_l'abbe@hc-sc.gc.ca	labbe, mary/AAC-3392-2020					Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; Bertinato J, 2003, J NUTR, V133, P28, DOI 10.1093/jn/133.1.28; Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Forbes JR, 2000, HUM MOL GENET, V9, P1927, DOI 10.1093/hmg/9.13.1927; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; Hopkins RG, 1997, J NUTR, V127, P257, DOI 10.1093/jn/127.2.257; Hopkins RG, 1999, J NUTR, V129, P596, DOI 10.1093/jn/129.3.596; Huang ZXL, 2000, J NUTR, V130, P1536, DOI 10.1093/jn/130.6.1536; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795; Klomp AEM, 2002, BIOCHEM J, V364, P497, DOI 10.1042/BJ20011803; Kodama K, 1999, PEDIATR INT, V41, P430, DOI 10.1046/j.1442-200x.1999.01091.x; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; Lee J, 2002, J BIOL CHEM, V277, P40253, DOI 10.1074/jbc.M208002200; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Pandit Anand, 2002, Indian Journal of Pediatrics, V69, P785, DOI 10.1007/BF02723693; Papadopoulou LC, 1999, NAT GENET, V23, P333; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2003, J BIOL CHEM, V278, P9639, DOI 10.1074/jbc.M209455200; Petris MJ, 2002, J BIOL CHEM, V277, P46736, DOI 10.1074/jbc.M208864200; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Reddy MCM, 2000, BIOCHEM J, V350, P855, DOI 10.1042/0264-6021:3500855; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Rothstein JD, 1999, J NEUROCHEM, V72, P422, DOI 10.1046/j.1471-4159.1999.0720422.x; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; Son M, 2003, J BIOL CHEM, V278, P14331, DOI 10.1074/jbc.M211698200; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7	43	86	89	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35071	35078		10.1074/jbc.M302242200	http://dx.doi.org/10.1074/jbc.M302242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832419	hybrid			2022-12-25	WOS:000185164400041
J	Shields, DJ; Altarejos, JY; Wang, X; Agellon, LB; Vance, DE				Shields, DJ; Altarejos, JY; Wang, X; Agellon, LB; Vance, DE			Molecular dissection of the S-adenosylmethionine-binding site of phosphatidylethanolamine N-methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE SYNTHESIS; LIVER PHOSPHATIDYLCHOLINE; SACCHAROMYCES-CEREVISIAE; METHYLATION; SEQUENCE; PROTEIN; BIOSYNTHESIS; LOCALIZATION; HOMOCYSTEINE; SPECIFICITY	Phosphatidylethanolamine N-methyltransferase (PEMT) is a quatrotopic membrane protein that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine through three sequential methylation reactions. Analysis of mice lacking a functional PEMT gene revealed a severe reduction in plasma homocysteine levels. Homocysteine is generated by the hydrolysis of S-adenosylhomocysteine, which is also a product of the PEMT reaction. To gain insight into the PEMT transmethylation reaction and the mechanism by which PEMT regulates homocysteine levels, we sought to define residues that are required for binding of the methyl group donor, S-adenosylmethionine (AdoMet). Bioinformatic analysis of the predicted amino acid sequence of human PEMT identified two putative AdoMet-binding motifs ((98)GXG(100) and (EE181)-E-180). Site-directed mutagenesis experiments demonstrated the requirement for the conserved motifs in PEMT specific activity. Analysis of the AdoMet binding ability of mutant recombinant PEMT derivatives established that residues Gly(100) and Glu(180) are essential for binding of the AdoMet moiety. A significantly elevated K-D with respect to AdoMet is observed following conservative mutagenesis of residues Gly(98) (400 pmol) and Glu(181) (666.7 pmol), relative to the unmodified enzyme (303.1 pmol), suggesting that these residues also participate in AdoMet binding. A model positions two separate AdoMet-binding motifs of PEMT in close proximity at the external leaflet of the endoplasmic reticulum membrane.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Pediat, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Dept Biochem, 320 HMRC, Edmonton, AB T6G 2S2, Canada.	Dennis.Vance@ualberta.ca						Agellon LB, 1999, HEPATOLOGY, V30, P725, DOI 10.1002/hep.510300305; ARONDEL V, 1993, J BIOL CHEM, V268, P16002; CAIN BD, 1984, J BIOL CHEM, V259, P942; Clarke S, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P63; CUI Z, 1993, J BIOL CHEM, V268, P16655; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; FAROOQUI JZ, 1983, BIOCHIM BIOPHYS ACTA, V757, P342; FAUMAN EB, 1999, S ADENOSYLMETHIONINE, P1, DOI DOI 10.1142/9789812813077_0001; FINKELSTEIN JD, 1986, J BIOL CHEM, V261, P1582; Finkelstein JD, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P92; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; FUJIOKA M, 1992, INT J BIOCHEM, V24, P1917, DOI 10.1016/0020-711X(92)90287-B; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; NishimakiMogami T, 1996, BBA-LIPID LIPID MET, V1304, P11, DOI 10.1016/S0005-2760(96)00101-4; NishimakiMogami T, 1996, BBA-LIPID LIPID MET, V1304, P21, DOI 10.1016/S0005-2760(96)00100-2; Noga AA, 2003, J BIOL CHEM, V278, P5952, DOI 10.1074/jbc.M212194200; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Refsum H, 1998, CURR OPIN LIPIDOL, V9, P533, DOI 10.1097/00041433-199812000-00004; Reo NV, 2000, TOXICOL APPL PHARM, V164, P113, DOI 10.1006/taap.2000.8901; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; RIDGWAY ND, 1992, METHOD ENZYMOL, V209, P366; Romano JD, 2001, MOL BIOL CELL, V12, P1957, DOI 10.1091/mbc.12.7.1957; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; Shields DJ, 2003, J BIOL CHEM, V278, P2956, DOI 10.1074/jbc.M210904200; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UELAND PM, 1979, FEBS LETT, V101, P184, DOI 10.1016/0014-5793(79)81322-8; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; VANCE JE, 1986, J BIOL CHEM, V261, P4486; Walkey CJ, 1999, BBA-MOL CELL BIOL L, V1436, P405, DOI 10.1016/S0005-2760(98)00147-7; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; Zhu YJ, 2001, P NATL ACAD SCI USA, V98, P10380, DOI 10.1073/pnas.181347498	36	36	37	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35826	35836		10.1074/jbc.M306308200	http://dx.doi.org/10.1074/jbc.M306308200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842883	hybrid			2022-12-25	WOS:000185164400132
J	Turko, IV; Murad, F				Turko, IV; Murad, F			Quantitative protein profiling in heart mitochondria from diabetic rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION/IONIZATION MASS-SPECTROMETRY; GEL-ELECTROPHORESIS; METABOLISM; PEPTIDES; SUBSTRATE	Quantitative protein profiling based on in vitro stable isotope labeling, two-dimensional polyacrylamide gel electrophoresis, and mass spectrometry is an accurate and reliable approach to measure simultaneously the relative abundance of many individual proteins within two different samples. In the present study, it was used to define a set of alterations caused by diabetes in heart mitochondria from streptozotocin-treated rats. We demonstrated that the expression of proteins from the myocardial tricarboxylic acid cycle was not altered in diabetes. However, up-regulation of the fatty acid beta-oxidation favored fatty acids over glucose as a source of acetyl CoA for the tricarboxylic acid cycle. Protein levels for several proteins involved in electron transport were modestly decreased. Whether this may depress overall ATP production remains to be established, since the protein level of ATP synthase seems to be unchanged. Other changes include down-regulation of protein levels for creatine kinase, voltage-dependent anion channel 1 (VDAC-1), HSP60, and Grp75. The mitochondria-associated level of albumin was decreased, while the level of catalase was substantially increased. All of the changes were evident as early as 1 week after streptozotocin administration. Taken together, these data point to a rapid and highly coordinated regulation of mitochondrial protein expression that occurs during the heart adaptation to diabetes.	Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; Univ Texas, Sch Med, Inst Mol Med, Houston, TX 77030 USA	University of Texas System; University of Texas System	Murad, F (corresponding author), Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, 6431 Fannin, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061731] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64221] Funding Source: Medline; NIGMS NIH HHS [GM61731] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cagney G, 2002, NAT BIOTECHNOL, V20, P163, DOI 10.1038/nbt0202-163; CHEN V, 1984, DIABETES, V33, P1078, DOI 10.2337/diabetes.33.11.1078; Depre C, 2000, J MOL CELL CARDIOL, V32, P985, DOI 10.1006/jmcc.2000.1139; Gehanne S, 2002, RAPID COMMUN MASS SP, V16, P1692, DOI 10.1002/rcm.773; Goodlett David R, 2002, Funct Integr Genomics, V2, P138; Goodlett DR, 2001, RAPID COMMUN MASS SP, V15, P1214, DOI 10.1002/rcm.362; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Mirgorodskaya OA, 2000, RAPID COMMUN MASS SP, V14, P1226, DOI 10.1002/1097-0231(20000730)14:14<1226::AID-RCM14>3.0.CO;2-V; MOKHTAR N, 1993, DIABETES, V42, P682, DOI 10.2337/diabetes.42.5.682; Munchbach M, 2000, ANAL CHEM, V72, P4047, DOI 10.1021/ac000265w; Pierce G N, 1985, Can J Cardiol, V1, P48; Sechi S, 2002, RAPID COMMUN MASS SP, V16, P1416, DOI 10.1002/rcm.734; Smolka M, 2002, MOL CELL PROTEOMICS, V1, P19, DOI 10.1074/mcp.M100013-MCP200; Snoeckx LHEH, 2001, PHYSIOL REV, V81, P1461, DOI 10.1152/physrev.2001.81.4.1461; Stanley WC, 1997, CARDIOVASC RES, V34, P25, DOI 10.1016/S0008-6363(97)00047-3; TANAKA Y, 1992, CARDIOVASC RES, V26, P409, DOI 10.1093/cvr/26.4.409; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Tomita M, 1996, JPN CIRC J, V60, P673, DOI 10.1253/jcj.60.673; Yao XD, 2001, ANAL CHEM, V73, P2836, DOI 10.1021/ac001404c; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999; Young ME, 2002, CIRCULATION, V105, P1861, DOI 10.1161/01.CIR.0000012467.61045.87	22	104	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35844	35849		10.1074/jbc.M303139200	http://dx.doi.org/10.1074/jbc.M303139200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12851409	hybrid			2022-12-25	WOS:000185164400134
J	Zhang, M; Su, XF; Mileykovskaya, E; Amoscato, AA; Dowhan, W				Zhang, M; Su, XF; Mileykovskaya, E; Amoscato, AA; Dowhan, W			Cardiolipin is not required to maintain mitochondrial DNA stability or cell viability for Saccharomyces cerevisiae grown at elevated temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN; YEAST; SYNTHASE; EXPRESSION; MEMBRANE; GENE; MANIPULATION; PROMOTER; SYSTEM; COX2	In eukaryotic cells, the phospholipid cardiolipin ( CL) is primarily found in the inner mitochondrial membrane. Saccharomyces cerevisiae mutants, unable to synthesize CL because of a null allele of the CRD1 gene ( encodes CL synthase), have been reported with different phenotypes. Some mutants, when grown on a nonfermentable carbon source at elevated temperatures, exhibit mitochondrial DNA instability, loss of viability, and significant defects in several functions that rely on the mitochondrial energy transducing system (ETS). These mutants also lack the immediate precursor to CL, phosphatidylglycerol ( PG), when grown on glucose as a carbon source. Other mutants show reduced growth efficiency on a nonfermentable carbon source but much milder phenotypes associated with growth at elevated temperatures and increased levels of PG when grown on glucose. We present evidence that mitochondrial DNA instability, loss of viability, and defects in the ETS exhibited at elevated temperatures by some mutants are caused by the reduced expression of the PET56 gene in the presence of the his3Delta200 allele and not the lack of CL alone. We also found that PG is present and elevated in all crd1Delta strains when grown on glucose. A supermolecular complex between complex III and complex IV of the mitochondrial ETS detected in wild type cells was missing in all of the above crd1Delta cells. The level of components of the ETS was also reduced in crd1Delta cells grown at elevated temperatures because of reduced gene expression and not reduced stability. These results suggest that all phenotypes reported for cells carrying the his3Delta200 allele and lacking CL should be re-evaluated.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA; Univ Pittsburgh, Ctr Biotechnol & Bioengn, Mass Spectrometry Facil, Pittsburgh, PA 15219 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA	University of Texas System; University of Texas System; University of Texas Health Science Center Houston; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Dowhan, W (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.	William.Dowhan@uth.tmc.edu	Zhang, Mei/G-8690-2014	Mileykovskaya, Eugenia/0000-0002-8775-4467; Amoscato, Andrew/0000-0002-1340-9150	NCI NIH HHS [CA92389] Funding Source: Medline; NIGMS NIH HHS [GM56389] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson MS, 1996, J BIOL CHEM, V271, P26596, DOI 10.1074/jbc.271.43.26596; CAMERON VL, 1989, J BIOL CHEM, V264, P13391; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; DOWHAN W, 1985, EMBO J, V4, P179, DOI 10.1002/j.1460-2075.1985.tb02334.x; FOX TD, 1991, METHOD ENZYMOL, V194, P149; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Green-Willms NS, 2001, J BIOL CHEM, V276, P6392, DOI 10.1074/jbc.M009856200; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; Jiang F, 1999, MOL MICROBIOL, V31, P373, DOI 10.1046/j.1365-2958.1999.01181.x; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; Ostrander DB, 2001, J BIOL CHEM, V276, P25262, DOI 10.1074/jbc.M103689200; Rieger KJ, 1997, YEAST, V13, P1547, DOI 10.1002/(SICI)1097-0061(199712)13:16<1547::AID-YEA230>3.3.CO;2-P; Sanchirico ME, 1998, EMBO J, V17, P5796, DOI 10.1093/emboj/17.19.5796; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Shen HF, 1998, J BIOL CHEM, V273, P11638, DOI 10.1074/jbc.273.19.11638; SIKORSKI RS, 1989, GENETICS, V122, P19; SIRUMCONNOLLY K, 1993, SCIENCE, V262, P1886, DOI 10.1126/science.8266080; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; STUART AL, 1975, BIOCHIM BIOPHYS ACTA, V376, P561, DOI 10.1016/0005-2728(75)90175-9; Tuller G, 1998, FEBS LETT, V421, P15, DOI 10.1016/S0014-5793(97)01525-1; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200	24	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35204	35210		10.1074/jbc.M306729200	http://dx.doi.org/10.1074/jbc.M306729200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12840009	hybrid			2022-12-25	WOS:000185164400057
J	Li, YF; Pei, J; Xia, H; Ke, HN; Wang, HY; Tao, WF				Li, YF; Pei, J; Xia, H; Ke, HN; Wang, HY; Tao, WF			Lats2, a putative tumor suppressor, inhibits G1/S transition	ONCOGENE			English	Article						Lats2; tumor suppressor; G1/S transition; cell cycle	PROTEIN-KINASE; HUMAN HOMOLOG; DNA-DAMAGE; CHECKPOINT PATHWAY; DEPENDENT KINASES; MITOTIC APPARATUS; DROSOPHILA LATS; CDK REGULATION; GENE; CANCER	Lats2 is a new member of the Lats tumor suppressor family. The human LATS2 gene is located at chromosome 13q11-12, which has been shown to be a hot spot (67%) for LOH in nonsmall cell lung cancer. In order to understand the function of LATS2 in the control of tumor development, we ectopically expressed mouse Lats2 via retroviral infection in NIH3T3/v-ras cells to examine whether Lats2 plays a role in suppressing tumor development and regulating cell proliferation. We have found that ectopic expression of Lats2 in NIH3T3/nu-ras cells suppresses development of tumors in athymic nude mice and inhibits proliferation of NIH3T3/nu-ras cells in an in vitro assay. Cell cycle profile analysis demonstrated that ectopic expression of Lats2 inhibited the G1/S transition. Further mechanistic studies revealed that cyclin E/CDK2 kinase activity was downregulated in Lats2-transduced NIH3T3/nu-ras cells, while other cell cycle regulators controlling the G1/S transition were not affected. We have also shown that LATS2 kinase activity and two LATS conserved domains (LCDs) are required for Lats2 to suppress tumorigenicity and to inhibit cell growth. In addition, the LATS2 protein is cytoplasmic during interphase in NIH3T3 cells, while it becomes localized to the mitotic apparatus during mitosis. Finally, we propose a model in which a combination of mammalian Lats2 and Lats1 control cell proliferation by negatively regulating different cell cycle check points.	Univ Minnesota, Sch Med, Stem Cell Inst, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Tao, WF (corresponding author), Univ Minnesota, Sch Med, Stem Cell Inst, Div Hematol Oncol & Transplantat, MMC716,420 Delaware St SE, Minneapolis, MN 55455 USA.							Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Blow JJ, 2001, EMBO J, V20, P3293, DOI 10.1093/emboj/20.13.3293; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Girard L, 2000, CANCER RES, V60, P4894; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hori T, 2000, ONCOGENE, V19, P3101, DOI 10.1038/sj.onc.1203659; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morinaga N, 2000, INT J ONCOL, V17, P1125; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817	29	161	173	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	2003	22	28					4398	4405		10.1038/sj.onc.1206603	http://dx.doi.org/10.1038/sj.onc.1206603			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853976				2022-12-25	WOS:000183978900009
J	Anastasi, S; Fiorentino, L; Fiorini, M; Fraioli, R; Sala, G; Castellani, L; Alema, S; Alimandi, M; Segatto, O				Anastasi, S; Fiorentino, L; Fiorini, M; Fraioli, R; Sala, G; Castellani, L; Alema, S; Alimandi, M; Segatto, O			Feedback inhibition by RALT controls signal output by the ErbB network	ONCOGENE			English	Article						ErbB; feedback inhibition; Mig-6; negative signaling; RALT	EPIDERMAL-GROWTH-FACTOR; CELL-CYCLE PROGRESSION; NEU DIFFERENTIATION FACTOR; ACTIVATED PROTEIN-KINASE; TYROSINE KINASES; BREAST-CANCER; TRANSCRIPTION FACTORS; RECEPTOR FAMILY; HETERODIMERIZATION; PHOSPHORYLATION	The ErbB-2 interacting protein receptor-associated late transducer (RALT) was previously identified as a feedback inhibitor of ErbB-2 mitogenic signals. We now report that RALT binds to ligand-activated epidermal growth factor receptor (EGFR), ErbB-4 and ErbB-2.ErbB-3 dimers. When ectopically expressed in 32D cells reconstituted with the above ErbB receptor tyrosine kinases (RTKs) RALT behaved as a pan-ErbB inhibitor. Importantly, when tested in either cell proliferation assays or biochemical experiments measuring activation of ERK and AKT, RALT affected the signalling activity of distinct ErbB dimers with different relative potencies. RALT DeltaEBR, a mutant unable to bind to ErbB RTKs, did not inhibit ErbB-dependent activation of ERK and AKT, consistent with RALT exerting its suppressive activity towards these pathways at a receptor-proximal level. Remarkably, RALT DeltaEBR retained the ability to suppress largely the proliferative activity of ErbB-2.ErbB-3 dimers over a wide range of ligand concentrations, indicating that RALT can intercept ErbB-2.ErbB-3 mitogenic signals also at a receptor-distal level. A suppressive function of RALT DeltaEBR towards the mitogenic activity of EGFR and ErbB-4 was detected at low levels of receptor occupancy, but was completely overcome by saturating concentrations of ligand. We propose that quantitative and qualitative aspects of RALT signalling concur in defining identity, strength and duration of signals generated by the ErbB network.	Regina Elena Inst Canc Res, I-00158 Rome, Italy; Univ Cassino, Cassino, Italy; Univ Roma Tor Vergata, INFM, Sez B, Rome, Italy; CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy; Univ Roma La Sapienza, Dept Expt Med, I-00161 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Cassino; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Segatto, O (corresponding author), Regina Elena Inst Canc Res, Via Delle Messi Oro 156, I-00158 Rome, Italy.		Rocco, Fraioli/J-2638-2017; Sala, Gianluca/C-2056-2017; anastasi, sergio/AAB-9585-2020; Alimandi, Maurizio/AAG-9246-2019	Rocco, Fraioli/0000-0001-7906-6077; Sala, Gianluca/0000-0002-4494-915X; anastasi, sergio/0000-0003-1009-6117; Alimandi, Maurizio/0000-0002-1409-6803; Castellani, Loriana/0000-0002-8519-3504; Segatto, Oreste/0000-0003-2561-1142; Alema, Stefano/0000-0002-9869-6354				Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; ALIMANDI M, 1995, ONCOGENE, V10, P1813; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Cook SJ, 1999, MOL CELL BIOL, V19, P330; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fiorini M, 2002, ONCOGENE, V21, P6530, DOI 10.1038/sj.onc.1205823; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Ghiglione C, 1999, DEV BIOL, V205, P181, DOI 10.1006/dbio.1998.9102; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Jones SM, 2001, FEBS LETT, V490, P110, DOI 10.1016/S0014-5793(01)02113-5; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Lawlor MA, 2001, J CELL SCI, V114, P2903; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LONARDO F, 1990, New Biologist, V2, P992; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Tang CK, 1998, CANCER RES, V58, P3415; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	92	97	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4221	4234		10.1038/sj.onc.1206516	http://dx.doi.org/10.1038/sj.onc.1206516			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833145				2022-12-25	WOS:000183979800009
J	Oien, KA; Vass, JK; Downie, I; Fullarton, G; Keith, WN				Oien, KA; Vass, JK; Downie, I; Fullarton, G; Keith, WN			Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach	ONCOGENE			English	Article						stomach; stomach neoplasms; adenocarcinoma; gene expression profiling; serial analysis of gene expression (SAGE)	SERIAL ANALYSIS; CANCER-CELLS; DIFFERENTIAL DISPLAY; TREFOIL PEPTIDES; BREAST-CANCER; IDENTIFICATION; PROTEIN; TRANSCRIPTOMES; ADENOCARCINOMA; DISCOVERY	Gastric carcinoma is the fourth most common cause of cancer death worldwide but its molecular biology is poorly understood. We catalogued the genes expressed in two gastric adenocarcinomas and normal stomach, using serial analysis of gene expression (SAGE), and compared the profiles on-line with other glandular epithelia. Candidates were validated by Northern blotting and immunohistochemistry. A total of 29480 transcripts, derived from 10 866 genes, were identified. In all, 1% of the genes were differentially expressed (greater than or equal tofivefold difference plus P-value less than or equal to0.01) between cancers and normal stomach. The most abundant transcripts included ribosomal and mitochondrial proteins, of which most were upregulated in the tumours, as were other widely expressed genes including transcription factors, signalling molecules (serine/threonine protein kinases), thymosin beta 10 and collagenase I. Transcripts abundant in normal stomach were functionally important, including gastrin, immunoglobulin alpha, lysozyme, MUC5, pS2 and pepsinogens, which were among 55 gastric-specific genes. Many transcripts were minimally characterized or new, some cancer-associated genes reflected their intestinal morphology, and some normal gastric genes had previously been considered as pancreatic carcinoma markers. The gastric carcinoma profiles resembled other tumours', supporting the existence of common cancer-associated targets. These data provide a catalogue from which to develop markers for better diagnosis and therapy of gastric carcinoma.	Univ Glasgow, Dept Med Oncol, Canc Res UK, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Glasgow Royal Infirm, Univ Dept Pathol, Glasgow G4 0SF, Lanark, Scotland; Beatson Inst Canc Res, Canc Res UK, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Gartnavel Royal Hosp, Dept Surg, Glasgow G12 0YN, Lanark, Scotland	Beatson Institute; Cancer Research UK; University of Glasgow; University of Glasgow; Beatson Institute; Cancer Research UK; Gartnavel Royal Hospital	Oien, KA (corresponding author), Univ Glasgow, Dept Med Oncol, Canc Res UK, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.oien@beatson.gla.ac.uk	Oien, Karin/AAH-3849-2019; Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580				Argani P, 2001, CANCER RES, V61, P4320; Bahrenberg G, 2000, BIOCHEM BIOPH RES CO, V275, P783, DOI 10.1006/bbrc.2000.3393; Beck F, 2000, BIOESSAYS, V22, P431, DOI 10.1002/(SICI)1521-1878(200005)22:5<431::AID-BIES5>3.0.CO;2-X; BERNER A, 1991, HISTOL HISTOPATHOL, V6, P317; Blok P, 1997, QJM-INT J MED, V90, P735; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Breitwieser GE, 1997, AM J PHYSIOL-CELL PH, V272, pC957, DOI 10.1152/ajpcell.1997.272.3.C957; Carulli JP, 1998, J CELL BIOCHEM, P286; Chan AOO, 1999, J GASTROEN HEPATOL, V14, P1150, DOI 10.1046/j.1440-1746.1999.02000.x; Chang K, 1996, P NATL ACAD SCI USA, V93, P136, DOI 10.1073/pnas.93.1.136; de Waard V, 1999, GENE, V226, P1, DOI 10.1016/S0378-1119(98)00577-0; Ebert MPA, 2000, CANCER RES, V60, P1995; El-Rifai W, 2001, INT J CANCER, V92, P832, DOI 10.1002/ijc.1264; Friedl A, 1999, HISTOCHEM J, V31, P433, DOI 10.1023/A:1003708808934; FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107; Gibson PR, 1999, CARCINOGENESIS, V20, P539, DOI 10.1093/carcin/20.4.539; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris RM, 2000, LIFE SCI, V67, P2051, DOI 10.1016/S0024-3205(00)00791-8; Harris V, 1998, CANC REGISTRATION ST, P182; Hibi K, 1998, CANCER RES, V58, P5690; Hippo Y, 2001, CANCER RES, V61, P889; Hippo Y, 2002, CANCER RES, V62, P233; Hough CD, 2000, CANCER RES, V60, P6281; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; ISAACSON P, 1982, GUT, V23, P578, DOI 10.1136/gut.23.7.578; Janke J, 2000, J EXP MED, V191, P1675, DOI 10.1084/jem.191.10.1675; Jung MH, 2000, GENOMICS, V69, P281, DOI 10.1006/geno.2000.6338; Lal A, 1999, CANCER RES, V59, P5403; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Ma TH, 1999, J PHYSIOL-LONDON, V517, P317, DOI 10.1111/j.1469-7793.1999.0317t.x; Machado JC, 2000, J PATHOL, V190, P437; Mitani M, 2000, WORLD J SURG, V24, P455, DOI 10.1007/s002689910072; Mori M, 2002, SURGERY, V131, pS39, DOI 10.1067/msy.2002.119292; Nacht M, 1999, CANCER RES, V59, P5464; Norton JD, 2000, J CELL SCI, V113, P3897; OWEN DA, 1986, AM J SURG PATHOL, V10, P48, DOI 10.1097/00000478-198601000-00006; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pradet-Balade B, 2001, TRENDS BIOCHEM SCI, V26, P225, DOI 10.1016/S0968-0004(00)01776-X; Roukos DH, 2000, CANCER TREAT REV, V26, P243, DOI 10.1053/ctrv.2000.0164; SALESIOTIS AN, 1995, CANCER LETT, V91, P47, DOI 10.1016/0304-3835(95)03717-B; Scheurle D, 2000, CANCER RES, V60, P4037; SESSA F, 1990, GASTROENTEROLOGY, V98, P1655, DOI 10.1016/0016-5085(90)91104-E; Velculescu VE, 2000, TRENDS GENET, V16, P423, DOI 10.1016/S0168-9525(00)02114-4; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Waghray A, 2001, CANCER RES, V61, P4283; Wang G, 2001, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V18, P43; Wheeler DL, 2001, NUCLEIC ACIDS RES, V29, P11, DOI 10.1093/nar/29.1.11; Wong WM, 1999, GUT, V44, P890, DOI 10.1136/gut.44.6.890; Yoshikawa Y, 2000, JPN J CANCER RES, V91, P459, DOI 10.1111/j.1349-7006.2000.tb00967.x; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	54	58	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4287	4300		10.1038/sj.onc.1206615	http://dx.doi.org/10.1038/sj.onc.1206615			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833151	Green Published			2022-12-25	WOS:000183979800015
J	Perez-Losada, J; Sanchez-Martin, M; Perez-Caro, M; Perez-Mancera, PA; Sanchez-Garcia, I				Perez-Losada, J; Sanchez-Martin, M; Perez-Caro, M; Perez-Mancera, PA; Sanchez-Garcia, I			The radioresistance biological function of the SCF/kit signaling pathway is mediated by the zinc-finger transcription factor Slug	ONCOGENE			English	Article						growth factors; hematopoietic development; transcription factor; radioresistance	STEM-CELL FACTOR; GASTROINTESTINAL STROMAL TUMORS; TYROSINE KINASE RECEPTOR; PROTOONCOGENE C-KIT; GROWTH-FACTOR; W-LOCUS; BREAST CARCINOMAS; PROTO-ONCOGENE; E-CADHERIN; SI-LOCUS	Radiation-induced destruction of the hematopoietic system is the primary cause of death based on the findings that transfer of normal bone marrow cells prevents death from lethal irradiation. The stem cell factor-c-kit signaling pathway (SCF/c-kit) has been previously implicated in the hematopoietic recovery which prevents death from lethal irradiation, but the molecular mechanisms that mediate this biological effect are unknown. Since mutations on SCF, c-kit and Slug genes have a similar phenotype in mice, we examined if Slug could complement the radiosensitivity of kit-deficient mice. In this report, we show that Slug acts as a radioprotection agent as lack of Slug results in increased radiosensitivity. This effect cannot be recovered by activating SCF/c-kit in lethally irradiated Slug-deficient mice, as SCF-treated mice did not demonstrate stimulation of hematopoietic recovery leading to survival of the Slug-deficient mice. We found that we could complement the hematopoietic failure in lethally irradiated c-kit-deficient mice by transducing them with a TAT-Slug protein. We conclude that the zinc-finger transcription factor Slug is absolutely necessary for survival from lethal irradiation and identify Slug as the molecular target that mediates the radioprotection through SCF/c-kit. These results indicate that Slug may be a molecular component conferring radioresistance to cancer cells.	Univ Salamanca, Inst Biol Mol & Celular Canc, Ctr Invest Canc, CSIC, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, Ctr Invest Canc, CSIC, Campus Unamuno, Salamanca 37007, Spain.		Pérez-Losada, Jesús/A-5883-2019; SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Sanchez-Martin, Manuel/N-5327-2016	Pérez-Losada, Jesús/0000-0003-2400-624X; Sanchez-Martin, Manuel/0000-0001-8370-1336; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905	NCI NIH HHS [1 R01 CA79955-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; del Barrio MG, 2002, DEVELOPMENT, V129, P1583; FLEMING WH, 1993, P NATL ACAD SCI USA, V90, P3760, DOI 10.1073/pnas.90.8.3760; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Hajra KM, 2002, CANCER RES, V62, P1613; HARRISON DE, 1972, BRIT J HAEMATOL, V22, P155, DOI 10.1111/j.1365-2141.1972.tb08797.x; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; INOUE M, 1994, CANCER RES, V54, P3049; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1016/S0012-1606(98)80005-5; KACZMAREK L, 1988, INT J RADIAT BIOL, V53, P703, DOI 10.1080/09553008814551071; KASTAN MB, 1991, CANCER RES, V51, P6304; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; LEE JM, 1994, ONCOGENE, V9, P3731; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUDA R, 1993, AM J PATHOL, V142, P339; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NETA R, 1993, BLOOD, V81, P324; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; Perez-Losada J, 2002, BLOOD, V100, P1274, DOI 10.1182/blood.V100.4.1274.h81602001274_1274_1286; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sanchez-Martin M, 2002, HUM MOL GENET, V11, P3231, DOI 10.1093/hmg/11.25.3231; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Silvers W.K., 1979, COAT COLORS MICE, P206; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U; ZSEBO KM, 1992, P NATL ACAD SCI USA, V89, P9464, DOI 10.1073/pnas.89.20.9464	38	68	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4205	4211		10.1038/sj.onc.1206467	http://dx.doi.org/10.1038/sj.onc.1206467			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833143				2022-12-25	WOS:000183979800007
J	Ben-Ya'acov, A; Ravid, S				Ben-Ya'acov, A; Ravid, S			Epidermal growth factor-mediated transient phosphorylation and membrane localization of myosin II-B are required for efficient chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ISOFORMS; PROTEIN-KINASE-C; MESSENGER-RNAS; CELLS; CYTOKINESIS; EXPRESSION; MOTILITY; DOMAINS; BINDING; NEURONS	Epidermal growth factor (EGF) stimulation of prostate metastatic tumor cells results in transient phosphorylation and cellular localization of non-muscle myosin heavy chain II-B (NMHC II-B) with kinetics similar to those seen in chemotaxis. We demonstrate that expression of 18- and 72-kDa fragments derived from the NMHC II-B C terminus that contain EGF-dependent NMHC II-B phosphorylation sites serve as dominant-negative mutations for EGF-dependent NMHC II-B phosphorylation and localization. Both fragments inhibited the EGF-dependent phosphorylation by competing with NMHC II-B on the myosin heavy chain kinase. However, only expression of the 72-kDa fragment resulted in cells with abnormalities in cell shape, focal adhesions, and chemotaxis. We found that the 72-kDa (but not 18-kDa) fragment is capable of self-assembly. To our knowledge, these results provide the first strong evidence that EGF-dependent NMHC II-B phosphorylation is required for the cellular localization of NMHC II-B and that NMHC II-B is required for normal cell attachment and for chemotactic response.	Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Sci, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Ravid, S (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Sci, Dept Biochem, IL-91120 Jerusalem, Israel.	ravid@md2.huji.ac.il						AbuElneel K, 1996, J BIOL CHEM, V271, P977, DOI 10.1074/jbc.271.2.977; CHENG TPO, 1992, FEBS LETT, V311, P91, DOI 10.1016/0014-5793(92)81374-U; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; GANGULY C, 1992, J BIOL CHEM, V267, P20905; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; IIZUMI T, 1987, J UROLOGY, V137, P1304, DOI 10.1016/S0022-5347(17)44488-0; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; KELLEY CA, 1991, J CELL SCI, P49; KUZNICKI J, 1983, J BIOL CHEM, V258, P6011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEE RJ, 1994, J CELL SCI, V107, P2875; Liang WC, 1999, J CELL BIOL, V147, P1039, DOI 10.1083/jcb.147.5.1039; MAUPIN P, 1994, J CELL SCI, V107, P3077; Milewski MI, 2002, J BIOL CHEM, V277, P34462, DOI 10.1074/jbc.M205420200; MILLER M, 1992, NEURON, V8, P25, DOI 10.1016/0896-6273(92)90106-N; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOUSSAVI RS, 1993, MOL CELL BIOCHEM, V128, P219, DOI 10.1007/BF01076773; Murakami N, 1998, BIOCHEMISTRY-US, V37, P1989, DOI 10.1021/bi971959a; Murakami N, 1995, BIOCHEMISTRY-US, V34, P16046, DOI 10.1021/bi00049a019; Murakami N, 2000, BIOCHEMISTRY-US, V39, P11441, DOI 10.1021/bi000347e; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Robinson DN, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-4; ROCHLIN MW, 1995, J CELL SCI, V108, P3661; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Straussman R, 2001, J CELL SCI, V114, P3047; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617	30	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40032	40040		10.1074/jbc.M306948200	http://dx.doi.org/10.1074/jbc.M306948200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12874274	hybrid			2022-12-25	WOS:000185713800093
J	Hingorani-Varma, K; Bitinaite, J				Hingorani-Varma, K; Bitinaite, J			Kinetic analysis of the coordinated interaction of SgrAI restriction endonuclease with different DNA targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 RECOGNITION SITES; ECORII ENDONUCLEASE; BINDING SITES; CLEAVAGE; ENZYME; SPECIFICITY; MECHANISM; ACCURACY	SgrAI restriction endonuclease cooperatively interacts and cleaves two target sites that include both the canonical sites, CPuCCGGPyG, and the secondary sites, CPuCCGGPy(A/T/C). It has been observed that the cleaved canonical sites stimulate SgrAI cleavage at the secondary sites. Equilibrium binding studies show that SgrAI binds to its canonical sites with a high affinity (K-a = 4 - 8 x 10(10) M-1) and that it has a 15-fold lower affinity for the cleaved canonical sites and a 30-fold lower affinity for the secondary sites. Steady-state kinetics reveals substrate cooperativity for SgrAI cleavage on both canonical and secondary sites. The specificity of SgrAI for the secondary site CACCGGCT, as measured by k(cat)/K is about 500-fold lower than that for the canonical site CACCGGCG, but this difference is reduced to 10-fold in the presence of the cleaved canonical sites. The efficiency of canonical site cleavage also increases by 3-fold when the cleaved canonical sites are present in the reaction. Furthermore, the substrate cooperativity for SgrAI cleavage is abolished for both types of sites in the presence of cleaved canonical sites. These results indicate that target site cleavage occurs via a coordinated interaction of two SgrAI protein subunits, where the subunit bound to the cleaved site stimulates the cleavage of the uncut site bound by the other subunit. The free subunits of SgrAI have the flexibility to bind different target sites and, consequently, assemble into various catalytically active complexes, which differ in their catalytic efficiencies.	New England Biolabs Inc, Beverly, MA 01915 USA		Bitinaite, J (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.	bitinait@neb.com		Bitinaite, Jurate/0000-0002-9190-6355				ALVES J, 1995, BIOCHEMISTRY-US, V34, P11191, DOI 10.1021/bi00035a026; Bath AJ, 2002, J BIOL CHEM, V277, P4024, DOI 10.1074/jbc.M108441200; BICKLE TA, 1993, MICROBIOL REV, V57, P434, DOI 10.1128/MMBR.57.2.434-450.1993; Bilcock DT, 1999, J BIOL CHEM, V274, P36379, DOI 10.1074/jbc.274.51.36379; Bitinaite J, 2002, P NATL ACAD SCI USA, V99, P1164, DOI 10.1073/pnas.022346799; Bitinaite J, 1998, P NATL ACAD SCI USA, V95, P10570, DOI 10.1073/pnas.95.18.10570; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P849; Colandene JD, 1998, P NATL ACAD SCI USA, V95, P3531, DOI 10.1073/pnas.95.7.3531; Conlan LH, 2002, BIOCHEMISTRY-US, V41, P14848, DOI 10.1021/bi026403o; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; Daniels LE, 2003, J MOL BIOL, V327, P579, DOI 10.1016/S0022-2836(03)00143-8; Deibert M, 2000, NAT STRUCT BIOL, V7, P792, DOI 10.1038/79032; Embleton ML, 1999, J MOL BIOL, V289, P785, DOI 10.1006/jmbi.1999.2822; Engler LE, 1997, J MOL BIOL, V269, P82, DOI 10.1006/jmbi.1997.1027; Engler LE, 2001, J MOL BIOL, V307, P619, DOI 10.1006/jmbi.2000.4428; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P208; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GABBARA S, 1992, J BIOL CHEM, V267, P18623; Halford SE, 2001, BIOCHEM SOC T, V29, P363, DOI 10.1042/BST0290363; Halford SE, 1999, BIOCHEM SOC T, V27, P696, DOI 10.1042/bst0270696; Huai Q, 2001, NAT STRUCT BIOL, V8, P665, DOI 10.1038/90366; ITAKURA K, 1984, ANNU REV BIOCHEM, V53, P323; KACZOROWSKI T, 1989, GENE, V80, P209, DOI 10.1016/0378-1119(89)90285-0; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; Mucke M, 2002, EMBO J, V21, P5262, DOI 10.1093/emboj/cdf514; Nastri HG, 1997, J BIOL CHEM, V272, P25761, DOI 10.1074/jbc.272.41.25761; Nobbs TJ, 1998, J MOL BIOL, V281, P419, DOI 10.1006/jmbi.1998.1966; PEIN CD, 1991, NUCLEIC ACIDS RES, V19, P5139, DOI 10.1093/nar/19.19.5139; PETRAUSKENE OV, 1992, EUR J BIOCHEM, V208, P617, DOI 10.1111/j.1432-1033.1992.tb17226.x; Petrauskene OV, 1998, FEBS LETT, V425, P29, DOI 10.1016/S0014-5793(98)00184-7; Pingoud A, 2001, NUCLEIC ACIDS RES, V29, P3705, DOI 10.1093/nar/29.18.3705; Pingoud V, 2002, J BIOL CHEM, V277, P14306, DOI 10.1074/jbc.M111625200; Roberts RJ, 2003, NUCLEIC ACIDS RES, V31, P1805, DOI 10.1093/nar/gkg274; Roberts RJ, 2001, NUCLEIC ACIDS RES, V29, P268, DOI 10.1093/nar/29.1.268; Siksnys V, 1999, J MOL BIOL, V291, P1105, DOI 10.1006/jmbi.1999.2977; TAUTZ N, 1990, NUCLEIC ACIDS RES, V18, P3087, DOI 10.1093/nar/18.10.3087; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; THIELKING V, 1990, BIOCHEMISTRY-US, V29, P4682, DOI 10.1021/bi00471a024; Vanamee ES, 2001, J MOL BIOL, V309, P69, DOI 10.1006/jmbi.2001.4635; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; Whitaker RD, 1999, J MOL BIOL, V285, P1525, DOI 10.1006/jmbi.1998.2409; YANG CC, 1992, BIOCHEMISTRY-US, V31, P9657, DOI 10.1021/bi00155a019	44	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40392	40399		10.1074/jbc.M304603200	http://dx.doi.org/10.1074/jbc.M304603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12851384	hybrid			2022-12-25	WOS:000185713800133
J	Karbarz, MJ; Kalb, SR; Cotter, RJ; Raetz, CRH				Karbarz, MJ; Kalb, SR; Cotter, RJ; Raetz, CRH			Expression cloning and biochemical characterization of a Rhizobium leguminosarum lipid A 1-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MEMBRANE-BOUND PHOSPHATASES; CELL-SURFACE ANTIGEN; ACYL CARRIER PROTEIN; ESCHERICHIA-COLI; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; LIPOPOLYSACCHARIDE CORE; SALMONELLA-TYPHIMURIUM; STRUCTURAL-CHARACTERIZATION; INNATE IMMUNITY; GENE	Lipid A of Rhizobium leguminosarum, a nitrogen-fixing plant endosymbiont, displays several significant structural differences when compared with Escherichia coli. An especially striking feature of R. leguminosarum lipid A is that it lacks both the 1- and 4'-phosphate groups. Distinct lipid A phosphatases that attack either the 1 or the 4' positions have previously been identified in extracts of R. leguminosarum and Rhizobium etli but not Sinorhizobium meliloti or E. coli. Here we describe the identification of a hybrid cosmid (pMJK-1) containing a 25-kb R. leguminosarum 3841 DNA insert that directs the overexpression of the lipid A 1- phosphatase. Transfer of pMJK-1 into S. meliloti 1021 results in heterologous expression of 1- phosphatase activity, which is normally absent in extracts of strain 1021, and confers resistance to polymyxin. Sequencing of a 7-kb DNA fragment derived from the insert of pMJK-1 revealed the presence of a lipid phosphatase ortholog (designated LpxE). Expression of lpxE in E. coli behind the T7lac promoter results in the appearance of robust 1- phosphatase activity, which is normally absent in E. coli membranes. Matrix-assisted laser-desorption/time of flight and radiochemical analysis of the product generated in vitro from the model substrate lipid IVA confirms the selective removal of the 1- phosphate group. These findings show that lpxE is the structural gene for the 1- phosphatase. The availability of lpxE may facilitate the re-engineering of lipid A structures in diverse Gram-negative bacteria and allow assessment of the role of the 1- phosphatase in R. leguminosarum symbiosis with plants. Possible orthologs of LpxE are present in some intracellular human pathogens, including Francisella tularensis, Brucella melitensis, and Legionella pneumophila.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Kalb, Suzanne/0000-0002-8067-136X	NIGMS NIH HHS [R37 GM051796-06, GM-08558, R37 GM051796] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051796, T32GM008558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Babinski KJ, 2002, J BIOL CHEM, V277, P25937, DOI 10.1074/jbc.M204067200; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BHAT UR, 1994, J BIOL CHEM, V269, P14402; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boman HG, 1998, SCAND J IMMUNOL, V48, P15; Borregaard N, 2000, IMMUNOL TODAY, V21, P68, DOI 10.1016/S0167-5699(99)01570-4; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; Brade H., 1999, ENDOTOXIN HLTH DIS; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; Caaveiro JMM, 1997, FEBS LETT, V410, P338, DOI 10.1016/S0014-5793(97)00613-3; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; Endre G, 2002, NATURE, V417, P962, DOI 10.1038/nature00842; FINAN TM, 1986, J BACTERIOL, V167, P66, DOI 10.1128/jb.167.1.66-72.1986; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; FRIEDMAN AM, 1982, GENE, V18, P289, DOI 10.1016/0378-1119(82)90167-6; FUNK CR, 1992, J BACTERIOL, V174, P205, DOI 10.1128/jb.174.1.205-213.1992; Galibert F, 2001, SCIENCE, V293, P668, DOI 10.1126/science.1060966; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1111/j.1574-6968.2001.tb10814.x; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GLAZEBROOK J, 1991, METHOD ENZYMOL, V204, P398; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; Goodner B, 2001, SCIENCE, V294, P2323, DOI 10.1126/science.1066803; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Gudlavalleti SK, 2003, J BIOL CHEM, V278, P3957, DOI 10.1074/jbc.M210491200; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Hoshino K, 1999, J IMMUNOL, V162, P3749; ICHO T, 1983, J BACTERIOL, V153, P722, DOI 10.1128/JB.153.2.722-730.1983; ICHO T, 1988, J BACTERIOL, V170, P5117, DOI 10.1128/jb.170.11.5117-5124.1988; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; JOHNSTON AWB, 1975, J GEN MICROBIOL, V87, P343, DOI 10.1099/00221287-87-2-343; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kaneko T, 2000, DNA RES, V7, P331, DOI 10.1093/dnares/7.6.331; Kanipes MI, 2003, J BIOL CHEM, V278, P16356, DOI 10.1074/jbc.M301255200; Kanipes MI, 2003, J BIOL CHEM, V278, P16365, DOI 10.1074/jbc.M301256200; Kanipes MI, 2001, J BIOL CHEM, V276, P1156, DOI 10.1074/jbc.M009019200; KANNENBERG EL, 1992, MOL MICROBIOL, V6, P2477, DOI 10.1111/j.1365-2958.1992.tb01424.x; KANNENBERG EL, 1994, J BACTERIOL, V176, P2021, DOI 10.1128/jb.176.7.2021-2032.1994; KANNENBERG EL, 1989, J BACTERIOL, V171, P4543, DOI 10.1128/jb.171.9.4543-4548.1989; Kannenberg Elmar L., 1994, Trends in Microbiology, V2, P277, DOI 10.1016/0966-842X(94)90004-3; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Lien E, 2002, CRIT CARE MED, V30, pS1, DOI 10.1097/00003246-200201001-00001; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; Moran AP, 1997, J BACTERIOL, V179, P6453, DOI 10.1128/jb.179.20.6453-6463.1997; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NISHIJIMA M, 1981, J BACTERIOL, V145, P113, DOI 10.1128/JB.145.1.113-121.1981; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; NOEL KD, 1984, J BACTERIOL, V158, P148, DOI 10.1128/JB.158.1.148-155.1984; OGAWA T, 1993, FEBS LETT, V332, P197, DOI 10.1016/0014-5793(93)80512-S; Ohl ME, 2001, ANNU REV MED, V52, P259, DOI 10.1146/annurev.med.52.1.259; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; Parrillo J E, 1993, N Engl J Med, V328, P1471; Persing DH, 2002, TRENDS MICROBIOL, V10, pS32, DOI 10.1016/S0966-842X(02)02426-5; Plotz BM, 2000, J BIOL CHEM, V275, P11222, DOI 10.1074/jbc.275.15.11222; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12120, DOI 10.1074/jbc.M300379200; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12109, DOI 10.1074/jbc.M300378200; QURESHI N, 1988, J BIOL CHEM, V263, P11971; QURESHI N, 1982, J BIOL CHEM, V257, P1808; RADIKA K, 1988, J BIOL CHEM, V263, P14859; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; ROANTREE RJ, 1967, ANNU REV MICROBIOL, V21, P443, DOI 10.1146/annurev.mi.21.100167.002303; RONSON CW, 1984, J BACTERIOL, V160, P903, DOI 10.1128/JB.160.3.903-909.1984; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; SINDHU SS, 1990, J BACTERIOL, V172, P1804, DOI 10.1128/jb.172.4.1804-1813.1990; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spaink HP, 2002, NATURE, V417, P910, DOI 10.1038/417910a; Stracke S, 2002, NATURE, V417, P959, DOI 10.1038/nature00841; Stukey J, 1997, PROTEIN SCI, V6, P469; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; Takeda K, 2003, CELL MICROBIOL, V5, P143, DOI 10.1046/j.1462-5822.2003.00264.x; Urbanik-Sypniewska T, 2000, IMMUNOBIOLOGY, V202, P408, DOI 10.1016/S0171-2985(00)80043-1; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; VANDENBOSCH KA, 1989, J BACTERIOL, V171, P4537, DOI 10.1128/jb.171.9.4537-4542.1989; Vandenplas ML, 2002, J BIOL CHEM, V277, P41811, DOI 10.1074/jbc.M205252200; Vinogradov E, 2002, EUR J BIOCHEM, V269, P6112, DOI 10.1046/j.1432-1033.2002.03321.x; Von Jagow G, 1994, PRACTICAL GUIDE MEMB; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	115	53	55	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39269	39279		10.1074/jbc.M305830200	http://dx.doi.org/10.1074/jbc.M305830200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869541	Green Accepted, hybrid			2022-12-25	WOS:000185713800003
J	Kaiser, L; Gronlund, H; Sandalova, T; Ljunggren, HG; van Hage-Hamsten, M; Achour, A; Schneider, G				Kaiser, L; Gronlund, H; Sandalova, T; Ljunggren, HG; van Hage-Hamsten, M; Achour, A; Schneider, G			The crystal structure of the major cat allergen Fel d 1, a member of the secretoglobin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FEL-D-I; BINDING PROTEIN; OXIDIZED UTEROGLOBIN; PROGESTERONE-BINDING; SEBACEOUS GLANDS; REFINEMENT; FORM; CRYSTALLIZATION; IMMUNOTHERAPY; TESTOSTERONE	The domestic cat (Felis domesticus) is one of the most important causes of allergic asthma worldwide. The dominating cat allergen, Fel d 1, is composed of two heterodimers. Recently, it has been shown that recombinant Fel d 1, consisting of chain 2 and chain 1 fused together without additional linker, has immunological properties indistinguishable from the natural heterodimeric protein. Herein, we report the crystal structure of recombinant monomeric Fel d 1 at 1.85-Angstrom resolution, determined by multi-wavelength anomalous diffraction using selenomethionine substituted protein. Fel d 1 is an all-helical protein and consists of eight helices. The two halves of the recombinant Fel d 1 molecule, corresponding to the wild-type Fel d 1 chains, are very similar in three-dimensional structure, despite the lack of significant sequence identity. The structure of the Fel d 1 presents a striking similarity to that of uteroglobin, a steroid-inducible cytokine-like molecule with anti-inflammatory and immunomodulatory properties. An internal, asymmetric cavity is formed in the Fel d 1 that could bind an endogenous ligand. The distribution of residues lining this cavity suggests that such a ligand must be amphipathic. The structure of Fel d 1 displays the localization of three previously defined Fel d 1 IgE epitopes on the surface of the protein. The three-dimensional structure provides a framework for rational design of hypoallergenic mutants aimed for treatment of cat allergy.	Huddinge Univ Hosp, Karolinska Inst, Dept Med, Ctr Infect Med, S-14186 Huddinge, Sweden; Karolinska Inst & Hosp L2 04, Dept Med, Unit Clin Immunol & Allergy, S-17176 Stockholm, Sweden; Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Achour, A (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Med, Ctr Infect Med, F59, S-14186 Huddinge, Sweden.	adnane.achour@mtc.ki.se	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Sandalova, Tatyana/0000-0002-7694-6420; Achour, Adnane/0000-0003-0432-710X; Gronlund, Hans/0000-0003-4882-7624; Schneider, Gunter/0000-0003-0622-5713				Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Almqvist C, 2001, AM J RESP CRIT CARE, V163, P694, DOI 10.1164/ajrccm.163.3.2006114; ANDERSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P563, DOI 10.1016/0091-6749(85)90776-6; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALLY R, 1989, J MOL BIOL, V206, P153, DOI 10.1016/0022-2836(89)90530-5; BARTHOLOME K, 1985, J ALLERGY CLIN IMMUN, V76, P503, DOI 10.1016/0091-6749(85)90734-1; BOND JF, 1993, MOL IMMUNOL, V30, P1529, DOI 10.1016/0161-5890(93)90461-J; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUEHNER M, 1982, J MOL BIOL, V159, P353, DOI 10.1016/0022-2836(82)90499-5; Callebaut I, 2000, ANN NY ACAD SCI, V923, P90; CHARPIN C, 1994, CLIN EXP ALLERGY, V24, P1174, DOI 10.1111/j.1365-2222.1994.tb03325.x; CHARPIN C, 1991, J ALLERGY CLIN IMMUN, V88, P77, DOI 10.1016/0091-6749(91)90303-6; DABROWSKI AJ, 1990, J ALLERGY CLIN IMMUN, V86, P462, DOI 10.1016/S0091-6749(05)80200-3; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; DUFFORT OA, 1991, MOL IMMUNOL, V28, P301, DOI 10.1016/0161-5890(91)90141-6; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GRIFFITH IJ, 1992, GENE, V113, P263, DOI 10.1016/0378-1119(92)90405-E; Gronlund H, 2003, J BIOL CHEM, V278, P40144, DOI 10.1074/jbc.M301416200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARD T, 1995, NAT STRUCT BIOL, V2, P983, DOI 10.1038/nsb1195-983; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaiser L, 2003, ACTA CRYSTALLOGR D, V59, P1103, DOI 10.1107/S0907444903007741; KEATING KM, 1995, MOL IMMUNOL, V32, P287, DOI 10.1016/0161-5890(94)00140-V; KLEINETEBBE J, 1993, INT ARCH ALLERGY IMM, V100, P256, DOI 10.1159/000236421; Klug J, 2000, ANN NY ACAD SCI, V923, P348; Kristensen AK, 1997, BIOL CHEM, V378, P899; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; MATTHEWS JH, 1994, PROTEINS, V20, P191, DOI 10.1002/prot.340200209; MIELE L, 1994, J ENDOCRINOL INVEST, V17, P679, DOI 10.1007/BF03349687; MORIZE I, 1987, J MOL BIOL, V194, P725, DOI 10.1016/0022-2836(87)90250-6; MORNON JP, 1980, J MOL BIOL, V137, P415, DOI 10.1016/0022-2836(80)90166-7; Mukherjee AB, 1999, CELL MOL LIFE SCI, V55, P771, DOI 10.1007/s000180050331; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; OHMAN JL, 1974, J IMMUNOL, V113, P1668; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Partti-Pellinen K, 2000, ALLERGY, V55, P65, DOI 10.1034/j.1398-9995.2000.00226.x; Pattabiraman N, 2000, ANN NY ACAD SCI, V923, P113; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; PETER W, 1991, J STEROID BIOCHEM, V38, P27, DOI 10.1016/0960-0760(91)90397-N; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; SLUNT JB, 1995, J ALLERGY CLIN IMMUN, V95, P1221, DOI 10.1016/S0091-6749(95)70079-X; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; UMLAND TC, 1994, NAT STRUCT BIOL, V1, P538, DOI 10.1038/nsb0894-538; UMLAND TC, 1992, J MOL BIOL, V224, P441, DOI 10.1016/0022-2836(92)91006-B; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Valenta R, 2001, IMMUNOL REV, V179, P119, DOI 10.1034/j.1600-065X.2001.790112.x; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223, DOI 10.1016/S0091-6749(99)70017-5; VANMILLIGEN FJ, 1994, J ALLERGY CLIN IMMUN, V93, P34, DOI 10.1016/0091-6749(94)90230-5; VANMILLIGEN FJ, 1990, INT ARCH ALLER A IMM, V92, P375, DOI 10.1159/000235168; ZIELONKA TM, 1994, CLIN EXP ALLERGY, V24, P1169, DOI 10.1111/j.1365-2222.1994.tb03324.x	55	88	94	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37730	37735		10.1074/jbc.M304740200	http://dx.doi.org/10.1074/jbc.M304740200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12851385	hybrid			2022-12-25	WOS:000185437200090
J	Maita, N; Nishio, K; Nishimoto, E; Matsui, T; Shikamoto, Y; Morita, T; Sadler, JE; Mizuno, H				Maita, N; Nishio, K; Nishimoto, E; Matsui, T; Shikamoto, Y; Morita, T; Sadler, JE; Mizuno, H			Crystal structure of von Willebrand factor A1 domain complexed with snake venom, bitiscetin - Insight into glycoprotein Ib alpha binding mechanism induced by snake venom proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIMERESURUS-FLAVOVIRIDIS; ANTICOAGULANT PROTEIN; ACCELERATED EVOLUTION; TYROSINE SULFATION; IDENTIFICATION; RESIDUES; RECEPTOR; REVEALS	Bitiscetin, a platelet adhesion inducer isolated from venom of the snake Bitis arietans, activates the binding of the von Willebrand factor (VWF) A1 domain to glycoprotein Ib (GPIb) in vitro. This activation requires the formation of a bitiscetin-VWF A1 complex, suggesting an allosteric mechanism of action. Here, we report the crystal structure of bitiscetin-VWF A1 domain complex solved at 2.85 Angstrom. In the complex structure, helix alpha5 of VWF A1 domain lies on a concave depression on bitiscetin, and binding sites are located at both ends of the depression. The binding sites correspond well with those proposed previously based on alanine-scanning mutagenesis (Matsui, T., Hamako, J., Matsushita, T., Nakayama, T., Fujimura, Y., and Titani, K. (2002) Biochemistry 41, 7939-7946). Against our expectations, the structure of the VWF A1 domain bound to bitiscetin does not differ significantly from the structure of the free A1 domain. These results are similar to the case of botrocetin, another snake-derived inducer of platelet aggregation, although the binding modes of botrocetin and bitiscetin are different. The modeled structure of the ternary bitiscetin-VWF A1-GPIb complex suggests that an electropositive surface of bitiscetin may interact with a favorably positioned anionic region of GPIb. These results suggest that snake venom proteins induce VWF A1-GPIbalpha binding by interacting with both proteins, and not by causing conformational changes in VWF A1.	Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan; Fujita Hlth Univ, Sch Hlth Sci, Dept Biol, Aichi 4701192, Japan; Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA	National Institute of Agrobiological Sciences - Japan; Fujita Health University; Meiji Pharmaceutical University; Howard Hughes Medical Institute; Washington University (WUSTL)	Mizuno, H (corresponding author), Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan.	mizuno@affrc.go.jp	Sadler, Evan/D-8556-2011; Maita, Nobuo/J-1443-2012	Maita, Nobuo/0000-0003-2260-5783; Sadler, J. Evan/0000-0001-5705-469X				Atoda H, 1997, THROMB RES, V87, P271, DOI 10.1016/S0049-3848(97)00129-1; ATODA H, 1991, J BIOL CHEM, V266, P14903; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Celikel R, 2000, NAT STRUCT BIOL, V7, P881; Chung DW, 2002, BIOCHEMISTRY-US, V41, P11065, DOI 10.1021/bi0204692; Deshimaru M, 1996, FEBS LETT, V397, P83, DOI 10.1016/S0014-5793(96)01144-1; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Dong JF, 2001, J BIOL CHEM, V276, P16690, DOI 10.1074/jbc.M101035200; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Fujimura Y, 1996, THROMB HAEMOSTASIS, V76, P633; Fukuda K, 2000, BIOCHEMISTRY-US, V39, P1915, DOI 10.1021/bi992134z; Fukuda K, 2002, STRUCTURE, V10, P943, DOI 10.1016/S0969-2126(02)00787-6; Hamako J, 1996, BIOCHEM BIOPH RES CO, V226, P273, DOI 10.1006/bbrc.1996.1345; Hirotsu S, 2001, BIOCHEMISTRY-US, V40, P13592, DOI 10.1021/bi0114933; HOYLAERTS MF, 1995, BIOCHEM J, V306, P453, DOI 10.1042/bj3060453; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; JENNIFER CD, 1996, NATURE, V379, P537; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; Matsui T, 2002, BIOCHEMISTRY-US, V41, P7939, DOI 10.1021/bi020004b; Matsushita T, 2000, J BIOL CHEM, V275, P11044, DOI 10.1074/jbc.275.15.11044; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miura S, 2000, J BIOL CHEM, V275, P7539, DOI 10.1074/jbc.275.11.7539; Miyata S, 1996, J BIOL CHEM, V271, P9046, DOI 10.1074/jbc.271.15.9046; Mizuno H, 1999, J MOL BIOL, V289, P103, DOI 10.1006/jmbi.1999.2756; Mizuno H, 1997, NAT STRUCT BIOL, V4, P438, DOI 10.1038/nsb0697-438; Mizuno H, 2001, P NATL ACAD SCI USA, V98, P7230, DOI 10.1073/pnas.131179698; NAKASHIMA K, 1993, P NATL ACAD SCI USA, V90, P5964, DOI 10.1073/pnas.90.13.5964; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PETERSON DM, 1987, BLOOD, V69, P625; Ruggeri ZM, 1999, THROMB HAEMOSTASIS, V82, P576; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Sen U, 2001, BIOCHEMISTRY-US, V40, P345, DOI 10.1021/bi0021737; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200	39	69	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37777	37781		10.1074/jbc.M305566200	http://dx.doi.org/10.1074/jbc.M305566200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12851390	hybrid			2022-12-25	WOS:000185437200096
J	Vanhoorelbeke, K; Depraetere, H; Romijn, RAP; Huizinga, EG; De Maeyer, M; Deckmyn, H				Vanhoorelbeke, K; Depraetere, H; Romijn, RAP; Huizinga, EG; De Maeyer, M; Deckmyn, H			A consensus tetrapeptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal Anti-VWF antibody that inhibits the von Willebrand factor-collagen interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA-2-BETA-1 VLA-2; PLATELET THROMBUS FORMATION; VONWILLEBRAND-FACTOR; BINDING-SITE; PEPTIDE LIBRARIES; GLYCOPROTEIN-VI; FLOW CONDITIONS; I-DOMAIN; SEQUENCE ALIGNMENT; IDENTIFICATION	Monoclonal antibody (mAb) 82D6A3 is an anti-von Willebrand factor (VWF) mAb directed against the A3-domain of VWF that inhibits the VWF binding to fibrillar collagens type I and III in vitro and in vivo. To identify the discontinuous epitope of this mAb, we used phage display, mutant analysis, and peptide modeling. All 82D6A3-binding phages displayed peptides containing the consensus sequence SPWR that could be aligned with P981W982 in the VWF A3-domain. Next, the binding of mAb 82D6A3 to 27 Ala mutants with mutations in the A3-domain of VWF revealed that amino acids Arg(963), Pro(981), Asp(1009), Arg(1016), Ser(1020), Met(1022), and His(1023) are part of the epitope of mAb 82D6A3. Inspection of residues Ser(1020), Arg(1016), Pro(981), and Trp(982) in the three-dimensional structure of the A3-domain demonstrated that these residues are close together in space, pointing out that the structure of the SPWR consensus sequence might mimic this discontinuous epitope. Modeling of a cyclic 6-mer peptide containing the consensus sequence and superposition of its three-dimensional structure onto the VWF A3-domain demonstrated that the Ser and Arg in the peptide matched the Ser(1020) and Arg(1016) in the A3-domain. The Pro residue of the peptide served as a spacer, and the side chain of the Trp pointed in the direction of Trp(982). In conclusion, to our knowledge, this is the first report where a modeled peptide containing a consensus sequence could be fitted onto the three-dimensional structure of the antigen, indicating that it might adopt the conformation of the discontinuous epitope.	Katholieke Univ Leuven, IRC, Lab Thrombosis Res, B-8500 Kortrijk, Belgium; Univ Utrecht, Med Ctr, Dept Haematol, Thrombosis & Haemostasis Lab, NL-3508 GA Utrecht, Netherlands; Katholieke Univ Leuven, Biomolec Modelling Lab, B-3001 Heverlee, Belgium	KU Leuven; Utrecht University; KU Leuven	Deckmyn, H (corresponding author), Katholieke Univ Leuven, IRC, Lab Thrombosis Res, Campus Kortrijk,E Sabbelaan 53, B-8500 Kortrijk, Belgium.		Deckmyn, Hans/L-9434-2015; Deckmyn, Hans/N-8932-2019	Deckmyn, Hans/0000-0003-3952-5501; Deckmyn, Hans/0000-0003-3952-5501; Vanhoorelbeke, Karen/0000-0003-2288-8277; Depraetere, Hilde/0000-0001-7196-7911				ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; BAHOU WF, 1994, BLOOD, V84, P3734, DOI 10.1182/blood.V84.11.3734.bloodjournal84113734; BEER JH, 1993, BLOOD, V82, P820; Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; CHRISTOPHE O, 1991, BLOOD, V78, P2310; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; COLOMBATTI A, 1991, BLOOD, V77, P2305; CORTESE R, 1994, TRENDS BIOTECHNOL, V12, P262, DOI 10.1016/0167-7799(94)90137-6; CRUZ MA, 1995, J BIOL CHEM, V270, P19668; DELHAISE P, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80028-3; Demangel C, 2000, EUR J BIOCHEM, V267, P2345, DOI 10.1046/j.1432-1327.2000.01244.x; Depraetere H, 1998, BLOOD, V92, P4207, DOI 10.1182/blood.V92.11.4207.423a02_4207_4211; Depraetere H, 1997, THROMB HAEMOSTASIS, V77, P981; Furmonaviciene R, 1999, CLIN EXP ALLERGY, V29, P1563, DOI 10.1046/j.1365-2222.1999.00686.x; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; HARSFALVI J, 1995, BLOOD, V85, P705, DOI 10.1182/blood.V85.3.705.bloodjournal853705; Hoylaerts MF, 1997, BIOCHEM J, V324, P185, DOI 10.1042/bj3240185; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; Kehrel B, 1998, BLOOD, V91, P491; Lankhof H, 1996, THROMB HAEMOSTASIS, V75, P950; Lankhof H, 1997, THROMB HAEMOSTASIS, V77, P1008; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; Mazzucato M, 1999, J BIOL CHEM, V274, P3033, DOI 10.1074/jbc.274.5.3033; MOHRI H, 1993, PEPTIDES, V14, P125, DOI 10.1016/0196-9781(93)90019-D; Moroi M, 1997, BLOOD, V90, P4413; Myers MA, 2000, J IMMUNOL, V165, P3830, DOI 10.4049/jimmunol.165.7.3830; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Nishida N, 2003, NAT STRUCT BIOL, V10, P53, DOI 10.1038/nsb876; Ravera MW, 1998, ONCOGENE, V16, P1993, DOI 10.1038/sj.onc.1201717; Romijn RA, 2003, J BIOL CHEM, V278, P15035, DOI 10.1074/jbc.M208977200; Romijn RAP, 2001, J BIOL CHEM, V276, P9985, DOI 10.1074/jbc.M006548200; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; SCHOOLMEESTER A, 2003, J THROMB HAEMOST S1, V1, pOC139; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SIXMA JJ, 1991, MAYO CLIN PROC, V66, P628, DOI 10.1016/S0025-6196(12)60523-0; SIXMA JJ, 1991, EUR J BIOCHEM, V196, P369, DOI 10.1111/j.1432-1033.1991.tb15826.x; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; SOBEL M, 1992, J BIOL CHEM, V267, P8857; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van der Plas RM, 2000, THROMB HAEMOSTASIS, V84, P1005; Vanhoorelbeke K, 2000, THROMB HAEMOSTASIS, V84, P621; Verkleij MW, 1999, THROMB HAEMOSTASIS, V82, P1137; Villard S, 2002, J BIOL CHEM, V277, P27232, DOI 10.1074/jbc.M203415200; Wu DM, 2002, BLOOD, V99, P3623, DOI 10.1182/blood.V99.10.3623; Yip YL, 1999, COMB CHEM HIGH T SCR, V2, P125; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200	49	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37815	37821		10.1074/jbc.M304289200	http://dx.doi.org/10.1074/jbc.M304289200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855711	Green Published, hybrid			2022-12-25	WOS:000185437200101
J	Krishnan, P; Gullen, EA; Lam, W; Dutschman, GE; Grill, SP; Cheng, YC				Krishnan, P; Gullen, EA; Lam, W; Dutschman, GE; Grill, SP; Cheng, YC			Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-B-VIRUS; PHOSPHORYLATION; METABOLISM; LAMIVUDINE; PYRIMIDINE; PHARMACOKINETICS; DIPHOSPHATES	L-Nucleoside analogs are a new class of clinically active antiviral and anticancer agents. The phosphorylation of these analogs from diphosphate to triphosphate metabolites is crucial for their biological action. We studied the role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the metabolism of L-nucleoside analogs, using small interfering RNAs to down-regulate the amount of this enzyme in HelaS3 and 2.2.15 cells, chosen as models for studying the impact of the enzyme on the anticancer and antihepatitis B virus activities of these analogs. Decrease in the expression of 3-phosphoglycerate kinase led to a corresponding decrease in the formation of the triphosphate metabolites of L-nucleoside analogs (but not D-nucleoside analogs), resulting in detrimental effects on their activity. The enzyme is important for generating as well as maintaining the steady state levels of L-nucleotides in the cells, thereby playing a key role in the activity of L-nucleoside analogs against human immunodeficiency virus, hepatitis B virus, and cancer. This study also indicates a structure-based distinction in the metabolism of L- and D-nucleoside analogs, disputing the classic notion that nucleoside diphosphate kinases are responsible for the phosphorylation of all classes of nucleoside analog diphosphates.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Cheng, YC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St,SHM B254, New Haven, CT 06520 USA.	cheng.lab@yale.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038204] Funding Source: NIH RePORTER; NCI NIH HHS [CA36477] Funding Source: Medline; NIAID NIH HHS [AI38204] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BALZARINI J, 1989, J BIOL CHEM, V264, P6127; Bourdais J, 1996, J BIOL CHEM, V271, P7887, DOI 10.1074/jbc.271.14.7887; Bridges E G, 1995, Prog Liver Dis, V13, P231; Chen SH, 2002, CURR MED CHEM, V9, P899, DOI 10.2174/0929867024606696; Cheng Yung-Chi, 2001, Cancer Letters, V162, pS33, DOI 10.1016/S0304-3835(00)00650-9; Cheng Yung-Chi, 2001, Antiviral Chemistry and Chemotherapy, V12, P5; Chong YH, 2002, BIOORG MED CHEM LETT, V12, P3459, DOI 10.1016/S0960-894X(02)00747-3; De Clercq E, 1999, INT J ANTIMICROB AG, V12, P81, DOI 10.1016/S0924-8579(99)00060-6; De Clercq E, 2002, MED RES REV, V22, P531; Dutschman GE, 1998, ANTIMICROB AGENTS CH, V42, P1799, DOI 10.1128/AAC.42.7.1799; Ecker Gerhard, 2002, Curr Opin Investig Drugs, V3, P1533; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; ENA J, 2003, HIV AIDS, V36, P1186; Fu L, 2000, ANTIMICROB AGENTS CH, V44, P3402, DOI 10.1128/AAC.44.12.3402-3407.2000; Galmarini CM, 2001, LEUKEMIA, V15, P875, DOI 10.1038/sj.leu.2402114; Giles Francis J, 2002, Expert Rev Anticancer Ther, V2, P261, DOI 10.1586/14737140.2.3.261; Gish RG, 2002, ANTIMICROB AGENTS CH, V46, P1734, DOI 10.1128/AAC.46.6.1734-1740.2002; GROVE KL, 1995, CANCER RES, V55, P3008; Karayiannis P, 2003, J ANTIMICROB CHEMOTH, V51, P761, DOI 10.1093/jac/dkg163; Kreimeyer A, 2001, ANTIVIR RES, V50, P147, DOI 10.1016/S0166-3542(01)00139-5; Krishnan P, 2002, J BIOL CHEM, V277, P5453, DOI 10.1074/jbc.M109025200; Krishnan P, 2002, J BIOL CHEM, V277, P31593, DOI 10.1074/jbc.M205115200; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Lin TS, 1996, J MED CHEM, V39, P1757, DOI 10.1021/jm950836q; Liou JY, 2002, CANCER RES, V62, P1624; Liu SH, 1998, ANTIMICROB AGENTS CH, V42, P833, DOI 10.1128/AAC.42.4.833; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Nevens F, 1997, GASTROENTEROLOGY, V113, P1258, DOI 10.1053/gast.1997.v113.pm9322520; Pai SB, 1996, ANTIMICROB AGENTS CH, V40, P380, DOI 10.1128/AAC.40.2.380; Perry CM, 1997, DRUGS, V53, P657, DOI 10.2165/00003495-199753040-00008; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P2432, DOI 10.1128/AAC.36.11.2432; Schneider B, 1998, J BIOL CHEM, V273, P11491, DOI 10.1074/jbc.273.19.11491; Seigneres B, 2003, ANTIMICROB AGENTS CH, V47, P1842, DOI 10.1128/AAC.47.6.1842-1852.2003; Tan XL, 1999, ADV DRUG DELIVER REV, V39, P117, DOI 10.1016/S0169-409X(99)00023-X; Tsimberidou Apostolia-Maria, 2002, Expert Rev Anticancer Ther, V2, P437, DOI 10.1586/14737140.2.4.437; Van Rompay AR, 1999, MOL PHARMACOL, V56, P562, DOI 10.1124/mol.56.3.562; Van Rompay AR, 2000, PHARMACOL THERAPEUT, V87, P189, DOI 10.1016/S0163-7258(00)00048-6	39	49	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36726	36732		10.1074/jbc.M307052200	http://dx.doi.org/10.1074/jbc.M307052200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12869554	hybrid			2022-12-25	WOS:000185318300104
J	Lai, KD; Harnish, DC; Evans, MJ				Lai, KD; Harnish, DC; Evans, MJ			Estrogen receptor alpha regulates expression of the orphan receptor small heterodimer partner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE FEEDBACK-REGULATION; HORMONE REPLACEMENT THERAPY; FACTOR-KAPPA-B; NUCLEAR RECEPTOR; GENE-EXPRESSION; X-RECEPTOR; ER-ALPHA; TRANSCRIPTIONAL ACTIVITY; DIFFERENTIAL REGULATION; INTERLEUKIN-6 PROMOTER	Hormonal status can influence diverse metabolic pathways. Small heterodimer partner (SHP) is an orphan nuclear receptor that can modulate the activity of several transcription factors. Estrogens are here shown to directly induce expression of the SHP in the mouse and rat liver and in human HepG2 cells. SHP is rapidly induced within 2 h following treatment of mice with ethynylestradiol (EE) or the estrogen receptor alpha (ERalpha)-selective compound propyl pyrazole triol (PPT). SHP induction by these estrogens is completely absent in ERalphaKO mice. Mutation of the human SHP promoter defined HNF-3, HNF-4, GATA, and AP-1 sites as important for basal activity, whereas EE induction required two distinct elements located between - 309 and - 267. One of these elements contains an estrogen response element half-site that bound purified ERalpha, and ERalpha with a mutated DNA binding domain was unable to stimulate SHP promoter activity. This ERalpha binding site overlaps the known farnesoid X receptor (FXR) binding site in the SHP promoter, and the combination of EE plus FXR agonists did not produce an additive induction of SHP expression in mice. Surprisingly, induction of SHP by EE did not inhibit expression of the known SHP target genes cholesterol 7alpha-hydroxylase (CYP7A1) or sterol 12alpha-hydroxylase (CYP8B1). However, the direct regulation of SHP expression may provide a basis for some of the numerous biological effects of estrogens.	Wyeth Res, Collegeville, PA 19426 USA	Pfizer	Evans, MJ (corresponding author), Wyeth Res, 500 Arcola Rd, Collegeville, PA 19426 USA.	Evansm@wyeth.com						Barkhem T, 2002, MOL PHARMACOL, V61, P1273, DOI 10.1124/mol.61.6.1273; BarrettConnor E, 1997, MATURITAS, V27, P261, DOI 10.1016/S0378-5122(97)00041-8; BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; BERGMAN MD, 1992, ENDOCRINOLOGY, V130, P1923, DOI 10.1210/en.130.4.1923; Brendel C, 2002, MOL ENDOCRINOL, V16, P2065, DOI 10.1210/me.2001-0194; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; Cui J, 2003, J BIOL CHEM, V278, P10214, DOI 10.1074/jbc.M209323200; del Castillo-Olivares A, 2001, NUCLEIC ACIDS RES, V29, P4035, DOI 10.1093/nar/29.19.4035; Desai PB, 2002, DRUG METAB DISPOS, V30, P608, DOI 10.1124/dmd.30.5.608; Ediger TR, 2002, MOL ENDOCRINOL, V16, P1828, DOI 10.1210/me.2001-0290; Evans MJ, 2002, ENDOCRINOLOGY, V143, P2559, DOI 10.1210/en.143.7.2559; Evans MJ, 2001, CIRC RES, V89, P823, DOI 10.1161/hh2101.098543; GHERSA P, 1992, J BIOL CHEM, V267, P19226; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; Gobinet J, 2001, BIOCHEMISTRY-US, V40, P15369, DOI 10.1021/bi011384o; Godsland IF, 2001, FERTIL STERIL, V75, P898, DOI 10.1016/S0015-0282(01)01699-5; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Goodwin B, 2003, MOL ENDOCRINOL, V17, P386, DOI 10.1210/me.2002-0246; Gruber CJ, 2002, NEW ENGL J MED, V346, P340, DOI 10.1056/NEJMra000471; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Harnish DC, 1998, J BIOL CHEM, V273, P9270, DOI 10.1074/jbc.273.15.9270; Harnish DC, 2000, ENDOCRINOLOGY, V141, P3403, DOI 10.1210/en.141.9.3403; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; Hyder SM, 1999, J PHARMACOL EXP THER, V290, P740; Jelinsky SA, 2003, ENDOCRINOLOGY, V144, P701, DOI 10.1210/en.2002-220728; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Kanamori H, 2000, J BIOL CHEM, V275, P5867, DOI 10.1074/jbc.275.8.5867; Kassam A, 2001, MOL CELL ENDOCRINOL, V176, P49, DOI 10.1016/S0303-7207(01)00475-0; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Kim YS, 2001, J BIOL CHEM, V276, P33736, DOI 10.1074/jbc.M101977200; Klinge CM, 2001, ARCH BIOCHEM BIOPHYS, V390, P64, DOI 10.1006/abbi.2001.2366; Kraichely DM, 2000, ENDOCRINOLOGY, V141, P3534, DOI 10.1210/en.141.10.3534; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lee HK, 1998, J BIOL CHEM, V273, P14398, DOI 10.1074/jbc.273.23.14398; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lee YK, 1999, J BIOL CHEM, V274, P20869, DOI 10.1074/jbc.274.30.20869; Lobo RA, 2001, FERTIL STERIL, V76, P13, DOI 10.1016/S0015-0282(01)01829-5; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; Luo Y, 2001, J BIOL CHEM, V276, P24767, DOI 10.1074/jbc.M100912200; Martini PGV, 2001, ENDOCRINOLOGY, V142, P3493, DOI 10.1210/en.142.8.3493; Munoz J, 2002, OBES RES, V10, P424, DOI 10.1038/oby.2002.59; Nishigori H, 2001, P NATL ACAD SCI USA, V98, P575, DOI 10.1073/pnas.98.2.575; Nishizawa H, 2002, J BIOL CHEM, V277, P1586, DOI 10.1074/jbc.M104301200; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paganini-Hill A, 2000, BREAST CANCER RES TR, V60, P167, DOI 10.1023/A:1006342300291; Pendaries C, 2002, P NATL ACAD SCI USA, V99, P2205, DOI 10.1073/pnas.042688499; Picard F, 2000, INT J OBESITY, V24, P830, DOI 10.1038/sj.ijo.0801240; POTTRATZ ST, 1994, J CLIN INVEST, V93, P944, DOI 10.1172/JCI117100; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Sanyal S, 2002, J BIOL CHEM, V277, P1739, DOI 10.1074/jbc.M106140200; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Shughrue PJ, 2002, ENDOCRINOLOGY, V143, P1643, DOI 10.1210/en.143.5.1643; Sites CK, 2001, METABOLISM, V50, P835, DOI 10.1053/meta.2001.24878; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; Tchernof A, 1998, CORONARY ARTERY DIS, V9, P503, DOI 10.1097/00019501-199809080-00006; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; WALMER DK, 1992, ENDOCRINOLOGY, V131, P1458, DOI 10.1210/en.131.3.1458; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Worzala K, 2001, ARCH INTERN MED, V161, P1448, DOI 10.1001/archinte.161.11.1448; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Zhang M, 2001, J BIOL CHEM, V276, P41690, DOI 10.1074/jbc.M105117200	69	70	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36418	36429		10.1074/jbc.M303913200	http://dx.doi.org/10.1074/jbc.M303913200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12842887	hybrid			2022-12-25	WOS:000185318300070
J	Pawar, A; Jump, DB				Pawar, A; Jump, DB			Unsaturated fatty acid regulation of peroxisome proliferator-activated receptor alpha activity in rat primary hepatoctes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1C; DOCOSAHEXAENOIC ACID; GENE-EXPRESSION; PPAR-ALPHA; LIGAND; TRANSCRIPTION; N-3; SUPPRESSION; TRIACYLGLYCEROL; EICOSANOIDS	Peroxisome proliferator-activated receptors (PPARs alpha, beta, gamma1, and gamma2) are widely regarded as monitors of intracellular nonesterified fatty acid ( NEFA) levels. As such, fatty acid binding to PPAR leads to changes in the transcription of many genes involved in lipid metabolism and storage. Although the composition of the intracellular NEFA pool is likely an important factor controlling PPAR activity, little information is available on factors affecting its composition. Accordingly, we have examined the effects of exogenous fatty acids on PPARalpha activity and NEFA pool composition in rat primary hepatocytes. Prior to the addition of fatty acids to primary hepatocytes, nonesterified unsaturated fatty acid levels are very low, representing less than or equal to 0.5% of the total fatty acid in the cell. The relative abundance of putative PPARalpha ligands in the NEFA pool is 20: 4n-6 = 18: 2n- 6 = 18: 1n- 9 > 22: 6n- 3 > 18: 3n- 3/6 = 20: 5n-3. Of these fatty acids, only 20: 5n-3 and 22: 6n- 3 consistently induced PPARalpha activity. Metabolic labeling of primary hepatocytes indicated that both C-14-18: 1n-9 and C-14-20: 5n-3 are rapidly assimilated into neutral and polar lipids. Although the addition of 18: 1n- 9 had no effect on NEFA pool composition, 20: 5n-3 mass increased > 15-fold within 90 min. Changes in NEFA pool 20: 5n-3 mass correlated with dynamic changes in the PPARalpha-regulated transcript mRNA(CYP4A). Metabolic labeling also indicated that a significant fraction of C-14-20: 5n- 3 was elongated to 22: 5n-3. Cells treated with 22: 5n- 3 or 22: 6n- 3 led to a significant accumulation of 20: 5n- 3 in the NEFA pool through a process that requires peroxisomal beta-oxidation and fatty acyl CoA thioesterase activity. Further analyses suggest that 20: 5n- 3 and 22: 6n- 3, but not 22: 5n- 3, are active ligands for PPARalpha. These studies suggest that basal fatty acid levels in the NEFA pool coupled with rates of fatty acid esterification, elongation, desaturation, peroxisomal beta-oxidation, and fatty acyl thioestease activity are important determinants controlling NEFA pool composition and PPARalpha activity.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Jump, DB (corresponding author), Michigan State Univ, Dept Physiol, 3165 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.	Jump@msu.edu	Pawar, Anjali/AAT-8945-2020	Pawar, Anjali/0000-0002-2133-8663	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43220, R01 DK043220] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amet Y, 1995, BIOCHEM PHARMACOL, V50, P1775, DOI 10.1016/0006-2952(95)02040-3; [Anonymous], [No title captured]; Berge RK, 1999, BIOCHEM J, V343, P191, DOI 10.1042/0264-6021:3430191; CHRISTIANSEN EN, 1991, BIOCHIM BIOPHYS ACTA, V1082, P57, DOI 10.1016/0005-2760(91)90299-W; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200; Jump DB, 2001, J BIOL CHEM, V276, P34419, DOI 10.1074/jbc.M105471200; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; LANG CA, 1990, J LIPID RES, V31, P2079; Lawrence JW, 2000, J LIPID RES, V41, P1390; LIEBICH HM, 1991, J CHROMATOGR-BIOMED, V572, P1, DOI 10.1016/0378-4347(91)80468-R; Luthria DL, 1996, J BIOL CHEM, V271, P16020, DOI 10.1074/jbc.271.27.16020; Malkowski MG, 2001, J BIOL CHEM, V276, P37547, DOI 10.1074/jbc.M105982200; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; Mater MK, 1999, J LIPID RES, V40, P1045; McArthur MJ, 1999, J LIPID RES, V40, P1371; Murphy EJ, 1999, BBA-MOL CELL BIOL L, V1436, P413, DOI 10.1016/S0005-2760(98)00150-7; Norris AW, 2002, J LIPID RES, V43, P646; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Pan DA, 2000, J LIPID RES, V41, P742; Pawar A, 2002, J BIOL CHEM, V277, P39243, DOI 10.1074/jbc.M206170200; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; Seo T, 2001, BIOCHEMISTRY-US, V40, P4756, DOI 10.1021/bi0022947; Sprecher H, 2000, BBA-MOL CELL BIOL L, V1486, P219, DOI 10.1016/S1388-1981(00)00077-9; Stahl A, 2001, TRENDS ENDOCRIN MET, V12, P266, DOI 10.1016/S1043-2760(01)00427-1; Willson TM, 2002, MOL ENDOCRINOL, V16, P1135, DOI 10.1210/me.16.6.1135; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	36	153	157	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35931	35939		10.1074/jbc.M306238200	http://dx.doi.org/10.1074/jbc.M306238200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12853447	hybrid			2022-12-25	WOS:000185318300010
J	Wong, D; DeMott, MS; Demple, B				Wong, D; DeMott, MS; Demple, B			Modulation of the 3 '-> 5 '-exonuclease activity of human apurinic endonuclease (Ape1) by its 5 '-incised abasic DNA product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE; NEGATIVE GENE-REGULATION; POLYMERASE-BETA; OXIDATIVE DAMAGE; EXONUCLEASE ACTIVITY; PROTEIN; SITE; IV; BINDING	The major abasic endonuclease of human cells, Ape1 protein, is a multifunctional enzyme with critical roles in base excision repair (BER) of DNA. In addition to its primary activity as an apurinic/apyrimidinic endonuclease in BER, Ape1 also possesses 3'-phosphodiesterase, 3'-phosphatase, and 3'-->5'-exonuclease functions specific for the 3' termini of internal nicks and gaps in DNA. The exonuclease activity is enhanced at 3' mismatches, which suggests a possible role in BER for Ape1 as a proofreading activity for the relatively inaccurate DNA polymerase beta. To elucidate this role more precisely, we investigated the ability of Ape1 to degrade DNA substrates that mimic BER intermediates. We found that the Ape1 exonuclease is active at both mismatched and correctly matched 3' termini, with preference for mismatches. In our hands, the exonuclease activity of Ape1 was more active at one-nucleotide gaps than at nicks in DNA, even though the latter should represent the product of repair synthesis by polymerase beta. However, the exonuclease activity was inhibited by the presence of nearby 5'-incised abasic residues, which result from the apurinic/apyrimidinic endonuclease activity of Ape1. The same was true for the recently described exonuclease activity of Escherichia coli endonuclease IV. Exonuclease III, the E. coli homolog of Ape1, did not discriminate among the different substrates. Removal of the 5' abasic residue by polymerase beta alleviated the inhibition of the Ape1 exonuclease activity. These results suggest roles for the Ape1 exonuclease during BER after both DNA repair synthesis and excision of the abasic deoxyribose-5-phosphate by polymerase beta.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.	bdemple@hsph.harvard.edu			NCI NIH HHS [T32CA009078, CA71993] Funding Source: Medline; NIEHS NIH HHS [ES00002] Funding Source: Medline; NIGMS NIH HHS [GM40000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071993, T32CA009078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atamna H, 2000, P NATL ACAD SCI USA, V97, P686, DOI 10.1073/pnas.97.2.686; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; Chou KM, 2000, J BIOL CHEM, V275, P31009, DOI 10.1074/jbc.M004082200; Chou KM, 2003, J BIOL CHEM, V278, P18289, DOI 10.1074/jbc.M212143200; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; Chung U, 1996, J BIOL CHEM, V271, P8593, DOI 10.1074/jbc.271.15.8593; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Demple B, 2002, ONCOGENE, V21, P8926, DOI 10.1038/sj.onc.1206178; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Gros L, 2002, ONCOGENE, V21, P8905, DOI 10.1038/sj.onc.1206005; Hadi MZ, 2002, J MOL BIOL, V316, P853, DOI 10.1006/jmbi.2001.5382; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Jiricny J, 2002, NATURE, V415, P593, DOI 10.1038/415593a; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Kelley MR, 2003, CANCER RES, V63, P549; Kerins SM, 2003, J BIOL CHEM, V278, P3048, DOI 10.1074/jbc.M210750200; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Kuninger DT, 2002, NUCLEIC ACIDS RES, V30, P823, DOI 10.1093/nar/30.3.823; Lebedeva NA, 2003, BIOCHEM BIOPH RES CO, V300, P182, DOI 10.1016/S0006-291X(02)02808-5; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; Levin JD, 1996, NUCLEIC ACIDS RES, V24, P885, DOI 10.1093/nar/24.5.885; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Ludwig DL, 1998, MUTAT RES-DNA REPAIR, V409, P17, DOI 10.1016/S0921-8777(98)00039-1; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; Meira LB, 2001, CANCER RES, V61, P5552; Mitra S, 2002, FREE RADICAL BIO MED, V33, P15, DOI 10.1016/S0891-5849(02)00819-5; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; Nakamura J, 1999, CANCER RES, V59, P2522; Nguyen LH, 2000, J MOL BIOL, V298, P447, DOI 10.1006/jmbi.2000.3653; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Pomposiello PJ, 2001, J BACTERIOL, V183, P3890, DOI 10.1128/JB.183.13.3890-3902.2001; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Ranalli TA, 2002, J BIOL CHEM, V277, P1719, DOI 10.1074/jbc.M109053200; Rogers S G, 1980, Methods Enzymol, V65, P201; Sander M, 1996, NUCLEIC ACIDS RES, V24, P3926, DOI 10.1093/nar/24.20.3926; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; WEISS B, 1987, ADV ENZYMOL RAMB, V60, P1; Wilson DM, 2003, J MOL BIOL, V330, P1027, DOI 10.1016/S0022-2836(03)00712-5; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	58	57	60	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36242	36249		10.1074/jbc.M306065200	http://dx.doi.org/10.1074/jbc.M306065200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857737	hybrid			2022-12-25	WOS:000185318300046
J	Hatakeyama, J; Sreenath, T; Hatakeyama, Y; Thyagarajan, T; Shum, L; Gibson, CW; Wright, JT; Kulkarni, AB				Hatakeyama, J; Sreenath, T; Hatakeyama, Y; Thyagarajan, T; Shum, L; Gibson, CW; Wright, JT; Kulkarni, AB			The receptor activator of nuclear factor-B ligand-mediated osteoclastogenic pathway is elevated in amelogenin-null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIODONTAL-LIGAMENT CELLS; ENAMEL MATRIX PROTEINS; PRIMARY RNA TRANSCRIPT; GENE SPLICE PRODUCTS; ROOT RESORPTION; INDUCE OSTEOCLASTOGENESIS; TRANSLATION PRODUCT; TNF-RECEPTOR; IN-VITRO; EXPRESSION	Amelogenins, major components of developing enamel, are predominantly involved in the formation of tooth enamel. Although amelogenins are also implicated in cementogenesis, their precise spatial expression pattern and molecular role are not clearly understood. Here, we report for the first time the expression of two alternate splice forms of amelogenins, M180 and the leucine-rich amelogenin peptide ( LRAP), in the periodontal region of mouse tooth roots. Lack of M180 and LRAP mRNA expression correlated with cementum defects observed in the amelogenin-null mice. The cementum defects were characterized by an increased presence of multinucleated cells, osteoclasts, and cementicles. These defects were associated with an increased expression of the receptor activator of the nuclear factor-kappaB ligand ( RANKL), a critical regulator of osteoclastogenesis. These findings indicate that the amelogenin splice variants, M180 and LRAP, are critical in preventing abnormal resorption of cementum.	NIDCR, Funct Genom Unit, NIH, Bethesda, MD 20892 USA; NIAMS, Cartilage Biol & Orthopaed Branch, NIH, Bethesda, MD 20892 USA; Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA; Univ N Carolina, Dept Pediat Dent, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill	Kulkarni, AB (corresponding author), NIDCR, Funct Genom Unit, NIH, 30 Convent Dr,Bldg 30,Rm 527, Bethesda, MD 20892 USA.		Wright, John Timothy/AAX-5755-2020		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000698, Z01DE000698] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALTHOFF J, 1986, J ORAL PATHOL MED, V15, P11, DOI 10.1111/j.1600-0714.1986.tb00557.x; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Borum MK, 1998, ENDOD DENT TRAUMATOL, V14, P31; Brezniak N, 2002, ANGLE ORTHOD, V72, P175; Cardaropoli G, 2002, J PERIODONTOL, V73, P501, DOI 10.1902/jop.2002.73.5.501; Collier PM, 1997, ARCH ORAL BIOL, V42, P235, DOI 10.1016/S0003-9969(96)00099-4; D'Errico JA, 1999, BONE, V25, P39, DOI 10.1016/S8756-3282(99)00096-4; DErrico JA, 1997, BONE, V20, P117, DOI 10.1016/S8756-3282(96)00348-1; DIEKWISCH T, 1993, DEVELOPMENT, V117, P471; Diekwisch TGH, 2001, INT J DEV BIOL, V45, P695; El-Mofty S, 2002, ORAL SURG ORAL MED O, V93, P296, DOI 10.1067/moe.2002.121545; Fong CD, 2000, ORAL SURG ORAL MED O, V90, P218, DOI 10.1067/moe.2000.107052; Fukae M, 2001, J BONE MINER METAB, V19, P236, DOI 10.1007/s007740170026; Gestrelius S, 1997, J CLIN PERIODONTOL, V24, P678, DOI 10.1111/j.1600-051X.1997.tb00249.x; GIBSON CW, 1991, BIOCHEM BIOPH RES CO, V174, P1306, DOI 10.1016/0006-291X(91)91564-S; Gibson CW, 2001, J BIOL CHEM, V276, P31871, DOI 10.1074/jbc.M104624200; Gravallese EM, 2001, ARTHRITIS RES, V3, P6, DOI 10.1186/ar134; Gunraj MN, 1999, ORAL SURG ORAL MED O, V88, P647, DOI 10.1016/S1079-2104(99)70002-8; Hamamoto Y, 1996, ORAL SURG ORAL MED O, V81, P703, DOI 10.1016/S1079-2104(96)80077-1; Hammarstrom L, 1997, J CLIN PERIODONTOL, V24, P669, DOI 10.1111/j.1600-051X.1997.tb00248.x; Hasegawa T, 2002, J PERIODONTAL RES, V37, P405, DOI 10.1034/j.1600-0765.2002.01603.x; Hasegawa T, 2002, TISSUE CELL, V34, P44, DOI 10.1054/tice.2002.0223; Kanzaki H, 2002, J BONE MINER RES, V17, P210, DOI 10.1359/jbmr.2002.17.2.210; Kanzaki H, 2001, J DENT RES, V80, P887, DOI 10.1177/00220345010800030801; Kawamoto S, 2002, ARCH ORAL BIOL, V47, P67, DOI 10.1016/S0003-9969(01)00086-3; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LAGERSTROM M, 1991, GENOMICS, V10, P971, DOI 10.1016/0888-7543(91)90187-J; LAU EC, 1992, BIOCHEM BIOPH RES CO, V188, P1253, DOI 10.1016/0006-291X(92)91366-X; Leach HA, 2001, BRIT DENT J, V190, P16, DOI 10.1038/sj.bdj.4800870a; LYNGSTADAAS SP, 1995, EMBO J, V14, P5224, DOI 10.1002/j.1460-2075.1995.tb00207.x; Oida S, 2002, J DENT RES, V81, P103, DOI 10.1177/154405910208100204; Papagerakis P, 2003, BONE, V32, P228, DOI 10.1016/S8756-3282(02)00978-X; SALIDO EC, 1992, AM J HUM GENET, V50, P303; Sashima M, 1996, J PERIODONTAL RES, V31, P470, DOI 10.1111/j.1600-0765.1996.tb01411.x; Shin JN, 2002, J BIOL CHEM, V277, P8346, DOI 10.1074/jbc.M110964200; SIMMER JP, 1994, CALCIFIED TISSUE INT, V55, P302, DOI 10.1007/BF00310410; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SLAVKIN HC, 1989, BIOCHIM BIOPHYS ACTA, V991, P12, DOI 10.1016/0304-4165(89)90021-4; SLAVKIN HC, 1976, J PERIODONTOL, V47, P249, DOI 10.1902/jop.1976.47.5.249; SLAVKIN HC, 1989, J PERIODONTAL RES, V24, P28, DOI 10.1111/j.1600-0765.1989.tb00854.x; Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756-3282(99)00210-0; Veis A, 2003, CELL MOL LIFE SCI, V60, P38, DOI 10.1007/s000180300003; Veis A, 2000, J BIOL CHEM, V275, P41263, DOI 10.1074/jbc.M002308200; Velasquez-Plata D, 2002, J PERIODONTOL, V73, P433, DOI 10.1902/jop.2002.73.4.433; WRIGHT JT, 1989, J DENT RES, V68, P1328, DOI 10.1177/00220345890680090801; Wright JT, 1997, ARCH ORAL BIOL, V42, P149, DOI 10.1016/S0003-9969(96)00096-9; Yagishita H, 2001, J ORAL PATHOL MED, V30, P499, DOI 10.1034/j.1600-0714.2001.030008499.x; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zeichner-David M, 2001, MATRIX BIOL, V20, P307, DOI 10.1016/S0945-053X(01)00155-X	49	73	76	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35743	35748		10.1074/jbc.M306284200	http://dx.doi.org/10.1074/jbc.M306284200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12851394	hybrid, Green Published			2022-12-25	WOS:000185164400121
J	Gruez, A; Roig-Zamboni, V; Valencia, C; Campanacci, VR; Cambillau, C				Gruez, A; Roig-Zamboni, V; Valencia, C; Campanacci, VR; Cambillau, C			The crystal structure of the Escherichia coli YfdW gene product reveals a new fold of two interlaced rings identifying a wide family of CoA transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A TRANSFERASE; OXALOBACTER-FORMIGENES; OXALATE; PROTEIN; PURIFICATION; MODEL	Because of its toxicity, oxalate accumulation from amino acid catabolism leads to acute disorders in mammals. Gut microflora are therefore pivotal in maintaining a safe intestinal oxalate balance through oxalate degradation. Oxalate catabolism was first identified in Oxalobacter formigenes, a specialized, strictly anaerobic bacterium. Oxalate degradation was found to be performed successively by two enzymes, a formyl-CoA transferase (frc) and an oxalate decarboxylase (oxc). These two genes are present in several bacterial genomes including that of Escherichia coli. The frc ortholog in E. coli is yfdW, with which it shares 61% sequence identity. We have expressed the YfdW open reading frame product and solved its crystal structure in the apo-form and in complex with acetyl-CoA and with a mixture of acetyl-CoA and oxalate. YfdW exhibits a novel and spectacular fold in which two monomers assemble as interlaced rings, defining the CoA binding site at their interface. From the structure of the complex with acetyl-CoA and oxalate, we propose a putative formyl/oxalate transfer mechanism involving the conserved catalytic residue Asp(169). The similarity of yfdW with bacterial orthologs (similar to 60% identity) and paralogs (similar to 20-30% identity) suggests that this new fold and parts of the CoA transfer mechanism are likely to be the hallmarks of a wide family of CoA transferases.	CNRS, Architecture & Fonct Macromol Biol, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Cambillau, C (corresponding author), CNRS, Architecture & Fonct Macromol Biol, UMR 6098, 31 Chemin J Aiguier, F-13402 Marseille 20, France.	cambillau@afmb.cnrs-mrs.fr		Campanacci, Valerie/0000-0001-6407-6395				ALLISON MJ, 1985, ARCH MICROBIOL, V141, P1, DOI 10.1007/BF00446731; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; BAETZ AL, 1990, J BACTERIOL, V172, P3537, DOI 10.1128/jb.172.7.3537-3540.1990; BAETZ AL, 1989, J BACTERIOL, V171, P2605, DOI 10.1128/jb.171.5.2605-2608.1989; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Claverie JM, 2002, COMB CHEM HIGH T SCR, V5, P511, DOI 10.2174/1386207023330002; DOANE LT, 1989, NUTR RES, V9, P957, DOI 10.1016/S0271-5317(89)80056-9; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Duncan SH, 2002, APPL ENVIRON MICROB, V68, P3841, DOI 10.1128/AEM.68.8.3841-3847.2002; Engel C, 1996, CURR OPIN STRUC BIOL, V6, P790, DOI 10.1016/S0959-440X(96)80009-1; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JAMES LF, 1972, CLIN TOXICOL, V5, P231, DOI 10.3109/15563657208991002; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RODBY RA, 1991, AM J MED, V90, P498; Roussel A, 1991, SILICON GRAPHICS GEO, P81; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Sidhu H, 1997, J BACTERIOL, V179, P3378, DOI 10.1128/jb.179.10.3378-3381.1997; Sulzenbacher G, 2002, ACTA CRYSTALLOGR D, V58, P2109, DOI 10.1107/S0907444902013938; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; WILLIAMS HE, 1968, AM J MED, V45, P715, DOI 10.1016/0002-9343(68)90207-6	29	27	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34582	34586		10.1074/jbc.C300282200	http://dx.doi.org/10.1074/jbc.C300282200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12844490	hybrid			2022-12-25	WOS:000185047500119
J	Taniguchi, Y; Kim, SH; Sisodia, SS				Taniguchi, Y; Kim, SH; Sisodia, SS			Presenilin-dependent "gamma-secretase" processing of deleted in colorectal cancer (DCC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; INTRACELLULAR DOMAIN; CLEAVAGE; RECEPTOR; RELEASE; NOTCH1; TRAFFICKING; EXPRESSION; DEFICIENCY; TIP60	The presenilin-gamma-secretase complex plays a critical role in mediating intramembranous proteolysis of several type I membrane proteins, including beta-amyloid precursor protein (APP) and Notch. We now show that deleted in colorectal cancer (DCC) is subject to proteolysis within the ectodomain segment both in cultured cells and in vivo and that the residual membrane-tethered DCC "stub" is subsequently processed by gamma-secretase to generate a derivative termed DCC-intracellular domain (ICD). The production of DCC-ICD is inhibited by selective gamma-secretase inhibitors, and by the expression of the dominant negative PS1 D385A variant. Moreover, the membrane-tethered DCC "stubs" accumulate to high levels in PS1-deficient embryos. We also demonstrate that expression of a DCC-Gal4 chimera is capable of activating transcription in a luciferase-based reporter assay and this activity is dependent on gamma-secretase activity. Our findings offer the proposal that DCC performs dual roles both as a cell surface receptor that modulates intracellular signaling pathways and as a transcriptional coactivator that relies on gamma-secretase-dependent production and nuclear translocation of the cytoplasmic domain.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Chicago	Sisodia, SS (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St,MC0926, Chicago, IL 60637 USA.		Taniguchi, Yoshihito/L-5746-2013		NIA NIH HHS [AG021494] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG021494] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Galko MJ, 2000, SCIENCE, V289, P1365, DOI 10.1126/science.289.5483.1365; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0	24	100	105	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30425	30428		10.1074/jbc.C300239200	http://dx.doi.org/10.1074/jbc.C300239200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12840034	hybrid			2022-12-25	WOS:000184658800004
J	Turella, P; Pedersen, JZ; Caccuri, AM; De Maria, F; Mastroberardino, P; Lo Bello, M; Federici, G; Ricci, G				Turella, P; Pedersen, JZ; Caccuri, AM; De Maria, F; Mastroberardino, P; Lo Bello, M; Federici, G; Ricci, G			Glutathione transferase superfamily behaves like storage proteins for dinitrosyl-diglutathionyl-iron complex in heterogeneous systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EVOLUTIONARY STRATEGIES; S-TRANSFERASES; T2-2 DISCLOSES; OPTIMIZATION; BINDING; SITE; RAT	Electron paramagnetic resonance and kinetics experiments have been made to determine the formation, stability, and fate of the natural nitric oxide carrier, dinitrosyl-diglutathionyl-iron complex (DNDGIC), in heterogeneous systems approaching in vivo conditions. Both in human placenta and rat liver homogenates DNDGIC is formed spontaneously from GSH, S-nitrosoglutathione, and trace amounts of ferrous ions. DNDGIC is unstable in homogenates depleted of glutathione S-transferase (GST); an initial phase of rapid decomposition is followed by a slower decay, which is inversely proportional to the concentration. In the crude human placenta homogenate, GSTP1-1, which represents 90% of the cytosolic GST isoenzymes, is the preferential target for DNDGIC. It binds the complex almost stoichiometrically and stabilizes it for several hours (t(1/2) = 8 h). In the presence of an excess of DNDGIC, negative cooperativity in GSTP1-1 opposes the complete loss of the usual detoxicating activity of this enzyme. In the rat liver homogenate, multiple endogenous GSTs (mainly Alpha and Mu class isoenzymes) bind the complex quantitatively and stabilize it (t(1/2) = 4.5 h); negative cooperativity is also seen for these GSTs. Thus, the entire pool of cytosolic GSTs, with the exception of the Theta GST, represents a target for stoichiometric amounts of DNDGIC and may act as storage proteins for nitric oxide. These results confirm the existence of a cross-link between NO metabolism and the GST superfamily.	Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Childrens Hosp IRCCS Bambin Gesu, I-00146 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Bambino Gesu	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Chem Sci & Technol, Via Ric Sci, I-00133 Rome, Italy.	riccig@uniroma2.it	Mastroberardino, Pier/D-5623-2009; CACCURI, ANNA MARIA/AFU-2643-2022	MASTROBERARDINO, PIER GIORGIO/0000-0003-2364-4258; CACCURI, ANNA MARIA/0000-0002-3756-4163; Ricci, Giorgio/0000-0002-7108-2846				ADANG AEP, 1990, BIOCHEM J, V269, P47, DOI 10.1042/bj2690047; Bentz BG, 2000, LARYNGOSCOPE, V110, P1642, DOI 10.1097/00005537-200010000-00013; Caccuri AM, 2001, J BIOL CHEM, V276, P5427, DOI 10.1074/jbc.M002819200; Caccuri AM, 2001, J BIOL CHEM, V276, P5432, DOI 10.1074/jbc.M002818200; De Maria F, 2003, J BIOL CHEM, V278, P42283, DOI 10.1074/jbc.M305568200; dErrico A, 1996, BIOMARKERS, V1, P149, DOI 10.3109/13547509609079352; Lo Bello M, 2001, J BIOL CHEM, V276, P42138; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; PEDERSEN JZ, 1988, J MAGN RESON, V77, P369, DOI 10.1016/0022-2364(88)90186-2; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; VANIN AF, 1987, BIOFIZIKA+, V32, P128; YEH HI, 1995, BIOCHEM J, V308, P69, DOI 10.1042/bj3080069	15	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42294	42299		10.1074/jbc.M305569200	http://dx.doi.org/10.1074/jbc.M305569200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12871931	hybrid			2022-12-25	WOS:000185989500089
J	Holzberg, D; Knight, CG; Dittrich-Breiholz, O; Schneider, H; Dorrie, A; Hoffmann, E; Resch, K; Kracht, M				Holzberg, D; Knight, CG; Dittrich-Breiholz, O; Schneider, H; Dorrie, A; Hoffmann, E; Resch, K; Kracht, M			Disruption of the c-JUN-JNK complex by a cell-permeable peptide containing the c-JUN delta domain induces apoptosis and affects a distinct set of interleukin-1-induced inflammatory genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; TRANSCRIPTION; EXPRESSION; PHOSPHORYLATION; GROWTH; AP-1; DEGRADATION; INHIBITION	The transcription factor activator protein (AP)-1 plays crucial roles in proliferation, cell death, and the immune response. c-JUN is an important component of AP-1, but only very few c-JUN response genes have been identified to date. Activity of c-JUN is controlled by NH2-terminal phosphorylation (JNP) of its transactivation domain by a family of JUN-NH2-terminal protein kinases (JNK). JNK form a stable complex with c-JUN in vitro and in vivo. We have targeted this interaction by means of a cell-permeable peptide containing the JNK-binding (delta) domain of human c-JUN. This peptide strongly and specifically induced apoptosis in HeLa tumor cells, which was paralleled by inhibition of seruminduced c-JUN phosphorylation and up-regulation of the cell cycle inhibitor p21(cip/waf). Application of the c-JUN peptide to interleukin (IL)-1-stimulated human primary fibroblasts resulted in up-regulation of four genes, namely COX-2, MnSOD, IkappaBalpha, and MAIL and down-regulation of 10 genes, namely CCL8, mPGES, SAA1, hIAP-1, hIAP-2, pent(r)axin-3, CXCL10, IL-1beta, ICAM-1, and CCL2. Only a small group of genes, namely pent(r)axin-3, CXCL10, ICAM-1, and IL-1beta, was inhibited by both the c-JUN peptide and the JNK inhibitor SP600125. Thereby, and by additional experiments using small interfering RNA to suppress endogenous c-JUN we identify for the first time three distinct groups of inflammatory genes whose IL-1-induced expression depends on c-JUN, on JNK, or on both. These results shed further light on the complexity of c-JUN-JNK-mediated gene regulation and also highlight the potential use of dissecting signaling downstream from JNK to specifically target proliferative diseases or the inflammatory response.	Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	Hannover Medical School; University of Cambridge	Kracht, M (corresponding author), Hannover Med Sch, Inst Pharmacol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Kracht.Michael@MH-Hannover.DE		Hoffmann-Lucke, Elke/0000-0002-2437-0140; Kracht, Michael/0000-0002-8501-043X				Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Chan WC, 2000, PRACT APPROACH SER, V222, P41; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Huang H, 1999, J PEPT RES, V53, P548, DOI 10.1034/j.1399-3011.1999.00059.x; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kracht M, 2002, CYTOKINE, V20, P91, DOI 10.1006/cyto.2002.0895; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; May GHW, 1998, J BIOL CHEM, V273, P33429, DOI 10.1074/jbc.273.50.33429; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 2002, CANCER RES, V62, P3257; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Wagner EF, 2001, ONCOGENE, V20, P2334, DOI 10.1038/sj.onc.1204416; Westermarck J, 2002, EMBO J, V21, P451, DOI 10.1093/emboj/21.3.451; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wiltshire C, 2002, BIOCHEM J, V367, P577, DOI 10.1042/BJ20020553; Wohr T, 1996, J AM CHEM SOC, V118, P9218, DOI 10.1021/ja961509q; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	41	85	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40213	40223		10.1074/jbc.M304058200	http://dx.doi.org/10.1074/jbc.M304058200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12832416	hybrid			2022-12-25	WOS:000185713800114
J	Chigaev, A; Zwartz, G; Graves, SW; Dwyer, DC; Tsuji, H; Foutz, TD; Edwards, BS; Prossnitz, ER; Larson, RS; Sklar, LA				Chigaev, A; Zwartz, G; Graves, SW; Dwyer, DC; Tsuji, H; Foutz, TD; Edwards, BS; Prossnitz, ER; Larson, RS; Sklar, LA			alpha(4)beta(1) integrin affinity changes govern cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ACTIVATION STATES; P-SELECTIN; MOLECULE-1 ICAM-1; T-CELLS; FLOW; RECEPTOR; BINDING; CHEMOKINES; EXPRESSION; VCAM-1	Integrin alpha(4)beta(1) is a receptor for vascular cell adhesion molecule-1 and fibronectin. It is important in lymphopoiesis, inflammatory recruitment of leukocytes, and other situations that require cell adhesion to the vascular endothelium. The avidity of the cells expressing alpha(4)beta(1) integrin can be rapidly changed by chemokines and chemoattractants. Different mechanisms, including changes in the number of interacting molecules due to the alteration of the receptor topology or changes in the affinity of the individual bonds, have been proposed to explain the nature of these fast changes in avidity. Recently, we described a fluorescent LDV- containing small molecule, which we used to monitor the affinity changes on live cells in real time (Chigaev, A., Blenc, A. M., Braaten, J. V., Kumaraswamy, N., Kepley, C. L., Andrews, R. P., Oliver, J. M., Edwards, B. S., Prossnitz, E. R., Larson, R. S. et al. (2001) J. Biol. Chem. 276, 48670 48678). Here we show that the affinity of the small molecule probe as well as the native ligand vascular cell adhesion molecule-1 varies in parallel when the integrin is modulated with divalent cations and that the affinity modulation leads to the changes in cell avidity. Using formyl peptide receptor-transfected U937 cells, we further show that the time course of avidity changes in response to the receptor activation coincides with the time course of the affinity changes. Taken together, these data are consistent with the idea that affinity regulation is a major factor that governs the avidity of cell adhesion mediated by the alpha(4) integrin.	Univ New Mexico, Dept Pathol, HSC, Albuquerque, NM 87131 USA; Univ New Mexico, Ctr Canc, HSC, Albuquerque, NM 87131 USA; Los Alamos Natl Lab, Natl Flow Cytometry Resource, Los Alamos, NM 87545 USA	University of New Mexico; University of New Mexico; United States Department of Energy (DOE); Los Alamos National Laboratory	Sklar, LA (corresponding author), Univ New Mexico, Dept Pathol, HSC, Albuquerque, NM 87131 USA.	lsklar@salud.unm.edu	Prossnitz, Eric R./B-4543-2008; Prossnitz, Eric/I-4599-2019; Chigaev, Alexandre/A-3103-2010	Prossnitz, Eric/0000-0001-9190-8302; Chigaev, Alexandre/0000-0002-7726-638X	NCRR NIH HHS [RR01315, RR14175] Funding Source: Medline; NHLBI NIH HHS [HL56384] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001315, R01RR014175] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056384] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Alon R, 2002, SEMIN IMMUNOL, V14, P93, DOI 10.1006/smim.2001.0346; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Chan JR, 2003, J IMMUNOL METHODS, V273, P43, DOI 10.1016/S0022-1759(02)00417-9; Chen C, 1999, J IMMUNOL, V162, P1084; Chen LL, 1999, J BIOL CHEM, V274, P13167, DOI 10.1074/jbc.274.19.13167; Chen SQ, 2001, P NATL ACAD SCI USA, V98, P950, DOI 10.1073/pnas.98.3.950; Chigaev A, 2001, J BIOL CHEM, V276, P48670, DOI 10.1074/jbc.M103194200; Dando J, 2002, ACTA CRYSTALLOGR D, V58, P233, DOI 10.1107/S0907444901020522; Edwards BS, 2000, J IMMUNOL, V165, P404, DOI 10.4049/jimmunol.165.1.404; FAULL RJ, 1995, STEM CELLS, V13, P38, DOI 10.1002/stem.5530130106; Feigelson S, 2001, J BIOL CHEM, V276, P13891, DOI 10.1074/jbc.M004939200; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Graves SW, 2002, CYTOMETRY, V47, P127, DOI 10.1002/cyto.10056; Haraldsen G, 1996, J IMMUNOL, V156, P2558; HAUGLAND RP, 2002, HDB FLUORESCENT PROB, P47; Johnston B, 1996, J EXP MED, V183, P1995, DOI 10.1084/jem.183.5.1995; Jun CD, 2001, J BIOL CHEM, V276, P29019, DOI 10.1074/jbc.M103394200; Jun CD, 2001, P NATL ACAD SCI USA, V98, P6830, DOI 10.1073/pnas.121186998; Kew RR, 1997, J LEUKOCYTE BIOL, V61, P329, DOI 10.1002/jlb.61.3.329; Labadia ME, 1998, J IMMUNOL, V161, P836; Laudanna C, 2002, IMMUNOL REV, V186, P37, DOI 10.1034/j.1600-065X.2002.18604.x; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Lichtman AH, 1997, J IMMUNOL, V158, P3640; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Lobb RR, 1995, CELL ADHES COMMUN, V3, P385, DOI 10.3109/15419069509081293; Loftus JC, 1997, J CLIN INVEST, V100, pS77; LYNAM EB, 1994, BLOOD, V83, P3303; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; Nolan John P., 1998, P19; NOLAN JP, 1995, CYTOMETRY, V21, P223, DOI 10.1002/cyto.990210302; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; Park SK, 2000, NEPHROL DIAL TRANSPL, V15, P596, DOI 10.1093/ndt/15.5.596; REILLY PL, 1995, J IMMUNOL, V155, P529; SANCHEZMATEOS P, 1993, J IMMUNOL, V151, P3817; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Sklar LA, 2002, ANNU REV BIOPH BIOM, V31, P97, DOI 10.1146/annurev.biophys.31.082901.134406; SKLAR LA, 1985, MOL PHARMACOL, V28, P323; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Waller A, 2001, CYTOMETRY, V45, P102, DOI 10.1002/1097-0320(20011001)45:2<102::AID-CYTO1152>3.0.CO;2-Z; Warnock RA, 1998, J EXP MED, V187, P205, DOI 10.1084/jem.187.2.205; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	49	66	70	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38174	38182		10.1074/jbc.M210472200	http://dx.doi.org/10.1074/jbc.M210472200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12844491	hybrid			2022-12-25	WOS:000185575100012
J	Hegde, R; Srinivasula, SM; Datta, P; Madesh, M; Wassell, R; Zhang, ZJ; Cheong, NE; Nejmeh, J; Fernandes-Alnemri, T; Hoshino, S; Alnemri, ES				Hegde, R; Srinivasula, SM; Datta, P; Madesh, M; Wassell, R; Zhang, ZJ; Cheong, NE; Nejmeh, J; Fernandes-Alnemri, T; Hoshino, S; Alnemri, ES			The polypeptide chain-releasing factor GSPT1/eRF3 is proteolytically processed into an IAP-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-DEATH; SERINE-PROTEASE; STRUCTURAL BASIS; LIGASE ACTIVITY; APOPTOSIS; DEGRADATION; REAPER; INHIBITOR; XIAP; GRIM	Smac/Diablo and HtrA2/Omi are inhibitors of apoptosis (IAP)-binding proteins released from the mitochondria of human cells during apoptosis and regulate apoptosis by liberating caspases from IAP inhibition. Here we describe the identification of a proteolytically processed isoform of the polypeptide chain-releasing factor GSPT1/eRF3 protein, which functions in translation, as a new IAP-binding protein. In common with other IAP-binding proteins, the processed GSPT1 protein harbors a conserved N-terminal IAP-binding motif (AKPF). Additionally, processed GSPT1 interacts biochemically with IAPs and could promote caspase activation, IAP ubiquitination and apoptosis. The IAP-binding motif of the processed GSPT1 is absolutely required for these activities. Our findings are consistent with a model whereby processing of GSPT1 into the IAP-binding isoform could potentiate apoptosis by liberating caspases from IAP inhibition, or target IAPs and the processed GSPT1 for proteasome-mediated degradation.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo 1130033, Japan	Jefferson University; Jefferson University; University of Tokyo	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,Rm 904,233 S 10th St, Philadelphia, PA 19107 USA.	E_Alnemri@lac.jci.tju.edu	Alnemri, Emad S/B-4526-2010	Hoshino, Shinichi/0000-0001-6135-7896	NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER; NCI NIH HHS [CA78890] Funding Source: Medline; NIA NIH HHS [AG13487] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Christich A, 2002, CURR BIOL, V12, P137, DOI 10.1016/S0960-9822(01)00658-3; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; EUSTICE DC, 1986, J MOL BIOL, V188, P207, DOI 10.1016/0022-2836(86)90305-0; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Hoshino S, 1998, J BIOL CHEM, V273, P22254, DOI 10.1074/jbc.273.35.22254; HOSHINO S, 1989, EMBO J, V8, P3807, DOI 10.1002/j.1460-2075.1989.tb08558.x; INGEVECHTOMOV SG, 1994, GENETIKA+, V30, P1022; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Reed JC, 2000, CELL, V102, P545, DOI 10.1016/S0092-8674(00)00076-3; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shi Y, 2002, CELL DEATH DIFFER, V9, P93, DOI 10.1038/sj/cdd/4400957; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 2002, CURR BIOL, V12, P125, DOI 10.1016/S0960-9822(01)00657-1; SURGUCHOV AP, 1980, FEBS LETT, V111, P175, DOI 10.1016/0014-5793(80)80786-1; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; Uchida N, 2002, J BIOL CHEM, V277, P50286, DOI 10.1074/jbc.M203029200; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2002, CURR BIOL, V12, P131, DOI 10.1016/S0960-9822(01)00664-9; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	44	70	75	4	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38699	38706		10.1074/jbc.M303179200	http://dx.doi.org/10.1074/jbc.M303179200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12865429	hybrid			2022-12-25	WOS:000185575100075
J	Matsumoto, Y; Oda, Y; Uryu, M; Hayakawa, Y				Matsumoto, Y; Oda, Y; Uryu, M; Hayakawa, Y			Insect cytokine growth-blocking peptide triggers a termination system of cellular immunity by inducing its binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMATOCYTE-SPREADING PEPTIDE; MOLECULAR-CLONING; BIOGENIC PEPTIDE; MANDUCA-SEXTA; IN-VITRO; HEMOLYMPH; IDENTIFICATION; HEMOCYTES; SILKWORM; HORMONE	Growth-blocking peptide (GBP) is a 25-amino acid cytokine found in lepidopteran insects that possesses diverse biological activities such as stimulation of immune cells (plasmatocytes), cell proliferation, and larval growth regulation. We found another novel function of GBP that induces a hemolysis of another class of blood cells (oenocytoids). In the lysate of oenocytoids we identified a GBP-binding protein that shows a specific affinity for GBP. The characterization of purified GBP-binding protein and its cDNA demonstrated it as a 49.5-kDa novel protein with a C-terminal region displaying limited homology to several insect lipoproteins. Results of Northern and Western blotting indicated that the GBP-binding protein should be synthesized only in blood cells. Immunoelectron microscopic analyses confirmed that indirect immunoreactive signals were mostly localized in oenocytoids. Kinetic and biological analyses of interaction between GBP and the binding protein showed their strong binding was followed by clearance of GBP from hemolymph, thus indicating that this protein might function as an inhibitory factor against GBP. Based on these results, we propose that insect cytokine GBP shows multifunctions even in cellular immunity: it serves to stimulate immune cells and afterward silences its own action by inducing the binding protein through specific hemolysis.	Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan	Hokkaido University	Hayakawa, Y (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan.	hayakawa@lowtem.hokudai.ac.jp						Aizawa T, 2001, J BIOL CHEM, V276, P31813, DOI 10.1074/jbc.M105251200; ASHIDA M, 1988, TISSUE CELL, V20, P599, DOI 10.1016/0040-8166(88)90061-4; BREHELIN MM, 1972, ACRIDA, V1, P165; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark KD, 1997, J BIOL CHEM, V272, P23440, DOI 10.1074/jbc.272.37.23440; Clark KD, 1998, BIOCHEM BIOPH RES CO, V250, P479, DOI 10.1006/bbrc.1998.9145; Clark KD, 2001, J BIOL CHEM, V276, P37431, DOI 10.1074/jbc.M105235200; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CRINE P, 1987, NEUROMETHODS, V6, P1; Franke H., 1960, Zoologische Jahrbuecher (Physiol), V69, P131; FRANKE HANS, 1960, ZOOL JAHRB ABT ALLG ZOOL UND PHYSIOL TIERE, V68, P499; Hayakawa Y, 1998, BIOCHEM BIOPH RES CO, V250, P194, DOI 10.1006/bbrc.1998.8959; HAYAKAWA Y, 1995, J INSECT PHYSIOL, V41, P1, DOI 10.1016/0022-1910(94)00077-T; HAYAKAWA Y, 1990, J BIOL CHEM, V265, P10813; HAYAKAWA Y, 1991, J BIOL CHEM, V266, P7982; HAYAKAWA Y, 1995, FEBS LETT, V376, P185, DOI 10.1016/0014-5793(95)01273-7; HAYAKAWA Y, 1992, BIOCHEM BIOPH RES CO, V185, P1141, DOI 10.1016/0006-291X(92)91745-C; Hayakawa Y, 1998, J INSECT PHYSIOL, V44, P859, DOI 10.1016/S0022-1910(98)00017-1; Hayakawa Y, 1998, EUR J BIOCHEM, V253, P810, DOI 10.1046/j.1432-1327.1998.2530810.x; HIRAOKA T, 1995, CELL TISSUE RES, V279, P465, DOI 10.1007/BF00318159; Kamimura M, 2001, BIOCHEM BIOPH RES CO, V286, P67, DOI 10.1006/bbrc.2001.5365; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARVINE MD, 2002, INSECT BIOCHEM MOLEC, V32, P1237; Martin JL, 1999, CONT ENDOCRINOL, V17, P227; MORI S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P129, DOI 10.1016/0167-4781(91)90048-Q; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; Ohnishi A, 2001, J BIOL CHEM, V276, P37974; PECH LL, 1994, CELL TISSUE RES, V277, P159, DOI 10.1007/BF00303092; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; RIZKI RM, 1990, J INSECT PHYSIOL, V36, P523, DOI 10.1016/0022-1910(90)90104-N; ROWLEY AF, 1980, IMMUNOLOGY, V40, P483; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SKINNER WS, 1991, J BIOL CHEM, V266, P12873; STRAND MR, 1995, ANNU REV ENTOMOL, V40, P31, DOI 10.1146/annurev.en.40.010195.000335; Strand MR, 1999, ARCH INSECT BIOCHEM, V42, P213, DOI 10.1002/(SICI)1520-6327(199911)42:3&lt;213::AID-ARCH5&gt;3.0.CO;2-4; Strand MR, 2000, J INSECT PHYSIOL, V46, P817, DOI 10.1016/S0022-1910(99)00171-7; Strand MR, 1999, ARCH INSECT BIOCHEM, V40, P41, DOI 10.1002/(SICI)1520-6327(1999)40:1&lt;41::AID-ARCH5&gt;3.0.CO;2-R; WANG X, 1988, J BIOL CHEM, V263, P8851; Wang Y, 1999, INSECT BIOCHEM MOLEC, V29, P1075, DOI 10.1016/S0965-1748(99)00086-7	41	46	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38579	38585		10.1074/jbc.M305986200	http://dx.doi.org/10.1074/jbc.M305986200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871935	hybrid			2022-12-25	WOS:000185575100061
J	Bondar, T; Mirkin, EV; Ucker, DS; Walden, WE; Mirkin, SM; Raychaudhuri, P				Bondar, T; Mirkin, EV; Ucker, DS; Walden, WE; Mirkin, SM; Raychaudhuri, P			Schizosaccharomyces pombe Ddb1 is functionally linked to the replication checkpoint pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE; DNA-DAMAGE; FISSION YEAST; KINASES CDS1; V PROTEIN; IN-VITRO; CHK1; MAINTENANCE; DEFINES; DOMAIN	Schizosaccharomyces pombe Ddb1 is homologous to the mammalian DDB1 protein, which has been implicated in damaged-DNA recognition and global genomic repair. However, a recent study suggested that the S. pombe Ddb1 is involved in cell division and chromosomal segregation. Here, we provide evidence that the S. pombe Ddb1 is functionally linked to the replication checkpoint control gene cds1. We show that the S. pombe strain lacking ddb1 has slow growth due to delayed replication progression. Flow cytometric analysis shows an extensive heterogeneity in DNA content. Furthermore, the Deltaddb1 strain is hypersensitive to UV irradiation in S phase and is unable to tolerate a prolonged replication block imposed by hydroxyurea. Interestingly, the Deltaddb1 strain exhibits a high level of the Cds1 kinase activity during passage through S phase. Moreover, mutation of the cds1 gene relieves the defects observed in Deltaddb1 strain. The results suggest that many of the defects observed in Deltaddb1 cells are linked to an aberrant activation of Cds1, and that Ddb1 is functionally linked to Cds1.	Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raychaudhuri, P (corresponding author), Univ Illinois, Dept Biochem & Mol Biol, M-C 536,1819 W Polk St, Chicago, IL 60612 USA.	Pradip@uic.edu	Mirkin, Sergei/A-7310-2010; Mirkin, Sergei/AAR-7226-2020; Bondar, Tanya/T-5576-2017	Mirkin, Sergei/0000-0003-4576-7582; Bondar, Tanya/0000-0003-4765-8910	NATIONAL CANCER INSTITUTE [R01CA077637, R01CA088863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047281] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038800, R01GM060987] Funding Source: NIH RePORTER; NCI NIH HHS [CA88863, CA77637] Funding Source: Medline; NIDDK NIH HHS [DK 47281] Funding Source: Medline; NIGMS NIH HHS [GM 60987, GM 38800] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Carlson CR, 1997, YEAST, V13, P1329; Christensen PU, 2000, P NATL ACAD SCI USA, V97, P2579, DOI 10.1073/pnas.97.6.2579; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Fung AD, 2002, MOL CELL BIOL, V22, P4477, DOI 10.1128/MCB.22.13.4477-4490.2002; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; Kim SM, 2001, EMBO J, V20, P6115, DOI 10.1093/emboj/20.21.6115; Krishnamoorthy RR, 1997, BIOCHEMISTRY-US, V36, P960, DOI 10.1021/bi961407c; Lin GY, 2000, J VIROL, V74, P9152, DOI 10.1128/JVI.74.19.9152-9166.2000; Lin GY, 1998, VIROLOGY, V249, P189, DOI 10.1006/viro.1998.9317; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Marchetti MA, 2002, P NATL ACAD SCI USA, V99, P7472, DOI 10.1073/pnas.112702399; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; MIZUKOSHI T, 1999, NUCL ACIDS S SER, V42, P265; Murakami H, 2002, NAT CELL BIOL, V4, P384, DOI 10.1038/ncb789; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Neuwald AF, 2000, NUCLEIC ACIDS RES, V28, P3570, DOI 10.1093/nar/28.18.3570; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; Rhind N, 2000, J CELL SCI, V113, P3889; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Snaith HA, 2000, MOL CELL BIOL, V20, P7922, DOI 10.1128/MCB.20.21.7922-7932.2000; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zolezzi F, 2000, GENE, V245, P151, DOI 10.1016/S0378-1119(00)00022-6; Zolezzi F, 2002, J BIOL CHEM, V277, P41183, DOI 10.1074/jbc.M207890200	36	15	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37006	37014		10.1074/jbc.M303003200	http://dx.doi.org/10.1074/jbc.M303003200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857752	hybrid			2022-12-25	WOS:000185437200006
J	Bowen, H; Lapham, A; Phillips, E; Yeung, I; Alter-Koltunoff, M; Levi, BZ; Perry, VH; Mann, DA; Barton, CH				Bowen, H; Lapham, A; Phillips, E; Yeung, I; Alter-Koltunoff, M; Levi, BZ; Perry, VH; Mann, DA; Barton, CH			Characterization of the murine Nramp1 promoter - Requirements for transactivation by Miz-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC REPRESSES; MACROPHAGE ACTIVATION; NATURAL-RESISTANCE; GENE-REGULATION; IN-VIVO; PROTEINS; EXPRESSION; TRANSPORT; BINDING; SUSCEPTIBILITY	Murine Nramp1 encodes a divalent cation transporter that is expressed in late endosomes/lysosomes of macrophages, and the transported cations facilitate intracellular pathogen growth control. The Nramp1 promoter is TATA box-deficient, has two initiator elements, and is repressed by c-Myc, in accordance with the notion that genes that deplete the iron content of the cell cytosol antagonize cell growth. Repression via c-Myc occurs at the initiator elements, whereas a c-Myc-interacting protein (Miz-1) stimulates transcription. Here we demonstrate that a non-canonical E box (CAACTG) inhibits basal promoter activity and activation by Miz-1. A consensus Sp1-binding site or GC box is also necessary for Miz-1-dependent transactivation, but not repression. Repression occurs by c-Myc competing with p300/CBP for binding Miz-1. Our results show that an Sp1 site mutant inhibits coactivation by p300 and that the murine Nramp1 promoter is preferentially expressed within macrophages ( relative to a beta-actin control) compared with non-macrophage cells. The effect of the Sp1 site mutation on promoter function shows cell-type specificity: stimulation in COS-1 and inhibition in RAW264.7 cells. Miz-1-directed RNA interference confirms a stimulatory role for Miz-1 in Nramp1 promoter function. c-Myc, Miz-1, and Sp1 were identified as binding to the Nramp1 core promoter in control cells and following acute stimulation with interferon-gamma and lipopolysaccharide. These results provide a description of sites that modulate the activity of the initiator-binding protein Miz-1 and indicate a stimulatory role for GC box-binding factors in macrophages and a inhibitory role for E box elements in proliferating cells.	Univ Southampton, Dept Biochem & Mol Biol, Div Biochem & Mol Biol, Southampton SO16 7PX, Hants, England; Univ Southampton, Southampton Neurosci Grp, Cent Nervous Syst Inflammat Grp, Southampton SO16 7PX, Hants, England; Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel; Univ Southampton, Southampton Gen Hosp, Liver Grp, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England	University of Southampton; University of Southampton; Technion Israel Institute of Technology; University of Southampton	Barton, CH (corresponding author), Univ Southampton, Dept Biochem & Mol Biol, Div Biochem & Mol Biol, Bassett Crescent E, Southampton SO16 7PX, Hants, England.	chb@soton.ac.uk	Perry, V. Hugh/Y-2935-2019	Mann, Derek/0000-0003-0950-243X				Arias M, 1997, J INFECT DIS, V176, P1552, DOI 10.1086/514154; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Baker ST, 2000, J LEUKOCYTE BIOL, V67, P501, DOI 10.1002/jlb.67.4.501; BARRERA LF, 1994, IMMUNOLOGY, V82, P457; BARTON CH, 1995, MOL MED, V1, P267, DOI 10.1007/BF03401551; BEAUMONT C, 2000, 2 INT C HIV IR BRUGG; Biggs TE, 2001, EUR J IMMUNOL, V31, P2060, DOI 10.1002/1521-4141(200107)31:7<2060::AID-IMMU2060>3.0.CO;2-L; Blackwell JM, 2003, IMMUNOL LETT, V85, P197, DOI 10.1016/S0165-2478(02)00231-6; Blackwell JM, 1999, IMMUNOL LETT, V65, P73, DOI 10.1016/S0165-2478(98)00127-8; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Bowen H, 2002, BIOCHEM SOC T, V30, P774, DOI 10.1042/bst0300774; Bowen H, 2002, J BIOL CHEM, V277, P34997, DOI 10.1074/jbc.M204232200; Buschman E, 2001, DRUG METAB DISPOS, V29, P471; CHEN HM, 1993, J BIOL CHEM, V268, P8230; Clarke S, 1998, J LEUKOCYTE BIOL, V63, P153, DOI 10.1002/jlb.63.2.153; Dlaska M, 1999, J IMMUNOL, V162, P6171; Drewett V, 2001, NUCLEIC ACIDS RES, V29, P479, DOI 10.1093/nar/29.2.479; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Forbes JR, 2001, TRENDS MICROBIOL, V9, P397, DOI 10.1016/S0966-842X(01)02098-4; FORMICA S, 1994, IMMUNOLOGY, V82, P42; Gomes MS, 1998, IMMUNOLOGY, V95, P165; Goswami T, 2001, BIOCHEM J, V354, P511, DOI 10.1042/0264-6021:3540511; GOVONI G, 1995, GENOMICS, V27, P9, DOI 10.1006/geno.1995.1002; Greaves DR, 2002, INT J HEMATOL, V76, P6, DOI 10.1007/BF02982713; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Jabado N, 2000, J EXP MED, V192, P1237, DOI 10.1084/jem.192.9.1237; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Kime L, 2003, BIOCHEM J, V370, P291, DOI 10.1042/BJ20021679; Kuhn DE, 1999, J LEUKOCYTE BIOL, V66, P113, DOI 10.1002/jlb.66.1.113; Levi BZ, 2002, J INTERF CYTOK RES, V22, P153, DOI 10.1089/107999002753452764; MALO D, 1994, GENOMICS, V23, P51, DOI 10.1006/geno.1994.1458; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Searle S, 1999, J MED GENET, V36, P295; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Ziegelbauer J, 2001, MOL CELL, V8, P339, DOI 10.1016/S1097-2765(01)00313-6	45	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36017	36026		10.1074/jbc.M304301200	http://dx.doi.org/10.1074/jbc.M304301200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12840021	hybrid			2022-12-25	WOS:000185318300020
J	Xu, HM; An, HZ; Yu, YZ; Zhang, MH; Qi, RZ; Cao, XT				Xu, HM; An, HZ; Yu, YZ; Zhang, MH; Qi, RZ; Cao, XT			Ras participates in CpG oligodeoxynucleotide signaling through association with Toll-like receptor 9 and promotion of interleukin-1 receptor-associated kinase/tumor necrosis factor receptor-associated factor 6 complex formation in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; GUANINE-NUCLEOTIDE EXCHANGE; BACTERIAL-DNA; ADAPTER MOLECULE; CUTTING EDGE; P38 MAPK; INDUCTION; MURINE; MOTIFS	CpG oligodeoxynucleotides (ODN) activate immune cells to produce immune mediators by Toll-like receptor 9 (TLR9)-mediated signal transduction, which activates mitogen-activated protein kinases (MAPKs) and nuclear factor-kappaB (NF-kappaB) through the MyD88/IRAK/TRAF6 kinases cascade. However, the precise mechanisms of CpG ODN activation of immune cells have not been fully elucidated. The small GTP-binding protein Ras mediates MAPK activation in response to a variety of stimuli. Up to now, it is not clear whether Ras plays a role in CpG ODN signaling. In the present study, we found that the dominant-negative version of Ras (RasN17) and specific Ras inhibitor, FTI-277, inhibited CpG ODN-induced nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha) production by murine macrophage cell line RAW264.7. While overexpression of wild-type Ras enhanced CpG ODN-induced extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and NF-kappaB activation, overexpression of RasN17 inhibited CpG ODN-induced ERK, JNK, and NF-kappaB activation. RasN17 overexpression also inhibited CpG ODN-induced IRAK1/ TRAF6 complex formation. Further studies revealed that CpG ODN activated Ras in a time- and dose-dependent manner, and Ras associated with TLR9 in a CpG ODN-dependent manner. Most interestingly, activation of Ras preceded the association of Ras with TLR9, giving rise to a possibility that Ras activation might not be dependent on the interaction between Ras and TLR9. Our data demonstrate for the first time that Ras can be activated by CpG ODN in macrophages, and Ras is involved in CpG ODN signaling as an early event by associating with TLR9 and promoting IRAK1/ TRAF6 complex formation, and MAPK and NF-kappaB activation.	Second Mil Med Univ, Inst Immunol, Shanghai 200433, Peoples R China	Naval Medical University	Cao, XT (corresponding author), Second Mil Med Univ, Inst Immunol, Shanghai 200433, Peoples R China.	caoxt@public3.sta.net.cn	yu, yizhi/ADP-7854-2022					Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; An HZ, 2002, IMMUNOL LETT, V81, P165, DOI 10.1016/S0165-2478(02)00010-X; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Ballas ZK, 1996, J IMMUNOL, V157, P1840; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Bouchier-Hayes L, 2001, J BIOL CHEM, V276, P44069, DOI 10.1074/jbc.M107373200; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Caunt CJ, 2001, J BIOL CHEM, V276, P6280, DOI 10.1074/jbc.M006772200; Dalpke A, 2002, BIODRUGS, V16, P419, DOI 10.2165/00063030-200216060-00003; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Imler JL, 2003, NAT IMMUNOL, V4, P105, DOI 10.1038/ni0203-105; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kline JN, 2000, CURR TOP MICROBIOL, V247, P211; Klinman DM, 1999, IMMUNITY, V11, P123, DOI 10.1016/S1074-7613(00)80087-4; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; McDermott EP, 2002, J BIOL CHEM, V277, P7808, DOI 10.1074/jbc.M108133200; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Neill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Shaye DD, 2002, NATURE, V420, P686, DOI 10.1038/nature01234; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8; Stacey KJ, 1996, J IMMUNOL, V157, P2116; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Takeshita S, 2000, CELL IMMUNOL, V206, P101, DOI 10.1006/cimm.2000.1735; Utaisincharoen P, 2002, CLIN EXP IMMUNOL, V128, P467, DOI 10.1046/j.1365-2249.2002.01866.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wei S, 2000, J IMMUNOL, V165, P3811, DOI 10.4049/jimmunol.165.7.3811; Weiner GJ, 2000, CURR TOP MICROBIOL, V247, P157; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wittinghofer F, 1998, NATURE, V394, P317, DOI 10.1038/28492; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yi AK, 1998, J IMMUNOL, V161, P4493; Yi AK, 2001, INT IMMUNOL, V13, P1391, DOI 10.1093/intimm/13.11.1391	53	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36334	36340		10.1074/jbc.M305698200	http://dx.doi.org/10.1074/jbc.M305698200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12867418	hybrid			2022-12-25	WOS:000185318300059
J	Llorente, A; Lauvrak, SU; van Deurs, B; Sandvig, K				Llorente, A; Lauvrak, SU; van Deurs, B; Sandvig, K			Induction of direct endosome to endoplasmic reticulum transport in Chinese hamster ovary (CHO) cells (LdlF) with a temperature-sensitive defect in epsilon-coatomer protein (epsilon-COP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROGRADE TRANSPORT; MEMBRANE-TRANSPORT; GOLGI-APPARATUS; SHIGA TOXIN; RICIN; PATHWAY; MUTANT; ER	In the present study we demonstrate that ricin, apparently without passing through the Golgi apparatus, reaches the endoplasmic reticulum (ER) and intoxicates cells in which the Golgi apparatus has been vesiculated by depletion of epsilon-COP, a subunit of COPI. LdlF cells contain a temperature-sensitive mutation in epsilon-COP. At the nonpermissive temperature epsilon-COP is degraded, and the Golgi apparatus undergoes a morphological change. To study ricin transport in these cells we used ricin sulf-2, a modified ricin molecule containing glycosylation and sulfation sites. Measurements of the incorporation of radioactive mannose into ricin sulf-2 showed that ricin reached the ER in cells depleted of epsilon-COP. Importantly, by investigating the glycosylation of ricin sulf-2 that was modified with radioactive sulfate in the trans-Golgi network, it was demonstrated that transport of ricin to the ER via the Golgi apparatus was severely inhibited. Moreover, we found that ricin was able to intoxicate ldlF cells depleted of epsilon-COP in the presence of brefeldin A. In contrast, control cells were completely protected against ricin by brefeldin A. In conclusion, our results suggest that in ldlF cells depleted of epsilon-COP ricin might be transported to the ER by an induced brefeldin A-resistant pathway that circumvents the Golgi apparatus.	Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway; Univ Copenhagen, Panum Inst, Dept Med Anat, Struct Cell Biol Unit, DK-2200 Copenhagen N, Denmark	University of Oslo; University of Copenhagen	Sandvig, K (corresponding author), Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway.		Llorente, Alicia/AAP-7349-2021	Llorente, Alicia/0000-0002-0045-071X				Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; Barlowe C, 2000, TRAFFIC, V1, P371, DOI 10.1034/j.1600-0854.2000.010501.x; Chen A, 2002, BBA-MOL CELL RES, V1589, P124, DOI 10.1016/S0167-4889(02)00163-5; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Gomez M, 2000, J BIOL CHEM, V275, P29162, DOI 10.1074/jbc.M003630200; Grimmer S, 2000, MOL BIOL CELL, V11, P4205, DOI 10.1091/mbc.11.12.4205; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Guo Q, 1996, J BIOL CHEM, V271, P11191, DOI 10.1074/jbc.271.19.11191; HOBBIE L, 1994, J BIOL CHEM, V269, P20958; Iversen TG, 2001, MOL BIOL CELL, V12, P2099, DOI 10.1091/mbc.12.7.2099; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lowe M, 1998, BBA-MOL CELL RES, V1404, P53, DOI 10.1016/S0167-4889(98)00046-9; Mallard F, 1998, J CELL BIOL, V143, P973, DOI 10.1083/jcb.143.4.973; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; Richards AA, 2002, MOL BIOL CELL, V13, P1750, DOI 10.1091/mbc.01-12-0592; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SANDVIG K, 1979, EXP CELL RES, V121, P15, DOI 10.1016/0014-4827(79)90439-7; Sandvig K, 2002, ANNU REV CELL DEV BI, V18, P1, DOI 10.1146/annurev.cellbio.18.011502.142107; Sandvig K, 2002, HISTOCHEM CELL BIOL, V117, P131, DOI 10.1007/s00418-001-0346-2; Scales SJ, 2000, INT REV CYTOL, V195, P67; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z	29	38	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35850	35855		10.1074/jbc.M303425200	http://dx.doi.org/10.1074/jbc.M303425200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12847103	hybrid			2022-12-25	WOS:000185164400135
J	Schulz, A; Schoneberg, T				Schulz, A; Schoneberg, T			The structural evolution of a P2Y-like G-protein-coupled receptor.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE ACTIVATION; AMINO-ACIDS; RHODOPSIN; IDENTIFICATION; SPECIFICITY; PREDICTION; CRYSTAL; MODELS	Based on the now available crystallographic data of the G-protein-coupled receptor ( GPCR) prototype rhodopsin, many studies have been undertaken to build or verify models of other GPCRs. Here, we mined evolution as an additional source of structural information that may guide GPCR model generation as well as mutagenesis studies. The sequence information of 61 cloned orthologs of a P2Y-like receptor (GPR34) enabled us to identify motifs and residues that are important for maintaining the receptor function. The sequence data were compared with available sequences of 77 rhodopsin orthologs. Under a negative selection mode, only 17% of amino acid residues were preserved during 450 million years of GPR34 evolution. On the contrary, in rhodopsin evolution similar to43% residues were absolutely conserved between fish and mammals. Despite major differences in their structural conservation, a comparison of structural data suggests that the global arrangement of the transmembrane core of GPR34 orthologs is similar to rhodopsin. The evolutionary approach was further applied to functionally analyze the relevance of common scaffold residues and motifs found in most of the rhodopsin-like GPCRs. Our analysis indicates that, in contrast to other GPCRs, maintaining the unique function of rhodopsin requires a more stringent network of relevant intramolecular constrains.	Univ Leipzig, Fac Med, Dept Mol Biochem,Inst Biochem, Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany; Free Univ Berlin, Fac Med, Inst Pharmacol, D-14195 Berlin, Germany	Leipzig University; Max Planck Society; Free University of Berlin	Schoneberg, T (corresponding author), Univ Leipzig, Fac Med, Dept Mol Biochem,Inst Biochem, Max Planck Inst Evolutionary Anthropol, Deutscher Pl 6, D-04103 Leipzig, Germany.	schoberg@medizin.uni-leipzig.de						Abbracchio MP, 2003, TRENDS PHARMACOL SCI, V24, P52, DOI 10.1016/S0165-6147(02)00038-X; [Anonymous], PHYLIP PHYLOGENY INF; Archer E, 2003, TRENDS PHARMACOL SCI, V24, P36, DOI 10.1016/S0165-6147(02)00009-3; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; Biebermann H, 1998, FASEB J, V12, P1461, DOI 10.1096/fasebj.12.14.1461; Brinkworth RI, 2003, P NATL ACAD SCI USA, V100, P74, DOI 10.1073/pnas.0134224100; Communi D, 2001, J BIOL CHEM, V276, P41479, DOI 10.1074/jbc.M105912200; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; De Souza SJ, 1998, P NATL ACAD SCI USA, V95, P5094, DOI 10.1073/pnas.95.9.5094; EGGERICKX D, 1995, BIOCHEM J, V309, P837, DOI 10.1042/bj3090837; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HITT M, 1995, VIRAL GENE TECHNIQUE, P13; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Ishii I, 1997, J BIOL CHEM, V272, P7846, DOI 10.1074/jbc.272.12.7846; Joost P, 2002, GENOME BIOL, V3; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Kostenis E, 2001, TRENDS PHARMACOL SCI, V22, P560, DOI 10.1016/S0165-6147(00)01810-1; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; Marie J, 1999, MOL PHARMACOL, V55, P92, DOI 10.1124/mol.55.1.92; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schoneberg T, 1999, BBA-GENE STRUCT EXPR, V1446, P57, DOI 10.1016/S0167-4781(99)00081-0; Schoneberg T, 2002, REV PHYSIOL BIOCH P, V144, P143; Schoneberg T, 1997, J CLIN INVEST, V100, P1547, DOI 10.1172/JCI119678; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vaidehi N, 2002, P NATL ACAD SCI USA, V99, P12622, DOI 10.1073/pnas.122357199; Yang CQ, 2000, TEXT CHEM COLOR AM D, V32, P43; Yang ZH, 1998, J MOL EVOL, V46, P409, DOI 10.1007/PL00006320	32	51	56	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35531	35541		10.1074/jbc.M303346200	http://dx.doi.org/10.1074/jbc.M303346200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12835326	hybrid			2022-12-25	WOS:000185164400096
J	Bryan-Lluka, LJ; Bonisch, H; Lewis, RJ				Bryan-Lluka, LJ; Bonisch, H; Lewis, RJ			chi-conopeptide MrIA partially overlaps desipramine and cocaine binding sites on the human norepinephrine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NORADRENALINE TRANSPORTER; STRUCTURAL DOMAINS; NEUROTRANSMITTER TRANSPORTERS; PLASMA-MEMBRANE; CATECHOLAMINES; INHIBITION; CHANNELS; RESIDUE	The interactions of chi-conopeptide MrIA with the human norepinephrine transporter (hNET) were investigated by determining the effects of hNET point mutations on the inhibitory potency of MrIA. The mutants were produced by site-directed mutagenesis and expressed in COS-7 cells. The potency of MrIA was greater for inhibition of uptake by hNET of [H-3] norepinephrine (K-i 1.89 muM) than [H-3] dopamine (K-i 4.33 muM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA ( to 7 muM). Of 18 mutations where hNET amino acid residues were exchanged with those of the human dopamine transporter, MrIA had increased potency for inhibition of [H-3] norepinephrine uptake for three mutations ( in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3). Of the 12 additional mutations in TMDs 2, 4, 5, and 11 and IL1, three mutations (in TMD2 and IL1) had reduced MrIA inhibitory potency. All of the other mutations tested had no influence on MrIA potency. A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant hNETs reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia; Univ Bonn, Dept Pharmacol & Toxicol, D-53113 Bonn, Germany	University of Queensland; University of Queensland; University of Bonn	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	r.lewis@imb.uq.edu.au	Lewis, Richard J/E-8674-2013; Lewis, Richard/T-8763-2019	Lewis, Richard J/0000-0003-3470-923X; Lewis, Richard/0000-0003-3470-923X				Bonisch H, 1998, METHOD ENZYMOL, V296, P259; BONISCH H, 1994, ANN NY ACAD SCI, V733, P193, DOI 10.1111/j.1749-6632.1994.tb17269.x; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DeFelice LJ, 2001, BIOSYSTEMS, V62, P57, DOI 10.1016/S0303-2647(01)00137-X; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; GIROS B, 1994, J BIOL CHEM, V269, P15985; GRAEFE KH, 1988, CATECHOLAMINES, V1, P193; HARDER R, 1985, J NEUROCHEM, V45, P1154, DOI 10.1111/j.1471-4159.1985.tb05536.x; Hoffman BJ, 1998, FRONT NEUROENDOCRIN, V19, P187, DOI 10.1006/frne.1998.0168; Jacobsen RB, 2000, J BIOL CHEM, V275, P24639, DOI 10.1074/jbc.C900990199; Kitayama S, 1996, JPN J PHARMACOL, V72, P195, DOI 10.1254/jjp.72.195; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Nielsen KJ, 2002, J BIOL CHEM, V277, P27247, DOI 10.1074/jbc.M201611200; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Paczkowski FA, 2001, MOL BRAIN RES, V97, P32, DOI 10.1016/S0169-328X(01)00295-9; Paczkowski FA, 1999, J PHARMACOL EXP THER, V290, P761; PACZKOWSKI FA, 2001, P 9 INT CAT S LYOT J; Roubert C, 2001, J BIOL CHEM, V276, P8254, DOI 10.1074/jbc.M009798200; Roubert C, 2001, MOL PHARMACOL, V60, P462; Sharpe IA, 2001, NAT NEUROSCI, V4, P902, DOI 10.1038/nn0901-902; Sharpe IA, 2003, J BIOL CHEM, V278, P40317, DOI 10.1074/jbc.M213030200; Sucic S, 2002, MOL BRAIN RES, V108, P40, DOI 10.1016/S0169-328X(02)00512-0; Sucic S, 2002, J NEUROCHEM, V81, P344, DOI 10.1046/j.1471-4159.2002.00826.x; Syringas M, 2000, MOL PHARMACOL, V58, P1404, DOI 10.1124/mol.58.6.1404	26	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40324	40329		10.1074/jbc.M213101200	http://dx.doi.org/10.1074/jbc.M213101200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12837768	hybrid			2022-12-25	WOS:000185713800125
J	van der Wijk, T; Tomassen, SFB; Houtsmuller, AB; de Jonge, HR; Tilly, BC				van der Wijk, T; Tomassen, SFB; Houtsmuller, AB; de Jonge, HR; Tilly, BC			Increased vesicle recycling in response to osmotic cell swelling - Cause and consequence of hypotonicity-provoked ATP release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; REGULATORY VOLUME DECREASE; EXTRACELLULAR ATP; CL-CONDUCTANCE; CYTOSOLIC CA2+; CULTURED HUMAN; KINASES ERK-1; ACTIVATION; EXOCYTOSIS; PROTEIN	Osmotic swelling of Intestine 407 cells leads to an immediate increase in cell surface membrane area as determined using the fluorescent membrane dye FM 1-43. In addition, as measured by tetramethylrhodamine isothiocyanate (TRITC)-dextran uptake, a robust (>100-fold) increase in the rate of endocytosis was observed, starting after a discrete lag time of 2-3 min and lasting for similar to10-15 min. The hypotonicity-induced increase in membrane surface area, like the cell swelling-induced release of ATP (Van der Wijk, T., De Jonge, H. R., and Tilly, B. C. (1999) Biochem. J. 343, 579-586), was diminished after 1,2-bis(2-aminophenoxy) ethane-N, N,N',N'-tetraacetic acid-acetoxymethyl ester loading or cytochalasin B treatment. Uptake of TRITC-dextrans, however, was not affected. Treatment of the cells with the vesicle-soluble N-ethylmaleimide-sensitive factor attachment protein receptor-specific protease Clostridium botulinum toxin F not only nearly eliminated the hypotonicity-induced increase in membrane surface area but also strongly diminished the release of ATP, indicating the involvement of regulated exocytosis. Both the ATP hydrolase apyrase and the MEK inhibitor PD098059 diminished the osmotic swelling-induced increase in membrane surface area as well as the subsequent uptake of TRITC-dextrans. Taken together, the results indicate that extracellular ATP is required for the hypotonicity-induced vesicle recycling and suggest that a positive feedback loop, involving purinergic activation of the Erk-1/2 pathway, may contribute to the release of ATP from hypo-osmotically stimulated cells.	Erasmus Univ, Med Ctr, Dept Biochem, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Pathol, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Tilly, BC (corresponding author), Erasmus Univ, Med Ctr, Dept Biochem, POB 1738, NL-3000 DR Rotterdam, Netherlands.	b.tilly@ErasmusMC.nl						ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; BRUCK R, 1992, AM J PHYSIOL, V262, pG806, DOI 10.1152/ajpgi.1992.262.5.G806; Cantiello HF, 1997, BIOSCIENCE REP, V17, P147, DOI 10.1023/A:1027381412574; Crepel V, 1998, J NEUROSCI, V18, P1196; CZEKAY RP, 1994, EUR J CELL BIOL, V63, P20; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; ETCHEBERRIGARAY R, 1991, ANN NY ACAD SCI, V635, P90, DOI 10.1111/j.1749-6632.1991.tb36484.x; Granja R, 1996, J NEUROCHEM, V67, P1056; GREGER R, 1993, PFLUG ARCH EUR J PHY, V424, P329, DOI 10.1007/BF00384360; Guo XW, 1997, AM J PHYSIOL-CELL PH, V273, pC804, DOI 10.1152/ajpcell.1997.273.3.C804; Han B, 1997, GASTROENTEROLOGY, V113, P1756, DOI 10.1053/gast.1997.v113.pm9352882; Haussinger D, 1996, BIOCHEM J, V313, P697; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; Hazama A, 2000, J PHYSIOL-LONDON, V523, P1, DOI 10.1111/j.1469-7793.2000.t01-6-00001.x; HAZAMA A, 1990, PFLUG ARCH EUR J PHY, V416, P710, DOI 10.1007/BF00370619; Holzinger A, 2001, METH MOL B, V161, P109; Humeau Y, 2000, BIOCHIMIE, V82, P427, DOI 10.1016/S0300-9084(00)00216-9; Jakab M, 2002, CELL PHYSIOL BIOCHEM, V12, P235, DOI 10.1159/000067895; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lee SC, 1999, BIOPHYS J, V76, P2297, DOI 10.1016/S0006-3495(99)77385-6; Light DB, 1999, AM J PHYSIOL-CELL PH, V277, pC480, DOI 10.1152/ajpcell.1999.277.3.C480; Lim W, 1997, PFLUG ARCH EUR J PHY, V435, P34, DOI 10.1007/s004240050481; Musante L, 1999, J BIOL CHEM, V274, P11701, DOI 10.1074/jbc.274.17.11701; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Noe B, 1996, GASTROENTEROLOGY, V110, P858, DOI 10.1053/gast.1996.v110.pm8608896; Nunez L, 1997, AM J PHYSIOL-ENDOC M, V272, pE1117, DOI 10.1152/ajpendo.1997.272.6.E1117; O'Neill WC, 1999, AM J PHYSIOL-CELL PH, V276, pC995, DOI 10.1152/ajpcell.1999.276.5.C995; OKADA Y, 1992, BIOCHIM BIOPHYS ACTA, V1107, P201, DOI 10.1016/0005-2736(92)90348-P; PFALLER W, 1993, J CELL PHYSIOL, V154, P248, DOI 10.1002/jcp.1041540206; Poulsen CR, 1999, DIABETES, V48, P2171, DOI 10.2337/diabetes.48.11.2171; Powell AD, 2000, J NEUROSCI, V20, P606, DOI 10.1523/JNEUROSCI.20-02-00606.2000; Raucher D, 1999, J CELL BIOL, V144, P497, DOI 10.1083/jcb.144.3.497; Roman RM, 1999, AM J PHYSIOL-GASTR L, V276, pG1391, DOI 10.1152/ajpgi.1999.276.6.G1391; Sadoshima J, 1996, EMBO J, V15, P5535, DOI 10.1002/j.1460-2075.1996.tb00938.x; Schliess F, 1996, BIOCHEM J, V320, P167, DOI 10.1042/bj3200167; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; Sinning R, 1997, FEBS LETT, V400, P163, DOI 10.1016/S0014-5793(96)01376-2; Smith CB, 1996, NATURE, V380, P531, DOI 10.1038/380531a0; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; TILLY BC, 1993, J BIOL CHEM, V268, P19919; Ulate G, 2000, PFLUG ARCH EUR J PHY, V439, P304, DOI 10.1007/s004240050944; van der Wijk T, 1999, BIOCHEM J, V343, P579, DOI 10.1042/0264-6021:3430579; van der Wijk T, 1998, BIOCHEM J, V331, P863, DOI 10.1042/bj3310863; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Zhang Z, 1998, AM J PHYSIOL-CELL PH, V275, pC1104, DOI 10.1152/ajpcell.1998.275.4.C1104	45	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40020	40025		10.1074/jbc.M307603200	http://dx.doi.org/10.1074/jbc.M307603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12871943	hybrid			2022-12-25	WOS:000185713800091
J	Inaba, T; Li, M; Alvarez-Huerta, M; Kessler, F; Schnell, DJ				Inaba, T; Li, M; Alvarez-Huerta, M; Kessler, F; Schnell, DJ			AtTic110 functions as a scaffold for coordinating the stromal events of protein import into chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER ENVELOPE MEMBRANE; ANION CHANNEL; SECONDARY STRUCTURE; OUTER-MEMBRANE; MACHINERY; RECEPTOR; IDENTIFICATION; TRANSLOCATION; COMPONENTS; APPARATUS	The translocon of the inner envelope membrane of chloroplasts ( Tic) mediates the late events in the translocation of nucleus-encoded preproteins into chloroplasts. Tic110 is a major integral membrane component of active Tic complexes and has been proposed to function as a docking site for translocation-associated stromal factors and as a component of the protein-conducting channel. To investigate the various proposed functions of Tic110, we have investigated the structure, topology, and activities of a 97.5-kDa fragment of Arabidopsis Tic110 ( atTic110) lacking only the amino-terminal transmembrane segments. The protein was expressed both in Escherichia coli and Arabidopsis as a stable, soluble protein with a high alpha-helical content. Binding studies demonstrate that a region of the at-Tic110-soluble domain selectively associates with chloroplast preproteins at the late stages of membrane translocation. These data support the hypothesis that the bulk of Tic110 extends into the chloroplast stroma and suggest that the domain forms a docking site for preproteins as they emerge from the Tic translocon.	Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA; Univ Neuchatel, Lab Physiol Vegetale, Inst Bot, CH-2007 Neuchatel, Switzerland	University of Massachusetts System; University of Massachusetts Amherst; University of Neuchatel	Schnell, DJ (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA.		Kessler, Felix Henrique/AAO-1722-2020; Li, Ming/A-1493-2011; Li, Ming/AAU-5026-2020	Li, Ming/0000-0002-1247-2377; Inaba, Takehito/0000-0003-1750-454X; Kessler, Felix/0000-0001-6409-5043				Akita M, 1997, J CELL BIOL, V136, P983, DOI 10.1083/jcb.136.5.983; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; Bauer J, 2002, J CELL BIOL, V159, P845, DOI 10.1083/jcb.200208018; Bauer J, 2001, CELL MOL LIFE SCI, V58, P420, DOI 10.1007/PL00000867; Caliebe A, 1997, EMBO J, V16, P7342, DOI 10.1093/emboj/16.24.7342; Chen XJ, 2002, PLANT CELL, V14, P641, DOI 10.1105/tpc.010336; Heins L, 2002, EMBO J, V21, P2616, DOI 10.1093/emboj/21.11.2616; Heuck AP, 2001, BIOCHEMISTRY-US, V40, P9065, DOI 10.1021/bi0155394; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; Jackson DT, 1998, J BIOL CHEM, V273, P16583, DOI 10.1074/jbc.273.26.16583; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kouranov A, 1998, J CELL BIOL, V143, P991, DOI 10.1083/jcb.143.4.991; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; Kouranov A, 1999, J BIOL CHEM, V274, P25181, DOI 10.1074/jbc.274.35.25181; Kuchler M, 2002, EMBO J, V21, P6136, DOI 10.1093/emboj/cdf621; Lubeck J, 1997, J CELL BIOL, V137, P1279, DOI 10.1083/jcb.137.6.1279; Lubeck J, 1996, EMBO J, V15, P4230, DOI 10.1002/j.1460-2075.1996.tb00797.x; Ma YK, 1996, J CELL BIOL, V134, P315, DOI 10.1083/jcb.134.2.315; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; Pelton JT, 2000, ANAL BIOCHEM, V277, P167, DOI 10.1006/abio.1999.4320; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; Smith MD, 2002, J CELL BIOL, V159, P833, DOI 10.1083/jcb.200208017; SMITH MD, 2002, CURRENT PROTOCOLS CE; Stahl T, 1999, J BIOL CHEM, V274, P37467, DOI 10.1074/jbc.274.52.37467; van den Wijngaard PWJ, 2000, EUR J BIOCHEM, V267, P3812, DOI 10.1046/j.1432-1327.2000.01419.x; van den Wijngaard PWJ, 1999, J BIOL CHEM, V274, P25201, DOI 10.1074/jbc.274.36.25201; vandenWijngaard PWJ, 1997, J BIOL CHEM, V272, P29430, DOI 10.1074/jbc.272.47.29430	35	97	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38617	38627		10.1074/jbc.M306367200	http://dx.doi.org/10.1074/jbc.M306367200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874276	hybrid, Green Submitted			2022-12-25	WOS:000185575100066
J	Olteanu, H; Banerjee, R				Olteanu, H; Banerjee, R			Redundancy in the pathway for redox regulation of mammalian methionine synthase - Reductive activation by the dual flavoprotein, novel reductase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTATION GROUP; CLONING; BINDING; POTENTIALS; MUTATIONS; MECHANISM; CDNA	Methionine synthase is an essential cobalamin-dependent enzyme in mammals that catalyzes the transfer of a methyl group from methyltetrahydrofolate to homocysteine to give tetrahydrofolate and methionine. It is oxidatively labile and requires for its sustained activity an auxiliary repair system that catalyzes a reductive methylation reaction. Genetic and biochemical studies have demonstrated that the soluble dual flavoprotein oxidoreductase, methionine synthase reductase, serves as a redox partner for methionine synthase in an NADPH-dependent reaction. However, three reports suggest the possibility of redundancy in this redox pathway. First, a hyperhomocysteinemic patient has been reported who has an isolated functional deficiency of methionine synthase but appears to be distinct from the cblE and cblG classes of patients with defects in methionine synthase reductase and methionine synthase, respectively. Second, another dual flavoprotein oxidoreductase with significant homology to methionine synthase reductase, NR1, has been described recently, but its function is unknown. Third, methionine synthase can be activated in vitro by a two-component redox system comprised of soluble cytochrome b(5) and P450 reductase. In this study, we demonstrate a function for human NR1 in vitro. It is able to fully activate methionine synthase in the presence of soluble cytochrome b(5) with a V-max of 2.8 +/- 0.1 mumol min(-1) mg(-1) protein, which is comparable with that seen with methionine synthase reductase. The K-actNR1 is 1.27 +/- 0.16 muM, and a 20-fold higher stoichiometry of reductase to methionine synthase is required for NR1 versus methionine synthase reductase, suggesting that it may represent a minor pathway in the cell, assuming that the two proteins are present at similar levels.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	rbanerjee1@unl.edu	Olteanu, Horatiu/AAH-1051-2021	Olteanu, Horatiu/0000-0001-5783-4485	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064959, R01DK045776, R29DK045776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45776, DK64959] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banerjee R, 2003, ANNU REV BIOCHEM, V72, P209, DOI 10.1146/annurev.biochem.72.121801.161828; Banerjee R, 1997, METHOD ENZYMOL, V281, P189; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; CHEN ZQ, 1995, J BIOL CHEM, V270, P19246, DOI 10.1074/jbc.270.33.19246; Chen ZQ, 1998, J BIOL CHEM, V273, P26248, DOI 10.1074/jbc.273.40.26248; CHEN ZQ, 1994, J BIOL CHEM, V269, P27193; Finn RD, 2003, EUR J BIOCHEM, V270, P1164, DOI 10.1046/j.1432-1033.2003.03474.x; Fowler B, 1997, J INHERIT METAB DIS, V20, P270, DOI 10.1023/A:1005369109055; FUJII K, 1977, ARCH BIOCHEM BIOPHYS, V178, P662, DOI 10.1016/0003-9861(77)90238-7; FUJII K, 1974, J BIOL CHEM, V249, P6745; Gulati S, 1996, HUM MOL GENET, V5, P1859, DOI 10.1093/hmg/5.12.1859; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; Leclerc D, 1996, HUM MOL GENET, V5, P1867, DOI 10.1093/hmg/5.12.1867; LEXA D, 1983, ACCOUNTS CHEM RES, V16, P235, DOI 10.1021/ar00091a001; Li YN, 1996, HUM MOL GENET, V5, P1851, DOI 10.1093/hmg/5.12.1851; Matthews RG, 2001, ACCOUNTS CHEM RES, V34, P681, DOI 10.1021/ar0000051; Olteanu H, 2001, J BIOL CHEM, V276, P35558, DOI 10.1074/jbc.M103707200; Paine MJI, 2000, J BIOL CHEM, V275, P1471, DOI 10.1074/jbc.275.2.1471; Perrin D. D., 2012, BUFFERS PH METAL ION; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; ROSENBLATT DS, 1995, INHERITED DISORDERS; Swanson DA, 2001, MOL CELL BIOL, V21, P1058, DOI 10.1128/MCB.21.4.1058-1065.2001; WILLARD HF, 1978, AM J HUM GENET, V30, P1; Wilson A, 1999, HUM MOL GENET, V8, P2009, DOI 10.1093/hmg/8.11.2009; Wilson A, 1998, AM J HUM GENET, V63, P409, DOI 10.1086/301976; Wolthers KR, 2003, BIOCHEMISTRY-US, V42, P3911, DOI 10.1021/bi027290b	26	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38310	38314		10.1074/jbc.M306282200	http://dx.doi.org/10.1074/jbc.M306282200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871938	hybrid			2022-12-25	WOS:000185575100029
J	Yang, HS; Zhou, JH; Ochs, RL; Henning, D; Jin, RY; Valdez, BC				Yang, HS; Zhou, JH; Ochs, RL; Henning, D; Jin, RY; Valdez, BC			Down-regulation of RNA helicase II/Gu results in the depletion of 18 and 28 S rRNAs in Xenopus oocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSE FIBRILLAR COMPONENTS; RIBOSOMAL-RNA; PROTEOMIC CHARACTERIZATION; PRERIBOSOMAL RNA; NUCLEOLAR RNA; U3 SNRNA; PROTEIN; DOMAIN; DISRUPTION; BINDING	Genetic manipulations have revealed the functions of RNA helicases in ribosomal RNA (rRNA) biogenesis in yeast. However, no report shows the role of an RNA helicase in rRNA formation in higher eukaryotes. This study reports the functional characterization of the frog homologue of nucleolar RNA helicase II/Gu (xGu or DDX21). Down-regulation of xGu in Xenopus laevis oocyte using an antisense oligodeoxynucleotide results in the depletion of 18 and 28 S rRNAs. The disappearance of 18 S rRNA is accompanied by an accumulation of 20 S, indicating that xGu is critical in the processing of 20 to 18 S rRNA. The degradation of 28 S rRNA into fragments smaller than 18 S is also associated with a specific decrease in the level of xGu protein. These effects are reversed in the presence of in vitro synthesized wild type xGu mRNA but not its helicase-deficient mutant form. Similar aberrant rRNA processing is observed when antibody against xGu is microinjected. The involvement of xGu in processing of rRNA is consistent with the localization of Gu protein to the granular and dense fibrillar components of PtK2 cell nucleoli by immunoelectron microscopy. Our results show that xGu is involved in the processing of 20 to 18 S rRNA and contributes to the stability of 28 S rRNA in Xenopus oocytes.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA; Precis Therapeut Inc, Pittsburgh, PA 15203 USA	Baylor College of Medicine	Valdez, BC (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	bvaldez@bcm.tmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052341] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52341] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allmang C, 2000, NUCLEIC ACIDS RES, V28, P1684, DOI 10.1093/nar/28.8.1684; AMALDI F, 1989, TRENDS BIOCHEM SCI, V14, P175, DOI 10.1016/0968-0004(89)90269-7; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Busch H, 1970, NUCLEOLUS, P1; CAIRNS C, 1995, J CELL SCI, V108, P3339; CAIZERGUESFERRER M, 1991, DEVELOPMENT, V112, P317; CHANG JH, 1990, J BIOL CHEM, V265, P18227; Dunbar DA, 1998, RNA, V4, P195; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; FLORESROZAS H, 1993, J BIOL CHEM, V268, P21372; Fujiyama S, 2002, J BIOL CHEM, V277, P23773, DOI 10.1074/jbc.M201181200; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; Gerbi SA, 1997, CHROMOSOMA, V105, P401, DOI 10.1007/BF02510476; Giles RV, 2000, METH MOL B, V160, P157; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GRAF JD, 1991, METHOD CELL BIOL, V36, P19; Gustafson WC, 1998, BIOCHEM J, V331, P387, DOI 10.1042/bj3310387; HADJIOLOV A., 1985, NUCL RIBOSOME BIOGEN; HEINE MA, 1993, MOL BIOL CELL, V4, P1189, DOI 10.1091/mbc.4.11.1189; Hong B, 1997, MOL CELL BIOL, V17, P378, DOI 10.1128/MCB.17.1.378; HOZAK P, 1994, J CELL SCI, V107, P639; Huang S, 2002, J CELL BIOL, V157, P739, DOI 10.1083/jcb.200204159; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Koberna K, 2002, J CELL BIOL, V157, P743, DOI 10.1083/jcb.200202007; KONDO K, 1992, J BIOL CHEM, V267, P16252; Leary DJ, 2001, FEBS LETT, V509, P145, DOI 10.1016/S0014-5793(01)03143-X; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; MALLER JL, 1989, J CELL SCI, P53; May A, 1997, J AM SOC NEPHROL, V8, P1813; OCHS RL, 1994, J CELL SCI, V107, P385; OCHS RL, 1985, CHROMOSOMA, V92, P330, DOI 10.1007/BF00327463; ODay CL, 1996, NUCLEIC ACIDS RES, V24, P3201, DOI 10.1093/nar/24.16.3201; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; Peculis BA, 1997, MOL CELL BIOL, V17, P3702, DOI 10.1128/MCB.17.7.3702; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; PERLAKY L, 1992, CANCER RES, V52, P428; RASKA I, 1995, J STRUCT BIOL, V114, P1, DOI 10.1006/jsbi.1995.1001; REDDY R, 1981, J BIOL CHEM, V256, P8452; Roger B, 2002, J BIOL CHEM, V277, P10209, DOI 10.1074/jbc.M106412200; SAMAHA RR, 1994, P NATL ACAD SCI USA, V91, P7884, DOI 10.1073/pnas.91.17.7884; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; SOLLNERWEBB B, 1996, RIBOSOMAL RNA STRUCT, P460; Stelzl U, 2000, P NATL ACAD SCI USA, V97, P4597, DOI 10.1073/pnas.090009297; STEVENS A, 1991, J BACTERIOL, V173, P7024, DOI 10.1128/jb.173.21.7024-7028.1991; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; UDEM SA, 1973, J BIOL CHEM, V248, P1412; Valdez BC, 2000, EUR J BIOCHEM, V267, P6395, DOI 10.1046/j.1432-1327.2000.01727.x; Valdez BC, 1998, BIOTECHNIQUES, V24, P1032, DOI 10.2144/98246cr03; Valdez BC, 2000, GENOMICS, V66, P184, DOI 10.1006/geno.2000.6209; Valdez BC, 2002, GENE, V284, P53, DOI 10.1016/S0378-1119(01)00888-5; Valdez BC, 1996, NUCLEIC ACIDS RES, V24, P1220, DOI 10.1093/nar/24.7.1220; Valdez BC, 1997, EUR J BIOCHEM, V250, P800, DOI 10.1111/j.1432-1033.1997.00800.x; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P372, DOI 10.1016/S0955-0674(00)00102-2; Warner JR, 2001, CELL, V107, P133, DOI 10.1016/S0092-8674(01)00531-1; Westermarck J, 2002, EMBO J, V21, P451, DOI 10.1093/emboj/21.3.451; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	71	30	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38847	38859		10.1074/jbc.M302258200	http://dx.doi.org/10.1074/jbc.M302258200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12851405	hybrid			2022-12-25	WOS:000185575100093
J	Scheper, W; Thaminy, S; Kais, S; Stagljar, I; Romisch, K				Scheper, W; Thaminy, S; Kais, S; Stagljar, I; Romisch, K			Coordination of N-glycosylation and protein translocation across the endoplasmic reticulum membrane by Sss1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR PRECURSOR; SECRETORY PROTEIN; OLIGOSACCHARYLTRANSFERASE COMPLEX; ER MEMBRANE; YEAST; TRANSPORT; DEGRADATION; BINDING; SEC61P; ATP	Secretory proteins are translocated across the endoplasmic reticulum ( ER) membrane through a channel formed by three proteins, namely Sec61p, Sbh1p, and Sss1p ( Johnson, A. E., and van Waes, M. A. ( 1999) Annu. Rev. Cell Dev. Biol. 15, 799 - 842). Sec61p and Sss1p are essential for translocation ( Esnault, Y., Blondel, M. O., Deshaies, R. J., Schekman, R., and Kepes, F. ( 1993) EMBO J. 12, 4083 - 4093). Sec61p is a polytopic membrane protein that lines the protein translocation channel. The role of Sss1p is unknown. During import into the ER through the Sec61p channel, many proteins are N-glycosylated before translocation is completed. In addition, both the Sec61 channel and oligosaccharyl transferase (OST) copurify with ribosomes from rough ER, suggesting that OST is located in close proximity to the Sec61 channel (Gorlich, D., Prehn, S., Hartmann, E., Kalies, K.- U., and Rapoport, T. A. ( 1992) Cell 71, 489 - 503 and Wang, L., and Dobberstein, B. ( 1999) FEBS Lett. 457, 316 322). Here, we demonstrate a direct interaction between Sss1p and a subunit of OST, Wbp1p, using the splitubiquitin system and co-immunoprecipitation. We generated mutants in the cytoplasmic domain of Sss1p that disturb the interaction with OST and are viable but display a translocation defect specific for proteins with glycosylation acceptor sites. Our data suggest that Sss1p coordinates translocation across the ER membrane and N-linked glycosylation of secretory proteins.	Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Clin Biochem, Cambridge CB2 2XY, England; Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	University of Cambridge; University of Cambridge; University of Zurich	Romisch, K (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 2XY, England.		Römisch, Karin/AAO-1210-2021; Scheper, Wiep/AAI-7323-2020	Römisch, Karin/0000-0003-0415-6558; Scheper, Wiep/0000-0002-1431-4559				Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; CAPLAN S, 1991, J BACTERIOL, V173, P627, DOI 10.1128/jb.173.2.627-635.1991; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; Fu J, 1997, J BIOL CHEM, V272, P29687, DOI 10.1074/jbc.272.47.29687; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; Harty C, 2001, MOL BIOL CELL, V12, P1093, DOI 10.1091/mbc.12.4.1093; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LYMAN SK, 1995, J CELL BIOL, V131, P1163, DOI 10.1083/jcb.131.5.1163; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Nikonov AV, 2002, J CELL BIOL, V158, P497, DOI 10.1083/jcb.200201116; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; THAMINY S, 2002, PROTEIN PROTEIN INTE, P395; Wang L, 1999, FEBS LETT, V457, P316, DOI 10.1016/S0014-5793(99)01075-3; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; Wilkinson BM, 1997, EMBO J, V16, P4549, DOI 10.1093/emboj/16.15.4549	34	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37998	38003		10.1074/jbc.M300176200	http://dx.doi.org/10.1074/jbc.M300176200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12860997	hybrid			2022-12-25	WOS:000185437200121
J	Tomasini, R; Samir, AA; Carrier, A; Isnardon, D; Cecchinelli, B; Soddu, S; Malissen, B; Dagorn, JC; Iovanna, JL; Dusetti, NJ				Tomasini, R; Samir, AA; Carrier, A; Isnardon, D; Cecchinelli, B; Soddu, S; Malissen, B; Dagorn, JC; Iovanna, JL; Dusetti, NJ			TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-DEPENDENT APOPTOSIS; POTENTIAL MEDIATOR; TUMOR SUPPRESSION; GENE-EXPRESSION; NUCLEAR-BODIES; PML; PATTERNS; GROWTH; STRESS; SIP	The TP53INP1 gene encodes two protein isoforms, TP53INP1alpha and TP53INP1beta, located into the nucleus. Their synthesis is increased during cellular stress by p53-mediated activation of transcription. Overexpression of these isoforms induces apoptosis, suggesting an involvement of TP53INP1s in p53-mediated cell death. It was recently shown that p53-dependent apoptosis is promoted by homeodomain-interacting protein kinase-2 (HIPK2), which is known to bind p53 and induce its phosphorylation in promyelocytic leukemia protein nuclear bodies (PML-NBs). In this work we show that TP53INP1s localize with p53, PML-IV, and HIPK2 into the PML-NBs. In addition, we show that TP53INP1s interact physically with HIPK2 and p53. In agreement with these results we demonstrate that TP53INP1s, in association with HIPK2, regulate p53 transcriptional activity on p21, mdm2, pig3, and bax promoters. Furthermore, TP53INP1s overexpression induces G(1) arrest and increases p53-mediated apoptosis. Although a TP53INP1s and HIPK2 additive effect was observed on apoptosis, G(1) arrest was weaker when HIPK2 was transfected together with TP53INP1. These results indicate that TP53INP1s and HIPK2 could be partners in regulating p53 activity.	INSERM, EMI 0116, Ctr Rech, F-13009 Marseille, France; CNRS Marseille Luminy, INSERM, Ctr Immunol, F-13288 Marseille 9, France; Inst J Paoli I Calmettes, F-13009 Marseille, France; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Dusetti, NJ (corresponding author), INSERM, EMI 0116, Ctr Rech, 163 Ave Luminy,BP172,Parc Sci & Technol Luminy, F-13009 Marseille, France.	dusetti@inserm-nacre.inserm-adr2.univ-mrs.fr	tomasini, richard/F-1130-2017; Soddu, Silvia/ABH-6774-2020; Dusetti, Nelson/O-7919-2017; Soddu, Silvia/K-2467-2018; Iovanna, Juan/M-9805-2017; Malissen, Bernard/AAK-4659-2020	tomasini, richard/0000-0003-0869-0811; Soddu, Silvia/0000-0001-8526-0044; Dusetti, Nelson/0000-0002-6161-8483; Soddu, Silvia/0000-0001-8526-0044; Iovanna, Juan/0000-0003-1822-2237; Malissen, Bernard/0000-0003-1340-9342				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Carrier A, 1999, IMMUNOGENETICS, V50, P255, DOI 10.1007/s002510050601; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; MIYASHITA T, 1995, CELL, V80, P293; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Tomasin R, 2001, J BIOL CHEM, V276, P44185, DOI 10.1074/jbc.M105647200; Tomasini R, 2002, EUR J CELL BIOL, V81, P294, DOI 10.1078/0171-9335-00248; Vasseur S, 2002, EMBO REP, V3, P165, DOI 10.1093/embo-reports/kvf023; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wiederschain D, 2001, J BIOL CHEM, V276, P27999, DOI 10.1074/jbc.M102400200; Zhao RB, 2000, GENE DEV, V14, P981; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	30	120	137	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37722	37729		10.1074/jbc.M301979200	http://dx.doi.org/10.1074/jbc.M301979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12851404	hybrid			2022-12-25	WOS:000185437200089
J	Wiberg, C; Klatt, AR; Wagener, R; Paulsson, M; Bateman, JF; Heinegard, D; Morgelin, M				Wiberg, C; Klatt, AR; Wagener, R; Paulsson, M; Bateman, JF; Heinegard, D; Morgelin, M			Complexes of matrilin-1 and biglycan or decorin connect collagen VI microfibrils to both collagen II and aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE MATRIX PROTEIN; SWARM RAT CHONDROSARCOMA; BOVINE NASAL CARTILAGE; VON-WILLEBRAND-FACTOR; ELECTRON-MICROSCOPY; INTERSTITIAL PROTEOGLYCANS; IMMUNOELECTRON MICROSCOPY; TISSUE DISTRIBUTION; MOLECULAR-STRUCTURE; INTIMA COLLAGEN	Native supramolecular assemblies containing collagen VI microfibrils and associated extracellular matrix proteins were isolated from Swarm rat chondrosarcoma tissue. Their composition and spatial organization were characterized by electron microscopy and immunological detection of molecular constituents. The small leucine-rich repeat (LRR) proteoglycans biglycan and decorin were bound to the N-terminal region of collagen VI. Chondroadherin, another member of the LRR family, was identified both at the N and C termini of collagen VI. Matrilin-1, -3, and -4 were found in complexes with biglycan or decorin at the N terminus. The interactions between collagen VI, biglycan, decorin, and matrilin-1 were studied in detail and revealed a biglycan/matrilin-1 or decorin/matrilin-1 complex acting as a linkage between collagen VI microfibrils and aggrecan or alternatively collagen II. The complexes between matrilin-1 and biglycan or decorin were also reconstituted in vitro. Colocalization of collagen VI and the different ligands in the pericellular matrix of cultured chondrosarcoma cells supported the physiological relevance of the observed interactions in matrix assembly.	Lund Univ, Dept Cell & Mol Biol, Sect Mol Pathogenesis, BMC, S-22184 Lund, Sweden; Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; Univ Melbourne, Murdoch Childrens Res Inst, Cell & Matrix Biol Res Unit, Parkville, Vic 3052, Australia	Lund University; University of Cologne; University of Melbourne; Murdoch Children's Research Institute; University of Melbourne	Morgelin, M (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Mol Pathogenesis, BMC, B14, S-22184 Lund, Sweden.			Bateman, John/0000-0001-8542-0730				BASCHONG W, 1985, HISTOCHEMISTRY, V83, P409, DOI 10.1007/BF00509201; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BRUNS RR, 1986, J CELL BIOL, V103, P393, DOI 10.1083/jcb.103.2.393; Deak F, 1999, MATRIX BIOL, V18, P55, DOI 10.1016/S0945-053X(98)00006-7; Deak F, 1997, J BIOL CHEM, V272, P9268; DOEGE K, 1987, J BIOL CHEM, V262, P17757; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; ENGEL J, 1985, ANN NY ACAD SCI, V460, P25, DOI 10.1111/j.1749-6632.1985.tb51154.x; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Fitzgerald J, 2001, J BIOL CHEM, V276, P187, DOI 10.1074/jbc.M008173200; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; HASCALL VC, 1972, J BIOL CHEM, V247, P4521; HASCALL VC, 1970, J BIOL CHEM, V245, P4920; Hauser N, 1996, J BIOL CHEM, V271, P32247, DOI 10.1074/jbc.271.50.32247; HAUSER N, 1994, J BIOL CHEM, V269, P25747; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEINEGARD D, 1985, BIOCHEM J, V225, P95, DOI 10.1042/bj2250095; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; HEINEGARD D, 1977, J BIOL CHEM, V252, P1971; Heinegard D., 2002, CONNECTIVE TISSUE IT, P271; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Keene DR, 1998, J HISTOCHEM CYTOCHEM, V46, P215, DOI 10.1177/002215549804600210; Klatt AR, 2000, J BIOL CHEM, V275, P3999, DOI 10.1074/jbc.275.6.3999; Klatt AR, 2002, MATRIX BIOL, V21, P289, DOI 10.1016/S0945-053X(02)00006-9; Klatt AR, 2001, J BIOL CHEM, V276, P17267, DOI 10.1074/jbc.M100587200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMANDER LS, 1980, J BIOL CHEM, V255, P6084; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; MORGELIN M, 1992, J BIOL CHEM, V267, P14275; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; OEGEMA TR, 1975, J BIOL CHEM, V250, P6151; PAULSSON M, 1979, BIOCHEM J, V183, P539, DOI 10.1042/bj1830539; PAULSSON M, 1982, BIOCHEM J, V207, P207, DOI 10.1042/bj2070207; Piecha D, 1999, J BIOL CHEM, V274, P13353, DOI 10.1074/jbc.274.19.13353; POOLE CA, 1988, J ORTHOPAED RES, V6, P408, DOI 10.1002/jor.1100060312; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; SLOT JW, 1981, J CELL BIOL, V90, P533, DOI 10.1083/jcb.90.2.533; SPISSINGER T, 1995, MATRIX BIOL, V14, P499, DOI 10.1016/0945-053X(95)90007-1; TRUEB B, 1986, EMBO J, V5, P2815, DOI 10.1002/j.1460-2075.1986.tb04573.x; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Wagener R, 1997, FEBS LETT, V413, P129, DOI 10.1016/S0014-5793(97)00895-8; Wagener R, 1998, FEBS LETT, V436, P123, DOI 10.1016/S0014-5793(98)01111-9; Wiberg C, 2002, J BIOL CHEM, V277, P49120, DOI 10.1074/jbc.M206891200; Wiberg C, 2001, J BIOL CHEM, V276, P18947, DOI 10.1074/jbc.M100625200; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307; Wu JJ, 1998, J BIOL CHEM, V273, P17433, DOI 10.1074/jbc.273.28.17433	54	196	203	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37698	37704		10.1074/jbc.M304638200	http://dx.doi.org/10.1074/jbc.M304638200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12840020	hybrid			2022-12-25	WOS:000185437200086
J	Chen, Q; Vazquez, EJ; Moghaddas, S; Hoppel, CL; Lesnefsky, EJ				Chen, Q; Vazquez, EJ; Moghaddas, S; Hoppel, CL; Lesnefsky, EJ			Production of reactive oxygen species by mitochondria - Central role of complex III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSPORT; GLUTATHIONE-PEROXIDASE; MYOCARDIAL-ISCHEMIA; SUPEROXIDE ANION; Q(O) SITE; Q-CYCLE; HEART; GENERATION; RADICALS; NADH	The mitochondrial respiratory chain is a major source of reactive oxygen species (ROS) under pathological conditions including myocardial ischemia and reperfusion. Limitation of electron transport by the inhibitor rotenone immediately before ischemia decreases the production of ROS in cardiac myocytes and reduces damage to mitochondria. We asked if ROS generation by intact mitochondria during the oxidation of complex I substrates ( glutamate, pyruvate/malate) occurred from complex I or III. ROS production by mitochondria of Sprague-Dawley rat hearts and corresponding submitochondrial particles was studied. ROS were measured as H2O2 using the amplex red assay. In mitochondria oxidizing complex I substrates, rotenone inhibition did not increase H2O2. Oxidation of complex I or II substrates in the presence of antimycin A markedly increased H2O2. Rotenone prevented antimycin A-induced H2O2 production in mitochondria with complex I substrates but not with complex II substrates. Catalase scavenged H2O2. In contrast to intact mitochondria, blockade of complex I with rotenone markedly increased H2O2 production from submitochondrial particles oxidizing the complex I substrate NADH. ROS are produced from complex I by the NADH dehydrogenase located in the matrix side of the inner membrane and are dissipated in mitochondria by matrix antioxidant defense. However, in submitochondrial particles devoid of antioxidant defense ROS from complex I are available for detection. In mitochondria, complex III is the principal site for ROS generation during the oxidation of complex I substrates, and rotenone protects by limiting electron flow into complex III.	Case Western Reserve Univ, Dept Med, Div Cardiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Div Clin Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Div Pharmacol, Cleveland, OH 44106 USA; Louis Stokes Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Cleveland, OH 44106 USA; Louis Stokes Vet Affairs Med Ctr, Med Serv, Cleveland, OH 44106 USA; Xuzhou Med Coll, Dept Anesthesiol, Xuzhou, Peoples R China	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Xuzhou Medical University	Lesnefsky, EJ (corresponding author), Louis Stokes Vet Affairs Med Ctr, Med Serv 111W, Cardiol Sect, 10701 E Blvd, Cleveland, OH 44106 USA.	EXL9@po.cwru.edu			NIA NIH HHS [1P0AG15885, 1K04AG00676] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K04AG000676, P01AG015885] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BABCOCK GT, 1993, J BIOENERG BIOMEMBR, V25, P71, DOI 10.1007/BF00762849; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; Demin OV, 1998, MOL CELL BIOCHEM, V184, P21, DOI 10.1023/A:1006849920918; Demin OV, 1998, BIOCHEMISTRY-MOSCOW+, V63, P634; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Gille L, 2001, ARCH BIOCHEM BIOPHYS, V388, P34, DOI 10.1006/abbi.2000.2257; Grigorieff N, 1999, CURR OPIN STRUC BIOL, V9, P476, DOI 10.1016/S0959-440X(99)80067-0; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; Herrero A, 1997, MECH AGEING DEV, V98, P95, DOI 10.1016/S0047-6374(97)00076-6; HOPPEL C, 1969, ARCH BIOCHEM BIOPHYS, V135, P184, DOI 10.1016/0003-9861(69)90529-3; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Kevin LG, 2003, AM J PHYSIOL-HEART C, V284, pH566, DOI 10.1152/ajpheart.00711.2002; Kumar D, 2002, HERZ, V27, P662, DOI 10.1007/s00059-002-2430-3; Lesnefsky EJ, 2003, FASEB J, V17, pA518; Lesnefsky EJ, 2001, AM J PHYSIOL-HEART C, V280, pH2770; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378; Lesnefsky EJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P117, DOI 10.1006/abbi.2000.2066; LESNEFSKY EJ, 1995, AM J PHYSIOL, V273, pH1544; Moghaddas S, 2003, ARCH BIOCHEM BIOPHYS, V414, P59, DOI 10.1016/S0003-9861(03)00166-8; Muller F, 2002, BIOCHEMISTRY-US, V41, P7866, DOI 10.1021/bi025581e; Ockaili RA, 2001, AM J PHYSIOL-HEART C, V280, pH2406, DOI 10.1152/ajpheart.2001.280.5.H2406; Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625; PALMER JW, 1977, J BIOL CHEM, V252, P8731; Pamplona R, 2002, FREE RADICAL RES, V36, P47, DOI 10.1080/10715760210165; Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5; PARTRIDGE RS, 1994, ARCH BIOCHEM BIOPHYS, V310, P210, DOI 10.1006/abbi.1994.1159; RADI R, 1991, J BIOL CHEM, V266, P22028; Raha S, 2000, FREE RADICAL BIO MED, V29, P170, DOI 10.1016/S0891-5849(00)00338-5; SIMMONS TW, 1989, BIOCHEM BIOPH RES CO, V165, P158, DOI 10.1016/0006-291X(89)91048-6; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; SUGIOKA K, 1988, BIOCHIM BIOPHYS ACTA, V936, P377, DOI 10.1016/0005-2728(88)90014-X; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; Trumpower BL, 2002, BBA-BIOENERGETICS, V1555, P166, DOI 10.1016/S0005-2728(02)00273-6; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P411, DOI 10.1016/0003-9861(82)90519-7; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; VAROTSIS C, 1993, P NATL ACAD SCI USA, V90, P237, DOI 10.1073/pnas.90.1.237; Venditti P, 2001, CELL MOL LIFE SCI, V58, P1528, DOI 10.1007/PL00000793; Wallace DC, 2000, AM HEART J, V139, pS70, DOI 10.1067/mhj.2000.103934	43	1202	1233	6	172	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36027	36031		10.1074/jbc.M304854200	http://dx.doi.org/10.1074/jbc.M304854200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12840017	hybrid			2022-12-25	WOS:000185318300021
J	Dillon, TJ; Karpitski, V; Wetzel, SA; Parker, DC; Shaw, AS; Stork, PJS				Dillon, TJ; Karpitski, V; Wetzel, SA; Parker, DC; Shaw, AS; Stork, PJS			Ectopic B-Raf expression enhances extracellular signal-regulated kinase (ERK) signaling in T cells and prevents antigen-presenting cell-induced anergy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; IL-2 GENE-TRANSCRIPTION; SMALL GTPASE RAP1; DEPENDENT ACTIVATION; CLONAL ANERGY; MAP KINASE; RECEPTOR; COSTIMULATION; CD28; PROLIFERATION	T cells that receive stimulation through the T cell receptor (TCR) in the absence of costimulation become anergic and are refractory to subsequent costimulation. This unresponsiveness is associated with the constitutive activation of the small G protein, Rap1, and the lack of Ras-dependent activation of ERK. Recent studies suggest that Rap1 can activate the MAP kinase kinase kinase B-Raf that is either endogenously or ectopically expressed. Peripheral T cells generally do not express B-Raf; therefore, to test the hypothesis that ectopic expression of B-Raf could permit Rap1 to activate ERK signaling, we generated transgenic mice expressing B-Raf within peripheral T cells. This converted Rap1 into an activator of ERK, to enhance ERK activation and proliferation following TCR engagement in the absence of costimulation. When T cells were incubated with engineered APCs presenting antigen on I-E-k and expressing low levels of B7, they became anergic, displayed constitutive activation of Rap1, and were deficient in Ras and ERK activation. However, when incubated with the same APCs, T cells expressing the B-Raf transgene proliferated upon restimulation and displayed elevated ERK activation. Thus B-Raf expression and enhanced ERK activation is sufficient to prevent anergy in a model of APC-induced T cell anergy. However, studies using anti-TCR antibody-induced anergy showed that the ability of ERKs to reverse T cell anergy is dependent on the anergic model utilized.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA	Oregon Health & Science University; Oregon Health & Science University; Washington University (WUSTL); Washington University (WUSTL)	Stork, PJS (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, L-474,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	stork@ohsu.edu	Parker, David C/A-5428-2008	Wetzel, Scott/0000-0001-6843-4583; Parker, David/0000-0003-4456-2788	NIAID NIH HHS [R01 AI47337] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047337] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amsen D, 2000, EUR J IMMUNOL, V30, P2832, DOI 10.1002/1521-4141(200010)30:10<2832::AID-IMMU2832>3.0.CO;2-D; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; BECKER JC, 1995, P NATL ACAD SCI USA, V92, P2375, DOI 10.1073/pnas.92.6.2375; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Carey KD, 2000, MOL CELL BIOL, V20, P8409, DOI 10.1128/MCB.20.22.8409-8419.2000; Carey KD, 2003, J BIOL CHEM, V278, P3185, DOI 10.1074/jbc.M207014200; CHEN CY, 1994, J IMMUNOL, V152, P2105; Chen TS, 1999, CANCER RES, V59, P213; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Crespi D, 2002, EUR J IMMUNOL, V32, P2500, DOI 10.1002/1521-4141(200209)32:9<2500::AID-IMMU2500>3.0.CO;2-S; Czyzyk J, 2000, MOL CELL BIOL, V20, P8740, DOI 10.1128/MCB.20.23.8740-8747.2000; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; DeSilva DR, 1996, J EXP MED, V183, P2017, DOI 10.1084/jem.183.5.2017; DESILVA DR, 1991, J IMMUNOL, V147, P3261; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Faris M, 1996, J BIOL CHEM, V271, P27366, DOI 10.1074/jbc.271.44.27366; Fields P, 1996, J MOL MED-JMM, V74, P673, DOI 10.1007/s001090050071; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; JENKINS MK, 1990, J IMMUNOL, V144, P16; JENKINS MK, 1990, J IMMUNOL, V144, P1585; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; KAYE J, 1992, J IMMUNOL, V148, P3342; KitagawaSakakida S, 1996, J IMMUNOL, V157, P2328; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mondino A, 1996, J IMMUNOL, V157, P2048; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; Ragazzo JL, 2001, P NATL ACAD SCI USA, V98, P241, DOI 10.1073/pnas.011397798; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; Reay PA, 2000, J IMMUNOL, V164, P5626, DOI 10.4049/jimmunol.164.11.5626; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; SAWADA S, 1991, MOL CELL BIOL, V11, P5506, DOI 10.1128/MCB.11.11.5506; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; Schmidt M, 2000, J BIOL CHEM, V275, P41011, DOI 10.1074/jbc.M003716200; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Telander DG, 1999, J IMMUNOL, V162, P1460; van den Brink MRM, 1999, J BIOL CHEM, V274, P11178, DOI 10.1074/jbc.274.16.11178; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wells AD, 2001, J CLIN INVEST, V108, P895, DOI 10.1172/JCI200113220; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Wetzel SA, 2002, J IMMUNOL, V169, P6092, DOI 10.4049/jimmunol.169.11.6092; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	55	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35940	35949		10.1074/jbc.M301506200	http://dx.doi.org/10.1074/jbc.M301506200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855697	hybrid			2022-12-25	WOS:000185318300011
J	Mandal, AK; Samaddar, S; Banerjee, R; Lahiri, S; Bhattacharyya, A; Roy, S				Mandal, AK; Samaddar, S; Banerjee, R; Lahiri, S; Bhattacharyya, A; Roy, S			Glutamate counteracts the denaturing effect of urea through its effect on the denatured state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; TRIMETHYLAMINE N-OXIDE; MOLTEN-GLOBULE STATE; PROTEIN; OSMOLYTE; POTASSIUM; STABILITY; MECHANISM; INSIGHTS; SYSTEM	The urea induced equilibrium denaturation behavior of glutaminyl-tRNA synthetase from Escherichia coli (GlnRS) in 0.25 M potassium L-glutamate, a naturally occurring osmolyte in E. coli, has been studied. Both the native to molten globule and molten globule to unfolded state transitions are shifted significantly toward higher urea concentrations in the presence of L-glutamate, suggesting that L-glutamate has the ability to counteract the denaturing effect of urea. D-Glutamate has a similar effect on the equilibrium denaturation of glutaminyl-tRNA synthetase, indicating that the effect of L-glutamate may not be due to substrate-like binding to the native state. The activation energy of unfolding is not significantly affected in the presence of 0.25 M potassium L-glutamate, indicating that the native state is not preferentially stabilized by the osmolyte. Dramatic increase of coefficient of urea concentration dependence ( m) values of both the transitions in the presence of glutamate suggests destabilization and increased solvent exposure of the denatured states. Four other osmolytes, sorbitol, trimethylamine oxide, inositol, and triethylene glycol, show either a modest effect or no effect on native to molten globule transition of glutaminyl-tRNA synthetase. However, glycine betaine significantly shifts the transition to higher urea concentrations. The effect of these osmolytes on other proteins is mixed. For example, glycine betaine counteracts urea denaturation of tubulin but promotes denaturation of S228N lambda-repressor and carbonic anhydrase. Osmolyte counteraction of urea denaturation depends on osmolyte-protein pair.	Bose Inst, Dept Biophys, Kolkata 700054, W Bengal, India	Department of Science & Technology (India); Bose Institute	Roy, S (corresponding author), Bose Inst, Dept Biophys, P-1-12 CIT Scheme VII M, Kolkata 700054, W Bengal, India.	sidroy@boseinst.ernet.in	Bhattacharyya, Arkka/AAS-9968-2020	Bhattacharyya, Arkka/0000-0002-7209-5681				Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P77, DOI 10.1016/S0968-0004(98)01345-0; BANIK U, 1992, EUR J BIOCHEM, V206, P15, DOI 10.1111/j.1432-1033.1992.tb16896.x; BHATTACHARYA A, 1994, J BIOL CHEM, V269, P28655; BHATTACHARYYA T, 1991, EUR J BIOCHEM, V200, P739, DOI 10.1111/j.1432-1033.1991.tb16239.x; Bolen DW, 2001, J MOL BIOL, V310, P955, DOI 10.1006/jmbi.2001.4819; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Burg MB, 1999, P NATL ACAD SCI USA, V96, P6517, DOI 10.1073/pnas.96.11.6517; BYCHKOVA VE, 1995, FEBS LETT, V359, P6, DOI 10.1016/0014-5793(95)00004-S; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Chatterjee S, 2002, PROTEINS, V49, P554, DOI 10.1002/prot.10236; CHIRIFE J, 1984, J APPL BACTERIOL, V56, P259, DOI 10.1111/j.1365-2672.1984.tb01346.x; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; DAS BK, 1995, BIOCHEMISTRY-US, V34, P5242, DOI 10.1021/bi00015a038; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; FERRER M, 1995, NAT STRUCT BIOL, V2, P211, DOI 10.1038/nsb0395-211; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Gazit E, 1999, J BIOL CHEM, V274, P16813, DOI 10.1074/jbc.274.24.16813; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.me.44.020193.001445; Jana NK, 2000, PROTEIN ENG, V13, P629, DOI 10.1093/protein/13.9.629; JENSEN WA, 1995, BIOCHEMISTRY-US, V34, P472, DOI 10.1021/bi00002a011; Kraegeloh A, 2002, EXTREMOPHILES, V6, P453, DOI 10.1007/s00792-002-0277-4; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; LAI MC, 1991, J BACTERIOL, V173, P5352, DOI 10.1128/jb.173.17.5352-5358.1991; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; Lever M, 2001, BBA-GEN SUBJECTS, V1528, P135, DOI 10.1016/S0304-4165(01)00184-2; LIN TY, 1994, BIOCHEMISTRY-US, V33, P12695, DOI 10.1021/bi00208a021; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; NAGELHUS EA, 1994, ADV EXP MED BIOL, V359, P325; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; Poklar N, 1997, BIOCHEMISTRY-US, V36, P14345, DOI 10.1021/bi971719v; Roberts MF, 2000, FRONT BIOSCI-LANDMRK, V5, pD796, DOI 10.2741/roberts; Serpell LC, 1997, CELL MOL LIFE SCI, V53, P871, DOI 10.1007/s000180050107; Shi ZS, 2002, P NATL ACAD SCI USA, V99, P9190, DOI 10.1073/pnas.112193999; SHORTLE D, 1995, ADV PROTEIN CHEM, V46, P217, DOI 10.1016/S0065-3233(08)60336-8; Shortle D, 2001, SCIENCE, V293, P487, DOI 10.1126/science.1060438; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; Wrabl J, 1999, NAT STRUCT BIOL, V6, P876; Yancey PH, 1999, J EXP BIOL, V202, P3597; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Zhang J, 1998, BIOCHEMISTRY-US, V37, P14881, DOI 10.1021/bi9811157; Zou Q, 2002, J AM CHEM SOC, V124, P1192, DOI 10.1021/ja004206b	41	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36077	36084		10.1074/jbc.M211207200	http://dx.doi.org/10.1074/jbc.M211207200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12844489	hybrid			2022-12-25	WOS:000185318300027
J	Molotkov, A; Duester, G				Molotkov, A; Duester, G			Genetic evidence that retinaldehyde dehydrogenase Raldh1 (Aldh1a1) functions downstream of alcohol dehydrogenase Adh1 in metabolism of retinol to retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OMEGA-HYDROXYFATTY ACIDS; VITAMIN-A TOXICITY; ALDEHYDE DEHYDROGENASE; TARGETED DISRUPTION; MOUSE; IDENTIFICATION; ENZYME; OXIDATION; TERATOGENICITY; 9-CIS	Vitamin A (retinol) is a nutrient that is essential for developmental regulation but toxic in large amounts. Previous genetic studies have revealed that alcohol dehydrogenase Adh1 is required for efficient clearance of excess retinol to prevent toxicity, thus demonstrating that the mechanism involves oxidation of excess retinol to retinoic acid (RA). Whereas Adh1 plays a dominant role in the first step of the clearance pathway (oxidation of retinol to retinaldehyde), it is unknown what controls the second step (oxidation of retinaldehyde to RA). We now present genetic evidence that aldehyde dehydrogenase Aldh1a1, also known as retinaldehyde dehydrogenase Raldh1, plays a dominant role in the second step of retinol clearance in adult mice. Serum RA levels following a 50 mg/kg dose of retinol were reduced 72% in Raldh1(-/-) mice and 82% in Adh1(-/-) mice. This represented reductions in RA synthesis of 77-78% for each mutant after corrections for altered RA degradation in each. After retinol dosing, serum retinaldehyde was increased 2.5-fold in Raldh1(-/-) mice (indicating defective retinaldehyde clearance) and decreased 3-fold in Adh1(-/-) mice (indicating defective retinaldehyde synthesis). Serum retinol clearance following retinol administration was decreased 7% in Raldh1(-/-) mice and 69% in Adh1(-/-) mice. LD50 studies indicated a small increase in retinol toxicity in Raldh1(-/-) mice and a large increase in Adh1(-/-) mice. These observations demonstrate that Raldh1 functions downstream of Adh1 in the oxidative metabolism of excess retinol and that toxicity correlates primarily with accumulating retinol rather than retinaldehyde.	Burnham Inst, OncoDev Biol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Duester, G (corresponding author), Burnham Inst, OncoDev Biol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	duester@burnham.org		Duester, Gregg/0000-0003-4335-3650	NEI NIH HHS [R01 EY013969-02, R01 EY013969, EY13969] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013969] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abu-Abed S, 2001, GENE DEV, V15, P226, DOI 10.1101/gad.855001; ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; Ang HL, 1999, DEV DYNAM, V215, P264, DOI 10.1002/(SICI)1097-0177(199907)215:3<264::AID-AJA8>3.0.CO;2-I; Ang HL, 1999, EUR J BIOCHEM, V260, P227, DOI 10.1046/j.1432-1327.1999.00139.x; Armstrong Robert B., 1994, P545; Blaner William S., 1994, P229; BLISS AF, 1951, ARCH BIOCHEM BIOPHYS, V31, P197, DOI 10.1016/0003-9861(51)90206-8; BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; Bray BJ, 2001, TOXICOL APPL PHARM, V173, P129, DOI 10.1006/taap.2001.9170; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chou CF, 2002, J BIOL CHEM, V277, P25209, DOI 10.1074/jbc.M201947200; Clagett-Dame M, 2002, ANNU REV NUTR, V22, P347, DOI 10.1146/annurev.nutr.22.010402.102745E; COLLINS MD, 1992, ARCH TOXICOL, V66, P652, DOI 10.1007/BF01981505; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Fan XH, 2003, MOL CELL BIOL, V23, P4637, DOI 10.1128/MCB.23.13.4637-4648.2003; FROLIK CA, 1984, RETINOIDS, V2, P177; FUTTERMAN S, 1962, J BIOL CHEM, V237, P677; Gagnon I, 2002, BBA-PROTEIN STRUCT M, V1596, P156, DOI 10.1016/S0167-4838(02)00213-3; GODBOUT R, 1992, EXP EYE RES, V54, P297, DOI 10.1016/S0014-4835(05)80219-2; Godbout R, 2001, J BIOL CHEM, V276, P32896, DOI 10.1074/jbc.M104372200; Grun F, 2000, J BIOL CHEM, V275, P41210, DOI 10.1074/jbc.M007376200; Haselbeck RJ, 1997, ALCOHOL CLIN EXP RES, V21, P1484; Haselbeck RJ, 1999, DEV GENET, V25, P353, DOI 10.1002/(SICI)1520-6408(1999)25:4<353::AID-DVG9>3.0.CO;2-G; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KAMM JJ, 1982, J AM ACAD DERMATOL, V6, P652, DOI 10.1016/S0190-9622(82)70054-4; KOCHHAR DM, 1967, ACTA PATHOL MIC SC, V70, P398; Kono H, 1999, AM J PHYSIOL-GASTR L, V277, pG1259, DOI 10.1152/ajpgi.1999.277.6.G1259; KURLANDSKY SB, 1995, J BIOL CHEM, V270, P17850, DOI 10.1074/jbc.270.30.17850; LABRECQUE J, 1995, BIOCHEM J, V305, P681, DOI 10.1042/bj3050681; Lapshina EA, 2003, BIOCHEMISTRY-US, V42, P776, DOI 10.1021/bi026836r; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LIEBER CS, 1994, J TOXICOL-CLIN TOXIC, V32, P631, DOI 10.3109/15563659409017974; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; LITCHFIELD JT, 1949, J PHARMACOL EXP THER, V96, P99; MCCAFFERY P, 1991, DEVELOPMENT, V112, P693; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; McSorley LC, 2000, BIOCHEM PHARMACOL, V60, P517, DOI 10.1016/S0006-2952(00)00356-7; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; Mic FA, 2002, DEVELOPMENT, V129, P2271; Mic FA, 2003, P NATL ACAD SCI USA, V100, P7135, DOI 10.1073/pnas.1231422100; Molotkov A, 2002, J BIOL CHEM, V277, P22553, DOI 10.1074/jbc.M201603200; Molotkov A, 2002, EUR J BIOCHEM, V269, P2607, DOI 10.1046/j.1432-1033.2002.02935.x; Molotkov A, 2002, J BIOL CHEM, V277, P13804, DOI 10.1074/jbc.M112039200; Molotkov A, 2002, P NATL ACAD SCI USA, V99, P5337, DOI 10.1073/pnas.082093299; Niederreither K, 2002, NAT GENET, V31, P84, DOI 10.1038/ng876; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; Romert A, 1998, P NATL ACAD SCI USA, V95, P4404, DOI 10.1073/pnas.95.8.4404; ROTHMAN KJ, 1995, NEW ENGL J MED, V333, P1369, DOI 10.1056/NEJM199511233332101; Sakai Y, 2001, GENE DEV, V15, P213, DOI 10.1101/gad.851501; SATRE MA, 1992, BIOL REPROD, V46, P802, DOI 10.1095/biolreprod46.5.802; Shang EY, 2002, J LIPID RES, V43, P590; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; WALD G, 1951, SCIENCE, V113, P287, DOI 10.1126/science.113.2933.287; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; ZACHMAN RD, 1961, J BIOL CHEM, V236, P2309; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P10868, DOI 10.1074/jbc.270.18.10868	62	111	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36085	36090		10.1074/jbc.M303709200	http://dx.doi.org/10.1074/jbc.M303709200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851412	hybrid			2022-12-25	WOS:000185318300028
J	Proussakova, OV; Rabaya, NA; Moshnikova, AB; Telegina, ES; Turanov, A; Nanazashvili, MG; Beletsky, IP				Proussakova, OV; Rabaya, NA; Moshnikova, AB; Telegina, ES; Turanov, A; Nanazashvili, MG; Beletsky, IP			Oligomerization of soluble Fas antigen induces its cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; T-CELLS; CYTOPLASMIC DOMAIN; CROSS-LINKING; CD95 LIGAND; IFN-GAMMA; APOPTOSIS; PROLIFERATION; INHIBITION; DEATH	Soluble Fas antigen can protect cells against Fas-mediated apoptosis. High level soluble Fas antigen characteristic for blood of patients with autoimmune disease or cancer is believed to prevent the elimination of autoimmune lymphocytes or tumor cells. Here we first report that human recombinant FasDeltaTM, i.e. soluble Fas generated by alternative splicing of the intact exon 6, is capable of inducing death of transformed cells by "reverse" apoptotic signaling via transmembrane Fas ligand. FasDeltaTM, as well as transmembrane Fas antigen, can be either monomeric or oligomeric, and both its forms are efficient in blocking Fas-mediated apoptosis, although the cytotoxic activity is exhibited solely by the latter. An in vivo analysis of soluble Fas antigen showed that unlike in healthy controls, nearly the total FasDeltaTM present in sera of rheumatoid arthritis patients was oligomeric. This resulted in suppression of cell proliferation in the experimental sera and in its promotion in controls. Thus, oligomerization/depolymerization of soluble Fas antigen can regulate its activity and contribute to the pathogenesis of autoimmune diseases and cancer.	Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142290, Russia; IM Sechenov Moscow Med Acad, Inst Mol Med, Moscow 119992, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Theoretical & Experimental Biophysics; Sechenov First Moscow State Medical University	Beletsky, IP (corresponding author), Russian Acad Sci, Inst Theoret & Expt Biophys, Institutska St 3, Pushchino 142290, Russia.	beletsky@iteb.ru						Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASCINO I, 1995, J IMMUNOL, V154, P2706; CAYABYAB M, 1994, J IMMUNOL, V152, P1523; Chan FKM, 2000, ANN RHEUM DIS, V59, P50, DOI 10.1136/ard.59.suppl_1.i50; Chen NJ, 2001, J IMMUNOL, V166, P270, DOI 10.4049/jimmunol.166.1.270; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Chou AH, 2001, J IMMUNOL, V167, P1347, DOI 10.4049/jimmunol.167.3.1347; Desbarats J, 1998, NAT MED, V4, P1377, DOI 10.1038/3965; HANE M, 1995, FEBS LETT, V373, P265, DOI 10.1016/0014-5793(95)01051-F; Hasunuma T, 1997, ARTHRITIS RHEUM, V40, P80, DOI 10.1002/art.1780400112; Ichikawa K, 2000, INT IMMUNOL, V12, P555, DOI 10.1093/intimm/12.4.555; Jodo S, 1997, CLIN EXP IMMUNOL, V107, P89, DOI 10.1046/j.1365-2249.1997.d01-901.x; Kamitani T, 1997, J BIOL CHEM, V272, P22307, DOI 10.1074/jbc.272.35.22307; Kawahara A, 1998, GENES CELLS, V3, P297, DOI 10.1046/j.1365-2443.1998.00189.x; KINOSHITA T, 1992, ANAL BIOCHEM, V206, P231, DOI 10.1016/0003-2697(92)90358-E; Knox PG, 2003, J IMMUNOL, V170, P677, DOI 10.4049/jimmunol.170.2.677; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SH, 2001, HUM PATHOL, V32, P250, DOI 10.1053/hupa.2001.22769; LIU CD, 1995, BIOCHEM J, V310, P957, DOI 10.1042/bj3100957; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mullauer L, 2001, MUTAT RES-REV MUTAT, V488, P211, DOI 10.1016/S1383-5742(01)00057-6; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nakamoto Y, 1999, ONCOL REP, V6, P733; Nishimura-Morita Y, 1997, INT IMMUNOL, V9, P1793, DOI 10.1093/intimm/9.12.1793; Ogawa Y, 2001, J RHEUMATOL, V28, P950; Papoff G, 1999, J BIOL CHEM, V274, P38241, DOI 10.1074/jbc.274.53.38241; POLLOK KE, 1994, EUR J IMMUNOL, V24, P367, DOI 10.1002/eji.1830240215; Shi GX, 2002, BLOOD, V100, P3279, DOI 10.1182/blood-2002-05-1404; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; Suzuki I, 2000, P NATL ACAD SCI USA, V97, P1707, DOI 10.1073/pnas.97.4.1707; Suzuki I, 2000, J IMMUNOL, V165, P5537, DOI 10.4049/jimmunol.165.10.5537; Suzuki I, 1998, J EXP MED, V187, P123, DOI 10.1084/jem.187.1.123; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Ulisse S, 2000, CELL DEATH DIFFER, V7, P916, DOI 10.1038/sj.cdd.4400716; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WALLACH D, 1984, J IMMUNOL, V132, P2464; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Watts AD, 1999, EMBO J, V18, P2119, DOI 10.1093/emboj/18.8.2119; Wenzel J, 2001, FEBS LETT, V509, P255, DOI 10.1016/S0014-5793(01)03174-X; Wiley SR, 1996, J IMMUNOL, V157, P3635; Yuen MF, 2001, CANCER, V92, P2136, DOI 10.1002/1097-0142(20011015)92:8<2136::AID-CNCR1555>3.0.CO;2-J	48	15	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36236	36241		10.1074/jbc.M305896200	http://dx.doi.org/10.1074/jbc.M305896200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855687	hybrid			2022-12-25	WOS:000185318300045
J	Saito, T; Okada, S; Yamada, E; Ohshima, K; Shimizu, H; Shimomura, K; Sato, M; Pessin, JE; Mori, M				Saito, T; Okada, S; Yamada, E; Ohshima, K; Shimizu, H; Shimomura, K; Sato, M; Pessin, JE; Mori, M			Syntaxin 4 and Synip (syntaxin 4 interacting protein) regulate insulin secretion in the pancreatic beta HC-9 cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELLS; GLUT4 TRANSLOCATION; GLUCOSE; ISLETS; EXOCYTOSIS; EXPRESSION; CA2+; IDENTIFICATION; ADIPOCYTES; TRANSPORT	Although syntaxin 1 is generally thought to function as the primary target-N-ethylmaleimide-sensitive factor attachment protein receptor required for pancreatic beta cell insulin secretion, we have observed that overexpression of a dominant-interfering syntaxin 4 mutant (syntaxin 4/DeltaTM) attenuated glucose-stimulated insulin secretion in betaHC-9 cells. Furthermore, these cells express the selective syntaxin 4-binding protein Synip (syntaxin 4 interacting protein), and Synip was specifically co-immunoprecipitated with syntaxin 4 but not syntaxin 1. Overexpression of the full-length Synip protein (Synip/wild type) inhibited VAMP2 association with syntaxin 4 and decreased glucose-stimulated insulin secretion. This did not occur with a Synip mutant (Synip/DeltaEF) that was incapable of binding syntaxin 4. Consistent with a functional role of syntaxin 4 in this process, expression of syntaxin 4/DeltaTM also inhibited glucose-stimulated insulin secretion. Furthermore, analysis of first and second phase insulin secretion demonstrated that syntaxin 4/DeltaTM mainly suppressed the second phase of insulin secretion. In contrast, overexpression of Synip resulted in an inhibition of both the first and second phase of glucose-stimulated insulin secretion. These data demonstrate that syntaxin 4 plays a functional role on insulin release and granule fusion in beta cells and that this process is regulated by the syntaxin 4-specific binding protein Synip.	Gunma Univ, Grad Sch Med, Dept Med & Mol Sci, Maebashi, Gumma 3718511, Japan; Gunma Univ, Hlth & Sci Ctr, Maebashi, Gumma 3718510, Japan; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	Gunma University; Gunma University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Okada, S (corresponding author), Gunma Univ, Grad Sch Med, Dept Med & Mol Sci, 3-39-15 Showa Machi, Maebashi, Gumma 3718511, Japan.	Okadash@showa.gunma-u.ac.jp						Anello M, 1999, BRIT J PHARMACOL, V127, P1883, DOI 10.1038/sj.bjp.0702731; ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; Barg S, 2002, DIABETES, V51, pS74, DOI 10.2337/diabetes.51.2007.S74; BOYD RS, 1995, J BIOL CHEM, V270, P18216, DOI 10.1074/jbc.270.31.18216; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Chan CB, 1999, DIABETES, V48, P997, DOI 10.2337/diabetes.48.5.997; Daniel S, 1999, DIABETES, V48, P1686, DOI 10.2337/diabetes.48.9.1686; DEAN PM, 1973, DIABETOLOGIA, V9, P115, DOI 10.1007/BF01230690; Detimary P, 1998, J BIOL CHEM, V273, P33905, DOI 10.1074/jbc.273.51.33905; Easom RA, 2000, SEMIN CELL DEV BIOL, V11, P253, DOI 10.1006/scdb.2000.0174; Edwardes MDD, 1998, STAT SINICA, V8, P393; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; HEINEMANN C, 1994, BIOPHYS J, V67, P2546, DOI 10.1016/S0006-3495(94)80744-1; Henquin JC, 2002, DIABETES, V51, pS60, DOI 10.2337/diabetes.51.2007.S60; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Katz B., 1969, RELEASE NEURAL TRANS; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Nagamatsu S, 1997, DIABETOLOGIA, V40, P1396, DOI 10.1007/s001250050841; OKADA S, 2003, DIABETES MELLITUS ME, P83; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Regazzi R, 1996, EMBO J, V15, P6951, DOI 10.1002/j.1460-2075.1996.tb01087.x; Rorsman P, 2000, NEWS PHYSIOL SCI, V15, P72; Rothman JE, 2002, NAT MED, V8, P1059, DOI 10.1038/nm770; Sadoul K, 1997, J BIOL CHEM, V272, P33023, DOI 10.1074/jbc.272.52.33023; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; TROITZA K, 2002, DIABETES, V51, pS83; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; Whyte JRC, 2002, J CELL SCI, V115, P2627	32	35	38	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36718	36725		10.1074/jbc.M305114200	http://dx.doi.org/10.1074/jbc.M305114200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855681	hybrid			2022-12-25	WOS:000185318300103
J	Tapia, JA; Garcia-Marin, LJ; Jensen, RT				Tapia, JA; Garcia-Marin, LJ; Jensen, RT			Cholecystokinin-stimulated protein kinase C-delta kinase activation, tyrosine phosphorylation, and translocation are mediated by Src tyrosine kinases in pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; PKC-DELTA; V-SRC; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; FAMILY KINASES; PHORBOL ESTERS; IN-VITRO; GROWTH; ASSOCIATION	Protein kinase C-delta (PKC-delta) is involved in growth, differentiation, tumor suppression, and regulation of other cellular processes. PKC-delta activation causes translocation, tyrosine phosphorylation, and serine-threonine kinase activity. However, little is known about the ability of G protein-coupled receptors to activate these processes or the mediators involved. In the present study, we explored the ability of the neurotransmitter/hormone, CCK, to stimulate these changes in PKC-delta and explored the mechanisms. In rat pancreatic acini under basal conditions, PKC-delta is almost exclusively located in cytosol. CCK and TPA stimulated a rapid PKC-delta translocation to membrane and nuclear fractions, which was transient with CCK. CCK stimulated rapid tyrosine phosphorylation of PKC-delta and increased kinase activity. Using tyrosine kinase (B44) and a tyrosine phosphatase inhibitor ( orthovanadate), changes in both CCK- and TPA-stimulated PKC-delta tyrosine phosphorylation were shown to correlate with changes in its kinase activity but not translocation. Both PKC-delta tyrosine phosphorylation and activation occur exclusively in particulate fractions. The Src kinase inhibitors, SU6656 and PP2, but not the inactive related compound, PP3, inhibited CCK- and TPA-stimulated PKC-delta tyrosine phosphorylation and activation. In contrast, PP2 also had a lesser effect on CCK- but not TPA-stimulated PKC-delta translocation. CCK stimulated the association of Src kinases with PKC-delta, demonstrated by co-immunoprecipitation. These results demonstrate that CCKA receptor activation results in rapid translocation, tyrosine phosphorylation, and activation of PKC-delta. Stimulation of PKC-delta translocation precedes tyrosine phosphorylation, which is essential for activation to occur. Activation of Src kinases is essential for the tyrosine phosphorylation and kinase activation to occur and plays a partial role in translocation.	NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Extremadura, Dept Fisiol, Caceres 10071, Spain	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Universidad de Extremadura	Jensen, RT (corresponding author), NIDDK, Digest Dis Branch, NIH, Bldg 10,Rm 9C-103,10 Ctr Dr MSC 1804, Bethesda, MD 20892 USA.	robertj@bdg10.niddk.nih.gov	Garcia-Marin, Luis J/L-4680-2014; Tapia, Jose A./C-5181-2008	Garcia-Marin, Luis J/0000-0002-1795-7381; Tapia, Jose A./0000-0002-3614-6867				BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; Benes C, 2001, AM J PHYSIOL-CELL PH, V280, pC1498, DOI 10.1152/ajpcell.2001.280.6.C1498; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Bradford MD, 1998, EUR J MORPHOL, V36, P176; Braiman L, 1999, MOL ENDOCRINOL, V13, P2002, DOI 10.1210/me.13.12.2002; Chen CC, 1995, MOL PHARMACOL, V48, P995; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Ferris HA, 1999, BIOCHEMISTRY-US, V38, P1497, DOI 10.1021/bi981903w; Garcia LJ, 1999, ADV MOL CELL ENDOCR, V3, P119; Garcia LJ, 1997, BIOCHEM J, V327, P461; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; Gerstin EH, 1998, J BIOL CHEM, V273, P16409, DOI 10.1074/jbc.273.26.16409; Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Ho AK, 1999, MOL CELL ENDOCRINOL, V150, P169, DOI 10.1016/S0303-7207(98)00227-5; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Jensen R.T., 1994, PHYSL GASTROINTESTIN, V2, P1377; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; JENSEN RT, 1989, TRENDS PHARMACOL SCI, V10, P418, DOI 10.1016/0165-6147(89)90192-2; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Lankisch TO, 1999, EUR J CELL BIOL, V78, P632, DOI 10.1016/S0171-9335(99)80048-X; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; Liddle RA., 1994, GUT PEPTIDES BIOCH P; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; MEYER BM, 1989, LANCET, V2, P12, DOI 10.1016/S0140-6736(89)90255-9; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MORAN TP, 1994, HUM-COMPUT INTERACT, V9, P1, DOI 10.1207/s15327051hci0901_1; Moussazadeh M, 1998, FEBS LETT, V438, P225, DOI 10.1016/S0014-5793(98)01302-7; Nozu F, 1999, AM J PHYSIOL-GASTR L, V276, pG915, DOI 10.1152/ajpgi.1999.276.4.G915; Nozu F, 2000, EUR J CELL BIOL, V79, P803, DOI 10.1078/0171-9335-00108; ODRISCOLL KR, 1995, MOL BIOL CELL, V6, P449, DOI 10.1091/mbc.6.4.449; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Parker EM, 2000, PANCREAS, V21, P219, DOI 10.1097/00006676-200010000-00001; POLLO DA, 1994, BBA-MOL CELL RES, V1224, P127, DOI 10.1016/0167-4889(94)90120-1; Popoff IJ, 1999, MOL IMMUNOL, V36, P1005, DOI 10.1016/S0161-5890(99)00128-5; RAFFANIELLO RD, 1998, BIOCHEM BIOPH RES CO, V246, P8579; RIVARD N, 1994, AM J PHYSIOL, V266, pG62, DOI 10.1152/ajpgi.1994.266.1.G62; Rodriguez-Martin E, 1999, FEBS LETT, V445, P356, DOI 10.1016/S0014-5793(99)00133-7; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; SCHNEFEL S, 1988, FEBS LETT, V230, P125, DOI 10.1016/0014-5793(88)80655-0; Shanmugam M, 1998, ONCOGENE, V16, P1649, DOI 10.1038/sj.onc.1201684; SOLOMON TE, 1994, PHYSL GASTROINTESTIN, V1, P1499; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SONG JG, 1993, BIOCHEM J, V294, P711, DOI 10.1042/bj2940711; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; Tapia JA, 1999, J BIOL CHEM, V274, P31261, DOI 10.1074/jbc.274.44.31261; Tsunoda Y, 1996, BIOCHEM BIOPH RES CO, V227, P876, DOI 10.1006/bbrc.1996.1599; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77; Yamamoto T, 2000, BIOCHEM BIOPH RES CO, V273, P960, DOI 10.1006/bbrc.2000.3048; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; YULE DI, 1994, PHYSL GASTROINTESTIN, V2, P1447; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	74	56	57	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35220	35230		10.1074/jbc.M303119200	http://dx.doi.org/10.1074/jbc.M303119200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842900	hybrid			2022-12-25	WOS:000185164400059
J	Snijders, AM; Fridlyand, J; Mans, DA; Segraves, R; Jain, AN; Pinkel, D; Albertson, DG				Snijders, AM; Fridlyand, J; Mans, DA; Segraves, R; Jain, AN; Pinkel, D; Albertson, DG			Shaping of tumor and drug-resistant genomes by instability and selection	ONCOGENE			English	Article						genetic instability; amplification; array CGH; mismatch repair	DNA MISMATCH REPAIR; FOLYLPOLYGLUTAMATE SYNTHETASE GENE; FRAGILE SITES; DIHYDROFOLATE-REDUCTASE; IN-SITU; AMPLIFICATION; METHOTREXATE; CELLS; EXPRESSION; CANCER	Tumors with defects in mismatch repair (MMR) show fewer chromosomal changes by cytogenetic analyses than most solid tumors, suggesting that a greater proportion of the alterations required for malignancy occur in genes with nucleotide sequences susceptible to errors normally corrected by MMR. Here, we used genome-wide microarray comparative genomic hybridization to carry out a higher resolution evaluation of the effect of MMR competence on genomic alterations occurring in 20 cell lines and to determine if characteristic aberrations arise in MMR-proficient and -deficient HCT116 cells undergoing selection for methotrexate resistance. We observed different spectra of aberrations in MMR-proficient compared to -deficient cell lines, as well as among cell lines with different types of MMR-deficiency. We also observed different genetic routes to drug resistance. Resistant MMR-deficient cells most frequently displayed no copy number alterations (16/29 cell pools), whereas all MMR-proficient cells had unique abnormalities involving chromosome 5, including amplicons centered on the target gene, DHFR and/or a neighboring novel locus (7/13 pools). These observations support the concept that tumor genomes are shaped by selection for alterations that promote survival and growth advantage, as well as by the particular dysfunctions in genes responsible for maintenance of genetic integrity.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Albertson, DG (corresponding author), Univ Calif San Francisco, Canc Res Inst, Box 0808, San Francisco, CA 94143 USA.	albertson@cc.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA083040, R33CA094407] Funding Source: NIH RePORTER; NCI NIH HHS [CA83040, CA94407] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aebi S, 1996, CANCER RES, V56, P3087; Albertson DG, 2003, BREAST CANCER RES TR, V78, P289, DOI 10.1023/A:1023025506386; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; BOCKER T, 1999, BIOCHIM BIOPHYS ACTA, V1423, P1; Chen ZS, 2002, CANCER RES, V62, P3144; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; Cole PD, 2001, CANCER RES, V61, P4599; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Duval A, 2002, CANCER RES, V62, P2447; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8; Fink D, 1998, INT J CANCER, V77, P741, DOI 10.1002/(SICI)1097-0215(19980831)77:5<741::AID-IJC13>3.0.CO;2-4; Frouin I, 2001, EUR J CANCER, V37, P1173, DOI 10.1016/S0959-8049(01)00095-8; Guan XY, 1996, CANCER RES, V56, P3446; HAWN MT, 1995, CANCER RES, V55, P3721; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; KOI M, 1994, CANCER RES, V54, P4308; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; KUO MT, 1994, MOL CELL BIOL, V14, P5202, DOI 10.1128/MCB.14.8.5202; Lin CT, 2001, NUCLEIC ACIDS RES, V29, P3304, DOI 10.1093/nar/29.16.3304; Loeb LA, 2001, CANCER RES, V61, P3230; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; MULERIS M, 1995, GENE CHROMOSOME CANC, V14, P223, DOI 10.1002/gcc.2870140312; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pipiras E, 1998, EMBO J, V17, P325, DOI 10.1093/emboj/17.1.325; RABINER LR, 1989, P IEEE, V77, P257, DOI 10.1109/5.18626; REMVIKOS Y, 1995, GENE CHROMOSOME CANC, V12, P272, DOI 10.1002/gcc.2870120406; Rots MG, 1999, BLOOD, V93, P1677, DOI 10.1182/blood.V93.5.1677.405a16_1677_1683; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Soulie P, 1999, CANCER GENET CYTOGEN, V115, P118, DOI 10.1016/S0165-4608(99)00073-4; Srimatkandada S, 2000, ONCOL RES, V12, P11; SUTHERLAND GR, 1991, GENET ANAL-BIOMOL E, V8, P161, DOI 10.1016/1050-3862(91)90056-W; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; Takemura Y, 1999, ANTI-CANCER DRUG, V10, P677, DOI 10.1097/00001813-199908000-00008; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Turner FB, 2000, J BIOL CHEM, V275, P35960, DOI 10.1074/jbc.M005228200; Waldman FM, 2000, JNCI-J NATL CANCER I, V92, P313, DOI 10.1093/jnci/92.4.313; Zeng H, 2001, CANCER RES, V61, P7225; Zhang L, 2001, CANCER RES, V61, P3801; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5; Zimonjic D, 2001, CANCER RES, V61, P8838	50	62	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4370	4379		10.1038/sj.onc.1206482	http://dx.doi.org/10.1038/sj.onc.1206482			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853973				2022-12-25	WOS:000183978900006
J	Sommer, KW; Schamberger, CJ; Schmidt, GE; Sasgary, S; Cerni, C				Sommer, KW; Schamberger, CJ; Schmidt, GE; Sasgary, S; Cerni, C			Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras	ONCOGENE			English	Article						survivin; c-H-ras; PI3-K; MEK1; HaCat; rat cell lines; apoptosis; transformation	WILD-TYPE P53; PHOSPHATIDYLINOSITOL-3-OH KINASE; SP1 PHOSPHORYLATION; ENDOTHELIAL-CELLS; CDK INHIBITORS; IN-VIVO; PATHWAY; GENE; EXPRESSION; CANCER	Among the inhibitors of apoptosis proteins (IAPs), survivin has attracted special attention through its involvement in human cancer. The mechanism underlying tumour-associated survivin re-expression is not known. We found a correlation between exogenous c-H-Ras oncoprotein and endogenous survivin in a series of rat cell lines, which expressed defined oncogenes. Moreover, human HaCat cells, transfected with a constitutively activated c-H-ras gene, had significantly increased survivin levels. To study the interdependence of the two proteins, we generated a rat cell line that expressed a dexamethasone-inducible c-H-ras construct. Induction of c-H-Ras expression was followed by rapid upregulation of survivin. Conversely, downregulation of the oncoprotein resulted in prompt reduction of survivin to baseline value. c-H-Ras-induced survivin was expressed constitutively and independent of cell cycle progression or proliferation. Compromising Ras-stimulated PI3-K activity and MEK1 by chemicals abolished survivin expression and was associated with apoptotic cell death. Upregulation of survivin appeared to be an important activity of c-H-Ras oncoprotein, since cotransfection of a survivin-antisense construct into c-myc/c-H-ras-transfected primary rat embryo cells resulted in profound reduction of transformed clones. It is tempted to speculate that the frequent presence of survivin in human cancer cells might be a consequence of activated Ras-signalling pathways.	Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria	University of Vienna	Cerni, C (corresponding author), Univ Vienna, Inst Canc Res, Borschkegasse 8A, A-1090 Vienna, Austria.	Christa.Cerni@univie.ac.at						Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bao RD, 2002, J NATL CANCER I, V94, P522; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CERNI C, 1986, CURR TOP MICROBIOL, V132, P193; CERNI C, 1995, ONCOGENE, V11, P587; Cerni C, 2002, ONCOGENE, V21, P447, DOI 10.1038/sj.onc.1205107; CERNI C, 1990, VIROLOGY, V177, P427, DOI 10.1016/0042-6822(90)90506-M; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Fortugno P, 2002, J CELL SCI, V115, P575; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Fuhrmann G, 2001, ONCOGENE, V20, P4542, DOI 10.1038/sj.onc.1204499; Fuhrmann G, 1999, MUTAT RES-REV MUTAT, V437, P205, DOI 10.1016/S1383-5742(99)00084-8; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Natesan S, 1997, NATURE, V390, P349, DOI 10.1038/37019; Notarbartolo M, 2002, CANCER LETT, V180, P91, DOI 10.1016/S0304-3835(01)00834-5; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Pruitt K, 2000, J BIOL CHEM, V275, P40916, DOI 10.1074/jbc.M006682200; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sarela AI, 2000, GUT, V46, P645, DOI 10.1136/gut.46.5.645; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Simonitsch I, 2001, FASEB J, V15, P1416, DOI 10.1096/fj.00-0678fje; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 1998, CANCER RES, V58, P5315; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Wurl P, 2002, LANCET, V359, P943, DOI 10.1016/S0140-6736(02)07990-4; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8	67	83	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4266	4280		10.1038/sj.onc.1206509	http://dx.doi.org/10.1038/sj.onc.1206509			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833149				2022-12-25	WOS:000183979800013
J	Lavi, R; Shainberg, A; Friedmann, H; Shneyvays, V; Rickover, O; Eichler, M; Kaplan, D; Lubart, R				Lavi, R; Shainberg, A; Friedmann, H; Shneyvays, V; Rickover, O; Eichler, M; Kaplan, D; Lubart, R			Low energy visible light induces reactive oxygen species generation and stimulates an increase of intracellular calcium concentration in cardiac cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC FREE CALCIUM; LEVEL LASER IRRADIATION; IN-VITRO; HYDROGEN-PEROXIDE; INOSITOL 1,4,5-TRISPHOSPHATE; RECEPTOR ACTIVATION; RYANODINE RECEPTORS; SIGNAL-TRANSDUCTION; REDOX REGULATION; PROLIFERATION	Low energy visible light (LEVL) irradiation has been shown to exert some beneficial effects on various cell cultures. For example, it increases the fertilizing capability of sperm cells, promotes cell proliferation, induces sprouting of neurons, and more. To learn about the mechanism of photobiostimulation, we studied the relationship between increased intracellular calcium ([Ca2+](i)) and reactive oxygen species production following LEVL illumination of cardiomyocytes. We found that visible light causes the production of O-2(radical anion) and H2O2 and that exogenously added H2O2 (12 muM) can mimic the effect of LEVL (3.6 J/cm(2)) to induce a slow and transient increase in [Ca2+](i). This [Ca2+](i) elevation can be reduced by verapamil, a voltage-dependent calcium channel inhibitor. The kinetics of [Ca2+](i) elevation and morphologic damage following light or addition of H2O2 were found to be dose-dependent. For example, LEVL, 3.6 J/cm(2), which induced a transient increase in [Ca2+](i), did not cause any cell damage, whereas visible light at 12 J/cm(2) induced a linear increase in [Ca2+](i) and damaged the cells. The linear increase in [Ca2+](i) resulting from high energy doses of light could be attenuated into a non-linear small rise in [Ca2+](i) by the presence of extracellular catalase during illumination. We suggest that the different kinetics of [Ca2+](i) elevation following various light irradiation or H2O2 treatment represents correspondingly different adaptation levels to oxidative stress. The adaptive response of the cells to LEVL represented by the transient increase in [Ca2+](i) can explain LEVL beneficial effects.	Bar Ilan Univ, Dept Chem, IL-52900 Ramat Gan, Israel; Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Inst Biol, Dept Phys Chem, Ness Ziona, Israel; Bar Ilan Univ, Dept Phys, IL-52900 Ramat Gan, Israel	Bar Ilan University; Bar Ilan University; Bar Ilan University	Lavi, R (corresponding author), Bar Ilan Univ, Dept Chem, IL-52900 Ramat Gan, Israel.	laviro@mail.biu.ac.il		Lubart, Rachel/0000-0001-7215-8462				Andrade FH, 1998, J PHYSIOL-LONDON, V509, P565, DOI 10.1111/j.1469-7793.1998.565bn.x; Anzai K, 2000, ANTIOXID REDOX SIGN, V2, P35, DOI 10.1089/ars.2000.2.1-35; BENHUR E, 1993, PHOTOCHEM PHOTOBIOL, V58, P890, DOI 10.1111/j.1751-1097.1993.tb04989.x; BENHUR E, 1991, PHOTOCHEM PHOTOBIOL, V54, P163, DOI 10.1111/j.1751-1097.1991.tb02002.x; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BLANKENSHIP RE, 1992, PHOTOSYNTH RES, V33, P111; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; Cohen N, 1998, PHOTOCHEM PHOTOBIOL, V68, P407, DOI 10.1111/j.1751-1097.1998.tb09700.x; Conlan MJ, 1996, J CLIN PERIODONTOL, V23, P492, DOI 10.1111/j.1600-051X.1996.tb00580.x; CRAWFORD DR, 1994, ENVIRON HEALTH PERSP, V102, P25, DOI 10.2307/3432208; CUNNINGHAM M L, 1985, Journal of Free Radicals in Biology and Medicine, V1, P381, DOI 10.1016/0748-5514(85)90150-3; Das DK, 2001, ANTIOXID REDOX SIGN, V3, P23, DOI 10.1089/152308601750100461; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Duan R, 2001, LASER SURG MED, V29, P174, DOI 10.1002/lsm.1106; Dulhunty A, 2000, ANTIOXID REDOX SIGN, V2, P27, DOI 10.1089/ars.2000.2.1-27; EPSTEIN JH, 1990, NEW ENGL J MED, V322, P1149, DOI 10.1056/NEJM199004193221609; FISHER AMR, 1993, PHOTOCHEM PHOTOBIOL, V58, P581, DOI 10.1111/j.1751-1097.1993.tb04936.x; FITZGERALD M, 1994, EUR J PHARM-MOLEC PH, V268, P275, DOI 10.1016/0922-4106(94)90200-3; Fixler D, 2002, CELL CALCIUM, V31, P279, DOI 10.1016/S0143-4160(02)00056-8; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; FRIEDMANN H, 1991, J PHOTOCH PHOTOBIO B, V11, P87, DOI 10.1016/1011-1344(91)80271-I; Goldman R, 1998, ARCH BIOCHEM BIOPHYS, V350, P10, DOI 10.1006/abbi.1997.0478; Gomez-Lechon MJ, 2002, TOXICOL SCI, V65, P299, DOI 10.1093/toxsci/65.2.299; Grossman N, 1998, LASER SURG MED, V22, P212, DOI 10.1002/(SICI)1096-9101(1998)22:4<212::AID-LSM5>3.0.CO;2-S; Guzzardella GA, 2002, LASER MED SCI, V17, P216, DOI 10.1007/s101030200031; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; KIJIMA Y, 1993, J BIOL CHEM, V268, P3499; Kokoska ER, 1998, AM J PHYSIOL-GASTR L, V275, pG322; Kokoska ER, 2000, J SURG RES, V88, P97, DOI 10.1006/jsre.1999.5740; Kreisler M, 2002, LASER SURG MED, V30, P365, DOI 10.1002/lsm.10060; KRISHNA MC, 1993, FREE RADICAL RES COM, V18, P239, DOI 10.3109/10715769309145873; Krizaj D, 2002, FRONT BIOSCI-LANDMRK, V7, pD2023, DOI 10.2741/krizaj; Lage C, 2000, J PHOTOCH PHOTOBIO B, V54, P155, DOI 10.1016/S1011-1344(00)00010-5; LALORAYA MM, 1994, BIOCHEM MOL BIOL INT, V33, P543; LIVINGSTON FR, 1992, ARCH BIOCHEM BIOPHYS, V299, P83, DOI 10.1016/0003-9861(92)90247-T; Lopez-Ongil S, 1999, FREE RADICAL BIO MED, V26, P501, DOI 10.1016/S0891-5849(98)00223-8; LUBART R, 1997, LASER SURG MED, V21, P1; LUBART R, 2003, IN PRESS LASER THER; Miller TA, 2001, LIFE SCI, V69, P3091, DOI 10.1016/S0024-3205(01)01415-1; Moor ACE, 2000, J PHOTOCH PHOTOBIO B, V57, P1, DOI 10.1016/S1011-1344(00)00065-8; Murrant CL, 2001, MICROSC RES TECHNIQ, V55, P236, DOI 10.1002/jemt.1173; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; Oren DA, 2001, BIOL PSYCHIAT, V49, P464, DOI 10.1016/S0006-3223(00)01106-9; Oron U, 2001, CIRCULATION, V103, P296; PENNING LC, 1993, BIOCHEM J, V292, P237, DOI 10.1042/bj2920237; PENNING LC, 1992, BIOCHIM BIOPHYS ACTA, V1107, P255, DOI 10.1016/0005-2736(92)90412-F; Rothstein EC, 2002, AM J PHYSIOL-HEART C, V283, pH598, DOI 10.1152/ajpheart.00198.2002; Roubaud V, 1997, ANAL BIOCHEM, V247, P404, DOI 10.1006/abio.1997.2067; Safran N, 2001, MOL CELL BIOCHEM, V217, P143, DOI 10.1023/A:1007209321969; Sauer H, 1997, FEBS LETT, V419, P201, DOI 10.1016/S0014-5793(97)01456-7; Sen CK, 2000, CURR TOP CELL REGUL, V36, P1; Shneyvays V, 2000, EXP CELL RES, V257, P111, DOI 10.1006/excr.2000.4882; SPECHT KG, 2000, BIOCHIM BIOPHYS ACTA, V1070, P60; Spikes J D, 1984, Prog Clin Biol Res, V170, P19; Stadler I, 2000, LASER SURG MED, V27, P255, DOI 10.1002/1096-9101(2000)27:3<255::AID-LSM7>3.0.CO;2-L; Suzuki YJ, 1999, J MOL CELL CARDIOL, V31, P345, DOI 10.1006/jmcc.1998.0872; Tarr M, 2001, PHOTOCHEM PHOTOBIOL, V73, P418, DOI 10.1562/0031-8655(2001)073<0418:PICOIC>2.0.CO;2; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Wang H, 2000, FREE RADICAL BIO MED, V28, P1222, DOI 10.1016/S0891-5849(00)00241-0; Wang SQ, 2001, NATURE, V410, P592, DOI 10.1038/35069083; Wartenberg M, 1997, AM J PHYSIOL-REG I, V272, pR1677, DOI 10.1152/ajpregu.1997.272.5.R1677; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; Yaakov N, 2000, BASIC RES CARDIOL, V95, P385, DOI 10.1007/s003950070037; Yamaoka K, 2000, PFLUG ARCH EUR J PHY, V440, P207, DOI 10.1007/s004249900242; YONUSCHOT G, 1992, J MOL CELL CARDIOL, V24, P1079, DOI 10.1016/0022-2828(92)93173-H; YU W, 1995, FASEB J, V9, pA239; Zhu QY, 1997, LASER SURG MED, V20, P332, DOI 10.1002/(SICI)1096-9101(1997)20:3<332::AID-LSM12>3.0.CO;2-F; Zucchi R, 2001, PHARMACOL THERAPEUT, V89, P47, DOI 10.1016/S0163-7258(00)00103-0	69	144	160	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40917	40922		10.1074/jbc.M303034200	http://dx.doi.org/10.1074/jbc.M303034200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12851407	hybrid			2022-12-25	WOS:000185847200063
J	Grangeasse, C; Obadia, B; Mijakovic, I; Deutscher, J; Cozzone, AJ; Doublet, P				Grangeasse, C; Obadia, B; Mijakovic, I; Deutscher, J; Cozzone, AJ; Doublet, P			Autophosphorylation of the Escherichia coli protein kinase wzc regulates tyrosine phosphorylation of Ugd, a UDP-glucose dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULAR POLYSACCHARIDE SYNTHESIS; STREPTOCOCCUS-PNEUMONIAE; MOLECULAR CHARACTERIZATION; ACINETOBACTER-JOHNSONII; SINORHIZOBIUM-MELILOTI; PHOSPHATASES PRPA; ACID SYNTHESIS; COLANIC ACID; GENE; CELLS	Autophosphorylation of protein-tyrosine kinases (PTKs) involved in exopolysaccharide and capsular polysaccharide biosynthesis and transport has been observed in a number of Gram-negative and Gram-positive bacteria. However, besides their own phosphorylation, little is known about other substrates targeted by these protein-modifying enzymes. Here, we present evidence that the protein-tyrosine kinase Wzc of Escherichia coli is able to phosphorylate an endogenous enzyme, UDPglucose dehydrogenase (Ugd), which participates in the synthesis of the exopolysaccharide colanic acid. The process of phosphorylation of Ugd by Wzc was shown to be stimulated by previous autophosphorylation of Wzc on tyrosine 569. The phosphorylation of Ugd was demonstrated to actually occur on tyrosine and result in a significant increase of its dehydrogenase activity. In addition, the phosphotyrosine-protein phosphatase Wzb, which is known to effectively dephosphorylate Wzc, exhibited only a low effect, if any, on the dephosphorylation of Ugd. These data were related to the recent observation that two other UDP-glucose dehydrogenases have been also shown to be phosphorylated by a PTK in the Gram-positive bacterium Bacillus subtilis. Comparative analysis of the activities of PTKs from Gram-negative and Gram-positive bacteria showed that they are regulated by different mechanisms that involve, respectively, either the autophosphorylation of kinases or their interaction with a membrane protein activator.	Univ Lyon, CNRS, Inst Biol & Chim Prot, F-69367 Lyon 07, France; Inst Natl Agron Paris Grignon, Inst Natl Rech Agron, CNRS, F-78850 Thiverval Grignon, France	Centre National de la Recherche Scientifique (CNRS); AgroParisTech; Centre National de la Recherche Scientifique (CNRS); INRAE	Grangeasse, C (corresponding author), Univ Lyon, CNRS, Inst Biol & Chim Prot, 7 Passage Vercors, F-69367 Lyon 07, France.	c.grangeasse@ibcp.fr	Doublet, Patricia/L-9480-2014; Mijakovic, Ivan/Q-5583-2016	Doublet, Patricia/0000-0001-5848-4317; Mijakovic, Ivan/0000-0002-8860-6853; Grangeasse, Christophe/0000-0002-5484-4589				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARRECUBIETA C, 1994, J BACTERIOL, V176, P6375, DOI 10.1128/jb.176.20.6375-6383.1994; Bender MH, 2001, J BIOL CHEM, V276, P47966, DOI 10.1074/jbc.M105448200; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; Breazeale SD, 2002, J BIOL CHEM, V277, P2886, DOI 10.1074/jbc.M109377200; BREAZEALE SD, 2003, J BIOL CHEM; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Chang KW, 2001, BIOCHEM BIOPH RES CO, V287, P550, DOI 10.1006/bbrc.2001.5591; CORTAY JC, 1991, METHOD ENZYMOL, V200, P214; DADSSI M, 1990, J BIOL CHEM, V265, P20996; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; Doublet P, 2002, J BIOL CHEM, V277, P37339, DOI 10.1074/jbc.M204465200; Doublet P, 1999, FEBS LETT, V445, P137, DOI 10.1016/S0014-5793(99)00111-8; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Ebel W, 1999, J BACTERIOL, V181, P577, DOI 10.1128/JB.181.2.577-584.1999; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Grangeasse C, 2002, J BIOL CHEM, V277, P7127, DOI 10.1074/jbc.M110880200; Grangeasse C, 1997, GENE, V204, P259, DOI 10.1016/S0378-1119(97)00554-4; Grangeasse C, 1998, J MOL BIOL, V278, P339, DOI 10.1006/jmbi.1998.1650; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ilan O, 1999, EMBO J, V18, P3241, DOI 10.1093/emboj/18.12.3241; Kennelly P.J., 1999, FRONT BIOSCI, V4, pD372, DOI [10.2741/kennelly, DOI 10.2741/KENNELLY]; Kereszt A, 1998, J BACTERIOL, V180, P5426, DOI 10.1128/JB.180.20.5426-5431.1998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y, 1996, J BACTERIOL, V178, P136, DOI 10.1128/jb.178.1.136-142.1996; MIJAKOVIC L, 2003, IN PRESS EMBO J; Missiakas D, 1997, EMBO J, V16, P1670, DOI 10.1093/emboj/16.7.1670; Morona JK, 2000, MOL MICROBIOL, V35, P1431, DOI 10.1046/j.1365-2958.2000.01808.x; Morona JK, 2003, J BACTERIOL, V185, P3009, DOI 10.1128/JB.185.10.3009-3019.2003; Morona JK, 2002, J BACTERIOL, V184, P577, DOI 10.1128/JB.184.2.577-583.2002; Mouslim C, 2003, MOL MICROBIOL, V47, P335, DOI 10.1046/j.1365-2958.2003.03318.x; Nakar D, 2003, J BACTERIOL, V185, P1001, DOI 10.1128/JB.185.3.1001-1009.2003; Naught LE, 2002, BIOCHEMISTRY-US, V41, P9637, DOI 10.1021/bi025862m; Niemeyer D, 2001, J BACTERIOL, V183, P5163, DOI 10.1128/JB.183.17.5163-5170.2001; Nunez C, 1999, J BACTERIOL, V181, P141; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Pagni M, 1999, MICROBIOL-UK, V145, P1049, DOI 10.1099/13500872-145-5-1049; Paiment A, 2002, J BACTERIOL, V184, P6437, DOI 10.1128/JB.184.23.6437-6447.2002; Pawson T, 2002, EUR J CANCER, V38, pS3, DOI 10.1016/S0959-8049(02)80597-4; POTTS M, 1993, J BIOL CHEM, V268, P7632; Preneta R, 2002, COMP BIOCHEM PHYS B, V131, P103, DOI 10.1016/S1096-4959(01)00490-0; Shi L, 2001, J BACTERIOL, V183, P7053, DOI 10.1128/JB.183.24.7053-7057.2001; Soulat D, 2002, J BACTERIOL, V184, P5194, DOI 10.1128/JB.184.18.5194-5199.2002; Stevenson G, 1996, J BACTERIOL, V178, P4885, DOI 10.1128/jb.178.16.4885-4893.1996; STOUT V, 1991, J BACTERIOL, V173, P1738, DOI 10.1128/jb.173.5.1738-1747.1991; STOUT V, 1990, J BACTERIOL, V172, P659, DOI 10.1128/jb.172.2.659-669.1990; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Vincent C, 1999, J BACTERIOL, V181, P3472, DOI 10.1128/JB.181.11.3472-3477.1999; Vincent C, 2000, J MOL BIOL, V304, P311, DOI 10.1006/jmbi.2000.4217; Wugeditsch T, 2001, J BIOL CHEM, V276, P2361, DOI 10.1074/jbc.M009092200	53	106	110	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39323	39329		10.1074/jbc.M305134200	http://dx.doi.org/10.1074/jbc.M305134200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12851388	hybrid			2022-12-25	WOS:000185713800009
J	Lu, YL; Yu, QH; Liu, JH; Zhang, JY; Wang, HW; Koul, D; McMurray, JS; Fang, XJ; Yung, WKA; Siminovitch, KA; Mills, GB				Lu, YL; Yu, QH; Liu, JH; Zhang, JY; Wang, HW; Koul, D; McMurray, JS; Fang, XJ; Yung, WKA; Siminovitch, KA; Mills, GB			Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID PHOSPHATASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR PTEN; BREAST-CANCER; MAMMARY-TUMORS; ENDOMETRIAL CARCINOMA; PHOSPHORYLATION SITES; GLIOMA-CELLS; CYCLIN D1; ACTIVATION	Src family protein-tyrosine kinases, which play an important role in signal integration, have been implicated in tumorigenesis in multiple lineages, including breast cancer. We demonstrate, herein, that Src kinases regulate the phosphatidylinositol 3-kinase (PI3K) signaling cascade via altering the function of the PTEN tumor suppressor. Overexpression of activated Src protein-tyrosine kinases in PTEN-deficient breast cancer cells does not alter AKT phosphorylation, an indicator of signal transduction through the PI3K pathway. However, in the presence of functional PTEN, Src reverses the activity of PTEN, resulting in an increase in AKT phosphorylation. Activated Src reduces the ability of PTEN to dephosphorylate phosphatidylinositols in micelles and promotes AKT translocation to cellular plasma membranes but does not alter PTEN activity toward water-soluble phosphatidylinositols. Thus, Src may alter the capacity of the PTEN C2 domain to bind cellular membranes rather than directly interfering with PTEN enzymatic activity. Tyrosine phosphorylation of PTEN is increased in breast cancer cells treated with pervanadate, suggesting that PTEN contains sites for tyrosine phosphorylation. Src kinase inhibitors markedly decreased pervanadate-mediated tyrosine phosphorylation of PTEN. Further, expression of activated Src results in marked tyrosine phosphorylation of PTEN. SHP-1, a SH2 domain-containing protein-tyrosine phosphatase, selectively binds and dephosphorylates PTEN in Src transfected cells. Both Src inhibitors and SHP-1 overexpression reverse Src-induced loss of PTEN function. Coexpression of PTEN with activated Src reduces the stability of PTEN. Taken together, the data indicate that activated Src inhibits PTEN function leading to alterations in signaling through the PI3K/AKT pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Div Canc Med, Houston, TX 77030 USA; Univ Toronto, Mt Sinai Res Inst, Dept Med & Immunol, Toronto, ON M5G 1X5, Canada; Univ Texas, MD Anderson Canc Ctr, Div Canc Med, Dept Neurooncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Texas System; UTMD Anderson Cancer Center	Mills, GB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Div Canc Med, Box 317,1515 Holcombe Blvd, Houston, TX 77030 USA.	Gmills@mdanderson.org	Siminovitch, Katherine/K-1475-2013		NCI NIH HHS [P50CA83639, R01 CA82716, 5-P30 CA 16672, P01CA099031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA083639, P30CA016672, P01CA099031, R01CA082716] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adey NB, 2000, CANCER RES, V60, P35; Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Bastola DR, 2002, MOL CELL BIOCHEM, V236, P75, DOI 10.1023/A:1016191913274; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Caffrey JJ, 2001, FEBS LETT, V499, P6, DOI 10.1016/S0014-5793(01)02500-5; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Davies MA, 1998, CANCER RES, V58, P5285; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Furnari FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 2000, CANCER RES, V60, P7033; Gottschalk AR, 2001, CANCER RES, V61, P2105; Grillo S, 2000, EUR J BIOCHEM, V267, P6642, DOI 10.1046/j.1432-1327.2000.01759.x; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Hynes NE, 2000, BREAST CANCER RES, V2, P154, DOI 10.1186/bcr48; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Koul D, 2002, ONCOGENE, V21, P2357, DOI 10.1038/sj/onc/1205296; Kurose K, 2001, AM J PATHOL, V158, P2097, DOI 10.1016/S0002-9440(10)64681-0; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Prenzel N, 2000, BREAST CANCER RES, V2, P184, DOI 10.1186/bcr52; Ptasznik Andrzej, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P27; Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S; Siminovitch KA, 1999, CURR TOP MICROBIOL, V246, P291; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Sugimura M, 2000, JPN J CANCER RES, V91, P395, DOI 10.1111/j.1349-7006.2000.tb00958.x; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Wiener JR, 2003, GYNECOL ONCOL, V88, P73, DOI 10.1006/gyno.2002.6851; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	57	200	211	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40057	40066		10.1074/jbc.M303621200	http://dx.doi.org/10.1074/jbc.M303621200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869565	hybrid			2022-12-25	WOS:000185713800096
J	Mogi, M; Yang, J; Lambert, JF; Colvin, GA; Shiojima, I; Skurk, C; Summer, R; Fine, A; Quesenberry, PJ; Walsh, K				Mogi, M; Yang, J; Lambert, JF; Colvin, GA; Shiojima, I; Skurk, C; Summer, R; Fine, A; Quesenberry, PJ; Walsh, K			Akt signaling regulates side population cell phenotype via Bcrp1 translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC STEM-CELLS; ENDOTHELIAL PROGENITOR CELLS; COLONY-FORMING CELLS; KINASE B-GAMMA; PROTEIN-KINASE; SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; P-GLYCOPROTEIN; GROWTH-FACTOR	Akt is an important regulator of cell survival, growth, and glucose metabolism in many cell types, but the role of this signaling molecule in hematopoietic stem cells is poorly defined. Side population (SP) cells are enriched for hematopoietic stem cell activity and are defined by their ability to efficiently efflux Hoechst 33342. Bone marrow from Akt1-null mice exhibited a reduced SP fraction. However, bone marrow cellularity, growth factor-responsive progenitor cultures, and engraftable stem cells were normal in these mice. Treatment of bone marrow with LY294002, an inhibitor of the Akt effector protein phosphatidylinositol 3-kinase, led to a reversible loss of the SP fraction. Bcrp1, which encodes the Hoechst dye transporter, was translocated from the membrane to the intracellular compartment under conditions that promote the SP-depleted state. Lentivirus-mediated overexpression of Akt1 in bone marrow markedly increased the SP fraction, whereas there was no effect on bone marrow from Bcrp(-/-) mice. These data suggest that Akt signaling modulates the SP cell phenotype by regulating the expression of Bcrp1.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Roger Williams Med Ctr, Ctr Stem Cell Biol, Providence, RI 02908 USA; Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA	Boston University; Roger Williams Medical Center; Boston University	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.			Fine, Alan/0000-0001-9351-3048	DIVISION OF HEART AND VASCULAR DISEASES [N01HV028178] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060090, R13DK064378, P01DK050222, R01DK027424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017241, R01AG015052, R37AG015052] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02-017, N01-HV-28178, P01 HL56920-03] Funding Source: Medline; NIAMS NIH HHS [AR40197] Funding Source: Medline; NIA NIH HHS [AG17241, AG15052] Funding Source: Medline; NICHD NIH HHS [HD23681] Funding Source: Medline; NIDDK NIH HHS [R13 DK064378-01, R01 DK60090-01A1, R01 DK60084, R01 DK27424-18, P01 DK50222-03] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altomare DA, 1996, CYTOGENET CELL GENET, V74, P248, DOI 10.1159/000134426; Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; BELLACOSA A, 1993, ONCOGENE, V8, P745; BERTONCELLO I, 1992, CURR TOP MICROBIOL, V177, P83; Bertoncello I, 1997, Methods Mol Biol, V75, P265; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Chen Y, 2000, ONCOGENE, V19, P3750, DOI 10.1038/sj.onc.1203726; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Coffer PJ, 1998, BIOCHEM J, V335, P1; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI200113152; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Geddis AE, 2002, CYTOKINE GROWTH F R, V13, P61, DOI 10.1016/S1359-6101(01)00030-2; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hekimi S, 2001, TRENDS GENET, V17, P712, DOI 10.1016/S0168-9525(01)02523-9; Hulspas R, 2000, CYTOMETRY, V40, P245, DOI 10.1002/1097-0320(20000701)40:3<245::AID-CYTO10>3.3.CO;2-X; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kim M, 2002, CLIN CANCER RES, V8, P22; KRIEGLER M, 1991, GENE TRANSFER EXPRES, P47; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI200113131; LOWRY PA, 1991, EXP HEMATOL, V19, P994; Majka SM, 2003, J CLIN INVEST, V111, P71, DOI 10.1172/JCI200316157; MCNIECE IK, 1990, INT J CELL CLONING, V8, P146, DOI 10.1002/stem.5530080302; Misra S, 1999, P NATL ACAD SCI USA, V96, P5814, DOI 10.1073/pnas.96.10.5814; Murthy SS, 2000, CYTOGENET CELL GENET, V88, P38, DOI 10.1159/000015481; Myklebust JH, 2002, EXP HEMATOL, V30, P990, DOI 10.1016/S0301-472X(02)00868-8; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Scheffer GL, 2000, CANCER RES, V60, P2589; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; SORRENTINO BP, 1995, BLOOD, V86, P491, DOI 10.1182/blood.V86.2.491.bloodjournal862491; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Storms RW, 2000, BLOOD, V96, P2125; Summer R, 2003, AM J PHYSIOL-LUNG C, V285, pL97, DOI 10.1152/ajplung.00009.2003; Uchida N, 2002, EXP HEMATOL, V30, P862, DOI 10.1016/S0301-472X(02)00879-2; Vanfleteren JR, 1999, NEUROBIOL AGING, V20, P487, DOI 10.1016/S0197-4580(99)00087-1; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	56	136	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39068	39075		10.1074/jbc.M306362200	http://dx.doi.org/10.1074/jbc.M306362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12851395	hybrid			2022-12-25	WOS:000185575100120
J	Wingens, M; Walma, T; van Ingen, H; Stortelers, C; van Leeuwen, JEM; van Zoelen, EJJ; Vuister, GW				Wingens, M; Walma, T; van Ingen, H; Stortelers, C; van Leeuwen, JEM; van Zoelen, EJJ; Vuister, GW			Structural analysis of an epidermal growth factor/transforming growth factor-alpha chimera with unique ErbB binding specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; RESOLUTION SOLUTION STRUCTURE; MODEL-FREE APPROACH; EGF-LIKE DOMAIN; PROTEIN STRUCTURES; BACKBONE DYNAMICS; CRYSTAL-STRUCTURE; FACTOR RECEPTOR; ERBB-2/ERBB-3 HETERODIMERS; EXTRACELLULAR DOMAIN	Various chimeras of the ErbB1-specific ligands epidermal growth factor (EGF) and transforming growth factor-alpha (TGFalpha) display an enlarged repertoire as activators of ErbB2.ErbB3 heterodimers. Mutational analysis indicated that particularly residues in the N terminus and B-loop region of these ligands are involved in the broadened receptor specificity. In order to understand the receptor specificity of T1E, a chimeric ligand constructed by the introduction of the linear N-terminal region of TGFalpha into EGF, we determined in this study the solution structure and dynamics of T1E by multidimensional NMR analysis. Subsequently, we studied the structural characteristics of T1E binding to both ErbB1 and ErbB3 by superposition modeling of its structure on the known crystal structures of ErbB3 and liganded ErbB1 complexes. The results show that the overall structure of T1E in solution is very similar to that of native EGF and TGFalpha but that its N terminus shows an extended structure that is appropriately positioned to form a triple beta-sheet with the large antiparallel beta-sheet in the B-loop region. This conformational effect of the N terminus together with the large overall flexibility of T1E, as determined by N-15 NMR relaxation analysis, may be a facilitative property for its broad receptor specificity. The structural superposition models indicate that hydrophobic and electrostatic interactions of the N terminus and B-loop of T1E are particularly important for its binding to ErbB3.	Univ Nijmegen, Dept Cell Biol, NL-6525 ED Nijmegen, Netherlands; Univ Nijmegen, Dept Biophys Chem, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Wingens, M (corresponding author), Univ Nijmegen, Dept Cell Biol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.		van Ingen, Hugo/Q-2883-2016; van Zoelen, Everardus J./D-9192-2012; van Leeuwen, Jeroen/G-3555-2010	van Ingen, Hugo/0000-0002-0808-3811; Vuister, Geerten/0000-0001-6172-5097				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0; Ballinger MD, 1998, J BIOL CHEM, V273, P11675, DOI 10.1074/jbc.273.19.11675; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BRUNGER AT, 1996, XPLOR VERSION 3 851; CAMPION SR, 1994, PROG NUCLEIC ACID RE, V49, P353; Carr PA, 1997, STRUCTURE, V5, P949, DOI 10.1016/S0969-2126(97)00248-7; CELDA B, 1995, J BIOMOL NMR, V5, P161; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fairbrother WJ, 1998, J MOL BIOL, V279, P1149, DOI 10.1006/jmbi.1998.1837; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; HARVEY TS, 1991, EUR J BIOCHEM, V198, P555, DOI 10.1111/j.1432-1033.1991.tb16050.x; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; IKURA T, 1993, PROTEINS, V16, P423, DOI 10.1002/prot.340160410; Jacobsen NE, 1996, BIOCHEMISTRY-US, V35, P3402, DOI 10.1021/bi952626l; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOHDA D, 1993, J BIOL CHEM, V268, P1976; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LI YC, 1995, BIOCHEMISTRY-US, V34, P2408, DOI 10.1021/bi00008a003; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Lu HS, 2001, J BIOL CHEM, V276, P34913, DOI 10.1074/jbc.M102874200; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Miura K, 2002, BIOCHEM BIOPH RES CO, V294, P1040, DOI 10.1016/S0006-291X(02)00585-5; MOY FJ, 1993, BIOCHEMISTRY-US, V32, P7334, DOI 10.1021/bi00080a003; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Schmidt M, 2002, INT J CANCER, V97, P349, DOI 10.1002/ijc.1618; Singer E, 2001, J BIOL CHEM, V276, P44266, DOI 10.1074/jbc.M105428200; Spronk CAEM, 2002, J BIOMOL NMR, V22, P281, DOI 10.1023/A:1014971029663; Stortelers C, 2003, J BIOL CHEM, V278, P12055, DOI 10.1074/jbc.M211948200; Stortelers C, 2002, BIOCHEMISTRY-US, V41, P8732, DOI 10.1021/bi025878c; Stortelers C, 2002, BIOCHEMISTRY-US, V41, P4292, DOI 10.1021/bi012016n; Tejero R, 1996, PROTEIN SCI, V5, P578; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Van Zoelen E J, 2000, Vitam Horm, V59, P99, DOI 10.1016/S0083-6729(00)59005-0; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; WOLFENDEN R, 1981, BIOCHEMISTRY-US, V20, P849, DOI 10.1021/bi00507a030; Wuthrich K, 1986, NMR PROTEINS NUCL AC	53	14	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39114	39123		10.1074/jbc.M305603200	http://dx.doi.org/10.1074/jbc.M305603200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12869572	hybrid			2022-12-25	WOS:000185575100125
J	Gee, K; Kozlowski, M; Kumar, A				Gee, K; Kozlowski, M; Kumar, A			Tumor necrosis factor-alpha induces functionally active hyaluronan-adhesive CD44 by activating sialidase through p38 mitogen-activated protein kinase in lipopolysaccharide-stimulated human monocytic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; PERIPHERAL-BLOOD MONOCYTES; TNF-ALPHA; CUTTING EDGE; KAPPA-B; SIGNALING MECHANISMS; LYSOSOMAL SIALIDASE; MOLECULAR-CLONING; CELL-ADHESION; EXPRESSION	Interaction of CD44, an adhesion molecule, with its ligand, hyaluronan ( HA), in monocytic cells plays a critical role in cell migration, inflammation, and immune responses. Most cell types express CD44 but do not bind HA. The biological functions of CD44 have been attributed to the generation of the functionally active, HA-adhesive form of this molecule. Although lipopolysaccharide (LPS) and cytokines induce HA-adhesive CD44, the molecular mechanism underlying this process remains unknown. In this study, we show that LPS-induced CD44-mediated HA (CD44-HA) binding in monocytes is regulated by endogenously produced tumor necrosis factor (TNF)- alpha and IL-10. Furthermore, p38 mitogen-activated protein kinase ( MAPK) activation was required for LPS- and TNF-alpha-induced, but not IL-10-induced, CD44-HA-binding in normal monocytes. To dissect the signaling pathways regulating CD44-HA binding independently of cross-regulatory IL-10-mediated effects, IL-10-refractory promonocytic THP-1 cells were employed. LPS- induced CD44-HA binding in THP-1 cells was regulated by endogenously produced TNF-alpha. Our results also suggest that lysosomal sialidase activation may be required for the acquisition of the HA-binding form of CD44 in LPS- and TNF-alpha-stimulated monocytic cells. Studies conducted to understand the role of MAPKs in the induction of sialidase activity revealed that LPS- induced sialidase activity was dependent on p42/44 MAPK-mediated TNF-alpha production. Blocking TNF-alpha production by PD98059, a p42/44 inhibitor, significantly reduced the LPS- induced sialidase activity and CD44-HA binding. Subsequently, TNF-alpha-mediated p38 MAPK activation induced sialidase activity and CD44-HA binding. Taken together, our results suggest that TNF-alpha-induced p38 MAPK activation may regulate the induction of functionally active HA-binding form of CD44 by activating sialidase in LPS- stimulated human monocytic cells.	Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1N 6N5, Canada; Childrens Hosp Eastern Ontario, Res Inst, Div Virol & Mol Immunol, Ottawa, ON K1H 8L1, Canada; Hlth Canada, Biol & Genet Therapies Directorate, Biol Res Ctr, Ottawa, ON K1A 0L2, Canada	University of Ottawa; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario; Health Canada	Kumar, A (corresponding author), Univ Ottawa, Childrens Hosp Eastern Ontario, Res Inst, Div Virol, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.		Gee, Katrina/H-3093-2016	Gee, Katrina/0000-0002-7535-2882				Achyuthan KE, 2001, COMP BIOCHEM PHYS B, V129, P29, DOI 10.1016/S1096-4959(01)00372-4; AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bonten EJ, 2000, J BIOL CHEM, V275, P37657, DOI 10.1074/jbc.M007380200; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; Brown KL, 2001, J IMMUNOL, V167, P5367, DOI 10.4049/jimmunol.167.9.5367; Daftarian PM, 1996, J IMMUNOL, V157, P12; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DE WMR, 1991, J EXP MED, V174, P1209; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fichter M, 1997, ONCOGENE, V14, P2817, DOI 10.1038/sj.onc.1201127; Fujii K, 2001, J IMMUNOL, V167, P1198, DOI 10.4049/jimmunol.167.3.1198; Gee K, 2002, J IMMUNOL, V169, P5660, DOI 10.4049/jimmunol.169.10.5660; Gee K, 2001, CELL IMMUNOL, V211, P131, DOI 10.1006/cimm.2001.1829; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; Hatzoglou A, 2000, J IMMUNOL, V165, P1322, DOI 10.4049/jimmunol.165.3.1322; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; Katoh S, 1999, J IMMUNOL, V162, P5058; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; Kryworuchko M, 1999, EXP CELL RES, V250, P241, DOI 10.1006/excr.1999.4524; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lesley J, 2000, J BIOL CHEM, V275, P26967; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; Levesque MC, 1996, J IMMUNOL, V156, P1557; Levesque MC, 1997, J IMMUNOL, V159, P6184; Levesque MC, 1999, CELL IMMUNOL, V193, P209, DOI 10.1006/cimm.1999.1456; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIU D, 1998, FRONT BIOSCI, V3, P631; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; Maiti A, 1998, SCIENCE, V282, P941, DOI 10.1126/science.282.5390.941; Mancuso G, 2002, J IMMUNOL, V169, P1401, DOI 10.4049/jimmunol.169.3.1401; MIYAGI T, 1985, J BIOL CHEM, V260, P6710; Miyagi T, 1999, J BIOL CHEM, V274, P5004, DOI 10.1074/jbc.274.8.5004; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; Nandi A, 2000, J BIOL CHEM, V275, P14939, DOI 10.1074/jbc.275.20.14939; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; NOTTENBURG C, 1989, P NATL ACAD SCI USA, V86, P8521, DOI 10.1073/pnas.86.21.8521; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; O'Farrell AM, 2000, J IMMUNOL, V164, P4607, DOI 10.4049/jimmunol.164.9.4607; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; Sawada M, 2002, INT J CANCER, V97, P180, DOI 10.1002/ijc.1598; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shi L, 2002, AM J PHYSIOL-CELL PH, V282, pC1205, DOI 10.1152/ajpcell.00511.2001; Siegelman MH, 1999, J LEUKOCYTE BIOL, V66, P315, DOI 10.1002/jlb.66.2.315; Sionov RV, 1998, CELL ADHES COMMUN, V6, P503, DOI 10.3109/15419069809010798; Stoop R, 2001, ARTHRITIS RHEUM, V44, P2922, DOI 10.1002/1529-0131(200112)44:12<2922::AID-ART480>3.0.CO;2-7; Takahashi K, 1996, J BIOL CHEM, V271, P9490, DOI 10.1074/jbc.271.16.9490; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Verhasselt V, 1997, J IMMUNOL, V158, P2919; Vinogradova MV, 1998, BIOCHEM J, V330, P641; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; Wittig B, 1998, J IMMUNOL, V161, P1069	65	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37275	37287		10.1074/jbc.M302309200	http://dx.doi.org/10.1074/jbc.M302309200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867430	hybrid			2022-12-25	WOS:000185437200036
J	Krem, MM; Di Cera, E				Krem, MM; Di Cera, E			Conserved ser residues, the shutter region, and speciation in serpin evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CODON USAGE; CONFORMATIONS; SUPERFAMILY; PROTEINASE; PROTEASES; SHEET; LOOP	The suicide inhibitory mechanism of serine protease inhibitors of the serpin superfamily depends heavily on their structural flexibility, which is controlled in large part by the breach and shutter regions of the central Abeta-sheet. We examined codon usage by the highly conserved residues, Ser-53 and Ser-56, of the shutter region and found a TCN-AGY usage dichotomy for Ser-56 that remarkably is linked to the protostome-deuterostome split. Our results suggest that serpin evolution was driven by phylogenetic speciation and not pressure to fulfill new physiologic functions mitigating against co-evolution with the family of serine proteases they inhibit.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.				NHLBI NIH HHS [HL49413, HL58141, HL73813] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL073813, R01HL058141, R01HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atchley WR, 2001, MOL BIOL EVOL, V18, P1502, DOI 10.1093/oxfordjournals.molbev.a003936; Brown JR, 2001, SYST BIOL, V50, P497, DOI 10.1080/10635150117729; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; DIAZLAZCOZ Y, 1995, J MOL BIOL, V250, P123, DOI 10.1006/jmbi.1995.0363; FELSENSTEIN J, 1999, PHYLIP PHYLOGENY INF; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Krem MM, 2001, EMBO J, V20, P3036, DOI 10.1093/emboj/20.12.3036; Krem MM, 1999, J BIOL CHEM, V274, P28063, DOI 10.1074/jbc.274.40.28063; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; Nakamura Y, 2000, NUCLEIC ACIDS RES, V28, P292, DOI 10.1093/nar/28.1.292; Olsen GJ, 1997, CELL, V89, P991, DOI 10.1016/S0092-8674(00)80284-6; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Rose T, 2002, J BIOL CHEM, V277, P19243, DOI 10.1074/jbc.C200132200; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trifonov EN, 2001, J MOL EVOL, V53, P394, DOI 10.1007/s002390010229; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; Whisstock JC, 2000, J MOL BIOL, V296, P685, DOI 10.1006/jmbi.1999.3520	21	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37810	37814		10.1074/jbc.M305088200	http://dx.doi.org/10.1074/jbc.M305088200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12847097	hybrid			2022-12-25	WOS:000185437200100
J	Takezawa, D				Takezawa, D			Characterization of a novel plant PP2C-like protein Ser/Thr phosphatase as a calmodulin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; GUARD-CELLS; ARABIDOPSIS-THALIANA; MUTATIONAL ANALYSIS; NEGATIVE REGULATOR; CALCIUM REGULATION; FISSION YEAST; 2C; KINASE; EXPRESSION	Protein phosphatases regulated by calmodulin (CaM) mediate the action of intracellular Ca2+ and modulate functions of various target proteins by dephosphorylation. In plants, however, the role of Ca2+ in the regulation of protein dephosphorylation is not well understood due to a lack of information on characteristics of CaM-regulated protein phosphatases. Screening of a cDNA library of the moss Physcomitrella patens by using S-35-labeled calmodulin as a ligand resulted in identification of a gene, PCaMPP, that encodes a protein serine/ threonine phosphatase with 373 amino acids. PCaMPP had a catalytic domain with sequence similarity to type 2C protein phosphatases (PP2Cs) with six conserved metal-associating amino acid residues and also had an extra C-terminal domain. Recombinant GST fusion proteins of PCaMPP exhibited Mn2+-dependent phosphatase activity, and the activity was inhibited by pyrophosphate and 1 mM Ca2+ but not by okadaic acid, orthovanadate, or beta-glycerophosphate. Furthermore, the PCaMPP activity was increased 1.7-fold by addition of CaM at nanomolar concentrations. CaM binding assays using deletion proteins and a synthetic peptide revealed that the CaM-binding region resides within the basic amphiphilic amino acid region 324 - 346 in the C-terminal domain. The CaM-binding region had sequence similarity to amino acids in one of three alpha-helices in the C-terminal domain of human PP2Calpha, suggesting a novel role of the C-terminal domains for the phosphatase activity. These results provide the first evidence showing possible regulation of PP2C-related phosphatases by Ca2+/CaM in plants. Genes similar to PCaMPP were found in genomes of various higher plant species, suggesting that PCaMPP-type protein phosphatases are conserved in land plants.	Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan	Hokkaido University	Takezawa, D (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan.	daisuket@pop.lowtem.hokudai.ac.jp	大輔, 竹澤/H-9175-2012					ALLEN GJ, 1995, PLANT CELL, V7, P1473; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; Gaits F, 1997, J BIOL CHEM, V272, P17873, DOI 10.1074/jbc.272.28.17873; Gosti F, 1999, PLANT CELL, V11, P1897, DOI 10.1105/tpc.11.10.1897; Hanada M, 2001, J BIOL CHEM, V276, P5753, DOI 10.1074/jbc.M007773200; Himmelbach A, 2002, EMBO J, V21, P3029, DOI 10.1093/emboj/cdf316; Kapranov P, 1999, P NATL ACAD SCI USA, V96, P1738, DOI 10.1073/pnas.96.4.1738; Kerk D, 2002, PLANT PHYSIOL, V129, P908, DOI 10.1104/pp.004002; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; Kinoshita T, 1999, PLANT CELL PHYSIOL, V40, P53, DOI 10.1093/oxfordjournals.pcp.a029474; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KLUMPP S, 1994, J BIOL CHEM, V269, P32774; KNIGHT MR, 1992, P NATL ACAD SCI USA, V89, P4967, DOI 10.1073/pnas.89.11.4967; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; Kobayashi T, 1998, FEBS LETT, V430, P222, DOI 10.1016/S0014-5793(98)00604-8; Kusuda K, 1998, BIOCHEM J, V332, P243, DOI 10.1042/bj3320243; LAWSON JE, 1993, BIOCHEMISTRY-US, V32, P8987, DOI 10.1021/bi00086a002; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; Li JX, 1998, PLANT PHYSIOL, V116, P785, DOI 10.1104/pp.116.2.785; MERAT DL, 1985, J BIOL CHEM, V260, P1053; Merlot S, 2001, PLANT J, V25, P295, DOI 10.1046/j.1365-313x.2001.00965.x; Meskiene I, 1998, P NATL ACAD SCI USA, V95, P1938, DOI 10.1073/pnas.95.4.1938; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; Minami A, 2003, J PLANT PHYSIOL, V160, P475, DOI 10.1078/0176-1617-00888; Miyazaki S, 1999, MOL GEN GENET, V261, P307, DOI 10.1007/s004380050971; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Pardo JM, 1998, P NATL ACAD SCI USA, V95, P9681, DOI 10.1073/pnas.95.16.9681; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; Poovaiah BW, 1996, J PLANT PHYSIOL, V149, P553, DOI 10.1016/S0176-1617(96)80333-6; REDDY ASN, 1993, PLANT SCI, V94, P109, DOI 10.1016/0168-9452(93)90012-O; Sheen J, 1998, P NATL ACAD SCI USA, V95, P975, DOI 10.1073/pnas.95.3.975; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; Snedden WA, 2001, NEW PHYTOL, V151, P35, DOI 10.1046/j.1469-8137.2001.00154.x; Tahtiharju S, 2001, PLANT J, V26, P461, DOI 10.1046/j.1365-313X.2001.01048.x; TAKEZAWA D, 1995, PLANT MOL BIOL, V27, P693, DOI 10.1007/BF00020223; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; Tan KML, 2001, J BIOL CHEM, V276, P44193, DOI 10.1074/jbc.M105880200; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	46	19	22	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38076	38083		10.1074/jbc.M301369200	http://dx.doi.org/10.1074/jbc.M301369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12860996	hybrid			2022-12-25	WOS:000185437200129
J	Bori-Sanz, T; Inoue, KS; Berndt, MC; Watson, SP; Tulasne, D				Bori-Sanz, T; Inoue, KS; Berndt, MC; Watson, SP; Tulasne, D			Delineation of the region in the glycoprotein VI tail required for association with the Fc receptor gamma-chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN RECEPTOR; TYROSINE PHOSPHORYLATION; FUNCTIONAL ASSOCIATION; ACTIVATION; EXPRESSION; PLATELETS; CONVULXIN; CLONING; DOMAIN; CELLS	The glycoprotein VI ( GPVI) . Fc receptor gamma-chain (FcR gamma-chain) complex is the major activation receptor for collagen on platelets. GPVI cross-linking mediates activation through tyrosine phosphorylation of an ITAM ( immunoreceptor tyrosine-based activation motif) in the FcR gamma-chain by Src family kinases. It has been previously shown that a transmembrane arginine and the cytoplasmic domain of GPVI are required for association with the FcR gamma-chain in immortalized cell lines. In this study, we have delineated the regions in the GPVI tail that promote binding to FcR gamma-chain and mediate functional responses to the snake venom convulxin by reconstitution of mutant forms of GPVI in RBL-2H3 cells. Sequential truncation of the cytoplasmic tail of GPVI revealed a major role for the basic region and a minor role for the juxtamembrane six amino acids in the association with FcR gamma-chain and functional responses to convulxin. Analysis of selective deletions in the GPVI tail supported this conclusion. In addition, we show that the proline-rich domain is required for optimal Ca2+ release, whereas it is dispensable for FcR gamma-chain association.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Med Sch Edgbaston, Div Med Sci, Birmingham B15 2TT, W Midlands, England; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	University of Oxford; Monash University	Bori-Sanz, T (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	teresa.bori-sanz@pharm.ox.ac.uk	Berndt, Michael C/D-5580-2012; Tulasne, David/A-8705-2008; Watson, Stephen P/Q-6292-2016; Tulasne, David/AAR-5287-2020	Watson, Stephen P/0000-0002-7846-7423; Tulasne, David/0000-0002-6764-7242				Andrews RK, 2002, BLOOD, V99, P4219, DOI 10.1182/blood-2001-11-0008; Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; Berlanga O, 2000, BLOOD, V96, P2740; Berlanga O, 2002, EUR J BIOCHEM, V269, P2951, DOI 10.1046/j.1432-1033.2002.02969.x; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Chen H, 2002, J BIOL CHEM, V277, P3011, DOI 10.1074/jbc.M109714200; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Ezumi Y, 2000, BIOCHEM BIOPH RES CO, V277, P27, DOI 10.1006/bbrc.2000.3624; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Locke D, 2003, J BIOL CHEM, V278, P15441, DOI 10.1074/jbc.M212338200; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MORTON HC, 1995, J BIOL CHEM, V270, P29781; Ono M, 1999, J BIOL CHEM, V274, P30288, DOI 10.1074/jbc.274.42.30288; Suzuki-Inoue K, 2002, J BIOL CHEM, V277, P21561, DOI 10.1074/jbc.M201012200; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; Zheng YM, 2001, J BIOL CHEM, V276, P12999, DOI 10.1074/jbc.M009344200	21	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35914	35922		10.1074/jbc.M301826200	http://dx.doi.org/10.1074/jbc.M301826200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847105	hybrid			2022-12-25	WOS:000185318300008
J	Carattino, MD; Hill, WG; Kleyman, TR				Carattino, MD; Hill, WG; Kleyman, TR			Arachidonic acid regulates surface expression of epithelial sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE A(2); NA+ CHANNEL; 5,8,11,14-EICOSATETRAYNOIC ACID; SUBUNIT STOICHIOMETRY; LIDDLE-SYNDROME; ALPHA-SUBUNIT; PY MOTIF; INHIBITION; TRAFFICKING; FUSION	Epithelial Na+ channels (ENaCs) are regulated by the phospholipase A(2) (PLA(2)) product arachidonic acid. Pharmacological inhibition of PLA(2) with aristolochic acid induced a significant increase in amiloride-sensitive currents in Xenopus oocytes expressing ENaC. Arachidonic acid or 5,8,11,14-eicosatetraynoic acid (ETYA), a non-metabolized analog of arachidonic acid, induced a time-dependent inhibition of Na+ transport. These effects were also observed by co-expression of a calcium-independent or a calcium-dependent PLA(2). Channels with a truncated alpha, beta, or gamma C terminus were not inhibited by arachidonic acid or ETYA. Furthermore, mutation of Tyr(618) in the PY motif of the beta subunit abrogated the inhibitory effect of ETYA, suggesting that intact PY motifs participate in arachidonic acid-mediated ENaC inhibition. Analyses of channels expressing a series of beta subunit C-terminal truncations revealed a second region N-terminal to the PY motif (spanning residues betaVal(580)-betaGly(599)) that allowed for ETYA-mediated ENaC inhibition. Analyses of both ENaC surface expression and ENaC trafficking with mutants that either gate channels open or closed in response to [(2-(trimethylammonium) ethyl] methanethiosulfonate bromide, or with brefeldin A, suggest that ETYA reduces channel surface expression by inhibiting ENaC exocytosis and increasing ENaC endocytosis.	Univ Pittsburgh, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kleyman, TR (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Dept Med, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	kleyman@pitt.edu	Hill, Warren/AAM-1917-2020	Hill, Warren/0000-0002-2772-7264	NIDDK NIH HHS [DK51391, DK54354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK051391, R01DK054354, R01DK051391] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; BOKOCH GM, 1981, J BIOL CHEM, V256, P4156; Bonventre JV, 1999, J AM SOC NEPHROL, V10, P404; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Chibalin AV, 1998, MOL BIOL CELL, V9, P1209, DOI 10.1091/mbc.9.5.1209; Choukroun GJ, 2000, J CLIN INVEST, V106, P983, DOI 10.1172/JCI8914; de Figueiredo P, 1998, P NATL ACAD SCI USA, V95, P8642, DOI 10.1073/pnas.95.15.8642; de Figueiredo P, 2001, J BIOL CHEM, V276, P47361, DOI 10.1074/jbc.M108508200; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Grandbois M, 1998, BIOPHYS J, V74, P2398, DOI 10.1016/S0006-3495(98)77948-2; Hirabayashi T, 2000, BBA-MOL CELL BIOL L, V1488, P124, DOI 10.1016/S1388-1981(00)00115-3; Huttner WB, 2000, CURR OPIN NEUROBIOL, V10, P543, DOI 10.1016/S0959-4388(00)00126-4; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Matsumoto PS, 1997, J MEMBRANE BIOL, V160, P27, DOI 10.1007/s002329900292; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; McIntosh TJ, 1999, BIOPHYS J, V76, P2090, DOI 10.1016/S0006-3495(99)77365-0; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nishio H, 1996, BIOCHEM J, V318, P981, DOI 10.1042/bj3180981; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; SALARI H, 1984, PROSTA LEUKOTR MED, V13, P53, DOI 10.1016/0262-1746(84)90102-1; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Sheng SH, 2001, J BIOL CHEM, V276, P44091, DOI 10.1074/jbc.M108522200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; TOBIAS LD, 1979, LIPIDS, V14, P181, DOI 10.1007/BF02533870; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4; Worrell RT, 2001, AM J PHYSIOL-CELL PH, V281, pC147, DOI 10.1152/ajpcell.2001.281.1.C147; YORIO T, 1978, NATURE, V271, P79, DOI 10.1038/271079a0; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	44	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36202	36213		10.1074/jbc.M300312200	http://dx.doi.org/10.1074/jbc.M300312200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12837767	hybrid			2022-12-25	WOS:000185318300042
J	Fukushima, K; Ikehara, Y; Kanai, M; Kochibe, N; Kuroki, M; Yamashita, K				Fukushima, K; Ikehara, Y; Kanai, M; Kochibe, N; Kuroki, M; Yamashita, K			A beta-N-acetylglucosaminyl phosphate diester residue is attached to the glycosylphosphatidylinositol anchor of human placental alkaline phosphatase - A target of the channel-forming toxin aerolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE MOIETIES; PURIFICATION; RECEPTOR; BINDING; BIOSYNTHESIS; GLYCOPROTEIN; CLONING; CHAINS	Glycosylphosphatidylinositol (GPI)-anchored proteins are ubiquitous in eukaryotes. The minimum conserved GPI core structure of all GPI-anchored glycans has been determined as EtN-PO4-6Manalpha1-2Manalpha1-6Manalpha1-4GlcN-myo-inositol-PO3H. Human placental alkaline phosphatase (AP) has been reported to be a GPI-anchored membrane protein. AP carries one N-glycan, (NeuAcalpha2-->3)(2)Gal(2)GlcNAc(2)Man(3)GlcNAc(+/-Fuc)GlcNAc, and a GPI anchor, which contains an ethanolamine phosphate diester group, as a side chain. However, we found that both sialidase-treated soluble AP (sAP) and its GPI-anchored glycan bound to a Psathyrella velutina lectin (PVL)-Sepharose column, which binds beta-GlcNAc residues. PVL binding of asialo-sAP and its GPI-anchored glycan was diminished by digestion with diplococcal beta-N-acetylhexosaminidase or by mild acid treatment. After sequential digestion of asialo-sAP with beta-N-acetylhexosaminidase and acid phosphatase, the elution patterns on chromatofocusing gels were changed in accordance with the negative charges of phosphate residues. Trypsin-digested sAP was analyzed by liquid chromatography/electrospray ionization mass spectrometry, and the structures of two glycopeptides with GPI-anchored glycans were confirmed as peptide-EtN-PO4-6Manalpha1-->2(GlcNAcbeta1-PO4-->6)Manalpha1-6(+/-EtN-PO4-->) Manalpha1-->4GlcN, which may be produced by endo-alpha-glucosaminidase. In addition to AP, GPI-anchored carcinoembryonic antigen, cholinesterase, and Tamm-Horsfall glycoprotein also bound to a PVL-Sepharose column, suggesting that the beta-N-acetylglucosaminyl phosphate diester residue is widely distributed in human GPI-anchored glycans. Furthermore, we found that the beta-N-acetylglucosaminyl phosphate diester residue is important for GPI anchor recognition of aerolysin, a channel-forming toxin derived from Aeromonas hydrophila.	Sasaki Inst, Dept Biochem, Chiyoda Ku, Tokyo 1010062, Japan; Japan Sci & Technol Corp, CREST, Chiyoda Ku, Tokyo 1010062, Japan; Fukuoka Univ, Sch Med, Dept Cell Biol, Jonan Ku, Fukuoka 8140133, Japan; Nihon Waters KK, Shinagawa Ku, Tokyo 1400001, Japan; Gunma Univ, Fac Educ, Dept Biol, Gunma 3710000, Japan; Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 8140133, Japan	Japan Science & Technology Agency (JST); Fukuoka University; Gunma University; Fukuoka University	Yamashita, K (corresponding author), Sasaki Inst, Dept Biochem, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.	yamashita@sasaki.or.jp	Kanai, Motomu/J-6807-2016	Kanai, Motomu/0000-0003-1977-7648				Cowell S, 1997, MOL MICROBIOL, V25, P343, DOI 10.1046/j.1365-2958.1997.4691828.x; Cuatrecasas P., 1971, METHOD ENZYMOL, V22, P345; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; ENDO T, 1988, J BIOCHEM-TOKYO, V103, P182, DOI 10.1093/oxfordjournals.jbchem.a122228; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HENTHORN PS, 1986, P NATL ACAD SCI USA, V83, P5597, DOI 10.1073/pnas.83.15.5597; Hong YJ, 2002, EMBO J, V21, P5047, DOI 10.1093/emboj/cdf508; ICHIKI S, 1986, JPN J CANCER RES, V77, P462; IKEZAWA H, 1976, BIOCHIM BIOPHYS ACTA, V450, P154; KAM W, 1985, P NATL ACAD SCI USA, V82, P8715, DOI 10.1073/pnas.82.24.8715; KOCHIBE N, 1989, J BIOL CHEM, V264, P173; Lacy DB, 1998, CURR OPIN STRUC BIOL, V8, P778; LOW MG, 1977, BIOCHEM J, V167, P281, DOI 10.1042/bj1670281; MacKenzie CR, 1999, J BIOL CHEM, V274, P22604, DOI 10.1074/jbc.274.32.22604; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MIKI A, 1986, EUR J BIOCHEM, V160, P41, DOI 10.1111/j.1432-1033.1986.tb09937.x; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; Nelson KL, 1997, J BIOL CHEM, V272, P12170, DOI 10.1074/jbc.272.18.12170; OGATA S, 1988, J BIOL CHEM, V263, P10489; OHKURA T, 1994, CANCER RES, V54, P55; REDMAN CA, 1994, BIOCHEM J, V302, P861, DOI 10.1042/bj3020861; TABAS I, 1980, J BIOL CHEM, V255, P6633; TAMM I, 1952, J EXP MED, V95, P71, DOI 10.1084/jem.95.1.71; WILLIAMS J, 1984, CARBOHYD RES, V134, P141, DOI 10.1016/0008-6215(84)85029-6; YAMASHITA K, 1987, CANCER RES, V47, P3451; YAMASHITA K, 1981, J BIOL CHEM, V256, P1283	28	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36296	36303		10.1074/jbc.M304341200	http://dx.doi.org/10.1074/jbc.M304341200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851398	hybrid			2022-12-25	WOS:000185318300053
J	McCormack, FX; Gibbons, R; Ward, SR; Kuzmenko, A; Wu, HX; Deepe, GS				McCormack, FX; Gibbons, R; Ward, SR; Kuzmenko, A; Wu, HX; Deepe, GS			Macrophage-independent fungicidal action of the pulmonary collectins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-A; HISTOPLASMA-CAPSULATUM; IMMUNITY; INDUCTION; INFECTION; ADHERENCE; INHIBIT; GROWTH; ACID; IRON	Histoplasma capsulatum (Hc) is a facultative intracellular fungal pathogen that causes acute and chronic pneumonia. In this study, we investigated the role of the pulmonary collectins, surfactant proteins (SP) A and D, in the clearance of Hc yeast from the lung. Exposure of yeast to either collectin induced a dose-dependent decrease in [H-3]leucine incorporation by several strains of Hc. This decrement was attributed to killing of the collectin-exposed yeast since it failed to grow on agar medium. Exposure to SP-A or -D resulted in increased yeast permeability based on a leak of protein from the organism and enhanced access of an impermeant substrate to intracellular alkaline phosphatase. Inbred and out-bred SP-A null (-/-) mice were modestly more susceptible to pulmonary infection with Hc than strain and age-matched SP-A (+/+) control mice. The increase in susceptibility was associated with a decrement in the number of CD8(+) cells in the lungs of SP-A-/- mice. Neither SP-A nor SP-D inhibited the growth of macrophage-internalized Hc. We conclude that the SP-A and SP-D are antimicrobial proteins that directly inhibit the growth of Hc by increasing permeability of the organism and that Hc gains asylum from collectin-mediated killing by rapid entry into pulmonary macrophages.	Univ Cincinnati, Coll Med, Div Pulm Crit Care Med, Dept Internal Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Div Infect Dis, Dept Internal Med, Cincinnati, OH 45267 USA; Vet Affairs Med Ctr, Cincinnati, OH 45220 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center	McCormack, FX (corresponding author), Univ Cincinnati, Coll Med, Div Pulm Crit Care Med, Dept Internal Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	frank.mccormack@uc.edu	Kuzmenko, Oleksandr/P-6059-2016; McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464	NHLBI NIH HHS [HL 61612, HL 68861] Funding Source: Medline; NIAID NIH HHS [AI 34361, AI 42747] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068861, R01HL061612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI042747, R01AI034361] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allendoerfer R, 1998, J IMMUNOL, V160, P6072; Allendorfer R, 1999, J IMMUNOL, V162, P7389; Borron P, 2000, AM J PHYSIOL-LUNG C, V278, pL840, DOI 10.1152/ajplung.2000.278.4.L840; Borron P, 1996, AM J RESP CELL MOL, V15, P115, DOI 10.1165/ajrcmb.15.1.8679215; BULLOCK WE, 1987, J EXP MED, V165, P195, DOI 10.1084/jem.165.1.195; Cain JA, 1998, INFECT IMMUN, V66, P1473, DOI 10.1128/IAI.66.4.1473-1481.1998; Chiba H, 2002, J BIOL CHEM, V277, P20379, DOI 10.1074/jbc.M201089200; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; Deepe GS, 1998, RES IMMUNOL, V149, P397, DOI 10.1016/S0923-2494(98)80763-3; DEEPE GS, 1994, J IMMUNOL, V152, P3491; DEEPE GSJ, 1999, PRINCIPLES PRACTICES, P2718; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; EISSENBERG LG, 1993, J EXP MED, V177, P1605, DOI 10.1084/jem.177.6.1605; EISSENBERG LG, 1988, J LEUKOCYTE BIOL, V43, P483, DOI 10.1002/jlb.43.6.483; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; Goerke J, 1998, BBA-MOL BASIS DIS, V1408, P79, DOI 10.1016/S0925-4439(98)00060-X; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KRATOCHVIL B, 1965, ANAL CHEM, V37, P111, DOI 10.1021/ac60220a028; Newman SL, 2000, INFECT IMMUN, V68, P5668, DOI 10.1128/IAI.68.10.5668-5672.2000; NEWMAN SL, 1994, J CLIN INVEST, V93, P1422, DOI 10.1172/JCI117119; Newman SL, 1997, J IMMUNOL, V158, P1779; NEWMAN SL, 1992, INFECT IMMUN, V60, P4593, DOI 10.1128/IAI.60.11.4593-4597.1992; Suwabe A, 1996, ARCH BIOCHEM BIOPHYS, V327, P285, DOI 10.1006/abbi.1996.0123; Timmerman MM, 1999, INFECT IMMUN, V67, P6403; van Rozendaal BAWM, 2000, J INFECT DIS, V182, P917, DOI 10.1086/315799; WEISS J, 1984, J IMMUNOL, V132, P3109; WOLF JE, 1992, INFECT IMMUN, V60, P2559, DOI 10.1128/IAI.60.7.2559-2564.1992; WOLF JE, 1987, J IMMUNOL, V138, P582; WORSHAM PL, 1988, J MED VET MYCOL, V26, P137; Wright SK, 1998, ANAL BIOCHEM, V265, P8, DOI 10.1006/abio.1998.2858; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; Zhou P, 1998, J EXP MED, V187, P1315, DOI 10.1084/jem.187.8.1315	34	98	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36250	36256		10.1074/jbc.M303086200	http://dx.doi.org/10.1074/jbc.M303086200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857753	hybrid			2022-12-25	WOS:000185318300047
J	Miller, DW; Ahmad, R; Hague, S; Baptista, MJ; Canet-Aviles, R; McLendon, C; Carter, DM; Zhu, PP; Stadler, J; Chandran, J; Klinefelter, GR; Blackstone, C; Cookson, MR				Miller, DW; Ahmad, R; Hague, S; Baptista, MJ; Canet-Aviles, R; McLendon, C; Carter, DM; Zhu, PP; Stadler, J; Chandran, J; Klinefelter, GR; Blackstone, C; Cookson, MR			L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SYNUCLEIN; CRYSTAL-STRUCTURE; PROTEIN LIGASE; IN-VITRO; GENE; DEGRADATION; MUTATIONS; FERTILITY; DYSTONIA; PATHWAY	Mutations in a gene on chromosome 1, DJ-1, have been reported recently to be associated with recessive, early-onset Parkinson's disease. While one mutation is a large deletion that is predicted to produce an effective knockout of the gene, the second is a point mutation, L166P, whose precise effects on protein function are unclear. In the present study, we show that L166P destabilizes DJ-1 protein and promotes its degradation through the ubiquitin-proteasome system. A double mutant (K130R, L166P) was more stable than L166P, suggesting that this lysine residue contributes to stability of the protein. Subcellular localization was broadly similar for both wild type and L166P forms of the protein, indicating that the effect of the mutation is predominantly on protein stability. These observations are reminiscent of other recessive gene mutations that produce an effective loss of function. The L166P mutation has the simple effect of promoting DJ-1 degradation, thereby reducing net DJ-1 protein within the cell.	NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA; NINDS, Cellular Neurol Unit, NIH, Bethesda, MD 20892 USA; US EPA, Natl Hlth & Environm Effects Res Lab, Reprod Toxicol Div, Res Triangle Pk, NC 27711 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); United States Environmental Protection Agency	Cookson, MR (corresponding author), NIA, Neurogenet Lab, NIH, Bldg 10,Rm 6C103,MSC 1589,9000 Rockville Pike, Bethesda, MD 20892 USA.	Cookson@mail.nih.gov	Cookson, Mark/AAW-2516-2021	Cookson, Mark/0000-0002-1058-3831	NATIONAL INSTITUTE ON AGING [ZIAAG000953, Z01AG000953] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baptista MJ, 2003, J NEUROCHEM, V85, P957, DOI 10.1046/j.1471-4159.2003.01742.x; Blackstone C, 2003, BIOCHEM BIOPH RES CO, V305, P345, DOI 10.1016/S0006-291X(03)00767-8; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Cookson MR, 2003, NEURON, V37, P7, DOI 10.1016/S0896-6273(02)01166-2; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Du XL, 2000, P NATL ACAD SCI USA, V97, P14079, DOI 10.1073/pnas.260503597; Galbiati F, 2000, J BIOL CHEM, V275, P37702, DOI 10.1074/jbc.M006657200; Gautreau A, 2002, J BIOL CHEM, V277, P31279, DOI 10.1074/jbc.C200125200; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gray TM, 1996, PROTEIN SCI, V5, P742; Hardy J, 2003, LANCET NEUROL, V2, P221, DOI 10.1016/S1474-4422(03)00350-8; Hod Y, 1999, J CELL BIOCHEM, V72, P435, DOI 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.3.CO;2-8; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Honbou K, 2003, J BIOL CHEM, V278, P31380, DOI 10.1074/jbc.M305878200; Hwu WL, 2000, ANN NEUROL, V48, P609, DOI 10.1002/1531-8249(200010)48:4<609::AID-ANA7>3.3.CO;2-8; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klinefelter GR, 2002, J ANDROL, V23, P48, DOI 10.1002/jand.2002.23.1.48; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Mitsumoto A, 2001, FREE RADICAL RES, V35, P885, DOI 10.1080/10715760100301381; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Niki T, 2003, MOL CANCER RES, V1, P247; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Quigley PM, 2003, P NATL ACAD SCI USA, V100, P3137, DOI 10.1073/pnas.0530312100; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Tao X, 2003, J BIOL CHEM, V278, P31372, DOI 10.1074/jbc.M304221200; Wagenfeld A, 1998, BIOCHEM BIOPH RES CO, V251, P545, DOI 10.1006/bbrc.1998.9512; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	35	192	200	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36588	36595		10.1074/jbc.M304272200	http://dx.doi.org/10.1074/jbc.M304272200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851414	hybrid			2022-12-25	WOS:000185318300089
J	Peter, JC; Eftekhari, P; Billiald, P; Wallukat, G; Hoebeke, J				Peter, JC; Eftekhari, P; Billiald, P; Wallukat, G; Hoebeke, J			scFv single chain antibody variable fragment as inverse agonist of the beta(2)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROCTONUS-AUSTRALIS-HECTOR; BETA-ADRENERGIC-RECEPTOR; MONOCLONAL-ANTIBODY; CONSTRUCTION; CONTRACTION; RHODOPSIN; EPITOPES; PROTEINS; SURFACE; COMPLEX	Antibodies directed against the second extracellular loop of G protein-coupled receptors were shown to possess functional activities. Using a functional monoclonal antibody against the human beta(2)-adrenergic receptor, a scFv fragment with high affinity for the target epitope was constructed and produced. The fragment recognized the beta(2)-adrenergic receptors on A431 cells, blocked cAMP accumulation induced by the beta(2)-agonist salbutamol, and decreased basal cAMP accumulation in the same cells. Their in vitro activity was tested on neonatal rat cardiomyocytes. The antibody fragments blocked the chronotropic activity induced by the beta(2)-agonist clenbuterol. They also decreased the in vivo heart beating frequency of mice pretreated with bisoprolol ( a beta(1)-adrenergic receptor antagonist) for 4 min after injection. The immunological approach presented here may serve as a strategy for the synthesis of a new class of allosteric modulators for G protein-coupled receptors.	Inst Biol Mol & Cellulaire, CNRS, UPR 9021, Lab Therapeut Chem & Immunol, F-67084 Strasbourg, France; Museum Nat Hist, F-75005 Paris, France; Sch Med, Inst Pharmacol, FORENAP Therapeut Discovery, F-67000 Strasbourg, France; Max Delbruck Centrum Mol Med, D-13092 Berlin, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Museum National d'Histoire Naturelle (MNHN); CHU Strasbourg; Universite de Franche-Comte; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Hoebeke, J (corresponding author), Inst Biol Mol & Cellulaire, CNRS, UPR 9021, Lab Therapeut Chem & Immunol, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	J.Hoebeke@ibmc.u-strasbg.fr	BILLIALD, Philippe/ABF-7417-2021	BILLIALD, Philippe/0000-0001-8148-5297				BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; Bes Cedric, 2001, Human Antibodies, V10, P67; CARROLL WL, 1988, MOL IMMUNOL, V25, P991, DOI 10.1016/0161-5890(88)90005-3; Chaves AA, 2003, LIFE SCI, V72, P2401, DOI 10.1016/S0024-3205(03)00137-1; Christopoulos A, 2002, NAT REV DRUG DISCOV, V1, P198, DOI 10.1038/nrd746; Daeffler L, 2000, FUND CLIN PHARMACOL, V14, P73, DOI 10.1111/j.1472-8206.2000.tb00395.x; DELAVIERKLUTCHKO C, 1984, FEBS LETT, V169, P151, DOI 10.1016/0014-5793(84)80308-7; Devaux C, 2001, EUR J BIOCHEM, V268, P694, DOI 10.1046/j.1432-1327.2001.01923.x; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; Eftekhari P, 2001, EUR J IMMUNOL, V31, P573, DOI 10.1002/1521-4141(200102)31:2<573::AID-IMMU573>3.0.CO;2-9; Evans MJ, 1995, MOL IMMUNOL, V32, P1183, DOI 10.1016/0161-5890(95)00099-2; Gong HB, 2002, CIRCULATION, V105, P2497, DOI 10.1161/01.CIR.0000017187.61348.95; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; LAROCHE Y, 1991, J BIOL CHEM, V266, P16343; Lebesgue D, 1998, EUR J PHARMACOL, V348, P123, DOI 10.1016/S0014-2999(98)00136-8; LEI SP, 1987, J BACTERIOL, V169, P4379, DOI 10.1128/jb.169.9.4379-4383.1987; Mijares A, 2000, MOL PHARMACOL, V58, P373, DOI 10.1124/mol.58.2.373; MILENIC DE, 1991, CANCER RES, V51, P6363; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Mousli M, 1999, FEBS LETT, V442, P183, DOI 10.1016/S0014-5793(98)01647-0; NEIMARK J, 1993, PEPTIDE RES, V6, P219; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; RichaletSecordel PM, 1997, ANAL BIOCHEM, V249, P165, DOI 10.1006/abio.1997.2183; Sogabe S, 1997, J MOL BIOL, V273, P882, DOI 10.1006/jmbi.1997.1336; WALLUKAT G, 1995, J MOL CELL CARDIOL, V27, P397, DOI 10.1016/S0022-2828(08)80036-3; Wijkhuisen A, 2003, EUR J PHARMACOL, V468, P175, DOI 10.1016/S0014-2999(03)01717-5; Worn A, 2001, J MOL BIOL, V305, P989, DOI 10.1006/jmbi.2000.4265; Zhou YY, 1999, J PHYSIOL-LONDON, V521, P351, DOI 10.1111/j.1469-7793.1999.00351.x	28	31	42	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36740	36747		10.1074/jbc.M306877200	http://dx.doi.org/10.1074/jbc.M306877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860977	hybrid			2022-12-25	WOS:000185318300106
J	Raibaud, S; Vachette, P; Guillier, M; Allemand, F; Chiaruttini, C; Dardel, F				Raibaud, S; Vachette, P; Guillier, M; Allemand, F; Chiaruttini, C; Dardel, F			How bacterial ribosomal protein L20 assembles with 23 S ribosomal RNA and its own messenger RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BIOLOGICAL MACROMOLECULES; SECONDARY STRUCTURE; BINDING-SITES; NMR; TRANSLATION; SUBUNIT; OPERON; S15; SCATTERING	In bacteria, the expression of ribosomal proteins is often feedback-regulated at the translational level by the binding of the protein to its own mRNA. This is the case for L20, which binds to two distinct sites of its mRNA that both resemble its binding site on 23 S rRNA. In the present work, we report an NMR analysis of the interaction between the C-terminal domain of L20 (L20C) and both its rRNA- and mRNA-binding sites. Changes in the NMR chemical shifts of the L20C backbone nuclei were used to show that the same set of residues are modified upon addition of either the rRNA or the mRNA fragments, suggesting a mimicry at the atomic level. In addition, small angle x-ray scattering experiments, performed with the rRNA fragment, demonstrated the formation of a complex made of two RNAs and two L20C molecules. A low resolution model of this complex was then calculated using (i) the rRNA/L20C structure in the 50 S context and (ii) NMR and small angle x-ray scattering results. The formation of this complex is interesting in the context of gene regulation because it suggests that translational repression could be performed by a complex of two proteins, each interacting with the two distinct L20-binding sites within the operator.	CNRS, Fac Pharm, UMR 8015, F-75006 Paris, France; Univ Paris 11, CNRS, UMR 00130, LURE, F-91898 Orsay, France; CNRS, Inst Biol Physicochim, UPR9073, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)	Dardel, F (corresponding author), CNRS, Fac Pharm, UMR 8015, 4 Ave Observ, F-75006 Paris, France.	dardel@pharmacie.univ-paris5.fr	Dardel, Frédéric/E-5805-2010	Dardel, Frédéric/0000-0002-9397-3965; Guillier, Maude/0000-0003-3769-4758				Agalarov SC, 2000, SCIENCE, V288, P107, DOI 10.1126/science.288.5463.107; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROT N, 1980, P NATL ACAD SCI-BIOL, V77, P2592, DOI 10.1073/pnas.77.5.2592; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; Chiaruttini C, 1996, EMBO J, V15, P4402, DOI 10.1002/j.1460-2075.1996.tb00813.x; Dubuisson JM, 1997, J APPL CRYSTALLOGR, V30, P49, DOI 10.1107/S002188989600876X; GREGORY RJ, 1988, J MOL BIOL, V204, P295, DOI 10.1016/0022-2836(88)90577-3; Guillier M, 2002, RNA, V8, P878, DOI 10.1017/S1355838202029084; Guinier A., 1955, SMALL ANGLE SCATTERI; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; HEROLD M, 1987, J BIOL CHEM, V262, P8826; Keener J, 1996, ESCHERICHIA COLI SAL, V2, P1417; LESAGE P, 1990, J MOL BIOL, V213, P465, DOI 10.1016/S0022-2836(05)80208-6; LESAGE P, 1992, J MOL BIOL, V228, P366, DOI 10.1016/0022-2836(92)90827-7; LINDAHL L, 1986, ANNU REV GENET, V20, P297; Nikulin A, 2000, NAT STRUCT BIOL, V7, P273; NOLLER HF, 1981, NUCLEIC ACIDS RES, V9, P6167, DOI 10.1093/nar/9.22.6167; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; PHILIPPE C, 1990, J MOL BIOL, V211, P415, DOI 10.1016/0022-2836(90)90362-P; Raibaud S, 2002, J MOL BIOL, V323, P143, DOI 10.1016/S0022-2836(02)00921-X; ROHL R, 1982, P NATL ACAD SCI-BIOL, V79, P729, DOI 10.1073/pnas.79.3.729; ROUH A, 1993, J MAGN RESON SER A, V102, P357, DOI 10.1006/jmra.1993.1117; SAID B, 1988, NUCLEIC ACIDS RES, V16, P10529, DOI 10.1093/nar/16.22.10529; Scott LG, 2001, J MOL BIOL, V314, P413, DOI 10.1006/jmbi.2001.5165; Serganov A, 2003, EMBO J, V22, P1898, DOI 10.1093/emboj/cdg170; Serganov A, 2002, J MOL BIOL, V320, P963, DOI 10.1016/S0022-2836(02)00553-3; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Tisne C, 2000, RNA, V6, P1403, DOI 10.1017/S1355838200000947; YATES JL, 1981, NATURE, V294, P190, DOI 10.1038/294190a0; YATES JL, 1980, CELL, V21, P517, DOI 10.1016/0092-8674(80)90489-4; YATES JL, 1980, P NATL ACAD SCI-BIOL, V77, P1837, DOI 10.1073/pnas.77.4.1837; ZENGEL JM, 1980, CELL, V21, P523, DOI 10.1016/0092-8674(80)90490-0; Zengel JM, 1995, BIOCHEM CELL BIOL, V73, P1105, DOI 10.1139/o95-119; Zhu G, 1999, J BIOMOL NMR, V13, P77, DOI 10.1023/A:1008398227519	37	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36522	36530		10.1074/jbc.M304717200	http://dx.doi.org/10.1074/jbc.M304717200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12840018	hybrid, Green Submitted			2022-12-25	WOS:000185318300081
J	Chen, Z; Manley, JL				Chen, Z; Manley, JL			In vivo functional analysis of the histone 3-like TAF9 and a TAF9-related factor, TAF9L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL TRANSCRIPTION FACTORS; PROGRAMMED CELL-DEATH; POLYMERASE-II TRANSCRIPTION; TATA-BINDING PROTEIN; TAF(II)-CONTAINING COMPLEXES; NUCLEOSOME ACETYLATION; PC12 CELLS; DROSOPHILA; POLYCOMB; CHROMATIN	The majority of the TATA-binding protein (TBP)-associated factors (TAFs) that constitute transcription factor II D (TFIID) contain histone fold motifs (HFMs). Our previous results utilizing DT40 cells containing a conditional TAF9 allele indicated that the histone 3-like TAF9 is essential for cell viability but largely dispensable for general transcription. In this study, we investigated further the role of TAF9 structural domains in TFIID integrity and cell growth and the functions of a TAF9-related factor, TAF9L. We first show that TAF9 depletion severely disrupts TFIID, indicating that the observed ongoing transcription is initiated with at least partially TAF-free TATA-binding protein. We also provide evidence for specific roles of TAF HFMs, highlighting the functional significance of HFM specificity observed in vitro and, importantly, of the TAF9-histone 3 similarity. Although we provide evidence that TAF9 and TAF9L are partly redundant, RNA interference experiments suggest that TAF9L is essential for HeLa cell growth. Strikingly, we provide evidence that TAF9L plays a role in transcriptional repression and/or silencing.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Manley, JL (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.			Manley, James/0000-0002-8341-1459	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037971] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37971] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Andel F, 1999, SCIENCE, V286, P2153, DOI 10.1126/science.286.5447.2153; Aoki T, 1997, BIOCHEM BIOPH RES CO, V234, P230, DOI 10.1006/bbrc.1997.6610; Aoyagi N, 2000, J CELL BIOL, V150, pF45, DOI 10.1083/jcb.150.2.F45; Aoyagi N, 2001, MOL CELL BIOL, V21, P6808, DOI 10.1128/MCB.21.20.6808-6819.2001; Bell B, 2001, MOL CELL, V8, P591, DOI 10.1016/S1097-2765(01)00325-2; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Chen Z, 2000, MOL CELL BIOL, V20, P5064, DOI 10.1128/MCB.20.14.5064-5076.2000; CHEN Z, 2003, IN PRESS MOL CELL BI; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Feng YQ, 2001, MOL CELL BIOL, V21, P298, DOI 10.1128/MCB.21.1.298-309.2001; Fiering S, 2000, BIOESSAYS, V22, P381, DOI 10.1002/(SICI)1521-1878(200004)22:4<381::AID-BIES8>3.0.CO;2-E; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; Gangloff YG, 2001, TRENDS BIOCHEM SCI, V26, P250, DOI 10.1016/S0968-0004(00)01741-2; Gangloff YG, 2001, MOL CELL BIOL, V21, P1841, DOI 10.1128/MCB.21.5.1841-1853.2001; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; Hiller MA, 2001, GENE DEV, V15, P1021, DOI 10.1101/gad.869101; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002; Li B, 2000, EMBO J, V19, P4091, DOI 10.1093/emboj/19.15.4091; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; Martianov I, 2002, SCIENCE, V298, P1036, DOI 10.1126/science.1076327; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Orlando V, 1998, EMBO J, V17, P5141, DOI 10.1093/emboj/17.17.5141; Perletti L, 1999, J BIOL CHEM, V274, P15301, DOI 10.1074/jbc.274.22.15301; Pikaart MI, 1998, GENE DEV, V12, P2852, DOI 10.1101/gad.12.18.2852; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; Selleck W, 2001, NAT STRUCT BIOL, V8, P695, DOI 10.1038/90408; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; Thompson A, 1999, BIOCHEM BIOPH RES CO, V262, P55, DOI 10.1006/bbrc.1999.1169; Thuault S, 2002, J BIOL CHEM, V277, P45510, DOI 10.1074/jbc.M206556200; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; Um M, 2001, MOL CELL BIOL, V21, P2435, DOI 10.1128/MCB.21.7.2435-2448.2001; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; Wang PJ, 2002, HUM MOL GENET, V11, P2341, DOI 10.1093/hmg/11.19.2341; Wang SL, 1997, DEV BIOL, V188, P322, DOI 10.1006/dbio.1997.8655; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303	60	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35172	35183		10.1074/jbc.M304241200	http://dx.doi.org/10.1074/jbc.M304241200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12837753	hybrid			2022-12-25	WOS:000185164400053
J	Deangelis, PL; Oatman, LC; Gay, DF				Deangelis, PL; Oatman, LC; Gay, DF			Rapid chemoenzymatic synthesis of monodisperse hyaluronan oligosaccharides with immobilized enzyme reactors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PASTEURELLA-MULTOCIDA; ANGIOGENIC OLIGOSACCHARIDES; BINDING PROTEINS; SYNTHASE; GLYCOSYLTRANSFERASES; ACID	We describe the chemoenzymatic synthesis of a variety of monodisperse hyaluronan (beta4-glucuronic acid-beta3-N- acetylglucosamine ( HA)) oligosaccharides. Potential medical applications for HA oligosaccharides (similar to 10 - 20 sugars in length) include killing cancerous tumors and enhancing wound vascularization. Previously, the lack of defined oligosaccharides has limited the exploration of these sugars as components of new therapeutics. The Pasteurella multocida HA synthase, pmHAS, a polymerizing enzyme that normally elongates HA chains rapidly (similar to1-100 sugars/s), was converted by mutagenesis into two single-action glycosyltransferases (glucuronic acid transferase and N-acetylglucosamine transferase). The two resulting enzymes were purified and immobilized individually onto solid supports. The two types of enzyme reactors were used in an alternating fashion to produce extremely pure sugar polymers of a single length (up to HA20) in a controlled, stepwise fashion without purification of the intermediates. These molecules are the longest, non-block, monodisperse synthetic oligosaccharides hitherto reported. This technology platform is also amenable to the synthesis of medicant-tagged or radioactive oligosaccharides for biomedical testing. Furthermore, these experiments with immobilized mutant enzymes prove both that pmHAS-catalyzed polymerization is non-processive and that a monomer of enzyme is the functional catalytic unit.	Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Deangelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DeAngelis PL, 1999, J BIOL CHEM, V274, P26557, DOI 10.1074/jbc.274.37.26557; DeAngelis PL, 2002, GLYCOBIOLOGY, V12, p9R, DOI 10.1093/glycob/12.1.9R; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Halkes KM, 1998, CARBOHYD RES, V309, P161, DOI 10.1016/S0008-6215(98)00116-5; Ikegami-Kawai M, 2002, ANAL BIOCHEM, V311, P157, DOI 10.1016/S0003-2697(02)00425-6; Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; JING W, 2003, IN PRESS GLYCOBIOLOG; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Koizumi S, 1998, NAT BIOTECHNOL, V16, P847, DOI 10.1038/nbt0998-847; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; LEES VC, 1995, LAB INVEST, V73, P259; Mahoney DJ, 2001, GLYCOBIOLOGY, V11, P1025, DOI 10.1093/glycob/11.12.1025; Slevin M, 2002, J BIOL CHEM, V277, P41046, DOI 10.1074/jbc.M109443200; Tawada A, 2002, GLYCOBIOLOGY, V12, P421, DOI 10.1093/glycob/cwf048; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340	21	73	78	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35199	35203		10.1074/jbc.M306431200	http://dx.doi.org/10.1074/jbc.M306431200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12840012	hybrid			2022-12-25	WOS:000185164400056
J	Klco, JM; Lassere, TB; Baranski, TJ				Klco, JM; Lassere, TB; Baranski, TJ			C5a receptor oligomerization - I. Disulfide trapping reveals oligomers and potential contact surfaces in a G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; DIRECTED CROSS-LINKING; FUNCTIONAL RECONSTITUTION; TRANSMEMBRANE DOMAIN; PROJECTION STRUCTURE; SENSORY RECEPTOR; STRUCTURAL BASIS; RHODOPSIN; ACTIVATION; DIMERIZATION	G protein-coupled receptors (GPCRs), stimulated by hormones and sensory stimuli, act as molecular switches to relay activation to heterotrimeric G proteins. Recent studies suggest that GPCRs form dimeric or oligomeric structures, a phenomenon that has long been established for growth factor receptors. The elucidation of the domains of GPCRs that mediate receptor association is of critical importance for understanding the function of GPCR oligomers. Using a disulfide-trapping strategy to probe the intermolecular contact surfaces, we demonstrate cross-linking of C5a receptors in membranes prepared from both human neutrophils and stably transfected mammalian cells that is mediated by a cysteine in the second intracellular loop. To explore other surfaces that might be involved in the oligomerization of C5a receptors, we constructed receptors with individual cysteines in other intracellular regions. C5a receptors with a cysteine in the first intracellular loop or the carboxyl terminus displayed the fastest kinetics of dimer formation, whereas an intracellular loop 3 cysteine displayed minimal cross-linking. Since the rate of disulfide trapping reflects the proximity of sulfhydryl groups, assuming similar accessibility and flexibility, these results imply a symmetric dimer interface that may involve either transmembrane helices 1 and 2 or helix 4. However, neither model can account for the ability of the native cysteine in the second intracellular loop to mediate efficient cross-linking. Based on these observations, we propose that C5a receptors form higher order oligomers (i.e. tetramers) or clusters in the membrane.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Baranski, TJ (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	baranski@pcg.wustl.edu	Klco, Jeffery/M-9717-2018	Klco, Jeffery/0000-0003-2961-6960	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063720] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63720-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Braun L, 2003, J BIOL CHEM, V278, P4277, DOI 10.1074/jbc.M210120200; BUHL AM, 1995, J BIOL CHEM, V270, P19828, DOI 10.1074/jbc.270.34.19828; CAI K, 1999, BIOCHEMISTRY-US, V38, P7825; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Davies A, 2001, J MOL BIOL, V314, P455, DOI 10.1006/jmbi.2001.5167; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; Filizola M, 2002, BIOPOLYMERS, V66, P317, DOI 10.1002/bip.10311; Floyd DH, 2003, J BIOL CHEM, V278, P35354, DOI 10.1074/jbc.M305607200; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Gerard C, 2003, NEW ENGL J MED, V348, P167, DOI 10.1056/NEJMcibr022995; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Hadac EM, 1999, J MED CHEM, V42, P2105, DOI 10.1021/jm980732q; Hamdan FF, 2002, BIOCHEMISTRY-US, V41, P7647, DOI 10.1021/bi016029c; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Klein-Seetharaman J, 1999, BIOCHEMISTRY-US, V38, P7938, DOI 10.1021/bi990013t; Krebs A, 1998, J MOL BIOL, V282, P991, DOI 10.1006/jmbi.1998.2070; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; LEE GF, 1994, J BIOL CHEM, V269, P29920; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lim WK, 2001, BIOCHEM J, V354, P337, DOI 10.1042/0264-6021:3540337; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MORGAN EL, 1993, J IMMUNOL, V151, P377; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; ROLLINS TE, 1988, J BIOL CHEM, V263, P520; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; SCHLEGEL W, 1979, J BIOL CHEM, V254, P5168; Schulz A, 2000, J BIOL CHEM, V275, P2381, DOI 10.1074/jbc.275.4.2381; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Tardif M, 2003, BIOCHEM J, V372, P453, DOI 10.1042/BJ20021803; Wachter RM, 1998, STRUCTURE, V6, P1267, DOI 10.1016/S0969-2126(98)00127-0; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	57	107	109	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35345	35353		10.1074/jbc.M305606200	http://dx.doi.org/10.1074/jbc.M305606200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12835319	hybrid			2022-12-25	WOS:000185164400074
J	De Fabiani, E; Mitro, N; Gilardi, F; Caruso, D; Galli, G; Crestani, M				De Fabiani, E; Mitro, N; Gilardi, F; Caruso, D; Galli, G; Crestani, M			Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE FEEDBACK-REGULATION; HEPATOCYTE NUCLEAR FACTOR-4; HEPATIC GLUCONEOGENESIS; HORMONAL-REGULATION; COACTIVATOR PGC-1; RECEPTOR FXR; DNA-BINDING; GENE CYP7A; IDENTIFICATION; BIOSYNTHESIS	Bile acid metabolism plays an essential role in cholesterol homeostasis and is critical for the initiation of atherosclerotic disease. However, despite the recent advances, the molecular mechanisms whereby bile acids regulate gene transcription and cholesterol homeostasis in mammals still need further investigations. Here, we show that bile acids suppress transcription of the gene (CYP7A1) encoding cholesterol 7alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis, also through an unusual mechanism not involving the bile acid nuclear receptor, farnesoid X receptor. By performing cell-based reporter assays, protein/protein interaction, and chromatin immunoprecipitation assays, we demonstrate that bile acids impair the recruitment of peroxisome proliferator-activated receptor-gamma coactivator-1alpha and cAMP response element-binding protein-binding protein by hepatocyte nuclear factor-4alpha, a master regulator of CYP7A1. We also show for the first time that bile acids inhibit transcription of the gene ( PEPCK) encoding phosphoenolpyruvate carboxykinase, the rate-limiting enzyme in gluconeogenesis, through the same farnesoid X receptor-independent mechanism. Chromatin immunoprecipitation assay revealed that bile acid-induced dissociation of coactivators from hepatocyte nuclear factor-4alpha decreased the recruitment of RNA polymerase II to the core promoter and downstream in the 3'-untranslated regions of these two genes, reflecting the reduction of gene transcription. Finally, we found that Cyp7a1 expression was stimulated in fasted mice in parallel to Pepck, whereas the same genes were repressed by bile acids. Collectively, these results reveal a novel regulatory mechanism that controls gene transcription in response to extracellular stimuli and argue that the transcription regulation by bile acids of genes central to cholesterol and glucose metabolism should be viewed dynamically in the context of the fasted-to-fed cycle.	Univ Milan, Fac Farm, Dipartimento Sci Farmacol, I-20133 Milan, Italy	University of Milan	Crestani, M (corresponding author), Univ Milan, Fac Farm, Dipartimento Sci Farmacol, Via Balzaretti 9, I-20133 Milan, Italy.		De Fabiani, Emma/B-6936-2015; caruso, donatella/A-3332-2014	De Fabiani, Emma/0000-0003-2406-1468; caruso, donatella/0000-0003-2115-778X; Crestani, Maurizio/0000-0001-9230-1078; Mitro, Nico/0000-0002-5000-3619; Gilardi, Federica/0000-0001-5421-2779				Borgius LJ, 2002, J BIOL CHEM, V277, P49761, DOI 10.1074/jbc.M205641200; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; CONSOLI A, 1990, ANN MED, V22, P191, DOI 10.3109/07853899009147268; CRESTANI M, 1995, J LIPID RES, V36, P2419; Crestani M, 1998, J LIPID RES, V39, P2192; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Guo HT, 2002, J BIOL CHEM, V277, P5054, DOI 10.1074/jbc.M109017200; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; JAVITT NB, 1994, FASEB J, V8, P1308, DOI 10.1096/fasebj.8.15.8001744; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Pullingr CR, 2002, J CLIN INVEST, V110, P109, DOI 10.1172/JCI200215387; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Spady DK, 1998, J BIOL CHEM, V273, P126, DOI 10.1074/jbc.273.1.126; Stroup D, 1997, AM J PHYSIOL-GASTR L, V273, pG508, DOI 10.1152/ajpgi.1997.273.2.G508; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Wang DP, 1996, J LIPID RES, V37, P1831; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871	38	159	161	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39124	39132		10.1074/jbc.M305079200	http://dx.doi.org/10.1074/jbc.M305079200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12865425	hybrid			2022-12-25	WOS:000185575100126
J	Katoh, K; Shibata, H; Suzuki, H; Nara, A; Ishidoh, K; Kominami, E; Yoshimori, T; Maki, M				Katoh, K; Shibata, H; Suzuki, H; Nara, A; Ishidoh, K; Kominami, E; Yoshimori, T; Maki, M			The ALG-2-interacting protein Alix associates with CHMP4b, a human homologue of yeast Snf7 that is involved in multivesicular body sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; DOWN-REGULATION; GENE-EXPRESSION; ALG-2 INTERACTS; ANNEXIN-XI; MOUSE SKD1; CLONING; COMPLEX; APOPTOSIS; IDENTIFICATION	Alix (ALG-2-interacting protein X) is a 95-kDa protein that interacts with an EF-hand type Ca2+-binding protein, ALG-2 (apoptosis-linked gene 2), through its C-terminal proline-rich region. In this study, we searched for proteins that interact with human AlixDeltaC (a truncated form not containing the C-terminal region) by using a yeast two-hybrid screen, and we identified two similar human proteins, CHMP4a and CHMP4b (chromatin-modifying protein; charged multivesicular body protein), as novel binding partners of Alix. The interaction of Alix with CHMP4b was confirmed by a glutathione S-transferase pull-down assay and by co-immunoprecipitation experiments. Fluorescence microscopic analysis revealed that CHMP4b transiently expressed in HeLa cells mainly exhibited a punctate distribution in the perinuclear area and co-localized with co-expressed Alix. The distribution of CHMP4b partly overlapped the distributions of early and late endosomal marker proteins, EEA1 (early endosome antigen 1) and Lamp-1 (lysosomal membrane protein-1), respectively. Transient overexpression of CHMP4b induced the accumulation of ubiquitinated proteins as punctate patterns that were partly overlapped with the distribution of CHMP4b and inhibited the disappearance of endocytosed epidermal growth factor. In contrast, stably expressed CHMP4b in HEK293 cells was observed diffusely in the cytoplasm. Transient overexpression of AlixDeltaC in stably CHMP4b-expressing cells, however, induced formation of vesicle-like structures in which CHMP4b and AlixDeltaC were colocalized. SKD1(E235Q), a dominant negative form of the AAA type ATPase SKD1 that plays critical roles in the endocytic pathway, was co-immunoprecipitated with CHMP4b. Furthermore, CHMP4b co-localized with SKD1E235Q as punctate patterns in the perinuclear area, and Alix was induced to exhibit dot-like distributions overlapped with SKD1E235Q in HeLa cells. These results suggest that CHMP4b and Alix participate in formation of multivesicular bodies by cooperating with SKD1.	Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Natl Inst Genet, Dept Cell Genet, Shizuoka 4118540, Japan; Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1138421, Japan	Nagoya University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Juntendo University	Maki, M (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	mmaki@agr.nagoya-u.ac.jp	Kominami, Eiki/D-3802-2009; Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491; Nara, Atsuki/0000-0002-4115-3017				Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Che SL, 1999, J BIOL CHEM, V274, P5522, DOI 10.1074/jbc.274.9.5522; Che SL, 1997, BBA-GENE STRUCT EXPR, V1354, P231, DOI 10.1016/S0167-4781(97)00112-7; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Denison SH, 2000, FUNGAL GENET BIOL, V29, P61, DOI 10.1006/fgbi.2000.1188; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Howard TL, 2001, J CELL SCI, V114, P2395; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kamura T, 2001, J BIOL CHEM, V276, P16528, DOI 10.1074/jbc.M010142200; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kitaura Y, 1999, BIOCHEM BIOPH RES CO, V263, P68, DOI 10.1006/bbrc.1999.1189; Kitaura Y, 2001, J BIOL CHEM, V276, P14053, DOI 10.1074/jbc.M008649200; Maki M, 2002, BBA-PROTEINS PROTEOM, V1600, P51, DOI 10.1016/S1570-9639(02)00444-2; Maki M, 1998, J BIOCHEM, V124, P1170, DOI 10.1093/oxfordjournals.jbchem.a022235; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; MUNO D, 1993, ARCH BIOCHEM BIOPHYS, V306, P103, DOI 10.1006/abbi.1993.1486; Nara A, 2002, CELL STRUCT FUNCT, V27, P29, DOI 10.1247/csf.27.29; NegreteUrtasun S, 1997, J BACTERIOL, V179, P1832, DOI 10.1128/jb.179.5.1832-1835.1997; Nickas ME, 1996, MOL CELL BIOL, V16, P2585; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Ohkouchi S, 2001, J BIOCHEM-TOKYO, V130, P207, DOI 10.1093/oxfordjournals.jbchem.a002974; Pelham HRB, 2002, CURR OPIN CELL BIOL, V14, P454, DOI 10.1016/S0955-0674(02)00352-6; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Satoh H, 2002, BBA-PROTEINS PROTEOM, V1600, P61, DOI 10.1016/S1570-9639(02)00445-4; Satoh H, 2002, BIOCHEM BIOPH RES CO, V291, P1166, DOI 10.1006/bbrc.2002.6600; Scheuring S, 1999, GENE, V234, P149, DOI 10.1016/S0378-1119(99)00163-8; Schmidt MHH, 2003, J CELL SCI, V116, P2845, DOI 10.1242/jcs.00522; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Springael JY, 2002, FEBS LETT, V517, P103, DOI 10.1016/S0014-5793(02)02586-3; Stauffer DR, 2001, J CELL SCI, V114, P2383; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; TU JL, 1993, GENETICS, V135, P17; Usuba T, 2001, INT J CANCER, V94, P662, DOI 10.1002/ijc.1524; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wu Y, 2001, DIFFERENTIATION, V67, P139, DOI 10.1046/j.1432-0436.2001.670406.x; Wu Y, 2002, ONCOGENE, V21, P6801, DOI 10.1038/sj.onc.1205849; Xu WJ, 2001, J BACTERIOL, V183, P6917, DOI 10.1128/JB.183.23.6917-6923.2001; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747; Zhang QH, 2000, GENOME RES, V10, P1546, DOI 10.1101/gr.140200	52	165	172	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39104	39113		10.1074/jbc.M301604200	http://dx.doi.org/10.1074/jbc.M301604200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12860994	hybrid			2022-12-25	WOS:000185575100124
J	Peng, H; He, HY; Hay, J; Ruyechan, WT				Peng, H; He, HY; Hay, J; Ruyechan, WT			Interaction between the varicella zoster virus IE62 major transactivator and cellular transcription factor Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY PROTEIN; PHYSICAL INTERACTION; DNA-BINDING; FUNCTIONAL INTERACTION; REGULATORY FUNCTIONS; BASAL TRANSCRIPTION; ACTIVATION DOMAINS; GENE-EXPRESSION; SP-FAMILY; C-JUN	The varicella zoster virus (VZV) IE62 protein is involved in the activation of expression of all three kinetic classes of VZV proteins. Analysis of the viral promoter for VZV glycoprotein I has shown that the cellular factor Sp1 is involved in or required for the observed IE62 mediated activation. Co-immunoprecipitation experiments show that the two proteins are present in a complex in VZV-infected cells. Protein affinity pull-down assays using recombinant proteins showed that IE62 and Sp1 interact in the absence of any other viral and cellular proteins. Mapping studies using GST-fusion proteins containing truncations of IE62 and Sp1 have delimited the interacting regions to amino acids 612 - 778 in Sp1 and amino acids 226 - 299 in IE62. The region identified in Sp1 is involved in DNA-binding, synergistic Sp1 activation, and Sp1 interaction with cellular transcription factors. The interacting region identified in IE62 overlaps with or borders on sites involved in interactions with the VZV IE4 protein and the cellular factors TBP and TFIIB. Assays using wild-type and mutant promoter elements indicate that Sp1 is involved in recruitment of IE62 to the gI promoter and IE62 enhances Sp1 and TBP binding.	SUNY Buffalo, Dept Microbiol, Buffalo, NY 14214 USA; SUNY Buffalo, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ruyechan, WT (corresponding author), SUNY Buffalo, Dept Microbiol, 151 Biomed Res Bldg, Buffalo, NY 14214 USA.	ruyechan@buffalo.edu			NIAID NIH HHS [AI18449] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI018449, R01AI018449, R21AI018449] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baudoux L, 2000, J BIOL CHEM, V275, P32822, DOI 10.1074/jbc.M001444200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Boucaud D, 1998, J INFECT DIS, V178, pS34, DOI 10.1086/514276; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; COHEN JI, 2001, VIROLOGY, P2707; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Datta PK, 2000, J BIOL CHEM, V275, P40014, DOI 10.1074/jbc.C000508200; DAVISON AJ, 1986, J GEN VIROL, V67, P2279, DOI 10.1099/0022-1317-67-10-2279; Defechereux P, 1997, J VIROL, V71, P7073, DOI 10.1128/JVI.71.9.7073-7079.1997; DEFECHEREUX P, 1993, J VIROL, V67, P4379, DOI 10.1128/JVI.67.7.4379-4385.1993; DISNEY GH, 1990, J GEN VIROL, V71, P2999, DOI 10.1099/0022-1317-71-12-2999; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Grondin B, 2000, J VIROL, V74, P11504, DOI 10.1128/JVI.74.24.11504-11510.2000; GU BH, 1995, MOL CELL BIOL, V15, P3618; GU BH, 1993, P NATL ACAD SCI USA, V90, P9528, DOI 10.1073/pnas.90.20.9528; He H, 2001, ARCH VIR S, V17, P57; IMBALZANO AN, 1991, J VIROL, V65, P565, DOI 10.1128/JVI.65.2.565-574.1991; INCHAUSPE G, 1989, VIROLOGY, V173, P700, DOI 10.1016/0042-6822(89)90583-7; Ito H, 2003, J VIROL, V77, P489, DOI 10.1128/JVI.77.1.489-498.2003; JACKERS P, 1992, J VIROL, V66, P3899, DOI 10.1128/JVI.66.6.3899-3903.1992; Kantakamalakul W, 1995, NEUROLOGY, V45, pS28, DOI 10.1212/WNL.45.12_Suppl_8.S28; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kim DB, 2002, J VIROL, V76, P6473, DOI 10.1128/JVI.76.13.6473-6479.2002; KOST RG, 1995, VIROLOGY, V209, P218, DOI 10.1006/viro.1995.1246; KRADY JK, 1995, MOL CELL BIOL, V15, P524, DOI 10.1128/MCB.15.1.524; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LING P, 1992, J VIROL, V66, P3690, DOI 10.1128/JVI.66.6.3690-3698.1992; Lynch JM, 2002, VIROLOGY, V302, P71, DOI 10.1006/viro.2002.1555; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MORIUCHI H, 1993, J VIROL, V67, P4290, DOI 10.1128/JVI.67.7.4290-4295.1993; MORIUCHI H, 1993, J VIROL, V67, P2739, DOI 10.1128/JVI.67.5.2739-2746.1993; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PERERA LP, 1994, J VIROL, V68, P2468, DOI 10.1128/JVI.68.4.2468-2477.1994; PERERA LP, 1992, J VIROL, V66, P5298, DOI 10.1128/JVI.66.9.5298-5304.1992; PERERA LP, 1993, J VIROL, V67, P4474, DOI 10.1128/JVI.67.8.4474-4483.1993; PERERA LP, 1992, VIROLOGY, V191, P346, DOI 10.1016/0042-6822(92)90197-W; Perera LP, 2000, J BIOL CHEM, V275, P487, DOI 10.1074/jbc.275.1.487; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Rahaus M, 1999, VIRUS RES, V62, P77, DOI 10.1016/S0168-1702(99)00075-1; Rahaus M, 2000, VIRUS RES, V69, P69, DOI 10.1016/S0168-1702(00)00180-5; Rohr O, 1997, J BIOL CHEM, V272, P31149, DOI 10.1074/jbc.272.49.31149; Rost B, 1996, METHOD ENZYMOL, V266, P525; Ruyechan William T., 2003, Journal of Medical Virology, V70, pS90, DOI 10.1002/jmv.10328; RUYECHAN WT, 1999, ENCY VIROLOGY, P1878; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Sommer MH, 2001, J VIROL, V75, P8224, DOI 10.1128/JVI.75.17.8224-8239.2001; Spengler ML, 2000, VIROLOGY, V272, P375, DOI 10.1006/viro.2000.0389; Steger G, 2002, J GEN VIROL, V83, P503, DOI 10.1099/0022-1317-83-3-503; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276; Trejo SR, 1997, J BIOL CHEM, V272, P27411, DOI 10.1074/jbc.272.43.27411; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61	65	41	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38068	38075		10.1074/jbc.M302259200	http://dx.doi.org/10.1074/jbc.M302259200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855699	hybrid			2022-12-25	WOS:000185437200128
J	Zhou, JM; Ryan, AJ; Medh, J; Mallampalli, RK				Zhou, JM; Ryan, AJ; Medh, J; Mallampalli, RK			Oxidized lipoproteins inhibit surfactant phosphatidylcholine synthesis via calpain-mediated cleavage of CTP: Phosphocholine cytidylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT NEUTRAL PROTEASE; ALVEOLAR EPITHELIAL-CELLS; RAT LUNG; LIPID ACTIVATION; II PNEUMOCYTES; REGULATES CTP; FATTY-ACIDS; IN-VITRO; ALPHA; DEGRADATION	We investigated effects of pro-atherogenic oxidized lipoproteins on phosphatidylcholine (PtdCho) biosynthesis in murine lung epithelial cells (MLE-12). Cells surface-bound, internalized, and degraded oxidized low density lipoproteins (Ox-LDL). Ox-LDL significantly reduced [H-3]choline incorporation into PtdCho in cells by selectively inhibiting the activity of the rate-regulatory enzyme, CTP: phosphocholine cytdylyltransferase (CCT). Ox-LDL coordinately increased the cellular turnover of CCTalpha protein as determined by [S-35] methionine pulse-chase studies by inducing the calcium-activated proteinase, calpain. Forced expression of calpain or exposure of cells to the calcium ionophore, A23187, increased CCTalpha degradation, whereas overexpression of the endogenous calpain inhibitor, calpastatin, attenuated OxLDL-induced CCTalpha degradation. The effects of Ox-LDL on CCTalpha breakdown were attenuated in calpain-deficient cells. In vitro calpain digestion of CCTalpha isolated from cells transfected with truncated or internal deletion mutants indicated multiple cleavage sites within the CCTalpha primary structure, leading to the generation of a 26-kDa (p26) fragment. Calpain hydrolysis of purified CCTalpha generated p26, which upon NH2-terminal sequencing localized a calpain attack site within the CCTalpha amino terminus. Expression of a CCTalpha mutant where the amino-terminal cleavage site and a putative carboxyl-terminal hydrolysis region were modified resulted in an enzyme that was significantly less sensitive to proteolytic cleavage and restored the ability of cells to synthesize surfactant PtdCho after Ox-LDL treatment. Thus, these results provide a critical link between proatherogenic lipoproteins and their metabolic target, CCTalpha, resulting in impaired surfactant metabolism.	Univ Iowa, Coll Med, Dept Internal Med, Div Pulm Dis Crit Care & Occupat Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Mallampalli, RK (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, Div Pulm Dis Crit Care & Occupat Med, Iowa City, IA 52242 USA.	rama-mallampalli@uiowa.edu	RYAN, Anderson/ACG-0319-2022	RYAN, Anderson/0000-0001-6241-7969	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071040, R01HL055584, R01HL068135] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL55584, R01 HL055584, R01 HL068135, HL68135, R01 HL068135-01, R01 HL071040-01, R01 HL071040, HL71040, R01 HL055584-04] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; BALIBREA CANTERO JL, 1994, AM J RESP CRIT CARE, V149, P699, DOI 10.1164/ajrccm.149.3.8118639; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOTBOL V, 1983, J BIOL CHEM, V258, P1942; CHAPPELL DA, 1993, J BIOL CHEM, V268, P25487; Chaudhuri P, 2003, ARTERIOSCL THROM VAS, V23, P218, DOI 10.1161/01.ATV.0000052673.77316.01; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Drobnies AE, 1999, BIOCHEMISTRY-US, V38, P15606, DOI 10.1021/bi991573v; EMMETT M, 1987, P SOC EXP BIOL MED, V184, P83; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FELDMAN DA, 1978, J BIOL CHEM, V253, P4980; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; GROBLEWSKI GE, 1995, J BIOL CHEM, V270, P1437, DOI 10.1074/jbc.270.3.1437; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Huang J, 1998, P NATL ACAD SCI USA, V95, P12100, DOI 10.1073/pnas.95.21.12100; Isakson BE, 2001, AM J PHYSIOL-LUNG C, V280, pL221, DOI 10.1152/ajplung.2001.280.2.L221; Jialal I, 1996, CLIN CHEM, V42, P498; Jobe AH, 1998, P ASSOC AM PHYSICIAN, V110, P489; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; Kolleck I, 1999, FREE RADICAL BIO MED, V27, P882, DOI 10.1016/S0891-5849(99)00139-2; Lagace TA, 2002, MOL CELL BIOL, V22, P4851, DOI 10.1128/MCB.22.13.4851-4862.2002; Longo CA, 1997, AM J RESP CELL MOL, V16, P605, DOI 10.1165/ajrcmb.16.5.9160843; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; Mallampalli RK, 1996, BIOCHEM J, V318, P333, DOI 10.1042/bj3180333; MALLAMPALLI RK, 1994, AM J PHYSIOL-LUNG C, V267, pL641, DOI 10.1152/ajplung.1994.267.6.L641; Mallampalli RK, 1997, J CLIN INVEST, V99, P2020, DOI 10.1172/JCI119370; Papen M, 2001, CELL PHYSIOL BIOCHEM, V11, P187, DOI 10.1159/000047805; Patzke H, 2002, J BIOL CHEM, V277, P8054, DOI 10.1074/jbc.M109645200; PELECH SL, 1983, J BIOL CHEM, V258, P6782; Ridsdale R, 2001, J BIOL CHEM, V276, P49148, DOI 10.1074/jbc.M103566200; ROONEY SA, 1985, AM REV RESPIR DIS, V131, P439; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P314; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; Ryan AJ, 2002, AM J PHYSIOL-LUNG C, V283, pL310, DOI 10.1152/ajplung.00021.2002; SASAKI T, 1984, J BIOL CHEM, V259, P2489; Schunemann HJ, 1997, AM J EPIDEMIOL, V146, P939; SHIRATORI Y, 1995, J BIOL CHEM, V270, P29894; SUZUKI K, 1988, ADV ENZYME REGUL, V27, P153; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; van der Luit AH, 2002, J BIOL CHEM, V277, P39541, DOI 10.1074/jbc.M203176200; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WANG YL, 1993, J BIOL CHEM, V268, P5899; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503	51	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37032	37040		10.1074/jbc.M304316200	http://dx.doi.org/10.1074/jbc.M304316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857760	hybrid, Green Accepted			2022-12-25	WOS:000185437200009
J	Lardinois, OM; de Montellano, PRO				Lardinois, OM; de Montellano, PRO			Intra- and intermolecular transfers of protein radicals in the reactions of sperm whale myoglobin with hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H2O2-MEDIATED CROSS-LINKING; CYTOCHROME-C PEROXIDASE; COMPOUND-I; AMINO-ACID; HEME; IDENTIFICATION; METMYOGLOBIN; TYR-151; LACTOPEROXIDASE; ISODITYROSINE	Reaction of sperm whale metmyoglobin (SwMb) with H2O2 produces a ferryl (MbFe(IV)=O) species and a protein radical and leads to the formation of oligomeric products. The ferryl species is maximally formed with one equivalent of H2O2, and the maximum yields of the dimer (28%) and trimer (17%) with 1 or 2 eq. Co-incubation of the SwMb Y151F mutant with native apoSwMb and H2O2 produced dimeric products, which requires radical transfer from the nondimerizing Y151F mutant to apoSwMb. Autoreduction of ferryl SwMb to the ferric state is biphasic with t = 3.4 and 25.9 min. An intramolecular autoreduction process is implicated at low protein concentrations, but oligomerization decreases the lifetime of the ferryl species at high protein concentrations. A fraction of the protein remained monomeric. This dimerization-resistant protein was in the ferryl state, but after autoreduction it underwent normal dimerization with H2O2. Proteolytic digestion established the presence of both dityrosine and isodityrosine cross-links in the oligomeric proteins, with the isodityrosine links primarily forged by Tyr(151)-Tyr(151) coupling. The tyrosine content decreased by 47% in the dimer and 14% in the recovered monomer, but the yields of isodityrosine and dityrosine in the dimer were only 15.2 and 6.8% of the original tyrosine content. Approximately 23% of the lost tyrosines therefore have an alternative but unknown fate. The results clearly demonstrate the concurrence of intra- and intermolecular electron transfer processes involving Mb protein radicals. Intermolecular electron transfers that generate protein radicals on bystander proteins are likely to propagate the cellular damage initiated by the reaction of metalloproteins with H2O2.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 600 16th St, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu			NIGMS NIH HHS [GM32488] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P44; Blodig W, 2001, J MOL BIOL, V305, P851, DOI 10.1006/jmbi.2000.4346; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; Colas C, 2002, J BIOL CHEM, V277, P7191, DOI 10.1074/jbc.M109523200; COURTIN F, 1984, BIOCHEM BIOPH RES CO, V121, P463, DOI 10.1016/0006-291X(84)90205-5; Davies MJ, 1999, FREE RADICAL BIO MED, V27, P1151, DOI 10.1016/S0891-5849(99)00206-3; DeGray JA, 1997, J BIOL CHEM, V272, P2359; Dorlet P, 2002, BIOCHEMISTRY-US, V41, P6107, DOI 10.1021/bi015871f; DUNFORD HB, 1999, HEME PEROXIDASES, P20; Egawa T, 2000, J BIOL CHEM, V275, P34858, DOI 10.1074/jbc.M004026200; Fancy DA, 1998, BIOCHEM BIOPH RES CO, V247, P420, DOI 10.1006/bbrc.1998.8558; Fenwick CW, 1996, J AM CHEM SOC, V118, P12236, DOI 10.1021/ja962764d; FOERDER CA, 1977, P NATL ACAD SCI USA, V74, P4214, DOI 10.1073/pnas.74.10.4214; FRY SC, 1984, METHOD ENZYMOL, V107, P388; GARNER MH, 1973, J BIOL CHEM, V248, P5451; GARRISON WM, 1987, CHEM REV, V87, P381, DOI 10.1021/cr00078a006; GIBSON JF, 1958, NATURE, V181, P1398, DOI 10.1038/1811398a0; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; Ivancich A, 1997, BIOCHEMISTRY-US, V36, P9356, DOI 10.1021/bi970886s; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; KING NK, 1963, J BIOL CHEM, V238, P1520; Lardinois OM, 1999, J BIOL CHEM, V274, P35441, DOI 10.1074/jbc.274.50.35441; Lardinois OM, 2001, J BIOL CHEM, V276, P23186, DOI 10.1074/jbc.M102084200; LeBrun LA, 2002, J BIOL CHEM, V277, P12755, DOI 10.1074/jbc.M112155200; Matsui T, 1999, J AM CHEM SOC, V121, P9952, DOI 10.1021/ja9914846; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Qian SY, 2002, BIOCHEM J, V363, P281, DOI 10.1042/0264-6021:3630281; RAO SI, 1993, J BIOL CHEM, V268, P803; Reeder BJ, 2002, BIOCHEMISTRY-US, V41, P367, DOI 10.1021/bi011335b; Rich PR, 2002, BBA-BIOENERGETICS, V1554, P137, DOI 10.1016/S0005-2728(02)00228-1; SATAKE K, 1960, J BIOCHEM-TOKYO, V47, P654, DOI 10.1093/oxfordjournals.jbchem.a127107; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; Stadtman ER, 1997, CHEM RES TOXICOL, V10, P485, DOI 10.1021/tx960133r; Svistunenko DA, 2002, BIOPHYS J, V83, P2845, DOI 10.1016/S0006-3495(02)75293-4; TEW D, 1988, J BIOL CHEM, V263, P17880; Thomas EL, 1985, LACTOPEROXIDASE SYST, P31; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; VOLKER V, 1992, P NATL ACAD SCI USA, V89, P996; WHITTAKER MM, 1990, J BIOL CHEM, V265, P9610; WILKS A, 1992, J BIOL CHEM, V267, P8827; Witting PK, 2000, J BIOL CHEM, V275, P20391, DOI 10.1074/jbc.M000373200; YONETANI T, 1967, J BIOL CHEM, V242, P1974	44	34	34	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36214	36226		10.1074/jbc.M304726200	http://dx.doi.org/10.1074/jbc.M304726200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855712	hybrid			2022-12-25	WOS:000185318300043
J	Poole, CB; Jin, JM; McReynolds, LA				Poole, CB; Jin, JM; McReynolds, LA			Cloning and biochemical characterization of blisterase, a subtilisin-like convertase from the filarial parasite, Onchocerca volvulus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; ALPHA-1-ANTITRYPSIN PORTLAND; PROPROTEIN CONVERTASE; ACTIVE-SITE; HUMAN FURIN; ENDOPROTEASE; CLEAVAGE; PROTEINS; PROTEASE; DOMAIN	Blisterase is a subtilisin-like proprotein convertase of nematodes. The enzyme is named after the blistered cuticle found in Caenorhabditis elegans with the bli-4 e937 mutation. The critical role of the enzyme in cuticle production makes it a potential drug target for parasitic nematodes. We have cloned and expressed blisterase from the parasitic nematode Onchocerca volvulus, a major cause of blindness in Africa. The catalytic domain of the protease exhibits 84% identity with the corresponding domain of its closest homologue, C. elegans blisterase. O. volvulus blisterase expressed in insect cells has maximal activity in 1 mM calcium at neutral pH. The protease is inhibited by EDTA, the suicide substrate decanoyl-RVKR-chloromethylketone, alpha(1)-antitrypsin Portland and by its own propeptide. Substrate assays with fluorescent peptides show that O. volvulus blisterase requires a P4 arginine and a basic amino acid at P1 for cleavage. The k(cat) of blisterase on the peptide substrate, t-butyloxycarbonyl-RVRR-4-methylcoumaryl-7-amide was determined to be 0.018 s-1. In vitro cleavage studies with the nematode polyprotein antigen demonstrated that blisterase cleaved at tetrabasic (RRKR) but not at dibasic (KR) sites. This report describes the first biochemical characterization of the nematode specific protease, blisterase.	New England Biolabs Inc, Mol Parasitol Div, Beverly, MA 01915 USA		McReynolds, LA (corresponding author), New England Biolabs Inc, Mol Parasitol Div, 32 Tozer Rd, Beverly, MA 01915 USA.	mcreynolds@neb.com						Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; [Anonymous], 1995, WHO TECHN REP SER; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Coombs GH, 1997, PARASITOLOGY, V114, pS61, DOI 10.1017/S003118209700111X; Despommier D, 2000, PARASITIC DIS; Dufour EK, 1998, FEBS LETT, V426, P41, DOI 10.1016/S0014-5793(98)00307-X; Evans TC, 1998, PROTEIN SCI, V7, P2256, DOI 10.1002/pro.5560071103; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GOMEZSALADIN E, 1994, CELL MOL NEUROBIOL, V14, P9, DOI 10.1007/BF02088586; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Jin JM, 1999, GENE, V237, P161, DOI 10.1016/S0378-1119(99)00282-6; Kennedy MW, 2000, PARASITOL TODAY, V16, P373, DOI 10.1016/S0169-4758(00)01743-9; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P85; KRAMER JM, 1997, C ELEGANS, V2, P471; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li C, 1999, ANN NY ACAD SCI, V897, P239, DOI 10.1111/j.1749-6632.1999.tb07895.x; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; MCREYNOLDS LA, 1993, PARASITOL TODAY, V9, P403, DOI 10.1016/0169-4758(93)90046-I; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Molyneux DH, 2001, CURR OPIN INFECT DIS, V14, P155, DOI 10.1097/00001432-200104000-00008; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OTTESEN EA, 1990, NEW ENGL J MED, V322, P1113, DOI 10.1056/NEJM199004193221604; PETERS K, 1991, GENETICS, V129, P95; Poole CB, 1996, MOL BIOCHEM PARASIT, V82, P51, DOI 10.1016/0166-6851(96)02721-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEGEL IH, 1975, ENZYME KINETICS, P18; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; SIEZEN RJ, 1995, INTRAMOLECULAR CHAPE, P233; Thacker C, 2000, BIOESSAYS, V22, P545, DOI 10.1002/(SICI)1521-1878(200006)22:6&lt;545::AID-BIES7&gt;3.0.CO;2-F; Thacker C, 1999, GENOME RES, V9, P348; THACKER C, 1995, GENE DEV, V9, P956, DOI 10.1101/gad.9.8.956; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsuji A, 1999, J BIOCHEM, V126, P591, DOI 10.1093/oxfordjournals.jbchem.a022491; WHO, 1991, TROP DIS PROGR RES 1; YANG J, 1994, MOL CELL BIOL, V14, P2722, DOI 10.1128/MCB.14.4.2722	45	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36183	36190		10.1074/jbc.M302601200	http://dx.doi.org/10.1074/jbc.M302601200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855702	hybrid			2022-12-25	WOS:000185318300040
J	Yang, YS; Poncet, J; Garnier, J; Zatylny, C; Bachere, E; Aumelas, A				Yang, YS; Poncet, J; Garnier, J; Zatylny, C; Bachere, E; Aumelas, A			Solution structure of the recombinant penaeidin-3, a shrimp antimicrobial peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHITIN-BINDING ACTIVITY; NMR-SPECTROSCOPY; CHEMICAL-SHIFTS; INSECT DEFENSIN; GENE-EXPRESSION; PROTEINS; HEMOCYTES; PROTEGRIN-1; ALIGNMENT; VANNAMEI	Penaeidins are a family of antimicrobial peptides of 47 - 63 residues isolated from several species of shrimp. These peptides display a proline-rich domain (N-terminal part) and a cysteine-rich domain (C-terminal part) stabilized by three conserved disulfide bonds whose arrangement has not yet been characterized. The recombinant penaeidin-3a of Litopenaeus vannamei ( 63 residues) and its [T8A]-Pen-3a analogue were produced in Saccharomyces cerevisiae and showed similar antimicrobial activity. The solution structure of the [ T8A]-Pen3a analogue was determined by using two-dimensional H-1 NMR and simulated annealing calculations. The proline-rich domain, spanning residues 1 - 28 was found to be unconstrained. In contrast, the cysteine-rich domain, spanning residues 29 - 58, displays a well defined structure, which consists of an amphipathic helix ( 41 - 50) linked to the upstream and the downstream coils by two disulfide bonds (Cys(32) -Cys(47) and Cys(48) -Cys(55)). These two coils are in turn linked together by the third disulfide bond (Cys(36) - Cys(54)). Such a disulfide bond packing, which is in agreement with the analysis of trypsin digests by ESI-MS, contributes to the highly hydrophobic core. Side chains of Arg(45) and Arg(50), which belong to the helix, and side chains of Arg(37) and Arg(53), which belong to the upstream and the downstream coils, are located in two opposite parts of this globular and compact structure. The environment of these positively charged residues, either by hydrophobic clusters at the surface of the cysteine-rich domain or by sequential hydrophobic residues in the unconstrained proline-rich domain, gives rise to the amphipathic character required for antimicrobial peptides. We hypothesize that the antimicrobial activity of penaeidins can be explained by a cooperative effect between the proline-rich and cysteine-rich features simultaneously present in their sequences.	Univ Montpellier, Fac Pharm, Ctr Biochim Struct, CNRS,UMR 5048,INSERM,U414, F-34093 Montpellier 5, France; CNRS, UPR 2580, Lab Genom Fonct, F-34094 Montpellier 5, France; Univ Montpellier 2, IFREMER, CNR, FRE 2626, F-34095 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Ifremer; Universite de Montpellier	Aumelas, A (corresponding author), Univ Montpellier, Fac Pharm, Ctr Biochim Struct, CNRS,UMR 5048,INSERM,U414, 15 Ave Charles Flahault, F-34093 Montpellier 5, France.	aumelas@cbs.cnrs.fr	Bachere, Evelyne/O-6117-2014	Zatylny-Gaudin, Celine/0000-0001-9258-9876				Aumelas A, 1996, EUR J BIOCHEM, V237, P575, DOI 10.1111/j.1432-1033.1996.0575p.x; Bachere E, 2000, AQUACULTURE, V191, P71, DOI 10.1016/S0044-8486(00)00419-1; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; Cuthbertson BJ, 2002, IMMUNOGENETICS, V54, P442, DOI 10.1007/s00251-002-0487-z; Destoumieux D, 2000, J CELL SCI, V113, P461; Destoumieux D, 1997, J BIOL CHEM, V272, P28398, DOI 10.1074/jbc.272.45.28398; Destoumieux D, 1999, EUR J BIOCHEM, V266, P335, DOI 10.1046/j.1432-1327.1999.00855.x; Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#; Fahrner RL, 1996, CHEM BIOL, V3, P543, DOI 10.1016/S1074-5521(96)90145-3; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Ganz T, 1999, SCIENCE, V286, P420, DOI 10.1126/science.286.5439.420; Gross PS, 2001, DEV COMP IMMUNOL, V25, P565, DOI 10.1016/S0145-305X(01)00018-0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hunter HN, 2002, J BIOL CHEM, V277, P37597, DOI 10.1074/jbc.M205305200; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; KAWANO K, 1990, J BIOL CHEM, V265, P15365; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; Mandard N, 1998, EUR J BIOCHEM, V256, P404, DOI 10.1046/j.1432-1327.1998.2560404.x; Mandard N, 1999, J BIOMOL STRUCT DYN, V17, P367, DOI 10.1080/07391102.1999.10508368; Mandard N, 2002, EUR J BIOCHEM, V269, P1190, DOI 10.1046/j.0014-2956.2002.02760.x; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; Markley JL, 1998, EUR J BIOCHEM, V256, P1, DOI 10.1046/j.1432-1327.1998.2560001.x; Munoz M, 2002, EUR J BIOCHEM, V269, P2678, DOI 10.1046/j.1432-1033.2002.02934.x; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; Oren Z, 1998, BIOPOLYMERS, V47, P451; Penin F, 1997, J MOL BIOL, V270, P496, DOI 10.1006/jmbi.1997.1123; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RANCE M, 1987, J MAGN RESON, V74, P557, DOI 10.1016/0022-2364(87)90277-0; REICHHART JM, 1992, INVERTEBR REPROD DEV, V21, P15, DOI 10.1080/07924259.1992.9672215; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Rojtinnakorn J, 2002, FISH SHELLFISH IMMUN, V13, P69, DOI 10.1006/fsim.2001.0382; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; TEPLYAKOV A, 1992, EUR J BIOCHEM, V208, P281, DOI 10.1111/j.1432-1033.1992.tb17184.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Wishart DS, 2001, METHOD ENZYMOL, V338, P3; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wuthrich K, 1986, NMR PROTEINS NUCL AC	45	53	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36859	36867		10.1074/jbc.M305450200	http://dx.doi.org/10.1074/jbc.M305450200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12842879	hybrid, Green Published			2022-12-25	WOS:000185318300119
J	Cartier, C; Hemonnot, B; Gay, B; Bardy, M; Sanchiz, L; Devaux, C; Briant, L				Cartier, C; Hemonnot, B; Gay, B; Bardy, M; Sanchiz, L; Devaux, C; Briant, L			Active cAMP-dependent protein kinase incorporated within highly purified HIV-1 particles is required for viral infectivity and interacts with viral capsid protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TYROSINE PHOSPHORYLATION; MATRIX; CELLS; IDENTIFICATION; TEGUMENT; PRODUCT; BINDING; VIRIONS; REGION	Host cell components, including protein kinases such as ERK-2/mitogen-activated protein kinase, incorporated within human immunodeficiency virus type 1 (HIV-1) virions play a pivotal role in the ability of HIV to infect and replicate in permissive cells. The present work provides evidence that the catalytic subunit of cAMP-dependent protein kinase (C-PKA) is packaged within HIV-1 virions as demonstrated using purified subtilisin-digested viral particles. Virus-associated C-PKA was shown to be enzymatically active and able to phosphorylate synthetic substrate in vitro. Suppression of virion-associated C-PKA activity by specific synthetic inhibitor had no apparent effect on viral precursor maturation and virus assembly. However, virus-associated C-PKA activity was demonstrated to regulate HIV-1 infectivity as assessed by single round infection assays performed by using viruses produced from cells expressing an inactive form of C-PKA. In addition, virus-associated C-PKA was found to co-precipitate with and to phosphorylate the CAp24gag protein. Altogether our results indicate that virus-associated C-PKA regulates HIV-1 infectivity, possibly by catalyzing phosphorylation of the viral CAp24gag protein.	Univ Montpellier 1, Inst Biol, Lab Infect Retrovirales & Signalisat Cellulaire, CNRS,UMR 5121,CS 89508, F-34960 Montpellier 2, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Briant, L (corresponding author), Univ Montpellier 1, Inst Biol, Lab Infect Retrovirales & Signalisat Cellulaire, CNRS,UMR 5121,CS 89508, 4 Bd Henri IV, F-34960 Montpellier 2, France.		Briant, Laurence/AAB-9281-2021	FAUVEL, Benedicte/0000-0003-1166-8391; Briant, Laurence/0000-0002-1995-3501				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Briant L, 1998, J VIROL, V72, P6207, DOI 10.1128/JVI.72.7.6207-6214.1998; Bukrinskaya AG, 1996, P NATL ACAD SCI USA, V93, P367, DOI 10.1073/pnas.93.1.367; Camaur D, 1997, J VIROL, V71, P6834, DOI 10.1128/JVI.71.9.6834-6841.1997; Cartier C, 1999, J BIOL CHEM, V274, P19434, DOI 10.1074/jbc.274.27.19434; Cartier C, 1997, J VIROL, V71, P4832, DOI 10.1128/JVI.71.6.4832-4837.1997; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; CHUNG TD, 1989, J VIROL, V63, P3389, DOI 10.1128/JVI.63.8.3389-3398.1989; CORBEAU P, 1993, J IMMUNOL, V150, P290; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; Dawson R. M. C., 1991, DATA BIOCH RES, V3rd, P363; Elliott G, 1996, VIROLOGY, V226, P140, DOI 10.1006/viro.1996.0638; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; Geldreich A, 1989, Virus Genes, V2, P313, DOI 10.1007/BF00684039; GUPTA AK, 1995, J GEN VIROL, V76, P365, DOI 10.1099/0022-1317-76-2-365; HATANAKA M, 1972, VIROLOGY, V47, P536, DOI 10.1016/0042-6822(72)90297-8; HOFMANN B, 1993, AIDS, V7, P659, DOI 10.1097/00002030-199305000-00008; Hui EKW, 2002, CELL MOL LIFE SCI, V59, P920, DOI 10.1007/s00018-002-8479-6; Jacque JM, 1998, EMBO J, V17, P2607, DOI 10.1093/emboj/17.9.2607; KANN M, 1994, J VIROL, V68, P7993, DOI 10.1128/JVI.68.12.7993-8000.1994; Morrison EE, 1998, J VIROL, V72, P7108, DOI 10.1128/JVI.72.9.7108-7114.1998; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muller B, 2002, J VIROL, V76, P1015, DOI 10.1128/JVI.76.3.1015-1024.2002; Muniz M, 1997, P NATL ACAD SCI USA, V94, P14461, DOI 10.1073/pnas.94.26.14461; Ott DE, 1996, J VIROL, V70, P7734, DOI 10.1128/JVI.70.11.7734-7743.1996; Ott DE, 2000, VIROLOGY, V266, P42, DOI 10.1006/viro.1999.0075; PARADIS H, 1991, J BIOL CHEM, V266, P9647; RATKA M, 1989, J VIROL, V63, P3954, DOI 10.1128/JVI.63.9.3954-3960.1989; Shabb JB, 2001, CHEM REV, V101, P2381, DOI 10.1021/cr000236l; STEVENSON M, 1994, J LEUKOCYTE BIOL, V56, P278, DOI 10.1002/jlb.56.3.278; STRAND M, 1971, NATURE-NEW BIOL, V233, P137, DOI 10.1038/newbio233137a0; VERONESE FD, 1987, AIDS RES HUM RETROV, V3, P253, DOI 10.1089/aid.1987.3.253; WILSON ME, 1985, VIROLOGY, V143, P526, DOI 10.1016/0042-6822(85)90391-5; Wolf DG, 1998, ARCH VIROL, V143, P1223, DOI 10.1007/s007050050370; ZHANG G, 1990, J GEN VIROL, V71, P1757, DOI 10.1099/0022-1317-71-8-1757	36	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35211	35219		10.1074/jbc.M301257200	http://dx.doi.org/10.1074/jbc.M301257200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842892	hybrid			2022-12-25	WOS:000185164400058
J	Hamaguchi, A; Suzuki, E; Murayama, K; Fujimura, T; Hikita, T; Iwabuchi, K; Handa, K; Withers, DA; Masters, SC; Fu, HA; Hakomori, S				Hamaguchi, A; Suzuki, E; Murayama, K; Fujimura, T; Hikita, T; Iwabuchi, K; Handa, K; Withers, DA; Masters, SC; Fu, HA; Hakomori, S			Sphingosine-dependent protein kinase-1, directed to 14-3-3, is identified as the kinase domain of protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID METABOLITES; PROTEOLYTIC ACTIVATION; MASS-SPECTROMETRY; INDUCED APOPTOSIS; CELLS; SPHINGOSINE-1-PHOSPHATE; DIFFERENTIATION; CERAMIDE; 1-PHOSPHATE; GROWTH	Some protein kinases are known to be activated by D-erythro-sphingosine (Sph) or N,N-dimethyl-D-erythrosphingosine (DMS), but not by ceramide, Sph-1-P, other sphingolipids, or phospholipids. Among these, a specific protein kinase that phosphorylates Ser(60), Ser(59), or Ser(58) of 14-3-3beta, 14-3-3eta, or 14-3-3zeta, respectively, was termed "sphingosine-dependent protein kinase-1" (SDK1) (Megidish, T., Cooper, J., Zhang, L., Fu, H., and Hakomori, S. (1998) J. Biol. Chem. 273, 21834 - 21845). We have now identified SDK1 as a protein having the C-terminal half kinase domain of protein kinase Cdelta (PKCdelta) based on the following observations. (i) Large-scale preparation and purification of proteins showing SDK1 activity from rat liver (by six steps of chromatography) gave a final fraction with an enhanced level of an similar to40-kDa protein band. This fraction had SDK1 activity similar to50,000-fold higher than that in the initial extract. (ii) This protein had similar to 53% sequence identity to the Ser/Thr kinase domain of PKCdelta based on peptide mapping using liquid chromatography/ mass spectrometry and liquid chromatography/ tandem mass spectrometry data. (iii) A search for amino acid homology based on the BLAST algorithm indicated that the only protein with high homology to the similar to40-kDa band is the kinase domain of PKCdelta. The kinase activity of PKCdelta did not depend on Sph or DMS; rather, it was inhibited by these sphingoid bases, i.e. PKCdelta did not display any SDK1 activity. However, strong SDK1 activity became detectable when PKCdelta was incubated with caspase-3, which releases the similar to40-kDa kinase domain. PKCdelta and SDK1 showed different lipid requirements and substrate specificity, although both kinase activities were inhibited by common PKC inhibitors. The high susceptibility of SDK1 to Sph and DMS accounts for their important modulatory role in signal transduction.	Pacific NW Res Inst, Div Biomembrane Res, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98122 USA; Juntendo Univ, Sch Med, Cent Lab Med Sci, Tokyo 1138421, Japan; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	University of Washington; University of Washington Seattle; Juntendo University; Emory University	Hakomori, S (corresponding author), Pacific NW Res Inst, Div Biomembrane Res, 720 Broadway, Seattle, WA 98122 USA.		Suzuki, Erika/B-3456-2008	Suzuki, Erika/0000-0002-4010-8716; Fujimura, Tsutomu/0000-0003-1744-7725	NCI NIH HHS [R01 CA82167] Funding Source: Medline; NIGMS NIH HHS [R01 GM53165] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053165] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Choudhary JS, 2001, TRENDS BIOTECHNOL, V19, pS17, DOI 10.1016/S0167-7799(01)01795-4; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Grant S, 2002, J CLIN INVEST, V109, P717, DOI 10.1172/JCI200215302; Graves PR, 2002, MICROBIOL MOL BIOL R, V66, P39, DOI 10.1128/MMBR.66.1.39-63.2002; Hancock WS, 2002, PROTEOMICS, V2, P352, DOI 10.1002/1615-9861(200204)2:4<352::AID-PROT352>3.0.CO;2-U; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; IGARASHI Y, 1989, BIOCHEM BIOPH RES CO, V164, P1411, DOI 10.1016/0006-291X(89)91827-5; Kihara A, 2003, J BIOL CHEM, V278, P14578, DOI 10.1074/jbc.M211416200; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Mano N, 1997, ANAL BIOCHEM, V244, P291, DOI 10.1006/abio.1996.9891; MEGIDISH T, 1995, BIOCHEM BIOPH RES CO, V216, P739, DOI 10.1006/bbrc.1995.2684; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Megidish T, 1999, BIOCHEMISTRY-US, V38, P3369, DOI 10.1021/bi982548c; Megidish T, 2000, METHOD ENZYMOL, V312, P381; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; Mineki R, 2002, PROTEOMICS, V2, P1672, DOI 10.1002/1615-9861(200212)2:12<1672::AID-PROT1672>3.0.CO;2-#; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Ogawa C, 2003, J BIOL CHEM, V278, P1268, DOI 10.1074/jbc.M209514200; OHTA H, 1995, CANCER RES, V55, P691; ONO Y, 1988, J BIOL CHEM, V263, P6927; Payne SG, 2002, FEBS LETT, V531, P54, DOI 10.1016/S0014-5793(02)03480-4; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Sato M, 2003, J BIOL CHEM, V278, P9276, DOI 10.1074/jbc.M211529200; Smith WL, 2002, J BIOL CHEM, V277, P25841, DOI 10.1074/jbc.R200011200; SNELL EE, 1970, CHEM PHYS LIPIDS, V5, P116, DOI 10.1016/0009-3084(70)90013-7; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang HZ, 2001, BBA-PROTEIN STRUCT M, V1547, P313, DOI 10.1016/S0167-4838(01)00202-3; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	48	57	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41557	41565		10.1074/jbc.M305294200	http://dx.doi.org/10.1074/jbc.M305294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12855683	hybrid			2022-12-25	WOS:000185847200137
J	Fowler, VM; Greenfield, NJ; Moyer, J				Fowler, VM; Greenfield, NJ; Moyer, J			Tropomodulin contains two actin filament pointed end-capping domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPOMYOSIN-BINDING PROTEIN; SKELETAL-MUSCLE; THIN-FILAMENTS; BARBED END; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; RATE CONSTANTS; ADP-ACTIN; IDENTIFICATION; ISOFORM	Tropomodulin 1 (Tmod1) is a similar to40-kDa tropomyosin binding and actin filament pointed end-capping protein that regulates pointed end dynamics and controls thin filament length in striated muscle. In vitro, the capping affinity of Tmod1 for tropomyosin-actin filaments (K-d similar to 50 pM) is several thousand-fold greater than for capping of pure actin filaments (K-d similar to 0.1 muM). The tropomyosin-binding region of Tmod1 has been localized to the amino-terminal portion between residues 1 and 130, but the location of the actin-capping domain is not known. We have now identified two distinct actin-capping regions on Tmod1 by testing a series of recombinant Tmod1 fragments for their ability to inhibit actin elongation from gelsolin-actin seeds using pyrene-actin polymerization assays. The carboxyl-terminal portion of Tmod1 (residues 160-359) contains the principal actin-capping activity (K-d similar to 0.4 muM), requiring residues between 323 and 359 for full activity, whereas the amino-terminal portion of Tmod1 (residues 1-130) contains a second, weaker actin-capping activity (K-d similar to 1.8 muM). Interestingly, 160-359 but not 1-130 enhances spontaneous actin nucleation, suggesting that the carboxyl-terminal domain may bind to two actin subunits across the actin helix at the pointed end, whereas the amino-terminal domain may bind to only one actin subunit. On the other hand, the actin-capping activity of the amino-terminal but not the carboxyl-terminal portion of Tmod1 is enhanced several thousand-fold in the presence of skeletal muscle tropomyosin. We conclude that the carboxyl-terminal capping domain of Tmod1 contains a TM-independent actin pointed end-capping activity, whereas the amino-terminal domain contains a TM-regulated pointed end actin-capping activity.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA	Scripps Research Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Fowler, VM (corresponding author), Scripps Res Inst, Dept Cell Biol, CB163,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034225] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-34225] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almenar-Queralt A, 1999, J BIOL CHEM, V274, P28466, DOI 10.1074/jbc.274.40.28466; BABCOCK GG, 1994, J BIOL CHEM, V269, P27510; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Bretscher A, 1997, J CELL SCI, V110, P3011; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; CALDWELL JE, 1989, BIOCHEMISTRY-US, V28, P8506, DOI 10.1021/bi00447a036; Conley CA, 2001, GENOMICS, V73, P127, DOI 10.1006/geno.2000.6501; Cox PR, 2003, MOL CELL NEUROSCI, V23, P1, DOI 10.1016/S1044-7431(03)00025-3; Cox PR, 2000, GENOMICS, V63, P97, DOI 10.1006/geno.1999.6061; Fischer RS, 2003, FEBS LETT, V547, P228, DOI 10.1016/S0014-5793(03)00711-7; Fischer RS, 2003, J CELL BIOL, V161, P371, DOI 10.1083/jcb.200209057; FOWLER VM, 1993, J CELL BIOL, V120, P411, DOI 10.1083/jcb.120.2.411; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FOWLER VM, 1987, J BIOL CHEM, V262, P12792; FOWLER VM, 1984, J BIOL CHEM, V259, P5978; Fujisawa T, 2001, FEBS LETT, V498, P67, DOI 10.1016/S0014-5793(01)02498-X; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Greenfield NJ, 2002, BIOPHYS J, V82, P2580, DOI 10.1016/S0006-3495(02)75600-2; GREGORIO CC, 1995, NATURE, V377, P83, DOI 10.1038/377083a0; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUG C, 1992, J CELL BIOL, V116, P923, DOI 10.1083/jcb.116.4.923; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kehres DG, 1997, J BIOL CHEM, V272, P20152, DOI 10.1074/jbc.272.32.20152; Kostyukova A, 2000, EUR J BIOCHEM, V267, P6470, DOI 10.1046/j.1432-1327.2000.01738.x; Kostyukova AS, 2001, BIOPHYS J, V81, P345, DOI 10.1016/S0006-3495(01)75704-9; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Krieger I, 2002, BIOPHYS J, V83, P2716, DOI 10.1016/S0006-3495(02)75281-8; Littlefield R, 2001, NAT CELL BIOL, V3, P544, DOI 10.1038/35078517; Mardahl-Dumesnil M, 2001, J CELL BIOL, V155, P1043, DOI 10.1083/jcb.200108026; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; McElhinny AS, 2001, J BIOL CHEM, V276, P583, DOI 10.1074/jbc.M005693200; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; POLLARD TD, 1983, ANAL BIOCHEM, V134, P406, DOI 10.1016/0003-2697(83)90316-0; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SREERAMA N, 1994, BIOCHEMISTRY-US, V33, P10022, DOI 10.1021/bi00199a028; SUNG LA, 1992, J BIOL CHEM, V267, P2616; SUSSMAN MA, 1992, EUR J BIOCHEM, V205, P355, DOI 10.1111/j.1432-1033.1992.tb16787.x; TOUMADJE A, 1992, ANAL BIOCHEM, V200, P321, DOI 10.1016/0003-2697(92)90473-K; Watakabe A, 1996, J CELL SCI, V109, P2299; Wear MA, 2003, CURR BIOL, V13, P1531, DOI 10.1016/S0960-9822(03)00559-1; Weber A, 1999, J BIOL CHEM, V274, P34637, DOI 10.1074/jbc.274.49.34637; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; Yamashita A, 2003, EMBO J, V22, P1529, DOI 10.1093/emboj/cdg167; YOUNG CL, 1990, BIOCHEMISTRY-US, V29, P2232, DOI 10.1021/bi00461a005	48	63	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40000	40009		10.1074/jbc.M306895200	http://dx.doi.org/10.1074/jbc.M306895200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12860976	hybrid			2022-12-25	WOS:000185713800089
J	Friesema, ECH; Ganguly, S; Abdalla, A; Fox, JEM; Halestrap, AP; Visser, TJ				Friesema, ECH; Ganguly, S; Abdalla, A; Fox, JEM; Halestrap, AP; Visser, TJ			Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; XENOPUS-LAEVIS OOCYTES; DEIODINASE FAMILY; RAT HEPATOCYTES; SKELETAL-MUSCLE; SYSTEM-T; MEMBRANE; 3,3',5'-TRIIODOTHYRONINE; EXPRESSION; CONFIRMS	Transport of thyroid hormone across the cell membrane is required for its action and metabolism. Recently, a T-type amino acid transporter was cloned which transports aromatic amino acids but not iodothyronines. This transporter belongs to the monocarboxylate transporter (MCT) family and is most homologous with MCT8 (SLC16A2). Therefore, we cloned rat MCT8 and tested it for thyroid hormone transport in Xenopus laevis oocytes. Oocytes were injected with rat MCT8 cRNA, and after 3 days immunofluorescence microscopy demonstrated expression of the protein at the plasma membrane. MCT8 cRNA induced an similar to10-fold increase in uptake of 10 nM I-125-labeled thyroxine (T-4), 3,3',5-triiodothyronine (T-3), 3,3',5similar to-triiodothyronine (rT(3)) and 3,3'-diiodothyronine. Because of the rapid uptake of the ligands, transport was only linear with time for <4 min. MCT8 did not transport Leu, Phe, Trp, or Tyr. [I-125]T-4 transport was strongly inhibited by L-T-4, D-T-4, L-T-3, D-T-3, 3,3',5-triiodothyroacetic acid, N-bromoacetyl-T-3, and bromosulfophthalein. T-3 transport was less affected by these inhibitors. Iodothyronine uptake in uninjected oocytes was reduced by albumin, but the stimulation induced by MCT8 was markedly increased. Saturation analysis provided apparent K-m values of 2-5 &mu;M for T-4, T-3, and rT(3). Immunohistochemistry showed high expression in liver, kidney, brain, and heart. In conclusion, we have identified MCT8 as a very active and specific thyroid hormone transporter.	Erasmus Univ, Med Ctr, Dept Internal Med, NL-3015 GE Rotterdam, Netherlands; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	Erasmus University Rotterdam; Erasmus MC; University of Bristol	Visser, TJ (corresponding author), Erasmus Univ, Med Ctr, Dept Internal Med, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.		Visser, Theo J/C-8059-2013; Halestrap, Andrew P/G-7275-2011	Visser, Theo J/0000-0002-6997-284X; Halestrap, Andrew/0000-0001-5374-2778				Abe T, 2002, TRENDS ENDOCRIN MET, V13, P215, DOI 10.1016/S1043-2760(02)00599-4; Docter R, 1997, ENDOCRINOLOGY, V138, P1841, DOI 10.1210/en.138.5.1841; Fox JEM, 2000, J PHYSIOL-LONDON, V529, P285, DOI 10.1111/j.1469-7793.2000.00285.x; Friesema ECH, 1998, ENDOCRINOLOGY, V139, P596, DOI 10.1210/en.139.2.596; Friesema ECH, 2001, ENDOCRINOLOGY, V142, P4339, DOI 10.1210/en.142.10.4339; Friesema ECH, 1999, BIOCHEM BIOPH RES CO, V254, P497, DOI 10.1006/bbrc.1998.9974; Hennemann G, 2001, ENDOCR REV, V22, P451, DOI 10.1210/er.22.4.451; Kim DK, 2002, GENOMICS, V79, P95, DOI 10.1006/geno.2001.6678; Kim DK, 2001, J BIOL CHEM, V276, P17221, DOI 10.1074/jbc.M009462200; Kohrle J, 1999, MOL CELL ENDOCRINOL, V151, P103, DOI 10.1016/S0303-7207(99)00040-4; KRENNING EP, 1979, FEBS LETT, V107, P227, DOI 10.1016/0014-5793(79)80501-3; KRENNING EP, 1982, FEBS LETT, V140, P229, DOI 10.1016/0014-5793(82)80900-9; LAFRENIERE RG, 1994, HUM MOL GENET, V3, P1133, DOI 10.1093/hmg/3.7.1133; MOL JA, 1985, ENDOCRINOLOGY, V117, P1; OPPENHEIMER JH, 1996, MOL BASIS TNYROID HO, P162; Pizzagalli F, 2002, MOL ENDOCRINOL, V16, P2283, DOI 10.1210/me.2001-0309; Poole RC, 1996, BIOCHEM J, V320, P817, DOI 10.1042/bj3200817; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; Price NT, 1998, BIOCHEM J, V329, P321; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SAMSON M, 1992, BIOCHIM BIOPHYS ACTA, V1108, P91, DOI 10.1016/0005-2736(92)90118-6; StGermain DL, 1997, THYROID, V7, P655; VISSER TJ, 1999, THYROID HORMONE META; Wilson MC, 1998, J BIOL CHEM, V273, P15920, DOI 10.1074/jbc.273.26.15920; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; ZHOU Y, 1992, BIOCHEM J, V281, P81, DOI 10.1042/bj2810081; ZHOU Y, 1990, J BIOL CHEM, V265, P17000	27	495	513	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40128	40135		10.1074/jbc.M300909200	http://dx.doi.org/10.1074/jbc.M300909200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12871948	hybrid			2022-12-25	WOS:000185713800105
J	Airhart, N; Yang, YF; Roberts, CT; Silberbach, M				Airhart, N; Yang, YF; Roberts, CT; Silberbach, M			Atrial natriuretic peptide induces natriuretic peptide receptor-cGMP-dependent protein kinase interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE-CYCLASE; SMOOTH-MUSCLE; CARDIAC MYOCYTES; DEFICIENT MICE; HEART-FAILURE; ACTIVATION; HYPERTROPHY; INHIBITION; GROWTH; CELLS	Circulating natriuretic peptides such as atrial natriuretic peptide (ANP) counterbalance the effects of hypertension and inhibit cardiac hypertrophy by activating cGMP-dependent protein kinase (PKG). Natriuretic peptide binding to type I receptors ( NPRA and NPRB) activates their intrinsic guanylyl cyclase activity, resulting in a rapid increase in cytosolic cGMP that subsequently activates PKG. Phosphorylation of the receptor by an unknown serine/threonine kinase is required before ligand binding can activate the cyclase. While searching for downstream PKG partners using a yeast two-hybrid screen of a human heart cDNA library, we unexpectedly found an upstream association with NPRA. PKG is a serine/threonine kinase capable of phosphorylating NPRA in vitro; however, regulation of NPRA by PKG has not been previously reported. Here we show that PKG is recruited to the plasma membrane following ANP treatment, an effect that can be blocked by pharmacological inhibition of PKG activation. Furthermore, PKG participates in a ligand-dependent gain-of-function loop that significantly increases the intrinsic cyclase activity of the receptor. PKG translocation is ANP-dependent but not nitric oxide-dependent. Our results suggest that anchoring of PKG to NPRA is a key event after ligand binding that determines distal effects. As such, the NPRA-PKG association may represent a novel mechanism for compartmentation of cGMP-mediated signaling and regulation of receptor sensitivity.	Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Silberbach, M (corresponding author), Doernbecher Mem Hosp Children, 707 SW Gaines Rd,Mail Code CDRC-P, Portland, OR 97239 USA.		Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772				Anthony TL, 2000, MOL PHARMACOL, V57, P576, DOI 10.1124/mol.57.3.576; APPEL RG, 1992, AM J PHYSIOL, V262, pF911, DOI 10.1152/ajprenal.1992.262.6.F911; BURNETT JC, 1986, SCIENCE, V231, P1145, DOI 10.1126/science.2935937; CAO L, 1995, HYPERTENSION, V25, P227, DOI 10.1161/01.HYP.25.2.227; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CODY R J, 1988, European Heart Journal, V9, P29; CURRIE MG, 1983, SCIENCE, V221, P71, DOI 10.1126/science.6857267; Delay RJ, 1997, J MEMBRANE BIOL, V159, P53, DOI 10.1007/s002329900268; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; Eigenthaler M, 1999, Rev Physiol Biochem Pharmacol, V135, P173, DOI 10.1007/BFb0033673; Fiedler B, 2002, P NATL ACAD SCI USA, V99, P11363, DOI 10.1073/pnas.162100799; FRANCIS SH, 1994, J BIOL CHEM, V269, P22477; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Hagen V, 1998, J PHOTOCH PHOTOBIO B, V42, P71, DOI 10.1016/S1011-1344(97)00125-5; Jiang LH, 2000, J BIOL CHEM, V275, P6135, DOI 10.1074/jbc.275.9.6135; Joubert S, 2001, BIOCHEMISTRY-US, V40, P11096, DOI 10.1021/bi010580s; Kishimoto I, 2001, P NATL ACAD SCI USA, V98, P2703, DOI 10.1073/pnas.051625598; Kishimoto I, 1996, P NATL ACAD SCI USA, V93, P6215, DOI 10.1073/pnas.93.12.6215; Knowles JW, 2001, J CLIN INVEST, V107, P975, DOI 10.1172/JCI11273; Ku DD, 1996, AM J PHYSIOL-HEART C, V271, pH2368, DOI 10.1152/ajpheart.1996.271.6.H2368; LAROSE L, 1992, MOL CELL BIOCHEM, V115, P203, DOI 10.1007/BF00230332; Levin ER, 1998, NEW ENGL J MED, V339, P321; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Matsumoto T, 1999, AM J PHYSIOL-HEART C, V276, pH1935, DOI 10.1152/ajpheart.1999.276.6.H1935; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; MORISHITA R, 1994, J CLIN INVEST, V94, P824, DOI 10.1172/JCI117402; Nara M, 2000, AM J PHYSIOL-CELL PH, V279, pC1938, DOI 10.1152/ajpcell.2000.279.6.C1938; Olson LJ, 1996, MOL PHARMACOL, V50, P430; Patel AI, 1997, J PHARMACOL EXP THER, V283, P885; Pedram A, 2000, J BIOL CHEM, V275, P7365, DOI 10.1074/jbc.275.10.7365; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Potter LR, 1999, MOL BIOL CELL, V10, P1811, DOI 10.1091/mbc.10.6.1811; Potter LR, 2001, J BIOL CHEM, V276, P6057, DOI 10.1074/jbc.R000033200; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; SCHULTZ HD, 1988, AM J PHYSIOL, V255, pR6, DOI 10.1152/ajpregu.1988.255.1.R6; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; Silberbach M, 1999, J BIOL CHEM, V274, P24858, DOI 10.1074/jbc.274.35.24858; Silberbach M, 2001, CELL SIGNAL, V13, P221, DOI 10.1016/S0898-6568(01)00139-5; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; Spencer ML, 2002, J BIOL CHEM, V277, P20160, DOI 10.1074/jbc.M201092200; TOHSE N, 1995, BRIT J PHARMACOL, V114, P1076, DOI 10.1111/j.1476-5381.1995.tb13316.x; TSUTAMOTO T, 1993, CIRCULATION, V87, P70, DOI 10.1161/01.CIR.87.1.70; Wiedemann K, 2000, EXP CLIN ENDOCR DIAB, V108, P5; Yamamoto S, 2001, ARCH BIOCHEM BIOPHYS, V393, P97, DOI 10.1006/abbi.2001.2505; Zolle O, 2000, J BIOL CHEM, V275, P25892, DOI 10.1074/jbc.M000786200	46	51	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38693	38698		10.1074/jbc.M304098200	http://dx.doi.org/10.1074/jbc.M304098200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12855709	hybrid			2022-12-25	WOS:000185575100074
J	Sun, L; Bittner, MA; Holz, RW				Sun, L; Bittner, MA; Holz, RW			Rim, a component of the presynaptic active zone and modulator of exocytosis, binds 14-3-3 through its N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAB3 EFFECTOR; PROTEIN; SECRETION; MUNC13-1; TARGET; DETERMINANTS; CALMODULIN; RIM1-ALPHA; RELEASE; DOMAIN	Rim1, a brain-specific Rab3a-binding protein, localizes to the presynaptic cytomatrix and plays an important role in synaptic transmission and synaptic plasticity. Rim2, a homologous protein, is more ubiquitously expressed and is found in neuroendocrine cells as well as in brain. Both Rim1 and Rim2 contain multiple domains, including an N-terminal zinc finger, which in Rim1 strongly enhances secretion in chromaffin and PC12 cells. The yeast two-hybrid technique identified 14-3-3 proteins as ligands of the N-terminal domain. In vitro protein binding experiments confirmed a high-affinity interaction between the N terminus of Rim1 and 14-3-3. The N-terminal domain of Rim2 also bound 14-3-3. The binding domains were localized to a short segment just C-terminal to the zinc finger. 14-3-3 proteins bind to specific phosphoserine residues. Alkaline phosphatase treatment of N-terminal domains of Rim1 and Rim2 almost completely inhibited the binding of 14-3-3. Two serine residues in Rim1 (Ser-241 and Ser-287) and one serine residue in Rim2 (Ser-335) were required for 14-3-3 binding. Incubation with Ca2+/calmodulin- dependent protein kinase II greatly stimulated the interaction of recombinant N-terminal Rim but not the S241/287A mutant with 14-3-3, again indicating the importance of the phosphorylation of these residues for the binding. Rabphilin3, another Rab3a effector, also bound 14-3-3. Serine-to-alanine mutations identified Ser-274 as the likely phosphorylated residue to which 14-3-3 binds. Because the phosphorylation of this residue had been shown to be stimulated upon depolarization in brain slices, the interaction of 14-3-3 with Rabphilin3 may be important in the dynamic function of central nervous system neurons.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Holz, RW (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 2301 MSRB 3, Ann Arbor, MI 48109 USA.	holz@umich.edu			NIDDK NIH HHS [R01-DK50177] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Betz A, 1997, J BIOL CHEM, V272, P2520; Broadie K, 1997, NEURON, V19, P391, DOI 10.1016/S0896-6273(00)80948-4; Castillo PE, 2002, NATURE, V415, P327, DOI 10.1038/415327a; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Coppola T, 2001, J BIOL CHEM, V276, P32756, DOI 10.1074/jbc.M100929200; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; DUNN LA, 1983, J BIOL CHEM, V258, P4989; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Foletti DL, 2001, J NEUROSCI, V21, P5473, DOI 10.1523/JNEUROSCI.21-15-05473.2001; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Garner CC, 2000, CURR OPIN NEUROBIOL, V10, P321, DOI 10.1016/S0959-4388(00)00093-3; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Iezzi M, 2000, FEBS LETT, V474, P66, DOI 10.1016/S0014-5793(00)01572-6; Joberty G, 1999, J CELL SCI, V112, P3579; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; Martin TFJ, 2002, NEURON, V34, P9, DOI 10.1016/S0896-6273(02)00651-7; MCKIERNAN CJ, 1993, J BIOL CHEM, V268, P24449; MOORE BW, 1968, J NEUROCHEM, V15, P265, DOI 10.1111/j.1471-4159.1968.tb11610.x; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; Sun L, 2001, J BIOL CHEM, V276, P12911, DOI 10.1074/jbc.M011110200; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wang XL, 2001, J BIOL CHEM, V276, P32480, DOI 10.1074/jbc.M103337200; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; WICK PF, 1993, J BIOL CHEM, V268, P10983; WILSON SP, 1995, ANAL BIOCHEM, V226, P212, DOI 10.1006/abio.1995.1216; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	41	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38301	38309		10.1074/jbc.M212801200	http://dx.doi.org/10.1074/jbc.M212801200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871946	hybrid			2022-12-25	WOS:000185575100028
J	Chevallet, M; Wagner, E; Luche, S; van Dorsselaer, A; Leize-Wagner, E; Rabilloud, T				Chevallet, M; Wagner, E; Luche, S; van Dorsselaer, A; Leize-Wagner, E; Rabilloud, T			Regeneration of peroxiredoxins during recovery after oxidative stress - Only some overoxidized peroxiredoxins can be reduced during recovery after oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; 2-DIMENSIONAL ELECTROPHORESIS; HYDROGEN-PEROXIDE; SITE CYSTEINE; IN-VIVO; PROTEIN; OVEROXIDATION; ACID; INACTIVATION; MECHANISM	Peroxiredoxins (prx) are redox enzymes using an activated cysteine as their active site. This activated cysteine can be easily overoxidized to cysteine sulfinic acid or cysteine sulfonic acid, especially under oxidative stress conditions. The regeneration of peroxiredoxins after a short, intense oxidative stress was studied, using a proteomics approach. Important differences in regeneration speed were found, prx2 being the fastest regenerated protein, followed by prx1, whereas prx3 and prx6 were regenerated very slowly. Further study of the mechanism of this regeneration by pulse-chase experiments using stable isotope labeling and cycloheximide demonstrated that the fast-regenerating peroxiredoxins are regenerated at least in part by a retroreduction mechanism. This demonstrates that the overoxidation can be reversible under certain conditions. The pathway of this retroreduction and the reasons explaining the various regeneration speeds of the peroxiredoxins remain to be elucidated.	CEA Grenoble, DRDC BECP, Lab Bioenerget Cellulaire & Pathol, F-38054 Grenoble 9, France; Ecole Chim Polymeres & Mat, Lab Spectrometrie Masse Bioorgan, CNRS, Unite Mixte Rech 7509, F-67002 Strasbourg, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Rabilloud, T (corresponding author), CEA Grenoble, DRDC BECP, Lab Bioenerget Cellulaire & Pathol, 17 Rue Martyrs,EA 2943, F-38054 Grenoble 9, France.	Thierry.rabilloud@cea.fr		Chevallet, Mireille/0000-0002-3001-8821				Baker LMS, 2003, J BIOL CHEM, V278, P9203, DOI 10.1074/jbc.M209888200; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Collin V, 2003, J BIOL CHEM, V278, P23747, DOI 10.1074/jbc.M302077200; Declercq JP, 2001, J MOL BIOL, V311, P751, DOI 10.1006/jmbi.2001.4853; GIANAZZA E, 1985, ELECTROPHORESIS, V6, P53, DOI 10.1002/elps.1150060113; Gorman JJ, 1996, RAPID COMMUN MASS SP, V10, P529, DOI 10.1002/(SICI)1097-0231(19960331)10:5<529::AID-RCM522>3.0.CO;2-9; Hamann M, 2002, METHOD ENZYMOL, V348, P146, DOI 10.1016/S0076-6879(02)48634-X; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; RABILLOUD T, 1994, ELECTROPHORESIS, V15, P1552, DOI 10.1002/elps.11501501223; Rabilloud T, 1997, ELECTROPHORESIS, V18, P307, DOI 10.1002/elps.1150180303; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Sinha P, 2001, PROTEOMICS, V1, P835, DOI 10.1002/1615-9861(200107)1:7<835::AID-PROT835>3.3.CO;2-U; Verdoucq L, 1999, J BIOL CHEM, V274, P19714, DOI 10.1074/jbc.274.28.19714; Wagner E, 2002, BIOCHEM J, V366, P777, DOI 10.1042/BJ20020525; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	27	132	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37146	37153		10.1074/jbc.M305161200	http://dx.doi.org/10.1074/jbc.M305161200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12853451	hybrid			2022-12-25	WOS:000185437200021
J	Latvanlehto, A; Snellman, A; Tu, H; Pihlajaniemi, T				Latvanlehto, A; Snellman, A; Tu, H; Pihlajaniemi, T			Type XIII collagen and some other transmembrane collagens contain two separate coiled-coil motifs, which may function as independent oligomerization domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; PROLYL 4-HYDROXYLASE; SCAVENGER RECEPTOR; MESSENGER-RNA; CELL-ADHESION; TRIPLE-HELIX; FORMS; GENE; TRANSCRIPTS; EXPRESSION	Type XIII collagen is a homotrimeric transmembrane collagen composed of a short intracellular domain, a single membrane-spanning region, and an extracellular ectodomain with three collagenous domains (COL1-3) separated by short non-collagenous domains (NC1-4). Several collagenous transmembrane proteins have been found to harbor a conserved sequence next to their membrane-spanning regions, and in the case of type XIII collagen this sequence has been demonstrated to be important for chain association. We show here that this 21-residue sequence is necessary but not sufficient for NC1 association. Furthermore, the NC1 association region was predicted to form an alpha-helical coiled-coil structure, which may already begin at the membrane-spanning region, as is also predicted for the related collagen types XXIII and XXV. Interestingly, a second coiled-coil structure is predicted to be located in the NC3 domain of type XIII collagen and in the corresponding domains of types XXIII and XXV. It is found experimentally that the absence of the NC1 coiled-coil domain leads to a lack of disulfide-bonded trimers and misfolding of the membrane-proximal collagenous domain COL1, whereas the COL2 and COL3 domains are correctly folded. We suggest that the NC1 coiled-coil domain is important for association of the N-terminal part of the type XIII collagen alpha chains, whereas the NC3 coiled-coil domain is implicated in the association of the C-terminal part of the molecule. All in all, we propose that two widely separated coiled-coil domains of type XIII and related collagens function as independent oligomerization domains participating in the folding of distinct areas of the molecule.	Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Oulu, Collagen Res Unit, Bioctr, FIN-90014 Oulu, Finland	University of Oulu; University of Oulu	Pihlajaniemi, T (corresponding author), Univ Oulu, Dept Med Biochem & Mol Biol, POB 5000, FIN-90014 Oulu, Finland.			Heikkinen, Anne/0000-0001-9852-773X; Pihlajaniemi, Taina/0000-0002-1664-9045				Akey DL, 2001, BIOCHEMISTRY-US, V40, P6352, DOI 10.1021/bi002829w; Balding SD, 1997, BIOCHEMISTRY-US, V36, P8821, DOI 10.1021/bi970675n; Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200; Bayes M, 1998, HUM MOL GENET, V7, P1661, DOI 10.1093/hmg/7.11.1661; Beck K, 1998, J STRUCT BIOL, V122, P17, DOI 10.1006/jsbi.1998.3965; Elomaa O, 1998, J BIOL CHEM, V273, P4530, DOI 10.1074/jbc.273.8.4530; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Ezer S, 1999, HUM MOL GENET, V8, P2079, DOI 10.1093/hmg/8.11.2079; FURTHMAYR H, 1971, ANAL BIOCHEM, V41, P510, DOI 10.1016/0003-2697(71)90173-4; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; Hagg P, 1998, J BIOL CHEM, V273, P15590, DOI 10.1074/jbc.273.25.15590; Hagg P, 2001, MATRIX BIOL, V19, P727, DOI 10.1016/S0945-053X(00)00119-0; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; High S, 1997, TRENDS CELL BIOL, V7, P206; JUVONEN M, 1992, J BIOL CHEM, V267, P24693; JUVONEN M, 1992, J BIOL CHEM, V267, P24700; JUVONEN M, 1993, LAB INVEST, V69, P541; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Kvist AP, 1999, MATRIX BIOL, V18, P261, DOI 10.1016/S0945-053X(99)00018-9; Kvist AP, 2001, AM J PATHOL, V159, P1581, DOI 10.1016/S0002-9440(10)62542-4; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; LI KH, 1993, J BIOL CHEM, V268, P8825; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Nakamura K, 2001, BIOCHEM BIOPH RES CO, V280, P1028, DOI 10.1006/bbrc.2000.4210; Nokelainen M, 1998, MATRIX BIOL, V16, P329, DOI 10.1016/S0945-053X(98)90004-X; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Peltonen S, 1997, DNA CELL BIOL, V16, P227, DOI 10.1089/dna.1997.16.227; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; Sato K, 2002, J BIOL CHEM, V277, P37678, DOI 10.1074/jbc.M205347200; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Snellman A, 2000, J BIOL CHEM, V275, P8936, DOI 10.1074/jbc.275.12.8936; Sund M, 2001, EMBO J, V20, P5153, DOI 10.1093/emboj/20.18.5153; Sund M, 2001, MATRIX BIOL, V20, P215, DOI 10.1016/S0945-053X(01)00134-2; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIKKA L, 1991, J BIOL CHEM, V266, P17713; Tu HM, 2002, J BIOL CHEM, V277, P23092, DOI 10.1074/jbc.M107583200	38	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37590	37599		10.1074/jbc.M305974200	http://dx.doi.org/10.1074/jbc.M305974200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12832406	hybrid			2022-12-25	WOS:000185437200074
J	Raychaudhuri, S; Rajasekharan, R				Raychaudhuri, S; Rajasekharan, R			Nonorganellar acyl carrier protein from oleaginous yeast is a homologue of ribosomal protein P2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; MEMBRANE PHOSPHOLIPID-SYNTHESIS; NADH-UBIQUINONE OXIDOREDUCTASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MOLECULAR-GENETICS; NEUROSPORA-CRASSA; CELL-GROWTH; PURIFICATION; SYNTHETASE	Acyl carrier protein (ACP) is responsible for carrying the growing fatty acid chain from one enzyme active site to the next during fatty acid biosynthesis. Here we report the identification, purification, immunocytochemical localization, and cloning of ACP from the oleaginous yeast, Rhodotorula glutinis. The soluble fraction of this organism can synthesize triacylglycerol and is able to accept the acyl group from acyl-ACP for the synthesis. The ACP, cloned from the system, showed a significant similarity with ribosomal protein P2. Expression and characterization of the recombinant protein showed that the ACP was acylated in vitro. The recombinant protein was post-translationally modified, since it was observed in [C-14]beta-alanine labeling and matrix-assisted laser desorption mass spectroscopic analysis. Site-directed mutants were generated to identify a serine residue responsible for phosphopantetheinylation and found that mutation of serine 59 to alanine abrogated the fatty acylation ability of the protein. These results demonstrate that a novel modification of ribosomal protein P2 allows it to act as an acyl carrier protein and participate in acylation reactions.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Rajasekharan, R (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	lipid@biochem.iisc.ernet.in	R, Rajasekharan/D-3420-2009; Rajasekharan, Ram/R-2257-2019	Ram, Rajasekharan/0000-0002-4114-0654; Rajasekharan, Ram/0000-0002-2124-6013; Raychaudhuri, Sumana/0000-0002-3164-0057				Ballesta JPG, 1999, FEMS MICROBIOL REV, V23, P537, DOI 10.1111/j.1574-6976.1999.tb00412.x; Bargis-Surgey P, 1999, EUR J BIOCHEM, V262, P606, DOI 10.1046/j.1432-1327.1999.00434.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; CHUMAN L, 1989, EUR J BIOCHEM, V184, P643, DOI 10.1111/j.1432-1033.1989.tb15061.x; COOPER CL, 1989, J BIOL CHEM, V264, P7384; Engvall E, 1980, Methods Enzymol, V70, P419; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; Flaman AS, 2001, J BIOL CHEM, V276, P35934, DOI 10.1074/jbc.M101849200; Gangar A, 2002, BIOCHEM J, V365, P577, DOI 10.1042/bj20011654; Gangar A, 2001, BIOCHEM J, V360, P471, DOI 10.1042/0264-6021:3600471; Gangar A, 2001, J BIOL CHEM, V276, P10290, DOI 10.1074/jbc.M009550200; GOETHALS K, 1989, MOL GEN GENET, V219, P289, DOI 10.1007/BF00261190; GREEN PR, 1981, J BIOL CHEM, V256, P1151; HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ, P131; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; Kalscheuer R, 2001, ARCH MICROBIOL, V177, P20, DOI 10.1007/s00203-001-0355-5; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; Keating MM, 2002, BBA-PROTEINS PROTEOM, V1601, P208, DOI 10.1016/S1570-9639(02)00470-3; Lipmann F, 1980, Adv Microb Physiol, V21, P227; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; RAUE HA, 1991, METHOD ENZYMOL, V194, P453; Raychaudhuri S, 2003, BIOCHEM J, V372, P587, DOI 10.1042/BJ20030160; Rock C O, 1981, Methods Enzymol, V71 Pt C, P163; Rock C O, 1981, Methods Enzymol, V71 Pt C, P341; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; Suh MC, 1999, PLANT J, V17, P679, DOI 10.1046/j.1365-313X.1999.00418.x; THERISOD H, 1987, P NATL ACAD SCI USA, V84, P8235, DOI 10.1073/pnas.84.23.8235; VANDENBOOM T, 1989, ANNU REV MICROBIOL, V43, P317, DOI 10.1146/annurev.micro.43.1.317; ZENSEN R, 1992, FEBS LETT, V310, P179, DOI 10.1016/0014-5793(92)81324-F	35	1	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37648	37657		10.1074/jbc.M305052200	http://dx.doi.org/10.1074/jbc.M305052200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869567	hybrid			2022-12-25	WOS:000185437200080
J	Sau, K; Mambula, SS; Latz, E; Henneke, P; Golenbock, DT; Levitz, SM				Sau, K; Mambula, SS; Latz, E; Henneke, P; Golenbock, DT; Levitz, SM			The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL ACTIVATION; INNATE IMMUNE-SYSTEM; SIGNAL-TRANSDUCTION; CUTTING EDGE; BACTERIAL LIPOPOLYSACCHARIDE; CRYPTOCOCCUS-NEOFORMANS; MONONUCLEAR-CELLS; WALL COMPONENTS; MESSENGER-RNA; LIPID RAFTS	Amphotericin B is the most effective drug for treating many life-threatening fungal infections. Amphotericin B administration is limited by infusion-related toxicity, including fever and chills, an effect postulated to result from proinflammatory cytokine production by innate immune cells. Because amphotericin B is a microbial product, we hypothesized that it stimulates immune cells via Toll-like receptors (TLRs) and CD14. We show here that amphotericin B induces signal transduction and inflammatory cytokine release from cells expressing TLR2 and CD14. Primary murine macrophages and human cell lines expressing TLR2, CD14, and the adapter protein MyD88 responded to amphotericin B with NF-kappaB-dependent reporter activity and cytokine release, whereas cells deficient in any of these failed to respond. Cells mutated in TLR4 were less responsive to amphotericin B stimulation than cells expressing normal TLR4. These data demonstrate that TLR2 and CD14 are required for amphotericin B-dependent inflammatory stimulation of innate immune cells and that TLR4 may also provide stimulation of these cells. Our results provide a putative molecular basis for inflammatory responses elicited by amphotericin B and suggest strategies to eliminate the acute toxicity of this drug.	Boston Univ, Sch Med, Dept Microbiol, Sect Infect Dis, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01655 USA	Boston University; Boston University; University of Massachusetts System; University of Massachusetts Worcester	Levitz, SM (corresponding author), Boston Univ, Sch Med, Dept Microbiol, Sect Infect Dis, 650 Albany St,Rm X626, Boston, MA 02118 USA.	slevitz@bu.edu	Latz, Eicke/H-3951-2014	Latz, Eicke/0000-0003-1488-5666	NCRR NIH HHS [RR14466] Funding Source: Medline; NHLBI NIH HHS [HL07501, HL07035] Funding Source: Medline; NIAID NIH HHS [AI-37532, AI-25780] Funding Source: Medline; NIDDK NIH HHS [DK50305] Funding Source: Medline; NIGMS NIH HHS [GM54060] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR014466] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037532, R01AI025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054060, R01GM054060] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSalah KM, 1996, BRIT J BIOMED SCI, V53, P122; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Arning M, 1995, MYCOSES, V38, P459, DOI 10.1111/j.1439-0507.1995.tb00020.x; Ayestaran A, 1996, ANTIMICROB AGENTS CH, V40, P609, DOI 10.1128/AAC.40.3.609; Bekersky I, 2002, ANTIMICROB AGENTS CH, V46, P828, DOI 10.1128/AAC.46.3.828-833.2002; Beutler B, 2002, CURR TOP MICROBIOL, V270, P1; Beutler B, 2001, CRIT CARE MED, V29, pS2, DOI 10.1097/00003246-200107001-00002; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; Bulut Y, 2001, J IMMUNOL, V167, P987, DOI 10.4049/jimmunol.167.2.987; Calandra T, 2001, J CHEMOTHERAPY, V13, P173, DOI 10.1179/joc.2001.13.Supplement-2.173; Carozzi AJ, 2000, TRAFFIC, V1, P326, DOI 10.1034/j.1600-0854.2000.010406.x; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; CLEARY JD, 1992, ANTIMICROB AGENTS CH, V36, P977, DOI 10.1128/AAC.36.5.977; CLEARY JD, 1988, DRUG INTEL CLIN PHAR, V22, P769, DOI 10.1177/106002808802201005; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Flo TH, 2002, J BIOL CHEM, V277, P35489, DOI 10.1074/jbc.M201366200; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; Harrison TS, 1997, J INFECT DIS, V176, P485, DOI 10.1086/514068; Hashimoto M, 2000, BIOCHEM BIOPH RES CO, V273, P164, DOI 10.1006/bbrc.2000.2921; Heine H, 1999, J IMMUNOL, V162, P6971; Heinemann V, 1997, ANTIMICROB AGENTS CH, V41, P728, DOI 10.1128/AAC.41.4.728; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kimbrell DA, 2001, NAT REV GENET, V2, P256, DOI 10.1038/35066006; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Lien E, 2002, CRIT CARE MED, V30, pS1, DOI 10.1097/00003246-200201001-00001; MA Y, 1993, INFECT IMMUN, V61, P3843, DOI 10.1128/IAI.61.9.3843-3853.1993; MANDELL GL, 2000, PRINCIPLES PRACTICE, V1, P448; McCarthy DO, 1998, NURS RES, V47, P19, DOI 10.1097/00006199-199801000-00005; Means TK, 2000, CYTOKINE GROWTH F R, V11, P219, DOI 10.1016/S1359-6101(00)00006-X; Means TK, 2000, LIFE SCI, V68, P241, DOI 10.1016/S0024-3205(00)00939-5; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Ozinsky A, 2000, J ENDOTOXIN RES, V6, P393, DOI 10.1179/096805100101532333; Paquet MJ, 2002, CHEM PHYS LIPIDS, V119, P1, DOI 10.1016/S0009-3084(02)00071-3; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pugin J, 1998, INFECT IMMUN, V66, P1174, DOI 10.1128/IAI.66.3.1174-1180.1998; Rehli M, 2002, TRENDS IMMUNOL, V23, P375, DOI 10.1016/S1471-4906(02)02259-7; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shoham S, 2001, J IMMUNOL, V166, P4620, DOI 10.4049/jimmunol.166.7.4620; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Suschek CV, 2000, BRIT J PHARMACOL, V131, P473, DOI 10.1038/sj.bjp.0703576; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Triantafilou M, 2002, J CELL SCI, V115, P2603; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Wang QL, 2001, INFECT IMMUN, V69, P2270, DOI 10.1128/IAI.69.4.2270-2276.2001; Wyllie DH, 2000, J IMMUNOL, V165, P7125, DOI 10.4049/jimmunol.165.12.7125; Yang ZG, 1996, J LEUKOCYTE BIOL, V59, P241, DOI 10.1002/jlb.59.2.241; Yoshimura A, 1999, J IMMUNOL, V163, P1	56	159	170	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37561	37568		10.1074/jbc.M306137200	http://dx.doi.org/10.1074/jbc.M306137200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12860979	hybrid			2022-12-25	WOS:000185437200070
J	Wise, LM; Ueda, N; Dryden, NH; Fleming, SB; Caesar, C; Roufail, S; Achen, MG; Stacker, SA; Mercer, AA				Wise, LM; Ueda, N; Dryden, NH; Fleming, SB; Caesar, C; Roufail, S; Achen, MG; Stacker, SA; Mercer, AA			Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet are uniformly active mitogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORF-VIRUS; CRYSTAL-STRUCTURE; FACTOR VEGF; TUMOR-CELLS; FACTOR-B; ANGSTROM RESOLUTION; TYROSINE KINASES; FLT-1 RECEPTOR; NEUROPILIN-1; PROTEIN	Infections of humans and ungulates by parapoxviruses result in skin lesions characterized by extensive vascular changes that have been linked to viral-encoded homologues of vascular endothelial growth factor ( VEGF). VEGF acts via a family of receptors ( VEGFRs) to mediate endothelial cell proliferation, vascular permeability, and angiogenesis. The VEGF genes from independent parapoxvirus isolates show an extraordinary degree of inter-strain sequence variation. We conducted functional comparisons of five representatives of the divergent viral VEGFs. These revealed that despite the sequence divergence, all were equally active mitogens, stimulating proliferation of human endothelial cells in vitro and vascularization of sheep skin in vivo with potencies equivalent to VEGF. This was achieved even though the viral VEGFs bound VEGFR-2 less avidly than did VEGF. Surprisingly the viral VEGFs varied in their ability to cross-link VEGFR-2, induce vascular permeability and bind neuropilin-1. Correlations between these three activities were detected. In addition it was possible to correlate these functional variations with certain sequence and structural motifs specific to the viral VEGFs. In contrast to the conserved ability to bind human VEGFR-2, the viral growth factors did not bind either VEGFR-1 or VEGFR-3. We propose that the extensive sequence divergence seen in the viral VEGFs was generated primarily by selection against VEGFR-1 binding.	Univ Otago, Dept Microbiol, Virus Res Unit, Dunedin, New Zealand; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia	University of Otago; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Mercer, AA (corresponding author), Univ Otago, Dept Microbiol, Virus Res Unit, POB 56, Dunedin, New Zealand.	andy.mercer@stonebow.otago.ac.nz	Stacker, Steven A/J-2205-2012; Mercer, Andrew A/G-6635-2015	Stacker, Steven A/0000-0003-4096-9273; Achen, Marc/0000-0002-3791-803X; Wise, Lyn/0000-0003-0646-8424; Mercer, Andrew/0000-0003-3697-1071				Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Baldwin ME, 2001, J BIOL CHEM, V276, P19166, DOI 10.1074/jbc.M100097200; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dvorak AM, 2001, J HISTOCHEM CYTOCHEM, V49, P419, DOI 10.1177/002215540104900401; DVORAK HF, 1995, AM J PATHOL, V146, P1029; EVANS MJ, 1995, J IMMUNOL METHODS, V184, P123, DOI 10.1016/0022-1759(95)00093-P; Feng D, 2000, J HISTOCHEM CYTOCHEM, V48, P545, DOI 10.1177/002215540004800412; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Fuh G, 2000, J BIOL CHEM, V275, P26690; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; GROVES RW, 1991, J AM ACAD DERMATOL, V25, P706, DOI 10.1016/0190-9622(91)70257-3; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haig DM, 1998, VET RES, V29, P311; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Joukov V, 1996, EMBO J, V15, P290; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; LYTTLE DJ, 1994, J VIROL, V68, P84, DOI 10.1128/JVI.68.1.84-92.1994; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Mercer A, 1997, ARCH VIROL, P25; Mercer AA, 2002, J GEN VIROL, V83, P2845, DOI 10.1099/0022-1317-83-11-2845; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PARK JE, 1994, J BIOL CHEM, V269, P25646; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robinson CJ, 2001, J CELL SCI, V114, P853; Savory LJ, 2000, J VIROL, V74, P10699, DOI 10.1128/JVI.74.22.10699-10706.2000; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shibuya M, 2001, INT J BIOCHEM CELL B, V33, P409, DOI 10.1016/S1357-2725(01)00026-7; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stacker SA, 1999, GROWTH FACTORS, V17, P1, DOI 10.3109/08977199909001058; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Staquet MJ, 2001, ARCH DERMATOL RES, V293, P26, DOI 10.1007/s004030000193; Taipale J, 1999, CURR TOP MICROBIOL, V237, P85; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Ueda N, 2003, VIROLOGY, V305, P298, DOI 10.1006/viro.2002.1750; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	59	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38004	38014		10.1074/jbc.M301194200	http://dx.doi.org/10.1074/jbc.M301194200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867434	hybrid			2022-12-25	WOS:000185437200122
J	Xu, WL; Shen, JY; Dunn, CA; Bessman, MJ				Xu, WL; Shen, JY; Dunn, CA; Bessman, MJ			A new subfamily of the nudix hydrolase superfamily active on 5-methyl-UTP (ribo-TTP) and UTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOSIDE TRIPHOSPHATASE; MUTT FAMILY; GENE; PURIFICATION; PYROPHOSPHATASE; ENZYMES; CLONING; IDENTIFICATION; MECHANISM	A new subfamily of the Nudix hydrolases, identified by conserved amino acids upstream and downstream of the Nudix box, has been characterized. The cloned, expressed, and purified orthologous enzymes have major activities on the non-canonical nucleoside triphosphate 5-methyl-UTP (ribo-TTP) and the canonical nucleotide UTP. In addition to their homologous signature sequences and their similar substrate specificities, the members of the subfamily are inhabitants of or are related to the bacterial rhizosphere. We propose the acronym and mnemonic, utp, for the gene designating this unique UTPase.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Bessman, MJ (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.			Dunn, Christopher/0000-0001-7899-0110	NIGMS NIH HHS [GM18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BJORK GR, 1975, J BACTERIOL, V124, P99; BULLIONS LC, 1993, THESIS J HOPKINS U; Cartwright JL, 2000, J BIOL CHEM, V275, P32925, DOI 10.1074/jbc.M005015200; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Espinosa JC, 1999, J BACTERIOL, V181, P4914, DOI 10.1128/JB.181.16.4914-4918.1999; Fiske CH, 1925, J BIOL CHEM, V66, P375; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; Gabelli SB, 2001, NAT STRUCT BIOL, V8, P467, DOI 10.1038/87647; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; JONG A, 1993, ARCH BIOCHEM BIOPHYS, V304, P197, DOI 10.1006/abbi.1993.1339; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; LORENSON MY, 1967, J BIOL CHEM, V242, P3332; NAKAYAMA C, 1980, NUCL ACIDS S SER, V8, P193; O'Handley SF, 2001, J BIOL CHEM, V276, P5421, DOI 10.1074/jbc.M004100200; OHANDLEY SF, 1995, FASEB J, V9, pA1299; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; SLAPIKOFF S, 1967, BIOCHEMISTRY-US, V12, P3654; Yan HG, 1999, ADV ENZYMOL RAMB, V73, P103, DOI 10.1002/9780470123195.ch4	26	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37492	37496		10.1074/jbc.M307639200	http://dx.doi.org/10.1074/jbc.M307639200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871944	hybrid			2022-12-25	WOS:000185437200062
J	Yoshida, A; Urasaki, Y; Waltham, M; Bergman, AC; Pourquier, P; Rothwell, DG; Inuzuka, M; Weinstein, JN; Ueda, T; Appella, E; Hickson, ID; Pommier, Y				Yoshida, A; Urasaki, Y; Waltham, M; Bergman, AC; Pourquier, P; Rothwell, DG; Inuzuka, M; Weinstein, JN; Ueda, T; Appella, E; Hickson, ID; Pommier, Y			Human apurinic/apyrimidinic endonuclease (Ape1) and its N-terminal truncated form (AN34) are involved in DNA fragmentation during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CASPASE-ACTIVATED DNASE; COLI EXONUCLEASE-III; CHROMATIN CONDENSATION; REPAIR ENZYME; DEOXYRIBONUCLEASE-II; BINDING ACTIVITY; RAT THYMOCYTES; ABASIC SITES; TUMOR-CELLS	We previously isolated a 34-kDa nuclease (AN34) from apoptotic human leukemia cells. Here, we identify AN34 as an N-terminally truncated form of human AP endonuclease (Ape1) lacking residues 1-35 (Delta35-Ape1). Although Ape1 has hitherto been considered specific for damaged DNA (specific to AP site), recombinant AN34 (Delta35-Ape1) possesses significant endonuclease activity on undamaged (normal) DNA and in chromatin. AN34 also displays enhanced 3'-5' exonuclease activity. Caspase-3 activates AN34 in a cell-free system, although caspase-3 cannot cleave Ape1 directly in vitro. We also found that Ape1 itself preferentially cleaves damaged chromatin DNA isolated from cells treated with apoptotic stimuli and that silencing of Ape1 expression decreases apoptotic DNA fragmentation in DFF40/CAD-deficient cells. Thus, we propose that AN34 and Ape1 participate in the process of chromatin fragmentation during apoptosis.	NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Fukui Med Univ, Dept Chem, Fukui 9101193, Japan; Fukui Med Univ, Dept Internal Med 1, Fukui 9101193, Japan; Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK Labs, Oxford OX3 9DS, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Fukui; University of Fukui; Cancer Research UK; University of Oxford	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bldg 37,Rm 5068, Bethesda, MD 20892 USA.		Pourquier, Philippe/O-8030-2018; Waltham, Mark/A-1728-2009; Hickson, Ian/AAJ-7548-2020	Pourquier, Philippe/0000-0001-5326-3005; Hickson, Ian/0000-0002-0583-566X; Rothwell, Dominic/0000-0002-8757-3893; Weinstein, John/0000-0001-9401-6908	NATIONAL CANCER INSTITUTE [Z01BC006161, Z01BC007349, ZIABC006150, Z01BC006150, ZIABC006161] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Chaudhry MA, 1999, BIOCHEM PHARMACOL, V57, P531, DOI 10.1016/S0006-2952(98)00327-X; Chou KM, 2000, J BIOL CHEM, V275, P31009, DOI 10.1074/jbc.M004082200; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; CLEAVER JE, 1972, BIOCHIM BIOPHYS ACTA, V262, P116, DOI 10.1016/0005-2787(72)90224-9; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Krieser RJ, 1998, J BIOL CHEM, V273, P30909, DOI 10.1074/jbc.273.47.30909; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; McIlroy D, 2000, GENE DEV, V14, P549; MIMNAUGH EG, 1989, CANCER RES, V49, P8; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Rauch F, 1997, J CELL BIOL, V137, P909, DOI 10.1083/jcb.137.4.909; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Rothwell DG, 2000, NUCLEIC ACIDS RES, V28, P2207, DOI 10.1093/nar/28.11.2207; SAFFHILL R, 1985, BIOCHIM BIOPHYS ACTA, V823, P111, DOI 10.1016/0304-419X(85)90009-5; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samejima K, 2001, J BIOL CHEM, V276, P45427, DOI 10.1074/jbc.M108844200; SEKI S, 1991, J BIOL CHEM, V266, P20797; Shimizu T, 1997, LEUKEMIA, V11, P1238, DOI 10.1038/sj.leu.2400734; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; WRIGHT SC, 1994, J EXP MED, V180, P2113, DOI 10.1084/jem.180.6.2113; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yoshida A, 1998, CANCER RES, V58, P2576; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	48	47	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37768	37776		10.1074/jbc.M304914200	http://dx.doi.org/10.1074/jbc.M304914200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12842873	hybrid			2022-12-25	WOS:000185437200095
J	Cook, CR; Kung, GS; Peterson, FC; Volkman, BF; Lei, M				Cook, CR; Kung, GS; Peterson, FC; Volkman, BF; Lei, M			A novel zinc finger is required for Mcm10 homocomplex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; BINDING PROPERTIES; HUMAN HOMOLOG; PROTEIN; INITIATION; ORIGINS; COMPLEX; COMPONENT; SYSTEM; MAINTENANCE	Mcm10 is a DNA replication factor that interacts with multiple subunits of the MCM2-7 hexameric complex. We report here that Mcm10 self-interacts and assembles into large homocomplexes (similar to 800 kDa). A conserved domain of 210 amino acid residues is sufficient for mediating self-interaction and complex assembly. A novel zinc finger within the conserved domain, CX10CX11CX2H, is essential for the homocomplex formation. Mutant alleles with amino acid substitutions at conserved cysteines and histidine in the zinc finger fail to assemble homocomplexes. A defect in homocomplex assembly correlates with defects in DNA replication and cell growth in the mutants. These observations suggest that homocomplex assembly is essential for Mcm10 function. Multisubunit Mcm10 homocomplexes may provide the structural basis for Mcm10 to interact with multiple subunits of the MCM2-7 hexamer.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Lei, M (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA.	mlei@mcw.edu	Volkman, Brian F./ABE-7306-2020; Volkman, Brian F./ABE-7312-2020	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179	NIGMS NIH HHS [GM6264901] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062649] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Amann BT, 2003, BIOCHEMISTRY-US, V42, P217, DOI 10.1021/bi026988m; Aves SJ, 1998, CURR GENET, V34, P164, DOI 10.1007/s002940050382; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Berg JM, 1997, ANNU REV BIOPH BIOM, V26, P357, DOI 10.1146/annurev.biophys.26.1.357; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Christensen TW, 2003, MOL BIOL CELL, V14, P2206, DOI 10.1091/mbc.E02-11-0706; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Davey MJ, 2003, J BIOL CHEM, V278, P4491, DOI 10.1074/jbc.M210511200; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Gao GX, 2002, SCIENCE, V297, P1703, DOI 10.1126/science.1074276; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Harlow E., 1988, ANTIBODIES LAB MANUA; Homesley L, 2000, GENE DEV, V14, P913; HOMESLEY LA, 1999, THESIS CORNELL U ITH; Izumi M, 2001, J BIOL CHEM, V276, P48526, DOI 10.1074/jbc.M107190200; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Lei M, 2002, J BIOL CHEM, V277, P30824, DOI 10.1074/jbc.M201816200; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lei M, 2001, J CELL SCI, V114, P1447; Liang DT, 2001, GENETICS, V159, P471; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAINE GT, 1984, GENETICS, V106, P365; Merchant AM, 1997, MOL CELL BIOL, V17, P3261, DOI 10.1128/MCB.17.6.3261; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLOMON NA, 1992, YEAST, V8, P273, DOI 10.1002/yea.320080405; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Worthington MT, 1996, P NATL ACAD SCI USA, V93, P13754, DOI 10.1073/pnas.93.24.13754; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; Yu X, 2002, EMBO REP, V3, P792, DOI 10.1093/embo-reports/kvf160	48	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36051	36058		10.1074/jbc.M306049200	http://dx.doi.org/10.1074/jbc.M306049200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12844493	hybrid			2022-12-25	WOS:000185318300024
J	Di Padova, M; Bruno, T; De Nicola, F; Iezzi, S; D'Angelo, C; Gallo, R; Nicosia, D; Corbi, N; Biroccio, A; Floridi, A; Passananti, C; Fanciulli, M				Di Padova, M; Bruno, T; De Nicola, F; Iezzi, S; D'Angelo, C; Gallo, R; Nicosia, D; Corbi, N; Biroccio, A; Floridi, A; Passananti, C; Fanciulli, M			Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21(WAF1/CIP1) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITOR; SUBEROYLANILIDE HYDROXAMIC ACID; WAF1/CIP1 GENE PROMOTER; TRANSCRIPTION FACTOR; CHROMATIN-STRUCTURE; SP1 SITES; GROWTH; CANCER; KINASE; IDENTIFICATION	Che-1 is a recently identified human RNA polymerase II binding protein involved in the regulation of gene transcription and cell proliferation. We previously demonstrated that Che-1 inhibits the Rb growth-suppressing function by interfering with Rb-mediated HDAC1 recruitment on E2F target gene promoters. By hybridization of cancer profile arrays, we found that Che-1 expression is strongly down-regulated in several tumors, including colon and kidney carcinomas, compared with the relative normal tissues. Consistent with these data, Che-1 overexpression inhibits proliferation of HCT116 and LoVo human colon carcinoma cell lines by activation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) in a p53-independent manner and by promoting growth arrest at the G(1) phase of the cell cycle. Che-1 activates p21(WAF1/Cip1) by displacing histone deacetylase ( HDAC) 1 from the Sp1 binding sites of the p21(WAF1/Cip1) gene promoter and accumulating acetylated histone H3 on these sites. Accordingly, Che-1-specific RNA interference negatively affects p21(WAF1/Cip1) transactivation and increases cell proliferation in HCT116 cells. Taken together, our results indicate that Che-1 can be considered a general HDAC1 competitor and its down-regulation is involved in colon carcinoma cell proliferation.	Regina Elena Inst Canc Res, Expt Res Ctr, Lab B, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Expt Res Ctr, Expt Chemotherapy Lab, I-00158 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; CNR, Ist Biol & Patol Mol, I-00137 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of L'Aquila; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR)	Fanciulli, M (corresponding author), Regina Elena Inst Canc Res, Expt Res Ctr, Lab B, Via Messi Oro 156, I-00158 Rome, Italy.	fanciulli@.ifo.it	fanciulli, maurizio/ABH-6745-2020; Iezzi, Simona/AAA-3275-2021; Corbi, Nicoletta/AAW-8835-2020; bruno, tiziana/AAC-4913-2022; Passananti, Claudio/K-9593-2016; Corbi, Nicoletta/K-2313-2014; Biroccio, Annamaria/B-2861-2018; De Nicola, Francesca/AAC-6887-2022	Iezzi, Simona/0000-0002-7484-5861; bruno, tiziana/0000-0003-0352-4523; Biroccio, Annamaria/0000-0003-3198-3532; PASSANANTI, CLAUDIO/0000-0002-9288-5736; De Nicola, FRANCESCA/0000-0002-2187-7544; CORBI, NICOLETTA/0000-0002-4505-1632; DI PADOVA, Monica/0000-0003-3808-7159	Telethon [A.160] Funding Source: Medline	Telethon(Fondazione Telethon)		Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Biroccio A, 2002, J BIOL CHEM, V277, P43763, DOI 10.1074/jbc.M207684200; Bruno T, 2002, CANCER CELL, V2, P387, DOI 10.1016/S1535-6108(02)00182-4; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Butler LM, 2000, CANCER RES, V60, P5165; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DelBufalo D, 1996, J CLIN INVEST, V98, P1165, DOI 10.1172/JCI118900; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fanciulli M, 2000, FASEB J, V14, P904, DOI 10.1096/fasebj.14.7.904; Finzer P, 2001, ONCOGENE, V20, P4768, DOI 10.1038/sj.onc.1204652; Fournel M, 2002, CANCER RES, V62, P4325; Gallo R, 2002, J CELL BIOL, V158, P731, DOI 10.1083/jcb.200202024; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Han JW, 2000, CANCER RES, V60, P6068; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARPER JW, 1993, CELL, V75, P805; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lindfors K, 2000, BIOCHEM BIOPH RES CO, V276, P660, DOI 10.1006/bbrc.2000.3480; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Page G, 1999, FEBS LETT, V462, P187, DOI 10.1016/S0014-5793(99)01529-X; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomas T, 2000, DEV BIOL, V227, P324, DOI 10.1006/dbio.2000.9915; VanLint C, 1996, GENE EXPRESSION, V5, P245; WALDMAN T, 1995, CANCER RES, V55, P5187; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamashita Y, 2003, INT J CANCER, V103, P572, DOI 10.1002/ijc.10699; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338	45	40	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36496	36504		10.1074/jbc.M306694200	http://dx.doi.org/10.1074/jbc.M306694200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847090	hybrid			2022-12-25	WOS:000185318300078
J	Woodcock, JM; Murphy, J; Stomski, FC; Berndt, MC; Lopez, AF				Woodcock, JM; Murphy, J; Stomski, FC; Berndt, MC; Lopez, AF			The dimeric versus monomeric status of 14-3-3 zeta is controlled by phosphorylation of Ser(58) at the dimer interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; MEDIATED PHOSPHORYLATION; APOPTOSIS; PROTEINS; KINASE; SPHINGOSINE; N,N-DIMETHYLSPHINGOSINE; IDENTIFICATION; INDUCTION; ISOFORMS	The 14-3-3 proteins play a central role in the regulation of cell growth, cycling, and apoptosis by modulating the functional activities of key signaling proteins. Through binding to a phosphoserine motif, 14-3-3 alters target proteins activities by sequestering them, relocalizing them, conformationally altering their functional activity, or by promoting interaction with other proteins. These functions of 14-3-3 are facilitated by, if not dependent on, its dimeric structure. We now show that the dimeric status of 14-3-3 is regulated by site-specific serine phosphorylation. We found that a sphingosine-dependent kinase phosphorylates 14-3-3 in vitro and in vivo on a serine residue (Ser(58)) located within the dimer interface. Furthermore, by developing an antibody that specifically recognizes 14-3-3zeta phosphorylated on Ser58 and employing native-PAGE and cross-linking techniques, we found that 14-3-3 phosphorylated on Ser58 is monomeric both in vitro and in vivo. Phosphorylated 14-3-3 was detected solely as a monomer, indicating that phosphorylation of a single monomer within a dimer is sufficient to disrupt the dimeric structure. Significantly, phosphorylation-induced monomerization did not prevent 14-3-3 binding to a phosphopeptide target. We propose that this regulated monomerization of 14-3-3 controls its ability to modulate the activity of target proteins and thus may have significant implications for 14-3-3 function and the regulation of many cellular processes.	Inst Med & Vet Sci, Hanson Inst, Div Human Immunol, Cytokine Receptor Lab, Adelaide, SA 5000, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; Monash University	Woodcock, JM (corresponding author), Inst Med & Vet Sci, Hanson Inst, Div Human Immunol, Cytokine Receptor Lab, GPO Box 14 Rundle Mall, Adelaide, SA 5000, Australia.	joanna.woodcock@imvs.sa.gov.au	Lopez, Angel F/E-2260-2011; Berndt, Michael C/D-5580-2012	Lopez, Angel F/0000-0001-7430-0135; Woodcock, Joanna/0000-0001-5127-9687				ABDELGHANY M, 1992, BIOCHIM BIOPHYS ACTA, V1137, P349, DOI 10.1016/0167-4889(92)90156-6; Aitken A, 2002, PLANT MOL BIOL, V50, P993, DOI 10.1023/A:1021261931561; Bodnar RJ, 2002, J BIOL CHEM, V277, P47080, DOI 10.1074/jbc.M208329200; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; ENDO K, 1991, CANCER RES, V51, P1613; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Guthridge MA, 2000, MOL CELL, V6, P99, DOI 10.1016/S1097-2765(00)00011-3; Jendiroba DB, 2002, LEUKEMIA RES, V26, P301, DOI 10.1016/S0145-2126(01)00129-1; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; LUI D, 1995, NATURE, V376, P191; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nakamura S, 1996, J BIOL CHEM, V271, P1255, DOI 10.1074/jbc.271.3.1255; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; OHTA H, 1995, CANCER RES, V55, P691; Powell DW, 2002, J BIOL CHEM, V277, P21639, DOI 10.1074/jbc.M203167200; Sakakura C, 1997, INT J ONCOL, V11, P31; Shirahama T, 1997, CLIN CANCER RES, V3, P257; Stomski FC, 1999, BLOOD, V94, P1933; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhou Y, 2003, J BIOL CHEM, V278, P10073, DOI 10.1074/jbc.M211907200	31	131	137	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36323	36327		10.1074/jbc.M304689200	http://dx.doi.org/10.1074/jbc.M304689200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12865427	hybrid			2022-12-25	WOS:000185318300057
J	Zhu, YJ; Hui, DY				Zhu, YJ; Hui, DY			Apolipoprotein E binding to low density lipoprotein receptor-related protein-1 inhibits cell migration via activation of cAMP-dependent protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; TYROSINE PHOSPHORYLATION; PLASMINOGEN-ACTIVATOR; UROKINASE RECEPTOR; TRANSGENIC MICE; GENE FAMILY; GROWTH; ATHEROSCLEROSIS; PROLIFERATION; LRP	Smooth muscle cell migration and proliferation contribute to neointimal hyperplasia and vascular stenosis after endothelial denudation. Previous studies revealed that apolipoprotein E (apoE) is an effective inhibitor of platelet-derived growth factor-directed smooth muscle cell migration and proliferation and that the anti-migratory function is mediated via apoE binding to low density lipoprotein receptor-related protein-1 (LRP-1). This study was undertaken to identify the intracellular pathway by which apoE binding to LRP-1 results in inhibition of smooth muscle cell migration. The results showed that apoE increased intracellular cAMP levels 3-fold after 5 min, and the increase was sustained for more than 1 h. As a consequence, apoE also increased protein kinase A (PKA) activity in smooth muscle cells. Importantly, suppression of PKA activity with a cell-permeable peptide inhibitor of PKA abolished the inhibitory effect of apoE on smooth muscle cell migration. These results indicated that apoE inhibition of smooth muscle cell migration is mediated via the activation of cAMP-dependent PKA. Additional experiments revealed that apoE also inhibited fibroblasts migration toward platelet-derived growth factor by a similar mechanism of cAMP-dependent PKA activation. It is noteworthy that apoE failed to increase cAMP levels or inhibit migration of LRP-1-negative mouse embryonic fibroblasts and LRP-1-deficient smooth muscle cells. Taken together, these findings established the mechanism by which apoE inhibits cell migration, i.e. via cAMP-dependent protein kinase A activation as a consequence of its binding to LRP-1.	Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Hui, DY (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	huidy@email.uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061332] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61332] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; BU GJ, 1993, J BIOL CHEM, V268, P13002; Cedazo-Minguez A, 2001, NEUROCHEM INT, V38, P615, DOI 10.1016/S0197-0186(00)00128-5; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; HERZ J, 1990, J BIOL CHEM, V265, P21355; HORIO T, 1995, CIRC RES, V77, P660, DOI 10.1161/01.RES.77.4.660; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; Ishigami M, 2000, ARTERIOSCL THROM VAS, V20, P1020, DOI 10.1161/01.ATV.20.4.1020; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; Itoh H, 2001, AM J PHYSIOL-HEART C, V281, pH359, DOI 10.1152/ajpheart.2001.281.1.H359; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MIMURA Y, 1995, BIOL PHARM BULL, V18, P1373; Narita M, 2002, J BIOCHEM, V132, P743, DOI 10.1093/oxfordjournals.jbchem.a003282; Node K, 2001, J BIOL CHEM, V276, P15983, DOI 10.1074/jbc.M100439200; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1986, METHOD ENZYMOL, V128, P273; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; Smith DM, 2002, BIOCHEM SOC T, V30, P432, DOI 10.1042/bst0300432; Sun JX, 2002, CIRC RES, V90, P1020, DOI 10.1161/01.RES.0000017727.35930.33; Swertfeger DK, 2002, J BIOL CHEM, V277, P4141, DOI 10.1074/jbc.M109124200; Swertfeger DK, 2001, J BIOL CHEM, V276, P25043, DOI 10.1074/jbc.M102357200; Thorngate FE, 2000, ARTERIOSCL THROM VAS, V20, P1939, DOI 10.1161/01.ATV.20.8.1939; Wijnberg MJ, 1997, THROMB HAEMOSTASIS, V78, P880; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHANG SH, 1994, J CLIN INVEST, V94, P937, DOI 10.1172/JCI117460	39	52	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36257	36263		10.1074/jbc.M303171200	http://dx.doi.org/10.1074/jbc.M303171200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857755	hybrid			2022-12-25	WOS:000185318300048
J	Borges, JC; Fischer, H; Craievich, AF; Hansen, LD; Ramos, CHI				Borges, JC; Fischer, H; Craievich, AF; Hansen, LD; Ramos, CHI			Free human mitochondrial GrpE is a symmetric dimer in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-DNA REPLICATION; HEAT-SHOCK PROTEINS; NUCLEOTIDE EXCHANGE FACTOR; ESCHERICHIA-COLI DNAK; SOLUTION SCATTERING; BIOLOGICAL MACROMOLECULES; SWISS-MODEL; SYSTEM; SEDIMENTATION; BACTERIOPHAGE	The co-chaperone GrpE is essential for the activities of the Hsp70 system, which assists protein folding. GrpE is present in several organisms, and characterization of homologous GrpEs is important for developing structure-function relationships. Cloning, producing, and conformational studies of the recombinant human mitochondrial GrpE are reported here. Circular dichroism measurements demonstrate that the purified protein is folded. Thermal unfolding of human GrpE measured both by circular dichroism and differential scanning calorimetry differs from that of prokaryotic GrpE. Analytical ultracentrifugation data indicate that human GrpE is a dimer, and the sedimentation coefficient agrees with an elongated shape model. Small angle x-ray scattering analysis shows that the protein possesses an elongated shape in solution and demonstrates that its envelope, determined by an ab initio method, is similar to the high resolution envelope of Escherichia coli GrpE bound to DnaK obtained from single crystal x-ray diffraction. However, in these conditions, the E. coli GrpE dimer is asymmetric because the monomer that binds DnaK adopts an open conformation. It is of considerable importance for structural GrpE research to answer the question of whether the GrpE dimer is only asymmetric while bound to DnaK or also as a free dimer in solution. The low resolution structure of human GrpE presented here suggests that GrpE is a symmetric dimer when not bound to DnaK. This information is important for understanding the conformational changes GrpE undergoes on binding to DnaK.	Lab Nacl Luz Sincroton, Ctr Biol Mol Estrutural, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, Inst Biol, Dept Bioquim, BR-13084971 Sao Paulo, Brazil; Univ Sao Paulo, Inst Fis, Dept Fis Aplicada, BR-05389970 Sao Paulo, Brazil; Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA	Laboratorio Nacional de Luz Sincrotron (LNLS); Universidade Estadual de Campinas; Universidade de Sao Paulo; Brigham Young University	Ramos, CHI (corresponding author), Lab Nacl Luz Sincroton, Ctr Biol Mol Estrutural, POB 6192, BR-13084971 Campinas, SP, Brazil.	cramos@lnls.br	Ramos, CH/C-1571-2012; Borges, Julio C/C-6160-2008; Fischer, Hannes/C-2215-2012; Craievich, Aldo F/A-2852-2013	Ramos, CH/0000-0002-7246-9081; Borges, Julio C/0000-0003-4856-748X; Fischer, Hannes/0000-0003-2984-2028; Craievich, Aldo F/0000-0002-5103-0248				ANG D, 1986, J BACTERIOL, V167, P25, DOI 10.1128/jb.167.1.25-29.1986; Baldi P, 1999, BIOINFORMATICS, V15, P937, DOI 10.1093/bioinformatics/15.11.937; Borges JC, 2001, GENET MOL BIOL, V24, P85, DOI 10.1590/S1415-47572001000100013; Choglay AA, 2001, GENE, V267, P125, DOI 10.1016/S0378-1119(01)00396-1; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; delaTorre JG, 1997, EUR BIOPHYS J BIOPHY, V25, P361, DOI 10.1007/s002490050049; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Feigin L. A., 1987, STRUCTURE ANAL SMALL, P839; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; Gelinas AD, 2002, J MOL BIOL, V323, P131, DOI 10.1016/S0022-2836(02)00915-4; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDBERG RJ, 1953, J PHYS CHEM-US, V57, P194, DOI 10.1021/j150503a014; Grimshaw JPA, 2001, J BIOL CHEM, V276, P6098, DOI 10.1074/jbc.M009290200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; JOHNSON C, 1989, J BACTERIOL, V171, P1590, DOI 10.1128/jb.171.3.1590-1596.1989; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kellermann G, 1997, J APPL CRYSTALLOGR, V30, P880, DOI 10.1107/S0021889897001829; Konarev PV, 2001, J APPL CRYSTALLOGR, V34, P527, DOI 10.1107/S0021889801006100; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Martin AS, 1997, ADV MATER OPT ELECTR, V7, P45, DOI 10.1002/(SICI)1099-0712(199701)7:1<45::AID-AMO246>3.0.CO;2-J; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; Mehl AF, 2001, BIOCHEM BIOPH RES CO, V282, P562, DOI 10.1006/bbrc.2001.4567; Naylor DJ, 1998, J BIOL CHEM, V273, P21169, DOI 10.1074/jbc.273.33.21169; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; Schlicher T, 1997, PLANT MOL BIOL, V33, P181, DOI 10.1023/A:1005784115363; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; SVERGUN DI, 1991, ACTA CRYSTALLOGR A, V47, P736, DOI 10.1107/S0108767391006414; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WU B, 1994, J BACTERIOL, V176, P6965, DOI 10.1128/JB.176.22.6965-6973.1994; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	49	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35337	35344		10.1074/jbc.M305083200	http://dx.doi.org/10.1074/jbc.M305083200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12840016	hybrid			2022-12-25	WOS:000185164400073
J	Cho, KJ; Moon, HE; Moini, H; Packer, L; Yoon, DY; Chung, AS				Cho, KJ; Moon, HE; Moini, H; Packer, L; Yoon, DY; Chung, AS			alpha-lipoic acid inhibits adipocyte differentiation by regulating pro-adipogenic transcription factors via mitogen-activated protein kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; LIPOPROTEIN-LIPASE GENE; RECEPTOR-GAMMA; SIGNALING PATHWAY; 3T3-L1 ADIPOCYTES; GLUCOSE-UPTAKE; PPAR-GAMMA; KAPPA-B; EXPRESSION; CELLS	Obesity is associated with a number of pathological disorders such as non-insulin-dependent diabetes, hypertension, hyperlipidemia, and cardiovascular diseases. alpha-Lipoic acid (LA) has been demonstrated to activate the insulin signaling pathway and to exert insulin-like actions in adipose and muscle cells. Based on this similarity LA is expected to promote adipogenesis in pre-adipocytes. Here, however, we report that LA inhibited differentiation of 3T3-L1 pre-adipocytes induced by a hormonal mixture or troglitazone. Northern blot analysis of cells demonstrated that this inhibition was accompanied with attenuated expression of adipocyte-specific fatty acid-binding protein and lipoprotein lipase. Electrophoretic mobility shift assay and Western blot analysis of cells demonstrated that LA modulates transcriptional activity and/or expression of a set of anti- or pro-adipogenic transcription factors. LA treatment of 3T3-L1 pre-adipocytes also resulted in prolonged activation of major mitogen-activated protein kinase signaling pathways but showed little or no effect on the activity of the insulin receptor/Akt signaling pathway. These findings suggest that LA inhibits insulin or the hormonal mixture-induced differentiation of 3T3-L1 pre-adipocytes by modulating activity and/or expression of pro- or anti- adipogenic transcription factors mainly through activating the MAPK pathways.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Korea Inst Biosci & Biotechnol, Cell Biol Lab, Taejon 305333, South Korea	Korea Advanced Institute of Science & Technology (KAIST); University of Southern California	Chung, AS (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Guseong Dong 373-1, Taejon 305701, South Korea.	aschung@kaist.ac.kr						BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Camp HS, 1997, J BIOL CHEM, V272, P10811; CARO JF, 1989, DIABETES METAB REV, V5, P665, DOI 10.1002/dmr.5610050804; Chakraborti S, 1998, CELL SIGNAL, V10, P675, DOI 10.1016/S0898-6568(98)00014-X; Cho KJ, 2000, TOXICOL APPL PHARM, V168, P64, DOI 10.1006/taap.2000.9001; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; Eason RC, 2002, DIABETES OBES METAB, V4, P29, DOI 10.1046/j.1463-1326.2002.00171.x; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Estrada DE, 1996, DIABETES, V45, P1798, DOI 10.2337/diabetes.45.12.1798; Hallakou S, 1997, DIABETES, V46, P1393, DOI 10.2337/diabetes.46.9.1393; Homma H, 2000, J BIOL CHEM, V275, P11404, DOI 10.1074/jbc.275.15.11404; Hsi LC, 2001, J BIOL CHEM, V276, P34545, DOI 10.1074/jbc.M100280200; Kim KY, 2001, J BIOL CHEM, V276, P40591, DOI 10.1074/jbc.M100975200; Leong KS, 1999, BEST PRACT RES CL EN, V13, P221, DOI 10.1053/beem.1999.0017; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Moini H, 2002, ARCH BIOCHEM BIOPHYS, V397, P384, DOI 10.1006/abbi.2001.2680; Moreno-Aliaga MJ, 1999, MOL PHARMACOL, V56, P91, DOI 10.1124/mol.56.1.91; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Renard P, 1999, CELL BIOL TOXICOL, V15, P341, DOI 10.1023/A:1007652414175; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; Ruan H, 2002, DIABETES, V51, P1319, DOI 10.2337/diabetes.51.5.1319; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Smas CM, 1999, J BIOL CHEM, V274, P12632, DOI 10.1074/jbc.274.18.12632; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Xia XM, 1999, J CELL PHYSIOL, V178, P9, DOI 10.1002/(SICI)1097-4652(199901)178:1<9::AID-JCP2>3.0.CO;2-#; Yamasaki S, 2002, CLIN EXP IMMUNOL, V129, P379, DOI 10.1046/j.1365-2249.2002.01876.x; YANG VW, 1989, P NATL ACAD SCI USA, V86, P3629, DOI 10.1073/pnas.86.10.3629; Yaworsky K, 2000, DIABETOLOGIA, V43, P294, DOI 10.1007/s001250050047; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	39	69	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34823	34833		10.1074/jbc.M210747200	http://dx.doi.org/10.1074/jbc.M210747200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12837769	hybrid			2022-12-25	WOS:000185164400013
J	Donald, LJ; Krokhin, OV; Duckworth, HW; Wiseman, B; Deemagarn, T; Singh, R; Switala, J; Carpena, X; Fita, I; Loewen, PC				Donald, LJ; Krokhin, OV; Duckworth, HW; Wiseman, B; Deemagarn, T; Singh, R; Switala, J; Carpena, X; Fita, I; Loewen, PC			Characterization of the catalase-peroxidase KatG from Burkholderia pseudomallei by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIUM-TUBERCULOSIS; ESCHERICHIA-COLI; MUTATIONS; GENE; PROTEINS	The electron density maps of the catalase-peroxidase from Burkholderia pseudomallei (BpKatG) presented two unusual covalent modifications. A covalent structure linked the active site Trp(111) with Tyr(238) and Tyr(238) with Met(264), and the heme was modified, likely by a perhydroxy group added to the vinyl group on ring I. Mass spectrometry analysis of tryptic digests of BpKatG revealed a cluster of ions at m/z 6585, consistent with the fusion of three peptides through Trp(111), Tyr(238), and Met(264), and a cluster at m/z similar to 4525, consistent with the fusion of two peptides linked through Trp(111) and Tyr(238). MS/MS analysis of the major ions at m/z 4524 and 4540 confirmed the expected sequence and suggested that the multiple ions in the cluster were the result of multiple oxidation events and transfer of CH3-S to the tyrosine. Neither cluster of ions at m/z 4525 or 6585 was present in the spectrum of a tryptic digest of the W111F variant of BpKatG. The spectrum of the tryptic digest of native BpKatG also contained a major ion for a peptide in which Met(264) had been converted to homoserine, consistent with the covalent bond between Tyr(238) and Met(264) being susceptible to hydrolysis, including the loss of the CH3-S from the methionine. Analysis of the tryptic digests of hydroperoxidase I (KatG) from Escherichia coli provided direct evidence for the covalent linkage between Trp(105) and Tyr(226) and indirect evidence for a covalent linkage between Tyr(226) and Met(252). Tryptic peptide analysis and N-terminal sequencing revealed that the N-terminal residue of BpKatG is Ser(22).	Univ Manitoba, Dept Microbiol, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Dept Chem, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Dept Phys, Winnipeg, MB R3T 2N2, Canada; CSIC, Inst Biol Mol Barcelona, ES-08034 Barcelona, Spain	University of Manitoba; University of Manitoba; University of Manitoba; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Loewen, PC (corresponding author), Univ Manitoba, Dept Microbiol, Winnipeg, MB R3T 2N2, Canada.		Carpena, Xavi/J-5877-2017; Deemagarn, Taweewat/AAR-4030-2020; Fita, Ignasi/R-4515-2019; Singh, Rahul/A-6891-2009	Carpena, Xavi/0000-0002-8646-0440; Fita, Ignasi/0000-0002-7521-2679; Singh, Rahul/0000-0002-1467-7915; Deemagarn, Taweewat/0000-0003-3368-1749; Wiseman, Benjamin/0000-0002-2994-5839				Carpena X, 2003, J MOL BIOL, V327, P475, DOI 10.1016/S0022-2836(03)00122-0; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; Hillar A, 2000, BIOCHEMISTRY-US, V39, P5868, DOI 10.1021/bi0000059; Jakopitsch C, 2003, J BIOL CHEM, V278, P20185, DOI 10.1074/jbc.M211625200; Krutchinsky AN, 1998, J AM SOC MASS SPECTR, V9, P569, DOI 10.1016/S1044-0305(98)00027-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; Loboda AV, 2000, RAPID COMMUN MASS SP, V14, P1047, DOI 10.1002/1097-0231(20000630)14:12<1047::AID-RCM990>3.0.CO;2-E; LOEWEN PC, 1990, BIOCHEM CELL BIOL, V68, P1037, DOI 10.1139/o90-153; MEAD DA, 1985, NUCLEIC ACIDS RES, V13, P1103, DOI 10.1093/nar/13.4.1103; Regelsberger G, 2000, J BIOL CHEM, V275, P22854, DOI 10.1074/jbc.M002371200; Regelsberger G, 2001, BIOCHEM SOC T, V29, P99; RORTH M, 1967, BIOCHIM BIOPHYS ACTA, V139, P171, DOI 10.1016/0005-2744(67)90124-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH AT, 1990, J BIOL CHEM, V265, P13335; VERENTCHIKOV AN, 1994, ANAL CHEM, V66, P126, DOI 10.1021/ac00073a022; WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	21	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35687	35692		10.1074/jbc.M304053200	http://dx.doi.org/10.1074/jbc.M304053200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832453	hybrid			2022-12-25	WOS:000185164400114
J	Stein, A; Vaseduvan, G; Carter, NS; Ullman, B; Landfear, SM; Kavanaugh, MP				Stein, A; Vaseduvan, G; Carter, NS; Ullman, B; Landfear, SM; Kavanaugh, MP			Equilibrative nucleoside transporter family members from Leishmania donovani are electrogenic proton symporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE TRANSPORTER; DEFICIENT MUTANT; CLONING; GENE; PROMASTIGOTES; COTRANSPORTER; EXPRESSION; PERSANTIN; KINETICS; RESCUE	Leishmania donovani express two members of the equilibrative nucleoside transporter family; LdNT1 encoded by two closely related and linked genes, LdNT1.1 and LdNT1.2, that transport adenosine and pyrimidine nucleosides and LdNT2 that transports inosine and guanosine exclusively. LdNT1.1, LdNT1.2, and LdNT2 have been expressed in Xenopus laevis oocytes and found to be electrogenic in the presence of nucleoside ligands for which they mediate transport. Further analysis revealed that ligand uptake and transport currents through LdNT1-type transporters are proton-dependent. In addition to the flux of protons that is coupled to the transport reaction, LdNT1 transporters mediate a variable constitutive proton conductance that is blocked by substrates and dipyridamole. Surprisingly, LdNT1.1 and LdNT1.2 exhibit different electrogenic properties, despite their close sequence homology. This electrophysiological study provides the first demonstration that members of the equilibrative nucleoside transporter family can be electrogenic and establishes that these three permeases, unlike their mammalian counterparts, are probably concentrative rather than facilitative transporters.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Landfear, SM (corresponding author), Univ Montana, Ctr Struct & Funct Neurosci, Missoula, MT 59812 USA.				NIAID NIH HHS [AI 23682, AI 44138, R01 AI044138] Funding Source: Medline; NINDS NIH HHS [NS 033270] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044138, R37AI023682, R01AI023682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARONOW B, 1987, MOL BIOCHEM PARASIT, V22, P29, DOI 10.1016/0166-6851(87)90066-1; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; Carter NS, 2000, J BIOL CHEM, V275, P20935, DOI 10.1074/jbc.M002418200; CARTER NS, 2003, MOL MED PARASITOLOGY, P197; de Koning HP, 1998, J BIOL CHEM, V273, P9486, DOI 10.1074/jbc.273.16.9486; DREW ME, 1995, MOL CELL BIOL, V15, P5508; GRAFF JC, 1977, J BIOL CHEM, V252, P4185; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; IOVANNISCI DM, 1984, MOL CELL BIOL, V4, P1013, DOI 10.1128/MCB.4.6.1013; KESSEL D, 1972, BIOCHIM BIOPHYS ACTA, V288, P190, DOI 10.1016/0005-2736(72)90237-4; Klamo EM, 1996, J BIOL CHEM, V271, P14937, DOI 10.1074/jbc.271.25.14937; Mohlmann T, 2001, FEBS LETT, V509, P370, DOI 10.1016/S0014-5793(01)03195-7; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; Vasudevan G, 2001, P NATL ACAD SCI USA, V98, P6092, DOI 10.1073/pnas.101537298; VIEIRA L, 1995, J BIOL CHEM, V270, P5299, DOI 10.1074/jbc.270.10.5299; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; Yao SY, 2002, AM J PHYSIOL-CELL PH, V283, pC155, DOI 10.1152/ajpcell.00587.2001; ZILBERSTEIN D, 1989, MOL BIOCHEM PARASIT, V36, P109, DOI 10.1016/0166-6851(89)90183-7; ZILBERSTEIN D, 1993, ADV PARASIT, V32, P261, DOI 10.1016/S0065-308X(08)60209-2	21	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35127	35134		10.1074/jbc.M306188200	http://dx.doi.org/10.1074/jbc.M306188200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12835315	hybrid, Green Published			2022-12-25	WOS:000185164400048
J	Zilberberg, L; Shinkaruk, S; Lequin, O; Rousseau, B; Hagedorn, M; Costa, F; Caronzolo, D; Balke, M; Canron X; Convert, O; Lain, G; Gionnet, K; Goncalves, M; Bayle, M; Bello, L; Chassaing, G; Deleris, G; Bikfalvi, A				Zilberberg, L; Shinkaruk, S; Lequin, O; Rousseau, B; Hagedorn, M; Costa, F; Caronzolo, D; Balke, M; Canron, X; Convert, O; Lain, G; Gionnet, K; Goncalves, M; Bayle, M; Bello, L; Chassaing, G; Deleris, G; Bikfalvi, A			Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; KINASE DOMAIN RECEPTOR; COMMON AMINO-ACIDS; FACTOR VEGF; IN-VIVO; CRYSTAL-STRUCTURE; CELL-PROLIFERATION; ANGSTROM RESOLUTION; NMR-SPECTROSCOPY; BINDING SITE	Blocking angiogenesis is an attractive strategy to inhibit tumor growth, invasion, and metastasis. We describe here the structure and the biological action of a new cyclic peptide derived from vascular endothelial growth factor ( VEGF). This 17-amino acid molecule designated cyclopeptidic vascular endothelial growth inhibitor (cyclo-VEGI, CBO-P11) encompasses residues 79 - 93 of VEGF which are involved in the interaction with VEGF receptor-2. In aqueous solution, cyclo-VEGI presents a propensity to adopt a helix conformation that was largely unexpected because only beta-sheet structures or random coil conformations have been observed for macrocyclic peptides. Cyclo-VEGI inhibits binding of iodinated VEGF(165) to endothelial cells, endothelial cells proliferation, migration, and signaling induced by VEGF(165). This peptide also exhibits anti-angiogenic activity in vivo on the differentiated chicken chorioallantoic membrane. Furthermore, cyclo-VEGI significantly blocks the growth of established intracranial glioma in nude and syngeneic mice and improves survival without side effects. Taken together, these results suggest that cyclo-VEGI is an attractive candidate for the development of novel angiogenesis inhibitor molecules useful for the treatment of cancer and other angiogenesis- related diseases.	Univ Bordeaux 1, INSERM, Mol Angiogenesis Lab, F-33405 Talence, France; Univ Bordeaux 2, INSERM, U577, Grp Chim Bioorgan, F-33076 Bordeaux, France; Univ Paris 06, CNRS, UMR 7613, F-75252 Paris, France; Univ Milan, Osped Maggiore Policlin, Ist Ric & Cura Carattere Sci, Dept Neurol Sci, I-20122 Milan, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Bikfalvi, A (corresponding author), Univ Bordeaux 1, INSERM, Mol Angiogenesis Lab, E 0113, F-33405 Talence, France.	a.bikfalvi@croissance.u-bordeaux.fr	Bello, Lorenzo/AAB-2884-2022; Hagedorn, Martin/B-4272-2008; Costa, Francesco/K-4341-2018	Bello, Lorenzo/0000-0001-6797-7105; Costa, Francesco/0000-0002-5191-9477; LEQUIN, Olivier/0000-0001-5307-3068; Shinkaruk, Svitlana/0000-0002-8150-0001; Hagedorn, Martin/0000-0002-0960-5116				ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; Avgeropoulos N G, 1999, Oncologist, V4, P209; Bae DG, 2000, J BIOL CHEM, V275, P13588, DOI 10.1074/jbc.275.18.13588; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bello L, 2002, CLIN CANCER RES, V8, P3539; Bello L, 2001, CANCER RES, V61, P8730; Bikfalvi A, 2002, TRENDS PHARMACOL SCI, V23, P576, DOI 10.1016/S0165-6147(02)02109-0; Binetruy-Tournaire R, 2000, EMBO J, V19, P1525, DOI 10.1093/emboj/19.7.1525; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; Compagni A, 2000, CANCER RES, V60, P7163; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dirix LY, 1997, BRIT J CANCER, V76, P238, DOI 10.1038/bjc.1997.368; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Fairbrother WJ, 1998, BIOCHEMISTRY-US, V37, P17754, DOI 10.1021/bi981931e; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gasparini G, 1997, J NATL CANCER I, V89, P139, DOI 10.1093/jnci/89.2.139; Gibbs AC, 1998, NAT STRUCT BIOL, V5, P284, DOI 10.1038/nsb0498-284; Hagedorn M, 2002, CANCER RES, V62, P6884; Hagedorn M, 2001, FASEB J, V15, P550; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Javerzat S, 2002, TRENDS MOL MED, V8, P483, DOI 10.1016/S1471-4914(02)02394-8; Ke LD, 2000, CLIN CANCER RES, V6, P2562; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Leenders W, 2002, LAB INVEST, V82, P473, DOI 10.1038/labinvest.3780440; Lei HT, 2002, J BIOL CHEM, V277, P43137, DOI 10.1074/jbc.M203103200; McInnes C, 2000, J BIOL CHEM, V275, P14287, DOI 10.1074/jbc.275.19.14287; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Rak J, 2002, CANCER RES, V62, P1931; Ramakrishnan S, 1996, CANCER RES, V56, P1324; Relf M, 1997, CANCER RES, V57, P963; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Shinkaruk S., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P95, DOI 10.2174/1568011033353452; Siemeister G, 1998, P NATL ACAD SCI USA, V95, P4625, DOI 10.1073/pnas.95.8.4625; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wedge SR, 2002, CANCER RES, V62, P4645; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; WILTING J, 1992, ANAT EMBRYOL, V186, P251; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WURHRICH K, 1986, NMR PROTEINS NUCL AC; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2	67	105	114	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35564	35573		10.1074/jbc.M304435200	http://dx.doi.org/10.1074/jbc.M304435200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12837752	hybrid, Green Published			2022-12-25	WOS:000185164400100
J	Ching, YP; Leong, VYL; Wong, CM; Kung, HF				Ching, YP; Leong, VYL; Wong, CM; Kung, HF			Identification of an autoinhibitory domain of p21-activated protein kinase 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-GTPASES; KINASE; EFFECTOR; CELLS; CDC42; BRAIN; PAK1	The p21-activated protein kinases (Paks) are serine/ threonine protein kinases activated by binding to Rho family small GTPases, Rac and Cdc42. Recently, Pak family members have been subdivided into two groups, I and II. Group II Paks, including Pak4, Pak5, and Pak6, does not contain the highly conserved autoinhibitory domain that is found in the group I Paks members, i.e. Pak1, Pak2, and Pak3. In the present study, we have purified the glutathione S-transferase fusion form of Pak5 and shown for the first time that Pak5 autophosphorylation can be activated by GTP bound form of Cdc42. Mutation of histidine residues 19 and 22 to leucine on the p21-binding domain of Pak5 completely abolished the binding of Cdc42 and the Cdc42-mediated autophosphorylation. On the other hand, mutation of tyrosine 40 to cysteine of Cdc42 did not knockout the binding of Pak5. Analysis of C-terminal deletion mutants has identified an autoinhibitory fragment of Pak5 that is absent from other group II Pak family members. Taken together, these results suggest that Pak5, like Pak1, contains an autoinhibitory domain and its activity is regulated by Cdc42.	Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Ching, YP (corresponding author), Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China.		Wong, Chi-Ming/A-7627-2013; Ching, Yick Pang/C-4244-2009	Wong, Chi-Ming/0000-0002-0025-7135; CHING, Yick Pang/0000-0002-6461-8358				Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Coleman ML, 2002, CELL DEATH DIFFER, V9, P493, DOI 10.1038/sj.cdd.4400987; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Owen D, 2000, BIOCHEMISTRY-US, V39, P1243, DOI 10.1021/bi991567z; Pandey A, 2002, ONCOGENE, V21, P3939, DOI 10.1038/sj.onc.1205478; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5	12	50	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33621	33624		10.1074/jbc.C300234200	http://dx.doi.org/10.1074/jbc.C300234200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12860998	hybrid, Green Published			2022-12-25	WOS:000185047500004
J	Lewandowicz, A; Tyler, PC; Evans, GB; Furneaux, RH; Schramm, VL				Lewandowicz, A; Tyler, PC; Evans, GB; Furneaux, RH; Schramm, VL			Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUCILLIN-H; BCX-1777; CELLS; DEFICIENCY; BINDING; TRIPHOSPHATE	Genetic deficiency of human purine nucleoside phosphorylase (PNP) causes T-cell immunodeficiency. The enzyme is therefore a target for autoimmunity disorders, tissue transplant rejection and T-cell malignancies. Transition state analysis of bovine PNP led to the development of immucillin-H (ImmH), a powerful inhibitor of bovine PNP but less effective for human PNP. The transition state of human PNP differs from that of the bovine enzyme and transition state analogues specific for the human enzyme were synthesized. Three first generation transition state analogues, ImmG (K-d=42 pM), ImmH (K-d=56 pM), and 8-aza-ImmH (K-d=180 pM), are compared with three second generation DADMe compounds (4'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillins) tailored to the transition state of human PNP. The second generation compounds, DADMe-ImmG (K-d=7pM), DADMe-ImmH (K-d=16 pM), and 8-aza-DADMe-ImmH (K-d=2.0 nM), are superior for inhibition of human PNP by binding up to 6-fold tighter. The DADMe-immucillins are the most powerful PNP inhibitors yet described, with K-m/K-d ratios up to 5,400,000. ImmH and DADMe-ImmH are orally available in mice; DADMe-ImmH is more efficient than ImmH. DADMe-ImmH achieves the ultimate goal in transition state inhibitor design in mice. A single oral dose causes inhibition of the target enzyme for the approximate lifetime of circulating erythrocytes.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Ind Res Ltd, Carbohydrate Chem Team, Lower Hutt, New Zealand	Yeshiva University; Albert Einstein College of Medicine; Callaghan Innovation	Schramm, VL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Furneaux, Richard Hubert/B-4157-2015; Evans, Gary/I-4123-2019; Evans, Gary/B-8343-2011	Furneaux, Richard Hubert/0000-0003-0973-2606; Evans, Gary/0000-0002-6973-2002; Evans, Gary/0000-0002-6973-2002; Lewandowicz, Andrzej/0000-0002-4207-9023				Bantia S, 2003, INT IMMUNOPHARMACOL, V3, P879, DOI 10.1016/S1567-5769(03)00076-6; Bantia S, 2002, INT IMMUNOPHARMACOL, V2, P913, DOI 10.1016/S1567-5769(02)00034-6; Bantia S, 2001, INT IMMUNOPHARMACOL, V1, P1199, DOI 10.1016/S1567-5769(01)00056-X; Berti PJ, 2002, ADV PHYS ORG CHEM, V37, P239, DOI 10.1016/S0065-3160(02)37004-7; CHAN T, 1978, CELL, V14, P523, DOI 10.1016/0092-8674(78)90238-6; COHEN A, 1978, J CLIN INVEST, V61, P1405, DOI 10.1172/JCI109058; Duvic M, 2001, J AM ACAD DERMATOL, V44, P940, DOI 10.1067/mjd.2001.113478; Evans GB, 2003, J MED CHEM, V46, P3412, DOI 10.1021/jm030145r; Evans GB, 2000, TETRAHEDRON, V56, P3053, DOI 10.1016/S0040-4020(00)00194-0; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; GAD SC, 1992, ANIMAL MODELS TOXICO, P168; GIBLETT ER, 1975, LANCET, V1, P1010, DOI 10.1016/S0140-6736(75)91950-9; Jiang YL, 2002, BIOCHEMISTRY-US, V41, P7116, DOI 10.1021/bi025694y; Kicska GA, 2002, BIOCHEMISTRY-US, V41, P14489, DOI 10.1021/bi026636f; Kicska GA, 2002, J BIOL CHEM, V277, P3219, DOI 10.1074/jbc.M105905200; Kicska GA, 2001, P NATL ACAD SCI USA, V98, P4593, DOI 10.1073/pnas.071050798; Kilpatrick JM, 2003, INT IMMUNOPHARMACOL, V3, P541, DOI 10.1016/S1567-5769(03)00044-4; KIM BK, 1968, J BIOL CHEM, V243, P1771; KLINE PC, 1995, BIOCHEMISTRY-US, V34, P1153, DOI 10.1021/bi00004a008; Lewandowicz A, 2003, BIOCHEMISTRY-US, V42, P6057, DOI 10.1021/bi0343830; Mansson E, 2003, BIOCHEM PHARMACOL, V65, P237, DOI 10.1016/S0006-2952(02)01484-3; Mao C, 1998, BIOCHEMISTRY-US, V37, P7135, DOI 10.1021/bi9723919; MCIVOR RS, 1985, MOL CELL BIOL, V5, P1349, DOI 10.1128/MCB.5.6.1349; Miles RW, 1998, BIOCHEMISTRY-US, V37, P8615, DOI 10.1021/bi980658d; MONTGOMERY JA, 1993, J MED CHEM, V36, P55, DOI 10.1021/jm00053a008; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; OSBORNE WRA, 1980, J BIOL CHEM, V255, P7089; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P5694, DOI 10.1021/bi034003a; Schramm VL, 2003, CURR TOP MED CHEM, V3, P525, DOI 10.2174/1568026033452465; ULLMAN B, 1980, J BIOL CHEM, V255, P8308	30	106	122	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31465	31468		10.1074/jbc.C300259200	http://dx.doi.org/10.1074/jbc.C300259200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12842889	hybrid			2022-12-25	WOS:000184782100003
J	Almholt, K; Nielsen, BS; Frandsen, TL; Brunner, N; Dano, K; Johnsen, M				Almholt, K; Nielsen, BS; Frandsen, TL; Brunner, N; Dano, K; Johnsen, M			Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice	ONCOGENE			English	Article						plasminogen activator inhibitor-1 (PAI-1); metastasis; breast cancer; angiogenesis	MATRIX-DEGRADING PROTEASES; UROKINASE-TYPE; MESSENGER-RNA; EXTRACELLULAR PROTEOLYSIS; IMMUNOHISTOCHEMICAL LOCALIZATION; PROGNOSTIC-SIGNIFICANCE; CELL-ADHESION; TUMOR-GROWTH; PAI-1; INVASION	The plasminogen activator inhibitor-1 (PAI-1) blocks the activation of plasmin(ogen), an extracellular protease vital to cancer invasion. PAI-1 is like the corresponding plasminogen activator uPA (urokinase-type plasminogen activator) consistently expressed in human breast cancer. Paradoxically, high levels of PAI-1 as well as uPA are equally associated with poor prognosis in cancer patients. PAI-1 is thought to play a vital role for the controlled extracellular proteolysis during tumor neovascularization. We have studied the effect of PAI-1 deficiency in a transgenic mouse model of metastasizing breast cancer. In these tumors, the expression pattern of uPA and PAI-1 resembles that of human ductal breast cancer and plasminogen is required for efficient metastasis. In a cohort of 63 transgenic mice that were either PAI-1-deficient or wild-type sibling controls, primary tumor growth and vascular density were unaffected by PAI-1 status. PAI-1 deficiency also did not significantly affect the lung metastatic burden. These results agree with the virtual lack of spontaneous phenotype in PAI-1-deficient mice and humans and may reflect that the plasminogen activation reaction is not rate limiting for tumor vascularization and metastasis, or that there is a functional redundancy between PAI-1 and other inhibitors of the uPA/plasmin system, masking the effect of PAI-1 deficiency.	Rigshosp, Finsen Lab, Dept 8621, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Inst Mol Biol, DK-1353 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen	Almholt, K (corresponding author), Rigshosp, Finsen Lab, Dept 8621, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	kasper@finsenlab.dk	Frandsen, Thomas L/H-7784-2017; Almholt, Kasper/D-6133-2013; Johnsen, Morten/L-8016-2014	Frandsen, Thomas L/0000-0001-8495-5274; Johnsen, Morten/0000-0003-3763-2362; Almholt, Kasper/0000-0002-9250-514X				ALMHOLT K, IN PRESS RECENT RESU, V162; ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BIANCHI E, 1995, INT J CANCER, V60, P597, DOI 10.1002/ijc.2910600505; BIANCHI E, 1994, CANCER RES, V54, P861; Biliran H, 2001, CANCER RES, V61, P8676; BROWN T, 1997, CURRENT PROTOCOLS MO, V1; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; DANO K, 1993, PORTL PR P, P239; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; DUFFY MJ, 1988, CANCER, V62, P531, DOI 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B; ESPANA F, 1993, THROMB HAEMOSTASIS, V70, P989; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Fay WP, 1997, BLOOD, V90, P204; Feng Q, 2001, PLACENTA, V22, P186, DOI 10.1053/plac.2000.0607; Frandsen TL, 2001, CANCER RES, V61, P532; Garlanda C, 1997, EUR J CELL BIOL, V73, P368; GrondahlHansen J, 1995, CLIN CANCER RES, V1, P1079; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Gutierrez LS, 2000, CANCER RES, V60, P5839; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HACKEL C, 1995, ANAT EMBRYOL, V192, P363, DOI 10.1007/BF00710105; Harbeck N, 1999, BREAST CANCER RES TR, V54, P147, DOI 10.1023/A:1006118828278; Hewitt R, 1996, ENZYME PROTEIN, V49, P163, DOI 10.1159/000468623; HOFMANN GE, 1994, AM J OBSTET GYNECOL, V170, P671, DOI 10.1016/S0002-9378(94)70246-2; JANICKE F, 1991, SEMIN THROMB HEMOST, V17, P303, DOI 10.1055/s-2007-1002624; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; KRISTENSEN P, 1991, J HISTOCHEM CYTOCHEM, V39, P341, DOI 10.1177/39.3.1899685; KRISTENSEN P, 1990, HISTOCHEMISTRY, V93, P559, DOI 10.1007/BF00272198; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lijnen HR, 2001, ANN NY ACAD SCI, V936, P226; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Look MP, 2002, JNCI-J NATL CANCER I, V94, P116, DOI 10.1093/jnci/94.2.116; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; Lund LR, 2000, DEVELOPMENT, V127, P4481; Maglione JE, 2001, CANCER RES, V61, P8298; Matrisian LM, 1999, CURR BIOL, V9, pR776, DOI 10.1016/S0960-9822(00)80011-1; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Montemurro P, 1999, BRIT J HAEMATOL, V107, P294, DOI 10.1046/j.1365-2141.1999.01698.x; NEKARDA H, 1994, CANCER RES, V54, P2900; Nielsen BS, 1996, LAB INVEST, V74, P168; Nielsen BS, 2001, LAB INVEST, V81, P1485, DOI 10.1038/labinvest.3780363; Nielsen BS, 2001, AM J PATHOL, V158, P1997, DOI 10.1016/S0002-9440(10)64671-8; Parfyonova YV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P119, DOI 10.1023/A:1013964517211; PEDERSEN H, 1994, CANCER RES, V54, P120; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; Pepper MS, 2001, THROMB HAEMOSTASIS, V86, P346; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PYKE C, 1991, CANCER RES, V51, P4067; PYKE C, 1993, CANCER RES, V53, P1911; Riisbro R, 2002, CLIN CANCER RES, V8, P1132; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; Shi HY, 2002, MOL THER, V5, P755, DOI 10.1006/mthe.2002.0602; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tapiovaara H, 1996, ADV CANCER RES, V69, P101, DOI 10.1016/S0065-230X(08)60861-1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Werb Z, 1996, BRAZ J MED BIOL RES, V29, P1087; Werb Z, 1999, APMIS, V107, P11, DOI 10.1111/j.1699-0463.1999.tb01521.x; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843	74	58	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4389	4397		10.1038/sj.onc.1206601	http://dx.doi.org/10.1038/sj.onc.1206601			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853975				2022-12-25	WOS:000183978900008
J	Barth, H; Schafer, C; Adah, MI; Zhang, FM; Linhardt, RJ; Toyoda, H; Kinoshita-Toyoda, A; Toida, T; van Kuppevelt, TH; Depla, E; von Weizsacker, F; Blum, HE; Baumert, TF				Barth, H; Schafer, C; Adah, MI; Zhang, FM; Linhardt, RJ; Toyoda, H; Kinoshita-Toyoda, A; Toida, T; van Kuppevelt, TH; Depla, E; von Weizsacker, F; Blum, HE; Baumert, TF			Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; AGAROSE-GEL ELECTROPHORESIS; STRUCTURAL PROTEINS; CANDIDATE RECEPTOR; HUMAN HEPATOCYTES; FEVER VIRUS; IN-VIVO; PARTICLES; INFECTION; ANTIBODIES	The conservation of positively charged residues in the N terminus of the hepatitis C virus (HCV) envelope glycoprotein E2 suggests an interaction of the viral envelope with cell surface glycosaminoglycans. Using recombinant envelope glycoprotein E2 and virus-like particles as ligands for cellular binding, we demonstrate that cell surface heparan sulfate proteoglycans ( HSPG) play an important role in mediating HCV envelope-target cell interaction. Heparin and liver-derived highly sulfated heparan sulfate but not other soluble glycosaminoglycans inhibited cellular binding and entry of virus-like particles in a dose-dependent manner. Degradation of cell surface heparan sulfate by pretreatment with heparinases resulted in a marked reduction of viral envelope protein binding. Surface plasmon resonance analysis demonstrated a high affinity interaction ( K-D 5.2 x 10(-9) M) of E2 with heparin, a structural homologue of highly sulfated heparan sulfate. Deletion of E2 hypervariable region-1 reduced E2-heparin interaction suggesting that positively charged residues in the N-terminal E2 region play an important role in mediating E2-HSPG binding. In conclusion, our results demonstrate for the first time that cellular binding of HCV envelope requires E2-HSPG interaction. Docking of E2 to cellular HSPG may be the initial step in the interaction between HCV and the cell surface resulting in receptor-mediated entry and initiation of infection.	Univ Freiburg, Dept Med 2, D-79106 Freiburg, Germany; Univ Iowa, Dept Chem, Iowa City, IA 52242 USA; Univ Iowa, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Nat Prod Chem, Iowa City, IA 52242 USA; Univ Iowa, Dept Chem & Biochem Engn, Iowa City, IA 52242 USA; Chiba Univ, Dept Analyt Chem, Chiba 2638522, Japan; Univ Med Ctr, NCMLS, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Innogenet NV, B-9052 Ghent, Belgium	University of Freiburg; University of Iowa; University of Iowa; University of Iowa; University of Iowa; Chiba University; Radboud University Nijmegen; Innogenetics NV	Baumert, TF (corresponding author), Univ Freiburg, Dept Med 2, Hugstetter Str 55, D-79106 Freiburg, Germany.	tbaumert@ukl.uni-freiburg.de	Baumert, Thomas/ABF-4718-2020; van Kuppevelt, A.H.M.S.M./L-4463-2015	Baumert, Thomas/0000-0002-8864-2168; Adah, Mohammed Ignatius/0000-0001-8077-5815				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; Baumert TF, 2000, HEPATOLOGY, V32, P610, DOI 10.1053/jhep.2000.9876; Bergstrom T, 1997, NAT MED, V3, P1177, DOI 10.1038/nm1197-1177b; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Birkmann A, 2001, J VIROL, V75, P11583, DOI 10.1128/JVI.75.23.11583-11593.2001; Blanchard E, 2002, J VIROL, V76, P4073, DOI 10.1128/JVI.76.8.4073-4079.2002; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Castet V, 2002, J VIROL, V76, P8189, DOI 10.1128/JVI.76.16.8189-8199.2002; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Cladera J, 2001, EMBO J, V20, P19, DOI 10.1093/emboj/20.1.19; Clayton RF, 2002, J VIROL, V76, P7672, DOI 10.1128/JVI.76.15.7672-7682.2002; Cocquerel L, 2002, EMBO J, V21, P2893, DOI 10.1093/emboj/cdf295; Combita AL, 2002, J VIROL, V76, P6480, DOI 10.1128/JVI.76.13.6480-6486.2002; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; Di Bisceglie AM, 2002, HEPATOLOGY, V36, pS121, DOI 10.1053/jhep.2002.36228; Ezelle HJ, 2002, J VIROL, V76, P12325, DOI 10.1128/JVI.76.23.12325-12334.2002; Flint M, 2000, REV MED VIROL, V10, P101, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;101::AID-RMV268&gt;3.0.CO;2-W; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Germi R, 2002, VIROLOGY, V292, P162, DOI 10.1006/viro.2001.1232; Gilbert JM, 1998, J VIROL, V72, P5323, DOI 10.1128/JVI.72.6.5323-5327.1998; Giroglou T, 2001, J VIROL, V75, P1565, DOI 10.1128/JVI.75.3.1565-1570.2001; Hamaia S, 2001, BLOOD, V98, P2293, DOI 10.1182/blood.V98.8.2293; Hilgard P, 2000, HEPATOLOGY, V32, P1069, DOI 10.1053/jhep.2000.18713; Hulst MM, 2001, J VIROL, V75, P9585, DOI 10.1128/JVI.75.20.9585-9595.2001; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; LINDENBACH BD, 2001, FIELDS VIROLOGY, V1, P991; MAJOR ME, 2001, FIELDS VIROLOGY, V1, P1127; Mandl CW, 2001, J VIROL, V75, P5627, DOI 10.1128/JVI.75.12.5627-5637.2001; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; Marks RM, 2001, J MED CHEM, V44, P2178, DOI 10.1021/jm000412i; Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968; Owsianka A, 2001, J GEN VIROL, V82, P1877, DOI 10.1099/0022-1317-82-8-1877; Patel J, 2001, VIROLOGY, V279, P58, DOI 10.1006/viro.2000.0693; Penin F, 2001, J VIROL, V75, P5703, DOI 10.1128/JVI.75.12.5703-5710.2001; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Putnak JR, 1997, NAT MED, V3, P828, DOI 10.1038/nm0897-828; Rosa D, 1996, P NATL ACAD SCI USA, V93, P1759, DOI 10.1073/pnas.93.5.1759; Saunier B, 2003, J VIROL, V77, P546, DOI 10.1128/JVI.77.1.546-559.2003; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Shimizu YK, 1996, HEPATOLOGY, V23, P205; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Takikawa S, 2000, J VIROL, V74, P5066, DOI 10.1128/JVI.74.11.5066-5074.2000; Tamura M, 2000, J VIROL, V74, P11589, DOI 10.1128/JVI.74.24.11589-11597.2000; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; Toida T, 1997, ANAL BIOCHEM, V251, P219, DOI 10.1006/abio.1997.2277; Toyoda H, 1997, J CHROMATOGR B, V704, P19, DOI 10.1016/S0378-4347(97)00478-7; Triyatni M, 2002, J VIROL, V76, P9335, DOI 10.1128/JVI.76.18.9335-9344.2002; Triyatni M, 2002, VIROLOGY, V298, P124, DOI 10.1006/viro.2002.1463; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; vanDoorn LJ, 1997, J MED VIROL, V52, P441, DOI 10.1002/(SICI)1096-9071(199708)52:4<441::AID-JMV17>3.0.CO;2-J; Volpi N, 1999, ANAL BIOCHEM, V273, P229, DOI 10.1006/abio.1999.4218; VOLPI N, 1993, CARBOHYD RES, V247, P263, DOI 10.1016/0008-6215(93)84259-9; Wellnitz S, 2002, J VIROL, V76, P1181, DOI 10.1128/JVI.76.3.1181-1193.2002; Wunschmann S, 2000, J VIROL, V74, P10055, DOI 10.1128/JVI.74.21.10055-10062.2000; Xiang JH, 2002, J MED VIROL, V68, P537, DOI 10.1002/jmv.10237; Yagnik AT, 2000, PROTEINS, V40, P355, DOI 10.1002/1097-0134(20000815)40:3<355::AID-PROT20>3.0.CO;2-K; Zhang FM, 2002, ANAL BIOCHEM, V304, P271, DOI 10.1006/abio.2002.5617; Zhang YJ, 2002, J VIROL, V76, P6332, DOI 10.1128/JVI.76.12.6332-6343.2002; Zhao XP, 2002, J CLIN INVEST, V109, P221, DOI 10.1172/JCI13011	66	369	405	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41003	41012		10.1074/jbc.M302267200	http://dx.doi.org/10.1074/jbc.M302267200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12867431	Green Published, hybrid			2022-12-25	WOS:000185847200074
J	Kolling, DRJ; Samoilova, RI; Holland, JT; Berry, EA; Dikanov, SA; Crofts, AR				Kolling, DRJ; Samoilova, RI; Holland, JT; Berry, EA; Dikanov, SA; Crofts, AR			Exploration of ligands to the Q(i) site semiquinone in the bc(1) complex using high-resolution EPR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURE QUADRUPOLE-RESONANCE; RHODOBACTER-SPHAEROIDES; AMINO-ACIDS; ELECTRON-TRANSFER; CYTOCHROME-B; QUINONE; N-14; UBIQUINOL; OXIDOREDUCTASE; MECHANISM	Pulsed EPR spectroscopy was used to explore the structural neighborhood of the semiquinone (SQ) stabilized at the Q(i) site of the bc(1) complex of Rhodobacter sphaeroides (EC 1.10.2.2) and to demonstrate that the nitrogen atom of a histidine imidazole group donates an H-bond to the SQ. Crystallographic structures show two different configurations for the binding of ubiquinone at the Q(i) site of mitochondrial bc1 complexes in which histidine (His-201 in bovine sequence) is either a direct H-bond donor or separated by a bridging water. The paramagnetic properties of the SQ formed at the site provide an independent method for studying the liganding of this intermediate species. The antimycin-sensitive SQ formed at the Q(i) site by either equilibrium redox titration, reduction of the oxidized complex by ascorbate, or addition of decylubihydroquinone to the oxidized complex in the presence of myxothiazol all showed similar properties. The electron spin echo envelope modulation spectra in the N-14 region were dominated by lines with frequencies at 1.7 and 3.1 MHz. Hyperfine sublevel correlation spectroscopy spectra showed that these were contributed by a single nitrogen. Further analysis showed that the N-14 nucleus was characterized by an isotropic hyperfine coupling of similar to0.8 MHz and a quadrupole coupling constant of similar to0.35 MHz. The nitrogen was identified as the N-epsilon or N-delta imidazole nitrogen of a histidine (it is likely to be His-217, or His-201 in bovine sequence). A distance of 2.5-3.1 Angstrom for the O-N distance between the carbonyl of SQ and the nitrogen was estimated. The mechanistic significance is discussed in the context of a dynamic role for the movement of His-217 in proton transfer to the site.	Univ Illinois, Dept Biochem, Roger Adams Lab 419, Urbana, IL 61801 USA; Univ Illinois, Dept Vet Clin Med, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Russian Acad Sci, Inst Chem Kinet & Combust, Novosibirsk 630090, Russia; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Russian Academy of Sciences; Voevodsky Institute of Chemical Kinetics & Combustion SB RAS; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Crofts, AR (corresponding author), Univ Illinois, Dept Biochem, Roger Adams Lab 419, 600 S Mathews Ave, Urbana, IL 61801 USA.	a-crofts@life.uiuc.edu	Samoilova, Rimma Ivanovna/T-7956-2017	Samoilova, Rimma Ivanovna/0000-0002-1649-1487	FIC NIH HHS [1 R03 TW01495] Funding Source: Medline; NCRR NIH HHS [S10-RR15878] Funding Source: Medline; NIGMS NIH HHS [GM 35438, GM 62954] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001495] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035438, R01GM062954] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1985, ENZYMES BIOL MEMBRAN, DOI DOI 10.1007/978-1-4684-4604-3_10; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15791, DOI 10.1021/bi990961u; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; CROFTS AR, 1995, PHOTOSYNTHESIS LIGHT, V2, P493; de Vries S., 1982, FUNCTION QUINONES EN, P235; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DELAROSA FF, 1983, FEBS LETT, V163, P140, DOI 10.1016/0014-5793(83)81181-8; Deligiannakis Y, 1999, J AM CHEM SOC, V121, P7653, DOI 10.1021/ja984209c; DEVRIES S, 1983, BIOCHIM BIOPHYS ACTA, V723, P91, DOI 10.1016/0005-2728(83)90013-0; DIKANOV SA, 1982, CHEM PHYS LETT, V90, P149, DOI 10.1016/0009-2614(82)83630-0; EDMONDS DT, 1973, J MAGN RESON, V12, P134, DOI 10.1016/0022-2364(73)90136-4; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P723, DOI 10.1021/bi00169a014; HACKER B, 1993, BIOCHEMISTRY-US, V32, P4403, DOI 10.1021/bi00067a033; Hoff A.J., 1989, ADV EPR APPL BIOCH B; HUNT MJ, 1976, J MAGN RESON, V22, P295, DOI 10.1016/0022-2364(76)90304-8; HUNT MJ, 1974, J MAGN RESON, V15, P402, DOI 10.1016/0022-2364(74)90143-7; HUNT MJ, 1975, CHEM PHYS LETT, V34, P473, DOI 10.1016/0009-2614(75)85542-4; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KAUTEN R, 1987, J BIOL CHEM, V262, P8658; Kuras R, 1998, BIOCHEMISTRY-US, V37, P16280, DOI 10.1021/bi9813476; MCDOWELL CA, 1986, J MAGN RESON, V69, P283, DOI 10.1016/0022-2364(86)90079-X; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; NITSCHKE W, 1997, PHOTOSYNTHESIS COMPR, P285; PALMER MH, 1987, CHEM PHYS, V115, P207, DOI 10.1016/0301-0104(87)80034-4; RICH PR, 1990, BIOCHIM BIOPHYS ACTA, V1018, P29, DOI 10.1016/0005-2728(90)90106-E; ROBERTSON DE, 1984, J BIOL CHEM, V259, P1758; SALERNO JC, 1990, BIOCHEMISTRY-US, V29, P6987, DOI 10.1021/bi00482a006; SALERNO JC, 1989, J BIOL CHEM, V264, P15398; Spoyalov AP, 1996, CHEM PHYS LETT, V263, P715, DOI 10.1016/S0009-2614(96)01255-9; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	34	46	49	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39747	39754		10.1074/jbc.M305913200	http://dx.doi.org/10.1074/jbc.M305913200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12874282	Green Submitted, hybrid			2022-12-25	WOS:000185713800060
J	Park, SG; Lee, SM; Jung, GH				Park, SG; Lee, SM; Jung, GH			Antisense oligodeoxynucleotides targeted against molecular chaperonin Hsp60 block human hepatitis B virus replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-LOOP STRUCTURE; REVERSE-TRANSCRIPTASE; IN-VITRO; DNA-POLYMERASE; OLIGONUCLEOTIDE; PROTEIN; EXPRESSION; INTERFERON; CELLS; RNA	The major role of hepatitis B virus polymerase (HBV pol) is polymerization of nucleotides, but it also participates in protein priming and the packaging of its own genome into capsids. Therefore, HBV pol may require many assistance factors for its roles. Previous reports have shown that Hsp60, a molecular chaperone, activates HBV pol both in vitro and ex vivo, such as inside insect cells. Moreover, HBV pol binds to Hsp60 in the HepG2 host cell line. In this report, we show that Hsp60 plays a role in the in vivo replication of HBV. Antisense oligodeoxynucleotides (A-ODNs) specifically directed against Hsp60 induced its down-regulation, severely reducing the level of replication-competent HBV without influencing cell proliferation and capsid assembly under these conditions. Furthermore, we found that Hsp60 did not encapsidate into nucleocapsids. Our results indicate that Hsp60 is important for HBV replication in vivo, presumably through activation of HBV pol before encapsidation of HBV pol into HBV core particle. In addition, A-ODNs specific for Hsp60 also inhibit replication of a mutant HBV strain that is resistant to the nucleoside analogue 3TC, which is the main drug used for HBV treatment, and we suggest that A-ODNs directed against Hsp60 are possible reagents as anti-HBV drugs. Conclusively, this report shows that the host factor, Hsp60, is essential for in vivo HBV replication and that mechanism of Hsp60 is probably through an activation of HBV pol by Hsp60.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea	Seoul National University (SNU)	Jung, GH (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.	drjung@snu.ac.kr		Jung, Guhung/0000-0001-6672-8473; Park, Sung-Gyoo/0000-0003-3702-5765				Allen MI, 1998, HEPATOLOGY, V27, P1670, DOI 10.1002/hep.510270628; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; COHEN JS, 1993, ANTISENSE RES APPL, P205; Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543; de Smet MD, 1999, OCUL IMMUNOL INFLAMM, V7, P189, DOI 10.1076/ocii.7.3.189.4007; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; FOSTER GR, 1994, ANTIVIR RES, V24, P131, DOI 10.1016/0166-3542(94)90061-2; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; HOWE AYM, 1992, BIOCHEM BIOPH RES CO, V189, P1170, DOI 10.1016/0006-291X(92)92327-T; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; Hu JM, 2002, J VIROL, V76, P269, DOI 10.1128/JVI.76.1.269-279.2002; Jeong JH, 1996, BIOCHEM BIOPH RES CO, V223, P264, DOI 10.1006/bbrc.1996.0882; KIM K T, 1988, Korean Biochemical Journal, V21, P319; KNAUS T, 1993, NUCLEIC ACIDS RES, V21, P3967, DOI 10.1093/nar/21.17.3967; LEE HJ, 1993, BIOTECHNOL LETT, V15, P821; Loeb KR, 2000, HEPATOLOGY, V32, P626, DOI 10.1053/jhep.2000.9878; Lott L, 2000, J VIROL, V74, P11479, DOI 10.1128/JVI.74.24.11479-11489.2000; MASON WS, 1983, VIROLOGY, V131, P375, DOI 10.1016/0042-6822(83)90505-6; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Ono-Nita SK, 1999, HEPATOLOGY, V29, P939, DOI 10.1002/hep.510290340; Pak JH, 2002, J BIOL CHEM, V277, P49927, DOI 10.1074/jbc.M204222200; Park SG, 2002, VIROLOGY, V298, P116, DOI 10.1006/viro.2002.1496; Park SG, 2001, J VIROL, V75, P6962, DOI 10.1128/JVI.75.15.6962-6968.2001; Parkin DM, 1999, CANCER SURV, V33, P5; POLLACK JR, 1993, J VIROL, V67, P3254, DOI 10.1128/JVI.67.6.3254-3263.1993; Ranganathan G, 2002, J BIOL CHEM, V277, P38669, DOI 10.1074/jbc.M206917200; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Sogos V, 1997, NEUROCHEM INT, V31, P447, DOI 10.1016/S0197-0186(96)00114-3; SOMMER W, 1999, METHOD ENZYMOL, V277, P261; STEINHOFF U, 1994, P NATL ACAD SCI USA, V91, P5085, DOI 10.1073/pnas.91.11.5085; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; Uhlmann E, 2000, METHOD ENZYMOL, V313, P268; Veal GJ, 1998, NUCLEIC ACIDS RES, V26, P5670, DOI 10.1093/nar/26.24.5670; WAGNER RW, 1995, NAT MED, V1, P1116, DOI 10.1038/nm1195-1116; Wagner RW, 1997, MOL MED TODAY, V3, P31, DOI 10.1016/S1357-4310(96)10053-8; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; Zignego AL, 1997, ARCH VIROL, V142, P535, DOI 10.1007/s007050050099; ZOULIM F, 1994, J VIROL, V68, P6, DOI 10.1128/JVI.68.1.6-13.1994	42	50	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39851	39857		10.1074/jbc.M301618200	http://dx.doi.org/10.1074/jbc.M301618200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869561	hybrid			2022-12-25	WOS:000185713800071
J	Tabancay, AP; Gau, CL; Machado, IMP; Uhlmann, EJ; Gutmann, DH; Guo, L; Tamanoi, F				Tabancay, AP; Gau, CL; Machado, IMP; Uhlmann, EJ; Gutmann, DH; Guo, L; Tamanoi, F			Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-RELATED PROTEIN; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; CELL-GROWTH; SACCHAROMYCES-CEREVISIAE; CANAVANINE RESISTANCE; NITROGEN STARVATION; MECHANISM; GENE; TRANSFORMATION	Rheb GTPases represent a unique family of the Ras superfamily of G-proteins. Studies on Rheb in Schizosaccharomyces pombe and Drosophila have shown that this small GTPase is essential and is involved in cell growth and cell cycle progression. The Drosophila studies also raised the possibility that Rheb is involved in the TOR/S6K signaling pathway. In this paper, we first report identification of dominant negative mutants of S. pombe Rheb (SpRheb). Screens of a randomly mutagenized SpRheb library yielded a mutant, SpRhebD60V, whose expression in S. pombe results in growth inhibition, G(1) arrest, and induction of fnx1(+), a gene whose expression is induced by the disruption of Rheb. Alteration of the Asp-60 residue to all possible amino acids by site-directed mutagenesis led to the identification of two particularly strong dominant negative mutants, D60I and D60K. Characterization of these dominant negative mutant proteins revealed that D60V and D60I exhibit preferential binding of GDP, while D60K lost the ability to bind both GTP and GDP. A possible use of the dominant negative mutants in the study of mammalian Rheb was explored by introducing dominant negative mutations into human Rheb. We show that transient expression of the wild type Rheb1 or Rheb2 causes activation of p70S6K, while expression of Rheb1D60K mutant results in inhibition of basal level activity of p70S6K. In addition, Rheb1D60K and Rheb1D60V mutants blocked nutrient- or serum-induced activation of p70S6K. This provides critical evidence that Rheb plays a role in the mTOR/S6K pathway in mammalian cells.	Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Jonsson Comprehens Canc Ctr, Inst Mol Biol, Los Angeles, CA 90095 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Washington University (WUSTL)	Tamanoi, F (corresponding author), Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Jonsson Comprehens Canc Ctr, Inst Mol Biol, 1602 Mol Sci Bldg, Los Angeles, CA 90095 USA.	fuyut@microbio.ucla.edu		Gutmann, David/0000-0002-3127-5045	NATIONAL CANCER INSTITUTE [F32CA094665, P01CA032737, P30CA016042, R01CA041996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER; NCI NIH HHS [F32-CA94665, CA41996, CA16042, CA32737] Funding Source: Medline; NIAID NIH HHS [AI28697] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arai A, 2002, ONCOGENE, V21, P2641, DOI 10.1038/sj.onc.1205346; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Bloor JW, 2002, DEVELOPMENT, V129, P3173; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHEN SY, 1994, ONCOGENE, V9, P2691; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Dimitrov K, 1998, MOL CELL BIOL, V18, P5239, DOI 10.1128/MCB.18.9.5239; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gromov PS, 1995, FEBS LETT, V377, P221, DOI 10.1016/0014-5793(95)01349-0; Hall BE, 2001, J BIOL CHEM, V276, P27629, DOI 10.1074/jbc.M101727200; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Mach KE, 2000, GENETICS, V155, P611; Marygold SJ, 2002, CURR BIOL, V12, pR785, DOI 10.1016/S0960-9822(02)01294-0; MITSUZAWA H, 1995, P NATL ACAD SCI USA, V92, P1704, DOI 10.1073/pnas.92.5.1704; MORENO S, 1991, METHOD ENZYMOL, V194, P795; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Panepinto JC, 2003, INFECT IMMUN, V71, P2819, DOI 10.1128/IAI.71.5.2819-2826.2003; Panepinto JC, 2002, FUNGAL GENET BIOL, V36, P207, DOI 10.1016/S1087-1845(02)00022-1; Patel PH, 2003, J CELL SCI, V116, P3601, DOI 10.1242/jcs.00661; Ray RM, 2002, GASTROENTEROLOGY, V123, P196, DOI 10.1053/gast.2002.34216; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; Urano J, 2001, METHOD ENZYMOL, V333, P217; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yang WL, 2001, MOL MICROBIOL, V41, P1339, DOI 10.1046/j.1365-2958.2001.02599.x; Yang WL, 2000, J BIOL CHEM, V275, P429, DOI 10.1074/jbc.275.1.429; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921	37	84	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39921	39930		10.1074/jbc.M306553200	http://dx.doi.org/10.1074/jbc.M306553200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869548	hybrid			2022-12-25	WOS:000185713800080
J	Blander, G; de Oliveira, RM; Conboy, CM; Haigis, M; Guarente, L				Blander, G; de Oliveira, RM; Conboy, CM; Haigis, M; Guarente, L			Superoxide dismutase 1 knock-down induces senescence in human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID CELLS; REPLICATIVE SENESCENCE; SPONTANEOUS IMMORTALIZATION; OXIDATIVE STRESS; LIFE-SPAN; IN-VIVO; P53; CANCER; EXTENSION; OXIDANTS	Reactive oxygen species (ROS) such as superoxide radicals are responsible for the pathogenesis of various human diseases. ROS are generated during normal metabolic process in all of the oxygen-utilizing organisms. The copper-zinc-containing SOD (SOD1) acts as a major defense against ROS by detoxifying the superoxide anion. In model organisms, SOD1 has been shown to play a role in the aging process. However, the exact role of the SOD1 protein in the human aging process remains to be resolved. We show that SOD1 RNA interference (RNAi) induces senescence in normal human fibroblasts. This premature senescence depends on p53 induction. In contrast, in human fibroblastic cells with inactivated p53, the SOD1 RNAi is without effect. Surprisingly, in cancer cells ( HeLa), the SOD1 RNAi induces cell death rather then senescence. Together, these findings support the notion that in normal human cells the SOD1 protein may play a role in the regulation of cellular lifespan by p53 and may also regulate the death signals in cancer cells.	MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Porto, Abel Salazar Inst Biomed Sci, Grad Program Basic & Appl Biol, P-4099003 Oporto, Portugal	Massachusetts Institute of Technology (MIT); Universidade do Porto	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		de Oliveira, Rita M/E-9696-2015	de Oliveira, Rita M/0000-0002-0970-4501; Conboy, Caitlin/0000-0001-8280-056X				Afrasyap L, 1998, Cancer Biochem Biophys, V16, P129; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BOND JA, 1995, CANCER RES, V55, P2404; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Casado A, 1998, Gac Med Mex, V134, P539; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; DIMRI G, 1992, P NATL ACAD SCI USA, V26, P9363; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Kong Q, 1998, MED HYPOTHESES, V51, P405, DOI 10.1016/S0306-9877(98)90036-6; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Noor Rana, 2002, Med Sci Monit, V8, pRA210; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PACKER L, 1977, NATURE, V267, P423, DOI 10.1038/267423a0; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Smith JR, 1997, AGING-CLIN EXP RES, V9, P437; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793	30	129	132	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38966	38969		10.1074/jbc.M307146200	http://dx.doi.org/10.1074/jbc.M307146200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871978	hybrid			2022-12-25	WOS:000185575100107
J	Gavin, AL; Ait-Azzouzene, D; Ware, CF; Nemazee, D				Gavin, AL; Ait-Azzouzene, D; Ware, CF; Nemazee, D			Delta BAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TNF FAMILY-MEMBER; CRYSTAL-STRUCTURE; LYMPHOCYTE STIMULATOR; AUTOIMMUNE-DISEASE; FAS LIGAND; BLYS; ACTIVATION; MATURATION; APRIL	The tumor necrosis family member BAFF is limiting for the survival of follicular B lymphocytes, but excessive BAFF signaling can lead to autoimmunity, suggesting that its activity must be tightly regulated. We have identified a conserved alternate splice isoform of BAFF, called DeltaBAFF, which lacks 57 nt encoding the A-A1 loop and is co-expressed with BAFF in many mouse and human myeloid cells. Mouse DeltaBAFF appears on the plasma membrane, but unlike BAFF it is inefficiently released by proteolysis. DeltaBAFF can associate with BAFF in heteromultimers and diminish BAFF bioactivity and release. Thus, alternative splicing of the BAFF gene suppresses BAFF B cell stimulatory function in several ways, and DeltaBAFF may promote other functions as well.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; La Jolla Inst Allergy & Immunol, Div Mol Immunol, San Diego, CA 92121 USA	Scripps Research Institute; La Jolla Institute for Immunology	Gavin, AL (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	agavin@scripps.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI058830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE017568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001743] Funding Source: NIH RePORTER; NIAID NIH HHS [R21 AI058830] Funding Source: Medline; NIA NIH HHS [AG01743, P01 AG001743] Funding Source: Medline; NIDCR NIH HHS [R01 DE017568] Funding Source: Medline; NIGMS NIH HHS [GM44809, R01 GM044809] Funding Source: Medline; PHS HHS [A133068] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Al-Zoubi AM, 2001, J BIOL CHEM, V276, P47202, DOI 10.1074/jbc.M104835200; Ayroldi E, 1999, BLOOD, V94, P3456, DOI 10.1182/blood.V94.10.3456.422k33_3456_3467; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BRADLEY JR, 1995, AM J PATHOL, V146, P27; Chen YW, 2001, P NATL ACAD SCI USA, V98, P7218, DOI 10.1073/pnas.131076098; Clise-Dwyer K, 2001, IMMUNOGENETICS, V53, P729, DOI 10.1007/s00251-001-0382-z; Do RKG, 2000, J EXP MED, V192, P953, DOI 10.1084/jem.192.7.953; GOH CR, 1991, PROTEIN ENG, V4, P785; Gordon NC, 2003, BIOCHEMISTRY-US, V42, P5977, DOI 10.1021/bi034017g; Granger SW, 2001, J IMMUNOL, V167, P5122, DOI 10.4049/jimmunol.167.9.5122; Gross JA, 2001, IMMUNITY, V15, P289, DOI 10.1016/S1074-7613(01)00183-2; Harless SM, 2001, CURR BIOL, V11, P1986, DOI 10.1016/S0960-9822(01)00598-X; Hsu BL, 2002, J IMMUNOL, V168, P5993, DOI 10.4049/jimmunol.168.12.5993; Karpusas M, 2002, J MOL BIOL, V315, P1145, DOI 10.1006/jmbi.2001.5296; Kelly K, 2000, CANCER RES, V60, P1021; Khare SD, 2000, P NATL ACAD SCI USA, V97, P3370, DOI 10.1073/pnas.050580697; Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890; Liu YF, 2003, NATURE, V423, P49, DOI 10.1038/nature01543; Liu YF, 2002, CELL, V108, P383, DOI 10.1016/S0092-8674(02)00631-1; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; Mackay F, 2002, TRENDS IMMUNOL, V23, P113, DOI 10.1016/S1471-4906(01)02159-7; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Mackenzie IS, 2002, CLIN MED, V2, P465, DOI 10.7861/clinmedicine.2-5-465; Nishimura H, 2000, J EXP MED, V191, P157, DOI 10.1084/jem.191.1.157; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Oren DA, 2002, NAT STRUCT BIOL, V9, P288, DOI 10.1038/nsb769; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Rolink AG, 2002, CURR OPIN IMMUNOL, V14, P266, DOI 10.1016/S0952-7915(02)00332-1; Roschke V, 2002, J IMMUNOL, V169, P4314, DOI 10.4049/jimmunol.169.8.4314; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; Shu HB, 1999, J LEUKOCYTE BIOL, V65, P680, DOI 10.1002/jlb.65.5.680; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; Van O. X., 1991, EMBO J, V10, P827; Vaux DL, 2002, J CLIN INVEST, V109, P17, DOI 10.1172/JCI14780; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; Ware CF, 2000, J EXP MED, V192, pF35, DOI 10.1084/jem.192.11.F35; Xu SL, 2001, MOL CELL BIOL, V21, P4067, DOI 10.1128/MCB.21.12.4067-4074.2001; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713; Yan MH, 2001, CURR BIOL, V11, P1547, DOI 10.1016/S0960-9822(01)00481-X; Yan MH, 2001, NAT IMMUNOL, V2, P638, DOI 10.1038/89790; Yu G, 2000, NAT IMMUNOL, V1, P252, DOI 10.1038/79802	47	84	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38220	38228		10.1074/jbc.M306852200	http://dx.doi.org/10.1074/jbc.M306852200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12867412	Green Accepted, hybrid			2022-12-25	WOS:000185575100018
J	Chang, DC; Xu, NH; Luo, KQ				Chang, DC; Xu, NH; Luo, KQ			Degradation of cyclin B is required for the onset of anaphase in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID SEPARATION; MATURATION-PROMOTING FACTOR; APC-DEPENDENT PROTEOLYSIS; BUDDING YEAST; M-PHASE; SACCHAROMYCES-CEREVISIAE; MITOTIC KINASE; MITOSIS; DESTRUCTION; PROTEIN	Recently, it has been shown that cyclin B1 was degraded mainly before the onset of anaphase in mammalian cells. When a nondegradable form of cyclin B1 was introduced into cells, the metaphase-anaphase transition was blocked. This blockage was not due to a failure in activating anaphase-promoting complex, nor was it due to a failure of degradation of securin. To resolve the question of whether this blockage by overexpressing the nondegradable form of cyclin B1 is physiologically relevant or not, we developed a novel method to estimate the relative protein level of the overexpressed cyclin B1 mutant within an individual cell. We found that a low level of nondegradable cyclin B1 ( less than 30% of the endogenous cyclin B1) was sufficient to block the metaphase-anaphase transition, implying that the blockage of anaphase onset by the nondegradable cyclin B1 was not due to an artifact of excessive M-phase-promoting factor activity. This result suggests that, in mammalian cells, the majority of cyclin B1 must be destroyed before the cell can enter anaphase.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China; Marine Biol Lab, Woods Hole, MA 02543 USA	Hong Kong University of Science & Technology; Marine Biological Laboratory - Woods Hole	Chang, DC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.		Chang, Donald/AAV-7180-2021; Xu, Naihan/C-2778-2018					Amon A, 1997, EMBO J, V16, P2693, DOI 10.1093/emboj/16.10.2693; Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Chang D C, 1997, Methods Mol Biol, V62, P307; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Farr KA, 1999, EUR J BIOCHEM, V263, P14, DOI 10.1046/j.1432-1327.1999.00510.x; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIRARD F, 1995, J CELL SCI, V108, P2599; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hinchcliffe EH, 1998, J CELL BIOL, V140, P1417, DOI 10.1083/jcb.140.6.1417; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; Jacobs HW, 2001, EMBO J, V20, P2376, DOI 10.1093/emboj/20.10.2376; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; LUO Q, 1994, J CELL SCI, V107, P3105; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Murray AW, 1996, P NATL ACAD SCI USA, V93, P12327, DOI 10.1073/pnas.93.22.12327; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Raff JW, 2002, J CELL BIOL, V157, P1139, DOI 10.1083/jcb.200203035; RIMMINGTON G, 1994, J CELL SCI, V107, P2729; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Stemmann O, 2001, CELL, V107, P715, DOI 10.1016/S0092-8674(01)00603-1; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Wheatley SP, 1997, J CELL BIOL, V138, P385, DOI 10.1083/jcb.138.2.385; Yamano H, 1996, EMBO J, V15, P5268, DOI 10.1002/j.1460-2075.1996.tb00912.x; Yeong FM, 2000, MOL CELL, V5, P501, DOI 10.1016/S1097-2765(00)80444-X; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	47	114	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37865	37873		10.1074/jbc.M306376200	http://dx.doi.org/10.1074/jbc.M306376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12865421	hybrid			2022-12-25	WOS:000185437200107
J	Chen, GP; Chen, XR				Chen, GP; Chen, XR			Arginine residues in the active site of human phenol sulfotransferase (SULT1A1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN M-FORM; CRYSTAL-STRUCTURE; BINDING-SITE; SUBSTRATE-SPECIFICITY; MUTATIONAL ANALYSIS; 2,3-BUTANEDIONE; PHENYLGLYOXAL; INACTIVATION; DOMAINS; REAGENT	Cytosolic sulfotransferases (STs) catalyze the sulfation of hydroxyl containing compounds. Human phenol sulfotransferase (SULT1A1) is the major human ST that catalyzes the sulfation of simple phenols. Because of its broad substrate specificity and lack of endogenous substrates, the biological function of SULT1A1 is believed to be an important detoxification enzyme. In this report, amino acid modification, computer structure modeling, and site-directed mutagenesis were used for studies of Arg residues in the active site of SULT1A1. The Arg-specific modification reagent, 2,3-butanedione, inactivated SULT1A1 in an efficient, time- and concentration-dependent manner, suggesting Arg residues play an important role in the catalytic activity of SULT1A1. According to the computer model, Arg(78), Arg(130), and Arg(257) may be important for SULT1A1 catalytic activity. Site-directed mutagenesis results demonstrated that the positive charge on Arg(78) is not critical for SULT1A1 because R78A is still active. In contrast, a negative charge at this position, R78E, completely inactivated SULT1A1. Arg(78) is in close proximity to the site of sulfuryl group transfer. Arg(257) is located very close to the 3'-phosphate in adenosine 3'-phosphate 5'-phosphosulfate ( PAPS). Site-directed mutagenesis demonstrated that Arg(257) is critical for SULT1A1: both R257A and R257E are inactive. Although Arg(130) is also located very close to the 3'-phosphate of PAPS, R130A and R130E are still active, suggesting that Arg(130) is not a critical residue for the catalytic activity of SULT1A1. Computer modeling suggests that the ionic interaction between the positive charge on Arg(257), and the negative charge on 3'-phosphate is the primary force stabilizing the specific binding of PAPS.	Oklahoma State Univ, Coll Vet Med, Dept Physiol Sci, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Chen, GP (corresponding author), Oklahoma State Univ, Coll Vet Med, Dept Physiol Sci, 264 McElroy Hall, Stillwater, OK 74078 USA.	cguang@okstate.edu			NIGMS NIH HHS [R01 GM059873-03, R01 GM059873-02, R01 GM059873-01A1, R01 GM059873, GM59873] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059873] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alkema WBL, 2002, BIOCHEM J, V365, P303, DOI 10.1042/BJ20011468; Bidwell LM, 1999, J MOL BIOL, V293, P521, DOI 10.1006/jmbi.1999.3153; BORCHARDT RT, 1982, BIOCHIM BIOPHYS ACTA, V708, P280, DOI 10.1016/0167-4838(82)90438-1; BORCHARDT RT, 1978, BIOCHEM BIOPH RES CO, V81, P841, DOI 10.1016/0006-291X(78)91428-6; BORCHARDT RT, 1977, BIOCHEM BIOPH RES CO, V78, P1067, DOI 10.1016/0006-291X(77)90529-0; Brix LA, 1999, BIOCHEMISTRY-US, V38, P10474, DOI 10.1021/bi990795q; Brix LA, 1999, BIOCHEM J, V337, P337, DOI 10.1042/0264-6021:3370337; Chen GP, 2002, J BIOCHEM MOL TOXIC, V16, P279, DOI 10.1002/jbt.10048; Chen GP, 1999, PROTEIN SCI, V8, P2151, DOI 10.1110/ps.8.10.2151; Chen GP, 2000, BIOCHEMISTRY-US, V39, P16000, DOI 10.1021/bi0021479; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; Duffel MW, 1998, CHEM-BIOL INTERACT, V109, P81, DOI 10.1016/S0009-2797(97)00122-1; Eriksson O, 1998, J BIOL CHEM, V273, P12669, DOI 10.1074/jbc.273.20.12669; Falany CN, 1995, ANN NY ACAD SCI, V774, P59, DOI 10.1111/j.1749-6632.1995.tb17372.x; FALANY CN, 1994, CHEM-BIOL INTERACT, V92, P57, DOI 10.1016/0009-2797(94)90053-1; Frame LT, 2000, DRUG METAB DISPOS, V28, P1063; Hsiao YS, 2002, BIOCHEMISTRY-US, V41, P12959, DOI 10.1021/bi0261239; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KOMATSU K, 1994, BIOCHEM BIOPH RES CO, V204, P1178, DOI 10.1006/bbrc.1994.2587; Liu MC, 2000, J BIOL CHEM, V275, P13460, DOI 10.1074/jbc.275.18.13460; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; Marsolais F, 1999, BIOCHEMISTRY-US, V38, P4066, DOI 10.1021/bi982239m; Marsolais F, 1997, EUR J BIOCHEM, V247, P1056, DOI 10.1111/j.1432-1033.1997.01056.x; NOSE Y, 1958, J BIOL CHEM, V233, P1348; Pedersen LC, 2000, FEBS LETT, V475, P61, DOI 10.1016/S0014-5793(00)01479-4; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; Petrotchenko EV, 1999, J BIOL CHEM, V274, P30019, DOI 10.1074/jbc.274.42.30019; RIORDAN JF, 1973, BIOCHEMISTRY-US, V12, P3915, DOI 10.1021/bi00744a020; Sakakibara Y, 1998, J BIOL CHEM, V273, P6242, DOI 10.1074/jbc.273.11.6242; Varin L, 1997, FASEB J, V11, P517, DOI 10.1096/fasebj.11.7.9212075; VARIN L, 1995, J BIOL CHEM, V270, P12498, DOI 10.1074/jbc.270.21.12498; WEINSHILBOUM R, 1994, CHEM-BIOL INTERACT, V92, P233, DOI 10.1016/0009-2797(94)90066-3; WILBORN TW, 1993, MOL PHARMACOL, V43, P70; YANKEELOV JA, 1968, J AM CHEM SOC, V90, P1664, DOI 10.1021/ja01008a056; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313	35	15	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36358	36364		10.1074/jbc.M306045200	http://dx.doi.org/10.1074/jbc.M306045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12867416	Green Accepted, hybrid			2022-12-25	WOS:000185318300062
J	Ohashi, M; Mizushima, N; Kabeya, Y; Yoshimori, T				Ohashi, M; Mizushima, N; Kabeya, Y; Yoshimori, T			Localization of mammalian NAD(P)H steroid dehydrogenase-like protein on lipid droplets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARY CELL MUTANT; ENDOPLASMIC-RETICULUM; 3-BETA-HYDROXYSTEROID DEHYDROGENASE; CHOLESTEROL ACYLTRANSFERASE; ANIMAL-CELLS; FATTY ACID; ACCUMULATION; MEMBRANE; TIP47; PARTICLES	Mammalian enzymes in late cholesterol biosynthesis have been localized uniformly over the endoplasmic reticulum by enzymatic methods. We report here the first mammalian cholesterol biosynthetic enzyme unequivocally localized at the surface of intracellular lipid storage droplets. NAD(P) H steroid dehydrogenase-like protein (Nsdhl), a mammalian C-3 sterol dehydrogenase involved in the conversion of lanosterol into cholesterol, was localized on lipid droplets by immunofluorescence microscopy and subcellular fractionation. Nsdhl was localized on lipid droplets even when cell growth exclusively depended on cholesterol biosynthesis mediated by this enzyme. Depletion of fatty acids in culture medium reduced the development of lipid droplets and caused Nsdhl redistribution to the endoplasmic reticulum. Elevating oleic acid in medium induced well developed, Nsdhl-positive lipid droplets, and simultaneously caused a reduction in cellular conversion of lanosterol into cholesterol. Manipulated human NSDHL with a missense mutation (G205S) causing a human embryonic developmental disorder, congenital hemidysplasia with ichthyosiform nevus and limb defects ( CHILD) syndrome, could no longer be localized on lipid droplets. Although the expression of wild-type NSDHL could restore the defective growth of a CHO cholesterol auxotroph, LEX2 in cholesterol-deficient medium, the expression of NSDHL( G205S) failed to do so. These results point to functional significance of the localization of Nsdhl on lipid droplets. Functional significance was also suggested by the colocalization of Nsdhl on lipid droplets with TIP47, a cargo selection protein for mannose 6-phosphate receptors from late endosomes to the trans-Golgi network. These results add to the growing notion that the lipid droplet is an organelle endowed with more complex roles in various biological phenomena.	Natl Inst Physiol Sci, Dept Mol Physiol, Okazaki, Aichi 4448585, Japan; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Natl Inst Genet, Dept Cell Genet, Mishima, Shizuoka 4118540, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Ohashi, M (corresponding author), Natl Inst Physiol Sci, Dept Mol Physiol, Okazaki, Aichi 4448585, Japan.	masato@nips.ac.jp	Mizushima, Noboru/C-3635-2009	Mizushima, Noboru/0000-0002-6258-6444				Barbero P, 2001, J BIOL CHEM, V276, P24348, DOI 10.1074/jbc.M102468200; Baumann O, 2001, INT REV CYTOL, V205, P149, DOI 10.1016/S0074-7696(01)05004-5; BERRY DJ, 1982, BIOCHEMISTRY-US, V21, P573, DOI 10.1021/bi00532a025; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 1997, J LIPID RES, V38, P2249; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWN MS, 1980, J LIPID RES, V21, P505; CHAM BE, 1976, J LIPID RES, V17, P176; CHANG TY, 1976, P NATL ACAD SCI USA, V73, P24, DOI 10.1073/pnas.73.1.24; CUNNANE SC, 1993, NUTRITION, V9, P423; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079; Ham R G, 1979, Methods Enzymol, V58, P44; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Konig A, 2000, AM J MED GENET, V90, P339; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; Liu XY, 1999, NAT GENET, V22, P182, DOI 10.1038/9700; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; Milla P, 2002, J BIOL CHEM, V277, P2406, DOI 10.1074/jbc.M104195200; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Miwako I, 2001, J CELL SCI, V114, P1765; Mobius W, 2003, TRAFFIC, V4, P222; Moebius FF, 2000, TRENDS ENDOCRIN MET, V11, P106, DOI 10.1016/S1043-2760(00)00235-6; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; NAGAI J, 1974, BIOCHEM BIOPH RES CO, V60, P555, DOI 10.1016/0006-291X(74)90276-9; Nilsson IM, 2001, J BIOL CHEM, V276, P41748, DOI 10.1074/jbc.M105823200; OHASHI M, 1992, EUR J CELL BIOL, V59, P116; Ohashi M, 1999, J CELL SCI, V112, P1125; Ohashi M, 2000, J CELL SCI, V113, P2187; Olivier LM, 2000, BBA-MOL CELL BIOL L, V1529, P89, DOI 10.1016/S1388-1981(00)00139-6; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; REINHART MP, 1987, J BIOL CHEM, V262, P9649; SPECTOR AA, 1969, ANAL BIOCHEM, V32, P297, DOI 10.1016/0003-2697(69)90089-X; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Sugii S, 2003, J LIPID RES, V44, P1033, DOI 10.1194/jlr.D200036-JLR200; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Uthayakumar S, 1995, CELL MOL BIOL RES, V41, P405; Wang YZ, 2000, TRAFFIC, V1, P952, DOI 10.1034/j.1600-0854.2000.011205.x; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	52	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36819	36829		10.1074/jbc.M301408200	http://dx.doi.org/10.1074/jbc.M301408200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12837764	hybrid			2022-12-25	WOS:000185318300115
J	Oxelmark, E; Knoblauch, R; Arnal, S; Su, LF; Schapira, M; Garabedian, MJ				Oxelmark, E; Knoblauch, R; Arnal, S; Su, LF; Schapira, M; Garabedian, MJ			Genetic dissection of p23, an Hsp90 cochaperone, reveals a distinct surface involved in estrogen receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID-RECEPTOR; CHAPERONE; ATP; BINDING; HSP70; CONFORMATION; COMPLEXES; CAPACITOR; KINASE	p23 is an Hsp90-associated protein that regulates signal transduction by the estrogen receptor alpha ( ER); however, the mechanism through which p23 governs ER function remains enigmatic. To obtain a collection of p23 molecules with distinct effects on ER signaling, we screened in yeast a series of random mutations as well as specific sequence alterations based on the p23 crystal structure and further analyzed these mutations for their effect on p23-Hsp90 association in vitro and in vivo. We found that the ability of the p23 mutants to decrease or increase ER signal transduction correlated with their association with Hsp90. We also identified a mutation in the C-terminal tail of p23, which displayed a dominant inhibitory effect on ER transcriptional activation and associates more avidly with Hsp90 relative to the wild type p23. Interestingly, this mutant interacts with Hsp90 in its non-ATP-bound state, whereas the wild type p23 protein interacts exclusively with the ATP-bound form of Hsp90, which may account for its dominant phenotype. In addition, we have uncovered a novel activity of p23 that antagonizes Hsp90 action during times of cell stress. Using molecular modeling and the p23 crystal structure, we found that the p23 mutations affecting ER signaling identified in the screen localized to one face of the molecule, whereas those that had no effect mapped to other parts of the protein. Thus, our structure/function analysis has identified an important regulatory surface on p23 involved in ER signaling and p23 binding to Hsp90.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Dept Urol, New York, NY 10016 USA; NYU, Sch Med, Dept Biol Struct, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University; New York University; New York University	Garabedian, MJ (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	garabm01@med.nyu.edu			NIGMS NIH HHS [T32 GM07308] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abagyan R, 1997, PROTEINS, P29; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Caplan Avrom J., 2003, EMBO Reports, V4, P126, DOI 10.1038/sj.embor.embor742; Cox MB, 2002, TOXICOL LETT, V129, P13, DOI 10.1016/S0378-4274(01)00465-9; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Donze O, 2001, EMBO J, V20, P3771, DOI 10.1093/emboj/20.14.3771; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Fliss AE, 2000, J STEROID BIOCHEM, V72, P223, DOI 10.1016/S0960-0760(00)00037-6; Forsythe HL, 2001, J BIOL CHEM, V276, P15571, DOI 10.1074/jbc.C100055200; Freeman BC, 2000, GENE DEV, V14, P422; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Knoblauch R, 1999, MOL CELL BIOL, V19, P3748; Morimoto RI, 2002, CELL, V110, P281, DOI 10.1016/S0092-8674(02)00860-7; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Morishima Y, 2001, BIOCHEMISTRY-US, V40, P1109, DOI 10.1021/bi002399+; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Parker MG, 1998, BIOCHEM SOC SYMP, P45; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SEGNITZ B, 1995, P NATL ACAD SCI USA, V92, P2179, DOI 10.1073/pnas.92.6.2179; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Sommer S, 2001, SEMIN CANCER BIOL, V11, P339, DOI 10.1006/scbi.2001.0389; Sullivan WP, 2002, J BIOL CHEM, V277, P45942, DOI 10.1074/jbc.M207754200; Weaver AJ, 2000, J BIOL CHEM, V275, P23045, DOI 10.1074/jbc.M003410200; Weikl T, 1999, J MOL BIOL, V293, P685, DOI 10.1006/jmbi.1999.3172; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930	35	31	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36547	36555		10.1074/jbc.M305960200	http://dx.doi.org/10.1074/jbc.M305960200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12835317	hybrid			2022-12-25	WOS:000185318300084
J	Taxis, C; Hitt, R; Park, SH; Deak, PM; Kostova, Z; Wolf, DH				Taxis, C; Hitt, R; Park, SH; Deak, PM; Kostova, Z; Wolf, DH			Use of modular substrates demonstrates mechanistic diversity and reveals differences in chaperone requirement of ERAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM DEGRADATION; TRANSMEMBRANE CONDUCTANCE REGULATOR; MANNOSIDASE-LIKE PROTEIN; SACCHAROMYCES-CEREVISIAE; QUALITY-CONTROL; CO-CHAPERONE; MOLECULAR CHAPERONES; CARBOXYPEPTIDASE YSCY; RETRO-TRANSLOCATION; MEMBRANE-PROTEIN	The endoplasmic reticulum (ER) harbors a protein quality control system, which monitors protein folding in the ER. Elimination of malfolded proteins is an important function of this protein quality control. Earlier studies with various soluble and transmembrane ER-associated degradation (ERAD) substrates revealed differences in the ER degradation machinery used. To unravel the nature of these differences we generated two type I membrane ERAD substrates carrying malfolded carboxypeptidase yscY (CPY*) as the ER-luminal ERAD recognition motif. Whereas the first, CT* (CPY*-TM), has no cytoplasmic domain, the second, CTG*, has the green fluorescent protein present in the cytosol. Together with CPY*, these three substrates represent topologically diverse malfolded proteins, degraded via ERAD. Our data show that degradation of all three proteins is dependent on the ubiquitin-proteasome system involving the ubiquitin-protein ligase complex Der3/Hrd1p-Hrd3p, the ubiquitin conjugating enzymes Ubc1p and Ubc7p, as well as the AAA-ATPase complex Cdc48-Ufd1-Npl4 and the 26S proteasome. In contrast to soluble CPY*, degradation of the membrane proteins CT* and CTG* does not require the ER proteins Kar2p (BiP) and Der1p. Instead, CTG* degradation requires cytosolic Hsp70, Hsp40, and Hsp104p chaperones.	Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany	University of Stuttgart	Wolf, DH (corresponding author), Univ Stuttgart, Inst Biochem, Pfaffenwaldring 55, D-70569 Stuttgart, Germany.	wolf@po.uni-stuttgart.de	Taxis, Christof/P-6188-2019; Taxis, Christof/AAP-7408-2021	Taxis, Christof/0000-0001-5952-7091; Park, Sae-Hun/0000-0002-8277-0732				Ausubel FM, 1992, CURRENT PROTOCOLS MO; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Becker J, 1996, MOL CELL BIOL, V16, P4378; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Costanzo MC, 2001, NUCLEIC ACIDS RES, V29, P75, DOI 10.1093/nar/29.1.75; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; EGNER R, 1995, MOL CELL BIOL, V15, P5879; Epple UD, 2001, J BACTERIOL, V183, P5942, DOI 10.1128/JB.183.20.5942-5955.2001; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Farinha CM, 2002, BIOCHEM J, V366, P797, DOI 10.1042/BJ20011717; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Frohlich KU, 2001, J CELL SCI, V114, P1601; Galan JM, 1998, FASEB J, V12, P315, DOI 10.1096/fasebj.12.3.315; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hill K, 2000, EMBO J, V19, P550, DOI 10.1093/emboj/19.4.550; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HILT W, 1999, POSTTRANSLATIONAL PR, P265; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Jakob CA, 2001, EMBO REP, V2, P423; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Jiang CW, 1998, AM J PHYSIOL-CELL PH, V275, pC171, DOI 10.1152/ajpcell.1998.275.1.C171; Johnson JL, 2001, J CELL BIOL, V152, P851, DOI 10.1083/jcb.152.4.851; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; KOSTOVA Z, 2002, PROTEIN TARGETING TR, P180; Lenk U, 2000, J BIOL CHEM, V275, P39403, DOI 10.1074/jbc.M006949200; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Neuwald AF, 1999, GENOME RES, V9, P27; NISHIKAWA S, 1994, MOL BIOL CELL, V5, P1129, DOI 10.1091/mbc.5.10.1129; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1999, J CELL SCI, V112, P4123; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Plemper RK, 1999, FEBS LETT, V443, P241, DOI 10.1016/S0014-5793(98)01724-4; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Taxis C, 2002, MOL BIOL CELL, V13, P1806, DOI 10.1091/mbc.01-08-0399; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tizon B, 1999, YEAST, V15, P145, DOI 10.1002/(SICI)1097-0061(19990130)15:2<145::AID-YEA346>3.0.CO;2-J; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Walter J, 2001, EMBO J, V20, P3124, DOI 10.1093/emboj/20.12.3124; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wilhovsky S, 2000, MOL BIOL CELL, V11, P1697, DOI 10.1091/mbc.11.5.1697; Wilkinson BM, 2000, J BIOL CHEM, V275, P521, DOI 10.1074/jbc.275.1.521; WOLF DH, 1975, J BACTERIOL, V123, P1150, DOI 10.1128/JB.123.3.1150-1156.1975; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1	82	154	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35903	35913		10.1074/jbc.M301080200	http://dx.doi.org/10.1074/jbc.M301080200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847107	hybrid			2022-12-25	WOS:000185318300007
J	Domergue, F; Abbadi, A; Ott, C; Zank, TK; Zahringer, U; Heinz, E				Domergue, F; Abbadi, A; Ott, C; Zank, TK; Zahringer, U; Heinz, E			Acyl carriers used as substrates by the desaturases and elongases involved in very long-chain polyunsaturated fatty acids biosynthesis reconstituted in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-LINOLENIC ACID; STORAGE LIPID-SYNTHESIS; FRONT-END-DESATURASES; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-CHARACTERIZATION; MICROSOMAL PREPARATIONS; LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE; MORTIERELLA-ALPINA; CLONING; GENE	The health benefits attributed to very long-chain polyunsaturated fatty acids and the long term goal to produce them in transgenic oilseed crops have led to the cloning of all the genes coding for the desaturases and elongases involved in their biosynthesis. The encoded activities have been confirmed in vivo by heterologous expression, but very little is known about the actual acyl substrates involved in these pathways. Using a Delta6-elongase and front-end desaturases from different organisms, we have reconstituted in Saccharomyces cerevisiae the biosynthesis of arachidonic acid from exogenously supplied linoleic acid in order to identify these acyl carriers. Acyl-CoA measurements strongly suggest that the elongation step involved in polyunsaturated fatty acids biosynthesis is taking place within the acyl-CoA pool. In contrast, detailed analyses of lipids revealed that the two desaturation steps (Delta5 and Delta6) occur predominantly at the sn-2 position of phosphatidylcholine when using Delta5- and Delta6-desaturases from lower plants, fungi, worms, and algae. The specificity of these Delta6-desaturases for the fatty acid acylated at this particular position as well as a limiting re-equilibration with the acyl-CoA pool result in the accumulation of gamma-linolenic acid at the sn-2 position of phosphatidylcholine and prevent efficient arachidonic acid biosynthesis in yeast. We confirm by using a similar experimental approach that, in contrast, the human Delta6-desaturase uses linoleoyl-CoA as substrate, which results in high efficiency of the subsequent elongation step. In addition, we report that Delta12-desaturases have no specificity toward the lipid polar headgroup or the sn-position.	Univ Hamburg, Inst Allgemeine Bot, D-22609 Hamburg, Germany; Res Ctr Borstel, Div Immunochem, D-23845 Borstel, Germany	University of Hamburg; Forschungszentrum Borstel	Domergue, F (corresponding author), Univ Hamburg, Inst Allgemeine Bot, Ohnhorststr 18, D-22609 Hamburg, Germany.	fredDo@botanik.uni-hamburg.de		Domergue, Frederic/0000-0002-0183-7000				Abbadi A, 2001, EUR J LIPID SCI TECH, V103, P106, DOI 10.1002/1438-9312(200102)103:2<106::AID-EJLT106>3.0.CO;2-V; AITZETMULLER K, 1994, J PLANT PHYSIOL, V143, P538, DOI 10.1016/S0176-1617(11)81820-1; Banas A, 2000, BIOCHEM SOC T, V28, P703, DOI 10.1042/BST0280703; Beaudoin F, 2000, P NATL ACAD SCI USA, V97, P6421, DOI 10.1073/pnas.110140197; BROKER M, 1991, APPL MICROBIOL BIOT, V34, P756; Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297; Domergue F, 2003, PLANT PHYSIOL, V131, P1648, DOI 10.1104/pp.102.018317; Domergue F, 2002, EUR J BIOCHEM, V269, P4105, DOI 10.1046/j.1432-1033.2002.03104.x; Drexler H, 2003, J PLANT PHYSIOL, V160, P779, DOI 10.1078/0176-1617-01025; FISCHER W, 1973, H-S Z PHYSIOL CHEM, V354, P1115, DOI 10.1515/bchm2.1973.354.2.1115; Galle-Le Bastard AM, 2000, PHYSIOL PLANTARUM, V108, P118, DOI 10.1034/j.1399-3054.2000.108002118.x; Ghanevati M, 2002, EUR J BIOCHEM, V269, P3531, DOI 10.1046/j.1432-1033.2002.03039.x; Girke T, 1998, PLANT J, V15, P39, DOI 10.1046/j.1365-313X.1998.00178.x; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; GRIFFITHS G, 1988, BIOCHEM J, V252, P641, DOI 10.1042/bj2520641; Huang YS, 1999, LIPIDS, V34, P649, DOI 10.1007/s11745-999-0410-8; Jackson FM, 1998, EUR J BIOCHEM, V252, P513, DOI 10.1046/j.1432-1327.1998.2520513.x; Jorasch P, 2000, EUR J BIOCHEM, V267, P3770, DOI 10.1046/j.1432-1327.2000.01414.x; KINSELLA JE, 1990, NUTRITION, V6, P24; Knutzon DS, 1998, J BIOL CHEM, V273, P29360, DOI 10.1074/jbc.273.45.29360; Larson TR, 2002, PLANT J, V32, P519, DOI 10.1046/j.1365-313X.2002.01440.x; Larson TR, 2001, PLANT J, V25, P115, DOI 10.1046/j.1365-313x.2001.00929.x; Leonard AE, 2000, BIOCHEM J, V350, P765, DOI 10.1042/0264-6021:3500765; Marquardt A, 2000, GENOMICS, V66, P175, DOI 10.1006/geno.2000.6196; Martinez-Rivas JM, 2001, MOL BREEDING, V8, P159, DOI 10.1023/A:1013324329322; Metz JG, 2001, SCIENCE, V293, P290, DOI 10.1126/science.1059593; Michaelson LV, 1998, FEBS LETT, V439, P215, DOI 10.1016/S0014-5793(98)01385-4; Oelkers P, 2002, J BIOL CHEM, V277, P8877, DOI 10.1074/jbc.M111646200; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; OKAYASU T, 1981, ARCH BIOCHEM BIOPHYS, V206, P21, DOI 10.1016/0003-9861(81)90061-8; Parker-Barnes JM, 2000, P NATL ACAD SCI USA, V97, P8284, DOI 10.1073/pnas.97.15.8284; Richard MG, 1998, LIPIDS, V33, P1229, DOI 10.1007/s11745-998-0328-1; Sandager L, 2002, J BIOL CHEM, V277, P6478, DOI 10.1074/jbc.M109109200; Schjerling CK, 1996, J BIOL CHEM, V271, P22514, DOI 10.1074/jbc.271.37.22514; Simopoulos AP, 1999, PROSTAG LEUKOTR ESS, V60, P421, DOI 10.1016/S0952-3278(99)80023-4; Sorger D, 2002, J BACTERIOL, V184, P519, DOI 10.1128/JB.184.2.519-524.2002; Spector AA, 1999, LIPIDS, V34, pS1, DOI 10.1007/BF02562220; Sperling P, 2000, EUR J BIOCHEM, V267, P3801, DOI 10.1046/j.1432-1327.2000.01418.x; Sperling P, 2003, ADVANCED RESEARCH ON PLANT LIPIDS, P113, DOI 10.1007/978-94-017-0159-4_25; Sperling P, 2003, PROSTAG LEUKOTR ESS, V68, P73, DOI 10.1016/S0952-3278(02)00258-2; SPERLING P, 1993, J BIOL CHEM, V268, P26935; Sperling P, 2001, EUR J LIPID SCI TECH, V103, P158, DOI 10.1002/1438-9312(200103)103:3<158::AID-EJLT158>3.0.CO;2-1; Sprecher H, 1999, Curr Opin Clin Nutr Metab Care, V2, P135, DOI 10.1097/00075197-199903000-00007; STYMNE S, 1986, BIOCHEM J, V240, P385, DOI 10.1042/bj2400385; STYMNE S, 1984, BIOCHEM J, V223, P305, DOI 10.1042/bj2230305; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; WAGNER S, 1994, YEAST, V10, P1429, DOI 10.1002/yea.320101106; Weerheim AM, 2002, ANAL BIOCHEM, V302, P191, DOI 10.1006/abio.2001.5552; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Zank TK, 2002, PLANT J, V31, P255, DOI 10.1046/j.1365-313X.2002.01354.x; Zou ZY, 2003, J BIOL CHEM, V278, P16414, DOI 10.1074/jbc.M210557200; Zou ZY, 2002, J BIOL CHEM, V277, P31062, DOI 10.1074/jbc.M205034200	52	115	158	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35115	35126		10.1074/jbc.M305990200	http://dx.doi.org/10.1074/jbc.M305990200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12835316	hybrid			2022-12-25	WOS:000185164400047
J	Fayard, E; Schoonjans, K; Annicotte, JS; Auwerx, J				Fayard, E; Schoonjans, K; Annicotte, JS; Auwerx, J			Liver receptor homolog 1 controls the expression of carboxyl ester lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; SMALL-HETERODIMER-PARTNER; FETOPROTEIN TRANSCRIPTION FACTOR; SALT-STIMULATED LIPASE; HUMAN INTESTINAL-CELLS; BILE-ACID TRANSPORTER; DNA-BINDING DOMAIN; CHOLESTEROL ABSORPTION; FEEDBACK-REGULATION; ESTROGEN-RECEPTORS	The orphan nuclear receptor liver receptor homolog 1 (LRH-1) plays a central role in cholesterol homeostasis by regulating a number of hepatic and intestinal genes critical for reverse cholesterol transport and bile acid homeostasis. Herein, we describe the identification of carboxyl ester lipase (CEL) as a novel target of LRH- 1 in pancreas, a tissue in which LRH- 1 is abundantly expressed. In situ hybridization and gene expression studies demonstrate that both LRH- 1 and CEL are co- expressed and confined to the exocrine pancreas. LRH- 1 interacts with a consensus LRH- 1 response element in the human CEL promoter, which is perfectly conserved in the rat gene, and induces CEL promoter activity in cotransfection assays. As reported for other LRH- 1 target genes, the nuclear receptor short heterodimer partner represses LRH- 1-induced CEL promoter activity. Chromatin immunoprecipitation demonstrates that binding of LRH- 1 to the CEL promoter increases histone H4 acetylation corresponding with the activation of endogenous CEL gene transcription. Our data, identifying CEL as the first pancreatic LRH- 1 target gene, indicate that LRH- 1 is an important player in enterohepatic cholesterol homeostasis.	Univ Strasbourg 1, IGBMC, CNRS, INSERM, F-67404 Illkirch Graffenstaden, CU de Strasbour, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Auwerx, J (corresponding author), Univ Strasbourg 1, IGBMC, CNRS, INSERM, BP 10142, F-67404 Illkirch Graffenstaden, CU de Strasbour, France.	auwerx@igbmc.u-strasbg.fr	Annicotte, Jean-Sébastien/H-4641-2018; Auwerx, Johan/ABE-9307-2021	Annicotte, Jean-Sébastien/0000-0002-2109-4849; Auwerx, Johan/0000-0002-5065-5393; Schoonjans, Kristina/0000-0003-1247-4265				BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BOSNER MS, 1988, P NATL ACAD SCI USA, V85, P7438, DOI 10.1073/pnas.85.20.7438; Brendel C, 2002, MOL ENDOCRINOL, V16, P2065, DOI 10.1210/me.2001-0194; BRODTEPPLEY J, 1995, BIOCHEM J, V306, P605, DOI 10.1042/bj3060605; BRODTEPPLEY J, 1994, J LIPID RES, V35, P27; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; CHEN H, 1992, BIOCHEM J, V286, P771, DOI 10.1042/bj2860771; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; ELLINGERZIEGELBAUER H, 1994, MOL CELL BIOL, V14, P2786, DOI 10.1128/MCB.14.4.2786; FIELD FJ, 1993, J CLIN INVEST, V92, P2609, DOI 10.1172/JCI116876; FONTAINE RN, 1991, BIOCHEMISTRY-US, V30, P7008, DOI 10.1021/bi00242a028; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; HUANG Y, 1991, J BIOL CHEM, V266, P6720; HUI DY, 1993, BIOCHEM J, V291, P65, DOI 10.1042/bj2910065; Inokuchi A, 2001, J BIOL CHEM, V276, P46822, DOI 10.1074/jbc.M104612200; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Kirby RJ, 2002, J BIOL CHEM, V277, P4104, DOI 10.1074/jbc.M107549200; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lee YK, 1999, J BIOL CHEM, V274, P20869, DOI 10.1074/jbc.274.30.20869; Lee YK, 2002, J BIOL CHEM, V277, P2463, DOI 10.1074/jbc.M105161200; Li M, 1998, J BIOL CHEM, V273, P29022, DOI 10.1074/jbc.273.44.29022; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Luo Y, 2001, J BIOL CHEM, V276, P24767, DOI 10.1074/jbc.M100912200; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; Masuda N, 1997, BBA-GENE STRUCT EXPR, V1350, P27, DOI 10.1016/S0167-4781(96)00196-0; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Pare JF, 2001, J BIOL CHEM, V276, P13136, DOI 10.1074/jbc.M010737200; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Rausa FM, 1999, MECH DEVELOP, V89, P185, DOI 10.1016/S0925-4773(99)00209-9; RIGTRUP KM, 1992, BIOCHEMISTRY-US, V31, P2920, DOI 10.1021/bi00126a011; Sanyal S, 2002, J BIOL CHEM, V277, P1739, DOI 10.1074/jbc.M106140200; Schoonjans K, 2000, J MOL BIOL, V304, P323, DOI 10.1006/jmbi.2000.4218; Schoonjans K, 2002, EMBO REP, V3, P1181, DOI 10.1093/embo-reports/kvf238; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; TRABER MG, 1990, GASTROENTEROLOGY, V98, P96, DOI 10.1016/0016-5085(90)91296-I; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; WANG CS, 1993, BIOCHIM BIOPHYS ACTA, V1166, P1, DOI 10.1016/0005-2760(93)90277-G; Weng W, 1999, BIOCHEMISTRY-US, V38, P4143, DOI 10.1021/bi981679a; Yazawa T, 2003, ENDOCRINOLOGY, V144, P1920, DOI 10.1210/en.2002-221070	48	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35725	35731		10.1074/jbc.M302370200	http://dx.doi.org/10.1074/jbc.M302370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12853459	hybrid			2022-12-25	WOS:000185164400119
J	Provoda, CJ; Stier, EM; Lee, KD				Provoda, CJ; Stier, EM; Lee, KD			Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PH-SENSITIVE LIPOSOMES; TARGETED IMMUNOFUSION PROTEINS; RIBOSOME-INACTIVATING PROTEINS; CLASS-I PRESENTATION; COMPLEX CLASS-I; CYTOSOLIC DELIVERY; ANTISENSE OLIGONUCLEOTIDES; CYTOPLASMIC DELIVERY; ESCHERICHIA-COLI; DRUG-DELIVERY	Gelonin is a type I plant toxin that has potential as an effective anti-tumor agent by virtue of its enzymatic capacity to inactivate ribosomes and arrest protein synthesis, thereby effectively limiting the growth of cancer cells. Being a hydrophilic macromolecule, however, gelonin has limited access to its target subcellular compartment, the cytosol; it is effectively plasma membrane-impermeant and subject to rapid degradation within endosomes and lysosomes upon cellular uptake as it lacks the membrane-translocating capability that is typically provided by a disulfide-linked B polypeptide found in the type II toxins (e.g. ricin). These inherent characteristics generate the need for the development of a specialized cytosolic delivery strategy for gelonin as an effective anti-tumor therapeutic agent. Here we describe an efficient means of delivering gelonin to the cytosol of B16 melanoma cells. Gelonin was co-encapsulated inside pH-sensitive liposomes with listeriolysin O, the pore-forming protein that mediates escape of the intracellular pathogen Listeria monocytogenes from the endosome into the cytosol. In in vitro experiments, co-encapsulated listeriolysin O enabled liposomal gelonin-mediated B16 cell killing with a gelonin IC50 of similar to0.1 nM with an extreme efficiency requiring an incubation time of only 1 h. By contrast, cells treated with equivalent concentrations of unencapsulated gelonin or gelonin encapsulated alone in pH-sensitive liposomes exhibited no detectable cytotoxicity. Moreover, treatment by direct intratumor injection into subcutaneous solid tumors of B16 melanoma in a mouse model showed that pH-sensitive liposomes containing both listeriolysin O and gelonin were more effective than control formulations in curtailing tumor growth rates.	Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Lee, KD (corresponding author), Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, 428 Church St, Ann Arbor, MI 48109 USA.	kdlee@umich.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010571, R01AI047173, R29AI042084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NIAID NIH HHS [R29AI42084, R01AI47173, F32AI010571] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALAM A, 1992, MOL CELL BIOCHEM, V112, P97; Allen TM, 1997, DRUGS, V54, P8, DOI 10.2165/00003495-199700544-00004; Allen TM, 1998, DRUGS, V56, P747, DOI 10.2165/00003495-199856050-00001; Atkinson SF, 2001, J BIOL CHEM, V276, P27930, DOI 10.1074/jbc.M102825200; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Beauregard KE, 1997, J EXP MED, V186, P1159, DOI 10.1084/jem.186.7.1159; BETTER M, 1995, J BIOL CHEM, V270, P14951, DOI 10.1074/jbc.270.25.14951; Better M, 1996, ANN NY ACAD SCI, V782, P544, DOI 10.1111/j.1749-6632.1996.tb40592.x; Bielinska A, 1996, NUCLEIC ACIDS RES, V24, P2176, DOI 10.1093/nar/24.11.2176; BRISCOE P, 1995, AM J PHYSIOL-LUNG C, V268, pL374, DOI 10.1152/ajplung.1995.268.3.L374; CHU CJ, 1990, PHARM RES-DORDR, V7, P824, DOI 10.1023/A:1015908831507; DARJI A, 1995, EUR J IMMUNOL, V25, P2967, DOI 10.1002/eji.1830251038; Darji A, 1997, EUR J IMMUNOL, V27, P1353, DOI 10.1002/eji.1830270609; Decatur AL, 2000, SCIENCE, V290, P992, DOI 10.1126/science.290.5493.992; Dietrich G, 2001, TRENDS MICROBIOL, V9, P23, DOI 10.1016/S0966-842X(00)01893-X; Dramsi S, 2002, J CELL BIOL, V156, P943, DOI 10.1083/jcb.200202121; Drummond DC, 2000, PROG LIPID RES, V39, P409, DOI 10.1016/S0163-7827(00)00011-4; Duzgunes N, 1999, ADV DRUG DELIVER REV, V40, P3, DOI 10.1016/S0169-409X(99)00037-X; EIKLID K, 1980, EXP CELL RES, V126, P321, DOI 10.1016/0014-4827(80)90270-0; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gedde MM, 2000, INFECT IMMUN, V68, P999, DOI 10.1128/IAI.68.2.999-1003.2000; Glomski IJ, 2002, J CELL BIOL, V156, P1029, DOI 10.1083/jcb.200201081; HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012; JOST LM, 1992, J IMMUNOL METHODS, V147, P153, DOI 10.1016/S0022-1759(12)80003-2; Kerr DE, 1997, BIOCONJUGATE CHEM, V8, P781, DOI 10.1021/bc970124+; Kreitman RJ, 1998, ADV DRUG DELIVER REV, V31, P53, DOI 10.1016/S0169-409X(97)00094-X; LAMBERT JM, 1985, J BIOL CHEM, V260, P2035; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; Lee KD, 1996, J BIOL CHEM, V271, P7249, DOI 10.1074/jbc.271.13.7249; Lety MA, 2001, MOL MICROBIOL, V39, P1124, DOI 10.1046/j.1365-2958.2001.02281.x; Mandal M, 2002, BBA-BIOMEMBRANES, V1563, P7, DOI 10.1016/S0005-2736(02)00368-1; MARTIN S, 1993, IMMUNOL LETT, V37, P97, DOI 10.1016/0165-2478(93)90017-V; Mathew E, 2003, GENE THER, V10, P1105, DOI 10.1038/sj.gt.3301966; MCINTOSH DP, 1982, BIOCHIM BIOPHYS ACTA, V690, P224, DOI 10.1016/0005-2736(82)90326-1; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MINAGAWA K, 1991, FEBS LETT, V295, P67, DOI 10.1016/0014-5793(91)81386-M; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NAIR S, 1992, J EXP MED, V175, P609, DOI 10.1084/jem.175.2.609; Papahadjopoulos Demetrios, 1996, Journal of Liposome Research, V6, P3, DOI 10.3109/08982109609037199; PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8720, DOI 10.1021/bi00489a031; Pattrick NG, 2001, J CONTROL RELEASE, V77, P225, DOI 10.1016/S0168-3659(01)00476-X; PLANK C, 1994, J BIOL CHEM, V269, P12918; PORTNOY DA, 1992, INFECT IMMUN, V60, P2710, DOI 10.1128/IAI.60.7.2710-2717.1992; PORTNOY DA, 1994, ANN NY ACAD SCI, V730, P15, DOI 10.1111/j.1749-6632.1994.tb44235.x; Provoda CJ, 2000, ADV DRUG DELIVER REV, V41, P209, DOI 10.1016/S0169-409X(99)00067-8; Robbins PD, 1998, TRENDS BIOTECHNOL, V16, P35, DOI 10.1016/S0167-7799(97)01137-2; Rosenblum MG, 1999, CLIN CANCER RES, V5, P865; Rosenblum MG, 1999, CANCER CHEMOTH PHARM, V44, P343, DOI 10.1007/s002800050987; Saito G, 2003, GENE THER, V10, P72, DOI 10.1038/sj.gt.3301859; SINGH V, 1989, MOL CELL ENDOCRINOL, V67, P217, DOI 10.1016/0303-7207(89)90212-8; SINGH V, 1989, J BIOL CHEM, V264, P3089; Slepushkin VA, 1997, J BIOL CHEM, V272, P2382; STIRPE F, 1980, J BIOL CHEM, V255, P6947; Storm G, 1998, PHARM SCI TECHNOL TO, V1, P19, DOI 10.1016/S1461-5347(98)00007-8; Veenendaal LM, 2002, P NATL ACAD SCI USA, V99, P7866, DOI [10.1073/pnas.122157899, 10.1073/pnas.162346299]; Woodle MC, 1998, ADV DRUG DELIVER REV, V32, P139, DOI 10.1016/S0169-409X(97)00136-1; Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5	58	60	61	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35102	35108		10.1074/jbc.M305411200	http://dx.doi.org/10.1074/jbc.M305411200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832408	hybrid			2022-12-25	WOS:000185164400045
J	Song, KS; Seong, JK; Chung, KC; Lee, WJ; Kim, CH; Cho, KN; Kang, CD; Koo, JS; Yoon, JH				Song, KS; Seong, JK; Chung, KC; Lee, WJ; Kim, CH; Cho, KN; Kang, CD; Koo, JS; Yoon, JH			Induction of MUC8 gene expression by interleukin-1 beta is mediated by a sequential ERK MAPK/RSK1/CREB cascade pathway in human airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NORMAL HUMAN NASAL; MESSENGER-RNA; TNF-ALPHA; PHOSPHORYLATION; TRANSCRIPTION; CREB; MAPK; MSK1; DIFFERENTIATION	Mucins are the major components of the mucus layer that covers and protects the respiratory, digestive, and reproductive tracts. Our previous studies showed that MUC8 gene expression was overexpressed in in vivo polyp epithelium in chronic sinusitis and was also increased by treatment with inflammatory mediators in an in vitro culture condition. However, the mechanisms by which the inflammatory mediators-induced MUC8 gene expression in normal nasal epithelial cells evolved remain unclear. We examined the mechanism by which the important proinflammatory mediator, interleukin (IL)-1beta, increases MUC8 gene expression levels. We found that pharmacologic and genetic inhibition of ERK MAPK pathway abolished IL-1beta-induced MUC8 gene expression in normal human nasal epithelial cells. Moreover, the overexpression of wide-type or of the dominant-negative mutant of p90 ribosomal S6 protein kinase 1 (RSK1) enhanced or suppressed, respectively, IL-1beta-induced MUC8 gene expression. RSK1 was found to directly phosphorylate cAMP-response element-binding protein ( CREB), and this event led to the stimulation of subsequent CRE-mediated gene transcription. In conclusion, IL-1beta was found to induce MUC8 gene expression via a sequential ERK/RSK1/CREB pathway in human airway epithelial cells.	Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Seoul Natl Univ, Coll Vet Med, Dept Dev Biol & Genom, Seoul 151742, South Korea; Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Pusan Natl Univ, Coll Med, Dept Biochem, Pusan 609735, South Korea; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Yonsei Univ, Coll Med, Dept Otorhinolaryngol, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Seoul National University (SNU); Yonsei University; Ewha Womans University; Pusan National University; University of Texas System; UTMD Anderson Cancer Center; Yonsei University; Yonsei University Health System	Yoon, JH (corresponding author), Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea.	jhyoon@yumc.yonsei.ac.kr	Yoon, Joo-Heon/E-5781-2016; Kim, Chang-Hoon/D-7205-2016; Koo, J Peter/AAE-6700-2019	Kim, Chang-Hoon/0000-0003-1238-6396; Seong, Je Kyung/0000-0003-1177-6958; Yoon, Joo-Heon/0000-0003-2404-7156				Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P1253, DOI 10.1038/sj.bjp.0704367; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Genersch E, 2000, J CELL SCI, V113, P4319; Gray T, 2001, BIOCHEM J, V353, P727, DOI 10.1042/0264-6021:3530727; Gum JR, 2002, BIOCHEM BIOPH RES CO, V291, P466, DOI 10.1006/bbrc.2002.6475; Hamm J, 2002, J BIOL CHEM, V277, P45793, DOI 10.1074/jbc.M205072200; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Kim CH, 2000, LARYNGOSCOPE, V110, P2110, DOI 10.1097/00005537-200012000-00026; Kim KW, 2001, J BIOL CHEM, V276, P13186, DOI 10.1074/jbc.M008092200; Kim SS, 2000, LARYNGOSCOPE, V110, P276, DOI 10.1097/00005537-200002010-00017; Laoukili J, 2001, J CLIN INVEST, V108, P1817, DOI 10.1172/JCI13557; Lapensee L, 1997, FERTIL STERIL, V68, P702, DOI 10.1016/S0015-0282(97)00317-8; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Martin LD, 1997, EUR RESPIR J, V10, P2139, DOI 10.1183/09031936.97.10092139; Melnick M, 2001, ARCH ORAL BIOL, V46, P745, DOI 10.1016/S0003-9969(01)00027-9; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Pallesen LT, 2002, EUR J BIOCHEM, V269, P2755, DOI 10.1046/j.1432-1033.2002.02949.x; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Plath KES, 2003, CLIN EXP ALLERGY, V33, P342, DOI 10.1046/j.1365-2222.2003.01610.x; Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Seong JK, 2002, ACTA OTO-LARYNGOL, V122, P401, DOI 10.1080/00016480260000094; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; Song KS, 2003, J BIOL CHEM, V278, P23243, DOI 10.1074/jbc.M300096200; van der Vliet A, 2000, AM J MED, V109, P398, DOI 10.1016/S0002-9343(00)00479-4; Van Seuningen I, 2001, FRONT BIOSCI-LANDMRK, V6, pD1216; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Williams SJ, 1999, CANCER RES, V59, P4083; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; Wu JM, 2002, J BIOL CHEM, V277, P42669, DOI 10.1074/jbc.M205501200; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yin BWT, 2001, J BIOL CHEM, V276, P27371, DOI 10.1074/jbc.M103554200; Yoon JH, 1999, ACTA OTO-LARYNGOL, V119, P905; Zhang Y, 2002, J BIOL CHEM, V277, P19042, DOI 10.1074/jbc.M112442200; Zhu JH, 2002, AM J PATHOL, V161, P2087, DOI 10.1016/S0002-9440(10)64487-2	41	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34890	34896		10.1074/jbc.M303911200	http://dx.doi.org/10.1074/jbc.M303911200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842905	hybrid			2022-12-25	WOS:000185164400020
J	Xu, P; Yoshioka, K; Yoshimura, D; Tominaga, Y; Nishioka, T; Ito, M; Nakabeppu, Y				Xu, P; Yoshioka, K; Yoshimura, D; Tominaga, Y; Nishioka, T; Ito, M; Nakabeppu, Y			In vitro development of mouse embryonic stem cells lacking JNK/stress-activated protein kinase-associated protein 1 (JSAP1) scaffold protein revealed its requirement during early embryonic neurogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; C-JUN; TRANSCRIPTION FACTOR; MICE LACKING; EXPRESSION; GENE; JNK; DIFFERENTIATION; WNT; PHOSPHORYLATION	The Jsap1 gene encodes a scaffold protein for c-Jun N-terminal kinase cascades. We established c-Jun N-terminal kinase (JNK)/stress-activated protein kinase-associated protein 1 (JSAP1)-null mouse embryonic stem cell lines by homologous recombination. The JSAP1-null embryonic stem cells were viable, however, exhibited hyperplasia of the ectoderm during embryoid body formation, and spontaneously differentiated into neurons more efficiently than did wild type. The expression of components of c-Jun N-terminal kinase cascades and a subset of marker mRNAs during early embryogenesis was altered in the JSAP1-null mutants. Retinoic acid dramatically increased the expression of JSAP1 and JNK3, which were co-precipitated with anti-JNK3 in the neuroectoderm of wild type but not JSAP1-null embryoid bodies. In the neurons differentiated from the wild type embryoid bodies, JSAP1 was localized in the soma, neurites, and growth cone-like structure of the neurites, and neurite outgrowth from the JSAP1-null embryoid bodies was apparently less efficient than from wild type. JSAP1 and c-Jun N-terminal kinase 3 were coexpressed in the embryonic ectoderm of E7.5 mouse embryo, whereas Wnt1 and Pax2 were coexpressed with JSAP1 at the midbrain-hindbrain junction in E12.5 mouse embryo, thus suggesting that JSAP1 is required for early embryonic neurogenesis.	Kyushu Univ, Med Inst Bioregulat, Div Neurofunct Genom, Dept Immunobiol & Neurosci, Fukuoka 8128582, Japan; CREST, Japan Sci & Technol Corp, Fukuoka 8128582, Japan; Kanazawa Univ, Canc Res Inst, Dept Mol & Cellular Biol, Div Cell Cycle Regulat, Kanazawa, Ishikawa 9200934, Japan; Kitasato Univ, Dept Biosci, Sch Sci, Kanagawa 2288555, Japan	Kyushu University; Japan Science & Technology Agency (JST); Kanazawa University; Kitasato University	Nakabeppu, Y (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Neurofunct Genom, Dept Immunobiol & Neurosci, Fukuoka 8128582, Japan.	yusaku@bioreg.kyushu-u.ac.jp	Nakabeppu, Yusaku/A-8902-2011; Sakai, Yasunari/S-7965-2018	Nakabeppu, Yusaku/0000-0002-6739-242X; Sakai, Yasunari/0000-0002-5747-8692				BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Bain G., 1998, CULTURING NERVE CELL, P189; BEDDINGTON R, 2002, PRINCIPLES DEV, P109; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Byrd DT, 2001, NEURON, V32, P787, DOI 10.1016/S0896-6273(01)00532-3; Cassia R, 1997, J NEUROSCI RES, V50, P421, DOI 10.1002/(SICI)1097-4547(19971101)50:3<421::AID-JNR8>3.0.CO;2-K; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; Cipelletti B, 2002, NEUROSCIENCE, V115, P657, DOI 10.1016/S0306-4522(02)00531-6; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Elion EA, 2001, J CELL SCI, V114, P3967; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Funahashi J, 1999, DEV GROWTH DIFFER, V41, P59; HERRMANN BG, 1994, TRENDS GENET, V10, P280, DOI 10.1016/0168-9525(90)90011-T; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Ide Y, 2003, GENOMICS, V81, P47, DOI 10.1016/S0888-7543(02)00009-5; Ito M, 1999, MOL CELL BIOL, V19, P7539; Ito M, 2000, GENE, V255, P229, DOI 10.1016/S0378-1119(00)00335-8; JOYNER AL, 1993, GENE TARGETING PRACT, P1; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P17; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kiecker C, 2001, DEVELOPMENT, V128, P4189; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kuboki Y, 2000, J BIOL CHEM, V275, P39815, DOI 10.1074/jbc.C000403200; Kudoh T, 2002, DEVELOPMENT, V129, P4335; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lagutin OV, 2003, GENE DEV, V17, P368, DOI 10.1101/gad.1059403; Mallamaci A, 2000, J NEUROSCI, V20, P1109, DOI 10.1523/JNEUROSCI.20-03-01109.2000; Martinez S, 2001, INT J DEV BIOL, V45, P367; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MURPHY TH, 1991, J NEUROCHEM, V57, P1862, DOI 10.1111/j.1471-4159.1991.tb06396.x; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659; Niehrs C, 1999, TRENDS GENET, V15, P314, DOI 10.1016/S0168-9525(99)01767-9; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; O'Shea KS, 1999, ANAT RECORD, V257, P32, DOI 10.1002/(SICI)1097-0185(19990215)257:1<32::AID-AR6>3.0.CO;2-2; Sano Y, 2001, GENOME RES, V11, P1833, DOI 10.1101/gr.194301; Schimenti J, 2000, TRENDS GENET, V16, P240, DOI 10.1016/S0168-9525(00)02020-5; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Tsuchimoto D, 2001, NUCLEIC ACIDS RES, V29, P2349, DOI 10.1093/nar/29.11.2349; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WILSON V, 1995, DEVELOPMENT, V121, P877; Wurst W, 2001, NAT REV NEUROSCI, V2, P99, DOI 10.1038/35053516; Xu P, 1998, VIRCHOWS ARCH, V432, P17, DOI 10.1007/s004280050129; Yamaguchi TP, 2001, CURR BIOL, V11, pR713, DOI 10.1016/S0960-9822(01)00417-1; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zandstra PW, 2000, BIOTECHNOL BIOENG, V69, P607, DOI 10.1002/1097-0290(20000920)69:6<607::AID-BIT4>3.3.CO;2-6	59	143	149	3	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48422	48433		10.1074/jbc.M307888200	http://dx.doi.org/10.1074/jbc.M307888200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12857738	hybrid			2022-12-25	WOS:000186731400128
J	Dyer, DH; Lovell, S; Thoden, JB; Holden, HM; Rayment, I; Lan, Q				Dyer, DH; Lovell, S; Thoden, JB; Holden, HM; Rayment, I; Lan, Q			The structural determination of an insect sterol carrier protein-2 with a ligand-bound C16 fatty acid at 1.35-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEINS; ACYL-COENZYME; HELIOTHIS-ZEA; LIPID-BINDING; CHOLESTEROL; GENE; SEQUENCE; PROGRAM; STIMULATION; METABOLISM	Yellow fever mosquito sterol carrier protein (SCP-2) is known to bind to cholesterol. We report here the three-dimensional structure of the complex of SCP-2 from Aedes aegypti with a C16 fatty acid to 1.35-Angstrom resolution. The protein fold is exceedingly similar to the human and rabbit proteins, which consist of a five-stranded beta-sheet that exhibits strand order 3-2-1-4-5 with an accompanying layer of four alpha-helices that cover the beta-sheet. A large cavity exists at the interface of the layer alpha-helices and the beta-sheet, which serves as the fatty acid binding site. The carboxylate moiety of the fatty acid is coordinated by a short loop that connects the first alpha-helix to the first beta-strand, whereas the acyl chain extends deep into the interior of the protein. Interestingly, the orientation of the fatty acid is opposite to the observed orientation for Triton X-100 in the SCP-2-like domain from the peroxisomal multifunctional enzyme (Haapalainen, A. M., van Aalten, D. M., Merilainen, G., Jalonen, J. E., Pirila, P., Wierenga, R. K., Hiltunen, J. K., and Glumoff, T. (2001) J. Mol. Biol. 313, 1127-1138). The present study suggests that the binding pocket in the SCP-2 family of proteins may exhibit conformational flexibility to allow coordination of a variety of lipids.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Rayment, I (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	Ivan_Rayment@biochem.wisc.edu; qlan@entomology.wisc.edu	rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035186] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35168] Funding Source: Medline; NIAMS NIH HHS [AR-35186] Funding Source: Medline; NIGMS NIH HHS [GM35332] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; BEYDON P, 1987, ARCH INSECT BIOCHEM, V5, P139, DOI 10.1002/arch.940050208; Chakravarty S, 2002, J BIOL CHEM, V277, P31345, DOI 10.1074/jbc.M201373200; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; Choinowski T, 2000, BIOCHEMISTRY-US, V39, P1897, DOI 10.1021/bi992742e; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CLAYTON RB, 1964, J LIPID RES, V5, P3; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; COLLES SM, 1995, LIPIDS, V30, P795, DOI 10.1007/BF02533954; DWIVEDI AK, 1982, ENTOMON, V7, P411; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; Fuchs M, 2001, J BIOL CHEM, V276, P48058, DOI 10.1074/jbc.M106732200; Gallegos AM, 2001, PROG LIPID RES, V40, P498, DOI 10.1016/S0163-7827(01)00015-7; Garcia FL, 2000, J MOL BIOL, V295, P595, DOI 10.1006/jmbi.1999.3355; Haapalainen AM, 2001, J MOL BIOL, V313, P1127, DOI 10.1006/jmbi.2001.5084; Huang H, 2002, BIOCHEMISTRY-US, V41, P12149, DOI 10.1021/bi0260536; Jouni ZE, 2002, ARCH INSECT BIOCHEM, V49, P167, DOI 10.1002/arch.10017; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kitamura T, 1996, DEV GROWTH DIFFER, V38, P373; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krebs KC, 2003, INSECT MOL BIOL, V12, P51, DOI 10.1046/j.1365-2583.2003.00386.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nes WD, 1997, LIPIDS, V32, P1317, DOI 10.1007/s11745-006-0170-5; NODA H, 1979, J INSECT PHYSIOL, V25, P443, DOI 10.1016/0022-1910(79)90012-X; RITTER KS, 1981, J INSECT PHYSIOL, V27, P175, DOI 10.1016/0022-1910(81)90125-6; Roussel A., 1991, SILICON GRAPHICS GEO, V86; Schroeder F, 2003, BIOCHEMISTRY-US, V42, P3189, DOI 10.1021/bi026904+; Schroeder F, 2000, J BIOL CHEM, V275, P25547, DOI 10.1074/jbc.M000431200; Seedorf U, 2000, BBA-MOL CELL BIOL L, V1486, P45, DOI 10.1016/S1388-1981(00)00047-0; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; SPATES GE, 1988, J INSECT PHYSIOL, V34, P1055, DOI 10.1016/0022-1910(88)90205-3; Thompson J, 1999, MOL CELL BIOCHEM, V192, P9, DOI 10.1023/A:1006806616963; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; VANNOORT M, 1988, BIOCHEM BIOPH RES CO, V154, P60, DOI 10.1016/0006-291X(88)90649-3; XU TS, 1991, J BIOL CHEM, V266, P6801; Zdobnov EM, 2002, SCIENCE, V298, P149, DOI 10.1126/science.1077061; Zimmerman AW, 2002, CELL MOL LIFE SCI, V59, P1096, DOI 10.1007/s00018-002-8490-y	42	83	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39085	39091		10.1074/jbc.M306214200	http://dx.doi.org/10.1074/jbc.M306214200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12754195	hybrid			2022-12-25	WOS:000185575100122
J	Shin, JH; Jiang, Y; Grabowski, B; Hurwitz, J; Kelman, Z				Shin, JH; Jiang, Y; Grabowski, B; Hurwitz, J; Kelman, Z			Substrate requirements for duplex DNA translocation by the eukaryal and archaeal minichromosome maintenance helicases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; SINGLE-STRANDED-DNA; LARGE TUMOR-ANTIGEN; REPLICATION-FORK; HEXAMERIC HELICASES; BIND CHROMATIN; ATP HYDROLYSIS; MCM PROTEINS; 3RD DOMAIN; COMPLEX	Replicative DNA helicases are ring-shaped hexamers that play an essential role in DNA synthesis by separating the two strands of chromosomal DNA to provide the single-stranded ( ss) substrate for replicative polymerases. Biochemical and structural studies suggest that these helicases translocate along one strand of the duplex, which passes through and interacts with the central channel of these ring-shaped hexamers, and displace the complementary strand. A number of these helicases were shown to also encircle both strands simultaneously and then translocate along double-stranded (ds) DNA. In this report it is shown that the Schizosaccharomyces pombe Mcm4,6,7 complex and archaeal minichromosome maintenance (MCM) helicase from Methanothermobacter thermautotrophicus move along duplex DNA. These two helicases, however, differ in the substrate required to support dsDNA translocation. Although the S. pombe Mcm4,6,7 complex required a 3'-overhang ssDNA region to initiate its association with the duplex, the archaeal protein initiated its transit along dsDNA in the absence of a 3'-overhang region, as well. Furthermore, DNA substrates containing a streptavidinbiotin steric block inhibited the movement of the eukaryotic helicase along ss and dsDNAs but not of the archaeal enzyme. The M. thermautotrophicus MCM helicase, however, was shown to displace a streptavidinbiotin complex from ss, as well as dsDNAs. The possible roles of dsDNA translocation by the MCM proteins during the initiation and elongation phases of chromosomal replication are discussed.	Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	University System of Maryland; University of Maryland Baltimore; Memorial Sloan Kettering Cancer Center	Kelman, Z (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	kelman@umbi.umd.edu	Kasiviswanathan, Rajesh/D-2744-2012	Bell, Stephen/0000-0002-8474-6592	NIGMS NIH HHS [GM 38559] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5253; Carpentieri F, 2002, J BIOL CHEM, V277, P12118, DOI 10.1074/jbc.M200091200; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Davey MJ, 2003, J BIOL CHEM, V278, P4491, DOI 10.1074/jbc.M210511200; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Enemark EJ, 2000, MOL CELL, V6, P149, DOI 10.1016/S1097-2765(00)00016-2; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Fouts ET, 1999, J BIOL CHEM, V274, P4447, DOI 10.1074/jbc.274.7.4447; GOETZ GS, 1988, J BIOL CHEM, V263, P383; Grabowski B, 2003, ANNU REV MICROBIOL, V57, P487, DOI 10.1146/annurev.micro.57.030502.090709; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jezewska MJ, 1998, BIOCHEMISTRY-US, V37, P3116, DOI 10.1021/bi972564u; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Kaplan DL, 2002, MOL CELL, V10, P647, DOI 10.1016/S1097-2765(02)00642-1; Kelman LM, 2003, MOL MICROBIOL, V48, P605, DOI 10.1046/j.1365-2958.2003.03369.x; Kelman Z, 2003, NAT STRUCT BIOL, V10, P148, DOI 10.1038/nsb0303-148; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Krude T, 1996, J CELL SCI, V109, P309; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Laskey RA, 2003, EMBO REP, V4, P26, DOI 10.1038/sj.embor.embor706; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; Morris PD, 1999, BIOCHEMISTRY-US, V38, P5164, DOI 10.1021/bi9822269; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Poplawski A, 2001, J BIOL CHEM, V276, P49371, DOI 10.1074/jbc.M108519200; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Shin JH, 2003, J BIOL CHEM, V278, P49053, DOI 10.1074/jbc.M308599200; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; You ZY, 1999, MOL CELL BIOL, V19, P8003; Yu X, 2002, EMBO REP, V3, P792, DOI 10.1093/embo-reports/kvf160	44	103	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49053	49062		10.1074/jbc.M308599200	http://dx.doi.org/10.1074/jbc.M308599200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12975364	hybrid			2022-12-25	WOS:000186829000067
J	Rajesh, D; Stenzel, RA; Howard, SP				Rajesh, D; Stenzel, RA; Howard, SP			Perillyl alcohol as a radio-/chemosensitizer in malignant glioma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLIOBLASTOMA CELL-LINES; FAS-LIGAND; INDUCED APOPTOSIS; IONIZING-RADIATION; CD95 LIGAND; SIGNALING PATHWAY; G0/G1 ARREST; TUMOR-CELLS; DNA-DAMAGE; ACTIVATION	The prognosis for patients with malignant glioma has not significantly changed in two decades, despite advances in surgery, radiation, and chemotherapy, emphasizing the growing need for novel approaches to glioma therapy. Perillyl alcohol (POH) is a naturally occurring monoterpene that has been shown to possess chemotherapeutic as well as chemopreventive activity in animal tumor models and is currently in Phase I and Phase II clinical trials. In the present study, we have demonstrated that POH is an effective radiosensitizer at clinically relevant doses of radiation using established glioma cell lines. POH caused a transient arrest in the G(2)/M phase of the cell cycle and induced apoptosis in glioma cells. POH treatment sensitized glioma cells to Fas-mediated apoptosis, which was further augmented in the presence of ionizing radiation and abrogated in the presence of antagonistic antibody. POH-induced radiosensitization was partially inhibited in glioma cells expressing dominant negative Fas-associated death domain and completely inhibited in glioma cells overexpressing the cytokine response modifier A. In addition, POH treatment resulted in a dose-dependent sensitization to cisplatin and doxorubicin induced cytotoxicity in glioma cells, highlighting its usefulness as a potent radio/chemosensitizer in the treatment of malignant glioma.	Univ Wisconsin, Dept Human Oncol, Ctr Comprehens Canc, Madison, WI 53792 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Howard, SP (corresponding author), CSC, K4-354,600 Highland Ave, Madison, WI 53792 USA.	howard@mail.humonc.wisc.edu		Roux, Jeremie/0000-0001-5712-8660	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051829] Funding Source: NIH RePORTER; NHLBI NIH HHS [1P50HL60288] Funding Source: Medline; NIDDK NIH HHS [DK51829] Funding Source: Medline; NIGMS NIH HHS [GM33551] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albasanz JL, 1997, EUR J PHARMACOL, V326, P85, DOI 10.1016/S0014-2999(97)00154-4; Ambar BB, 1999, HUM GENE THER, V10, P1641, DOI 10.1089/10430349950017644; Ariazi EA, 1999, CANCER RES, V59, P1917; Bailey HH, 2002, GYNECOL ONCOL, V85, P464, DOI 10.1006/gyno.2002.6647; BALTUCH GH, 1993, NEUROSURGERY, V33, P495; Belanger J T, 1998, Altern Med Rev, V3, P448; Chamberlain MC, 2001, J CLIN ONCOL, V19, P3997, DOI 10.1200/JCO.2001.19.19.3997; Chmura SJ, 1997, CANCER RES, V57, P1270; Clark SS, 2002, LEUKEMIA, V16, P213, DOI 10.1038/sj.leu.2402369; CROWELL PL, 1992, CARCINOGENESIS, V13, P1261, DOI 10.1093/carcin/13.7.1261; Crowell PL, 1996, ADV EXP MED BIOL, V401, P131; Darzynkiewicz Z, 1998, Adv Biochem Eng Biotechnol, V62, P33, DOI 10.1007/BFb0102305; Del Bino G, 1999, CELL PROLIFERAT, V32, P25, DOI 10.1046/j.1365-2184.1999.00130.x; Ezennia EI, 1997, J CHROMATOGR B, V688, P354, DOI 10.1016/S0378-4347(96)00322-2; Feldman D., 1996, SYNTHETIC POLYM, DOI [DOI 10.1002/(SICI)1097-4644(1996)25+<1::AID-JCB1>3.0.CO;2-4, 10.1002/(SICI)1097-0126(199701)42:13.0.CO;2-G, DOI 10.1002/(SICI)1097-0126(199701)42:13.0.CO;2-G]; FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Fulda S, 1998, INT J CANCER, V76, P105; Fulda S, 1998, KLIN PADIATR, V210, P148, DOI 10.1055/s-2008-1043870; Gorczyca W, 1998, METH MOL B, V91, P217; Goto K, 2002, ORAL ONCOL, V38, P16, DOI 10.1016/S1368-8375(00)00134-2; GOULD MN, 1994, CANCER RES, V54, P3540; GOULD MN, 1995, J CELL BIOCHEM, P139; Gould MN, 1997, ENVIRON HEALTH PERSP, V105, P977, DOI 10.2307/3433313; Gratas C, 1997, BRAIN PATHOL, V7, P863, DOI 10.1111/j.1750-3639.1997.tb00889.x; Green DR, 1997, P NATL ACAD SCI USA, V94, P5986, DOI 10.1073/pnas.94.12.5986; Green DR, 2001, NAT REV MOL CELL BIO, V2, P917, DOI 10.1038/35103104; HAAG JD, 1994, CANCER CHEMOTH PHARM, V34, P477, DOI 10.1007/BF00685658; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hudes GR, 2000, CLIN CANCER RES, V6, P3071; Kimura K, 2000, J BIOL CHEM, V275, P8610, DOI 10.1074/jbc.275.12.8610; Krammer P H, 1999, Adv Immunol, V71, P163; Maecker HL, 2000, CANCER RES, V60, P4638; MARIN LA, 1991, INT J RADIAT ONCOL, V21, P397, DOI 10.1016/0360-3016(91)90788-6; Mehta M, 2001, Int J Radiat Oncol Biol Phys, V51, P11; Mehta M P, 2000, Curr Oncol Rep, V2, P438, DOI 10.1007/s11912-000-0064-2; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; MISHIMA K, 1994, BIOCHEM BIOPH RES CO, V201, P363, DOI 10.1006/bbrc.1994.1710; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muller M, 1998, EUR CYTOKINE NETW, V9, P685; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Pinkoski MJ, 1999, CELL DEATH DIFFER, V6, P1174, DOI 10.1038/sj.cdd.4400611; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Reddy BS, 1997, CANCER RES, V57, P420; Reimer T, 2000, CANCER RES, V60, P822; Ren ZB, 1998, CARCINOGENESIS, V19, P827, DOI 10.1093/carcin/19.5.827; Riboni L, 2002, GLIA, V39, P105, DOI 10.1002/glia.10087; Ripple GH, 1998, CLIN CANCER RES, V4, P1159; Ripple GH, 2000, CLIN CANCER RES, V6, P390; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; Roth W, 1998, J NEUROIMMUNOL, V87, P121, DOI 10.1016/S0165-5728(98)00079-4; Roth W, 1998, BRIT J CANCER, V77, P404, DOI 10.1038/bjc.1998.64; Sahin MB, 1999, LEUKEMIA, V13, P1581, DOI 10.1038/sj.leu.2401536; Satomi Y, 1999, CARCINOGENESIS, V20, P1957, DOI 10.1093/carcin/20.10.1957; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sheard MA, 1999, BRIT J CANCER, V80, P1689, DOI 10.1038/sj.bjc.6690585; Sheard MA, 2001, INT J CANCER, V96, P213, DOI 10.1002/ijc.1020; Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1; Shinohara H, 2000, CANCER RES, V60, P1766; Shinoura N, 2000, CANCER GENE THER, V7, P224, DOI 10.1038/sj.cgt.7700110; Shinoura N, 2000, CANCER GENE THER, V7, P732, DOI 10.1038/sj.cgt.7700160; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Solary E, 1998, B CANCER, V85, P685; Stayrook KR, 1997, CARCINOGENESIS, V18, P1655, DOI 10.1093/carcin/18.8.1655; Stayrook KR, 1998, ANTICANCER RES, V18, P823; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Stupp R, 2002, J CLIN ONCOL, V20, P1375, DOI 10.1200/JCO.20.5.1375; Su S, 1997, BIOTECHNIQUES, V22, P1107, DOI 10.2144/97226st02; Tachibana O, 1996, ACTA NEUROPATHOL, V92, P431, DOI 10.1007/s004010050542; Tao LH, 1998, J CHROMATOGR A, V793, P71, DOI 10.1016/S0021-9673(97)00867-4; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Unlu S, 2000, J CARDIOVASC PHARM, V35, P341, DOI 10.1097/00005344-200002000-00025; Wang JL, 1997, ANTICANCER RES, V17, P4615; Watters D, 1999, IMMUNOL CELL BIOL, V77, P263, DOI 10.1046/j.1440-1711.1999.00824.x; Weller M, 1998, BRAIN PATHOL, V8, P285; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1997, NEUROLOGY, V48, P1704, DOI 10.1212/WNL.48.6.1704; Yount GL, 1998, CANCER RES, V58, P3819; Yount GL, 1999, CANCER RES, V59, P1362; Yount GL, 2001, ONCOGENE, V20, P2826, DOI 10.1038/sj.onc.1204393; Zimmermann KC, 2001, J ALLERGY CLIN IMMUN, V108, pS99, DOI 10.1067/mai.2001.117819	83	102	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35968	35978		10.1074/jbc.M303280200	http://dx.doi.org/10.1074/jbc.M303280200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12837761	hybrid			2022-12-25	WOS:000185318300014
